PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Tanaka, T; Iwasa, Y; Kondo, S; Hiai, H; Toyokuni, S				Tanaka, T; Iwasa, Y; Kondo, S; Hiai, H; Toyokuni, S			High incidence of allelic loss on chromosome 5 and inactivation of p15(INK4B) and p16(INK4A) tumor suppressor genes in oxystress-induced renal cell carcinoma of rats	ONCOGENE			English	Article						oxidative stress; renal cell carcinoma; loss of heterozygosity; p15(INK4B); p16(INK4A); methylation, rat	FERRIC NITRILOTRIACETATE; CARCINOGENESIS; MODEL; METHYLATION; MUTATIONS; CANCER; TSC2; RAS	Ferric nitrilotriacetate induces oxidative damage in renal proximal tubules, a consequence of Fenton-like reaction, that ultimately leads to a high incidence of renal cell carcinoma (RCC) in rats. In order to find common genetic alterations in this oxystress-induced carcinogenesis model, RCCs were produced in F1 hybrid rats between Wistar and Long-Evans strains and genomes were screened for loss of heterozygosity (LOH) with microsatellite polymorphic markers by PCR. Five consecutive markers on chromosome 5 (D5Mgh5, D5Mit9, D5Mgh6, D5Mit11 and D5Mit6) showed LOH in greater than or equal to 40% of the RCCs. As possible candidate tumor suppressor genes on chromosome 5, p15(INK4B) and p16(INK4A) were investigated for genetic alteration and aberrant methylation by Southern blot, PCR/SSCP/ sequencing and methylation-specific PCR. Genetic alteration (homozygous or hemizygous deletion with or without point mutation) or aberrant methylation were found in 30.7 and 53.8% of the RCC cases, respectively, which was proportionally associated with the histological nuclear grade and metastatic activity. Our data suggest that inactivation of p15 and p16 genes could be one of the major pathways responsible for oxystress-induced carcinogenesis.	Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Toyokuni, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068501, Japan.		Toyokuni, Shinya/ABE-7714-2021; Toyokuni, Shinya/C-1358-2010	Toyokuni, Shinya/0000-0002-5757-1109; Toyokuni, Shinya/0000-0002-5757-1109				CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CAIRNS P, 1995, CANCER RES, V55, P224; EBINA Y, 1986, J NATL CANCER I, V76, P107; Halliwell B, 1993, DNA FREE RADICALS; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HINO O, 1994, CANCER LETT, V83, P117, DOI 10.1016/0304-3835(94)90307-7; HINO O, 1995, MOL CARCINOGEN, V14, P23, DOI 10.1002/mc.2940140106; KNAPEK DF, 1995, CANCER RES, V55, P1607; KNUDSON AG, 1975, P NATL ACAD SCI USA, V72, P5116, DOI 10.1073/pnas.72.12.5116; MCBRIDE TJ, 1991, BIOCHEMISTRY-US, V30, P207, DOI 10.1021/bi00215a030; Nishiyama Y, 1995, JPN J CANCER RES, V86, P1150, DOI 10.1111/j.1349-7006.1995.tb03308.x; OSAKA M, 1995, CANCER LETT, V91, P25, DOI 10.1016/0304-3835(94)03714-T; Schwerdtle RF, 1996, CANCER RES, V56, P2927; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; Toyokuni S, 1999, PATHOL INT, V49, P91, DOI 10.1046/j.1440-1827.1999.00829.x; TOYOKUNI S, 1994, INT J CANCER, V57, P123, DOI 10.1002/ijc.2910570122; Toyokuni S, 1996, FREE RADICAL BIO MED, V20, P553, DOI 10.1016/0891-5849(95)02111-6; TOYOKUNI S, 1994, P NATL ACAD SCI USA, V91, P2616, DOI 10.1073/pnas.91.7.2616; TOYOKUNI S, 1993, CARCINOGENESIS, V14, P223, DOI 10.1093/carcin/14.2.223; Toyokuni S, 1998, JPN J CANCER RES, V89, P814, DOI 10.1111/j.1349-7006.1998.tb00633.x	21	101	104	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	1999	18	25					3793	3797		10.1038/sj.onc.1202707	http://dx.doi.org/10.1038/sj.onc.1202707			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391689	Green Submitted			2022-12-17	WOS:000081140200015
J	Kosako, H; Goto, H; Yanagida, M; Matsuzawa, K; Fujita, M; Tomono, Y; Okigaki, T; Odai, H; Kaibuchi, K; Inagaki, M				Kosako, H; Goto, H; Yanagida, M; Matsuzawa, K; Fujita, M; Tomono, Y; Okigaki, T; Odai, H; Kaibuchi, K; Inagaki, M			Specific accumulation of Rho-associated kinase at the cleavage furrow during cytokinesis: cleavage furrow-specific phosphorylation of intermediate filaments	ONCOGENE			English	Article						cell cycle; cytokinesis; cleavage furrow; Rho-associated kinase (Rho-kinase); intermediate filament	BINDING PROTEIN-RHO; MYOSIN PHOSPHATASE; PLASMA-MEMBRANE; ERM PROTEINS; VIMENTIN; MITOSIS; SITES; TRANSITION; ADHESION; GTPASES	The small GTPase Rho and one of its targets, Rho-associated kinase (Rho-kinase), are implicated in a wide spectrum of cellular functions, including cytoskeletal rearrangements, transcriptional activation and smooth muscle contraction, Since Rho also plays an essential role in cytokinesis, Rho-kinase may possibly mediate some biological aspects of cytokinesis. Here, using a series of monoclonal antibodies that can specifically recognize distinct phosphorylated sites on glial fibrillary acidic protein (GFAP) and vimentin, phosphorylation sites by Rho-kinase in vitro were revealed to be identical to in vivo phosphorylation sites on these intermediate filament (IF) proteins at the cleavage furrow in dividing cells, We then found, by preparing two types of anti-Rho-kinase antibodies, that Rho-kinase accumulated highly and circumferentially at the cleavage furrow in various cell lines, This subcellular distribution during cytokinesis was very similar to that of ezrin/radixin/moesin (ERM) proteins and Ser(19)-phosphorylated myosin light chain, These results raise the possibility that Rho-kinase might be involved in the formation of the contractile ring by modulating these F-actin-binding proteins during cytokinesis and in the phosphorylation and regulation of if proteins at the cleavage furrow.	Aichi Canc Ctr, Res Inst, Biochem Lab, Aichi 4648681, Japan; Mie Univ, Sch Med, Dept Pediat, Tsu, Mie 5148507, Japan; Hokkaido Univ, Inst Immunol Sci, Sapporo, Hokkaido 0600815, Japan; Aichi Canc Ctr, Res Inst, Lab Viral Oncol, Aichi 4648681, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Yokohama, Kanagawa 2360004, Japan; Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan	Aichi Cancer Center; Mie University; Hokkaido University; Aichi Cancer Center; Kirin Brewery Company Limited; Nara Institute of Science & Technology	Inagaki, M (corresponding author), Aichi Canc Ctr, Res Inst, Biochem Lab, Aichi 4648681, Japan.		Inagaki, Masaki/B-9920-2016	Goto, Hidemasa/0000-0002-6796-4467; Fujita, Masatoshi/0000-0001-6617-2452				Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; GEORGATOS SD, 1987, J CELL BIOL, V105, P105, DOI 10.1083/jcb.105.1.105; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Ho CL, 1998, J CELL SCI, V111, P1767; Hunt T, 1991, Semin Cell Biol, V2, P213; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Inagaki M, 1997, J BIOCHEM, V121, P407; Inagaki N, 1997, J BIOL CHEM, V272, P25195, DOI 10.1074/jbc.272.40.25195; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kosako H, 1997, J BIOL CHEM, V272, P10333; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; MATSUOKA Y, 1992, EMBO J, V11, P2895, DOI 10.1002/j.1460-2075.1992.tb05358.x; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OGAWARA M, 1995, J CELL BIOL, V131, P1055, DOI 10.1083/jcb.131.4.1055; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; SATO N, 1991, J CELL BIOL, V113, P321, DOI 10.1083/jcb.113.2.321; Sekimata M, 1996, J CELL BIOL, V132, P635, DOI 10.1083/jcb.132.4.635; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Takai Y, 1996, J CELL BIOL, V133, P141, DOI 10.1083/jcb.133.1.141; TAKAISHI K, 1995, ONCOGENE, V11, P39; TSUJIMURA K, 1994, J BIOL CHEM, V269, P31097; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	38	101	103	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2783	2788		10.1038/sj.onc.1202633	http://dx.doi.org/10.1038/sj.onc.1202633			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348354				2022-12-17	WOS:000080124900015
J	Ettenberg, SA; Keane, MM; Nau, MM; Frankel, M; Wang, LM; Pierce, JH; Lipkowitz, S				Ettenberg, SA; Keane, MM; Nau, MM; Frankel, M; Wang, LM; Pierce, JH; Lipkowitz, S			cbl-b inhibits epidermal growth factor receptor signaling	ONCOGENE			English	Article						cbl proteins; EGF receptor; signal transduction	PROTEIN-COUPLED RECEPTORS; PROTOONCOGENE C-CBL; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; V-CBL; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; T-CELLS; KINASE; ACTIVATION	The role of cbl-b in signaling by the epidermal growth factor receptor (EGFR),vas studied and compared with c-cbl, We demonstrate in vivo, that chl-b, like c-cbl, is phosphorylated and recruited to the EGFR upon EGF stimulation and both cbl proteins can bind to the Grb2 adaptor protein, To investigate the functional role of chi proteins in EGFR signaling, we transfected cbl-b or c-cbl into 32D cells overexpressing the EGFR (32D/EGFR), This cell line is absolutely dependent on exogenous IL-3 or EGF for sustained growth. 32D/EGFR cells overexpressing cbl-b showed markedly inhibited growth in EGF compared to c-cbl transfectants and vector controls, This growth inhibition by cbl-b was the result of a dramatic increase in the number of cells undergoing apoptosis, Consistent with this finding, chl-b overexpression markedly decreased the amplitude and duration of AKT activation upon EGF stimulation compared to either vector controls or c-cbl overexpressing cells. In addition, the duration of EGF mediated MAP kinase and Jun kinase activation in cells overespressing cbl-b is shortened. These data demonstrate that cbl-b inhibits EGF-induced cell growth and that cbl-b and c-cbl have distinct roles in EGF mediated signaling.	USN Hosp, NCI, Med Branch, Dept Genet, Bethesda, MD 20889 USA; Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; NCI, Mol & Cellular Biol Lab, Div Basic Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lipkowitz, S (corresponding author), USN Hosp, NCI, Med Branch, Dept Genet, Bethesda, MD 20889 USA.				NATIONAL CANCER INSTITUTE [ZIASC007263, Z01SC007263] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; Andoniou CE, 1996, ONCOGENE, V12, P1981; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BENSASSON SA, 1995, METHOD CELL BIOL, V46, P29; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CRESPO P, 1994, J BIOL CHEM, V269, P21103; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; IHLE JN, 1981, J IMMUNOL, V126, P2184; IHLE JN, 1982, J IMMUNOL, V129, P2431; JONGEWARD GD, 1995, GENETICS, V139, P1553; KEANE MM, 1995, ONCOGENE, V10, P2367; Khwaja A, 1996, ONCOGENE, V12, P2491; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Levkowitz G, 1996, ONCOGENE, V12, P1117; Liu YC, 1997, J BIOL CHEM, V272, P168; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Odai H, 1995, JPN J CANCER RES, V86, P1119, DOI 10.1111/j.1349-7006.1995.tb03303.x; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; PRYSTOWSKY MB, 1982, J IMMUNOL, V129, P2337; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	46	101	111	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1855	1866		10.1038/sj.onc.1202499	http://dx.doi.org/10.1038/sj.onc.1202499			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086340				2022-12-17	WOS:000079090000009
J	Zhang, LS; Lau, YK; Xi, L; Hong, RL; Kim, DS; Chen, CF; Hortobagyi, GN; Chang, CJ; Hung, MC				Zhang, LS; Lau, YK; Xi, L; Hong, RL; Kim, DS; Chen, CF; Hortobagyi, GN; Chang, CJ; Hung, MC			Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties	ONCOGENE			English	Article						emodin; anthraquinone; HER-2/neu; tyrosine kinase; experimental metastasis	GROWTH-FACTOR-RECEPTOR; BREAST-CANCER CELLS; NEU ONCOGENE; LUNG-CANCER; PROGNOSTIC-SIGNIFICANCE; POINT MUTATION; TUMOR-CELL; EXPRESSION; GENE; C-ERBB-2	We have previously shown that emodin suppresses tyrosine kinase activity of HER-2/neu-encoded p185(neu) receptor tyrosine kinase. In this study, we examine the relationship between the chemical structure and the activity of emodin and nine derivatives, and identified that one methyl, one hydroxy, and one carbonyl functional groups are critical for the biological activities of emodin. We also found that one of the derivatives 10-(4-acetamidobenzylidene)-9-anthrone (DK-V-47) is more effective than emodin in repressing the tyrosine phosphorylation of p185(neu) and in inhibiting the proliferation and transformation of HER-2/neu-overexpressing human breast cancer cells. Using mutation-activated HER-2/neu transformed 3T3 cells, we also investigated whether emodin and DK-V-47 can inhibit malignant transformation induced solely by the HER-2/neu oncogene. We found that DK-V-47 is more potent than emodin in suppressing transformation phenotypes of activated HER-2/neu transformed 3T3 cells including anchorage-dependent and -independent growth, metastasis-associated properties. These results clearly indicate that the inhibition of p185(neu) tyrosine kinase by both emodin and DK-V-47 is capable of suppressing the HER-2/neu associated transformed phenotypes including the ability to induce metastatic potential. Our results also support the chemotherapeutic implications of the use of either emodin or DK-V-47 to target HER-2/neu-overexpressing cancer cells.	Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Natl Taiwan Univ, Dept Oncol, Taipei 10764, Taiwan; Purdue Univ, Dept Med Chem & Pharmacognosy, W Lafayette, IN 47907 USA; Natl Res Inst Chinese Med, Taipei 11211, Taiwan; Natl Yang Ming Med Coll, Taipei 11211, Taiwan; Univ Texas, MD Anderson Cancer Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; National Taiwan University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; National Research Institute of Chinese Medicine; National Yang Ming Chiao Tung University; University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Box 79, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Hong, Ruey-Long/0000-0001-8100-7914	NATIONAL CANCER INSTITUTE [R01CA060856, R01CA058880, U01CA050743] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60856, CA 50743, CA 58880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HOU L, 1992, CANCER LETT, V65, P215, DOI 10.1016/0304-3835(92)90234-M; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; JAYASURIYA H, 1992, J NAT PROD, V55, P696, DOI 10.1021/np50083a026; KIM DSH, IN PRESS NATL PROD L; Kiyokawa N, 1997, J BIOL CHEM, V272, P18656, DOI 10.1074/jbc.272.30.18656; LACROIX H, 1989, ONCOGENE, V4, P145; LIOTTA LA, 1986, CANCER RES, V46, P1; MCCANN AH, 1991, CANCER RES, V51, P3186; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MYERS RB, 1994, J NATL CANCER I, V86, P1140, DOI 10.1093/jnci/86.15.1140; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; NICOLSON G L, 1991, Current Opinion in Oncology, V3, P75, DOI 10.1097/00001622-199102000-00012; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113; SADASIVAN R, 1993, J UROLOGY, V150, P126, DOI 10.1016/S0022-5347(17)35413-7; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SCHOLAR EM, 1994, CANCER LETT, V87, P159, DOI 10.1016/0304-3835(94)90217-8; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; TAUCHI K, 1989, VIRCHOWS ARCH A, V416, P65, DOI 10.1007/BF01606471; TOIKKANEN S, 1992, J CLIN ONCOL, V10, P1044, DOI 10.1200/JCO.1992.10.7.1044; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; VELTRI RW, 1994, J CELL BIOCHEM, P249; VIJVER M, 1987, MOL CELL BIOL, V7, P2019; WEINER DB, 1990, CANCER RES, V50, P421; Xia WY, 1997, CLIN CANCER RES, V3, P3; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YOKOTA J, 1988, ONCOGENE, V2, P283; YOSHIDA K, 1989, VIRCHOWS ARCH B, V57, P285, DOI 10.1007/BF02899093; YU DH, 1991, ONCOGENE, V6, P1991; Yu DH, 1996, ONCOGENE, V13, P1359; YU DH, 1994, CANCER RES, V54, P3150; YUSA K, 1990, J NATL CANCER I, V82, P1633, DOI 10.1093/jnci/82.20.1633; ZHAN HE, 1990, MOL CARCINOGEN, V3, P254; ZHANG LS, 1995, CANCER RES, V55, P3890; Zhang LS, 1996, ONCOGENE, V12, P571; ZHANG X, 1989, ONCOGENE, V4, P985	46	101	110	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	1998	16	22					2855	2863		10.1038/sj.onc.1201813	http://dx.doi.org/10.1038/sj.onc.1201813			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671406	Bronze			2022-12-17	WOS:000073988200004
J	Li, JJ; Rhim, JS; Schlegel, R; Vousden, KH; Colburn, NH				Li, JJ; Rhim, JS; Schlegel, R; Vousden, KH; Colburn, NH			Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappa B transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes	ONCOGENE			English	Article						dominant negative c-Jun; transcription factor; HPV; transformation; human keratinocytes	HUMAN PAPILLOMAVIRUS TYPE-16; PROMOTER-INDUCED TRANSFORMATION; TRANSGENIC MICE; GENE-PRODUCT; C-JUN; MULTISTAGE CARCINOGENESIS; TRANSCRIPTION FACTORS; RESISTANT VARIANTS; EPIDERMAL-CELLS; JB6 CELLS	AP-1 transactivation appears to be required for mouse JB6 cell neoplastic transformation induced by the tumor promoter TPA or epidermal growth factor (EGF). Exposure to AP-1 transrepressing retinoids and glucocorticoids and expression of a dominant negative c-jun (TAM67) blocked tumor promoter-induced AP-1 transactivation and neoplastic transformation. The aim of the present study was to extend the inquiry of the role of AP-1 and other transcription factors to human neoplastic progression. Expression of human papilloma-virus (HPV) 16 or 18 E6 and E7 immortalizes human keratinocytes and inhibits serum/calcium-stimulated differentiation. Further transformation by v-fos coexpression renders these keratinocytes tumorigenic in nude mice. We have analysed two series of E6/E7 immortalized human keratinocyte cell lines that show progressing phenotypes ranging from differentiation sensitive to anchorage-independent to tumorigenic in nude mice. We analysed the activities of AP-1 and NF-kappa B which may 'cross-talk'. Both DNA binding and transactivation of AP-1 and NF-kappa B transcription factors showed elevation in the anchorage-independent (16RH) and tumorigenic (18 v-fos) keratinocyte lines compared to the less progressed but immortalized cell lines. HPV E7 was expressed at a constant level shown by quantitative RT-PCR in both the more and the less progressed lines, indicating that E7 is not the factor limiting this progression. Blocked shift/supershift analysis indicates that Fos family member proteins especially Fra-1 and Fra-2 are related to progression and no changes found in the Jun family member proteins although they are present in the AP-1/DNA binding complex. When a dominant negative mutant c-jun driven by a human keratin 14 promoter was cotransfected with AP-1 or NF-kappa B reporters, both AP-1 and NF-kappa B activities were suppressed in the more progressed cell lines 16RH add 18 v-fos but not in the less progressed 16RL or 18 cell lines. Overexpression of the same dominant negative c-jun did not inhibit p53 dependent reporter transactivation, indicating the specificity of inhibition of AP-1 and NF-kappa B transactivation in the HPV-immortalized cells. Stable transfectants of this mutant c-jun in the two more progressed cell lines 16RH and 18 v-fos showed reduced AP-1 and NF-kappa B activation and reduced anchorage-independent growth. Together, these results indicate that activation of AP-1, NF-kappa B or both may contribute to neoplastic progression in HPV immortalized human keratinocytes and that specific targeting of the elevated levels seen in benign or malignant tumors might be effective for prevention or treatment of human cancer.	NCI, Frederick Canc Res & Dev Ctr, Lab Biochem Physiol, Frederick, MD 21702 USA; Georgetown Univ, Washington, DC USA; NCI, Frederick Canc Res & Dev Ctr, ABL, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Li, JJ (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Lab Biochem Physiol, Frederick, MD 21702 USA.			Li, Jian Jian/0000-0003-3694-9675				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; CARROLL R, 1991, J VIROL, V65, P3460, DOI 10.1128/JVI.65.7.3460-3467.1991; CHEN TM, 1993, CANCER RES, V53, P1167; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; COLBURN NH, 1982, J CELL BIOCHEM, V18, P261, DOI 10.1002/jcb.1982.240180302; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CZEGLEDY J, 1994, INT J CANCER, V56, P182, DOI 10.1002/ijc.2910560206; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DRINKWATER NR, 1989, GENES SIGNAL TRANSDU, P3; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GREENHALGH DA, 1995, CELL GROWTH DIFFER, V6, P579; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; Joseloff E, 1997, MOL CARCINOGEN, V18, P26, DOI 10.1002/(SICI)1098-2744(199701)18:1<26::AID-MC4>3.0.CO;2-P; KEMP CJ, 1994, COLD SPRING HARB SYM, V59, P427, DOI 10.1101/SQB.1994.059.01.048; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; Li JJ, 1996, CANCER RES, V56, P483; Li JJ, 1997, CANCER RES, V57, P3569; LI JJ, 1995, ONCOGENE, V10, P1989; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; PEI XF, 1993, VIROLOGY, V196, P855, DOI 10.1006/viro.1993.1546; Rosenberger SF, 1996, ONCOGENE, V12, P2301; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STELLMACH V, 1991, P NATL ACAD SCI USA, V88, P4582, DOI 10.1073/pnas.88.11.4582; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WATTS RG, 1995, MOL CARCINOGEN, V13, P27, DOI 10.1002/mc.2940130106; WEINBERG RA, 1989, CANCER RES, V49, P3713; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wilding J, 1996, CANCER RES, V56, P5285; Yamagata T, 1997, MOL CELL BIOL, V17, P4272, DOI 10.1128/MCB.17.8.4272	49	101	104	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	1998	16	21					2711	2721		10.1038/sj.onc.1201798	http://dx.doi.org/10.1038/sj.onc.1201798			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652737				2022-12-17	WOS:000073812200002
J	Wang, HC; Shao, NS; Ding, QM; Cui, JQ; Reddy, ESP; Rao, VN				Wang, HC; Shao, NS; Ding, QM; Cui, JQ; Reddy, ESP; Rao, VN			BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases	ONCOGENE			English	Article						BRCA1a; BRCA1b; zinc finger; cyclins; CDKs; E2F	OVARIAN-CANCER INCIDENCE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; BREAST-CANCER; GENE-PRODUCT; EXPRESSION; LOCALIZATION; SEQUENCE; BINDING; CELL	BRCA1, a familial breast and ovarian canter susceptibility gene encodes nuclear phosphoproteins that function as tumor suppressors in human breast cancer cells, Previously, we have shown that overexpression of a BRCA1 splice variant BRCA1a accelerates apoptosis in human breast cancer cells, In an attempt to determine whether the subcellular localization of BRCA1 is cell cycle regulated, we have studied the subcellular distribution of BRCA1 in asynchronous and growth arrested normal, breast and ovarian cancer cells using different BRCA1 antibodies by immunofluorescence and immunohistochemical staining, Upon serum starvation of NIH3T3, some breast and ovarian cancer cells, most of the BRCA1 protein redistributed to the nucleus revealing a new type of regulation that may modulate the activity of BRCA1 gene, We have also characterized two new variant BRCA1 proteins (BRCA1a/p110 and BRCA1b/p100) which are phosphoproteins containing phosphotyrosine, Immunofluorescence and Western blotting analysis indicate cytoplasmic and nuclear localization of BRCA1a and BRCA1b proteins. To elucidate the biological function of BRCA1, we created a bacterial fusion protein of glutathione-transferase (GST) and BRCA1 zinc finger domain and detected two cellular proteins with molecular weights of approximately 32 and 65 kD, one of which contains phosphotyrosine designated p32 and p65 BRCA1 interacting proteins (BIP) that specifically interact with BRCA1, Western blot analysis of BIP with cyclins/CDKs and E2F antisera indicated association with cdc2, cdk2, cdk4, cyclin B, cyclin D, cyclin A and E2F-4 but not with cdk3, cdk5, cdk6, E2F-1, E2F-2, E2F-3, E2F-5 and cyclin E, Furthermore, we have also demonstrated a direct interaction of in vitro translated BRCA1a and BRCA1b proteins with recombinant cyclin A, cyclin B1, cyclin D1, cdc2, cdk2 and E2F fusion proteins in vitro, Taken together these results seem to suggest that BRCA1 could be an important negative regulator of cell cycle that functions through interaction with E2F transcriptional factors and phosphorylation by cyclins/cdk complexes with the zinc ring finger functioning as a major protein-protein interaction domain, If the interactions we observe in vitro is also seen in vivo then it may be possible that lack or impaired binding of the disrupted BRCA1 proteins to E2F, cyclins/CDKs in patients with mutations in the zinc finger domain could deprive the cell of an important mechanism for braking cell proliferation leading to the development of breast and ovarian cancers.	ALLEGHENY UNIV HLTH SCI, DEPT HUMAN GENET, DIV CANC GENET, PHILADELPHIA, PA 19102 USA	Drexel University					NCI NIH HHS [CA 57322, CA 51083, CA 50507] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083, P01CA050507, R01CA057322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, SCIENCE, V272, P125, DOI 10.1126/science.272.5258.125; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; EASTON DF, 1995, AM J HUM GENET, V56, P265; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FORD D, 1995, AM J HUM GENET, V57, P1457; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Rao VN, 1996, ONCOGENE, V12, P523; RAO VN, 1993, CANCER RES, V53, P3449; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Shao NS, 1996, ONCOGENE, V13, P1; SHARAN SK, 1995, HUM MOL GENET, V4, P2275, DOI 10.1093/hmg/4.12.2275; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SINGH H, 1989, BIOTECHNIQUES, V7, P252; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; WU CJ, 1996, NAT GENET, V14, P430	42	101	114	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	1997	15	2					143	157		10.1038/sj.onc.1201252	http://dx.doi.org/10.1038/sj.onc.1201252			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244350				2022-12-17	WOS:A1997XK37200003
J	Shtivelman, E				Shtivelman, E			A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma	ONCOGENE			English	Article						metastasis; apoptosis; SCLC	L-DOPA DECARBOXYLASE; C-MYC; DNA FRAGMENTATION; CANCER; EXPRESSION; GENE; IDENTIFICATION; AMPLIFICATION; CHROMOGRANIN; ENDOCRINE	A novel human gene CC3 with properties of a metastasis suppresor gene for small cell lung carcinoma (SCLC) is described. CC3 is an evolutionary conserved gene that is expressed ubiquitously in human tissues. CC3 RNA is absent in a subset of SCLC cell lines known as variant (V-SCLC) that are derived from tumors characterized by highly aggressive metastatic behavior. Introduction of CC3 into a variant SCLC line results in significant suppression of its metastasis in vivo. When deprived of growth factors in vitro, v-SCLC cells modified to express CC3 undergo rapid and massive cell death that at least partially could be ascribed to the activation of the apoptotic pathway. In addition, expression of CC3 in v-SCLC cells increases induction of apoptosis by chemoterapeutic drugs. Loss of CC3 in highly metastatic cells such as SCLC might render them resistant to death-inducing signals and thus help to ensure their survival under unfavorable conditions encountered in the metastatic process.			Shtivelman, E (corresponding author), CALIF PACIFIC MED CTR,GERALDINE BRUSH CANC RES INST,2330 CLAY ST,ROOM 201,SAN FRANCISCO,CA 94115, USA.				NATIONAL CANCER INSTITUTE [R01CA071422] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1CA71422-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AISNER SC, 1990, J CLIN ONCOL, V8, P402, DOI 10.1200/JCO.1990.8.3.402; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BISONETTE RP, 1992, NATURE, V359, P552; BUNN PA, 1985, BLOOD, V65, P764; CARNEY DN, 1988, SEMIN ONCOL, V15, P199; CARNEY DN, 1983, CANCER RES, V43, P2806; CARNEY DN, 1985, CANCER RES, V45, P2913; DEARING MP, 1990, J CLIN ONCOL, V8, P1042, DOI 10.1200/JCO.1990.8.6.1042; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GAZDAR AF, 1985, CANCER RES, V45, P2924; GAZDAR AF, 1988, CANCER RES, V48, P4078; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; IKEGAKI N, 1994, CANCER RES, V54, P6; JENSEN SM, 1990, CANCER RES, V50, P6068; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MORSTYN G, 1984, JNCI-J NATL CANCER I, V73, P801; RADICE PA, 1982, CANCER-AM CANCER SOC, V50, P2894, DOI 10.1002/1097-0142(19821215)50:12<2894::AID-CNCR2820501232>3.0.CO;2-G; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Reeve JG, 1996, BRIT J CANCER, V73, P1193, DOI 10.1038/bjc.1996.230; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHTIVELMAN E, 1995, P NATL ACAD SCI USA, V92, P4661, DOI 10.1073/pnas.92.10.4661; SIEFFER EJ, 1988, SEMIN ONCOL, V15, P278; WEIDENMANN B, 1986, P NATL ACAD SCI USA, V83, P3500	31	101	116	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 8	1997	14	18					2167	2173		10.1038/sj.onc.1201059	http://dx.doi.org/10.1038/sj.onc.1201059			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174052				2022-12-17	WOS:A1997WX93800005
J	Stachowiak, EK; Maher, PA; Tucholski, J; Mordechai, E; Joy, A; Moffett, J; Coons, S; Stachowiak, MK				Stachowiak, EK; Maher, PA; Tucholski, J; Mordechai, E; Joy, A; Moffett, J; Coons, S; Stachowiak, MK			Nuclear accumulation of fibroblast growth factor receptors in human glial cells - Association with cell proliferation	ONCOGENE			English	Article						FGF-2; FGF receptor; nuclear localization; cell proliferation; astrocytes; glioma	ENDOTHELIAL-CELLS; GENE-EXPRESSION; BINDING; MODULATION; FAMILY; FLG	In this study we describe the presence of high affinity FGF-2 binding sites in the nuclei of U251MG glioma cells (K-d=7 pM). Immunoprecipitation of total cell extracts with FGF receptor (FGFR) 1-4 antibodies showed that U251MG glioma cells express only FGFR1. [I-125]FGF-2 cross linking to nuclear extracts followed by FGFR1 immunoprecipitation showed that FGFR1 may account for the nuclear FGF-2 binding sites. Western blot analysis demonstrated the presence of 103, 118 kDa and small amounts of 145 kDa FGFR1 isoforms in the nuclei of glioma cells. All isoforms contain both the C-and N-terminal domains. Nuclear FGFR1 retains kinase activity, Immunocytochemistry using confocal microscopy showed specific FGFR1 immunoreactivity within the nuclear interior, In continuously proliferating glioma cells, nuclear FGFR1 is constitutively expressed, independent of cell density. In contrast, in nontransformed human astrocytes, nuclear FGFR1 levels fluctuate with the proliferative state of the cell. In quiescent, confluent astrocytes nuclear FGFR1 protein was depleted. An accumulation of nuclear FGFR1 was observed following the transition to a subconfluent, proliferating state, Transfection of a pcDNA3.1-FGFR1 expression vector into glioma cells that do not express FGFR1 resulted in the nuclear accumulation of FGFR1, increased cell proliferation, and stimulated transition from the G(0)/G(1) to the S-phase of the cell cycle, The increased proliferative rate was resistant to inhibition by the cell-impermeable FGF binding antagonist, myoinositol hexakis [dihydrogen phosphate], Our results suggest that the constitutive nuclear presence of FGFR1 contributes to the increased proliferation of glioma cells while the transient nuclear accumulation of FGFR1 in normal astrocytes may play a role in the transition to a reactive state.	BARROW NEUROL INST, PHOENIX, AZ 85013 USA; SCRIPPS RES INST, LA JOLLA, CA 92037 USA	Barrow Neurological Institute; Scripps Research Institute					NHLBI NIH HHS [HL49376-01A1] Funding Source: Medline; NINDS NIH HHS [NS28121] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS028121] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON BJ, 1994, GLIA, V11, P73, DOI 10.1002/glia.440110110; BERENS M E, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P46; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BINGER DD, 1981, J NEUROPATHOL EXP NE, V40, P201; BOYLE WJ, 1985, MOL CELL BIOL, V5, P3017, DOI 10.1128/MCB.5.11.3017; BRASAEMLE DL, 1988, BIOTECHNIQUES, V6, P418; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DRAPER NR, 1966, APPLIED REGRESSION A, P263; DUVERGER E, 1995, J CELL SCI, V108, P1325; ENG LF, 1992, PROG BRAIN RES, V94, P353; HANNEKEN A, 1995, J CELL BIOL, V128, P1221, DOI 10.1083/jcb.128.6.1221; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; Joy A, 1997, ONCOGENE, V14, P171, DOI 10.1038/sj.onc.1200823; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Latham KE, 1996, ONCOGENE, V12, P827; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MCCONNELL SK, 1988, BRAIN RES REV, V13, P1, DOI 10.1016/0165-0173(88)90002-1; MCMILLIAN MK, 1994, TRENDS NEUROSCI, V17, P138, DOI 10.1016/0166-2236(94)90086-8; Moffett J, 1996, P NATL ACAD SCI USA, V93, P2470, DOI 10.1073/pnas.93.6.2470; MORRISON RS, 1994, CANCER RES, V54, P2794; MORRISON RS, 1994, IN VITRO CELL DEV-AN, V30A, P783; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUBERT D, 1987, J CELL BIOL, V104, P635, DOI 10.1083/jcb.104.3.635; SHERMAN K, 1993, DEVELOPMENT, V24, P791; Stachowiak MK, 1996, MOL BIOL CELL, V7, P1299, DOI 10.1091/mbc.7.8.1299; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; WILKIE AOM, 1995, CURR BIOL, V5, P500; XU JM, 1992, J BIOL CHEM, V267, P17792	41	101	103	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	1997	14	18					2201	2211		10.1038/sj.onc.1201057	http://dx.doi.org/10.1038/sj.onc.1201057			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174056				2022-12-17	WOS:A1997WX93800009
J	Wick, W; Petersen, I; Schmutzler, RK; Wolfarth, B; Lenartz, D; Bierhoff, E; Hummerich, J; Muller, DJ; Stangl, AP; Schramm, J; Wiestler, OD; vonDeimling, A				Wick, W; Petersen, I; Schmutzler, RK; Wolfarth, B; Lenartz, D; Bierhoff, E; Hummerich, J; Muller, DJ; Stangl, AP; Schramm, J; Wiestler, OD; vonDeimling, A			Evidence for a novel tumor suppressor gene on chromosome 15 associated with progression to a metastatic stage in breast cancer	ONCOGENE			English	Article						tumor suppressor gene; breast carcinoma; metastasis; allelic loss; chromosome 15	CELL CARCINOMA; ALLELOTYPE; THROMBOSPONDIN; NM23; HETEROZYGOSITY; ANGIOGENESIS; INHIBITION; EXPRESSION	Loss of heterozygosity (LOH) studies have emerged as a valuable indicator for tumor suppressor genes involved in the formation or progression of carcinomas. We here present data indicating that human chromosome 15 harbours a novel putative tumor suppressor gene which appears to play a role during later stages of carcinogenesis and which may be associated with metastasis in breast cancer. In this study, 153 primary and metastatic carcinomas from 101 patients have been analysed for LOH with 13 polymorphic microsatellite markers on chromosome 15. The tumors included carcinoma of the lung in 49 patients, breast carcinoma in 29, colorectal carcinoma in nine, renal carcinoma in five, pancreatic carcinoma in five, urinary bladder carcinoma in two and prostate carcinoma and ovarial carcinoma in one patient each. LOH15 was seen in 42/99 (42%) informative patients. Tn metastatic tumors, LOH15 was observed in 37/68 (54%). High incidences of allelic losses were detected in metastases from lung (56%), breast (70%) and colorectal (67%) carcinomas. In carcinomas of the breast, there was a significant difference (P<0.01) in LOH15 frequencies between non-metastatic tumors (11%) and brain metastases (70%). Such a difference was not observed on the chromosomal arm 17p which yielded high proportions of LOH in both non metastatic breast tumor (73%) and breast carcinoma metastases (90%). In 16 patients, interstitial deletions could be detected. The common region of overlap extended from D15S231 to D15S641, thus mapping this putative tumor suppressor gene to chromosome 15q14. Our data indicate that a gene on chromosome 15 contributes to the pathogenesis of metastatic carcinoma.	UNIV BONN,MED CTR,DEPT NEUROPATHOL,D-53105 BONN,GERMANY; CHARITE,DEPT PATHOL,BERLIN,GERMANY; UNIV BONN,MED CTR,DEPT OBSTET & GYNECOL,D-53105 BONN,GERMANY; UNIV HOSP FREIBURG,INST PATHOL,FREIBURG,GERMANY; HOSP COLOGNE MERHEIM,DEPT NEUROSURG,D-51109 COLOGNE,GERMANY; UNIV HOSP BONN,DEPT PATHOL,D-53105 BONN,GERMANY; UNIV HOSP BONN,DEPT NEUROSURG,D-53105 BONN,GERMANY	University of Bonn; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Bonn; University of Freiburg; University of Bonn; University of Bonn			Müller, Daniel J./L-4159-2016; Wick, Wolfgang/AAA-2545-2020; Mueller, Daniel Josef/GVT-7899-2022; von Deimling, Andreas/F-7774-2013	Müller, Daniel J./0000-0003-4978-4400; Wick, Wolfgang/0000-0002-6171-634X; Mueller, Daniel Josef/0000-0003-4978-4400; von Deimling, Andreas/0000-0002-5863-540X				BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V170, P867, DOI 10.1016/0006-291X(90)92171-U; BENDER B, 1994, BIOTECHNIQUES, V16, P204; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BOUKAMP P, 1995, ONCOGENE, V11, P961; BUDOWLE B, 1991, AM J HUM GENET, V48, P137; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CLIBY W, 1993, CANCER RES, V53, P2393; DEVILEE P, 1991, ONCOGENE, V6, P1705; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; FUJIMORI M, 1991, CANCER RES, V51, P89; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HAHN M, 1993, CLIN CHEM, V39, P549; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEONE A, 1991, CANCER RES, V51, P2490; LOUIS DN, 1992, AM J PATHOL, V141, P777; MORITA R, 1991, CANCER RES, V51, P820; RASHEED BKA, 1995, ONCOGENE, V10, P2243; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; Sambrook J., 1989, MOL CLONING; SATO S, 1994, CANCER RES, V54, P5652; SATO T, 1990, CANCER RES, V50, P7184; SHISEKI M, 1994, CANCER RES, V54, P5643; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VONDEIMLING A, 1993, NEUROPATH APPL NEURO, V19, P524; VONDEIMLING A, 1994, INT J CANCER, V57, P676, DOI 10.1002/ijc.2910570511; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504	32	101	104	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					973	978						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649814				2022-12-17	WOS:A1996UA88400004
J	PRAML, C; FINKE, LH; HERFARTH, C; SCHLAG, P; SCHWAB, M; AMLER, L				PRAML, C; FINKE, LH; HERFARTH, C; SCHLAG, P; SCHWAB, M; AMLER, L			DELETION MAPPING DEFINES DIFFERENT REGIONS IN 1P34.2-PTER THAT MAY HARBOR GENETIC INFORMATION RELATED TO HUMAN COLORECTAL-CANCER	ONCOGENE			English	Article						CHROMOSOME 1; LOSS OF HETEROZYGOSITY (LOH); MICROSATELLITE; MOM1; TUMOR SUPPRESSOR-GENE	MULTIPLE INTESTINAL NEOPLASIA; FAMILIAL ADENOMATOUS POLYPOSIS; HUMAN CHROMOSOME-1; COLON-CARCINOMA; CELL-LINE; SHORT ARM; IDENTIFICATION; TUMORS; MOUSE; LOCUS	Cytogenetic and molecular analyses of colorectal cancer cells have revealed deletions at 1p as prominent alterations, suggesting that genetic information on the short arm of chromosome 1 has a role in tumorigenesis. In this study we have used 33 microsatellite markers to fine map deletions at 1p in primary colorectal carcinomas. We found 1p-deletions in 84% of the cases (31/37). High frequencies of loss of heterozygosity (LOH), often the result of small independent interstitial deletions in the same tumor, defined three regions, that may harbor genetic information relevant for colorectal cancer: (i) region A between D1S243 and D1S468 (7cM; 1p36.3); (ii) region B between D1S436 and D1S199 (7cM; 1p35.1-36.31) and (iii) region C between D1S496 and D1S255 (1cM; 1p34.2-35). In addition we identified seven cell lines with LOH at 1p, all of which have deletions that span at least from the distal border of region A to the proximal border of region C.	MDC, UKVR ROBERT ROSSLE KLIN, CHIRURG ONKOL ABT, D-13122 BERLIN, GERMANY; UNIV HEIDELBERG, CHIRURG KLIN, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg	PRAML, C (corresponding author), GERMAN CANC RES CTR, DEPT CYTOGENET 0130, NEUENHEIMER FELD 280, D-69120 HEIDELBERG, GERMANY.							AMLER LC, 1995, ONCOGENE, V10, P1095; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARDI G, 1993, CANCER RES, V53, P1895; BARDI G, 1995, GENE CHROMOSOME CANC, V12, P97, DOI 10.1002/gcc.2870120204; BOMME L, 1994, GENE CHROMOSOME CANC, V10, P190, DOI 10.1002/gcc.2870100307; BRUDERLEIN S, 1990, GENE CHROMOSOME CANC, V2, P63, DOI 10.1002/gcc.2870020112; CHENG NC, 1995, ONCOGENE, V10, P291; COUTURIERTURPIN MH, 1992, HUM GENET, V88, P431, DOI 10.1007/BF00215678; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DRACOPOLI NC, 1994, CYTOGENET CELL GENET, V67, P143, DOI 10.1159/000133816; ENGELSTEIN M, 1993, GENOMICS, V15, P251, DOI 10.1006/geno.1993.1054; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LEISTER I, 1990, CANCER RES, V50, P7232; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; MARTH JD, 1986, P NATL ACAD SCI USA, V83, P7400, DOI 10.1073/pnas.83.19.7400; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MIYAKI M, 1990, CANCER RES, V50, P7166; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; NADEAU JH, 1991, MAMM GENOME, V1, P461; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; REICHMANN A, 1984, CANCER GENET CYTOGEN, V12, P295, DOI 10.1016/0165-4608(84)90062-1; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; TANAKA K, 1993, ONCOGENE, V8, P2253; VANROY N, 1993, GENOMICS, V18, P71, DOI 10.1006/geno.1993.1427; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOLPI EV, 1994, CYTOGENET CELL GENET, V67, P187, DOI 10.1159/000133819; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; YANGFENG TL, 1985, AM J HUM GENET, V37, P1117; YANOSHITA R, 1992, CANCER RES, V52, P3965; YOUNG J, 1994, ONCOGENE, V9, P1053; YOUNG J, 1992, CANCER RES, V52, P285	42	101	104	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1357	1362						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478557				2022-12-17	WOS:A1995RY96700017
J	LEBWOHL, DE; MUISEHELMERICKS, R; SEPPLORENZINO, L; SERVE, S; TIMAUL, M; BOL, R; BORGEN, P; ROSEN, N				LEBWOHL, DE; MUISEHELMERICKS, R; SEPPLORENZINO, L; SERVE, S; TIMAUL, M; BOL, R; BORGEN, P; ROSEN, N			A TRUNCATED CYCLIN D1 GENE ENCODES A STABLE MESSENGER-RNA IN A HUMAN BREAST-CANCER CELL-LINE	ONCOGENE			English	Article							GROWTH-FACTORS; MESSENGER-RNA; MOLECULAR-CLONING; HUMAN-TUMORS; BCL-1 GENE; AMPLIFICATION; EXPRESSION; HST; CARCINOMAS; ONCOGENE	The G1 cyclin D1 is amplified in approximately 20% of human breast cancers and is frequently overexpressed as part of an amplicon in these tumors, suggesting a potential role for this gene in the pathogenesis of breast cancer. Although amplification of cyclin D1 occurs in human breast cancer, it is possible that another gene in the amplicon is the relevant oncogene in these cancers. We now report a truncation of the cyclin D1 gene in a human breast cancer cell line, associated with overexpression of a short cyclin D1 mRNA. In a survey of breast cancer cell lines and tumors by Southern blot hybridization, using a 1.2 kb human cyclin D1 cDNA, we observed that genomic DNA derived from the MDA MB-453 cell line contains an extra band in the Bg1II and BamHI digests, suggesting that one allele of gene is altered. Moreover, the altered allele is amplified three-fold relative to the normal allele, and contains a 3' deletion. On Northern analysis, the MDA MB-453 line has a marked increase in 1.1 to 1.3 kb transcripts, which are truncated at the 3' end, in contrast to the normally predominant 4.2 kb transcript. The 1.1 - 1.3 kb cyclin D1 mRNA has a longer half-life than the 4.2 kb mRNA, indicating that the 3' truncation may contribute an increased stability and therefore an elevated steady-state level of the short mRNA. These alterations in the cyclin D1 gene and mRNA suggest that altered expression of cyclin D1 may be important in the malignant transformation of this cell line, and support the identification of cyclin D1 as a dominant oncogene at 11q13 in human breast cancer.	MEM SLOAN KETTERING CANC CTR, DEPT SURG, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	LEBWOHL, DE (corresponding author), MEM SLOAN KETTERING CANC CTR, DEPT MED, 1275 YORK AVE, NEW YORK, NY 10021 USA.		Rosen, Neal/ABF-2677-2020					ALI IU, 1989, ONCOGENE, V4, P89; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; CULLEN KJ, 1991, CANCER INVEST, V9, P443, DOI 10.3109/07357909109084643; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FAUST JB, 1992, CANCER RES, V52, P2460; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAMMIE GA, 1991, ONCOGENE, V6, P439; LIPPMAN ME, 1989, RECENT PROG HORM RES, V45, P383; LISCIA DS, 1989, ONCOGENE, V4, P1219; Maniatis T., 1982, MOL CLONING; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHUURING E, 1992, ONCOGENE, V7, P355; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; THEILLET C, 1989, ONCOGENE, V4, P915; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	29	101	101	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					1925	1929						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208539				2022-12-17	WOS:A1994NR68500016
J	MAISONPIERRE, PC; BARREZUETA, NX; YANCOPOULOS, GD				MAISONPIERRE, PC; BARREZUETA, NX; YANCOPOULOS, GD			EHK-1 AND EHK-2 - 2 NOVEL MEMBERS OF THE EPH RECEPTOR-LIKE TYROSINE KINASE FAMILY WITH DISTINCTIVE STRUCTURES AND NEURONAL EXPRESSION	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTORS; CENTRAL-NERVOUS-SYSTEM; CONSERVED FEATURES; MOLECULAR-CLONING; PROTEIN-KINASES; TRK FAMILY; C-KIT; GENE; IDENTIFICATION; CELLS	We have identified two novel members of the Eph RTK family, termed Ehk (eph homology kinase) -1 and -2. Compared to the amino acid sequences of various Eph family members, Ehk-1 and Ehk-2 are closest to the Sek and Cek-4/Mek-4/Hek kinases, and both are more similar to the Elk kinase than they are to the Eck or Eph kinases. Analysis of Ehk-1 cDNAs from various brain libraries reveals alternatively spliced transcripts: that can encode five different forms of Ehk-1 transmembrane proteins. By contrast, Ehk-2 cDNAs revealed only a single form of protein coding region. However, the structure of Ehk-2 differs from all known members of the Eph family based on a 42 amino acid insert positioned between homology regions IV and V in the kinase domain. Ehk-1 and Ehk-2 are almost exclusively expressed in the nervous system. RNA in situ hybridization analyses on adult brain show that the Ehks are predominantly expressed in neurons and display overlapping, but distinct patterns of expression in various neuronal populations.			MAISONPIERRE, PC (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOYD AW, 1992, J BIOL CHEM, V267, P3262; Brownstein MJ, 1984, HDB CHEM NEUROANAT 1, P23; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHAN J, 1991, ONCOGENE, V6, P1057; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAUB O, 1990, P NATL ACAD SCI USA, V87, P8022, DOI 10.1073/pnas.87.20.8022; Hefti F., 1993, NEUROTROPHIC FACTORS, P25; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUGHES RA, 1993, NEURON, V10, P369, DOI 10.1016/0896-6273(93)90327-N; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KILPATRICK TJ, 1993, NEURON, V10, P255, DOI 10.1016/0896-6273(93)90316-J; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LINDSAY RM, 1993, NEUROTROPHIC FACTORS, P257; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MOTRO B, 1991, DEVELOPMENT, V113, P1207; Nei M., 1987, MOL EVOLUTIONARY GEN; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; SAJJADI FG, 1991, NEW BIOL, V3, P769; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	101	118	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3277	3288						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	7504232				2022-12-17	WOS:A1993MG78200011
J	TARUNINA, M; JENKINS, JR				TARUNINA, M; JENKINS, JR			HUMAN P53 BINDS DNA AS A PROTEIN HOMODIMER BUT MONOMERIC VARIANTS RETAIN FULL TRANSCRIPTION TRANSACTIVATION ACTIVITY	ONCOGENE			English	Article							WILD-TYPE P53; CELLULAR TUMOR-ANTIGEN; MONOCLONAL-ANTIBODIES; T-ANTIGEN; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; ONCOGENE PRODUCT; GENE; SEQUENCE; AMPLIFICATION	Wild-type human p53 protein is able to self-associate and consists predominantly of homotetramers in solution. In earlier work we identified the protein sequence motifs involved in p53 quaternary structure and showed that while monomeric p53 protein retains tumour suppressor function, monomeric tumour mutant p53 lacks dominant transforming activity. In this report we use point mutated and truncated cDNA genes encoding self-association defective human p53 proteins to investigate the relationship between p53 protein quaternary structure and the associated activities of transcription transactivation and target specific DNA binding. We show that p53 binds to a target oligonucleotide as a protein homodimer and that p53 dimerisation is required for detectable DNA binding. We found no evidence for p53 tetramer:DNA complexes and we suggest that the quaternary structure status of p53 may regulate a DNA binding associated activity. Monomeric p53 proteins failed to bind DNA in these assays but exhibited increased transactivating activity. Thus, both transcription transactivation and tumour suppressor functions act independently of p53 protein self-association and DNA binding. We propose that our results validate the p53 dimerisation motif as a target for rational anticancer drug design. We predict that compounds able to block p53 dimer assembly would inhibit the dominant transforming activities of mutant p53 in tumours retaining expression of a mutant allele, while leaving intact the wild-type p53 associated activities of transcription transactivation and transformation suppression in unaffected tissue.	MARIE CURIE RES INST, CELL PROLIFERAT LAB, OXTED RH8 0TL, SURREY, ENGLAND									ADDISON C, 1990, ONCOGENE, V5, P423; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BRAIN R, 1993, UNPUB; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CARDER P, 1993, ONCOGENE, V8, P1397; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHUMAKOV P, 1990, J CELL BIOCH S14C, V106, P269; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DAVID YB, 1988, ONCOGENE, V3, P179; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JENKINS JR, 1988, ONCOGENE HDB, P403; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KUBERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MURTHY SCS, 1985, P NATL ACAD SCI USA, V82, P2230, DOI 10.1073/pnas.82.8.2230; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; ROVINSKI B, 1988, ONCOGENE, V2, P445; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHMEIG F, 1988, VIROLOGY, V194, P132; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	59	101	102	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					3165	3173						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414520				2022-12-17	WOS:A1993MC09300035
J	BERBERICH, S; HYDEDERUYSCHER, N; ESPENSHADE, P; COLE, M				BERBERICH, S; HYDEDERUYSCHER, N; ESPENSHADE, P; COLE, M			MAX ENCODES A SEQUENCE-SPECIFIC DNA-BINDING PROTEIN AND IS NOT REGULATED BY SERUM GROWTH-FACTORS	ONCOGENE			English	Note							MAJOR LATE PROMOTER; TRANSCRIPTION FACTOR; MYC; DAUGHTERLESS; EXPRESSION; UPSTREAM; MYOD; GENE	Max and c-Myc proteins, produced in bacteria, were studied for DNA-binding activity using the electrophoretic band-shift assay (EMSA). Both Max homodimers and c-Myc-Max heterodimers selected the same sequence CA(C/T)GTG from an initial pool of 10(6) DNA molecules. From the pool of sequence-specific binding sites, the palindromic site (CACGTG) was preferentially selected over the CATGTG site using two different degenerate oligonucleotide probes. max expression is identical in myc-induced tumor cell lines relative to other cells. Furthermore, max expression is constant in both confluent and serum-stimulated A31 fibroblasts, in contrast to c-myc expression, which is barely detectable in confluent fibroblasts and induced 20-fold by serum growth factors. Based on recognition of the same DNA sequence by Max and c-Myc-Max complexes and differential expression of the two genes, we propose that Max homodimers and c-Myc-Max heterodimers may bind to a common set of cellular target genes.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University					NIGMS NIH HHS [GM14675-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CLINE TW, 1989, CELL, V59, P231, DOI 10.1016/0092-8674(89)90280-8; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	17	101	102	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					775	779						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565473				2022-12-17	WOS:A1992HQ68200022
J	VENTER, DJ; BEVAN, KL; LUDWIG, RL; RILEY, TEW; JAT, PS; THOMAS, DGT; NOBLE, MD				VENTER, DJ; BEVAN, KL; LUDWIG, RL; RILEY, TEW; JAT, PS; THOMAS, DGT; NOBLE, MD			RETINOBLASTOMA GENE DELETIONS IN HUMAN GLIOBLASTOMAS	ONCOGENE			English	Article							GENOMIC ORGANIZATION; SUSCEPTIBILITY GENE; OSTEO-SARCOMA; HUMAN DNA; NEOPLASMS; TUMORS; CANCER	The retinoblastoma susceptibility gene, RB, is the best characterised of the tumour suppressor genes, or 'anti-oncogenes'. Abnormal function of the RB protein is thought to result in loss of an inhibitory effect on cell growth, and thus contribute towards the development of certain human cancers. One group of human cancers of particular interest in relationship to retinoblastoma gene function are the gliomas, which are central nervous system tumours thought to originate from the neuroectoderm, the embryological tissue which also gives rise to retinoblastomas. We have therefore examined a group of benign and malignant gliomas for evidence of structural alterations of the RB gene. Four out of nine (44%) glioblastomas, the most malignant gliomas, showed loss of heterozygosity of a locus within this gene. In addition, one of these hemizygous tumours showed deletion of part of the RB protein-coding region, and this abnormality was also present in cells cultured from the tumour. These findings suggest that RB gene abnormalities may contribute to the development of glioblastomas.	LUDWIG INST CANC RES,91 RIDING HOUSE ST,LONDON W1P 8BT,ENGLAND	Ludwig Institute for Cancer Research								ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; BIGNER SH, 1986, CANCER GENET CYTOGEN, V22, P121, DOI 10.1016/0165-4608(86)90172-X; BOOKSTEIN R, 1988, P NATL ACAD SCI USA, V85, P2210, DOI 10.1073/pnas.85.7.2210; CAVANEE WK, 1983, NATURE, V305, P779; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MEADOWS AT, 1985, J CLIN ONCOL, V3, P532, DOI 10.1200/JCO.1985.3.4.532; MIDDLETON PG, 1986, NUCLEIC ACIDS RES, V14, P1925, DOI 10.1093/nar/14.4.1925; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; REISSMANN PT, 1989, ONCOGENE, V4, P839; REY JA, 1987, CANCER GENET CYTOGEN, V29, P201, DOI 10.1016/0165-4608(87)90232-9; ROARTY JD, 1988, OPHTHALMOLOGY, V95, P1583; SEEMAYER TA, 1989, LAB INVEST, V60, P585; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; TANG A, 1989, ONCOGENE, V4, P401; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x	27	101	101	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					445	448						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011399				2022-12-17	WOS:A1991FT34400014
J	MORISHITA, K; PARGANAS, E; DOUGLASS, EC; IHLE, JN				MORISHITA, K; PARGANAS, E; DOUGLASS, EC; IHLE, JN			UNIQUE EXPRESSION OF THE HUMAN EVI-1 GENE IN AN ENDOMETRIAL CARCINOMA CELL-LINE - SEQUENCE OF CDNAS AND STRUCTURE OF ALTERNATIVELY SPLICED TRANSCRIPTS	ONCOGENE			English	Article									ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital					NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P6687, DOI 10.1073/pnas.82.19.6687; IHLE JN, 1984, ADV VIRAL ONCOL, V4, P95; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KURAMOTO H, 1972, Acta Obstetrica et Gynaecologica Japonica (English Edition), V19, P47; KURAMOTO H, 1972, AM J OBSTET GYNECOL, V114, P1012, DOI 10.1016/0002-9378(72)90861-7; Maniatis T., 1982, MOL CLONING; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MORISHITA K, 1990, ONCOGENE RES, V5, P221; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0	18	101	105	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					963	971						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	2115646				2022-12-17	WOS:A1990DP41500003
J	De Marchi, E; Orioli, E; Pegoraro, A; Sangaletti, S; Portararo, P; Curti, A; Colombo, MP; Di Virgilio, F; Adinolfi, E				De Marchi, Elena; Orioli, Elisa; Pegoraro, Anna; Sangaletti, Sabina; Portararo, Paola; Curti, Antonio; Colombo, Mario Paolo; Di Virgilio, Francesco; Adinolfi, Elena			The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment	ONCOGENE			English	Article							P2X(7) RECEPTOR; INCREASES; CANCER; OX40; MICROVESICLES; INFLAMMATION; STIMULATION; MACROPHAGES; INVOLVEMENT; PANNEXIN-1	In the tumor microenvironment (TME) ATP and its receptor P2X7 exert a pivotal influence on cancer growth and tumor-host interactions. Here we analyzed the different effect of P2X7 genetic deficiency versus its antagonism on response against P2X7-expressing implanted tumors. We focused on immune cell expression of ATP degrading enzymes CD39 and CD73 and in vivo measured TME's ATP. The immune infiltrate of tumors growing in P2X7 null mice shows a decrease in CD8(+) cells and an increased number of Tregs, overexpressing the fitness markers OX40, PD-1, and CD73. A similar Treg phenotype is also present in the spleen of tumor-bearing P2X7 null mice and it is paralleled by a decrease in proinflammatory cytokines and an increase in TGF-beta. Differently, systemic administration of the P2X7 blocker A740003 in wild-type mice left unaltered the number of tumor-infiltrating CD8(+) and Treg lymphocytes but increased CD4(+) effector cells and decreased their expression of CD39 and CD73. P2X7 blockade did not affect spleen immune cell composition or ectonucleotidase expression but increased circulating INF-gamma. Augmented CD73 in P2X7 null mice was mirrored by a decrease in TME ATP concentration and nucleotide reduced secretion from immune cells. On the contrary, TME ATP levels remained unaltered upon P2X7 antagonism, owing to release of ATP from cancerous cells and diminished ectonucleotidase expression by CD4(+) and dendritic cells. These data point at P2X7 receptor as a key determinant of TME composition due to its combined action on immune cell infiltrate, ectonucleotidases, and ATP release.	[De Marchi, Elena; Orioli, Elisa; Pegoraro, Anna; Di Virgilio, Francesco; Adinolfi, Elena] Univ Ferrara, Sect Pathol Oncol & Expt Biol, Dept Morphol Surg & Expt Med, Via Luigi Borsari 46, I-44121 Ferrara, Italy; [Sangaletti, Sabina; Portararo, Paola; Colombo, Mario Paolo] Ist Nazl Tumori IRCCS, Mol Immunol Unit, Dept Expt Oncol, Via Amadeo 42, I-20133 Milan, Italy; [Curti, Antonio] Univ Bologna, S Orsola Malpighi Hosp, Inst Hematol L & A Seragnoli, Dept Expt Diagnost & Specialty Med, Via Massarenti 9, I-40138 Bologna, Italy	University of Ferrara; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna	Adinolfi, E (corresponding author), Univ Ferrara, Sect Pathol Oncol & Expt Biol, Dept Morphol Surg & Expt Med, Via Luigi Borsari 46, I-44121 Ferrara, Italy.	elena.adinolfi@unife.it	Portararo, Paola/P-8231-2019; Curti, Antonio/AAB-9461-2019; Colombo, Mario P./V-7166-2017; Pegoraro, Anna/AAV-7894-2021; Sangaletti, Sabina/AAB-5873-2019; Pegoraro, Anna/AAC-4573-2022; Di Virgilio, Francesco/J-3754-2018; Adinolfi, Elena/F-9169-2010; DI VIRGILIO, Francesco/O-4634-2019	Portararo, Paola/0000-0003-0085-6901; Curti, Antonio/0000-0002-7752-6049; Colombo, Mario P./0000-0003-0042-7955; Sangaletti, Sabina/0000-0001-7047-287X; Di Virgilio, Francesco/0000-0003-3566-1362; Adinolfi, Elena/0000-0001-8129-9929; DI VIRGILIO, Francesco/0000-0003-3566-1362; Pegoraro, Anna/0000-0002-7045-5161; De Marchi, Elena/0000-0003-0064-4335	Italian Association for Cancer Research Investigator Grant (AIRC) [IG 16812, IG 13025, IG 18581]	Italian Association for Cancer Research Investigator Grant (AIRC)(Fondazione AIRC per la ricerca sul cancro)	The authors thank Marzia Scarletti, Federica Poletti, and Asia Milani for technical assistance. This study was funded by an Italian Association for Cancer Research Investigator Grant to EA (AIRC, IG 16812) and to FDV (AIRC, IG 13025 and IG 18581).	Adinolfi E, 2005, MOL BIOL CELL, V16, P3260, DOI 10.1091/mbc.E04-11-1025; Adinolfi E, 2018, BIOCHEM PHARMACOL, V151, P234, DOI 10.1016/j.bcp.2017.12.021; Adinolfi E, 2015, CANCER RES, V75, P635, DOI 10.1158/0008-5472.CAN-14-1259; Adinolfi E, 2012, CANCER RES, V72, P2957, DOI 10.1158/0008-5472.CAN-11-1947; Adinolfi E, 2010, FASEB J, V24, P3393, DOI 10.1096/fj.09-153601; Adinolfi E, 2009, J BIOL CHEM, V284, P10120, DOI 10.1074/jbc.M805805200; Allard B, 2017, IMMUNOL REV, V276, P121, DOI 10.1111/imr.12528; Allard D., 2018, IMMUNOL LETT; Amores-Iniesta J, 2017, CELL REP, V21, P3414, DOI 10.1016/j.celrep.2017.11.079; Amoroso F, 2015, ONCOGENE, V34, P5240, DOI 10.1038/onc.2014.444; Amoroso F, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.105; Amoroso F, 2016, ONCOTARGET, V7, P49664, DOI 10.18632/oncotarget.10430; Anderson KG, 2017, CANCER CELL, V31, P311, DOI 10.1016/j.ccell.2017.02.008; Savio LEB, 2017, MOL NEUROBIOL, V54, P6459, DOI 10.1007/s12035-016-0168-9; Baroni M, 2007, FASEB J, V21, P1926, DOI 10.1096/fj.06-7238com; Buchan SL, 2018, BLOOD, V131, P39, DOI 10.1182/blood-2017-07-741025; Castro F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00847; Colombo MP, 2017, CLIN CANCER RES, V23, P5999, DOI 10.1158/1078-0432.CCR-17-2332; De Marchi E, 2016, ADV PROTEIN CHEM STR, V104, P39, DOI 10.1016/bs.apcsb.2015.11.004; Di Virgilio F, 2017, ONCOGENE, V36, P293, DOI 10.1038/onc.2016.206; Di Virgilio F, 2018, NAT REV CANCER, V18, P601, DOI 10.1038/s41568-018-0037-0; Di Virgilio F, 2017, IMMUNITY, V47, P15, DOI 10.1016/j.immuni.2017.06.020; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Furler RL, 2018, CANCERS, V10, DOI 10.3390/cancers10060199; Giannuzzo A, 2016, INT J CANCER, V139, P2540, DOI 10.1002/ijc.30380; Giuliani AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107224; Gulinelli S, 2012, EUR J IMMUNOL, V42, P3334, DOI 10.1002/eji.201142268; Hattori F, 2012, EUR J PHARMACOL, V695, P20, DOI 10.1016/j.ejphar.2012.09.001; Hofman P, 2015, CANCER RES, V75, P835, DOI 10.1158/0008-5472.CAN-14-1778; Honore P, 2006, J PHARMACOL EXP THER, V319, P1376, DOI 10.1124/jpet.106.111559; Hyman MC, 2009, J CLIN INVEST, V119, P1136, DOI 10.1172/JCI36433; Janssen B, 2014, J LABELLED COMPD RAD, V57, P509, DOI 10.1002/jlcr.3206; Kepp O, 2017, IMMUNOL REV, V280, P83, DOI 10.1111/imr.12571; Kuhny M, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0040-3; Lecciso M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01918; Lemaire I, 2006, J IMMUNOL, V177, P7257, DOI 10.4049/jimmunol.177.10.7257; Lemaire I, 2011, J IMMUNOL, V187, P3878, DOI 10.4049/jimmunol.1002780; Levesque SA, 2010, EUR J IMMUNOL, V40, P1473, DOI 10.1002/eji.200939741; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Orioli E, 2017, CURR MED CHEM, V24, P2261, DOI 10.2174/0929867324666170303161659; Pellegatti P, 2005, MOL BIOL CELL, V16, P3659, DOI 10.1091/mbc.E05-03-0222; Pellegatti P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002599; Piconese S, 2010, EUR J IMMUNOL, V40, P2902, DOI 10.1002/eji.201040505; Pietrocola F, 2016, CANCER CELL, V30, P147, DOI 10.1016/j.ccell.2016.05.016; Pizzirani C, 2007, BLOOD, V109, P3856, DOI 10.1182/blood-2005-06-031377; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Salaro E, 2016, SCI REP-UK, V6, DOI 10.1038/srep26280; Shitara K, 2018, ANN NY ACAD SCI, V1417, P104, DOI 10.1111/nyas.13625; Syberg S, 2012, J OSTEOPOROS, V2012, DOI 10.1155/2012/391097; Vandenabeele P, 2016, ADV EXP MED BIOL, V930, P133, DOI 10.1007/978-3-319-39406-0_6; Vijayan D, 2017, NAT REV CANCER, V17, P765, DOI 10.1038/nrc.2017.110; Wilhelm K, 2010, NAT MED, V16, P1434, DOI 10.1038/nm.2242; Yang DH, 2015, IMMUNITY, V43, P923, DOI 10.1016/j.immuni.2015.10.009; Younas M, 2013, J IMMUNOL, V191, P3161, DOI 10.4049/jimmunol.1203547; 2018, NATURE, V559, P264, DOI DOI 10.1038/S41586-018-0282-0	55	100	100	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3636	3650		10.1038/s41388-019-0684-y	http://dx.doi.org/10.1038/s41388-019-0684-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30655604	hybrid, Green Published			2022-12-17	WOS:000467379600006
J	van Staalduinen, J; Baker, D; ten Dijke, P; van Dam, H				van Staalduinen, Jente; Baker, David; ten Dijke, Peter; van Dam, Hans			Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?	ONCOGENE			English	Review							E-CADHERIN EXPRESSION; REPRESSES E-CADHERIN; REGULATES E-CADHERIN; EMT-ACTIVATOR ZEB1; BREAST-CANCER; DRUG-RESISTANCE; OVARIAN-CANCER; PD-L1 EXPRESSION; CISPLATIN-RESISTANCE; PROMOTES METASTASIS	Chemoresistance remains a major complication of cancer treatments. Recent data provide strong evidence that chemoresistance is linked to epithelial-mesenchymal transition (EMT), a latent developmental process, which is reactivated during cancer progression. EMT involves transcriptional reprogramming and is driven by specific EMT transcription factors (EMT-TFs). In this review, we provide support for the idea that EMT-TFs contribute to the development of resistance against cancer therapy and discuss how EMT-TFs might be targeted to advance novel therapeutic approaches to the treatment of cancer.	[van Staalduinen, Jente; Baker, David; ten Dijke, Peter; van Dam, Hans] Leiden Univ, Med Ctr, Oncode Inst, Dept Cell & Chem Biol, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	ten Dijke, P (corresponding author), Leiden Univ, Med Ctr, Oncode Inst, Dept Cell & Chem Biol, Leiden, Netherlands.	p.ten_dijke@lumc.nl	Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; van Dam, Hans/0000-0002-8307-4325	Cancer Genomics Centre Netherlands	Cancer Genomics Centre Netherlands	Our studies on epithelial cell plasticity and cancer are supported by Cancer Genomics Centre Netherlands. We are grateful to Jonas Fuxe for critical comments on the manuscript.	Abba ML, 2016, J CLIN MED, V5, DOI 10.3390/jcm5010008; Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Adam L, 2009, CLIN CANCER RES, V15, P5060, DOI 10.1158/1078-0432.CCR-08-2245; Aghdassi A, 2012, GUT, V61, P439, DOI 10.1136/gutjnl-2011-300060; Aiello NM, 2017, NATURE, V547, pE7, DOI 10.1038/nature22963; Nieto MA, 2017, NAT CELL BIOL, V19, P416, DOI 10.1038/ncb3520; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Baguley BC, 2010, MOL BIOTECHNOL, V46, P308, DOI 10.1007/s12033-010-9321-2; Bai WD, 2014, INT J CANCER, V135, P1356, DOI 10.1002/ijc.28782; Ban YQ, 2016, INT J CLIN EXP MED, V9, P10018; Baritaki S, 2009, CANCER RES, V69, P8376, DOI 10.1158/0008-5472.CAN-09-1069; Baulida J, 2017, MOL ONCOL, V11, P847, DOI 10.1002/1878-0261.12080; Beerling E, 2016, CELL REP, V14, P2281, DOI 10.1016/j.celrep.2016.02.034; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Bonde AK, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-35; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cao MX, 2017, ONCOTARGET, V8, P12472, DOI 10.18632/oncotarget.13957; Catalano A, 2004, J BIOL CHEM, V279, P46706, DOI 10.1074/jbc.M406696200; Chang TH, 2011, AM J RESP CRIT CARE, V183, P1071, DOI 10.1164/rccm.201009-1440OC; Chen LM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6241; Chen Y, 2013, MOL MED REP, V7, P1579, DOI 10.3892/mmr.2013.1403; Chen YL, 2012, CHEMOTHERAPY, V58, P264, DOI 10.1159/000341860; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Cheung KJ, 2016, P NATL ACAD SCI USA, V113, pE854, DOI 10.1073/pnas.1508541113; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Chockley PJ, 2016, J IMMUNOL, V197, P691, DOI 10.4049/jimmunol.1600458; Cieply B, 2013, CANCER RES, V73, P6299, DOI 10.1158/0008-5472.CAN-12-4082; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Cosset E, 2011, BLOOD, V117, P1673, DOI 10.1182/blood-2009-11-254680; Cui TX, 2013, IMMUNITY, V39, P611, DOI 10.1016/j.immuni.2013.08.025; Deng JJ, 2016, INT J ONCOL, V48, P1117, DOI 10.3892/ijo.2016.3342; Dennis M, 2012, OTOLARYNG HEAD NECK, V147, P726, DOI 10.1177/0194599812446407; Diaz VM, 2016, SEMIN CANCER BIOL, V36, P71, DOI 10.1016/j.semcancer.2015.10.003; Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Eddy RJ, 2017, TRENDS CELL BIOL, V27, P595, DOI 10.1016/j.tcb.2017.03.003; Fabregat I, 2016, J CLIN MED, V5, DOI 10.3390/jcm5030037; Fang CY, 2017, J GASTROEN HEPATOL, V32, P1204, DOI 10.1111/jgh.13646; Fang ST, 2014, NANOSCALE, V6, P10084, DOI 10.1039/c4nr01518e; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Fletcher JI, 2010, NAT REV CANCER, V10, P147, DOI 10.1038/nrc2789; Francart ME, 2018, DEV DYNAM, V247, P432, DOI 10.1002/dvdy.24506; Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118; Fukagawa A, 2015, CANCER MED-US, V4, P125, DOI 10.1002/cam4.347; Funaki S, 2017, ONCOL REP, V38, P2277, DOI 10.3892/or.2017.5894; Fuxe J, 2012, SEMIN CANCER BIOL, V22, P455, DOI 10.1016/j.semcancer.2012.05.004; Gao HX, 2016, MOL MED REP, V14, P4135, DOI 10.3892/mmr.2016.5770; Gao S, 2009, MOL CELL, V36, P457, DOI 10.1016/j.molcel.2009.09.043; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gopal SK, 2017, BIOCHEM J, V474, P21, DOI 10.1042/BCJ20160006; Goswami KK, 2017, CELL IMMUNOL, V316, P1, DOI 10.1016/j.cellimm.2017.04.005; Grassian AR, 2012, J BIOL CHEM, V287, P42180, DOI 10.1074/jbc.M112.417832; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grigore AD, 2016, J CLIN MED, V5, P51, DOI 10.3390/jcm5050051; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Gupta S, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00068; Han H, 2017, MOL CELL, V65, P539, DOI 10.1016/j.molcel.2017.01.011; Hanrahan K, 2017, MOL ONCOL, V11, P251, DOI 10.1002/1878-0261.12030; Hara J, 2014, ONCOL REP, V31, P589, DOI 10.3892/or.2013.2876; Harada K, 2014, INT J ONCOL, V44, P1302, DOI 10.3892/ijo.2014.2270; Haslehurst AM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-91; He MJ, 2017, PHARMACOL THERAPEUT, V177, P96, DOI 10.1016/j.pharmthera.2017.03.001; Herhaus L, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3519; Hirai M, 2017, INT J ONCOL, V50, P41, DOI 10.3892/ijo.2016.3785; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Hong T, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004569; Hsu DSS, 2010, CLIN CANCER RES, V16, P4561, DOI 10.1158/1078-0432.CCR-10-0593; Huang SD, 2012, CELL, V151, P937, DOI 10.1016/j.cell.2012.10.035; Inoue Y, 2016, CURR CANCER DRUG TAR, V16, P110, DOI 10.2174/1568009616666151112122126; Jeon YK, 2017, CELL DEATH DIFFER, V24, P469, DOI 10.1038/cdd.2016.143; Ji H, 2015, MOL MED REP, V12, P3841, DOI 10.3892/mmr.2015.3867; Jia DY, 2015, ONCOTARGET, V6, P15436, DOI 10.18632/oncotarget.3623; Jiang Y, 2014, J MOL CELL BIOL, V6, P352, DOI 10.1093/jmcb/mju019; Johansson J, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00003; Jolly MK, 2015, ONCOTARGET, V6, P25161, DOI 10.18632/oncotarget.4629; Jolly MK, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00155; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Kajiyama H, 2007, INT J ONCOL, V31, P277; Katz LH, 2013, EXPERT OPIN THER TAR, V17, P743, DOI 10.1517/14728222.2013.782287; Khoo BL, 2015, ONCOTARGET, V6, P15578; Kim AY, 2015, TOX RESEARCH, V31, P151, DOI 10.5487/TR.2015.31.2.151; Kim S, 2016, HUM PATHOL, V58, P7, DOI 10.1016/j.humpath.2016.07.007; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Labernadie A, 2017, NAT CELL BIOL, V19, P224, DOI 10.1038/ncb3478; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lee HJ, 2016, MOL CELL, V63, P1021, DOI 10.1016/j.molcel.2016.08.009; Li J, 2016, ONCOL RES, V23, P205, DOI 10.3727/096504016X14549667334007; Li T, 2015, CANCER RES, V75, P3181, DOI 10.1158/0008-5472.CAN-14-3721; Li YW, 2009, CANCER RES, V69, P6704, DOI 10.1158/0008-5472.CAN-09-1298; Li YQ, 2015, INT J ONCOL, V46, P1461, DOI 10.3892/ijo.2015.2878; Lim S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066558; Lin YW, 2017, ONCOTARGET, V8, P75127, DOI 10.18632/oncotarget.20561; Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63; Lindsey S, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00358; Liu SF, 2016, ONCOTARGET, V7, P32876, DOI 10.18632/oncotarget.8765; Liu SJ, 2016, INT J BIOCHEM CELL B, V76, P135, DOI 10.1016/j.biocel.2016.05.001; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Liu ZX, 2013, J BIOL CHEM, V288, P4334, DOI 10.1074/jbc.M112.419168; Loriot C, 2012, J CLIN ENDOCR METAB, V97, pE954, DOI 10.1210/jc.2011-3437; Lu M, 2013, P NATL ACAD SCI USA, V110, P18144, DOI 10.1073/pnas.1318192110; Lu SM, 2014, MOL MED REP, V10, P53, DOI 10.3892/mmr.2014.2212; Ma CC, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0367-2; Ma JL, 2016, TUMOR BIOL, V37, P6177, DOI 10.1007/s13277-015-4458-z; Mak MP, 2016, CLIN CANCER RES, V22, P609, DOI 10.1158/1078-0432.CCR-15-0876; Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030; Manavalan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062334; Mancini M, 2010, CELL SIGNAL, V22, P1247, DOI 10.1016/j.cellsig.2010.04.002; Marechal R, 2012, GASTROENTEROLOGY, V143, P664, DOI 10.1053/j.gastro.2012.06.006; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Maseki S, 2012, BRIT J CANCER, V106, P1196, DOI 10.1038/bjc.2012.24; Masui T, 2014, INT J ONCOL, V44, P693, DOI 10.3892/ijo.2013.2225; Meidhof S, 2015, EMBO MOL MED, V7, P831, DOI 10.15252/emmm.201404396; Mimeault M, 2013, J CELL MOL MED, V17, P30, DOI 10.1111/jcmm.12004; Mirzoeva OK, 2013, MOL CANCER THER, V12, P2213, DOI 10.1158/1535-7163.MCT-13-0104; Mishra VK, 2017, NUCLEIC ACIDS RES, V45, P6334, DOI 10.1093/nar/gkx212; Namba T, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.172; Nishijima N, 2016, INT J ONCOL, V48, P937, DOI 10.3892/ijo.2016.3331; Ock CY, 2016, ONCOTARGET, V7, P15901, DOI 10.18632/oncotarget.7431; Pang MF, 2016, ONCOGENE, V35, P748, DOI 10.1038/onc.2015.133; Park SH, 2015, MOL CELLS, V38, P20, DOI 10.14348/molcells.2015.2120; Pattabiraman DR, 2016, COLD SH Q B, V81, P11, DOI 10.1101/sqb.2016.81.030957; Paz H, 2014, ONCOGENE, V33, P4193, DOI 10.1038/onc.2013.393; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Pitts TM, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00035; Ramsdale R, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab1111; Ren J, 2013, J CELL BIOCHEM, V114, P1395, DOI 10.1002/jcb.24481; Richard G, 2016, EMBO MOL MED, V8, P1143, DOI 10.15252/emmm.201505971; Richards EJ, 2015, J BIOL CHEM, V290, P6857, DOI 10.1074/jbc.M114.610915; Roberts CM, 2017, NANOMED-NANOTECHNOL, V13, P965, DOI 10.1016/j.nano.2016.11.010; Roca H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076773; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; Sahu SK, 2015, EMBO J, V34, P2162, DOI 10.15252/embj.201490693; Sanchez-Tillo E, 2014, CELL DEATH DIFFER, V21, P247, DOI 10.1038/cdd.2013.123; Sanchez-Tillo E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102; Saxena M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.61; Schliekelman MJ, 2011, CANCER RES, V71, P7670, DOI 10.1158/0008-5472.CAN-11-0964; Sciacovelli M, 2017, FEBS J, V284, P3132, DOI 10.1111/febs.14090; Sciacovelli M, 2016, NATURE, V537, P544, DOI 10.1038/nature19353; Serrano-Gomez SJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0502-x; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Shih JY, 2005, NEW ENGL J MED, V353, P207, DOI 10.1056/NEJM200507143530217; Shimbo T, 2016, ADV EXP MED BIOL, V945, P303, DOI 10.1007/978-3-319-43624-1_13; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Strauss R, 2009, CANCER RES, V69, P5115, DOI 10.1158/0008-5472.CAN-09-0645; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Sun LD, 2016, CELL MOL LIFE SCI, V73, P4493, DOI 10.1007/s00018-016-2303-1; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Terabe M, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1308616; Terabe M, 2009, CLIN CANCER RES, V15, P6560, DOI 10.1158/1078-0432.CCR-09-1066; Tian XJ, 2013, BIOPHYS J, V105, P1079, DOI 10.1016/j.bpj.2013.07.011; Tilghman SL, 2013, MOL CELL PROTEOMICS, V12, P2440, DOI 10.1074/mcp.M112.023861; Tran Hung D, 2014, Cancer Res, V74, P6330, DOI 10.1158/0008-5472.CAN-14-0923; Triner D, 2016, J CLIN INVEST, V126, P3689, DOI 10.1172/JCI84430; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Tsukasa K, 2015, HUM CELL, V28, P167, DOI 10.1007/s13577-015-0117-3; Uchibori K, 2012, INT J ONCOL, V40, P1005, DOI 10.3892/ijo.2011.1300; Vannini I, 2007, CELL ONCOL, V29, P279; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Vesuna F, 2012, ONCOGENE, V31, P3223, DOI 10.1038/onc.2011.483; Vichalkovski A, 2010, ONCOGENE, V29, P3554, DOI 10.1038/onc.2010.115; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Wang H, 2014, EUR J PHARMACOL, V723, P156, DOI 10.1016/j.ejphar.2013.12.004; Wang R, 2015, ONCOTARGET, V6, P7000, DOI 10.18632/oncotarget.3193; Wang T, 2014, ONCOL LETT, V7, P1102, DOI 10.3892/ol.2014.1816; Wang XH, 2004, ONCOGENE, V23, P474, DOI 10.1038/sj.onc.1207128; Warzecha CC, 2012, SEMIN CANCER BIOL, V22, P417, DOI 10.1016/j.semcancer.2012.04.003; Wu KJ, 2012, MOL ENDOCRINOL, V26, P1496, DOI 10.1210/me.2011-1360; Wu YD, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14228; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Wu Y, 2017, BREAST CANCER RES TR, V163, P449, DOI 10.1007/s10549-017-4211-y; Wu YY, 2012, MOL CANCER RES, V10, P1597, DOI 10.1158/1541-7786.MCR-12-0155-T; Xiao HB, 2015, ONCOTARGET, V6, P38005, DOI 10.18632/oncotarget.5357; Xu M, 2015, ONCOTARGET, V6, P979, DOI 10.18632/oncotarget.2825; Xu YX, 2017, P NATL ACAD SCI USA, V114, P11494, DOI 10.1073/pnas.1618091114; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Yang F, 2012, EMBO J, V31, P110, DOI 10.1038/emboj.2011.364; Yang H, 2015, ONCOTARGET, V6, P6310, DOI 10.18632/oncotarget.3355; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Ye X, 2017, NATURE, V547, pE1, DOI 10.1038/nature22816; Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012; Yin T, 2007, J SURG RES, V141, P196, DOI 10.1016/j.jss.2006.09.027; Yoshida T, 2016, PLOS ONE, V11, DOI DOI 10.1371/JOURNAL.PONE.0147344; Yu Q, 2017, CANC CELL MICROENVIR, V4, P2; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhang JY, 2016, J CLIN MED, V5, DOI 10.3390/jcm5040041; Zhang JY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005304; Zhang KJ, 2011, MED ONCOL, V28, pS301, DOI 10.1007/s12032-010-9759-x; Zhang P, 2014, INT J MOL MED, V33, P151, DOI 10.3892/ijmm.2013.1538; Zhang PJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6671; Zhang P, 2014, NAT CELL BIOL, V16, P864, DOI 10.1038/ncb3013; Zhang T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12231; Zhang WJ, 2012, BIOCHEM BIOPH RES CO, V417, P679, DOI 10.1016/j.bbrc.2011.11.142; Zhang X, 2017, NAT COMMUN, V8, P1, DOI [10.1038/ncomms14542, 10.1038/s41467-017-01968-5, 10.1038/s41467-017-00321-0]; Zhang XM, 2007, INT J CANCER, V120, P1891, DOI 10.1002/ijc.22489; Zhao Y, 2018, CELL REP, V22, P2442, DOI 10.1016/j.celrep.2018.02.007; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zhou GH, 2017, BIOMED PHARMACOTHER, V85, P113, DOI 10.1016/j.biopha.2016.11.100; Zhou H, 2016, AGING-US, V8, P2023, DOI 10.18632/aging.101048; Zhu DJ, 2015, AM J CANCER RES, V5, P2000; Zhu X, 2016, ONCOGENE, V35, P323, DOI 10.1038/onc.2015.84	204	100	101	1	32	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2018	37	48					6195	6211		10.1038/s41388-018-0378-x	http://dx.doi.org/10.1038/s41388-018-0378-x			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC2HE	30002444				2022-12-17	WOS:000451622100001
J	Shi, ZM; Wang, L; Shen, H; Jiang, CF; Ge, X; Li, DM; Wen, YY; Sun, HR; Pan, MH; Li, W; Shu, YQ; Liu, LZ; Peiper, SC; He, J; Jiang, BH				Shi, Z-M; Wang, L.; Shen, H.; Jiang, C-F; Ge, X.; Li, D-M; Wen, Y-Y; Sun, H-R; Pan, M-H; Li, W.; Shu, Y-Q; Liu, L-Z; Peiper, S. C.; He, J.; Jiang, B-H			Downregulation of miR-218 contributes to epithelialmesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTORS; CARCINOMA METASTASIS; PANCREATIC-CANCER; DRUG-RESISTANCE; OVARIAN-CANCER; COLON-CANCER; NUDE-MICE; TGF-BETA; CELLS	Epithelial-mesenchymal transition (EMT) has been recognized as a key element of cell migration and invasion in lung cancer; however, the underlying mechanisms are not fully elucidated. Recently, emerging evidence suggest that miRNAs have crucial roles in control of EMT and EMT-associated traits such as migration, invasion and chemoresistance. Here, we found that miR-218 expression levels were significantly downregulated in lung cancer tissues compared with adjacent non-cancerous tissues, and the levels of miR-218 were significantly associated with histological grades and lymph node metastasis. Overexpression of miR-218 inhibited cell migration and invasion as well as the EMT process. Of particular importance, miR-218 was involved in the metastatic process of lung cancer cells in vivo by suppressing local invasion and distant colonization. We identified Slug and ZEB2 as direct functional targets of miR-218. Inverse correlations were observed between miR-218 levels and Slug/ZEB2 levels in cancer tissue samples. In addition, overexpression of miR-218 in H1299 increased chemosensitivity of cells to cisplatin treatment through suppression of Slug and ZEB2. These findings highlight an important role of miR-218 in the regulation of EMT-related traits and metastasis of lung cancer in part by modulation of Slug/ZEB2 signaling, and provide a potential therapeutic strategy by targeting miR-218 in NSCLC.	[Shi, Z-M] Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China; [Shi, Z-M; Wang, L.; Jiang, C-F; Ge, X.; Li, D-M; Wen, Y-Y; Sun, H-R; Jiang, B-H] Nanjing Med Univ, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Key Lab Human Funct Genom Jiangsu Prov, State Key Lab Reprod Med,Canc Ctr,Dept Pathol, Nanjing, Jiangsu, Peoples R China; [Shen, H.; Shu, Y-Q] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China; [Pan, M-H] Nanjing Med Univ, Affiliated Hosp 1, Dept Pathol, Nanjing, Jiangsu, Peoples R China; [Li, W.] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Pathol, Nanjing, Jiangsu, Peoples R China; [Liu, L-Z; Peiper, S. C.; He, J.; Jiang, B-H] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, 1020 Locust St,Suite 334,Jefferson Alumni Hall, Philadelphia, PA 19107 USA	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing University; Jefferson University	He, J; Jiang, BH (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, 1020 Locust St,Suite 334,Jefferson Alumni Hall, Philadelphia, PA 19107 USA.; Jiang, BH (corresponding author), Nanjing Med Univ, Dept Pathol, Nanjing 211166, Jiangsu, Peoples R China.	Jun.he@jefferson.edu; binghjiang@yahoo.com	Jiang, Chengfei/AFW-5879-2022; sun, hao/GRS-7732-2022; Shu, Yongqian/ABD-5698-2021	Hartl, Carla/0000-0001-9769-7462; Liu, Ling-Zhi/0000-0001-9234-457X; He, Jun/0000-0002-5162-6041; Jiang, Bing-Hua/0000-0003-4526-2031	National Natural Science Foundation of China [81472944, 81320108019, 81302182, 81270736, 81502170]; Research Special Fund for Public Welfare Industry of Health [201402008]; National Institutes of Health grants [R01ES020868, R01CA193511]; American Cancer Society [RSG NEC -129306]; NATIONAL CANCER INSTITUTE [R01CA193511] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES020868] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Special Fund for Public Welfare Industry of Health; National Institutes of Health grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported in part by National Natural Science Foundation of China (81472944, 81320108019, 81302182, 81270736 and 81502170); The Research Special Fund for Public Welfare Industry of Health (201402008); by National Institutes of Health grants (R01ES020868 and R01CA193511); and by American Cancer Society (RSG NEC -129306).	An ZL, 1996, ANTICANCER RES, V16, P2545; [Anonymous], 2014, IEEE IJCNN; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Cai JC, 2013, J CLIN INVEST, V123, P566, DOI 10.1172/JCI65871; Castoldi M, 2006, RNA, V12, P913, DOI 10.1261/rna.2332406; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chang TH, 2011, AM J RESP CRIT CARE, V183, P1071, DOI 10.1164/rccm.201009-1440OC; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Fang S, 2014, EXP MOL PATHOL, V96, P438, DOI 10.1016/j.yexmp.2014.04.008; FENG B, 2015, CLIN SCI, V129, P673; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; FU XY, 1991, P NATL ACAD SCI USA, V88, P9345, DOI 10.1073/pnas.88.20.9345; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guan HY, 2013, J CLIN ENDOCR METAB, V98, pE1334, DOI 10.1210/jc.2013-1053; Hahn S, 2013, EMBO J, V32, P3079, DOI 10.1038/emboj.2013.236; Hammond SM, 2015, ADV DRUG DELIVER REV, V87, P3, DOI 10.1016/j.addr.2015.05.001; Haslehurst AM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-91; Heist RS, 2012, CANCER CELL, V21; Izumchenko E, 2014, CANCER RES, V74, P3995, DOI 10.1158/0008-5472.CAN-14-0110; Jin YJ, 2014, INT J CANCER, V134, P2294, DOI 10.1002/ijc.28568; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Katz MH, 2004, CLIN EXP METASTAS, V21, P7, DOI 10.1023/B:CLIN.0000017160.93812.3b; Ko H, 2013, CANCER LETT, V335, P205, DOI 10.1016/j.canlet.2013.02.018; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Li CH, 2013, GASTROENTEROLOGY, V144, P1086, DOI 10.1053/j.gastro.2013.01.058; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Liu LZ, 2008, CANCER RES, V68, P8183, DOI 10.1158/0008-5472.CAN-08-0819; Mallini P, 2014, CANCER TREAT REV, V40, P341, DOI 10.1016/j.ctrv.2013.09.008; Miow QH, 2015, ONCOGENE, V34, P1899, DOI 10.1038/onc.2014.136; Nagaraju GP, 2015, MOL CARCINOGEN, V54, P1147, DOI 10.1002/mc.22185; Nasarre P, 2013, CANCER RES, V73, P7111, DOI 10.1158/0008-5472.CAN-13-1755; Okada N, 2014, GENE DEV, V28, P438, DOI 10.1101/gad.233585.113; Oktyabri D, 2014, BIOCHEM BIOPH RES CO, V453, P124, DOI 10.1016/j.bbrc.2014.09.082; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pavelic SK, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-22; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Qu JJ, 2015, INT J ONCOL, V47, P2141, DOI 10.3892/ijo.2015.3187; Sachdeva M, 2014, J CLIN INVEST, V124, P4305, DOI 10.1172/JCI77116; Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sun L, 2012, ONCOGENE, V31, P432, DOI 10.1038/onc.2011.263; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Tu YY, 2013, CANCER RES, V73, P6046, DOI 10.1158/0008-5472.CAN-13-0358; Valeri N, 2014, CANCER CELL, V25, P469, DOI 10.1016/j.ccr.2014.03.006; Valeri N, 2010, P NATL ACAD SCI USA, V107, P21098, DOI 10.1073/pnas.1015541107; Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002; Wang BR, 2016, ARCH TOXICOL, V90, P449, DOI 10.1007/s00204-014-1435-z; Wilson C, 2014, ONCOTARGET, V5, P7328, DOI 10.18632/oncotarget.2397; Wu YC, 2016, ONCOGENE, V35, P2123, DOI 10.1038/onc.2015.274; Xia HP, 2013, HEPATOLOGY, V58, P629, DOI 10.1002/hep.26369; Xie J, 2016, TUMOR BIOL, V37, P1197, DOI 10.1007/s13277-015-3831-2; Yang LH, 2015, SCI REP-UK, V5, DOI 10.1038/srep13677; Yang M, 1999, CANCER RES, V59, P781; Zhang CL, 2013, ACTA BIOCH BIOPH SIN, V45, P1055, DOI 10.1093/abbs/gmt109; Zhang JY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005304; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zhou XX, 2016, J AM SOC NEPHROL, V27, P2092, DOI 10.1681/ASN.2015040457; Zhu KG, 2016, ONCOTARGET, V7, P28075, DOI 10.18632/oncotarget.8576; Zhu X, 2016, ONCOGENE, V35, P323, DOI 10.1038/onc.2015.84	63	100	104	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2577	2588		10.1038/onc.2016.414	http://dx.doi.org/10.1038/onc.2016.414			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	28192397	hybrid, Green Published			2022-12-17	WOS:000400597300008
J	Ratnikov, BI; Scott, DA; Osterman, AL; Smith, JW; Ronai, ZA				Ratnikov, B. I.; Scott, D. A.; Osterman, A. L.; Smith, J. W.; Ronai, Z. A.			Metabolic rewiring in melanoma	ONCOGENE			English	Review							ENDOTHELIAL GROWTH-FACTOR; PYRUVATE-KINASE; GLUTAMINE-METABOLISM; MITOCHONDRIAL METABOLISM; ONCOMETABOLITE 2-HYDROXYGLUTARATE; OXIDATIVE-PHOSPHORYLATION; CELLULAR ADAPTATION; METASTATIC MELANOMA; MALIGNANT-MELANOMA; GLUCOSE-METABOLISM	Oncogene-driven metabolic rewiring is an adaptation to low nutrient and oxygen conditions in the tumor microenvironment that enables cancer cells of diverse origin to hyperproliferate. Aerobic glycolysis and enhanced reliance on glutamine utilization are prime examples of such rewiring. However, tissue of origin as well as specific genetic and epigenetic changes determines gene expression profiles underlying these metabolic alterations in specific cancers. In melanoma, activation of the mitogen-activated protein kinase (MAPK) pathway driven by mutant BRAF or NRAS is a primary cause of malignant transformation. Activity of the MAPK pathway, as well as other factors, such as HIF1 alpha, Myc and MITF, are among those that control the balance between non oxidative and oxidative branches of central carbon metabolism. Here, we discuss the nature of metabolic alterations that underlie melanoma development and affect its response to therapy.	[Ratnikov, B. I.; Scott, D. A.; Osterman, A. L.; Smith, J. W.; Ronai, Z. A.] Sanford Burnham Prebys Med Discovery Inst, Ctr Canc, 10901 North Torrey Pines Rd, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Ratnikov, BI; Ronai, ZA (corresponding author), Sanford Burnham Prebys Med Discovery Inst, Ctr Canc, 10901 North Torrey Pines Rd, La Jolla, CA 92037 USA.	bratnikov@SBPDiscovery.org; zeev@ronailab.net		Scott, David/0000-0002-8668-2449	NATIONAL CANCER INSTITUTE [R35CA197465, P30CA030199, R01CA188372] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA030199, R01 CA188372, R35 CA197465, P01 CA128814] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abildgaard C, 2015, TRENDS MOL MED, V21, P164, DOI 10.1016/j.molmed.2014.12.007; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Baenke F, 2016, MOL ONCOL, V10, P73, DOI 10.1016/j.molonc.2015.08.003; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bertolotto C, 2011, NATURE, V480, P94, DOI 10.1038/nature10539; Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016; Bogunovic D, 2009, P NATL ACAD SCI USA, V106, P20429, DOI 10.1073/pnas.0905139106; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; Cassago A, 2012, P NATL ACAD SCI USA, V109, P1092, DOI 10.1073/pnas.1112495109; Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; De Ingeniis J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045190; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Dey S, 2015, J CLIN INVEST, V125, P2592, DOI 10.1172/JCI78031; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007; Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236; Filipp FV, 2012, PIGM CELL MELANOMA R, V25, P732, DOI 10.1111/pcmr.12000; Filipp FV, 2012, PIGM CELL MELANOMA R, V25, P375, DOI 10.1111/j.1755-148X.2012.00989.x; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; Gaglio D, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.56; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Godic A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/860479; Goodman M, 2011, FREE RADICAL BIO MED, V51, P1068, DOI 10.1016/j.freeradbiomed.2011.05.018; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Gupta V, 2014, CURR PHARM DESIGN, V20, P2595, DOI 10.2174/13816128113199990484; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Handschin C, 2007, J BIOL CHEM, V282, P30014, DOI 10.1074/jbc.M704817200; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Haq R, 2011, J CLIN ONCOL, V29, P3474, DOI 10.1200/JCO.2010.32.6223; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; HARRIS M, 1980, SOMAT CELL GENET, V6, P699, DOI 10.1007/BF01538969; Hernandez-Davies JE, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0581-2; Ho JH, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-76; Hobbs GA, 2015, FREE RADICAL BIO MED, V79, P237, DOI 10.1016/j.freeradbiomed.2014.09.027; Hobbs G Aaron, 2014, Small GTPases, V5, pe28579, DOI 10.4161/sgtp.28579; Israelsen WJ, 2013, CELL, V155, P397, DOI 10.1016/j.cell.2013.09.025; Janzer A, 2014, P NATL ACAD SCI USA, V111, P10574, DOI 10.1073/pnas.1409844111; Jiang BH, 1997, CANCER RES, V57, P5328; Kang HB, 2015, MOL CELL, V59, P345, DOI 10.1016/j.molcel.2015.05.037; Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154; Kaufman HL, 2013, NAT REV CLIN ONCOL, V10, P588, DOI 10.1038/nrclinonc.2013.153; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Koch A, 2015, ONCOTARGET, V6, P32748, DOI 10.18632/oncotarget.4977; Kraehn GM, 2001, BRIT J CANCER, V84, P72, DOI 10.1054/bjoc.2000.1535; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kuphal S, 2010, EUR J CANCER, V46, P1159, DOI 10.1016/j.ejca.2010.01.031; Labuschagne CF, 2014, CELL REP, V7, P1248, DOI 10.1016/j.celrep.2014.04.045; Le Gal K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad3740; Leo MA, 1997, J NATL CANCER I, V89, P1722, DOI 10.1093/jnci/89.22.1722; Lewis CA, 2014, MOL CELL, V55, P253, DOI 10.1016/j.molcel.2014.05.008; Li Y, 2015, CANCER RES, V75, P1191, DOI 10.1158/0008-5472.CAN-14-2615; Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033; Lin JY, 2007, NATURE, V445, P843, DOI 10.1038/nature05660; Liu W, 2012, P NATL ACAD SCI USA, V109, P8983, DOI 10.1073/pnas.1203244109; Lo JA, 2014, SCIENCE, V346, P945, DOI 10.1126/science.1253735; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Lunt SY, 2015, MOL CELL, V57, P95, DOI 10.1016/j.molcel.2014.10.027; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Mari M, 2009, ANTIOXID REDOX SIGN, V11, P2685, DOI [10.1089/ars.2009.2695, 10.1089/ARS.2009.2695]; Mazure NM, 1996, CANCER RES, V56, P3436; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; McPherson PAC, 2012, J PHYSIOL BIOCHEM, V68, P141, DOI 10.1007/s13105-011-0112-4; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; Miniotis MF, 2013, CANCER RES, V73, P4039, DOI 10.1158/0008-5472.CAN-12-1969; Mitchell L, 2013, ANTIOXID REDOX SIGN, V18, P250, DOI 10.1089/ars.2012.4687; Moore SR, 2008, CLIN CANCER RES, V14, P2927, DOI 10.1158/1078-0432.CCR-07-4068; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Mullarky E, 2011, PIGM CELL MELANOMA R, V24, P1112, DOI 10.1111/j.1755-148X.2011.00919.x; Niehr F, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-76; Olenchock BA, 2013, CELL, V153, P1429, DOI 10.1016/j.cell.2013.06.001; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217; Pieter A, 2012, CANCER BIOL THER, V13, P1185, DOI 10.4161/cbt.21348; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Porporato PE, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00049; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Ratnikov B, 2015, ONCOTARGET, V6, P7379, DOI 10.18632/oncotarget.3132; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Sayin VI, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007653; Schell JC, 2014, MOL CELL, V56, P400, DOI 10.1016/j.molcel.2014.09.026; Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Scott DA, 2011, J BIOL CHEM, V286, P42626, DOI 10.1074/jbc.M111.282046; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Shibata T, 2011, AM J PATHOL, V178, P1395, DOI 10.1016/j.ajpath.2010.12.011; Shtivelman E, 2014, ONCOTARGET, V5, P1701, DOI 10.18632/oncotarget.1892; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Vacanti NM, 2014, MOL CELL, V56, P425, DOI 10.1016/j.molcel.2014.09.024; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Van Vranken JG, 2015, CELL, V162, P471, DOI 10.1016/j.cell.2015.07.027; Vazquez F, 2013, CANCER CELL, V23, P287, DOI 10.1016/j.ccr.2012.11.020; WARBURG O, 1956, SCIENCE, V124, P269; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wawrzyniak JA, 2013, CELL REP, V5, P493, DOI 10.1016/j.celrep.2013.09.015; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Weinberg F, 2009, ANN NY ACAD SCI, V1177, P66, DOI 10.1111/j.1749-6632.2009.05039.x; Westerlund A, 2011, ANN ONCOL, V22, P967, DOI 10.1093/annonc/mdq456; Willcox JK, 2004, CRIT REV FOOD SCI, V44, P275, DOI 10.1080/10408690490468489; Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003; Wishart DS, 2013, NUCLEIC ACIDS RES, V41, pD801, DOI 10.1093/nar/gks1065; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yang CD, 2014, MOL CELL, V56, P414, DOI 10.1016/j.molcel.2014.09.025; Ye JB, 2014, CANCER DISCOV, V4, P1406, DOI 10.1158/2159-8290.CD-14-0250; Ye JB, 2012, P NATL ACAD SCI USA, V109, P6904, DOI 10.1073/pnas.1204176109; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Yokoyama S, 2011, NATURE, V480, P99, DOI 10.1038/nature10630; Yuan P, 2013, P NATL ACAD SCI USA, V110, P18226, DOI 10.1073/pnas.1317577110; Yun J, 2015, SCIENCE, V350, P1391, DOI 10.1126/science.aaa5004; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Yuneva MO, 2012, CELL METAB, V15, P157, DOI 10.1016/j.cmet.2011.12.015; Zhang J, 2014, MOL CELL, V56, P205, DOI 10.1016/j.molcel.2014.08.018; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944	134	100	103	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					147	157		10.1038/onc.2016.198	http://dx.doi.org/10.1038/onc.2016.198			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27270434	Green Accepted			2022-12-17	WOS:000393938100001
J	Garcia, PL; Miller, AL; Kreitzburg, KM; Council, LN; Gamblin, TL; Christein, JD; Heslin, MJ; Arnoletti, JP; Richardson, JH; Chen, D; Hanna, CA; Cramer, SL; Yang, ES; Qi, J; Bradner, JE; Yoon, KJ				Garcia, P. L.; Miller, A. L.; Kreitzburg, K. M.; Council, L. N.; Gamblin, T. L.; Christein, J. D.; Heslin, M. J.; Arnoletti, J. P.; Richardson, J. H.; Chen, D.; Hanna, C. A.; Cramer, S. L.; Yang, E. S.; Qi, J.; Bradner, J. E.; Yoon, K. J.			The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models	ONCOGENE			English	Article							SALMONELLA-TYPHIMURIUM A1-R; C-MYC; CELL-CYCLE; SELECTIVE-INHIBITION; CLINICAL BENEFIT; GENE-EXPRESSION; CANCER-CELLS; THERAPY; CDC25B; TARGET	The primary aim of this study was to evaluate the antitumor efficacy of the bromodomain inhibitor JQ1 in pancreatic ductal adenocarcinoma (PDAC) patient-derived xenograft (tumorgraft) models. A secondary aim of the study was to evaluate whether JQ1 decreases expression of the oncogene c-Myc in PDAC tumors, as has been reported for other tumor types. We used five PDAC tumorgraft models that retain specific characteristics of tumors of origin to evaluate the antitumor efficacy of JQ1. Tumor-bearing mice were treated with JQ1 (50 mg/kg daily for 21 or 28 days). Expression analyses were performed with tumors harvested from host mice after treatment with JQ1 or vehicle control. An nCounter PanCancer Pathways Panel (NanoString Technologies) of 230 cancer-related genes was used to identify gene products affected by JQ1. Quantitative RT-PCR, immunohistochemistry and immunoblots were carried out to confirm that changes in RNA expression reflected changes in protein expression. JQ1 inhibited the growth of all five tumorgraft models (P < 0.05), each of which harbors a KRAS mutation; but induced no consistent change in expression of c-Myc protein. Expression profiling identified CDC25B, a regulator of cell cycle progression, as one of the three RNA species (TIMP3, LMO2 and CDC25B) downregulated by JQ1 (P < 0.05). Inhibition of tumor progression was more closely related to decreased expression of nuclear CDC25B than to changes in c-Myc expression. JQ1 and other agents that inhibit the function of proteins with bromodomains merit further investigation for treating PDAC tumors. Work is ongoing in our laboratory to identify effective drug combinations that include JQ1.	[Garcia, P. L.; Miller, A. L.; Kreitzburg, K. M.; Gamblin, T. L.; Yoon, K. J.] Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; [Hanna, C. A.] Univ Alabama Birmingham, Div Anat Pathol, Dept Pathol, Birmingham, AL USA; [Christein, J. D.; Heslin, M. J.; Arnoletti, J. P.; Richardson, J. H.] Univ Alabama Birmingham, Div Gen Surg Gastrointestinal Surg Surg Oncol, Dept Surg, Birmingham, AL USA; [Chen, D.] Univ Alabama Birmingham, Div Prevent Med, Dept Med, Birmingham, AL USA; [Cramer, S. L.] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA; [Yang, E. S.] Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL USA; [Qi, J.; Bradner, J. E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Harvard University; Dana-Farber Cancer Institute	Yoon, KJ (corresponding author), Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA.	kyoon@uab.edu			UAB/UMN SPORE in pancreatic cancer [P50 CA101955]; NATIONAL CANCER INSTITUTE [P30CA013148, P50CA101955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008111] Funding Source: NIH RePORTER	UAB/UMN SPORE in pancreatic cancer(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs Donald J Buchsbaum, William E Grizzle, Mary-Ann Bjornsti and Christopher Klug for their insightful guidance and helpful discussions. This research was supported in part by UAB/UMN SPORE in pancreatic cancer (P50 CA101955).	American Cancer Society, 2014, CANC FACTS FIG 2014; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Bandopadhayay P, 2014, CLIN CANCER RES, V20, P912, DOI 10.1158/1078-0432.CCR-13-2281; BORN TL, 1994, MOL CELL BIOL, V14, P5710, DOI 10.1128/MCB.14.9.5710; Briasoulis E, 1998, ANTICANCER RES, V18, P1907; Bryant KL, 2014, TRENDS BIOCHEM SCI, V39, P91, DOI 10.1016/j.tibs.2013.12.004; Burris H, 1997, EUR J CANCER, V33, pS18, DOI 10.1016/S0959-8049(96)00324-3; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Chandra S, 2013, J CELL SCI, V126, P3782, DOI 10.1242/jcs.124719; Chen YH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-246; Cheng ZX, 2013, CLIN CANCER RES, V19, P1748, DOI 10.1158/1078-0432.CCR-12-3066; Da Costa D, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.24; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Feng Q, 2014, CELL RES, V24, P809, DOI 10.1038/cr.2014.71; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fowler T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087003; FU XY, 1992, P NATL ACAD SCI USA, V89, P5645, DOI 10.1073/pnas.89.12.5645; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Garcia PL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078183; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; GERDES J, 1984, J IMMUNOL, V133, P1710; Gillen S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000267; Guerra L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008924; Guo JC, 2004, ONCOGENE, V23, P71, DOI 10.1038/sj.onc.1206926; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hiroshima Y, 2014, ONCOTARGET, V5, P12346, DOI 10.18632/oncotarget.2641; Hiroshima Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114310; Hiroshima Y, 2014, J CELL BIOCHEM, V115, P1254, DOI 10.1002/jcb.24769; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Knoechel B, 2014, NAT GENET, V46, P364, DOI 10.1038/ng.2913; Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015; Kulkarni MV, 2011, MOL ONCOL, V5, P24, DOI 10.1016/j.molonc.2010.10.004; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lin WC, 2013, CANCER RES, V73, P1821, DOI 10.1158/0008-5472.CAN-12-2067; Lindqvist A, 2004, J CELL SCI, V117, P4979, DOI 10.1242/jcs.01395; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109; Loosveld M, 2014, ONCOTARGET, V5, P3168, DOI 10.18632/oncotarget.1873; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Matsumura I, 2003, CELL CYCLE, V2, P333, DOI 10.4161/cc.2.4.428; Matzuk MM, 2012, CELL, V150, P673, DOI 10.1016/j.cell.2012.06.045; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x; Ott CJ, 2012, BLOOD, V120, P2843, DOI 10.1182/blood-2012-02-413021; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Roderick JE, 2014, BLOOD, V123, P1040, DOI 10.1182/blood-2013-08-522698; Rozenblum E, 1997, CANCER RES, V57, P1731; Sahai V, 2014, MOL CANCER THER, V13, P1907, DOI 10.1158/1535-7163.MCT-13-0925; Schleger C, 2002, MODERN PATHOL, V15, P462, DOI 10.1038/modpathol.3880547; Schuldiner O, 2001, ONCOGENE, V20, P4984, DOI 10.1038/sj.onc.1204459; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shimamura T, 2013, CLIN CANCER RES, V19, P6183, DOI 10.1158/1078-0432.CCR-12-3904; Sibani S, 2005, J CELL SCI, V118, P3247, DOI 10.1242/jcs.02427; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Suetsugu A, 2012, ANTICANCER RES, V32, P3063; Suetsugu A, 2012, J CELL BIOCHEM, V113, P2290, DOI 10.1002/jcb.24099; Suetsugu A, 2012, ANTICANCER RES, V32, P1175; Trabucco SE, 2015, CLIN CANCER RES, V21, P113, DOI 10.1158/1078-0432.CCR-13-3346; Wang WJ, 2013, CANCER RES, V73, P1219, DOI 10.1158/0008-5472.CAN-12-1408; Yu XY, 2012, ASIAN PAC J CANCER P, V13, P931, DOI 10.7314/APJCP.2012.13.3.931	69	100	102	1	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					833	845		10.1038/onc.2015.126	http://dx.doi.org/10.1038/onc.2015.126			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25961927	Green Accepted			2022-12-17	WOS:000370332200004
J	Mavrou, A; Brakspear, K; Hamdollah-Zadeh, M; Damodaran, G; Babaei-Jadidi, R; Oxley, J; Gillatt, DA; Ladomery, MR; Harper, SJ; Bates, DO; Oltean, S				Mavrou, A.; Brakspear, K.; Hamdollah-Zadeh, M.; Damodaran, G.; Babaei-Jadidi, R.; Oxley, J.; Gillatt, D. A.; Ladomery, M. R.; Harper, S. J.; Bates, D. O.; Oltean, S.			Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; IN-VITRO EXPRESSION; SPLICE VARIANT; VEGF; ANGIOGENESIS; VEGF(165)B; VIVO; BEVACIZUMAB; PROGRESSION; THERAPIES	Angiogenesis is required for tumour growth and is induced principally by vascular endothelial growth factor A (VEGF-A). VEGF-A pre-mRNA is alternatively spliced at the terminal exon to produce two families of isoforms, pro- and anti-angiogenic, only the former of which is upregulated in prostate cancer (PCa). In renal epithelial cells and colon cancer cells, the choice of VEGF splice isoforms is controlled by the splicing factor SRSF1, phosphorylated by serine-arginine protein kinase 1 (SRPK1). Immunohistochemistry staining of human samples revealed a significant increase in SRPK1 expression both in prostate intraepithelial neoplasia lesions as well as malignant adenocarcinoma compared with benign prostate tissue. We therefore tested the hypothesis that the selective upregulation of pro-angiogenic VEGF in PCa may be under the control of SRPK1 activity. A switch in the expression of VEGF(165) towards the anti-angiogenic splice isoform, VEGF(165)b, was seen in PC-3 cells with SRPK1 knockdown (KD). PC-3 SRPK1-KD cells resulted in tumours that grew more slowly in xenografts, with decreased microvessel density. No effect was seen as a result of SRPK1-KD on growth, proliferation, migration and invasion capabilities of PC-3 cells in vitro. Small-molecule inhibitors of SRPK1 switched splicing towards the anti-angiogenic isoform VEGF(165)b in PC-3 cells and decreased tumour growth when administered intraperitoneally in an orthotopic mouse model of PCa. Our study suggests that modulation of SRPK1 and subsequent inhibition of tumour angiogenesis by regulation of VEGF splicing can alter prostate tumour growth and supports further studies for the use of SRPK1 inhibition as a potential anti-angiogenic therapy in PCa.	[Mavrou, A.; Brakspear, K.; Hamdollah-Zadeh, M.; Damodaran, G.; Harper, S. J.; Bates, D. O.; Oltean, S.] Univ Bristol, Sch Physiol & Pharmacol, Bristol BS1 3NY, Avon, England; [Babaei-Jadidi, R.; Bates, D. O.] Univ Nottingham, Sch Med, Div Canc & Stem Cells, Canc Biol, Nottingham NG2 7QT, England; [Oxley, J.] North Bristol NHS Trust, Dept Cellular Pathol, Bristol, Avon, England; [Gillatt, D. A.] North Bristol NHS Trust, Dept Urol Sci, Bristol, Avon, England; [Ladomery, M. R.] Univ W England, Fac Hlth & Appl Sci, Ctr Res Biosci, Bristol BS16 1QY, Avon, England	University of Bristol; University of Nottingham; North Bristol NHS Trust; North Bristol NHS Trust; University of West England	Bates, DO (corresponding author), Univ Nottingham, Sch Med, Div Canc & Stem Cells, Canc Biol, Nottingham NG2 7QT, England.	david.bates@nottingham.ac.uk; sebastian.oltean@bristol.ac.uk		Bates, David/0000-0003-4850-2360; Oltean, Sebastian/0000-0001-7890-8439; Damodaran, Gopinath/0000-0002-1697-0357	Prostate Cancer Research UK; BBSRC [BB/J007293/1]; Medical Research Council [G10002073]; Cancer Research UK [C11392/A10484]; Richard Bright VEGF Research Trust (North Bristol Cancer Research Projects Fund) [96464]; BBSRC [BB/J007293/2] Funding Source: UKRI; MRC [G1002073, MR/K020366/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/J007293/1] Funding Source: researchfish; Medical Research Council [G1002073, MR/K020366/1] Funding Source: researchfish	Prostate Cancer Research UK; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Richard Bright VEGF Research Trust (North Bristol Cancer Research Projects Fund); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Dr Andrew Armstrong (Duke University) for critical reading of the manuscript and helpful suggestions and the staff from AntiCancer Research Ltd. (San Diego) for training Athina Mavrou in the orthotopic prostate cancer model. This work was supported by Prostate Cancer Research UK, BBSRC (BB/J007293/1), the Medical Research Council (G10002073), Cancer Research UK (C11392/A10484) and Richard Bright VEGF Research Trust (North Bristol Cancer Research Projects Fund no. 96464).	Amin EM, 2011, CANCER CELL, V20, P768, DOI 10.1016/j.ccr.2011.10.016; Bates DO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068399; Bates DO, 2012, CLIN CANCER RES, V18, P6384, DOI 10.1158/1078-0432.CCR-12-2223; Bates DO, 2002, CANCER RES, V62, P4123; Bok RA, 2001, CANCER RES, V61, P2533; Clarke JM, 2013, CURR TREAT OPTION ON, V14, P109, DOI 10.1007/s11864-012-0222-4; Drake CG, 2014, ONCOGENE, V33, P5053, DOI 10.1038/onc.2013.497; Duque JLF, 1999, UROLOGY, V54, P523, DOI 10.1016/S0090-4295(99)00167-3; Duque José Luis Ferreira, 2006, Clinics, V61, P401, DOI 10.1590/S1807-59322006000500006; Ferrer FA, 1998, UROLOGY, V51, P161, DOI 10.1016/S0090-4295(97)00491-3; Ferrer FA, 1997, J UROLOGY, V157, P2329, DOI 10.1016/S0022-5347(01)64775-X; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; Fukuhara T, 2006, P NATL ACAD SCI USA, V103, P11329, DOI 10.1073/pnas.0604616103; Gammons MV, 2013, INVEST OPHTH VIS SCI, V54, P6052, DOI 10.1167/iovs.13-12422; Gatta G, 2013, ANN ONCOL, V24, P1660, DOI 10.1093/annonc/mdt030; Gout S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046539; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harper SJ, 2008, NAT REV CANCER, V8, P880, DOI 10.1038/nrc2505; Hayes GM, 2007, CANCER RES, V67, P2072, DOI 10.1158/0008-5472.CAN-06-2969; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Kelly WK, 2012, J CLIN ONCOL, V30, P1534, DOI 10.1200/JCO.2011.39.4767; Lambrechts D, 2013, J CLIN ONCOL, V31, P1219, DOI 10.1200/JCO.2012.46.2762; Malvezzi M, 2013, ANN ONCOL, V24, P792, DOI 10.1093/annonc/mdt010; Mukherji D, 2013, CRIT REV ONCOL HEMAT, V87, P122, DOI 10.1016/j.critrevonc.2013.01.002; Nowak DG, 2010, J BIOL CHEM, V285, P5532, DOI 10.1074/jbc.M109.074930; Odunsi K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051030; Oltean S, 2012, BIOCHEM SOC T, V40, P831, DOI 10.1042/BST20120051; Quaglia A, 2013, SURG ONCOL, V22, pE31, DOI 10.1016/j.suronc.2013.02.010; Rennel ES, 2008, BRIT J CANCER, V98, P1250, DOI 10.1038/sj.bjc.6604309; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Suarez SC, 2006, CELL MOL LIFE SCI, V63, P2067, DOI 10.1007/s00018-006-6254-9; Varey AHR, 2008, BRIT J CANCER, V98, P1366, DOI 10.1038/sj.bjc.6604308; WEIDNER N, 1993, AM J PATHOL, V143, P401; Whang YE, 2013, UROL ONCOL-SEMIN ORI, V31, P82, DOI 10.1016/j.urolonc.2010.09.018; Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934; Yang M, 2005, PROSTATE, V62, P374, DOI 10.1002/pros.20125; Zhou B, 2013, MOL CELL BIOCHEM, V379, P191, DOI 10.1007/s11010-013-1641-7; Zhou ZH, 2012, MOL CELL, V47, P422, DOI 10.1016/j.molcel.2012.05.014	39	100	104	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4311	4319		10.1038/onc.2014.360	http://dx.doi.org/10.1038/onc.2014.360			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25381816	Green Accepted			2022-12-17	WOS:000359494400003
J	Li, BS; Zuo, QF; Zhao, YL; Xiao, B; Zhuang, Y; Mao, XH; Wu, C; Yang, SM; Zeng, H; Zou, QM; Guo, G				Li, B-S; Zuo, Q-F; Zhao, Y-L; Xiao, B.; Zhuang, Y.; Mao, X-H; Wu, C.; Yang, S-M; Zeng, H.; Zou, Q-M; Guo, G.			MicroRNA-25 promotes gastric cancer migration, invasion and proliferation by directly targeting transducer of ERBB2, 1 and correlates with poor survival	ONCOGENE			English	Article							CELL-PROLIFERATION; TUMOR-SUPPRESSOR; TOB; EXPRESSION; APOPTOSIS; PROTEIN; MIR-25; CONTRIBUTES; NODE	Gastric cancer (GC) is one of the most common tumors and the molecular mechanism underlying its metastasis is still largely unclear. Here, we show that miR-25 was overexpressed in plasma and primary tumor tissues of GC patients with tumor node metastasis stage (III or IV) or lymph node metastasis. MiR-25 inhibition significantly decreased the metastasis, invasion and proliferation of GC cells in vitro, and reduced their capacity to develop distal pulmonary metastases and peritoneal dissemination in vivo. Furthermore, miR-25 repressed transducer of ERBB2, 1 (TOB1) expression by directly binding to TOB1-3'-UTR, and the inverse correlation was observed between the expressions of miR-25 and TOB1 mRNA in primary GC tissues. Moreover, the loss of TOB1 increased the metastasis, invasion and proliferation of GC cells, and the restoration of TOB1 led to suppressed metastasis, invasion and proliferation. The receiver operating characteristics analysis yielded an area under the curve value of 0.7325 in distinguishing the GC patients with death from those with survival. The analysis of optimal cutoff value revealed poor survival in GC patients with high plasma concentrations of miR-25 (40.2333 amol/mu l). Taken together, miR-25 promotes GC progression by directly downregulating TOB1 expression, and may be a noninvasive biomarker for the prognosis of GC patients.	[Li, B-S; Zuo, Q-F; Xiao, B.; Zhuang, Y.; Mao, X-H; Wu, C.; Zeng, H.; Zou, Q-M; Guo, G.] Third Mil Med Univ, Coll Pharm, Natl Engn Res Ctr Immunol Prod, Dept Microbiol & Biochem Pharm, Chongqing 400038, Peoples R China; [Zhao, Y-L] Third Mil Med Univ, Southwest Hosp, Gen Surg, Chongqing 400038, Peoples R China; [Zhao, Y-L] Third Mil Med Univ, Southwest Hosp, Ctr Minimally Invas Gastrointestinal Surg, Chongqing 400038, Peoples R China; [Yang, S-M] Third Mil Med Univ, Xinqiao Hosp, Dept Gastroenterol, Chongqing 400038, Peoples R China	Army Medical University; Army Medical University; Army Medical University; Army Medical University	Zou, QM (corresponding author), Third Mil Med Univ, Coll Pharm, Dept Microbiol & Biochem Pharm, 30 Gao Tan Yan Rd, Chongqing 400038, Peoples R China.	Qmzou2007@163.com; guogang7001@163.com			National Science Foundation of China (NSFC) [81301729, 81202310]	National Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	We thank the staff at National Engineering Research Center of Immunological Products. This work was supported by grants from the National Science Foundation of China (NSFC): grant no. 81301729 (to LBS) and 81202310 (to XB).	AKAGI T, 1976, ACTA MED OKAYAMA, V30, P215; Brett JO, 2011, AGING-US, V3, P108, DOI 10.18632/aging.100285; Esposito F, 2012, J CLIN ENDOCR METAB, V97, pE710, DOI 10.1210/jc.2011-3068; Eulalio A, 2012, NATURE, V492, P376, DOI 10.1038/nature11739; Ezzeddine N, 2007, MOL CELL BIOL, V27, P7791, DOI 10.1128/MCB.01254-07; Gao P, 2013, ONCOGENE, V32, P491, DOI 10.1038/onc.2012.61; Helms MW, 2009, CANCER RES, V69, P5049, DOI 10.1158/0008-5472.CAN-08-4154; Iwanaga K, 2003, CANCER LETT, V202, P71, DOI 10.1016/j.canlet.2003.08.019; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jiao Y, 2012, ACTA PHARMACOL SIN, V33, P250, DOI 10.1038/aps.2011.163; Kan T, 2009, GASTROENTEROLOGY, V136, P1689, DOI 10.1053/j.gastro.2009.02.002; Kim BH, 2013, J SURG ONCOL, V107, P505, DOI 10.1002/jso.23271; Kim YK, 2009, NUCLEIC ACIDS RES, V37, P1672, DOI 10.1093/nar/gkp002; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kundu J, 2012, INT J ONCOL, V41, P839, DOI 10.3892/ijo.2012.1517; Kurashige J, 2012, ANN SURG ONCOL, V19, pS656, DOI 10.1245/s10434-012-2217-6; Leite KRM, 2013, UROL ONCOL-SEMIN ORI, V31, P796, DOI 10.1016/j.urolonc.2011.07.002; Li BS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041629; Li Q, 2013, CANCER LETT, V335, P168, DOI 10.1016/j.canlet.2013.02.029; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Matsuda S, 1996, ONCOGENE, V12, P705; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Pineau P, 2010, P NATL ACAD SCI USA, V107, P264, DOI 10.1073/pnas.0907904107; Razumilava N, 2012, HEPATOLOGY, V55, P465, DOI 10.1002/hep.24698; Scapoli L, 2010, INT J IMMUNOPATH PH, V23, P1229, DOI 10.1177/039463201002300427; Swarbrick A, 2010, NAT MED, V16, P1134, DOI 10.1038/nm.2227; Ushijima T, 2004, CANCER CELL, V5, P121, DOI 10.1016/S1535-6108(04)00033-9; Wahlquist C, 2014, NATURE, V508, P531, DOI 10.1038/nature13073; Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026; Xiong B, 2006, DEV CELL, V11, P225, DOI 10.1016/j.devcel.2006.06.012; Xu XH, 2012, BIOCHEM BIOPH RES CO, V421, P640, DOI 10.1016/j.bbrc.2012.03.048; Yao QY, 2013, CANCER LETT, V335, P219, DOI 10.1016/j.canlet.2013.02.031; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7; Yoshida Y, 2003, MECH DEVELOP, V120, P629, DOI 10.1016/S0925-4773(03)00020-0; Yu JC, 2011, MOL CELLS, V32, P47, DOI 10.1007/s10059-011-2316-4; Zhang CX, 2009, CURR OPIN MOL THER, V11, P641; Zhao HY, 2014, MOL CELL BIOCHEM, V385, P207, DOI 10.1007/s11010-013-1829-x; Zhao X, 2013, ONCOGENE, V32, P1363, DOI 10.1038/onc.2012.156; Zheng B, 2012, ONCOGENE, V31, P4509, DOI 10.1038/onc.2011.581	39	100	107	1	28	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2556	2565		10.1038/onc.2014.214	http://dx.doi.org/10.1038/onc.2014.214			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25043310				2022-12-17	WOS:000354541300002
J	Hansen, MT; Forst, B; Cremers, N; Quagliata, L; Ambartsumian, N; Grum-Schwensen, B; Klingelhofer, J; Abdul-Al, A; Herrmann, P; Osterland, M; Stein, U; Nielsen, GH; Scherer, PE; Lukanidin, E; Sleeman, JP; Grigorian, M				Hansen, M. T.; Forst, B.; Cremers, N.; Quagliata, L.; Ambartsumian, N.; Grum-Schwensen, B.; Klingelhoefer, J.; Abdul-Al, A.; Herrmann, P.; Osterland, M.; Stein, U.; Nielsen, G. H.; Scherer, P. E.; Lukanidin, E.; Sleeman, J. P.; Grigorian, M.			A link between inflammation and metastasis: serum amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4	ONCOGENE			English	Article						inflammation; metastasis; S100A4; serum amyloid A	PROTEIN S100A4; RHEUMATOID-ARTHRITIS; UP-REGULATION; KAPPA-B; EXPRESSION; RECEPTOR; CELLS; PROGRESSION; BINDING; GROWTH	S100A4 is implicated in metastasis and chronic inflammation, but its function remains uncertain. Here we establish an S100A4-dependent link between inflammation and metastatic tumor progression. We found that the acute-phase response proteins serum amyloid A (SAA) 1 and SAA3 are transcriptional targets of S100A4 via Toll-like receptor 4 (TLR4)/nuclear factor-kappa B signaling. SAA proteins stimulated the transcription of RANTES (regulated upon activation normal T-cell expressed and presumably secreted), G-CSF (granulocyte-colony-stimulating factor) and MMP2 (matrix metalloproteinase 2), MMP3, MMP9 and MMP13. We have also shown for the first time that SAA stimulate their own transcription as well as that of proinflammatory S100A8 and S100A9 proteins. Moreover, they strongly enhanced tumor cell adhesion to fibronectin, and stimulated migration and invasion of human and mouse tumor cells. Intravenously injected S100A4 protein induced expression of SAA proteins and cytokines in an organ-specific manner. In a breast cancer animal model, ectopic expression of SAA1 or SAA3 in tumor cells potently promoted widespread metastasis formation accompanied by a massive infiltration of immune cells. Furthermore, coordinate expression of S100A4 and SAA in tumor samples from colorectal carcinoma patients significantly correlated with reduced overall survival. These data show that SAA proteins are effectors for the metastasis-promoting functions of S100A4, and serve as a link between inflammation and tumor progression.	[Hansen, M. T.; Forst, B.; Ambartsumian, N.; Grum-Schwensen, B.; Klingelhoefer, J.; Abdul-Al, A.; Lukanidin, E.; Grigorian, M.] Danish Canc Soc Res Ctr, Copenhagen, Denmark; [Cremers, N.; Quagliata, L.; Sleeman, J. P.] Heidelberg Univ, Univ Med Mannheim, Mannheim, Germany; [Cremers, N.; Sleeman, J. P.] KIT Karlsruhe, Eggenstein Leopoldshafen, Germany; [Ambartsumian, N.; Klingelhoefer, J.; Grigorian, M.] Univ Copenhagen, Inst Neurosci & Pharmacol, Neurooncol Grp, Lab Neural Plast, DK-2200 Copenhagen, Denmark; [Osterland, M.; Stein, U.; Nielsen, G. H.] Charite, Max Delbruck Ctr Mol Med, Expt & Clin Res Ctr, D-13353 Berlin, Germany; [Nielsen, G. H.] Air Liquide Danmark AS, Horsens, Denmark; [Scherer, P. E.] Univ Texas SW Med Ctr Dallas, Touchstone Diabet Ctr, Dallas, TX 75390 USA	Danish Cancer Society; Ruprecht Karls University Heidelberg; University of Copenhagen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Air Liquide; University of Texas System; University of Texas Southwestern Medical Center Dallas	Grigorian, M (corresponding author), Univ Copenhagen, Inst Neurosci & Pharmacol, Neurooncol Grp, Lab Neural Plast, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark.	grigorian@sund.ku.dk	Quagliata, Luca/B-8321-2015; Scherer, Philipp E/K-7819-2012; Sleeman, Jonathan P/H-2515-2013	Quagliata, Luca/0000-0001-8249-9914; Scherer, Philipp E/0000-0003-0680-3392; Sleeman, Jonathan P/0000-0003-1718-7687; Grum-Schwensen, Birgitte/0000-0001-6677-1869; Stein, Ulrike/0000-0001-7006-282X	European Union (TuMIC) [Health-F2-2008-201662]; INARMERA [FP7-INCO-2010-6]; Danish Cancer Society; Dansk Kraeftforsknings Fond	European Union (TuMIC); INARMERA; Danish Cancer Society(Danish Cancer Society); Dansk Kraeftforsknings Fond	We thank Ekaterina Dulina, Inge Skibshoj and Lene Bregnholt Larsen for careful technical assistance. We gratefully acknowledge funding by the European Union (TuMIC, Health-F2-2008-201662) and INARMERA (FP7-INCO-2010-6), the Danish Cancer Society and the Dansk Kraeftforsknings Fond.	Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Ambartsumian N, 2005, CELL BIOL, V1, P363; Ambartsumian NS, 1996, ONCOGENE, V13, P1621; Bang CA, 2007, AM J PHYSIOL-RENAL, V293, pF1325, DOI 10.1152/ajprenal.00039.2007; Baumann P, 2005, CANCER RES, V65, P10783, DOI 10.1158/0008-5472.CAN-05-0619; Cabezon T, 2007, INT J CANCER, V121, P1433, DOI 10.1002/ijc.22850; Cerezo LA, 2011, RHEUMATOLOGY, V50, P1766, DOI 10.1093/rheumatology/ker218; Cunnane G, 2001, CURR OPIN RHEUMATOL, V13, P67, DOI 10.1097/00002281-200101000-00011; Davies MPA, 1996, ONCOGENE, V13, P1631; DeNardo DG, 2008, CANCER METAST REV, V27, P11, DOI 10.1007/s10555-007-9100-0; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; Ehrchen JM, 2009, J LEUKOCYTE BIOL, V86, P557, DOI 10.1189/jlb.1008647; Forst B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010374; Fridman WH, 2011, CANCER RES, V71, P5601, DOI 10.1158/0008-5472.CAN-11-1316; Fritz G, 2010, FEBS J, V277, P4578, DOI 10.1111/j.1742-4658.2010.07887.x; Furlaneto CJ, 2000, BIOCHEM BIOPH RES CO, V268, P405, DOI 10.1006/bbrc.2000.2143; Gregory AD, 2011, CANCER RES, V71, P2411, DOI 10.1158/0008-5472.CAN-10-2583; GRIGORIAN M, 1994, ELECTROPHORESIS, V15, P463, DOI 10.1002/elps.1150150163; Grigorian M, 1996, INT J CANCER, V67, P831, DOI 10.1002/(SICI)1097-0215(19960917)67:6<831::AID-IJC13>3.0.CO;2-4; Grigorian M, 2008, CURR MOL MED, V8, P492, DOI 10.2174/156652408785747942; Grum-Schwensen B, 2010, CANCER RES, V70, P936, DOI 10.1158/0008-5472.CAN-09-3220; He R, 2006, J IMMUNOL, V177, P4072, DOI 10.4049/jimmunol.177.6.4072; He RL, 2009, BLOOD, V113, P429, DOI 10.1182/blood-2008-03-139923; Helfman DM, 2005, BRIT J CANCER, V92, P1955, DOI 10.1038/sj.bjc.6602613; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Klingelhofer J, 2007, ARTHRITIS RHEUM-US, V56, P779, DOI 10.1002/art.22398; Klingelhofer J, 2012, NEOPLASIA, V14, P1260, DOI 10.1593/neo.121554; Klingelhofer J, 2009, FEBS J, V276, P5936, DOI 10.1111/j.1742-4658.2009.07274.x; Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031; Larson MA, 2003, BIOCHEM BIOPH RES CO, V301, P1030, DOI 10.1016/S0006-291X(03)00045-7; Lee HY, 2005, BIOCHEM BIOPH RES CO, V330, P989, DOI 10.1016/j.bbrc.2005.03.069; Lin Y, 2001, J BIOL CHEM, V276, P42077, DOI 10.1074/jbc.M107101200; Lukanidin E, 2012, SEMIN CANCER BIOL, V22, P216, DOI 10.1016/j.semcancer.2012.02.006; Maelandsmo GM, 1996, CANCER RES, V56, P5490; Malle E, 2009, CELL MOL LIFE SCI, V66, P9, DOI 10.1007/s00018-008-8321-x; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Moller HD, 2011, MOL CANCER RES, V9, P553, DOI 10.1158/1541-7786.MCR-11-0093; Mullan RH, 2006, ARTHRITIS RHEUM-US, V54, P105, DOI 10.1002/art.21518; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Okamoto H, 2008, J RHEUMATOL, V35, P752; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Schmid MC, 2010, J ONCOL, V2010, DOI 10.1155/2010/201026; Schmidt-Hansen B, 2004, J BIOL CHEM, V279, P24498, DOI 10.1074/jbc.M400441200; Song CJ, 2009, ATHEROSCLEROSIS, V207, P374, DOI 10.1016/j.atherosclerosis.2009.05.007; Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889; Sung HJ, 2011, J PROTEOME RES, V10, P1383, DOI 10.1021/pr101154j; Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707; Yamada T, 1999, CLIN CHEM LAB MED, V37, P381, DOI 10.1515/CCLM.1999.063; Zhao YL, 2009, J VASC RES, V46, P64, DOI 10.1159/000139134; Zibert JR, 2010, J INVEST DERMATOL, V130, P150, DOI 10.1038/jid.2009.206	52	100	105	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					424	435		10.1038/onc.2013.568	http://dx.doi.org/10.1038/onc.2013.568			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469032				2022-12-17	WOS:000348451300003
J	Yu, YH; Chen, HA; Chen, PS; Cheng, YJ; Hsu, WH; Chang, YW; Chen, YH; Jan, Y; Hsiao, M; Chang, TY; Liu, YH; Jeng, YM; Wu, CH; Huang, MT; Su, YH; Hung, MC; Chien, MH; Chen, CY; Kuo, ML; Su, JL				Yu, Y-H; Chen, H-A; Chen, P-S; Cheng, Y-J; Hsu, W-H; Chang, Y-W; Chen, Y-H; Jan, Y.; Hsiao, M.; Chang, T-Y; Liu, Y-H; Jeng, Y-M; Wu, C-H; Huang, M-T; Su, Y-H; Hung, M-C; Chien, M-H; Chen, C-Y; Kuo, M-L; Su, J-L			MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol	ONCOGENE			English	Article						FOXC2; miR-520h; resveratrol; metastasis	PROTEIN PHOSPHATASE 2A; EPITHELIAL-MESENCHYMAL TRANSITION; KAPPA-B KINASE; TRANSCRIPTION FACTORS; COLORECTAL-CANCER; SIGNALING PATHWAY; TUMOR-SUPPRESSOR; EXPRESSION; CELL; METASTASIS	Resveratrol, a phytochemical found in various plants and Chinese herbs, is associated with multiple tumor-suppressing activities, has been tested in clinical trials. However, the molecular mechanisms involved in resveratrol-mediated tumor suppressing activities are not yet completely defined. Here, we showed that treatment with resveratrol inhibited cell mobility through induction of the mesenchymal-epithelial transition (MET) in lung cancer cells. We. also found that downregulation of FOXC2 (forkhead box C2) is critical for resveratrol-mediated suppression of tumor metastasis in an in vitro and in vivo models. We also identified a signal cascade, namely, resveratrol-vertical bar miRNA-520h-vertical bar PP2A/C-vertical bar Akt -> NF-kappa B -> FOXC2, in which resveratrol inhibited the expression of FOXC2 through regulation of miRNA-520h-mediated signal cascade. This study identified a new miRNA-520h-related signal cascade involved in resveratrol-mediated tumor suppression activity and provide the clinical significances of miR-520h, PP2A/C and FOXC2 in lung cancer patients. Our results indicated a functional link between resveratrol-mediated miRNA-520h regulation and tumor suppressing ability, and provide a new insight into the role of resveratrol-induced molecular and epigenetic regulations in tumor suppression. Oncogene (2013) 32, 431-443; doi:10.1038/onc.2012.74; published online 12 March 2012	[Yu, Y-H; Hsu, W-H] China Med Univ Hosp, Dept Internal Med, Div Pulm Med, Taichung, Taiwan; [Yu, Y-H; Hsu, W-H] China Med Univ Hosp, Div Crit Care Med, Taichung, Taiwan; [Yu, Y-H] China Med Univ, Grad Inst Clin Med Sci, Taichung 40402, Taiwan; [Chen, H-A; Wu, C-H; Huang, M-T; Su, Y-H; Chien, M-H] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan; [Chen, H-A; Wu, C-H; Huang, M-T; Su, Y-H] Taipei Med Univ, Shuang Ho Hosp, Dept Surg, Div Gen Surg, Taipei, Taiwan; [Chen, P-S; Kuo, M-L] Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei, Taiwan; [Chen, P-S; Kuo, M-L] Natl Taiwan Univ, Angiogenesis Res Ctr, Taipei 10764, Taiwan; [Chen, P-S; Kuo, M-L] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan; [Cheng, Y-J; Chang, T-Y; Hung, M-C; Su, J-L] China Med Univ, Coll Med, Grad Inst Canc Biol, Taichung 40402, Taiwan; [Chang, Y-W] Natl Yang Ming Univ, Grad Inst Biochem & Mol Biol, Taipei 112, Taiwan; [Chen, Y-H; Liu, Y-H; Hung, M-C; Su, J-L] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan; [Jan, Y.; Hsiao, M.] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Jeng, Y-M] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 100, Taiwan; [Chien, M-H] Taipei Med Univ, Wan Fang Hosp, Taipei, Taiwan; [Chen, C-Y] China Med Univ Hosp, Ctr Canc, Taichung, Taiwan; [Su, J-L] China Med Univ, Canc Biol & Drug Discovery PhD Degree Program, Taichung 40402, Taiwan; [Su, J-L] Asia Univ, Dept Biotechnol, Taichung, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Taipei Medical University; Taipei Medical University; Shuang Ho Hospital; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; China Medical University Taiwan; National Yang Ming Chiao Tung University; China Medical University Taiwan; China Medical University Hospital - Taiwan; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital; Taipei Medical University; Taipei Municipal WanFang Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Asia University Taiwan	Su, JL (corresponding author), China Med Univ, Coll Med, Grad Inst Canc Biol, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.	mhchien1976@gmail.com; jlsu@mail.cmu.edu.tw	Hsiao, Michael/U-6238-2019; Chen, Pai-Sheng/G-2130-2012; Hung, Mien-Chie/ABD-5911-2021	Hsiao, Michael/0000-0001-8529-9213; Chen, Pai-Sheng/0000-0003-0513-1467; Hung, Mien-Chie/0000-0003-4317-4740; JENG, YUNG-MING/0000-0002-3878-4491; KUO, MIN-LIANG/0000-0002-7139-0144; Su, Yen-Hao/0000-0001-8288-3772	National Science Council [NSC-2632-B-001-MY3, NSC 96-2320-B-004-MY2, NSC 97-2320-B-039-039-MY3, NSC 98-2815-C-039-082-B]; National Health Research Institutes Grant from Taiwan [NHRI-EX98-9712BC, NHRI-EX99-9712BC, NHRI-EX100-9712BC]; Department of Health, Executive Yuan Grant from Taiwan [DOH99-TD-G111-011]; China Medical University [CMU96-220, CMU97-077, CMU97-277, CMU-99-NTU-08, CMU100-TS-06, DMR-101-014]	National Science Council(Ministry of Science and Technology, Taiwan); National Health Research Institutes Grant from Taiwan; Department of Health, Executive Yuan Grant from Taiwan; China Medical University(China Medical University)	This work was partially supported by the National Science Council Grant (NSC-2632-B-001-MY3, NSC 96-2320-B-004-MY2, NSC 97-2320-B-039-039-MY3 and NSC 98-2815-C-039-082-B to J-LS); National Health Research Institutes Grant from Taiwan (NHRI-EX98-9712BC, NHRI-EX99-9712BC and NHRI-EX100-9712BC to J-LS); Department of Health, Executive Yuan Grant from Taiwan (DOH99-TD-G111-011 to J-LS); Grants from China Medical University (CMU96-220, CMU97-077 and CMU97-277 to J-LS; CMU-99-NTU-08, CMU100-TS-06 and DMR-101-014 to Y-HY).	Agarwal A, 2005, ONCOGENE, V24, P1021, DOI 10.1038/sj.onc.1208296; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Aggarwal BB, 2004, ANTICANCER RES, V24, P2783; Alves CC, 2009, FRONT BIOSCI-LANDMRK, V14, P3041, DOI 10.2741/3433; Athar M, 2009, ARCH BIOCHEM BIOPHYS, V486, P95, DOI 10.1016/j.abb.2009.01.018; Aziz MH, 2006, MOL CANCER THER, V5, P1335, DOI 10.1158/1535-7163.MCT-05-0526; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Browne G, 2010, CELL CYCLE, V9, P886, DOI 10.4161/cc.9.5.10839; Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833; Choi HK, 2006, CANCER LETT, V242, P198, DOI 10.1016/j.canlet.2005.11.005; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Feschenko MS, 2002, J PHARMACOL EXP THER, V302, P111, DOI 10.1124/jpet.302.1.111; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Gronning LM, 2002, MOL ENDOCRINOL, V16, P873, DOI 10.1210/me.16.4.873; Hader C, 2010, ONCOGENE, V29, P1031, DOI 10.1038/onc.2009.397; Hamamori Y, 1997, MOL CELL BIOL, V17, P6563, DOI 10.1128/MCB.17.11.6563; Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103; Hayashi H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002401; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Holmes-McNary M, 2000, CANCER RES, V60, P3477; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Korpal M, 2008, RNA BIOL, V5, P115, DOI 10.4161/rna.5.3.6558; Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651; Kuhn H, 2002, EUR RESPIR J, V20, P703, DOI 10.1183/09031936.02.00294502; Kume T, 2001, GENE DEV, V15, P2470, DOI 10.1101/gad.907301; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Li Q, 2009, AM J PHYSIOL-ENDOC M, V4, P965; Liao Y, 2004, CANCER RES, V64, P5938, DOI 10.1158/0008-5472.CAN-04-1533; Lu YB, 2005, J LEUKOCYTE BIOL, V78, P259, DOI 10.1189/jlb.0904498; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Matsuoka Y, 2003, BRIT J PHARMACOL, V138, P1303, DOI 10.1038/sj.bjp.0705182; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Neviani P, 2005, CANCER CELL, V8, P355, DOI 10.1016/j.ccr.2005.10.015; Ngan CY, 2007, BRIT J CANCER, V96, P986, DOI 10.1038/sj.bjc.6603651; Nishida N, 2011, ANN SURG ONCOL, V18, P535, DOI 10.1245/s10434-010-1274-y; PAGET S, 1989, CANCER METAST REV, V8, P98; Perrotti D, 2008, CANCER METAST REV, V27, P159, DOI 10.1007/s10555-008-9119-x; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Saiko P, 2008, MUTAT RES-REV MUTAT, V658, P68, DOI 10.1016/j.mrrev.2007.08.004; Sano H, 2010, BIOCHEM BIOPH RES CO, V392, P201, DOI 10.1016/j.bbrc.2010.01.015; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Stewart JR, 1999, BIOCHEMISTRY-US, V38, P13244, DOI 10.1021/bi990875u; Stewart JR, 2000, BIOCHEM PHARMACOL, V60, P1355, DOI 10.1016/S0006-2952(00)00450-0; Su JL, 2010, CANCER RES, V70, P5096, DOI 10.1158/0008-5472.CAN-09-4148; Sun HZ, 2010, J ENDOCRINOL, V204, P311, DOI 10.1677/JOE-09-0270; Tili E, 2010, BIOCHEM PHARMACOL, V80, P2057, DOI 10.1016/j.bcp.2010.07.003; Tili E, 2010, CARCINOGENESIS, V31, P1561, DOI 10.1093/carcin/bgq143; Timmerman LA, 2004, GENE DEV, V18, P99, DOI 10.1101/gad.276304; Topczewska JM, 2001, GENE DEV, V15, P2483, DOI 10.1101/gad.907401; Woo JH, 2004, ONCOGENE, V23, P1845, DOI 10.1038/sj.onc.1207307; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069	54	100	109	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2013	32	4					431	443		10.1038/onc.2012.74	http://dx.doi.org/10.1038/onc.2012.74			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22410781				2022-12-17	WOS:000315551300004
J	Zhang, S; Shan, C; Kong, G; Du, Y; Ye, L; Zhang, X				Zhang, S.; Shan, C.; Kong, G.; Du, Y.; Ye, L.; Zhang, X.			MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-kappa B-inducing kinase (NIK)	ONCOGENE			English	Article						microRNA-520e; DNA methylation; hepatocellular carcinoma; cell proliferation; NF-kappa B-inducing kinase	HUMAN HEPATOCELLULAR-CARCINOMA; FREQUENT EPIGENETIC INACTIVATION; HUMAN CANCER-CELLS; CONSTITUTIVE ACTIVATION; P38 MAPK; EXPRESSION; PROLIFERATION; BIOGENESIS; TUMORS; FAMILY	MicroRNAs (miRNAs) are small, non-coding RNAs that can act as oncogenes or tumor suppressor genes in human cancer. Emerging evidence indicates that deregulation of miRNAs contributes to the hepatocarcinogenesis. In the present study, we demonstrated that the levels of miR-520e were dramatically decreased in examined hepatoma cell lines and clinical hepatocellular carcinoma (HCC) tissues. Moreover, we found that DNA hypermethylation in the upstream region of miR-520e resulted in the downregulation of miR-520e. Next, we demonstrated that introduction of miR-520e dramatically suppressed the growth of hepatoma cells in vitro and in vivo, whereas silencing the expression of miR-520e by anti-miR-520e resulted in a promoted cell proliferation, suggesting that miR-520e may be a novel tumor suppressor. Further studies revealed that NF-kappa B-inducing kinase (NIK) was one of the direct target genes of miR-520e, as miR-520e directly bound to the 3'untranslated region of NIK, which reduced the expression of NIK at the levels of mRNA and protein. Moreover, silencing of NIK was able to inhibit the growth of hepatoma cells, similar to the effect of miR-520e overexpression on growth of hepatoma cells. Meanwhile, the knockdown of NIK expression reversed the enhanced proliferation mediated by anti-miR-520e. In addition, miR-520e significantly decreased the phosphorylation of ERK1/2 (p-ERK1/2) and depressed the transcriptional activity and nuclear translocation of nuclear factor kappa B (NF-kappa B) (p65). These results suggest that miR-520e suppresses the growth of hepatoma cells by targeting NIK involving the NIK/p-ERK1/2/NF-kappa B signaling pathway. Finally, we showed that the intratumoral injection with miR-520e was able to directly repress the growth of hepatoma cells in the nude mice. Thus, our finding provides new insight into the mechanism of hepatocarcinogenesis, indicating a therapeutic potential of miR-520e in the treatment of HCC. Oncogene (2012) 31, 3607-3620; doi:10.1038/onc.2011.523; published online 21 November 2011	[Zhang, S.; Shan, C.; Kong, G.; Du, Y.; Zhang, X.] Nankai Univ, Key Lab Mol Microbiol & Technol, Dept Canc Res, Minist Educ,Inst Mol Biol,Coll Life Sci, Tianjin 300071, Peoples R China; [Ye, L.] Nankai Univ, Coll Life Sci, Dept Biochem, Tianjin 300071, Peoples R China	Nankai University; Nankai University	Zhang, X (corresponding author), Nankai Univ, Key Lab Mol Microbiol & Technol, Dept Canc Res, Minist Educ,Inst Mol Biol,Coll Life Sci, 94 Weijin Rd, Tianjin 300071, Peoples R China.	yelihong@nankai.edu.cn; zhangxd@nankai.edu.cn	Kong, Guangyao/L-2162-2013; Shan, changliang/L-9029-2016		National Basic Research Program of China (973 Program) [2009CB521702]; National Natural Science Foundation of China [81071624]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Basic Research Program of China (973 Program, No. 2009CB521702) and National Natural Science Foundation of China (No. 81071624).	Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brown KD, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2457; Calin GA, 2007, J CLIN INVEST, V117, P2059, DOI 10.1172/JCI32577; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen KH, 2007, BIOCHEM PHARMACOL, V73, P215, DOI 10.1016/j.bcp.2006.09.018; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Cui W, 2010, CANCER BIOL THER, V10, P232; Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Fazi F, 2007, CANCER CELL, V12, P457, DOI 10.1016/j.ccr.2007.09.020; Foehr ED, 2000, J BIOL CHEM, V275, P34021, DOI 10.1074/jbc.C000507200; Gessi M, 2011, NEUROPATH APPL NEURO, V37, P406, DOI 10.1111/j.1365-2990.2010.01151.x; Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607; Gramantieri L, 2008, J CELL MOL MED, V12, P2189, DOI 10.1111/j.1582-4934.2008.00533.x; Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Ji JF, 2009, CANCER BIOL THER, V8, P1683, DOI 10.4161/cbt.8.18.8898; Jiang J, 2008, CLIN CANCER RES, V14, P419, DOI 10.1158/1078-0432.CCR-07-0523; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Kim VN, 2006, TRENDS GENET, V22, P165, DOI 10.1016/j.tig.2006.01.003; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Li MH, 2009, CANCER CELL, V16, P533, DOI 10.1016/j.ccr.2009.10.025; Li Q, 2010, J GASTROEN HEPATOL, V25, P164, DOI 10.1111/j.1440-1746.2009.05971.x; Li S, 2009, HEPATOLOGY, V49, P1194, DOI 10.1002/hep.22757; Liang LH, 2010, HEPATOLOGY, V52, P1731, DOI 10.1002/hep.23904; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Lyle R, 2000, NAT GENET, V25, P19, DOI 10.1038/75546; Mercatelli N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004029; Nishina T, 2009, BIOCHEM BIOPH RES CO, V388, P96, DOI 10.1016/j.bbrc.2009.07.125; Nojima M, 2007, ONCOGENE, V26, P4699, DOI 10.1038/sj.onc.1210259; Rangaswami H, 2004, J BIOL CHEM, V279, P38921, DOI 10.1074/jbc.M404674200; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178; Selaru FM, 2009, HEPATOLOGY, V49, P1595, DOI 10.1002/hep.22838; Shan CL, 2010, CELL RES, V20, P563, DOI 10.1038/cr.2010.49; Xu T, 2009, HEPATOLOGY, V50, P113, DOI 10.1002/hep.22919; Yamaguchi N, 2009, CANCER SCI, V100, P1668, DOI 10.1111/j.1349-7006.2009.01228.x; Ying SY, 2005, BIOCHEM BIOPH RES CO, V326, P515, DOI 10.1016/j.bbrc.2004.10.215	45	100	106	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	31					3607	3620		10.1038/onc.2011.523	http://dx.doi.org/10.1038/onc.2011.523			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985EG	22105365				2022-12-17	WOS:000307245600004
J	Ferrao, PT; Bukczynska, EP; Johnstone, RW; McArthur, GA				Ferrao, P. T.; Bukczynska, E. P.; Johnstone, R. W.; McArthur, G. A.			Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells	ONCOGENE			English	Article						CHK inhibitors; DNA damage; p53; p19ARF; E mu-myc	DNA-DAMAGE RESPONSE; ONCOGENE-INDUCED SENESCENCE; CHECKPOINT KINASE 1; C-MYC; CANCER-THERAPY; SIGNALING PATHWAY; TUMOR-SUPPRESSOR; TRANSGENIC MICE; IN-VIVO; REPLICATION	CHK1 and CHK2 function as effectors of cell cycle checkpoint arrest following DNA damage. Small molecule inhibitors of CHK proteins are under clinical evaluation in combination with chemotherapeutic agents known to induce DNA damage. We examined whether CHK inhibitors could be effective as single agents in malignant cells with inherent DNA damage because of deregulated expression of the oncogene c-Myc. E mu-myc lymphoma cells showed a dramatic increase in the extent of DNA damage and DNA damage response (DDR) signalling within 1 h of treatment with CHK1 inhibitors followed by caspase-dependent apoptosis and cell death. In p53 wild-type/ARF null E mu-myc lymphoma cells, apoptotic cell death was preceded by accumulation of DNA damage and the amount of DNA damage correlated with the extent of cell death. This effect was not observed in normal B cells indicating that DNA damage accumulation following CHK inhibition was specific to E mu-myc lymphoma cells that exhibit inherent DNA damage because of MYC-induced replication stress. Similar results were obtained with another structurally distinct CHK-inhibitor. E mu-myc p53 null lymphoma cells were more sensitive to a dual CHK1/CHK2 inhibitor than to a CHK1-specific inhibitor. In all cases, the level of DNA damage following treatment was the most consistent indicator of drug sensitivity. Our results suggest that CHK inhibitors would be beneficial therapeutic agents in MYC-driven cancers. We propose that inhibitors of CHK can act in a synthetically lethal manner in cancers with replication stress as a result of these cancers being reliant on CHK proteins for an effective DDR and cell survival. Oncogene (2012) 31, 1661-1672; doi:10.1038/onc.2011.358; published online 15 August 2011	[Ferrao, P. T.; Bukczynska, E. P.; Johnstone, R. W.; McArthur, G. A.] Peter MacCallum Canc Inst, Div Res, Mol Oncol Lab, Melbourne, Vic 3002, Australia; [Ferrao, P. T.; Bukczynska, E. P.; Johnstone, R. W.; McArthur, G. A.] Peter MacCallum Canc Inst, Div Res, Canc Therapeut Program, Melbourne, Vic 3002, Australia; [Ferrao, P. T.; McArthur, G. A.] Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic, Australia; [Johnstone, R. W.; McArthur, G. A.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; St Vincent's Hospital Melbourne; University of Melbourne; University of Melbourne	Ferrao, PT (corresponding author), Peter MacCallum Canc Inst, Div Res, Mol Oncol Lab, St Andrews Pl, Melbourne, Vic 3002, Australia.	petranel.ferrao@petermac.org	Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237; McArthur, Grant/0000-0001-8908-6071	Pfizer Inc.; National Health and Medical Research Council of Australia; Cancer Council of Victoria	Pfizer Inc.(Pfizer); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria)	GAM, PTF and RWJ receive research support from Pfizer Inc.; This work was supported by grants from the National Health and Medical Research Council of Australia to GAM and to RWJ. GAM is a recipient of the Weary Dunlop Clinical Research Fellowship of the Cancer Council of Victoria. The statistical analysis and data presentation of dose response curves was performed by Dr Robert N Jorissen (LCCI, Ludwig Institute for Cancer Research). The MetaMorph Journal for measuring the Olive Tail Moment was provided by Cameron J Nowell of the Centre for Advanced Microscopy at the Ludwig Institute for Cancer Research. Pfizer Oncology, La Jolla, CA, USA provided PF-0477736 for this study. Dr Sreesha Srinivasa and Dr Wendy Levin (Pfizer Oncology) contributed to scientific discussion.	Abulaiti A, 2006, CANCER RES, V66, P10505, DOI 10.1158/0008-5472.CAN-06-2351; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Ashwell S, 2008, CLIN CANCER RES, V14, P4032, DOI 10.1158/1078-0432.CCR-07-5138; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bertwistle D, 2007, BLOOD, V109, P792, DOI 10.1182/blood-2006-07-033985; Blasina A, 2008, MOL CANCER THER, V7, P2394, DOI 10.1158/1535-7163.MCT-07-2391; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Chanoux RA, 2009, J BIOL CHEM, V284, P5994, DOI 10.1074/jbc.M806739200; Cole KA, 2011, P NATL ACAD SCI USA, V108, P3336, DOI 10.1073/pnas.1012351108; Dai Y, 2010, CLIN CANCER RES, V16, P376, DOI 10.1158/1078-0432.CCR-09-1029; Deans AJ, 2006, CANCER RES, V66, P8219, DOI 10.1158/0008-5472.CAN-05-3945; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Enders GH, 2008, J BIOL CHEM, V283, P17749, DOI 10.1074/jbc.R800021200; Giroux V, 2006, FASEB J, V20, P1982, DOI 10.1096/fj.06-6239com; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Janetka JW, 2007, CURR OPIN DRUG DISC, V10, P473; Kastan MB, 2008, MOL CANCER RES, V6, P517, DOI 10.1158/1541-7786.MCR-08-0020; Lindemann RK, 2007, P NATL ACAD SCI USA, V104, P8071, DOI 10.1073/pnas.0702294104; Liu QH, 2000, GENE DEV, V14, P1448; Lord CJ, 2009, CLIN CANCER RES, V15, P3241, DOI 10.1158/1078-0432.CCR-09-0434; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; Mallette FA, 2007, CELL CYCLE, V6, P1831, DOI 10.4161/cc.6.15.4516; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Mercurio Ciro, 2004, Proceedings of the American Association for Cancer Research Annual Meeting, V45, P190; Morgan MA, 2010, CANCER RES, V70, P4972, DOI 10.1158/0008-5472.CAN-09-3573; Myers K, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000324; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Newbold A, 2008, MOL CANCER THER, V7, P1066, DOI 10.1158/1535-7163.MCT-07-2256; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; Parsels LA, 2009, MOL CANCER THER, V8, P45, DOI 10.1158/1535-7163.MCT-08-0662; R Development Core Team, 2009, R LANG ENV STAT COMP; Redon CE, 2010, CLIN CANCER RES, V16, P4532, DOI 10.1158/1078-0432.CCR-10-0523; Reimann M, 2007, BLOOD, V110, P2996, DOI 10.1182/blood-2007-02-075614; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Wall M, 2008, BLOOD, V112, P2305, DOI 10.1182/blood-2007-09-111856; Wilsker D, 2008, P NATL ACAD SCI USA, V105, P20752, DOI 10.1073/pnas.0806917106; Xiao Z, 2006, MOL CANCER THER, V5, P1935, DOI 10.1158/1535-7163.MCT-06-0077; Zabludoff SD, 2008, MOL CANCER THER, V7, P2955, DOI 10.1158/1535-7163.MCT-08-0492; Zenvirt S, 2010, ONCOGENE, V29, P6149, DOI 10.1038/onc.2010.343; Zhao Y, 2006, CANCER RES, V66, P5354, DOI 10.1158/0008-5472.CAN-05-4275	50	100	104	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	13					1661	1672		10.1038/onc.2011.358	http://dx.doi.org/10.1038/onc.2011.358			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21841818				2022-12-17	WOS:000302231400005
J	van Veelen, W; Korsse, SE; van de Laar, L; Peppelenbosch, MP				van Veelen, W.; Korsse, S. E.; van de Laar, L.; Peppelenbosch, M. P.			The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling	ONCOGENE			English	Review						mTOR; rapamycin; hamartoma syndromes; cancer; PTEN/PI3K/PKB signaling	TUBEROUS SCLEROSIS COMPLEX; PEUTZ-JEGHERS-SYNDROME; ACTIVATED PROTEIN-KINASE; RAPAMYCIN ANALOG CCI-779; RENAL-CELL CARCINOMA; EKER RAT MODEL; TUMOR-SUPPRESSOR; MOUSE MODEL; MAMMALIAN TARGET; UP-REGULATION	The liver kinase B1 (LKB1)/adenosine mono-phosphate-activated protein kinase (AMPK)/tuberous sclerosis complex (TSC)/mammalian target of rapamycin (mTOR) complex (mTORC1) cassette constitutes a canonical signaling pathway that integrates information on the metabolic and nutrient status and translates this into regulation of cell growth. Alterations in this pathway are associated with a wide variety of cancers and hereditary hamartoma syndromes, diseases in which hyperactivation of mTORC1 has been described. Specific mTORC1 inhibitors have been developed for clinical use, and these drugs have been anticipated to provide efficient treatment for these diseases. In the present review, we provide an overview of the metabolic LKB1/AMPK/TSC/mTORC1 pathway, describe how its aberrant signaling associates with cancer development, and indicate the difficulties encountered when biochemical data are extrapolated to provide avenues for rational treatment of disease when targeting this signaling pathway. A careful examination of preclinical and clinical studies performed with rapamycin or derivatives thereof shows that although results are encouraging, we are only half way in the long and winding road to design rationale treatment targeted at the LKB1/AMPK/TSC/mTORC1 pathway. Inherited cancer syndromes associated with this pathway such as the Peutz-Jeghers syndrome and TSC, provide perfect models to study the relationship between genetics and disease phenotype, and to delineate the complexities that underlie translation of biochemical and genetical information to clinical management, and thus provide important clues for devising novel rational medicine for cancerous diseases in general. Oncogene (2011) 30, 2289-2303; doi: 10.1038/onc.2010.630; published online 24 January 2011	[van Veelen, W.; Korsse, S. E.; van de Laar, L.; Peppelenbosch, M. P.] Erasmus Med Univ Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Peppelenbosch, MP (corresponding author), Erasmus MC, Dept Gastroenterol & Hepatol, Room L-457,S Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands.	m.peppelenbosch@erasmusmc.nl	Peppelenbosch, Maikel P./U-5304-2019	Peppelenbosch, Maikel/0000-0001-9112-6028	Foundation 'Michelle'; TOP-institute pharma scheme of the Dutch government	Foundation 'Michelle'; TOP-institute pharma scheme of the Dutch government	We wish to acknowledge the financial support from the Foundation 'Michelle' as well as from the TOP-institute pharma scheme of the Dutch government for their studies.	Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Baybis M, 2004, ANN NEUROL, V56, P478, DOI 10.1002/ana.20211; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Brajenovic M, 2004, J BIOL CHEM, V279, P12804, DOI 10.1074/jbc.M312171200; Calva D, 2008, SURG CLIN N AM, V88, P779, DOI 10.1016/j.suc.2008.05.002; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; Carretero J, 2007, ONCOGENE, V26, P1616, DOI 10.1038/sj.onc.1209951; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Chan HY, 2010, ADV THER, V27, P495, DOI 10.1007/s12325-010-0045-2; Chan JA, 2004, J NEUROPATH EXP NEUR, V63, P1236, DOI 10.1093/jnen/63.12.1236; Chong-Kopera H, 2006, J BIOL CHEM, V281, P8313, DOI 10.1074/jbc.C500451200; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Contreras CM, 2008, CANCER RES, V68, P759, DOI 10.1158/0008-5472.CAN-07-5014; Cook JD, 2004, CURR MOL MED, V4, P813, DOI 10.2174/1566524043359656; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Corsenca A, 2007, NEPHROL DIAL TRANSPL, V22, P3330, DOI 10.1093/ndt/gfm552; Curatolo P, 2008, LANCET, V372, P657, DOI 10.1016/S0140-6736(08)61279-9; Davies DM, 2008, NEW ENGL J MED, V358, P200, DOI 10.1056/NEJMc072500; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dorfman J, 2008, MOL BIOL CELL, V19, P1614, DOI 10.1091/mbc.E07-05-0454; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; Dworakowska D, 2009, ENDOCR-RELAT CANCER, V16, P45, DOI 10.1677/ERC-08-0142; Ehninger D, 2008, NAT MED, V14, P843, DOI 10.1038/nm1788; El-Hashemite N, 2003, CANCER RES, V63, P5173; Ess KC, 2010, CURR OPIN NEUROL, V23, P189, DOI 10.1097/WCO.0b013e32832c4ff5; Franz DN, 2006, ANN NEUROL, V59, P490, DOI 10.1002/ana.20784; Godlewski J, 2010, MOL CELL, V37, P620, DOI 10.1016/j.molcel.2010.02.018; Gurumurthy S, 2008, CANCER RES, V68, P55, DOI 10.1158/0008-5472.CAN-07-3225; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Habib SL, 2010, CARCINOGENESIS, V31, P2022, DOI 10.1093/carcin/bgq189; Haemel AK, 2010, ARCH DERMATOL, V146, P715, DOI 10.1001/archdermatol.2010.125; Haidinger M, 2010, TRANSPL INT, V23, P777, DOI 10.1111/j.1432-2277.2009.01041.x; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hegedus B, 2008, CANCER RES, V68, P1520, DOI 10.1158/0008-5472.CAN-07-5916; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Herry I, 2007, EUR J INTERN MED, V18, P76, DOI 10.1016/j.ejim.2006.07.017; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Hezel AF, 2008, MOL CELL BIOL, V28, P2414, DOI 10.1128/MCB.01621-07; Hino O, 2004, CURR MOL MED, V4, P807, DOI 10.2174/1566524043359692; Hofbauer GFL, 2008, BRIT J DERMATOL, V159, P473, DOI 10.1111/j.1365-2133.2008.08677.x; Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Huang SL, 2003, CANCER BIOL THER, V2, P222, DOI 10.4161/cbt.2.3.360; Huang X, 2008, BIOCHEM J, V412, P211, DOI 10.1042/BJ20080557; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Ikeda Y, 2009, J BIOL CHEM, V284, P35839, DOI 10.1074/jbc.M109.057273; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2005, MICROBIOL MOL BIOL R, V69, P79, DOI 10.1128/MMBR.69.1.79-100.2005; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Jaleel M, 2005, FEBS LETT, V579, P1417, DOI 10.1016/j.febslet.2005.01.042; Jansen M, 2009, PHYSIOL REV, V89, P777, DOI 10.1152/physrev.00026.2008; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jiang WG, 2005, EUR J CANCER, V41, P1628, DOI 10.1016/j.ejca.2005.03.023; Jishage K, 2002, P NATL ACAD SCI USA, V99, P8903, DOI 10.1073/pnas.122254599; Johannessen CM, 2008, CURR BIOL, V18, P56, DOI 10.1016/j.cub.2007.11.066; Jozwiak J, 2009, AM J DERMATOPATH, V31, P68, DOI 10.1097/DAD.0b013e3181882c09; Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249; Kantidakis T, 2010, P NATL ACAD SCI USA, V107, P11823, DOI 10.1073/pnas.1005188107; Kasper M, 2009, CARCINOGENESIS, V30, P903, DOI 10.1093/carcin/bgp048; Katajisto P, 2008, NAT GENET, V40, P455, DOI 10.1038/ng.98; Kenerson H, 2005, PEDIATR RES, V57, P67, DOI 10.1203/01.PDR.0000147727.78571.07; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Knowles MA, 2003, BIOCHEM SOC T, V31, P597, DOI 10.1042/BST0310597; Kobayashi T, 1999, CANCER RES, V59, P1206; Koenig MK, 2008, J CHILD NEUROL, V23, P1238, DOI 10.1177/0883073808321764; Kola B, 2006, TRENDS ENDOCRIN MET, V17, P205, DOI 10.1016/j.tem.2006.05.006; Krischock L, 2010, ARCH DIS CHILD, V95, P391, DOI 10.1136/adc.2009.159210; Krueger DA, 2010, NEW ENGL J MED, V363, P1801, DOI 10.1056/NEJMoa1001671; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lam C, 2010, PEDIATR BLOOD CANCER, V54, P476, DOI 10.1002/pbc.22298; Law BK, 2005, CRIT REV ONCOL HEMAT, V56, P47, DOI 10.1016/j.critrevonc.2004.09.009; Lee L, 2005, GENE CHROMOSOME CANC, V42, P213, DOI 10.1002/gcc.20118; Lee L, 2006, GENE CHROMOSOME CANC, V45, P933, DOI 10.1002/gcc.20357; Lee PS, 2010, AM J RESP CELL MOL, V42, P227, DOI 10.1165/rcmb.2009-0050OC; Lim CT, 2010, J MOL ENDOCRINOL, V44, P87, DOI 10.1677/JME-09-0063; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Massoumi R, 2007, THESCIENTIFICWORLDJO, V7, P1413, DOI 10.1100/tsw.2007.200; McCarthy A, 2009, J PATHOL, V219, P306, DOI 10.1002/path.2599; McGarrity TJ, 2006, CELL MOL LIFE SCI, V63, P2135, DOI 10.1007/s00018-006-6080-0; MCNAMARA EK, 2010, J DERMATOLOG TREAT; Meikle L, 2008, J NEUROSCI, V28, P5422, DOI 10.1523/JNEUROSCI.0955-08.2008; Mi RF, 2009, J GENET GENOMICS, V36, P355, DOI 10.1016/S1673-8527(08)60124-1; Michels AA, 2010, MOL CELL BIOL, V30, P3749, DOI 10.1128/MCB.00319-10; Missiaglia E, 2010, J CLIN ONCOL, V28, P245, DOI 10.1200/JCO.2008.21.5988; Miyata H, 2004, ANN NEUROL, V56, P510, DOI 10.1002/ana.20234; Miyoshi H, 2002, CANCER RES, V62, P2261; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; Muncy J, 2009, J CHILD NEUROL, V24, P477, DOI 10.1177/0883073808324535; NELLIST M, 1993, CELL, V75, P1305; Onda H, 2002, MOL CELL NEUROSCI, V21, P561, DOI 10.1006/mcne.2002.1184; Orlova KA, 2010, ANN NY ACAD SCI, V1184, P87, DOI 10.1111/j.1749-6632.2009.05117.x; Ouyang JY, 2011, J BIOL CHEM, V286, P1, DOI 10.1074/jbc.M110.121806; Papanas N, 2010, EXPERT OPIN INV DRUG, V19, P913, DOI 10.1517/13543784.2010.499122; Parrinello S, 2009, TRENDS CELL BIOL, V19, P395, DOI 10.1016/j.tcb.2009.05.003; Pearson HB, 2008, CANCER RES, V68, P2223, DOI 10.1158/0008-5472.CAN-07-5169; Peces R, 2010, NEPHROL DIAL TRANSPL, V25, P3787, DOI 10.1093/ndt/gfq456; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Pollizzi K, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-38; Pressey JG, 2010, PEDIATR BLOOD CANCER, V54, P1035, DOI 10.1002/pbc.22401; Rennebeck G, 1998, P NATL ACAD SCI USA, V95, P15629, DOI 10.1073/pnas.95.26.15629; Robinson J, 2009, J PATHOL, V219, P35, DOI 10.1002/path.2562; Rosner M, 2008, MUTAT RES-REV MUTAT, V658, P234, DOI 10.1016/j.mrrev.2008.01.001; Sancak O, 2005, EUR J HUM GENET, V13, P731, DOI 10.1038/sj.ejhg.5201402; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Schwartz RA, 2007, J AM ACAD DERMATOL, V57, P189, DOI 10.1016/j.jaad.2007.05.004; SEHGAL SN, 1975, J ANTIBIOT, V28, P727, DOI 10.7164/antibiotics.28.727; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shackelford DB, 2009, P NATL ACAD SCI USA, V106, P11137, DOI 10.1073/pnas.0900465106; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005; Sparagana SP, 2010, PEDIATR NEUROL, V42, P443, DOI 10.1016/j.pediatrneurol.2010.01.016; Spicer J, 2003, ONCOGENE, V22, P4752, DOI 10.1038/sj.onc.1206669; Squarize CH, 2008, CANCER RES, V68, P7066, DOI 10.1158/0008-5472.CAN-08-0922; Tarasewicz A, 2009, TRANSPL P, V41, P3677, DOI 10.1016/j.transproceed.2009.06.227; Tomlinson IPM, 1997, J MED GENET, V34, P1007, DOI 10.1136/jmg.34.12.1007; Uhlmann EJ, 2004, GLIA, V47, P180, DOI 10.1002/glia.20036; Uhlmann EJ, 2002, ANN NEUROL, V52, P285, DOI 10.1002/ana.10283; van Lier MGF, 2010, J CELL MOL MED, V14, P181, DOI 10.1111/j.1582-4934.2009.00977.x; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721; Villanueva A, 2008, GASTROENTEROLOGY, V135, P1972, DOI 10.1053/j.gastro.2008.08.008; Wei C, 2008, CLIN CANCER RES, V14, P1167, DOI 10.1158/1078-0432.CCR-07-4007; Wei CJ, 2009, CANCER LETT, V277, P149, DOI 10.1016/j.canlet.2008.11.036; WICKER LS, 1990, EUR J IMMUNOL, V20, P2277, DOI 10.1002/eji.1830201017; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wienecke R, 2006, AM J KIDNEY DIS, V48, pE27, DOI 10.1053/j.ajkd.2006.05.018; Woodrum C, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-14; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Yalon M, 2011, CHILD NERV SYST, V27, P179, DOI 10.1007/s00381-010-1222-y; Yeung RS, 2004, CURR MOL MED, V4, P799, DOI 10.2174/1566524043359791; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074; Yoo LI, 2002, NAT REV CANCER, V2, P529, DOI 10.1038/nrc843; Zeng LH, 2008, ANN NEUROL, V63, P444, DOI 10.1002/ana.21331; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	149	100	103	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	20					2289	2303		10.1038/onc.2010.630	http://dx.doi.org/10.1038/onc.2010.630			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	766NF	21258412				2022-12-17	WOS:000290789200001
J	Altman, BJ; Jacobs, SR; Mason, EF; Michalek, RD; MacIntyre, AN; Coloff, JL; Ilkayeva, O; Jia, W; He, YW; Rathmell, JC				Altman, B. J.; Jacobs, S. R.; Mason, E. F.; Michalek, R. D.; MacIntyre, A. N.; Coloff, J. L.; Ilkayeva, O.; Jia, W.; He, Y-W; Rathmell, J. C.			Autophagy is essential to suppress cell stress and to allow BCR-Abl-mediated leukemogenesis	ONCOGENE			English	Article						autophagy; BCR-Abl; Puma; apoptosis; metabolism; p53	INDUCED ACTIVATION; INDUCED APOPTOSIS; METABOLIC STRESS; TUMOR-SUPPRESSOR; STEM-CELLS; SURVIVAL; PROTEIN; DEATH; CANCER; GROWTH	Hematopoietic cells normally require cell extrinsic signals to maintain metabolism and survival. In contrast, cancer cells can express constitutively active oncogenic kinases such as BCR-Abl that promote these processes independent of extrinsic growth factors. When cells receive insufficient growth signals or when oncogenic kinases are inhibited, glucose metabolism decreases and the self-digestive process of autophagy is elevated to degrade bulk cytoplasm and organelles. Although autophagy has been proposed to provide a cell-intrinsic nutrient supply for mitochondrial oxidative metabolism and to maintain cellular homeostasis through degradation of damaged organelles or protein aggregates, its acute role in growth factor deprivation or inhibition of oncogenic kinases remains poorly understood. We therefore developed a growth factor-dependent hematopoietic cell culture model in which autophagy can be acutely disrupted through conditional Cre-mediated excision of the autophagy-essential gene Atg3. Treated cells rapidly lost their ability to perform autophagy and underwent cell cycle arrest and apoptosis. Although Atg3 was essential for optimal upregulation of mitochondrial oxidative pathways in growth factor withdrawal, this metabolic contribution of autophagy did not appear critical for cell survival, as provision of exogenous pyruvate or lipids could not completely rescue Atg3 deficiency. Instead, autophagy suppressed a stress response that otherwise led to p53 phosphorylation and upregulation of p21 and the proapoptotic Bcl-2 family protein Puma. Importantly, BCR-Abl-expressing cells had low basal levels of autophagy, but were highly dependent on this process, and rapidly underwent apoptosis upon disruption of autophagy through Atg3 deletion or treatment with chemical autophagy inhibitors. This dependence on autophagy extended in vivo, as Atg3 deletion also prevented BCR-Abl-mediated leukemogenesis in a cell transfer model. Together these data demonstrate a critical role for autophagy to mitigate cell stress, and that cells expressing the oncogenic kinase BCR-Abl appear particularly dependent on autophagy for cell survival and leukemogenesis. Oncogene (2011) 30, 1855-1867; doi: 10.1038/onc.2010.561; published online 13 December 2010	[Altman, B. J.; Jacobs, S. R.; Mason, E. F.; Michalek, R. D.; MacIntyre, A. N.; Coloff, J. L.; Ilkayeva, O.; Rathmell, J. C.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; [Ilkayeva, O.; Rathmell, J. C.] Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA; [Jia, W.; He, Y-W; Rathmell, J. C.] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Rathmell, JC (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	jeff.rathmell@duke.edu	Altman, Brian J./X-2783-2019	Altman, Brian J./0000-0002-3954-4916; Macintyre, Andrew/0000-0002-5297-0207	NIH [R01 CA123350, F30 HL094044]; Leukemia and Lymphoma Society Scholar Award; Cancer Research Institute; NATIONAL CANCER INSTITUTE [R01CA123350] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F30HL094044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI074944] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia and Lymphoma Society Scholar Award(Leukemia and Lymphoma Society); Cancer Research Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by NIH R01 CA123350 (JCR), Leukemia and Lymphoma Society Scholar Award (JCR), Alex's Lemonade Stand (JCR) and Gabrielle's Angel Foundation for Cancer Research (JCR). JCR is the Bernard Osher Fellow of the American Asthma Foundation. EFM is supported by NIH F30 HL094044 and RDM is supported by the Irvington Institute Postdoctoral Fellowship from the Cancer Research Institute.	Altman BJ, 2009, AUTOPHAGY, V5, P569, DOI 10.4161/auto.5.4.8254; Altman BJ, 2009, MOL BIOL CELL, V20, P1180, DOI 10.1091/mbc.E08-08-0829; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; An J, 2004, NAT MED, V10, P268, DOI 10.1038/nm995; Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660; Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260; Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Darzynkiewicz Z, 2001, Curr Protoc Cytom, VChapter 7, DOI 10.1002/0471142956.cy0705s00; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200; Ishihara T, 2007, BIOCHEM BIOPH RES CO, V356, P711, DOI 10.1016/j.bbrc.2007.03.034; Iwata J, 2006, J BIOL CHEM, V281, P4035, DOI 10.1074/jbc.M512283200; Jacobs SR, 2010, J IMMUNOL, V184, P3461, DOI 10.4049/jimmunol.0902593; Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269; Jin S, 2007, J CELL SCI, V120, P379, DOI 10.1242/jcs.03349; Kamitsuji Y, 2008, CELL DEATH DIFFER, V15, P1712, DOI 10.1038/cdd.2008.107; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Karawajew L, 2005, BLOOD, V105, P4767, DOI 10.1182/blood-2004-09-3428; Kharas NG, 2005, CANCER RES, V65, P2047, DOI 10.1158/0008-5472.CAN-04-3888; Kim I, 2007, ARCH BIOCHEM BIOPHYS, V462, P245, DOI 10.1016/j.abb.2007.03.034; Kiyono K, 2009, CANCER RES, V69, P8844, DOI 10.1158/0008-5472.CAN-08-4401; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Lainez S, 2010, FASEB J, V24, P1958, DOI 10.1096/fj.09-151472; Legesse-Miller A, 2000, J BIOL CHEM, V275, P32966, DOI 10.1074/jbc.M000917200; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liu B, 2008, FREE RADICAL BIO MED, V44, P1529, DOI 10.1016/j.freeradbiomed.2008.01.011; Lomonaco SL, 2009, INT J CANCER, V125, P717, DOI 10.1002/ijc.24402; Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Mason EF, 2010, CANCER RES, V70, P8066, DOI 10.1158/0008-5472.CAN-10-0608; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Modi H, 2007, BLOOD, V109, P5411, DOI 10.1182/blood-2006-06-032490; Niizuma K, 2009, J NEUROCHEM, V109, P133, DOI 10.1111/j.1471-4159.2009.05897.x; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; Ren JH, 2010, CANCER BIOTHER RADIO, V25, P75, DOI 10.1089/cbr.2009.0701; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976; Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Wan GH, 2008, J BIOL CHEM, V283, P21540, DOI 10.1074/jbc.M800214200; Weidberg H, 2010, EMBO J, V29, P1792, DOI 10.1038/emboj.2010.74; Wiernan HL, 2007, MOL BIOL CELL, V18, P1437, DOI 10.1091/mbc.E06-07-0593; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhao Y, 2007, MOL CELL BIOL, V27, P4328, DOI 10.1128/MCB.00153-07; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	59	100	111	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	16					1855	1867		10.1038/onc.2010.561	http://dx.doi.org/10.1038/onc.2010.561			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21151168	Green Accepted			2022-12-17	WOS:000289777700002
J	Santo, L; Vallet, S; Hideshima, T; Cirstea, D; Ikeda, H; Pozzi, S; Patel, K; Okawa, Y; Gorgun, G; Perrone, G; Calabrese, E; Yule, M; Squires, M; Ladetto, M; Boccadoro, M; Richardson, PG; Munshi, NC; Anderson, KC; Raje, N				Santo, L.; Vallet, S.; Hideshima, T.; Cirstea, D.; Ikeda, H.; Pozzi, S.; Patel, K.; Okawa, Y.; Gorgun, G.; Perrone, G.; Calabrese, E.; Yule, M.; Squires, M.; Ladetto, M.; Boccadoro, M.; Richardson, P. G.; Munshi, N. C.; Anderson, K. C.; Raje, N.			AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3 beta activation and RNA polymerase II inhibition	ONCOGENE			English	Article						myeloma; cyclin-dependent kinase; GSK-3 beta; RNA pol II	GLYCOGEN-SYNTHASE KINASE-3; DOWN-REGULATION; CELL-CYCLE; PROTEIN-KINASE; SELICICLIB CYC202; R-ROSCOVITINE; CANCER-CELLS; KAPPA-B; TRANSCRIPTION; SURVIVAL	Dysregulated cell cycling is a universal hallmark of cancer and is often mediated by abnormal activation of cyclin-dependent kinases (CDKs) and their cyclin partners. Overexpression of individual complexes are reported in multiple myeloma (MM), making them attractive therapeutic targets. In this study, we investigate the preclinical activity of a novel small-molecule multi-CDK inhibitor, AT7519, in MM. We show the anti-MM activity of AT7519 displaying potent cytotoxicity and apoptosis; associated with in vivo tumor growth inhibition and prolonged survival. At the molecular level, AT7519 inhibited RNA polymerase II (RNA pol II) phosphorylation, a CDK9, 7 substrate, associated with decreased RNA synthesis confirmed by [(3)H] Uridine incorporation. In addition, AT7519 inhibited glycogen synthase kinase 3 beta (GSK-3 beta) phosphorylation; conversely pretreatment with a selective GSK-3 inhibitor and shRNA GSK-3 beta knockdown restored MM survival, suggesting the involvement of GSK-3 beta in AT7519-induced apoptosis. GSK-3 beta activation was independent of RNA pol II dephosphorylation confirmed by alpha-amanitin, a specific RNA pol II inihibitor, showing potent inhibition of RNA pol II phosphorylation without corresponding effects on GSK-3 beta phosphorylation. These results offer new insights into the crucial, yet controversial role of GSK-3 beta in MM and show significant anti-MM activity of AT7519, providing the rationale for its clinical evaluation in MM. Oncogene (2010) 29, 2325-2336; doi:10.1038/onc.2009.510; published online 25 January 2010	[Santo, L.; Vallet, S.; Hideshima, T.; Cirstea, D.; Ikeda, H.; Pozzi, S.; Okawa, Y.; Gorgun, G.; Perrone, G.; Calabrese, E.; Richardson, P. G.; Munshi, N. C.; Anderson, K. C.; Raje, N.] Harvard Univ, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Sch Med, Boston, MA 02115 USA; [Vallet, S.; Pozzi, S.; Patel, K.; Raje, N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02115 USA; [Yule, M.; Squires, M.] Astex Therapeut Ltd, Cambridge, England; [Ladetto, M.; Boccadoro, M.] Univ Turin, Div Ematol, Turin, Italy	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Astex Pharmaceuticals; University of Turin	Santo, L (corresponding author), Harvard Univ, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Sch Med, 44 Binney St, Boston, MA 02115 USA.	loredana_santo@dfci.harvard.edu	Pozzi, Samantha/A-7617-2012; ladetto, marco/AAA-5546-2022; Vallet, Sonia/AHE-3935-2022; Perrone, Giulia/L-4565-2017; Munshi, Nikhil/ABE-2338-2021	Pozzi, Samantha/0000-0001-7917-1774; ladetto, marco/0000-0002-8283-2681; Vallet, Sonia/0000-0003-0146-8089; Perrone, Giulia/0000-0002-4312-0577; Boccadoro, Mario/0000-0001-8130-5209; Patel, Kishan/0000-0002-5526-2900	ASCO CDA; Multiple Myeloma Research Foundation (MMRF); International Myeloma Foundation (IMF); Leukemia and Lymphoma Society; NATIONAL CANCER INSTITUTE [P50CA100707, P01CA078378] Funding Source: NIH RePORTER	ASCO CDA; Multiple Myeloma Research Foundation (MMRF); International Myeloma Foundation (IMF); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by ASCO CDA, Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF) and Leukemia and Lymphoma Society Clinical Scholar Award.	Bergsagel PL, 2005, J CLIN ONCOL, V23, P6333, DOI 10.1200/JCO.2005.05.021; Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200; Cai DP, 2006, CANCER RES, V66, P9270, DOI 10.1158/0008-5472.CAN-06-1758; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chen R, 2005, BLOOD, V106, P2513, DOI 10.1182/blood-2005-04-1678; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Deshpande A, 2005, ONCOGENE, V24, P2909, DOI 10.1038/sj.onc.1208618; Ely S, 2005, CANCER RES, V65, P11345, DOI 10.1158/0008-5472.CAN-05-2159; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; G-Amlak M, 2002, BIOCHEM BIOPH RES CO, V297, P760, DOI 10.1016/S0006-291X(02)02278-7; Gojo I, 2002, CLIN CANCER RES, V8, P3527; Grimes CA, 2001, PROG NEUROBIOL, V65, P497, DOI 10.1016/S0301-0082(01)00024-7; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood-2004-01-0037; Hideshima T, 2007, BRIT J HAEMATOL, V138, P783, DOI 10.1111/j.1365-2141.2007.06714.x; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Loyer P, 2005, CELL SIGNAL, V17, P1033, DOI 10.1016/j.cellsig.2005.02.005; MacCallum DE, 2005, CANCER RES, V65, P5399, DOI 10.1158/0008-5472.CAN-05-0233; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; McInnes C, 2008, DRUG DISCOV TODAY, V13, P875, DOI 10.1016/j.drudis.2008.06.012; Menu E, 2008, CANCER RES, V68, P5519, DOI 10.1158/0008-5472.CAN-07-6404; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Nakagawa Y, 2006, AM J HEMATOL, V81, P824, DOI 10.1002/ajh.20656; Nekhai S, 2002, BIOCHEM J, V364, P649, DOI 10.1042/BJ20011191; Neri A, 2008, LEUKEMIA LYMPHOMA, V49, P1374, DOI 10.1080/10428190802078289; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; Oelgeschlager T, 2002, J CELL PHYSIOL, V190, P160, DOI 10.1002/JCP.10058; Ougolkov AV, 2007, BLOOD, V110, P735, DOI 10.1182/blood-2006-12-060947; Raje N, 2005, BLOOD, V106, P1042, DOI 10.1182/blood-2005-01-0320; Raje N, 2009, LEUKEMIA, V23, P961, DOI 10.1038/leu.2008.378; Santamaria D, 2006, FRONT BIOSCI-LANDMRK, V11, P1164, DOI 10.2741/1871; Shakoori A, 2005, BIOCHEM BIOPH RES CO, V334, P1365, DOI 10.1016/j.bbrc.2005.07.041; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Squires MS, 2009, MOL CANCER THER, V8, P324, DOI 10.1158/1535-7163.MCT-08-0890; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Tu YP, 2000, CANCER RES, V60, P6763; Vene R, 2008, CANCER RES, V68, P6987, DOI 10.1158/0008-5472.CAN-07-6362; Wang Z, 2008, NATURE, V455, P1205, DOI 10.1038/nature07284; WIELAND T, 1991, EXPERIENTIA, V47, P1186, DOI 10.1007/BF01918382; Wyatt PG, 2008, J MED CHEM, V51, P4986, DOI 10.1021/jm800382h; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885	45	100	105	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	16					2325	2336		10.1038/onc.2009.510	http://dx.doi.org/10.1038/onc.2009.510			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20101221	Green Accepted			2022-12-17	WOS:000276951500002
J	Horn, HF; Vousden, KH				Horn, H. F.; Vousden, K. H.			Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway	ONCOGENE			English	Article						p53; MDM2; L5; L11	POLYMERASE-III TRANSCRIPTION; UBIQUITIN LIGASE ACTIVITY; TUMOR-SUPPRESSOR P53; RING FINGER DOMAIN; 5S RNA; ONCOPROTEIN MDM2; MOLECULAR-BASIS; NUCLEAR EXPORT; CELL-CYCLE; IN-VITRO	MDM2 is a ubiquitin ligase that plays a key role in regulating the stability of the p53 tumor suppressor protein. Several proteins have been shown to activate the p53 pathway by interacting with and inhibiting the E3 function of MDM2, thereby leading to an accumulation of p53. These include the alternate reading frame (ARF) proteins and the ribosomal proteins L5 and L11. We found that when overexpressed alone, L11 is much less potent in inhibiting MDM2 than p14(ARF). However, L11 cooperates with L5, resulting in a robust inhibition of the E3 activity of MDM2, and a stabilization and activation of p53 approaching that achieved by p14(ARF). We further showed that the ability of L11 to bind the 5S rRNA is important for the cooperation with L5, and a mutant L11, which cannot bind the 5S rRNA, cannot cooperate with L5 in inhibiting MDM2.	[Horn, H. F.; Vousden, K. H.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Vousden, KH (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	k.vousden@beatson.gla.ac.uk		Horn, Henning/0000-0002-5885-8996	Cancer Research, UK	Cancer Research, UK(Cancer Research UK)	We are grateful to Professor Dr Joachim Hauber for sending us a human L5 expression plasmid (p3L5) and anti-human L5 antibody. This work was funded by Cancer Research, UK.	Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P1881, DOI 10.1073/pnas.68.8.1881; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Carter S, 2007, NAT CELL BIOL, V9, P428, DOI 10.1038/ncb1562; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Crighton D, 2003, EMBO J, V22, P2810, DOI 10.1093/emboj/cdg265; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2006, J BIOL CHEM, V281, P24304, DOI 10.1074/jbc.M602596200; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Efeyan A, 2006, NATURE, V443, P159, DOI 10.1038/443159a; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; GRAY PN, 1972, EUR J BIOCHEM, V28, P412, DOI 10.1111/j.1432-1033.1972.tb01927.x; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Iwasaki K, 2002, BIOSCI BIOTECH BIOCH, V66, P103, DOI 10.1271/bbb.66.103; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KNIGHT E, 1967, J MOL BIOL, V28, P491, DOI 10.1016/S0022-2836(67)80099-8; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; Lukashchuk N, 2007, MOL CELL BIOL, V27, P8284, DOI 10.1128/MCB.00050-07; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARION MJ, 1981, BIOCHIM BIOPHYS ACTA, V652, P193, DOI 10.1016/0005-2787(81)90222-7; MARSTON NJ, 1994, ONCOGENE, V9, P2707; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nakashima T, 2001, RNA, V7, P692, DOI 10.1017/S1355838201002345; Perederina A, 2002, RNA, V8, P1548, DOI 10.1017/S1355838202029953; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Schatz O, 1998, P NATL ACAD SCI USA, V95, P1607, DOI 10.1073/pnas.95.4.1607; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6; SPIERER P, 1978, BIOCHEMISTRY-US, V17, P2474, DOI 10.1021/bi00606a002; STEITZ JA, 1988, J CELL BIOL, V106, P545, DOI 10.1083/jcb.106.3.545; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sun XX, 2008, J BIOL CHEM, V283, P12387, DOI 10.1074/jbc.M801387200; Szymanski M, 2003, BIOCHEM J, V371, P641, DOI 10.1042/BJ20020872; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Toledo F, 2006, CANCER CELL, V9, P273, DOI 10.1016/j.ccr.2006.03.014; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yuan XJ, 2005, MOL CELL, V19, P77, DOI 10.1016/j.molcel.2005.05.023; Zhang JY, 2007, GENE DEV, V21, P2580, DOI 10.1101/gad.1569307; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	64	100	104	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2008	27	44					5774	5784		10.1038/onc.2008.189	http://dx.doi.org/10.1038/onc.2008.189			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QC	18560357				2022-12-17	WOS:000259722400002
J	Cheresh, DA; Stupack, DG				Cheresh, D. A.; Stupack, D. G.			Regulation of angiogenesis: apoptotic cues from the ECM	ONCOGENE			English	Review						apoptosis; integrin; survival; endothelial; pericyte	FOCAL ADHESION KINASE; ENDOTHELIAL PROGENITOR CELLS; INTEGRIN ALPHA(V)BETA(3)-MEDIATED ACTIVATION; TUMOR-ASSOCIATED MACROPHAGES; FACTOR-KAPPA-B; EXTRACELLULAR-MATRIX; INHIBITS ANGIOGENESIS; PROTEIN-KINASE; GLANZMANN THROMBASTHENIA; VASCULAR MORPHOGENESIS	The extracellular matrix (ECM) acts both as a physical scaffold for cells and as a repository for growth factors. Moreover, ECM structure and physical-chemical properties convey precise information to cells that profoundly influences their biology by interactions with cell surface receptors termed integrins. During angiogenesis, the perivascular ECM plays a critical role in determining the proliferative, invasive and survival responses of the local vascular cells to the angiogenic growth factors. Dynamic changes in both the ECM and the local vascular cells act in concert to regulate new blood vessel growth. The digestion of ECM components by proteolysis is critical for the invasive capacity of endothelial cells, but also creates ECM fragments, which antagonize the mechanosensory function of integrins, and can be apoptogenic. Here, we discuss the roles of integrins in modulating cellular responses to a changing ECM, in particular the regulation of survival and invasion among invasive endothelial cells.	[Cheresh, D. A.; Stupack, D. G.] UCSD Sch Med, Moores UCSD Canc Ctr, Dept Pathol, La Jolla, CA 92039 USA	University of California System; University of California San Diego	Cheresh, DA (corresponding author), UCSD Sch Med, Moores UCSD Canc Ctr, Dept Pathol, 3855 Hlth Sci Dr, La Jolla, CA 92039 USA.	dcheresh@ucsd.edu	Peng, Chunwei/F-6788-2010		NCI NIH HHS [R01 CA107263] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acevedo LM, 2008, BLOOD, V111, P2674, DOI 10.1182/blood-2007-08-110205; Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Algvere PV, 2008, ACTA OPHTHALMOL, V86, P352, DOI 10.1111/j.1755-3768.2008.01317.x; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Banno A, 2008, BIOCHEM SOC T, V36, P229, DOI 10.1042/BST0360229; Barbero S, 2008, J BIOL CHEM, V283, P13031, DOI 10.1074/jbc.M800549200; Beekman KW, 2006, CLIN GENITOURIN CANC, V4, P299, DOI 10.3816/CGC.2006.n.012; Ben-Yosef Y, 2005, AM J PHYSIOL-CELL PH, V289, pC1321, DOI 10.1152/ajpcell.00079.2005; Bieler G, 2007, ONCOGENE, V26, P5722, DOI 10.1038/sj.onc.1210354; Blystone SD, 1999, J CELL BIOL, V145, P889, DOI 10.1083/jcb.145.4.889; Boger DL, 2001, J AM CHEM SOC, V123, P1280, DOI 10.1021/ja003579+; Boudreau N, 1997, J CELL BIOL, V139, P257, DOI 10.1083/jcb.139.1.257; Brassard DL, 1999, EXP CELL RES, V251, P33, DOI 10.1006/excr.1999.4559; Bredesen DE, 2005, CELL DEATH DIFFER, V12, P1031, DOI 10.1038/sj.cdd.4401680; Brindle NPJ, 2006, CIRC RES, V98, P1014, DOI 10.1161/01.RES.0000218275.54089.12; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Bruhl T, 2004, CIRC RES, V94, P743, DOI 10.1161/01.RES.0000120861.27064.09; Bussolino F, 2006, ENDOTHELIUM-J ENDOTH, V13, P81, DOI 10.1080/10623320600698003; Chen YH, 2006, THROMB HAEMOSTASIS, V95, P668, DOI 10.1160/TH05-11-0757; Chen Y, 2008, BLOOD, V111, P1217, DOI 10.1182/blood-2007-07-104133; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; COLLER BS, 1991, BLOOD, V77, P75; Courter DL, 2005, J BIOL CHEM, V280, P12145, DOI 10.1074/jbc.M412555200; CRAFT PS, 1994, ANN ONCOL, V5, P305, DOI 10.1093/oxfordjournals.annonc.a058829; Croll SD, 2004, EXP NEUROL, V187, P388, DOI 10.1016/j.expneurol.2004.02.010; Cursi S, 2006, EMBO J, V25, P1895, DOI 10.1038/sj.emboj.7601085; Dallabrida SM, 2005, CIRC RES, V96, DOI 10.1161/01.RES.0000158285.57191.60; Davis GE, 2008, CURR OPIN HEMATOL, V15, P197, DOI 10.1097/MOH.0b013e3282fcc321; Dickson PV, 2007, CLIN CANCER RES, V13, P3942, DOI 10.1158/1078-0432.CCR-07-0278; DRANSFIELD I, 1992, J CELL BIOL, V116, P1527, DOI 10.1083/jcb.116.6.1527; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; El-Sheikh A, 2005, CANCER RES, V65, P11109, DOI 10.1158/0008-5472.CAN-05-2733; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Erdreich-Epstein A, 2005, BLOOD, V105, P4353, DOI 10.1182/blood-2004-08-3098; Essick E, 2008, MOL CELL BIOCHEM, V314, P151, DOI 10.1007/s11010-008-9776-7; Felding-Habermann B, 1997, J CELL BIOL, V139, P1567, DOI 10.1083/jcb.139.6.1567; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Firth JA, 2002, J ANAT, V200, P541, DOI 10.1046/j.1469-7580.2002.00059.x; Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Fukasawa M, 2007, CANCER BIOL THER, V6, P1173; Fukuhara S, 2008, NAT CELL BIOL, V10, P513, DOI 10.1038/ncb1714; Garmy-Susini B, 2005, BRIT J CANCER, V93, P855, DOI 10.1038/sj.bjc.6602808; Garmy-Susini B, 2005, J CLIN INVEST, V115, P1542, DOI 10.1172/JCI23445; Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200; Gasparini G, 1996, CLIN CANCER RES, V2, P1191; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giannone G, 2006, TRENDS CELL BIOL, V16, P213, DOI 10.1016/j.tcb.2006.02.005; Gounis MJ, 2005, GENE THER, V12, P762, DOI 10.1038/sj.gt.3302481; Grothey A, 2008, CANCER J, V14, P170, DOI 10.1097/PPO.0b013e318178d9de; Hall H, 2004, MICROVASC RES, V68, P169, DOI 10.1016/j.mvr.2004.07.001; Hall Heike, 2004, Angiogenesis, V7, P213, DOI 10.1007/s10456-004-1328-5; Hoang MV, 2004, P NATL ACAD SCI USA, V101, P1874, DOI 10.1073/pnas.0308525100; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Hristov M, 2007, THROMB HAEMOSTASIS, V98, P274, DOI 10.1160/TH07-03-0181; Imanishi Y, 2007, CANCER RES, V67, P4254, DOI 10.1158/0008-5472.CAN-06-4100; Ingber DE, 2002, CIRC RES, V91, P877, DOI 10.1161/01.RES.0000039537.73816.E5; Ishida S, 2003, NAT MED, V9, P781, DOI 10.1038/nm877; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jin H, 2006, J CLIN INVEST, V116, P652, DOI 10.1172/JCI24751; Jin H, 2006, CANCER RES, V66, P2146, DOI 10.1158/0008-5472.CAN-05-2704; John H, 2005, BBA-PROTEINS PROTEOM, V1747, P161, DOI 10.1016/j.bbapap.2004.10.013; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Kim SY, 2007, ARCH BIOCHEM BIOPHYS, V459, P40, DOI 10.1016/j.abb.2006.11.001; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; Kiosses WB, 2002, CIRC RES, V90, P697, DOI 10.1161/01.RES.0000014227.76102.5D; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Kohl K, 2007, EUR J CELL BIOL, V86, P719, DOI 10.1016/j.ejcb.2007.06.007; Larsen M, 2006, CURR OPIN CELL BIOL, V18, P463, DOI 10.1016/j.ceb.2006.08.009; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Loges S, 2007, BIOCHEM BIOPH RES CO, V357, P1016, DOI 10.1016/j.bbrc.2007.04.060; Lominadze D, 2005, AM J PHYSIOL-HEART C, V288, pH1257, DOI 10.1152/ajpheart.00856.2004; LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Mace KA, 2005, J CELL SCI, V118, P2567, DOI 10.1242/jcs.02399; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Marnmoto A, 2008, CURR OPIN HEMATOL, V15, P228, DOI 10.1097/MOH.0b013e3282fa7445; Marti Hugo H., 1999, Thrombosis and Haemostasis, V82, P44; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Mavria G, 2006, CANCER CELL, V9, P33, DOI 10.1016/j.ccr.2005.12.021; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Meerovitch K, 2003, VASC PHARMACOL, V40, P77, DOI 10.1016/S1537-1891(02)00339-7; Moldovan NI, 2003, ADV EXP MED BIOL, V522, P1; Myers C, 2002, AM J PATHOL, V161, P2099, DOI 10.1016/S0002-9440(10)64488-4; Myers C, 2000, J CELL BIOL, V148, P343, DOI 10.1083/jcb.148.2.343; Nagy JA, 2006, EXP CELL RES, V312, P538, DOI 10.1016/j.yexcr.2005.10.017; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; Parri M, 2007, J BIOL CHEM, V282, P19619, DOI 10.1074/jbc.M701319200; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Patel S, 2005, CANCER RES, V65, P1414, DOI 10.1158/0008-5472.CAN-04-3431; Porta C, 2007, ADV EXP MED BIOL, V604, P67, DOI 10.1007/978-0-387-69116-9_5; Potter MD, 2005, J BIOL CHEM, V280, P31906, DOI 10.1074/jbc.M505568200; Raguse JD, 2004, ORAL ONCOL, V40, P228, DOI 10.1016/j.oraloncology.2003.08.003; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Rose DM, 2007, IMMUNOL REV, V218, P126, DOI 10.1111/j.1600-065X.2007.00536.x; Rose DM, 2003, J IMMUNOL, V170, P5912, DOI 10.4049/jimmunol.170.12.5912; Ruegg C, 2002, ENDOTHELIUM-J ENDOTH, V9, P151, DOI 10.1080/10623320290016591; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Saharinen P, 2008, NAT CELL BIOL, V10, P527, DOI 10.1038/ncb1715; Salven P, 2003, BLOOD, V101, P168, DOI 10.1182/blood-2002-03-0755; Scatena MT, 2002, TRENDS CARDIOVAS MED, V12, P83, DOI 10.1016/S1050-1738(01)00151-7; SCHLAEPFER DD, 1994, NATURE, V372, P786; Senft J, 2007, CANCER RES, V67, P11505, DOI 10.1158/0008-5472.CAN-07-5755; Sha G, 2007, HUM REPROD, V22, P3159, DOI 10.1093/humrep/dem266; Shaut CA, 2007, DEV DYNAM, V236, P951, DOI 10.1002/dvdy.21077; Shim WSN, 2007, MOL CANCER RES, V5, P655, DOI 10.1158/1541-7786.MCR-07-0072; Silletti S, 2001, P NATL ACAD SCI USA, V98, P119, DOI 10.1073/pnas.011343298; Silletti S, 2000, J CELL BIOL, V149, P1485, DOI 10.1083/jcb.149.7.1485; Storgard CM, 1999, J CLIN INVEST, V103, P47, DOI 10.1172/JCI3756; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Stupack DG, 2005, CELL DEATH DIFFER, V12, P1021, DOI 10.1038/sj.cdd.4401658; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; STUPACK DG, 1992, EXP CELL RES, V203, P443, DOI 10.1016/0014-4827(92)90019-5; STUPACK DG, 1994, CELL IMMUNOL, V155, P237, DOI 10.1006/cimm.1994.1116; Szekanecz Z, 2007, CURR OPIN RHEUMATOL, V19, P289, DOI 10.1097/BOR.0b013e32805e87ae; Todorovic V, 2005, J CELL BIOL, V171, P559, DOI 10.1083/jcb.200504015; Tsakadze NL, 2004, AM J PHYSIOL-CELL PH, V287, pC55, DOI 10.1152/ajpcell.00585.2003; Ueno M, 2007, CURR MED CHEM, V14, P1199, DOI 10.2174/092986707780597943; Uyen HD, 2002, J CELL SCI, V115, P3073; van Hinsbergh VWM, 2008, CARDIOVASC RES, V78, P203, DOI 10.1093/cvr/cvm102; van Hinsbergh VWM, 2006, ARTERIOSCL THROM VAS, V26, P716, DOI 10.1161/01.ATV.0000209518.58252.17; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; Vieira JM, 2007, DEVELOPMENT, V134, P1833, DOI 10.1242/dev.002402; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Weis SM, 2007, BLOOD, V109, P1962, DOI 10.1182/blood-2005-10-038893; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/S1535-6108(04)00305-8; Wu CC, 2007, P NATL ACAD SCI USA, V104, P1254, DOI 10.1073/pnas.0609806104; Wu Y, 2007, ARTERIOSCL THROM VAS, V27, P1968, DOI 10.1161/ATVBAHA.107.148759; Xu R, 2001, BIOCHEM BIOPH RES CO, V289, P264, DOI 10.1006/bbrc.2001.5970; Zhai JB, 2003, J BIOL CHEM, V278, P24865, DOI 10.1074/jbc.M302381200; Zhao HB, 2005, MOL ENDOCRINOL, V19, P771, DOI 10.1210/me.2004-0161; Zheng LX, 2006, MOL CELL BIOL, V26, P3505, DOI 10.1128/MCB.26.9.3505-3513.2006	144	100	103	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	48					6285	6298		10.1038/onc.2008.304	http://dx.doi.org/10.1038/onc.2008.304			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	361YB	18931694				2022-12-17	WOS:000260162800009
J	Kitisin, K; Ganesan, N; Tang, Y; Jogunoori, W; Volpe, EA; Kim, SS; Katuri, V; Kallakury, B; Pishvaian, M; Albanese, C; Mendelson, J; Zasloff, M; Rashid, A; Fishbein, T; Evans, SRT; Sidawy, A; Reddy, EP; Mishra, B; Johnson, LB; Shetty, K; Mishra, L				Kitisin, K.; Ganesan, N.; Tang, Y.; Jogunoori, W.; Volpe, E. A.; Kim, S. S.; Katuri, V.; Kallakury, B.; Pishvaian, M.; Albanese, C.; Mendelson, J.; Zasloff, M.; Rashid, A.; Fishbein, T.; Evans, S. R. T.; Sidawy, A.; Reddy, E. P.; Mishra, B.; Johnson, L. B.; Shetty, K.; Mishra, L.			Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation	ONCOGENE			English	Article						hepatocellular carcinoma; ELF; cyclin D1; transforming growth factor-beta; cell cycle	HEPATITIS-B-VIRUS; TGF-BETA; MICROSATELLITE INSTABILITY; CARCINOMA; EXPRESSION; RECEPTOR; GENE; CATENIN; TUMOR; P53	Transforming growth factor-beta (TGF-beta) signaling members, TGF-beta receptor type II ( TBRII), Smad2, Smad4 and Smad adaptor, embryonic liver fodrin ( ELF), are prominent tumor suppressors in gastrointestinal cancers. Here, we show that 40% of elf(-+/-) mice spontaneously develop hepatocellular cancer ( HCC) with markedly increased cyclin D1, cyclin-dependent kinase 4 (Cdk4), c-Myc and MDM2 expression. Reduced ELF but not TBRII, or Smad4 was observed in 8 of 9 human HCCs (P < 0.017). ELF and TBRII are also markedly decreased in human HCC cell lines SNU-398 and SNU-475. Restoration of ELF and TBRII in SNU-398 cells markedly decreases cyclin D1 as well as hyperphosphorylated-retinoblastoma ( hyperphosphorylated-pRb). Thus, we show that TGF-b signaling and Smad adaptor ELF suppress human hepatocarcinogenesis, potentially through cyclin D1 deregulation. Loss of ELF could serve as a primary event in progression toward a fully transformed phenotype and could hold promise for new therapeutic approaches in human HCCs.	Georgetown Univ, Sch Med, Dept Surg Sci, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA; Georgetown Univ, Sch Med, Dept Pathol, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA; Georgetown Univ, Sch Med, Dept Med Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA; Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Dept Vet Affairs Med Ctr, Washington, DC USA; Temple Univ, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA	Georgetown University; Georgetown University; Georgetown University; Georgetown University; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Mishra, L (corresponding author), Georgetown Univ, Dept Surg, Med Dent Bldg,Room NW 207-213,Reservoir Rd,NW, Washington, DC 20007 USA.	lm229@georgetown.edu	Reddy, E. Premkumar/F-6233-2011; Volpe, Eugene A./D-2000-2012; Ganesan, Natarajan/C-8080-2012	Volpe, Eugene A./0000-0002-9128-754X; Mishra, Lopa/0000-0002-6850-0808	NATIONAL CANCER INSTITUTE [R01CA042857, R01CA106614, P01CA095569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056111] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA4285718A, P01CA095569, R01 CA106614, P01 CA095569, R01 CA106614A, R01 CA042857] Funding Source: Medline; NIDDK NIH HHS [R01 DK056111, R01 DK56111, R01 DK58637] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Breuhahn K, 2006, ONCOGENE, V25, P3787, DOI 10.1038/sj.onc.1209556; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Edamoto Y, 2003, INT J CANCER, V106, P334, DOI 10.1002/ijc.11254; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013; Feitelson MA, 1999, J CELL PHYSIOL, V181, P188; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Huo TI, 2001, ONCOGENE, V20, P3620, DOI 10.1038/sj.onc.1204495; Ishizaki Y, 2004, INT J ONCOL, V24, P1077; Ito Y, 1999, HEPATOLOGY, V30, P90, DOI 10.1002/hep.510300114; Joo M, 2001, LIVER, V21, P89, DOI 10.1034/j.1600-0676.2001.021002089.x; Kanzler S, 2001, ONCOGENE, V20, P5015, DOI 10.1038/sj.onc.1204544; Kiss A, 1997, CLIN CANCER RES, V3, P1059; Knudsen KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; Longerich T, 2004, VIRCHOWS ARCH, V445, P589, DOI 10.1007/s00428-004-1118-x; Macdonald GA, 1998, HEPATOLOGY, V28, P90, DOI 10.1002/hep.510280114; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Masaki T, 2003, HEPATOLOGY, V37, P534, DOI 10.1053/jhep.2003.50112; Mishra L, 1999, ONCOGENE, V18, P353, DOI 10.1038/sj.onc.1202313; Mishra L, 2005, ONCOGENE, V24, P5775, DOI 10.1038/sj.onc.1208924; Park YN, 2004, HEPATO-GASTROENTEROL, V51, P396; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Pavio N, 2005, ONCOGENE, V24, P6119, DOI 10.1038/sj.onc.1208749; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Roberts LR, 2005, SEMIN LIVER DIS, V25, P212, DOI 10.1055/s-2005-871200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; SUE SR, 1995, ANN SURG, V222, P171, DOI 10.1097/00000658-199508000-00009; Sundarrajan M, 2002, CELL BIOL INT, V26, P699, DOI 10.1006/cbir.2002.0923; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tang Y, 2005, CANCER RES, V65, P4228, DOI 10.1158/0008-5472.CAN-04-4585; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Tang Y, 2002, ONCOGENE, V21, P5255, DOI 10.1038/sj.onc.1205548; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; TINIAKOS D, 1993, HEPATO-GASTROENTEROL, V40, P37; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Ueta T, 2002, ONCOL REP, V9, P1197; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866; Yamamoto H, 2000, INT J ONCOL, V16, P543; Zhang YJ, 2002, MOL CARCINOGEN, V33, P125, DOI 10.1002/mc.10028	44	100	103	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2007	26	50					7103	7110		10.1038/sj.onc.1210513	http://dx.doi.org/10.1038/sj.onc.1210513			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17546056	Green Accepted			2022-12-17	WOS:000250715000004
J	Laine, A; Ronai, Z				Laine, A.; Ronai, Z.			Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1	ONCOGENE			English	Article						p53; WWP1; ubiquitin; HECHT; E3 ligases; transcription	UBIQUITIN-PROTEIN LIGASE; KRUPPEL-LIKE FACTOR; DEGRADATION; STABILITY; DEATH; MDM2; ACTIVATION; PROMOTES; PATHWAY; MOTIFS	As a key cellular regulatory protein p53 is subject to tight regulation by several E3 ligases. Here, we demonstrate the role of HECT domain E3 ligase, WWP1, in regulating p53 localization and activity. WWP1 associates with p53 and induces p53 ubiquitylation. Unlike other E3 ligases, WWP1 increases p53 stability; inhibition of WWP1 expression or expression of a ligase-mutant form results in decreased p53 expression. WWP1-mediated stabilization of p53 is associated within creased accumulation of p53 in cytoplasm witha concomitant decrease in its transcriptional activities. WWP1 effects are independent of Mdm2 as they are seen in cells lacking Mdm2 expression. Whereas WWP1 limits p53 activity, p53 reduces expression of WWP1, pointing to a possible feedback loop mechanism. Taken together, these findings identify the first instance of a ubiquitin ligase that causes stabilization of p53 while inactivating its transcriptional activities.	Burnham Inst Med Res, Signal Transduct Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Ronai, Z (corresponding author), Burnham Inst Med Res, Signal Transduct Program, La Jolla, CA 92037 USA.	ronai@burnham.org		RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA78419, R01 CA078419-08, R01 CA078419] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078419] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen CS, 2005, J BIOL CHEM, V280, P41553, DOI 10.1074/jbc.M506183200; Conkright MD, 2001, J BIOL CHEM, V276, P29299, DOI 10.1074/jbc.M103670200; DORAN D, 2004, NATURE, V429, P86; Galinier R, 2002, BIOCHEMISTRY-US, V41, P14299, DOI 10.1021/bi020125b; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huang K, 2000, GENE, V252, P137, DOI 10.1016/S0378-1119(00)00216-X; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Kasanov J, 2001, CHEM BIOL, V8, P231, DOI 10.1016/S1074-5521(01)00005-9; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Martin-Serrano J, 2005, J CELL BIOL, V168, P89, DOI 10.1083/jcb.200408155; Moren A, 2005, J BIOL CHEM, V280, P22115, DOI 10.1074/jbc.M414027200; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Poyurovsky MV, 2006, GENE DEV, V20, P125, DOI 10.1101/gad.1397506; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Shmueli A, 2005, CELL, V121, P963, DOI 10.1016/j.cell.2005.06.018; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Verdecia MA, 2003, MOL CELL, V11, P249, DOI 10.1016/S1097-2765(02)00774-8; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang ZX, 2004, ONCOGENE, V23, P8146, DOI 10.1038/sj.onc.1207992; Xu HM, 2004, J BIOL CHEM, V279, P23495, DOI 10.1074/jbc.M400516200; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhang XL, 2004, BIOCHEM BIOPH RES CO, V316, P139, DOI 10.1016/j.bbrc.2004.02.033; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200	34	100	102	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1477	1483		10.1038/sj.onc.1209924	http://dx.doi.org/10.1038/sj.onc.1209924			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16924229	Green Accepted			2022-12-17	WOS:000244558800012
J	Kawano, Y; Kitaoka, M; Hamada, Y; Walker, MM; Waxman, J; Kypta, RM				Kawano, Y.; Kitaoka, M.; Hamada, Y.; Walker, M. M.; Waxman, J.; Kypta, R. M.			Regulation of prostate cell growth and morphogenesis by Dickkopf-3	ONCOGENE			English	Article						Dkk-3; prostate cancer; proliferation; immunohistochemistry; acinar formation	BETA-CATENIN; PROMOTER-HYPERMETHYLATION; ALPHA-6-BETA-1 INTEGRIN; ACINAR DIFFERENTIATION; REDUCED EXPRESSION; GENE-EXPRESSION; DOWN-REGULATION; CANCER; REIC/DKK-3; PROLIFERATION	Wnt signalling plays a critical role in the development of cancer. Recent studies indicate that Wnt signalling is negatively regulated by secreted Wnt antagonists such as secreted frizzled related proteins (sFRPs) and Dick-kopfs (Dkks). We compared Dkk family expression levels in normal prostate and prostate cancer cells and found a reduction in Dkk-3 expression in cancer cells. Ectopic expression of Dkk-3 inhibited colony formation in LNCaP and PC3 prostate cancer cell lines and inducible expression of Dkk-3 reduced LNCaP cell proliferation. Moreover, small interfering RNA-mediated downregulation of Dkk-3 enhanced cell cycle progression in untransformed RWPE-1 prostate epithelial cells. Immunohistochemical analysis revealed that Dkk-3 is expressed in a subset of normal prostate gland acini and that Dkk-3 expression is reduced in prostate tumours, particularly those with a high Gleason grade, suggesting a role for Dkk-3 in postmitotic differentiation. Consistent with this, depletion of Dkk-3 disrupted acinar morphogenesis of RWPE-1 cells in a three-dimensional cell culture model. Our results are consistent with the loss of Dkk-3 expression resulting in impairment of glandular structure and uncontrolled prostate epithelial cell ( PrEC) proliferation,	Univ London Imperial Coll Sci Technol & Med, Prostate Canc Res Grp, Harris Lab, Dept Oncol,Div SORA, London W12 0NN, England; Kumamoto Gen Hosp, Kumamoto, Japan; Univ London Imperial Coll Sci Technol & Med, Dept Histopathol, London, England; Cell Biol & Stem Cells Unit, CIC BioGUNE, Bizkaia, Spain	Imperial College London; Imperial College London; CIC bioGUNE	Kawano, Y (corresponding author), Univ London Imperial Coll Sci Technol & Med, Prostate Canc Res Grp, Harris Lab, Dept Oncol,Div SORA, DuCane Rd, London W12 0NN, England.	y.kawano@ic.ac.uk; rkypta@cicbiogune.es	cancer, biogune/H-7276-2012; Kypta, Robert/F-7699-2011; Walker, Marjorie Mary/F-6504-2013	Kypta, Robert/0000-0002-2389-310X; 				Abarzua F, 2005, CANCER RES, V65, P9617, DOI 10.1158/0008-5472.CAN-05-0829; Barrantes ID, 2006, MOL CELL BIOL, V26, P2317, DOI 10.1128/MCB.26.6.2317-2326.2006; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Bello-DeOcampo D, 2001, MUTAT RES-FUND MOL M, V480, P209, DOI 10.1016/S0027-5107(01)00201-9; Bello-Deocampo D, 2001, PROSTATE, V46, P142, DOI 10.1002/1097-0045(20010201)46:2<142::AID-PROS1018>3.0.CO;2-B; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Byun T, 2005, J CLIN PATHOL, V58, P515, DOI 10.1136/jcp.2004.018598; Caricasole A, 2003, J BIOL CHEM, V278, P37024, DOI 10.1074/jbc.M300191200; Cheng L, 2000, CLIN CANCER RES, V6, P1896; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Gamble SC, 2004, ONCOGENE, V23, P2996, DOI 10.1038/sj.onc.1207444; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Halvorsen OJ, 2003, CLIN CANCER RES, V9, P1474; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; Hoffman MP, 1996, J CELL SCI, V109, P2013; Hsieh SY, 2004, ONCOGENE, V23, P9183, DOI 10.1038/sj.onc.1208138; Huppi K, 2005, MOL CELL, V17, P1, DOI 10.1016/j.molcel.2004.12.017; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kobayashi K, 2002, GENE, V282, P151, DOI 10.1016/S0378-1119(01)00838-1; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Kurose K, 2004, J UROLOGY, V171, P1314, DOI 10.1097/01.ju.0000101047.64379.d4; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Li XF, 2005, NAT GENET, V37, P945, DOI 10.1038/ng1614; Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mazor M, 2004, ONCOGENE, V23, P7882, DOI 10.1038/sj.onc.1208068; Menko AS, 2002, DEV DYNAM, V224, P321, DOI 10.1002/dvdy.10111; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Naylor MJ, 2005, J CELL BIOL, V171, P717, DOI 10.1083/jcb.200503144; Nozaki I, 2001, INT J ONCOL, V19, P117; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Roman-Gomez J, 2004, BLOOD, V104, P2492, DOI 10.1182/blood-2004-03-0954; Roman-Gomez J, 2004, BRIT J CANCER, V91, P707, DOI 10.1038/sj.bjc.6602008; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Suwa T, 2003, J ENDOCRINOL, V178, P149, DOI 10.1677/joe.0.1780149; Tsuji T, 2000, BIOCHEM BIOPH RES CO, V268, P20, DOI 10.1006/bbrc.1999.2067; Tsuji T, 2001, BIOCHEM BIOPH RES CO, V289, P257, DOI 10.1006/bbrc.2001.5972; Waltregny D, 2001, MOL ENDOCRINOL, V15, P765, DOI 10.1210/me.15.5.765; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Webber MM, 1997, CARCINOGENESIS, V18, P1225, DOI 10.1093/carcin/18.6.1225; Zhu HN, 2004, CANCER RES, V64, P7918, DOI 10.1158/0008-5472.CAN-04-2704	49	100	104	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2006	25	49					6528	6537		10.1038/sj.onc.1209661	http://dx.doi.org/10.1038/sj.onc.1209661			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16751809				2022-12-17	WOS:000241395100009
J	Jubb, AM; Chalasani, S; Frantz, GD; Smits, R; Grabsch, HI; Kavi, V; Maughan, NJ; Hillan, KJ; Quirke, P; Koeppen, H				Jubb, AM; Chalasani, S; Frantz, GD; Smits, R; Grabsch, HI; Kavi, V; Maughan, NJ; Hillan, KJ; Quirke, P; Koeppen, H			Achaete-scute like 2 (ascl2) is a target of Wnt signalling and is upregulated in intestinal neoplasia	ONCOGENE			English	Article						small intestinal cancer; colorectal cancer; colorectal adenomas; Wnt signalling; achaete-scute like 2	CANCER CELLS; COLON-CANCER; EXPRESSION; TRANSCRIPTION; METHYLATION; SURVIVIN; PROTEINS; FEATURES; TISSUE; CYCLE	Achaete-scute like (ASCL)2 is a basic helix-loop-helix transcription factor essential for the maintenance of proliferating trophoblasts during placental development. Using oligonucleotide microarrays we identified ascl2 as a gene significantly upregulated in colorectal adenocarcinomas (n=36 cancers, n=16 normals; 15-fold, P < 0.0001). This finding was confirmed by quantitative reverse transcriptase (RT)-PCR on large intestinal cancers (n=29 cancers, n=16 normals; 10-fold, P < 0.0001). In situ hybridization for ascl2 demonstrated expression at the base of small and large intestinal crypts (n=304), but in no other normal tissues excepting placenta. By in situ hybridization, 52-71% of colorectal adenomas (n=187), 50-73% of large (n=327) and 33-64% of small intestinal adenocarcinomas (n=124) were positive for ascl2 expression. Upregulation of murine ascl2 was also observed using oligonucleotide microarrays, quantitative RT-PCR and in situ hybridization on apc(min/+) and apc(1638N/+) smad4(-/+) tumours. Tumour cell lines stably transfected with LEF1(DN) or APC2, or transiently transfected with short-interfering RNA (siRNA) against beta-catenin showed a significant downregulation of ascl2. Colocalization of ascl2 with nuclear beta-catenin was observed in 73 small intestinal adenocarcinomas (P < 0.0008) and apc(min/+) tumours. Preliminary in vitro data suggest ascl2 may promote progression through the G2/M cell cycle checkpoint. In summary, ascl2 is a putative regulator of proliferation that is overexpressed in intestinal neoplasia.	Univ Leeds, Acad Unit Pathol, Leeds Inst Mol Med, St James Hosp, Leeds LS9 7TF, W Yorkshire, England; Erasmus Univ, Med Ctr, Rotterdam, Netherlands; Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA	Saint James's University Hospital; University of Leeds; Erasmus University Rotterdam; Erasmus MC; Roche Holding; Genentech	Jubb, AM (corresponding author), Univ Leeds, Acad Unit Pathol, Leeds Inst Mol Med, St James Hosp, Level 4,IMMECR JIF Bldg, Leeds LS9 7TF, W Yorkshire, England.	adrianjubb@gmail.com	Quirke, Philip/AAI-1362-2019	Quirke, Philip/0000-0002-3597-5444				Alders M, 1997, HUM MOL GENET, V6, P859, DOI 10.1093/hmg/6.6.859; Banerjea A, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-21; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; GUILLEMOT F, 1995, NAT GENET, V9, P235, DOI 10.1038/ng0395-235; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hernandez S, 2001, LAB INVEST, V81, P465, DOI 10.1038/labinvest.3780254; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; Jubb AM, 2003, J PATHOL, V200, P577, DOI 10.1002/path.1371; Leow CC, 2004, CANCER RES, V64, P6050, DOI 10.1158/0008-5472.CAN-04-0290; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Miyamoto T, 2002, J ASSIST REPROD GEN, V19, P240, DOI 10.1023/A:1015362903486; Morison IM, 2005, TRENDS GENET, V21, P457, DOI 10.1016/j.tig.2005.06.008; Myohanen SK, 1998, CANCER RES, V58, P591; Olmeda D, 2003, MOL BIOL CELL, V14, P2844, DOI 10.1091/mbc.E03-01-0865; Rodel F, 2005, CANCER RES, V65, P4881, DOI 10.1158/0008-5472.CAN-04-3028; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Westerman Ba, 2002, CLIN CANCER RES, V8, P1082; Westerman BA, 2001, PLACENTA, V22, P511, DOI 10.1053/plac.2001.0695; Yang SY, 2002, ARTERIOSCL THROM VAS, V22, P1797, DOI 10.1161/01.ATV.0000038995.31179.24; Zhang T, 2001, CANCER RES, V61, P8664; Zheng SC, 2000, CARCINOGENESIS, V21, P2057, DOI 10.1093/carcin/21.11.2057	25	100	110	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2006	25	24					3445	3457		10.1038/sj.onc.1209382	http://dx.doi.org/10.1038/sj.onc.1209382			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16568095				2022-12-17	WOS:000238448100009
J	Jeanblanc, M; Mousli, M; Hopfner, R; Bathami, K; Martinet, N; Abbady, AQ; Siffert, JC; Mathieu, E; Muller, CD; Bronner, C				Jeanblanc, M; Mousli, M; Hopfner, R; Bathami, K; Martinet, N; Abbady, AQ; Siffert, JC; Mathieu, E; Muller, CD; Bronner, C			The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle	ONCOGENE			English	Article						cell cycle; ICBP90; methylated promoter; retinoblastoma protein	II-ALPHA EXPRESSION; CCAAT-BINDING-PROTEIN; S-PHASE ENTRY; TRANSCRIPTIONAL REPRESSION; CONTACT INHIBITION; DOWN-REGULATION; CPG ISLAND; RB; CANCER; ARREST	The retinoblastoma protein (pRB) is encoded by the RB1 gene whose promoter contains several putative binding sites for ICBP90 (Inverted CCAAT box Binding Protein of 90 kDa), a transcriptional regulator of the topoisomerase II alpha gene. ICBP90 has two consensus binding sites for pRB in its primary sequence. Here, we show that pRB and ICBP90 co-immunoprecipitate in cell extracts of proliferating human lung fibroblasts and of proliferating or confluent Jurkat cells. GST pull-down assays and immunocytochemistry, after cell synchronization in late G1 phase, con. firmed this interaction. Overexpression of ICBP90 induces downregulation of pRB expression in lung. fibroblasts as a result of mRNA decrease. DNA chromatin immunoprecipitation experiment shows that ICBP90 binds to the RB1 gene promoter under its methylated status. Overexpression of ICBP90 increases the S and G2/M phase cell fractions of serum-starved lung fibroblasts as assessed by. flow cytometry analysis and increases topoisomerase IIa expression. Together, these results show that ICBP90 regulates pRB at the protein and gene transcription levels, thus favoring the entry into the S phase of the cells. We propose that ICBP90 overexpression, found in cancer cells, is involved in the altered checkpoint controls occurring in cancerogenesis.	INSERM, UMR S392, Fac Pharm, F-60024 Illkirch Graffenstaden, France; CNRS, UMR 7034, Fac Pharm, F-67401 Illkirch Graffenstaden, France; INSERM, EMI 0014, Fac Med, F-54511 Vandoeuvre Les Nancy, France; Ctr Hosp Belfort Montbeliard, Lab Biochim Immunochim, F-90016 Belfort, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine	Bronner, C (corresponding author), INSERM, UMR S392, Fac Pharm, 74 Route Rhin,BP 60024, F-60024 Illkirch Graffenstaden, France.	bronner@pharma.u-strasbg.fr	Abbady, Abdul Qader/O-2761-2015; Bronner, Christian/R-8488-2016; MULLER, Christian D./F-8399-2010; Mousli, Marc/Q-1722-2017	Abbady, Abdul Qader/0000-0002-3898-5269; Bronner, Christian/0000-0002-3101-9279; MULLER, Christian D./0000-0002-3463-1025; Mousli, Marc/0000-0001-9759-6864				ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Angus SP, 2002, EXP CELL RES, V276, P201, DOI 10.1006/excr.2002.5510; Arima Y, 2004, GENES CELLS, V9, P131, DOI 10.1111/j.1356-9597.2004.00710.x; Betticher DC, 1997, INT J CANCER, V74, P556, DOI 10.1002/(SICI)1097-0215(19971021)74:5<556::AID-IJC14>3.0.CO;2-4; Bhattacharya S, 2003, ONCOGENE, V22, P2443, DOI 10.1038/sj.onc.1206339; Bonapace IM, 2002, J CELL BIOL, V157, P909, DOI 10.1083/jcb.200201025; Bronner C, 2002, ANTICANCER RES, V22, P605; Chan HM, 2001, ONCOGENE, V20, P6152, DOI 10.1038/sj.onc.1204793; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHENG CH, 1993, BIOCHEMISTRY-US, V32, P8568, DOI 10.1021/bi00084a025; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Citterio E, 2004, MOL CELL BIOL, V24, P2526, DOI 10.1128/MCB.24.6.2526-2535.2004; COPPOLA JA, 1990, ONCOGENE, V5, P1731; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; Fang XJ, 1998, ONCOGENE, V16, P1, DOI 10.1038/sj.onc.1201525; Gonzalez-Gomez P, 2003, BRIT J CANCER, V88, P109, DOI 10.1038/sj.bjc.6600737; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; Hopfner R, 2002, ANTICANCER RES, V22, P3165; Hopfner R, 2000, CANCER RES, V60, P121; Kaelin WG, 1997, CANCER INVEST, V15, P243, DOI 10.3109/07357909709039722; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Meerson A, 2004, FEBS LETT, V559, P152, DOI 10.1016/S0014-5793(04)00027-4; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Mousli M, 2003, BRIT J CANCER, V89, P120, DOI 10.1038/sj.bjc.6601068; Muto M, 2002, J BIOL CHEM, V277, P34549, DOI 10.1074/jbc.M205189200; Nakamura M, 2001, LAB INVEST, V81, P77, DOI 10.1038/labinvest.3780213; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Pradhan S, 2002, EMBO J, V21, P779, DOI 10.1093/emboj/21.4.779; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; Roncalli M, 1998, LAB INVEST, V78, P1049; Simpson DJ, 2001, CARCINOGENESIS, V22, P1149, DOI 10.1093/carcin/22.8.1149; Simpson DJ, 2000, CANCER RES, V60, P1211; SLACK RS, 1993, ONCOGENE, V8, P1585; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Trotzier MA, 2004, BIOCHEM BIOPH RES CO, V319, P590, DOI 10.1016/j.bbrc.2004.05.028; Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053; Vasquez RJ, 1997, MOL BIOL CELL, V8, P973, DOI 10.1091/mbc.8.6.973; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N; Wang G, 2000, EXP CELL RES, V254, P64, DOI 10.1006/excr.1999.4743; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Young AP, 2004, ONCOGENE, V23, P2587, DOI 10.1038/sj.onc.1207330; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403	51	100	111	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7337	7345		10.1038/sj.onc.1208878	http://dx.doi.org/10.1038/sj.onc.1208878			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16007129				2022-12-17	WOS:000233142100010
J	Thomas, M; Massimi, P; Navarro, C; Borg, JP; Banks, L				Thomas, M; Massimi, P; Navarro, C; Borg, JP; Banks, L			The hScrib/Dlg apico-basal control complex is differentially targeted by HPV-16 and HPV-18 E6 proteins	ONCOGENE			English	Article						HPV; PDZ proteins; tumour suppressor; polarity	LARGE TUMOR-SUPPRESSOR; PROTEASOME-MEDIATED DEGRADATION; LETHAL-GIANT-LARVAE; PROLIFERATION CONTROL; DROSOPHILA EPITHELIA; MUTATIONAL ANALYSIS; HUMAN SCRIBBLE; CELL POLARITY; HUMAN HOMOLOG; PDZ DOMAIN	The E6 proteins of the high-risk Human papillomaviruses (HPV) types have a well-documented ability to target certain cellular proteins for ubiquitin-mediated degradation via the proteasome. Previous studies have shown that E6 proteins interact differently with different target proteins, and that the viral proteins, depending upon the target, may recruit diverse cellular ubiquitin-protein ligases. In this study, we have examined the abilities of E6 proteins from HPV-16 and HPV-18 to interact with and induce the degradation of two PDZ domain-containing targets, Dlg and hScrib. We have also mapped the binding site of E6 on hScrib and shown that the interaction of E6 with hScrib is distinct from its interactions with other PDZ domain-containing targets. This is reflected in the efficiency with which the two viral E6 proteins can inhibit hScrib's suppression of cell transformation. Dlg and hScrib have complementary activities in the control of epithelial cell polarity and the fact that both are targeted by high-risk HPV E6 proteins underlines their importance. Our finding that they are each targeted differently by HPV-16 and HPV-18 E6s suggests that the two viruses are subjected to somewhat different constraints and provides a possible explanation for the apparent redundancy in targeting both parts of this important control mechanism.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Inst J Paoli I Calmettes, INSERM, INst Rech Canc Marseille, UMR 599, F-13009 Marseille, France	International Center for Genetic Engineering & Biotechnology (ICGEB); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org	Borg, Jean-Paul/AAX-8096-2020	Borg, Jean-Paul/0000-0001-8418-3382				Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bryant PJ, 2000, NAT CELL BIOL, V2, pE141, DOI 10.1038/35019616; Cavatorta AL, 2004, INT J CANCER, V111, P373, DOI 10.1002/ijc.20275; Dobrosotskaya IY, 2001, BIOCHEM BIOPH RES CO, V283, P969, DOI 10.1006/bbrc.2001.4880; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2002, J GEN VIROL, V83, P283, DOI 10.1099/0022-1317-83-2-283; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Grifoni D, 2004, ONCOGENE, V23, P8688, DOI 10.1038/sj.onc.1208023; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Legouis R, 2003, EMBO REP, V4, P1096, DOI 10.1038/sj.embor.7400006; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; Massimi P, 2003, EXP CELL RES, V290, P265, DOI 10.1016/S0014-4827(03)00317-3; Mathew D, 2002, CURR BIOL, V12, P531, DOI 10.1016/S0960-9822(02)00758-3; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Petit MM, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-1; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Pim D, 2002, ONCOGENE, V21, P8140, DOI 10.1038/sj.onc.1206026; PIM D, 1994, ONCOGENE, V9, P1869; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Watson RA, 2003, J CELL SCI, V116, P4925, DOI 10.1242/jcs.00809; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Woods DF, 1997, DEV GENET, V20, P111, DOI 10.1002/(SICI)1520-6408(1997)20:2<111::AID-DVG4>3.3.CO;2-O; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	40	100	101	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6222	6230		10.1038/sj.onc.1208757	http://dx.doi.org/10.1038/sj.onc.1208757			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16103886				2022-12-17	WOS:000231877100003
J	Seemann, S; Hainaut, P				Seemann, S; Hainaut, P			Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity	ONCOGENE			English	Article						p53; thioredoxin; APE/Ref-1; redox regulation; base excision repair	DNA-BINDING ACTIVITY; REPORTER GENE TRANSACTIVATION; NF-KAPPA-B; EXCISION-REPAIR; GENOTOXIC STRESS; REDOX REGULATION; TRANSCRIPTION FACTOR; DIRECT ASSOCIATION; METAL-IONS; IN-VITRO	The p53 protein is redox-sensitive in vitro but in vivo effectors of this sensitivity are not known. In yeasts deficient for thioredoxin (Trx) reductase (TRR), p53 accumulates in an inactive, oxidized form, suggesting a role for TRR-Trx in controlling p53. In mammalian cells, p53 binds to redox factor-1 (APE/Ref-1), an enzyme containing an abasic endonuclease domain involved in base excision repair, and a thiol reductase domain recycled by Trx and involved in regulating the transcription factor AP-1. To evaluate the role of TRR and APE/Ref-1 in p53 regulation, we have abrogated their expression using RNA interference in cell lines expressing wild-type p53. Inhibition of TRR resulted in accumulation of oxidized Trx and increased levels and DNA-binding activity of p53, with no phosphorylation of Ser15 or Ser20. In contrast, inhibition of APE/Ref-1 accelerated p53 protein turnover, resulting in a decrease in p53 levels and activity. However, inhibition of either TRR or APE/Ref-1 did not prevent activation and accumulation of p53 in response to DNA-damage by doxorubicin. When both factors were inhibited, basal levels of p53 were restored. These results suggest that TRR-Trx and APE/Ref-1 cooperate in the control of basal p53 activity, but not in its induction by DNA-damage.	Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon, France	World Health Organization; International Agency for Research on Cancer (IARC)	Hainaut, P (corresponding author), Int Agcy Res Canc, Grp Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon, France.	hainaut@iarc.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				Achanta G, 2004, CANCER RES, V64, P6233, DOI 10.1158/0008-5472.CAN-04-0494; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Bersani NA, 2002, METHOD ENZYMOL, V347, P317; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Freemerman AJ, 1999, CANCER RES, V59, P4090; Fritz G, 2003, TOXICOLOGY, V193, P67, DOI 10.1016/S0300-483X(03)00290-7; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; HAINAUT P, 1993, CANCER RES, V53, P1739; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hainaut P, 2001, ANTIOXID REDOX SIGN, V3, P611, DOI 10.1089/15230860152542961; HAINAUT P, 1993, CANCER RES, V53, P4469; Hirota K, 2001, FEBS LETT, V489, P134, DOI 10.1016/S0014-5793(01)02094-4; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Kelley MR, 2003, CANCER RES, V63, P549; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Meplan C, 2000, ONCOGENE, V19, P5227, DOI 10.1038/sj.onc.1203907; Merrill GF, 1999, CANCER RES, V59, P3175; Merwin JR, 2002, CARCINOGENESIS, V23, P1609, DOI 10.1093/carcin/23.10.1609; Offer H, 2001, CANCER RES, V61, P88; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TAKAHASHI K, 1993, INT J CANCER, V55, P453, DOI 10.1002/ijc.2910550322; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wei SJ, 2000, CANCER RES, V60, P6688; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914; Zurer I, 2004, CARCINOGENESIS, V25, P11, DOI 10.1093/carcin/bgg186	43	100	100	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3853	3863		10.1038/sj.onc.1208549	http://dx.doi.org/10.1038/sj.onc.1208549			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15824742				2022-12-17	WOS:000229435300001
J	Fan, SJ; Gao, M; Meng, QH; Laterra, JJ; Symons, MH; Coniglio, S; Pestell, RG; Goldberg, ID; Rosen, AM				Fan, SJ; Gao, M; Meng, QH; Laterra, JJ; Symons, MH; Coniglio, S; Pestell, RG; Goldberg, ID; Rosen, AM			Role of NF-kappa B signaling in hepatocyte growth factor scatter factor-mediated cell protection	ONCOGENE			English	Article						NF-kappa B; I kappa B; p65; super-repressor; hepatocyte growth factor (HGF); scatter factor (SF)	TUMOR-NECROSIS-FACTOR; BREAST-CANCER CELLS; FACTOR/SCATTER FACTOR; FACTOR RECEPTOR; CARCINOMA-CELLS; ACTIVATION; EXPRESSION; APOPTOSIS; PROTEIN; PATHWAY	The cytokine scatter factor/hepatocyte growth factor (HGF/SF) protects epithelial, carcinoma, and other cell types against cytotoxicity and apoptosis induced by DNA-damaging agents such as ionizing radiation and adriamycin (ADR, a topoisomerase IIalpha inhibitor). We investigated the role of nuclear factor kappa B (NF-kappaB) signaling in HGF/SF-mediated protection of human prostate cancer (DU-145) and Madin-Darby canine kidney (MDCK) epithelial cells against ADR. HGF/SF caused the rapid nuclear translocation of the p65 ( RelA) subunit of NF-kappaB associated with the transient loss of the inhibitory subunit IkappaB-alpha. Exposure to HGF/SF caused the activation of an NF-kappaB luciferase reporter that was blocked or attenuated by the expression of a mutant 'super-repressor' IkappaB-alpha. Electrophoretic mobility shift assay supershift assays revealed that HGF/SF treatment induced the transient binding of various NF-kappaB family proteins ( p65, p50, c-Rel, and RelB) with radiolabeled NF-kappaB-binding oligonucleotides. The HGF/SF-mediated protection of DU-145 and MDCK cells against ADR ( demonstrated using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays) was abrogated by the IkappaB-alpha super-repressor. The ability of HGF/SF to activate NF-kappaB signaling was dependent on c-Akt-->Pak1 (p21-associated kinase-1) signaling ( with Pak1 downstream of c-Akt) and was inhibited by the tumor suppressor PTEN ( phosphatase and tensin homolog). Inhibitors of phosphatidylinositol-3'-kinase and Src family kinases significantly inhibited HGF/SF-mediated activation of NF-kappaB, while inhibitors of MEK, protein kinase C, and p70 S6 kinase had a modest effect or no effect on NF-kappaB activity. HGF/SF induced the expression of several known NF-kappaB target genes (cIAP-1 ( cellular inhibitor of apoptosis-1), cIAP-2, and TRAF-2 (TNF receptor-associated factor- 2)) in an NF-kappaB-dependent manner; HGF/SF blocked the inhibition of expression of these genes by ADR. Experimental manipulation of expression of these genes suggests that they ( particularly TRAF-2 and cIAP-2) contribute to the protection against ADR by HGF/SF. These findings suggest that HGF/SF activates NF-kappaB through a c-Akt-->Pak1 signaling pathway that is also dependent on Src, and that NF-kappaB contributes to HGF/SF-mediated protection against ADR.	Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20057 USA; Long Isl Jewish Med Ctr, N Shore Long Isl Jewish Res Inst, Dept Radiat Oncol, New Hyde Pk, NY 11040 USA; Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; N Shore Long Isl Jewish Res Inst, N Shore Long Isl Jewish Hlth Syst, Manhasset, NY 11030 USA	Georgetown University; Northwell Health; Johns Hopkins University; Kennedy Krieger Institute; Northwell Health	Rosen, AM (corresponding author), Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, 3970 Reservoir Rd,NW Box 571469, Washington, DC 20057 USA.	emr36@georgetown.edu	Meng, Q./GSI-6185-2022		NATIONAL CANCER INSTITUTE [R01CA080000, R01CA082599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA013122] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA82599, R01-CA80000] Funding Source: Medline; NIAAA NIH HHS [R21AA13122] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169] Funding Source: Medline; NINDS NIH HHS [R01-NS43987] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; ALLEY MC, 1988, CANCER RES, V48, P589; Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Bell S, 2003, CELL SIGNAL, V15, P1, DOI 10.1016/S0898-6568(02)00080-3; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bouzahzah B, 2001, MOL MED, V7, P816, DOI 10.1007/BF03401974; Bowers DC, 2000, CANCER RES, V60, P4277; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Carter KB, 2000, J BIOL CHEM, V275, P27858; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Davis ME, 2004, J BIOL CHEM, V279, P163, DOI 10.1074/jbc.M307528200; DeMeester SL, 2001, FASEB J, V15, P270, DOI 10.1096/fj.00-0170hyp; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; Foryst-Ludwig A, 2000, J BIOL CHEM, V275, P39779, DOI 10.1074/jbc.M007617200; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Gao M, 2001, J BIOL CHEM, V276, P47257, DOI 10.1074/jbc.M106791200; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Guiet C, 2002, CELL DEATH DIFFER, V9, P138, DOI 10.1038/sj/cdd/4400947; Gupta S, 2003, INT J ONCOL, V22, P15; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hellerbrand C, 1998, AM J PHYSIOL-GASTR L, V275, pG269, DOI 10.1152/ajpgi.1998.275.2.G269; Janssen-Heininger YMW, 1999, AM J RESP CELL MOL, V20, P942, DOI 10.1165/ajrcmb.20.5.3452; Jiang BB, 2004, J BIOL CHEM, V279, P1323, DOI 10.1074/jbc.M307521200; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Kawamata S, 1998, J BIOL CHEM, V273, P5808, DOI 10.1074/jbc.273.10.5808; KAWAMATA S, 1998, P NATL ACAD SCI USA, V95, P565; Kurland JF, 2003, J BIOL CHEM, V278, P32465, DOI 10.1074/jbc.M212919200; Lee SY, 1998, J EXP MED, V188, P1381, DOI 10.1084/jem.188.7.1381; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Liu R, 2001, J LEUKOCYTE BIOL, V70, P961; Magnani M., 2000, Current Drug Targets, V1, P387, DOI 10.2174/1389450003349056; Matteucci E, 2003, ONCOGENE, V22, P4062, DOI 10.1038/sj.onc.1206519; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Muller M, 2002, MOL CELL BIOL, V22, P1060, DOI 10.1128/MCB.22.4.1060-1072.2002; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; Ozes ON, 1999, NATURE, V401, P82; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; Rahmani M, 2001, ONCOGENE, V20, P5132, DOI 10.1038/sj.onc.1204678; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; Rosen EM, 1998, NATO ADV SCI I A-LIF, V298, P415; Saijo K, 2003, NAT IMMUNOL, V4, P274, DOI 10.1038/ni893; Shen BJ, 1997, DNA CELL BIOL, V16, P703, DOI 10.1089/dna.1997.16.703; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Yuan RQ, 2001, CANCER RES, V61, P8022; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200	64	100	105	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1749	1766		10.1038/sj.onc.1208327	http://dx.doi.org/10.1038/sj.onc.1208327			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15688034				2022-12-17	WOS:000227345100011
J	Reed, KR; Sansom, OJ; Hayes, AJ; Gescher, AJ; Winton, DJ; Peters, JM; Clarke, AR				Reed, KR; Sansom, OJ; Hayes, AJ; Gescher, AJ; Winton, DJ; Peters, JM; Clarke, AR			PPAR delta status and Apc-mediated tumourigenesis in the mouse intestine	ONCOGENE			English	Article						PPARdelta; tumourigenesis; Apc; intestine; PPARbeta	ACTIVATED RECEPTOR-DELTA; COLORECTAL-CANCER CELLS; GENE-EXPRESSION; BETA-CATENIN; TARGETED DISRUPTION; ADENOMA; GROWTH; BRAIN; MICE	Based on recent reports that peroxisome proliferator-activated receptor delta (PPARdelta) activation promotes tumourigenesis, we have investigated the role of this protein in Apc-mediated intestinal tumourigenesis. We demonstrate that the inactivation of Apc in the adult small intestine, while causing the expected nuclear accumulation of beta-catenin, does not cause the expected increase in PPARdelta mRNA or protein but conversely, the levels of PPARdelta mRNA and protein are lowered. Furthermore, we find that Apc(Min)PPARdelta-null mice exhibit an increased predisposition to intestinal tumourigenesis. Our data suggest that PPARdelta is not directly regulated by beta-catenin, and that inhibition of PPARdelta activity is unlikely to be an appropriate strategy for the chemoprevention or chemotherapy of intestinal malignancies.	Univ Wales Coll Cardiff, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Leicester, Dept Canc Studies, Leicester LE2 7LX, Leics, England; Cambridge Inst Med Res, Canc Res UK Dept Oncol, Cambridge CB2 2XY, England; Penn State Univ, Dept Vet Sci, Ctr Mol Toxicol, Fenske Lab 226, University Pk, PA 16802 USA	Cardiff University; University of Leicester; Cancer Research UK; University of Cambridge; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Clarke, AR (corresponding author), Univ Wales Coll Cardiff, Cardiff Sch Biosci, Museum Ave, Cardiff CF10 3US, S Glam, Wales.	clarkear@cf.ac.uk	Hayes, Anthony/F-2658-2012; Peters, Jeffrey/D-8847-2011; Reed, Karen/B-8813-2011; clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Reed, Karen/0000-0002-7467-1718; Clarke, Alan/0000-0002-4281-426X; Sansom, Owen J./0000-0001-9540-3010; Peters, Jeffrey/0000-0003-2782-2998				Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Chen LC, 2004, CANCER RES, V64, P3694, DOI 10.1158/0008-5472.CAN-03-3264; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Gupta RA, 2004, NAT MED, V10, P245, DOI 10.1038/nm993; Harman FS, 2004, NAT MED, V10, P481, DOI 10.1038/nm1026; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kongkanuntn R, 1999, ONCOGENE, V18, P7219, DOI 10.1038/sj.onc.1203181; Notterman DA, 2001, CANCER RES, V61, P3124; Orner GA, 2003, CARCINOGENESIS, V24, P263, DOI 10.1093/carcin/24.2.263; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Rosenberger TA, 2002, LIPIDS, V37, P495, DOI 10.1007/s11745-002-0923-1; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100; Stephen RL, 2004, CANCER RES, V64, P3162, DOI 10.1158/0008-5472.CAN-03-2760; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0	20	100	102	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8992	8996		10.1038/sj.onc.1208143	http://dx.doi.org/10.1038/sj.onc.1208143			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480419				2022-12-17	WOS:000225354600015
J	Kato, Y; Sasagawa, I; Kaneko, M; Osawa, M; Fujita, N; Tsuruo, T				Kato, Y; Sasagawa, I; Kaneko, M; Osawa, M; Fujita, N; Tsuruo, T			Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors	ONCOGENE			English	Article						Aggrus; seminoma; embryonal carcinoma; germ cell tumor	EUROPEAN COUNTRIES; EXPRESSION; T1-ALPHA; CANCER; IDENTIFICATION; ANTIGENS; PROTEIN; BIRTH; RAT	Aggrus ( also known as T1alpha/podoplanin) is a membrane sialoglycoprotein whose function in tumors is unknown. We recently determined that Aggrus possessed the ability of inducing platelet aggregation and that its expression was frequently upregulated in colorectal tumors. Thus, Aggrus expression might be associated with tumor-induced platelet aggregation and tumor metastasis. Here we show, by means of cancer pro. ling array and real-time PCR, that aggrus mRNA expression is frequently upregulated in testicular germ cell tumors when compared with the surrounding normal tissue. Immunohistochemical staining revealed that Aggrus protein expression was detected in 10 of 11 seminomas (90.9%), but its expression was not observed in embryonal carcinomas (0/4; 0%). Specific markers for seminomas have not been reported, and Aggrus is a potential diagnostic marker for seminomas and may be associated with malignancies of the testis.	Univ Tokyo, Lab Cell Growth & Regulat, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Yamagata Univ, Sch Med, Dept Expt & Forens Pathol, Yamagata 9909585, Japan; Yamagata Univ, Sch Med, Dept Urol, Yamagata 9909585, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Yamagata University; Yamagata University; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Lab Cell Growth & Regulat, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	ttsuruo@iam.u-tokyo.ac.jp	Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264; K. Kaneko, Mika/0000-0002-4158-9208; Kato, Yukinari/0000-0001-5385-8201				ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108; Bergstrom R, 1996, J NATL CANCER I, V88, P727, DOI 10.1093/jnci/88.11.727; Cheville JC, 1999, MODERN PATHOL, V12, P974; DEJONG B, 1990, CANCER GENET CYTOGEN, V48, P143, DOI 10.1016/0165-4608(90)90115-Q; FOGEL M, 1990, DIFFERENTIATION, V45, P242, DOI 10.1111/j.1432-0436.1990.tb00478.x; IZQUIERDO MA, 1995, J PATHOL, V177, P253, DOI 10.1002/path.1711770307; Jungbluth AA, 2000, INT J CANCER, V85, P460, DOI 10.1002/(SICI)1097-0215(20000215)85:4<460::AID-IJC3>3.0.CO;2-N; Kato Y, 2003, J BIOL CHEM, V278, P51599, DOI 10.1074/jbc.M309935200; Ma TH, 1998, AM J RESP CELL MOL, V19, P143, DOI 10.1165/ajrcmb.19.1.2953; MOLLER H, 1993, EUR UROL, V23, P8; Ramirez MI, 2003, DEV BIOL, V256, P61, DOI 10.1016/S0012-1606(02)00098-2; RICHIE JP, 2003, UROL ONCOL, V21, P91; Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342; WATANABE M, 1988, CANCER RES, V48, P6411; Wetterwald A, 1996, BONE, V18, P125, DOI 10.1016/8756-3282(95)00457-2; Williams MC, 1996, AM J RESP CELL MOL, V14, P577, DOI 10.1165/ajrcmb.14.6.8652186	16	100	137	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8552	8556		10.1038/sj.onc.1207869	http://dx.doi.org/10.1038/sj.onc.1207869			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15361850				2022-12-17	WOS:000224870700016
J	Mazor, M; Kawano, Y; Zhu, HN; Waxman, J; Kypta, RM				Mazor, M; Kawano, Y; Zhu, HN; Waxman, J; Kypta, RM			Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth	ONCOGENE			English	Article						GSK-3; beta-catenin; androgen receptor; prostate cancer	ADENOMATOUS POLYPOSIS-COLI; SMALL-MOLECULE INHIBITORS; BETA-CATENIN; TRANSCRIPTIONAL ACTIVITY; NEGATIVE REGULATOR; SIGNALING PATHWAY; GENE-EXPRESSION; AXIN; PHOSPHORYLATION; COMPLEX	The transcriptional activity of the androgen receptor (AR) is regulated by interaction with various coregulators, one of which is beta-catenin., Interest in the role of beta-catenin in prostate cancer has been stimulated by reports showing that it is aberrantly expressed in the cytoplasm and/or nucleus in up to 38% of hormone-refractory tumours and that overexpression of beta-catenin results in activation of AR transcriptional activity. We have examined the effect of depleting endogenous beta-catenin on AR activity using Axin and RNA interference. Axin, which promotes beta-catenin degradation, inhibited AR transcriptional activity. However, this did not require the beta-catenin-binding domain of Axin. Depletion of beta-catenin using RNA interference increased, rather than decreased, AR activity, suggesting that endogenous beta-catenin is not a transcriptional coactivator for the AR. The glycogen synthase kinase-3 (GSK-3)-binding domain of Axin prevented formation of a GSK-3-AR complex and was both necessary and sufficient for inhibition of AR-dependent transcription. A second GSK-3-binding protein, FRAT, also inhibited AR transcriptional activity, as did the GSK-3 inhibitors SB216763 and SB415286. Finally, inhibition of GSK-3 reduced the growth of AR-expressing prostate cancer cell lines. Our observations suggest a potential new therapeutic application for GSK-3 inhibitors in prostate cancer.	Univ London Imperial Coll Sci Technol & Med, Div Med, Dept Canc Cell Biol, Prostate Canc Res Grp, London W12 0NN, England	Imperial College London	Kypta, RM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Med, Dept Canc Cell Biol, Prostate Canc Res Grp, London W12 0NN, England.	r.kypta@imperial.ac.uk	Kypta, Robert/F-7699-2011	Kypta, Robert/0000-0002-2389-310X				Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Chesire DR, 2003, ENDOCR-RELAT CANCER, V10, P537, DOI 10.1677/erc.0.0100537; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cronauer MV, 2003, INT J ONCOL, V23, P1095; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; Demarchi F, 2003, J BIOL CHEM, V278, P39583, DOI 10.1074/jbc.M305676200; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Franca-Koh J, 2002, J BIOL CHEM, V277, P43844, DOI 10.1074/jbc.M207265200; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829; Giannini AL, 2000, J BIOL CHEM, V275, P21883, DOI 10.1074/jbc.M001929200; Gregory CW, 2001, CANCER RES, V61, P2892; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Hsu W, 2001, J CELL BIOL, V155, P1055, DOI 10.1083/jcb.200107066; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Liao XB, 2004, ENDOCRINOLOGY, V145, P2941, DOI 10.1210/en.2003-1519; Lin HK, 2003, J BIOL CHEM, V278, P50902, DOI 10.1074/jbc.M300676200; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Orme MH, 2003, MOL CELL NEUROSCI, V24, P673, DOI 10.1016/S1044-7431(03)00229-X; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Salas TR, 2004, J BIOL CHEM, V279, P19191, DOI 10.1074/jbc.M309560200; Salas TR, 2003, J BIOL CHEM, V278, P41338, DOI 10.1074/jbc.M302972200; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Truica CI, 2000, CANCER RES, V60, P4709; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Wang L, 2004, J BIOL CHEM, V279, P32444, DOI 10.1074/jbc.M313963200; WOODGETT JR, 2001, SCI STKE, pRE12; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8	42	100	113	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7882	7892		10.1038/sj.onc.1208068	http://dx.doi.org/10.1038/sj.onc.1208068			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15361837				2022-12-17	WOS:000224331600014
J	Reagan-Shaw, S; Afaq, F; Aziz, MH; Ahmad, N				Reagan-Shaw, S; Afaq, F; Aziz, MH; Ahmad, N			Modulations of critical cell cycle regulatory events during chemoprevention of ultraviolet B-mediated responses by resveratrol in SKH-1 hairless mouse skin	ONCOGENE			English	Article						resveratrol; cell cycle; ultraviolet (UV); skin cancer	GREEN TEA POLYPHENOL; GENE-EXPRESSION; KAPPA-B; PHOTOCARCINOGENESIS; CANCER; ACTIVATION; PREVENTION; CARCINOMA; LIGHT; MICE	Multiple exposures to solar ultraviolet (UV) radiation cause critical damages that may lead to the development of several cutaneous disorders including skin cancer, the most frequently diagnosed malignancy in the USA. Therefore, efforts are needed to: (i) study the mechanism(s) of UV-mediated cutaneous damages, and (ii) design novel approaches for the management of skin cancer. 'Chemoprevention' via plant-based agents may be a useful approach for the management of neoplasia. Here, we evaluated the involvement of cell cycle regulatory molecules during resveratrol-mediated protection from multiple exposures of UVB ( 180 mJ/cm(2); on alternate days x 7 exposures) radiations in the SKH-1 hairless mouse skin. Resveratrol was topically applied on the skin of SKH-1 hairless mice at a dose of 10 mumol/mouse ( in 0.2 ml acetone; 30 min prior to each UVB exposure). Studies were performed at 24 h following the last UVB exposure. Topical application of resveratrol resulted in significant decrease in UVB-induced bi-fold skin thickness, hyperplasia, and infiltration of leukocytes. The data from immunoblot and/or immunohistochemical analyses revealed that multiple exposure to UVB radiations causes significant upregulation in: ( i) proliferating cell nuclear antigen ( PCNA), a marker of cellular proliferation, and ( ii) cyclin-dependent kinase (cdk)- 2, - 4 and - 6, cyclin-D1, and cyclin-D2. Resveratrol treatment resulted in significant downregulation in UV-mediated increases in these critical cell cycle regulatory proteins. An interesting observation of this study was that resveratrol treatment resulted in a further stimulation of UVB-mediated increases in cyclin kinase inhibitor WAF1/p21 and tumor suppressor p53. Further, resveratrol was also found to cause significant decreases in UVB-mediated upregulation of: ( i) the mitogen-activated protein kinase kinase, and ( ii) the 42 kDa isotype of mitogen-activated protein kinase ( MAPK). Thus, our data suggested that the antiproliferative effects of resveratrol might be mediated via modulation in the expression and function of cell cycle regulatory proteins cyclin-D1 and -D2, cdk-2, -4 and -6, and WAF1/p21. Our data further suggest that the modulation of cki-cyclin-cdk network by resveratrol may be associated with inhibition of the MAPK pathway. We suggest that resveratrol may be useful for the prevention of UVB-mediated cutaneous damages including skin cancer.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA; Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA; Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ahmad, N (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, 1300 Univ Ave, Madison, WI 53706 USA.	nahmad@wisc.edu	Ahmad, Nihal/AAR-4249-2021	Ahmad, Nihal/0000-0002-4239-9887	NATIONAL CANCER INSTITUTE [R03CA099076, R03CA098368] Funding Source: NIH RePORTER; NCI NIH HHS [R03 CA 99076, R03 CA 98368] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; Adhami VM, 2003, NEOPLASIA, V5, P74, DOI 10.1016/S1476-5586(03)80019-2; Adhami VM, 2001, BIOCHEM BIOPH RES CO, V288, P579, DOI 10.1006/bbrc.2001.5819; Afaq F, 2003, ONCOGENE, V22, P9254, DOI 10.1038/sj.onc.1207035; Afaq F, 2003, TOXICOL APPL PHARM, V186, P28, DOI 10.1016/S0041-008X(02)00014-5; Afaq F, 2002, FRONT BIOSCI-LANDMRK, V7, pD784, DOI 10.2741/afaq; Ahmad N, 2001, CLIN CANCER RES, V7, P1466; Ahmad N, 2001, SKIN PHARMACOL APPL, V14, P69, DOI 10.1159/000056336; Ahmed NU, 1999, J DERMATOL SCI, V19, P175, DOI 10.1016/S0923-1811(98)00068-1; Bickers D R, 2000, J Dermatol, V27, P691; Black HS, 1997, J PHOTOCH PHOTOBIO B, V40, P29, DOI 10.1016/S1011-1344(97)00021-3; Bowden GT, 2004, NAT REV CANCER, V4, P23, DOI 10.1038/nrc1253; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen WX, 1999, ONCOGENE, V18, P7469, DOI 10.1038/sj.onc.1203210; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; de Gruijl FR, 2002, SKIN PHARMACOL APPL, V15, P316, DOI 10.1159/000064535; Dreher F, 2001, CURR PROBL DERMATOL, V29, P157; Eckert RL, 2002, J INVEST DERM SYMP P, V7, P36, DOI 10.1046/j.1523-1747.2002.19634.x; Einspahr JG, 2003, RECENT RESULTS CANC, V163, P151; F'guyer S, 2003, PHOTODERMATOL PHOTO, V19, P56, DOI 10.1034/j.1600-0781.2003.00019.x; Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513; Hatoko M, 2001, ANN PLAS SURG, V47, P425, DOI 10.1097/00000637-200110000-00011; Katiyar SK, 2001, TOXICOL APPL PHARM, V176, P110, DOI 10.1006/taap.2001.9276; Katiyar SK, 1999, CARCINOGENESIS, V20, P2117, DOI 10.1093/carcin/20.11.2117; Katiyar SK, 2001, J LEUKOCYTE BIOL, V69, P719; Katiyar SK, 1997, JNCI-J NATL CANCER I, V89, P556, DOI 10.1093/jnci/89.8.556; Kim AL, 2002, PHOTOCHEM PHOTOBIOL, V75, P58, DOI 10.1562/0031-8655(2002)075<0058:SSAOCE>2.0.CO;2; Kulms D, 2002, J DERMATOL, V29, P189, DOI 10.1111/j.1346-8138.2002.tb00248.x; Lu YP, 1999, CANCER RES, V59, P4591; Lu YP, 2000, CANCER RES, V60, P4785; Murphy M, 2002, J CLIN PATHOL, V55, P829, DOI 10.1136/jcp.55.11.829; Naylor MF, 1997, ARCH DERMATOL, V133, P373, DOI 10.1001/archderm.133.3.373; Petrocelli T, 2000, ONCOGENE, V19, P4480, DOI 10.1038/sj.onc.1203808; Petrocelli T, 1996, ONCOGENE, V12, P1387; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Sander CS, 2003, BRIT J DERMATOL, V148, P913, DOI 10.1046/j.1365-2133.2003.05303.x; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; Terada Y, 1999, KIDNEY INT, V56, P1258, DOI 10.1046/j.1523-1755.1999.00704.x; Terada Y, 1999, KIDNEY INT, V56, P1378, DOI 10.1046/j.1523-1755.1999.00665.x; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; Wang WG, 2003, CANCER BIOL THER, V2, pS55; Yamamoto H, 2002, CANCER RES, V62, P1641; Yano S, 2003, BIOCHEM BIOPH RES CO, V301, P841, DOI 10.1016/S0006-291X(03)00060-3	43	100	110	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5151	5160		10.1038/sj.onc.1207666	http://dx.doi.org/10.1038/sj.onc.1207666			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122319				2022-12-17	WOS:000222382500005
J	Bourdeau, I; Antonini, SR; Lacroix, A; Kirschner, LS; Matyakhina, L; Lorang, D; Libutti, SK; Stratakis, CA				Bourdeau, I; Antonini, SR; Lacroix, A; Kirschner, LS; Matyakhina, L; Lorang, D; Libutti, SK; Stratakis, CA			Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several candidate genes as molecular mediators	ONCOGENE			English	Article; Proceedings Paper	84th Annual Meeting of the Endocrine-Society	JUN 19-22, 2002	SAN FRANCISCO, CA	Endocrine Soc		adrenal cortex; Cushing syndrome; macronodular hyperplasia; genetics	GASTRIC-INHIBITORY POLYPEPTIDE; DEPENDENT CUSHINGS-SYNDROME; SPORADIC ADRENOCORTICAL TUMORS; FAMILIAL ADENOMATOUS POLYPOSIS; GENOMIC HYBRIDIZATION ANALYSIS; ENDOCRINE NEOPLASIA TYPE-1; MEMBRANE HORMONE-RECEPTORS; ALPHA-CATENIN; CARNEY COMPLEX; HUMAN-DISEASE	Corticotropin (ACTH)-independent macronodular adrenal hyperplasia (AIMAH) is a heterogeneous condition in which cortisol secretion may be mediated by gastrointestinal peptide (GIP), vasopressin, catecholamines and other hormones. We studied the expression pro. le of AIMAH by genomic cDNA microarray analysis. Total RNA was extracted from eight tissues (three GIP-dependent) and compared to total RNA obtained from adrenal glands from 62 normal subjects. Genes had to be altered in 75% of the patients, and be up- or downregulated at a cutoff ratio of at least 2.0; 82 and 31 genes were found to be consistently up- and downregulated, respectively. Among the former were regulators of transcription, chromatin remodeling, and cell cycle and adhesion. Downregulated sequences included genes involved in immune responses and insulin signaling. Hierarchical clustering correlated with the two main AIMAH diagnostic groups: GIP-dependent and non-GIP-dependent. The genes encoding the 7B2 protein (SGNE1) and WNT1-inducible signaling pathway protein 2 (WISP2) were specifically overexpressed in the GIP-dependent AIMAH. For these, and six more genes, the data were validated by semiquantitative amplification in samples from a total of 32 patients (the original eight, six more cases of AIMAH, and 18 other adrenocortical hyperplasias and tumors) and the H295R adrenocortical cancer cell line. In conclusion, our data confirmed AIMAH's clinical heterogeneity by identifying molecularly distinct diagnostic subgroups. Several candidate genes that may be responsible for AIMAH formation and/or progression were also identified, suggesting pathways that affect the cell cycle, adhesion and transcription as possible mediators of adrenocortical hyperplasia.	NICHHD, Sect Genet & Endocrinol, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; CHUM, Hotel Dieu, Div Endocrinol, Montreal, PQ, Canada; NCI, Surg Branch, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Laval University; Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Stratakis, CA (corresponding author), NICHHD, Sect Genet & Endocrinol, Dev Endocrinol Branch, NIH, Bldg 10,Room 10N262,10 Ctr Dr MSC1862, Bethesda, MD 20892 USA.	stratakc@mail.nih.gov	Levesque, Isabelle/A-1899-2012; Antonini, Sonir RR/J-5264-2015; Lacroix, Andre/AAI-5645-2020; Stratakis, Constantine A./AAP-4745-2020	Antonini, Sonir/0000-0003-4778-8803	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000642, ZIAHD000642] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01SC010368] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ai ZW, 2000, J CLIN INVEST, V105, P161, DOI 10.1172/JCI7798; BAUMAN A, 1982, JAMA-J AM MED ASSOC, V248, P3140, DOI 10.1001/jama.248.23.3140; Bergeron F, 2002, FEBS LETT, V512, P259, DOI 10.1016/S0014-5793(02)02277-9; BERTHERAT J, 2002, END SOC 84 ANN M SAN; Bornstein SR, 1999, ANN INTERN MED, V130, P759, DOI 10.7326/0003-4819-130-9-199905040-00017; BOSTON BA, 1994, J CLIN ENDOCR METAB, V79, P890, DOI 10.1210/jc.79.3.890; Boulle N, 1998, J CLIN ENDOCR METAB, V83, P1713, DOI 10.1210/jc.83.5.1713; Bourdeau I, 2002, AM J HUM GENET, V71, P189; Bourdeau I, 2002, ANN NY ACAD SCI, V968, P240, DOI 10.1111/j.1749-6632.2002.tb04339.x; Bourdeau I, 2001, J CLIN ENDOCR METAB, V86, P5534, DOI 10.1210/jc.86.11.5534; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Figueiredo BC, 1999, J CLIN ENDOCR METAB, V84, P1116, DOI 10.1210/jc.84.3.1116; Fujita M, 2001, CANCER RES, V61, P7722; Giordano TJ, 2003, AM J PATHOL, V162, P521, DOI 10.1016/S0002-9440(10)63846-1; Goldstein LSB, 2001, P NATL ACAD SCI USA, V98, P6999, DOI 10.1073/pnas.111145298; HAMWI GJ, 1957, NEW ENGL J MED, V257, P1153, DOI 10.1056/NEJM195712122572402; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heikkila M, 2002, ENDOCRINOLOGY, V143, P4358, DOI 10.1210/en.2002-220275; Heppner C, 1999, J CLIN ENDOCR METAB, V84, P216, DOI 10.1210/jc.84.1.216; Janssens B, 1999, BBA-GENE STRUCT EXPR, V1447, P341, DOI 10.1016/S0167-4781(99)00170-0; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kartheuser A, 1999, J MED GENET, V36, P65; Kikuchi E, 2000, BIOMED PHARMACOTHER, V54, p194S, DOI 10.1016/S0753-3322(00)80043-8; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; Kjellman M, 1996, CANCER RES, V56, P4219; Koch CA, 2000, MED KLIN, V95, P224, DOI 10.1007/PL00002112; Lacroix A, 2001, ENDOCR REV, V22, P75, DOI 10.1210/er.22.1.75; LACROIX A, 1992, NEW ENGL J MED, V327, P974, DOI 10.1056/NEJM199210013271402; Lacroix A, 1997, NEW ENGL J MED, V337, P1429, DOI 10.1056/NEJM199711133372004; Lebrethon MC, 1998, J CLIN ENDOCR METAB, V83, P4514, DOI 10.1210/jc.83.12.4514; Marchesa P, 1997, DIS COLON RECTUM, V40, P1023, DOI 10.1007/BF02050923; Mircescu H, 2000, J CLIN ENDOCR METAB, V85, P3531, DOI 10.1210/jc.85.10.3531; N'Diaye N, 1998, J CLIN ENDOCR METAB, V83, P2781, DOI 10.1210/jc.83.8.2781; N'Diaye N, 1999, J CLIN ENDOCR METAB, V84, P2616, DOI 10.1210/jc.84.8.2616; PANG S, 1981, PEDIATRICS, V68, P242; Park B, 2002, J BIOL CHEM, V277, P45361, DOI 10.1074/jbc.M202447200; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; RAINEY WE, 1994, MOL CELL ENDOCRINOL, V100, P45, DOI 10.1016/0303-7207(94)90277-1; Rampazzo C, 2000, P NATL ACAD SCI USA, V97, P8239, DOI 10.1073/pnas.97.15.8239; REINCKE M, 1993, J CLIN ENDOCR METAB, V77, P1419, DOI 10.1210/jc.77.5.1419; Reincke M, 2000, EUR J CLIN INVEST, V30, P63, DOI 10.1046/j.1365-2362.2000.0300s3063.x; REZNIK Y, 1992, NEW ENGL J MED, V327, P981, DOI 10.1056/NEJM199210013271403; Saxena N, 2001, MOL CELL BIOCHEM, V228, P99, DOI 10.1023/A:1013338912642; Semenza GL, 2000, GENE DEV, V14, P1983; Sidhu S, 2002, J CLIN ENDOCR METAB, V87, P3467, DOI 10.1210/jc.87.7.3467; SKOGSEID B, 1992, J CLIN ENDOCR METAB, V75, P76, DOI 10.1210/jc.75.1.76; Stratakis CA, 1999, ANN INTERN MED, V131, P585, DOI 10.7326/0003-4819-131-8-199910190-00006; Stratakis CA, 2003, TRENDS ENDOCRIN MET, V14, P404, DOI 10.1016/j.tem.2003.08.005; Stratakis CA, 1998, HORM METAB RES, V30, P456, DOI 10.1055/s-2007-978914; Suwa T, 2003, J ENDOCRINOL, V178, P149, DOI 10.1677/joe.0.1780149; SUZUKI H, 1995, STEROIDS, V60, P42, DOI 10.1016/0039-128X(94)00025-8; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wakatsuki S, 1998, HUM PATHOL, V29, P302, DOI 10.1016/S0046-8177(98)90052-1; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; Yamamoto Y, 2003, HEPATOLOGY, V37, P528, DOI 10.1053/jhep.2003.50029; Zhang JS, 1998, GENOMICS, V54, P149, DOI 10.1006/geno.1998.5458; Zhao JM, 1999, AM J PATHOL, V155, P1039, DOI 10.1016/S0002-9440(10)65205-4; Zwermann O, 2000, EUR J ENDOCRINOL, V142, P689, DOI 10.1530/eje.0.1420689	64	100	104	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1575	1585		10.1038/sj.onc.1207277	http://dx.doi.org/10.1038/sj.onc.1207277			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14767469				2022-12-17	WOS:000189219500011
J	Kumar, D; Gokhale, P; Broustas, C; Chakravarty, D; Ahmad, I; Kasid, U				Kumar, D; Gokhale, P; Broustas, C; Chakravarty, D; Ahmad, I; Kasid, U			Expression of SCC-S2, an antiapoptotic molecule, correlates with enhanced proliferation and tumorigenicity of MDA-MB 435 cells	ONCOGENE			English	Article						SCC-S2; subcellular localization; cell growth regulation in vitro and in vivo	NF-KAPPA-B; DEATH-EFFECTOR DOMAIN; NECROSIS-FACTOR-ALPHA; FLICE-INHIBITORY PROTEIN; DISEASE TUMOR-CELLS; C-FLIP; PANCREATIC ADENOCARCINOMA; CONSTITUTIVE ACTIVATION; MEDIATED APOPTOSIS; RADIATION RESPONSE	SCC-S2/GG2-1/NDED is a recently discovered antiapoptotic molecule induced by the activation of the transcription factor NF-kappaB. Here we have examined a role of SCC-S2 in cell growth regulation in vitro and in vivo. Western blotting using an antipeptide antibody revealed endogenous SCC-S2 as a similar to21kDa cytosolic protein in human breast cancer cells (MDA-MB 231) and renal carcinoma cells (RCC-RS). The immunofluorescence detection method showed the cytosolic localization of FLAG-tagged human SCC-S2 in COS-1 transfectants. MDA-MB 435 human cancer cells stably transfected with the FLAG-tagged SCC-S2 cDNA exhibited increased growth rate as compared to control vector transfectants, as measured by the cell viability (>twofold; n=3; P<0.005) and thymidine-labeling procedures (similar to sixfold; n=3; P<0.0001). SCC-S2 transfectants also displayed an increase in cell migration in collagen I as compared to control transfectants (similar totwofold; n=3; P<0.005). In athymic mice, SCC-S2 transfectants showed significantly enhanced tumor growth as compared to control transfectants (mean tumor volumes, day 16: control, 56.86 +/- 19.82 mm(3); SCC-S2, 127.54 +/- 18.78 mm(3); n=5; P<0.03). The examination of a limited number of clinical specimens revealed higher expression levels of SCC-S2 protein in certain human tumor tissues as compared to the matched normal adjacent tissues. Taken together, the present studies demonstrate SCC-S2 as a novel oncogenic factor in cancer cells.	Georgetown Univ, Med Ctr, Dept Radiat Med, Lombardi Canc Ctr, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Lombardi Canc Ctr, Washington, DC 20057 USA; Neopharm Inc, Lake Forest, IL 60045 USA	Georgetown University; Georgetown University	Kasid, U (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Lombardi Canc Ctr, E208,Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.	kasidu@georgetown.edu		Broustas, Constantinos/0000-0001-7169-807X; Chakravarty, Debyani/0000-0001-8629-5732	NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA74175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelsman MA, 1999, MOL BIOL CELL, V10, P2861, DOI 10.1091/mbc.10.9.2861; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Hackam AS, 2000, J BIOL CHEM, V275, P41299, DOI 10.1074/jbc.M008408200; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hinz M, 2002, J EXP MED, V196, P605, DOI 10.1084/jem.20020062; Horrevoets AJG, 1999, BLOOD, V93, P3418, DOI 10.1182/blood.V93.10.3418.410k23_3418_3431; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Isaacs JS, 2001, J BIOL CHEM, V276, P18497, DOI 10.1074/jbc.M100638200; Kaufmann M, 2002, FEBS LETT, V527, P250, DOI 10.1016/S0014-5793(02)03146-0; Keleg Shereen, 2003, Mol Cancer, V2, P14, DOI 10.1186/1476-4598-2-14; Kumar D, 2000, J BIOL CHEM, V275, P2973, DOI 10.1074/jbc.275.4.2973; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LEUNG SW, 1993, CANCER-AM CANCER SOC, V71, P2276, DOI 10.1002/1097-0142(19930401)71:7<2276::AID-CNCR2820710718>3.0.CO;2-7; Lim JW, 2002, J BIOL CHEM, V277, P46093, DOI 10.1074/jbc.M206603200; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Mori N, 1999, BLOOD, V93, P2360; MUELLER SC, 1992, J CELL BIOL, V119, P1309, DOI 10.1083/jcb.119.5.1309; Nair A, 2003, ONCOGENE, V22, P50, DOI 10.1038/sj.onc.1206043; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; Patel S, 1997, ORAL ONCOL, V33, P197, DOI 10.1016/S0964-1955(96)00065-6; Ryu BK, 2001, J PATHOL, V194, P15, DOI 10.1002/path.835; Scaife CL, 2002, CANCER RES, V62, P6870; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Tibbetts MD, 2003, NAT IMMUNOL, V4, P404, DOI 10.1038/ni0503-404; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Wang J, 2000, EUR J IMMUNOL, V30, P155, DOI 10.1002/1521-4141(200001)30:1<155::AID-IMMU155>3.3.CO;2-O; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Wang WX, 1999, CLIN CANCER RES, V5, P119; Xiao CW, 2003, ENDOCRINOLOGY, V144, P623, DOI 10.1210/en.2001-211024; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; You ZB, 2001, J BIOL CHEM, V276, P26398, DOI 10.1074/jbc.M102464200; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597	39	100	117	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					612	616		10.1038/sj.onc.1207123	http://dx.doi.org/10.1038/sj.onc.1207123			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724590				2022-12-17	WOS:000188098300033
J	Hirose, T; Sowa, Y; Takahashi, S; Saito, S; Yasuda, C; Shindo, N; Furuichi, K; Sakai, T				Hirose, T; Sowa, Y; Takahashi, S; Saito, S; Yasuda, C; Shindo, N; Furuichi, K; Sakai, T			p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y	ONCOGENE			English	Article						HDAC inhibitor; Gadd45; Oct-1; CCAAT; promoter	WAF1/CIP1 GENE PROMOTER; SP1 SITES; IN-VIVO; P53; BUTYRATE; ACETYLATION; ACTIVATION; EXPRESSION; BINDING; ARREST	Histone deacetylase ( HDAC) inhibitors cause growth arrest at the G1 and/ or G2/M phases, and induce differentiation and/ or apoptosis in a wide variety of tumour cells. The growth arrest at G1 phase by HDAC inhibitors is thought to be highly dependent on the upregulation of p21/WAF1, but the precise mechanism by which HDAC inhibitors cause G2/M arrest or apoptosis in tumour cells is unknown. Gadd45 causes cell cycle arrest at the G2/M phase transition and participates in genotoxic stress-induced apoptosis. We show here that it is also induced by a typical HDAC inhibitor, trichostatin A (TSA), through its promoter, in a p53-independent manner. To identify the mechanism of activation of the gadd45 promoter, we performed luciferase reporter analyses and electrophoretic mobility shift assays. These revealed that both the Oct-1 and CCAAT sites are needed for the full activation by TSA. We also found that the transcription factors Oct-1 and NF-Y specifically bind to each site. Thus, HDAC inhibitors can induce Gadd45 through its promoter without the need for functional p53, and both the Oct-1 and NF-Y concertedly participate in TSA-induced activation of the gadd45 promoter.	Kyoto Prefectural Univ Med, Dept Prevent Med, Kamigyo Ku, Kyoto 6028566, Japan; Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Labs, Tsukuba, Ibaraki 3058585, Japan	Kyoto Prefectural University of Medicine; Astellas Pharmaceuticals	Sowa, Y (corresponding author), Kyoto Prefectural Univ Med, Dept Prevent Med, Kamigyo Ku, Kyoto 6028566, Japan.	ysowa@basic.kpu-m.ac.jp						Adachi N, 2000, GENE, V245, P49, DOI 10.1016/S0378-1119(00)00040-8; Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4; Blagosklonny MV, 2001, CANCER RES, V61, P4301; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; Chen ZX, 2002, CANCER LETT, V188, P127, DOI 10.1016/S0304-3835(02)00322-1; Della Ragione F, 2001, FEBS LETT, V499, P199, DOI 10.1016/S0014-5793(01)02539-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Espinos E, 1999, MOL CELL BIOL, V19, P3474; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Kakizawa T, 2001, J BIOL CHEM, V276, P9720, DOI 10.1074/jbc.M008531200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kojima H, 1999, J IMMUNOL, V162, P5063; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Li CJ, 1999, P NATL ACAD SCI USA, V96, P13369, DOI 10.1073/pnas.96.23.13369; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; SAKAI T, 1996, JPN J HYG, V50, P1036; SAMBROOK J, 2001, MOL CLONING, pCH17; Schwachtgen JL, 1998, BLOOD, V92, P1247, DOI 10.1182/blood.V92.4.1247.416k08_1247_1258; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Sowa Y, 2000, BIOFACTORS, V12, P283, DOI 10.1002/biof.5520120142; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Takahashi S, 2001, CANCER RES, V61, P1187; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Xu Y, 2001, GENE, V269, P141, DOI 10.1016/S0378-1119(01)00445-0; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang W, 2001, INT J ONCOL, V18, P749	48	100	106	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2003	22	49					7762	7773		10.1038/sj.onc.1207091	http://dx.doi.org/10.1038/sj.onc.1207091			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586402				2022-12-17	WOS:000186240200006
J	Post, DE; Van Meir, EG				Post, DE; Van Meir, EG			A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy	ONCOGENE			English	Article						hypoxia; adenovirus; HIF; gene delivery; oncolysis; tumor	REPLICATION-SELECTIVE ADENOVIRUS; GENE-EXPRESSION; CELL; GENERATION; EFFICACY; VECTORS; SYSTEM; MUTANT; GLIOMA	New therapy targeting the hypoxic fraction of tumors needs to be designed as this population of cells is the most resistant to radio- and chemotherapies. Hypoxia-inducible factor (HIF) mediates transcriptional responses to hypoxia by binding to hypoxia-responsive elements (HRE) in target genes. We developed a <(hyp)under bar>oxia/HIF-dependent replicative <(ad)under bar>enovirus (HYPR-Ad) to target hypoxic cells. HYPR-Ad displays hypoxia-dependent E1A expression and conditional cytolysis of hypoxic but not normoxic cells. This work provides proof-of-principle evidence that an attenuated oncolytic adenovirus that selectively lyses cells under hypoxia can be generated. This therapeutic approach can be used to treat all solid tumors that develop hypoxia, regardless of their tissue origin or genetic alterations.	Emory Univ, Winship Canc Ctr, Mol Neurooncol Lab, Dept Neurosurg, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Ctr, Mol Neurooncol Lab, Dept Hematol Oncol, Atlanta, GA 30322 USA	Emory University; Emory University	Van Meir, EG (corresponding author), Emory Univ, Winship Canc Ctr, Mol Neurooncol Lab, Dept Neurosurg, 1365-B Clifton Rd NE,Rm B5103, Atlanta, GA 30322 USA.	evanmei@emory.edu	Core, Vector/CAF-4832-2022	Van Meir, Erwin G./0000-0003-2444-7707	NCI NIH HHS [CA87830] Funding Source: Medline; NINDS NIH HHS [NS41403] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS041403] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BETT AJ, 1995, VIRUS RES, V39, P75; Boast K, 1999, HUM GENE THER, V10, P2197, DOI 10.1089/10430349950017185; Brown JM, 2000, MOL MED TODAY, V6, P157, DOI 10.1016/S1357-4310(00)01677-4; Dachs GU, 1997, NAT MED, V3, P515, DOI 10.1038/nm0597-515; DERY CV, 1987, ONCOGENE, V2, P15; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; Fulci G, 2003, FRONT BIOSCI-LANDMRK, V8, pE346, DOI 10.2741/976; GLENN GM, 1988, VIRUS RES, V9, P73, DOI 10.1016/0168-1702(88)90051-2; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Griffiths L, 2000, GENE THER, V7, P255, DOI 10.1038/sj.gt.3301058; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Kirn D, 2001, GENE THER, V8, P89, DOI 10.1038/sj.gt.3301377; Koshikawa N, 2000, CANCER RES, V60, P2936; Kruyt FAE, 2002, HUM GENE THER, V13, P485, DOI 10.1089/10430340252809784; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; Modlich U, 2000, GENE THER, V7, P896, DOI 10.1038/sj.gt.3301177; PARKS CL, 1988, J VIROL, V62, P54, DOI 10.1128/JVI.62.1.54-67.1988; Post DE, 2001, GENE THER, V8, P1801, DOI 10.1038/sj.gt.3301605; Prentice H, 1997, CARDIOVASC RES, V35, P567, DOI 10.1016/S0008-6363(97)00158-2; Ruan Hangjun, 1999, Neoplasia (New York), V1, P431, DOI 10.1038/sj.neo.7900059; Ruan HJ, 2001, NEOPLASIA, V3, P255, DOI 10.1038/sj.neo.7900157; Semenza GL, 2000, GENE DEV, V14, P1983; Shibata T, 2000, GENE THER, V7, P493, DOI 10.1038/sj.gt.3301124; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; TOLLEFSON AE, 1999, METH MOLEC MED, V21, P1; Tsukuda K, 2002, CANCER RES, V62, P3438; Zhong H, 1999, CANCER RES, V59, P5830	28	100	116	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2065	2072		10.1038/sj.onc.1206464	http://dx.doi.org/10.1038/sj.onc.1206464			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687009				2022-12-17	WOS:000182066900001
J	Simone, C; Stiegler, P; Bagella, L; Pucci, B; Bellan, C; De Falco, G; De Luca, A; Guanti, G; Puri, PL; Giordano, A				Simone, C; Stiegler, P; Bagella, L; Pucci, B; Bellan, C; De Falco, G; De Luca, A; Guanti, G; Puri, PL; Giordano, A			Activation of MyoD-dependent transcription by cdk9/cyclin T2	ONCOGENE			English	Article						cdk9; cyclins; MyoD; muscle differentiation; phosphorylation	RNA-POLYMERASE-II; P-TEFB KINASE; CARBOXY-TERMINAL DOMAIN; MUSCLE GENE-EXPRESSION; HELIX-LOOP-HELIX; CELL-CYCLE; HIV-1 TAT; IN-VITRO; CDC2-RELATED KINASE; MADS-BOX	Myogenic transcription is repressed in myoblasts by serum-activated cyclin-dependent kinases, such as cdk2 and cdk4. Serum withdrawal promotes muscle-specific gene expression at least in part by down-regulating the activity of these cdks. Unlike the other cdks, cdk9 is not serum- or cell cycle-regulated and is instead involved in the regulation of transcriptional elongation by phosphorylating the carboxyl-terminal domain (CTD) of RNA polymerase It. While ectopic expression of cdk2 together with its regulatory subunits (cyclins E and A) inhibits myogenic transcription, overproduction of cdk9 and its associated cyclin (cyclin T2a) strengthens MyoD-dependent transcription and stimulates myogenic differentiation in both MyoD-converted fibroblasts and C2C12 muscle cells. Conversely, inhibition of cdk9 activity by a dominant negative form (cdk9-dn) represses the myogenic program. Cdk9, cyclinT2 and MyoD can be detected in a multimeric complex in C2C12 cells, with the minimal cdk9-binding region of MyoD mapping within 101-161 aa of the bHLH region. Finally, cdk9 can phosphorylate MyoD in vitro, suggesting the possibility that cdk9/cycT2a regulation of muscle differentiation includes the direct enzymatic activity of the kinase on MyoD.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Bari, Div Med Genet, Dept Internal Med & Publ Med, I-70124 Bari, Italy; Univ Siena, Inst Pathol Anat & Histol, I-53100 Siena, Italy; Univ Naples 2, Sch Med, Inst Topog Anat, I-80138 Naples, Italy; Univ Roma La Sapienza, Fdn Andrea Cesalpino, Gene Express Lab, I-00161 Rome, Italy; Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92093 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; Universita degli Studi di Bari Aldo Moro; University of Siena; Universita della Campania Vanvitelli; Sapienza University Rome; Salk Institute	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Biolife Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.		Giordano, Antonio/F-1927-2010; De Luca, Antonio/AAD-9562-2020; BELLAN, CRISTIANA/L-3903-2013; BELLAN, CRISTIANA/ABG-4750-2021; Simone, Cristiano/K-3452-2018	Giordano, Antonio/0000-0002-5959-016X; De Luca, Antonio/0000-0002-3905-6154; BELLAN, CRISTIANA/0000-0001-6119-9007; BELLAN, CRISTIANA/0000-0001-6119-9007; Simone, Cristiano/0000-0002-2628-7658; BAGELLA, Luigi/0000-0003-2815-037X; Puri, Pier Lorenzo/0000-0003-4964-0095	Telethon [TCP00081] Funding Source: Medline	Telethon(Fondazione Telethon)		Bagella L, 1998, J CELL PHYSIOL, V177, P206, DOI 10.1002/(SICI)1097-4652(199811)177:2<206::AID-JCP2>3.3.CO;2-W; Bagella L, 2000, J CELL BIOCHEM, V78, P170, DOI 10.1002/(SICI)1097-4644(20000701)78:1<170::AID-JCB16>3.3.CO;2-1; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; DeLuca A, 1997, J CELL PHYSIOL, V172, P265, DOI 10.1002/(SICI)1097-4652(199708)172:2<265::AID-JCP13>3.3.CO;2-C; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; Foskett SM, 2001, J VIROL, V75, P1220, DOI 10.1128/JVI.75.3.1220-1228.2001; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Garriga J, 1998, ONCOGENE, V17, P3093, DOI 10.1038/sj.onc.1202548; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; Herrmann CH, 1998, J VIROL, V72, P9881, DOI 10.1128/JVI.72.12.9881-9888.1998; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Kitzmann M, 1999, MOL CELL BIOL, V19, P3167; Kwak YT, 1999, J MOL BIOL, V288, P57, DOI 10.1006/jmbi.1999.2664; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lis JT, 2000, GENE DEV, V14, P792; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P467, DOI 10.1002/(SICI)1097-4644(19981215)71:4<467::AID-JCB2>3.3.CO;2-7; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McGrew MJ, 1996, MOL CELL BIOL, V16, P4524; MCLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Napolitano G, 2000, GENE, V254, P139, DOI 10.1016/S0378-1119(00)00278-X; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 2000, GENE DEV, V14, P574; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SARTORELLI V, 2001, FRONT BIOSCI, V6, pD1073; SIMONE C, 2001, FRONT BIOSCI, V6, pD1024; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wei Q, 2001, FEBS LETT, V490, P171, DOI 10.1016/S0014-5793(01)02120-2; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; Wimmer J, 1999, VIROLOGY, V255, P182, DOI 10.1006/viro.1998.9589; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	52	100	106	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4137	4148		10.1038/sj.onc.1205493	http://dx.doi.org/10.1038/sj.onc.1205493			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037670				2022-12-17	WOS:000176186000008
J	Bhat-Nakshatri, P; Sweeney, CJ; Nakshatri, H				Bhat-Nakshatri, P; Sweeney, CJ; Nakshatri, H			Identification of signal transduction pathways involved in constitutive NF-kappa B activation in breast cancer cells	ONCOGENE			English	Article						breast cancer; NF-kappa B; oncogenes; ErbB	TUMOR PROGRESSION; INDUCED APOPTOSIS; C-MYC; TRANSFORMATION; HEREGULIN; GROWTH; DIFFERENTIATION; PHOSPHORYLATION; PARTHENOLIDE; CONTRIBUTES	Nuclear factor-kappaB (NF-kappaB) is usually maintained in an, inactive form in the cytoplasm through its association with inhibitor of kappaB (IkappaB) proteins, and is activated upon stimulation of cells with a variety of signals. However, constitutive activation of NF-kappaB is observed in a number of cancers including breast cancer. The signaling pathways that are involved in constitutive NF-kappaB activation remain largely unknown. Using breast cancer cell lines derived from transgenic mice that overexpress specific oncogene/growth factors in the mammary gland, we show that heregulin but not her2/neu, c-Myc or v-Ha-ras plays a major role in constitutive NT-kappaB activation. Her2/neu potentiated tumor necrosis factor alpha (TNFchi)-inducible NF-kappaB activation whereas c-Myc potentiated 12-o-tetracecanyolphorbol-13-acetate (TPA)-induced NT-kappaB activation. Heregulin-mediated NF-kappaB activation correlated with phosphorylation of epidermal growth factor receptor (EGFR) and ErbB3 but not her2/neu. Tryphostin AG1517, which inhibits heregulin-mediated phosphorylation of EGFR, her2/neu and ErbB3 reduced NF-kappaB activation. In contrast, emodin, which blocks phosphorylation of her2/neu by heregulin, failed to reduce NF-kappaB activation. These results suggest that heregulin induces NF-kappaB independent of her2/neu. PI3 kinase/AKT, protein kinase A (PKA) and IkappaB kinase appear to be downstream signaling molecules involved in NF-kappaB activation as specific inhibitors of these kinases but not inhibitors of ERK/MAP kinase or protein kinase C reduced heregulin-mediated NF-kappaB activation. Based on these results, we propose that heregulin increases the expression of pro-invasive, prometastatic and anti-apoptotic genes in cancer cells through autocrine activation of NF-kappaB, which leads to invasive and drug-resistant growth of breast cancer.	Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46208 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Nakshatri, H (corresponding author), Indiana Canc Res Inst, R4-202,1044 W Walnut St, Indianapolis, IN 46202 USA.	hnakshat@iupui.edu		Nakshatri, Harikrishna/0000-0001-8876-0052				Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; Clarkson RWE, 2000, J BIOL CHEM, V275, P12737, DOI 10.1074/jbc.275.17.12737; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong G, 1999, CANCER RES, V59, P3495; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hehner SP, 1999, J IMMUNOL, V163, P5617; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Kroiher M, 2001, BIOESSAYS, V23, P69, DOI 10.1002/1521-1878(200101)23:1<69::AID-BIES1009>3.3.CO;2-B; Lee H, 1998, ONCOGENE, V16, P3243, DOI 10.1038/sj.onc.1201866; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Nozaki S, 2000, BIOCHEM BIOPH RES CO, V275, P60, DOI 10.1006/bbrc.2000.3241; Nozaki S, 2001, ONCOGENE, V20, P2178, DOI 10.1038/sj.onc.1204292; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Ozes ON, 1999, NATURE, V401, P82; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Sweeney C, 2001, J BIOL CHEM, V276, P22685, DOI 10.1074/jbc.M100602200; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Yen L, 2000, ONCOGENE, V19, P3460, DOI 10.1038/sj.onc.1203685; ZHANG LS, 1995, CANCER RES, V55, P3890; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	47	100	107	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2066	2078		10.1038/sj.onc.1205243	http://dx.doi.org/10.1038/sj.onc.1205243			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960379				2022-12-17	WOS:000174827000013
J	Oehler, MK; Norbury, C; Hague, S; Rees, MCP; Bicknell, R				Oehler, MK; Norbury, C; Hague, S; Rees, MCP; Bicknell, R			Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: a possible promotion mechanism for tumour growth	ONCOGENE			English	Article						adrenomedullin; Bcl-2; hypoxia; apoptosis; cell death; survival	ANGIOGENIC FACTOR ADRENOMEDULLIN; GENE-RELATED PEPTIDE; BREAST-CANCER; IN-VIVO; PROTEIN FAMILY; APOPTOSIS; EXPRESSION; TAMOXIFEN; PREVENTION; INDUCTION	Regions of hypoxia are a common feature of solid tumours, When tumour cells are exposed to hypoxic stress, transcription of a battery of genes is initiated. The angiogenic factor adrenomedullin (ADM) is a hypoxia regulated gene, ADM is thought to act through the G protein-coupled receptor calcitonin receptor-like receptor (CRLR), with specificity being conferred by the receptor associated modifying protein 2 (RAMP2), Here we report for the! first time that ADM treated or stably transfected Ishikawa cells overexpressing ADM show increased resistance to hypoxia induced apoptosis, These cells also show an upregulation of the oncoprotein Bcl-2, which is protective against hypoxic cell death when transiently transfected into Ishikawa cells. Since Ishikawa cells express the putative ADM-receptor CRLR-RAMP2 the production and secretion of ADM with the consecutive upregulation of Bcl-2 could establish an autocrine/paracrine mechanism rescuing malignant cells from hypoxic cell death. These results, taken together with our previous findings that ADM is an angiogenic factor which is upregulated by the nonsteroidal antiestrogen tamoxifen (TAM) in endometrial cells, implicate this peptide as a promoter of tumour growth and a possible target for anticancer strategies. Oncogene (2001) 20, 2937-2945.	Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund,Mol Angiogenesis Lab, Oxford OX3 9DS, England; Univ Oxford, Cell Cycle Grp, Oxford OX3 9DS, England; Univ Oxford, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England	University of Oxford; University of Oxford; University of Oxford	Bicknell, R (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund,Mol Angiogenesis Lab, Oxford OX3 9DS, England.			Bicknell, Roy/0000-0002-0941-8919				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alarcon RM, 1996, CANCER RES, V56, P4315; Barakat RR, 1996, CLIN OBSTET GYNECOL, V39, P629, DOI 10.1097/00003081-199609000-00012; Bergman L, 2000, LANCET, V356, P881, DOI 10.1016/S0140-6736(00)02677-5; Blancher C, 1998, CANCER METAST REV, V17, P187, DOI 10.1023/A:1006002419244; Caron KM, 2001, P NATL ACAD SCI USA, V98, P615, DOI 10.1073/pnas.021548898; Carthew P, 2000, CARCINOGENESIS, V21, P793, DOI 10.1093/carcin/21.4.793; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; CORY S, 1999, CANCER RES, V59, P1685; Cuzick J, 2000, EUR J CANCER, V36, P1298, DOI 10.1016/S0959-8049(00)00106-4; Elkas J, 2000, OBSTET GYNECOL, V95, P697, DOI 10.1016/S0029-7844(99)00660-2; Evans SM, 1997, CANCER RES, V57, P5155; FURMAN E, 1992, J STEROID BIOCHEM, V43, P189, DOI 10.1016/0960-0760(92)90207-Y; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hague S, 2000, CLIN CANCER RES, V6, P2808; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Hockel M, 1999, CANCER RES, V59, P4525; Hofbauer KH, 2000, AM J PHYSIOL-REG I, V278, pR513, DOI 10.1152/ajpregu.2000.278.2.R513; ISHIMITSU T, 1994, BIOCHEM BIOPH RES CO, V203, P631, DOI 10.1006/bbrc.1994.2229; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; Kamitani S, 1999, FEBS LETT, V448, P111, DOI 10.1016/S0014-5793(99)00358-0; Kato H, 1997, ENDOCRINOLOGY, V138, P2615, DOI 10.1210/en.138.6.2615; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; McGill Gael, 1997, Frontiers in Bioscience (online), V2, pD353; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Miller MJ, 1996, J BIOL CHEM, V271, P23345; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nakayama M, 1998, BIOCHEM BIOPH RES CO, V243, P514, DOI 10.1006/bbrc.1998.8131; Nguyen SV, 1999, BIOCHEM BIOPH RES CO, V265, P382, DOI 10.1006/bbrc.1999.1674; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; ONGKEKO W, 1995, J CELL SCI, V108, P2897; Parameswaran N, 1999, EUR J PHARMACOL, V372, P85, DOI 10.1016/S0014-2999(99)00022-9; Pellegrini M, 1999, J CLIN IMMUNOL, V19, P365, DOI 10.1023/A:1020598632068; PETERSEN NE, 1995, CLIN CHEM, V41, P1605; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; Sakuragi N, 1998, INT J CANCER, V79, P153, DOI 10.1002/(SICI)1097-0215(19980417)79:2<153::AID-IJC10>3.0.CO;2-B; Shichiri M, 1999, MOL ENDOCRINOL, V13, P1353, DOI 10.1210/me.13.8.1353; Shimizu S, 1996, CANCER RES, V56, P2161; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; THOMLINSON R, 1995, BRIT J CANCER, V9, P539; Vaupel Peter W., 1993, P53; Wimalawansa SJ, 1997, CRIT REV NEUROBIOL, V11, P167, DOI 10.1615/CritRevNeurobiol.v11.i2-3.40; Yamabe K, 1998, BIOCHEM BIOPH RES CO, V243, P217, DOI 10.1006/bbrc.1997.7925; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhao Y, 1998, ONCOGENE, V16, P409, DOI 10.1038/sj.onc.1201768	47	100	112	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2937	2945		10.1038/sj.onc.1204422	http://dx.doi.org/10.1038/sj.onc.1204422			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420706				2022-12-17	WOS:000168901800009
J	Edamatsu, H; Gau, CL; Nemoto, T; Guo, L; Tamanoi, F				Edamatsu, H; Gau, CL; Nemoto, T; Guo, L; Tamanoi, F			Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines	ONCOGENE			English	Article						anti-cancer drug; FTI; Cdk inhibitor; apoptosis	FARNESYL-PROTEIN TRANSFERASE; CYCLIN-DEPENDENT KINASES; RAS-TRANSFORMED CELLS; TRANSGENIC MICE; SELECTIVE-INHIBITION; CYTOCHROME-C; TUMOR-CELLS; GROWTH; DEATH; ACTIVATION	Farnesyltransferase inhibitor (FTI) induces apoptosis of transformed cells. This involves changes in mitochondria, including decrease of mitochondrial membrane potential and the release of cytochrome c, The released cytochrome c then induces events leading to the activation of caspase-3, In this study, we report that purine derivative cyclin-dependent kinase (Cdk) inhibitors, roscovitine and olomoucine, dramatically enhance this FTI-induced apoptosis of human cancer cell lines. We noticed the synergy between Cdk inhibitors and FTI through our screen to identify compounds that enhance FTI-induced apoptosis of promyelocytic leukemic cell line HL-60, The Cdk inhibitors by themselves do not induce apoptosis at the concentrations used, Roscovitine synergizes with FTI to release cytochrome c from mitochondria, In addition, we detected synergistic effects of FTI and roscovitine to inhibit hyperphosphorylation of retinoblastoma protein. Enhancement of FTI-induced apoptosis by roscovitine is not unique to HL-60 cells, since similar synergy was observed with a leukemic cell line CEM and a prostate cancer cell line LNCaP, In LNCaP cells, in addition to roscovitine and olomoucine, phophatidylinositol 3-kinase (PI 3-kinase) inhibitor, LY294002, was effective in enhancing FTI-induced apoptosis, However, the effects of roscovitine appear to be distinct from those of LY294002, since roscovitine did not affect Akt activity while LY294002 significantly decreased the activity of Akt, Our finding of the synergy between FTI and Cdk inhibitor is significant for understanding the mechanism of action of FTI as well as for clinical use of FTI.	Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Tamanoi, F (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA.			Edamatsu, Hironori/0000-0002-1335-4217	NATIONAL CANCER INSTITUTE [R01CA041996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185] Funding Source: NIH RePORTER; NCI NIH HHS [CA41996] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; Chang YT, 1999, CHEM BIOL, V6, P361, DOI 10.1016/S1074-5521(99)80048-9; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; DER CJ, 1996, ANTI-CANCER DRUG, V7, P165; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Du W, 1999, CANCER RES, V59, P4208; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; Havlicek L, 1997, J MED CHEM, V40, P408, DOI 10.1021/jm960666x; Hung WC, 1998, INT J ONCOL, V12, P137; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Lebowitz PF, 1997, CANCER RES, V57, P708; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Liu M, 1998, CANCER RES, V58, P4947; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Moasser MM, 1998, P NATL ACAD SCI USA, V95, P1369, DOI 10.1073/pnas.95.4.1369; NAGASU T, 1995, CANCER RES, V55, P5310; Norgaard P, 1999, CLIN CANCER RES, V5, P35; OKADA T, 1994, J BIOL CHEM, V269, P3563; ONGKEKO W, 1995, J CELL SCI, V108, P2897; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; SATTLER I, 1996, REGULATION RAS SIGNA, P95; Sepp-Lorenzino L, 1998, J BIOL CHEM, V273, P20243, DOI 10.1074/jbc.273.32.20243; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Strickland CL, 1999, J MED CHEM, V42, P2125, DOI 10.1021/jm990030g; SUN JZ, 1995, CANCER RES, V55, P4243; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P10499, DOI 10.1073/pnas.95.18.10499; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P15356, DOI 10.1073/pnas.95.26.15356; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	48	100	104	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2000	19	27					3059	3068		10.1038/sj.onc.1203625	http://dx.doi.org/10.1038/sj.onc.1203625			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871858				2022-12-17	WOS:000087903900003
J	Wang, YZ; Wharton, W; Garcia, R; Kraker, A; Jove, R; Pledger, WU				Wang, YZ; Wharton, W; Garcia, R; Kraker, A; Jove, R; Pledger, WU			Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity	ONCOGENE			English	Article						PDGF; STATs; Src	PROTEIN-TYROSINE KINASE; STIMULATING FACTOR-RECEPTOR; FACTOR-ALPHA RECEPTOR; CELL-PROLIFERATION; PDGF RECEPTOR; C-SRC; PHOSPHORYLATION SITES; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; CYTOPLASMIC REGION	Members of the STAT family of transcriptional regulators modulate the expression of a variety of gene products that promote cell proliferation, survival and transformation. Although initially identified as mediators of cytokine signaling, the STAT proteins are also activated by, and thus mag contribute to the actions of, polypeptide growth factors. To define the mechanism by which these factors activate STATs, me examined the process of Stat3 activation in Balb/c-3T3 fibroblasts treated with platelet-derived growth factor (PDGF), As STATs are activated by tyrosine phosphorylation, and as PDGF receptors are ligand-activated tyrosine kinases, we considered the possibility that Stat3 interacts with and is phosphorylated by PDGF receptors, We find that Stat3 associates with PDGF beta receptors in both the presence and, surprisingly, the absence of PDGF, Moreover, Stat3 was phosphorylated on tyrosine in PDGF beta receptor immunoprecipitates of PDGF-treated but not untreated cells. Although required, receptor activation was insufficient for Stat3 activation. When added to cells in combination with a pharmacologic agent (PD180970) that specifically inhibits the activity of Src family tyrosine kinases, PDGF did not activate Stat3 as monitored by electrophoretic mobility shift assay. PD180970 did not affect MAPK activation by PDGF or the JAK-dependent activation of Stat3 by interleukin-6, The necessity of Src activity for Stat3 activation by PDGF was further evidenced by data showing the presence of Src in complexes containing both Stat3 and PDGF beta receptors in PDGF-treated cells. These results suggest a novel mechanism of STAT activation in which inactive Stat3 pre-assembles with inactive PDGF receptors, and in response to ligand binding and in a manner dependent on Src kinase activity, is rapidly phosphorylated and activated. Additional data demonstrate that Src kinase activity is also required for PDGF stimulation of DNA synthesis in density-arrested cells.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Med Chem, Ann Arbor, MI 48105 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Pfizer	Pledger, WU (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NCI NIH HHS [CA67360, CA55652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067360, R01CA055652] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Allgayer H, 1999, J BIOL CHEM, V274, P18428, DOI 10.1074/jbc.274.26.18428; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Choudhury GG, 1996, KIDNEY INT, V49, P19, DOI 10.1038/ki.1996.3; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; COATS SR, 1994, BIOCHEM J, V297, P379, DOI 10.1042/bj2970379; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; DROZDOFF V, 1991, J BIOL CHEM, V266, P17165; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; GarciaOlivares A, 1997, ENVIRONMETRICS, V8, P1, DOI 10.1002/(SICI)1099-095X(199701)8:1<1::AID-ENV230>3.3.CO;2-2; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HARRINGTON MA, 1985, J CELL BIOCHEM, V27, P67, DOI 10.1002/jcb.240270202; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; Heldin CH, 1996, CANCER SURV, V27, P7; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Marais R, 1996, CANCER SURV, V27, P101; MARENGERE LEM, 1994, J CELL SCI, P97; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; OLASHAW NE, 1991, J BIOL CHEM, V266, P10234; OLASHAW NE, 1983, NATURE, V306, P272, DOI 10.1038/306272a0; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; Roginskaya V, 1999, LEUKEMIA, V13, P855, DOI 10.1038/sj.leu.2401429; Sachsenmaier C, 1999, ONCOGENE, V18, P3583, DOI 10.1038/sj.onc.1202694; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SEEDORF K, 1995, METABOLISM, V44, P24, DOI 10.1016/0026-0495(95)90217-1; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; Yamamoto H, 1996, EXP CELL RES, V222, P125, DOI 10.1006/excr.1996.0016; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	63	100	103	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2000	19	17					2075	2085		10.1038/sj.onc.1203548	http://dx.doi.org/10.1038/sj.onc.1203548			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815799				2022-12-17	WOS:000086728000001
J	Stambolic, V; Mak, TW; Woodgett, JR				Stambolic, V; Mak, TW; Woodgett, JR			Modulation of cellular apoptotic potential: contributions to oncogenesis	ONCOGENE			English	Review						apoptosis; cell survival; PI3 ' K; PTEN	PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; PLECKSTRIN HOMOLOGY DOMAIN; TUMOR-SUPPRESSOR GENE; BANNAYAN-ZONANA-SYNDROME; MYC-INDUCED APOPTOSIS; PHOSPHOINOSITIDE 3-KINASE; CAENORHABDITIS-ELEGANS; PHOSPHATIDYLINOSITOL 3-KINASE; COWDEN-DISEASE	The importance of apoptosis as a natural means to eliminate unwanted or damaged cells has been realized ol er the past decade. Many components required to exercise programmed cell death have been identified and shown to pre-exist in most, if not all, cells, Such ubiquity requires that apoptosis be tightly controlled and suggests the propensity of cells to trigger the cellular death machinery can be regulated. Recently several signaling pathways have been demonstrated to impact the apoptotic potential of cells, most notably the phosphatidylinositol 3' kinase (PI3'K) pathway. The 3' phosphorylated lipid products generated by this enzyme promote activation of a protein-serine kinase, PKB/AKT, which is necessary and sufficient to confer cell P13'K-dependent survival signals. The relevance of this pathway to human cancer was revealed by the recent finding that the product of the PTEN tumor suppressor gene acts to antagonize P13'K. This review focuses on the regulation and mechanisms by which PKB activation protects cells and the oncologic consequences of dysregulation of the pathway.	Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Amgen Inst, Toronto, ON M5G 2C1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Woodgett, JR (corresponding author), Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.		Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797; Stambolic, Vuk/0000-0001-8853-3239				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bostrom J, 1998, CANCER RES, V58, P29; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cairns P, 1997, CANCER RES, V57, P4997; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHAFFANET M, 1992, EUR J CANCER, V28A, P11, DOI 10.1016/0959-8049(92)90374-B; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Coffer PJ, 1998, BIOCHEM J, V335, P1; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Dahia PLM, 1997, CANCER RES, V57, P4710; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies MA, 1999, CANCER RES, V59, P2551; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; delPeso L, 1997, SCIENCE, V278, P687; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eng C, 1998, INT J ONCOL, V12, P701; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Gil EB, 1999, P NATL ACAD SCI USA, V96, P2925, DOI 10.1073/pnas.96.6.2925; Guldberg P, 1997, CANCER RES, V57, P3660; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hayashi K, 1999, J CELL BIOL, V145, P727, DOI 10.1083/jcb.145.4.727; Hekimi S, 1998, TRENDS GENET, V14, P14, DOI 10.1016/S0168-9525(97)01299-7; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hinton HJ, 1999, J IMMUNOL, V162, P7002; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li DM, 1997, CANCER RES, V57, P2124; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Liu WG, 1997, CANCER RES, V57, P5254; LO SH, 1994, J BIOL CHEM, V269, P22310; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, J MED GENET, V35, P881, DOI 10.1136/jmg.35.11.881; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Mihaylova VT, 1999, P NATL ACAD SCI USA, V96, P7427, DOI 10.1073/pnas.96.13.7427; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Pastorino JG, 1999, J BIOL CHEM, V274, P19411, DOI 10.1074/jbc.274.27.19411; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rasheed BKA, 1997, CANCER RES, V57, P4187; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Risinger JI, 1998, CLIN CANCER RES, V4, P3005; Risinger JI, 1997, CANCER RES, V57, P4736; Rouault JP, 1999, CURR BIOL, V9, P329, DOI 10.1016/S0960-9822(99)80143-2; Roush W, 1997, SCIENCE, V277, P897, DOI 10.1126/science.277.5328.897; Sarkaria JN, 1998, CANCER RES, V58, P4375; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Smits A, 1998, HISTOL HISTOPATHOL, V13, P511, DOI 10.14670/HH-13.511; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Takeuchi H, 1997, BBA-MOL CELL RES, V1359, P275, DOI 10.1016/S0167-4889(97)00109-2; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; Thomas JH, 1998, BIOESSAYS, V20, P113, DOI 10.1002/(SICI)1521-1878(199802)20:2&lt;113::AID-BIES3&gt;3.0.CO;2-U; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang SI, 1997, CANCER RES, V57, P4183; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yao R, 1996, ONCOGENE, V13, P343; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	141	100	106	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	1999	18	45			SI		6094	6103		10.1038/sj.onc.1203126	http://dx.doi.org/10.1038/sj.onc.1203126			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251LL	10557100				2022-12-17	WOS:000083447100003
J	McIlroy, D; Sakahira, H; Talanian, RV; Nagata, S				McIlroy, D; Sakahira, H; Talanian, RV; Nagata, S			Involvement of caspase 3-activated DNase in internucleosomal DNA cleavage induced by diverse apoptotic stimuli	ONCOGENE			English	Article						apoptosis; caspase; DNase; anti-cancer drugs	PROGRAMMED CELL-DEATH; THYMOCYTE APOPTOSIS; RAT THYMOCYTES; GRANZYME-B; PROTEASES; IDENTIFICATION; FRAGMENTATION; ACTIVATION; INHIBITOR; FAMILY	Degradation of chromosomal DNA into nucleosome-sized fragments is one of the characteristics of apoptotic cell death. Here, we examined whether caspase-activated DNase (CAD) is responsible for the DNA fragmentation that occurs upon exposure to various apoptotic stimuli. When human Jurkat cells were exposed to etoposide, or UV or gamma radiation, a caspase-3-like protease was activated, and nuclear DNA was fragmented. Human TF-1 cells, which are dependent on granulocyte-macrophage colony-stimulating factor (GM-CSF), also underwent apoptosis accompanied by the activation of caspase-3-like protease and DNA fragmentation, when cultured without the cytokine. Both Jurkat and TF-1 cells expressed two forms of ICAD, ICAD-L and ICAD-S, which were cleaved upon exposure to these apoptotic stimuli. Among eight different caspases examined, recombinant caspases 3 and 7 specifically cleaved ICAD synthesized in a cell-free system. An expression plasmid containing mouse ICAD-L mutated at the caspase-3-recognition sites was then introduced into Jurkat and TF-1 cells. When the transformants were induced to undergo apoptosis (by treatment with etoposide, UV or gamma radiation for Jurkat cells, or factor withdrawal for TF-1 cells) they did not show DNA fragmentation, although they still died as a result of these stimuli. These results indicated that CAD, released from ICAD by caspase activation, is involved in the nuclear DNA fragmentation induced by these apoptotic stimuli.	Osaka Univ, Sch Med, Dept Genet, Osaka 5650871, Japan; BASF Biores Corp, Worcester, MA 01605 USA	Osaka University; BASF	Nagata, S (corresponding author), Osaka Univ, Sch Med, Dept Genet, 2-2 Yamadaoka, Osaka 5650871, Japan.		McILROY, Dorian/AAE-4398-2021; Nagata, Shigekazu/AAG-3203-2019	McILROY, Dorian/0000-0002-3731-4017; Nagata, Shigekazu/0000-0001-9758-8426				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MONTAGUE JW, 1994, J BIOL CHEM, V269, P18877; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Shiokawa D, 1998, APOPTOSIS, V3, P89, DOI 10.1023/A:1009692807692; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	36	100	107	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	1999	18	31					4401	4408		10.1038/sj.onc.1202868	http://dx.doi.org/10.1038/sj.onc.1202868			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442630				2022-12-17	WOS:000081813500001
J	Volloch, VZ; Sherman, MY				Volloch, VZ; Sherman, MY			Oncogenic potential of Hsp72	ONCOGENE			English	Article						Hsp72; oncogene; fibroblasts	HEAT-SHOCK PROTEINS; CELLS; THERMOTOLERANCE; GENE	Hsp72 is the major heat shock-inducible protein capable of protecting cells from a variety of stresses. In nontransformed cells at normal conditions Hsp72 is expressed at very low levels. It is, however, present at elevated levels in the major fraction of tumors and in many transformed cell lines. It is commonly assumed that in tumor cells the expression of Hsp72 at elevated levels is the consequence of oncogenic transformation. In the present study we addressed an alternative possibility that Hsp72 plays an active, role in the process of oncogenic transformation. We report hero that when Hsp72 was expressed in the Rat-1 fibroblasts either constitutively or from an adenovirus-based construct, cells become oncogenically transformed by the following criteria: loss of contact inhibition and formation of foci characteristic for oncogenically transformed cells; acquisition of the ability to grow in an anchorage-independent manner and to form colonies in soft agar; generation of tumors upon injection into mice. Furthermore, we also report that turning off the Hsp72 expression led to the reversal of the transformed phenotype. We also show that oncogenic potential of Hsp72 is confined in its peptide binding domain since the expression of this domain alone nas sufficient for oncogenic transformation of Rat-1 cells.	Tufts Univ, Ctr Biotechnol, Medford, MA 02155 USA; Boston Biomed Res Inst, Boston, MA 02114 USA	Tufts University; Boston Biomedical Research Institute	Volloch, VZ (corresponding author), Tufts Univ, Ctr Biotechnol, 4 Colby St,Room 142, Medford, MA 02155 USA.							AMICI C, 1993, EXP CELL RES, V207, P230, DOI 10.1006/excr.1993.1188; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; CLARK G, 1995, METHOD ENZYMOL, V225, P395; FEDER JH, 1992, GENE DEV, V6, P1402, DOI 10.1101/gad.6.8.1402; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; HEYDARI AR, 1994, EXPERIENTIA, V50, P1092, DOI 10.1007/BF01923466; Jani A, 1997, J VIROL METHODS, V64, P111, DOI 10.1016/S0166-0934(96)02138-6; LI GC, 1995, INT J HYPERTHER, V11, P459, DOI 10.3109/02656739509022483; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Mosser DD, 1997, BIOTECHNIQUES, V22, P150, DOI 10.2144/97221rr02; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Rattan SIS, 1996, EXP GERONTOL, V31, P33, DOI 10.1016/0531-5565(95)02022-5; Seo JS, 1996, BIOCHEM BIOPH RES CO, V218, P582, DOI 10.1006/bbrc.1996.0103	15	100	125	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3648	3651		10.1038/sj.onc.1202525	http://dx.doi.org/10.1038/sj.onc.1202525			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380887				2022-12-17	WOS:000080891700011
J	Pineau, P; Nagai, H; Prigent, S; Wei, Y; Gyapay, G; Weissenbach, J; Tiollais, P; Buendia, MA; Dejean, A				Pineau, P; Nagai, H; Prigent, S; Wei, Y; Gyapay, G; Weissenbach, J; Tiollais, P; Buendia, MA; Dejean, A			Identification of three distinct regions of allelic deletions on the short arm of chromosome 8 in hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; chromosome 8p; loss of heterozygosity; tumor suppressor gene; microsatellite marker	COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENES; COLORECTAL-CANCER; BREAST-CANCER; REPEAT POLYMORPHISMS; SQUAMOUS CARCINOMA; CELL CARCINOMAS; LONG ARM; IN-SITU; MAP	The chromosome 8p is associated with a large number of allelic imbalances in epithelial tumors including hepatocellular carcinoma (HCC), However, no tumor suppressor gene has been identified so far in this particular region of the genome. To further clarify the pattern of allelic deletions on chromosome 8p in HCC, we have undertaken high-density polymorphic marker analysis of 109 paired normal and primary tumor samples using 40 microsatellites positioned every 2 cm in average throughout 8p, We found that 60% of the tumors exhibited loss of heterozygosity (LOH) at one or more loci at 8p with three distinct minimal deleted areas : a 13 cm region in the distal part of 8p21, a 9 cm area in the more proximal portion of 8p22 and a 5 cm area in 8p23, These data strongly suggest the presence of at least three novel tumor suppressor loci on 8p in hepatocellular carcinoma.	Inst Pasteur, INSERM, Unite Recombinaison & Express Genet, U163, F-75724 Paris 15, France; Genethon, CNRS, URA 1922, F-91000 Evry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS)	Dejean, A (corresponding author), Inst Pasteur, INSERM, Unite Recombinaison & Express Genet, U163, 28 Rue Docteur Roux, F-75724 Paris 15, France.		Pineau, Pascal/AAP-5614-2020; Wei, Yu/A-7289-2016; Dejean, Anne/L-5145-2018	Pineau, Pascal/0000-0002-9407-1592; 				ADAMSON D, 1995, AM J HUM GENET, V57, P619; Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; Anbazhagan R, 1998, AM J PATHOL, V152, P815; Becker SA, 1996, CANCER RES, V56, P5092; Boige V, 1997, CANCER RES, V57, P1986; Brat DJ, 1997, AM J PATHOL, V150, P383; CHER ML, 1994, GENE CHROMOSOME CANC, V11, P153, DOI 10.1002/gcc.2870110304; CHUAQUI RF, 1995, CANCER RES, V55, P4995; CLIBY W, 1993, CANCER RES, V53, P2393; Courjal F, 1997, CANCER RES, V57, P4360; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; El-Naggar AK, 1998, ONCOGENE, V16, P2983, DOI 10.1038/sj.onc.1201808; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; EMI M, 1993, GENE CHROMOSOME CANC, V7, P152, DOI 10.1002/gcc.2870070307; EMMERTBUCK MR, 1995, CANCER RES, V55, P2959; Farrington SM, 1996, ONCOGENE, V12, P1803; FUJIWARA Y, 1993, CANCER RES, V53, P857; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; FUJIWARA Y, 1993, CANCER RES, V53, P1172; Gronwald J, 1997, CANCER RES, V57, P481; Gustafson CE, 1996, CANCER RES, V56, P5238; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; Hammoud ZT, 1996, CANCER RES, V56, P4499; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; *J HOPK U SCH MED, 1997, GEN DAT BAS; James LA, 1997, ONCOGENE, V14, P1059, DOI 10.1038/sj.onc.1200923; Johansson B, 1996, GENE CHROMOSOME CANC, V16, P155, DOI 10.1002/(SICI)1098-2264(199607)16:3<155::AID-GCC1>3.0.CO;2-Y; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LITT M, 1993, BIOTECHNIQUES, V15, P280; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.3.CO;2-N; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; NORDER H, 1993, ARCH VIROL, P189; Pineau P, 1998, J GEN VIROL, V79, P591, DOI 10.1099/0022-1317-79-3-591; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; ROSIN MP, 1995, CANC RES, V55; Roylance R, 1997, SEMIN CANCER BIOL, V8, P37, DOI 10.1006/scbi.1997.0051; Seitz S, 1997, ONCOGENE, V14, P741, DOI 10.1038/sj.onc.1200881; SHEFFIELD VC, 1995, HUM MOL GENET, V4, P1837, DOI 10.1093/hmg/4.10.1837; Simonic I, 1996, HUM GENET, V97, P524; Sunwoo JB, 1996, GENE CHROMOSOME CANC, V16, P164, DOI 10.1002/(SICI)1098-2264(199607)16:3<164::AID-GCC2>3.0.CO;2-X; Tishkoff SA, 1996, HUM GENET, V97, P759; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; Van Hul W, 1998, GENOMICS, V47, P230, DOI 10.1006/geno.1997.5101; Vocke CD, 1996, CANCER RES, V56, P2411; VOORTER C, 1995, AM J PATHOL, V146, P1341; WOOD S, 1991, CYTOGENET CELL GENET, V58, P1932; Wu CL, 1997, GENE CHROMOSOME CANC, V20, P347, DOI 10.1002/(SICI)1098-2264(199712)20:4<347::AID-GCC5>3.0.CO;2-1	51	100	103	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	1999	18	20					3127	3134		10.1038/sj.onc.1202648	http://dx.doi.org/10.1038/sj.onc.1202648			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340384	hybrid			2022-12-17	WOS:000080388000008
J	Zhu, JH; Jiang, JY; Zhou, WJ; Zhu, KC; Chen, XB				Zhu, JH; Jiang, JY; Zhou, WJ; Zhu, KC; Chen, XB			Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity	ONCOGENE			English	Article						p53; p21(wafl/cipl); apoptosis; cell cycle arrest	WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION; GROWTH ARREST; TUMOR-CELLS; IN-VIVO; PATHWAY; P21(WAF1/CIP1); IDENTIFICATION; SUPPRESSION; INHIBITOR	Activation of the p53 tumor suppressor protein can lead to either cell cycle arrest or apoptosis. Several functional domains necessary for mediating cell cycle arrest and apoptosis in p53 have been mapped, e.g., the proline-rich domain. The proline-rich domain is located within residues 60-90, which comprise five PXXP motifs (where P represents proline and X any amino acid). To further delineate the function of the proline-rich domain and its potential role in transactivation, we generated several groups of cell lines that inducibly express various p53 mutants using a tetracycline-regulated expression system. We found that p53(Delta 62-91), which lacks all five PXXP motifs in human p53, is capable of inducing cell cycle arrest but not apoptosis, while p53(gln22-ser23/Delta 62-91), which contains a double point mutation in the activation domain as well as deletion of the proline-rich domain, completely loses its activity. However, p53(Delta 74-91), which contains only one PXXP motif at its N-terminus, is not only capable of inducing cell cycle arrest but also retains a partial apoptotic activity. Furthermore, we found that deletion of the proline-rich region has no or very mild effects on activation of several transiently transfected p53 target gene promoters, i.e., the p21, MDM2, BAX, and GADD45 promoters. However, such deletion differentially affects p53 induction of endogenous target genes, i.e., induction of p21, MDM2, BTG2, p85, PIG3, PIG6 and PIG11 was reduced or abrogated but induction of BAX, KILLER/DR5, PIG2, PIG7 and PIGS was not substantially affected. Interestingly, induction of GADD45 was enhanced. These results suggest that the proline-rich region may play a role in chromatin remodeling, which counteracts chromatin-mediated repression for some of the endogenous p53 target genes.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, CB-2803, Augusta, GA 30912 USA.			Zhu, Kuichun/0000-0002-3594-5616	NATIONAL CANCER INSTITUTE [R01CA076069, R29CA076069] Funding Source: NIH RePORTER; NCI NIH HHS [CA76069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; GOTTLIEB TM, 1996, IOCH BIOPHYS ACTA, V1287, P77; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	30	100	102	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2149	2155		10.1038/sj.onc.1202533	http://dx.doi.org/10.1038/sj.onc.1202533			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321740				2022-12-17	WOS:000079346200013
J	Yamamoto, H; Kihara-Negishi, F; Yamada, T; Hashimoto, Y; Oikawa, T				Yamamoto, H; Kihara-Negishi, F; Yamada, T; Hashimoto, Y; Oikawa, T			Physical and functional interactions between the transcription factor PU.1 and the coactivator CBP	ONCOGENE			English	Article						PU.1; CBP; transcription factor	NUCLEAR-PROTEIN CBP; C-MYB; ACTIVATION; P300; DIFFERENTIATION; ERYTHROLEUKEMIA; FAMILY; CREB; ONCOPROTEIN; SIMILARITY	Yeast two-hybrid system was employed to isolate novel proteins that physically interact with PU.1, a member of Ets family transcription factors. Sequence analyses of several isolated clones positive for beta-galactosidase activity revealed that one of these clones was confirmed to encode a transcriptional coactivator, CREB binding protein (CBP), GST binding assay showed that the interacting sites were located at the transcriptional activation domain of PU,1 through 74-122 and the region spanning residues 1283-1915 of CBP. CBP potentiated PU.1-mediated transcription of the reporter gene driven by the multimerized PU.1-binding sites, suggesting that CBP functions as a coactivator for PU.1. Considering that CBP is a limited cellular component to function as a coactivator for several transcription factors, CBP may mediate synergistic and antagonistic interactions between PU.1 and other transcription factors during the process of hematopoietic cell differentiation.	Sasaki Inst, Dept Cell Genet, Chiyoda Ku, Tokyo 1010062, Japan		Oikawa, T (corresponding author), Sasaki Inst, Dept Cell Genet, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.							ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bellon T, 1997, BLOOD, V90, P1828, DOI 10.1182/blood.V90.5.1828; Beug H, 1996, BBA-REV CANCER, V1288, pM35, DOI 10.1016/S0304-419X(96)00032-7; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Gong QH, 1996, MOL CELL BIOL, V16, P6055; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kihara-Negishi F, 1998, INT J CANCER, V76, P523, DOI 10.1002/(SICI)1097-0215(19980518)76:4<523::AID-IJC14>3.0.CO;2-8; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; TENEN DG, 1997, BLOOD, V90, P498; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	47	100	100	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1495	1501		10.1038/sj.onc.1202427	http://dx.doi.org/10.1038/sj.onc.1202427			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050886				2022-12-17	WOS:000078651600011
J	Reichert, M; Eick, D				Reichert, M; Eick, D			Analysis of cell cycle arrest in adipocyte differentiation	ONCOGENE			English	Article						3T3-L1 cells; differentiation; adipocytes; cell cycle; Rb; SV40 large T antigen	LARGE T-ANTIGEN; BINDING-PROTEIN-ALPHA; MYC-INDUCED APOPTOSIS; LARGE TUMOR-ANTIGEN; SV40 LARGE-T; C-MYC; DNA-REPLICATION; C/EBP-ALPHA; DEPENDENT KINASES; TRANSCRIPTIONAL REGULATION	Confluent 3T3-L1 preadipocytes differentiate to adipocytes in the presence of insulin, dexamethasone, and isobutylmethylxanthine (IDI), A transient increase of DNA synthesis is induced in 3T3-L1 cells 18 h after addition of IDI, followed by an arrest in the G1 phase of the cell cycle. Growth arrested cells express the protooncogene oncogene c-myc and gene for the CCAAT/enhancer binding protein (C/EBP alpha) between day 2 and 5, While c-Myc is strongly implicated in cell proliferation, C/EBP alpha is a differentiation-specific transcription factor with antiproliferative, activity. Here we have characterized the cell cycle arrest in differentiating 3T3-L1 cells. Arrested cells express the Cdk inhibitors p21 and p27, but, at the same time, show hyperphosphorylation of Rb and expression of the E2F-regulated thymidine kinase gene. The addition of new serum to arrested cells resulted in cyclin A expression and Cdk2 activity, but not in DNA synthesis, Simian virus 40 large tumor antigen (LTAg) is a potent mitogen, The mutant LTAg-K1, deficient in binding of pocket proteins and unable to induce DNA synthesis in serum-starved 3T3-L1 cells, efficiently induced DNA synthesis in differentiating 3T3-L1 cells. This indicates that pocket proteins are probably not in,ol,ed in the control of the cell cycle arrest during 3T3-L1 cell differentiation. Our data suggest that the differentiation-specific cell cycle block in 3T3-L1 cells is resistant to high levels of c-Myc, inactivation of pocket proteins, upregulation of cyclin A levels, and Cdk2 activation, but can be abolished by a function of LTAg that is independent of binding to pocket proteins.	GSF Forschungszentrum Umwelt & Gesundheit, Inst Klin Mol Biol & Tumorgenet, D-81377 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Eick, D (corresponding author), GSF Forschungszentrum Umwelt & Gesundheit, Inst Klin Mol Biol & Tumorgenet, Marchioninistr 25, D-81377 Munich, Germany.							BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Constance CM, 1996, MOL CELL BIOL, V16, P3878; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Fajas L, 1998, CURR OPIN CELL BIOL, V10, P165, DOI 10.1016/S0955-0674(98)80138-5; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; GRANA X, 1995, ONCOGENE, V11, P211; GRATZNER HG, 1985, CYTOMETRY, V6, P563, DOI 10.1002/cyto.990060610; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; KIESS M, 1995, ONCOGENE, V10, P159; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LESAGE F, 1994, NUCLEIC ACIDS RES, V22, P3685, DOI 10.1093/nar/22.18.3685; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MEUTH M, 1974, CELL, V3, P367, DOI 10.1016/0092-8674(74)90052-X; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; OHKUBO Y, 1994, EXP CELL RES, V214, P270, DOI 10.1006/excr.1994.1258; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Sambrook J, 1989, MOL CLONING LAB MANU; SCHNEIDER MD, 1987, MOL CELL BIOL, V7, P1973, DOI 10.1128/MCB.7.5.1973; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WOLF DA, 1995, ONCOGENE, V10, P2067; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	51	100	101	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					459	466		10.1038/sj.onc.1202308	http://dx.doi.org/10.1038/sj.onc.1202308			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927202				2022-12-17	WOS:000078166500018
J	Korpelainen, EI; Karkkainen, M; Gunji, Y; Vikkula, M; Alitalo, K				Korpelainen, EI; Karkkainen, M; Gunji, Y; Vikkula, M; Alitalo, K			Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response	ONCOGENE			English	Article						STAT; VEGF; VEGF receptors; Tek; Tie; p21; signal transduction	EPIDERMAL GROWTH-FACTOR; CELL-GROWTH; CYTOKINE RECEPTORS; GENE-EXPRESSION; PLC-GAMMA; VEGF-C; TRANSCRIPTION; PROTEIN; BMX; PHOSPHORYLATION	Endothelial receptor tyrosine kinases (RTKs) and their signaling mechanisms are of interest because they may control tumor angiogenesis and thereby tumor growth, In this report we have examined activation of the signal transducers and activators of transcription (STATs) by the three known vascular endothelial growth factor receptors (VEGFR1-3), as well as by the endothelial Tie-1 and -2 receptors, We also studied signaling by the R849W mutant of Tie-2 (MTie-2), which has been shown to cause venous malformations. When overexpressed in 293T cells, MTie-2 activated STAT1 while the other endothelial RTKs failed to do so, In contrast, the three VEGFRs were strong activators of STAT3 and STAT5, suggesting that they activate only a specific subset of these signal transducers. STAT3 and STAT5 were also activated by Tie-2 and, more so, by MTie-2, Tyrosine phosphorylation and DNA binding of STAXs correlated with their ability to activate transcription as judged by luciferase assays. When co-expressed with STAT5, VEGFR-1 as well as both the Tie-2 receptor forms increased expression of the cell cycle inhibitor p21, Interestingly, co-expression of the Tie-2 receptors with STAT1 resulted in appearance of a novel, p21 related transcript. Taken together, these findings identify STAT proteins as novel targets for signal transduction by the endothelial RTKs, suggesting that they may be involved in the regulation of endothelial function.	Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Catholic Univ Louvain, Lab Human Mol Genet, Brussels, Belgium; Christian Duve Inst, Brussels, Belgium	University of Helsinki; Universite Catholique Louvain	Alitalo, K (corresponding author), Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland.		Alitalo, Kari K/J-5013-2014; Vikkula, Miikka/Q-1038-2018	Alitalo, Kari K/0000-0002-7331-0902; Vikkula, Miikka/0000-0002-6236-338X; Korpelainen, Eija/0000-0002-4406-5602				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Batard P, 1996, BLOOD, V87, P2212, DOI 10.1182/blood.V87.6.2212.bloodjournal8762212; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Ekman N, 1997, CIRCULATION, V96, P1729, DOI 10.1161/01.CIR.96.6.1729; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HUANG LW, 1995, ONCOGENE, V11, P2097; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kaukonen J, 1996, BRIT J HAEMATOL, V94, P455; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; May P, 1996, FEBS LETT, V394, P221, DOI 10.1016/0014-5793(96)00955-6; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; Poon RYC, 1998, ONCOGENE, V16, P1333, DOI 10.1038/sj.onc.1201897; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Saharinen P, 1997, BLOOD, V90, P4341; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Tchou WW, 1996, J BIOL CHEM, V271, P29556, DOI 10.1074/jbc.271.47.29556; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; Weil D, 1997, BLOOD, V90, P4332, DOI 10.1182/blood.V90.11.4332.4332_4332_4340; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; ZIEGLER SF, 1993, ONCOGENE, V8, P663	63	100	110	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					1	8		10.1038/sj.onc.1202288	http://dx.doi.org/10.1038/sj.onc.1202288			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926914				2022-12-17	WOS:000078166000001
J	Blaydes, JP; Hupp, TR				Blaydes, JP; Hupp, TR			DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site	ONCOGENE			English	Article						p53; CK2; DRB; UV-irradiation; phosphorylation	CASEIN KINASE-II; C-TERMINAL DOMAIN; RNA-POLYMERASE-II; WILD-TYPE P53; TRANSCRIPTIONALLY ACTIVE P53; TUMOR-SUPPRESSOR PROTEIN; CELL-CYCLE ARREST; BINDING ACTIVITY; IN-VITRO; HEAT-SHOCK	The sequence-specific DNA binding activity of p53 is negatively regulated by a C-terminal domain whose phosphorylation in vitro can activate the latent DNA binding function of the protein. The DNA binding activity of p53 is a core component of its stress-activated transcription function, yet it is not yet clear whether phosphorylation within the C-terminal domain plays a role in the p53 damage response in vise. As the casein kinase 2 (CK2) site at serine 392 is the C-terminal phosphorylation motif that exhibits the most pronounced conservation at the primary amino acid level, we have focused on determining whether the CK2 site is modified in vivo and whether radiation effects the extent of that phosphorylation. Using antibodies that can detect serine 392-phosphorylation of p53, we demonstrate that UV radiation can trigger extensive phosphorylation at the CK2 site. The CK2 inhibitor, 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB), can partially inhibit the UV-induced phosphorylation at serine 392, suggesting that CK2 is one of the major serine 392-kinases. However, a striking increase in UV-induced serine 392 phosphorylation and p53 transactivation function at higher levels of DRB suggests that a DRB-resistant/stress-activated pathway may target serine 392 irt vivo. These data demonstrate that radiation-induced phosphorylation of p53 can occur in vivo at serine 392 and implicate a CK2-independent signal cascade that can function to modulate serine 392 phosphorylation in cells.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland	University of Dundee	Hupp, TR (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				ABARZUA P, 1995, CANCER RES, V55, P3490; AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; APPEL K, 1995, ONCOGENE, V11, P1971; BARETTINO D, 1988, BIOCHEM CELL BIOL, V66, P1177, DOI 10.1139/o88-135; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL C, 1993, CANCER RES, V53, P2697; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; Critchfield JW, 1997, P NATL ACAD SCI USA, V94, P6110, DOI 10.1073/pnas.94.12.6110; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dubois MF, 1997, NUCLEIC ACIDS RES, V25, P694, DOI 10.1093/nar/25.4.694; DUBOIS MF, 1994, J CELL PHYSIOL, V158, P417, DOI 10.1002/jcp.1041580305; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FISCELLA M, 1994, ONCOGENE, V9, P3249; Friedberg E. C., 1995, DNA REPAIR MUTAGENES, P1; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; FUCHS B, 1995, EUR J BIOCHEM, V228, P2866; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALL PA, 1993, ONCOGENE, V8, P203; Hansen S, 1996, J BIOL CHEM, V271, P3917; Hansen S, 1996, J BIOL CHEM, V271, P30922, DOI 10.1074/jbc.271.48.30922; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Harlow E LD, 1988, ANTIBODIES LAB MANUA; Hecker D, 1996, ONCOGENE, V12, P953; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KASTAN MB, 1991, CANCER RES, V51, P6304; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MacCallum DE, 1996, ONCOGENE, V13, P2575; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERRITT AJ, 1994, CANCER RES, V54, P614; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Nikiforov MA, 1996, ONCOGENE, V13, P1709; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SEHGAL PB, 1975, SCIENCE, V190, P282, DOI 10.1126/science.1179208; SEHGAL PB, 1976, SCIENCE, V194, P431, DOI 10.1126/science.982026; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SOUSSI T, 1990, ONCOGENE, V5, P945; STONEWOLFF DS, 1981, MUTAT RES, V82, P147, DOI 10.1016/0027-5107(81)90146-9; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TAMM I, 1976, J CELL BIOL, V69, P229, DOI 10.1083/jcb.69.2.229; TARUNINA M, 1993, ONCOGENE, V8, P3165; THIAGALINGAM S, 1995, P NATL ACAD SCI USA, V92, P6062, DOI 10.1073/pnas.92.13.6062; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TISHLER RB, 1995, CANCER RES, V55, P6021; TRIGON S, 1995, J BIOL CHEM, V270, P13091, DOI 10.1074/jbc.270.22.13091; VENETIANER A, 1995, EUR J BIOCHEM, V233, P83, DOI 10.1111/j.1432-1033.1995.083_1.x; VOJTESEK B, 1995, ONCOGENE, V10, P389; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; ZANDOMENI RO, 1989, BIOCHEM J, V262, P469, DOI 10.1042/bj2620469	83	100	102	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					1045	1052		10.1038/sj.onc.1202014	http://dx.doi.org/10.1038/sj.onc.1202014			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747884				2022-12-17	WOS:000075560900013
J	Zisch, AH; Kalo, MS; Chong, LD; Pasquale, EB				Zisch, AH; Kalo, MS; Chong, LD; Pasquale, EB			Complex formation between EphB2 and Src requires phosphorylation of tyrosine 611 in the EphB2 juxtamembrane region	ONCOGENE			English	Article						autophosphorylation sites; neuronal signaling pathways; receptor tyrosine kinase; two-hybrid system	PROTEIN KINASE-C; GROWTH-FACTOR; IN-VITRO; SIGNAL-TRANSDUCTION; NEURAL RETINA; COMMISSURAL AXONS; DOMAIN BINDING; CDNA CLONING; SH2 DOMAIN; RECEPTOR	The cellular components of the neuronal signaling pathways of Eph receptor tyrosine kinases are only beginning to be elucidated. Here we show that in vivo tyrosine phosphorylation sites of the Eph receptors EphA3, EphA4, and EphB2 in embryonic retina serve as binding sites for the Src-homology 2 (SH2) domain of Src kinase, Furthermore, tyrosine-phosphorylated EphB2 was detected in Src immunoprecipitates from transfected Cos cells, indicating that EphB2 and Src can physically associate. Interestingly, a form of Src with reduced electrophoretic mobility and increased tyrosine phosphorylation was detected in Cos cells expressing tyrosine-phosphorylated EphB2, suggesting a functional interaction between EphB2 and Src. Yeast two-hybrid analysis in conjunction with site-directed mutagenesis demonstrated that phosphorylated tyrosine 611 in the juxtamembrane region of EphB2 is crucial for the interaction with the SH2 domain of Src, In contrast, binding of the carboxy-terminal SH2 domain of phospholipase C gamma was not abolished upon mutation of tyrosine 611 in EphB2, Phosphopeptide mapping of autophosphorylated full-length EphB2, and wild-type and tyrosine to phenylalanine mutants of the EphB2 cytoplasmic domain fused to LexA, showed tyrosine 611 in the sequence motif YEDP as a major site of autophosphorylation in EphB2, Our mutational analysis also indicated that tyrosines 605 and 611 are important for EphB2 kinase activity. We propose Src kinase as a downstream effector that mediates the neuron's response to Eph receptor activation.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Pasquale, EB (corresponding author), Burnham Inst, La Jolla, CA 92037 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025938] Funding Source: NIH RePORTER; NEI NIH HHS [EY105576] Funding Source: Medline; NICHD NIH HHS [HD25938] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ausubel FM, 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BIXBY JL, 1993, J NEUROSCI, V13, P3421; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Brambilla R, 1995, MOL CELL NEUROSCI, V6, P487, DOI 10.1006/mcne.1995.0001; Brunton VG, 1997, ONCOGENE, V14, P283, DOI 10.1038/sj.onc.1200827; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Ellis C, 1996, ONCOGENE, V12, P1727; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Flanagan JG, 1997, CELL, V90, P403; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; FOX GM, 1995, ONCOGENE, V10, P897; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; Hall CL, 1996, ONCOGENE, V13, P2213; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; Holash JA, 1997, DEV BIOL, V182, P256, DOI 10.1006/dbio.1996.8496; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; INGRAHAM CA, 1992, ONCOGENE, V7, P95; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Lombardo CR, 1995, BIOCHEMISTRY-US, V34, P16456, DOI 10.1021/bi00050a029; Maness P.F., 1992, Seminars in Cell Biology, V3, P117; Meima L, 1997, MOL CELL NEUROSCI, V9, P314, DOI 10.1006/mcne.1997.0621; Meima L, 1997, EUR J NEUROSCI, V9, P177, DOI 10.1111/j.1460-9568.1997.tb01365.x; Monschau B, 1997, EMBO J, V16, P1258, DOI 10.1093/emboj/16.6.1258; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; Park S, 1997, EMBO J, V16, P3106, DOI 10.1093/emboj/16.11.3106; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; SAJJADI FG, 1993, ONCOGENE, V8, P1807; Schindelholz B, 1997, J NEUROSCI, V17, P8391; SHAO HN, 1994, J BIOL CHEM, V269, P26606; Soans C, 1996, J CELL BIOL, V135, P781, DOI 10.1083/jcb.135.3.781; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stover DR, 1996, J BIOL CHEM, V271, P12481, DOI 10.1074/jbc.271.21.12481; SUDOL M, 1993, ONCOGENE, V8, P823; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; TWAMLEYSTEIN GM, 1993, ONCOGENE, V7, P1893; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WARREN SL, 1988, MOL CELL BIOL, V8, P632, DOI 10.1128/MCB.8.2.632; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; ZHENG XF, 1989, ONCOGENE, V4, P99; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zisch AH, 1997, J NEUROSCI RES, V47, P655, DOI 10.1002/(SICI)1097-4547(19970315)47:6<655::AID-JNR12>3.0.CO;2-U; ZISCH AH, 1995, MOL CELL NEUROSCI, V6, P263, DOI 10.1006/mcne.1995.1021	83	100	103	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	1998	16	20					2657	2670		10.1038/sj.onc.1201823	http://dx.doi.org/10.1038/sj.onc.1201823			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632142				2022-12-17	WOS:000073698200010
J	Takaoka, A; Hinoda, Y; Satoh, S; Adachi, Y; Itoh, F; Adachi, M; Imai, K				Takaoka, A; Hinoda, Y; Satoh, S; Adachi, Y; Itoh, F; Adachi, M; Imai, K			Suppression of invasive properties of colon cancer cells by a metastasis suppressor KAI1 gene	ONCOGENE			English	Article						colon cancer; KAI1 gene; invasion; metastasis	SPAN-TRANSMEMBRANE PROTEIN; PROSTATE-CANCER; TUMOR-CELLS; COLORECTAL-CARCINOMA; DECREASED EXPRESSION; SYNCYTIUM FORMATION; COLORIMETRIC ASSAY; MOLECULAR-CLONING; BASEMENT-MEMBRANE; LIVER METASTASES	KA11 is a potential metastatic suppressor gene for prostate cancer, We found by Northern blot analysis that six of ten (60%) gastric and colon cancer cell lines exhibited undetectable or very low expression level of KA11 mRNA. The effects of KA11 on the adhesion, motility and invasiveness of colon cancer cells was therefore investigated by using two kinds of stable transfectants, i.e., antisense transfectants of BM314 cells whose KA11 mRNA expression was suppressed by transfer of antisense KA11 cDNA and sense transfectants of DLD-1 cells with the enhanced KA11 mRNA by sense cDNA transfer. The following results were obtained: (1) KA11 gene expression had no significant effect on in vitro cell growth rate of colon cancer BM314 and DLD-1 cells; (2) Cell aggregation assay showed that KA11 enhanced the Ca++-independent aggregatability of those colon cancer cells; (3) It was revealed by cell motility and invasion assays that KA11 suppressed both the motility and in vitro invasiveness of those cells and (4) Furthermore, both the binding to fibronectin and the migration on fibronectin-coated plates of those cells were inhibited by KA11 expression, These suggest that reduced KA11 gene expression may contribute to the invasiveness and metastatic ability of colon cancer cells.	Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 060, Japan	Sapporo Medical University	Hinoda, Y (corresponding author), Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 060, Japan.							Adachi M, 1996, CANCER RES, V56, P1751; ALBINI A, 1987, CANCER RES, V47, P3239; ALBRECHTBUEHLER G, 1977, CELL, V11, P359; AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; AZORSA DO, 1991, BLOOD, V78, P280; BARNES R, 1990, AM J PATHOL, V139, P254; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BELL GM, 1992, J EXP MED, V175, P527, DOI 10.1084/jem.175.2.527; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; BURK RR, 1973, P NATL ACAD SCI USA, V70, P369, DOI 10.1073/pnas.70.2.369; Chintala SK, 1996, CANCER LETT, V103, P201, DOI 10.1016/0304-3835(96)04215-2; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; FEARON DT, 1993, CURR OPIN IMMUNOL, V5, P341, DOI 10.1016/0952-7915(93)90051-S; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; FURUKAWA T, 1993, J SURG ONCOL, V53, P10, DOI 10.1002/jso.2930530105; GAUGITSCH HW, 1991, EUR J IMMUNOL, V21, P377, DOI 10.1002/eji.1830210219; GIL ML, 1992, J IMMUNOL, V148, P2826; Guo XZ, 1996, CANCER RES, V56, P4876; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; HOREJSI V, 1991, FEBS LETT, V288, P1, DOI 10.1016/0014-5793(91)80988-F; HOTTA H, 1988, CANCER RES, V48, P2955; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; IMAI T, 1992, J IMMUNOL, V149, P2879; ITOH F, 1993, INT J CANCER, V53, P260, DOI 10.1002/ijc.2910530215; Jass JR, 1989, WHO INT HISTOLOGICAL, V2nd; KONDOH M, 1993, MELANOMA RES, V3, P241; LEBELBINAY S, 1995, J IMMUNOL, V155, P101; LEBELBINAY S, 1995, J LEUKOCYTE BIOL, V57, P956, DOI 10.1002/jlb.57.6.956; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LIOTTA LA, 1991, CANCER RES, V51, pS5054; MARX J, 1995, SCIENCE, V268, P799, DOI 10.1126/science.7754364; *MIN HLTH WELF, 1996, STAT INF DEP VIT STA, P52; MIYAKE M, 1995, CANCER RES, V55, P4127; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MYEROFF LL, 1993, J NATL CANCER I, V85, P147, DOI 10.1093/jnci/85.2.147; OHE Y, 1994, JPN J CANCER RES, V85, P400, DOI 10.1111/j.1349-7006.1994.tb02373.x; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; PARISH CR, 1992, INT J CANCER, V52, P378, DOI 10.1002/ijc.2910520309; REPESH LA, 1989, INVAS METAST, V9, P192; RINKERSCHAEFFER CW, 1994, CANCER RES, V54, P6249; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; Ruoslahti E, 1996, TUMOR BIOL, V17, P117, DOI 10.1159/000217975; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SATO Y, 1986, AM J PATHOL, V125, P431; SCHALEPFER DD, 1994, NATURE, V372, P786; SEEHAFER JG, 1991, BIOCHEM BIOPH RES CO, V179, P401, DOI 10.1016/0006-291X(91)91384-O; STRAUS AH, 1989, EXP CELL RES, V183, P126, DOI 10.1016/0014-4827(89)90423-0; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; UEDA T, 1991, CELL, V66, P107; WANG LM, 1993, CANCER RES, V53, P717; WHITE K, 1993, J COLL STUDENT DEV, V34, P289; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; WU CY, 1993, J BIOL CHEM, V268, P21883	62	100	109	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1443	1453		10.1038/sj.onc.1201648	http://dx.doi.org/10.1038/sj.onc.1201648			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525743				2022-12-17	WOS:000072572400008
J	Mohanam, S; Chintala, SK; Go, Y; Bhattacharya, A; Venkaiah, B; Boyd, D; Gokaslan, ZL; Sawaya, R; Rao, JS				Mohanam, S; Chintala, SK; Go, Y; Bhattacharya, A; Venkaiah, B; Boyd, D; Gokaslan, ZL; Sawaya, R; Rao, JS			In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor	ONCOGENE			English	Article						plasminogen activators; receptors; glioblastoma; invasiveness	PLASMINOGEN-ACTIVATOR RECEPTOR; TRANSFORMED HUMAN FIBROBLASTS; HUMAN GLIOMA-CELLS; UROKINASE RECEPTOR; MATRIX METALLOPROTEINASES; BREAST-CANCER; TUMOR-CELLS; IN-VITRO; INVASION; EXPRESSION	The cell surface urokinase-type plasminogen activator receptor (uPAR) has been shown to be a key molecule in regulating plasminogen-mediated extracellular proteolysis, To investigate the role of uPAR in invasion of brain tumors, human glioblastoma cell line SNB19 was stably transfected with a vector capable of expressing an antisense transcript complementary to the 300 base pair of the 5' end of the uPAR mRNA, Parental and stably transfected (vector, sense, and antisense) cell lines were analysed for uPAR mRNA transcript by Northern blot analysis, and receptor protein levels were measured by radioreceptor assays and Western blotting. Significant reduction of uPAR sites was observed in the antisense transfected cell lines, The levels of uPAR mRNA were significantly decreased in antisense clones compared to control, vector and sense clones, The invasive potential of the cell lines in vitro was measured by Matrigel invasion assay and migration of cells from spheroids to monolayers. The antisense transfected cells showed a markedly lower level of invasion and migration than the controls, The antisense clones were more adhesive to the ECM components compared to parental, vector and sense clones, All transfected (vector, sense and antisense) clones and parental cells produced similar levels of uPA activity without any significant difference however, MMP-2 activity was decreased in antisense clones compared to controls, These results demonstrate that uPAR expression is critical for the invasiveness of human gliomas and down regulation of uPAR expression may be a feasible approach to decrease invasiveness.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT NEUROSURG, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA058311, R01CA056792] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58311, CA56792] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE T, 1994, CLIN EXP METASTAS, V12, P296, DOI 10.1007/BF01753836; ANDERSSON C, 1993, INT J DEV NEUROSCI, V11, P555, DOI 10.1016/0736-5748(93)90045-F; AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; BIANCHI E, 1994, CANCER RES, V54, P861; BLASI F, 1988, Fibrinolysis, V2, P73, DOI 10.1016/0268-9499(88)90370-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN RL, 1991, BLOOD, V78, P479; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; ELLIS V, 1992, ANN NY ACAD SCI, V667, P13, DOI 10.1111/j.1749-6632.1992.tb51591.x; GLADSON CL, 1995, AM J PATHOL, V146, P1150; KARIKO K, 1993, CANCER RES, V53, P3109; KOBAYASHI H, 1993, BRIT J CANCER, V67, P537, DOI 10.1038/bjc.1993.99; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPSON LA, 1992, CANCER RES, V52, P1018; LANGER DJ, 1993, CIRC RES, V72, P330, DOI 10.1161/01.RES.72.2.330; LUNDJOHANSEN M, 1990, SPHEROID CULTURE CAN, P3; MOHANAM S, 1993, CANCER RES, V53, P4143; MOLLER LB, 1993, BLOOD COAGUL FIBRIN, V4, P293; NAKAGAWA T, 1994, J NEUROSURG, V81, P69, DOI 10.3171/jns.1994.81.1.0069; NAKAJIMA M, 1990, J NATL CANCER I, V82, P1890, DOI 10.1093/jnci/82.24.1890; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; OSSOWSKI L, 1992, CANCER RES, V52, P6754; PEDERSEN H, 1994, CANCER RES, V54, P4671; PEDERSEN PH, 1993, CANCER RES, V53, P5158; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; POLLANEN J, 1991, ADV CANCER RES, V57, P273; QUATTRONE A, 1995, CANCER RES, V55, P90; QUATTRONE A, 1995, ANTI-CANCER DRUG DES, V10, P97; RAY JM, 1995, EMBO J, V14, P908, DOI 10.1002/j.1460-2075.1995.tb07072.x; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RUSSEL DC, 1989, PATHOL TUMOURS NER, P42; Saleh M, 1996, CANCER RES, V56, P393; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMITT M, 1992, FIBRINOLYSIS, V6, P3; STAHL A, 1994, CANCER RES, V54, P3066; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WILHELM O, 1994, FEBS LETT, V337, P131, DOI 10.1016/0014-5793(94)80259-9; YAMAMOTO M, 1994, CANCER RES, V54, P5016; YAMAMOTO M, 1994, CANCER RES, V54, P3656	45	100	104	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	1997	14	11					1351	1359		10.1038/sj.onc.1200963	http://dx.doi.org/10.1038/sj.onc.1200963			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178895				2022-12-17	WOS:A1997WP10900010
J	Yi, HK; Fujimura, Y; Ouchida, M; Prasad, DDK; Rao, VN; Reddy, ESP				Yi, HK; Fujimura, Y; Ouchida, M; Prasad, DDK; Rao, VN; Reddy, ESP			Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias	ONCOGENE			English	Article						Ewing's sarcoma; human myeloid leukemias; EWS- and TLS-fusion proteins; apoptosis; therapy	RNA-BINDING PROTEIN; HUMAN MYELOID-LEUKEMIA; ETS-RELATED GENE; EWINGS-SARCOMA TRANSLOCATION; ROUND-CELL TUMOR; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; CHROMOSOMAL TRANSLOCATION; EWS GENE; FUSION TRANSCRIPTS	Two ets family members, namely erg and Fli-1 are fused with two EWS familiy members namely EWS and TLS/FUS as a result of chromosome translocation in human solid tumors and leukemias. EWS-erg and EWS-FLi-1, which are involved in greater than 95% of Ewing family of tumors, were shown to function as transcriptional activators. TLS/FUS-erg, which is involved in human myeloid leukemias also functions as a transcriptional activator. Expression of these fusion proteins (EWS-erg and EWS-FLi-1) are shown to be essential for maintaining the oncogenic and tumorigenic properties of tumor cells. Cancer is thought to be caused not only by uncontrolled cell proliferation but also by deregulation of programmed cell death. Therefore, we have studied the role of normal (Fli-1 and erg) and aberrant fusion proteins (EWS-erg, EWS-Fli-1 and TLS/FUS-erg) in apoptosis. We have found that expression of normal (Fli-1 and erg) and aberrant fusion proteins inhibit the apoptosis of NIH3T3 cells induced by either serum deprivation or by treatment with calcium ionophore. We have also observed similar suppression of apoptosis in Ewing's sarcoma cells expressing EWS-Fli-1 and EWS-erg proteins suggesting that these fusionproteins may be responsible for the decreased ability of these tumor cells to undergo apoptosis. Inhibition of the expression of these aberrant fusion proteins by antisense RNA technique resulted in increased susceptibility to apoptosis leading to the death of tumor cells. Therefore, our results suggest that one can use therapeutic agents which can down regulate the expression of fusion proteins in combination with chemotherapeutic agents as an effective treatment for these human solid tumors and leukemias.	ALLEGHENY UNIV HLTH SCI,DEPT HUMAN GENET,DIV CANC GENET,PHILADELPHIA,PA 19102; KIMMEL CANC INST,JEFFERSON MED COLL,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Drexel University; Jefferson University					NATIONAL CANCER INSTITUTE [P01CA051083, R01CA058642, R01CA057322] Funding Source: NIH RePORTER; NCI NIH HHS [CA51083, CA58642, CA57322] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BEDI A, 1994, BLOOD, V83, P2038; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; Clark J, 1996, ONCOGENE, V12, P229; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUNN T, 1994, CANCER GENET CYTOGEN, V76, P19, DOI 10.1016/0165-4608(94)90063-9; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; Fujimura Y, 1996, ONCOGENE, V12, P159; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; HELM S, 1994, GENES CHROM CANC, V11, P256; HOFFMAN B, 1994, ONCOGENE, V9, P1807; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; LADANYI M, 1994, CANCER RES, V54, P2837; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MITELMAN F, 1991, CATALOG CHROMOSOME A; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Panagopoulos I, 1996, ONCOGENE, V12, P489; PRASAD DDK, 1994, ONCOGENE, V9, P669; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1993, ONCOGENE, V8, P2167; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; Shao NS, 1996, ONCOGENE, V13, P1; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRICHE TJ, 1993, CURR TOP PATHOL, V89, P47; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	52	100	104	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 20	1997	14	11					1259	1268		10.1038/sj.onc.1201099	http://dx.doi.org/10.1038/sj.onc.1201099			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178886				2022-12-17	WOS:A1997WP10900001
J	LEE, YY; WILCZYNSKI, SP; CHUMAKOV, A; CHIH, D; KOEFFLER, HP				LEE, YY; WILCZYNSKI, SP; CHUMAKOV, A; CHIH, D; KOEFFLER, HP			CARCINOMA OF THE VULVA - HPV AND P53 MUTATIONS	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; POLYMERASE CHAIN-REACTION; SQUAMOUS-CELL CARCINOMA; CHRONIC MYELOCYTIC-LEUKEMIA; CERVICAL-CARCINOMA; INSITU HYBRIDIZATION; POINT MUTATIONS; BLAST CRISIS; N-RAS; GENE	Recent evidence suggests that squamous cell carcinoma of the vulva may have more than one etiology, with only some tumors associated with human papillomavirus (HPV). Cells infected with HPV produce a viral protein (E6) which binds to and causes rapid degradation of p53, possibly contributing to cellular transformation. In several human malignancies, point mutations of p53 alter activity of the p53 protein contributing to cellular transformation. We tested, for the first time, the possibility that HPV-negative tumors of the vulva may have a high incidence of inactivating mutations of p53; while HPV-containing vulvar tumors rarely would have p53 mutations. Twenty-one tumors of the vulva were evaluated for the presence of HPV sequences by amplication with the polymerase chain reaction (PCR) and Southern blotting. These were evaluated for p53 mutations by single strand conformation polymorphism and sequencing of PCR products. HPV DNA sequences were found in 12 of 21 (57%) cancers of the vulva; only one of these 12 (8%) HPV-positive samples had a missense mutation of p53. In contrast, four of nine (44%) HPV-negative vulvar tumors had point mutations of p53. The p53 mutations were found in only metastatic lesion and the only recurrent tumor samples suggesting that the acquisition of p53 mutations may be associated with neoplastic progression. In conclusion, alterations in p53 activity appear to be important in the development of carcinoma of the vulva.	UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90048; CITY HOPE NATL MED CTR,DEPT PATHOL,DUARTE,CA 91010	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; City of Hope			Chumakov, Alexey/N-1541-2014	Chumakov, Alexey/0000-0003-2733-3166	NATIONAL CANCER INSTITUTE [R29CA053005, P01CA042710, P30CA042710] Funding Source: NIH RePORTER; NCI NIH HHS [CA53005, CA42710] Funding Source: Medline; NIDDK NIH HHS [DK42702] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; ANDERSEN WA, 1991, AM J OBSTET GYNECOL, V165, P329, DOI 10.1016/0002-9378(91)90086-7; BISHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766; BLOSS JD, 1991, HUM PATHOL, V22, P711, DOI 10.1016/0046-8177(91)90294-Y; BORRESEN AL, 1992, LANCET, V339, P1350; BOSHART M, 1986, J VIROL, V58, P963, DOI 10.1128/JVI.58.3.963-966.1986; BUSBYEARLE RMC, 1992, LANCET, V339, P1350, DOI 10.1016/0140-6736(92)91993-I; BUSCEMA J, 1988, OBSTET GYNECOL, V71, P601; CARSON LF, 1988, OBSTET GYNECOL, V72, P63; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, ONCOGENE, V6, P873; CRUM CP, 1992, OBSTET GYNECOL, V79, P448, DOI 10.1097/00006250-199203000-00025; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FOTI A, 1991, BLOOD, V77, P2441; FUJITA M, 1992, CANCER RES, V52, P5323; FULTS D, 1992, CANCER RES, V52, P674; GUPTA J, 1987, AM J PATHOL, V127, P206; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUBBERT M, 1990, BLOOD, V75, P1163; MANOS MM, 1989, CANCER CEL, V7, P209; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; NUOVO GJ, 1988, OBSTET GYNECOL, V72, P770; NUOVO GJ, 1991, GYNECOL ONCOL, V43, P275, DOI 10.1016/0090-8258(91)90035-4; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAQUETTE RL, 1990, ONCOGENE, V5, P1659; PAQUETTE RL, 1993, CANCER-AM CANCER SOC, V72, P1272, DOI 10.1002/1097-0142(19930815)72:4<1272::AID-CNCR2820720420>3.0.CO;2-Q; PARK DJ, 1993, IN PRESS ONCOGENE; PFISTER H, 1987, ADV CANCER RES, V48, P113, DOI 10.1016/S0065-230X(08)60691-0; PILOTTI S, 1990, MODERN PATHOL, V3, P442; SAKASHITA A, 1992, BLOOD, V79, P477; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SOUSSI T, 1990, ONCOGENE, V5, P945; STRETCH JR, 1991, CANCER RES, V51, P5976; TAMURA G, 1991, CANCER RES, V51, P3056; TOKI T, 1991, INT J GYNECOL PATHOL, V10, P107, DOI 10.1097/00004347-199104000-00001; TWIGGS LB, 1988, INT J GYNECOL PATHOL, V7, P48, DOI 10.1097/00004347-198803000-00005; VENUTI A, 1989, J GEN VIROL, V70, P1587, DOI 10.1099/0022-1317-70-6-1587; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	42	100	103	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1655	1659						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183560				2022-12-17	WOS:A1994NL81500017
J	TRIMBLE, MS; XIN, JH; GUY, CT; MULLER, WJ; HASSELL, JA				TRIMBLE, MS; XIN, JH; GUY, CT; MULLER, WJ; HASSELL, JA			PEA3 IS OVEREXPRESSED IN MOUSE METASTATIC MAMMARY ADENOCARCINOMAS	ONCOGENE			English	Article							HUMAN-BREAST-CANCER; DNA-BINDING DOMAIN; NEU ONCOGENE; POLYOMAVIRUS ENHANCER; GENE FAMILY; PROTOONCOGENE; EXPRESSION; PROMOTER; AP-1; ACTIVATION	Transgenic mice bearing the rat neu proto-oncogene under the transcriptional control of the mouse mammary tumor virus (MMTV) promoter develop focal mammary adenocarcinomas after long latency that are metastatic to the lung in a high percentage of the tumor-bearing animals. Because expression of the neu gene in the mammary epithelium precedes the occurrence of tumors, it appears that another genetic event in addition to neu transgene expression is required for tumorigenesis. We have investigated the expression of PEA3, a new member of the ets oncogene family of transcriptional regulatory factors, in neu-induced mammary tumors to learn whether PEA3 plays a role in tumor progression in this organ. We observed high levels of PEA3 RNA in neu-induced tumors, but little, if any, PEA3 RNA in the surrounding mammary epithelium. Moreover, mammary tumors that had metastasized to the lung also overexpressed the PEA3 gene, whereas normal lung tissue did not. Similar results were obtained after analyses of other transgenic mouse lines bearing metastatic mammary tumors induced by polyomavirus middle T antigen. These findings suggest that enhanced expression of PEA3 may be required to facilitate mammary tumor progression and metastasis.	MCMASTER UNIV,INST MOLEC BIOL & BIOTECHNOL,1280 MAIN ST W,HAMILTON L8S 4K1,ONTARIO,CANADA	McMaster University								ASANO M, 1990, J VIROL, V64, P5927, DOI 10.1128/JVI.64.12.5927-5938.1990; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAGUIRE HC, 1989, SEMIN ONCOL, V16, P148; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULLER WJ, 1991, CANCER METAST REV, V10, P217, DOI 10.1007/BF00050793; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NAKANO N, 1966, TOHOKU J EXP MED, V88, P69, DOI 10.1620/tjem.88.69; NERLOV C, 1991, ONCOGENE, V6, P1583; PARNES JR, 1981, P NATL ACAD SCI-BIOL, V78, P2253, DOI 10.1073/pnas.78.4.2253; Sambrook J., 1989, MOL CLONING LAB MANU; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	28	100	101	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3037	3042						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	7692372				2022-12-17	WOS:A1993MC09300018
J	KOHNO, T; TAKAYAMA, H; HAMAGUCHI, M; TAKANO, H; YAMAGUCHI, N; TSUDA, H; HIROHASHI, S; VISSING, H; SHIMIZU, M; OSHIMURA, M; YOKOTA, J				KOHNO, T; TAKAYAMA, H; HAMAGUCHI, M; TAKANO, H; YAMAGUCHI, N; TSUDA, H; HIROHASHI, S; VISSING, H; SHIMIZU, M; OSHIMURA, M; YOKOTA, J			DELETION MAPPING OF CHROMOSOME-3P IN HUMAN UTERINE CERVICAL-CANCER	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; VONHIPPEL-LINDAU DISEASE; HUMAN-BREAST CARCINOMA; LUNG-CANCER; SHORT ARM; SMALL REGION; HETEROZYGOSITY; GENE; RECEPTOR; ALLELES	Deletion mapping of chromosome 3p was performed on 47 cases of human uterine cervical cancer using 24 polymorphic DNA markers including five inter-Alu DNA markers and two NotI-boundary cosmid markers obtained in our laboratory. The most likely order of these 24 polymorphic DNA markers was determined as being cen-[D3S4, H8]-D3S693-D3S659-D3S30-D3S687-[D3S2, UR9, UR47]-J36-J17-GNA12B-D3F15S2-D3S643-D3S32-D3S23-D3S686-H35-UR189-D3S685-D3S11-D3S12-THRB-D3S22-pter, based on the data from radiation hybrid mapping, genetic linkage analysis and in situ hybridization. Loss of heterozygosity (LOH) at one or more loci on chromosome 3p was detected in 21 of 47 cases (45%). Four tumors showed partial or interstitial deletions, and the common region of LOH in these tumors was 3p13-p21.1 between the D3S30 marker and the D3S2 marker. Candidates for tumor-suppressor genes, APEH, D8, GNAI2B, ZNF35, RARB, THRB and RAFI, were all mapped outside of the common region in uterine cervical cancer. However, this region is commonly deleted in carcinoma of the lung, breast and kidney, and encompasses the breakpoint of the (3;8) translocation in hereditary renal cell carcinoma. This result indicates the presence of a novel tumor-suppressor gene in the region of 3p13-p21.1, which is involved in the development of several human cancers.	NATL CANC CTR,RES INST,1-1 TSUKIJI 5-CHOME,CHUO KU,TOKYO 104,JAPAN; HAGEDORN RES INST,DEPT MOLEC ENDOCRINOL,DK-2820 GENTOFTE,DENMARK; TOTTORI UNIV,SCH LIFE SCI,YONAGO,TOTTORI 683,JAPAN	National Cancer Center - Japan; Novo Nordisk; Hagedorn Research Institute; Tottori University				takano, hirokuni/0000-0002-6465-7883				ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; BONNER T, 1984, SCIENCE, V223, P71, DOI 10.1126/science.6691137; CARRITT B, 1992, CANCER RES, V52, P1536; COTTER FE, 1990, GENOMICS, V7, P257, DOI 10.1016/0888-7543(90)90548-9; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DIDSBURY JR, 1987, FEBS LETT, V211, P160, DOI 10.1016/0014-5793(87)81428-X; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; DRABKIN H, 1988, P NATL ACAD SCI USA, V85, P9258, DOI 10.1073/pnas.85.23.9258; EHREN T, 1990, ONCOGENE, V5, P219; ERLANDSSON R, 1991, ONCOGENE, V6, P1293; FALK CT, 1991, GENOMICS, V9, P120, DOI 10.1016/0888-7543(91)90228-7; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; GEBERT JF, 1991, ONCOGENE, V6, P1859; GINZINGER DG, 1992, AM J HUM GENET, V50, P826; GORADIA TM, 1991, GENOMICS, V10, P748, DOI 10.1016/0888-7543(91)90459-R; GROSVELD FG, 1982, NUCLEIC ACIDS RES, V10, P6715, DOI 10.1093/nar/10.21.6715; GROVER T, 1984, HUM GENET, V67, P136; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HARMER MH, 1978, TNM CLASSIFICATION M; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HIBI K, 1992, ONCOGENE, V7, P445; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; JOHNSON BE, 1988, J CLIN INVEST, V82, P502, DOI 10.1172/JCI113624; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LANFRANCONE L, 1992, GENOMICS, V12, P720, DOI 10.1016/0888-7543(92)90301-8; LEDUC F, 1989, AM J HUM GENET, V44, P282; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; MAGOVCEVIC I, 1992, GENOMICS, V12, P125, DOI 10.1016/0888-7543(92)90414-N; MAHER ER, 1991, GENOMICS, V10, P957, DOI 10.1016/0888-7543(91)90185-H; MATTEI MG, 1988, HUM GENET, V80, P189, DOI 10.1007/BF00702867; MORI N, 1989, CANCER RES, V49, P5130; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NAYLOR SL, 1989, GENOMICS, V4, P355, DOI 10.1016/0888-7543(89)90342-X; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; POULSEN HE, 1975, INT HISTOLOGICAL CLA, V13; RAPP UR, 1988, LUNG CANCER, V4, P162; SATO T, 1991, CANCER RES, V51, P5794; SEIZINGER BR, 1991, P NATL ACAD SCI USA, V88, P2864, DOI 10.1073/pnas.88.7.2864; SHIMIZU M, 1990, ONCOGENE, V5, P185; SITHANANDAM G, 1989, ONCOGENE, V4, P451; TAMARI M, 1992, GENOMICS, V13, P705, DOI 10.1016/0888-7543(92)90145-I; WANG N, 1984, CANCER GENET CYTOGEN, V11, P479, DOI 10.1016/0165-4608(84)90028-1; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1989, CANCER RES, V49, P3598; YOKOYAMA S, 1992, CANCER RES, V52, P873; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; 1991, CYTOGENET CELL GENET, V58, P1	51	100	100	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1825	1832						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8099726				2022-12-17	WOS:A1993LG68200014
J	RESCIGNO, J; MANSUKHANI, A; BASILICO, C				RESCIGNO, J; MANSUKHANI, A; BASILICO, C			A PUTATIVE RECEPTOR TYROSINE KINASE WITH UNIQUE STRUCTURAL TOPOLOGY	ONCOGENE			English	Note							ADHESION MOLECULE L1; IMMUNOGLOBULIN SUPERFAMILY; HUMAN CHROMOSOME-19Q; HOMOLOGY; MEMBER; SIGNAL; FAMILY; RECOGNITION; FIBRONECTIN; SEQUENCE	We have cloned a murine cDNA on the basis of homology to the tyrosine kinase domain of the bek fibroblast growth factor receptor. This cDNA encodes a putative tyrosine kinase receptor with a unique structural pattern in its extracellular domain. It is a new member of the immunoglobulin superfamily with two immunoglobulin-like domains. It also contains two fibronectin type III domains which are found on diverse proteins such as receptor tyrosine phosphatases and neural cell adhesion molecules. This protein tyrosine kinase called ark (adhesion-related kinase) is likely to represent a new class of receptor tyrosine kinase. Ark mRNA appears to be expressed in most cell lines and adult tissues examined except those of hematopoietic lineage. It is undetectable in undifferentiated teratocarcinoma cells, F9 and N Tera 2.	NYU, SCH MED, DEPT MICROBIOL, NEW YORK, NY 10016 USA; NYU, SCH MED, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	New York University; New York University				Mansukhani, Alka/0000-0003-1020-3242	NCI NIH HHS [CA 42568] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042568] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASTIANI MJ, 1986, J NEUROSCI, V6, P3542; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURRIDGE K, 1987, J CELL SCI, P211; CAVANNA JS, 1990, GENOMICS, V7, P12, DOI 10.1016/0888-7543(90)90513-T; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DEUSTACHIO P, 1988, J NEUROCHEM, V50, P589, DOI 10.1111/j.1471-4159.1988.tb02951.x; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; GENNARINI G, 1989, J CELL BIOL, V109, P775, DOI 10.1083/jcb.109.2.775; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JENKINS RB, 1989, CANCER GENET CYTOGEN, V39, P253, DOI 10.1016/0165-4608(89)90192-1; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NORTON PA, 1990, CELL, V61, P15, DOI 10.1016/0092-8674(90)90209-W; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; RINDLER MJ, 1982, J CELL BIOL, V95, pA262; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONK D, 1990, CYTOGENET CELL GENET, V54, P15; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	35	100	126	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1991	6	10					1909	1913						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1840679				2022-12-17	WOS:A1991GX11800027
J	DENNIS, JW; KOSH, K; BRYCE, DM; BREITMAN, ML				DENNIS, JW; KOSH, K; BRYCE, DM; BREITMAN, ML			ONCOGENES CONFERRING METASTATIC POTENTIAL INDUCE INCREASED BRANCHING OF ASN-LINKED OLIGOSACCHARIDES IN RAT2 FIBROBLASTS	ONCOGENE			English	Article									UNIV TORONTO, DEPT MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto	DENNIS, JW (corresponding author), MT SINAI HOSP, RES INST, DIV CANC & CELL BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA.		Dennis, James/E-7268-2013	Bryce, Dawn/0000-0002-7403-2940				AUERSPERG N, 1987, CANCER RES, V47, P6341; BRILES EB, 1982, INT REV CYTOL, V75, P101, DOI 10.1016/S0074-7696(08)61003-7; BROCKHAUSEN I, 1988, BIOCHEM CELL BIOL, V66, P1134, DOI 10.1139/o88-131; CHEN JW, 1988, J BIOL CHEM, V263, P8754; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; DEKORTE D, 1987, CANCER RES, V47, P1841; DENNIS JW, 1989, CANCER RES, V49, P945; DENNIS JW, 1986, CANCER RES, V46, P5131; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMMARSTROM S, 1982, P NATL ACAD SCI-BIOL, V79, P1611, DOI 10.1073/pnas.79.5.1611; HUMPHRIES MJ, 1986, CANCER RES, V46, P5215; KERBEL RS, 1979, AM J PATHOL, V97, P609; LAFERTE S, 1989, BIOCHEM J, V259, P569, DOI 10.1042/bj2590569; LAFERTE S, 1988, CANCER RES, V48, P4743; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAUNTENBERG JA, 1981, P NATL ACAD SCI USA, V78, P1518; MCGUIRE WL, 1987, SCIENCE, V235, P177; MUSCHEL RJ, 1985, AJP, V21, P1; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PIERCE M, 1986, J BIOL CHEM, V261, P772; SANTER UV, 1984, CANCER RES, V44, P3730; SANTER UV, 1979, BIOCHEMISTRY-US, V18, P2533, DOI 10.1021/bi00579a016; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMETS LA, 1983, BIOCHIM BIOPHYS ACTA, V738, P237, DOI 10.1016/0304-419X(83)90006-9; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; TAKASAKI S, 1980, BIOCHEM BIOPH RES CO, V92, P735, DOI 10.1016/0006-291X(80)90765-2; TRIMBLE WS, 1986, NATURE, V321, P782, DOI 10.1038/321782a0; VOUSDEN KH, 1986, INT J CANCER, V37, P425, DOI 10.1002/ijc.2910370315; WAGHORNE C, 1987, ONCOGENE, V1, P149; WARREN L, 1972, P NATL ACAD SCI USA, V69, P1838, DOI 10.1073/pnas.69.7.1838; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WEINMASTER G, 1986, J BIOL CHEM, V261, P328; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1984, J BIOL CHEM, V259, P834	36	100	100	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1989	4	7					853	860						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2666906				2022-12-17	WOS:A1989AE58400006
J	BLAM, SB; MITCHELL, R; TISCHER, E; RUBIN, JS; SILVA, M; SILVER, S; FIDDES, JC; ABRAHAM, JA; AARONSON, SA				BLAM, SB; MITCHELL, R; TISCHER, E; RUBIN, JS; SILVA, M; SILVER, S; FIDDES, JC; ABRAHAM, JA; AARONSON, SA			ADDITION OF GROWTH-HORMONE SECRETION SIGNAL TO BASIC FIBROBLAST GROWTH-FACTOR RESULTS IN CELL-TRANSFORMATION AND SECRETION OF ABERRANT FORMS OF THE PROTEIN	ONCOGENE			English	Article									CALIF BIOTECHNOL INC,MT VIEW,CA 94043		BLAM, SB (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,ROOM 1E24,BETHESDA,MD 20892, USA.				NCI NIH HHS [CA 07843-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA007843] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ADELMAN JP, 1983, DNA-J MOLEC CELL BIO, V2, P183, DOI 10.1089/dna.1983.2.183; BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CRABB JW, 1986, BIOCHEM BIOPH RES CO, V136, P1155, DOI 10.1016/0006-291X(86)90455-9; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOTTO GP, 1985, NATURE, V318, P472; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIESEL R, 1986, J BIOL CHEM, V261, P7581; GOSPODAROWICZ D, 1986, MOL CELL ENDOCRINOL, V46, P187, DOI 10.1016/0303-7207(86)90001-8; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V127, P121, DOI 10.1002/jcp.1041270116; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KARIN M, 1984, CELL, V36, P371, DOI 10.1016/0092-8674(84)90230-7; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAL F, 1985, SCIENCE, V230, P327, DOI 10.1126/science.2996133; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARTIAL JA, 1979, SCIENCE, V205, P602, DOI 10.1126/science.377496; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOSCATELLI D, 1987, P NATL ACAD SCI USA, V84, P5778, DOI 10.1073/pnas.84.16.5778; MOSCATELLI D, 1986, J CELL PHYSIOL, V129, P273, DOI 10.1002/jcp.1041290220; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; PRESTA M, 1986, MOL CELL BIOL, V6, P4060, DOI 10.1128/MCB.6.11.4060; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SCHAEFFER WI, 1976, CANCER LETT, V1, P259; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SHARMA S, 1985, EMBO J, V4, P1479, DOI 10.1002/j.1460-2075.1985.tb03806.x; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SOMMER A, 1987, BIOCHEM BIOPH RES CO, V144, P543, DOI 10.1016/S0006-291X(87)80001-3; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STORY MT, 1987, BIOCHEM BIOPH RES CO, V142, P702, DOI 10.1016/0006-291X(87)91471-9; SUNG WL, 1986, P NATL ACAD SCI USA, V83, P561, DOI 10.1073/pnas.83.3.561; THOMAS KA, 1987, FASEB J, V1, P434, DOI 10.1096/fasebj.1.6.3315806; Tooze J, 1980, DNA TUMOR VIRUSES; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UENO N, 1986, BIOCHEM BIOPH RES CO, V138, P580, DOI 10.1016/S0006-291X(86)80536-8; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	55	100	104	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					129	136						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	3412772				2022-12-17	WOS:A1988Q053400001
J	RANDO, RF; PELLETT, PE; LUCIW, PA; BOHAN, CA; SRINIVASAN, A				RANDO, RF; PELLETT, PE; LUCIW, PA; BOHAN, CA; SRINIVASAN, A			TRANSACTIVATION OF HUMAN-IMMUNODEFICIENCY-VIRUS BY HERPESVIRUSES	ONCOGENE			English	Article									CTR DIS CONTROL,CTR INFECT DIS,AIDS PROGRAM,ATLANTA,GA 30333; CTR DIS CONTROL,DIV VIRAL DIS,VIRAL EXANTHEMS & HERPESVIRUS BRANCH,ATLANTA,GA 30333; UNIV CALIF DAVIS,DEPT MED PATHOL,DAVIS,CA 95616	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of California System; University of California Davis				Pellett, Philip/0000-0002-8536-8343				ALIZON M, 1984, NATURE, V312, P757, DOI 10.1038/312757a0; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; BLASER MJ, 1986, REV INFECT DIS, V8, P21; BOYD AL, 1980, VIROLOGY, V103, P228, DOI 10.1016/0042-6822(80)90140-3; BROOME S, 1985, CELL, V40, P537, DOI 10.1016/0092-8674(85)90202-8; CHEN ISY, 1986, CELL, V47, P1, DOI 10.1016/0092-8674(86)90359-4; CORTINI R, 1978, J GEN VIROL, V39, P259, DOI 10.1099/0022-1317-39-2-259; COUEZ D, 1984, J VIROL, V49, P615, DOI 10.1128/JVI.49.2.615-620.1984; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; CURRAN JW, 1985, SCIENCE, V229, P1352, DOI 10.1126/science.2994217; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DALRYMPLE MA, 1985, NUCLEIC ACIDS RES, V13, P7865, DOI 10.1093/nar/13.21.7865; DERSE D, 1985, SCIENCE, V227, P317, DOI 10.1126/science.2981431; EVERETT RD, 1984, NUCLEIC ACIDS RES, V12, P5969, DOI 10.1093/nar/12.15.5969; EVERETT RD, 1984, NUCLEIC ACIDS RES, V12, P3037, DOI 10.1093/nar/12.7.3037; EVERETT RD, 1984, EMBO J, V3, P3135, DOI 10.1002/j.1460-2075.1984.tb02270.x; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELDMAN LT, 1982, P NATL ACAD SCI-BIOL, V79, P4952, DOI 10.1073/pnas.79.16.4952; FOLKS T, 1986, SCIENCE, V231, P600, DOI 10.1126/science.3003906; FRANCIS DP, 1985, ANN INTERN MED, V103, P719, DOI 10.7326/0003-4819-103-5-719; FROST E, 1978, VIROLOGY, V91, P39, DOI 10.1016/0042-6822(78)90353-7; GLUCKMAN JC, 1986, ANNU REV IMMUNOL, V4, P97, DOI 10.1146/annurev.iy.04.040186.000525; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; GRUTTOLA VD, 1986, REV INFECT DIS, V8, P295; GUINAN ME, 1984, ANN INTERN MED, V100, P213, DOI 10.7326/0003-4819-100-2-213; HAHN BH, 1984, NATURE, V312, P166, DOI 10.1038/312166a0; HALL LM, 1982, J VIROL, V43, P596; HESS LL, 1985, SCIENCE, V229, P682; HOXIE JA, 1985, SCIENCE, V229, P1400, DOI 10.1126/science.2994222; IMPERIALE MJ, 1983, CELL, V35, P127, DOI 10.1016/0092-8674(83)90215-5; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOUSOULAS E, 1984, VIROLOGY, V135, P379; LANDESMAN SH, 1985, NEW ENGL J MED, V312, P521, DOI 10.1056/NEJM198502213120829; LANG JC, 1984, EMBO J, V3, P389, DOI 10.1002/j.1460-2075.1984.tb01817.x; LUCIW PA, 1984, NATURE, V312, P760, DOI 10.1038/312760a0; MAVROMARANAZOS P, 1986, VIROLOGY, V149, P152, DOI 10.1016/0042-6822(86)90117-0; MCKNIGHT JLC, 1986, IN PRESS CANCER CELL; NOTARIANNI EL, 1982, VIROLOGY, V123, P113, DOI 10.1016/0042-6822(82)90299-9; OHARE P, 1984, J VIROL, V52, P522, DOI 10.1128/JVI.52.2.522-531.1984; PELLETT PE, 1985, P NATL ACAD SCI USA, V82, P5870, DOI 10.1073/pnas.82.17.5870; PETERLIN BM, 1986, IN PRESS P NATL ACAD; QUINLAN MP, 1985, MOL CELL BIOL, V5, P957, DOI 10.1128/MCB.5.5.957; RABSON AB, 1985, CELL, V40, P477, DOI 10.1016/0092-8674(85)90189-8; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROSEN CA, 1986, NATURE, V319, P555, DOI 10.1038/319555a0; ROSEN CA, 1985, SCIENCE, V227, P321; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SCHOLER HR, 1984, CELL, V36, P403, DOI 10.1016/0092-8674(84)90233-2; SCHRIER RD, 1985, SCIENCE, V230, P1048, DOI 10.1126/science.2997930; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; VENKATGOPAL T, 1985, SCIENCE, V229, P1102; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WATSON RJ, 1980, NATURE, V285, P329, DOI 10.1038/285329a0; WEISS R, 1985, RNA TUMOR VIRUSES, V2; WONGSTAAL F, 1985, NATURE, V317, P395, DOI 10.1038/317395a0; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	61	100	100	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1987	1	1					13	18						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6351	2830574				2022-12-17	WOS:A1987J635100002
J	Pinato, DJ; Guerra, N; Fessas, P; Murphy, R; Mineo, T; Mauri, FA; Mukherjee, SK; Thursz, M; Wong, CN; Sharma, R; Rimassa, L				Pinato, David J.; Guerra, Nadia; Fessas, Petros; Murphy, Ravindhi; Mineo, Takashi; Mauri, Francesco A.; Mukherjee, Sujit K.; Thursz, Mark; Wong, Ching Ngar; Sharma, Rohini; Rimassa, Lorenza			Immune-based therapies for hepatocellular carcinoma	ONCOGENE			English	Review							REGULATORY T-CELLS; GROWTH-FACTOR-BETA; CHRONIC HEPATITIS-B; SUPPRESSOR-CELLS; DENDRITIC CELLS; TUMOR MICROENVIRONMENT; DOUBLE-BLIND; TGF-BETA; ADOPTIVE IMMUNOTHERAPY; LIVER-CANCER	Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.	[Pinato, David J.; Fessas, Petros; Murphy, Ravindhi; Mauri, Francesco A.; Wong, Ching Ngar; Sharma, Rohini] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Du Cane Rd, London W12 0HS, England; [Guerra, Nadia] Imperial Coll London, Dept Life Sci, South Kensington Campus,Exhibit Rd, London SW7 2AZ, England; [Mineo, Takashi] Tokyo Med & Dent Univ, Tokyo, Japan; [Mukherjee, Sujit K.; Thursz, Mark] Imperial Coll London, Dept Metab Digest & Reprod, St Marys Hosp, Praed St, London, England; [Rimassa, Lorenza] Humanitas Clin & Res Ctr IRCCS, Med Oncol & Haematol Unit, Humanitas Canc Ctr, Via Manzoni 56, I-20089 Milan, Italy; [Rimassa, Lorenza] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini, I-20090 Milan, Italy	Imperial College London; Imperial College London; Tokyo Medical & Dental University (TMDU); Imperial College London; Humanitas University	Pinato, DJ (corresponding author), Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Du Cane Rd, London W12 0HS, England.	david.pinato@imperial.ac.uk	Pinato, David James/ABB-3719-2020; Rimassa, Lorenza/N-4884-2016	Rimassa, Lorenza/0000-0001-9957-3615; Thursz, Mark/0000-0002-8218-192X; Pinato, David James/0000-0002-3529-0103; Mauri, Francesco/0000-0003-4818-8500	Wellcome Trust Strategic Fund [PS3416]; Cancer Research UK [C57701/A26137]; Wellcome Trust	Wellcome Trust Strategic Fund; Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission)	The authors would like to acknowledge the infrastructure support provided by Imperial Experimental Cancer Medicine Centre, Cancer Research UK Imperial Centre. DJP is supported by grant funding from the Wellcome Trust Strategic Fund (PS3416) and Cancer Research UK for the immune phenotyping of HCC (Postdoctoral Bursary Grant Ref. C57701/A26137). SJM is funded by a Wellcome Trust Clinical Research Training Fellowship.	Ahn E, 2018, P NATL ACAD SCI USA, V115, P4749, DOI 10.1073/pnas.1718217115; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alissafi T, 2019, J AUTOIMMUN, V104, DOI 10.1016/j.jaut.2019.102310; An Y, 2018, WORLD J GASTROENTERO, V24, P2733, DOI 10.3748/wjg.v24.i25.2733; Anderson AC, 2014, CANCER IMMUNOL RES, V2, P393, DOI 10.1158/2326-6066.CIR-14-0039; Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014; Ang Celina, 2019, Oncotarget, V10, P4018, DOI 10.18632/oncotarget.26998; Anguille S, 2015, PHARMACOL REV, V67, P731, DOI 10.1124/pr.114.009456; Arihara F, 2013, CANCER IMMUNOL IMMUN, V62, P1421, DOI 10.1007/s00262-013-1447-1; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Bertuccio P, 2017, J HEPATOL, V67, P302, DOI 10.1016/j.jhep.2017.03.011; Bilate AM, 2012, ANNU REV IMMUNOL, V30, P733, DOI 10.1146/annurev-immunol-020711-075043; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; Bruix J, 2017, LANCET, V389, P56, DOI 10.1016/S0140-6736(16)32453-9; Budhu A, 2006, CANCER CELL, V10, P99, DOI 10.1016/j.ccr.2006.06.016; Buttner R, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2018-000442; Bunt SK, 2007, CANCER RES, V67, P10019, DOI 10.1158/0008-5472.CAN-07-2354; Butterfield LH, 2006, CLIN CANCER RES, V12, P2817, DOI 10.1158/1078-0432.CCR-05-2856; Chambers CA, 2001, ANNU REV IMMUNOL, V19, P565, DOI 10.1146/annurev.immunol.19.1.565; Chang H, 2017, APMIS, V125, P690, DOI 10.1111/apm.12703; Chen J, 2016, ANN ONCOL, V27, P409, DOI 10.1093/annonc/mdv615; Chen KJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024671; Chen YC, 2015, HEPATOLOGY, V61, P1591, DOI 10.1002/hep.27665; Chen YC, 2014, HEPATOLOGY, V59, P1435, DOI 10.1002/hep.26790; Cheng A., 2019, ANN ONCOL S9, V30, DOI DOI 10.1093/ANNONC/MDZ446; Chiou SH, 2005, J REPROD IMMUNOL, V67, P35, DOI 10.1016/j.jri.2005.06.002; Dapito DH, 2012, CANCER CELL, V21, P504, DOI 10.1016/j.ccr.2012.02.007; Ding W, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013301; Dougall WC, 2017, IMMUNOL REV, V276, P112, DOI 10.1111/imr.12518; Duffy AG, 2017, J HEPATOL, V66, P545, DOI 10.1016/j.jhep.2016.10.029; Dunham RM, 2013, J IMMUNOL, V190, P2009, DOI 10.4049/jimmunol.1201937; El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2; Fabregat I, 2016, FEBS J, V283, P2219, DOI 10.1111/febs.13665; Fang L, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0076-7; Finn RS, 2020, J CLIN ONCOL, V38, P193, DOI 10.1200/JCO.19.01307; Finn RS, 2018, J HEPATOL, V69, P353, DOI 10.1016/j.jhep.2018.04.010; Flynn MJ, 2019, HEPATOLOGY, V69, P2258, DOI 10.1002/hep.30337; Gao Q, 2007, J CLIN ONCOL, V25, P2586, DOI 10.1200/JCO.2006.09.4565; Gao XH, 2017, HEPATOL RES, V47, P1061, DOI 10.1111/hepr.12831; George B, 2016, J THORAC ONCOL, V11, pS211, DOI 10.1016/j.jtho.2016.08.068; Ghadially H, 2017, BRIT J CANCER, V116, P1208, DOI 10.1038/bjc.2017.79; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Greten TF, 2019, J HEPATOL, V70, P999, DOI 10.1016/j.jhep.2019.01.027; Greten TF, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-209; Grosso JF, 2007, J CLIN INVEST, V117, P3383, DOI 10.1172/JCI31184; Guerra N, 1999, EUR CYTOKINE NETW, V10, P357; Guillot A, 2019, HEPATOL COMMUN, V3, P730, DOI 10.1002/hep4.1356; Hammers HJ, 2017, J CLIN ONCOL, V35, P3851, DOI 10.1200/JCO.2016.72.1985; Harmon C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01502; Harmon C, 2016, EUR J IMMUNOL, V46, P2111, DOI 10.1002/eji.201646559; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Heymann F, 2016, NAT REV GASTRO HEPAT, V13, P88, DOI 10.1038/nrgastro.2015.200; Heymann F, 2015, HEPATOLOGY, V62, P279, DOI 10.1002/hep.27793; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoechst B, 2008, GASTROENTEROLOGY, V135, P234, DOI 10.1053/j.gastro.2008.03.020; Hochst B, 2013, J HEPATOL, V59, P528, DOI 10.1016/j.jhep.2013.04.033; Hokuto D, 2015, EUR J CANCER, V51, P157, DOI 10.1016/j.ejca.2014.11.004; Hudspeth K, 2016, J AUTOIMMUN, V66, P40, DOI 10.1016/j.jaut.2015.08.011; Jiang JW, 2019, HEPATOB PANCREAT DIS, V18, P19, DOI 10.1016/j.hbpd.2018.11.002; Jiang ZW, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00690; Jiaqiang, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0814-7; Jinushi M, 2003, INT J CANCER, V104, P354, DOI 10.1002/ijc.10966; Jung HI, 2017, CANCER RES TREAT, V49, P246, DOI 10.4143/crt.2016.066; Kahraman A, 2010, HEPATOLOGY, V51, P92, DOI 10.1002/hep.23253; Kamimura H, 2012, J HEPATOL, V56, P381, DOI 10.1016/j.jhep.2011.06.017; Karkampouna S, 2012, CURR PHARM DESIGN, V18, P4103, DOI 10.2174/138161212802430521; Kelley RK, 2019, J CLIN ONCOL S15, V35, P4072; Kelly AM, 2006, CYTOKINE, V35, P171, DOI 10.1016/j.cyto.2006.07.019; Kennedy PTF, 2008, J VIRAL HEPATITIS, V15, P901, DOI 10.1111/j.1365-2893.2008.01049.x; Kim D, 2019, HEPATOLOGY, V69, P1064, DOI 10.1002/hep.30161; KNOLLE P, 1995, J HEPATOL, V22, P226, DOI 10.1016/0168-8278(95)80433-1; Knolle PA, 1998, CLIN EXP IMMUNOL, V114, P427; Knolle PA, 1999, J IMMUNOL, V162, P1401; Kuang DM, 2009, J EXP MED, V206, P1327, DOI 10.1084/jem.20082173; Kudo M, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.4072; Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1; Kudo M, 2017, LIVER CANCER, V6, P16, DOI 10.1159/000449343; Langhans B, 2019, CANCER IMMUNOL IMMUN, V68, P2055, DOI 10.1007/s00262-019-02427-4; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Larmonier N, 2007, CANCER IMMUNOL IMMUN, V56, P48, DOI 10.1007/s00262-006-0160-8; Lee JH, 2015, GASTROENTEROLOGY, V148, P1383, DOI 10.1053/j.gastro.2015.02.055; Lee WC, 2005, J IMMUNOTHER, V28, P496, DOI 10.1097/01.cji.0000171291.72039.e2; Li F, 2018, CANCER MANAG RES, V10, P941, DOI 10.2147/CMAR.S162478; Liao HT, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00883; Liao Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060444; Liu XD, 2015, CANCER IMMUNOL RES, V3, P1017, DOI 10.1158/2326-6066.CIR-14-0244; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.TPS4152; Lohitesh K, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0538-7; Lu LC, 2019, LIVER CANCER, V8, P110, DOI 10.1159/000489021; Ma J, 2016, ONCOTARGETS THER, V9, P183, DOI 10.2147/OTT.S96999; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Mazzaferro V, 2018, GASTROENTEROLOGY, V154, P128, DOI 10.1053/j.gastro.2017.09.025; Mehrfeld C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00635; Meyer T, 2017, LANCET GASTROENTEROL, V2, P565, DOI 10.1016/S2468-1253(17)30156-5; Michelet X, 2018, NAT IMMUNOL, V19, P1330, DOI 10.1038/s41590-018-0251-7; Mittal D, 2014, CURR OPIN IMMUNOL, V27, P16, DOI 10.1016/j.coi.2014.01.004; Mizukoshi E, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0742-5; Norris S, 1998, J HEPATOL, V28, P84, DOI 10.1016/S0168-8278(98)80206-7; Oliviero B, 2009, GASTROENTEROLOGY, V137, P1151, DOI 10.1053/j.gastro.2009.05.047; Palmer DH, 2009, HEPATOLOGY, V49, P124, DOI 10.1002/hep.22626; Pan ZY, 2018, CANCER IMMUNOL IMMUN, V67, P1621, DOI 10.1007/s00262-018-2221-1; Parry RV, 2005, MOL CELL BIOL, V25, P9543, DOI 10.1128/MCB.25.21.9543-9553.2005; Patsoukis N, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002796; Pedroza-Gonzalez A, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1008355; Pinato DJ, 2019, ANN ONCOL, V30, P288; Pinato DJ, 2019, BRIT J CANCER, V120, P1033, DOI 10.1038/s41416-019-0466-x; Pinato DJ, 2017, J HEPATOL, V66, P338, DOI 10.1016/j.jhep.2016.09.008; PISHVAIAN MJ, 2018, ANN ONCOL S8, V29, P718, DOI DOI 10.1093/ANNONC/MDY424.028; PISHVAIAN MJ, 2018, ANN ONCOL S8, V29; Prieto J, 2015, NAT REV GASTRO HEPAT, V12, P681, DOI 10.1038/nrgastro.2015.173; Qin SK, 2019, FUTURE ONCOL, V15, P1811, DOI 10.2217/fon-2019-0097; Qin SK., 2018, ANN ONCOL, V29, pVIII719, DOI [DOI 10.1093/ANNONC/MDY424.029, 10.1093/annonc/mdy424.029]; Ramjiawan RR, 2017, ANGIOGENESIS, V20, P185, DOI 10.1007/s10456-017-9552-y; Raulet DH, 2009, NAT REV IMMUNOL, V9, P568, DOI 10.1038/nri2604; Ren L, 2016, ONCOTARGET, V7, P75763, DOI 10.18632/oncotarget.12409; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Sabado RL, 2017, CELL RES, V27, P74, DOI 10.1038/cr.2016.157; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; Sanchez-Correa B, 2019, CANCERS, V11, DOI 10.3390/cancers11060877; Sangro B, 2013, J HEPATOL, V59, P81, DOI 10.1016/j.jhep.2013.02.022; Schaaf MB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0061-0; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; Schildberg FA, 2011, HEPATOLOGY, V54, P1108, DOI 10.1002/hep.24565; Schildberg FA, 2011, HEPATOLOGY, V54, P262, DOI 10.1002/hep.24352; Schmidt N, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.954919; Shen H, 1998, CELL, V92, P535, DOI 10.1016/S0092-8674(00)80946-0; Sheppard S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01808; Shetty S, 2018, NAT REV GASTRO HEPAT, V15, P555, DOI 10.1038/s41575-018-0020-y; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Shi FD, 2011, NAT REV IMMUNOL, V11, P658, DOI 10.1038/nri3065; Shimizu K, 2014, HUM VACC IMMUNOTHER, V10, P970, DOI 10.4161/hv.27678; Sia D, 2017, GASTROENTEROLOGY, V153, P812, DOI 10.1053/j.gastro.2017.06.007; Stegmann KA, 2016, SCI REP-UK, V6, DOI 10.1038/srep26157; Sun HY, 2019, HEPATOLOGY, V70, P168, DOI 10.1002/hep.30347; Tacke F, 2017, J HEPATOL, V66, P1300, DOI 10.1016/j.jhep.2017.02.026; Takayama T, 2000, LANCET, V356, P802, DOI 10.1016/S0140-6736(00)02654-4; Tauber Catrin, 2019, Oncotarget, V10, P5194, DOI 10.18632/oncotarget.27146; Thomas M, 2009, J GASTROENTEROL, V44, P136, DOI 10.1007/s00535-008-2252-z; Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126; Tray N, 2018, CANCER IMMUNOL RES, V6, P1122, DOI 10.1158/2326-6066.CIR-18-0214; Ugel S, 2015, J CLIN INVEST, V125, P3365, DOI 10.1172/JCI80006; Unitt E, 2005, HEPATOLOGY, V41, P722, DOI 10.1002/hep.20644; van Montfoort N, 2018, CELL, V175, P1744, DOI 10.1016/j.cell.2018.10.028; Varchetta S, 2012, HEPATOLOGY, V56, P841, DOI 10.1002/hep.25723; Varol C, 2015, ANNU REV IMMUNOL, V33, P643, DOI 10.1146/annurev-immunol-032414-112220; Vey Norbert, 2018, Oncotarget, V9, P17675, DOI 10.18632/oncotarget.24832; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Wada Y, 1998, HEPATOLOGY, V27, P407, DOI 10.1002/hep.510270214; Wainberg ZA, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4071; Wang XC, 2019, J HEPATOL, V71, P731, DOI 10.1016/j.jhep.2019.05.015; Yamamoto H, 2000, INT J ONCOL, V16, P543; Yan J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058006; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Yau T, 2019, ANN ONCOL, V30, DOI DOI 10.1093/ANNONC/MDZ394.029; Yau T, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.4012; Yegin EG, 2016, HEPATOB PANCREAT DIS, V15, P234, DOI 10.1016/S1499-3872(16)60097-8; Yen C-J, 2017, ANN ONCOL, V28, piii54, DOI [DOI 10.1093/ANNONC/MDX261.139, 10.1093/annonc/mdx261.139]; Yoshimoto S, 2013, NATURE, V499, P97, DOI 10.1038/nature12347; Zhang C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09212-y; Zhang JP, 2009, J HEPATOL, V50, P980, DOI 10.1016/j.jhep.2008.12.033; Zhao F, 2012, J IMMUNOL, V188, P6055, DOI 10.4049/jimmunol.1102918; Zhao QY, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1254855; Zhao WX, 2011, INT J CANCER, V129, P2651, DOI 10.1002/ijc.25920; Zheng CH, 2017, CELL, V169, P1342, DOI 10.1016/j.cell.2017.05.035; Zheng Y, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0650-9; Zhou GY, 2017, GASTROENTEROLOGY, V153, P1107, DOI 10.1053/j.gastro.2017.06.017; Zhou YL, 2002, J IMMUNOTHER, V25, P289, DOI 10.1097/00002371-200207000-00001; Zhu AX, 2018, LANCET ONCOL, V19, P940, DOI 10.1016/S1470-2045(18)30351-6; Zucman-Rossi J, 2015, GASTROENTEROLOGY, V149, P1226, DOI 10.1053/j.gastro.2015.05.061	171	99	105	7	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3620	3637		10.1038/s41388-020-1249-9	http://dx.doi.org/10.1038/s41388-020-1249-9		MAR 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32157213	Green Published, hybrid			2022-12-17	WOS:000518886000005
J	Campos, B; Olsen, LR; Urup, T; Poulsen, HS				Campos, B.; Olsen, L. R.; Urup, T.; Poulsen, H. S.			A comprehensive profile of recurrent glioblastoma	ONCOGENE			English	Review							CELL MARKER CD133; CANCER STEM-CELLS; ADJUVANT TEMOZOLOMIDE; PROMOTER METHYLATION; TUMOR; EXPRESSION; SURVIVAL; RADIOTHERAPY; HETEROGENEITY; CONCOMITANT	In spite of relentless efforts to devise new treatment strategies, primary glioblastomas invariably recur as aggressive, therapy-resistant relapses and patients rapidly succumb to these tumors. Many therapeutic agents are first tested in clinical trials involving recurrent glioblastomas. Remarkably, however, fundamental knowledge on the biology of recurrent glioblastoma is just slowly emerging. Here, we review current knowledge on recurrent glioblastoma and ask whether and how therapies change intra-tumor heterogeneity, molecular traits and growth pattern of glioblastoma, and to which extent this information can be exploited for therapeutic decision-making. We conclude that the ability to characterize and predict therapy-induced changes in recurrent glioblastoma will determine, whether, one day, glioblastoma can be contained in a state of chronic disease.	[Campos, B.] Heidelberg Univ, Dept Neurosurg, Div Expt Neurosurg, INF 400, D-69120 Heidelberg, Germany; [Olsen, L. R.] Tech Univ Denmark, Dept Syst Biol, Ctr Biol Sequence Anal, Lyngby, Denmark; [Urup, T.; Poulsen, H. S.] Copenhagen Univ Hosp, Finsen Ctr, Dept Radiat Biol, Copenhagen, Denmark	Ruprecht Karls University Heidelberg; Technical University of Denmark; University of Copenhagen	Campos, B (corresponding author), Heidelberg Univ, Dept Neurosurg, Div Expt Neurosurg, INF 400, D-69120 Heidelberg, Germany.	benito.campos@med.uni-heidelberg.de	Urup, Thomas/AAC-9953-2020	Olsen, Lars Ronn/0000-0002-6725-7850				Andor N, 2014, BIOINFORMATICS, V30, P50, DOI 10.1093/bioinformatics/btt622; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; BILZER T, 1991, ANTICANCER RES, V11, P547; Brandes AA, 2009, J CLIN ONCOL, V27, P1275, DOI 10.1200/JCO.2008.19.4969; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; BURGER PC, 1983, J NEUROSURG, V58, P159, DOI 10.3171/jns.1983.58.2.0159; Campos B, 2014, J PATHOL, V234, P23, DOI 10.1002/path.4366; Campos B, 2011, INT J CANCER, V128, P501, DOI 10.1002/ijc.25687; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Christmann M, 2010, INT J CANCER, V127, P2106, DOI 10.1002/ijc.25229; De Bonis P, 2013, CLIN NEUROL NEUROSUR, V115, P37, DOI 10.1016/j.clineuro.2012.04.005; Deleyrolle LP, 2011, BRAIN, V134, P1331, DOI 10.1093/brain/awr081; Furuta T, 2014, BRAIN TUMOR PATHOL, V31, P32, DOI 10.1007/s10014-013-0142-4; Glas M, 2010, ANN NEUROL, V68, P264, DOI 10.1002/ana.22036; Ilhan-Mutlu A, 2013, J NEURO-ONCOL, V112, P347, DOI 10.1007/s11060-013-1078-6; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Iwamoto FM, 2009, NEUROLOGY, V73, P1200, DOI 10.1212/WNL.0b013e3181bc0184; Johnson BE, 2014, SCIENCE, V343, P189, DOI 10.1126/science.1239947; Keunen O, 2011, P NATL ACAD SCI USA, V108, P3749, DOI 10.1073/pnas.1014480108; Kim H, 2015, GENOME RES, V25, P316, DOI 10.1101/gr.180612.114; Kim J, 2015, CANCER CELL, V28, P318, DOI 10.1016/j.ccell.2015.07.013; Lathia JD, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.80; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Liu QH, 2009, J NEURO-ONCOL, V94, P1, DOI 10.1007/s11060-009-9919-z; Lu-Emerson C, 2013, NEURO-ONCOLOGY, V15, P1079, DOI 10.1093/neuonc/not082; Martinez R, 2003, BRAIN PATHOL, V13, P598; Martinez R, 2007, CARCINOGENESIS, V28, P1264, DOI 10.1093/carcin/bgm014; Martinez R, 2010, J NEURO-ONCOL, V96, P321, DOI 10.1007/s11060-009-9967-4; Marucci G, 2015, PATHOLOGICA, V107, P1; Mittal D, 2014, CURR OPIN IMMUNOL, V27, P16, DOI 10.1016/j.coi.2014.01.004; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Pallini R, 2011, CANCER-AM CANCER SOC, V117, P162, DOI 10.1002/cncr.25581; Pistollato F, 2010, STEM CELLS, V28, P851, DOI 10.1002/stem.415; Poulsen HS, 2014, CANCER MANAG RES, V6, P373, DOI 10.2147/CMAR.S39306; Qazi MA, 2016, J NEURO-ONCOL, V126, P57, DOI 10.1007/s11060-015-1951-6; Reis RM, 2001, J NEUROPATH EXP NEUR, V60, P208, DOI 10.1093/jnen/60.2.208; Richichi C, 2013, NEOPLASIA, V15, P840, DOI 10.1593/neo.13662; Sampson JH, 2010, J CLIN ONCOL, V28, P4722, DOI 10.1200/JCO.2010.28.6963; Sathornsumetee S, 2008, J CLIN ONCOL, V26, P271, DOI 10.1200/JCO.2007.13.3652; Shinsato Y, 2013, ONCOTARGET, V4, P2261, DOI 10.18632/oncotarget.1302; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Smets T, 2013, EUR RADIOL, V23, P1467, DOI 10.1007/s00330-012-2762-1; Snuderl M, 2011, CANCER CELL, V20, P810, DOI 10.1016/j.ccr.2011.11.005; Sottoriva A, 2013, P NATL ACAD SCI USA, V110, P4009, DOI 10.1073/pnas.1219747110; Stark AM, 2003, J NEUROL NEUROSUR PS, V74, P779, DOI 10.1136/jnnp.74.6.779; Stark AM, 2010, NEUROL RES, V32, P816, DOI 10.1179/016164110X12645013515052; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Szerlip NJ, 2012, P NATL ACAD SCI USA, V109, P3041, DOI 10.1073/pnas.1114033109; Tamura K, 2013, J NEUROSURG, V119, P1145, DOI 10.3171/2013.7.JNS122417; Van Nifterik KA, 2006, J NEUROSURG, V105, P739, DOI 10.3171/jns.2006.105.5.739; Weller M, 2013, NEURO-ONCOLOGY, V15, P4, DOI 10.1093/neuonc/nos273; Yao XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057188; Zeppernick F, 2008, CLIN CANCER RES, V14, P123, DOI 10.1158/1078-0432.CCR-07-0932	56	99	104	3	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5819	5825		10.1038/onc.2016.85	http://dx.doi.org/10.1038/onc.2016.85			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27041580				2022-12-17	WOS:000387560800001
J	Li, J; Wu, H; Li, W; Yin, L; Guo, S; Xu, X; Ouyang, Y; Zhao, Z; Liu, S; Tian, Y; Tian, Z; Ju, J; Ni, B; Wang, H				Li, J.; Wu, H.; Li, W.; Yin, L.; Guo, S.; Xu, X.; Ouyang, Y.; Zhao, Z.; Liu, S.; Tian, Y.; Tian, Z.; Ju, J.; Ni, B.; Wang, H.			Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-kappa B signaling	ONCOGENE			English	Article							SPHINGOSINE KINASE 1; MESENCHYMAL TRANSITION; DUCTAL ADENOCARCINOMA; CISPLATIN RESISTANCE; MICRORNA EXPRESSION; TUMOR-SUPPRESSOR; NETWORK; SURVIVAL; GROWTH; PROLIFERATION	The aberrant expression of microRNAs (miRNAs) has emerged as an important hallmark of cancer. However, the molecular mechanisms underlying the changes in miRNA expression remain unclear. In this study, we discovered a novel epigenetic mechanism of miR-506 regulation and investigated its functional significance in pancreatic cancer. Sequencing analysis revealed that the miR-506 promoter is highly methylated in pancreatic cancer tissues compared with non-cancerous tissues. Reduced miR-506 expression was significantly associated with clinical stage, pathologic tumor status, distant metastasis and decreased survival of pancreatic cancer patients. miR-506 inhibited cell proliferation, induced cell cycle arrest at the G1/S transition and enhanced apoptosis and chemosensitivity of pancreatic cancer cells. Furthermore, we identified sphingosine kinase 1 (SPHK1) as a novel target of miR-506, the expression of which inhibited the SPHK1/Akt/NF-kappa B signaling pathway, which is activated in pancreatic cancer. High SPHK1 expression was significantly associated with poor survival in a large cohort of pancreatic cancer specimens. Our data suggest that miR-506 acts as a tumor suppressor miRNA and is epigenetically silenced in pancreatic cancer. The newly identified miR-506/SPHK1 axis represents a novel therapeutic strategy for future pancreatic cancer treatment.	[Li, J.; Yin, L.; Guo, S.; Xu, X.; Ouyang, Y.; Zhao, Z.; Liu, S.; Wang, H.] Third Mil Med Univ, Southwest Hosp, Inst Hepatopancreatobiliary Surg, 30 Gaotanyan St, Chongqing 400038, Peoples R China; [Wu, H.] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Pancreat Surg, Wuhan, Peoples R China; [Li, W.] Third Mil Med Univ, Southwest Hosp, Dept Oncol, Chongqing, Peoples R China; [Li, W.] Third Mil Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing, Peoples R China; [Tian, Y.; Tian, Z.; Ni, B.] Third Mil Med Univ, Inst Immunol PLA, Chongqing, Peoples R China; [Ju, J.] SUNY Stony Brook, Dept Pathol, Translat Res Lab, Stony Brook, NY USA; [Ni, B.] Third Mil Med Univ, Dept Pathophysiol & High Altitude Pathol, Chongqing, Peoples R China	Army Medical University; Huazhong University of Science & Technology; Army Medical University; Army Medical University; Army Medical University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Army Medical University	Ju, J; Ni, B; Wang, H (corresponding author), Third Mil Med Univ, Southwest Hosp, Inst Hepatopancreatobiliary Surg, 30 Gaotanyan St, Chongqing 400038, Peoples R China.	jingfang.ju@stonybrookmedicine.edu; nibingxi@126.com; whuaizhi@gmail.com	Yin, Liangyu/AAE-4982-2021	Yin, Liangyu/0000-0001-8876-2680; Ni, Bing/0000-0002-4297-5346	National Natural Science Foundation of China [81372242]; National High Technology Research and Development Program of China (Program 863) [2012AA021105]; Research Special Fund for Public Welfare Industry of Health [201202007]; NATIONAL CANCER INSTITUTE [R01CA197098] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program of China (Program 863)(National High Technology Research and Development Program of China); Research Special Fund for Public Welfare Industry of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Professor Renyi Qin from the Department of Biliary-Pancreatic Surgery (Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan) and Professor Yijun Zhao from the Department of Hepatobiliary Surgery (the First Affiliated Hospital of Anhui Medical University, Hefei) for providing human pancreatic cancer samples. This work was supported by the following grants: the National Natural Science Foundation of China (No. 81372242); the National High Technology Research and Development Program of China (Program 863; No. 2012AA021105); and the Research Special Fund for Public Welfare Industry of Health (No. 201202007).	Arora H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064273; Babar IA, 2012, P NATL ACAD SCI USA, V109, pE1695, DOI 10.1073/pnas.1201516109; Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Bouchie A, 2013, NAT BIOTECHNOL, V31, P577, DOI 10.1038/nbt0713-577; Bracken CP, 2015, CANCER RES, V75, P2594, DOI 10.1158/0008-5472.CAN-15-0287; Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; Drayton RM, 2014, CLIN CANCER RES, V20, P1990, DOI 10.1158/1078-0432.CCR-13-2805; Frampton AE, 2015, EUR J CANCER, V51, P1389, DOI 10.1016/j.ejca.2015.04.006; Frampton AE, 2014, GASTROENTEROLOGY, V146, P268, DOI 10.1053/j.gastro.2013.10.010; Gao W, 2015, ONCOGENE, V34, P1629, DOI 10.1038/onc.2014.101; Garrido-Laguna I, 2015, NAT REV CLIN ONCOL, V12, P319, DOI 10.1038/nrclinonc.2015.53; Guillermet-Guibert J, 2009, MOL CANCER THER, V8, P809, DOI 10.1158/1535-7163.MCT-08-1096; Guo SX, 2014, CANCER LETT, V344, P40, DOI 10.1016/j.canlet.2013.10.009; Jamieson NB, 2012, CLIN CANCER RES, V18, P534, DOI 10.1158/1078-0432.CCR-11-0679; Kapitonov D, 2009, CANCER RES, V69, P6915, DOI 10.1158/0008-5472.CAN-09-0664; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Kawamori T, 2009, FASEB J, V23, P405, DOI 10.1096/fj.08-117572; Kong KL, 2012, GUT, V61, P33, DOI 10.1136/gutjnl-2011-300178; Lai NS, 2015, BRIT J CANCER, V112, P1241, DOI 10.1038/bjc.2015.91; Lennox KA, 2011, GENE THER, V18, P1111, DOI 10.1038/gt.2011.100; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Li J, 2008, CLIN CANCER RES, V14, P6996, DOI 10.1158/1078-0432.CCR-08-0754; Li W, 2009, CLIN CANCER RES, V15, P1393, DOI 10.1158/1078-0432.CCR-08-1158; Liu G, 2014, J PATHOL, V233, P308, DOI 10.1002/path.4348; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Nagahashi M, 2012, CANCER RES, V72, P726, DOI 10.1158/0008-5472.CAN-11-2167; Oettle H, 2013, JAMA-J AM MED ASSOC, V310, P1473, DOI 10.1001/jama.2013.279201; Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875; Sakimura S, 2015, ANN SURG ONCOL, V22, pS1436, DOI 10.1245/s10434-015-4418-2; Shida D, 2008, CURR DRUG TARGETS, V9, P662, DOI 10.2174/138945008785132402; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Song LB, 2011, CLIN CANCER RES, V17, P1839, DOI 10.1158/1078-0432.CCR-10-0720; St Hilaire C, 2011, NEW ENGL J MED, V364, P432, DOI [10.1056/NEJMoa0912923, 10.1056/NEJMc1102515]; Streicher KL, 2012, ONCOGENE, V31, P1558, DOI 10.1038/onc.2011.345; Su JA, 2010, INT J BIOCHEM CELL B, V42, P2047, DOI 10.1016/j.biocel.2010.09.009; Sun Y, 2015, J PATHOL, V235, P25, DOI 10.1002/path.4443; Tang YC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091551; Tong JL, 2011, FEBS LETT, V585, P3560, DOI 10.1016/j.febslet.2011.10.021; Wang P, 2014, ONCOGENE, V33, P514, DOI 10.1038/onc.2012.598; Wen SY, 2014, ONCOGENE, V34, P717, DOI DOI 10.1038/0NC.2014.9; Xi YG, 2007, RNA, V13, P1668, DOI 10.1261/rna.642907; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yin M, 2015, ONCOGENE, V34, P691, DOI 10.1038/onc.2013.597; Zhang SY, 2011, CARCINOGENESIS, V32, P1183, DOI 10.1093/carcin/bgr105	47	99	106	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5501	5514		10.1038/onc.2016.90	http://dx.doi.org/10.1038/onc.2016.90			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27065335	hybrid, Green Published			2022-12-17	WOS:000386998200005
J	Navab, R; Strumpf, D; To, C; Pasko, E; Kim, KS; Park, CJ; Hai, J; Liu, J; Jonkman, J; Barczyk, M; Bandarchi, B; Wang, YH; Venkat, K; Ibrahimov, E; Pham, NA; Ng, C; Radulovich, N; Zhu, CQ; Pintilie, M; Wang, D; Lu, A; Jurisica, I; Walker, GC; Gullberg, D; Tsao, MS				Navab, R.; Strumpf, D.; To, C.; Pasko, E.; Kim, K. S.; Park, C. J.; Hai, J.; Liu, J.; Jonkman, J.; Barczyk, M.; Bandarchi, B.; Wang, Y. H.; Venkat, K.; Ibrahimov, E.; Pham, N-A; Ng, C.; Radulovich, N.; Zhu, C-Q; Pintilie, M.; Wang, D.; Lu, A.; Jurisica, I.; Walker, G. C.; Gullberg, D.; Tsao, M-S			Integrin alpha 11 beta 1 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer	ONCOGENE			English	Article							FOCAL ADHESION KINASE; COLLAGEN-BINDING; LYSYL OXIDASE; FIBROBLASTS; RECEPTOR; GROWTH; ALPHA-2-BETA-1; REORGANIZATION; MACROPHAGES; EXPRESSION	Integrin alpha 11 beta 1 is a stromal cell-specific receptor for fibrillar collagens and is overexpressed in carcinoma-associated fibroblasts (CAFs). We have investigated its direct role in cancer progression by generating severe combined immune deficient (SCID) mice deficient in integrin alpha 11 (alpha 11) expression. The growth of A549 lung adenocarcinoma cells and two patient-derived non-small cell lung carcinoma (NSCLC) xenografts in these alpha 11 knockout (alpha 11(-/-)) mice was significantly impeded, as compared with wild-type (alpha 11(+/+)) SCID mice. Orthotopic implantation of a spontaneously metastatic NCI-H460SM cell line into the lungs of alpha 11(-/-) and alpha 11(+/+) mice showed significant reduction in the metastatic potential of these cells in the alpha 11(-/-) mice. We identified that collagen cross-linking is associated with stromal alpha 11 expression, and the loss of tumor stromal alpha 11 expression was correlated with decreased collagen reorganization and stiffness. This study shows the role of integrin alpha 11 beta 1, a receptor for fibrillar collagen in differentiation of fibroblasts into CAFs. Furthermore, our data support an important role for alpha 11 signaling pathway in CAFs, promoting tumor growth and metastatic potential of NSCLC cells and being closely associated with collagen cross-linking and the organization and stiffness of fibrillar collagen matrices.	[Navab, R.; Strumpf, D.; To, C.; Pasko, E.; Park, C. J.; Hai, J.; Liu, J.; Jonkman, J.; Bandarchi, B.; Wang, Y. H.; Venkat, K.; Ibrahimov, E.; Pham, N-A; Ng, C.; Radulovich, N.; Zhu, C-Q; Pintilie, M.; Wang, D.; Lu, A.; Jurisica, I.; Tsao, M-S] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 2C4, Canada; [Navab, R.; Strumpf, D.; To, C.; Pasko, E.; Park, C. J.; Hai, J.; Liu, J.; Jonkman, J.; Bandarchi, B.; Wang, Y. H.; Venkat, K.; Ibrahimov, E.; Pham, N-A; Ng, C.; Radulovich, N.; Zhu, C-Q; Pintilie, M.; Wang, D.; Lu, A.; Jurisica, I.; Tsao, M-S] Univ Hlth Network, Campbell Family Inst Canc Res, Toronto, ON M5G 2C4, Canada; [Pasko, E.; Tsao, M-S] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Kim, K. S.; Walker, G. C.] Univ Toronto, Dept Chem, 80 St George St, Toronto, ON M5S 1A1, Canada; [Barczyk, M.; Gullberg, D.] Univ Bergen, Dept Biomed, Bergen, Norway; [Barczyk, M.; Gullberg, D.] Univ Bergen, Ctr Canc Biomarkers, Bergen, Norway; [Jurisica, I.] Univ Toronto, Dept Comp Sci, Toronto, ON, Canada; [Jurisica, I.; Tsao, M-S] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Bergen; University of Bergen; University of Toronto; University of Toronto	Tsao, MS (corresponding author), Univ Hlth Network, Dept Med Biophys & Lab Med & Pathobiol, 200 Elizabeth St,11th Floor, Toronto, ON M5G 2C4, Canada.	ming.tsao@uhn.on.ca	Navab, Roya/AGD-7380-2022; Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022; Gullberg, Donald/H-2495-2016; Hai, Josephine/AAO-9919-2020	Tsao, Ming Sound/0000-0002-9160-5405; Gullberg, Donald/0000-0002-7245-4437; Wang, Dennis/0000-0003-0068-1005; Kim, Kris/0000-0002-8912-520X; Zhu, ChangQi/0000-0002-9992-0258; Hai, Josephine/0000-0002-5842-7686; Pham, Nhu-An/0000-0003-3063-0292	Canadian Cancer Society [019293, 020527]; Canadian Institutes of Health Research [MOP-115174]; Terry Fox Foundation STIHR; CIHR [TGT-53912]; Norwegian Centre of Excellence; Research Council of Norway [223250]; Ontario Ministry of Health and Long Term Care	Canadian Cancer Society(Canadian Cancer Society (CCS)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Terry Fox Foundation STIHR; CIHR(Canadian Institutes of Health Research (CIHR)); Norwegian Centre of Excellence; Research Council of Norway(Research Council of Norway); Ontario Ministry of Health and Long Term Care(Ministry of Health and Long-Term Care, Ontario)	This work was supported by grants from the Canadian Cancer Society (# 019293 and # 020527), Canadian Institutes of Health Research grant MOP-115174, Terry Fox Foundation STIHR, CIHR grant TGT-53912 (BB), Norwegian Centre of Excellence grant, The Research Council of Norway grants 223250 (DG) and the Ontario Ministry of Health and Long Term Care. Dr Tsao is the M. Qasim Choksi chair in Lung Cancer Translational research. Dr Jurisica is the Canada Research Chair in Integrative Computational Biology. The data reported in this paper have been deposited into the Gene Expression Omnibus (GEO) database, http://ncbi.nlm.nih.gov/geo/(accession no. GSE51722).	Barczyk MM, 2009, J DENT RES, V88, P621, DOI 10.1177/0022034509339291; Barczyk M, 2010, CELL TISSUE RES, V339, P269, DOI 10.1007/s00441-009-0834-6; Blumbach K, 2012, J BIOL CHEM, V287, P6431, DOI 10.1074/jbc.M111.283119; Brown E, 2003, NAT MED, V9, P796, DOI 10.1038/nm879; Campagnola PJ, 2003, NAT BIOTECHNOL, V21, P1356, DOI 10.1038/nbt894; Carracedo S, 2010, J BIOL CHEM, V285, P10434, DOI 10.1074/jbc.M109.078766; Cheng T, 2014, J MOL CELL BIOL, V6, P506, DOI 10.1093/jmcb/mju039; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Egeblad M, 2008, DIS MODEL MECH, V1, P155, DOI 10.1242/dmm.000596; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Gullberg DE, 2002, PROG HISTOCHEM CYTO, V37, P9; HARALICK RM, 1973, IEEE T SYST MAN CYB, VSMC3, P610, DOI 10.1109/TSMC.1973.4309314; Hertz H, 1881, J REINE ANGEW MATH C, V92, P156, DOI 10.1515/crll.1882.92.156; HUTTER JL, 1993, REV SCI INSTRUM, V64, P1868, DOI 10.1063/1.1143970; John T, 2011, CLIN CANCER RES, V17, P134, DOI 10.1158/1078-0432.CCR-10-2224; Jokinen J, 2004, J BIOL CHEM, V279, P31956, DOI 10.1074/jbc.M401409200; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; Littell RC, 1998, J ANIM SCI, V76, P1216; Liu J, 2004, ONCOGENE, V23, P6316, DOI 10.1038/sj.onc.1207795; Lu N, 2010, MATRIX BIOL, V29, P166, DOI 10.1016/j.matbio.2009.11.003; Malkoski SP, 2012, CLIN CANCER RES, V18, P2173, DOI 10.1158/1078-0432.CCR-11-2557; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Nakasone ES, 2012, CANCER CELL, V21, P488, DOI 10.1016/j.ccr.2012.02.017; Navab R, 2011, P NATL ACAD SCI USA, V108, P7160, DOI 10.1073/pnas.1014506108; Navab R, 2009, NEOPLASIA, V11, P1292, DOI 10.1593/neo.09622; Ostman A, 2009, CURR OPIN GENET DEV, V19, P67, DOI 10.1016/j.gde.2009.01.003; Owen KA, 2007, J CELL BIOL, V179, P1275, DOI 10.1083/jcb.200708093; Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045; Popova SN, 2007, ACTA PHYSIOL, V190, P179, DOI 10.1111/j.1748-1716.2007.01718.x; Popova SN, 2004, DEV BIOL, V270, P427, DOI 10.1016/j.ydbio.2004.03.006; Popova SN, 2007, MOL CELL BIOL, V27, P4306, DOI 10.1128/MCB.00041-07; Provenzano PP, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-38; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Schulz JN, 2015, J INVEST DERMATOL, V135, P1435, DOI 10.1038/jid.2015.24; Sneddon I., 1965, INT J ENG SCI, V3, P47, DOI 10.1016/0020-7225(65)90019-4; Svendsen OS, 2009, ARTERIOSCL THROM VAS, V29, P1864, DOI 10.1161/ATVBAHA.109.194308; Talior-Volodarsky I, 2012, CARDIOVASC RES, V96, P265, DOI 10.1093/cvr/cvs259; Tiger CF, 2001, DEV BIOL, V237, P116, DOI 10.1006/dbio.2001.0363; Tilghman RW, 2005, J CELL SCI, V118, P2613, DOI 10.1242/jcs.02380; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; Wang K, 2002, ONCOGENE, V21, P7598, DOI 10.1038/sj.onc.1205953; Wilgus ML, 2011, CANCER-AM CANCER SOC, V117, P2186, DOI 10.1002/cncr.25768; Williams RM, 2005, BIOPHYS J, V88, P1377, DOI 10.1529/biophysj.104.047308; Xiao Q, 2012, CANCER MICROENVIRON, V5, P261, DOI 10.1007/s12307-012-0105-z; Xing F, 2010, FRONT BIOSCI-LANDMRK, V15, P166, DOI 10.2741/3613; Yamauchi Mitsuo, 2008, V446, P95, DOI 10.1007/978-1-60327-084-7_7; Zeltz C, 2014, ADV EXP MED BIOL, V819, P73, DOI 10.1007/978-94-017-9153-3_5; Zeltz C, 2014, BBA-GEN SUBJECTS, V1840, P2533, DOI 10.1016/j.bbagen.2013.12.022; Zhang WM, 2003, J BIOL CHEM, V278, P7270, DOI 10.1074/jbc.M210313200; Zhu CQ, 2007, P NATL ACAD SCI USA, V104, P11754, DOI 10.1073/pnas.0703040104; Zweers MC, 2007, J INVEST DERMATOL, V127, P467, DOI 10.1038/sj.jid.5700546	57	99	100	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1899	1908		10.1038/onc.2015.254	http://dx.doi.org/10.1038/onc.2015.254			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26148229	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000374010300003
J	Xiang, T; Long, H; He, L; Han, X; Lin, K; Liang, Z; Zhuo, W; Xie, R; Zhu, B				Xiang, T.; Long, H.; He, L.; Han, X.; Lin, K.; Liang, Z.; Zhuo, W.; Xie, R.; Zhu, B.			Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133(+) cancer stem-like cells in ovarian cancer	ONCOGENE			English	Article						cancer stem cells; IL-17; self-renewal; ovarian cancer	BREAST-CANCER; INITIATING CELLS; IL-17 PROMOTES; MESSENGER-RNA; LUNG-CANCER; EXPRESSION; GROWTH; POPULATION; BETA; DIFFERENTIATION	Inflammatory cytokines, components of cancer stem cells (CSCs) niche, could affect the characteristics of CSCs such as self-renewal and metastasis. Interleukin-17 (IL-17) is a new pro-inflammatory cytokine mainly produced by T-helper (Th17) cells and macrophages. The effects of IL-17 on the characteristics of CSCs remain to be explored. Here we first demonstrated a role of IL-17 in promoting the self-renewal of ovarian CD133(+) cancer stem-like cells (CSLCs). We detected IL-17-producing cells (CD4(+) cells and CD68(+) macrophages) in the niche of CD133(+) CSLCs. Meanwhile, there was IL-17 receptor expression on CD133(+)CSLCs derived from A2780 cell line and primary ovarian cancer tissues. By recombinant human IL-17 stimulation and IL-17 transfection, the growth and sphere formation capacities of ovarian CD133(+)CSLCs were significantly enhanced in a dose-dependent manner. Moreover, ovarian CD133(+)CSLCs transfected with IL-17 showed greater tumorigenesis capacity in nude mice. These data suggest that IL-17 promoted the self-renewal of ovarian CD133(+)CSLCs. Further investigation through gene profiling revealed that the stimulation function of IL-17 on self-renewal of ovarian CD133(+)CSLCs might be mediated by the nuclear factor (NF)-kappa B and p38 mitogen-activated protein kinases (MAPK) signaling pathway. NF-kappa B and p38 MAPK were activated by IL-17. More importantly, IL-17 promoted self-renewal was inhibited by specific inhibitors of NF-kappa B and p38 MAPK. Taken together, our data indicate that IL-17 contributed to ovarian cancer malignancy through promoting the self-renewal of CD133(+)CSLCs and that IL-17 and its signaling pathway might serve as therapeutic targets for the treatment of ovarian cancer.	[Xiang, T.; Long, H.; He, L.; Han, X.; Lin, K.; Zhuo, W.; Xie, R.; Zhu, B.] Third Mil Med Univ, Xinqiao Hosp, Inst Canc, Chongqing 400037, Peoples R China; [Liang, Z.] Third Mil Med Univ, Southwest Hosp, Dept Obstet & Gynecol, Chongqing 400037, Peoples R China; [Xie, R.] Third Mil Med Univ, Xinqiao Hosp, Dept Obstet & Gynecol, Chongqing 400037, Peoples R China; [Zhu, B.] Third Mil Med Univ, Biomed Anal Ctr, Chongqing 400037, Peoples R China	Army Medical University; Army Medical University; Army Medical University; Army Medical University	Xie, R (corresponding author), Third Mil Med Univ, Xinqiao Hosp, Dept Obstet & Gynecol, Chongqing 400037, Peoples R China.	xrkai@163.com; b.davis.zhu@gmail.com			National Nature Science Foundation of China [81070018, 81071772, 81222031]; outstanding Youth Scientist Foundation of Chongqing [CSTC 2008BA5035]; National Key Basic Research Program of China (973 program) [2010CB529404, 2012CB526603]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); outstanding Youth Scientist Foundation of Chongqing; National Key Basic Research Program of China (973 program)(National Basic Research Program of China)	This work was supported by National Nature Science Foundation of China (grant nos. 81070018, 81071772 and 81222031), by the outstanding Youth Scientist Foundation of Chongqing (no. CSTC, 2008BA5035) and by National Key Basic Research Program of China (973 program, grant nos. 2010CB529404 and 2012CB526603).	Antonysamy MA, 1999, J IMMUNOL, V162, P577; Armstrong L, 2006, HUM MOL GENET, V15, P1894, DOI 10.1093/hmg/ddl112; Azzi S, 2011, J NATL CANCER I, V103, P1884, DOI 10.1093/jnci/djr451; Baba T, 2009, ONCOGENE, V28, P209, DOI 10.1038/onc.2008.374; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Chang SH, 2006, J BIOL CHEM, V281, P35603, DOI 10.1074/jbc.C600256200; Chen X, 2010, CANCER SCI, V101, P2384, DOI 10.1111/j.1349-7006.2010.01684.x; Ciucci A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060145; Curley MD, 2009, STEM CELLS, V27, P2875, DOI 10.1002/stem.236; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Du JW, 2012, MOL MED REP, V6, P1099, DOI 10.3892/mmr.2012.1036; Filatova A, 2013, BBA-GEN SUBJECTS, V1830, P2496, DOI 10.1016/j.bbagen.2012.10.008; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; HAMILTON TC, 1983, P AM ASSOC CANC RES, V24, P313; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hu L, 2010, BRIT J CANCER, V102, P1276, DOI 10.1038/sj.bjc.6605626; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Kang ZH, 2013, NAT NEUROSCI, V16, P1401, DOI 10.1038/nn.3505; Kato T, 2001, BIOCHEM BIOPH RES CO, V282, P735, DOI 10.1006/bbrc.2001.4618; Kusumbe AP, 2009, STEM CELLS, V27, P498, DOI 10.1634/stemcells.2008-0868; Lai DM, 2012, CANCER IMMUNOL IMMUN, V61, P979, DOI 10.1007/s00262-011-1166-4; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Lan CY, 2013, CELL TISSUE RES, V352, P351, DOI 10.1007/s00441-013-1567-0; Le Gouvello S, 2008, GUT, V57, P772, DOI 10.1136/gut.2007.123794; Long HX, 2012, STEM CELLS, V30, P2309, DOI 10.1002/stem.1194; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Miyahara Y, 2008, P NATL ACAD SCI USA, V105, P15505, DOI 10.1073/pnas.0710686105; Murugaiyan G, 2009, J IMMUNOL, V183, P4169, DOI 10.4049/jimmunol.0901017; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Numasaki M, 2004, IMMUNOL LETT, V93, P39, DOI 10.1016/j.imlet.2004.01.014; Numasaki M, 2005, J IMMUNOL, V175, P6177, DOI 10.4049/jimmunol.175.9.6177; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Pasquier J, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/630782; ROUVIER E, 1993, J IMMUNOL, V150, P5445; Sfanos KS, 2008, CLIN CANCER RES, V14, P3254, DOI 10.1158/1078-0432.CCR-07-5164; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Shostak K, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2886; Silva IA, 2011, CANCER RES, V71, P3991, DOI 10.1158/0008-5472.CAN-10-3175; Steiner GE, 2003, PROSTATE, V56, P171, DOI 10.1002/pros.10238; Subramaniam SV, 1999, BIOCHEM BIOPH RES CO, V259, P172, DOI 10.1006/bbrc.1999.0746; Subramaniam SV, 1999, BIOCHEM BIOPH RES CO, V262, P14, DOI 10.1006/bbrc.1999.1156; Takahashi H, 2005, IMMUNOL LETT, V98, P189, DOI 10.1016/j.imlet.2004.11.012; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Villalva C, 2011, INT J CANCER, V128, P826, DOI 10.1002/ijc.25416; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Yi LA, 2011, J NEUROIMMUNOL, V232, P75, DOI 10.1016/j.jneuroim.2010.10.011; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364; Zhu XW, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2195	50	99	104	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					165	176		10.1038/onc.2013.537	http://dx.doi.org/10.1038/onc.2013.537			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24362529				2022-12-17	WOS:000347790500004
J	Geng, L; Chaudhuri, A; Talmon, G; Wisecarver, JL; Are, C; Brattain, M; Wang, J				Geng, L.; Chaudhuri, A.; Talmon, G.; Wisecarver, J. L.; Are, C.; Brattain, M.; Wang, J.			MicroRNA-192 suppresses liver metastasis of colon cancer	ONCOGENE			English	Article						colon cancer; liver metastasis; miR-192; Bcl-2; Zeb2; VEGFA	GROWTH-FACTOR-BETA; EPITHELIAL-MESENCHYMAL TRANSITION; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; REPRESSORS ZEB1; EXPRESSION; RECEPTOR; CARCINOMA; CELLS; GENES	Metastasis causes most deaths from colon cancer yet mechanistic understanding and therapeutic options remain limited. Here we show that expression of microRNA (miR)-192 is inversely correlated with metastatic potential of colon cancer cells. Ectopic expression of miR-192 sensitizes colon cancer cells to growth factor deprivation stress-induced apoptosis, whereas inhibition of miR-192 confers resistance. Overexpression of miR-192 inhibits metastatic colonization to the liver in an orthotopic mouse model of colon cancer. Alterations associated with the metastatic phenotype in the primary tumors include increased apoptosis, decreased proliferation and angiogenesis. Further studies indicate that miR-192 downregulates expression of Bcl-2, Zeb2 and VEGFA in vitro and in vivo, which is responsible for enhanced apoptosis, increased expression of E-cadherin and decreased angiogenesis in vivo, respectively. Finally, studies performed on human colonic adenocarcinoma show that expression of miR-192 is significantly reduced in neoplastic cells as compared with normal colonic epithelium. Importantly, there is a significant decrease in miR-192 expression in stage IV tumors when compared with stage I or II lesions. These findings indicate that miR-192 has an important role in colon cancer development and progression. Our studies underscore the clinical relevance and prognostic significance of miR-192 expression in colon cancer. Therefore, a major implication of our studies is that restoration of miR-192 expression or antagonism of its target genes (Bcl-2, Zeb2 or VEGFA) may have considerable therapeutic potential for anti-metastatic therapy in patients with colon cancer.	[Geng, L.; Chaudhuri, A.; Brattain, M.; Wang, J.] Eppley Inst Res Canc & Allied Dis, Omaha, NE USA; [Talmon, G.; Wisecarver, J. L.] Dept Pathol & Microbiol, Omaha, NE USA; [Are, C.] Univ Nebraska Med Ctr, Dept Surg Oncol, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA; [Wang, J.] Dept Genet Cell Biol & Anat, Omaha, NE USA; [Wang, J.] Dept Biochem & Mol Biol, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center	Wang, J (corresponding author), Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Eppley Inst Res Canc & Allied Dis, 985950 Nebraska Med Ctr, Omaha, NE 68198 USA.	jjwang@unmc.edu	Chaudhuri, Anathbandhu/F-2501-2017	Chaudhuri, Anathbandhu/0000-0003-4833-3077	NIH/NCI [R01CA140988-01]; Nebraska Department of Health and Human Services [(LB506) 2013-40]; NATIONAL CANCER INSTITUTE [R01CA140988] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Nebraska Department of Health and Human Services; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH/NCI funding R01CA140988-01 and Nebraska Department of Health and Human Services (LB506) 2013-40 to JW.	Agui T, 2002, ANTICANCER RES, V22, P1769; Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bendardaf R, 2008, ANTICANCER RES, V28, P3865; Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90; BOYD DD, 1988, CANCER RES, V48, P2469; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chiang YP, 2012, EXP THER MED, V3, P560, DOI 10.3892/etm.2011.436; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Du TT, 2005, DEVELOPMENT, V132, P4645, DOI 10.1242/dev.02070; Fang L, 2012, CELL CYCLE, V11, P4352, DOI 10.4161/cc.22670; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Forrester E, 2005, CANCER RES, V65, P2296, DOI 10.1158/0008-5472.CAN-04-3272; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Grady WM, 1999, CANCER RES, V59, P320; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jiang YJ, 2011, CANCER RES, V71, P234, DOI 10.1158/0008-5472.CAN-10-1487; Jin Z, 2011, ONCOGENE, V30, P1577, DOI 10.1038/onc.2010.534; Kahlert C, 2011, CLIN CANCER RES, V17, P7654, DOI 10.1158/1078-0432.CCR-10-2816; Kang MH, 2009, CLIN CANCER RES, V15, P1126, DOI 10.1158/1078-0432.CCR-08-0144; Karakas T, 1998, ANN ONCOL, V9, P159, DOI 10.1023/A:1008255511404; Kato M, 2009, NAT CELL BIOL, V11, P881, DOI 10.1038/ncb1897; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Klinger M, 2010, ANN SURG ONCOL, V17, P2059, DOI 10.1245/s10434-010-0972-9; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kriegel AJ, 2010, NUCLEIC ACIDS RES, V38, P8338, DOI 10.1093/nar/gkq718; Krupa A, 2010, J AM SOC NEPHROL, V21, P438, DOI 10.1681/ASN.2009050530; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liu XQ, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M111.221697; Majid S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046743; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mehrotra S, 2010, CANCER CELL, V17, P53, DOI 10.1016/j.ccr.2009.11.021; Meng FY, 2012, CANCER METAST REV, V31, P455, DOI 10.1007/s10555-012-9379-3; Moreira JN, 2006, REV RECENT CLIN TRIA, V1, P217, DOI 10.2174/157488706778250050; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Salovaara R, 2002, GUT, V51, P56, DOI 10.1136/gut.51.1.56; Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425; Simms NAK, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-221; Stoeltzing O, 2003, ANN SURG ONCOL, V10, P722, DOI 10.1245/ASO.2003.07.019; Tejpar S, 2012, ONCOLOGIST, V17, P1039, DOI 10.1634/theoncologist.2012-0068; Tian Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048958; Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965; Wang B, 2010, DIABETES, V59, P1794, DOI 10.2337/db09-1736; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Ye SC, 1999, CANCER RES, V59, P4725; Yokoi K, 2005, CANCER RES, V65, P3716, DOI 10.1158/0008-5472.CAN-04-3700; Yokota J, 2000, CARCINOGENESIS, V21, P497, DOI 10.1093/carcin/21.3.497; Yue X, 2012, ONCOL REP, V27, P1200, DOI 10.3892/or.2011.1588; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhao SJ, 2008, CANCER RES, V68, P4221, DOI 10.1158/0008-5472.CAN-07-5123; Zubeldia IG, 2013, EXP CELL RES, V319, P12, DOI 10.1016/j.yexcr.2012.11.004	59	99	108	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2014	33	46					5332	5340		10.1038/onc.2013.478	http://dx.doi.org/10.1038/onc.2013.478			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MF	24213572	Green Accepted			2022-12-17	WOS:000345120600003
J	Yu, T; Liu, K; Wu, Y; Fan, J; Chen, J; Li, C; Yang, Q; Wang, Z				Yu, T.; Liu, K.; Wu, Y.; Fan, J.; Chen, J.; Li, C.; Yang, Q.; Wang, Z.			MicroRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the Wnt/beta-catenin signaling pathway	ONCOGENE			English	Article						microRNA-9; CXC chemokine receptor 4; lentivirus; cell proliferation; oral squamous cell carcinoma; wnt/beta-catenin pathway	DOWN-REGULATION; CANCER; MIR-9; MIGRATION; TONGUE; IDENTIFICATION; INVASION; CADHERIN	Aberrant expression of microRNAs (miRNAs) has been involved in the development and progression of malignancy. MicroRNA-9 (miR-9) has been confirmed to be underexpressed in many types of cancers. However, the relationship between miR-9 and the Wnt/beta-catenin signaling pathway in oral squamous cell carcinoma (OSCC) remains largely unknown. Here we showed that the miR-9 was underexpressed in patients with OSCC and several OSCC cell lines. Lentivirus-mediated miR-9 overexpression in highly aggressive (Tca8113 and SCC-9) tumor cells significantly inhibited proliferation of the two cell lines in vitro and in vivo. Furthermore, we found that the CXC chemokine receptor 4 (CXCR4) gene was a direct target of miR-9. RNA interference silencing of CXCR4 proved that miR-9 underexpression led to constitutive activation of beta-catenin through activation of CXCR4 expression in OSCC cells. Finally, we also analyzed the possible relationship between miR-9 and the genes downstream of the Wnt/beta-catenin pathway in OSCC development and progression. These results provide new evidence of miR-9 as a promising tumor gene therapeutic target for OSCC patients.	[Yu, T.; Liu, K.; Fan, J.; Chen, J.; Li, C.; Yang, Q.; Wang, Z.] Sichuan Canc Hosp, Dept Head & Neck Oncol Surg, Chengdu 610041, Sichuan, Peoples R China; [Wu, Y.] Sichuan Univ, West China Coll Stomatol, State Key Lab Oral Dis, Chengdu 610064, Peoples R China	Sichuan University	Yu, T (corresponding author), Sichuan Canc Hosp, Dept Head & Neck Oncol Surg, 55 Sec 4,Renminnan Rd, Chengdu 610041, Sichuan, Peoples R China.	vince8181@163.com; zhaohuiwang512@163.com	YU, TAO/AAA-3089-2022					Al-Aynati MM, 2004, CLIN CANCER RES, V10, P1235, DOI 10.1158/1078-0432.CCR-03-0087; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Avissar M, 2009, CARCINOGENESIS, V30, P2059, DOI 10.1093/carcin/bgp277; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638; Bandyopadhyay Sanghamitra, 2010, Silence, V1, P6, DOI 10.1186/1758-907X-1-6; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Caruz A, 1998, FEBS LETT, V426, P271, DOI 10.1016/S0014-5793(98)00359-7; Chiyomaru T, 2010, BRIT J CANCER, V102, P883, DOI 10.1038/sj.bjc.6605570; Choe Y, 2012, DEV NEUROSCI-BASEL, V34, P502, DOI 10.1159/000345353; Fracalossi ACC, 2010, EXP MOL PATHOL, V88, P176, DOI 10.1016/j.yexmp.2009.11.004; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; Gao F, 2013, BIOCHEM BIOPH RES CO, V431, P610, DOI 10.1016/j.bbrc.2012.12.097; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Hu JZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058273; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Janda CY, 2012, SCIENCE, V337, P59, DOI 10.1126/science.1222879; Jiang L, 2010, INT J CANCER, V127, P505, DOI 10.1002/ijc.25320; Jin Z, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-480; Jing LJ, 2011, NEUROREPORT, V22, P206, DOI 10.1097/WNR.0b013e328344a666; Kademani D, 2007, MAYO CLIN PROC, V82, P878, DOI 10.4065/82.7.878; Kessler P, 2008, BRIT J ORAL MAX SURG, V46, P1, DOI 10.1016/j.bjoms.2007.08.006; Laios A, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-35; Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251; Leucci E, 2012, ONCOGENE, V31, P5081, DOI 10.1038/onc.2012.15; Li JS, 2009, CLIN CANCER RES, V15, P3998, DOI 10.1158/1078-0432.CCR-08-3053; Liu NN, 2012, ONCOL REP, V28, P961, DOI 10.3892/or.2012.1905; Liu SJ, 2012, J PATHOL, V226, P61, DOI 10.1002/path.2964; Lowy AM, 2003, ANN SURG ONCOL, V10, P284, DOI 10.1245/ASO.2003.05.003; Luo HC, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-82; Nass D, 2009, BRAIN PATHOL, V19, P375, DOI 10.1111/j.1750-3639.2008.00184.x; Nie K, 2008, AM J PATHOL, V173, P242, DOI 10.2353/ajpath.2008.080009; Omura N, 2008, CANCER BIOL THER, V7, P1146, DOI 10.4161/cbt.7.7.6208; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Petersen PE, 2003, COMMUNITY DENT ORAL, V31, P3, DOI 10.1046/j..2003.com122.x; Rotkrua P, 2011, INT J CANCER, V129, P2611, DOI 10.1002/ijc.25923; Selcuklu SD, 2012, J BIOL CHEM, V287, P29516, DOI 10.1074/jbc.M111.335943; Selcuklu SD, 2009, BIOCHEM SOC T, V37, P918, DOI 10.1042/BST0370918; Sun Z, 2013, MOL ONCOL; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Uchida F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056381; Wong TS, 2008, INT J CANCER, V123, P251, DOI 10.1002/ijc.23583; Yu T, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-64	47	99	103	2	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2014	33	42					5017	5027		10.1038/onc.2013.448	http://dx.doi.org/10.1038/onc.2013.448			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OB	24141785				2022-12-17	WOS:000343768000006
J	Lu, X; Mazur, SJ; Lin, T; Appella, E; Xu, Y				Lu, X.; Mazur, S. J.; Lin, T.; Appella, E.; Xu, Y.			The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis	ONCOGENE			English	Article						nanog; breast cancer; tumorigenesis; metastasis	GENE-EXPRESSION; STEM-CELLS; SIGNALING PATHWAYS; OCT4; MIGRATION; INVASION; NETWORK; MICE	Nanog is a transcription factor required for maintaining the pluripotency of embryonic stem cells, and is not expressed in most normal adult tissues. However, recent studies have indicated that Nanog is overexpressed in many types of human cancers, including breast cancer. To elucidate the physiological roles of Nanog in tumorigenesis, we developed an inducible Nanog transgenic mouse model, in which the expression of Nanog in adult tissues can be induced via LoxP/Cre-mediated deletion. Our findings indicate that overexpression of Nanog in the mammary gland is not sufficient to induce mammary tumor. However, when coexpressed with Wnt-1 in the mouse mammary gland, it promotes mammary tumorigenesis and metastasis. In this context, Nanog promotes the migration and invasion of breast cancer cells. Microarray analysis has shown that the ectopic expression of Nanog deregulates the expression of numerous genes associated with tumorigenesis and metastasis, such as the PDGFR alpha gene. Our findings demonstrate the involvement of Nanog in breast cancer metastasis, and provide the basis for the reported correlation between Nanog expression and poor prognosis of human breast cancer patients. As Nanog is not expressed in most adult tissues, these findings identify Nanog as a potential therapeutic target in the treatment of Nanog-expressing metastatic breast cancer.	[Lu, X.; Xu, Y.] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; [Mazur, S. J.; Appella, E.] NCI, Lab Cell Biol, NIH, Bethesda, MD 20892 USA; [Lin, T.] Guangdong Prov Acad Chinese Med Sci, Ctr Regenerat Med & Translat Med, Guangzhou, Guangdong, Peoples R China	University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Guangzhou University of Chinese Medicine	Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yangxu@ucsd.edu	Lin, Tongxiang/I-4695-2013	Lin, Tongxiang/0000-0001-7033-6982; Xu, Yang/0000-0001-5574-921X	NIH [CA94254, CA124834]; Intramural Research Program of the National Cancer Institute, National Institutes of Health; NATIONAL CANCER INSTITUTE [R01CA094254, R01CA124834, ZIABC005599] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural Research Program of the National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Y Li for providing the Wnt-1 transgenic mice. This work was supported by NIH grants (CA94254 and CA124834) to YX and by the Intramural Research Program of the National Cancer Institute, National Institutes of Health.	Almstrup K, 2004, CANCER RES, V64, P4736, DOI 10.1158/0008-5472.CAN-04-0679; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Barbosa-Morais NL, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp942; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638; Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Esselens C, 2010, J BIOL CHEM, V285, P2463, DOI 10.1074/jbc.M109.055129; Ezeh UI, 2005, CANCER-AM CANCER SOC, V104, P2255, DOI 10.1002/cncr.21432; Fields S, 2007, SCIENCE, V316, P1441, DOI 10.1126/science.1144479; Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Hart AH, 2005, CANCER, V104, P2092, DOI 10.1002/cncr.21435; Hatano S, 2005, MECH DEVELOP, V122, P67, DOI 10.1016/j.mod.2004.08.008; Herman JG, 2007, INT J ONCOL, V30, P1231; Ibrahim EE, 2012, STEM CELLS, V30, P2076, DOI 10.1002/stem.1182; Ishiguro T, 2012, BIOCHEM BIOPH RES CO, V418, P199, DOI 10.1016/j.bbrc.2011.10.123; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jeter CR, 2011, ONCOGENE, V30, P3833, DOI 10.1038/onc.2011.114; Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29; Johnson DS, 2007, SCIENCE, V316, P1497, DOI 10.1126/science.1141319; Kelleher FC, 2006, ACTA ONCOL, V45, P375, DOI 10.1080/02841860600602946; Kohler EE, 2011, BLOOD, V117, P1761, DOI 10.1182/blood-2010-07-295261; Lee EK, 2010, J PROTEOME RES, V9, P5108, DOI 10.1021/pr100378z; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Liu DP, 2010, ONCOGENE, V29, P949, DOI 10.1038/onc.2009.376; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nagata T, 2014, BREAST CANCER-TOKYO, V21, P96, DOI 10.1007/s12282-012-0357-y; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Ouyang ZQ, 2009, P NATL ACAD SCI USA, V106, P21521, DOI 10.1073/pnas.0904863106; Park SJ, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S1-S50; Pesce M, 1998, BIOESSAYS, V20, P722, DOI 10.1002/(SICI)1521-1878(199809)20:9&lt;722::AID-BIES5&gt;3.0.CO;2-I; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Sharov AA, 2006, DNA RES, V13, P123, DOI 10.1093/dnares/dsl005; Siu MKY, 2013, ONCOGENE, V32, P3500, DOI 10.1038/onc.2012.363; Sonoshita M, 2011, CANCER CELL, V19, P125, DOI 10.1016/j.ccr.2010.11.008; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yeom YI, 1996, DEVELOPMENT, V122, P881; Zhang JY, 2010, ONCOL LETT, V1, P457, DOI 10.3892/ol_00000081	52	99	105	2	29	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2655	2664		10.1038/onc.2013.209	http://dx.doi.org/10.1038/onc.2013.209			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23770853	Green Accepted			2022-12-17	WOS:000336502700011
J	Lei, R; Tang, J; Zhuang, X; Deng, R; Li, G; Yu, J; Liang, Y; Xiao, J; Wang, HY; Yang, Q; Hu, G				Lei, R.; Tang, J.; Zhuang, X.; Deng, R.; Li, G.; Yu, J.; Liang, Y.; Xiao, J.; Wang, H-Y; Yang, Q.; Hu, G.			Suppression of MIM by microRNA-182 activates RhoA and promotes breast cancer metastasis	ONCOGENE			English	Article						microRNA-182; MIM; breast cancer; metastasis; RhoA; cytoskeleton	HEDGEHOG-RESPONSIVE GENE; DOWN-REGULATION; 1 MTSS1; ACTIN; MIR-182; EXPRESSION; PROGRESSION; CYTOSKELETON; VARIANTS; PROTEIN	Breast cancer is the most common type of cancer among women worldwide, and metastasis represents the most devastating stage of the disease. Recent studies have revealed that microRNAs (miRNA) have critical roles to regulate cancer cell invasion and metastasis. Here we present evidence to show the role of miR-182 in breast cancer metastasis. miR-182 is upregulated in the malignant cell line variants of both human MCF10 and mouse 4T1 series. Ectopic expression of miR-182 enhanced breast cancer cell motility and invasiveness, whereas miR-182 inhibition resulted in opposite changes. In nude mice, miR-182 led to increased pulmonary colonization of cancer cells. We further demonstrated that miR-182 directly targets MIM (Missing in Metastasis), which suppresses metastasis by inhibiting ras homolog family member A (RhoA) activity and stress fiber formation in breast cancer cells. Restoring MIM expression completely blocked the pro-metastasis function of miR-182, while RhoA inhibition reversed the phenotypes of both miR-182 overexpression and MIM knockdown. In breast tumor samples, miR-182 induction is linked to downregulation of MIM, RhoA activation and poor prognosis. Hence, our data delineates the molecular pathway by which miR-182 promotes breast cancer invasion and metastasis, and may have important implication for the treatment of metastatic cancers.	[Lei, R.; Zhuang, X.; Li, G.; Yu, J.; Liang, Y.; Hu, G.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai, Peoples R China; [Lei, R.; Zhuang, X.; Li, G.; Yu, J.; Liang, Y.; Hu, G.] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200025, Peoples R China; [Tang, J.] Sun Yat Sen Univ, Ctr Canc, Dept Breast Oncol, Guangzhou 510275, Guangdong, Peoples R China; [Tang, J.; Deng, R.; Wang, H-Y] Sun Yat Sen Univ, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China; [Xiao, J.] Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed Oncol, Shanghai, Peoples R China; [Yang, Q.] Shandong Univ, Qilu Hosp, Dept Breast Surg, Jinan 250100, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Naval Medical University; Shandong University	Hu, G (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Biol Sci,Chinese Acad Sci, Key Lab Stem Cell Biol,Inst Hlth Sci, 225 South Chongqing Rd, Shanghai 200025, Peoples R China.	ghhu@sibs.ac.cn	Xiao, Jian/GYU-4351-2022; yang, qiang/GYJ-0971-2022	Hu, Guohong/0000-0002-2980-5166; Li, Gang/0000-0001-9761-1323; Yang, Qifeng/0000-0003-0576-8513	Ministry of Science and Technology of China [2011CB510105, 2012ZX09506-001-005]; National Natural Science Foundation of China [81071754, 81222032]; Chinese Academy of Sciences [2009OHTP08, KSCX2-YW-R-192]; Shanghai Pujiang Talent Program [10PJ1411600]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Academy of Sciences(Chinese Academy of Sciences); Shanghai Pujiang Talent Program	We thank Dr Eva Hernando for providing the miR-182 overexpression plasmid. The study was funded by the grants from the Ministry of Science and Technology of China (2011CB510105, 2012ZX09506-001-005), National Natural Science Foundation of China (81071754, 81222032), Chinese Academy of Sciences (2009OHTP08, KSCX2-YW-R-192) and the Shanghai Pujiang Talent Program (10PJ1411600).	Acharya PS, 2008, J CELL SCI, V121, P1393, DOI 10.1242/jcs.021683; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bompard G, 2005, J CELL SCI, V118, P5393, DOI 10.1242/jcs.02640; Callahan CA, 2004, GENE DEV, V18, P2724, DOI 10.1101/gad.1221804; Dawson JC, 2012, ONCOGENE, V31, P1781, DOI 10.1038/onc.2011.376; Du P, 2011, ANTICANCER RES, V31, P3205; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gokhale A, 2010, J CANCER RES THER, V6, P521, DOI 10.4103/0973-1482.77072; Gonzalez-Quevedo R, 2005, J CELL BIOL, V168, P453, DOI 10.1083/jcb.200409078; Guttilla IK, 2009, J BIOL CHEM, V284, P23204, DOI 10.1074/jbc.M109.031427; Hall A, 2009, CANCER METAST REV, V28, P5, DOI 10.1007/s10555-008-9166-3; Hicks DG, 2006, CLIN CANCER RES, V12, P6702, DOI 10.1158/1078-0432.CCR-06-0635; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; Huynh C, 2011, ONCOGENE, V30, P1481, DOI 10.1038/onc.2010.523; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jiang LL, 2010, AM J PATHOL, V177, P29, DOI 10.2353/ajpath.2010.090812; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231; Li HQ, 2010, J NEUROSCI, V30, P3254, DOI 10.1523/JNEUROSCI.4948-09.2010; Lin JX, 2005, ONCOGENE, V24, P2059, DOI 10.1038/sj.onc.1208412; Liu K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-428; Liu ZJ, 2012, J PATHOL, V228, P204, DOI 10.1002/path.4000; Lu X, 2010, J BIOL CHEM, V285, P9317, DOI 10.1074/jbc.C110.104448; Ma S, 2007, HUM PATHOL, V38, P1201, DOI 10.1016/j.humpath.2007.01.004; Mattila PK, 2003, J BIOL CHEM, V278, P8452, DOI 10.1074/jbc.M212113200; Moskwa P, 2011, MOL CELL, V41, P210, DOI 10.1016/j.molcel.2010.12.005; Nixdorf S, 2004, CANCER LETT, V215, P209, DOI 10.1016/j.canlet.2004.05.002; Parr C, 2009, EUR J CANCER, V45, P1673, DOI 10.1016/j.ejca.2009.02.019; Rajnicek AM, 2006, J CELL SCI, V119, P1723, DOI 10.1242/jcs.02896; Saarikangas J, 2011, J CELL SCI, V124, P1245, DOI 10.1242/jcs.082610; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Saus E, 2010, HUM MOL GENET, V19, P4017, DOI 10.1093/hmg/ddq316; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022; Stittrich AB, 2010, NAT IMMUNOL, V11, P1057, DOI 10.1038/ni.1945; Strickland LB, 2000, BREAST CANCER RES TR, V64, P235, DOI 10.1023/A:1026562720218; Sun YH, 2010, BIOCHEM BIOPH RES CO, V396, P501, DOI 10.1016/j.bbrc.2010.04.127; Wang D, 2011, J GASTROINTEST SURG, V15, P1205, DOI 10.1007/s11605-011-1546-2; Wang Y, 2007, CANCER INVEST, V25, P79, DOI 10.1080/07357900701205457; Woodings JA, 2003, BIOCHEM J, V371, P463, DOI 10.1042/BJ20021962; Xie F, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-95; Xie Fei, 2011, Front Biosci (Schol Ed), V3, P621, DOI 10.2741/s175; Xu SB, 2007, J BIOL CHEM, V282, P25053, DOI 10.1074/jbc.M700501200; Yamagishi A, 2004, J BIOL CHEM, V279, P14929, DOI 10.1074/jbc.M309408200	47	99	107	2	27	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1287	1296		10.1038/onc.2013.65	http://dx.doi.org/10.1038/onc.2013.65			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23474751				2022-12-17	WOS:000332631100009
J	Hagenbuchner, J; Kuznetsov, AV; Obexer, P; Ausserlechner, MJ				Hagenbuchner, J.; Kuznetsov, A. V.; Obexer, P.; Ausserlechner, M. J.			BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery	ONCOGENE			English	Article						chemotherapy; FOXO3; mitochondrial respiration; reactive oxygen species; Warburg effect	OXIDATIVE STRESS; HUMAN NEUROBLASTOMA; CELL-PROLIFERATION; CYTOCHROME-C; EXPRESSION; APOPTOSIS; SURVIVIN; PROTEIN; CANCER; FISSION	Gain of chromosome 17q correlates with high-stage disease, an adverse clinical outcome and leads to the overexpression of the antiapoptotic protein BIRC5/Survivin in neuroblastoma (NB). We have shown before that Survivin defines a threshold for the sensitivity of NB cells to DNA-damaging chemotherapeutic agents that require FOXO3 activation for apoptosis induction. To investigate the molecular basis of apoptosis inhibition we analyzed the function of Survivin at mitochondria and uncovered that Survivin induces mitochondrial fragmentation, reduces mitochondrial respiration and represses BCL2L11/Bim. Mitochondrial fission depends on Survivin-induced recruitment of the fission regulator DNM1L/Drp1 to mitochondria. In parallel, Survivin expression inhibits the respiratory complex-I, thereby preventing reactive oxygen species accumulation and, as a consequence, FOXO3-induced apoptosis. The loss of energy production via oxidative phosphorylation is compensated by increased glycolysis in Survivin-overexpressing NB tumor cells. Glycolysis inhibitors neutralize the antiapoptotic effect of Survivin and sensitize high-stage NB to DNA-damaging drugs. This suggests that glycolysis inhibitors target an 'archilles heel' of Survivin-overexpressing NB and may be highly useful as chemosensitizers in the treatment of high-stage NB.	[Hagenbuchner, J.; Obexer, P.] Med Univ Innsbruck, Dept Pediat 2, A-6020 Innsbruck, Austria; [Hagenbuchner, J.; Obexer, P.; Ausserlechner, M. J.] Tyrolean Canc Res Inst, Innsbruck, Austria; [Kuznetsov, A. V.] Med Univ Innsbruck, Dept Cardiac Surg, Cardiac Surg Res Lab, A-6020 Innsbruck, Austria; [Ausserlechner, M. J.] Med Univ Innsbruck, Dept Pediat 1, A-6020 Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck	Obexer, P (corresponding author), Med Univ Innsbruck, Dept Pediat 2, Innrain 66, A-6020 Innsbruck, Austria.	Petra.Obexer@i-med.ac.at; Michael.J.Ausserlechner@i-med.ac.at		Hagenbuchner, Judith/0000-0003-1396-3407; Ausserlechner, Michael/0000-0002-1015-2302	COMET Center ONCOTYROL; Austrian Federal Ministries BMVIT/BMWFJ (via FFG); Tiroler Zukunftsstiftung/Standortagentur Tirol (SAT); 'Kinderkrebshilfe Tirol und Vorarlberg'; 'Krebshilfe Sudtirol'; 'SVP-Frauen-Initiative'; 'Kinderkrebshilfe Sudtirol-Regenbogen'; Austrian Science Fund [P22080-B20]; Medical University Innsbruck for young scientists MUI-START [P2012032014]; OeNB Anniversary Fund [P12582]; 'Tiroler Landeskrankenanstalten Ges.m.b.H. (TILAK)'; 'Tyrolean Cancer Society'; Austrian Science Fund (FWF) [P 22080] Funding Source: researchfish	COMET Center ONCOTYROL; Austrian Federal Ministries BMVIT/BMWFJ (via FFG); Tiroler Zukunftsstiftung/Standortagentur Tirol (SAT); 'Kinderkrebshilfe Tirol und Vorarlberg'; 'Krebshilfe Sudtirol'; 'SVP-Frauen-Initiative'; 'Kinderkrebshilfe Sudtirol-Regenbogen'; Austrian Science Fund(Austrian Science Fund (FWF)); Medical University Innsbruck for young scientists MUI-START; OeNB Anniversary Fund; 'Tiroler Landeskrankenanstalten Ges.m.b.H. (TILAK)'; 'Tyrolean Cancer Society'; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We thank Dr Martin Hermann und Dr Albert Amberger (Medical University Innsbruck) for valuable discussion. This work was supported by the COMET Center ONCOTYROL, which is funded by the Austrian Federal Ministries BMVIT/BMWFJ (via FFG) and the Tiroler Zukunftsstiftung/Standortagentur Tirol (SAT) and by grants from 'Kinderkrebshilfe Tirol und Vorarlberg', the 'Krebshilfe Sudtirol', the 'SVP-Frauen-Initiative', the 'Kinderkrebshilfe Sudtirol-Regenbogen', the Austrian Science Fund (P22080-B20), by the intramural funding program of the Medical University Innsbruck for young scientists MUI-START (P2012032014) and by the OeNB Anniversary Fund (P12582). The Tyrolean Cancer Research Institute and this study are supported by the 'Tiroler Landeskrankenanstalten Ges.m.b.H. (TILAK)' and the 'Tyrolean Cancer Society'.	Almeida A, 2010, P NATL ACAD SCI USA, V107, P738, DOI 10.1073/pnas.0913668107; Ausserlechner MJ, 2006, MOL CANCER THER, V5, P1927, DOI 10.1158/1535-7163.MCT-05-0500; Benard G, 2007, J CELL SCI, V120, P838, DOI 10.1242/jcs.03381; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen K, 2003, J BIOL CHEM, V278, P39527, DOI 10.1074/jbc.M304423200; Chen QR, 2010, J PROTEOME RES, V9, P373, DOI 10.1021/pr900701v; Connell CM, 2008, J BIOL CHEM, V283, P3289, DOI 10.1074/jbc.M704461200; Connor KM, 2005, J BIOL CHEM, V280, P16916, DOI 10.1074/jbc.M410690200; De Lena M, 2001, EUR J CANCER, V37, P364, DOI 10.1016/S0959-8049(00)00400-7; Di Cosimo S, 2003, DRUGS TODAY, V39, P157, DOI 10.1358/dot.2003.39.3.799451; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Dohi T, 2007, MOL CELL, V27, P17, DOI 10.1016/j.molcel.2007.06.004; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Geiger K, 2012, MOL BIOL CELL, V23, P2226, DOI 10.1091/mbc.E11-06-0535; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Grignani F, 1998, CANCER RES, V58, P14; Guha M, 2009, CANCER RES, V69, P4954, DOI 10.1158/0008-5472.CAN-09-0584; Hagenbuchner J, 2012, J CELL SCI, V125, P1191, DOI 10.1242/jcs.092098; Hagenbuchner J, 2010, J BIOL CHEM, V285, P6904, DOI 10.1074/jbc.M109.038331; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Herrero-Mendez A, 2009, NAT CELL BIOL, V11, P747, DOI 10.1038/ncb1881; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Kang BH, 2011, J BIOL CHEM, V286, P16758, DOI 10.1074/jbc.M110.210120; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Kuznetsov AV, 2008, NAT PROTOC, V3, P965, DOI 10.1038/nprot.2008.61; Obexer P, 2007, CELL DEATH DIFFER, V14, P534, DOI 10.1038/sj.cdd.4402017; Obexer P, 2009, MOL BIOL CELL, V20, P2041, DOI 10.1091/mbc.E08-07-0699; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Rossignol R, 2004, CANCER RES, V64, P985, DOI 10.1158/0008-5472.CAN-03-1101; Sheridan C, 2008, MOL CELL, V31, P570, DOI 10.1016/j.molcel.2008.08.002; Simonnet H, 2002, CARCINOGENESIS, V23, P759, DOI 10.1093/carcin/23.5.759; Singh DH, 2005, STRAHLENTHER ONKOL, V181, P507, DOI 10.1007/s00066-005-1320-z; Smith DJ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-259; Stern R, 2002, EXP CELL RES, V276, P24, DOI 10.1006/excr.2002.5508; Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009; Vazquez A, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-58; Wu SN, 2011, FEBS J, V278, P941, DOI 10.1111/j.1742-4658.2011.08010.x	40	99	103	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2013	32	40					4748	4757		10.1038/onc.2012.500	http://dx.doi.org/10.1038/onc.2012.500			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23146905				2022-12-17	WOS:000325274700003
J	Tang, Y; Horikawa, I; Ajiro, M; Robles, AI; Fujita, K; Mondal, AM; Stauffer, JK; Zheng, ZM; Harris, CC				Tang, Y.; Horikawa, I.; Ajiro, M.; Robles, A. I.; Fujita, K.; Mondal, A. M.; Stauffer, J. K.; Zheng, Z-M; Harris, C. C.			Downregulation of splicing factor SRSF3 induces p53 beta, an alternatively spliced isoform of p53 that promotes cellular senescence	ONCOGENE			English	Article						SRSF3; p53; isoform; cellular senescence; alternative splicing	PRE-MESSENGER-RNA; SR PROTEIN-PHOSPHORYLATION; ONCOGENE-INDUCED SENESCENCE; FACTOR SRP20; EXPRESSION; GENE; SF2/ASF; BINDING; PLURIPOTENCY; REQUIRES	Most human pre-mRNA transcripts are alternatively spliced, but the significance and fine-tuning of alternative splicing in different biological processes is only starting to be understood. SRSF3 (SRp20) is a member of a highly conserved family of splicing factors that have critical roles in key biological processes, including tumor progression. Here, we show that SRSF3 regulates cellular senescence, a p53-mediated process to suppress tumorigenesis, through TP53 alternative splicing. Downregulation of SRSF3 was observed in normal human fibroblasts undergoing replicative senescence, and was associated with the upregulation of p53 beta, an alternatively spliced isoform of p53 that promotes p53-mediated senescence. Knockdown of SRSF3 by short interfering RNA ( siRNA) in early-passage fibroblasts induced senescence, which was associated with elevated expression of p53 beta at mRNA and protein levels. Knockdown of p53 partially rescued SRSF3-knockdown-induced senescence, suggesting that SRSF3 acts on p53-mediated cellular senescence. RNA pulldown assays demonstrated that SRSF3 binds to an alternatively spliced exon uniquely included in p53b mRNA through the consensus SRSF3-binding sequences. RNA crosslinking and immunoprecipitation assays ( CLIP) also showed that SRSF3 in vivo binds to endogenous p53 pre-mRNA at the region containing the p53 beta-unique exon. Splicing assays using a transfected TP53 minigene in combination with siRNA knockdown of SRSF3 showed that SRSF3 functions to inhibit the inclusion of the p53 beta-unique exon in splicing of p53 pre-mRNA. These data suggest that downregulation of SRSF3 represents an endogenous mechanism for cellular senescence that directly regulates the TP53 alternative splicing to generate p53 beta. This study uncovers the role for general splicing machinery in tumorigenesis, and suggests that SRSF3 is a direct regulator of p53.	[Tang, Y.; Horikawa, I.; Robles, A. I.; Fujita, K.; Mondal, A. M.; Harris, C. C.] NCI, Human Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Ajiro, M.; Zheng, Z-M] NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Stauffer, J. K.] NCI, Canc & Inflammat Program, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, Ctr Canc Res, NIH, Bldg 37,Room 3068,37 Convent Dr, Bethesda, MD 20892 USA.	Curtis_Harris@nih.gov	Tang, Yizhe/A-8682-2014	Tang, Yizhe/0000-0001-5354-478X; Zheng, Zhi-Ming/0000-0001-5547-7912; Robles, Ana/0000-0001-5019-4374	Intramural Research Program of the NIH; NCI; NATIONAL CANCER INSTITUTE [ZIABC011496, ZIASC010357, ZIABC005795] Funding Source: NIH RePORTER	Intramural Research Program of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the Intramural Research Program of the NIH, NCI. We thank the NIH Fellows Editorial Board for improving the readability of the manuscript.	Anko ML, 2010, NAT STRUCT MOL BIOL, V17, P962, DOI 10.1038/nsmb.1862; Akgul C, 2004, CELL MOL LIFE SCI, V61, P2189, DOI 10.1007/s00018-004-4001-7; Aubol BE, 2011, BIOCHEMISTRY-US, V50, P6888, DOI 10.1021/bi2007993; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Celotto AM, 2001, GENETICS, V159, P599; Chen WY, 2001, GENE CHROMOSOME CANC, V32, P281, DOI 10.1002/gcc.1191; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Ebrahimi M, 2008, ORAL ONCOL, V44, P156, DOI 10.1016/j.oraloncology.2007.01.014; Ezponda T, 2010, CLIN CANCER RES, V16, P4113, DOI 10.1158/1078-0432.CCR-10-0076; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Fujita K, 2010, NAT CELL BIOL, V12, P1205, DOI 10.1038/ncb2123; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Gabut M, 2011, CELL, V147, P132, DOI 10.1016/j.cell.2011.08.023; Garcia-Alai MM, 2008, PROTEIN SCI, V17, P1671, DOI 10.1110/ps.036996.108; Goldschneider D, 2006, NUCLEIC ACIDS RES, V34, P5603, DOI 10.1093/nar/gkl619; Grosso AR, 2008, EMBO REP, V9, P1087, DOI 10.1038/embor.2008.189; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; He X, 2011, ONCOGENE, V30, P356, DOI 10.1038/onc.2010.426; He XL, 2004, CLIN CANCER RES, V10, P4652, DOI 10.1158/1078-0432.CCR-03-0439; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Jia R, 2010, INT J BIOL SCI, V6, P806; Jia R, 2009, J VIROL, V83, P167, DOI 10.1128/JVI.01719-08; Jiang K, 2009, ENDOCRINOLOGY, V150, P2087, DOI 10.1210/en.2008-0818; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Jumaa H, 1997, MOL CELL BIOL, V17, P3116, DOI 10.1128/MCB.17.6.3116; Jumaa H, 1997, EMBO J, V16, P5077, DOI 10.1093/emboj/16.16.5077; Kang JG, 2011, J VIROL, V85, P2620, DOI 10.1128/JVI.02144-10; Kanj SS, 2006, VIROLOGY, V345, P280, DOI 10.1016/j.virol.2005.09.060; Kannan K, 2011, P NATL ACAD SCI USA, V108, P9172, DOI 10.1073/pnas.1100489108; Karni R, 2008, P NATL ACAD SCI USA, V105, P15323, DOI 10.1073/pnas.0801376105; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Khoury Marie P, 2011, Genes Cancer, V2, P453, DOI 10.1177/1947601911408893; Klinck R, 2008, CANCER RES, V68, P657, DOI 10.1158/0008-5472.CAN-07-2580; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lanigan F, 2011, ONCOGENE, V30, P2901, DOI 10.1038/onc.2011.34; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Luco RF, 2010, SCIENCE, V327, P996, DOI 10.1126/science.1184208; Majerciak V, 2006, J BIOL CHEM, V281, P28365, DOI 10.1074/jbc.M603095200; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Olshavsky NA, 2010, CANCER RES, V70, P3975, DOI 10.1158/0008-5472.CAN-09-3468; Prieur A, 2008, CURR OPIN CELL BIOL, V20, P150, DOI 10.1016/j.ceb.2008.01.007; Rajan P, 2008, BIOCHEM SOC T, V36, P505, DOI 10.1042/BST0360505; Rohaly G, 2005, CELL, V122, P21, DOI 10.1016/j.cell.2005.04.032; Salomonis N, 2010, P NATL ACAD SCI USA, V107, P10514, DOI 10.1073/pnas.0912260107; Sanford JR, 1999, GENE DEV, V13, P1513, DOI 10.1101/gad.13.12.1513; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Sciabica KS, 2003, EMBO J, V22, P1608, DOI 10.1093/emboj/cdg166; Sen S, 2009, MOL CELL BIOL, V29, P871, DOI 10.1128/MCB.01709-08; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shaw SD, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000854; Shen HH, 2006, GENE DEV, V20, P1755, DOI 10.1101/gad.1422106; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; Thorsen K, 2008, MOL CELL PROTEOMICS, V7, P1214, DOI 10.1074/mcp.M700590-MCP200; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; WynfordThomas D, 1996, J PATHOL, V180, P118, DOI 10.1002/(SICI)1096-9896(199610)180:2<118::AID-PATH673>3.0.CO;2-I; Xi LQ, 2008, NUCLEIC ACIDS RES, V36, P6535, DOI 10.1093/nar/gkn697; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; Zheng ZM, 2004, J BIOMED SCI, V11, P278, DOI 10.1159/000077096; Zhong XY, 2009, GENE DEV, V23, P482, DOI 10.1101/gad.1752109; Zhu J, 2000, GENE DEV, V14, P3166, DOI 10.1101/gad.189500	75	99	101	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2792	2798		10.1038/onc.2012.288	http://dx.doi.org/10.1038/onc.2012.288			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22777358	Green Accepted			2022-12-17	WOS:000319808000010
J	Mueller, AC; Sun, D; Dutta, A				Mueller, A. C.; Sun, D.; Dutta, A.			The miR-99 family regulates the DNA damage response through its target SNF2H	ONCOGENE			English	Article						microRNA; DNA repair; cancer; SNF2H; miR-99	STRAND BREAK REPAIR; GENE-EXPRESSION; DOWN-REGULATION; MICRORNA; IDENTIFICATION; INO80; PHOSPHORYLATION; GAMMA-H2AX; COMPLEX; GLIOMA	Chromatin remodeling factors are becoming known as crucial facilitators of recruitment of repair proteins to sites of DNA damage. Multiple chromatin remodeling protein complexes are now known to be required for efficient double strand break repair. In a screen for microRNAs (miRNAs) that modulate the DNA damage response, we discovered that expression of the miR-99 family of miRNAs correlates with radiation sensitivity. These miRNAs were also transiently induced following radiation. The nniRNAs target the SWI/SNF chromatin remodeling factor SNF2H/SMARCA5, a component of the ACF1 complex. We found that by reducing levels of SNF2H, miR-99a and miR-100 reduced BRCA1 localization to sites of DNA damage. Introduction of the miR-99 family of miRNAs into cells reduced the rate and overall efficiency of repair by both homologous recombination and non-homologous end joining. Finally, induction of the miR-99 family following radiation prevents an increase in SNF2H expression and reduces the recruitment of BRCA1 to the sites of DNA damage following a second dose of radiation, reducing the efficiency of repair after multiple rounds of radiation, as used in fractionated radiotherapy. Oncogene (2013) 32, 1164-1172; doi:10.1038/onc.2012.131; published online 23 April 2012	[Mueller, A. C.; Sun, D.; Dutta, A.] Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Dutta, A (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	ad8q@virginia.edu	Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073; Mueller, Adam/0000-0003-2678-0159	DOD BCRP predoctoral traineeship [BC073568]; DOD PCRP predoctoral traineeship [PC094499];  [P01CA104106]; NATIONAL CANCER INSTITUTE [R01CA134697, P01CA104106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER	DOD BCRP predoctoral traineeship; DOD PCRP predoctoral traineeship; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	AM was supported by DOD BCRP predoctoral traineeship BC073568. DS was supported by DOD PCRP predoctoral traineeship PC094499. This work was supported by P01CA104106 to AD. We thank members of the Dutta Laboratory for their help and discussion.	Bruno IG, 2011, MOL CELL, V42, P500, DOI 10.1016/j.molcel.2011.04.018; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Dey BK, 2011, MOL CELL BIOL, V31, P203, DOI 10.1128/MCB.01009-10; Doghman M, 2010, CANCER RES, V70, P4666, DOI 10.1158/0008-5472.CAN-09-3970; Doil C, 2009, CELL, V136, P435, DOI 10.1016/j.cell.2008.12.041; Gagan J, 2011, J BIOL CHEM, V286, P19431, DOI 10.1074/jbc.M111.219006; Golding SE, 2009, MOL CANCER THER, V8, P2894, DOI 10.1158/1535-7163.MCT-09-0519; Golding SE, 2009, CANCER BIOL THER, V8, P730, DOI 10.4161/cbt.8.8.7927; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2; Hu HL, 2011, J MOL CELL BIOL, V3, P151, DOI 10.1093/jmcb/mjq042; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409; Jha S, 2008, MOL CELL BIOL, V28, P2690, DOI 10.1128/MCB.01983-07; Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034; Lal A, 2009, NAT STRUCT MOL BIOL, V16, P492, DOI 10.1038/nsmb.1589; Lan L, 2010, MOL CELL, V40, P976, DOI 10.1016/j.molcel.2010.12.003; Larsen DH, 2010, J CELL BIOL, V190, P731, DOI 10.1083/jcb.200912135; Lee HS, 2010, EMBO J, V29, P1434, DOI 10.1038/emboj.2010.27; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222; Mailand N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040; Marcu LG, 2010, CANCER TREAT REV, V36, P606, DOI 10.1016/j.ctrv.2010.04.004; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Mladenov E, 2011, MUTAT RES-FUND MOL M, V711, P61, DOI 10.1016/j.mrfmmm.2011.02.005; Morrison AJ, 2004, CELL, V119, P767, DOI 10.1016/j.cell.2004.11.037; Moskwa P, 2011, MOL CELL, V41, P210, DOI 10.1016/j.molcel.2010.12.005; Nakamura K, 2011, MOL CELL, V41, P515, DOI 10.1016/j.molcel.2011.02.002; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Ransburgh DJR, 2010, CANCER RES, V70, P988, DOI 10.1158/0008-5472.CAN-09-2850; Roberts SA, 2007, J BIOL CHEM, V282, P10605, DOI 10.1074/jbc.M611125200; Sirotkin AV, 2010, J CELL PHYSIOL, V223, P49, DOI 10.1002/jcp.21999; Skvortsova I, 2008, PROTEOMICS, V8, P4521, DOI 10.1002/pmic.200800113; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Sun DD, 2011, CANCER RES, V71, P1313, DOI 10.1158/0008-5472.CAN-10-1031; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; van Attikum H, 2004, CELL, V119, P777, DOI 10.1016/j.cell.2004.11.033; van Attikum H, 2005, NAT REV MOL CELL BIO, V6, P757, DOI 10.1038/nrm1737; van Attikum H, 2007, EMBO J, V26, P4113, DOI 10.1038/sj.emboj.7601835; van Attikum H, 2009, TRENDS CELL BIOL, V19, P207, DOI 10.1016/j.tcb.2009.03.001; Wang P, 2009, CANCER RES, V69, P8157, DOI 10.1158/0008-5472.CAN-09-1996	47	99	106	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1164	1172		10.1038/onc.2012.131	http://dx.doi.org/10.1038/onc.2012.131			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22525276	Green Accepted			2022-12-17	WOS:000316428800010
J	Thomas, M; Lange-Grunweller, K; Weirauch, U; Gutsch, D; Aigner, A; Grunweller, A; Hartmann, RK				Thomas, M.; Lange-Gruenweller, K.; Weirauch, U.; Gutsch, D.; Aigner, A.; Gruenweller, A.; Hartmann, R. K.			The proto-oncogene Pim-1 is a target of miR-33a	ONCOGENE			English	Article						Pim-1; microRNA; miR-33a; proliferation; RNAi; siRNA	PROSTATE-CANCER CELLS; C-MYC; PROTEIN-KINASE; MICRORNAS; PHOSPHORYLATION; GENES; RNA; AKT; APOPTOSIS; GROWTH	The constitutively active serine/threonine kinase Pim-1 is upregulated in different cancer types, mainly based on the action of several interleukines and growth factors at the transcriptional level. So far, a regulation of oncogenic Pim-1 by microRNAs (miRNAs) has not been reported. Here, we newly establish miR-33a as a miRNA with potential tumor suppressor activity, acting through inhibition of Pim-1. A screen for miRNA expression in K562 lymphoma, LS174T colon carcinoma and several other cell lines revealed generally low endogenous miR33a levels relative to other miRNAs. Transfection of K562 and LS174T cells with a miR-33a mimic reduced Pim-1 levels substantially. In contrast, the cell-cycle regulator cyclin-dependent kinase 6 predicted to be a conserved miR-33a target, was not downregulated by the miR-33a mimic. Seed mutagenesis of the Pim-1 30-untranslated region in a luciferase reporter construct and in a Pim-1 cDNA expressed in Pim-1-deficient Skov-3 cells demonstrated specific and direct downregulation of Pim-1 by the miR-33a mimic. The persistence of this effect was comparable to that of a small interfering RNA-mediated knockdown of Pim-1, resulting in decelerated cell proliferation. In conclusion, we demonstrate the potential of miR-33a to act as a tumor suppressor miRNA, which suggests miR-33a replacement therapy through delivery of miR mimics as a novel therapeutic strategy. Oncogene (2012) 31, 918-928; doi: 10.1038/onc.2011.278; published online 11 July 2011	[Gruenweller, A.] Univ Marburg, Inst Pharmaceut Chem, Fac Pharm, AG Hartmann, D-35037 Marburg, Germany; [Weirauch, U.; Gutsch, D.; Aigner, A.] Univ Marburg, Inst Pharmacol, Fac Med, D-35037 Marburg, Germany	Philipps University Marburg; Philipps University Marburg	Grunweller, A (corresponding author), Univ Marburg, Inst Pharmaceut Chem, Fac Pharm, AG Hartmann, Marbacher Weg 6, D-35037 Marburg, Germany.	arnold.gruenweller@staff.uni-marburg.de; roland.hartmann@staff.uni-marburg.de	Aigner, Achim/R-4429-2017	Aigner, Achim/0000-0002-2778-6256	Fritz Thyssen Stiftung [10.06.1.186]; Deutsche Krebshilfe [109260, 106992]; DFG Forschergruppe Nanohale [AI 24/6-1]	Fritz Thyssen Stiftung; Deutsche Krebshilfe(Deutsche Krebshilfe); DFG Forschergruppe Nanohale(German Research Foundation (DFG))	We thank Robert Prinz, Dorothee Hartmann, Dennis Streng, Meike Thomas and Heide Marika Genau for technical support. This study was supported by the Fritz Thyssen Stiftung (reference no. 10.06.1.186 to AG and RKH), the Deutsche Krebshilfe (reference no. 109260 to AG, RKH and AA, and reference no. 106992 to AA) and DFG Forschergruppe Nanohale (AI 24/6-1).	Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Aqeilan RI, 2010, CELL DEATH DIFFER, V17, P215, DOI 10.1038/cdd.2009.69; Bachmann M, 2005, INT J BIOCHEM CELL B, V37, P726, DOI 10.1016/j.biocel.2004.11.005; Bachmann M, 2004, J BIOL CHEM, V279, P48319, DOI 10.1074/jbc.M404440200; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Brault L, 2010, HAEMATOL-HEMATOL J, V95, P1004, DOI 10.3324/haematol.2009.017079; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chen WW, 2005, MOL CANCER RES, V3, P443, DOI 10.1158/1541-7786.MCR-05-0007; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Crowell JA, 2007, MOL CANCER THER, V6, P2139, DOI 10.1158/1535-7163.MCT-07-0120; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Grunweller A, 2003, NUCLEIC ACIDS RES, V31, P3185, DOI 10.1093/nar/gkg409; Herrera-Merchan A, 2010, CELL CYCLE, V9, P3277, DOI 10.4161/cc.9.16.12598; Huang JX, 2009, BIOCHEM SOC T, V37, P217, DOI 10.1042/BST0370217; Ibrahim AF, 2011, CANCER RES, V71, P5214, DOI 10.1158/0008-5472.CAN-10-4645; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liu JD, 2005, NAT CELL BIOL, V7, P719, DOI 10.1038/ncb1274; Martelli AM, 2007, CURR MED CHEM, V14, P2009; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Muraski JA, 2007, NAT MED, V13, P1467, DOI 10.1038/nm1671; Najafi-Shoushtari SH, 2010, SCIENCE, V328, P1566, DOI 10.1126/science.1189123; Nawijn MC, 2011, NAT REV CANCER, V11, P23, DOI 10.1038/nrc2986; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Qian KC, 2005, J BIOL CHEM, V280, P6130, DOI 10.1074/jbc.M409123200; Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862; Rehwinkel J, 2005, RNA, V11, P1640, DOI 10.1261/rna.2191905; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Venturini L, 2007, BLOOD, V109, P4399, DOI 10.1182/blood-2006-09-045104; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Wang HW, 2009, NAT STRUCT MOL BIOL, V16, P1148, DOI 10.1038/nsmb.1673; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Xia ZP, 2009, J MED CHEM, V52, P74, DOI 10.1021/jm800937p; Xie Y, 2006, ONCOGENE, V25, P70, DOI 10.1038/sj.onc.1209058; Yang ZZ, 2004, BIOCHEM SOC T, V32, P350, DOI 10.1042/BST0320350; Zhang T, 2010, J SURG ONCOL, V101, P513, DOI 10.1002/jso.21524; ZHANG W, 1993, CANCER RES, V53, P4772; Zhang Y, 2008, ONCOGENE, V27, P4809, DOI 10.1038/onc.2008.123; Zhang YD, 2007, MOL CANCER RES, V5, P909, DOI 10.1158/1541-7786.MCR-06-0388; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618	58	99	102	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	7					918	928		10.1038/onc.2011.278	http://dx.doi.org/10.1038/onc.2011.278			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21743487				2022-12-17	WOS:000300615800010
J	Chandarlapaty, S; Scaltriti, M; Angelini, P; Ye, Q; Guzman, M; Hudis, CA; Norton, L; Solit, DB; Arribas, J; Baselga, J; Rosen, N				Chandarlapaty, S.; Scaltriti, M.; Angelini, P.; Ye, Q.; Guzman, M.; Hudis, C. A.; Norton, L.; Solit, D. B.; Arribas, J.; Baselga, J.; Rosen, N.			Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth	ONCOGENE			English	Article						p95-HER2; Trastuzumab; breast cancer; HER2	BREAST-CANCER CELLS; MAMMARY EPITHELIUM; ANTITUMOR-ACTIVITY; FACTOR RECEPTOR; KINASE DOMAIN; NEU ONCOGENE; CYCLIN D1; HER2; EXPRESSION; MICE	The anti-HER2 antibody Trastuzumab (Herceptin) has been proven to be effective in the treatment of HER2-overexpressing breast cancer; resistance, however, invariably emerges in metastatic tumors. The expression of p95-HER2, a form of HER2 with a truncated extracellular domain that lacks the Trastuzumab binding epitope, has been implicated as a mechanism of resistance to the antibody. We utilized an in vivo tumor model that overexpresses p95-HER2 and showed it to be resistant to the signaling and antitumor effects of Trastuzumab. We find that both full-length and p95-HER2 interact with the HSP90 chaperone protein and are degraded in tumor cells exposed to HSP90 inhibitors in tissue culture and in vivo. Loss of expression of p95-HER2 is accompanied by downregulation of the phosphoinositide-3 kinase/AKT and extracellular signal-regulated kinase signaling pathways and inhibition of cell proliferation. Chronic administration of HSP90 inhibitors in vivo results in sustained loss of HER2 and p95-HER2 expression and inhibition of AKT activation, together with induction of apoptosis and complete inhibition of tumor growth in Trastuzumab-resistant, p95-HER2-overexpressing models. Thus, p95-HER2 is an HSP90 client protein, the expression and function of which can be effectively suppressed in vivo by HSP90 inhibitors. HSP90 inhibition is therefore a potentially effective therapeutic strategy for p95-HER2-mediated Trastuzumab-resistant breast cancer. Oncogene (2010) 29, 325-334; doi:10.1038/onc.2009.337; published online 26 October 2009	[Chandarlapaty, S.; Hudis, C. A.; Norton, L.; Solit, D. B.; Rosen, N.] Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol, Dept Med, New York, NY 10065 USA; [Scaltriti, M.; Guzman, M.; Baselga, J.] Vall dHebron Univ Hosp, Med Oncol Serv, Barcelona, Spain; [Angelini, P.; Arribas, J.] Vall dHebron Univ Hosp, Med Oncol Res Program, Barcelona, Spain; [Angelini, P.; Arribas, J.] Autonomous Univ Barcelona, Dept Biochem & Mol Biol, Bellaterra, Spain; [Solit, D. B.; Rosen, N.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Arribas, J.] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain	Memorial Sloan Kettering Cancer Center; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Memorial Sloan Kettering Cancer Center; ICREA	Rosen, N (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol, Dept Med, 1275 York Ave,Room Z-1760, New York, NY 10065 USA.	rosenn@mskcc.org	Rosen, Neal/ABF-2677-2020; Arribas, Joaquin/M-4482-2014; Solit, David B./AAC-5309-2019; Hudis, Clifford/AAW-9482-2021	Arribas, Joaquin/0000-0002-0504-0664; Hudis, Clifford/0000-0001-7144-8791; Norton, Larry/0000-0003-3701-9250	National Institute of Health Program [P01-CA094060]; Breast Cancer Research Foundation; Arlene Taub; ASCO Foundation Young Investigator Award; NATIONAL CANCER INSTITUTE [P01CA094060] Funding Source: NIH RePORTER; ICREA Funding Source: Custom	National Institute of Health Program; Breast Cancer Research Foundation; Arlene Taub; ASCO Foundation Young Investigator Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ICREA(ICREA)	We thank Gail Lewis Phillips and Mark Sliwkowski for providing the Fo5 tumors for this study. We also thank Elisa DeStanchina and Wai Wong for their assistance with animal studies. This work is supported by the National Institute of Health Program Grant P01-CA094060, the Breast Cancer Research Foundation and the generous support of Arlene Taub. S Chandarlapaty is supported by an ASCO Foundation Young Investigator Award.	Anido J, 2006, EMBO J, V25, P3234, DOI 10.1038/sj.emboj.7601191; Baselga J, 1998, CANCER RES, V58, P2825; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Benezra R, 2005, COLD SH Q B, V70, P375, DOI 10.1101/sqb.2005.70.006; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Chandarlapaty S, 2008, CLIN CANCER RES, V14, P240, DOI 10.1158/1078-0432.CCR-07-1667; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cuello M, 2001, CANCER RES, V61, P4892; Finkle D, 2004, CLIN CANCER RES, V10, P2499, DOI 10.1158/1078-0432.CCR-03-0448; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hermanto U, 2001, ONCOGENE, V20, P7551, DOI 10.1038/sj.onc.1204964; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; MODI S, 2008, ASCO 2008 ANN CHIC I; Modi S, 2007, J CLIN ONCOL, V25, P5410, DOI 10.1200/JCO.2007.11.7960; Molina MA, 2002, CLIN CANCER RES, V8, P347; Molina MA, 2001, CANCER RES, V61, P4744; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Munster PN, 2002, CANCER RES, V62, P3132; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Pedersen K, 2009, MOL CELL BIOL, V29, P3319, DOI 10.1128/MCB.01803-08; Pegram MD, 2000, SEMIN ONCOL, V27, P21; Phillips GDL, 2008, CANCER RES, V68, P9280, DOI 10.1158/0008-5472.CAN-08-1776; RICE J, 2008, AACR ANN M SAN DIEG; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Saez R, 2006, CLIN CANCER RES, V12, P424, DOI 10.1158/1078-0432.CCR-05-1807; Sawai A, 2008, CANCER RES, V68, P589, DOI 10.1158/0008-5472.CAN-07-1570; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Shattuck DL, 2008, CANCER RES, V68, P1471, DOI 10.1158/0008-5472.CAN-07-5962; She QB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003065; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tikhomirov O, 2003, CANCER RES, V63, P39; Workman P, 2007, ANN NY ACAD SCI, V1113, P202, DOI 10.1196/annals.1391.012; Xia WL, 2004, ONCOGENE, V23, P646, DOI 10.1038/sj.onc.1207166; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yakes FM, 2002, CANCER RES, V62, P4132; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	42	99	99	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					325	334		10.1038/onc.2009.337	http://dx.doi.org/10.1038/onc.2009.337			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19855434	Green Accepted			2022-12-17	WOS:000273793200002
J	Ren, L; Hong, SH; Cassavaugh, J; Osborne, T; Chou, AJ; Kim, SY; Gorlick, R; Hewitt, SM; Khanna, C				Ren, L.; Hong, S. H.; Cassavaugh, J.; Osborne, T.; Chou, A. J.; Kim, S. Y.; Gorlick, R.; Hewitt, S. M.; Khanna, C.			The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC	ONCOGENE			English	Article						ezrin; ERM; PKC; tumor metastasis	EZRIN/RADIXIN/MOESIN ERM PROTEINS; KINASE-C; PLASMA-MEMBRANE; EPITHELIAL-CELLS; CARCINOMA-CELLS; T-LYMPHOCYTES; CRUCIAL ROLE; PHOSPHORYLATION; EXPRESSION; MOESIN	Ezrin is a member of the ERM (ezrin, radixin, moesin) protein family and links F-actin to the cell membrane following phosphorylation. Ezrin has been associated with tumor progression and metastasis in several cancers including the pediatric solid tumors, osteosarcoma and rhabdomyosarcoma. In this study, we were surprised to find that ezrin was not constitutively phosphorylated but rather was dynamically regulated during metastatic progression in osteosarcoma. Metastatic osteosarcoma cells expressed phosphorylated ERM early after their arrival in the lung, and then late in progression, only at the invasive front of larger metastatic lesions. To pursue mechanisms for this regulation, we found that inhibitors of PKC (protein kinase C) blocked phosphorylation of ezrin, and that ezrin coimmunoprecipitated in cells with PKC alpha, PKC iota and PKC gamma. Furthermore, phosphorylated forms of ezrin and PKC had identical expression patterns at the invasive front of pulmonary metastatic lesions in murine and human patient samples. Finally, we showed that the promigratory effects of PKC were linked to ezrin phosphorylation. These data are the first to suggest a dynamic regulation of ezrin phosphorylation during metastasis and to connect the PKC family members with this regulation.	[Khanna, C.] NCI, Tumor & Metastasis Biol Sect, Pediat Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Chou, A. J.] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; [Gorlick, R.] Childrens Hosp Montefiore, Albert Einstein Coll Med, Dept Pediat, Bronx, NY USA; [Hewitt, S. M.] NCI, Tissue Array Res Program, Pathol Lab, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center; Yeshiva University; Albert Einstein College of Medicine; Childrens Hospital at Montefiore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Khanna, C (corresponding author), NCI, Tumor & Metastasis Biol Sect, Pediat Oncol Branch, Ctr Canc Res, 37 Convent Dr,Rm 2144, Bethesda, MD 20892 USA.	khannac@mail.nih.gov		Hewitt, Stephen/0000-0001-8283-1788; GORLICK, RICHARD/0000-0001-8995-2929; Chou, Alexander/0000-0002-7926-3326	Intramural NIH HHS [Z01 BC010566] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIGBC010931, Z01BC010931, Z01BC010566, ZIABC011024, Z01BC011024, ZIABC010566] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRYMAN M, 1993, J CELL SCI, V105, P1025; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Bretscher A, 1997, J CELL SCI, V110, P3011; Brown MJ, 2003, BLOOD, V102, P3890, DOI 10.1182/blood-2002-12-3807; Bruce B, 2007, CLIN EXP METASTAS, V24, P69, DOI 10.1007/s10585-006-9050-x; Cant SH, 2005, MOL BIOL CELL, V16, P3088, DOI 10.1091/mbc.E04-10-0877; Chuan YC, 2006, J BIOL CHEM, V281, P29938, DOI 10.1074/jbc.M602237200; Dard N, 2004, DEV BIOL, V271, P87, DOI 10.1016/j.ydbio.2004.03.024; Elliott BE, 2005, BREAST CANCER RES, V7, pR365, DOI 10.1186/bcr1006; Fievet BT, 2004, J CELL BIOL, V164, P653, DOI 10.1083/jcb.200307032; Forte E, 2008, BBA-MOL CELL RES, V1783, P334, DOI 10.1016/j.bbamcr.2007.11.004; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; HERBERT JM, 1993, BIOCHEM PHARMACOL, V45, P527, DOI 10.1016/0006-2952(93)90123-E; Hishiya A, 1999, J BIOL CHEM, V274, P26705, DOI 10.1074/jbc.274.38.26705; Ilmonen S, 2005, MODERN PATHOL, V18, P503, DOI 10.1038/modpathol.3800300; Khanna C, 2000, CLIN EXP METASTAS, V18, P261, DOI 10.1023/A:1006767007547; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Khanna C, 2001, CANCER RES, V61, P3750; Kivela T, 2000, CELL TISSUE RES, V301, P217, DOI 10.1007/s004410000225; Kobel M, 2006, INT J GYNECOL PATHOL, V25, P121, DOI 10.1097/01.pgp.0000185410.39050.ac; Koivunen J, 2004, CANCER RES, V64, P5693, DOI 10.1158/0008-5472.CAN-03-3511; KRIEG J, 1992, J BIOL CHEM, V267, P19258; Krishnan K, 2006, CLIN EXP METASTAS, V23, P227, DOI 10.1007/s10585-006-9033-y; Makitie T, 2001, INVEST OPHTH VIS SCI, V42, P2442; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Musashi M, 2000, INT J HEMATOL, V72, P12; Nakamura N, 2000, GENES CELLS, V5, P571, DOI 10.1046/j.1365-2443.2000.00348.x; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Ohtani K, 1999, CANCER LETT, V147, P31, DOI 10.1016/S0304-3835(99)00272-4; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; Pang ST, 2004, UROLOGY, V63, P609, DOI 10.1016/j.urology.2003.09.068; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Polesello C, 2004, TRENDS CELL BIOL, V14, P294, DOI 10.1016/j.tcb.2004.04.003; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Saotome I, 2004, DEV CELL, V6, P855, DOI 10.1016/j.devcel.2004.05.007; Serrador JM, 1999, TRENDS CELL BIOL, V9, P228, DOI 10.1016/S0962-8924(99)01553-6; Simons PC, 1998, BIOCHEM BIOPH RES CO, V253, P561, DOI 10.1006/bbrc.1998.9823; Srivastava J, 2005, MOL BIOL CELL, V16, P1481, DOI 10.1091/mbc.e04-08-0721; Sullivan RM, 2000, MOL PHARMACOL, V58, P729, DOI 10.1124/mol.58.4.729; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Wald FA, 2008, J CELL SCI, V121, P644, DOI 10.1242/jcs.016246; Weng WH, 2005, CLIN CANCER RES, V11, P6198, DOI 10.1158/1078-0432.CCR-05-0548; Wu KL, 2004, J BIOL CHEM, V279, P26280, DOI 10.1074/jbc.M400814200; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zh LX, 2007, AM J PHYSIOL-CELL PH, V293, pC874, DOI 10.1152/ajpcell.00111.2007	51	99	111	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					792	802		10.1038/onc.2008.437	http://dx.doi.org/10.1038/onc.2008.437			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19060919	Green Accepted			2022-12-17	WOS:000263320000002
J	Veuger, SJ; Hunter, JE; Durkacz, BW				Veuger, S. J.; Hunter, J. E.; Durkacz, B. W.			Ionizing radiation-induced NF-kappa B activation requires PARP-1 function to confer radioresistance	ONCOGENE			English	Article						NF-kappa B; PARP-1; ionizing radiation	ADP-RIBOSE POLYMERASE-1; APOPTOSIS PROTEIN XIAP; BREAST-CANCER CELLS; X-LINKED INHIBITOR; POLY(ADP-RIBOSE) POLYMERASE-1; TRANSCRIPTION FACTORS; THERAPEUTIC TARGET; BINDING-ACTIVITY; GENE-EXPRESSION; TUMOR-CELLS	Recent reports implicate poly(ADP-ribose) polymerase-1 (PARP-1) in the activation of nuclear factor kappaB (NF-kappa B). We investigated the role of PARP-1 in the NF-kappa B signalling cascade induced by ionizing radiation (IR). AG14361, a potent PARP-1 inhibitor, was used in two breast cancer cell lines expressing different levels of constitutively activated NF-kappa B, as well as mouse embryonic fibroblasts (MEFs) proficient or deficient for PARP-1 or NF-kappa B p65. In the breast cancer cell lines, AG14361 had no effect on IR-induced degradation of I kappa B alpha or nuclear translocation of p50 or p65. However, AG14361 inhibited IR-induced NF-kappa B-dependent transcription of a luciferase reporter gene. Similarly, in PARP-1(-/-) MEFs, IR-induced nuclear translocation of p50 and p65 was normal, but kappa B binding and transcriptional activation did not occur. AG14361 sensitized both breast cancer cell lines to IR-induced cell killing, inhibited IR-induced XIAP expression and increased caspase-3 activity. However, AG14361 failed to increase IR-induced caspase activity when p65 was knocked down by siRNA. Consistent with this, AG14361 sensitized p65(+/+) but not p65(-/-) MEFs to IR. We conclude that PARP-1 activity is essential in the upstream regulation of IR-induced NF-kappa B activation. These data indicate that potentiation of IR-induced cytotoxicity by AG14361 is mediated solely by inhibition of NF-kappa B activation.	[Veuger, S. J.; Hunter, J. E.; Durkacz, B. W.] Univ Newcastle, No Inst Canc Res, Sch Med, Newcastle Upon Tyne, Tyne & Wear, England	Newcastle University - UK	Durkacz, BW (corresponding author), Newcastle Univ, No Inst Canc Res, Sch Med, Paul OGorman Bldg, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	b.w.durkacz@newcastle.ac.uk			Breast Cancer Campaign, UK; Cancer Research UK	Breast Cancer Campaign, UK; Cancer Research UK(Cancer Research UK)	This work was supported by the Breast Cancer Campaign, UK and Cancer Research UK.	ALTHAUS FR, 1994, MOL CELL BIOCHEM, V138, P53, DOI 10.1007/BF00928443; Andela VB, 2000, CANCER RES, V60, P6557; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Biswas DK, 2001, P NATL ACAD SCI USA, V98, P10386, DOI 10.1073/pnas.151257998; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; Calabrese CR, 2004, J NATL CANCER I, V96, P56, DOI 10.1093/jnci/djh005; Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934; Cardoso SM, 2003, FREE RADICAL RES, V37, P967, DOI 10.1080/10715760310001595757; Carrillo A, 2004, NUCLEIC ACIDS RES, V32, P757, DOI 10.1093/nar/gkh239; Chalmers A, 2004, INT J RADIAT ONCOL, V58, P410, DOI 10.1016/j.ijrobp.2003.09.053; Chang WJ, 2001, J BIOL CHEM, V276, P47664, DOI 10.1074/jbc.M104666200; Chiarugi A, 2003, J NEUROCHEM, V85, P306, DOI 10.1046/j.1471-4159.2003.01684.x; Concin N, 2003, BREAST CANCER RES TR, V79, P37, DOI 10.1023/A:1023351717408; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Ferreira CG, 2001, ANN ONCOL, V12, P799, DOI 10.1023/A:1011167113067; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GRUBE K, 1991, ANAL BIOCHEM, V193, P236, DOI 10.1016/0003-2697(91)90015-L; Hassa PO, 2005, J BIOL CHEM, V280, P40450, DOI 10.1074/jbc.M507553200; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; Jung M, 2001, SEMIN RADIAT ONCOL, V11, P346, DOI 10.1053/srao.2001.26034; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Martin-Oliva D, 2006, CANCER RES, V66, P5744, DOI 10.1158/0008-5472.CAN-05-3050; Nakajima H, 2004, J BIOL CHEM, V279, P42774, DOI 10.1074/jbc.M407923200; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Pande V, 2005, CURR MED CHEM, V12, P357, DOI 10.2174/0929867053363180; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Penolazzi L, 2003, BIOCHEM PHARMACOL, V66, P1189, DOI 10.1016/S0006-2952(03)00470-2; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Pratt MAC, 2003, MOL CELL BIOL, V23, P6887, DOI 10.1128/MCB.23.19.6887-6900.2003; Raju U, 1998, INT J RADIAT BIOL, V74, P617, DOI 10.1080/095530098141195; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; Scott FL, 2005, EMBO J, V24, P645, DOI 10.1038/sj.emboj.7600544; Skalitzky DJ, 2003, J MED CHEM, V46, P210, DOI 10.1021/jm0255769; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Veuger SJ, 2003, CANCER RES, V63, P6008; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wu JT, 2005, J SURG RES, V123, P158, DOI 10.1016/j.jss.2004.06.006; Xiao CW, 2001, ENDOCRINOLOGY, V142, P557, DOI 10.1210/en.142.2.557; Yang L, 2003, CANCER RES, V63, P6815; Zhou YM, 2005, INT J BIOCHEM CELL B, V37, P1130, DOI 10.1016/j.biocel.2004.09.006	52	99	108	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					832	842		10.1038/onc.2008.439	http://dx.doi.org/10.1038/onc.2008.439			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19060926	Green Accepted			2022-12-17	WOS:000263320000006
J	Yu, JW; Shi, Y				Yu, J. W.; Shi, Y.			FLIP and the death effector domain family	ONCOGENE			English	Review						apoptosis; extrinsic cell death; caspase-8; DED; FLIP; NF-kappa B	NF-KAPPA-B; APOPTOSIS-INDUCING LIGAND; T-CELL PROLIFERATION; REGULATES FAS/TNFR1-INDUCED APOPTOSIS; RECEPTOR-INDUCED APOPTOSIS; SIGNALING COMPLEX DISC; FAS-MEDIATED APOPTOSIS; C-FLIPL; CRYSTAL-STRUCTURE; CASPASE-8 ACTIVATION	Death effector domains (DEDs) are protein interaction modules found in a number of proteins known to regulate apoptosis from death receptors. The core DED family members that orchestrate programmed cell death from death receptors include the adaptor protein FADD, the initiator caspases procaspases-8 and -10 and the regulatory protein c-FLIP. Through homotypic DED interactions, these proteins assemble into the death-inducing signaling complex (DISC) to regulate initiator caspase activation and launch the apoptotic proteolytic cascade. A considerable body of evidence, however, is revealing that the same core group of DED-containing proteins also paradoxically promotes survival and proliferation in lymphocytes and possibly other cell types. This review delves into recent findings regarding these two opposing functional aspects of the core DED proteins. We discuss the current effort expanding our structural and biochemical view of how DED proteins assemble into the DISC to fully activate initiator caspases and execute cell death, and finally we examine details linking the same proteins to proliferation and describe how this outcome might be achieved through restricted activation of initiator caspases.	[Yu, J. W.; Shi, Y.] Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA	Princeton University	Yu, JW (corresponding author), Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA.	jwyu@princeton.edu; ygshi@princeton.edu			National Institutes of Health [2 R01 CA90269]; Damon Runyon Cancer Research Foundation [DRG-1905-06]; NATIONAL CANCER INSTITUTE [R01CA090269] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Damon Runyon Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Work from Yigong Shi's laboratory in this area of research was supported by a grant from the National Institutes of Health (2 R01 CA90269). Jong W Yu is a Damon Runyon Fellow supported by the Damon Runyon Cancer Research Foundation (DRG-1905-06).	Abe K, 2000, ANN NY ACAD SCI, V926, P52; Alappat EC, 2005, MOL CELL, V19, P321, DOI 10.1016/j.molcel.2005.06.024; Alcivar A, 2003, ONCOGENE, V22, P291, DOI 10.1038/sj.onc.1206099; ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bagneris C, 2008, MOL CELL, V30, P620, DOI 10.1016/j.molcel.2008.04.029; Bang S, 2000, J BIOL CHEM, V275, P36217, DOI 10.1074/jbc.M006620200; Bao Q, 2007, CELL DEATH DIFFER, V14, P56, DOI 10.1038/sj.cdd.4402028; Beisner DR, 2005, J IMMUNOL, V175, P3469, DOI 10.4049/jimmunol.175.6.3469; Berglund H, 2000, J MOL BIOL, V302, P171, DOI 10.1006/jmbi.2000.4011; Bidere N, 2006, CURR BIOL, V16, P1666, DOI 10.1016/j.cub.2006.06.062; Boatright KM, 2004, BIOCHEM J, V382, P651, DOI 10.1042/BJ20040809; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Boissonnas A, 2002, EUR J IMMUNOL, V32, P3007, DOI 10.1002/1521-4141(2002010)32:10<3007::AID-IMMU3007>3.0.CO;2-9; Carrington PE, 2006, MOL CELL, V22, P599, DOI 10.1016/j.molcel.2006.04.018; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chau H, 2005, J EXP MED, V202, P405, DOI 10.1084/jem.20050118; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Curtin JF, 2003, CELL SIGNAL, V15, P983, DOI 10.1016/S0898-6568(03)00093-7; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Desbarats J, 2000, NAT MED, V6, P920, DOI 10.1038/78688; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; Dohrman A, 2005, J IMMUNOL, V174, P5270, DOI 10.4049/jimmunol.174.9.5270; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Golks A, 2005, J BIOL CHEM, V280, P14507, DOI 10.1074/jbc.M414425200; Golks A, 2006, J EXP MED, V203, P1295, DOI 10.1084/jem.20051556; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Guasparri I, 2006, EMBO REP, V7, P114, DOI 10.1038/sj.embor.7400580; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hill JM, 2004, J BIOL CHEM, V279, P1474, DOI 10.1074/jbc.M304996200; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jeong EJ, 1999, J BIOL CHEM, V274, P16337, DOI 10.1074/jbc.274.23.16337; Kataoka T, 2004, MOL CELL BIOL, V24, P2627, DOI 10.1128/MCB.24.7.2627-2636.2004; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kaufmann M, 2002, FEBS LETT, V527, P250, DOI 10.1016/S0014-5793(02)03146-0; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lee HJ, 2007, NAT CELL BIOL, V9, P1303, DOI 10.1038/ncb1650; Lens SMA, 2002, MOL CELL BIOL, V22, P5419, DOI 10.1128/MCB.22.15.5419-5433.2002; Li FY, 2006, J BIOL CHEM, V281, P2960, DOI 10.1074/jbc.M511074200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maedler K, 2002, P NATL ACAD SCI USA, V99, P8236, DOI 10.1073/pnas.122686299; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Misra RS, 2007, J BIOL CHEM, V282, P19365, DOI 10.1074/jbc.M610610200; Mitsiades CS, 2006, CLIN CANCER RES, V12, P3705, DOI 10.1158/1078-0432.CCR-05-2493; Muppidi JR, 2006, CELL DEATH DIFFER, V13, P1641, DOI 10.1038/sj.cdd.4401855; Muppidi JR, 2004, NAT IMMUNOL, V5, P182, DOI 10.1038/ni1024; Naito M, 2004, MOL CELL BIOL, V24, P8418, DOI 10.1128/MCB.24.19.8418-8427.2004; Nakagiri S, 2005, MOL CELL BIOL, V25, P9249, DOI 10.1128/MCB.25.21.9249-9258.2005; Nakajima A, 2006, EMBO J, V25, P5549, DOI 10.1038/sj.emboj.7601423; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Peter ME, 2007, CELL, V129, P447, DOI 10.1016/j.cell.2007.04.031; Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200; Qi W, 2007, EMBO J, V26, P65, DOI 10.1038/sj.emboj.7601483; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Rathmell JC, 2002, CELL, V109, pS97, DOI 10.1016/S0092-8674(02)00704-3; Rawlings DJ, 2006, NAT REV IMMUNOL, V6, P799, DOI 10.1038/nri1944; Reed J. C., 2004, SCI STKE, V2004, pre9, DOI DOI 10.1126/STKE.2392004RE9; Renganathan H, 2005, BIOCHEM J, V390, P729, DOI 10.1042/BJ20050378; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Sandu C, 2006, CELL DEATH DIFFER, V13, P2052, DOI 10.1038/sj.cdd.4401966; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Siegel RM, 2004, J CELL BIOL, V167, P735, DOI 10.1083/jcb.200406101; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stilo R, 2003, BIOCHEM BIOPH RES CO, V303, P1034, DOI 10.1016/S0006-291X(03)00487-X; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Thomas LR, 2004, J BIOL CHEM, V279, P32780, DOI 10.1074/jbc.M401680200; Thomas LR, 2002, J BIOL CHEM, V277, P34343, DOI 10.1074/jbc.M204169200; Thorburn J, 2005, MOL BIOL CELL, V16, P1189, DOI 10.1091/mbc.E04-10-0906; Vaux DL, 2000, CURR OPIN IMMUNOL, V12, P719, DOI 10.1016/S0952-7915(00)00168-0; Vilimanovich U, 2008, CELL MOL LIFE SCI, V65, P814, DOI 10.1007/s00018-008-7513-8; Wajant H, 2003, ESSAYS BIOCHEM, V39, P53, DOI 10.1042/bse0390053; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Yang JK, 2005, MOL CELL, V20, P939, DOI 10.1016/j.molcel.2005.10.023; Yao Z, 2007, EMBO J, V26, P1068, DOI 10.1038/sj.emboj.7601571; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang N, 2005, J EXP MED, V202, P395, DOI 10.1084/jem.20050117	106	99	103	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	48					6216	6227		10.1038/onc.2008.299	http://dx.doi.org/10.1038/onc.2008.299			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	361YB	18931689				2022-12-17	WOS:000260162800004
J	Maimets, T; Neganova, I; Armstrong, L; Lako, M				Maimets, T.; Neganova, I.; Armstrong, L.; Lako, M.			Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells	ONCOGENE			English	Article						cell cycle; differentiation; human embryonic stem cells; p53-p21 pathway; tumour suppression	SELF-RENEWAL; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; PROLIFERATION; CANCER; GENE; P21; ANTAGONISTS; QUIESCENCE; SITES	p53 is an important regulator of normal cell response to stress and frequently mutated in human tumours. Here, we studied the effects of activation of p53 and its target gene p21 in human embryonic stem cells. We show that activation of p53 with small-molecule activator nutlin leads to rapid differentiation of stem cells evidenced by changes in cell morphology and adhesion, expression of cell-specific markers for primitive endoderm and trophectoderm lineages and loss of pluripotency markers. p21 is quickly and dose-dependently activated by nutlin. It can also be activated independently from p53 by sodium butyrate, which leads to the differentiation events very similar to the ones induced by p53. During differentiation, the activating phosphorylation site of CDK2 Thr-160 becomes dephosphorylated and cyclins A and E become degraded. The target for CDK2 kinase in p53 molecule, Ser-315, also becomes dephosphorylated. We conclude that the main mechanism responsible for differentiation of human stem cells by p53 is abolition of S-phase entry and subsequent stop of cell cycle in G0/G1 phase accompanied by p21 activation.	[Maimets, T.] Univ Tartu, Inst Mol & Cell Biol, EE-51010 Tartu, Estonia; [Maimets, T.; Neganova, I.; Armstrong, L.; Lako, M.] Univ Newcastle Upon Tyne, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Neganova, I.; Armstrong, L.; Lako, M.] Univ Newcastle Upon Tyne, North East Stem Cell Inst, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of Tartu; Newcastle University - UK; Newcastle University - UK	Maimets, T (corresponding author), Univ Tartu, Inst Mol & Cell Biol, Riia 23, EE-51010 Tartu, Estonia.	toivo.maimets@ut.ee	Maimets, Toivo/E-9268-2017; Lako, Majlinda/B-6297-2013; Armstrong, Lyle/B-7812-2013	Maimets, Toivo/0000-0001-6461-3365; armstrong, lyle/0000-0002-7234-9362; lako, majlinda/0000-0003-1327-8573	Estonian Science Foundation [ETF6459]; Citrina Foundation (TM); One North East Regional Developmental Agency (ML); MRC [G0301182] Funding Source: UKRI	Estonian Science Foundation; Citrina Foundation (TM); One North East Regional Developmental Agency (ML); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Ian Dimmick for help in flow cytometry and Stuart Atkinson for assistance with Quantitative real-time-PCR. This work has been supported by grants from Estonian Science Foundation (ETF6459) and Citrina Foundation (TM) and One North East Regional Developmental Agency (ML).	Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Dravid G, 2005, STEM CELLS, V23, P1489, DOI 10.1634/stemcells.2005-0034; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Hyslop L, 2005, STEM CELLS, V23, P1035, DOI 10.1634/stemcells.2005-0080; Hyslop Louise A., 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405009804; Joers A, 1998, ONCOGENE, V17, P2351, DOI 10.1038/sj.onc.1202146; Kippin TE, 2005, GENE DEV, V19, P756, DOI 10.1101/gad.1272305; LANE DP, 1992, NATURE, V358, P16; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Meletis K, 2006, DEVELOPMENT, V133, P363, DOI 10.1242/dev.02208; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Qin H, 2007, J BIOL CHEM, V282, P5842, DOI 10.1074/jbc.M610464200; Stojkovic M, 2004, STEM CELLS, V22, P790, DOI 10.1634/stemcells.22-5-790; TANAKA M, 1990, CELL, V60, P75; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153	27	99	114	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2008	27	40					5277	5287		10.1038/onc.2008.166	http://dx.doi.org/10.1038/onc.2008.166			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	346UW	18521083				2022-12-17	WOS:000259096100001
J	Kargiotis, O; Chetty, C; Gondi, CS; Tsung, AJ; Dinh, DH; Gujrati, M; Lakka, SS; Kyritsis, AP; Rao, JS				Kargiotis, O.; Chetty, C.; Gondi, C. S.; Tsung, A. J.; Dinh, D. H.; Gujrati, M.; Lakka, S. S.; Kyritsis, A. P.; Rao, J. S.			Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma	ONCOGENE			English	Article						MMP-2; gliomas; invasion; angiogenesis; intracranial; siRNAs	MATRIX METALLOPROTEINASES; GLIOMA-CELLS; IV COLLAGENASE; MALIGNANT GLIOMAS; METASTASIS; EXPRESSION; MIGRATION; RECEPTOR; STRATEGIES; THERAPY	Invasive tumors, including gliomas, utilize proteinases to degrade extracellular matrix components and diffuse into the adjacent tissues or migrate toward distant ones. In addition, proteinase activity is required for the formation of new blood vessels within the tumor. Levels of the proteinase matrix metalloproteinase-2 (MMP-2) are highly increased in gliomas. In this study, we examined the effect of the downregulation of MMP-2 via adenovirus-mediated siRNA in gliomas. Here, we show that siRNA delivery significantly decreased levels of MMP-2 in the glioblastoma cell lines U-87 and U-251. U-87 and U-251 cells showed impaired invasion through matrigel as well as decreased migration from tumor spheroids transfected with adenoviral vector expressing siRNA against MMP-2. Additionally, tumor-induced angiogenesis was decreased in in vitro experiments in cultured human microvascular endothelial cells (HMECs) in serum-free conditioned medium of glioblastoma cells transfected with these constructs and co-cultures of glioma cells with HMECs. We also observed decreased angiogenesis in the in vivo dorsal skin-fold chamber model. Moreover, MMP-2 inhibition induced apoptotic cell death in vitro, and suppressed tumor growth of preestablished U-251 intracranial xenografts in nude mice. Thus, specific targeting of MMP-2 may provide a novel, efficient approach for the treatment of gliomas and improve the poor outcomes of patients with these brain tumors.	[Kargiotis, O.; Chetty, C.; Gondi, C. S.; Lakka, S. S.; Rao, J. S.] Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA; [Tsung, A. J.; Dinh, D. H.; Rao, J. S.] Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61605 USA; [Gujrati, M.] Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61605 USA; [Kyritsis, A. P.] Univ Ioannina, Sch Med, Dept Neurol, GR-45110 Ioannina, Greece	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Ioannina	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, 1 Illini Dr, Peoria, IL 61605 USA.	jsrao@uic.edu		Gondi, Christopher/0000-0002-3036-9920	NCI NIH HHS [R01 CA075557, R01 CA095058-04, CA 116708, R01 CA092393, R01 CA116708-02, R01 CA116708, CA 95058, CA 75557, R01 CA092393-04, R01 CA095058, R01 CA075557-09, CA 92393] Funding Source: Medline; NINDS NIH HHS [NS 47699, R01 NS057529, R01 NS047699-03, R01 NS047699, R01 NS061835, NS61835, NS57529, R01 NS057529-01, R01 NS061835-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092393, R01CA116708, R01CA095058, R01CA075557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047699, R01NS061835, R01NS057529] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE T, 1994, CLIN EXP METASTAS, V12, P296, DOI 10.1007/BF01753836; Belotti D, 2003, CANCER RES, V63, P5224; BENELLI R, 1994, ONCOL RES, V6, P251; Castro MG, 2003, PHARMACOL THERAPEUT, V98, P71, DOI 10.1016/S0163-7258(03)00014-7; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chetty C, 2006, MOL CANCER THER, V5, P2289, DOI 10.1158/1535-7163.MCT-06-0169; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Deryugina EI, 2002, CANCER RES, V62, P580; Deryugina EI, 1998, CANCER RES, V58, P3743; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Forsyth PA, 1999, BRIT J CANCER, V79, P1828, DOI 10.1038/sj.bjc.6690291; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Giese A, 1996, NEUROSURGERY, V39, P235, DOI 10.1097/00006123-199608000-00001; Goldbrunner RH, 1999, ACTA NEUROCHIR, V141, P295, DOI 10.1007/s007010050301; Gondi CS, 2004, NEURON GLIA BIOL, V1, P165, DOI 10.1017/S1740925X04000237; Gondi CS, 2004, ONCOGENE, V23, P8486, DOI 10.1038/sj.onc.1207879; Itoh T, 1998, CANCER RES, V58, P1048; Kaliski A, 2005, MOL CANCER THER, V4, P1717, DOI 10.1158/1535-7163.MCT-05-0179; Komatsu Kyoko, 2004, Brain Tumor Pathol, V21, P105, DOI 10.1007/BF02482184; Lakka SS, 2005, BRAIN PATHOL, V15, P327; Lakka SS, 2005, J BIOL CHEM, V280, P21882, DOI 10.1074/jbc.M408520200; Lakka SS, 2002, ONCOGENE, V21, P8011, DOI 10.1038/sj.onc.1205894; Lal S, 2000, J NEUROSURG, V92, P326, DOI 10.3171/jns.2000.92.2.0326; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; NAKAOHAYASHI J, 1992, ATHEROSCLEROSIS, V92, P141, DOI 10.1016/0021-9150(92)90273-J; Park CM, 2006, CANCER RES, V66, P8511, DOI 10.1158/0008-5472.CAN-05-4340; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; RAY JM, 1994, EUR RESPIR J, V7, P2062; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; Sawaya R, 1998, BIOCHEM BIOPH RES CO, V251, P632, DOI 10.1006/bbrc.1998.9466; Sawaya RE, 1996, CLIN EXP METASTAS, V14, P35, DOI 10.1007/BF00157684; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; Wang JG, 2003, IEEE T MOBILE COMPUT, V2, P65, DOI 10.1109/TMC.2003.1195152; Wild-Bode C, 2001, CANCER RES, V61, P2744; WOESSNER JF, 1991, J RHEUMATOL, V18, P99; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739	43	99	104	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2008	27	35					4830	4840		10.1038/onc.2008.122	http://dx.doi.org/10.1038/onc.2008.122			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18438431	Green Accepted			2022-12-17	WOS:000258445100008
J	Ho, LH; Read, SH; Dorstyn, L; Lambrusco, L; Kumar, S				Ho, L. H.; Read, S. H.; Dorstyn, L.; Lambrusco, L.; Kumar, S.			Caspase-2 is required for cell death induced by cytoskeletal disruption	ONCOGENE			English	Article						apoptosis; caspase-2 activation; Bid; Bax; initiator caspase; cytoskeleton	CYTOCHROME-C RELEASE; INDUCED APOPTOSIS; MITOCHONDRIAL PERMEABILIZATION; CANCER-CELLS; DNA-DAMAGE; GENE CED-3; ACTIVATION; ENCODES; COMPLEX; STRESS	Caspase-2 is one of the most conserved caspases, yet its biological function remains a matter of controversy. In the present article we analysed mouse embryonic fibroblasts (MEFs) from caspase-2 knockout mice for their sensitivity to various apoptosis inducing agents. We found that cell death induced by drugs that disrupt cytoskeleton is significantly inhibited in Casp2(-/-) MEFs. These drugs included zoledronic acid, vincristine, cytochalasin D and paclitaxel. We demonstrate that MEFs lacking Casp2 show clonogenic survival following drug treatment, whereas all Casp2(-/-) MEFs die, indicating that caspase-2 is required for apoptosis induced by cytoskeletal disruption. We further found that caspase-2 mediates apoptosis via Piddosome, Bid and Bax activation, and cytochrome c release. In the absence of caspase-2, Bid and Bax activation, and cytochrome c release are significantly delayed following drug treatment. Our data provide strong support for a context-dependent function of caspase-2 in apoptosis.	[Ho, L. H.; Read, S. H.; Dorstyn, L.; Lambrusco, L.; Kumar, S.] Inst Med & Vet Sci, Div Haematol, Hanson Inst, Adelaide, SA 5000, Australia; [Kumar, S.] Univ Adelaide, Dept Med, Adelaide, SA 5001, Australia	Hanson Institute; Institute Medical & Veterinary Science Australia; University of Adelaide	Kumar, S (corresponding author), Inst Med & Vet Sci, Div Haematol, Hanson Inst, POB 14,Rundle Mall, Adelaide, SA 5000, Australia.	sharad.kumar@imvs.sa.gov.au	Kumar, Sharad/AAX-7787-2020; Dorstyn, Loretta/F-3673-2013	Kumar, Sharad/0000-0001-7126-9814; Dorstyn, Loretta/0000-0001-9886-0989				Antignani A, 2006, CURR OPIN CELL BIOL, V18, P685, DOI 10.1016/j.ceb.2006.10.004; Baliga BC, 2004, CELL DEATH DIFFER, V11, P1234, DOI 10.1038/sj.cdd.4401492; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; Bonzon C, 2006, MOL BIOL CELL, V17, P2150, DOI 10.1091/mbc.E05-12-1107; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Colussi PA, 1998, J BIOL CHEM, V273, P26566, DOI 10.1074/jbc.273.41.26566; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Ekert PG, 2004, J CELL BIOL, V165, P835, DOI 10.1083/jcb.200312031; Gourlay CW, 2005, NAT REV MOL CELL BIO, V6, P583, DOI 10.1038/nrm1682; Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9-90004-3; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Handrick R, 2006, RADIOTHER ONCOL, V80, P199, DOI 10.1016/j.radonc.2006.07.021; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Holleman A, 2005, BLOOD, V106, P1817, DOI 10.1182/blood-2004-11-4296; Kepp O, 2007, EMBO J, V26, P825, DOI 10.1038/sj.emboj.7601533; Kong JY, 2005, BIOCHEM CELL BIOL, V83, P608, DOI 10.1139/o05-066; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 2007, CELL DEATH DIFFER, V14, P32, DOI 10.1038/sj.cdd.4402060; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kumar S, 2000, CELL DEATH DIFFER, V7, P1039, DOI 10.1038/sj.cdd.4400756; Kumar S, 2002, SCIENCE, V297, P1290, DOI 10.1126/science.1076118; KUMAR S, 1995, FEBS LETT, V368, P69, DOI 10.1016/0014-5793(95)00602-6; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj.cdd.4400989; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lavrik IN, 2006, BLOOD, V108, P559, DOI 10.1182/blood-2005-07-007096; Marsden VS, 2004, J CELL BIOL, V165, P775, DOI 10.1083/jcb.200312030; Martin SS, 2004, BBA-MOL CELL RES, V1692, P145, DOI 10.1016/j.bbamcr.2004.02.008; Mhaidat NM, 2007, MOL CANCER THER, V6, P752, DOI 10.1158/1535-7163.MCT-06-0564; Milleron RS, 2006, J BIOL CHEM, V281, P16991, DOI 10.1074/jbc.M512754200; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Panaretakis T, 2005, MOL BIOL CELL, V16, P3821, DOI 10.1091/mbc.E04-10-0862; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Shearwin-Whyatt L, 2001, BIOCHEM BIOPH RES CO, V282, P1114, DOI 10.1006/bbrc.2001.4699; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Shih YL, 2006, MICROBIOL MOL BIOL R, V70, P729, DOI 10.1128/MMBR.00017-06; Shin S, 2005, EMBO J, V24, P3532, DOI 10.1038/sj.emboj.7600827; THEIRAULT RL, 2003, EXPERT REV ANTICANC, V3, P157; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang YF, 2004, CANCER CHEMOTH PHARM, V54, P322, DOI 10.1007/s00280-004-0831-0; Waterhouse NJ, 2003, CELL DEATH DIFFER, V10, P853, DOI 10.1038/sj.cdd.4401263; Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660; Yeung BHY, 2006, J BIOL CHEM, V281, P11923, DOI 10.1074/jbc.M508533200; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhivotovsky B, 2005, BIOCHEM BIOPH RES CO, V331, P859, DOI 10.1016/j.bbrc.2005.03.191	49	99	100	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	24					3393	3404		10.1038/sj.onc.1211005	http://dx.doi.org/10.1038/sj.onc.1211005			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193089				2022-12-17	WOS:000256309900004
J	Oleinik, NV; Krupenko, NI; Krupenko, SA				Oleinik, N. V.; Krupenko, N. I.; Krupenko, S. A.			Cooperation between JNK1 and JNK2 in activation of p53 apoptotic pathway	ONCOGENE			English	Article						apoptosis; FDH; jun kinases; p53; RNAi	CELL-CYCLE PROGRESSION; PROTEIN-KINASE INHIBITORS; PHOSPHORYLATED IN-VITRO; C-JUN KINASE; 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE; CANCER-CELLS; SIGNAL-TRANSDUCTION; STRESS; IDENTIFICATION; VIVO	FDH (10-formyltetrahydrofolate dehydrogenase) is strongly downregulated in tumors while its elevation suppresses proliferation of cancer cells and induces p53-dependent apoptosis. We have previously shown that FDH induces phosphorylation of p53 at Ser6, which is a required step in the activation of apoptosis. In the present study, we report that FDH-induced p53 phosphorylation is carried out by JNK1 and JNK2 (c-Jun N-terminal kinases) working in concert. We have demonstrated that FDH induces phosphorylation of JNK1 and JNK2, while treatment of FDH-expressing cells with JNK inhibitor SP600125, as well as knockdown of JNK1 or JNK2 by siRNA, prevents phosphorylation of p53 at Ser6 and protects cells from apoptosis. Interestingly, the knockdown of JNK1 abolished phosphorylation of JNK2 in response to FDH, while knockdown of JNK2 did not prevent JNK1 phosphorylation. Pull-down assay with the p53-specific antibody has shown that JNK2, but not JNK1, is physically associated with p53. Our studies revealed a novel mechanism in which phosphorylation of JNK2 is mediated by JNK1 before phosphorylation of p53, and then p53 is directly phosphorylated by JNK2 at Ser6.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Krupenko, SA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Rm 512-B BSB, Charleston, SC 29425 USA.	Krupenko@musc.edu			NATIONAL CANCER INSTITUTE [R01CA095030] Funding Source: NIH RePORTER; NCI NIH HHS [CA95030] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anguera MC, 2006, J BIOL CHEM, V281, P18335, DOI 10.1074/jbc.M510623200; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bost F, 1999, MOL CELL BIOL, V19, P1938; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; CHAMPION KM, 1994, P NATL ACAD SCI USA, V91, P11338, DOI 10.1073/pnas.91.24.11338; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Fogarty MP, 2003, BIOCHEM J, V371, P789, DOI 10.1042/BJ20021660; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kelemen BR, 2002, J BIOL CHEM, V277, P8741, DOI 10.1074/jbc.M108459200; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Krupenko SA, 2002, CELL GROWTH DIFFER, V13, P227; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MIN H, 1988, BIOCHIM BIOPHYS ACTA, V967, P348, DOI 10.1016/0304-4165(88)90097-9; Oleinik NV, 2005, BIOCHEM J, V391, P503, DOI 10.1042/BJ20050533; Oleinik NV, 2003, MOL CANCER RES, V1, P577; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; Tafolla E, 2005, J BIOL CHEM, V280, P19992, DOI 10.1074/jbc.M500331200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Ventura JJ, 2006, MOL CELL, V21, P701, DOI 10.1016/j.molcel.2006.01.018; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	43	99	103	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2007	26	51					7222	7230		10.1038/sj.onc.1210526	http://dx.doi.org/10.1038/sj.onc.1210526			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17525747				2022-12-17	WOS:000250955600006
J	Rea, S; Xouri, G; Akhtar, A				Rea, S.; Xouri, G.; Akhtar, A.			Males absent on the first (MOF): from flies to humans	ONCOGENE			English	Review						MOF; MSL; histone acetyltransferase; H4K16; DNA damage; cancer	ACUTE MYELOID-LEUKEMIA; HISTONE ACETYLTRANSFERASE ACTIVITY; ZINC-FINGER PROTEIN; HEMATOPOIETIC STEM-CELLS; ACUTE MONOCYTIC LEUKEMIA; DROSOPHILA MSL COMPLEX; DOSAGE COMPENSATION; TRANSCRIPTIONAL REGULATION; H4 ACETYLATION; RECEPTOR COACTIVATOR	Histone modi. cations such as acetylation, methylation and phosphorylation have been implicated in fundamental cellular processes such as epigenetic regulation of gene expression, organization of chromatin structure, chromosome segregation, DNA replication and DNA repair. Males absent on the first ( MOF) is responsible for acetylating histone H4 at lysine 16 ( H4K16) and is a key component of the MSL complex required for dosage compensation in Drosophila. The human ortholog of MOF ( hMOF) has the same substrate specific city and recent purification of the human and Drosophila MOF complexes showed that these complexes were also highly conserved through evolution. Several studies have shown that loss of hMOF in mammalian cells leads to a number of different phenotypes; a G(2)/M cell cycle arrest, nuclear morphological defects, spontaneous chromosomal aberrations, reduced transcription of certain genes and an impaired DNA repair response upon ionizing irradiation. Moreover, hMOF is involved in ATM activation in response to DNA damage and acetylation of p53 by hMOF influences the cell's decision to undergo apoptosis instead of a cell cycle arrest. These data, highlighting hMOF as an important component of many cellular processes, as well as links between hMOF and cancer will be discussed.	European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Akhtar, A (corresponding author), European Mol Biol Lab, Gene Express Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.	akhtar@embl.de		Rea, Stephen/0000-0001-5797-5157				Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; ALLFREY VG, 1968, SCIENCE, V159, P314, DOI 10.1126/science.159.3812.314; Anderson JD, 2001, J MOL BIOL, V307, P977, DOI 10.1006/jmbi.2001.4528; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Bristow CAP, 2003, NUCLEIC ACIDS RES, V31, P2735, DOI 10.1093/nar/gkg401; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; Champagne N, 2001, ONCOGENE, V20, P404, DOI 10.1038/sj.onc.1204114; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Clark J, 2002, GENE CHROMOSOME CANC, V34, P104, DOI 10.1002/gcc.10039; Contzler R, 2006, BIOCHEM BIOPH RES CO, V350, P208, DOI 10.1016/j.bbrc.2006.09.030; Corona DFV, 2002, EMBO REP, V3, P242, DOI 10.1093/embo-reports/kvf056; Deguchi K, 2003, CANCER CELL, V3, P259, DOI 10.1016/S1535-6108(03)00051-5; Deissler H, 2004, ONCOL REP, V11, P1281; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Dion MF, 2005, P NATL ACAD SCI USA, V102, P5501, DOI 10.1073/pnas.0500136102; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; EhrenhoferMurray AE, 1997, GENETICS, V145, P923; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2006, BRIT J CANCER, V94, P179, DOI 10.1038/sj.bjc.6602918; Favreau C, 2003, EXP CELL RES, V282, P14, DOI 10.1006/excr.2002.5669; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Goldman RD, 2004, P NATL ACAD SCI USA, V101, P8963, DOI 10.1073/pnas.0402943101; Groth A, 2007, CELL, V128, P721, DOI 10.1016/j.cell.2007.01.030; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gupta A, 2005, MOL CELL BIOL, V25, P5292, DOI 10.1128/MCB.25.12.5292-5305.2005; Halkidou K, 2003, ONCOGENE, V22, P2466, DOI 10.1038/sj.onc.1206342; Hashimoto T, 1999, CANCER RES, V59, P5572; Hayes VM, 1999, BRAIN PATHOL, V9, P463, DOI 10.1111/j.1750-3639.1999.tb00535.x; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Iizuka M, 2006, MOL CELL BIOL, V26, P1098, DOI 10.1128/MCB.26.3.1098-1108.2006; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Katan-Khaykovich Y, 2005, EMBO J, V24, P2138, DOI 10.1038/sj.emboj.7600692; Katsumoto T, 2006, GENE DEV, V20, P1321, DOI 10.1101/gad.1393106; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; Kimura A, 1998, GENES CELLS, V3, P789, DOI 10.1046/j.1365-2443.1998.00229.x; Kindle KB, 2005, MOL CELL BIOL, V25, P988, DOI 10.1128/MCB.25.3.988-1002.2005; Kitabayashi I, 2001, LEUKEMIA, V15, P89, DOI 10.1038/sj.leu.2401983; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Leitao MM, 2004, GYNECOL ONCOL, V93, P301, DOI 10.1016/j.ygyno.2004.01.043; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu J, 2000, MOL BIOL CELL, V11, P3937, DOI 10.1091/mbc.11.11.3937; Lleonart ME, 2006, ONCOL REP, V16, P603; Lucchesi JC, 2005, ANNU REV GENET, V39, P615, DOI 10.1146/annurev.genet.39.073003.094210; Mendjan S, 2006, MOL CELL, V21, P811, DOI 10.1016/j.molcel.2006.02.007; Mendjan S, 2007, CHROMOSOMA, V116, P95, DOI 10.1007/s00412-006-0089-x; MEYERS FJ, 1993, J NATL CANCER I, V85, P1856, DOI 10.1093/jnci/85.22.1856; MUNKS RJL, 1991, FEBS LETT, V284, P245, DOI 10.1016/0014-5793(91)80695-Y; Ohta K, 2007, BIOCHEM J, V402, P559, DOI 10.1042/BJ20061194; Panagopoulos I, 2001, HUM MOL GENET, V10, P395, DOI 10.1093/hmg/10.4.395; Pardo PS, 2002, J BIOL CHEM, V277, P50860, DOI 10.1074/jbc.M203839200; Pelletier N, 2002, ONCOGENE, V21, P2729, DOI 10.1038/sj.onc.1205367; Prokocimer M, 2006, J STRUCT BIOL, V155, P351, DOI 10.1016/j.jsb.2006.02.016; Rea S, 2006, CURR TOP MICROBIOL, V310, P117; Reifnyder C, 1997, NAT GENET, V16, P109, DOI 10.1038/ng0597-109b; Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902; Sanjuan R, 2001, MOL BIOL EVOL, V18, P330, DOI 10.1093/oxfordjournals.molbev.a003809; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Shia WJ, 2005, J BIOL CHEM, V280, P11987, DOI 10.1074/jbc.M500276200; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Smith ER, 2005, MOL CELL BIOL, V25, P9175, DOI 10.1128/MCB.25.21.9175-9188.2005; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007; Stedman W, 2004, J VIROL, V78, P12566, DOI 10.1128/JVI.78.22.12566-12575.2004; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Straub T, 2007, NAT REV GENET, V8, P47, DOI 10.1038/nrg2013; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; SUTTON WS, 1903, BIOL BULL, V4, P5; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Taipale M, 2005, MOL CELL BIOL, V25, P6798, DOI 10.1128/MCB.25.15.6798-6810.2005; Tamburini BA, 2005, MOL CELL BIOL, V25, P4903, DOI 10.1128/MCB.25.12.4903-4913.2005; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Thomas T, 2006, GENE DEV, V20, P1175, DOI 10.1101/gad.1382606; Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; Utley RT, 2005, MOL CELL BIOL, V25, P8179, DOI 10.1128/MCB.25.18.8179-8190.2005; Vousden KH, 2006, J CELL SCI, V119, P5015, DOI 10.1242/jcs.03293; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Yamada T, 2004, EMBO J, V23, P1792, DOI 10.1038/sj.emboj.7600138; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Zink D, 2004, NAT REV CANCER, V4, P677, DOI 10.1038/nrc1430; Zong HL, 2005, FEBS LETT, V579, P3579, DOI 10.1016/j.febslet.2005.05.039	97	99	104	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5385	5394		10.1038/sj.onc.1210607	http://dx.doi.org/10.1038/sj.onc.1210607			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694080				2022-12-17	WOS:000248674300007
J	Oricchio, E; Sciamanna, I; Beraldi, R; Tolstonog, GV; Schumann, GG; Spadafora, C				Oricchio, E.; Sciamanna, I.; Beraldi, R.; Tolstonog, G. V.; Schumann, G. G.; Spadafora, C.			Distinct roles for LINE-1 and HERV-K retroelements in cell proliferation, differentiation and tumor progression	ONCOGENE			English	Article						retrotransposons; endogenous retroviruses; cell proliferation; differentiation; tumorigenesis	ENDOGENOUS REVERSE-TRANSCRIPTASE; NUCLEAR LAMINA; EXPRESSION; ENVELOPE; GROWTH; RETROVIRUS; MICE	Transformed cells express high levels of non-telomeric reverse-transcriptase (RT) activity of retrotransposon and endogenous retrovirus origin. We previously reported that RT inhibition, either pharmacological or through transient silencing of RT-encoding LINE-1 (L1) elements by RNA interference (RNAi), reduced proliferation, induced differentiation and reprogrammed gene expression in human tumorigenic cell lines. Moreover, the antiretroviral drug efavirenz antagonized tumor progression in animal models in vivo. To get insight into the role of retroelements in tumorigenesis, we have now produced two cell lines derived from A-375 melanoma, in which the expression of either L1 retrotransposon, or HERV-K endogenous retrovirus, was stably suppressed by RNAi. Compared to the parental A-375 cell line, cells with stably interfered L1 expression show a lower proliferation rate, a differentiated morphology and lower tumorigenicity when inoculated in nude mice. L1 silencing modulates expression of several genes and, unexpectedly, also downregulates HERV-K expression. In HERV-K interfered cells, instead, L1 expression was unaffected, and cell proliferation and differentiation remained unchanged compared to parental A-375 cells. In vivo, however, their tumorigenic potential was found to be reduced after inoculation in nude mice. These results suggest that L1 and HERV-K play specific and distinct roles in cell transformation and tumor progression.	Ist Super Sanita, Serv BGSA, I-00161 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Rome, Italy; Univ Siena, Dept Pediat & Obstet, I-53100 Siena, Italy; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-2000 Hamburg, Germany; Paul Ehrlich Inst, Div Med Biotechnol, D-6070 Langen, Germany	Istituto Superiore di Sanita (ISS); University of Rome Tor Vergata; University of Siena; Heinrich Pette Institute; University of Hamburg; Paul Ehrlich Institute	Spadafora, C (corresponding author), Ist Super Sanita, Serv BGSA, Viale Regina Elena 299, I-00161 Rome, Italy.	cspadaf@tin.it		Sciamanna, Ilaria/0000-0002-5629-6184; Spadafora, Corrado/0000-0002-5743-3224; Oricchio, Elisa/0000-0002-1690-0447				Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798; Beraldi R, 2006, MOL REPROD DEV, V73, P279, DOI 10.1002/mrd.20423; Blaise S, 2001, J GEN VIROL, V82, P1597, DOI 10.1099/0022-1317-82-7-1597; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Dent P, 2005, J CELL BIOCHEM, V95, P712, DOI 10.1002/jcb.20502; Ergun S, 2004, J BIOL CHEM, V279, P27753, DOI 10.1074/jbc.M312985200; Farag SS, 2006, BLOOD REV, V20, P123, DOI 10.1016/j.blre.2005.10.001; Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502; Gruenbaum Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/nrm1550; Gruenbaum Y, 2003, INT REV CYTOL, V226, P1, DOI 10.1016/S0074-7696(03)01001-5; Han JS, 2005, BIOESSAYS, V27, P775, DOI 10.1002/bies.20257; HASUI M, 1989, CELL IMMUNOL, V120, P230, DOI 10.1016/0008-8749(89)90190-1; Humer J, 2006, CANCER RES, V66, P1658, DOI 10.1158/0008-5472.CAN-05-2452; Kazazian HH, 2004, SCIENCE, V303, P1626, DOI 10.1126/science.1089670; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Landriscina M, 2005, J CLIN ENDOCR METAB, V90, P5663, DOI 10.1210/jc.2005-0367; Mangeney M, 2005, CANCER RES, V65, P2588, DOI 10.1158/0008-5472.CAN-04-4231; Mangeney M, 1998, P NATL ACAD SCI USA, V95, P14920, DOI 10.1073/pnas.95.25.14920; Mangeney M, 2001, J GEN VIROL, V82, P2515, DOI 10.1099/0022-1317-82-10-2515; Mangiacasale R, 2003, ONCOGENE, V22, P2750, DOI 10.1038/sj.onc.1206354; Nickerson JA, 1997, P NATL ACAD SCI USA, V94, P4446, DOI 10.1073/pnas.94.9.4446; ORGEL LE, 1980, NATURE, V284, P604, DOI 10.1038/284604a0; Pittoggi C, 2003, MOL REPROD DEV, V66, P225, DOI 10.1002/mrd.10349; Qian F, 2005, BIOCHEM BIOPH RES CO, V333, P1269, DOI 10.1016/j.bbrc.2005.06.039; Ross DA, 2006, EJSO-EUR J SURG ONC, V32, P80, DOI 10.1016/j.ejso.2005.08.005; Sauter ER, 2002, CANCER RES, V62, P3200; Sciamanna E, 2005, ONCOGENE, V24, P3923, DOI 10.1038/sj.onc.1208562; Shapiro JA, 2005, BIOL REV, V80, P227, DOI 10.1017/S1464793104006657; Sinibaldi-Vallebona P, 2006, GENE CHROMOSOME CANC, V45, P1, DOI 10.1002/gcc.20266; Umekita Y, 1996, P NATL ACAD SCI USA, V93, P11802, DOI 10.1073/pnas.93.21.11802	30	99	105	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4226	4233		10.1038/sj.onc.1210214	http://dx.doi.org/10.1038/sj.onc.1210214			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17237820				2022-12-17	WOS:000247619900005
J	Herzig, M; Savarese, F; Novatchkova, M; Semb, H; Christofori, G				Herzig, M.; Savarese, F.; Novatchkova, M.; Semb, H.; Christofori, G.			Tumor progression induced by the loss of E-cadherin independent of beta-catenin/Tcf-mediated Wnt signaling	ONCOGENE			English	Article						beta-catenin; cell adhesion; E-cadherin; Tcf; tumorigenesis; Wnt signaling	EPITHELIAL-MESENCHYMAL TRANSITION; CELL-ADHESION; TRANSGENIC MICE; SUPPRESSOR GENE; CANCER CELLS; TUMORIGENESIS; EXPRESSION; INVASION; OVEREXPRESSION; MUTATIONS	E-cadherin-mediated cell-cell adhesion is frequently lost during the development of malignant epithelial cancers. Employing a transgenic mouse model of beta-cell carcinogenesis (Rip1Tag2) we have previously shown that the loss of E-cadherin is a rate-limiting step in the progression from adenoma to carcinoma. However, the mere loss of cell adhesion may not be sufficient and additional signals are required to cause tumor cells to permeate the basal membrane and to invade surrounding tissue. Besides being an important component of the E-cadherin cell-adhesion complex, beta-catenin plays a critical role in canonical Wnt signaling. We report here that beta-catenin-mediated Wnt signaling does not contribute to tumor progression in Rip1Tag2 mice. E-cadherin downregulates beta-catenin/Tcf-mediated transcriptional activity by sequestrating beta-catenin into E-cadherin cell-adhesion complexes even in the presence of activated Wnt signaling. Upon loss of E-cadherin expression, beta-catenin is degraded and Tcf/beta-catenin-mediated transcriptional activity is not induced. Moreover, forced expression of constitutive-active beta-catenin or genetic ablation of Tcf/beta-catenin transcriptional activity in tumor cells of Rip1Tag2 transgenic mice does not affect tumor progression. Together, the data indicate that signals other than beta-catenin/Tcf-mediated Wnt signaling are induced by the loss of E-cadherin during tumor progression in Rip1Tag2 transgenic mice.	Univ Basel, Biomed Ctr, Dept Clin Biol Sci, Inst Biochem & Genet, CH-4058 Basel, Switzerland; Res Inst Mol Pathol, A-1030 Vienna, Austria; Lund Univ, Stem Cell Ctr, Lund, Sweden	University of Basel; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Lund University	Christofori, G (corresponding author), Univ Basel, Biomed Ctr, Dept Clin Biol Sci, Inst Biochem & Genet, Mattenstr 28, CH-4058 Basel, Switzerland.	gerhard.christofori@unibas.ch						BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Caca K, 1999, CELL GROWTH DIFFER, V10, P369; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Crnic I, 2004, CANCER RES, V64, P8630, DOI 10.1158/0008-5472.CAN-04-2523; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Harada N, 2002, CANCER RES, V62, P1971; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Herzig M, 1999, BIOL CHEM, V380, P203, DOI 10.1515/BC.1999.028; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuphal F, 2006, EXP CELL RES, V312, P457, DOI 10.1016/j.yexcr.2005.11.007; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Orsulic S, 1999, J CELL SCI, V112, P1237; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; Romagnolo B, 1999, CANCER RES, V59, P3875; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; van de Wetering M, 2001, CANCER RES, V61, P278; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wicki A, 2006, CANCER CELL, V9, P261, DOI 10.1016/j.ccr.2006.03.010	33	99	105	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2007	26	16					2290	2298		10.1038/sj.onc.1210029	http://dx.doi.org/10.1038/sj.onc.1210029			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17043652				2022-12-17	WOS:000245466000005
J	Benzeno, S; Lu, F; Guo, M; Barbash, O; Zhang, F; Herman, JG; Klein, PS; Rustgi, A; Diehl, JA				Benzeno, S.; Lu, F.; Guo, M.; Barbash, O.; Zhang, F.; Herman, J. G.; Klein, P. S.; Rustgi, A.; Diehl, J. A.			Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1	ONCOGENE			English	Article						cyclin D1; GSK-3 beta; CDK4; nuclear export; cancer	GLYCOGEN-SYNTHASE KINASE-3; CDK INHIBITORS; CELL-CYCLE; ESTROGEN-RECEPTOR; SUBSTRATE-SPECIFICITY; BARRETTS-ESOPHAGUS; HUMAN CANCER; PROTEIN; GENE; RAS	Although cyclin D1 is overexpressed in a significant number of human cancers, overexpression alone is insufficient to promote tumorigenesis. In vitro studies have revealed that inhibition of cyclin D1 nuclear export unmasks its neoplastic potential. Cyclin D1 nuclear export depends upon phosphorylation of a C-terminal residue, threonine 286, (Thr-286) which in turn promotes association with the nuclear exportin, CRM1. Mutation of Thr-286 to a non-phosphorylatable residue results in a constitutively nuclear cyclin D1 protein with significantly increased oncogenic potential. To determine whether cyclin D1 is subject to mutations that inhibit its nuclear export in human cancer, we have sequenced exon 5 of cyclin D1 in primary esophageal carcinoma samples and in cell lines derived from esophageal cancer. Our work reveals that cyclin D1 is subject to mutations in primary human cancer. The mutations identified specifically disrupt phosphorylation of cyclin D1 at Thr-286, thereby enforcing nuclear accumulation of cyclin D1. Through characterization of these mutants, we also de. ne an acidic residue within the C-terminus of cyclin D1 that is necessary for recognition and phosphorylation of cyclin D1 by glycogen synthase kinase-3 beta. Finally, through construction of compound mutants, we demonstrate that cell transformation by the cancer-derived cyclin D1 alleles correlates with their ability to associate with and activate CDK4. Our data reveal that cyclin D1 is subject to mutations in primary human cancer that specifically disrupt phosphorylation-dependent nuclear export of cyclin D1 and suggest that such mutations contribute to the genesis and progression of neoplastic growth.	Univ Penn, Leonard & Madlyn Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Dept Hematol Oncol, Baltimore, MD 21205 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Johns Hopkins University; Johns Hopkins Medicine; University of Pennsylvania	Diehl, JA (corresponding author), Univ Penn, Leonard & Madlyn Abramson Family Canc Res Inst, Dept Canc Biol, 454 BRB II-III,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA093237, R01CA111360] Funding Source: NIH RePORTER; NCI NIH HHS [CA111360, R01 CA093237, CA93237] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADELAIDE J, 1995, BRIT J CANCER, V71, P64, DOI 10.1038/bjc.1995.13; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alt JR, 2002, J BIOL CHEM, V277, P8517, DOI 10.1074/jbc.M108867200; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Arber N, 1996, CANCER EPIDEM BIOMAR, V5, P457; Bani-Hani K, 2000, J NATL CANCER I, V92, P1316, DOI 10.1093/jnci/92.16.1316; Bax B, 2001, STRUCTURE, V9, P1143, DOI 10.1016/S0969-2126(01)00679-7; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Benzeno S, 2004, J BIOL CHEM, V279, P56061, DOI 10.1074/jbc.M411910200; Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Calbo J, 2002, J BIOL CHEM, V277, P50263, DOI 10.1074/jbc.M209181200; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Collecchi P, 2000, CYTOMETRY, V42, P254; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; Fry DW, 2004, MOL CANCER THER, V3, P1427; Fry DW, 2001, J BIOL CHEM, V276, P16617, DOI 10.1074/jbc.M008867200; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; GLADDEN AB, 2005, ONCOGENE, V25, P1620; Hagen T, 2002, J BIOL CHEM, V277, P23330, DOI 10.1074/jbc.M201364200; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; Hedgepeth CM, 1999, MOL CELL BIOL, V19, P7147; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Hirai H, 1996, MOL CELL BIOL, V16, P6457; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lamb J, 2000, MOL CELL BIOL, V20, P8667, DOI 10.1128/MCB.20.23.8667-8675.2000; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Lin J, 2004, SEMIN ONCOL, V31, P476, DOI 10.1053/j.seminoncol.2004.04.019; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Lu FM, 2003, CANCER RES, V63, P7056; LUKAS J, 1994, ONCOGENE, V9, P2159; Moreno-Bueno G, 2003, ONCOGENE, V22, P6115, DOI 10.1038/sj.onc.1206868; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; PARK IK, 1994, J BIOL CHEM, V269, P944; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Rimerman RA, 2000, J BIOL CHEM, V275, P14736, DOI 10.1074/jbc.M910241199; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Winston JT, 1996, ONCOGENE, V12, P127; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	75	99	100	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2006	25	47					6291	6303		10.1038/sj.onc.1209644	http://dx.doi.org/10.1038/sj.onc.1209644			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16732330				2022-12-17	WOS:000241218200006
J	Genovese, C; Trani, D; Caputi, M; Claudio, PP				Genovese, C.; Trani, D.; Caputi, M.; Claudio, P. P.			Cell cycle control and beyond: emerging roles for the retinoblastoma gene family	ONCOGENE			English	Review						cell cycle; retinoblastoma; DNA damage; DNA repair; chromatin remodelling	DOUBLE-STRAND BREAKS; DNA-DAMAGE; HISTONE DEACETYLASE; S-PHASE; TRANSCRIPTIONAL REPRESSION; TUMOR-SUPPRESSOR; KINASE-ACTIVITY; G(1) CONTROL; IN-VIVO; P107	Rb family proteins (pRb/p105, Rb2/p130 and p107) play a key role in cell cycle control and are worthily involved in transcription repression and tumor suppression. The mechanisms of transcriptional activation and repression by the Rb gene family has been extensively investigated: pRb, pRb2/p130 and p107 interact with different E2F family factors and can inhibit E2F responsive promoters, interfering with progression of cell cycle, gene transcription, initiation of apoptotic process and cell differentiation. Recent studies have indicated that Rb and Rb2/p130 may be involved in cellular response to DNA damage events, by influencing the transcription of factors involved in DNA repair pathways. In particular, evidences suggest that Rb loss and target gene deregulation impacts on the repair of UV-induced pyrimidine pyrimidone photoproducts (6-4 PP) by regulating the expression of several DNA damage factors involved in UV DNA damage repair processes, including proliferating cell nuclear antigen. Ongoing studies are focused on the mechanisms by which Rb family genes drive cell cycle exit following DNA damage induction, and how Rb gene family's interaction with chromatin remodeling factors can influence DNA repair dynamics.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Naples 2, Osp A Monaldi, Dipartimento Sci Cardio Toraciche & Resp, Naples, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Universita della Campania Vanvitelli	Claudio, PP (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, BioLife Sci Bldg Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.	claudio@temple.edu	Claudio, Pier Paolo/AAW-7282-2021	Claudio, Pier Paolo/0000-0001-7790-1622				Angus SP, 2004, MOL CELL BIOL, V24, P5404, DOI 10.1128/MCB.24.12.5404-5420.2004; Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Bartek J, 2003, NATURE, V421, P486, DOI 10.1038/421486a; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bosco EE, 2005, NUCLEIC ACIDS RES, V33, P1581, DOI 10.1093/nar/gki283; Bosco EE, 2004, NUCLEIC ACIDS RES, V32, P25, DOI 10.1093/nar/gkg919; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Classon M, 2000, P NATL ACAD SCI USA, V97, P10820, DOI 10.1073/pnas.190343497; Claudio P, 2002, GENOME BIOL, V3; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Galderisi U, 2003, ONCOGENE, V22, P5208, DOI 10.1038/sj.onc.1206558; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Howard CM, 1998, J NATL CANCER I, V90, P1451, DOI 10.1093/jnci/90.19.1451; Howard CM, 2000, CANCER RES, V60, P2737; Hsieh JK, 2002, MOL CELL BIOL, V22, P78, DOI 10.1128/MCB.22.1.78-93.2002; Hunter N, 2001, NAT GENET, V27, P236, DOI 10.1038/85781; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Jorl FP, 2005, CELL DEATH DIFFER, V12, P65, DOI 10.1038/sj.cdd.4401499; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Korenjak M, 2004, CELL, V119, P181, DOI 10.1016/j.cell.2004.09.034; Kulms D, 2002, J DERMATOL, V29, P189, DOI 10.1111/j.1346-8138.2002.tb00248.x; Lan ZD, 2002, J BIOL CHEM, V277, P8372, DOI 10.1074/jbc.M108906200; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Markey MP, 2002, CANCER RES, V62, P6587; Mayhew Christopher N, 2004, Methods Mol Biol, V281, P3; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Munger K, 2003, P NATL ACAD SCI USA, V100, P2165, DOI 10.1073/pnas.0630419100; Naderi S, 2002, CELL CYCLE, V1, P193, DOI 10.4161/cc.1.3.125; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Paggi MG, 2001, CANCER RES, V61, P4651; Pastwa E, 2003, ACTA BIOCHIM POL, V50, P891; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rodier G, 2005, J CELL BIOL, V168, P55, DOI 10.1083/jcb.200404146; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Ross JF, 2001, GENE DEV, V15, P392, DOI 10.1101/gad.858501; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Ruiz S, 2003, DEVELOPMENT, V130, P2341, DOI 10.1242/dev.00453; Sabelli PA, 2005, P NATL ACAD SCI USA, V102, P13005, DOI 10.1073/pnas.0506160102; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Sharova NP, 2005, BIOCHEMISTRY-MOSCOW+, V70, P275, DOI 10.1007/s10541-005-0113-4; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stiegler P, 1998, CANCER RES, V58, P5049; Taylor-Harding B, 2004, MOL CELL BIOL, V24, P9124, DOI 10.1128/MCB.24.20.9124-9136.2004; Tonini T, 2002, J CELL PHYSIOL, V192, P138, DOI 10.1002/jcp.10117; Wang JYJ, 2001, ACTA ONCOL, V40, P689; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	75	99	102	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5201	5209		10.1038/sj.onc.1209652	http://dx.doi.org/10.1038/sj.onc.1209652			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936738				2022-12-17	WOS:000240064100003
J	Hao, B; Miao, X; Li, Y; Zhang, X; Sun, T; Liang, G; Zhao, Y; Zhou, Y; Wang, H; Chen, X; Zhang, L; Tan, W; Wei, Q; Lin, D; He, F				Hao, B.; Miao, X.; Li, Y.; Zhang, X.; Sun, T.; Liang, G.; Zhao, Y.; Zhou, Y.; Wang, H.; Chen, X.; Zhang, L.; Tan, W.; Wei, Q.; Lin, D.; He, F.			A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer	ONCOGENE			English	Article						base excision repair; non-small cell lung cancer; single nucleotide polymorphism; transcription regulation	ACID SUBSTITUTION VARIANTS; LINKAGE PHASE; ASSOCIATIONS; TRANSCRIPTION; ADDUCTS; XPD; SUSCEPTIBILITY; IDENTIFICATION; CARCINOGENS; BIOMARKERS	X-ray repair cross-complementing 1 (XRCC1) plays a key role in DNA base excision repair and cells lacking its activity are hypersensitive to DNA damage. Recently, we reported a SNP (rs3213245, -77T > C) in the XRCC1 gene 5' untranslated region (UTR) was significantly associated with the risk of developing esophageal squamous-cell carcinoma. Computer analysis predicted that this SNP was in the core of Sp1-binding motif, which suggested its functional significance. Gel shift and super shift assays confirmed that -77T > C polymorphic site in the XRCC1 promoter was within the Sp1-binding motif and the T > C substitution greatly enhanced the binding affinity of Sp1 to this region. Luciferase assays indicated that the Sp1-high-affinity C-allelic XRCC1 promoter was associated with a reduced transcriptional activity. The association between -77T > C and three other amino-acid substitution-causing polymorphisms in XRCC1 and risk of lung cancer was examined in 1024 patients and 1118 controls and the results showed that only the -77T > C polymorphism was significantly associated with an increased risk of developing lung cancer. Multivariate logistic regression analysis found that an increased risk of lung cancer was associated with the variant XRCC1 -77 genotypes (TC and CC) compared with the TT genotype (OR 1.46, 95% CI 1.18-1.82; P = 0.001) and the increased risk was more pronounced in smokers (OR 1.63, 95% CI 1.20-2.21) than in non-smokers (OR 1.28, 95% CI 0.94-1.76). Taken together, these results showed that the functional SNP -77T > C in XRCC1 5'UTR was associated with cancer development owing to the decreased transcriptional activity of C-allele-containing promoter with higher affinity to Sp1 binding.	Chinese Acad Med Sci, Dept Etiol & Carcinogenesis, Canc Inst & Hosp, Beijing 100037, Peoples R China; Peking Union Med Coll, Beijing, Peoples R China; Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China; Beijing Inst Radiat Med, Lab Syst Biol, Beijing, Peoples R China; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Tsinghua University; Academy of Military Medical Sciences - China; University of Texas System; UTMD Anderson Cancer Center	Lin, D (corresponding author), Chinese Acad Med Sci, Dept Etiol & Carcinogenesis, Inst Canc, Beijing 100021, Peoples R China.	dlin@public.bta.net.cn; hefc@nic.bmi.ac.cn	miao, xiaoping/C-4336-2011; Zhao, Yanlin/L-2773-2013; Wang, Weili/D-1546-2011; zhang, xuemei/F-3818-2010; Zhao, Yanlin/M-2360-2013; hao, Bingtao/G-6648-2011	miao, xiaoping/0000-0002-6818-9722; Zhao, Yanlin/0000-0002-0278-7543; Zhao, Yanlin/0000-0002-0278-7543; hao, Bingtao/0000-0003-1997-9338				Caldecott KW, 2003, DNA REPAIR, V2, P955, DOI 10.1016/S1568-7864(03)00118-6; Dean G, 2000, J BIOL CHEM, V275, P32664, DOI 10.1074/jbc.275.42.32664; Ding KY, 2003, BIOINFORMATICS, V19, P2147, DOI 10.1093/bioinformatics/btg276; Duell EJ, 2000, CARCINOGENESIS, V21, P965, DOI 10.1093/carcin/21.5.965; GONZALEZ FJ, 1995, CANCER RES, V55, P710; Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513; Hao BT, 2004, CANCER RES, V64, P4378, DOI 10.1158/0008-5472.CAN-04-0372; Hecht SS, 2003, NAT REV CANCER, V3, P733, DOI 10.1038/nrc1190; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hu JJ, 2001, CARCINOGENESIS, V22, P917, DOI 10.1093/carcin/22.6.917; Hu ZB, 2005, PHARMACOGENET GENOM, V15, P457, DOI 10.1097/01.fpc.0000167329.85163.0d; Ioannidis JPA, 2003, LANCET, V361, P567, DOI 10.1016/S0140-6736(03)12516-0; Kelsey KT, 2004, CANCER EPIDEM BIOMAR, V13, P1337; Lake SL, 2003, HUM HERED, V55, P56, DOI 10.1159/000071811; Li J, 2001, J VIROL, V75, P8400, DOI 10.1128/JVI.75.18.8400-8406.2001; Liang G, 2003, INT J CANCER, V105, P669, DOI 10.1002/ijc.11136; Lunn RM, 1999, CANCER RES, V59, P2557; Matullo G, 2001, INT J CANCER, V92, P562, DOI 10.1002/ijc.1228; Matullo G, 2001, CARCINOGENESIS, V22, P1437, DOI 10.1093/carcin/22.9.1437; Mohrenweiser HW, 2002, CANCER EPIDEM BIOMAR, V11, P1054; NAKACHI K, 1993, CANCER RES, V53, P2994; Pagliuca A, 1998, J BIOL CHEM, V273, P7668, DOI 10.1074/jbc.273.13.7668; Palli D, 2001, INT J CANCER, V94, P121, DOI 10.1002/ijc.1433; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; Shen MR, 1998, CANCER RES, V58, P604; Shou YP, 1998, J BIOL CHEM, V273, P5716, DOI 10.1074/jbc.273.10.5716; Shu XO, 2003, CANCER EPIDEM BIOMAR, V12, P1462; Sturgis EM, 1999, CARCINOGENESIS, V20, P2125, DOI 10.1093/carcin/20.11.2125; Sun T, 2004, JNCI-J NATL CANCER I, V96, P1030, DOI 10.1093/jnci/djh187; Tebbs RS, 1999, DEV BIOL, V208, P513, DOI 10.1006/dbio.1999.9232; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; Vineis P, 1997, INT J CANCER, V71, P1, DOI 10.1002/(SICI)1097-0215(19970328)71:1<1::AID-IJC1>3.0.CO;2-Y; Wang HJ, 2003, CANCER RES, V63, P8057; Wang YF, 2003, DNA REPAIR, V2, P901, DOI 10.1016/S1568-7864(03)00085-5; WEINFELD M, 2001, CELL, V104, P107; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Xing DY, 2002, INT J CANCER, V100, P600, DOI 10.1002/ijc.10528; Zhou W, 2003, CANCER EPIDEM BIOMAR, V12, P359	39	99	107	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3613	3620		10.1038/sj.onc.1209355	http://dx.doi.org/10.1038/sj.onc.1209355			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16652158				2022-12-17	WOS:000238448200014
J	Mathis, JM; Stoff-Khalili, MA; Curiel, DT				Mathis, JM; Stoff-Khalili, MA; Curiel, DT			Oncolytic adenoviruses - selective retargeting to tumor cells	ONCOGENE			English	Review						adenovirus; oncolytic; transduction; retargeting; virotherapy	REPLICATION-COMPETENT ADENOVIRUS; VESICULAR STOMATITIS-VIRUS; GROWTH-FACTOR RECEPTOR; CANCER GENE-THERAPY; PHASE-I TRIAL; 2 CANINE ADENOVIRUSES; PSEUDOTYPED RETROVIRAL VECTORS; MEDIATED TRANSGENE EXPRESSION; RECURRENT PROSTATE-CANCER; EPITHELIAL OVARIAN-CANCER	Virotherapy is an approach for the treatment of cancer, in which the replicating virus itself is the anticancer agent. Virotherapy exploits the lytic property of virus replication to kill tumor cells. As this approach relies on viral replication, the virus can self-amplify and spread in the tumor from an initial infection of only a few cells. The success of this approach is fundamentally based on the ability to deliver the replication-competent viral genome to target cells with a requisite level of efficiency. With virotherapy, while a number of transcriptional retargeting strategies have been utilized to restrict viral replication to tumor cells, this review will focus primarily on transductional retargeting strategies, whereby oncolytic viruses can be designed to selectively infect tumor cells. Using the adenoviral vector paradigm, there are three broad strategies useful for viral retargeting. One strategy uses heterologous retargeting ligands that are bispecific in that they bind both to the viral vector as well as to a cell surface target. A second strategy uses genetically modified viral vectors in which a cellular retargeting ligand is incorporated. A third strategy involves the construction of chimeric recombinant vectors, in which a capsid protein from one virus is exchanged for that of another. These transductional retargeting strategies have the potential for reducing deleterious side effects, and increasing the therapeutic index of virotherapeutic agents.	Univ Alabama, Dept Med, Div Human & Gene Therapy, Birmingham, AL 35294 USA; Univ Alabama, Dept Pathol, Div Human & Gene Therapy, Birmingham, AL 35294 USA; Univ Alabama, Dept Surg, Div Human & Gene Therapy, Birmingham, AL 35294 USA; Louisiana State Univ, Hlth Sci Ctr, Gene Therapy Program, Dept Cellular Biol & Anat, Shreveport, LA 71130 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Curiel, DT (corresponding author), Univ Alabama, Dept Med, Div Human & Gene Therapy, 901 19th St S,BMR2-508, Birmingham, AL 35294 USA.	david.curiel@ccc.uab.edu	Mathis, J. Michael/J-1379-2018	Mathis, J. Michael/0000-0001-5528-5195	NATIONAL CANCER INSTITUTE [P50CA086306] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA86306] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi Y, 2001, CANCER RES, V61, P7882; Akalu A, 1999, J VIROL, V73, P6182, DOI 10.1128/JVI.73.7.6182-6187.1999; Alemany R, 2000, J GEN VIROL, V81, P2605, DOI 10.1099/0022-1317-81-11-2605; Alemany R, 2000, NAT BIOTECHNOL, V18, P723, DOI 10.1038/77283; Alemany R, 2001, GENE THER, V8, P1347, DOI 10.1038/sj.gt.3301515; Anderson BD, 2004, CANCER RES, V64, P4919, DOI 10.1158/0008-5472.CAN-04-0884; Arai T, 1998, J VIROL, V72, P1115, DOI 10.1128/JVI.72.2.1115-1121.1998; Arnberg N, 2000, J VIROL, V74, P42, DOI 10.1128/JVI.74.1.42-48.2000; Arnberg N, 2002, VIROLOGY, V302, P33, DOI 10.1006/viro.2002.1503; Asaoka K, 2000, J NEUROSURG, V92, P1002, DOI 10.3171/jns.2000.92.6.1002; Atkins GJ, 2004, CURR CANCER DRUG TAR, V4, P597, DOI 10.2174/1568009043332754; Banerjee NS, 2004, MOL CANCER THER, V3, P437; Barker SD, 2003, GENE THER, V10, P1198, DOI 10.1038/sj.gt.3301974; Baxi MK, 2000, VIROLOGY, V278, P234, DOI 10.1006/viro.2000.0661; Belousova N, 2003, J VIROL, V77, P11367, DOI 10.1128/JVI.77.21.11367-11377.2003; Belousova N, 2002, J VIROL, V76, P8621, DOI 10.1128/JVI.76.17.8621-8631.2002; Bennett JJ, 2001, NAT MED, V7, P859, DOI 10.1038/89991; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bergelson JM, 1998, J VIROL, V72, P415, DOI 10.1128/JVI.72.1.415-419.1998; Bhaumik S, 2002, P NATL ACAD SCI USA, V99, P377, DOI 10.1073/pnas.012611099; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Blackwell JL, 1999, ARCH OTOLARYNGOL, V125, P856, DOI 10.1001/archotol.125.8.856; Blackwell JL, 2000, HUM GENE THER, V11, P1657, DOI 10.1089/10430340050111313; Borovjagin AV, 2005, CANCER GENE THER, V12, P475, DOI 10.1038/sj.cgt.7700806; Breidenbach M, 2004, HUM GENE THER, V15, P509, DOI 10.1089/10430340460745829; Brunetti-Pierri N, 2004, HUM GENE THER, V15, P35, DOI 10.1089/10430340460732445; Buller RE, 2002, CANCER GENE THER, V9, P553, DOI 10.1038/sj.cgt.7700472; Cashman SM, 2004, VIROLOGY, V324, P129, DOI 10.1016/j.virol.2004.04.001; Chen J, 2005, GENE THER, V12, P1079, DOI 10.1038/sj.gt.3302494; Chen J, 2001, HUM GENE THER, V12, P61, DOI 10.1089/104303401450979; Cherenova LV, 2004, VIRUS RES, V100, P257, DOI 10.1016/j.virusres.2003.11.018; Chiocca EA, 2004, MOL THER, V10, P958, DOI 10.1016/j.ymthe.2004.07.021; Cho JY, 2002, GENE THER, V9, P1139, DOI 10.1038/sj.gt.3301787; Christ M, 2000, HUM GENE THER, V11, P415, DOI 10.1089/10430340050015888; COLBY WW, 1981, J VIROL, V39, P977, DOI 10.1128/JVI.39.3.977-980.1981; Cosset FL, 1996, GENE THER, V3, P946; Cripe TP, 2001, CANCER RES, V61, P2953; Csatary LK, 2004, J NEURO-ONCOL, V67, P83, DOI 10.1023/B:NEON.0000021735.85511.05; Curiel D, 2002, ADENOVIRAL VECTORS G; CURTIS R, 1983, VET REC, V112, P347, DOI 10.1136/vr.112.15.347; Davydova J, 2004, CANCER RES, V64, P4319, DOI 10.1158/0008-5472.CAN-04-0064; Denby L, 2004, HUM GENE THER, V15, P1054, DOI 10.1089/hum.2004.15.1054; DEVAUX C, 1990, J MOL BIOL, V215, P567, DOI 10.1016/S0022-2836(05)80169-X; DeWeese TL, 2001, CANCER RES, V61, P7464; Dingli D, 2004, BLOOD, V103, P1641, DOI 10.1182/blood-2003-07-2233; Dirven CMF, 2002, J NEUROSURG, V97, P441, DOI 10.3171/jns.2002.97.2.0441; Dmitriev I, 2000, J VIROL, V74, P6875, DOI 10.1128/JVI.74.15.6875-6884.2000; Dmitriev I, 1998, J VIROL, V72, P9706, DOI 10.1128/JVI.72.12.9706-9713.1998; Dmitriev IP, 2002, J VIROL, V76, P6893, DOI 10.1128/JVI.76.14.6893-6899.2002; Doronin K, 2000, J VIROL, V74, P6147, DOI 10.1128/JVI.74.13.6147-6155.2000; Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574; Ebert O, 2005, CANCER GENE THER, V12, P350, DOI 10.1038/sj.cgt.7700794; Edwards BK, 2002, CANCER-AM CANCER SOC, V94, P2766, DOI 10.1002/cncr.10593; Einfeld DA, 1999, J VIROL, V73, P9130, DOI 10.1128/JVI.73.11.9130-9136.1999; Everett RS, 2003, HUM GENE THER, V14, P1715, DOI 10.1089/104303403322611737; Everts M, 2005, GENE THER, V12, P1042, DOI 10.1038/sj.gt.3302491; Farina SF, 2001, J VIROL, V75, P11603, DOI 10.1128/JVI.75.23.11603-11613.2001; Freytag SO, 2002, CANCER RES, V62, P4968; Freytag SO, 2003, CANCER RES, V63, P7497; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; Fuxe J, 2003, INT J CANCER, V103, P723, DOI 10.1002/ijc.10891; Galanis E, 2001, BRIT J CANCER, V85, P1432, DOI 10.1054/bjoc.2001.2129; Galanis E, 2005, GENE THER, V12, P437, DOI 10.1038/sj.gt.3302436; Gall J, 1996, J VIROL, V70, P2116, DOI 10.1128/JVI.70.4.2116-2123.1996; Ganly I, 2000, CLIN CANCER RES, V6, P798; Ganly I, 2001, GENE THER, V8, P369, DOI 10.1038/sj.gt.3301402; Geoerger B, 2003, BRIT J CANCER, V89, P577, DOI 10.1038/sj.bjc.6601102; Glasgow JN, 2004, VIROLOGY, V324, P103, DOI 10.1016/j.virol.2004.03.028; Glotzer JB, 2001, J VIROL, V75, P2421, DOI 10.1128/JVI.75.5.2421-2434.2001; Goldman CK, 1997, CANCER RES, V57, P1447; Goossens PH, 2001, ARTHRITIS RHEUM, V44, P570, DOI 10.1002/1529-0131(200103)44:3<570::AID-ANR105>3.0.CO;2-Y; Grill J, 2001, CLIN CANCER RES, V7, P641; GRUBER WC, 1993, VIROLOGY, V196, P603, DOI 10.1006/viro.1993.1516; Habib N, 2002, CANCER GENE THER, V9, P254, DOI 10.1038/sj.cgt.7700431; Haisma HJ, 2000, CANCER GENE THER, V7, P901, DOI 10.1038/sj.cgt.7700198; Hallden G, 2003, MOL THER, V8, P412, DOI 10.1016/S1525-0016(03)00199-0; Hallenbeck PL, 1999, HUM GENE THER, V10, P1721, DOI 10.1089/10430349950017725; Hammond JM, 2005, VET J, V169, P17, DOI 10.1016/j.tvjl.2003.09.007; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Harrow S, 2004, GENE THER, V11, P1648, DOI 10.1038/sj.gt.3302289; Haviv YS, 2002, CANCER RES, V62, P4273; Hay JG, 2004, TRENDS BIOTECHNOL, V22, P501, DOI 10.1016/j.tibtech.2004.08.002; Hay JG, 1999, HUM GENE THER, V10, P579, DOI 10.1089/10430349950018652; HEDLEY SJ, 2005, IN PRESS GENE THERAP; HEINZERLING L, 2005, BLOOD           0616; Hemmi S, 1998, HUM GENE THER, V9, P2363, DOI 10.1089/hum.1998.9.16-2363; Hemminki A, 2001, MOL THER, V4, P223, DOI 10.1006/mthe.2001.0446; Henning P, 2005, GENE THER, V12, P211, DOI 10.1038/sj.gt.3302408; HENRY LJ, 1994, J VIROL, V68, P5239, DOI 10.1128/JVI.68.8.5239-5246.1994; HERRERO YC, 2004, INT J CANCER, V109, P76, DOI DOI 10.1002/IJC.11626; Herschman HR, 2004, ADV CANCER RES, V92, P29, DOI 10.1016/S0065-230X(04)92003-9; Hong JS, 1996, J VIROL, V70, P7071, DOI 10.1128/JVI.70.10.7071-7078.1996; Hong SS, 1997, EMBO J, V16, P2294, DOI 10.1093/emboj/16.9.2294; Hu J, 2003, MOL THER, V8, P611, DOI 10.1016/S1525-0016(03)00239-9; Irving J, 2004, CANCER GENE THER, V11, P174, DOI 10.1038/sj.cgt.7700666; Itoh A, 2003, J GENE MED, V5, P929, DOI 10.1002/jgm.430; Joung I, 2005, BIOCHEM BIOPH RES CO, V328, P1182, DOI 10.1016/j.bbrc.2005.01.080; Kanerva A, 2002, CLIN CANCER RES, V8, P275; Kanerva A, 2005, GENE THER, V12, P87, DOI 10.1038/sj.gt.3302387; Kanerva A, 2004, GENE THER, V11, P552, DOI 10.1038/sj.gt.3302181; Kashentseva EA, 2002, CANCER RES, V62, P609; Kawakami Y, 2003, CANCER RES, V63, P1262; Kawashima H, 2003, CANCER SCI, V94, P70, DOI 10.1111/j.1349-7006.2003.tb01354.x; Kelly FJ, 2000, CLIN CANCER RES, V6, P4323; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kim J, 2002, J VIROL, V76, P1892, DOI 10.1128/JVI.76.4.1892-1903.2002; Kim M, 2003, BRIT J CANCER, V88, P1411, DOI 10.1038/sj.bjc.6600932; Kim M, 2002, EUR J CANCER, V38, P1917, DOI 10.1016/S0959-8049(02)00131-4; Kim SH, 2005, EUR J CANCER, V41, P313, DOI 10.1016/j.ejca.2004.10.018; Kirby TO, 2004, CLIN CANCER RES, V10, P8697, DOI 10.1158/1078-0432.CCR-04-1166; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Koizumi N, 2003, J GENE MED, V5, P267, DOI 10.1002/jgm.348; Korn T, 2004, J GENE MED, V6, P642, DOI 10.1002/jgm.555; Korokhov N, 2003, J VIROL, V77, P12931, DOI 10.1128/JVI.77.24.12931-12940.2003; Kraaij R, 2005, PROSTATE, V62, P253, DOI 10.1002/pros.20150; Krasnykh V, 1998, J VIROL, V72, P1844, DOI 10.1128/JVI.72.3.1844-1852.1998; Krasnykh V, 2001, J VIROL, V75, P4176, DOI 10.1128/JVI.75.9.4176-4183.2001; Krasnykh VN, 1996, J VIROL, V70, P6839, DOI 10.1128/JVI.70.10.6839-6846.1996; Kremer EJ, 2000, J VIROL, V74, P505, DOI 10.1128/JVI.74.1.505-512.2000; Kremer EJ, 2004, J GENE MED, V6, pS139, DOI 10.1002/jgm.497; Kruyt FAE, 2002, HUM GENE THER, V13, P485, DOI 10.1089/10430340252809784; Kurihara T, 2000, J CLIN INVEST, V106, P763, DOI 10.1172/JCI9180; Lam JT, 2004, J GENE MED, V6, P1333, DOI 10.1002/jgm.635; Lamont JP, 2000, ANN SURG ONCOL, V7, P588, DOI 10.1007/BF02725338; Lang FF, 2003, J CLIN ONCOL, V21, P2508, DOI 10.1200/JCO.2003.21.13.2508; Le LP, 2004, MOL IMAGING, V3, P105, DOI 10.1162/1535350041464874; Lee H, 2001, GENE THER, V8, P268, DOI 10.1038/sj.gt.3301390; Lehmberg E, 1999, J CHROMATOGR B, V732, P411, DOI 10.1016/S0378-4347(99)00316-3; Li DQ, 1999, CLIN CANCER RES, V5, P4175; Li J, 2005, VIROLOGY, V338, P247, DOI 10.1016/j.virol.2005.04.005; Liang Q, 2002, GENE THER, V9, P1659, DOI 10.1038/sj.gt.3301899; Lichty BD, 2004, HUM GENE THER, V15, P821, DOI 10.1089/1043034041839208; Liu R, 2005, GENE THER, V12, P647, DOI 10.1038/sj.gt.3302445; Liu RB, 2005, CANCER RES, V65, P1532, DOI 10.1158/0008-5472.CAN-04-3353; LOUIS N, 1994, J VIROL, V68, P4104, DOI 10.1128/JVI.68.6.4104-4106.1994; Lu W, 2004, WORLD J GASTROENTERO, V10, P3634, DOI 10.3748/wjg.v10.i24.3634; Lutz P, 1997, J VIROL, V71, P5102, DOI 10.1128/JVI.71.7.5102-5109.1997; Magnusson MK, 2002, J GENE MED, V4, P356, DOI 10.1002/jgm.285; Magnusson MK, 2001, J VIROL, V75, P7280, DOI 10.1128/JVI.75.16.7280-7289.2001; Makower D, 2003, CLIN CANCER RES, V9, P693; MARUSYK RG, 1972, MICROBIOS, V5, P259; MARUSYK RG, 1972, CAN J MICROBIOL, V18, P817, DOI 10.1139/m72-127; MARUSYK RG, 1970, J VIROL, V5, P507, DOI 10.1128/JVI.5.4.507-512.1970; MARUSYK RG, 1971, CAN J MICROBIOL, V17, P151, DOI 10.1139/m71-026; Mastrangeli A, 1996, HUM GENE THER, V7, P79, DOI 10.1089/hum.1996.7.1-79; McDonald D, 1999, GENE THER, V6, P1512, DOI 10.1038/sj.gt.3301006; Mercier GT, 2004, P NATL ACAD SCI USA, V101, P6188, DOI 10.1073/pnas.0400542101; Meulenbroek RA, 2004, MOL THER, V9, P617, DOI 10.1016/j.ymthe.2004.01.012; MICHAEL SI, 1995, GENE THER, V2, P660; Miller CR, 1998, CANCER RES, V58, P5738; Miyazawa N, 1999, J VIROL, V73, P6056, DOI 10.1128/JVI.73.7.6056-6065.1999; Mizuguchi H, 2001, GENE THER, V8, P730, DOI 10.1038/sj.gt.3301453; Mulvihlll S, 2001, GENE THER, V8, P308, DOI 10.1038/sj.gt.3301398; Muster T, 2004, INT J CANCER, V110, P15, DOI 10.1002/ijc.20078; Myers R, 2005, CANCER GENE THER, V12, P593, DOI 10.1038/sj.cgt.7700823; Nakamura T, 2003, J VIROL, V77, P2512, DOI 10.1128/JVI.77.4.2512-2521.2003; Nemunaitis J, 2001, J CLIN ONCOL, V19, P289, DOI 10.1200/JCO.2001.19.2.289; Nettelbeck DM, 2002, CANCER RES, V62, P4663; Nicklin SA, 2001, MOL THER, V4, P534, DOI 10.1006/mthe.2001.0489; Nicol CG, 2004, MOL THER, V10, P344, DOI 10.1016/j.ymthe.2004.05.020; Nilson BHK, 1996, GENE THER, V3, P280; Nilsson M, 2004, J GENE MED, V6, P631, DOI 10.1002/jgm.543; Norman KL, 2004, P NATL ACAD SCI USA, V101, P11099, DOI 10.1073/pnas.0404310101; NOUREDDINI SC, 2005, IN PRESS J VIROL; Pagliaro LC, 2003, J CLIN ONCOL, V21, P2247, DOI 10.1200/JCO.2003.09.138; Parikh NS, 2005, PEDIATR BLOOD CANCER, V44, P469, DOI 10.1002/pbc.20268; Peng KW, 2002, NAT MED, V8, P527, DOI 10.1038/nm0502-527; Penuelas I, 2005, GASTROENTEROLOGY, V128, P1787, DOI 10.1053/j.gastro.2005.03.024; Portella G, 2002, J CLIN ENDOCR METAB, V87, P2525, DOI 10.1210/jc.87.6.2525; Qin M, 2003, CLIN CANCER RES, V9, P4992; Raki M, 2005, GENE THER, V12, P1198, DOI 10.1038/sj.gt.3302517; Raper SE, 2003, MOL GENET METAB, V80, P148, DOI 10.1016/j.ymgme.2003.08.016; Raykov Z, 2004, INT J CANCER, V109, P742, DOI 10.1002/ijc.20013; Reddy PS, 2003, VIROLOGY, V311, P384, DOI 10.1016/S0042-6822(03)00161-2; Reid T, 2001, GENE THER, V8, P1618, DOI 10.1038/sj.gt.3301512; Rein DT, 2005, CLIN CANCER RES, V11, P1327; Reynolds PN, 2000, MOL THER, V2, P562, DOI 10.1006/mthe.2000.0205; Rivera AA, 2004, GENE THER, V11, P1694, DOI 10.1038/sj.gt.3302346; ROUX P, 1989, P NATL ACAD SCI USA, V86, P9079, DOI 10.1073/pnas.86.23.9079; RUIGROK RWH, 1990, J MOL BIOL, V215, P589, DOI 10.1016/S0022-2836(05)80170-6; Sachs MD, 2002, UROLOGY, V60, P531, DOI 10.1016/S0090-4295(02)01748-X; Sauthoff H, 2002, HUM GENE THER, V13, P1859, DOI 10.1089/104303402760372954; Schaack J, 2005, VIRAL IMMUNOL, V18, P79, DOI 10.1089/vim.2005.18.79; Schuler M, 2001, J CLIN ONCOL, V19, P1750, DOI 10.1200/JCO.2001.19.6.1750; Segerman A, 2003, J VIROL, V77, P9183, DOI 10.1128/JVI.77.17.9183-9191.2003; Segerman A, 2003, J VIROL, V77, P1157, DOI 10.1128/JVI.77.2.1157-1162.2003; Shayakhmetov DM, 2000, J VIROL, V74, P2567, DOI 10.1128/JVI.74.6.2567-2583.2000; Shayakhmetov DM, 2005, J VIROL, V79, P7478, DOI 10.1128/JVI.79.12.7478-7491.2005; Shayakhmetov DM, 2005, J VIROL, V79, P1053, DOI 10.1128/JVI.79.2.1053-1061.2005; Shayakhmetov DM, 2004, J VIROL, V78, P5368, DOI 10.1128/JVI.78.10.5368-5381.2004; Shi J, 2005, CANCER RES, V65, P1687, DOI 10.1158/0008-5472.CAN-04-2749; Shillitoe EJ, 2005, CLIN CANCER RES, V11, P3109, DOI 10.1158/1078-0432.CCR-04-2302; Shinoura N, 2000, JPN J CANCER RES, V91, P1028, DOI 10.1111/j.1349-7006.2000.tb00881.x; Shinozaki K, 2004, MOL THER, V9, P368, DOI 10.1016/j.ymthe.2003.12.004; Short JJ, 2004, VIROLOGY, V322, P349, DOI 10.1016/j.virol.2004.02.016; Sinclair AM, 1997, GENE THER, V4, P918, DOI 10.1038/sj.gt.3300479; SINKOVICS J, 1993, INTERVIROLOGY, V36, P193, DOI 10.1159/000150339; Sirena D, 2004, J VIROL, V78, P4454, DOI 10.1128/JVI.78.9.4454-4462.2004; Soudais C, 2000, J VIROL, V74, P10639, DOI 10.1128/JVI.74.22.10639-10649.2000; STEVENSON SC, 1995, J VIROL, V69, P2850, DOI 10.1128/JVI.69.5.2850-2857.1995; STEWART PL, 1991, CELL, V67, P145, DOI 10.1016/0092-8674(91)90578-M; STOFFKHALILI MA, 2005, GENE THERAPY    0721; Stone D, 2005, J VIROL, V79, P5090, DOI 10.1128/JVI.79.8.5090-5104.2005; Tao NJ, 2001, MOL THER, V3, P28, DOI 10.1006/mthe.2000.0227; Tekant Y, 2005, SURGERY, V137, P527, DOI 10.1016/j.surg.2004.12.014; Ternovoi VV, 2005, J VIROL, V79, P1308, DOI 10.1128/JVI.79.2.1308-1311.2005; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Toth K, 2005, HUM GENE THER, V16, P139, DOI 10.1089/hum.2005.16.139; Tseng JC, 2004, NAT BIOTECHNOL, V22, P70, DOI 10.1038/nbt917; Tseng JC, 2004, CANCER RES, V64, P6684, DOI 10.1158/0008-5472.CAN-04-1924; UCHINO J, 2005, CANC GENE THER  0429; Unno Y, 2005, CLIN CANCER RES, V11, P4553, DOI 10.1158/1078-0432.CCR-04-2610; van Beusechem VW, 2000, GENE THER, V7, P1940, DOI 10.1038/sj.gt.3301323; van der Poel HG, 2002, J UROLOGY, V168, P266, DOI 10.1016/S0022-5347(05)64905-1; Vanderkwaak TJ, 1999, GYNECOL ONCOL, V74, P227, DOI 10.1006/gyno.1999.5432; VANOOSTRUM J, 1985, J VIROL, V56, P439, DOI 10.1128/JVI.56.2.439-448.1985; Vasey PA, 2002, J CLIN ONCOL, V20, P1562, DOI 10.1200/JCO.20.6.1562; Vellinga J, 2005, J GEN VIROL, V86, P1581, DOI 10.1099/vir.0.80877-0; Vellinga J, 2004, J VIROL, V78, P3470, DOI 10.1128/JVI.78.7.3470-3479.2004; Vigne E, 1999, J VIROL, V73, P5156, DOI 10.1128/JVI.73.6.5156-5161.1999; Voeks D, 2002, GENE THER, V9, P759, DOI 10.1038/sj.gt.3301698; Vollmer CM, 1999, CANCER RES, V59, P4369; Volpers C, 2003, J VIROL, V77, P2093, DOI 10.1128/JVI.77.3.2093-2104.2003; Weir HK, 2003, JNCI-J NATL CANCER I, V95, P1276, DOI 10.1093/jnci/djg040; Wesseling JG, 2001, GENE THER, V8, P969, DOI 10.1038/sj.gt.3301473; Wickham TJ, 1996, NAT BIOTECHNOL, V14, P1570, DOI 10.1038/nbt1196-1570; Wickham TJ, 1997, J VIROL, V71, P8221, DOI 10.1128/JVI.71.11.8221-8229.1997; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Witlox AM, 2004, CLIN CANCER RES, V10, P61, DOI 10.1158/1078-0432.CCR-0609-03; Wolf JK, 2004, GYNECOL ONCOL, V94, P442, DOI 10.1016/j.ygyno.2004.05.041; Wu E, 2004, J VIROL, V78, P3897, DOI 10.1128/JVI.78.8.3897-3905.2004; Wu E, 2001, VIROLOGY, V279, P78, DOI 10.1006/viro.2000.0703; Wu H, 2004, GENE THER, V11, P874, DOI 10.1038/sj.gt.3302249; Wu HJ, 2005, J VIROL, V79, P3382, DOI 10.1128/JVI.79.6.3382-3390.2005; Wu HJ, 2002, HUM GENE THER, V13, P1647, DOI 10.1089/10430340260201734; Xia HB, 2000, J VIROL, V74, P11359, DOI 10.1128/JVI.74.23.11359-11366.2000; Yamamoto M, 2003, GASTROENTEROLOGY, V125, P1203, DOI 10.1016/S0016-5085(03)01196-X; Yang M, 2000, P NATL ACAD SCI USA, V97, P12278, DOI 10.1073/pnas.97.22.12278; Yoshida Y, 1998, HUM GENE THER, V9, P2503, DOI 10.1089/hum.1998.9.17-2503; You ZB, 2001, CANCER GENE THER, V8, P168, DOI 10.1038/sj.cgt.7700284; Yun CO, 2005, HUM GENE THER, V16, P248, DOI 10.1089/hum.2005.16.248; Zabner J, 1999, J VIROL, V73, P8689, DOI 10.1128/JVI.73.10.8689-8695.1999; Zakhartchouk A, 2003, VIROLOGY, V313, P377, DOI 10.1016/S0042-6822(03)00286-1; Zeimet AG, 2003, LANCET ONCOL, V4, P415, DOI 10.1016/S1470-2045(03)01139-2; Zhang J, 2004, J GENE MED, V6, P1082, DOI 10.1002/jgm.605; Zhang LN, 2005, VIRUS RES, V110, P169, DOI 10.1016/j.virusres.2005.02.008; Zhang LO, 2003, J GEN VIROL, V84, P687, DOI 10.1099/vir.0.18666-0; Zhu ZB, 2005, INT J ONCOL, V27, P237; Zhu ZB, 2004, VIROLOGY, V325, P116, DOI 10.1016/j.virol.2004.04.021; Zinn KR, 2000, J NUCL MED, V41, P887	250	99	109	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7775	7791		10.1038/sj.onc.1209044	http://dx.doi.org/10.1038/sj.onc.1209044			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299537				2022-12-17	WOS:000233372600013
J	Veuger, SJ; Curtin, NJ; Smith, GCM; Durkacz, BW				Veuger, SJ; Curtin, NJ; Smith, GCM; Durkacz, BW			Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair	ONCOGENE			English	Article						DNA-dependent protein kinase; poly(ADP-ribose) polymerase-1	DOUBLE-STRAND BREAK; BIOCHEMICAL-CHARACTERIZATION; IONIZING-RADIATION; MAMMALIAN-CELLS; COMPLEX; PARP-1; DAMAGE; RECOMBINATION; ASSOCIATION; SUPPRESSION	DNA-dependent protein kinase (DNA-PK) and poly (ADP-ribose) polymerase-1 (PARP-1) participate in nonhomologous end joining and base excision repair, respectively, and are key determinants of radio- and chemo-resistance. Both PARP-1 and DNA-PK have been identified as therapeutic targets for anticancer drug development. Here we investigate the effects of specific inhibitors on enzyme activities and DNA double-strand break (DSB) repair. The enzyme activities were investigated using purified enzymes and in permeabilized cells. Inhibition, or loss of activity, was compared using potent inhibitors of DNA-PK (NU7026) and PARP-1 (AG14361), and cell lines proficient or deficient for DNA-PK or PARP-1. Inactive DNA-PK suppressed the activity of PARP-1 and vice versa. This was not the consequence of simple substrate competition, since DNA ends were provided in excess. The inhibitory effect of DNA-PK on PARP activity was confirmed in permeabilized cells. Both inhibitors prevented ionizing radiation-induced DSB repair, but only AG14361 prevented single-strand break repair. An increase in DSB levels caused by inhibition of PARP-1 was shown to be caused by a decrease in DSB repair, and not by the formation of additional DSBs. These data point to combined inhibition of PARP-1 and DNA-PK as a powerful strategy for tumor radiosensitization.	Newcastle Univ, No Inst Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; KuDOS Pharmaceut, Cambridge CB4 4WG, England	Newcastle University - UK; AstraZeneca	Durkacz, BW (corresponding author), Newcastle Univ, No Inst Canc Res, Paul OGorman Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	b.w.durkacz@newcastle.ac.uk		Curtin, Nicola/0000-0003-1369-1843	NCI NIH HHS [F31 CA260794] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Boulton S, 1999, CARCINOGENESIS, V20, P199, DOI 10.1093/carcin/20.2.199; Boulton S, 1996, CARCINOGENESIS, V17, P2285, DOI 10.1093/carcin/17.11.2285; BRADLEY MO, 1979, NUCLEIC ACIDS RES, V7, P793, DOI 10.1093/nar/7.3.793; Calsou P, 1999, J BIOL CHEM, V274, P7848, DOI 10.1074/jbc.274.12.7848; D'Silva I, 1999, BBA-PROTEIN STRUCT M, V1430, P119, DOI 10.1016/S0167-4838(98)00278-7; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Dibiase SJ, 2000, CANCER RES, V60, P1245; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FORNACE AJ, 1977, BIOCHIM BIOPHYS ACTA, V477, P343, DOI 10.1016/0005-2787(77)90253-2; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HALLDORSSON H, 1978, FEBS LETT, V85, P349, DOI 10.1016/0014-5793(78)80489-X; Izzard RA, 1999, CANCER RES, V59, P2581; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; Kim CH, 2002, J PHARMACOL EXP THER, V303, P753, DOI 10.1124/jpet.102.038505; KOHN KW, 1981, DNA REPAIR LAB MAN B, V2, P379; Li BM, 2004, J BIOL CHEM, V279, P13659, DOI 10.1074/jbc.M311606200; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Merkle D, 2002, BIOCHEMISTRY-US, V41, P12706, DOI 10.1021/bi0263558; Omori S, 2002, DNA REPAIR, V1, P299, DOI 10.1016/S1568-7864(02)00006-X; Peng YL, 2002, CANCER RES, V62, P6400; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Rudat V, 2001, INT J RADIAT BIOL, V77, P303, DOI 10.1080/09553000010009026; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; Sak A, 2002, CANCER RES, V62, P6621; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; Skalitzky DJ, 2003, J MED CHEM, V46, P210, DOI 10.1021/jm0255769; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smulson ME, 1998, CANCER RES, V58, P3495; Susse S, 2004, NUCLEIC ACIDS RES, V32, P669, DOI 10.1093/nar/gkh227; Tentori L, 2002, PHARMACOL RES, V45, P73, DOI 10.1006/phrs.2001.0935; Veuger SJ, 2003, CANCER RES, V63, P6008; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/s0079-6603(08)60611-x; Yang YG, 2004, ONCOGENE, V23, P3872, DOI 10.1038/sj.onc.1207491	45	99	104	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7322	7329		10.1038/sj.onc.1207984	http://dx.doi.org/10.1038/sj.onc.1207984			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15286704				2022-12-17	WOS:000224021400003
J	Armstrong, F; Duplantier, MM; Trempat, P; Hieblot, C; Lamant, L; Espinos, E; Racaud-Sultan, C; Allouche, M; Campo, E; Delsol, G; Touriol, C				Armstrong, F; Duplantier, MM; Trempat, P; Hieblot, C; Lamant, L; Espinos, E; Racaud-Sultan, C; Allouche, M; Campo, E; Delsol, G; Touriol, C			Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells	ONCOGENE			English	Article						anaplastic lymphoma kinase (ALK); anaplastic large-cell lymphoma; X-ALK variants	ANAPLASTIC LYMPHOMA KINASE; NON-HODGKINS-LYMPHOMA; GROWTH-FACTOR; TYROSINE KINASE; TROPOMYOSIN SYNTHESIS; ATIC-ALK; GENE; NPM; TRANSLOCATIONS; SUPPRESSION	Majority of anaplastic large-cell lymphomas (ALCLs) are associated with the t(2;5)(p23; q35) translocation, fusing the NPM ( nucleophosmin) and ALK (anaplastic lymphoma kinase) genes (NPM-ALK). Recent studies demonstrated that ALK may also be involved in variant translocations, namely, t(1;2)(q25;p23), t(2;3)(p23;q21), t(2;17)(p23;q23) and inv(2)(p23q35), which create the TPM3-ALK, TFG-ALK5, CLTC-ALK, and ATIC-ALK fusion genes, respectively. Although overexpression of NPM-ALK has previously been shown to transform fibroblasts, the transforming potential of variant X-ALK proteins has not been precisely investigated. We stably transfected the cDNAs coding for NPM-ALK, TPM3-ALK, TFG-ALK, CLTC-ALK or ATIC-ALK into nonmalignant NIH3T3 cells. All X-ALK variants are tyrosine phosphorylated and their subcellular distribution was in agreement with that observed in tumors. Moreover, our results show that the in vitro transforming capacity of NIH3T3-transfected cells are in relation to the level of X-ALK fusion proteins excepted for TPM3-ALK for which there is an inverse correlation. The differences between the five X-ALK variants with regard to proliferation rate, colony formation in soft agar, invasion, migration through the endothelial barrier and tumorigenicity seem to be due to differential activation of various signaling pathways such as PI3-kinase/AKT. These findings may have clinical implications in the pathogenesis and prognosis of ALK-positive ALCLs.	Ctr Physiopathol Toulouse Purpan, INSERM, U563, Dept Oncogenesis & Signaling Hematopoiet Cells, Toulouse, France; CHU Rangueil, INSERM, U589, F-31054 Toulouse, France; Univ Barcelona, Hosp Clin, Pathol Lab, E-08036 Barcelona, Spain	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Barcelona; Hospital Clinic de Barcelona	Delsol, G (corresponding author), CHU Purpan, Anat Pathol Lab, Pl Dr Baylac, F-31059 Toulouse, France.	delsol.g@chu-toulouse.fr	Campo, Elias/AAC-5593-2019; TOURIOL, Christian/O-8949-2014; Hieblot, Corinne/O-4734-2019; Espinos, Estelle/A-4661-2015; Allouche, Michele/P-4865-2019	Campo, Elias/0000-0001-9850-9793; TOURIOL, Christian/0000-0003-1219-4693; Espinos, Estelle/0000-0002-5693-8941; Racaud-Sultan, Claire/0000-0002-6549-1088				Arnaud E, 1999, MOL CELL BIOL, V19, P505; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Bowden ET, 2002, J BIOL CHEM, V277, P35862, DOI 10.1074/jbc.M203963200; Bridge JA, 2001, AM J PATHOL, V159, P411, DOI 10.1016/S0002-9440(10)61711-7; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; CHIARLE R, 2002, BLOOD, V7, P7; Colleoni GWB, 2000, AM J PATHOL, V156, P781, DOI 10.1016/S0002-9440(10)64945-0; Cools J, 2002, GENE CHROMOSOME CANC, V34, P354, DOI 10.1002/gcc.10033; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COOPER HL, 1987, CANCER RES, V47, P4493; Cooper JA, 2002, CURR BIOL, V12, pR523, DOI 10.1016/S0960-9822(02)01028-X; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Falini B, 2002, BLOOD, V99, P409, DOI 10.1182/blood.V99.2.409; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Hernandez L, 1999, BLOOD, V94, P3265; JOOSS KU, 1995, ONCOGENE, V10, P603; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Lamant L, 2003, GENE CHROMOSOME CANC, V37, P427, DOI 10.1002/gcc.10232; Lamant L, 1999, BLOOD, V93, P3088; Lawrence B, 2000, AM J PATHOL, V157, P377, DOI 10.1016/S0002-9440(10)64550-6; Lee TH, 2003, J BIOL CHEM, V278, P5277, DOI 10.1074/jbc.M210063200; Ma ZG, 2000, BLOOD, V95, P2144, DOI 10.1182/blood.V95.6.2144; Mason DY, 1998, CANCER RES, V58, P1057; Miething C, 2003, ONCOGENE, V22, P4642, DOI 10.1038/sj.onc.1206575; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MORRIS SW, 1995, SCIENCE, V267, P316, DOI 10.1126/science.267.5196.316-b; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Prasad SC, 1997, ELECTROPHORESIS, V18, P629, DOI 10.1002/elps.1150180348; Pulford K, 1997, BLOOD, V89, P1394, DOI 10.1182/blood.V89.4.1394; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; Schweitzer KM, 1997, LAB INVEST, V76, P25; Slupianek A, 2001, CANCER RES, V61, P2194; Sotsios Y, 2000, IMMUNOL REV, V177, P217, DOI 10.1034/j.1600-065X.2000.17712.x; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; TAKENAGA K, 1988, BIOCHEM BIOPH RES CO, V157, P1111, DOI 10.1016/S0006-291X(88)80988-4; TAKENAGA K, 1994, CANCER LETT, V87, P47, DOI 10.1016/0304-3835(94)90408-1; Tort F, 2001, LAB INVEST, V81, P419, DOI 10.1038/labinvest.3780249; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Trinei M, 2000, CANCER RES, V60, P793; URBANCIKOVA M, 1982, NEOPLASMA, V29, P655; Weber KSC, 2001, MOL BIOL CELL, V12, P3074, DOI 10.1091/mbc.12.10.3074; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAMAJI H, 1992, APPL MICROBIOL BIOT, V37, P244; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	54	99	103	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6071	6082		10.1038/sj.onc.1207813	http://dx.doi.org/10.1038/sj.onc.1207813			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208656				2022-12-17	WOS:000223261000007
J	Yatabe, N; Kyo, S; Maida, Y; Nishi, H; Nakamura, M; Kanaya, T; Tanaka, M; Isaka, K; Ogawa, S; Inoue, M				Yatabe, N; Kyo, S; Maida, Y; Nishi, H; Nakamura, M; Kanaya, T; Tanaka, M; Isaka, K; Ogawa, S; Inoue, M			HIF-1-mediated activation of telomerase in cervical cancer cells	ONCOGENE			English	Article						hypoxia; telomerase; HIF-1; hTERT; cervical cancer	HYPOXIA-INDUCIBLE FACTOR-1; FACTOR 1-ALPHA; C-MYC; UNFAVORABLE PROGNOSIS; TUMOR ANGIOGENESIS; GENE-EXPRESSION; O-2 TENSION; FACTOR-I; TRANSCRIPTION; OVEREXPRESSION	Hypoxia-inducible factor 1 (HIF-1) is a key regulator of O-2 homeostasis, which regulates the expression of several genes linked to angiogenesis and energy metabolism. Tumor hypoxia has been shown to be associated with poor prognosis in a variety of tumors, and HIF-1 induced by hypoxia plays pivotal roles in tumor progression. The presence of putative HIF-1-binding sites on the promoter of human telomerase reverse transcriptase gene ( hTERT) prompted us to examine the involvement of HIF-1 in the regulation of hTERT and telomerase in tumor hypoxia. The telomeric repeat amplification protocol (TRAP) assay revealed that hypoxia activated telomerase in cervical cancer ME180 cells, with peak induction at 24-48 h of hypoxia. Notably, hTERT mRNA expression was upregulated at 6-12 h of hypoxia, concordant with the elevation of HIF-1 protein levels at 6 h. hTERT protein levels were subsequently upregulated at 24 h and later. Luciferase assays using reporter plasmids containing hTERT core promoter revealed that hTERT transcription was significantly activated in hypoxia and by HIF-1 overexpression, and that the two putative binding sites within the core promoter are responsible for this activation. Chromatin immunoprecipitation assay identfied the specific binding of HIF-1 to these sites (competing with c-Myc), which was enhanced in hypoxia. The present findings suggest that hypoxia activates telomerase via transcriptional activation of hTERT, and that HIF-1 plays a critical role as a transcription factor. They also suggest the existence of novel mechanisms of telomerase activation in cancers, and have implications for the molecular basis of hypoxia-induced tumor progression and HIF-1-based cancer gene therapy.	Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan; Tokyo Med Univ, Dept Obstet & Gynecol, Shinjuku Ku, Tokyo 1600023, Japan; Kanazawa Univ, Sch Med, Dept Neuroanat, Kanazawa, Ishikawa 9208641, Japan	Kanazawa University; Tokyo Medical University; Kanazawa University	Kyo, S (corresponding author), Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.	satoruky@med.kanazawa-u.ac.jp						Akakura N, 2001, CANCER RES, V61, P6548; Birner P, 2000, CANCER RES, V60, P4693; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; HOCKEL M, 1993, RADIOTHER ONCOL, V26, P45, DOI 10.1016/0167-8140(93)90025-4; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Krishnamachary B, 2003, CANCER RES, V63, P1138; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Mazure NM, 2002, CANCER RES, V62, P1158; Minamino T, 2001, MOL CELL BIOL, V21, P3336, DOI 10.1128/MCB.21.10.3336-3342.2001; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Ravi R, 2000, GENE DEV, V14, P34; RUSSO CA, 1995, CANCER RES, V55, P1122; Schindl M, 2002, CLIN CANCER RES, V8, P1831; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seimiya H, 1999, BIOCHEM BIOPH RES CO, V260, P365, DOI 10.1006/bbrc.1999.0910; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Sivridis E, 2002, CANCER-AM CANCER SOC, V95, P1055, DOI 10.1002/cncr.10774; Takakura M, 1999, CANCER RES, V59, P551; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yasumoto S, 1996, ONCOGENE, V13, P433	30	99	108	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3708	3715		10.1038/sj.onc.1207460	http://dx.doi.org/10.1038/sj.onc.1207460			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15048086	Green Submitted			2022-12-17	WOS:000221101700023
J	Horejsi, Z; Falck, J; Bakkenist, CJ; Kastan, MB; Lukas, J; Bartek, J				Horejsi, Z; Falck, J; Bakkenist, CJ; Kastan, MB; Lukas, J; Bartek, J			Distinct functional domains of Nbs1 modulate the timing and magnitude of ATM activation after low doses of ionizing radiation	ONCOGENE			English	Article						Nbs1; ATM; DNA damage; ionizing radiation; cell cycle checkpoints	NIJMEGEN-BREAKAGE-SYNDROME; S-PHASE CHECKPOINT; TELANGIECTASIA-MUTATED ATM; DOUBLE-STRAND BREAKS; ATAXIA-TELANGIECTASIA; DNA-DAMAGE; DEPENDENT PHOSPHORYLATION; FOCUS FORMATION; MRE11 COMPLEX; IN-VIVO	The ATM kinase is a tumour suppressor and a key activator of genome integrity checkpoints in mammalian cells exposed to ionizing radiation (IR) and other insults that elicit DNA double-strand breaks (DSBs). In response to IR, autophosphorylation on serine 1981 causes dissociation of ATM dimers and initiates cellular ATM kinase activity. Here, we show that the kinetics and magnitude of ATM Ser1981 phosphorylation after exposure of human fibroblasts to low doses (2 Gy) of IR are altered in cells deficient in Nbs1, a substrate of ATM and a component of the MRN (Mre11-Rad50-Nbs1) complex involved in processing/repair of DSBs and ATM-dependent cell cycle checkpoints. Timely phosphorylation of both ATM Ser1981 and the ATM substrate Smc1 after IR were rescued via retrovirally mediated reconstitution of Nbs1-deficient cells by wild-type Nbs1 or mutants of Nbs1 defective in the FHA domain or nonphosphorylatable by ATM, but not by Nbs1 lacking the Mre11-interaction domain. Our data indicate that apart from its role downstream of ATM in the DNA damage checkpoint network, the MRN complex serves also as a modulator/amplifier of ATM activity. Although not absolutely required for ATM activation, the MRN nuclease complex may help reach the threshold activity of ATM necessary for optimal genome maintenance and prevention of cancer.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; St Jude Childrens Res Hosp, Memphis, TN 38105 USA	Danish Cancer Society; St Jude Children's Research Hospital	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.	bartek@biobase.dk	Bartek, Jiri/G-5870-2014	Licenikova Horejsi, Zuzana/0000-0002-9943-1649; Lukas, Jiri/0000-0001-9087-506X	NCI NIH HHS [CA 71387, CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071387, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn JY, 2000, CANCER RES, V60, P5934; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Cerosaletti KM, 2003, J BIOL CHEM, V278, P21944, DOI 10.1074/jbc.M211689200; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Girard PM, 2002, ONCOGENE, V21, P4191, DOI 10.1038/sj.onc.1205596; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Lee JH, 2003, MOL CANCER RES, V1, P674; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Sorensen CS, 2000, MOL CELL BIOL, V20, P7613, DOI 10.1128/MCB.20.20.7613-7623.2000; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhao S, 2002, NUCLEIC ACIDS RES, V30, P4815, DOI 10.1093/nar/gkf612	41	99	107	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3122	3127		10.1038/sj.onc.1207447	http://dx.doi.org/10.1038/sj.onc.1207447			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15048089				2022-12-17	WOS:000220845200017
J	Jinnin, M; Ihn, H; Asano, Y; Yamane, K; Trojanowska, M; Tamaki, K				Jinnin, M; Ihn, H; Asano, Y; Yamane, K; Trojanowska, M; Tamaki, K			Tenascin-C upregulation by transforming growth factor-beta in human dermal broblasts involves Smad3, Sp1, and Ets1	ONCOGENE			English	Article						CREB-binding protein; P300; extracellular matrix	EXTRACELLULAR-MATRIX PROTEIN; HUMAN SKIN FIBROBLASTS; BREAST-CANCER CELLS; 2(I) COLLAGEN GENE; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; INCREASED EXPRESSION; FUNCTIONAL-CHARACTERIZATION; SCLERODERMA FIBROBLASTS; IN-VITRO	In cultured human dermal fibroblasts, transforming growth factor ( TGF)-beta induced the mRNA expression of tenascin-C (TN-C). The molecular mechanism(s) underlying this process is not presently understood. In this study, we performed serial 50 deletion and a transient transfection analysis to de. ne a region in the TN-C promoter mediating the inducible responsiveness to TGF-beta. This region contains an atypical nucleotide recognition element for the Smad family of transcriptional regulators. A DNA affinity precipitation assay revealed that Smad2/ Smad3 bound to this site in a transient and specific manner. Overexpression of Smad3 or Smad4 activated the TN-C promoter activity and superinduced the TN-C promoter activity stimulated by TGF-beta. Moreover, simultaneous cotransfection of Smad3 and Smad4 activated the TN-C promoter activity in a synergistic manner. Mutation of the Smad-binding sites, the Ets-binding sites, or Sp1/3-binding sites in the TN-C promoter abrogated the TGF-beta/Smad-inducible promoter activity. Immunoprecipitation analysis revealed that Smad3, Sp1, and Ets1 form a transcriptionally active complex. Furthermore, the interaction between Smads and CBP/p300 in TGF-beta signaling was confirmed. These findings demonstrate the existence of a novel, functional binding element in the proximal region of the TN-C promoter mediating responsiveness to TGF-beta involving Smad3/4, Sp1, Ets1, and CBP/p300.	Univ Tokyo, Fac Med, Dept Dermatol, Bunkyo Ku, Tokyo 1138655, Japan; Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29425 USA	University of Tokyo; Medical University of South Carolina	Ihn, H (corresponding author), Univ Tokyo, Fac Med, Dept Dermatol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	IN-DER@h.u-tokyo.ac.jp		Trojanowska, Maria/0000-0001-9550-7178				Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BORSI L, 1994, CELL ADHES COMMUN, V1, P307, DOI 10.3109/15419069409097262; Boyes WK, 1997, FUND APPL TOXICOL, V40, P175, DOI 10.1006/faat.1997.2388; Candia AF, 1997, DEVELOPMENT, V124, P4467; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chin GS, 2001, PLAST RECONSTR SURG, V108, P423, DOI 10.1097/00006534-200108000-00022; CHIQUET M, 1994, PERSPECT DEV NEUROBI, V2, P67; CHIQUETEHRISMANN R, 1995, EXPERIENTIA, V51, P853, DOI 10.1007/BF01921736; CHIQUETEHRISMANN R, 1989, CANCER RES, V49, P4322; Crossin KL, 1996, J CELL BIOCHEM, V61, P592; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Dandachi N, 2001, J PATHOL, V193, P181, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH752>3.0.CO;2-V; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; EKBLOM P, 1989, International Journal of Developmental Biology, V33, P71; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GHERZI R, 1995, J BIOL CHEM, V270, P3429, DOI 10.1074/jbc.270.7.3429; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Gore-Hyer E, 2002, AM J PHYSIOL-RENAL, V283, pF707, DOI 10.1152/ajprenal.00007.2002; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Ihn H, 2002, J IMMUNOL, V168, P1895, DOI 10.4049/jimmunol.168.4.1895; Ihn H, 2001, ARTHRITIS RHEUM, V44, P474, DOI 10.1002/1529-0131(200102)44:2<474::AID-ANR67>3.0.CO;2-#; Ihn H, 2002, CURR OPIN RHEUMATOL, V14, P681, DOI 10.1097/00002281-200211000-00009; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kawakami T, 1998, J INVEST DERMATOL, V110, P47, DOI 10.1046/j.1523-1747.1998.00073.x; Kucich U, 2002, AM J RESP CELL MOL, V26, P183, DOI 10.1165/ajrcmb.26.2.4666; LACOUR JP, 1992, BRIT J DERMATOL, V127, P328, DOI 10.1111/j.1365-2133.1992.tb00450.x; Lai CF, 2000, J BIOL CHEM, V275, P36400, DOI 10.1074/jbc.M002131200; LEROY EC, 1992, ANN RHEUM DIS, V51, P286, DOI 10.1136/ard.51.2.286; Lindemann RK, 2001, J BIOL CHEM, V276, P46661, DOI 10.1074/jbc.M105816200; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Mackie EJ, 1997, INT J BIOCHEM CELL B, V29, P1133, DOI 10.1016/S1357-2725(97)00031-9; Makhluf HA, 1996, J INVEST DERMATOL, V107, P856, DOI 10.1111/1523-1747.ep12331160; MCCACHREN SS, 1992, ARTHRITIS RHEUM, V35, P1185, DOI 10.1002/art.1780351011; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NATALI PG, 1991, INT J CANCER, V47, P811, DOI 10.1002/ijc.2910470603; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; RETTIG WJ, 1989, J HISTOCHEM CYTOCHEM, V37, P1777, DOI 10.1177/37.12.2685108; RETTIG WJ, 1994, J CELL SCI, V107, P487; RODNAN GP, 1979, ARTHRITIS RHEUM, V22, P130, DOI 10.1002/art.1780220205; SHARIFI BG, 1992, J BIOL CHEM, V267, P23910; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Taylor LM, 2000, J BIOL CHEM, V275, P16709, DOI 10.1074/jbc.275.22.16709; TUCKER RP, 1993, J CELL SCI, V104, P69; Varga J, 2002, ARTHRITIS RHEUM-US, V46, P1703, DOI 10.1002/art.10413; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Yagi K, 2002, J BIOL CHEM, V277, P854, DOI 10.1074/jbc.M104170200; You LT, 2002, INVEST OPHTH VIS SCI, V43, P72; Yuan WH, 2001, J BIOL CHEM, V276, P38502, DOI 10.1074/jbc.M107081200	71	99	102	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1656	1667		10.1038/sj.onc.1207064	http://dx.doi.org/10.1038/sj.onc.1207064			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	15001984				2022-12-17	WOS:000220029300002
J	Roos, W; Baumgartner, M; Kaina, B				Roos, W; Baumgartner, M; Kaina, B			Apoptosis triggered by DNA damage O-6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1	ONCOGENE			English	Article						apoptosis; DNA damage; DNA repair; alkyltransferase; lymphocytes; Fas; p53	MISMATCH REPAIR; METHYLTRANSFERASE MGMT; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; CHROMOSOMAL-ABERRATIONS; METHYLATING AGENTS; ALKYLATING-AGENTS; BCL-2 DECLINE; CELL-DEATH; V79 CELLS; EXPRESSION	Various tumor-therapeutic drugs and environmental carcinogens alkylate DNA inducing O-6-methylguanine (O(6)MeG) that provokes cell death by apoptosis. In rodent fibroblasts, apoptosis triggered by O(6)MeG is executed via the mitochondrial damage pathway. Conversion of O(6)MeG into critical downstream lesions requires mismatch repair (MMR). This is thought to signal apoptosis upon binding to O(6)MeG lesions mispaired with thymine. Alternatively, O(6)MeG lesions might be processed by MMR giving rise to DNA double-strand breaks (DSBs) during replication that finally provoke apoptosis. To test this, we examined apoptosis triggered by O(6)MeG in human peripheral lymphocytes in which O-6-methylguanine-DNA methyltransferase (MGMT) had been inactivated by O-6-benzylguanine (O(6)BG) and which were not proliferating or proliferating upon CD3/CD28 stimulation. Treatment with N-methyl-N#8242;-nitro-N-nitrosoguanidine (MNNG) or the anticancer drug temozolomide induced apoptosis only in proliferating, but not resting cells. With exceptional high alkylation doses (greater than or equal to15 muM of MNNG), apoptosis was also observed in resting lymphocytes, albeit at a lower level than in proliferating cells. This response was not affected by O(6)BG, suggesting that replication-independent apoptosis at high dose levels is caused by lesions other than O(6)MeG. O(6)MeG-triggered apoptosis in proliferating lymphocytes was preceded by a wave of DSBs, which coincided with p53 and Fas receptor upregulation, while Fas ligand, Bax and Bcl-2 expression was not altered. Treatment with anti-Fas neutralizing antibody attenuated MNNG-induced apoptosis in MGMT-depleted proliferating lymphocytes. The data suggest that O(6)MeG is converted by MMR and DNA replication into DSBs that trigger apoptosis by p53 stabilization and Fas/CD95/Apo-1 upregulation. This is supported by the finding that ionizing radiation, inducing DSBs on its own, provokes apoptosis in lymphocytes in a replication-independent way. The strict proliferation dependence of apoptosis triggered by O(6)MeG may explain the specific killing response of MGMT-deficient proliferating cells, including tumors, to O(6)MeG generating anticancer drugs and suggests that tumor proliferation rate, Fas responsiveness, MGMT and MMR status are important prognosis parameters.	Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany		Kaina, B (corresponding author), Inst Toxicol, Div Appl Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	Kaina@mail.uni-mainz.de	Roos, Wynand/B-4846-2008	Roos, Wynand/0000-0002-0474-7414				Becker K, 1996, CANCER RES, V56, P3244; Becker R, 2002, BRIT J CANCER, V86, P130, DOI 10.1038/sj.bjc.6600027; BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2; BRENNAND J, 1986, P NATL ACAD SCI USA, V83, P6292, DOI 10.1073/pnas.83.17.6292; COQUERELLE T, 1995, MUTAT RES-DNA REPAIR, V336, P9, DOI 10.1016/0921-8777(94)00035-5; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Dikomey E, 1998, INT J RADIAT BIOL, V73, P269, DOI 10.1080/095530098142365; Dosch J, 1996, ONCOGENE, V13, P1927; Dosch J, 1998, CARCINOGENESIS, V19, P567, DOI 10.1093/carcin/19.4.567; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Dunkern TR, 2001, ONCOGENE, V20, P6026, DOI 10.1038/sj.onc.1204754; Dunkern TR, 2002, MOL BIOL CELL, V13, P348, DOI 10.1091/mbc.01-05-0225; Dunkern TR, 2001, MUTAT RES-DNA REPAIR, V486, P249, DOI 10.1016/S0921-8777(01)00095-7; DUNKERN TR, 2003, IN PRESS MUTATION RE; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; GALLOWAY SM, 1995, MUTAT RES LETT, V346, P231, DOI 10.1016/0165-7992(95)90040-3; Gerson SL, 1996, BLOOD, V88, P1649; Hammond LA, 1999, J CLIN ONCOL, V17, P2604, DOI 10.1200/JCO.1999.17.8.2604; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; Janssen K, 2001, ARCH TOXICOL, V75, P306, DOI 10.1007/s002040100226; Jones DT, 2001, BLOOD, V98, P2800, DOI 10.1182/blood.V98.9.2800; KAINA B, 1993, ENVIRON MOL MUTAGEN, V22, P283, DOI 10.1002/em.2850220418; KAINA B, 1985, MUTAT RES, V142, P49, DOI 10.1016/S0165-7992(85)80012-9; KAINA B, 1991, CARCINOGENESIS, V12, P1857; Kaina B, 1997, MUTAT RES-FUND MOL M, V381, P227, DOI 10.1016/S0027-5107(97)00187-5; KARRAN P, 1990, MUTAT RES, V236, P269, DOI 10.1016/0921-8777(90)90010-3; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Lips J, 2001, CARCINOGENESIS, V22, P579, DOI 10.1093/carcin/22.4.579; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; Margison GP, 2002, BIOESSAYS, V24, P255, DOI 10.1002/bies.10063; Marra G, 2001, P NATL ACAD SCI USA, V98, P7164, DOI 10.1073/pnas.121136498; Meikrantz W, 1998, CARCINOGENESIS, V19, P369, DOI 10.1093/carcin/19.2.369; MORITZ T, 1995, CANCER RES, V55, P2608; MOSCHEL RC, 1992, J MED CHEM, V35, P4486, DOI 10.1021/jm00101a028; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Ochs K, 2000, CANCER RES, V60, P5815; Ochs K, 2002, CANCER RES, V62, P1524; OLIVE PL, 1991, CANCER RES, V51, P4671; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Raju U, 2000, INT J RADIAT BIOL, V76, P1045, DOI 10.1080/09553000050111514; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Tominaga Y, 1997, CARCINOGENESIS, V18, P889, DOI 10.1093/carcin/18.5.889; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I	46	99	103	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					359	367		10.1038/sj.onc.1207080	http://dx.doi.org/10.1038/sj.onc.1207080			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724564				2022-12-17	WOS:000188098300005
J	Weber, A; Langhanki, L; Sommerer, F; Markwarth, A; Wittekind, C; Tannapfel, A				Weber, A; Langhanki, L; Sommerer, F; Markwarth, A; Wittekind, C; Tannapfel, A			Mutations of the BRAF gene in squamous cell carcinoma of the head and neck	ONCOGENE			English	Article						squamous cell carcinoma of the head and neck; BRAF; KRAS2	RAS MUTATIONS; ACTIVATION; TUMORIGENESIS; FREQUENCY; PATHWAY; CANCER; KINASE; LIVER; P53	The RAF/MEK/ERK (MAPK) signal transduction cascade is an important mediator of a number of cellular fates including growth, proliferation and survival. The BRAF gene, one of the human isoforms of RAF, is activated by oncogenic RAS, leading to cooperative effects in cells responding to growth factor signals. This study was performed to elucidate a possible function of BRAF in squamous cell carcinoma of the head and neck (HNSCC). Mutations of BRAF and KRAS2 were evaluated in 89 HNSCC and corresponding normal mucosa by direct DNA sequencing analyses after microdissection. The results obtained were correlated with histopathological variables. Activating BRAF missense mutations were identified in 3/89 HNSCC (3%). KRAS2 mutations were found in five out of 89 (6%) HNSCC examined. There were no mutations of KRAS2 and BRAF in non-neoplastic mucosa. We failed to observe a correlation between BRAF or KRAS2 mutations and histopathological factors. Our data indicate that BRAF gene mutations are relatively rare events in HNSCC. Although uncommon, BRAF mutations may identify a subset of patients with HNSCC sensitive to targeted therapy.	Univ Leipzig, Inst Pathol, D-04103 Leipzig, Germany; Univ Leipzig, Dept Otorhinolaryngol Head & Neck Surg, D-04103 Leipzig, Germany	Leipzig University; Leipzig University	Tannapfel, A (corresponding author), Univ Leipzig, Inst Pathol, Liebigstr 26, D-04103 Leipzig, Germany.							Brose MS, 2002, CANCER RES, V62, P6997; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Fitzgerald K, 2000, ONCOGENE, V19, P4191, DOI 10.1038/sj.onc.1203766; Garcia J, 2001, MOL CELL BIOL, V21, P2659, DOI 10.1128/MCB.21.8.2659-2670.2001; Gire V, 2000, ONCOGENE, V19, P737, DOI 10.1038/sj.onc.1203399; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Hao D, 2002, CANCER INVEST, V20, P387, DOI 10.1081/CNV-120001184; Hoa M, 2002, CANCER RES, V62, P7154; Leder A, 2002, ONCOGENE, V21, P6657, DOI 10.1038/sj.onc.1205795; Liao YH, 2001, J BIOL CHEM, V276, P28478, DOI 10.1074/jbc.M101737200; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Naoki K, 2002, CANCER RES, V62, P7001; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pindborg JJ, 1997, HISTOLOGICAL TYPING; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Shanmugaratnam K, 1991, HISTOLOGICAL TYPING; Sobin L., 1997, UICC TNM CLASSIFICAT, P184; Tannapfel A, 2000, GUT, V47, P721, DOI 10.1136/gut.47.5.721; Tannapfel A, 2001, EUR ARCH OTO-RHINO-L, V258, P83, DOI 10.1007/s004050000303; Tannapfel A, 2001, ONCOGENE, V20, P7104, DOI 10.1038/sj.onc.1204902; Weber CK, 2001, CANCER RES, V61, P3595; Xu J, 1998, CANCER-AM CANCER SOC, V83, P204, DOI 10.1002/(SICI)1097-0142(19980715)83:2<204::AID-CNCR2>3.0.CO;2-Q; Yuen ST, 2002, CANCER RES, V62, P6451	25	99	103	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4757	4759		10.1038/sj.onc.1206705	http://dx.doi.org/10.1038/sj.onc.1206705			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879021				2022-12-17	WOS:000184157000017
J	Hattori, T; Ohoka, N; Inoue, Y; Hayashi, H; Onozaki, K				Hattori, T; Ohoka, N; Inoue, Y; Hayashi, H; Onozaki, K			C/EBP family transcription factors are degraded by the proteasome but stabilized by forming dimer	ONCOGENE			English	Article						C/EBP; degradation; proteasome; ubiquitination; dimer; leucine zipper	ENHANCER-BINDING-PROTEIN; NUCLEAR-PROTEIN; ADIPOCYTE DIFFERENTIATION; NEGATIVE INHIBITOR; MESSENGER-RNA; FACTOR CHOP; GENE; DNA; EXPRESSION; ACTIVATION	CCAAT/enhancer-binding protein (C/EBP) family transcription factors are critical for transcription of several genes involved in tissue development and cellular function, proliferation, and differentiation. Here we show that inhibitory/regulatory C/EBP family proteins, Ig/EBP (C/EBPgamma) and CHOP (C/EBPxi), but not positively functioning NF-IL6 (C/EBPbeta), are constitutively multiubiquitinated and subsequently degraded by the proteasome. In addition, ubiquitination and degradation of these proteins are suppressed by forming dimer through their leucine zipper domains. Deletion of leucine zipper domain in NF-IL6 caused the loss of its homodimerization activity and the degradation of protein by the ubiquitin-proteasome system. In addition, Ig/EBP with its leucine zipper domain substituted for that of NF-IL6 formed homodimer and was stabilized. These observations suggest that mammalian cells equip a novel regulatory system abrogating the excess C/EBP family transcription factors bereft of dimerizing partner.	Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Mol Hlth Sci, Nagoya, Aichi 4678603, Japan	Nagoya City University	Onozaki, K (corresponding author), Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Mol Hlth Sci, Nagoya, Aichi 4678603, Japan.							CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Hattori T, 2001, J INTERF CYTOK RES, V21, P323, DOI 10.1089/107999001300177510; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347	18	99	102	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1273	1280		10.1038/sj.onc.1206204	http://dx.doi.org/10.1038/sj.onc.1206204			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618752				2022-12-17	WOS:000181360900001
J	Ngan, ESW; Hashimoto, Y; Ma, ZQ; Tsai, MJ; Tsai, SY				Ngan, ESW; Hashimoto, Y; Ma, ZQ; Tsai, MJ; Tsai, SY			Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer	ONCOGENE			English	Article						coactivator; Cdc25B; prostate cancer; androgen receptor	TYROSINE PHOSPHATASES; EXPRESSION; MECHANISM; DOMAIN; ROLES	Cdc25B is a dual-specific phosphatase that mediates cell cycle progression by activating the cyclin-dependent kinases. It has been shown to possess oncogenic potential. To elucidate its potential contribution to human prostate cancer development, the expression profile of Cdc25B protein in human patients was analysed by immunohistocytochemistry. Cdc25B is frequently overexpressed in human prostate cancer tissues (29 of 30; 97%). In addition, the overexpression is more profound in the tumors of high combined Gleason scores and in late stages. Subsequently, we demonstrated that Cdc25B acts as a coactivator for AR in a hormone-dependent manner in the prostate cancer cell line, LNCaP. This coactivator function, surprisingly, is independent of its cell cycle functions. Cdc25B, on the other hand, directly interacts with AR as evidenced in GST-pull down and mammalian two-hybrid assays. In addition, it is also able to enhance AR-mediated transcription in synergy with other coactivators, including CREB-binding protein (CBP) and p300/ CBP associated factor. Therefore, upregulation of Cdc25B in human prostate cancer and its interplay with AR may contribute to prostate cancer development.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Tsai, SY (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Ngan, Elly/N-1543-2019	Ngan, Elly/0000-0002-0022-7999				CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; Eckstein J., 1997, BIOCHIM BIOPHYS ACTA, V1332, P53; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; Gnanapragasam VJ, 2001, BRIT J CANCER, V85, P1928, DOI 10.1054/bjoc.2001.2179; Gregory CW, 2001, CANCER RES, V61, P4315; Hernandez S, 1998, CANCER RES, V58, P1762; Lombardi DP, 1999, CANCER RES, V59, P5724; Ma ZQ, 1999, ONCOGENE, V18, P4564, DOI 10.1038/sj.onc.1202809; Ma ZQ, 1999, J STEROID BIOCHEM, V69, P155, DOI 10.1016/S0960-0760(98)00154-X; Ma ZQ, 2001, MOL CELL BIOL, V21, P8056, DOI 10.1128/MCB.21.23.8056-8067.2001; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; NAGATA A, 1991, NEW BIOL, V3, P959; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Xu X, 1996, J BIOL CHEM, V271, P5118; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	17	99	104	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					734	739		10.1038/sj.onc.1206121	http://dx.doi.org/10.1038/sj.onc.1206121			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569365				2022-12-17	WOS:000180642100010
J	Kawamata, S; Du, CC; Li, KJ; Lavau, C				Kawamata, S; Du, CC; Li, KJ; Lavau, C			Overexpression of the Notch target genes Hes in vivo induces lymphoid and myeloid alterations	ONCOGENE			English	Article						Hes; Notch; B cells; hematopoiesis	DEVELOPING NERVOUS-SYSTEM; CELL-DEVELOPMENT; MOLECULAR CHARACTERIZATION; CHROMOSOMAL LOCUS; DROSOPHILA-HAIRY; LINEAGE DECISION; PRECURSOR CELLS; BONE-MARROW; DIFFERENTIATION; EXPRESSION	To examine the effects of Notch signaling on hematopoiesis, we transplanted mice with progenitors transduced with a constitutively active form of Notch1 (Notch1IC) or the Notch1 target genes Hes. Notch1IC-transduced cells induce T cell tumors and cannot generate B lymphocytes in vivo. Hes-transplanted mice remained healthy but cells transduced with Hes1 or Hes5 were partially impaired in their ability to differentiate into B cells. Both Hes1 and Hes5 were upregulated in the BM of Notch1IC mice and their ability to interfere with the transcriptional activity of E2A in a reporter assay was comparable to that of Notch1IC. This suggests that the inhibition of B cell development in the Notch1IC-transduced cells could be mediated by the interference of HES1/HES5 proteins with E2A. Hest1-, Hes5- and Notch1IC-transduced bone marrow cells cultured ex vivo in a colony forming assay in the presence of cytokines that promote myeloid differentiation remained very immature, indicating that the myeloid potential of these bone marrow cells was altered. Thymocytes overexpressing Hes1, Hes5 or Notch1IC matured normally into CD4 and CD8 single positive cells in vivo. Altogether our data suggest that Notch1IC induces T cell tumors independently of Hes genes but that its interference with lymphoid B and myeloid maturation is partly mediated by Hes1 and Hes5.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; SyStemix Inc, Palo Alto, CA 94304 USA	Stanford University; Stanford University; Novartis	Lavau, C (corresponding author), Hop St Louis, CNRS UPR 9051, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.		Lavau, Catherine/Q-2928-2019; Du, Changchun/AAW-6540-2020	kawamata, shin/0000-0001-5148-1949; Lavau, Catherine/0000-0003-4800-1320				AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Carlesso N, 1999, BLOOD, V93, P838, DOI 10.1182/blood.V93.3.838.403k29_838_848; Condorelli GL, 1997, MOL CELL BIOL, V17, P2954, DOI 10.1128/MCB.17.5.2954; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Deftos ML, 2000, IMMUNITY, V13, P73, DOI 10.1016/S1074-7613(00)00009-1; Du CC, 1999, BLOOD, V94, P793, DOI 10.1182/blood.V94.2.793.414k43_793_802; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HAWLEY RG, 1994, GENE THER, V1, P136; Hirata H, 2000, J BIOL CHEM, V275, P19083, DOI 10.1074/jbc.M001075200; ISHIBASHI M, 1993, EUR J BIOCHEM, V215, P645, DOI 10.1111/j.1432-1033.1993.tb18075.x; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Kaneta M, 2000, J IMMUNOL, V164, P256, DOI 10.4049/jimmunol.164.1.256; Kawamata S, 1998, J BIOL CHEM, V273, P5808, DOI 10.1074/jbc.273.10.5808; Kim HK, 1998, MOL CELL BIOL, V18, P7166, DOI 10.1128/MCB.18.12.7166; Koch U, 2001, IMMUNITY, V15, P225, DOI 10.1016/S1074-7613(01)00189-3; Lu FM, 1996, P NATL ACAD SCI USA, V93, P5663, DOI 10.1073/pnas.93.11.5663; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; Milner LA, 1996, P NATL ACAD SCI USA, V93, P13014, DOI 10.1073/pnas.93.23.13014; Nishimura M, 1998, GENOMICS, V49, P69, DOI 10.1006/geno.1998.5213; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Osborne B, 1999, IMMUNITY, V11, P653, DOI 10.1016/S1074-7613(00)80140-5; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Ross DA, 2001, MOL CELL BIOL, V21, P7537, DOI 10.1128/MCB.21.22.7537-7544.2001; Schroeder T, 2000, EMBO J, V19, P2558, DOI 10.1093/emboj/19.11.2558; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SCREPANTI I, 1989, J IMMUNOL, V142, P3378; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Tomita K, 1999, GENE DEV, V13, P1203, DOI 10.1101/gad.13.9.1203; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; Wilson A, 2001, J EXP MED, V194, P1003, DOI 10.1084/jem.194.7.1003; Wolfer A, 2001, NAT IMMUNOL, V2, P235, DOI 10.1038/85294	43	99	101	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3855	3863		10.1038/sj.onc.1205487	http://dx.doi.org/10.1038/sj.onc.1205487			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032823				2022-12-17	WOS:000175847200004
J	Dallol, A; Forgacs, E; Martinez, A; Sekido, Y; Walker, R; Kishida, T; Rabbitts, P; Maher, ER; Minna, JD; Latif, F				Dallol, A; Forgacs, E; Martinez, A; Sekido, Y; Walker, R; Kishida, T; Rabbitts, P; Maher, ER; Minna, JD; Latif, F			Tumour specific promoter region methylation of the human homologue of the Drosophilia Roundabout gene DUTT1 (ROBO1) in human cancers	ONCOGENE			English	Article						methylation; 3p12 tumour suppressor gene; DUTT1/ROBO1	RENAL-CELL CARCINOMA; SUPPRESSOR GENE; BREAST-CANCER; LUNG-CANCER; CLEAR-CELL; EPIGENETIC INACTIVATION; HOMOZYGOUS DELETION; GUIDANCE RECEPTORS; DNA METHYLATION; CHROMOSOME 3P12	The human homologue of the Drosophila Roundabout gene DUTT1 (Deleted in U Twenty Twenty) or ROBO1 (Locus Link ID 6091), a member of the NCAM family of receptors, was recently cloned from the lung cancer tumour suppressor gene region 2 (LCTSGR2 or U2020 region) at 3p12. DUTT1 maps within a region of overlapping homozygous deletions characterized in both small cell lung cancer lines (SCLC) and in a breast cancer line. In this report we (a) defined the genomic organization of the DUTT1 gene, (b) performed mutation and expression analysis of DUTT1 in lung, breast and kidney cancers, (c) identified tumour specific promoter region methylation of DUTT1 in human cancers. The gene was found to contain 29 exons and spans at least 240 kb of genomic sequence. The 5' region contains a CpG island, and the poly(A)(+) tail has an atypical 5'-GATAAA-3' signal. We analysed DUTT1 for mutations in lung, breast and kidney cancers, no inactivating mutations were detected by PCR-SSCP. However, seven germline missense changes were found and characterized. DUTT1 expression was not detectable in one out of 18 breast tumour lines analysed by RTPCR. Bisulfite sequencing of the promoter region of DUTT1 gene in the HTB-19 breast tumour cell line (not expressing DUTT1) showed complete hypermethylation of CpG sites within the promoter region of the DUTT1 gene (-244 to +27 relative to the translation start site). The expression of DUTT1 gene was reactivated in HTB-19 after treatment with the demethylating agent 5-aza-2'-deoxycytidine. The same region was also found to be hypermethylated in six out of 32 (19%) primary invasive breast carcinomas and eight out of 44 (18%) primary clear cell renal cell carcinomas (CC-RCC) and in one out of 26 (4%) primary NSCLC tumours. Furthermore 80% of breast and 75% of CC-RCC tumours showing DUTT1 methylation had allelic losses for 3p12 markers hence obeying Knudson's two hit hypothesis. Our findings suggest that DUTT1 warrants further analysis as a candidate for the tumour suppressor gene (TSG) at 3p12, a region defined by hemi and homozygous deletions and functional analysis.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; Univ Leicester, Glenfield Hosp, Breast Canc Res Unit, Leicester, Leics, England; Yokohama City Univ, Sch Med, Dept Urol, Yokohama, Kanagawa 232, Japan; Univ Cambridge, MRC,Mol Oncol Grp, Dept Oncol, MRC Ctr, Cambridge CB2 2QH, England; Univ Birmingham, Sch Med, Res UK Renal Mol Oncol Res Grp, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; Yokohama City University; MRC Laboratory Molecular Biology; University of Cambridge; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	flatif@hgmp.mrc.ac.uk	MAHER, EAMONN R/A-9507-2008; Dallol, Ashraf/H-8661-2012; Sekido, Yoshitaka/P-9756-2015	MAHER, EAMONN R/0000-0002-6226-6918; Dallol, Ashraf/0000-0002-8803-228X; Sekido, Yoshitaka/0000-0002-2428-3848	NCI NIH HHS [P50 CA 70907] Funding Source: Medline; Breast Cancer Now [1999:98] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Now; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; ANGELONI D, 2000, CANC GENETICS TUMOR; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Baylin SB, 1998, ADV CANCER RES, V72, P141; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; DRABKIN HA, 1992, GENE CHROMOSOME CANC, V5, P67, DOI 10.1002/gcc.2870050110; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Foster K, 1995, EUR J CANCER, V31A, P2392, DOI 10.1016/0959-8049(95)00437-8; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; LATIF F, 1992, GENE CHROMOSOME CANC, V5, P119, DOI 10.1002/gcc.2870050205; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lerman MI, 2000, CANCER RES, V60, P6116; Lott ST, 1998, CANCER RES, V58, P3533; Lovell M, 1999, CANCER RES, V59, P2182; LUBINSKI J, 1994, CANCER RES, V54, P3710; Martinez A, 2000, J CLIN PATHOL-MOL PA, V53, P137, DOI 10.1136/mp.53.3.137; Martinez A, 2001, J CLIN PATHOL-MOL PA, V54, P300, DOI 10.1136/mp.54.5.300; Mau S, 1996, CANCER RES, V56, P5484; Morrissey C, 2001, CANCER RES, V61, P7277; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Phelps RM, 1996, J CELL BIOCHEM, P32; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; Sato K, 2001, BRIT J CANCER, V85, P199, DOI 10.1054/bjoc.2001.1888; Shaw JA, 1996, BRIT J CANCER, V73, P1393, DOI 10.1038/bjc.1996.264; SHUIN T, 1994, CANCER RES, V54, P2852; Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445; Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103; Sundaresan V, 1998, MOL CELL NEUROSCI, V11, P29, DOI 10.1006/mcne.1998.0672; THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2; Todd S, 1997, CANCER RES, V57, P1344; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 1998, CLIN CANCER RES, V4, P2931; Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616	42	99	108	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3020	3028		10.1038/sj.onc.1205421	http://dx.doi.org/10.1038/sj.onc.1205421			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082532				2022-12-17	WOS:000175262700009
J	Koul, D; Parthasarathy, R; Shen, RJ; Davies, MA; Jasser, SA; Chintala, SK; Rao, JS; Sun, Y; Benvenisite, EN; Liu, TJ; Yung, WKA				Koul, D; Parthasarathy, R; Shen, RJ; Davies, MA; Jasser, SA; Chintala, SK; Rao, JS; Sun, Y; Benvenisite, EN; Liu, TJ; Yung, WKA			Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN	ONCOGENE			English	Article						MMAC/PTEN; glioma; invasion; matrix metalloproteinases-2; tumor suppression	TUMOR-SUPPRESSOR; IV COLLAGENASE; PLASMINOGEN-ACTIVATOR; ADHESION MOLECULES; GERMLINE MUTATIONS; TISSUE INHIBITORS; PTEN; BREAST; PROTEINASES; PTEN/MMAC1	Human gliomas are highly invasive, and remain to be a major obstacle for any effective therapeutic remedy. Among many other factors, gliomas express elevated levels of matrix metalloproteinases (MMPs), which have been implicated to play an important role in tumor invasion as well as neovascularization. The tumor suppressor gene mutated in multiple advanced cancers/phosphatase and tensin homologue (MMAC/PTEN) has been shown to inhibit cell migration, spreading, and focal adhesion. In this study, we determined whether MMAC/PTEN inhibits tumor invasion by modulating MMP-2 activity. Our results showed that reintroduction of the MMAC/PTEN gene into human glioma U251 and U87 cells modified their phenotype and growth characteristics. The ability of MMAC/PTEN to induce anoikis in U251 cells was accompanied by a significant inhibition of in vitro invasion (70%). Expression of MMAC/PTEN in U251 and U87 cells inhibited MMP-2 enzymatic activity as determined by zymography. Furthermore, MMAC/PTEN expression strongly decreased MMP-2 mRNA levels, which correlated well with the inhibition of invasion capacity in these cells. Concomitant with MMP-2 expression and activity, MMP-2 promoter activity was also reduced in MMAC/PTEN expressing cells. Our observations suggest that MMAC/PTEN inhibits tumor cell invasion in part by regulating MMP-2 gene transcription and thereby its enzymatic activity. Further characterization of this regulation will facilitate the development of MMAC/PTEN based gene therapy for gliomas.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Parke Davis Pharmaceut Res, Dept Mol Biol, Ann Arbor, MI 48105 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Pfizer; University of Alabama System; University of Alabama Birmingham	Yung, WKA (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Box 100, Houston, TX 77030 USA.	wyung@mdanderson.org	Davies, Michael/GWV-2527-2022		NATIONAL CANCER INSTITUTE [P30CA016672, R01CA051148] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, R01 CA 51148] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL C, 1994, CANCER RES, V54, P943; ALBELDA SM, 1993, LAB INVEST, V68, P4; ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; APODACA G, 1990, CANCER RES, V50, P2322; Barille S, 1997, BLOOD, V90, P1649, DOI 10.1182/blood.V90.4.1649.1649_1649_1655; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; BJERKVIG R, 1986, CANCER RES, V46, P4071; Cairns P, 1997, CANCER RES, V57, P4997; Cheney IW, 1998, CANCER RES, V58, P2331; Chintala S.K., 1996, FRONT BIOSCI, V1, pd324, DOI 10.2741/a135; Chintala SK, 1996, CANCER LETT, V103, P201, DOI 10.1016/0304-3835(96)04215-2; COCKETT MI, 1994, BIOCHEM SOC T, V22, P55, DOI 10.1042/bst0220055; DAVIES B, 1993, CANCER RES, V53, P5365; Davies MA, 1998, CANCER RES, V58, P5285; Deryugina EI, 1997, ANTICANCER RES, V17, P3201; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Edwards DR, 1996, INT J OBES RELAT MET, V20, P9; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Guldberg P, 1997, CANCER RES, V57, P3660; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; Kim HG, 2000, BIOCHEM BIOPH RES CO, V269, P401; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maier D, 1999, CANCER RES, V59, P5479; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MOHANAM S, 1993, CANCER RES, V53, P4143; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; MOSER TL, 1994, INT J CANCER, V56, P552, DOI 10.1002/ijc.2910560415; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; NAKAJIMA M, 1993, CANCER RES, V53, P5802; NAKANO A, 1995, J NEUROSURG, V83, P298, DOI 10.3171/jns.1995.83.2.0298; Qin HW, 1998, J IMMUNOL, V161, P6664; RAO JS, 1994, J NEURO-ONCOL, V18, P129, DOI 10.1007/BF01050419; Rhei E, 1997, CANCER RES, V57, P3657; RUCKLIDGE GJ, 1994, BIOCHEM SOC T, V22, P63, DOI 10.1042/bst0220063; SATO H, 1992, ONCOGENE, V7, P77; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SEFTOR REB, 1993, CANCER RES, V53, P3411; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tashiro H, 1997, CANCER RES, V57, P3935; Tian XX, 1999, J NEUROPATH EXP NEUR, V58, P472, DOI 10.1097/00005072-199905000-00006; Uhm JH, 1996, CLIN EXP METASTAS, V14, P421, DOI 10.1007/BF00128958; Uhm JH, 1997, CAN J NEUROL SCI, V24, P3, DOI 10.1017/S0317167100021028; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; Wang SI, 1997, CANCER RES, V57, P4183; Xuan JW, 1998, ANTICANCER RES, V18, P743; Yong VW, 1998, TRENDS NEUROSCI, V21, P75	60	99	113	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2001	20	46					6669	6678		10.1038/sj.onc.1204799	http://dx.doi.org/10.1038/sj.onc.1204799			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709701				2022-12-17	WOS:000171551600003
J	Ram, PT; Iyengar, R				Ram, PT; Iyengar, R			G protein coupled receptor signaling through the Src and Stat3 pathway: role in proliferation and transformation	ONCOGENE			English	Article						G protein alpha subunit; Src; Stat3; transformation	MUTANT ALPHA-SUBUNIT; NIH 3T3 CELLS; SERINE PHOSPHORYLATION; V-SRC; TYROSINE PHOSPHORYLATION; JAK/STAT PATHWAY; BINDING PROTEINS; CHROMAFFIN CELLS; IN-VIVO; KINASE	Extracellular signals when routed through signaling pathways that use heterotrimeric G proteins can engage multiple signaling pathways leading to diverse biological consequences, One locus at which signal sorting occurs is at the level of G proteins, G protein a-subunits appear to be capable of interacting with different effecters leading to engagement of distinct signaling pathways. Regulation of different pathways in turn leads to different biological outcomes, The process of neoplastic transformation is controlled to a large extent through the activation and inhibition of signaling pathways, Signaling pathways such as the Ras-MAPK, v-Src-Stat3 pathways are activated in the process of transformation. Expression of activated G alpha subunits have been shown to cause transformation of cells, While activation of the MAPK 1,2 pathway by various G alpha subunits has been reported for several years, recent studies show the activation and involvement of Src and Stat3 pathways in G alphao and G alphai mediated transformation of cells. Recent studies also suggest that both G alphai and G alphas may be able to interact with and activate Src, The activation of Src and Stat3 by G proteins has also been demonstrated by Ligand-induced activation of G protein receptors, So increasingly it is becoming clear that the Src and Stat3 pathways are potential effecters for G proteins and that they may play a role in G protein function.	CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ram, PT (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol, Box 1215, New York, NY 10029 USA.			Ram, Prahlad/0000-0003-4739-3166	NCI NIH HHS [CA81050, F32 CA79134] Funding Source: Medline; NIGMS NIH HHS [GM54508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081050, F32CA079134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Buggy JJ, 1998, BIOCHEM J, V331, P211, DOI 10.1042/bj3310211; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Ceresa BP, 1997, ENDOCRINOLOGY, V138, P4131, DOI 10.1210/en.138.10.4131; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; Chen LT, 1999, J BIOL CHEM, V274, P26931, DOI 10.1074/jbc.274.38.26931; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Corre I, 1999, ONCOGENE, V18, P6335, DOI 10.1038/sj.onc.1203010; DiversePierluissi M, 1997, P NATL ACAD SCI USA, V94, P5417, DOI 10.1073/pnas.94.10.5417; DIVERSEPIERLUISSI M, 1993, NEURON, V10, P753, DOI 10.1016/0896-6273(93)90175-Q; Fan XM, 2000, J BIOL CHEM, V275, P32129, DOI 10.1074/jbc.M004577200; FFRENCHMULLEN JMH, 1994, J PHYSIOL-LONDON, V474, P21, DOI 10.1113/jphysiol.1994.sp019998; GIERSCHIK P, 1986, P NATL ACAD SCI USA, V83, P2258, DOI 10.1073/pnas.83.7.2258; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Hermouet S, 1996, CELL SIGNAL, V8, P159, DOI 10.1016/0898-6568(95)02049-7; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KROLL SD, 1991, P NATL ACAD SCI USA, V88, P5182, DOI 10.1073/pnas.88.12.5182; KROLL SD, 1992, J BIOL CHEM, V267, P23183; Liang HY, 1999, J BIOL CHEM, V274, P19846, DOI 10.1074/jbc.274.28.19846; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; NEER EJ, 1984, J BIOL CHEM, V259, P4222; Niu GL, 1999, CANCER RES, V59, P5059; Nusse O, 1996, J CELL SCI, V109, P221; OHARAIMAIZUMI M, 1992, J NEUROCHEM, V58, P2275, DOI 10.1111/j.1471-4159.1992.tb10974.x; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Shen Y, 1996, J CLIN ENDOCR METAB, V81, P4159, DOI 10.1210/jc.81.11.4159; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Smith PD, 1998, BIOCHEM J, V331, P381, DOI 10.1042/bj3310381; SONTAG JM, 1991, BIOCHEM J, V274, P339, DOI 10.1042/bj2740339; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Uddin S, 2000, J BIOL CHEM, V275, P27634; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	61	99	111	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	2001	20	13					1601	1606		10.1038/sj.onc.1204186	http://dx.doi.org/10.1038/sj.onc.1204186			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313907				2022-12-17	WOS:000168089800010
J	Mashour, GA; Ratner, N; Khan, GA; Wang, HL; Martuza, RL; Kurtz, A				Mashour, GA; Ratner, N; Khan, GA; Wang, HL; Martuza, RL; Kurtz, A			The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells	ONCOGENE			English	Article						neurofibromatosis; midkine; pleiotrophin; schwann cells	FIBROBLAST GROWTH-FACTORS; TYPE-1 GENE-PRODUCT; DIFFERENTIAL EXPRESSION; ADULT-RAT; PLEIOTROPHIN; SURVIVAL; TUMORS; BRAIN; MOUSE; MK	Loss of the tumor suppressor gene NF1 in neurofibromatosis type 1 (NF1) contributes to the development of a variety of tumors, including malignant peripheral nerve sheath tumors (MPNST) and benign neurofibromas, Of the different cell types found in neurofibromas, Schwann cells usually provide between 40 and 80%, and are thought to be critical for tumor growth. Here we describe the identification of growth factors that are upregulated in NF1-/- mouse Schwann cells and are potential regulators of angiogenesis and cell growth. Basic fibroblast growth factor (FGF-2), platelet-derived growth factor (PDGF) and midkine (MK) were found to be induced by loss of neurofibromin and MK was further characterized. MK was induced in human neurofibromas, schwannomas, and various nervous system tumors associated with NF1 or NF2; midkine showed an expression pattern overlapping but distinct from its homolog pleiotrophin (PTN), Immunohistochemistry revealed expression of MK in S-100 positive Schwann cells of dermal and plexiform neurofibromas, and in endothelial cells of tumor blood vessels, but not in normal blood vessels, Furthermore, MK demonstrated potent mitogenic activity for human systemic and brain endothelial cells in vitro and stimulated proliferation and soft agar colony formation of human MPNST derived S100 positive cells and fibroblastoid cells derived from an NF1 neurofibroma, The data support a possible central role for MK as a mediator of angiogenesis and neurofibroma growth in NF1.	Harvard Univ, Sch Med, MGH, Charlestown, MA 02129 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Georgetown Univ, Sch Med, Dept Neurosurg, Vincent T Lombardi Canc Ctr, Washington, DC 20007 USA	Harvard University; University System of Ohio; University of Cincinnati; Georgetown University	Kurtz, A (corresponding author), Harvard Univ, Sch Med, MGH, Bldg 149,13th St, Charlestown, MA 02129 USA.			Kurtz, Andreas/0000-0003-3301-6546; RATNER, NANCY/0000-0001-5030-9354	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS037895, R01NS028840] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS28840, R29-NS37895] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Badache A, 1998, J CELL PHYSIOL, V177, P334, DOI 10.1002/(SICI)1097-4652(199811)177:2<334::AID-JCP15>3.0.CO;2-9; BERNARDS A, 1995, BBA-REV CANCER, V1242, P43, DOI 10.1016/0304-419X(95)00003-X; BLOCH B, 1992, DEV BRAIN RES, V70, P267, DOI 10.1016/0165-3806(92)90206-C; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHEN JK, 1991, J NEUROSCI RES, V30, P321, DOI 10.1002/jnr.490300207; Choudhuri R, 1997, CANCER RES, V57, P1814; COSTELLO P, 1990, J NEURO-ONCOL, V8, P231, DOI 10.1007/BF00177356; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; Dugoff L, 1996, AM J MED GENET, V66, P7, DOI 10.1002/(SICI)1096-8628(19961202)66:1<7::AID-AJMG2>3.0.CO;2-R; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GARVER RI, 1994, CANCER, V74, P1584, DOI 10.1002/1097-0142(19940901)74:5<1584::AID-CNCR2820740514>3.0.CO;2-V; GAVRILOVIC J, 1995, EUR J NEUROSCI, V7, P77, DOI 10.1111/j.1460-9568.1995.tb01022.x; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; GUTMANN DH, 1995, METABOLIC MOL BASES, P667; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Ikematsu S, 2000, BRIT J CANCER, V83, P701, DOI 10.1054/bjoc.2000.1339; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; Kadomatsu K, 1997, BRIT J CANCER, V75, P354, DOI 10.1038/bjc.1997.58; Kaname T, 1996, BIOCHEM BIOPH RES CO, V219, P256, DOI 10.1006/bbrc.1996.0214; Kaneda N, 1996, J BIOCHEM-TOKYO, V119, P1150; Kato S, 1999, J NEUROPATH EXP NEUR, V58, P430, DOI 10.1097/00005072-199905000-00002; KIKUCHI S, 1993, NEUROSCI LETT, V160, P9, DOI 10.1016/0304-3940(93)90904-Y; KIM HA, 1995, ONCOGENE, V11, P325; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; Kretschmer P J, 1991, Growth Factors, V5, P99, DOI 10.3109/08977199109000275; KURTZ A, 1994, DEVELOPMENT, V120, P2637; Kurtz A, 1995, CRIT REV ONCOGENESIS, V6, P151; Mashour GA, 1999, J INVEST DERMATOL, V113, P398, DOI 10.1046/j.1523-1747.1999.00699.x; MATSUMOTO K, 1994, NEUROSCI LETT, V178, P216, DOI 10.1016/0304-3940(94)90762-5; Milhiet PE, 1998, J ENDOCRINOL, V158, P389, DOI 10.1677/joe.0.1580389; Mishima K, 1997, NEUROSCI LETT, V233, P29, DOI 10.1016/S0304-3940(97)00619-8; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; NAKAMOTO M, 1992, J BIOCHEM-TOKYO, V112, P346, DOI 10.1093/oxfordjournals.jbchem.a123903; OBrien T, 1996, CANCER RES, V56, P2515; Ohtani Y, 1999, INT J ONCOL, V15, P453; PANOSKALTSISMORTARI A, 1995, BIOTECHNIQUES, V18, P300; RATNER N, 1990, ANN NEUROL, V27, P298, DOI 10.1002/ana.410270312; Salvesen HB, 1999, INT J CANCER, V84, P539; SCHUBERT D, 1992, J NEUROBIOL, V23, P143, DOI 10.1002/neu.480230205; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; SHEELA S, 1990, J CELL BIOL, V111, P645, DOI 10.1083/jcb.111.2.645; TSUTSUI J, 1991, BIOCHEM BIOPH RES CO, V176, P792, DOI 10.1016/S0006-291X(05)80255-4; Tuszynski GP, 1996, BIOESSAYS, V18, P71, DOI 10.1002/bies.950180113; VANDERWINDEN JM, 1992, ANAT EMBRYOL, V186, P387; VOGEL KS, 1995, CELL, V82, P733, DOI 10.1016/0092-8674(95)90470-0; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; Zhang N, 1999, Curr Opin Hematol, V6, P44, DOI 10.1097/00062752-199901000-00008; Zoller MET, 1997, CANCER-AM CANCER SOC, V79, P2125	51	99	106	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					97	105		10.1038/sj.onc.1204026	http://dx.doi.org/10.1038/sj.onc.1204026			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244508				2022-12-17	WOS:000166361400011
J	Senderowicz, AM				Senderowicz, AM			Small molecule modulators of cyclin-dependent kinases for cancer therapy	ONCOGENE			English	Article						cell cycle; flavopiridol; UCN-01; cyclin-dependent kinases; cyclin D1; protein kinases; apoptosis	BREAST-CARCINOMA CELLS; FLAVOPIRIDOL INDUCES APOPTOSIS; CHRONIC LYMPHOCYTIC-LEUKEMIA; HUMAN EPIDERMOID CARCINOMA; PROTEIN-KINASE; SELECTIVE INHIBITOR; 7-HYDROXYSTAUROSPORINE UCN-01; ANTITUMOR-ACTIVITY; IN-VITRO; RADIOSENSITIZING AGENT	The majority of human malignancies have aberrancies in the Retinoblastoma (Rb) pathway, Loss in Rb function results from the phosphorylation and inactivation of Rb by the cyclin-dependent kinases (cdks), main regulators of cell cycle progression, Thus, modulators of cdks mag have a role in the treatment of human malignancies. Flavopiridol, the first cdk modulator tested in clinical trials, demonstrates interesting preclinical features: cell cycle block, induction of apoptosis, promotion of differentiation, inhibition of angiogenic processes and modulation of transcriptional events. Initial clinical trials with infusional flavopiridol demonstrated activity in some patients with lymphomas and renal, colon gastric carcinomas. Main side effects were diarrhea and hypotension. Phase 2 trials with infusional flavopiridol, other schedules and combination with standard chemotherapies are ongoing, The second cdk modulator tested in clinical trials, UCN-01, is a PKC inhibitor that can also modulate cdk activity. Similar to flavopiridol, UCN-01 blocks cell cycle progression and promotes apoptosis. Moreover, UCN-01 may abrogate checkpoints induced by genotoxic stress due to inhibition of chk1 kinase. The first clinical trial of UCN-01 demonstrated very prolonged half-life (similar to 600 h), due to high binding affinity of UCN-01 to the human alpha-1-acid glycoprotein. Main side effects mere headaches, vomiting, hypoxemia and hyperglycemia. Clinical activity was observed in some patients with melanoma and lymphoma. Trials of shorter infusions of UCN-01 or in combination with standard chemotherapeutic agents are ongoing. Although several important basic and clinical questions remain unanswered, development of cdk modulators is a reasonable strategy for cancer therapy.	NIDCR, Mol Therapeut Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Senderowicz, AM (corresponding author), NIDCR, Mol Therapeut Unit, Oral & Pharyngeal Canc Branch, NIH, Bldg 30,Room 211,30 Convent Dr, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000701] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Achenbach TV, 2000, J BIOL CHEM, V275, P32089, DOI 10.1074/jbc.M005267200; AKINAGA S, 1993, CANCER CHEMOTH PHARM, V32, P183, DOI 10.1007/BF00685833; AKINAGA S, 1994, CANCER CHEMOTH PHARM, V33, P273; AKINAGA S, 1991, CANCER RES, V51, P4888; Akiyama T, 1999, ANTI-CANCER DRUG, V10, P67, DOI 10.1097/00001813-199901000-00009; Akiyama T, 1997, CANCER RES, V57, P1495; Arguello F, 1998, BLOOD, V91, P2482; BENNETT S, 1999, P AM SOC CLIN ONCOLO, V18; Bible KC, 1996, CANCER RES, V56, P4856; Bible KC, 1997, CANCER RES, V57, P3375; Brusselbach S, 1998, INT J CANCER, V77, P146; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Bunch RT, 1997, CELL GROWTH DIFFER, V8, P779; Busby EC, 2000, CANCER RES, V60, P2108; Byrd JC, 1998, BLOOD, V92, P3804, DOI 10.1182/blood.V92.10.3804; Carlson B, 1999, CANCER RES, V59, P4634; Carlson B. A., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P424; Carlson BA, 1996, CANCER RES, V56, P2973; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Chien M, 1999, CANCER CHEMOTH PHARM, V44, P81, DOI 10.1007/s002800050948; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Fuse E, 1998, CANCER RES, V58, P3248; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GRANA X, 1995, ONCOGENE, V11, P211; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GUEDEZ L, 1999, P 19 ANN M AM ASS CA; Hatakeyama M, 1995, Prog Cell Cycle Res, V1, P9; Hsueh CT, 1998, CLIN CANCER RES, V4, P2201; Husain A, 1997, CLIN CANCER RES, V3, P2089; KAUR G, 1992, J NATL CANCER I, V84, P1736, DOI 10.1093/jnci/84.22.1736; Kawakami K, 1996, BIOCHEM BIOPH RES CO, V219, P778, DOI 10.1006/bbrc.1996.0310; Kerr JS, 1999, ANTICANCER RES, V19, P959; Kitada S, 2000, BLOOD, V96, P393; Konig A, 1997, BLOOD, V90, P4307; Lahusen J, 2000, P 20 ANN M AM ASS CA; Lee HR, 1999, INT J ONCOL, V15, P161; Li YW, 2000, INT J ONCOL, V17, P755; Li YW, 2000, CLIN CANCER RES, V6, P223; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; Meijer L, 1997, METHOD ENZYMOL, V283, P113; Melillo G, 1999, CANCER RES, V59, P5433; MICHALIDES R, 1995, CANCER RES, V55, P975; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Okami K, 1999, ONCOGENE, V18, P3541, DOI 10.1038/sj.onc.1202837; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; Parker BW, 1998, BLOOD, V91, P458, DOI 10.1182/blood.V91.2.458.458_458_465; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; Pollack IF, 1996, J NEUROSURG, V84, P1024, DOI 10.3171/jns.1996.84.6.1024; Rickert P, 1996, ONCOGENE, V12, P2631; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schrump DS, 1998, CLIN CANCER RES, V4, P2885; Schwartz GK, 1997, CLIN CANCER RES, V3, P1467; Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; Shao RG, 1997, CANCER RES, V57, P4029; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu E, 1996, ONCOLOGY-BASEL, V53, P494; TAKAHASHI I, 1989, J ANTIBIOT, V42, P571, DOI 10.7164/antibiotics.42.571; TAKAHASHI I, 1987, J ANTIBIOT, V40, P1782, DOI 10.7164/antibiotics.40.1782; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; Tsuchida E, 1997, INT J RADIAT ONCOL, V39, P1153, DOI 10.1016/S0360-3016(97)00549-X; WANG QZ, 1995, CELL GROWTH DIFFER, V6, P927; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WORLAND PJ, 1993, BIOCHEM PHARMACOL, V46, P1831, DOI 10.1016/0006-2952(93)90590-S; Yu LJ, 1998, J BIOL CHEM, V273, P33455, DOI 10.1074/jbc.273.50.33455; Zaharevitz DW, 1999, CANCER RES, V59, P2566	77	99	106	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6600	6606		10.1038/sj.onc.1204085	http://dx.doi.org/10.1038/sj.onc.1204085			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426645				2022-12-17	WOS:000167704000006
J	Trojanowska, M				Trojanowska, M			Ets factors and regulation of the extracellular matrix	ONCOGENE			English	Article						Ets; ECM; stroma; fibrosis; MMP; collagen	EPIDERMAL GROWTH-FACTOR; TRANSCRIPTION FACTOR; GENE-EXPRESSION; BINDING-SITES; TUMOR INVASION; STROMELYSIN PROMOTER; SIGNALING PATHWAY; EPITHELIAL-CELLS; TISSUE INHIBITOR; TRANSGENIC MICE	Ets factors are critical mediators of extracellular matrix (ECM) remodelling. As the spectrum of Ets-regulated target genes widens, so does their role in various pathological and physiological processes. Regulation of matrix degrading proteases by Ets factors in tumor invasion and metastasis is well established, Emerging evidence suggests that they may also play a role in the pathology of autoimmune diseases. Newly characterized Ets target genes such as tenascin-C and collagen type I suggest their role in diseases characterized by aberrant collagen deposition (fibrosis), Ets function is also critical in bone and cartilage development. There is increasing knowledge of the complex regulatory mechanisms involved in transcription of Ets target genes. Ets factors may function as activators or as repressors via association with specific cofactors depending on the promoter context. Signaling pathways can modulate the activation status of Ets factors and their transcriptional partners, Precise understanding of the role of Ets factors in the complex cellular network governing the expression of ECM proteins and the enzymes that degrade them will be a focus of future studies.	Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29401 USA	Medical University of South Carolina	Trojanowska, M (corresponding author), Med Univ S Carolina, Div Rheumatol & Immunol, 96 Jonathan Lucas St, Charleston, SC 29401 USA.			Trojanowska, Maria/0000-0001-9550-7178				AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; BOLON I, 1995, AM J PATHOL, V147, P1298; BORCHERS AH, 1994, EXP CELL RES, V213, P143, DOI 10.1006/excr.1994.1183; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Buttice G, 1996, ONCOGENE, V13, P2297; Calmels TPG, 1995, BIOL CELL, V84, P53, DOI 10.1016/0248-4900(96)81318-9; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; Dooley S, 1996, ANN RHEUM DIS, V55, P298, DOI 10.1136/ard.55.5.298; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; Forget MA, 1999, CAN J PHYSIOL PHARM, V77, P465; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Georgiou P, 1996, INT J ONCOL, V9, P9; Gilles F, 1996, EXP CELL RES, V222, P370, DOI 10.1006/excr.1996.0046; Goodman RH, 2000, GENE DEV, V14, P1553; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Hanzawa M, 2000, CARCINOGENESIS, V21, P1079, DOI 10.1093/carcin/21.6.1079; Hida K, 1997, ORAL ONCOL, V33, P426, DOI 10.1016/S0964-1955(97)00047-X; Hida K, 1997, AM J PATHOL, V150, P2125; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HultgardhNilsson A, 1996, CIRC RES, V78, P589, DOI 10.1161/01.RES.78.4.589; Ito M, 1998, BIOCHEM BIOPH RES CO, V246, P123, DOI 10.1006/bbrc.1998.8585; Ito T, 1998, MODERN PATHOL, V11, P209; Iwamoto M, 2000, J CELL BIOL, V150, P27, DOI 10.1083/jcb.150.1.27; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Johansson N, 2000, HISTOL HISTOPATHOL, V15, P225, DOI 10.14670/HH-15.225; Kauppila S, 1998, J PATHOL, V186, P262, DOI 10.1002/(SICI)1096-9896(1998110)186:3<262::AID-PATH191>3.0.CO;2-3; Kauppila S, 1999, CANCER, V86, P1299, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1299::AID-CNCR27>3.0.CO;2-6; Kim KR, 2000, ONCOGENE, V19, P1764, DOI 10.1038/sj.onc.1203502; Kitange G, 1999, LAB INVEST, V79, P407; Kleinbaum LA, 1999, BIOCHEM BIOPH RES CO, V264, P119, DOI 10.1006/bbrc.1999.1493; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LENGYEL E, 1995, BBA-MOL CELL RES, V1268, P65, DOI 10.1016/0167-4889(95)00050-3; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Malemud Charles J., 1999, Frontiers in Bioscience, V4, pd762; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Naito S, 2000, PATHOL RES PRACT, V196, P103, DOI 10.1016/S0344-0338(00)80041-2; Nakayama T, 1999, MODERN PATHOL, V12, P61; Nakayama T, 1996, AM J PATHOL, V149, P1931; NERLOV C, 1991, ONCOGENE, V6, P1583; Nishioka Y, 2000, JPN J CANCER RES, V91, P612, DOI 10.1111/j.1349-7006.2000.tb00989.x; Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x; Patton SE, 1998, CANCER RES, V58, P2253; Ried S, 1999, J BIOL CHEM, V274, P16377, DOI 10.1074/jbc.274.23.16377; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; Rutter JL, 1998, CANCER RES, V58, P5321; Santala M, 1998, BRIT J CANCER, V77, P1825, DOI 10.1038/bjc.1998.303; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Stracke M L, 1994, In Vivo, V8, P49; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; Teitell MA, 1999, LAB INVEST, V79, P1535; Trojanowska M, 1998, J MOL MED, V76, P266, DOI 10.1007/s001090050216; Van Rompaey L., 1999, Neoplasia (New York), V1, P526; Vary CPH, 2000, EXP CELL RES, V257, P213, DOI 10.1006/excr.2000.4879; VINCENTI MP, 1994, ARTHRITIS RHEUM, V37, P1115, DOI 10.1002/art.1780370802; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Wernert N, 1997, VIRCHOWS ARCH, V430, P433, DOI 10.1007/s004280050053; WERNERT N, 1994, CANCER RES, V54, P5683; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	77	99	102	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2000	19	55					6464	6471		10.1038/sj.onc.1204043	http://dx.doi.org/10.1038/sj.onc.1204043			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175362				2022-12-17	WOS:000166595000008
J	Truong, AHL; Ben-David, Y				Truong, AHL; Ben-David, Y			The role of Fli-1 in normal cell function and malignant transformation	ONCOGENE			English	Article						Fli-1; transcription factor; gene regulation; cancer	MURINE LEUKEMIA-VIRUS; ETS TRANSCRIPTION FACTORS; TERNARY COMPLEX FACTORS; DNA-BINDING; EWINGS-SARCOMA; PROVIRAL INTEGRATION; INDUCED ERYTHROLEUKEMIA; GENE-EXPRESSION; FUSION GENE; F-MULV	Aberrant expression of the Fli-1 transcription factor following genetic mutation has been recognized as a seminal event in the initiation of certain types of malignant transformation. Indeed, the etiology of a number of virally induced leukemias, including Friend virus-induced erythroleukemia, has been associated with Fli-1 overexpression, The clinical relevance of Fli-1 becomes apparent in human Ewing's sarcoma in which Fli-1 is the target of a characteristic chromosomal translocation, As such, Fli-1 has generated considerable interest over the past several years for its role in malignant transformation and tumor progression. This review will present a synopsis of the current research on Fli-1 with emphasis on its function in malignant transformation. Moreover, the possible role of Fli-1 in cellular proliferation, differentiation and survival, as well as the recent development of transgenic and knock-out mice to investigate the function of Fli-1 will be discussed. Finally, the significance of identifying target genes that are regulated by Fli-1 and their role in cellular function will be reviewed.	Sunnybrook & Womens Coll Hlth Sci Ctr, Div Canc Biol Res, Toronto, ON M4N 3M5, Canada; TSRCC, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Ben-David, Y (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Div Canc Biol Res, 2075 Bayview Ave,S Wing,Room S216, Toronto, ON M4N 3M5, Canada.							Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; Athanasiou M, 2000, LEUKEMIA, V14, P439, DOI 10.1038/sj.leu.2401689; Athanasiou M, 1996, CELL GROWTH DIFFER, V7, P1525; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Barbeau B, 1999, ONCOGENE, V18, P5535, DOI 10.1038/sj.onc.1202913; Barbeau B, 1996, BBA-GENE STRUCT EXPR, V1307, P220, DOI 10.1016/0167-4781(96)00060-7; Bastian LS, 1999, BLOOD, V93, P2637, DOI 10.1182/blood.V93.8.2637.408k20_2637_2644; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BERGERON D, 1991, J VIROL, V65, P7, DOI 10.1128/JVI.65.1.7-15.1991; Brown LA, 2000, MECH DEVELOP, V90, P237, DOI 10.1016/S0925-4773(99)00256-7; Dalgleish P, 2000, NUCLEIC ACIDS RES, V28, P560, DOI 10.1093/nar/28.2.560; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Denicourt C, 1999, J VIROL, V73, P4439, DOI 10.1128/JVI.73.5.4439-4442.1999; Deramaudt BMJM, 1999, J CELL BIOCHEM, V72, P311, DOI 10.1002/(SICI)1097-4644(19990301)72:3<311::AID-JCB1>3.3.CO;2-7; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; Dhulipala PDK, 1998, ONCOGENE, V17, P1149, DOI 10.1038/sj.onc.1202030; GOBEL MG, 1990, CELL, V61, P1165; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HOWARD JC, 1993, ONCOGENE, V8, P2721; Howard JC, 1996, ONCOGENE, V12, P1405; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; Lin PP, 1999, CANCER RES, V59, P1428; Mager AM, 1998, INT J DEV BIOL, V42, P561; MAO X, 1994, J BIOL CHEM, V269, P16216; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Melet F, 1996, MOL CELL BIOL, V16, P2708; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; OTT DE, 1994, VIROLOGY, V205, P563, DOI 10.1006/viro.1994.1680; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; PETER M, 1995, BRIT J CANCER, V72, P96, DOI 10.1038/bjc.1995.283; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; PFLEIDERER C, 1995, INT J CANCER, V64, P135, DOI 10.1002/ijc.2910640211; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAO VN, 1993, ONCOGENE, V8, P2167; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; Sarrazin S, 2000, MOL CELL BIOL, V20, P2959, DOI 10.1128/MCB.20.9.2959-2969.2000; SELLERI L, 1994, CYTOGENET CELL GENET, V67, P129, DOI 10.1159/000133813; SELS FT, 1992, ONCOGENE, V7, P643; SETH A, 1993, ONCOGENE, V8, P1783; Seth A, 1999, CELL DEATH DIFFER, V6, P902, DOI 10.1038/sj.cdd.4400567; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Starck J, 1999, MOL CELL BIOL, V19, P121; Szymczyna BR, 2000, J BIOL CHEM, V275, P28363, DOI 10.1074/jbc.M004294200; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Thompson AD, 1996, ONCOGENE, V13, P2649; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961; Zochodne B, 2000, ONCOGENE, V19, P2296, DOI 10.1038/sj.onc.1203590	69	99	105	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2000	19	55					6482	6489		10.1038/sj.onc.1204042	http://dx.doi.org/10.1038/sj.onc.1204042			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175364				2022-12-17	WOS:000166595000010
J	Giehl, K; Skripczynski, B; Mansard, A; Menke, A; Gierschik, P				Giehl, K; Skripczynski, B; Mansard, A; Menke, A; Gierschik, P			Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration	ONCOGENE			English	Article						pancreatic cancer; Ras; MAPK; signal transduction; growth factors	PROTEIN-KINASE; SIGNAL-TRANSDUCTION; CANCER CELLS; FACTOR RECEPTOR; FACTOR-ALPHA; N-RAS; MAMMALIAN-CELLS; BINDING DOMAIN; HUMAN-COLON; HA-RAS	Human ductal adenocarcinoma of the pancreas frequently carry activating point mutations in the K-ras protooncogene. We have anal! sed the activity of the Ras-Raf-MEK-MAPK cascade in the human pancreatic carcinoma cell line PANC-1 carrying an activating K-ras mutation. Serum-starved cells and cells grown in medium with serum did not show constitutively activated c-Raf, MEK-1, or p42 MAPK. Stimulation bf cells with epidermal growth factor (EGF) or fetal calf serum (FCS) resulted in activation of N-Ras, but not K-Ras, as well as activation of c-Raf, MEK-1, and p42 MAPK. Preincubation of serum-starved cells with MEK-1 inhibitor PD98059 abolished EGF- and FCS-induced MAPK activation, identifying MEK as the upstream activator of MAPK. PANC-1 cells exhibited marked serum-dependence of anchorage-dependent and -independent cell growth as well as cell migration. EGF, alone or in combination with insulin and transferrin, did not induce cell proliferation of serum-starved PANC-1 cells, indicating that activation of MAPK alone was not sufficient to induce cell proliferation, FCS-induced DNA synthesis was inhibited by 40% by the MEK-1 inhibitor. On the other hand, treatment with either FCS or EGF alone resulted in marked, MEK-dependent increase of directed cell migration. Collectively, our results show that the activating K-ras mutation in PANC-1 cells does not result in constitutively increased Raf-MEK-MAPK signaling. Signal transduction via the Ras-Raf-MEK-MAPK cascade is maintained in these cells and is required for growth factor-induced cell proliferation and directed cell migration.	Univ Ulm, Dept Pharmacol & Toxicol, D-89069 Ulm, Germany; Univ Ulm, Dept Internal Med 1, D-89069 Ulm, Germany	Ulm University; Ulm University	Giehl, K (corresponding author), Univ Ulm, Dept Pharmacol & Toxicol, D-89069 Ulm, Germany.							AnandApte B, 1997, STEM CELLS, V15, P259, DOI 10.1002/stem.150259; Aoki K, 1997, MOL CARCINOGEN, V20, P251, DOI 10.1002/(SICI)1098-2744(199710)20:2<251::AID-MC12>3.0.CO;2-9; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BEAUCHAMP RD, 1990, PANCREAS, V5, P369, DOI 10.1097/00006676-199007000-00001; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BOS JL, 1989, CANCER RES, V49, P4682; Brat DJ, 1997, AM J PATHOL, V150, P383; Buard A, 1996, INT J CANCER, V67, P539, DOI 10.1002/(SICI)1097-0215(19960807)67:4<539::AID-IJC13>3.0.CO;2-2; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CALDAS C, 1995, INT J PANCREATOL, V18, P1; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; COX AD, 1995, METHOD ENZYMOL, V255, P195; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fan JG, 1997, ONCOGENE, V14, P2595, DOI 10.1038/sj.onc.1201105; FREEDMAN RR, 1995, MENOPAUSE, V2, P163; Friess H, 1996, J MOL MED-JMM, V74, P35, DOI 10.1007/BF00202070; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GILLESPIE J, 1993, BRIT J CANCER, V68, P1122, DOI 10.1038/bjc.1993.491; Grewe M, 1999, CANCER RES, V59, P3581; Hamilton M, 1998, ONCOGENE, V16, P1417, DOI 10.1038/sj.onc.1201653; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HRUBAN RH, 1993, AM J PATHOL, V143, P545; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; Kita K, 1999, INT J CANCER, V80, P553, DOI 10.1002/(SICI)1097-0215(19990209)80:4<553::AID-IJC12>3.0.CO;2-6; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; Laird AD, 1997, CELL SIGNAL, V9, P249, DOI 10.1016/S0898-6568(96)00176-3; LIEBER M, 1975, INT J CANCER, V15, P741, DOI 10.1002/ijc.2910150505; Longnecker DS, 1998, PANCREAS, V17, P323, DOI 10.1097/00006676-199811000-00001; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAHER J, 1995, ONCOGENE, V11, P1639; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; Moepps B, 1999, GENOMICS, V60, P199, DOI 10.1006/geno.1999.5901; Okada S, 1998, PANCREAS, V16, P349, DOI 10.1097/00006676-199804000-00023; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RODRIGUEZ VP, 1997, CELL, V89, P457; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SETH A, 1992, J BIOL CHEM, V267, P24796; Seufferlein T, 1999, GASTROENTEROLOGY, V116, P1441, DOI 10.1016/S0016-5085(99)70509-3; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUMI S, 1994, PANCREAS, V9, P657, DOI 10.1097/00006676-199409000-00018; TAN MH, 1986, CANCER INVEST, V4, P15, DOI 10.3109/07357908609039823; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Verbeek BS, 1998, FEBS LETT, V425, P145, DOI 10.1016/S0014-5793(98)00224-5; Watanabe M, 1996, INT J CANCER, V67, P264, DOI 10.1002/(SICI)1097-0215(19960717)67:2<264::AID-IJC18>3.0.CO;2-B; Wells A, 1998, MICROSC RES TECHNIQ, V43, P395, DOI 10.1002/(SICI)1097-0029(19981201)43:5<395::AID-JEMT6>3.0.CO;2-T; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Yip-Schneider MT, 1999, INT J ONCOL, V15, P271	63	99	105	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2000	19	25					2930	2942		10.1038/sj.onc.1203612	http://dx.doi.org/10.1038/sj.onc.1203612			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871844				2022-12-17	WOS:000087544500007
J	Harhaj, EW; Good, L; Xiao, GT; Uhlik, M; Cvijic, ME; Rivera-Walsh, I; Sun, SC				Harhaj, EW; Good, L; Xiao, GT; Uhlik, M; Cvijic, ME; Rivera-Walsh, I; Sun, SC			Somatic mutagenesis studies of NF-kappa B signaling in human T cells: evidence for an essential role of IKK gamma in NF-kappa B activation by T-cell costimulatory signals and HTLV-I Tax protein	ONCOGENE			English	Article						IKK signaling; HTLV Tax; T-cell costimulation; somatic cell mutagenesis	VIRUS TYPE-I; KINASE-ALPHA; C-REL; TRANSCRIPTION FACTORS; LEUKEMIA; BETA; PHOSPHORYLATION; EXPRESSION; GENE; DEGRADATION	NF-kappa B plays a pivotal role in normal T-cell activation and may also mediate human T-cell leukemia virus (HTLV)-induced T-cell transformation. Activation of NF-kappa B by both T-cell costimulatory signals and the HTLV Tax protein involves stimulation of I kappa B kinase (IKK), As a genetic approach to dissect the intermediate steps involved in NF-kappa B activation in human T cells, me performed somatic cell mutagenesis to isolate signaling-defective mutant Jurkat T-cell lines, One of the mutant cell lines was shown to have a specific blockade in the IKK signaling pathway but remained competent in the c-Jun N-terminal kinase and MAP kinase pathways. Interestingly, this mutant cell line lacks expression of IKK gamma, a non-catalytic component of the IKK complex, Expression of exogenous IKK gamma in the mutant cells restored NF-kappa B activation by both the T-cell costimulation agents and Tax. These findings provide genetic evidence for the requirement of IKK gamma in NF-kappa B signaling triggered by both T-cell costimulatory signals and HTLV-I Tax protein.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.				NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA68471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BRYAN RG, 1994, MOL CELL BIOL, V14, P7933, DOI 10.1128/MCB.14.12.7933; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Gerondakis S, 1998, CURR OPIN IMMUNOL, V10, P353, DOI 10.1016/S0952-7915(98)80175-1; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Harhaj EW, 1998, J BIOL CHEM, V273, P25185, DOI 10.1074/jbc.273.39.25185; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LAI JH, 1994, J BIOL CHEM, V269, P30077; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Ressler S, 1996, FEMS MICROBIOL LETT, V140, P99, DOI 10.1016/0378-1097(96)00166-8; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 1996, MOL CELL BIOL, V16, P1058; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547	59	99	100	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2000	19	11					1448	1456		10.1038/sj.onc.1203445	http://dx.doi.org/10.1038/sj.onc.1203445			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723136				2022-12-17	WOS:000085942700010
J	Wu, GS; Burns, TF; McDonald, ER; Meng, RD; Kao, G; Muschel, R; Yen, T; El-Deiry, WS				Wu, GS; Burns, TF; McDonald, ER; Meng, RD; Kao, G; Muschel, R; Yen, T; El-Deiry, WS			Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest	ONCOGENE			English	Article						p53; KILLER/DR5; TRAIL; ATM; G1 arrest; apoptosis	CELL-CYCLE CHECKPOINT; FADD-DEPENDENT APOPTOSIS; CYTOTOXIC LIGAND TRAIL; TUMOR-SUPPRESSOR P53; NF-KAPPA-B; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; IN-VITRO; BAX GENE	The TRAIL death receptor KILLER/DR5 is induced by DNA damaging agents in wild-type p53-expressing cells. Here me show that, unlike the p53-target CDK-inhibitor p21(WAF1/CIP1), the TRAIL death receptor KILLER/DR5 is only induced in cells undergoing p53-dependent apoptosis and not cell cycle arrest. Thus GM glioblastoma cells carrying an inducible MMTV-driven p53 gene undergo cell cycle arrest and upregulate p21 but not KILLER/DR5 expression upon dexamethasone exposure. W138 normal lung fibroblasts undergoing cell cycle arrest in response to ionizing irradiation also induce p21 but not KILLER/DR5 gene expression. KILLER/DR5 upregulation is also deficient in irradiated lymphoblastoid cells derived from patients with Ataxia Teleangiectasia suggesting a role for the ATM-p53 pathway in regulating KILLER/DR5 expression after DNA damage. Inhibition of transcription by Actinomycin D blocks both KILLER/DR5 and p21 induction in cells undergoing p53-dependent apoptosis. Our results suggest that the p53-dependent transcriptional induction of KILLER/DR5 death receptor is restricted to cells undergoing apoptosis and not cells undergoing exclusively p53-dependent GI arrest.	Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Med,Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Genet,Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Radiat Oncol,Lab Mol Oncol & Cell Cycle Regu, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Pathol,Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Howard Hughes Medical Institute; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Fox Chase Cancer Center	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Med,Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266; Yen, Tim/0000-0003-2159-0997	NCI NIH HHS [CA75138-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA075138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO;2-6; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARPER JW, 1993, CELL, V75, P805; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; HOPKIN K, 1997, J NIH RES, V9, P22; Kastan M, 1997, NAT GENET, V17, P130, DOI 10.1038/ng1097-130; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; LEONARDO AD, 1994, GENE DEV, V8, P2540; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Meng RD, 1998, CLIN CANCER RES, V4, P251; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5	52	99	99	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6411	6418		10.1038/sj.onc.1203025	http://dx.doi.org/10.1038/sj.onc.1203025			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597242				2022-12-17	WOS:000083709200002
J	Still, IH; Hamilton, M; Vince, P; Wolfman, A; Cowell, JK				Still, IH; Hamilton, M; Vince, P; Wolfman, A; Cowell, JK			Cloning of TACC1, an embryonically expressed, potentially transforming coiled coil containing gene, from the 8p11 breast cancer amplicon	ONCOGENE			English	Article						TACC1; embryonic; transforming; breast cancer	AMPLIFICATION; REGION; RECEPTORS; CARCINOMA; DOMAINS	Amplification of several chromosomal regions have been observed in human breast carcinomas. One such region, 8p11, is amplified in 10-15% of tumor samples, Although the FGFR1 gene is located close to this region, and is often included within the amplicon, the observation that tumors exhibiting 8p11 amplification do not always overexpress FGFR1 suggests that another gene located close to FGFR1 is involved in the tumorigenic process. We now report the precise location of four expressed sequence tags (ESTs) within this region and the cloning of a novel gene, designated TACC1 (transforming acidic coiled coil gene 1), which encodes an 8 kb transcript and which is expressed at high levels during early embryogenesis. Constitutive expression of this gene under the control of the cytomegalovirus (CMV) promoter in mouse fibroblasts, results in cellular transformation and anchorage independent growth, suggesting that inappropriate expression can impart a proliferative advantage. This observation raises the possibility that amplification of TACC1 could promotemalignant growth, thereby making TACC1 an attractive candidate for the gene promoting tumorigenicity as a result of the 8p11 amplification in human breast cancers.	Cleveland Clin Fdn, Lerner Res Inst, Ctr Mol Genet, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Still, IH (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Ctr Mol Genet, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Cowell, John/0000-0002-2079-5950	NIGMS NIH HHS [GM49652] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM049652, R01GM049652] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; ADNANE J, 1991, ONCOGENE, V6, P659; Courjal F, 1997, CANCER RES, V57, P4360; DIB A, 1995, ONCOGENE, V10, P995; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Hawthorn L, 1995, GENOMICS, V30, P425, DOI 10.1006/geno.1995.1260; MCLESKEY SW, 1994, CANCER RES, V54, P523; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; SCLESSINGER U, 1992, NEURON, V9, P383; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; THEILLET C, 1990, ONCOGENE, V5, P147; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WEYMAN CM, 1996, ADVANCES IN ONCOBIOL, V1, P159	16	99	105	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					4032	4038		10.1038/sj.onc.1202801	http://dx.doi.org/10.1038/sj.onc.1202801			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435627				2022-12-17	WOS:000081327800014
J	Cappellen, D; deMedina, SGD; Chopin, D; Thiery, JP; Radvanyi, F				Cappellen, D; deMedina, SGD; Chopin, D; Thiery, JP; Radvanyi, F			Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder	ONCOGENE			English	Article						bladder; human; transitional cell carcinoma; tumour progression; chromosome 10; loss of heterozygosity	SUPPRESSOR LOCI; ALLELIC LOSS; PROSTATE-CANCER; MXI1 GENE; LONG ARM; DELETION; IDENTIFICATION; PROGRESSION; REGION; HYBRIDIZATION	Loss of heterozygosity (LOH) on chromosome 10 has been observed in several human cancers including glioblastomas, meningiomas, melanomas and endometrial and prostate carcinomas, We have investigated the incidence of LOH on chromosome 10 in 36 human transitional cell carcinomas (TCCs) of the bladder, three upper urinary tract TCCs and one lymph node metastasis, using a panel of 27 highly polymorphic markers spanning 10p (short arm) and 10q (long arm), Fourteen bladder tumours (39%), the three upper urinary tract tumours and the lymph node metastasis showed LOH for at least one locus on chromosome 10, Remarkably, LOH on chromosome 10 was observed mainly in muscle-invasive (P=0.01) and high grade tumours (P=0.03). For five tumours and the lymph node metastasis, LOH was found at all informative loci, indicating monosomy or isodisomy of chromosome 10, The deletion mapping of the tumours with partial loss delineated two minimal regions of loss on chromosome 10q, One region, the most telomeric, was bounded by markers D10S214 and D10S169 and the other, the most proximal, was bounded by markers D10S222 and D10S531, Our results demonstrate that chromosome 10q LOH is common in muscle-invasive bladder cancers and that two potential tumour suppressor loci, at 10q24.1-q24.3 and 10q26.1-q26.2, may contribute to the malignant progression of these tumours. Localization of the smallest common regions of loss in bladder tumours provides a starting point for the identification of the genes involved.	INST CURIE,CNRS,UMR 144,SECT RECH,F-75248 PARIS 05,FRANCE; CHU HENRI MONDOR,GRP ETUD TUMEURS UROL,F-94010 CRETEIL,FRANCE; CHU HENRI MONDOR,UROL SERV,F-94010 CRETEIL,FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP			Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020; Radvanyi, Francois/0000-0002-5696-6424	NCI NIH HHS [2RO1 CA 49417-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049417] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBAROSA R, 1995, HUM GENET, V95, P709; ATKIN NB, 1985, CANCER GENET CYTOGEN, V15, P253, DOI 10.1016/0165-4608(85)90169-4; BABU VR, 1987, CANCER RES, V47, P6800; BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; BrayWard P, 1996, GENOMICS, V32, P1, DOI 10.1006/geno.1996.0070; BREWSTER SF, 1994, BRIT J CANCER, V70, P697, DOI 10.1038/bjc.1994.376; CAIRNS P, 1993, ONCOGENE, V8, P1083; CAIRNS P, 1991, ONCOGENE, V6, P2305; CHANG WYH, 1995, CANCER RES, V55, P3246; COOMBS LM, 1990, ANAL BIOCHEM, V188, P338, DOI 10.1016/0003-2697(90)90617-I; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; GIBAS Z, 1984, CANCER RES, V44, P1257; GRAY IC, 1995, CANCER RES, V55, P4800; HABUCHI T, 1995, ONCOGENE, V11, P1671; HERBST RA, 1994, CANCER RES, V54, P3111; Ittmann M, 1996, CANCER RES, V56, P2143; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; KAYE KW, 1982, J UROLOGY, V128, P31, DOI 10.1016/S0022-5347(17)52738-X; KNOWLES MA, 1994, CANCER RES, V54, P531; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; MATTEI MG, 1991, HUM GENET, V87, P84, DOI 10.1007/BF01213098; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Mostofi FK, 1973, INT HISTOLOGICAL CLA; OLUMI AF, 1990, CANCER RES, V50, P7081; PEIFFER SL, 1995, CANCER RES, V55, P1922; POLASCIK TJ, 1995, CANCER RES, V55, P5396; RASHEED BKA, 1995, ONCOGENE, V10, P2243; RODRIGUEZ E, 1994, CANCER RES, V54, P3398; ROSIN MP, 1995, CANCER RES, V55, P5213; RUPPERT JM, 1993, CANCER RES, V53, P5093; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; SIMON M, 1995, CANCER RES, V55, P4696; SMEETS W, 1987, CANCER GENET CYTOGEN, V29, P29, DOI 10.1016/0165-4608(87)90028-8; SPIESSL B, 1992, TNM ATLAS ILLUSTRATE, P214; SPRUCK CH, 1994, CANCER RES, V54, P784; Trybus TM, 1996, CANCER RES, V56, P2263; TSAI YC, 1990, CANCER RES, V50, P44; WANG MR, 1994, CANCER GENET CYTOGEN, V73, P8, DOI 10.1016/0165-4608(94)90175-9; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	47	99	100	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3059	3066		10.1038/sj.onc.1201154	http://dx.doi.org/10.1038/sj.onc.1201154			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223669				2022-12-17	WOS:A1997XG10000008
J	Toki, T; Itoh, J; Kitazawa, J; Arai, K; Hatakeyama, K; Akasaka, J; Igarashi, K; Nomura, N; Yokoyama, M; Yamamoto, M; Ito, E				Toki, T; Itoh, J; Kitazawa, J; Arai, K; Hatakeyama, K; Akasaka, J; Igarashi, K; Nomura, N; Yokoyama, M; Yamamoto, M; Ito, E			Human small Maf proteins form heterodimers with CNC family transcription factors and recognize the NF-E2 motif	ONCOGENE			English	Article						NF-E2; small Maf; MafK; MafG; Nrf1; Nrf2	DOMINANT CONTROL REGION; LEUCINE ZIPPER PROTEIN; LOCUS-CONTROL REGION; GLOBIN GENE; EXPRESSION; CLONING; ONCOGENE; SUBUNIT; COMPLEX; DOMAIN	The transcription factor NF-E2, a heterodimeric protein complex composed of p45 and small Maf family proteins, is considered crucial for the regulation of erythroid gene expression and platelet formation. To facilitate the characterization of NF-E2 functions in human cells, we isolated cDNAs encoding two members of the small Maf family, MafK and MafG. The human mafK and mafG genes encode proteins of 156 and 162 amino acid residues, respectively, whose deduced amino acid sequences show approximately 95% identity to their respective chicken counterparts. Expression of mafK mRNA is high in heart, skeletal muscle and placenta, whereas mafG mRNA is abundant in skeletal muscle and is moderately expressed in heart and brain. Both are expressed in all hematopoietic cell lines, including those of erythroid and megakaryocytic lineages. In electrophoretic gel mobility shift assays binding to NF-E2 sites was found to depend on formation of homodimers or heterodimers with p45 and p45-related CNC family proteins. The results suggest that the small Maf family proteins function in human cells through interaction with various basic-leucine zipper-type transcription factors.	HIROSAKI UNIV,SCH MED,DEPT PEDIAT,HIROSAKI,AOMORI 036,JAPAN; HIROSAKI UNIV,SCH MED,DEPT MED,HIROSAKI,AOMORI 036,JAPAN; HIROSAKI UNIV,FAC SCI,DEPT BIOL,HIROSAKI,AOMORI 036,JAPAN; TOHOKU UNIV,SCH MED,DEPT BIOCHEM,SENDAI,MIYAGI 98077,JAPAN; UNIV TSUKUBA,INST BASIC MED SCI,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,CTR TARA,TSUKUBA,IBARAKI 305,JAPAN; KAZUSA DNA INST,KISARAZU 292,JAPAN	Hirosaki University; Hirosaki University; Hirosaki University; Tohoku University; University of Tsukuba; University of Tsukuba; Kazusa DNA Research Institute			Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436; Ito, Etsuro/0000-0002-0168-2475; Igarashi, Kazuhiko/0000-0002-2470-2475				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KOMATSU N, 1991, CANCER RES, V51, P341; KOTLOW KJ, 1995, MOL CELL BIOL, V15, P4640; KOTLOW KJ, 1996, P NATL ACAD SCI USA, V93, P3514; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; LUNA L, 1994, GENOMICS, V22, P553, DOI 10.1006/geno.1994.1428; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; Toki T, 1996, BIOCHEM BIOPH RES CO, V219, P760, DOI 10.1006/bbrc.1996.0307; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384	30	99	104	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 24	1997	14	16					1901	1910		10.1038/sj.onc.1201024	http://dx.doi.org/10.1038/sj.onc.1201024			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150357				2022-12-17	WOS:A1997WV80400003
J	Seitz, S; Rohde, K; Bender, E; Nothnagel, A; Kolble, K; Schlag, PM; Scherneck, S				Seitz, S; Rohde, K; Bender, E; Nothnagel, A; Kolble, K; Schlag, PM; Scherneck, S			Strong indication for a breast cancer susceptibility gene on chromosome 8p12-p22: Linkage analysis in German breast cancer families	ONCOGENE			English	Article						breast cancer gene; loss of heterozygosity; linkage analysis; chromosome 8p	HETEROZYGOSITY; CARCINOMA; ALLELOTYPE; DISEASE; ONSET; LOCI; 8P	Chromosomal losses involving the short arm of chromosome 8 are frequent in a variety of tumor types, including breast cancer, suggesting the presence of one or more tumor suppressor genes in this region, Previous linkage analysis and studies of loss of heterozygosity (LOH) have suggested the presence of a putative third breast cancer susceptibility gene around D8S505 at 8p12-p22, We have performed linkage analysis in two German breast cancer families, showing negative lod scores with 17q and 13q markers, using seven adjacent microsatellite markers from 8p12-p22, Incorporating LOH data from tumors of the affected family members a maximum cumulative three-point lod score of 3.30 at Theta = 0.00 was obtained with D8S137 and D8S131, Our findings considerably strengthen the evidence for a third breast cancer susceptibility locus (BRCA3) mapping to the short arm of human chromosome 8.	MAX DELBRUCK CTR MOL MED,DEPT TUMOR GENET,D-13122 BERLIN,GERMANY; MAX DELBRUCK CTR MOL MED,DEPT BIOINFORMAT,D-13122 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,DEPT PATHOL,D-10117 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,ROBERT ROESSLE CLIN,DEPT SURG ONCOL,D-13122 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Humboldt University of Berlin								CLAUS EB, 1991, AM J HUM GENET, V48, P232; CLIBY W, 1993, CANCER RES, V53, P2393; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; DEVILEE P, 1991, ONCOGENE, V6, P1705; EMI M, 1992, CANCER RES, V52, P5368; Imbert A, 1996, GENOMICS, V32, P29, DOI 10.1006/geno.1996.0073; KELEMEN PR, 1994, GENE CHROMOSOME CANC, V11, P195, DOI 10.1002/gcc.2870110308; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; KNOWLES MA, 1993, ONCOGENE, V8, P1357; MACOSKA JA, 1995, CANCER RES, V55, P5390; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; ROHDE K, 1995, HUM HERED, V45, P337, DOI 10.1159/000154302; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SOBOL H, 1994, LANCET, V344, P1151, DOI 10.1016/S0140-6736(94)90655-6; Stratton MR, 1996, CURR OPIN GENET DEV, V6, P93, DOI 10.1016/S0959-437X(96)90017-9; WASYLYSHYN ML, 1991, SURGERY, V110, P268; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; ZIMMERMANN W, 1993, AM J HUM GENET, V52, P789; ZUPPAN P, 1991, AM J HUM GENET, V48, P1065	21	99	101	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					741	743		10.1038/sj.onc.1200881	http://dx.doi.org/10.1038/sj.onc.1200881			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038382				2022-12-17	WOS:A1997WG43000013
J	Menon, AG; Rutter, JL; vonSattel, JP; Synder, H; Murdoch, C; Blumenfeld, A; Martuza, RL; vonDeimling, A; Gusella, JF; Houseal, TW				Menon, AG; Rutter, JL; vonSattel, JP; Synder, H; Murdoch, C; Blumenfeld, A; Martuza, RL; vonDeimling, A; Gusella, JF; Houseal, TW			Frequent loss of chromosome 14 in atypical and malignant meningioma: Identification of a putative 'tumor progression' locus	ONCOGENE			English	Article						loss of heterozygosity; chromosome 14; meningioma	CYTOGENETIC ANALYSIS; BRAIN TUMORS; GENES; EVOLUTION; AMPLIFICATION; TUMORIGENESIS; RECOMBINATION; METAPHASE; FRAGMENTS; PROBES	Formation of meningiomas has been associated with the loss of genetic material on chromosome 22. To approach the additional chromosomal events that underlie progression of these tumors to malignancy, we have examined several other chromosomal regions for loss of heterozygosity (LOH) in these tumors. Fifty-eight tumors, comprising 43 benign meningiomas, 11 atypical meningiomas and four malignant meningiomas, were examined. While the loss of chromosome 22 was seen in approximately half of all these tumors, regardless of their malignancy, the most frequent chromosomal losses observed in the malignant and atypical tumors were on the long arm of chromosome 14. Thirty-nine tumors were informative for at least one of the three markers on chromosome 14 that we tested. Of these, 7/14 malignant and atypical tumors showed LOH in contrast to only 1/25 benign tumors. Other loci that showed LOH in malignant tumors, although at a much lower frequency, were on chromosomes 17p and 1p, The high frequency of LOH for loci on chromosome 14q in atypical and malignant tumors suggests the presence of a tumor progression gene at this locus. In one of the malignant meningiomas heterozygosity was lost at D14S13 and D14S16 but retained at the proximal marker D14S43 as well as the more distal marker D14S23. This suggests that an interstitial deletion occurred in this tumor which should be useful for further refining the position of the putative tumor progression locus.	MASSACHUSETTS GEN HOSP,MOL NEUROGENET LAB,CHARLESTOWN,MA 02129; GEORGETOWN UNIV,DEPT NEUROSURG,WASHINGTON,DC 20007; UNIV BONN,INST NEUROPATHOL,D-5300 BONN,GERMANY; GENZYME GENET,FRAMINGHAM,MA 01701	Harvard University; Massachusetts General Hospital; Georgetown University; University of Bonn; Sanofi-Aventis; Genzyme Corporation	Menon, AG (corresponding author), UNIV CINCINNATI,MED CTR,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267, USA.		von Deimling, Andreas/F-7774-2013	von Deimling, Andreas/0000-0002-5863-540X; Rutter, Joni/0000-0002-6502-2361	NINDS NIH HHS [NS31145-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P20NS031145] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALSAADI A, 1987, CANCER GENET CYTOGEN, V26, P127, DOI 10.1016/0165-4608(87)90140-3; ATKIN NB, 1990, CANCER GENET CYTOGEN, V44, P229, DOI 10.1016/0165-4608(90)90052-C; BELLO MJ, 1989, NEOPLASMA, V36, P71; BIGNER SH, 1986, CANCER GENET CYTOGEN, V22, P121, DOI 10.1016/0165-4608(86)90172-X; BOGHOSIAN L, 1989, CANCER GENET CYTOGEN, V43, P39, DOI 10.1016/0165-4608(89)90125-8; CASALONE R, 1990, CANCER GENET CYTOGEN, V45, P237, DOI 10.1016/0165-4608(90)90088-R; CASARTELLI C, 1989, CANCER GENET CYTOGEN, V40, P33, DOI 10.1016/0165-4608(89)90143-X; CHALLA VR, 1992, NEUROSURGERY, V1, P613; CHAUM E, 1984, CYTOGENET CELL GENET, V38, P82, DOI 10.1159/000132037; CREMER T, 1988, HUM GENET, V80, P235, DOI 10.1007/BF01790091; CROCE CM, 1985, SCIENCE, V227, P1044, DOI 10.1126/science.3919442; DUMANSKI JP, 1987, P NATL ACAD SCI USA, V84, P9275, DOI 10.1073/pnas.84.24.9275; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEBHART E, 1986, BREAST CANCER RES TR, V8, P125, DOI 10.1007/BF01807701; HOFKER MH, 1990, GENOMICS, V6, P33, DOI 10.1016/0888-7543(90)90445-Z; KATSUYAMA J, 1986, CANCER GENET CYTOGEN, V22, P63, DOI 10.1016/0165-4608(86)90138-X; KLINGER K, 1992, AM J HUM GENET, V51, P55; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; NAKAMURA Y, 1989, GENOMICS, V4, P76, DOI 10.1016/0888-7543(89)90317-0; *NIH CEPH COLL MAP, 1992, SCIENCE, V258, P67; PEDERSEN MI, 1989, CANCER GENET CYTOGEN, V41, P185, DOI 10.1016/0165-4608(89)90245-8; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RUSSELL DS, 1990, PATHOLOGY TUMORS NER; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; SHARMA V, 1991, NUCLEIC ACIDS RES, V19, P1722, DOI 10.1093/nar/19.7.1722; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SRIVATSAN ES, 1991, PROG CLIN BIOL RES, V366, P91; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; SUZUKI T, 1989, CANCER RES, V49, P1095; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; ZANKL H, 1972, HUMANGENETIK, V14, P167, DOI 10.1007/BF00273305	34	99	105	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					611	616		10.1038/sj.onc.1200853	http://dx.doi.org/10.1038/sj.onc.1200853			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053860				2022-12-17	WOS:A1997WF52400013
J	Marks, JR; Huper, G; Vaughn, JP; Davis, PL; Norris, J; McDonnell, DP; Wiseman, RW; Futreal, PA; Iglehart, JD				Marks, JR; Huper, G; Vaughn, JP; Davis, PL; Norris, J; McDonnell, DP; Wiseman, RW; Futreal, PA; Iglehart, JD			BRCA1 expression is not directly responsive to estrogen	ONCOGENE			English	Article						BRCA1; estrogen response; cell cycle; antiestrogen; proliferation	BREAST-CANCER-CELLS; GROWTH-FACTOR; GENE; RECEPTOR; MUTATIONS; TISSUES; DIFFERENTIATION; TRANSCRIPTION; ANTIESTROGENS; CULTURE	Expression of the breast cancer susceptibility gene, BRCA1, is induced by 17-beta estradiol (E(2)) in estrogen receptor containing breast cancer cell lines, Our previous studies have shown that BRCA1 transcription is also regulated with the cell cycle, reaching maximal levels just before the onset of DNA synthesis, In this study, we have examined whether the estrogen induction of BRCA1 is direct or is a result of the mitogenic activity of the hormone, Four lines of evidence lead us to conclude that E(2) induces BRCA1 primarily through an increase in DNA synthesis: (1) The kinetics and magnitude of induction are different from the directly E(2) inducible gene, pS2; (2) Induction of BRCA1, but not pS2, is blocked by cycloheximide indicating that de novo protein synthesis is required; (3) Other hormonal and growth factor treatments that induce DNA synthesis have a similar effect, including IGF-1, EGF and DNA synthetic flares induced by tamoxifen and retinoic acid; (4) BRCA1 genomic fragments near the 5' end of the gene containing putative estrogen response elements fail to respond to E(2) when transfected into breast cancer cell lines, The most consistent explanation for these findings and other published studies is that BRCA1 transcription is induced as a result of the mitogenic activity of E(2) in estrogen receptor positive cells.	DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; NIEHS, MOL CARCINOGENESIS LAB, RES TRIANGLE PK, NC 27709 USA; DUKE UNIV, MED CTR, DEPT GENET, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Duke University	Marks, JR (corresponding author), DUKE UNIV, MED CTR, DEPT SURG, BOX 3873, DURHAM, NC 27710 USA.			Norris, John/0000-0001-6553-8053	NATIONAL CANCER INSTITUTE [P50CA068438, R01CA061218] Funding Source: NIH RePORTER; NCI NIH HHS [CA68438, CA63786, CA61218] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; DANA SL, 1994, MOL ENDOCRINOL, V8, P1193, DOI 10.1210/me.8.9.1193; EASTON DF, 1995, AM J HUM GENET, V56, P265; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; FORD D, 1995, AM J HUM GENET, V57, P1457; FREED KA, 1989, J MOL ENDOCRINOL, V3, P183, DOI 10.1677/jme.0.0030183; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GUDAS JM, 1995, CANCER RES, V55, P4561; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Haslam S. Z., 1987, The mammary gland. Development, regulation, and function., P499; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; IMAI Y, 1982, CANCER RES, V42, P4394; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; MARKS JR, 1989, J VIROL, V63, P790, DOI 10.1128/JVI.63.2.790-797.1989; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MATSUSHIMA M, 1995, HUM MOL GENET, V4, P1953, DOI 10.1093/hmg/4.10.1953; MCDONNELL DP, 1995, ANN NY ACAD SCI, V761, P121, DOI 10.1111/j.1749-6632.1995.tb31374.x; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; RAMKUMAR T, 1995, ENDOCRINOLOGY, V136, P536, DOI 10.1210/en.136.2.536; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; VAUGHN JP, 1995, P NATL ACAD SCI USA, V92, P8338, DOI 10.1073/pnas.92.18.8338; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WANG SQ, 1990, ENDOCRINOLOGY, V127, P2183, DOI 10.1210/endo-127-5-2183; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; ZEIMET AG, 1994, J STEROID BIOCHEM, V49, P365, DOI 10.1016/0960-0760(94)90281-X	37	99	102	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	1997	14	1					115	121		10.1038/sj.onc.1200808	http://dx.doi.org/10.1038/sj.onc.1200808			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010238				2022-12-17	WOS:A1997WB76000011
J	Thompson, AD; Braun, BS; Arvand, A; Stewart, SD; May, WA; Chen, E; Korenberg, J; Denny, C				Thompson, AD; Braun, BS; Arvand, A; Stewart, SD; May, WA; Chen, E; Korenberg, J; Denny, C			EAT-2 is a novel SH2 domain containing protein that is up regulated by Ewing's sarcoma EWS/FLI1 fusion gene	ONCOGENE			English	Article						SH2 domain; transcription factor; oncogenes; cellular transformation; sarcoma	RNA-BINDING PROTEIN; ROUND-CELL TUMORS; TRANSCRIPTIONAL ACTIVATOR; DNA-BINDING; EWS GENE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; INSULIN-RECEPTOR; TRANSLOCATION; FAMILY	The EWS/FLI1 fusion protein is created by the translocation between chromosomes 11 and 22 that appears in most Ewing's sarcomas, This chimeric protein has been demonstrated to be an aberrant transcription factor. Genes up regulated by EWS/FLI1 but not by full-length FLI1 were identified by representational difference analysis (RDA), We have characterized a novel gene, EWS/FLI1 activated transcript 2 (EAT-2) that was cloned from a murine cDNA library using a differentially expressed RDA fragment. EAT-2 expression is seen within 4-8 h of EWS/FLI1 induction, Its expression correlates with transformation of NIH3T3 cells by chimeric proteins related to EWS/FLI1 but not by unrelated genes, EAT-2 is expressed in normal murine tissues and contains a unique but biochemically functional SH2 domain, An homologous sequence in the human genome has been identified and mapped to chromosome 1q22, Human EAT-2 transcripts were identified by reverse transcriptase-polymerase chain reaction (RT-PCR) in Ewing's sarcoma cell tumour cell lines. EAT-2's unique structure and correlation with transformation make it a candidate for playing a role in the transformation of NIH3T3 cells and the oncogenesis of Ewing's sarcoma.	UNIV CALIF LOS ANGELES,SCH MED,INST MOL BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT EXPT PATHOL & LAB MED,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,INTERCAMPUS MED GENET TRAINING PROGRAM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,AHMANSON DEPT PEDIAT,DIV GENET,CEDARS SINAI MED CTR,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,DIV HEMATOL ONCOL,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCI NIH HHS [CA32737, CA09056] Funding Source: Medline; NIGMS NIH HHS [GM08042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA032737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1984, J BIOL CHEM, V259, P7835; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUNN T, 1994, CANCER GENET CYTOGEN, V76, P19, DOI 10.1016/0165-4608(94)90063-9; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; Gotoh N, 1995, ONCOGENE, V11, P2525; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; Heim S, 1995, CANC CYTOGENETICS; HELDIN CH, 1991, TRENDS BIOCHEM SCI, V16, P450, DOI 10.1016/0968-0004(91)90175-U; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; JEON IS, 1995, ONCOGENE, V10, P1229; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KORNBERG JR, 1995, CYTOGENET CELL GENET, V69, P196; LESSNICK SL, 1995, ONCOGENE, V10, P429; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; Parmar K, 1996, J VIROL, V70, P1009, DOI 10.1128/JVI.70.2.1009-1015.1996; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SHAH NP, 1991, MOL CELL BIOL, V11, P1854, DOI 10.1128/MCB.11.4.1854; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, NAT GENET, V6, P146; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TAYLOR JA, 1995, MOL CELL BIOL, V15, P4149; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	50	99	103	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2649	2658						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000139				2022-12-17	WOS:A1996VZ65400015
J	Packham, G; Porter, CW; Cleveland, JL				Packham, G; Porter, CW; Cleveland, JL			C-Myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways	ONCOGENE			English	Article						c-Myc; ODC; apoptosis; cell cycle	ORNITHINE DECARBOXYLASE; SIGNALING PATHWAYS; EXPRESSION; PROTEIN; GENE; TRANSCRIPTION; ARREST; GROWTH; DEATH; BCL-2	Enforced c-Myc expression promotes inappropriate cell cycle progression of growth factor deprived cells and triggers concomitant apoptosis. However, it is not clear what role dysregulation of the cell cycle plays in c-Myc induced apoptosis. Ornithine decarboxylase (ODC) is a transcriptional target of c-Myc and contributes to c-Myc induced apoptosis. Here we have established that high levels of ODC overexpression in interleukin-3 (IL-3)dependent 32D.3 myeloid cells induces apoptosis at rates comparable to those induced by enforced c-Myc expression. However, ODC-induced apoptosis was not accompanied by dysregulation of cell cycle controls, indicating that cell death was not triggered by inappropriate cell cycle progression. Nonetheless, ODC was required downstream of c-Myc for myeloid cell growth. These results suggested that c-Myc-induced pathways leading to cell cycle progression and apoptosis are separable, yet that they share common mediators. In agreement with this concept, treatment of cells overexpressing c-Myc with the inhibitory agent dibutyryl cyclic AMP (Bt(2)cAMP) arrested these cells G(1), without inducing apoptosis. However, c-Myc retained the ability to induce apoptosis of Bt(2)cAMP-arrested cells following removal of IL-3, demonstrating that Bt(2)cAMP selectively inhibits c-Myc-induced pathways promoting cell cycle progression but not apoptosis. These results suggest a 'multiple effecters' model in which c-Myc regulates the expression of mediators which alone are sufficient to induce apoptosis in the absence of survival factors, yet are required in concert to promote cell cycle progression.	ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; ROSWELL PK CANC INST, GRACE CANC DRUG CTR, BUFFALO, NY 14263 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	Imperial College London; Ludwig Institute for Cancer Research; St Jude Children's Research Hospital; Roswell Park Cancer Institute; University of Tennessee System; University of Tennessee Health Science Center					NCI NIH HHS [P0 CA 21765, CA 22153] Funding Source: Medline; NIDDK NIH HHS [DK 44158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA022153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; ASKEW DS, 1991, ONCOGENE, V6, P1915; ASKEW DS, 1993, BLOOD, V82, P2079; BARRETT JF, 1995, J BIOL CHEM, V270, P15923, DOI 10.1074/jbc.270.27.15923; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOWLIN TL, 1986, CELL IMMUNOL, V98, P341, DOI 10.1016/0008-8749(86)90294-7; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; CLEVELAND JL, 1994, PEZC S AP, P85; Cleveland John L., 1994, Cancer Bulletin (Houston), V46, P167; DEAN M, 1987, ONCOGENE RES, V1, P279; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Green D R, 1994, Important Adv Oncol, P37; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HARRINGTON H, 1994, SCIENCE, V265, P2091; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KRAMER D, 1995, J BIOL CHEM, V270, P2124, DOI 10.1074/jbc.270.5.2124; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; MAMONT PS, 1978, BIOCHEM BIOPH RES CO, V81, P58, DOI 10.1016/0006-291X(78)91630-3; MCKINNEY JD, 1991, TRENDS BIOCHEM SCI, V16, P430, DOI 10.1016/0968-0004(91)90170-Z; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PENA A, 1993, J BIOL CHEM, V268, P27277; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; Roth P, 1992, Curr Top Microbiol Immunol, V181, P141; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251	43	99	103	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	1996	13	3					461	469						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760287				2022-12-17	WOS:A1996VB32800003
J	Bao, JX; Zervos, AS				Bao, JX; Zervos, AS			Isolation and characterization of Nmi, a novel partner of Myc proteins	ONCOGENE			English	Article						Myc oncoproteins; transcription; two-hybrid screen	C-MYC; INCREASED EXPRESSION; DNA-BINDING; MAX; GENE; TRANSFORMATION; RECOGNITION; SEQUENCE; CLONING; TARGET	The Myc family of oncogenes is thought to play an important role In cell proliferation, differentiation, and neoplastic transformation. Although the structure and expression of Myc genes are well characterized, the function and biochemical properties of the Myc proteins are less well understood, Here, using a yeast genetic screen, we identified a novel gene, Nmi, that binds to N-myc and C-myc, It also interacts with other transcription factors in yeast. The carboxyl terminus of Nmi shows homology to an interferon-induced leucine zipper protein, IFP 35, whereas its amino terminus is homologous to a coiled-coil heptad repeat in the C. elegans protein, CEF59, Go-precipitation studies of Nmi with N-myc and C-myc confirmed the interaction in mammalian cells, Nmi mRNA is expressed at low levels in all fetal and adult human tissues tested, except brain, Among several cancer cell lines, high expression of Nmi was found in myeloid leukemias, which also express high levels of C-myc. Nmi gene is localized on human chromosome 22q13.3. Translocations of this region have been reported In some human leukemias.	HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,CHARLESTOWN,MA 02129	Harvard University; Massachusetts General Hospital								ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BANGE FC, 1994, J BIOL CHEM, V269, P1091; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1992, FASEB J, V6, P30565; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LARSSON LG, 1987, P NATL ACAD SCI USA, V84, P223, DOI 10.1073/pnas.84.1.223; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NESSLINGER NJ, 1994, AM J HUM GENET, V54, P464; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; PRENDERGAST GC, 1991, CELL, V67, P641; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Sambrook J, 1989, MOL CLONING LAB MANU; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SCHREIBERAGUS N, 1995, CELL, V80, P77; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; VINSON CR, 1992, NEW BIOL, V4, P396; WANG T, 1994, SCIENCE, V256, P674; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	45	99	103	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2171	2176						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668343				2022-12-17	WOS:A1996UP28300016
J	Ellis, C; Kasmi, F; Ganju, P; Walls, E; Panayotou, G; Reith, AD				Ellis, C; Kasmi, F; Ganju, P; Walls, E; Panayotou, G; Reith, AD			A juxtamembrane autophosphorylation site in the Eph family receptor tyrosine kinase, Sek, mediates high affinity interaction with p59fyn	ONCOGENE			English	Article						Sek; Eph-like receptors; p59fyn; SH2-binding motif; autophosphorylation sites	GROWTH-FACTOR RECEPTOR; GLUTATHIONE-S-TRANSFERASE; SH2 DOMAINS; SRC FAMILY; PHOSPHORYLATION SITES; ESCHERICHIA-COLI; PDGF RECEPTOR; BETA-RECEPTOR; PROTEINS; BINDING	The large subfamily of receptor tyrosine kinases (RTKs) for which Eph is the prototype have likely roles in intercellular communication during normal mammalian development, but the biochemical signalling pathways utilised by this family are poorly characterised, We have now identified two in vitro autophosphorylation sites within the juxtamembrane domain of the Eph family member Sek, and a candidate binding protein for the activated Sek kinase, Specific antibodies defined Sek as a 130 kDa glycoprotein with protein kinase activity expressed in keratinocytes, whilst a bacterially expressed gst-Sek kinase domain fusion protein autophosphorylated exclusively on tyrosine residues, confirming that Sek encodes an authentic protein tyrosine kinase, Two dimensional phosphopeptide mapping and site-directed mutagenesis defined juxtamembrane residue Y602 as a major site of in vitro autophosphorylation in Sek, whilst Y596 was phosphorylated to a lower stoichiometry. Complementary approaches of in vitro binding assays and BIAcore analysis revealed a high affinity association between the Y602 Sek autophosphorylation site and the cytoplasmic tyrosine kinase p59fyn, an interaction mediated through the SH2 domain of this intracellular signalling molecule, Moreover, these data identify the novel phosphotyrosyl motif pYEDP as mediating high affinity association with fyn-SH2, extending the previously defined consensus motif for this interaction, The extensive conservation of this fyn-binding motif within the juxtamembrane domain of Eph family RTKs suggests that signalling through fyn, or fyn-related, tyrosine kinases may be utilised by many members of this large subclass of transmembrane receptors.	INST CANC RES, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; UNIV LONDON UNIV COLL, DEPT BIOCHEM & MOLEC BIOL, LONDON WC1E 6BT, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Ludwig Institute for Cancer Research; University of London; University College London								ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ANDRES AC, 1994, ONCOGENE, V9, P1461; BARE DJ, 1993, ONCOGENE, V8, P1429; CHAN J, 1991, ONCOGENE, V6, P1057; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GANJU P, 1994, ONCOGENE, V9, P1613; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; INGRAHAM CA, 1992, ONCOGENE, V7, P95; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KIYOKAWA E, 1994, CANCER RES, V54, P3645; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LUO K, 1990, ONCOGENE, V5, P921; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARU Y, 1990, ONCOGENE, V5, P445; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NIETO MA, 1992, DEVELOPMENT, V116, P1137; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REITH AD, 1991, GENOME ANAL, V3, P105; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; YAGI T, 1993, ONCOGENE, V8, P3343; YAGI T, 1994, ONCOGENE, V9, P2433; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	56	99	107	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1727	1736						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622893				2022-12-17	WOS:A1996UG45800015
J	Rao, VN; Shao, NS; Ahmad, M; Reddy, ESP				Rao, VN; Shao, NS; Ahmad, M; Reddy, ESP			Antisense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts	ONCOGENE			English	Article						BRCA1 proteins; antisense RNA; tumor suppressor; breast and ovarian cancers	FAMILIAL BREAST; OVARIAN-CANCER; CHROMOSOME; REGION	Recently, BRCA1, a familial breast and ovarian cancer susceptible gene has been cloned and shown to be either lost or mutated in families with breast and ovarian cancers, BRCA1 has been postulated to encode a tumor suppressor, a protein that acts as a negative regulator of tumor growth, We have characterized the BRCA1 gene products by Western blot and immunoprecipitation analysis in mouse and tumor cells. Multiple BRCA1 polypeptides of approximately 225, 185, 160, 145, 100, 52 and 38 kD were identified in these cells, BRCA1 proteins were found to be localized mainly in the nucleus of normal Rat1 cells and human breast cancer cells, Tn order to understand the role of BRCA1 in cell transformation, we have established a stable NIH3T3 cell line expressing BRCA1 antisense RNA. The inhibition of expression of endogenous BRCA1 protein was detected in NIH3T3 transfectants by Western blot analysis, The antisense BRCA1 expressing NIH3T3 cells showed accelerated growth rate, anchorage independent growth and tumorigenicity in nude mice unlike the parental and sense transfectants, These results provide the first direct biological evidence for the possible function of BRCA1 as a tumor suppressor gene.			Rao, VN (corresponding author), THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT MICROBIOL & IMMUNOL, 233 S 10TH ST, PHILADELPHIA, PA 19107 USA.				NATIONAL CANCER INSTITUTE [P01CA050507, R01CA057322, R01CA057157] Funding Source: NIH RePORTER; NCI NIH HHS [CA 57322, CA 57157, CA 50507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CLAUS EB, 1991, AM J HUM GENET, V48, P232; EASTON DF, 1993, AM J HUM GENET, V52, P678; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; ISZAT JG, 1984, CELL, V36, P1007; KELSELL DP, 1993, HUM MOL GENET, V2, P1823; LOVELAND BE, 1992, BIOCHEM INT, V27, P501; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; SMITH HS, 1993, J CELL BIOCHEM, P144; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; TAKAHASHI H, 1995, CANCER RES, V55, P2998; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444	15	99	101	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					523	528						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637708				2022-12-17	WOS:A1996TV59700008
J	LENNY, N; MEYERS, S; HIEBERT, SW				LENNY, N; MEYERS, S; HIEBERT, SW			FUNCTIONAL DOMAINS OF THE T(8-21) FUSION PROTEIN, AML-1/ETO	ONCOGENE			English	Article						AML-1; TRANSCRIPTION; REPRESSION; TRANSLOCATION	ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; E2F TRANSCRIPTION FACTOR; DNA-BINDING; AML1 GENE; SECONDARY-STRUCTURE; TRANSLOCATION; RUNT; IDENTIFICATION; EXPRESSION	The AML-1/ETO fusion protein is created by the (8;21) translocation, the second most frequent chromosomal abnormality associated with acute myeloid leukemia. In the fusion protein the AML-1 rant homology domain, which is responsible for DNA binding and CBF beta interaction, is linked to ETO, a gene of unknown function. The primary sequences of the rant homology domain indicates no known DNA binding motifs, but is predicted to contain six beta-strands, two alpha-helices and a nucleotide binding motif, Mutagenesis of AML-1/ETO was performed to delimit the functional domains of the chimeric protein. Most mutations in the runt homology domain that resulted in reduced CBF beta binding also inhibited DNA binding, indicating that the DNA and CBF beta binding sequences are tightly linked. However, these activities were separated by a point mutation of residue 144, within the putative ATP binding motif, which nearly eliminated DNA binding, but did not affect CBF beta binding, Random mutagenesis identified the hydrophobic face of the amphipathic fifth beta-strand, adjacent to the putative ATP binding motif, as critical for both DNA and CBF beta binding. C-terminal deletion mutants of AML-1/ETO indicated that ETO sequences are essential for interference with AML-1B-mediated transcriptional activation, and that residue 540 defines the C-terminal boundary of a potential repression domain. Thus, these mutational analyses define the regions of AML-1/ETO which regulate its function and that may be important in promoting leukemia.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital			Hiebert, Scott W/C-9979-2010		NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA 21765] Funding Source: Medline; PHS HHS [R01-64140] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DOWNING JR, 1993, BLOOD, V81, P2860; ERICKSON P, 1992, BLOOD, V80, P1825; FRANK R, 1995, IN PRESS ONCOGENE; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTSCHALK LR, 1990, MOL CELL BIOL, V10, P5486, DOI 10.1128/MCB.10.10.5486; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Leung DW, 1989, TECHNIQUE, V1, P11; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MADDEN SL, 1993, ONCOGENE, V8, P1713; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; WANG S, 1993, EMBO J, V13, P3324; WOLIN M, 1993, ONCOGENE, V8, P1905; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	39	99	104	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1761	1769						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478604				2022-12-17	WOS:A1995TD09400011
J	HAN, EKH; SGAMBATO, A; JIANG, W; ZHANG, YJ; SANTELLA, RM; DOKI, Y; CACACE, AM; SCHIEREN, I; WEINSTEIN, IB				HAN, EKH; SGAMBATO, A; JIANG, W; ZHANG, YJ; SANTELLA, RM; DOKI, Y; CACACE, AM; SCHIEREN, I; WEINSTEIN, IB			STABLE OVEREXPRESSION OF CYCLIN D1 IN A HUMAN MAMMARY EPITHELIAL-CELL LINE PROLONGS THE S-PHASE AND INHIBITS GROWTH	ONCOGENE			English	Article						CYCLINS; CELL CYCLE; BREAST CANCER	PROTEIN-KINASE-C; HEPATOCELLULAR-CARCINOMA; RETINOBLASTOMA PROTEIN; RAT FIBROBLASTS; DEPENDENT KINASES; CHROMOSOME 11Q13; MAMMALIAN-CELLS; SQUAMOUS-CELL; BREAST-CANCER; EXPRESSION	Amplification and/or increased expression of cyclin D1 occurs in an appreciable fraction of primary human breast carcinomas and several other types of human cancer. In addition, overexpression of cyclin D1 in rodent fibroblasts enhances growth and malignant transformation. The present study demonstrates that the extent of amplification and expression of cyclin D1 varies widely amongst a series of cell lines established from normal human mammary epithelium or human breast carcinomas, The HBL-100;mammary epithelial cell line did not display amplification or increased expression of cyclin D1. We used retrovirus-mediated transduction to obtain derivatives of this cell line that stably expressed relatively high levels of an exogenous cyclin D1 cDNA. These derivatives displayed an increased doubling time, decreased saturation density, decreased cloning efficiency, decreased anchorage-independent growth, an increased fraction of cells in the S-phase, and decreased tumorigenicity. Thus, increased expression of cyclin D1 in this cell line markedly inhibits rather than enhances growth, which may be due to the prolongation of S-phase.	COLUMBIA UNIV,COLL PHYS & SURG,COLUMBIA PRESBYTERIAN CANC CTR,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,CANC RES INST,NEW YORK,NY 10032	Columbia University; Columbia University			; Sgambato, Alessandro/K-7266-2016	Jiang, Wei/0000-0002-2309-9571; Sgambato, Alessandro/0000-0002-9487-4563				BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BERENSON JR, 1990, ONCOGENE, V5, P1343; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CACACE AM, 1993, ONCOGENE, V8, P2095; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1994, CANCER RES, V54, P1169; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1993, CANCER SURV, V18, P77; FAVOLORO J, 1980, METHOD ENZYMOL, V65, P718; GAFFNEY EV, 1982, CELL TISSUE RES, V227, P563, DOI 10.1007/BF00204786; GILLETT C, 1994, CANCER RES, V54, P1812; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HAN EKH, 1993, J CELL BIOL, V122, P461, DOI 10.1083/jcb.122.2.461; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1993, CURR OPIN GENET DEV, V3, P1, DOI 10.1016/S0959-437X(05)80333-8; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; KAMB A, 1994, SCIENCE, V264, P440; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOVEC H, 1994, ONCOGENE, V9, P323; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, GENE DEV, V8, P9; PROCTOR AJ, 1991, ONCOGENE, V6, P789; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SAINTRUF C, 1988, EXP CELL RES, V176, P60, DOI 10.1016/0014-4827(88)90120-6; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; SCHUURING E, 1992, ONCOGENE, V7, P355; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SOUTTOU B, 1994, CELL GROWTH DIFFER, V5, P615; TAM SW, 1994, ONCOGENE, V9, P2663; TSAI LH, 1993, ONCOGENE, V8, P1593; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG J, 1992, ONCOGENE, V7, P1653; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WIMMEL A, 1994, ONCOGENE, V9, P995; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	76	99	103	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					953	961						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898937				2022-12-17	WOS:A1995QL03800017
J	GUJULUVA, CN; BAEK, JH; SHIN, KH; CHERRICK, HM; PARK, NH				GUJULUVA, CN; BAEK, JH; SHIN, KH; CHERRICK, HM; PARK, NH			EFFECT OF UV-IRRADIATION ON CELL-CYCLE, VIABILITY AND THE EXPRESSION OF P53, GADD153 AND GADD45 GENES IN NORMAL AND HPV-IMMORTALIZED HUMAN ORAL KERATINOCYTES	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENES; DNA-DAMAGING AGENTS; WILD-TYPE P53; HUMAN PAPILLOMAVIRUS; GROWTH ARREST; PROTEIN; CARCINOGENESIS; TRANSFORMATION; PARTICIPATION; INITIATION	We previously demonstrated neoplastic conversion of HPV-immortalized human oral keratinocytes by exposing cells to chemical carcinogens, but failed to transform normal human oral keratinocytes with same chemical carcinogens in vitro. Though the reason for different responses of normal and HPV-immortalized oral keratinocytes to chemical carcinogens remains speculative, the difference may be due to the capacity of normal cells and incapacity of HPV-immortalized cells for repairing damaged DNA induced by carcinogens, Since (1) the repair of damaged DNA takes place in G(1)/G(2) phases of cell cycle, (2) wild type p53 plays major role in the induction of transient G(1) and/or G(2) arrests, and (3) the expression of gadd45 and gadd153 is also associated with the cell cycle arrest and DNA damage, we investigated transient cell cycle arrest and the expression of p53, gadd45 and gadd153 in normal human oral keratinocytes, HPV-immortalized oral keratinocytes, and an oral cancer cell line expressing mutant p53 after exposing cells to UV light. Normal cells demonstrated transient G(1) arrest after exposure to UV light, but other tested cells did not. While UV-irradiation significantly increased the level of intranuclear wild type p53 protein in normal cells, it did not alter p53 protein levels in HPV-immortalized and oral cancer cells. The level of gadd45 transcripts was enhanced in all tested cells, but normal cells demonstrated higher increase in the level of gadd45 after UV-exposure compared to other tested cells. The level of gadd153 gene transcripts was only increased in normal oral keratinocytes after UV-irradiation. These data indicate that UV-induced transient G(1) arrest in normal oral keratinocytes may be associated with both enhanced levels of intranuclear wild type p53 protein and gadd45 and gadd153 transcripts.	UNIV CALIF LOS ANGELES,SCH DENT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010049] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE 10049] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDIERY WS, 1993, CELL, V75, P817; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1993, FASEB J, V7, P1188, DOI 10.1096/fasebj.7.12.8375618; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KIM MS, 1993, ANTICANCER RES, V13, P1405; KIM MS, 1993, CANCER RES, V53, P4811; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI SL, 1992, CARCINOGENESIS, V13, P1981, DOI 10.1093/carcin/13.11.1981; LI SL, 1992, ORAL ONCOL, V28B, P129, DOI 10.1016/0964-1955(92)90041-X; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MIN BM, 1994, IN PRESS ORAL ONCOL; MULLAART E, 1990, MUTAT RES, V237, P189, DOI 10.1016/0921-8734(90)90001-8; NAGANO T, 1993, ARCH DERMATOL, V129, P1157, DOI 10.1001/archderm.129.9.1157; NAQUI A, 1986, ANNU REV BIOCHEM, V55, P137, DOI 10.1146/annurev.biochem.55.1.137; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SAKAI E, 1992, ONCOGENE, V7, P927; SCHAFFNER M, 1990, CELL, V63, P1129; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHIN KH, 1994, MOL CARCINOGEN, V9, P76, DOI 10.1002/mc.2940090205; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	40	99	103	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1819	1827						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208528				2022-12-17	WOS:A1994NR68500003
J	BERGELSON, S; PINKUS, R; DANIEL, V				BERGELSON, S; PINKUS, R; DANIEL, V			INDUCTION OF AP-1 (FOS/JUN) BY CHEMICAL-AGENTS MEDIATES ACTIVATION OF GLUTATHIONE-S-TRANSFERASE AND QUINONE REDUCTASE GENE-EXPRESSION	ONCOGENE			English	Article							YA-SUBUNIT GENE; ELECTROPHILE-RESPONSIVE ELEMENT; INDUCIBLE EXPRESSION; REGULATORY ELEMENTS; C-JUN; PROTO-ONCOGENE; PROTEINS; STRESS; CELLS; FOS	A regulatory element, EpRE, was found to be responsible for the induction of mouse glutathione S-transferase (GST) Ya gene expression by a variety of chemical agents such as planar aromatic hydrocarbons, diphenols, phorbol ester, phenobarbital and electrophilic compounds. The EpRE is composed of two adjacent AP-1-like binding sites and was recently found to be activated by Fos/Jun heterodimeric complex (AP-1). In this report we show that regulatory elements ARE, previously demonstrated to mediate the chemical induction of rat GST Ya and quinone reductase genes, have a similar structure with EpRE and are activated by Fos/Jun complex. The activation of GST Ya and quinone reductase genes by a variety of chemical inducers is found to be associated with an increase in AP-1 binding activity. We present evidence that chemical agents induce expression of c-fos and c-jun proto-oncogenes and an enhanced synthesis of protein components of AP-1 complex. We suggest that the increased synthesis of AP-1 complex followed by an AP-l-mediated transcriptional activation of GST Ya and quinone reductase genes may provide a molecular mechanism for the induction of these drug-metabolizing enzymes by chemical agents.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794; DANIEL V, 1989, DNA-J MOLEC CELL BIO, V8, P399, DOI 10.1089/dna.1.1989.8.399; DANIEL V, 1993, STRUCTURE FUNCTION G, P129; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; KIM YJ, 1983, J CELL BIOL, V96, P393, DOI 10.1083/jcb.96.2.393; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LI GC, 1983, J CELL PHYSIOL, V115, P116, DOI 10.1002/jcp.1041150203; LI Y, 1992, J BIOL CHEM, V267, P15097; MACKENZIE PI, 1990, J BIOL CHEM, V265, P11328; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; PINKUS R, 1993, BIOCHEM J, V290, P637, DOI 10.1042/bj2900637; PROCHASKA HJ, 1988, CANCER RES, V48, P4776; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHELTON KR, 1986, J BIOL CHEM, V261, P1935; Talalay P, 1987, CANCER BIOL THERAPEU, P187	29	99	99	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					565	571						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290267				2022-12-17	WOS:A1994MW24800024
J	HAJNAL, A; KLEMENZ, R; SCHAFER, R				HAJNAL, A; KLEMENZ, R; SCHAFER, R			SUBTRACTION CLONING OF H-REV107, A GENE SPECIFICALLY EXPRESSED IN H-RAS RESISTANT FIBROBLASTS	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENES; GTPASE-ACTIVATING PROTEIN; WILD-TYPE P53; TRANSFORMED PHENOTYPE; FLAT REVERTANTS; CARCINOMA-CELLS; ADENOVIRUS E1A; T-ANTIGEN; V-MOS; ONCOGENE EXPRESSION	We have isolated by subtractive hybridization a novel gene, called H-rev107, which is specifically expressed in a phenotypic revertant of H-ras transformed 208F rat fibroblasts. Apart from oncogene revertants, strong expression of H-rev107 was found in REF52 and EK-3 cells, two fibroblast lines resistant to transformation by activated H-vas oncogenes. In contrast, transformation-sensitive fibroblasts like 208F or NIH3T3 cells expressed only very little H-rev107 RNA. In H-r as or v-src transformed fibroblasts, H-rev107 RNA was undetectable. Introduction of the adenovirus E1A nuclear oncogene into ras-resistant REF52 cells abolished their transformation resistance and repressed the H-rev107 gene. H-rev107 encodes a protein with a molecular weight of 18 kDa without any structural similarity to known proteins. p18(H-rev107) exists in two forms which can be distinguished by their electrophoretic mobility; one is localized predominantly in cell membranes, the other in the cytoplasm. In confluent contact-inhibited 208F cells, p18(H-rev107) accumulated in cell membranes, while growth arrest induced by serum starvation did not induce H-rev107. In REF52, cell density had no influence on the expression or localization of p18(H-rev107). Repression of the H-rev107 gene may be closely associated with the loss of density-dependent growth inhibition and with the expression of the neoplastic phenotype.	UNIV ZURICH,DEPT PATHOL,DIV CANC RES,CH-8091 ZURICH,SWITZERLAND	University of Zurich				Schafer, Reinhold/0000-0001-7952-2124				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BASSIN RH, 1987, ADV VIRAL ONCOL, V6, P103; BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHINNADURAI G, 1983, CELL, V33, P759, DOI 10.1016/0092-8674(83)90018-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CIZDZIEL PE, 1991, MOL CARCINOGEN, V4, P14, DOI 10.1002/mc.2940040105; CRAIG RW, 1985, P NATL ACAD SCI USA, V82, P2062, DOI 10.1073/pnas.82.7.2062; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DEPPERT W, 1991, ONCOGENE, V6, P1931; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FUJITA H, 1990, EXP CELL RES, V186, P115, DOI 10.1016/0014-4827(90)90217-X; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAJNAL A, 1993, CANCER RES, V53, P1; HIGGINS PJ, 1991, BIOCHEM J, V279, P883, DOI 10.1042/bj2790883; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, ONCOGENE, V6, P1211; Iten E, 1989, Recent Results Cancer Res, V113, P78; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; JELINEK MA, 1992, ONCOGENE, V7, P1687; KANEKO M, 1989, BRIT J CANCER, V60, P880, DOI 10.1038/bjc.1989.384; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KATZ E, 1989, EUR J CELL BIOL, V49, P221; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KIKKAWA U, 1986, ANN REV CELL BIOL, V2, P146; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KOLCH W, 1993, ONCOGENE, V8, P361; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; KUZUMAKI N, 1989, MOL CELL BIOL, V9, P2258, DOI 10.1128/MCB.9.5.2258; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LOMBARDI L, 1990, CELL MOTIL CYTOSKEL, V15, P220, DOI 10.1002/cm.970150405; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MERCER WE, 1990, ONCOGENE, V5, P973; MIRANTI C, 1990, SOMAT CELL MOLEC GEN, V16, P67, DOI 10.1007/BF01650481; MORRIS JF, 1991, ONCOGENE, V6, P2339; NEVINS JR, 1992, SCIENCE, V258, P424; NIELSCH U, 1991, ONCOGENE, V6, P1031; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; OKAYAMA H, 1982, MOL CELL BIOL, V2, P280; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; QUADE K, 1979, VIROLOGY, V98, P461, DOI 10.1016/0042-6822(79)90569-5; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SAKAI R, 1989, P NATL ACAD SCI USA, V86, P9946, DOI 10.1073/pnas.86.24.9946; SAMID D, 1984, BIOCHEM BIOPH RES CO, V119, P21, DOI 10.1016/0006-291X(84)91612-7; SANTOS E, 1984, FED PROC, V43, P2280; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SELIGER B, 1988, J VIROL, V62, P619, DOI 10.1128/JVI.62.2.619-621.1988; SELIGER B, 1987, J VIROL, V61, P2567, DOI 10.1128/JVI.61.8.2567-2572.1987; SERGIESCU D, 1986, P NATL ACAD SCI USA, V83, P5764, DOI 10.1073/pnas.83.16.5764; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; STODDART JH, 1989, EXP CELL RES, V184, P16; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; VANDAM H, 1989, ONCOGENE, V4, P1207; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YAMADA H, 1991, J BIOL CHEM, V266, P4002; YANAGIHARA K, 1990, ONCOGENE, V5, P1179; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	85	99	112	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					479	490						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290259				2022-12-17	WOS:A1994MW24800015
J	IIDA, S; SETO, M; YAMAMOTO, K; KOMATSU, H; TOJO, A; ASANO, S; KAMADA, N; ARIYOSHI, Y; TAKAHASHI, T; UEDA, R				IIDA, S; SETO, M; YAMAMOTO, K; KOMATSU, H; TOJO, A; ASANO, S; KAMADA, N; ARIYOSHI, Y; TAKAHASHI, T; UEDA, R			MLLT3 GENE ON 9P22 INVOLVED IN T(9-11) LEUKEMIA ENCODES A SERINE PROLINE-RICH PROTEIN HOMOLOGOUS TO MLLT1 ON 19P13	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; RNA POLYMERASE-II; 11Q23 TRANSLOCATIONS; CHROMOSOMAL TRANSLOCATIONS; DROSOPHILA-TRITHORAX; LARGEST SUBUNIT; BREAKPOINT; CLONING; T(4-11); T(11-19)(Q23-P13)	Recently, the MLL gene at 11q23 was found to be involved in a subset of leukemias with an 11q23 abnormality. In the present study, we isolated chimeric cDNAs between the MLL and a gene designated MLLT3 at 9p22 from a cDNA library of an IMS-M1 cell line with a t(9;11)(p22;q23) translocation, a representative karyotypic abnormality seen in acute monocytic leukemia. We also isolated a normal MLLT3 cDNA and found an open reading frame encoding at least 318 amino acids with high serine/proline content (24.8%). The chimeric mRNAs were demonstrated to be fused to MLL in frame, as found in t(11;19) and t(4;11) leukemias. The predicted MLLT3 protein demonstrated a significant homology to that of the MLLT1 gene at 19p13 involved in t(11;19) leukemia. The highest homology, up to 74.1%, was found in 86 amino acids of the C-terminus, suggesting that this region is of particular importance for leukemogenesis in t(9;11) leukemia. Northern blot analysis with the MLLT3 cDNA probe against normal tissues revealed multiple transcripts in lymphoid organs. A survey of hematopoietic cell lines demonstrated relatively stronger signals in cells belonging to megakaryocytic and erythroid lineages. As previously found in t(11;19) leukemia, heterogeneous MLL-MLLT3 chimeric mRNAs could be detected by the reverse transcriptase-polymerase chain reaction (RT-PCR) in t(9;11) leukemia samples.	AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR HOSP,DEPT HEMATOL & CHEMOTHERAPY,CHIKUSA KU,NAGOYA 464,JAPAN; AICHI CANC CTR,RES INST,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; UNIV TOKYO,INST MED SCI,DEPT MED,MINATO KU,TOKYO 108,JAPAN; HIROSHIMA UNIV,NUCL MED & BIOL RES INST,DEPT MED,MINAMI KU,HIROSHIMA 734,JAPAN	Aichi Cancer Center; Aichi Cancer Center; University of Tokyo; Hiroshima University								ABE R, 1984, CANCER GENET CYTOGEN, V13, P121, DOI 10.1016/0165-4608(84)90053-0; AHEARN JM, 1987, J BIOL CHEM, V262, P10695; AKAO Y, 1992, CANCER RES, V52, P6083; BERGER R, 1980, LEUKEMIA RES, V4, P119, DOI 10.1016/0145-2126(80)90051-X; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRODEUR GM, 1983, CANCER GENET CYTOGEN, V8, P93, DOI 10.1016/0165-4608(83)90041-9; CIMINO G, 1992, CANCER RES, V52, P3811; CIMINO G, 1991, CANCER RES, V51, P6712; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DYER MJS, 1990, BLOOD, V75, P709; GIBBONS B, 1990, BRIT J HAEMATOL, V74, P264, DOI 10.1111/j.1365-2141.1990.tb02581.x; GOMEZMARQUEZ J, 1988, FEBS LETT, V226, P217, DOI 10.1016/0014-5793(88)81425-X; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HAGEMEIJER A, 1982, CANCER GENET CYTOGEN, V5, P95, DOI 10.1016/0165-4608(82)90001-2; IIDA S, 1992, LEUKEMIA RES, V16, P1155, DOI 10.1016/0145-2126(92)90113-L; IIDA S, 1993, JPN J CANCER RES, V84, P532, DOI 10.1111/j.1349-7006.1993.tb00172.x; KANEKO Y, 1986, BLOOD, V67, P484; KANEKO Y, 1982, BLOOD, V60, P389; KATZ F, 1988, BLOOD, V71, P1438; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MCCABE NR, 1992, P NATL ACAD SCI USA, V89, P11794, DOI 10.1073/pnas.89.24.11794; MORGAN GJ, 1992, BLOOD, V80, P2172; MORRISSEY J, 1993, BLOOD, V81, P1124; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PUI CH, 1991, BLOOD, V77, P440; PUI CH, 1987, BLOOD, V69, P1289; RAIMONDI SC, 1989, BLOOD, V73, P1627; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; SETO M, 1992, ONCOGENE, V7, P1401; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; YAMAMOTO K, 1993, ONCOGENE, V8, P479; YAMAMOTO K, 1993, IN PRESS ONCOGENE; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	36	99	99	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3085	3092						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414510				2022-12-17	WOS:A1993MC09300025
J	REISS, K; PORCU, P; SELL, C; PIETRZKOWSKI, Z; BASERGA, R				REISS, K; PORCU, P; SELL, C; PIETRZKOWSKI, Z; BASERGA, R			THE INSULIN-LIKE GROWTH FACTOR-I RECEPTOR IS REQUIRED FOR THE PROLIFERATION OF HEMATOPOIETIC-CELLS	ONCOGENE			English	Article							MYELOID LEUKEMIC-CELLS; HUMAN-BREAST-CANCER; FACTOR-I RECEPTORS; HUMAN-LYMPHOCYTES; NUCLEAR ANTIGEN; C-MYC; EXPRESSION; DIFFERENTIATION; BINDING; CYCLE	We have investigated the role of the insulin-like growth factor one (IGF1) receptor and its relationship to the proto-oncogene c-myb in the growth of two types of hemopoietic cells: mitogen-stimulated human peripheral blood mononuclear cells and a human promyelocytic cell line (HL-60). Using the antisense strategy and the reverse transcriptase polymerase chain reaction (RT-PCR), we show that expression of the IGF1 receptor is required for the entry into S phase of both stimulated lymphocytes and HL-60 cells. The inhibition of DNA synthesis by antisense oligomers to the IGF1 receptor RNA is accompanied by an inhibition of the expression of the mRNA for a DNA synthesis gene, proliferating cell nuclear antigen (PCNA), the co-factor of DNA polymerase delta. Inhibition of c-myb expression results in a decrease in IGF1 receptor mRNA levels; on the other hand, inhibition of IGF1 receptor expression has no effect on c-myb mRNA levels. A tentative temporal relationship between these three genes (c-myb, IGF1 receptor, PCNA) is proposed.	THOMAS JEFFERSON UNIV,JEFFERSON CANC CTR,BLUEMLE LIFE SCI BLGD,233 S 10TH ST,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL CANCER INSTITUTE [R01CA053484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042383] Funding Source: NIH RePORTER; NCI NIH HHS [CA53484] Funding Source: Medline; NIGMS NIH HHS [GM 42383] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BASERGA R, IN PRESS CELL BIOL B; BASERGA R, 1992, IN PRESS ANN NY ACAD; BRAVO R, 1987, NATURE, V326, P545; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CLEMMONS DR, 1981, TISSUE GROWTH FACTOR, P161; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; CRAIG RW, 1984, CANCER RES, V44, P442; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLDRING MB, 1991, EUKARYOTIC GENE EXPR, V1, P301; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GROSSO LE, 1985, CANCER RES, V45, P847; HARTMANN W, 1988, LEUKEMIA, V2, P241; HIZUKA N, 1987, ENDOCRINOL JAPON, V34, P81; JANICOT M, 1991, J BIOL CHEM, V266, P9382; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; KACZMAREK L, 1985, P NATL ACAD SCI USA, V82, P5375, DOI 10.1073/pnas.82.16.5375; KACZMAREK L, 1987, J CELL BIOL, V104, P183, DOI 10.1083/jcb.104.2.183; KELLERER M, 1990, J BIOL CHEM, V265, P9340; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOZAK RW, 1987, CELL IMMUNOL, V109, P318, DOI 10.1016/0008-8749(87)90315-7; LEE PDK, 1986, J CLIN ENDOCR METAB, V62, P28, DOI 10.1210/jcem-62-1-28; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P9774, DOI 10.1073/pnas.86.24.9774; LIU YC, 1989, BIOCHEMISTRY-US, V28, P2967, DOI 10.1021/bi00433a034; MIGLIACCIO G, 1990, EXP HEMATOL, V18, P1049; PEKONEN F, 1988, CANCER RES, V48, P1353; PEPE MG, 1987, J CELL PHYSIOL, V133, P219, DOI 10.1002/jcp.1041330204; PEYRAT JP, 1988, CANCER RES, V48, P6429; PHILLIPS PD, 1987, J CELL PHYSIOL, V133, P135, DOI 10.1002/jcp.1041330117; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; REED JC, 1986, P NATL ACAD SCI USA, V84, P3892; REISS K, 1991, CANCER RES, V51, P5997; SELL C, 1992, IN PRESS J CELL PHYS; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; SURMACZ E, 1992, EXP CELL RES, V199, P275, DOI 10.1016/0014-4827(92)90435-B; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VENTURELLI D, 1990, CANCER RES, V50, P7371; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	46	99	101	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2243	2248						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1359494				2022-12-17	WOS:A1992JW66500016
J	VANDENBARK, GR; DECASTRO, CM; TAYLOR, H; DEWKNIGHT, S; KAUFMAN, RE				VANDENBARK, GR; DECASTRO, CM; TAYLOR, H; DEWKNIGHT, S; KAUFMAN, RE			CLONING AND STRUCTURAL-ANALYSIS OF THE HUMAN C-KIT GENE	ONCOGENE			English	Article								The recent identification of the mouse White spotting and Steel loci as genes encoding the c-kit receptor and its ligand, respectively, has shed light on the importance of this ligand and receptor in embryogenesis, melanogenesis and hematopoiesis. In order to determine if the c-kit proto-oncogene is involved in human disease, we isolated seven overlapping lambda recombinants, using a fetal brain cDNA, and characterized the normal human gene (KIT). The longest mapped transcript is 5230 bp, is alternatively spliced and includes 21 exons that span more than 70 kb of DNA. From the exon-intron structure, we have localized an alternative splice site to the 3' end of exon 9. The overall c-kit gene structure closely resembles that found in the CSF-1R gene (c-fms). This similarity includes a large first intron, the same number of exons containing translated sequence and very similar exon-intron boundaries. Using pulsed-field gel electrophoresis, we have linked KIT to the platelet-derived growth factor receptor A gene, with both residing on a 700-kb BssHI fragment. These data will allow investigation into the control of KIT expression and the potential to identify mutations or altered expression of this gene in human disease.	DUKE UNIV, MED CTR, DEPT NEUROSCI, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University; Duke University	VANDENBARK, GR (corresponding author), DUKE UNIV, MED CTR, DEPT MED, DIV HEMATOL ONCOL, BOX 3167, DURHAM, NC 27710 USA.			Kaufman, Russell/0000-0003-4612-4861	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038699] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38699] Funding Source: Medline; PHS HHS [H102643] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDRE C, 1989, ONCOGENE, V4, P1047; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU G, 1986, SCIENCE, V232, P65; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P10885, DOI 10.1073/pnas.88.23.10885; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HAMPE A, 1989, ONCOGENE RES, V4, P9; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; MAJUMDER S, 1988, MOL CELL BIOL, V8, P4896, DOI 10.1128/MCB.8.11.4896; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; METCALF D, 1991, P NATL ACAD SCI USA, V88, P6239, DOI 10.1073/pnas.88.14.6239; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OGURA M, 1985, BLOOD, V66, P1384; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SARVELLA PATRICIA A., 1956, JOUR HEREDITY, V47, P123; SEKIDO Y, 1991, CANCER RES, V51, P2416; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHERR CJ, 1990, BLOOD, V75, P1; SHIBUYA M, 1990, ONCOGENE, V5, P519; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STROHMEYER T, 1991, CANCER RES, V51, P1811; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; ULICH TR, 1991, BLOOD, V78, P645; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG C, 1989, LEUKEMIA, V3, P699; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; [No title captured]; [No title captured]	55	99	111	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1992	7	7					1259	1266						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1377810				2022-12-17	WOS:A1992HZ97100002
J	ARII, M; TAKADA, S; KOIKE, K				ARII, M; TAKADA, S; KOIKE, K			IDENTIFICATION OF 3 ESSENTIAL REGIONS OF HEPATITIS-B VIRUS X-PROTEIN FOR TRANSACTIVATION FUNCTION	ONCOGENE			English	Article							LONG TERMINAL REPEAT; HEPATOCELLULAR-CARCINOMA; NUCLEOTIDE-SEQUENCE; GENE-PRODUCT; TRANSCRIPTIONAL ACTIVATION; ESCHERICHIA-COLI; CELL-LINES; DNA; POLYMERASE; EXPRESSION	The X protein of hepatitis B virus (HBV) consists of 154 amino acids and trans-activates various cellular and viral promoters and enhancers. To investigate the essential amino acid sequences of X protein for trans-activation function, various mutations were introduced into the X open reading frame and analysed for trans-activation activity by chloramphenicol acetyltransferase assay. The amino acid sequences 46-52 (especially Pro-46, His-49 and His-52), 61-69 (especially Cys-61, Gly-67 to Pro-68 and Cys-69) and 132-139 (especially Phe-132, Cys-137 and His-139) of HBV X protein were found to be essential for the trans-activation function. These three sequences are included in the conserved amino acid sequences among hepadna virus X proteins. The first one could form a domain-like structure characteristic of histidine/aspartic acid requirement. The second and the third are homologous to the Kunitz domain of Kunitz-type serine protease inhibitors. The amino acids 5-27 region was found to make no positive contribution to the transactivation function like the last 12 amino acids in the carboxy-terminal region [Takada, S. & Koike, K. (1990). Proc. Natl. Acad. Sci. USA, 87, 5628-5632]. From these findings, the trans-activation function of X protein appears to be dependent on at least two types of domain-like structures.	JAPANESE FDN CANC RES,INST CANC,DEPT GENE RES,TOSHIMA KU,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research								AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BEASLEY RP, 1981, LANCET, V2, P1129; CHANG LJ, 1990, J VIROL, V64, P5553, DOI 10.1128/JVI.64.11.5553-5558.1990; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FAKTOR O, 1990, ONCOGENE, V5, P867; GALIBERT F, 1982, J VIROL, V41, P51, DOI 10.1128/JVI.41.1.51-65.1982; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1986, ENZYMES, V17, P191; KAY A, 1985, EMBO J, V4, P1287, DOI 10.1002/j.1460-2075.1985.tb03774.x; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOBAYASHI M, 1984, GENE, V30, P227; KOIKE K, 1989, MOL BIOL MED, V6, P151; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MEYERS ML, 1986, J VIROL, V57, P101, DOI 10.1128/JVI.57.1.101-109.1986; MORIARTY AM, 1985, SCIENCE, V227, P429, DOI 10.1126/science.2981434; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; RADZIWILL G, 1990, J VIROL, V64, P613, DOI 10.1128/JVI.64.2.613-620.1990; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SEEGER C, 1984, J VIROL, V51, P367, DOI 10.1128/JVI.51.2.367-375.1984; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TAKADA S, 1990, J VIROL, V64, P822, DOI 10.1128/JVI.64.2.822-828.1990; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TAKADA S, 1990, JPN J CANCER RES, V81, P1191, DOI 10.1111/j.1349-7006.1990.tb02675.x; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678; YAGINUMA K, 1989, J VIROL, V63, P2914, DOI 10.1128/JVI.63.7.2914-2920.1989; ZHOU DX, 1990, J VIROL, V64, P4025, DOI 10.1128/JVI.64.8.4025-4028.1990	46	99	103	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					397	403						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549357				2022-12-17	WOS:A1992HK00500001
J	YAMADA, H; WAKE, N; FUJIMOTO, S; BARRETT, JC; OSHIMURA, M				YAMADA, H; WAKE, N; FUJIMOTO, S; BARRETT, JC; OSHIMURA, M			MULTIPLE CHROMOSOMES CARRYING TUMOR SUPPRESSOR ACTIVITY FOR A UTERINE ENDOMETRIAL CARCINOMA CELL-LINE IDENTIFIED BY MICROCELL-MEDIATED CHROMOSOME TRANSFER	ONCOGENE			English	Article									TOTTORI UNIV,FAC MED,MOLEC & CELL GENET LAB,YONAGO,TOTTORI 683,JAPAN; KYUSHU UNIV,MED INST BIOREGULAT,DEPT REPROD PHYSIOL & ENDOCRINOL,BEPPU,OITA 874,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT OBSTET & GYNECOL,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709	Tottori University; Kyushu University; Hokkaido University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)								ATKIN NB, 1977, HUM GENET, V38, P25, DOI 10.1007/BF00295804; ATKIN NB, 1979, CANCER, V44, P604, DOI 10.1002/1097-0142(197908)44:2<604::AID-CNCR2820440230>3.0.CO;2-G; ATKIN NB, 1986, CANCER GENET CYTOGEN, V21, P279, DOI 10.1016/0165-4608(86)90206-2; BECHER R, 1983, CANCER RES, V43, P5010; BENEDICT WF, 1984, CANCER RES, V44, P3471; BRITOBABAPULLE V, 1981, CANCER GENET CYTOGEN, V4, P215, DOI 10.1016/0165-4608(81)90015-7; CAVANEE WK, 1983, NATURE, V305, P779; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; COUTURIER J, 1986, INT J CANCER, V38, P17, DOI 10.1002/ijc.2910380104; EVANS EP, 1982, J CELL SCI, V56, P113; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FUJITA H, 1985, CANCER GENET CYTOGEN, V18, P283, DOI 10.1016/0165-4608(85)90149-9; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GIBAS Z, 1987, CANCER GENET CYTOGEN, V25, P21, DOI 10.1016/0165-4608(87)90155-5; GILBERT F, 1984, CANCER RES, V44, P5444; HARPER ME, 1981, P NATL ACAD SCI-BIOL, V78, P4458, DOI 10.1073/pnas.78.7.4458; HARRIS H, 1988, CANCER RES, V48, P3302; HORGAS G, 1988, CANCER GENET CYTOGEN, V35, P269, DOI 10.1016/0165-4608(88)90250-6; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; ISHIWATA I, 1984, GYNECOL ONCOL, V17, P281, DOI 10.1016/0090-8258(84)90212-9; KAKATI S, 1976, CANCER, V38, P770, DOI 10.1002/1097-0142(197608)38:2<770::AID-CNCR2820380220>3.0.CO;2-0; KLEIN G, 1971, J CELL SCI, V8, P659; KLINGER HP, 1983, JNCI-J NATL CANCER I, V71, P559; KOI M, 1989, JPN J CANCER RES, V80, P122, DOI 10.1111/j.1349-7006.1989.tb02278.x; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; LESTER SC, 1980, SOMAT CELL GENET, V6, P241, DOI 10.1007/BF01538799; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; OSHIMURA M, 1984, CANCER RES, V44, P5017; OSHIMURA M, 1988, CANCER RES, V48, P1623; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; PEEHL DM, 1981, INT J CANCER, V27, P625, DOI 10.1002/ijc.2910270509; SAGER R, 1978, SOMAT CELL GENET, V4, P375, DOI 10.1007/BF01542849; SAGER R, 1986, CANCER RES, V46, P1573; SANDBERG AA, 1988, CANCER RES, V48, P1049; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; SHIMIZU M, 1990, ONCOGENE, V5, P185; STANBRIDGE EJ, 1981, SOMAT CELL GENET, V7, P699, DOI 10.1007/BF01538758; STANBRIDGE EJ, 1981, ISRAEL J MED SCI, V17, P563; STOLER A, 1985, P NATL ACAD SCI USA, V82, P570, DOI 10.1073/pnas.82.2.570; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; YAMADA H, 1989, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V41, P122; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOSHIDA MA, 1986, CANCER GENET CYTOGEN, V20, P159, DOI 10.1016/0165-4608(86)90119-6; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	52	99	104	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1141	1147						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	2392323				2022-12-17	WOS:A1990DX36100005
J	ASSELIN, C; NEPVEU, A; MARCU, KB				ASSELIN, C; NEPVEU, A; MARCU, KB			MOLECULAR REQUIREMENTS FOR TRANSCRIPTIONAL INITIATION OF THE MURINE C-MYC GENE	ONCOGENE			English	Article									SUNY STONY BROOK,DEPT BIOCHEM,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT MICROBIOL & PATHOL,STONY BROOK,NY 11794; LUDWIG INST,MONTREAL H3A 1A1,QUEBEC,CANADA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			/AAB-8315-2020		NCI NIH HHS [CA36246] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036246] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DEAN M, 1986, J BIOL CHEM, V261, P9161; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FERAMISCO JR, 1982, J BIOL CHEM, V257, P1024; FRIEDMAN DI, 1987, ANNU REV GENET, V21, P453; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GREENBERG ME, 1984, NATURE, V311, P438; HALL DJ, 1987, J BIOL CHEM, V262, P15302; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HENTSCHEL CC, 1982, NATURE, V295, P714, DOI 10.1038/295714a0; HERNANDEZ N, 1988, EMBO J, V7, P3125, DOI 10.1002/j.1460-2075.1988.tb03179.x; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHIHAMA A, 1988, TRENDS GENET, V4, P282, DOI 10.1016/0168-9525(88)90170-9; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; MACE HAF, 1983, NATURE, V304, P555, DOI 10.1038/304555a0; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MARCU KB, 1987, NUCLEAR ONCOGENES, P165; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCCAFFREY P, 1987, J BIOL CHEM, V262, P1442; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MEDRANO EE, 1980, P NATL ACAD SCI-BIOL, V77, P4123, DOI 10.1073/pnas.77.7.4123; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1987, ONCOGENE, V1, P243; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; OI VT, 1983, P NATL ACAD SCI-BIOL, V80, P825, DOI 10.1073/pnas.80.3.825; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; RAN W, 1986, P NATL ACAD SCI USA, V83, P8216, DOI 10.1073/pnas.83.21.8216; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SCHLOKAT U, 1986, EMBO J, V5, P3251, DOI 10.1002/j.1460-2075.1986.tb04636.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WATSON RJ, 1988, MOL CELL BIOL, V8, P938; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x; ZECH L, 1976, INT J CANCER, V17, P47, DOI 10.1002/ijc.2910170108	60	99	99	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					549	558						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2471130				2022-12-17	WOS:A1989U768800004
J	Zhang, JX; Chen, ZH; Chen, DL; Tian, XP; Wang, CY; Zhou, ZW; Gao, Y; Xu, Y; Chen, C; Zheng, ZS; Weng, HW; Ye, S; Kuang, M; Xie, D; Peng, S				Zhang, Jia-Xing; Chen, Zhen-Hua; Chen, Dong-Liang; Tian, Xiao-Peng; Wang, Chen-Yuan; Zhou, Zhi-Wei; Gao, Ying; Xu, Yi; Chen, Cui; Zheng, Zhou-San; Weng, Hui-Wen; Ye, Sheng; Kuang, Ming; Xie, Dan; Peng, Sui			LINC01410-miR-532-NCF2-NF-kappa B feedback loop promotes gastric cancer angiogenesis and metastasis	ONCOGENE			English	Article							COMPETING ENDOGENOUS RNA; NONCODING RNA; EXPRESSION; CERNA; IDENTIFICATION; PROLIFERATION; BIOMARKERS; NETWORKS; INVASION; GENE	Dysregulation of non-coding RNAs, including miRNAs and lncRNAs has been reported to play vital roles in gastric cancer (GC) carcinogenesis, but the mechanism involved is largely unknown. Using the cancer genome atlas (TCGA) data set and bioinformatics analyses, we identified miR-532-5p as a potential tumor suppressor in GC, and found that lncRNA LINC01410 might be a negative regulator of miR-532-5p. We then conducted a series of in vivo and in vitro assays to explore the effect of LINC01410 on miR-532-5p-mediated GC malignancy and the underlying mechanism involved. MiR-532-5p overexpression inhibited GC metastasis and angiogenesis in vitro and in vivo, whereas miR-532-5p silencing had the opposite effect. Further study showed that miR-532-5p attenuated NF-kappa B signaling by directly inhibiting NCF2 expression, while miR-532-5p silencing in GC enhanced NF-kappa B activity. Furthermore, we demonstrated miR-532-5p down-regulation was caused by aberrantly high expression of LINC01410 in GC. Mechanistically, overexpression of LINC01410 promoted GC angiogenesis and metastasis by binding to and suppressing miR-532-5p, which resulted in up-regulation of NCF2 and sustained NF-kappa B pathway activation. Interestingly, NCF2 could in turn increase the promoter activity and expression of LINC01410 via NF-kappa B, thus forming a positive feedback loop that drives the malignant behavior of GC. Finally, high expression of LINC01410, along with low expression of miR-532-5p, was associated with poor survival outcome in GC patients. Our studies uncover a mechanism for constitutive LINC1410-miR-532-5p-NCF2-NF-kappa B feedback loop activation in GC, and consequently, as a potential therapeutic target in GC treatment.	[Zhang, Jia-Xing; Gao, Ying; Xu, Yi; Chen, Cui; Zheng, Zhou-San; Weng, Hui-Wen; Ye, Sheng; Peng, Sui] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Guangdong, Peoples R China; [Zhang, Jia-Xing; Gao, Ying; Xu, Yi; Chen, Cui; Zheng, Zhou-San; Weng, Hui-Wen; Ye, Sheng; Peng, Sui] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol & Hepatol, Guangzhou, Guangdong, Peoples R China; [Zhang, Jia-Xing; Chen, Dong-Liang; Wang, Chen-Yuan; Xie, Dan] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Chen, Zhen-Hua] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou, Guangdong, Peoples R China; [Tian, Xiao-Peng] Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou, Guangdong, Peoples R China; [Zhou, Zhi-Wei] Sun Yat Sen Univ, Dept Gastr & Pancreat Surg, Canc Ctr, Guangzhou, Peoples R China; [Kuang, Ming] Sun Yat Sen Univ, Affiliated Hosp 1, Div Intervent Ultrasound, Dept Med Ultrasound, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Peng, S (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Guangdong, Peoples R China.; Peng, S (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol & Hepatol, Guangzhou, Guangdong, Peoples R China.; Xie, D (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China.	xiedan@sysucc.org.cn; pengsui@vip.163.com			National Key R&D Program of China [2017YFC1309001, 2016YFC1302305]; Natural Science Foundation of China [81772514, 81772513, 81401991, 81572359]; Pearl River S&T Nova Program of Guangzhou [201806010005]	National Key R&D Program of China; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Pearl River S&T Nova Program of Guangzhou	This work was supported by National Key R&D Program of China (2017YFC1309001, 2016YFC1302305), the Natural Science Foundation of China (Nos. 81772514, 81772513, 81401991, and 81572359), and Pearl River S&T Nova Program of Guangzhou (201806010005).	Adams BD, 2017, J CLIN INVEST, V127, P761, DOI 10.1172/JCI84424; Block K, 2012, NAT REV CANCER, V12, P627, DOI 10.1038/nrc3339; Chen DL, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0420-1; Guo LL, 2015, WORLD J GASTROENTERO, V21, P11680, DOI 10.3748/wjg.v21.i41.11680; Gupta SC, 2017, INT J CANCER, V140, P1955, DOI 10.1002/ijc.30546; Hao NB, 2017, ONCOTARGET, V8, P81572, DOI 10.18632/oncotarget.19197; Hunt RH, 2015, GUT, V64, P1650, DOI 10.1136/gutjnl-2014-307595; Italiano D, 2012, CELL CYCLE, V11, P4589, DOI 10.4161/cc.22853; Klingenberg M, 2017, J HEPATOL, V67, P603, DOI 10.1016/j.jhep.2017.04.009; Kong PF, 2017, MOL THER, V25, P1027, DOI 10.1016/j.ymthe.2017.01.013; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Li R, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050702; Lu MH, 2016, ONCOGENE, V35, P3524, DOI 10.1038/onc.2015.413; Muise AM, 2012, GUT, V61, P1028, DOI 10.1136/gutjnl-2011-300078; Nakanishi K, 2016, WIRES RNA, V7, P637, DOI 10.1002/wrna.1356; Osama A, 2016, CANCER BIOMARK, V17, P155, DOI 10.3233/CBM-160626; Roviello G, 2016, GASTRIC CANCER, V19, P31, DOI 10.1007/s10120-015-0537-5; Rudolph TK, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.290re7; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Seok H, 2018, CELL MOL LIFE SCI, V75, P797, DOI 10.1007/s00018-017-2656-0; Shinohara M, 2010, J BIOL CHEM, V285, P4481, DOI 10.1074/jbc.M109.071779; Song JH, 2012, GASTROENTEROLOGY, V143, P35, DOI 10.1053/j.gastro.2012.05.003; Sun M, 2016, CANCER RES, V76, P6299, DOI 10.1158/0008-5472.CAN-16-0356; Sun TT, 2016, CANCER DISCOV, V6, P784, DOI 10.1158/2159-8290.CD-15-0921; Tan WQ, 2011, J UROLOGY, V186, P2071, DOI 10.1016/j.juro.2011.06.049; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Teng H, 2016, MOL THER, V24, P1806, DOI 10.1038/mt.2016.103; Veneziano D, 2016, HUM MUTAT, V37, P1283, DOI 10.1002/humu.23066; Xu MD, 2017, CLIN CANCER RES, V23, P2071, DOI 10.1158/1078-0432.CCR-16-0742; Yang JS, 2011, MOL CELL, V43, P892, DOI 10.1016/j.molcel.2011.07.024; Yang S, 2016, ONCOTARGET, V7, P85728, DOI 10.18632/oncotarget.13828; Yuan SX, 2016, HEPATOLOGY, V63, P499, DOI 10.1002/hep.27893; Zhang JX, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0586-y; Zhang JX, 2017, CLIN CANCER RES, V23, P298, DOI 10.1158/1078-0432.CCR-16-0414	34	98	103	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	20					2660	2675		10.1038/s41388-018-0162-y	http://dx.doi.org/10.1038/s41388-018-0162-y			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG2TH	29483646	Green Published, hybrid			2022-12-17	WOS:000432545100004
J	Niu, J; Xue, A; Chi, Y; Xue, J; Wang, W; Zhao, Z; Fan, M; Yang, CH; Shao, ZM; Pfeffer, LM; Wu, J; Wu, ZH				Niu, J.; Xue, A.; Chi, Y.; Xue, J.; Wang, W.; Zhao, Z.; Fan, M.; Yang, C. H.; Shao, Z-M; Pfeffer, L. M.; Wu, J.; Wu, Z-H			Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer	ONCOGENE			English	Article							NF-KAPPA-B; SQUAMOUS-CELL CARCINOMA; DNA-DAMAGE RESPONSE; TARGETING MICRORNAS; UP-REGULATION; EXPRESSION; PATHWAY; PHOSPHORYLATION; CHEMORESISTANCE; ACTIVATION	Acquired therapeutic resistance is the major drawback to effective systemic therapies for cancers. Aggressive triple-negative breast cancers (TNBC) develop resistance to chemotherapies rapidly, whereas the underlying mechanisms are not completely understood. Here we show that genotoxic treatments significantly increased the expression of miR-181a in TNBC cells, which enhanced TNBC cell survival and metastasis upon Doxorubicin treatment. Consistently, high miR-181a level associated with poor disease free survival and overall survival after treatments in breast cancer patients. The upregulation of miR-181a was orchestrated by transcription factor STAT3 whose activation depended on NF-kappa B-mediated IL-6 induction in TNBC cells upon genotoxic treatment. Intriguingly, activated STAT3 not only directly bound to MIR181A1 promoter to drive transcription but also facilitated the recruitment of MSK1 to the same region where MSK1 promoted a local active chromatin state by phosphorylating histone H3. We further identified BAX as a direct functional target of miR-181a, whose suppression decreased apoptosis and increased invasion of TNBC cells upon Dox treatment. These results were further confirmed by evidence that suppression of miR-181a significantly enhanced therapeutic response and reduced lung metastasis in a TNBC orthotopic model. Collectively, our data suggested that miR-181a induction had a critical role in promoting therapeutic resistance and aggressive behavior of TNBC cells upon genotoxic treatment. Antagonizing miR-181a may serve as a promising strategy to sensitize TNBC cells to chemotherapy and mitigate metastasis.	[Niu, J.; Wang, W.; Fan, M.; Yang, C. H.; Pfeffer, L. M.; Wu, Z-H] Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA; [Niu, J.; Chi, Y.; Wang, W.; Fan, M.; Yang, C. H.; Pfeffer, L. M.; Wu, Z-H] Univ Tennessee, Ctr Hlth Sci, Canc Res Ctr, Memphis, TN 38163 USA; [Xue, A.; Zhao, Z.] Fudan Univ, Shanghai Med Coll, Dept Forens Med, Shanghai 200032, Peoples R China; [Chi, Y.; Xue, J.; Shao, Z-M; Wu, J.] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Chi, Y.; Xue, J.; Shao, Z-M; Wu, J.] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, 270 Dong An Rd, Shanghai 200032, Peoples R China	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Fudan University; Fudan University; Fudan University	Wu, J (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, 270 Dong An Rd, Shanghai 200032, Peoples R China.; Wu, ZH (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pathol, 19S Manassas St, Memphis, TN 38163 USA.	wujiong1122@vip.sina.com; zwu6@uthsc.edu		Pfeffer, Lawrence/0000-0003-2809-1234; fan, meiyun/0000-0002-0185-5065	National Cancer Institute [R01 CA149251]; American Cancer Society [RSG-13-186-01-CSM]; National Natural Science Foundation of China (NSFC) [81272924]; NATIONAL CANCER INSTITUTE [R01CA140346, R01CA149251] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Bert Vogelstein (Johns Hopkins University) for wild-type and DICER - / - HCT116 cells. The BAX expression construct was a generous gift from Dr Douglas Green (St Jude Children's Research Hospital). We also thank Dr R. Laribee (UTHSC) for stimulating discussion and critical reading of the manuscript. This work was supported in part by grants from National Cancer Institute (R01 CA149251 to ZW), American Cancer Society (RSG-13-186-01-CSM to ZW), and National Natural Science Foundation of China (NSFC) (81272924 to JW).	Baek SH, 2011, MOL CELL, V42, P274, DOI 10.1016/j.molcel.2011.03.022; Baldwin AS, 2012, IMMUNOL REV, V246, P327, DOI 10.1111/j.1600-065X.2012.01095.x; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Boldin MP, 2012, IMMUNOL REV, V246, P205, DOI 10.1111/j.1600-065X.2011.01089.x; Bonnay F, 2014, EMBO J, V33, P2349, DOI 10.15252/embj.201488456; Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154; Chaudhry MA, 2010, DNA CELL BIOL, V29, P553, DOI 10.1089/dna.2009.0978; Chen YR, 2014, EXP CELL RES, V320, P12, DOI 10.1016/j.yexcr.2013.10.014; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; Fan MY, 2013, J BIOL CHEM, V288, P27480, DOI 10.1074/jbc.M113.491803; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Galluzzi L, 2010, CANCER RES, V70, P1793, DOI 10.1158/0008-5472.CAN-09-3112; Garofalo M, 2013, DRUG RESIST UPDATE, V16, P47, DOI 10.1016/j.drup.2013.05.001; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Gehani SS, 2010, MOL CELL, V39, P886, DOI 10.1016/j.molcel.2010.08.020; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hedrich CM, 2014, P NATL ACAD SCI USA, V111, P13457, DOI 10.1073/pnas.1408023111; Hickey CJ, 2013, BLOOD, V121, P159, DOI 10.1182/blood-2012-05-428573; Ji DB, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-86; Jiao XY, 2013, BREAST CANCER RES TR, V139, P717, DOI 10.1007/s10549-013-2607-x; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Kato M, 2009, ONCOGENE, V28, P2419, DOI 10.1038/onc.2009.106; Lau PNI, 2011, P NATL ACAD SCI USA, V108, P2801, DOI 10.1073/pnas.1012798108; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Liu M, 2013, BIOCHEM BIOPH RES CO, V441, P364, DOI 10.1016/j.bbrc.2013.10.051; Llambi F, 2011, MOL CELL, V44, P517, DOI 10.1016/j.molcel.2011.10.001; McCool KW, 2012, IMMUNOL REV, V246, P311, DOI 10.1111/j.1600-065X.2012.01101.x; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Niu JX, 2013, EMBO J, V32, P3206, DOI 10.1038/emboj.2013.247; Niu JX, 2012, J BIOL CHEM, V287, P21783, DOI 10.1074/jbc.M112.355495; Ouyang M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096228; Ouyang YB, 2012, MITOCHONDRION, V12, P213, DOI 10.1016/j.mito.2011.09.001; Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508; Parikh A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3977; Riaz M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3415; Sansone P, 2012, J CLIN ONCOL, V30, P1005, DOI 10.1200/JCO.2010.31.8907; Sawicka A, 2014, GENOME RES, V24, P1808, DOI 10.1101/gr.176255.114; Tan GY, 2012, J BIOL CHEM, V287, P33036, DOI 10.1074/jbc.M112.383273; Tartey S, 2014, EMBO J, V33, P2332, DOI 10.15252/embj.201488447; Taylor MA, 2013, J CLIN INVEST, V123, P150, DOI 10.1172/JCI64946; Wakahara R, 2012, GENES CELLS, V17, P132, DOI 10.1111/j.1365-2443.2011.01575.x; Wang Y, 2011, ONCOGENE, V30, P1470, DOI 10.1038/onc.2010.531; Wu ZH, 2007, J MOL MED, V85, P1187, DOI 10.1007/s00109-007-0227-9; Yang CH, 2010, CANCER RES, V70, P8108, DOI 10.1158/0008-5472.CAN-10-2579; Yang JB, 2010, P NATL ACAD SCI USA, V107, P21499, DOI 10.1073/pnas.1016147107; Zhang XN, 2011, MOL CELL, V41, P371, DOI 10.1016/j.molcel.2011.01.020; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007	49	98	101	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1302	1313		10.1038/onc.2015.189	http://dx.doi.org/10.1038/onc.2015.189			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26028030	Green Accepted			2022-12-17	WOS:000371763100010
J	Keklikoglou, I; Hosaka, K; Bender, C; Bott, A; Koerner, C; Mitra, D; Will, R; Woerner, A; Muenstermann, E; Wilhelm, H; Cao, Y; Wiemann, S				Keklikoglou, I.; Hosaka, K.; Bender, C.; Bott, A.; Koerner, C.; Mitra, D.; Will, R.; Woerner, A.; Muenstermann, E.; Wilhelm, H.; Cao, Y.; Wiemann, S.			MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes	ONCOGENE			English	Article							NF-KAPPA-B; HUMAN-ENDOTHELIAL-CELLS; TUMOR LYMPHANGIOGENESIS; DUCTAL ADENOCARCINOMA; PROMOTES ANGIOGENESIS; TRANSCRIPTION FACTOR; CANCER; GROWTH; SUPPRESSOR; EXPRESSION	Recent advances in cancer biology have emerged important roles for microRNAs (miRNAs) in regulating tumor responses. However, their function in mediating intercellular communication within the tumor microenvironment is thus far poorly explored. Here, we found miR-206 to be abrogated in human pancreatic ductal adenocarcinoma (PDAC) specimens and cell lines. We show that miR-206 directly targets the oncogenes KRAS and annexin a2 (ANXA2), thereby acting as tumor suppressor in PDAC cells by blocking cell cycle progression, cell proliferation, migration and invasion. Importantly, we identified miR-206 as a negative regulator of oncogenic KRAS-induced nuclear factor-kappa B transcriptional activity, resulting in a concomitant reduction of the expression and secretion of pro-angiogenic and pro-inflammatory factors including the cytokine interleukin-8, the chemokines (C-X-C motif) ligand 1 and (C-C motif) ligand 2, and the granulocyte macrophage colony-stimulating factor. We further show that miR-206 abrogates the expression and secretion of the potent pro-lymphangiogenic factor vascular endothelial growth factor C in pancreatic cancer cells through an NF-kappa B-independent mechanism. By using in vitro and in vivo approaches, we reveal that re-expression of miR-206 in PDAC cells is sufficient to inhibit tumor blood and lymphatic vessel formation, thus leading to a significant delay of tumor growth and progression. Taken together, our study sheds light onto the role of miR-206 as a pleiotropic modulator of different hallmarks of cancer, and as such raising the intriguing possibility that miR-206 may be an attractive candidate for miRNA-based anticancer therapies.	[Keklikoglou, I.; Bender, C.; Bott, A.; Koerner, C.; Mitra, D.; Woerner, A.; Muenstermann, E.; Wilhelm, H.; Wiemann, S.] German Canc Res Ctr, Div Mol Genome Anal, D-69120 Heidelberg, Germany; [Keklikoglou, I.] Swiss Fed Inst Technol Lausanne EPFL, Swiss Inst Expt Canc Res ISREC, Sch Life Sci, Lausanne, Switzerland; [Hosaka, K.; Cao, Y.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Will, R.] German Canc Res Ctr, Genom & Prote Core Facil, Heidelberg, Germany; [Cao, Y.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England; [Cao, Y.] Glenfield Gen Hosp, NIHR Leicester Cardiovasc Biomed Res Unit, Leicester LE3 9QP, Leics, England; [Cao, Y.] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden	Helmholtz Association; German Cancer Research Center (DKFZ); Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; Karolinska Institutet; Helmholtz Association; German Cancer Research Center (DKFZ); University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; Linkoping University	Keklikoglou, I (corresponding author), German Canc Res Ctr, Div Mol Genome Anal, Neuenheimer Feld 580, D-69120 Heidelberg, Germany.	ioanna.keklikoglou@epfl.ch; s.wiemann@dkfz-heidelberg.de	Wiemann, Stefan/E-4424-2013	Wiemann, Stefan/0000-0003-4683-3174; Keklikoglou, Ioanna/0000-0003-1219-6912	German Federal Ministry of Education and Research (NGFN grant) [01GS0816]; Deutsche Forschungsgemeinschaft (DIP project) [WI3499/1-1]	German Federal Ministry of Education and Research (NGFN grant); Deutsche Forschungsgemeinschaft (DIP project)	We thank Prof George Mosialos and Dr Joerg Hoheisel for kindly providing us with the 3xKBL and pCMV-p65 vectors, and the BxPC-3, MiaPaca-2, Colo357, Capan-1 and CFPAC-1 cell lines, respectively. We thank Dr Christoph Roesli for providing us with the HPNE and HPDE cell lines and the DKFZ Genomics and Proteomics Core Facility for performing excellent services. This work was supported with funding from the German Federal Ministry of Education and Research (NGFN grant 01GS0816) and the Deutsche Forschungsgemeinschaft (DIP project WI3499/1-1).	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Brownstein C, 2004, BLOOD, V103, P317, DOI 10.1182/blood-2003-04-1304; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; Campbell PM, 2007, CANCER RES, V67, P2098, DOI 10.1158/0008-5472.CAN-06-3752; Cao RH, 2012, P NATL ACAD SCI USA, V109, P15894, DOI 10.1073/pnas.1208324109; Cao YH, 2005, NAT REV CANCER, V5, P735, DOI 10.1038/nrc1693; Donahue TR, 2012, CLIN CANCER RES, V18, P1352, DOI 10.1158/1078-0432.CCR-11-1539; du Rieu MC, 2010, CLIN CHEM, V56, P603, DOI 10.1373/clinchem.2009.137364; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fujioka S, 2003, CLIN CANCER RES, V9, P346; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hofmann I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044146; Hudson RS, 2012, NUCLEIC ACIDS RES, V40, P3689, DOI 10.1093/nar/gkr1222; Keane MP, 2004, J IMMUNOL, V172, P2853, DOI 10.4049/jimmunol.172.5.2853; Keklikoglou I, 2012, ONCOGENE, V31, P4150, DOI 10.1038/onc.2011.571; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Liou GY, 2013, J CELL BIOL, V202, P563, DOI 10.1083/jcb.201301001; Low-Marchelli JM, 2013, CANCER RES, V73, P662, DOI 10.1158/0008-5472.CAN-12-0653; Madureira PA, 2011, BLOOD, V118, P4789, DOI 10.1182/blood-2011-06-334672; Matsuo Y, 2009, INT J CANCER, V125, P1027, DOI 10.1002/ijc.24383; Miyake M, 2013, LAB INVEST, V93, P768, DOI 10.1038/labinvest.2013.71; Munding JB, 2012, INT J CANCER, V131, pE86, DOI 10.1002/ijc.26466; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Sarkar S, 2011, GASTROENTEROLOGY, V140, P583, DOI 10.1053/j.gastro.2010.08.054; Seckinger A, 2012, BLOOD, V120, P1087, DOI 10.1182/blood-2012-03-415588; Sharma M, 2012, EXP MOL PATHOL, V92, P175, DOI 10.1016/j.yexmp.2011.10.003; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Singh A, 2013, J CLIN INVEST, V123, P2921, DOI 10.1172/JCI66353; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stahlhut C, 2012, DEVELOPMENT, V139, P4356, DOI 10.1242/dev.083774; Stamatovic SM, 2006, J IMMUNOL, V177, P2651, DOI 10.4049/jimmunol.177.4.2651; Stupack Dwayne G, 2002, Sci STKE, V2002, ppe7, DOI 10.1126/stke.2002.119.pe7; Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045; Taulli R, 2009, J CLIN INVEST, V119, P2366, DOI 10.1172/JCI38075; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Tuveson DA, 2005, COLD SH Q B, V70, P65, DOI 10.1101/sqb.2005.70.040; Wang CY, 2012, J BIOL CHEM, V287, P32512, DOI 10.1074/jbc.M112.351957; Wang DZ, 2006, J EXP MED, V203, P941, DOI 10.1084/jem.20052124; Wang WX, 1999, CLIN CANCER RES, V5, P119; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Ying HQ, 2011, CANCER DISCOV, V1, P158, DOI 10.1158/2159-8290.CD-11-0031; Zhang G, 2012, J CONTROL SCI ENG, V2012, P7, DOI DOI 10.1371/J0URNAL.P0NE.0044568; Zheng L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019390	47	98	99	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2015	34	37					4867	4878		10.1038/onc.2014.408	http://dx.doi.org/10.1038/onc.2014.408			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR0YP	25500542	Green Published, hybrid			2022-12-17	WOS:000361050000007
J	Li, JJ; Xie, D				Li, J-J; Xie, D.			RACK1, a versatile hub in cancer	ONCOGENE			English	Review							PROTEIN-KINASE-C; RECEPTOR-INTERACTING PROTEIN; HEPATOCELLULAR-CARCINOMA; TYROSINE-PHOSPHATASE; SCAFFOLD PROTEIN; BINDING-PROTEIN; DOWN-REGULATION; CELL-MIGRATION; BETA-SUBUNIT; INTERFERON RECEPTOR	RACK1 is a highly conserved intracellular adaptor protein with significant homology to G beta and was originally identified as the anchoring protein for activated protein kinase C. In the past 20 years, the number of binding partners and validated cellular functions for RACK1 has increased, which facilitates clarification of its involvement in different biological events. In this review, we will focus on its role in cancer, summarizing its aberrant expression, pro- or anti-oncogenic effects and the underlying mechanisms in various cancers.	[Li, J-J; Xie, D.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Ctr Canc Res, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Xie, D (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Hong Kong New World Joint Lab, Shanghai 200031, Peoples R China.	dxie@sibs.ac.cn		Xie, Dong/0000-0002-1150-8657	National Basic Research Program of China [2010CB912102]; Ministry of Science and Technology Key Program [2012ZX10002009-017]; National Natural Science Foundation of China [81230058, 30930023, 31100551, 31201046, 81021002]; CAS/SAFEA International Partnership Program for Creative Research Teams, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences [SIBS2012004]; Technology Commission of Shanghai Municipality [12XD1405600]; Young Scientist Fund of National Science Foundation of China [31201046]; Sanofi-Aventis-Sibs Scholarship Program	National Basic Research Program of China(National Basic Research Program of China); Ministry of Science and Technology Key Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAS/SAFEA International Partnership Program for Creative Research Teams, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences; Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Young Scientist Fund of National Science Foundation of China; Sanofi-Aventis-Sibs Scholarship Program	This work was supported by the National Basic Research Program of China (2010CB912102), Ministry of Science and Technology Key Program (2012ZX10002009-017), the National Natural Science Foundation of China (81230058, 30930023, 31100551, 31201046, 81021002), CAS/SAFEA International Partnership Program for Creative Research Teams, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (SIBS2012004) and Technology Commission of Shanghai Municipality (12XD1405600) to DX. This work was also supported by the Young Scientist Fund of National Science Foundation of China (31201046) and Sanofi-Aventis-Sibs Scholarship Program (2011) to J-JL.	Al-Reefy S, 2010, BREAST CANCER RES TR, V123, P911, DOI 10.1007/s10549-010-1020-y; Baum S, 2004, BIOCHEM J, V380, P823, DOI 10.1042/BJ20031962; Belozerov VE, 2014, MOL CELL BIOL, V34, P474, DOI 10.1128/MCB.00824-13; Berns H, 2000, FASEB J, V14, P2549, DOI 10.1096/fj.99-1038com; Besson A, 2002, J BIOL CHEM, V277, P22073, DOI 10.1074/jbc.M111644200; Bird RJ, 2010, BIOCHEM J, V432, P207, DOI 10.1042/BJ20101010; Boner W, 2002, VIRUS RES, V90, P113, DOI 10.1016/S0168-1702(02)00145-4; Buensuceso CS, 2005, J BIOL CHEM, V280, P644, DOI 10.1074/jbc.M410229200; Buensuceso CS, 2001, J CELL SCI, V114, P1691; Cao XR, 2010, DISCRETE EVENT DYN S, V20, P1, DOI 10.1007/s10626-010-0088-1; Cao XX, 2011, BREAST CANCER RES TR, V126, P555, DOI 10.1007/s10549-010-0955-3; Ceci M, 2003, NATURE, V426, P579, DOI 10.1038/nature02160; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Choi DS, 2003, MOL PHARMACOL, V64, P1541, DOI 10.1124/mol.64.6.1541; Cox EA, 2003, MOL BIOL CELL, V14, P658, DOI 10.1091/mbc.E02-03-0142; Daniels CC, 2008, VIROLOGY, V375, P550, DOI 10.1016/j.virol.2008.01.034; Dave JM, 2013, J BIOL CHEM, V288, P30720, DOI 10.1074/jbc.M113.512467; Deng YZ, 2012, GASTROENTEROLOGY, V142, P812, DOI 10.1053/j.gastro.2011.12.046; Feng C, 2012, J BIOL CHEM, V287, P10714, DOI 10.1074/jbc.M111.299594; Gallina A, 2001, VIROLOGY, V283, P7, DOI 10.1006/viro.2001.0855; Gomez-Bougie P, 2005, EUR J IMMUNOL, V35, P971, DOI 10.1002/eji.200425878; GUILLEMOT F, 1989, P NATL ACAD SCI USA, V86, P4594, DOI 10.1073/pnas.86.12.4594; Guo YY, 2013, HEPATOLOGY, V57, P140, DOI 10.1002/hep.25978; Harada H, 2004, P NATL ACAD SCI USA, V101, P15313, DOI 10.1073/pnas.0406837101; He X, 2011, ONCOGENE, V30, P535, DOI 10.1038/onc.2010.427; Hellberg CB, 2002, J BIOL CHEM, V277, P11165, DOI 10.1074/jbc.M112157200; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Hu FQ, 2013, TUMOR BIOL, V34, P3893, DOI 10.1007/s13277-013-0977-7; Ikebuchi Y, 2010, DRUG METAB DISPOS, V38, P2320, DOI 10.1124/dmd.110.034603; Ikebuchi Y, 2009, HEPATOL RES, V39, P1091, DOI 10.1111/j.1872-034X.2009.00544.x; Isacson CK, 2007, AM J PHYSIOL-CELL PH, V292, pC1459, DOI 10.1152/ajpcell.00322.2006; Kiely PA, 2005, J BIOL CHEM, V280, P7624, DOI 10.1074/jbc.M412889200; Kiely PA, 2002, J BIOL CHEM, V277, P22581, DOI 10.1074/jbc.M201758200; Kiely PA, 2008, J BIOL CHEM, V283, P22952, DOI 10.1074/jbc.M800802200; Kraft C, 2005, MOL CELL, V18, P543, DOI 10.1016/j.molcel.2005.04.023; Kraus S, 2006, CANCER RES, V66, P11047, DOI 10.1158/0008-5472.CAN-06-0596; Kubota T, 2002, J VIROL, V76, P12676, DOI 10.1128/JVI.76.24.12676-12682.2002; Lacombe J, 2013, INT J CANCER, V132, P1105, DOI 10.1002/ijc.27766; Lee HS, 2002, OSTEOARTHR CARTILAGE, V10, P890, DOI 10.1053/joca.2002.0842; Li G, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1675; Li J, 2012, J CANCER RES CLIN, V138, P563, DOI 10.1007/s00432-011-1097-7; Li YC, 2009, MOL CELL BIOL, V29, P3953, DOI 10.1128/MCB.00449-09; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Lopez-Bergami P, 2005, MOL CELL, V19, P309, DOI 10.1016/j.molcel.2005.06.025; Lu F, 2012, ONCOL REP, V27, P1646, DOI 10.3892/or.2012.1629; Mamidipudi V, 2007, ONCOGENE, V26, P2914, DOI 10.1038/sj.onc.1210091; Mamidipudi V, 2009, ONCOGENE, V28, P4421, DOI 10.1038/onc.2009.293; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; McLeod M, 2000, MOL CELL BIOL, V20, P4016, DOI 10.1128/MCB.20.11.4016-4027.2000; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Nagashio R, 2010, LUNG CANCER, V69, P54, DOI 10.1016/j.lungcan.2009.09.015; Peng RJ, 2013, ONCOL REP, V30, P2195, DOI 10.3892/or.2013.2723; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Rosdahl JA, 2002, MOL CELL NEUROSCI, V19, P292, DOI 10.1006/mcne.2001.1071; Ruan YY, 2012, J CLIN INVEST, V122, P2554, DOI 10.1172/JCI58488; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Seidl P, 2002, INT J CANCER, V102, P129, DOI 10.1002/ijc.10675; Sengupta J, 2004, NAT STRUCT MOL BIOL, V11, P957, DOI 10.1038/nsmb822; Serrels B, 2010, CURR BIOL, V20, P1086, DOI 10.1016/j.cub.2010.04.042; Severino A, 2004, J CELL PHYSIOL, V199, P134, DOI 10.1002/jcp.10448; Shi S, 2012, J BIOL CHEM, V287, P7845, DOI 10.1074/jbc.M111.315416; Shor B, 2003, J BIOL CHEM, V278, P49119, DOI 10.1074/jbc.M303968200; Subauste MC, 2009, CANCER BIOL THER, V8, P2297; Sutton P, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-76; Trerotola M, 2012, J CELL PHYSIOL, V227, P3670, DOI 10.1002/jcp.24074; Usacheva A, 2001, J BIOL CHEM, V276, P22948, DOI 10.1074/jbc.M100087200; Vomastek T, 2007, MOL CELL BIOL, V27, P8296, DOI 10.1128/MCB.00598-07; Wang Z, 2009, EUR J CANCER, V45, P490, DOI 10.1016/j.ejca.2008.11.012; Wehner P, 2011, DEVELOPMENT, V138, P1321, DOI 10.1242/dev.056291; Wu J, 2013, BIOMED PHARMACOTHER, V67, P313, DOI 10.1016/j.biopha.2013.01.011; Wu YY, 2010, CELL SIGNAL, V22, P1495, DOI 10.1016/j.cellsig.2010.05.018; Zhang DL, 2013, MOL CELL BIOCHEM, V384, P197, DOI 10.1007/s11010-013-1798-0; Zhang WZ, 2008, J BIOL CHEM, V283, P16416, DOI 10.1074/jbc.M802360200; Zhang WZ, 2006, MOL CELL BIOL, V26, P413, DOI 10.1128/MCB.26.2.413-424.2006; Zhong XW, 2013, ANN SURG ONCOL, V20, P1044, DOI 10.1245/s10434-012-2377-4	77	98	103	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1890	1898		10.1038/onc.2014.127	http://dx.doi.org/10.1038/onc.2014.127			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24882575				2022-12-17	WOS:000352725600003
J	Wang, Z; Wang, B; Shi, Y; Xu, C; Xiao, HL; Ma, LN; Xu, SL; Yang, L; Wang, QL; Dang, WQ; Cui, W; Yu, SC; Ping, YF; Cui, YH; Kung, HF; Qian, C; Zhang, X; Bian, XW				Wang, Z.; Wang, B.; Shi, Y.; Xu, C.; Xiao, H. L.; Ma, L. N.; Xu, S. L.; Yang, L.; Wang, Q. L.; Dang, W. Q.; Cui, W.; Yu, S. C.; Ping, Y. F.; Cui, Y. H.; Kung, H. F.; Qian, C.; Zhang, X.; Bian, X. W.			Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2	ONCOGENE			English	Article							FORMYLPEPTIDE RECEPTOR; MICRORNA POLYCISTRON; MIR-17-92 CLUSTER; TUMOR PROGRESSION; CANCER; PROLIFERATION; EXPRESSION; INVASION; BRAIN; DIFFERENTIATION	Emerging evidence has shown that cancer stem cells (CSCs) are the cellular determinants to promote cancer invasion and metastasis. However, the mechanism underlying CSC invasion remains unknown. MicroRNAs are evolutionally conserved small noncoding RNAs that are critical for the regulation of gene expression, and their expressions are often dysregulated in cancers. In the present study, we demonstrated that two functionally related microRNAs, miR-20a and -106a (miR-20a/106a), were capable of enhancing the invasiveness of CD133(+) glioma stem cells (GSCs) isolated from both glioblastoma cell line U87 and primary human glioma specimens. We found that the level of miR-20a/106a in GSCs was significantly higher than that in the committed CD133(-) glioma cells, and correlated with the invasive capability of GSCs. By bioinformatic analysis, we identified tissue inhibitor of metalloproteinases-2 (TIMP-2) as one of the miR-20a/106a-targeted genes. TIMP-2 level correlated inversely with miR-20/106 expression. Directly targeting by miR-20a/106a on 3'-untranslation region (3'-UTR) of TIMP-2 mRNA was confirmed by 3'-UTR dual-luciferase reporter assay. Knockdown of miR-20a/106a in GSCs increased endogenous TIMP-2 protein abundance, thereby inhibiting GSC invasion. We also found that Nordy, a synthetic lipoxygenase inhibitor, inhibited GSC invasiveness by elevating the expression of TIMP-2 via downregulation of miR-20a/106a. Our results indicate that miR-20a/106a has a key role in GSC invasion and may serve as targets for treatment of glioblastoma.	[Zhang, X.] Third Mil Med Univ, Southwest Hosp, Inst Pathol, Key Lab Tumor Immunopathol,Minist Educ China, Chongqing 400038, Peoples R China; Third Mil Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China	Army Medical University; Ministry of Education, China; Army Medical University	Zhang, X (corresponding author), Third Mil Med Univ, Southwest Hosp, Inst Pathol, Key Lab Tumor Immunopathol,Minist Educ China, 30 Gaotanyan, Chongqing 400038, Peoples R China.	zhangxia45@gmail.com; zhangxia45@gmail.com; bianxiuwu@263.net	Bian, Xiu-Wu/D-4736-2017; Zhang, Xia/B-8152-2008	Bian, Xiu-Wu/0000-0003-4383-0197; Zhang, Xia/0000-0002-9040-1486; XU, CHUAN/0000-0002-5320-2277	National Natural Science Foundation of China (NSFC) [81101606, 81101631, 30725035, 30930103]; National Basic Research Program of China (973 Program) [2010CB529403]; Natural Science Foundation Project of CQ CSTC [CSTC2012JJA10124]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China (973 Program)(National Basic Research Program of China); Natural Science Foundation Project of CQ CSTC(Natural Science Foundation Project of CQ CSTC)	We are grateful to our colleagues for helpful comments. This work was supported by the grants from National Natural Science Foundation of China (NSFC, Nos. 81101606, 81101631, 30725035 and 30930103), National Basic Research Program of China (973 Program, No. 2010CB529403) and Natural Science Foundation Project of CQ CSTC (CSTC2012JJA10124).	ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; Ara T, 1998, J PEDIATR SURG, V33, P1272, DOI 10.1016/S0022-3468(98)90167-1; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bian XW, 2008, PROTEOMICS, V8, P484, DOI 10.1002/pmic.200700054; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Caraglia M, 2012, CURR CANCER DRUG TAR, V12, P185, DOI 10.2174/156800912799277458; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen JH, 2006, BIOCHEM BIOPH RES CO, V342, P1368, DOI 10.1016/j.bbrc.2006.02.113; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; Croce CM, 2011, NAT MED, V17, P935, DOI 10.1038/nm0811-935; Davis F G, 2001, Expert Rev Anticancer Ther, V1, P395, DOI 10.1586/14737140.1.3.395; DECLERCK YA, 1991, CANCER RES, V51, P2151; Drappatz J, 2009, EXPERT REV NEUROTHER, V9, P519, DOI [10.1586/ern.09.10, 10.1586/ERN.09.10]; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Foshay KM, 2009, DEV BIOL, V326, P431, DOI 10.1016/j.ydbio.2008.11.016; Furstenberger G, 2006, INT J CANCER, V119, P2247, DOI 10.1002/ijc.22153; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Gunther HS, 2008, ONCOGENE, V27, P2897, DOI 10.1038/sj.onc.1210949; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hossain A, 2006, MOL CELL BIOL, V26, P8191, DOI 10.1128/MCB.00242-06; Hyde CAC, 2009, INT IMMUNOPHARMACOL, V9, P701, DOI 10.1016/j.intimp.2009.02.003; Imren S, 1996, CANCER RES, V56, P2891; Le Mercier M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045475; Legler JM, 1999, JNCI-J NATL CANCER I, V91, P1382, DOI 10.1093/jnci/91.16.1382; Li F, 2007, CELL RES, V17, P3, DOI 10.1038/sj.cr.7310118; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu JQ, 2011, CLIN CANCER RES, V17, P3638, DOI 10.1158/1078-0432.CCR-10-2456; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu Y, 2007, DEV BIOL, V310, P442, DOI 10.1016/j.ydbio.2007.08.007; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Nakada M, 2007, CELL MOL LIFE SCI, V64, P458, DOI 10.1007/s00018-007-6342-5; Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371; Pidgeon GP, 2007, CANCER METAST REV, V26, P503, DOI 10.1007/s10555-007-9098-3; Ping YF, 2011, CURR MOL MED, V11, P69, DOI 10.2174/156652411794474383; Ping YF, 2011, J PATHOL, V224, P344, DOI 10.1002/path.2908; Ping YF, 2011, STEM CELLS, V29, P888, DOI 10.1002/stem.650; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sayed D, 2011, PHYSIOL REV, V91, P827, DOI 10.1152/physrev.00006.2010; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Slack FJ, 2008, NEW ENGL J MED, V359, P2720, DOI 10.1056/NEJMe0808667; Uziel T, 2009, P NATL ACAD SCI USA, V106, P2812, DOI 10.1073/pnas.0809579106; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang B, 2011, STEM CELL REV REP, V7, P458, DOI 10.1007/s12015-010-9175-9; Wienholds E, 2005, FEBS LETT, V579, P5911, DOI 10.1016/j.febslet.2005.07.070; Wong P, 2010, CANCER RES, V70, P3833, DOI 10.1158/0008-5472.CAN-09-3268; Xu C, 2013, CANCER RES, V73, P3181, DOI 10.1158/0008-5472.CAN-12-4403; Yang XJ, 2013, INT IMMUNOPHARMACOL, V15, P191, DOI 10.1016/j.intimp.2012.12.002; Yao XH, 2008, J PATHOL, V215, P369, DOI 10.1002/path.2356; Ye XZ, 2012, J IMMUNOL, V189, P444, DOI 10.4049/jimmunol.1103248; Yi L, 2007, MODERN PATHOL, V20, P1061, DOI 10.1038/modpathol.3800942; Yu SC, 2008, CANCER LETT, V265, P124, DOI 10.1016/j.canlet.2008.02.010; Yu SC, 2009, STEM CELL REV REP, V5, P66, DOI 10.1007/s12015-008-9047-8; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103; Zhao Y, 2012, BIOCHEM BIOPH RES CO, V418, P647, DOI 10.1016/j.bbrc.2012.01.068	58	98	105	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1407	1419		10.1038/onc.2014.75	http://dx.doi.org/10.1038/onc.2014.75			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24704830				2022-12-17	WOS:000350806500007
J	Liao, Q; Zeng, Z; Guo, X; Li, X; Wei, F; Zhang, W; Li, X; Chen, P; Liang, F; Xiang, B; Ma, J; Wu, M; Tang, H; Deng, M; Zeng, X; Tang, K; Xiong, W; Li, G				Liao, Q.; Zeng, Z.; Guo, X.; Li, X.; Wei, F.; Zhang, W.; Li, X.; Chen, P.; Liang, F.; Xiang, B.; Ma, J.; Wu, M.; Tang, H.; Deng, M.; Zeng, X.; Tang, K.; Xiong, W.; Li, G.			LPLUNC1 suppresses IL-6-induced nasopharyngeal carcinoma cell proliferation via inhibiting the Stat3 activation	ONCOGENE			English	Article						nasopharyngeal carcinoma; tumor-associated macrophages; interleukin-6; LPLUNC1; signal transducer and activator of transcription 3	TUMOR-ASSOCIATED MACROPHAGES; CANCER-RELATED INFLAMMATION; UPPER AIRWAYS; INTERLEUKIN-6; EXPRESSION; MICROENVIRONMENT; PLUNC; GENE; PROGRESSION; INITIATION	Tumor-associated macrophage (TAM)-related chronic inflammation and interleukin-6 (IL-6) contribute to the progression of nasopharyngeal carcinoma (NPC). In this study, we characterized TAMs and IL-6 expression in 212 biopsied NPC and 119 non-tumor nasopharyngeal epithelium (NPE) tissues by tissue array. In comparison with that in the NPE tissues, more TAM infiltrates and a higher density of IL-6 expression were detected in NPC tissues, which were associated with the poor survival of NPC patients. In contrast, little or no LPLUNC1, a regulator of inflammation, expression was detected in NPC tissues, and the levels of LPLUNC1 expression in the NPC were associated negatively with the numbers of TAMs and the levels of IL-6 expression, but positively with the survival of NPC patients. Induction of LPLUNC1 overexpression in NPC cells mitigated lipopolysaccharide (LPS)-induced IL-6, IL-8, tumor necrosis factor-alpha and IL-1 beta expression or treatment of THP-1 macrophages with LPLUNC1 inhibited spontaneous and LPS-induced IL-6 expression in vitro. IL-6-promoted NPC cell proliferation in a dose- and time-dependent manner, accompanied by increasing cyclin D1 and Bcl-2 expression and the Stat3 activation, but inhibiting Bax and p21 expression. Induction of LPLUNC1 overexpression inhibited NPC cell proliferation, induced NPC cell arrest, promoted NPC cell apoptosis even after IL-6 stimulation and inhibited the growth of implanted NPC tumors in vivo, which were associated with decreasing cyclin D1 and Bcl-2 expression and the Janus kinase 2 (JAK2)/Stat3 activation, but enhancing Bax and p21 expression. These results suggest that LPLUNC1 can inhibit inflammation and NPC growth by downregulating the Stat3 pathway.	[Liao, Q.; Zeng, Z.; Li, X.; Ma, J.; Wu, M.; Xiong, W.; Li, G.] Cent S Univ, Xiangya Sch Med, Hunan Prov Tumor Hosp, Changsha 410013, Hunan, Peoples R China; [Liao, Q.; Zeng, Z.; Li, X.; Ma, J.; Wu, M.; Xiong, W.; Li, G.] Cent S Univ, Xiangya Sch Med, Affiliated Tumor Hosp, Changsha 410013, Hunan, Peoples R China; [Liao, Q.; Zeng, Z.; Li, X.; Li, X.; Ma, J.; Wu, M.; Xiong, W.; Li, G.] Cent S Univ, Xiangya Hosp 3, Dis Genome Res Ctr, Hunan Key Lab Nonresolving Inflammat & Canc, Changsha 410013, Hunan, Peoples R China; [Liao, Q.; Zeng, Z.; Guo, X.; Li, X.; Wei, F.; Zhang, W.; Chen, P.; Liang, F.; Xiang, B.; Ma, J.; Wu, M.; Tang, H.; Deng, M.; Zeng, X.; Tang, K.; Xiong, W.; Li, G.] Cent S Univ, Canc Res Inst, Minist Hlth, Key Lab Carcinogenesis, Changsha 410013, Hunan, Peoples R China; [Liao, Q.; Zeng, Z.; Guo, X.; Li, X.; Wei, F.; Zhang, W.; Chen, P.; Liang, F.; Xiang, B.; Ma, J.; Wu, M.; Tang, H.; Deng, M.; Zeng, X.; Tang, K.; Xiong, W.; Li, G.] Cent S Univ, Canc Res Inst, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha 410013, Hunan, Peoples R China	Central South University; Central South University; Central South University; Central South University; Central South University	Xiong, W (corresponding author), Cent S Univ, Xiangya Sch Med, Hunan Prov Tumor Hosp, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.	xiongwei@xysm.net; ligy@xysm.net		Zeng, Xi/0000-0001-6835-9691	National High Technology Research and Development Program of China [2012AA02A206]; National Natural Science Foundation of China [91229122, 81071644, 81172189, 81101509, 81171930, 81272254, 81272298]; 111 project [111-2-12]; Program for New Century Excellent Talents in University [NCET-11-0520]; Hunan Province Natural Sciences Foundation of China [10JJ7003]	National High Technology Research and Development Program of China(National High Technology Research and Development Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 111 project(Ministry of Education, China - 111 Project); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); Hunan Province Natural Sciences Foundation of China(Natural Science Foundation of Hunan Province)	This study was supported by grants from the National High Technology Research and Development Program of China (2012AA02A206), the National Natural Science Foundation of China (91229122, 81071644, 81172189, 81101509, 81171930, 81272254 and 81272298), the 111 project (111-2-12), the Program for New Century Excellent Talents in University (NCET-11-0520) and the Hunan Province Natural Sciences Foundation of China (10JJ7003).	Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Ataie-Kachoie P, 2013, CYTOKINE GROWTH F R, V24, P163, DOI 10.1016/j.cytogfr.2012.09.001; Baay M, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/565187; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Balkwill FR, 2012, SEMIN CANCER BIOL, V22, P33, DOI 10.1016/j.semcancer.2011.12.005; Becker C, 2005, CELL CYCLE, V4, P217; Bingle CD, 2000, BBA-GENE STRUCT EXPR, V1493, P363, DOI 10.1016/S0167-4781(00)00196-2; Bingle CD, 2002, HUM MOL GENET, V11, P937, DOI 10.1093/hmg/11.8.937; Bingle CD, 2010, HISTOCHEM CELL BIOL, V133, P505, DOI 10.1007/s00418-010-0683-0; Bingle L, 2011, BIOCHEM SOC T, V39, P1023, DOI 10.1042/BST0391023; Candido J, 2013, J CLIN IMMUNOL, V33, pS79, DOI 10.1007/s10875-012-9847-0; Canny G, 2008, TRENDS IMMUNOL, V29, P541, DOI 10.1016/j.it.2008.07.012; Chen HL, 2001, J VIROL, V75, P2929, DOI 10.1128/JVI.75.6.2929-2937.2001; Chow KC, 2003, ONCOL REP, V10, P813; Cocco C, 2012, IMMUNOTHERAPY-UK, V4, P667, DOI 10.2217/imt.12.56; de Visser KE, 2006, CONTRIB MICROBIOL, V13, P118, DOI 10.1159/000092969; Di YP, 2003, J BIOL CHEM, V278, P1165, DOI 10.1074/jbc.M210523200; Fan SQ, 2006, HUM PATHOL, V37, P593, DOI 10.1016/j.humpath.2006.01.010; Fukuda Koji, 2012, Front Biosci (Schol Ed), V4, P787; Hao NB, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/948098; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hong DS, 2007, CANCER-AM CANCER SOC, V110, P1911, DOI 10.1002/cncr.22999; Hsiao JR, 2003, BRIT J CANCER, V89, P344, DOI 10.1038/sj.bjc.6601003; Hsu HS, 2012, LUNG CANCER, V75, P167, DOI 10.1016/j.lungcan.2011.07.001; Hussain SP, 2007, INT J CANCER, V121, P2373, DOI 10.1002/ijc.23173; Ishihara K, 2002, CYTOKINE GROWTH F R, V13, P357, DOI 10.1016/S1359-6101(02)00027-8; Kim SR, 2009, BIOCHEM BIOPH RES CO, V387, P342, DOI 10.1016/j.bbrc.2009.07.022; Kishimoto T, 2005, ANNU REV IMMUNOL, V23, P1, DOI 10.1146/annurev.immunol.23.021704.115806; Liao Q, 2011, J CANCER RES CLIN, V138, P57; Lin CM, 2010, J AGR FOOD CHEM, V58, P7082, DOI 10.1021/jf100421w; Lu HT, 2006, MOL CANCER RES, V4, P221, DOI 10.1158/1541-7786.MCR-05-0261; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mantovani A, 2006, CANCER METAST REV, V25, P315, DOI 10.1007/s10555-006-9001-7; Mantovani A, 2009, NATURE, V457, P36, DOI 10.1038/457036b; Motilva V, 2012, CURR PHARM DESIGN, V18, P3829, DOI 10.2174/138161212802083671; Musa M, 2012, CELL TISSUE RES, V350, P455, DOI 10.1007/s00441-012-1490-9; Park EK, 2007, INFLAMM RES, V56, P45, DOI 10.1007/s00011-007-6115-5; Rodriguez-Vita J, 2010, CYTOKINE GROWTH F R, V21, P61, DOI 10.1016/j.cytogfr.2009.11.006; Sgambato A, 2010, EUR REV MED PHARMACO, V14, P263; Shih J, 2006, J CANC MOL, V2, P6; Shin OS, 2011, J INFECT DIS, V204, P1349, DOI 10.1093/infdis/jir544; Sica A, 2008, CANCER LETT, V267, P204, DOI 10.1016/j.canlet.2008.03.028; Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385; Steidl C, 2010, NEW ENGL J MED, V362, P875, DOI 10.1056/NEJMoa0905680; STRASSMANN G, 1992, J CLIN INVEST, V89, P1681, DOI 10.1172/JCI115767; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Takayama H, 2009, J UROLOGY, V181, P1894, DOI 10.1016/j.juro.2008.11.090; Tan EL, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-227; Vargas PA, 2008, ORAL DIS, V14, P613, DOI 10.1111/j.1601-0825.2007.01429.x; Wang R, 2011, LUNG CANCER, V74, P188, DOI 10.1016/j.lungcan.2011.04.009; Yang YX, 2007, MOL IMMUNOL, V44, P984, DOI 10.1016/j.molimm.2006.03.013; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang BC, 2003, GENE CHROMOSOME CANC, V38, P80, DOI 10.1002/gcc.10247; Zhang BC, 2011, MED ONCOL, V28, P1447, DOI 10.1007/s12032-010-9638-5; Zhang XL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020965	55	98	104	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2098	2109		10.1038/onc.2013.161	http://dx.doi.org/10.1038/onc.2013.161			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23708661				2022-12-17	WOS:000334599100009
J	Porsch, H; Bernert, B; Mehic, M; Theocharis, AD; Heldin, CH; Heldin, P				Porsch, H.; Bernert, B.; Mehic, M.; Theocharis, A. D.; Heldin, C-H; Heldin, P.			Efficient TGF beta-induced epithelial-mesenchymal transition depends on hyaluronan synthase HAS2	ONCOGENE			English	Article						EMT; growth factors; TGF beta; hyaluronan synthase 2; migration	GROWTH-FACTOR-BETA; INTRACELLULAR HYALURONAN; CELL-PROLIFERATION; EXPRESSION; RECEPTOR; CLONING; TRAF6; FIBROBLASTS; SUPPRESSES; ACTIVATION	Epithelial-mesenchymal transition (EMT) is a developmental program, which can be adopted by cancer cells to increase their migration and ability to form metastases. Transforming growth factor beta (TGF beta) is a well-studied inducer of EMT. We demonstrate that TGF beta potently stimulates hyaluronan synthesis via upregulation of hyaluronan synthase 2 (HAS2) in NMuMG mammary epithelial cells. This stimulatory effect requires the kinase active type I TGF beta receptor and is dependent on Smad signaling and activation of the p38 mitogen-activated protein kinase. Knockdown of HAS2 inhibited the TGF beta-induced EMT by about 50%, as determined by the phase contrast microscopy and immunostaining using the EMT marker ZO-1. Furthermore, real-time PCR analysis of the EMT markers fibronectin, Snail1 and Zeb1 revealed decreased expressions upon HAS2 suppression, using specific small interfering RNA (siRNA) for HAS2. Removal of the extracellular hyaluronan by Streptomyces hyaluronidase or inhibiting the binding to its cell surface receptor CD44 by blocking antibodies, did not inhibit TGF beta-induced EMT. Interestingly, HAS2 suppression completely abolished the TGF beta-induced cell migration, whereas CD44 knockdown did not. These observations suggest that TGF beta-dependent HAS2 expression, but not extracellular hyaluronan, has an important regulatory role in TGF beta-induced EMT.	[Porsch, H.; Bernert, B.; Mehic, M.; Theocharis, A. D.; Heldin, C-H; Heldin, P.] Uppsala Univ, Biomed Ctr, Sci life Lab, Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research; Uppsala University	Heldin, P (corresponding author), Uppsala Univ, Biomed Ctr, Sci life Lab, Ludwig Inst Canc Res, Box 595, SE-75124 Uppsala, Sweden.	Evi.Heldin@LICR.uu.se	theocharis, achilleas/F-6903-2010	Theocharis, Achilleas/0000-0001-8611-2297; Mehic, Merima/0000-0001-8249-5526	Swedish Cancer Society; Agnes and Mac Rudberg Foundation; Gurli and Edward Brunnberg Foundation; Mizutani Foundation for Glycoscience	Swedish Cancer Society(Swedish Cancer Society); Agnes and Mac Rudberg Foundation; Gurli and Edward Brunnberg Foundation; Mizutani Foundation for Glycoscience	This work was supported in part by grants from the Swedish Cancer Society, Agnes and Mac Rudberg Foundation, Gurli and Edward Brunnberg Foundation and Mizutani Foundation for Glycoscience. We thank Drs A Moustakas and L van der Heide (Ludwig Institute for Cancer Research, Uppsala, Sweden) for advice.	Anttila MA, 2000, CANCER RES, V60, P150; Auvinen P, 2000, AM J PATHOL, V156, P529, DOI 10.1016/S0002-9440(10)64757-8; Bakkers J, 2004, DEVELOPMENT, V131, P525, DOI 10.1242/dev.00954; Bernert B, 2011, J BIOL CHEM, V286, P42349, DOI 10.1074/jbc.M111.278598; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Boregowda Rajeev K, 2006, J Carcinog, V5, P2, DOI 10.1186/1477-3163-5-2; Brinck J, 1999, EXP CELL RES, V252, P342, DOI 10.1006/excr.1999.4645; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Camenisch TD, 2002, NAT MED, V8, P850, DOI 10.1038/nm742; Evanko SP, 2004, J HISTOCHEM CYTOCHEM, V52, P1525, DOI 10.1369/jhc.4A6356.2004; Evanko SP, 2001, INTRACELLULAR HYALUR; Gal A, 2008, ONCOGENE, V27, P1218, DOI 10.1038/sj.onc.1210741; Hascall VC, 2004, BBA-GEN SUBJECTS, V1673, P3, DOI 10.1016/j.bbagen.2004.02.013; HELDIN P, 1989, BIOCHEM J, V258, P919, DOI 10.1042/bj2580919; Heldin P, 1996, ONCOL REP, V3, P1011; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Jacobson A, 2000, BIOCHEM J, V348, P29, DOI 10.1042/0264-6021:3480029; Karousou E, 2010, J BIOL CHEM, V285, P23647, DOI 10.1074/jbc.M110.127050; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Li LL, 2007, BIOCHEM J, V404, P327, DOI 10.1042/BJ20061757; Li Y, 2001, BRIT J CANCER, V85, P600, DOI 10.1054/bjoc.2001.1922; Li YJ, 2000, AM J RESP CELL MOL, V23, P411, DOI 10.1165/ajrcmb.23.3.4102; Li YJ, 2007, INT J CANCER, V120, P2557, DOI 10.1002/ijc.22550; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Meran S, 2007, J BIOL CHEM, V282, P25687, DOI 10.1074/jbc.M700773200; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; Mu YB, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1332; Okuda H, 2012, CANCER RES, V72, P537, DOI 10.1158/0008-5472.CAN-11-1678; Olsson M, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001332; Sato N, 2004, CANCER RES, V64, P6950, DOI 10.1158/0008-5472.CAN-04-0677; Schiller M, 2010, J BIOL CHEM, V285, P409, DOI 10.1074/jbc.M109.038620; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Simpson RML, 2010, AM J PATHOL, V176, P1215, DOI 10.2353/ajpath.2010.090802; Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Spicer AP, 1997, J BIOL CHEM, V272, P8957; Stuhlmeier KM, 2004, J BIOL CHEM, V279, P8753, DOI 10.1074/jbc.M303945200; Takahashi E, 2010, J BIOL CHEM, V285, P4060, DOI 10.1074/jbc.M109.056523; Takebe N, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2876; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Toole BP, 2008, SEMIN CANCER BIOL, V18, P244, DOI 10.1016/j.semcancer.2008.03.009; Unger K, 2010, ENDOCR-RELAT CANCER, V17, P87, DOI 10.1677/ERC-09-0065; Usui T, 2000, INVEST OPHTH VIS SCI, V41, P3261; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang AM, 2011, FEBS J, V278, P1412, DOI 10.1111/j.1742-4658.2011.08069.x; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Williams CM, 2008, CANCER RES, V68, P3185, DOI 10.1158/0008-5472.CAN-07-2673; Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002; Zoltan-Jones A, 2003, J BIOL CHEM, V278, P45801, DOI 10.1074/jbc.M308168200	55	98	102	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2013	32	37					4355	4365		10.1038/onc.2012.475	http://dx.doi.org/10.1038/onc.2012.475			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23108409	Green Published, hybrid			2022-12-17	WOS:000324404200004
J	Lopez-Lago, MA; Posner, S; Thodima, VJ; Molina, AM; Motzer, RJ; Chaganti, RSK				Lopez-Lago, M. A.; Posner, S.; Thodima, V. J.; Molina, A. M.; Motzer, R. J.; Chaganti, R. S. K.			Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression	ONCOGENE			English	Article						kidney cancer; metastasis; neutrophil	COMPARATIVE GENOMIC HYBRIDIZATION; GENE-EXPRESSION; NUDE-MICE; CANCER METASTASIS; MELANOMA-CELLS; BREAST-CANCER; INTERLEUKIN-8; GROWTH; IL-8; INFILTRATION	The mechanism by which renal cell carcinoma (RCC) colonizes the lung microenvironment during metastasis remains largely unknown. To investigate this process, we grafted human RCC cells with varying lung metastatic potential in mice. Gene expression profiling of the mouse lung stromal compartment revealed a signature enriched for neutrophil-specific functions that was induced preferentially by poorly metastatic cells. Analysis of the gene expression signatures of tumor cell lines showed an inverse correlation between metastatic activity and the levels of a number of chemokines, including CXCL5 and IL8. Enforced depletion of CXCL5 and IL8 in these cell lines enabled us to establish a functional link between lung neutrophil infiltration, secretion of chemokines by cancer cells and metastatic activity. We further show that human neutrophils display a higher cytotoxic activity against poorly metastatic cells compared with highly metastatic cells. Together, these results support a model in which neutrophils recruited to the lung by tumor-secreted chemokines build an antimetastatic barrier with loss of neutrophil chemokines in tumor cells acting as a critical rate-limiting step during lung metastatic seeding. Oncogene (2013) 32, 1752-1760; doi: 10.1038/onc.2012.201; published online 4 June 2012	[Lopez-Lago, M. A.; Posner, S.; Thodima, V. J.; Chaganti, R. S. K.] Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; [Molina, A. M.; Motzer, R. J.; Chaganti, R. S. K.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Chaganti, RSK (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.	chagantr@mskcc.org		Motzer, Robert/0000-0001-6925-2327	National Cancer Institute [CA-121327]; V-Foundation; Syms kidney cancer award; NATIONAL CANCER INSTITUTE [R01CA121327] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); V-Foundation; Syms kidney cancer award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by research grants from the National Cancer Institute (CA-121327), the V-Foundation and a Syms kidney cancer award. We thank Marco Seandel and Eric Pamer for critical reading of the manuscript. The MSKCC Genomics Core Facility provided expert assistance in performing the gene expression profiling assays. R Chaganti is a Board member and a paid consultant of Cancer Genetics Inc., Rutherford, NJ, USA.	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Arenberg DA, 1998, J CLIN INVEST, V102, P465, DOI 10.1172/JCI3145; Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bellocq A, 1998, AM J PATHOL, V152, P83; Bissig H, 1999, AM J PATHOL, V155, P267, DOI 10.1016/S0002-9440(10)65120-6; Buonocore S, 2008, J LEUKOCYTE BIOL, V84, P713, DOI 10.1189/jlb.0108075; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Dakhova O, 2009, CLIN CANCER RES, V15, P3979, DOI 10.1158/1078-0432.CCR-08-1899; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Di Carlo E, 2001, BLOOD, V97, P339, DOI 10.1182/blood.V97.2.339; EBERT T, 1990, CANCER RES, V50, P5531; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Finak G, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1608; Foekens JA, 2003, CANCER RES, V63, P337; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Gorbachev AV, 2007, J IMMUNOL, V178, P2278, DOI 10.4049/jimmunol.178.4.2278; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Jensen HK, 2009, J CLIN ONCOL, V27, P4709, DOI 10.1200/JCO.2008.18.9498; Jiang F, 2000, CANCER RES, V60, P6503; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kondo T, 2004, J UROLOGY, V171, P2171, DOI 10.1097/01.ju.0000127726.25609.87; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; Lee LF, 2000, J IMMUNOL, V164, P2769, DOI 10.4049/jimmunol.164.5.2769; Linehan WM, 2003, J UROLOGY, V170, P2163, DOI 10.1097/01.ju.0000096060.92397.ed; Lopez-Lago MA, 2010, CANC RES; Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009; McAllister SS, 2010, J CLIN ONCOL, V28, P4022, DOI 10.1200/JCO.2010.28.4257; Miyazaki H, 2006, CANCER RES, V66, P4279, DOI 10.1158/0008-5472.CAN-05-4398; Monti P, 2003, CANCER RES, V63, P7451; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; MURPHY GP, 1973, JNCI-J NATL CANCER I, V50, P1013, DOI 10.1093/jnci/50.4.1013; NAITO S, 1989, CLIN EXP METASTAS, V7, P381, DOI 10.1007/BF01753659; NAITO S, 1986, CANCER RES, V46, P4109; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Ostrand-Rosenberg S, 2008, CURR OPIN GENET DEV, V18, P11, DOI 10.1016/j.gde.2007.12.007; PAGET S, 1989, CANCER METAST REV, V8, P98; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; Schaider H, 2003, INT J CANCER, V103, P335, DOI 10.1002/ijc.10775; SINGH RK, 1994, CANCER RES, V54, P3242; Speetjens FM, 2008, CLIN CANCER RES, V14, P2276, DOI 10.1158/1078-0432.CCR-07-4045; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Takahashi H, 2005, IMMUNOL LETT, V98, P189, DOI 10.1016/j.imlet.2004.11.012; Talmadge JE, 2007, CANCER METAST REV, V26, P373, DOI 10.1007/s10555-007-9072-0; Tan XJ, 2008, INT J CANCER, V123, P1080, DOI 10.1002/ijc.23637; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wong YF, 2007, ONCOGENE, V26, P1971, DOI 10.1038/sj.onc.1209986	50	98	105	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2013	32	14					1752	1760		10.1038/onc.2012.201	http://dx.doi.org/10.1038/onc.2012.201			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22665059	Green Accepted			2022-12-17	WOS:000317043900002
J	Paul, I; Ahmed, SF; Bhowmik, A; Deb, S; Ghosh, MK				Paul, I.; Ahmed, S. F.; Bhowmik, A.; Deb, S.; Ghosh, M. K.			The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity	ONCOGENE			English	Article						Hsp70; Hsp90; c-Myc; CHIP (STUB1); proteasome	PROTEASOMAL DEGRADATION; CELL PROLIFERATION; PROTEIN STABILITY; PHOSPHORYLATION; MUTATIONS; PATHWAYS; COMPLEX; GLIOMA; TUMOR; SKP2	c-Myc is a proto-oncogenic transcription factor and its rapid turnover mediated by the ubiquitin-proteasome system is critical for maintaining normal cellular homeostasis. Multiple ubiquitin ligases have been assigned for c-Myc regulation till date. However, the available data suggest for the possible existence of additional E3 ligase(s). Here, we report a new E3 ligase for c-Myc, the carboxyl terminus of Hsc70-interacting protein or CHIP, which is a chaperone-associated Ubox-containing E3 ligase. In this report, we show that CHIP interacts and ubiquitinates c-Myc, thus targeting it for proteasome-mediated degradation. Overexpression of CHIP could accelerate the turnover rate of c-Myc protein. Conversely, knockdown of CHIP by RNAi stabilizes endogenous c-Myc. The interaction between CHIP and c-Myc depends on the N-terminally located tetratricopeptide repeats of CHIP, which has been implicated as a chaperone-binding motif. Inhibition of Hsp90 chaperone activity by 17-N-allylamino-17-demethoxygeldanamycin reduces c-Myc protein level. We found that the association between CHIP and c-Myc is dependent on the chaperones; particularly Hsp70. CHIP antagonizes the transcriptional activity of c-Myc and decreases the abundance of the transcripts of its target genes. Overall, CHIP-knockdown increases malignant behavior of C6 glioma cells. To the best of our knowledge, this is the first report of c-Myc being regulated by a bona-fide chaperone-associated E3 ligase in HEK293 as well as glioma cells. Because CHIP has been reported earlier to be negatively regulating Akt1, BCR-ABL and hTERT, and now c-Myc, the present study may strengthen the view that CHIP acts as a tumor suppressor. Oncogene (2013) 32, 1284-1295; doi:10.1038/onc.2012.144; published online 30 April 2012	[Paul, I.; Ahmed, S. F.; Bhowmik, A.; Deb, S.; Ghosh, M. K.] CSIR, IICB, Lab Signal Transduct Canc & Stem Cells, Kolkata 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Ghosh, MK (corresponding author), CSIR, IICB, Lab Signal Transduct Canc & Stem Cells, 4 Raja SC Mullick Rd, Kolkata 700032, W Bengal, India.	mrinal.res@gmail.com	Ahmed, Syed Feroj/D-7860-2014; Paul, Indranil/AAX-7638-2021	Ahmed, Syed Feroj/0000-0003-1033-2538; Paul, Indranil/0000-0003-0327-5002; Deb, Satamita/0000-0003-0315-7030	Council of Scientific and Industrial Research, CSIR (EMPOWER); DST	Council of Scientific and Industrial Research, CSIR (EMPOWER); DST(Department of Science & Technology (India))	This work was supported by grants provided by Council of Scientific and Industrial Research, CSIR (EMPOWER) and DST to MKG.	Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Belova L, 2006, BIOCHEM J, V400, P235, DOI 10.1042/BJ20060905; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Carystinos GD, 2003, MOL PHARMACOL, V63, P821, DOI 10.1124/mol.63.4.821; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Choi SH, 2010, GENE DEV, V24, P1236, DOI 10.1101/gad.1920310; CLARK HM, 1994, CANCER RES, V54, P3383; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; Deribe YL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000576; Dickey CA, 2008, P NATL ACAD SCI USA, V105, P3622, DOI 10.1073/pnas.0709180105; Ding XD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005949; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Ghosh MK, 2005, ONCOGENE, V24, P7290, DOI 10.1038/sj.onc.1208894; Grobben B, 2002, CELL TISSUE RES, V310, P257, DOI 10.1007/s00441-002-0651-7; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; HENRIKSSON M, 1992, EXP CELL RES, V203, P383, DOI 10.1016/0014-4827(92)90012-W; Herbst A, 2004, ONCOGENE, V23, P3863, DOI 10.1038/sj.onc.1207492; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Kajiro M, 2009, NAT CELL BIOL, V11, P312, DOI 10.1038/ncb1839; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Ko HS, 2009, P NATL ACAD SCI USA, V106, P2897, DOI 10.1073/pnas.0810123106; Kundrat L, 2010, BIOCHEMISTRY-US, V49, P7428, DOI 10.1021/bi100386w; Levens David, 2010, Genes Cancer, V1, P547; Li F, 2009, J BIOL CHEM, V284, P20090, DOI 10.1074/jbc.M109.017046; Li XN, 2008, J CELL BIOL, V181, P959, DOI 10.1083/jcb.200711044; McLean PJ, 2004, BIOCHEM BIOPH RES CO, V321, P665, DOI 10.1016/j.bbrc.2004.07.021; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; NAGANO N, 1993, ACTA NEUROPATHOL, V86, P117, DOI 10.1007/BF00334878; Nie L, 2008, J BIOL CHEM, V283, P684, DOI 10.1074/jbc.M704981200; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Popov N, 2010, NAT CELL BIOL, V12, P973, DOI 10.1038/ncb2104; PULVERER BJ, 1994, ONCOGENE, V9, P59; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sha JF, 2010, J VIROL, V84, P4050, DOI 10.1128/JVI.02131-09; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; Sittler A, 2001, HUM MOL GENET, V10, P1307, DOI 10.1093/hmg/10.12.1307; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Whittle IR, 1998, J NEURO-ONCOL, V36, P231, DOI 10.1023/A:1005831111337; Xia T, 2007, AM J PHYSIOL-HEART C, V293, pH3080, DOI 10.1152/ajpheart.00579.2007; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217	44	98	102	3	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2013	32	10					1284	1295		10.1038/onc.2012.144	http://dx.doi.org/10.1038/onc.2012.144			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22543587				2022-12-17	WOS:000316454500009
J	Pullamsetti, SS; Banat, GA; Schmall, A; Szibor, M; Pomagruk, D; Hanze, J; Kolosionek, E; Wilhelm, J; Braun, T; Grimminger, F; Seeger, W; Schermuly, RT; Savai, R				Pullamsetti, S. S.; Banat, G. A.; Schmall, A.; Szibor, M.; Pomagruk, D.; Haenze, J.; Kolosionek, E.; Wilhelm, J.; Braun, T.; Grimminger, F.; Seeger, W.; Schermuly, R. T.; Savai, R.			Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF	ONCOGENE			English	Article						lung cancer; hypoxia; phosphodiesterases; proliferation; angiogenesis	TUMOR-GROWTH; CELLS; HYPOXIA; INHIBITION; EXPRESSION; APOPTOSIS; COMPONENTS; MIGRATION; LEUKEMIA; TARGETS	Lung cancer is the leading cause of cancer death worldwide. Recent data suggest that cyclic nucleotide phosphodiesterases (PDEs) are relevant in various cancer pathologies. Pathophysiological role of phosphodiesterase 4 (PDE4) with possible therapeutic prospects in lung cancer was investigated. We exposed 10 different lung cancer cell lines (adenocarcinoma, squamous and large cell carcinoma) to hypoxia and assessed expression and activity of PDE4 by real-time PCR, immunocytochemistry, western blotting and PDE activity assays. Expression and activity of distinct PDE4 isoforms (PDE4A and PDE4D) increased in response to hypoxia in eight of the studied cell lines. Furthermore, we analyzed various in silico predicted hypoxia-responsive elements (p-HREs) found in PDE4A and PDE4D genes. Performing mutation analysis of the p-HRE in luciferase reporter constructs, we identified four functional HRE sites in the PDE4A gene and two functional HRE sites in the PDE4D gene that mediated hypoxic induction of the reporter. Silencing of hypoxia-inducible factor subunits (HIF1 alpha and HIF2 alpha by small interfering RNA reduced hypoxic induction of PDE4A and PDE4D. Vice versa, using a PDE4 inhibitor (PDE4i) as a cyclic adenosine monophosphate (cAMP) -elevating agent, cAMP analogs or protein kinase A (PKA)-modulating drugs and an exchange protein directly activated by cAMP (EPAC) activator, we demonstrated that PDE4-cAMP-PKA/EPAC axis enhanced HIF signaling as measured by HRE reporter gene assay, HIF and HIF target genes expression ((lactate dehydrogenase A), LDHA, (pyruvate dehydrogenase kinase 1) PDK1 and (vascular endothelial growth factor A) VEGFA). Notably, inhibition of PDE4 by PDE4i or silencing of PDE4A and PDE4D reduced human lung tumor cell proliferation and colony formation. On the other hand, overexpression of PDE4A or PDE4D increased human lung cancer proliferation. Moreover, PDE4i treatment reduced hypoxia-induced VEGF secretion in human cells. In vivo, PDE4i inhibited tumor xenograft growth in nude mice by attenuating proliferation and angiogenesis. Our findings suggest that PDE4 is expressed in lung cancer, crosstalks with HIF signaling and promotes lung cancer progression. Thus, PDE4 may represent a therapeutic target for lung cancer therapy. Oncogene (2013) 32, 1121-1134; doi:10.1038/onc.2012.136; published online 23 April 2012	[Pullamsetti, S. S.; Schmall, A.; Seeger, W.; Schermuly, R. T.; Savai, R.] Max Planck Inst Heart & Lung Res, Dept Lung Dev & Remodelling, D-61231 Bad Nauheim, Germany; [Pullamsetti, S. S.; Banat, G. A.; Pomagruk, D.; Kolosionek, E.; Wilhelm, J.; Grimminger, F.; Seeger, W.; Schermuly, R. T.] Univ Giessen, Univ Giessen Lung Ctr, D-35390 Giessen, Germany; [Szibor, M.; Braun, T.] Max Planck Inst Heart & Lung Res, Dept Cardiac Dev & Remodelling, D-61231 Bad Nauheim, Germany; [Haenze, J.] Philipps Univ, Dept Urol & Pediat Urol, Marburg, Germany	Max Planck Society; Justus Liebig University Giessen; Max Planck Society; Philipps University Marburg	Savai, R (corresponding author), Max Planck Inst Heart & Lung Res, Pk Str 1, D-61231 Bad Nauheim, Germany.	rajkumar.savai@mpi-bn.mpg.de	Braun, Thomas/B-2310-2008; Wilhelm, Jochen/AAX-4302-2021	Wilhelm, Jochen/0000-0001-5544-9647; Savai, Rajkumar/0000-0003-1538-2091; Hanze, Jorg/0000-0001-5424-7808; Pullamsetti, Soni Savai/0000-0003-0440-8831; Seeger, Werner/0000-0003-1946-0894; Grimminger, Friedrich/0000-0001-8725-6276; Schermuly, Ralph/0000-0002-5167-6970; Braun, Thomas/0000-0002-6165-4804	STARTUP AWARD from Justus-Liebig University Giessen, Germany; LOEWE-Center UGMLC (University of Giessen); LOEWE-Center UGMLC (University of Marburg Lung Center)	STARTUP AWARD from Justus-Liebig University Giessen, Germany; LOEWE-Center UGMLC (University of Giessen); LOEWE-Center UGMLC (University of Marburg Lung Center)	The authors thank Marianne Hoeck and Katharina Weidl for her excellent technical assistance. Dr Rajkumar Saves research was supported by the STARTUP AWARD from Justus-Liebig University Giessen, Germany and LOEWE-Center UGMLC (Universities of Giessen and Marburg Lung Center).	Chen TC, 2002, CANCER BIOL THER, V1, P268, DOI 10.4161/cbt.80; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; Conti M, 2007, ANNU REV BIOCHEM, V76, P481, DOI 10.1146/annurev.biochem.76.060305.150444; Cox G, 2000, LUNG CANCER, V29, P169, DOI 10.1016/S0169-5002(00)00124-0; Dastidar SG, 2007, CURR OPIN INVEST DR, V8, P364; Deguchi A, 2004, CANCER RES, V64, P3966, DOI 10.1158/0008-5472.CAN-03-3740; Goldhoff P, 2008, CLIN CANCER RES, V14, P7717, DOI 10.1158/1078-0432.CCR-08-0827; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hung JJ, 2009, THORAX, V64, P1082, DOI 10.1136/thx.2009.115691; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kolosionek E, 2009, MOL BIOL CELL, V20, P4751, DOI 10.1091/mbc.E09-01-0019; Lerner A, 2006, BIOCHEM J, V393, P21, DOI 10.1042/BJ20051368; Lipworth BJ, 2005, LANCET, V365, P167, DOI 10.1016/S0140-6736(05)17708-3; Malec V, 2010, FREE RADICAL BIO MED, V48, P1626, DOI 10.1016/j.freeradbiomed.2010.03.008; Marko D, 2000, CHEM RES TOXICOL, V13, P944, DOI 10.1021/tx000090l; Marko Doris, 1998, Cell Biochemistry and Biophysics, V28, P75, DOI 10.1007/BF02737806; McEwan DG, 2007, CANCER RES, V67, P5248, DOI 10.1158/0008-5472.CAN-07-0097; Millen J, 2006, EUR J CELL BIOL, V85, P679, DOI 10.1016/j.ejcb.2006.01.006; Mouratidis PXE, 2009, PANCREAS, V38, P78, DOI 10.1097/MPA.0b013e318183d72f; Murata K, 2001, CLIN EXP METASTAS, V18, P599, DOI 10.1023/A:1011926116777; Narita M, 2007, ONCOL REP, V17, P1133; Nunes AR, 2009, ADV EXP MED BIOL, V648, P113, DOI 10.1007/978-90-481-2259-2_13; Ogawa R, 2002, BLOOD, V99, P3390, DOI 10.1182/blood.V99.9.3390; Omori K, 2007, CIRC RES, V100, P309, DOI 10.1161/01.RES.0000256354.95791.f1; Pallis AG, 2009, EUR J CANCER, V45, P2473, DOI 10.1016/j.ejca.2009.06.005; Rossi Antonio, 2009, Curr Drug Discov Technol, V6, P91; Savai R, 2005, INT J ONCOL, V27, P393; Semenza GL, 2006, EXP PHYSIOL, V91, P803, DOI 10.1113/expphysiol.2006.033498; Sowter HM, 2003, CANCER RES, V63, P6130; Swinson DEB, 2006, CLIN LUNG CANCER, V7, P250, DOI 10.3816/CLC.2006.n.002; Timoshenko AV, 2003, EXP CELL RES, V289, P265, DOI 10.1016/S0014-4827(03)00269-6; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Yamanaka Y, 2002, CANCER LETT, V176, P143, DOI 10.1016/S0304-3835(01)00764-9; Zhang LZ, 2008, P NATL ACAD SCI USA, V105, P19532, DOI 10.1073/pnas.0806152105	34	98	102	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1121	1134		10.1038/onc.2012.136	http://dx.doi.org/10.1038/onc.2012.136			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22525277				2022-12-17	WOS:000316428800006
J	Yoon, S; Woo, SU; Kang, JH; Kim, K; Shin, HJ; Gwak, HS; Park, S; Chwae, YJ				Yoon, S.; Woo, S. U.; Kang, J. H.; Kim, K.; Shin, H-J; Gwak, H-S; Park, S.; Chwae, Y-J			NF-kappa B and STAT3 cooperatively induce IL6 in starved cancer cells	ONCOGENE			English	Article						cancer; ER stress; IL6; NF-kappa B; STAT3	ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; ACTIVATES TRANSCRIPTION; INDUCED AUTOPHAGY; NADPH OXIDASE; PATHWAY; BINDING; SURVIVAL; INHIBITION; MECHANISMS	A number of genes involved in tumorigenesis have been known to be controlled by signal transducer and activator of transcription 3 (STAT3) and NF-kappa B, either synergistically or individually. In starved cancer cells, we found that NF-kappa B was activated through endoplasmic reticulum stress signals, which depend on reactive oxygen species, cytosolic calcium and preserved translation of NF-kappa B p65 subunit, but independent of I kappa B alpha serine phosphorylation, thereby resulting in IL6 induction. STAT3 was required for proper induction of IL6 by NF-kappa B. They existed as identical nuclear complexes in proximal IL6 promoters, and STAT3 had critical roles in binding to IL6 promoters as well as nuclear retention of NF-kappa B. The conditioned media from starved cancer cells contained various secretory factors, such as IL6, IL9, VWF (von Willebrand factor), FREM1 (FRAS1 related extracellular matrix 1), SAA1 (serum amyloid A1), SDK1 (sidekick homolog 1) and ADAM12 (ADAM metallopeptidase domain 12), induced by NF-kappa B and STAT3 and promoted clonogenic capacities of cancer cells, and proliferation and migration of human umbilical vein endothelial cells. These results suggest novel survival strategies of cancer cells by which two oncogenic transcriptional factors, NF-kappa B and STAT3, are activated simultaneously by an intrinsic mechanism during stressful conditions of cancer cells, and they cooperatively induce various survival factors. Oncogene (2012) 31, 3467-3481; doi:10.1038/onc.2011.517; published online 21 November 2011	[Yoon, S.; Woo, S. U.; Kang, J. H.; Kim, K.; Shin, H-J; Park, S.; Chwae, Y-J] Ajou Univ, Sch Med, Dept Microbiol, Suwon 443721, Gyeonggi Do, South Korea; [Gwak, H-S] Natl Canc Ctr Korea, Neurooncol Clin, Koyang, South Korea	Ajou University; National Cancer Center - Korea (NCC)	Chwae, YJ (corresponding author), Ajou Univ, Sch Med, Dept Microbiol, San 5 Woncheon Dong, Suwon 443721, Gyeonggi Do, South Korea.	ponggo67@ajou.ac.kr			National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [2011-0005804, 2009-0076174, 2011-0089971]; Korea Science and Engineering Foundation (KOSEF) through the Chronic Inflammatory Disease Research Center (CIDRC) [R13-2003-019]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Korea Science and Engineering Foundation (KOSEF) through the Chronic Inflammatory Disease Research Center (CIDRC)(Korea Science and Engineering Foundation)	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (No. 2011-0005804, No. 2009-0076174, and No. 2011-0089971), and a Korea Science and Engineering Foundation (KOSEF) Grant (R13-2003-019) through the Chronic Inflammatory Disease Research Center (CIDRC). We are grateful to Mogam Biotechnology Research Institute (Yongin, Korea) for providing us with HUVEC and U87MG cell lines. We are very thankful to Professor Kyung-Sup Kim (Yonsei University College of Medicine, Seoul, Korea) and Professor Woon Ki Baek for critical reading and proofreading of the manuscript.	Ba XQ, 2010, J BIOL CHEM, V285, P11596, DOI 10.1074/jbc.M109.076984; Bosco N, 2010, CANCER GENET CYTOGEN, V202, P47, DOI 10.1016/j.cancergencyto.2010.06.008; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Frank David A, 2003, Cancer Treat Res, V115, P267; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Gil-Bazo I, 2003, Rev Med Univ Navarra, V47, P22; Gloire G, 2006, ONCOGENE, V25, P5485, DOI 10.1038/sj.onc.1209542; Gorlach A, 2006, ANTIOXID REDOX SIGN, V8, P1391, DOI 10.1089/ars.2006.8.1391; Goswami R, 2011, J IMMUNOL, V186, P3283, DOI 10.4049/jimmunol.1003049; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Groner B, 2008, SEMIN CELL DEV BIOL, V19, P341, DOI 10.1016/j.semcdb.2008.06.005; Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200; Hu P, 2006, MOL CELL BIOL, V26, P3071, DOI 10.1128/MCB.26.8.3071-3084.2006; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Jacobsen J, 2009, CURR PHARM DESIGN, V15, P2300, DOI 10.2174/138161209788682389; Jiang HY, 2005, BIOCHEM J, V385, P371, DOI 10.1042/BJ20041164; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kang MJ, 2008, GASTROENTEROLOGY, V135, P2030, DOI 10.1053/j.gastro.2008.08.009; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2006, MOL CARCINOGEN, V45, P355, DOI 10.1002/mc.20217; Khabar KSA, 2010, CELL MOL LIFE SCI, V67, P2937, DOI 10.1007/s00018-010-0383-x; Kilberg MS, 2009, TRENDS ENDOCRIN MET, V20, P436, DOI 10.1016/j.tem.2009.05.008; Kitamura M, 2009, ANTIOXID REDOX SIGN, V11, P2353, DOI 10.1089/ARS.2008.2391; Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015; Lee JK, 2007, GASTROENTEROLOGY, V133, P1637, DOI 10.1053/j.gastro.2007.08.022; Li J, 2008, CELL DEATH DIFFER, V15, P1460, DOI 10.1038/cdd.2008.81; Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361; Marciniak SJ, 2006, PHYSIOL REV, V86, P1133, DOI 10.1152/physrev.00015.2006; Mattarollo SR, 2010, NAT IMMUNOL, V11, P981, DOI 10.1038/ni1110-981; Murray PJ, 2007, J IMMUNOL, V178, P2623, DOI 10.4049/jimmunol.178.5.2623; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Pahl HL, 1996, FEBS LETT, V392, P129, DOI 10.1016/0014-5793(96)00800-9; Shang J, 2004, BIOCHEMISTRY-US, V43, P9576, DOI 10.1021/bi049358o; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Smyth I, 2004, P NATL ACAD SCI USA, V101, P13560, DOI 10.1073/pnas.0402760101; Souza V, 2009, TOXICOL LETT, V187, P180, DOI 10.1016/j.toxlet.2009.02.021; Vales LD, 2002, J BIOL CHEM, V277, P42438, DOI 10.1074/jbc.M207363200; Wu TY, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-160; Xiao GT, 2011, AM J CANCER RES, V1, P192; Yang JB, 2007, GENE DEV, V21, P1396, DOI 10.1101/gad.1553707; Yang XR, 2009, INT J CANCER, V125, P2912, DOI 10.1002/ijc.24622; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Ye JP, 1996, MOL CELL BIOL, V16, P4744; Yoon S, 2010, AUTOPHAGY, V6, P1125, DOI 10.4161/auto.6.8.13547; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203	47	98	100	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	29					3467	3481		10.1038/onc.2011.517	http://dx.doi.org/10.1038/onc.2011.517			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	976FN	22105366				2022-12-17	WOS:000306566400007
J	Vichalkovski, A; Gresko, E; Hess, D; Restuccia, DF; Hemmings, BA				Vichalkovski, A.; Gresko, E.; Hess, D.; Restuccia, D. F.; Hemmings, B. A.			PKB/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in response to DNA damage	ONCOGENE			English	Article						PKB/Akt; Twist-1 transcription factor; DNA damage; cancer	PROTEIN-KINASE B/AKT; SAETHRE-CHOTZEN-SYNDROME; BREAST-CANCER CELLS; TUMOR SUPPRESSION; UP-REGULATION; EXPRESSION; METASTASIS; SURVIVAL; RESISTANCE; INVASION	Protein kinase B (PKB/Akt) is ubiquitously expressed in cells. Phosphorylation of its multiple targets in response to various stimuli, including growth factors or cytokines, promotes cell survival and inhibits apoptosis. PKB is upregulated in many different cancers and a significant amount of the enzyme is present in its activated form. Here we show that PKB phosphorylates one of the anti-apoptotic proteins-transcription factor Twist-1 at Ser42. Cells expressing Twist-1 displayed inefficient p53 upregulation in response to DNA damage induced by gamma-irradiation or the genotoxic drug adriamycin. This influenced the activation of p53 target genes such as p21(Waf1) and Bax and led to aberrant cell-cycle regulation and the inhibition of apoptosis. The impaired induction of these p53 effector molecules is likely to be mediated by PKB-dependent phosphorylation of Twist-1 because, unlike the wild-type mutant, the Twist-1 S42A mutant did not confer cell resistance to DNA damage. Moreover, phosphorylation of Twist-1 at Ser42 was shown in vivo in various human cancer tissues, suggesting that this post-translational modi. cation ensures functional activation of Twist-1 after promotion of survival during carcinogenesis. Oncogene (2010) 29, 3554-3565; doi:10.1038/onc.2010.115; published online 19 April 2010	[Vichalkovski, A.; Gresko, E.; Hess, D.; Restuccia, D. F.; Hemmings, B. A.] Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hemmings, BA (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	brian.hemmings@fmi.ch	Restuccia, David/D-7114-2012	Restuccia, David/0000-0001-7131-8065	Novartis Research Foundation; Swiss Cancer League Grant [OCS 01667-02-2005]	Novartis Research Foundation; Swiss Cancer League Grant	We thank S Bichet and A Bogucki for their help with immunohistochemistry and P King for critical comments on the article. This work was supported by the Novartis Research Foundation and the Swiss Cancer League Grant OCS 01667-02-2005 (to EG).	Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; Cai JL, 2005, BIOESSAYS, V27, P1102, DOI 10.1002/bies.20313; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elias MC, 2005, NEOPLASIA, V7, P824, DOI 10.1593/neo.04352; Fayard E, 2005, J CELL SCI, V118, P5675, DOI 10.1242/jcs.02724; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Firulli AB, 2008, CURR MED CHEM, V15, P2641, DOI 10.2174/092986708785908987; Firulli BA, 2005, NAT GENET, V37, P373, DOI 10.1038/ng1525; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; Funato N, 2005, HUM MUTAT, V25, P550, DOI 10.1002/humu.20176; GHOUZZI V, 2001, FEBS LETT, V492, P112; Gitelman I, 1997, DEV BIOL, V189, P205, DOI 10.1006/dbio.1997.8614; Gripp KW, 2000, HUM MUTAT, V15, P150, DOI 10.1002/(SICI)1098-1004(200002)15:2<150::AID-HUMU3>3.0.CO;2-D; Guenou H, 2006, AM J PATHOL, V169, P1303, DOI 10.2353/ajpath.2006.060102; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hayashi M, 2007, J CELL SCI, V120, P1350, DOI 10.1242/jcs.000067; Hess D, 2008, J BIOL CHEM, V283, P7354, DOI 10.1074/jbc.M710251200; Hosono S, 2007, BRIT J CANCER, V96, P314, DOI 10.1038/sj.bjc.6603533; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Kwok WK, 2007, CARCINOGENESIS, V28, P2467, DOI 10.1093/carcin/bgm185; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Kyo S, 2006, HUM PATHOL, V37, P431, DOI 10.1016/j.humpath.2005.12.021; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pham CG, 2007, MOL CELL BIOL, V27, P3920, DOI 10.1128/MCB.01219-06; Puisieux A, 2006, BRIT J CANCER, V94, P13, DOI 10.1038/sj.bjc.6602876; Restuccia DF, 2009, SCIENCE, V325, P1083, DOI 10.1126/science.1179972; Shibata K, 2008, ANN ONCOL, V19, P81, DOI 10.1093/annonc/mdm344; Shiota M, 2008, CANCER RES, V68, P98, DOI 10.1158/0008-5472.CAN-07-2981; Singh S, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-47; Smit MA, 2009, MOL CELL BIOL, V29, P3722, DOI 10.1128/MCB.01164-08; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; Stasinopoulos IA, 2005, J BIOL CHEM, V280, P2294, DOI 10.1074/jbc.M411018200; THISSE B, 1987, NUCLEIC ACIDS RES, V15, P3439, DOI 10.1093/nar/15.8.3439; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; Vichalkovski A, 2008, CURR BIOL, V18, P1889, DOI 10.1016/j.cub.2008.10.060; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yang J, 2006, CANCER RES, V66, P4549, DOI 10.1158/0008-5472.CAN-05-3850; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yoeli-Lerner M, 2006, CELL CYCLE, V5, P603, DOI 10.4161/cc.5.6.2561; Zhang XM, 2007, INT J CANCER, V120, P1891, DOI 10.1002/ijc.22489; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	54	98	104	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	2010	29	24					3554	3565		10.1038/onc.2010.115	http://dx.doi.org/10.1038/onc.2010.115			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20400976				2022-12-17	WOS:000278835400010
J	Shiota, M; Yokomizo, A; Tada, Y; Inokuchi, J; Kashiwagi, E; Masubuchi, D; Eto, M; Uchiumi, T; Naito, S				Shiota, M.; Yokomizo, A.; Tada, Y.; Inokuchi, J.; Kashiwagi, E.; Masubuchi, D.; Eto, M.; Uchiumi, T.; Naito, S.			Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression	ONCOGENE			English	Article						AR; CRPC; oxidative stress; prostate cancer; ROS; Twist1	ANTIOXIDANT ENZYMES; EXPRESSION; DAMAGE; GENE; MUTATIONS; RADIATION; PROTEIN; AGE	There are few successful therapies for castration-resistant prostate cancer (CRPC). Recently, CRPC has been thought to result from augmented androgen/androgen receptor (AR) signaling pathway, for most of which AR overexpression has been observed. In this study, Twist1, a member of basic helix-loop-helix transcription factors as well as AR was upregulated in response to hydrogen peroxide, and the response to which was abolished by an addition of N-acetyl-L-cysteine and Twist1 knockdown. In addition, castration-resistant LNCaP derivatives and hydrogen peroxide-resistant LNCaP derivatives exhibited a similar phenotype to each other. Then, both castration and AR knockdown increased intracellular reactive oxygen species level. Moreover, Twist1 was shown to regulate AR expression through binding to E-boxes in AR promoter region. Silencing of Twist1 suppressed cell growth of AR-expressing LNCaP cells as well as castration-resistant LNCaP derivatives by inducing cell-cycle arrest at G1 phase and cellular apoptosis. These findings indicated that castration-induced oxidative stress may promote AR overexpression through Twist1 overexpression, which could result in a gain of castration resistance. Modulation of castration-induced oxidative stress or Twist1/AR signaling might be a useful strategy for developing a novel therapeutics in prostate cancer, even in CRPC, which remains dependent on AR signaling by overexpressing AR. Oncogene (2010) 29, 237-250; doi:10.1038/onc.2009.322; published online 5 October 2009	[Shiota, M.; Yokomizo, A.; Tada, Y.; Inokuchi, J.; Kashiwagi, E.; Masubuchi, D.; Naito, S.] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Higashi Ku, Fukuoka 8128252, Japan; [Uchiumi, T.] Kyushu Univ, Grad Sch Med Sci, Dept Clin Chem & Lab Med, Fukuoka 8128252, Japan; [Eto, M.] Kumamoto Univ, Grad Sch Med, Dept Urol, Kumamoto, Japan	Kyushu University; Kyushu University; Kumamoto University	Yokomizo, A (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Urol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128252, Japan.	yokoa@uro.med.kyushu-u.ac.jp	Shiota, Masaki/Q-9387-2019; Inokuchi, Junichi/AAO-3297-2020	Inokuchi, Junichi/0000-0002-6791-905X; Shiota, Masaki/0000-0002-3306-4858	Ministry of Health, Labor and Welfare, Japan [016]; Japanese Urological Association, Japan	Ministry of Health, Labor and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); Japanese Urological Association, Japan	This work was supported in part by Health Sciences Research Grants for Clinical Research for evidence-based medicine and grants-in-aid for Cancer Research (016), from the Ministry of Health, Labor and Welfare, Japan, Young Researcher Promotion Grant from the Japanese Urological Association, Japan. We are grateful to Dr Chawnshang Chang for providing the pCMV-AR plasmid. We would like to thank Dr Dongchon Kang (Kyushu University, Fukuoka, Japan) for helping with quantitative real-time PCR and flow cytometry, and Noriko Hakoda, Hitomi Matoba and Seiko Kamori for their technical assistances.	Benz CC, 2008, NAT REV CANCER, V8, P875, DOI 10.1038/nrc2522; Best CJM, 2005, CLIN CANCER RES, V11, P6823, DOI 10.1158/1078-0432.CCR-05-0585; BILLIS A, 1996, J UROL PATHOL, V5, P1; Bostwick DG, 2000, CANCER, V89, P123, DOI 10.1002/1097-0142(20000701)89:1<123::AID-CNCR17>3.0.CO;2-9; Castanon I, 2001, DEVELOPMENT, V128, P3145; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Debes JD, 2002, CANCER LETT, V187, P1, DOI 10.1016/S0304-3835(02)00413-5; Ghatak S, 1996, BIOCHEM BIOPH RES CO, V222, P362, DOI 10.1006/bbrc.1996.0749; Gregory CW, 1998, CANCER RES, V58, P5718; Gronberg H, 2003, LANCET, V361, P859, DOI 10.1016/S0140-6736(03)12713-4; Hakimian P, 2008, BJU INT, V102, P1509, DOI 10.1111/j.1464-410X.2008.07933.x; Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731; Hsing AW, 2001, EPIDEMIOL REV, V23, P3, DOI 10.1093/oxfordjournals.epirev.a000792; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lee DK, 2003, J CLIN ENDOCR METAB, V88, P4043, DOI 10.1210/jc.2003-030261; Linja MJ, 2001, CANCER RES, V61, P3550; Lu T, 2008, EXP CELL RES, V314, P1918, DOI 10.1016/j.yexcr.2008.01.011; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Maynard S, 2009, CARCINOGENESIS, V30, P2, DOI 10.1093/carcin/bgn250; Mitsiades N, 2008, SEMIN ONCOL, V35, P569, DOI 10.1053/j.seminoncol.2008.08.002; Oberley TD, 2000, PROSTATE, V44, P144, DOI 10.1002/1097-0045(20000701)44:2<144::AID-PROS7>3.0.CO;2-G; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Pang ST, 2002, ENDOCRINOLOGY, V143, P4897, DOI 10.1210/en.2002-220327; Patel BJ, 2000, J UROLOGY, V164, P1420, DOI 10.1016/S0022-5347(05)67210-2; Pathak S, 2008, CANCER LETT, V261, P74, DOI 10.1016/j.canlet.2007.11.015; Pinthus JH, 2007, NEOPLASIA, V9, P68, DOI 10.1593/neo.06739; Reddy GPV, 2006, J CELL BIOCHEM, V98, P1408, DOI 10.1002/jcb.20927; Ripple MO, 1997, JNCI-J NATL CANCER I, V89, P40, DOI 10.1093/jnci/89.1.40; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Sakr WA, 1996, EUR UROL, V30, P138; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Shiota M, 2008, ONCOGENE, V27, P5543, DOI 10.1038/onc.2008.176; Shiota M, 2008, CANCER RES, V68, P98, DOI 10.1158/0008-5472.CAN-07-2981; Shiota M, 2009, CANCER RES, V69, P3148, DOI 10.1158/0008-5472.CAN-08-2334; Stasinopoulos IA, 2005, J BIOL CHEM, V280, P2294, DOI 10.1074/jbc.M411018200; Tam NNC, 2003, AM J PATHOL, V163, P2513, DOI 10.1016/S0002-9440(10)63606-1; Taplin ME, 2003, J CLIN ONCOL, V21, P2673, DOI 10.1200/JCO.2003.11.102; Tso CL, 2000, CANCER J, V6, P220; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; van Doorn R, 2004, CANCER RES, V64, P5578, DOI 10.1158/0008-5472.CAN-04-1253; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008	45	98	99	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					237	250		10.1038/onc.2009.322	http://dx.doi.org/10.1038/onc.2009.322			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19802001				2022-12-17	WOS:000273650000007
J	Guo, C; Gasparian, AV; Zhuang, Z; Bosykh, DA; Komar, AA; Gudkov, AV; Gurova, KV				Guo, C.; Gasparian, A. V.; Zhuang, Z.; Bosykh, D. A.; Komar, A. A.; Gudkov, A. V.; Gurova, K. V.			9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappa B and p53 pathways	ONCOGENE			English	Article						proteomics; quinacrine; cell death; PI3 kinase-gamma; PTEN	MESSENGER-RNAS; INFLAMMATION; PI3K-GAMMA; TRANSLATION; INHIBITION; ACTIVATION; MECHANISM; RAPAMYCIN; CELLS; MDM2	Acquisition of a transformed phenotype involves deregulation of several signal transduction pathways contributing to unconstrained cell growth. Understanding the interplay of different cancer-related signaling pathways is important for development of efficacious multitargeted anticancer drugs. The small molecule 9-aminoacridine (9AA) and its derivative, the antimalaria drug quinacrine, have selective toxicity for tumor cells and can simultaneously suppress nuclear factor-kappa B (NF-kappa B) and activate p53 signaling. To investigate the mechanism underlying these drug activities, we used a combination of two-dimensional protein separation by gel electrophoresis and mass spectrometry to identify proteins whose expression is altered in tumor cells by 9AA treatment. We found that 9AA treatment results in selective downregulation of a specific catalytic subunit of the phosphoinositide 3-kinase (PI3K) family, p110 gamma. Further exploration of this observation demonstrated that the mechanism of action of 9AA involves inhibition of the prosurvival AKT/ mammalian target of rapamycin (mTOR) pathway that lies downstream of PI3K. p110 gamma translation appears to be regulated by mTOR and feeds back to further modulate mTOR and AKT, there by impacting the p53 and NF-kappa B pathways as well. These results reveal functional interplay among the PI3K/AKT/mTOR, p53 and NF-kappa B pathways that are frequently deregulated in cancer and suggest that their simultaneous targeting by a single small molecule such as 9AA could result in efficacious and selective killing of transformed cells.	[Gudkov, A. V.; Gurova, K. V.] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; [Guo, C.] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; [Guo, C.] Lerner Res Inst, Dept Mol Genet, Cleveland, OH USA; [Gasparian, A. V.; Bosykh, D. A.; Gudkov, A. V.; Gurova, K. V.] Cleveland Biolabs Inc, Buffalo, NY USA; [Zhuang, Z.] Natl Inst Hlth, Bethesda, MD USA; [Komar, A. A.] Cleveland State Univ, Dept Biol, Ctr Gene Regulat Hlth & Dis, Cleveland, OH 44115 USA	Roswell Park Cancer Institute; Case Western Reserve University; Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; University System of Ohio; Cleveland State University	Gudkov, AV (corresponding author), Roswell Pk Canc Inst, Dept Cell Stress Biol, BLSC L3-301,Elm & Carlton St, Buffalo, NY 14263 USA.	andrei.gudkov@roswellpark.org; katerina.gurova@roswellpark.org		Komar, Anton/0000-0003-4188-0633; Gudkov, Andrei/0000-0003-2548-0154				Bensaad K, 2005, NAT MED, V11, P1278, DOI 10.1038/nm1205-1278; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Furuta M, 2004, ONCOGENE, V23, P6806, DOI 10.1038/sj.onc.1207770; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Gudkov AV, 2005, PROTEIN REV, V2, P225, DOI 10.1007/0-387-30127-5_10; Gurova KV, 2005, P NATL ACAD SCI USA, V102, P17448, DOI 10.1073/pnas.0508888102; Huang SL, 2003, CANCER BIOL THER, V2, P222, DOI 10.4161/cbt.2.3.360; Jeong SJ, 2005, ONCOGENE, V24, P6719, DOI 10.1038/sj.onc.1208825; Jung KJ, 2008, J VIROL, V82, P8537, DOI 10.1128/JVI.00690-08; Kang S, 2006, P NATL ACAD SCI USA, V103, P1289, DOI 10.1073/pnas.0510772103; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Komar AA, 2005, J BIOL CHEM, V280, P23425, DOI 10.1074/jbc.R400041200; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Okamoto H, 2007, CANCER BIOL THER, V6, P391, DOI 10.4161/cbt.6.3.3731; Ozes ON, 1999, NATURE, V401, P82; Rommel C, 2007, NAT REV IMMUNOL, V7, P191, DOI 10.1038/nri2036; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STONE KL, 1993, PRACTICAL GUIDE PROT; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Yamboliev IA, 2000, AM J PHYSIOL-CELL PH, V279, pC352, DOI 10.1152/ajpcell.2000.279.2.C352	29	98	102	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	8					1151	1161		10.1038/onc.2008.460	http://dx.doi.org/10.1038/onc.2008.460			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19137016				2022-12-17	WOS:000263722900010
J	Mazan-Mamczarz, K; Hagner, PR; Corl, S; Srikantan, S; Wood, WH; Becker, KG; Gorospe, M; Keene, JD; Levenson, AS; Gartenhaus, RB				Mazan-Mamczarz, K.; Hagner, P. R.; Corl, S.; Srikantan, S.; Wood, W. H.; Becker, K. G.; Gorospe, M.; Keene, J. D.; Levenson, A. S.; Gartenhaus, R. B.			Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype	ONCOGENE			English	Article						post-transcriptional operon; MCT-1 oncogene; TSP1; HuR; RNA-binding protein; tumor angiogenesis	BINDING PROTEIN HUR; RNA-STABILITY FACTOR; MESSENGER-RNA; RIBONUCLEOPROTEIN COMPLEXES; TRANSLATIONAL REPRESSION; EXPRESSION; RICH; REGION; STABILIZATION; TRANSLOCATION	In a breast tumor xenograft model, the MCT-1 oncogene increases the in vivo tumorgenicity of MCF7 cells by promoting angiogenesis and inhibiting apoptosis. Increases in the tumor microvascular density are accompanied by a strong reduction in the levels of the angiogenesis inhibitor thrombospondin-1 (TSP1), but the mechanisms underlying this process are unknown. We show that TSP1 expression is controlled, at least in part, by post-transcriptional events. Using RNA interference to knock down the expression of the RNA-binding protein HuR in MCF7 cells as well as HuR overexpression, we demonstrate that HuR plays an important role in translation of the TSP1 mRNA. Furthermore, employing the RIP-Chip assay yielded 595 transcripts with significantly altered binding to HuR in the more tumorigenic breast cancer clones compared with the weakly tumorigenic clones. These mRNAs clustered in several pathways implicated in the transformed phenotype, such as the RAS pathway (involved in mitogenesis), the PI3K pathway (evasion of apoptosis) and pathways mediating angiogenesis and the cellular response to hypoxia. These findings demonstrate for the first time that global changes in HuR-bound mRNAs are implicated in the evolution to a more tumorigenic phenotype in an in vivo tumor model and underscore the role of global mRNA-protein interactions toward tumor progression.	[Mazan-Mamczarz, K.; Hagner, P. R.; Corl, S.; Gartenhaus, R. B.] Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA; [Srikantan, S.; Gorospe, M.] NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA; [Wood, W. H.; Becker, K. G.] NIA, Gene Express & Genom Unit, NIH, Baltimore, MD 21224 USA; [Keene, J. D.] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC USA; [Levenson, A. S.] Northwestern Univ, Dept Urol, Feinberg Sch Med, Chicago, IL 60611 USA; [Levenson, A. S.] Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Duke University; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Robert H. Lurie Comprehensive Cancer Center	Gartenhaus, RB (corresponding author), Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, 9-011 BRB,655 W Baltimore St,22 S Greene St, Baltimore, MD 21201 USA.	rgartenhaus@som.umaryland.edu	, Jack/L-6806-2019	srikantan, subramanya/0000-0003-1810-6519; Becker, Kevin/0000-0002-6794-6656	National Institute on Aging Intramural Research Program; NIH; NATIONAL INSTITUTE ON AGING [Z01AG000392, ZICAG000616, Z01AG000511, ZIAAG000511, Z01AG000616, ZIAAG000392] Funding Source: NIH RePORTER	National Institute on Aging Intramural Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Dr Y Zhang for assistance with the statistical analysis of the RIP-Chip array data and Dr J Hasday for technical support. A Merit Review Award from the Department of Veterans Affairs to RBG supported this work. MG and SS were supported by the National Institute on Aging Intramural Research Program, NIH.	Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; AGHIB DF, 1990, ONCOGENE, V5, P707; Akool ES, 2003, MOL CELL BIOL, V23, P4901, DOI 10.1128/MCB.23.14.4901-4916.2003; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985; Cheadle C, 2003, J MOL DIAGN, V5, P73, DOI 10.1016/S1525-1578(10)60455-2; De Silanes IL, 2004, GENE EXPRESSION, V12, P49, DOI 10.3727/000000004783992215; Galban S, 2003, MOL CELL BIOL, V23, P7083, DOI 10.1128/MCB.23.20.7083-7095.2003; Galban S, 2008, MOL CELL BIOL, V28, P93, DOI 10.1128/MCB.00973-07; Gorospe M, 2003, CELL CYCLE, V2, P412, DOI 10.4161/cc.2.5.491; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HOLLIS GF, 1988, MOL CELL BIOL, V8, P124, DOI 10.1128/MCB.8.1.124; Katsanou V, 2005, MOL CELL, V19, P777, DOI 10.1016/j.molcel.2005.08.007; Kawai T, 2006, MOL CELL BIOL, V26, P3295, DOI 10.1128/MCB.26.8.3295-3307.2006; Keene JD, 2007, NAT REV GENET, V8, P533, DOI 10.1038/nrg2111; Keene JD, 2006, NAT PROTOC, V1, P302, DOI 10.1038/nprot.2006.47; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Keene JD, 2001, P NATL ACAD SCI USA, V98, P7018, DOI 10.1073/pnas.111145598; Kim HS, 2007, MOL CELL BIOL, V27, P6806, DOI 10.1128/MCB.01036-07; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; Lal A, 2005, EMBO J, V24, P1852, DOI 10.1038/sj.emboj.7600661; Lal A, 2006, MOL CELL, V22, P117, DOI 10.1016/j.molcel.2006.03.016; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Leandersson K, 2006, NUCLEIC ACIDS RES, V34, P3988, DOI 10.1093/nar/gkl571; Levenson AS, 2005, CANCER RES, V65, P10651, DOI 10.1158/0008-5472.CAN-05-0845; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Liao BS, 2007, NAT STRUCT MOL BIOL, V14, P511, DOI 10.1038/nsmb1249; Lopez de Silanes I., 2005, RNA BIOL, V2, P11, DOI DOI 10.4161/RNA.2.1.1552; Mazan-Mamczarz K, 2006, MOL CELL BIOL, V26, P2716, DOI 10.1128/MCB.26.7.2716-2727.2006; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; Meng Z, 2005, NUCLEIC ACIDS RES, V33, P2962, DOI 10.1093/nar/gki603; Millard SS, 2000, MOL CELL BIOL, V20, P5947, DOI 10.1128/MCB.20.16.5947-5959.2000; Nabors LB, 2001, CANCER RES, V61, P2154; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Prosniak M, 1998, CANCER RES, V58, P4233; Pullmann R, 2007, MOL CELL BIOL, V27, P6265, DOI 10.1128/MCB.00500-07; Ren B, 2006, BBA-REV CANCER, V1765, P178, DOI 10.1016/j.bbcan.2005.11.002; Sheflin LG, 2004, BIOCHEM BIOPH RES CO, V322, P644, DOI 10.1016/j.bbrc.2004.07.173; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; WANG RK, 2000, P SOC PHOTO-OPT INS, V1, P12; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Weidner N, 1998, J PATHOL, V184, P119, DOI 10.1002/(SICI)1096-9896(199802)184:2<119::AID-PATH17>3.0.CO;2-D; Wilusz CJ, 2004, TRENDS GENET, V20, P491, DOI 10.1016/j.tig.2004.07.011; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209	49	98	102	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	47					6151	6163		10.1038/onc.2008.215	http://dx.doi.org/10.1038/onc.2008.215			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18641687	Green Accepted			2022-12-17	WOS:000260083100008
J	O'Neil, J; Look, AT				O'Neil, J.; Look, A. T.			Mechanisms of transcription factor deregulation in lymphoid cell transformation	ONCOGENE			English	Review						TAL1; NOTCH; PAX5; MLL; E2A; TEL-AML1	ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING DOMAIN; C-MYC ONCOGENE; SITE-SPECIFIC DELETIONS; LIM-PROTEIN RBTN2; T-CELL; CHROMOSOMAL TRANSLOCATIONS; BURKITT-LYMPHOMA; HOMEOBOX GENE; NOTCH1 MUTATIONS	The most frequent targets of genetic alterations in human lymphoid leukemias are transcription factor genes with essential functions in blood cell development. TAL1, LYL1, HOX11 and other transcription factors essential for normal hematopoiesis are often misexpressed in the thymus in T- cell acute lymphoblastic leukemia ( T- ALL), leading to differentiation arrest and cell transformation. Recent advances in the ability to assess DNA copy number have led to the discovery that the MYB transcription factor oncogene is tandemly duplicated in T- ALL. The NOTCH1 gene, which is essential for key embryonic cell-fate decisions in multicellular organisms, was found to be activated by mutation in a large percentage of T- ALL patients. The gene encoding the FBW7 protein ubiquitin ligase, which regulates the turnover of the intracellular form of NOTCH ( ICN), is also mutated in T- ALL, resulting in stabilization of the ICN and activation of the NOTCH signaling pathway. In mature B- lineage ALL and Burkitt lymphoma, the MYC transcription factor oncogene is overexpressed due to translocation into the IG locus. PAX5, a transcription factor essential for B- lineage commitment, is inactivated in 32% of cases of B- progenitor ALL. Translocations resulting in oncogenic fusion transcription factors also occur frequently in this form of ALL. The most frequent transcription factor chimeric fusion, TEL- AML1, is an initiating event in B- progenitor ALL that acts by repressing transcription. Therefore, deregulated transcription and its consequent effects on key developmental pathways play a major role in the molecular pathogenesis of lymphoid malignancy. Once the full complement of cooperating mutations in transformed B- and T- progenitor cells is known, and the deregulated downstream pathways have been elucidated, it will be possible to identify vulnerable components and to target them with small- molecule inhibitors.	Harvard Univ, Sch Med, Dept Pediat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Look, AT (corresponding author), Harvard Univ, Sch Med, Dept Pediat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.	Thomas_Look@dfci.harvard.edu			NCI NIH HHS [CA109901] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA109901] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; Andreasson P, 2001, CANCER GENET CYTOGEN, V130, P93, DOI 10.1016/S0165-4608(01)00518-0; APLAN PD, 1992, BLOOD, V79, P1327; APLAN PD, 1991, MOL CELL BIOL, V11, P5462, DOI 10.1128/MCB.11.11.5462; Armstrong SA, 2005, J CLIN ONCOL, V23, P6306, DOI 10.1200/JCO.2005.05.047; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; ARNOLD A, 1983, NEW ENGL J MED, V309, P1593, DOI 10.1056/NEJM198312293092601; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Badiani PA, 1996, ONCOGENE, V13, P2205; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; Ballerini P, 2002, BLOOD, V100, P991, DOI 10.1182/blood-2001-11-0093; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; Berger R, 2003, LEUKEMIA, V17, P1851, DOI 10.1038/sj.leu.2403061; BERNARD O, 1991, ONCOGENE, V6, P1477; Bernard OA, 2001, LEUKEMIA, V15, P1495, DOI 10.1038/sj.leu.2402249; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Bousquet M, 2007, BLOOD, V109, P3417, DOI 10.1182/blood-2006-05-025221; BREIT TM, 1993, J EXP MED, V177, P965, DOI 10.1084/jem.177.4.965; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; Cave H, 1997, LEUKEMIA, V11, P1459, DOI 10.1038/sj.leu.2400798; Chan SM, 2007, BLOOD, V110, P278, DOI 10.1182/blood-2006-08-039883; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; Clappier E, 2007, BLOOD, V110, P1251, DOI 10.1182/blood-2006-12-064683; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; Cobaleda C, 2007, NAT IMMUNOL, V8, P463, DOI 10.1038/ni1454; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; CROCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P6922, DOI 10.1073/pnas.80.22.6922; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DEAR TN, 1995, DEVELOPMENT, V121, P2909; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; Drynan LF, 2005, EMBO J, V24, P3136, DOI 10.1038/sj.emboj.7600760; DUBE ID, 1991, BLOOD, V78, P2996; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; EMANUEL BS, 1984, P NATL ACAD SCI-BIOL, V81, P2444, DOI 10.1073/pnas.81.8.2444; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P7581, DOI 10.1073/pnas.80.24.7581; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Ferrando AA, 2000, SEMIN HEMATOL, V37, P381, DOI 10.1053/shem.2000.16447; Ferrando AA, 2004, BLOOD, V103, P1909, DOI 10.1182/blood-2003-07-2577; Ferrando AA, 2003, SEMIN HEMATOL, V40, P274, DOI 10.1016/S0037-1963(03)00195-1; Ferrando AA, 2003, BLOOD, V102, P262, DOI 10.1182/blood-2002-10-3221; FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692; FISCH P, 1992, ONCOGENE, V7, P2389; Forster A, 2003, CANCER CELL, V3, P449, DOI 10.1016/S1535-6108(03)00106-5; Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; HOLLIS GF, 1984, NATURE, V307, P752, DOI 10.1038/307752a0; Hsu K, 2003, CANCER CELL, V4, P81, DOI 10.1016/S1535-6108(03)00192-2; Hunger SP, 1996, BLOOD, V87, P1211, DOI 10.1182/blood.V87.4.1211.bloodjournal8741211; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; Inoue A, 2002, CANCER CELL, V2, P279, DOI 10.1016/S1535-6108(02)00155-1; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kees UR, 2003, LEUKEMIA, V17, P887, DOI 10.1038/sj.leu.2402892; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; Lahortiga I, 2007, NAT GENET, V39, P593, DOI 10.1038/ng2025; LARSON RC, 1995, ONCOGENE, V11, P853; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LARSON RC, 1994, ONCOGENE, V9, P3675; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; LEBRUN DP, 1994, ONCOGENE, V9, P1641; Lewis HD, 2007, CHEM BIOL, V14, P209, DOI 10.1016/j.chembiol.2006.12.010; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lin YW, 2006, BLOOD, V107, P2540, DOI 10.1182/blood-2005-07-3013; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; LU QA, 1995, MOL CELL BIOL, V15, P3786; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Malecki MJ, 2006, MOL CELL BIOL, V26, P4642, DOI 10.1128/MCB.01655-05; Malyukova A, 2007, CANCER RES, V67, P5611, DOI 10.1158/0008-5472.CAN-06-4381; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; Mauvieux L, 2002, LEUKEMIA, V16, P2417, DOI 10.1038/sj.leu.2402709; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MCKEITHAN TW, 1986, P NATL ACAD SCI USA, V83, P6636, DOI 10.1073/pnas.83.17.6636; McLean TW, 1996, BLOOD, V88, P4252; MELLENTIN JD, 1990, GENE CHROMOSOME CANC, V2, P239, DOI 10.1002/gcc.2870020313; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; Metzler M, 2006, ONCOGENE, V25, P3093, DOI 10.1038/sj.onc.1209636; Metzstein MM, 1999, MOL CELL, V4, P309, DOI 10.1016/S1097-2765(00)80333-0; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; Mikkola HKA, 2003, NATURE, V421, P547, DOI 10.1038/nature01345; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; Morrow M, 2007, ONCOGENE, V26, P4404, DOI 10.1038/sj.onc.1210227; Morrow M, 2004, BLOOD, V103, P3890, DOI 10.1182/blood-2003-10-3695; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; NEALE GAM, 1995, BLOOD, V86, P3060; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; O'Neil J, 2006, BLOOD, V107, P781, DOI 10.1182/blood-2005-06-2553; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; O'Neil J, 2001, ONCOGENE, V20, P3897, DOI 10.1038/sj.onc.1204519; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Owens BM, 2006, BRIT J HAEMATOL, V132, P216, DOI 10.1111/j.1365-2141.2005.05850.x; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Pearson R, 2000, EMBO J, V19, P6112, DOI 10.1093/emboj/19.22.6112; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Radtke F, 2004, NAT IMMUNOL, V5, P247, DOI 10.1038/ni1045; RAJU K, 1993, MECH DEVELOP, V44, P51, DOI 10.1016/0925-4773(93)90016-Q; RAPPOLD GA, 1984, EMBO J, V3, P2951, DOI 10.1002/j.1460-2075.1984.tb02239.x; REEVES R, 1990, J BIOL CHEM, V265, P8573; Riz I, 2005, ONCOGENE, V24, P5561, DOI 10.1038/sj.onc.1208727; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; ROBERTS CWM, 1995, AM J PATHOL, V146, P1089; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; Sabaawy HE, 2006, P NATL ACAD SCI USA, V103, P15166, DOI 10.1073/pnas.0603349103; SCHILLINGER M, 1993, MED MICROBIOL LETT, V2, P296; Sharma VM, 2006, MOL CELL BIOL, V26, P8022, DOI 10.1128/MCB.01091-06; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; SHIMA EA, 1986, P NATL ACAD SCI USA, V83, P3439, DOI 10.1073/pnas.83.10.3439; Shirasawa S, 2000, NAT GENET, V24, P287, DOI 10.1038/73516; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; Soulier J, 2005, BLOOD, V106, P274, DOI 10.1182/blood-2004-10-3900; Takeuchi S, 1997, LEUKEMIA, V11, P1220, DOI 10.1038/sj.leu.2400743; TAUB R, 1984, CELL, V37, P511, DOI 10.1016/0092-8674(84)90381-7; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Thompson CB, 1996, NATURE, V382, P492, DOI 10.1038/382492a0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Tsuzuki S, 2004, P NATL ACAD SCI USA, V101, P8443, DOI 10.1073/pnas.0402063101; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Van Rompaey L, 2000, ONCOGENE, V19, P5244, DOI 10.1038/sj.onc.1203899; Van Vlierberghe P, 2006, BLOOD, V108, P3520, DOI 10.1182/blood-2006-04-019927; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1995, MECH DEVELOP, V52, P99, DOI 10.1016/0925-4773(95)00394-G; Vilimas T, 2007, NAT MED, V13, P70, DOI 10.1038/nm1524; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WALDMANN TA, 1985, NEW ENGL J MED, V313, P776, DOI 10.1056/NEJM198509263131303; Wang JJ, 2000, P NATL ACAD SCI USA, V97, P3497, DOI 10.1073/pnas.97.7.3497; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wilson A, 2006, FEBS LETT, V580, P2860, DOI 10.1016/j.febslet.2006.03.024; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; YOSHIHARA T, 1995, MOL CELL BIOL, V15, P3247; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; Zeisig BB, 2003, ONCOGENE, V22, P1629, DOI 10.1038/sj.onc.1206104; Zhu YM, 2006, CLIN CANCER RES, V12, P3043, DOI 10.1158/1078-0432.CCR-05-2832; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	170	98	98	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6838	6849		10.1038/sj.onc.1210766	http://dx.doi.org/10.1038/sj.onc.1210766			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934490				2022-12-17	WOS:000250147000014
J	Allen, NPC; Donninger, H; Vos, MD; Eckfeld, K; Hesson, L; Gordon, L; Birrer, MJ; Latif, F; Clark, GJ				Allen, N. P. C.; Donninger, H.; Vos, M. D.; Eckfeld, K.; Hesson, L.; Gordon, L.; Birrer, M. J.; Latif, F.; Clark, G. J.			RASSF6 is a novel member of the RASSF family of tumor suppressors	ONCOGENE			English	Article						Ras; RASSF6; tumor suppressor	NF-KAPPA-B; EPIGENETIC INACTIVATION; EFFECTOR; ACTIVATION; GENE; ASSOCIATION; PROTEIN; NORE1; SUSCEPTIBILITY; IDENTIFICATION	RASSF family proteins are tumor suppressors that are frequently downregulated during the development of human cancer. The best-characterizedmember of the family is RASSF1A, which is downregulated by promoter methylation in 40-90% of primary human tumors. We now identify and characterize a novel member of the RASSF family, RASSF6. Like the other family members, RASSF6 possesses a Ras Association domain and binds activated Ras. Exogenous expression of RASSF6 promotedapoptosis, synergized with activated K-Ras to induce cell death and inhibited the survival of specific tumor cell lines. Suppression of RASSF6 enhanced the tumorigenic phenotype of a human lung tumor cell line. Furthermore, RASSF6 is often downregulated in primary human tumors. RASSF6 shares some similar overall properties as other RASSF proteins. However, there are significant differences in biological activity between RASSF6 and other family members including a discrete tissue expression pro. le, cell killing specificity and impact on signaling pathways. Moreover, RASSF6 may play a role in dictating the degree of in. ammatory response to the respiratory syncytial virus. Thus, RASSF6 is a novel RASSF family member that demonstrates the properties of a Ras effector and tumor suppressor but exhibits biological properties that are unique and distinct from those of other family members.	Natl Canc Inst, Dept Cell Canc Biol, Rockville, MD USA; Univ Louisville, JG Brown Canc Ctr, Dept Med, Mol Targets Grp, Louisville, KY USA; Univ Birmingham, Med Sect Mol Genet, Birmingham, W Midlands, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Louisville; University of Birmingham	Clark, GJ (corresponding author), Univ Louisville, Dept Med, Targets Grp, 580 S Preston Str, Louisville, KY 40202 USA.	gjclar01@louisville.edu	Hesson, Luke/HDM-0311-2022; Donninger, Howard/I-9874-2019	Donninger, Howard/0000-0002-8589-1660	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018733] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCRR NIH HHS [RR018733] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Akino K, 2005, GASTROENTEROLOGY, V129, P156, DOI 10.1053/j.gastro.2005.03.051; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Bitko V, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-28; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Chen JD, 2003, CANCER CELL, V4, P405, DOI 10.1016/S1535-6108(03)00269-1; Clark GJ, 1996, P NATL ACAD SCI USA, V93, P1577, DOI 10.1073/pnas.93.4.1577; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Diep CB, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-6; Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065; Ellis CA, 2002, P NATL ACAD SCI USA, V99, P9876, DOI 10.1073/pnas.142193799; Feig LA, 2002, CURR BIOL, V12, pR259, DOI 10.1016/S0960-9822(02)00787-X; Fiordalisi JJ, 2001, METHOD ENZYMOL, V332, P3; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Hull J, 2004, HUM GENET, V114, P272, DOI 10.1007/s00439-003-1038-x; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Nicke B, 2005, MOL CELL, V20, P673, DOI 10.1016/j.molcel.2005.10.038; Okada T, 1996, J BIOL CHEM, V271, P4671; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Smyth RL, 2006, LANCET, V368, P312, DOI 10.1016/S0140-6736(06)69077-6; SOLSKI PA, 1995, METHOD ENZYMOL, V250, P435; Tommasi S, 2005, CANCER RES, V65, P92; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Vos MD, 2006, J BIOL CHEM, V281, P4557, DOI 10.1074/jbc.M512128200; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200	39	98	108	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6203	6211		10.1038/sj.onc.1210440	http://dx.doi.org/10.1038/sj.onc.1210440			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17404571				2022-12-17	WOS:000249401300011
J	Tomlinson, D; Hurst, CD; Knowles, MA				Tomlinson, D. C.; Hurst, C. D.; Knowles, M. A.			Knockdown by shRNA identifes S249C mutant FGFR3 as a potential therapeutic target in bladder cancer	ONCOGENE			English	Article						FGFR3; urothelial cell carcinoma; shRNA; therapeutic target	GROWTH-FACTOR RECEPTOR-3; UROTHELIAL CELL-CARCINOMA; MULTIPLE-MYELOMA PATIENTS; ACTIVATING MUTATIONS; GENE-MUTATIONS; TUMOR PROGRESSION; STAT ACTIVATION; LOW-GRADE; EXPRESSION; PROLIFERATION	More than 60% of low-grade non-invasive papillary urothelial cell carcinomas contain activating point mutations of fibroblast growth factor receptor 3 ( FGFR3). The phenotypic consequences of constitutive activation of FGFR3 in bladder cancer have not been elucidated and further studies are required to con. firm the consequences of inhibiting receptor activity in urothelial cells. We measured FGFR3 transcript levels and demonstrated that transcript levels were significantly more abundant in low-stage and grade tumours. We identified a tumour cell line, 97-7, expressing the most common FGFR3 mutation ( S249C) at similar FGFR3 transcript levels to low-stage and grade tumours. In these cells, S249C FGFR3 protein formed stable homodimers and was constitutively phosphorylated. We used retrovirus-mediated delivery of shRNA to knockdown S249C FGFR3. This induced cell. flattening, decreased cell proliferation and reduced clonogenicity on plastic and in soft agar. However, no effects of knockdown of wild-type FGFR3 were observed in telomerase immortalized normal human urothelial cells, indicating possible dependence of the tumour cell line on mutant FGFR3. Re-expression of S249C FGFR3 in shRNA-expressing 97-7 cells resulted in a reversal of phenotypic changes, con. firming the specificity of the shRNA. These results indicate that targeted inhibition of S249C FGFR3 may represent a useful therapeutic approach in superficial bladder cancer.	St James Univ Hosp, Leeds Inst Mol Med, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital; University of Leeds	Knowles, MA (corresponding author), St James Univ Hosp, Leeds Inst Mol Med, Canc Res UK Clin Ctr, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	margaret.knowles@cancer.org.uk		Knowles, Margaret/0000-0002-9363-8657; Tomlinson, Darren/0000-0003-4134-7484	Cancer Research UK [A5433] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Adar R, 2002, J BONE MINER RES, V17, P860, DOI 10.1359/jbmr.2002.17.5.860; Bakkar AA, 2003, CANCER RES, V63, P8108; Bernard-Pierrot I, 2006, CARCINOGENESIS, V27, P740, DOI 10.1093/carcin/bgi290; Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chapman EJ, 2006, ONCOGENE, V25, P5037, DOI 10.1038/sj.onc.1209513; Chen J, 2005, ONCOGENE, V24, P8259, DOI 10.1038/sj.onc.1208989; Chesi M, 2002, CURR OPIN HEMATOL, V9, P288, DOI 10.1097/00062752-200207000-00005; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Davies-Adetugbo AA, 1998, TROP MED INT HEALTH, V3, P9, DOI 10.1046/j.1365-3156.1998.00162.x; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Gomez-Roman JJ, 2005, CLIN CANCER RES, V11, P459; Grand EK, 2004, LEUKEMIA, V18, P962, DOI 10.1038/sj.leu.2403347; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; Hart KC, 2001, MOL BIOL CELL, V12, P931, DOI 10.1091/mbc.12.4.931; HOLMANG S, 1995, J UROLOGY, V153, P1823, DOI 10.1016/S0022-5347(01)67321-X; HOLMANG S, 1995, J UROLOGY, V153, P1826; Intini D, 2001, BRIT J HAEMATOL, V114, P362, DOI 10.1046/j.1365-2141.2001.02957.x; Jebar AH, 2005, ONCOGENE, V24, P5218, DOI 10.1038/sj.onc.1208705; Keats JJ, 2005, BLOOD, V105, P4060, DOI 10.1182/blood-2004-09-3704; Kimura T, 2001, CANCER-AM CANCER SOC, V92, P2555, DOI 10.1002/1097-0142(20011115)92:10<2555::AID-CNCR1607>3.0.CO;2-M; Knowles MA, 2006, CARCINOGENESIS, V27, P361, DOI 10.1093/carcin/bgi310; KURTH KH, 1995, EUR J CANCER, V31A, P1840, DOI 10.1016/0959-8049(95)00287-S; Logie A, 2005, HUM MOL GENET, V14, P1153, DOI 10.1093/hmg/ddi127; Martinez-Torrecuadrada JM, 2005, CLIN CANCER RES, V11, P6280, DOI 10.1158/1078-0432.CCR-05-0282; Matsukura S, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng077; Matsumoto M, 2004, ONCOL REP, V12, P967; Mhawrech-Fauceglia P, 2006, EJSO-EUR J SURG ONC, V32, P231, DOI 10.1016/j.ejso.2005.11.018; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Paterson JL, 2004, BRIT J HAEMATOL, V124, P595, DOI 10.1111/j.1365-2141.2004.04814.x; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Ronchetti D, 2001, ONCOGENE, V20, P3553, DOI 10.1038/sj.onc.1204465; Sarkar S, 2000, CANCER RES, V60, P3862; Sibley K, 2000, GENE CHROMOSOME CANC, V29, P378, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1045>3.0.CO;2-K; SOUTHGATE J, 1994, LAB INVEST, V71, P583; Strausberg RL, 2004, NATURE, V429, P469, DOI 10.1038/nature02627; Tomlinson DC, 2005, CANCER RES, V65, P10441, DOI 10.1158/0008-5472.CAN-05-1718; Trudel S, 2005, BLOOD, V105, P2941, DOI 10.1182/blood-2004-10-3913; Trudel S, 2004, BLOOD, V103, P3521, DOI 10.1182/blood-2003-10-3650; Trudel S, 2006, BLOOD, V107, P4039, DOI 10.1182/blood-2005-10-4179; van Rhijn BWG, 2001, CANCER RES, V61, P1265; van Rhijn BWG, 2003, CLIN CANCER RES, V9, P257; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697; Zhu LJ, 2005, MOL CANCER THER, V4, P787, DOI 10.1158/1535-7163.MCT-04-0330	52	98	126	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2007	26	40					5889	5899		10.1038/sj.onc.1210399	http://dx.doi.org/10.1038/sj.onc.1210399			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17384684	Green Accepted			2022-12-17	WOS:000249123100006
J	Yemelyanov, A; Czwornog, J; Chebotaev, D; Karseladze, A; Kulevitch, E; Yang, X; Budunova, I				Yemelyanov, A.; Czwornog, J.; Chebotaev, D.; Karseladze, A.; Kulevitch, E.; Yang, X.; Budunova, I.			Tumor suppressor activity of glucocorticoid receptor in the prostate	ONCOGENE			English	Article						prostate carcinoma; PIN; glucocorticoid receptor; PC marker; transcription factor; MAPKs	METHYLACYL-COA RACEMASE; ANDROGEN RECEPTOR; DIFFERENTIAL EXPRESSION; MOLECULAR-MECHANISMS; CANCER; APOPTOSIS; PATHWAY; KINASE; GROWTH; DEXAMETHASONE	Glucocorticoids are extensively used in combination chemotherapy of advanced prostate cancer (PC). Little is known, however, about the status of the glucocorticoid receptor (GR) in PC. We evaluated over 200 prostate samples and determined that GR expression was strongly decreased or absent in 70 - 85% of PC. Similar to PC tumors, some PC cell lines, including LNCaP, also lack GR. To understand the role of GR, we reconstituted its expression in LNCaP cells using lentiviral approach. Treatment of LNCaP-GR cells with the glucocorticoids strongly inhibited proliferation in the monolayer cultures and blocked anchorage-independent growth. This was accompanied by upregulation of p21 and p27, downregulation of cyclin D1 expression and c-Myc phosphorylation. Importantly, the activation of GR resulted in normalized expression of PC markers hepsin, AMACR, and maspin. On the signaling level, GR decreased expression and inhibited activity of the MAP-kinases (MAPKs) including p38, JNK/SAPK, Mek1/2 and Erk1/2. We also found that activation of GR inhibited activity of numerous transcription factors (TF) including AP-1, SRF, NF-kappa B, p53, ATF-2, CEBP alpha, Ets-1, Elk-1, STAT1 and others, many of which are regulated via MAPK cascade. The structural analysis of hepsin and AMACR promoters provided the mechanistic rationale for PC marker downregulation by glucocorticoids via inhibition of specific TFs. Our data suggest that GR functions as a tumor suppressor in prostate, and inhibits multiple signaling pathways and transcriptional factors involved in proliferation and transformation.	Northwestern Univ, Feinberg Med Sch, Dept Dermatol, Chicago, IL 60611 USA; Russian Acad Med Sci, NN Blokhin Canc Res Ctr, Dept Pathol, Moscow, Russia; Northwestern Univ, Feinberg Med Sch, Dept Pathol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; N.N. Blokhin Russian Cancer Research Center; Russian Academy of Medical Sciences; Northwestern University; Feinberg School of Medicine	Budunova, I (corresponding author), Northwestern Univ, Feinberg Med Sch, Dept Dermatol, Ward Bldg 9-332,303 E Chicago Ave, Chicago, IL 60611 USA.	i_budunova@northwestern.edu						Ananthanarayanan V, 2005, PROSTATE, V63, P341, DOI 10.1002/pros.20196; Bourcier T, 2000, INVEST OPHTH VIS SCI, V41, P4133; Bruna A, 2003, EMBO J, V22, P6035, DOI 10.1093/emboj/cdg590; Budunova IV, 1997, MOL CARCINOGEN, V18, P177, DOI 10.1002/(SICI)1098-2744(199703)18:3<177::AID-MC7>3.3.CO;2-U; Chen ZX, 2003, J UROLOGY, V169, P1316, DOI 10.1097/01.ju.0000050648.40164.0d; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Fakih M, 2002, UROLOGY, V60, P553, DOI 10.1016/S0090-4295(02)01741-7; Fixemer T, 2003, PROSTATE, V54, P79, DOI 10.1002/pros.10171; Gioeli D, 2006, MOL ENDOCRINOL, V20, P503, DOI 10.1210/me.2005-0351; Greenberg AK, 2002, AM J RESP CELL MOL, V27, P320, DOI 10.1165/rcmb.4710; Greenstein S, 2002, CLIN CANCER RES, V8, P1681; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Jiang X, 2004, J BIOL CHEM, V279, P38480, DOI 10.1074/jbc.M403948200; Jiang Z, 2004, ADV ANAT PATHOL, V11, P316, DOI 10.1097/01.pap.0000146924.14246.be; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Klezovitch O, 2004, CANCER CELL, V6, P185, DOI 10.1016/j.ccr.2004.07.008; Koutsilieris M, 2002, EXPERT OPIN INV DRUG, V11, P283; Li CL, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 1, P172; Maroni Paul D, 2004, Cell Commun Signal, V2, P5, DOI 10.1186/1478-811X-2-5; Mimeault M, 2003, GROWTH FACTORS, V21, P1, DOI 10.1080/0897719031000094921; Mohler JL, 1996, CLIN CANCER RES, V2, P889; Necela Brian M, 2004, Proc Am Thorac Soc, V1, P239, DOI 10.1513/pats.200402-005MS; Nishimura K, 2001, J NATL CANCER I, V93, P1739, DOI 10.1093/jnci/93.22.1739; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; Quinn DI, 2005, EUR J CANCER, V41, P858, DOI 10.1016/j.ejca.2004.12.035; Ray DW, 1996, J ENDOCRINOL, V149, P1, DOI 10.1677/joe.0.1490001; Ricote M, 2006, J PATHOL, V208, P401, DOI 10.1002/path.1910; ROSENBERG I, 1996, PROTEIN ANAL PURIFIC, P103; Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8; Schaefer JS, 2003, CURR MOL MED, V3, P653, DOI 10.2174/1566524033479519; SCHUG J, 2005, EUR J CANCER, V41, P858; Torlakovic E, 2005, INT J CANCER, V117, P381, DOI 10.1002/ijc.21174; Weaver ICG, 2005, J NEUROSCI, V25, P11045, DOI 10.1523/JNEUROSCI.3652-05.2005; Wu W, 2004, CANCER RES, V64, P1757, DOI 10.1158/0008-5472.CAN-03-2546; Zha S, 2003, CANCER RES, V63, P7365	36	98	109	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1885	1896		10.1038/sj.onc.1209991	http://dx.doi.org/10.1038/sj.onc.1209991			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17016446				2022-12-17	WOS:000245117700006
J	Barber, RC; Hickenbotham, P; Hatch, T; Kelly, D; Topchiy, N; Almeida, GM; Jones, GDD; Johnson, GE; Parry, JM; Rothkamm, K; Dubrova, YE				Barber, R. C.; Hickenbotham, P.; Hatch, T.; Kelly, D.; Topchiy, N.; Almeida, G. M.; Jones, G. D. D.; Johnson, G. E.; Parry, J. M.; Rothkamm, K.; Dubrova, Y. E.			Radiation-induced transgenerational alterations in genome stability and DNA damage	ONCOGENE			English	Editorial Material						radiation; transgenerational instability; mutations; DNA damage; mouse; germ line	F-1 MICE BORN; IONIZING-RADIATION; MULTIPLE MUTATIONS; DEFICIENT MICE; COMET ASSAY; IN-VITRO; INSTABILITY; CANCER; INDUCTION; EXPOSURE	Mutation induction in directly exposed cells is currently regarded as the main component of the genetic risk of ionizing radiation for humans. However, recent data on the transgenerational increases in mutation rates in the offspring of irradiated parents indicate that the genetic risk could be greater than predicted previously. Here, we have analysed transgenerational changes in mutation rates and DNA damage in the germline and somatic tissues of non-exposed first-generation offspring of irradiated inbred male CBA/Ca and BALB/c mice. Mutation rates at an expanded simple tandem repeat DNA locus and a protein-coding gene (hprt) were significantly elevated in both the germline (sperm) and somatic tissues of all the offspring of irradiated males. The transgenerational changes in mutation rates were attributed to the presence of a persistent subset of endogenous DNA lesions (double- and single-strand breaks), measured by the phosphorylated form of histone H2AX (gamma-H2AX) and alkaline Comet assays. Such remarkable transgenerational destabilization of the F-1 genome may have important implications for cancer aetiology and genetic risk estimates. Our data also provide important clues on the still unknown mechanisms of radiation-induced genomic instability.	Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE1 7RH, Leics, England; Univ Coll Swansea, Ctr Mol Genet & Toxicol, Swansea, W Glam, Wales; Gray Canc Inst, Northwood, Middx, England	University of Leicester; University of Leicester; Swansea University; University of Oxford	Dubrova, YE (corresponding author), Univ Leicester, Dept Genet, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.	yed2@le.ac.uk	Rothkamm, Kai/A-2164-2014; Almeida, Gabriela/A-8160-2012; Dubrova, Yuri/ABA-7148-2020; Topchiy, Nataliya/AAD-5215-2020; Barber, Ruth/A-1051-2008; Almeida, Gabriela/GXV-3687-2022; Johnson, George/J-2488-2014	Rothkamm, Kai/0000-0001-7414-5729; Almeida, Gabriela/0000-0001-8712-7394; Dubrova, Yuri/0000-0001-5281-7539; Johnson, George/0000-0001-5643-9942; Jones, George/0000-0002-9543-2206; Topchiy, Nataliya/0000-0003-4694-5707	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Almeida GM, 2006, DNA REPAIR, V5, P219, DOI 10.1016/j.dnarep.2005.09.010; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Barber R, 2002, P NATL ACAD SCI USA, V99, P6877, DOI 10.1073/pnas.102015399; Barber RC, 2004, MUTAT RES-FUND MOL M, V554, P287, DOI 10.1016/j.mrfmmm.2004.05.003; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bol SAM, 1998, CANCER RES, V58, P2850; Breger KS, 2004, CANCER RES, V64, P8231, DOI 10.1158/0008-5472.CAN-04-0879; Collins Andrew R, 2002, Methods Mol Biol, V186, P147; Cosentino L, 2000, MUTAT RES-FUND MOL M, V454, P1, DOI 10.1016/S0027-5107(00)00125-1; Dubrova YE, 2005, RADIAT RES, V163, P200, DOI 10.1667/RR3296; Dubrova YE, 2000, NATURE, V405, P37, DOI 10.1038/35011135; Dubrova YE, 2003, ONCOGENE, V22, P7087, DOI 10.1038/sj.onc.1206993; FRIEDBERG EC, 1995, DNA REPAIR REPAIR MU; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; Garcia CL, 2001, MUTAT RES-GEN TOX EN, V492, P59, DOI 10.1016/S1383-5718(01)00149-8; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; Huang L, 2003, ONCOGENE, V22, P5848, DOI 10.1038/sj.onc.1206697; Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4; Kassie F, 2000, MUTAT RES-REV MUTAT, V463, P13, DOI 10.1016/S1383-5742(00)00041-7; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Lorimore SA, 2003, ONCOGENE, V22, P7058, DOI 10.1038/sj.onc.1207044; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Niwa O, 2001, P NATL ACAD SCI USA, V98, P1705, DOI 10.1073/pnas.031439298; Nomura T, 2003, MUTAT RES-REV MUTAT, V544, P425, DOI 10.1016/j.mrrev.2003.06.006; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shiraishi K, 2002, RADIAT RES, V157, P661, DOI 10.1667/0033-7587(2002)157[0661:PIOSRO]2.0.CO;2; Tawn EJ, 2005, MUTAT RES-GEN TOX EN, V583, P198, DOI 10.1016/j.mrgentox.2005.03.007; Yauk CL, 2002, MUTAT RES-FUND MOL M, V500, P147, DOI 10.1016/S0027-5107(02)00005-2; Zheng NJ, 2000, ENVIRON MOL MUTAGEN, V36, P134, DOI 10.1002/1098-2280(2000)36:2<134::AID-EM8>3.0.CO;2-D	33	98	108	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7336	7342		10.1038/sj.onc.1209723	http://dx.doi.org/10.1038/sj.onc.1209723			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16751800				2022-12-17	WOS:000242419100002
J	Lee, JS; Thorgeirsson, SS				Lee, J-S; Thorgeirsson, S. S.			Comparative and integrative functional genomics of HCC	ONCOGENE			English	Review						DNA microarray; gene expression profile; hepatocellular carcinoma (HCC); comparative functional genomics; integrative functional genomics	GENE-EXPRESSION PROFILES; HEPATITIS-B-VIRUS; HEPATOCELLULAR-CARCINOMA; BETA-CATENIN; PEROXISOME PROLIFERATORS; MOLECULAR-FEATURES; NATURAL-HISTORY; WIDE ANALYSIS; MOUSE MODELS; LUNG-CANCER	Global gene expression pro. ling of hepatocellular carcinoma (HCC) is a promising new technology that has already refined the diagnosis and prognostic predictions of HCC patients. This has been accomplished by identifying genes whose expression pattern is associated with clinicopathological features of HCC tumors. Molecular characterization of HCC from gene expression pro. ling studies will undoubtedly improve the prediction of treatment responses, selection of treatments for specific molecular subtypes of HCC and ultimately the clinical outcome of HCC patients. The research focus is now shifting toward the identification of genetic determinants that are components of the specific regulatory pathways altered in cancers, and that may constitute novel therapeutic targets. Here we review the recent advances in gene expression pro. ling of HCC and discuss the future strategies for analysing large and complicated data sets from microarray studies and how to integrate these with diverse genomic data.	NCI, Lab Expt Carcinogenesis, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thorgeirsson, SS (corresponding author), NCI, Lab Expt Carcinogenesis, Ctr Canc Res, NIH, 37 Convent Dr,Bldg 37,Room 4146, Bethesda, MD 20892 USA.	snorri_thorgeirsson@nih.gov			NATIONAL CANCER INSTITUTE [Z01SC010385] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bruix J, 2004, CANCER CELL, V5, P215, DOI 10.1016/S1535-6108(04)00058-3; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; CALVET X, 1990, HEPATOLOGY, V12, P753, DOI 10.1002/hep.1840120422; Calvisi DF, 2004, GASTROENTEROLOGY, V126, P1374, DOI 10.1053/j.gastro.2004.02.014; Calvisi DF, 2001, CANCER RES, V61, P2085; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Cheung C, 2004, CANCER RES, V64, P3849, DOI 10.1158/0008-5472.CAN-04-0322; Chevret S, 1999, J HEPATOL, V31, P133, DOI 10.1016/S0168-8278(99)80173-1; Cooper GM, 2003, CURR OPIN GENET DEV, V13, P604, DOI 10.1016/j.gde.2003.10.001; Dave SS, 2004, NEW ENGL J MED, V351, P2159, DOI 10.1056/NEJMoa041869; Davila JA, 2004, GASTROENTEROLOGY, V127, P1372, DOI 10.1053/j.gastro.2004.07.020; Eddy SR, 2002, CELL, V109, P137, DOI 10.1016/S0092-8674(02)00727-4; EL SH, 1999, NEW ENGL J MED, V340, P745; El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; Gonzalez FJ, 1998, J NATL CANCER I, V90, P1702, DOI 10.1093/jnci/90.22.1702; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hardison RC, 1997, GENOME RES, V7, P959, DOI 10.1101/gr.7.10.959; Hsu HC, 2000, AM J PATHOL, V157, P763, DOI 10.1016/S0002-9440(10)64590-7; Iizuka N, 2003, LANCET, V361, P923, DOI 10.1016/S0140-6736(03)12775-4; Kim BY, 2004, BBA-MOL BASIS DIS, V1739, P50, DOI 10.1016/j.bbadis.2004.07.004; KIMURA M, 1968, NATURE, V217, P624, DOI 10.1038/217624a0; KING JL, 1969, SCIENCE, V164, P788, DOI 10.1126/science.164.3881.788; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Lee JS, 2005, CARCINOGENESIS, V26, P1013, DOI 10.1093/carcin/bgi030; Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; Lee JS, 2002, HEPATOLOGY, V35, P1134, DOI 10.1053/jhep.2002.33165; Lee JS, 2004, GASTROENTEROLOGY, V127, pS51, DOI 10.1053/j.gastro.2004.09.015; Lenhard Boris, 2003, J Biol, V2, P13, DOI 10.1186/1475-4924-2-13; Llovet JM, 1999, HEPATOLOGY, V29, P62, DOI 10.1002/hep.510290145; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Lossos IS, 2004, NEW ENGL J MED, V350, P1828, DOI 10.1056/NEJMoa032520; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Manghisi G, 1998, HEPATOLOGY, V28, P751; Mao TL, 2001, J PATHOL, V193, P95, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH720>3.0.CO;2-3; McNeil C, 1998, J NATL CANCER I, V90, P882, DOI 10.1093/jnci/90.12.882; Murphy WJ, 2004, TRENDS GENET, V20, P631, DOI 10.1016/j.tig.2004.09.005; Nam SW, 2005, HEPATOLOGY, V42, P809, DOI 10.1002/hep.20878; Neo SY, 2004, HEPATOLOGY, V39, P944, DOI 10.1002/hep.20105; Okabe H, 2001, CANCER RES, V61, P2129; OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RAO MS, 1984, CANCER RES, V44, P1072; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; Roepman P, 2005, NAT GENET, V37, P182, DOI 10.1038/ng1502; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sargent LM, 1999, AM J PATHOL, V154, P1047, DOI 10.1016/S0002-9440(10)65357-6; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Tan CK, 2003, J CLIN ONCOL, V21, P2294, DOI 10.1200/JCO.2003.03.151; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Ureta-Vidal A, 2003, NAT REV GENET, V4, P251, DOI 10.1038/nrg1043; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843	69	98	100	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	27					3801	3809		10.1038/sj.onc.1209561	http://dx.doi.org/10.1038/sj.onc.1209561			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799621				2022-12-17	WOS:000238559600007
J	Wang, S; Zhan, M; Yin, J; Abraham, JM; Mori, Y; Sato, F; Xu, Y; Olaru, A; Berki, AT; Li, H; Schulmann, K; Kan, T; Hamilton, JP; Paun, B; Yu, MM; Jin, Z; Cheng, Y; Ito, T; Mantzur, C; Greenwald, BD; Meltzer, SJ				Wang, S.; Zhan, M.; Yin, J.; Abraham, J. M.; Mori, Y.; Sato, F.; Xu, Y.; Olaru, A.; Berki, A. T.; Li, H.; Schulmann, K.; Kan, T.; Hamilton, J. P.; Paun, B.; Yu, M. M.; Jin, Z.; Cheng, Y.; Ito, T.; Mantzur, C.; Greenwald, B. D.; Meltzer, S. J.			Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis	ONCOGENE			English	Article						Barrett's esophagus; esophageal adenocarcinoma; transcriptional profiling; bioinformatics; early detection	GENE-EXPRESSION PROFILE; INTESTINAL METAPLASIA; MICROSATELLITE INSTABILITY; TUMOR PROGRESSION; OXIDATIVE DAMAGE; BETA-CATENIN; DIAGNOSIS; PROTEIN; HETEROZYGOSITY; EPIDEMIOLOGY	To investigate the relationship between Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC), we determined gene expression profiles of discrete pathological stages of esophageal neoplasia using a sequence-verified human cDNA microarray. Fifty one RNAs, comprising 24 normal esophagi ( NE), 18 BEs, and nine EACs were hybridized to cDNA microarrays. Five statistical analyses were used for the data analysis. Genes showing significantly different expression levels among the three sample groups were identified. Genes were grouped into functional categories based on the Gene Ontology Consortium. Surprisingly, the expression pattern of BE was significantly more similar to EAC than to NE, notwithstanding the known histopathologic differences between BE and EAC. The pattern of NE was clearly distinct from that of EAC. Thirty-six genes were the most differentially modulated, according to these microarray data, in BE-associated neoplastic progression. Twelve genes were significantly differentially expressed in cancer-associated BE's plus EAC (as a single combined tissue group) vs noncancer-associated BE's. These genes represent potential biomarkers to diagnose EAC at its early stages. Our results demonstrate that molecular events at the transcriptional level in BE are remarkably similar to BE's-associated adenocarcinoma of the esophagus. This finding alarmingly implies that BE is biologically closer to cancer than to normal esophagus, and that the cancer risk of BE is perhaps higher than we had imagined. These findings suggest that changes modulated at the molecular biologic level supervene earlier than histologic changes, and that BE is an early intermediate stage in the process of EAC.	Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Div Gastroenterol, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Baltimore VA Hosp, Baltimore, MD USA; NIA, Bioinformat Unit, NIH, Baltimore, MD 21224 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Meltzer, SJ (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, 22 S Greene St,Rm N3W62, Baltimore, MD 21201 USA.	smeltzer@medicine.umaryland.edu	Schulmann, Karsten/N-2230-2016	Berki, Agnes/0000-0003-1515-016X	NCI NIH HHS [CA95323, CA01808, CA85069, CA10676] Funding Source: Medline; NIDDK NIH HHS [T32 DK067872, DK67872] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA085069, R01CA001808, R01CA095323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK067872] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham JM, 1996, CELL GROWTH DIFFER, V7, P855; Blot WJ, 1999, SEMIN ONCOL, V26, P2; BOYNTON RF, 1991, CANCER RES, V51, P5766; Brabender J, 2004, ONCOGENE, V23, P4780, DOI 10.1038/sj.onc.1207663; Burdiles P, 2003, REV MED CHILE, V131, P587; Buttar NS, 2002, GASTROENTEROLOGY, V122, P1101, DOI 10.1053/gast.2002.32371; Cameron AJ, 2002, DIS ESOPHAGUS, V15, P106, DOI 10.1046/j.1442-2050.2002.00216.x; Cesar ACG, 2004, CANCER GENET CYTOGEN, V153, P127, DOI 10.1016/j.cancergencyto.2004.01.017; Chang Y, 2004, WORLD J GASTROENTERO, V10, P3194; Chen XX, 2000, CARCINOGENESIS, V21, P257, DOI 10.1093/carcin/21.2.257; Chen XX, 2001, CARCINOGENESIS, V22, P1119, DOI 10.1093/carcin/22.8.1119; Chen XX, 2002, CARCINOGENESIS, V23, P2095, DOI 10.1093/carcin/23.12.2095; Chung GG, 2004, CANCER, V100, P2084, DOI 10.1002/cncr.20232; Cossentino Mark J, 2003, Semin Gastrointest Dis, V14, P128; Ferguson MK, 2002, J GASTROINTEST SURG, V6, P29, DOI 10.1016/S1091-255X(01)00052-X; Fujii T, 2003, ONCOL REP, V10, P427; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Going JJ, 2002, GUT, V50, P373, DOI 10.1136/gut.50.3.373; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/ng0501-53; Hyun DH, 2004, J NEUROCHEM, V90, P422, DOI 10.1111/j.1471-4159.2004.02493.x; Kimos MC, 2004, INT J CANCER, V111, P415, DOI 10.1002/ijc.20267; Li AH, 2004, CLIN EXP METASTAS, V21, P571; LI H, 1994, SURGERY, V115, P176; Matsushima T, 1998, ONCOL REP, V5, P73; McManus DT, 2004, CANCER RES, V64, P1561, DOI 10.1158/0008-5472.CAN-03-2438; Meighan-Mantha RL, 1999, J BIOL CHEM, V274, P33166, DOI 10.1074/jbc.274.46.33166; MELTZER SJ, 1994, CANCER RES, V54, P3379; Mori M, 2002, SURGERY, V131, pS39, DOI 10.1067/msy.2002.119292; Mori Y, 2003, CANCER RES, V63, P4577; Offner FA, 1996, HUM PATHOL, V27, P885, DOI 10.1016/S0046-8177(96)90213-0; Powell J, 1992, Eur J Cancer Prev, V1, P265, DOI 10.1097/00008469-199204000-00008; RASKIND WH, 1992, CANCER RES, V52, P2946; REID BJ, 1987, GASTROENTEROLOGY, V93, P1; Sanz-Ortega J, 2003, HEPATO-GASTROENTEROL, V50, P404; Schwartz DR, 2003, CANCER RES, V63, P2913; Selaru FM, 2002, ONCOGENE, V21, P475, DOI 10.1038/sj.onc.1205111; Shirvani VN, 2000, GASTROENTEROLOGY, V118, P487, DOI 10.1016/S0016-5085(00)70254-X; Spechler SJ, 2002, MED CLIN N AM, V86, P1423, DOI 10.1016/S0025-7125(02)00082-2; Stoltzing O, 1998, Langenbecks Arch Chir Suppl Kongressbd, V115, P485; Suspiro A, 2003, AM J GASTROENTEROL, V98, P728, DOI 10.1016/S0002-9270(03)00129-1; Tamoto E, 2004, CLIN CANCER RES, V10, P3629, DOI 10.1158/1078-0432.CCR-04-0048; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Umansky M, 2001, ONCOGENE, V20, P7987, DOI 10.1038/sj.onc.1204947; von Rahden Burkhard H A, 2003, Curr Oncol Rep, V5, P203; Wang SN, 2003, ONCOGENE, V22, P467, DOI 10.1038/sj.onc.1206125; Wiley SR, 2003, CYTOKINE GROWTH F R, V14, P241, DOI 10.1016/S1359-6101(03)00019-4; Wilson KT, 1998, CANCER RES, V58, P2929; Xu Y, 2002, CANCER RES, V62, P3493; Yamamoto H, 2004, CARCINOGENESIS, V25, P325, DOI 10.1093/carcin/bgh011; Zhai Y, 2002, AM J PATHOL, V160, P1229, DOI 10.1016/S0002-9440(10)62550-3	53	98	100	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3346	3356		10.1038/sj.onc.1209357	http://dx.doi.org/10.1038/sj.onc.1209357			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16449976				2022-12-17	WOS:000237951200013
J	Wang, RA; Zhang, H; Balasenthil, S; Medina, D; Kumar, R				Wang, R-A; Zhang, H.; Balasenthil, S.; Medina, D.; Kumar, R.			PAK1 hyperactivation is sufficient for mammary gland tumor formation	ONCOGENE			English	Article						PAK1; transgenic mice; mammary tumors; breast cancer	P21-ACTIVATED-KINASE-1; KINASES; EXPRESSION; PHOSPHORYLATES; ORGANIZATION; HYPERPLASIA; ONCOGENE; REGION; ALPHA; CDC42	Emerging data suggest that p21- activated kinase 1 ( Pak1), a downstream signaling molecule of the small GTPases, growth factors, and lipid signaling, is upregulated or hyperactivated in human breast cancer. Until now, however, no direct causative role had been found for Pak1 in mammary tumor formation. We therefore sought to identify the role that Pak1 plays in mammary gland tumorigenesis. Our results showed that in a transgenic mouse model, overexpression of catalytically active Pak1 leads to the development of malignant mammary tumors and to a variety of other breast lesions, including focal solid nodules, ductal hyperplasia, and mini- intraductal neoplasm and adenoma. We also found that Pak1 hyperactivation increases the stimulation of downstream proliferative signaling effectors MEK1/ 2 and p38- MAPK in mammary tumor epithelial cells. Moreover, in our study, we detected expression of estrogen receptor- alpha expression and progesterone receptor expression during early stages of the lesions, but their expression was lost during the cells' transition to malignant invasive tumors. Finally, we found that consistent with a role in breast tumor progression, Pak1 expression and its nuclear accumulation was increased progressively during the transition from ductal hyperplasia to ductal carcinoma in situ to adenocarcinoma in widely used multistep polyoma- middle T- antigen transgenic mice. Together, these findings provide the first direct evidence that Pak1 deregulation may be sufficient for the formation of mammary gland tumors.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org	Wang, Brian/HGA-9535-2022		NCI NIH HHS [CA 65746, CA 90970] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065746, R01CA090970, U01CA065746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; BARKAN D, 2004, MOUSE MODELS HUMAN C, P103; Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; Bocchinfuso WP, 1999, CANCER RES, V59, P1869; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Knowles HJ, 2001, ANTICANCER RES, V21, P2305; Kumar R, 2002, MICROSC RES TECHNIQ, V59, P49, DOI 10.1002/jemt.10176; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Medina D, 2003, CANCER RES, V63, P1067; Medina D, 2000, METHODS MAMMARY GLAN, P101; Salh B, 2002, INT J CANCER, V98, P148, DOI 10.1002/ijc.10147; Schraml P, 2003, AM J PATHOL, V163, P985, DOI 10.1016/S0002-9440(10)63458-X; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Singh RR, 2005, J BIOL CHEM, V280, P18130, DOI 10.1074/jbc.M412607200; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Wang RA, 2003, J CELL BIOL, V161, P583, DOI 10.1083/JCB.200212066; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	24	98	102	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2931	2936		10.1038/sj.onc.1209309	http://dx.doi.org/10.1038/sj.onc.1209309			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16331248				2022-12-17	WOS:000237448200011
J	Li, R; Wang, H; Bekele, BN; Yin, Z; Caraway, NP; Katz, RL; Stass, SA; Jiang, F				Li, R; Wang, H; Bekele, BN; Yin, Z; Caraway, NP; Katz, RL; Stass, SA; Jiang, F			Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach	ONCOGENE			English	Article						lung cancer; microarrays; proteomics; tissue microarray	CANCER TISSUES; EXPRESSION; PROTEIN; HYBRIDIZATION; DNA; AMPLIFICATION; PROFILES; CELLS	Amplification and overexpression of putative oncogenes confer growth advantages for tumor development. We used a functional genomic approach that integrated simultaneous genomic and transcript microarray, proteomics, and tissue microarray analyses to directly identify putative oncogenes in lung adenocarcinoma. We first identified 183 genes with increases in both genomic copy number and transcript in six lung adenocarcinoma cell lines. Next, we used two-dimensional polyacrylamide gel electrophoresis and mass spectrometry to identify 42 proteins that were overexpressed in the cancer cells relative to normal cells. Comparing the 183 genes with the 42 proteins, we identified four genes - PRDX1, EEF1A2, CALR, and KCIP-1-in which elevated protein expression correlated with both increased DNA copy number and increased transcript levels ( all r > 0.84, two-sided P < 0.05). These findings were validated by Southern, Northern, and Western blotting. Specific inhibition of EEF1A2 and KCIP-1 expression with siRNA in the four cell lines tested suppressed proliferation and induced apoptosis. Parallel fluorescence in situ hybridization and immunohistochemical analyses of EEF1A2 and KCIP-1 in tissue microarrays from patients with lung adenocarcinoma showed that gene amplification was associated with high protein expression for both genes and that protein overexpression was related to tumor grade, disease stage, Ki-67 expression, and a shorter survival of patients. The amplification of EEF1A2 and KCIP-1 and the presence of overexpressed protein in tumor samples strongly suggest that these genes could be oncogenes and hence potential targets for diagnosis and therapy in lung adenocarcinoma.	Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Internal Med, Houston, TX 77030 USA	University System of Maryland; University of Maryland Baltimore; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Jiang, F (corresponding author), Univ Maryland, Sch Med, Dept Pathol, 10 S Pine St,MSTF 7th Floor, Baltimore, MD 21201 USA.	fjiang@som.umaryland.edu			NCI NIH HHS [CA113707-01, P50 CA70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA113707, P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anand N, 2002, NAT GENET, V31, P301, DOI 10.1038/ng904; Barrett MT, 2004, P NATL ACAD SCI USA, V101, P17765, DOI 10.1073/pnas.0407979101; Chen GA, 2002, MOL CELL PROTEOMICS, V1, P304, DOI 10.1074/mcp.M200008-MCP200; Feng J, 2004, NEOPLASIA, V6, P623, DOI 10.1593/neo.04142; Hyman E, 2002, CANCER RES, V62, P6240; Jiang F, 2005, ONCOGENE, V24, P3409, DOI 10.1038/sj.onc.1208459; Jiang F, 2002, J MOL DIAGN, V4, P144, DOI 10.1016/S1525-1578(10)60695-2; Kim HJ, 2003, CELL BIOL TOXICOL, V19, P285, DOI 10.1023/B:CBTO.0000004952.07979.3d; Lee Jonathan M, 2003, Reprod Biol Endocrinol, V1, P69, DOI 10.1186/1477-7827-1-69; Luk C, 2001, CANCER GENET CYTOGEN, V125, P87, DOI 10.1016/S0165-4608(00)00363-0; Martin B, 2004, BRIT J CANCER, V91, P2018, DOI 10.1038/sj.bjc.6602233; Oates J, 2000, HISTOPATHOLOGY, V36, P341; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Qi WQ, 2005, INT J CANCER, V113, P359, DOI 10.1002/ijc.20492; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; Shen JJ, 2004, CANCER RES, V64, P9018, DOI 10.1158/0008-5472.CAN-04-3262; Thomas D, 2005, CURR TOP DEV BIOL, V67, P285, DOI 10.1016/S0070-2153(05)67009-3; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; Wang HJ, 2005, INT J CANCER, V116, P285, DOI 10.1002/ijc.21035	19	98	111	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2628	2635		10.1038/sj.onc.1209289	http://dx.doi.org/10.1038/sj.onc.1209289			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16369491				2022-12-17	WOS:000237099400006
J	Yemelyanov, A; Gasparian, A; Lindholm, P; Dang, L; Pierce, JW; Kisseljov, F; Karseladze, A; Budunova, I				Yemelyanov, A; Gasparian, A; Lindholm, P; Dang, L; Pierce, JW; Kisseljov, F; Karseladze, A; Budunova, I			Effects of IKK inhibitor PS1145 on NF-kappa B function, proliferation, apoptosis and invasion activity in prostate carcinoma cells	ONCOGENE			English	Article						prostate carcinoma; NF-kappa B; IKK; apoptosis; invasion	NECROSIS-FACTOR-ALPHA; CANCER CELLS; CONSTITUTIVE ACTIVATION; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; THERAPEUTIC TARGET; BINDING-SITES; TNF-ALPHA; IN-VITRO; KINASE	A key antiapoptotic transcription factor, nuclear factor kappa-B (NF-kappa B), is known to be critically important for tumor cell growth, angiogenesis and development of metastatic lesions. We and others showed previously that NF-kappa B transcription factor was constitutively activated in androgen- independent prostate carcinoma (PC) cell lines due to the upregulated activity of inhibitor of NF-kappa B kinases (IKK). In this work, using luciferase assay, electrophoretic mobility shift assay and Northern blot analysis of expression of endogenous kappa B-responsive genes, we demonstrate that a novel highly specific small-molecule IKK inhibitor, PS1145, efficiently inhibited both basal and induced NF-kappa B activity in PC cells. We found that PS1145 induced caspase 3/7-dependent apoptosis in PC cells and significantly sensitized PC cells to apoptosis induced by tumor necrosis factor alpha. We also showed that PS1145 inhibited PC cell proliferation. Effects of PS1145 on proliferation and apoptosis correlated with inhibition of interleukin (IL)- 6, cyclin D1, D2, inhibitor of apoptosis (IAP)-1 and IAP-2 gene expression and decreased IL-6 protein level. In addition, we found that incubation with PS1145 inhibited the invasion activity of highly invasive PC3-S cells in invasion chamber assay in a dose-dependent manner. Overall, this study provides the framework for development of a novel therapeutic approach targeting NF-kappa B transcription factor to treat advanced PC.	Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA; NN Nlokhin Russian Canc Res Ctr, Moscow, Russia; Millennium Pharmaceut Inc, Cambridge, MA USA	Northwestern University; Feinberg School of Medicine; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Budunova, I (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Ward Bldg 9-332,303 E Chicago Ave, Chicago, IL 60611 USA.	i-budunova@northwestern.edu						Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Baxter A, 2004, BIOORG MED CHEM LETT, V14, P2817, DOI 10.1016/j.bmcl.2004.03.058; Burke JR, 2003, J BIOL CHEM, V278, P1450, DOI 10.1074/jbc.M209677200; Castro AC, 2003, BIOORG MED CHEM LETT, V13, P2419, DOI 10.1016/S0960-894X(03)00408-6; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Chau BN, 2000, MOL CELL, V6, P31, DOI 10.1016/S1097-2765(00)00005-8; Chen CD, 2002, MOL CELL BIOL, V22, P2862, DOI 10.1128/MCB.22.8.2862-2870.2002; Culig Z, 2004, J STEROID BIOCHEM, V92, P265, DOI 10.1016/j.jsbmb.2004.10.003; Figueroa B, 2004, BIOTECHNOL BIOENG, V85, P589, DOI 10.1002/bit.10913; Gasparian AV, 2002, J CELL SCI, V115, P141; GASPARIAN AV, 2003, P AACR, V44, P1451; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; Glasgow JN, 2000, J NEUROCHEM, V75, P1377, DOI 10.1046/j.1471-4159.2000.0751377.x; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Gupta S, 2002, ONCOGENE, V21, P3727, DOI 10.1038/sj.onc.1205474; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Huynh QK, 2000, J BIOL CHEM, V275, P25883, DOI 10.1074/jbc.M000296200; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2004, ANN RHEUM DIS, V63, P62, DOI 10.1136/ard.2004.028274; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Lam LT, 2005, CLIN CANCER RES, V11, P28; Li L, 2005, PROSTATE CANCER P D, V8, P108, DOI 10.1038/sj.pcan.4500776; Lindholm PF, 2001, CLIN EXP METASTAS, V18, P471, DOI 10.1023/A:1011845725394; Lyakh LA, 2000, J IMMUNOL, V165, P3647, DOI 10.4049/jimmunol.165.7.3647; Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100; Muenchen HJ, 2000, CLIN CANCER RES, V6, P1969; Murata T, 2004, BIOORG MED CHEM LETT, V14, P4013, DOI 10.1016/j.bmcl.2004.05.040; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Peter Marcus E, 2004, Biochem J, V382, pe1; Rapp UR, 2004, BBA-MOL CELL RES, V1644, P149, DOI 10.1016/j.bbamcr.2003.10.015; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; ROSENBERG IM, 1996, BENCHTOP TECHNIQUES; Ross JS, 2004, CLIN CANCER RES, V10, P2466, DOI 10.1158/1078-0432.CCR-0543-3; Shishodia S, 2004, J BIOL CHEM, V279, P47148, DOI 10.1074/jbc.M408093200; Shukla S, 2004, NEOPLASIA, V6, P390, DOI 10.1593/neo.04112; Shukla S, 2004, CLIN CANCER RES, V10, P3169, DOI 10.1158/1078-0432.CCR-03-0586; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Sweeney C, 2004, CLIN CANCER RES, V10, P5501, DOI 10.1158/1078-0432.CCR-0571-03; TOTH CR, 1995, J BIOL CHEM, V270, P7661, DOI 10.1074/jbc.270.13.7661; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Yasui H, 2003, ANN NY ACAD SCI, V1010, P273, DOI 10.1196/annals.1299.047; Zerbini LF, 2003, CANCER RES, V63, P2206; Ziegelbauer K, 2005, BRIT J PHARMACOL, V145, P178, DOI 10.1038/sj.bjp.0706176	57	98	102	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					387	398		10.1038/sj.onc.1209066	http://dx.doi.org/10.1038/sj.onc.1209066			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16170348				2022-12-17	WOS:000234714100007
J	Bousquet, M; Quelen, C; De Mas, V; Duchayne, E; Roquefeuil, B; Delsol, G; Laurent, G; Dastugue, N; Brousset, P				Bousquet, M; Quelen, C; De Mas, V; Duchayne, E; Roquefeuil, B; Delsol, G; Laurent, G; Dastugue, N; Brousset, P			The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene	ONCOGENE			English	Article						atypical chronic myeloid leukaemia; JAK2; PCM1	TYROSINE KINASE JAK2; MUTATION; RECEPTOR; BCR; CARCINOMA; PDGFRA; TARGET	Several tyrosine kinase genes are involved in chromosomal translocations in chronic myeloproliferative disorders, but there are still uncharacterized translocations in some cases. We report two such cases corresponding to atypical chronic myeloid leukaemia with a t(8; 9) p22; p24) translocation. By fluorescence in situ hybridisation ( FISH) on the corresponding metaphases with a bacterial artificial chromosome probe encompassing the janus kinase 2 (JAK2) gene at 9p24, we observed a split for both patients, suggesting that this gene was rearranged. The locus at 8p22 contains different candidate genes including the pericentriolar material 1 gene (PCM1), already implicated in reciprocal translocations. The rearrangement of the PCM1 gene was demonstrated by FISH, for both patients. By RT-PCR, we confirmed the fusion of 30 part of JAK2 with the 50 part of PCM1. Sequence analysis of the chimeric PCM1-JAK2 mRNA suggests that the putative protein displays the coiled-coil domains of PCM1 and the tyrosine kinase domain of JAK2. This newtranslocation identifies JAK2 as a possible therapeutic target for compounds with antityrosine kinase activity.	CHU Purpan, INSERM, U563, CPTP, F-31059 Toulouse, France; CHU Purpan, Lab Cytogenet Hemopathies, F-31059 Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Brousset, P (corresponding author), CHU Purpan, INSERM, U563, CPTP, Pl Baylac, F-31059 Toulouse, France.	brousset.p@chu-toulouse.fr	Bousquet, Marina/H-2901-2016; QUELEN, Cathy/G-4974-2017	Bousquet, Marina/0000-0001-8333-1144; Quelen, Cathy/0000-0003-0576-2234				BALCZON R, 1994, J CELL BIOL, V124, P783, DOI 10.1083/jcb.124.5.783; Balczon R, 2002, CELL MOTIL CYTOSKEL, V52, P183, DOI 10.1002/cm.10043; BARBER DL, 1994, MOL CELL BIOL, V14, P6506, DOI 10.1128/MCB.14.10.6506; Baxter EJ, 2002, HUM MOL GENET, V11, P1391, DOI 10.1093/hmg/11.12.1391; Baxter EJ, 2003, BRIT J HAEMATOL, V120, P251, DOI 10.1046/j.1365-2141.2003.04051.x; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Bhattacharya N, 2003, INDIAN J MED RES, V118, P77; Carron C, 2000, BLOOD, V95, P3891; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Corvi R, 2000, ONCOGENE, V19, P4236, DOI 10.1038/sj.onc.1203772; Dammermann A, 2004, DEV CELL, V7, P815, DOI 10.1016/j.devcel.2004.10.015; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; EMI M, 1992, CANCER RES, V52, P5368; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Nguyen MHH, 2001, J BIOL CHEM, V276, P32704, DOI 10.1074/jbc.M103100200; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Reiter A, 2005, CANCER RES, V65, P2662, DOI 10.1158/0008-5472.CAN-04-4263; Trempat P, 2003, ONCOGENE, V22, P5702, DOI 10.1038/sj.onc.1206543; Valdembri D, 2001, FASEB J, V15, P225, DOI 10.1096/fj.01-0633fje	23	98	109	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7248	7252		10.1038/sj.onc.1208850	http://dx.doi.org/10.1038/sj.onc.1208850			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16091753				2022-12-17	WOS:000232990100013
J	Borlak, J; Meier, T; Halter, R; Spanel, R; Spanel-Borowski, K				Borlak, J; Meier, T; Halter, R; Spanel, R; Spanel-Borowski, K			Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours	ONCOGENE			English	Article						HCC; EGF; transgenic mice; tumour stages; gene expression profiling	FACTOR-ALPHA; C-FOS; ACTIVATION; RECEPTOR; CELLS; MICE; OVEREXPRESSION; CARCINOGENESIS; CYTOKINESIS; PROGRESSION	Epidermal growth factor is an important mitogen for hepatocytes. Its overexpression promotes hepatocellular carcinogenesis. To identify the network of genes regulated through EGF, we investigated the liver transcriptome during various stages of hepatocarcinogenesis in EGF2B transgenic mice. Targeted overexpression of IgEGF induced distinct hepatocellular lesions and eventually solid tumours at the age of 6-8 months, as evidenced by histopathology. We used the murine MG U74Av2 oligonucleotide microarrays to identify transcript signatures in 12 tumours of small ( n = 5, pooled), medium ( n = 4) and large sizes ( n = 3), and compared the findings with three nontumorous transgenic livers and four control livers. Global gene expression analysis at successive stages of carcinogenesis revealed hallmarks linked to tumour size. A comparison of gene expression profiles of nontumorous transgenic liver versus control liver provided insight into the initial events predisposing liver cells to malignant transformation, and we found overexpression of c-fos, eps-15, TGIF, IGFBP1, Alcam, ets-2 and repression of Gas-1 as distinct events. Further, when gene expression profiles of small manifested tumours were compared with nontumorous transgenic liver, additional changes were obvious and included overexpression of junB, Id-1, minopontin, villin, claudin-7, RR M2, p34cdc2, cyclinD1 and cyclinB1 among others. These genes are therefore strongly associated with tumour formation. Our study provided new information on the tumour stage-dependent network of EGF-regulated genes, and we identified candidate genes linked to tumorigenes and progression of disease.	Fraunhofer Inst Toxicol & Expt Med, Dept Pharmacol & Mol Med, D-30625 Hannover, Germany; Inst Pathol, Viersen, Germany; Univ Leipzig, Inst Anat, D-7010 Leipzig, Germany	Fraunhofer Gesellschaft; Leipzig University	Borlak, J (corresponding author), Fraunhofer Inst Toxicol & Expt Med, Dept Pharmacol & Mol Med, Nikolai Fuchsstr 1, D-30625 Hannover, Germany.	Borlak@item.fraunhofer.de						ALVAREZ CV, 1995, J BIOL CHEM, V270, P16271, DOI 10.1074/jbc.270.27.16271; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; Chen SY, 2000, ANTISENSE NUCLEIC A, V10, P111, DOI 10.1089/oli.1.2000.10.111; Choi S, 2000, CLIN EXP METASTAS, V18, P45, DOI 10.1023/A:1026507713080; Chung YH, 2000, CANCER, V89, P977, DOI 10.1002/1097-0142(20000901)89:5<977::AID-CNCR6>3.0.CO;2-I; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; DEY A, 1991, DNA CELL BIOL, V10, P537, DOI 10.1089/dna.1991.10.537; Evdokiou A, 1998, EXP CELL RES, V240, P359, DOI 10.1006/excr.1998.4011; Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905; Gotoh M, 2002, PATHOL INT, V52, P19, DOI 10.1046/j.1440-1827.2002.01316.x; HOGAN B, 1994, MANIPULATING MOUSE E; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Kubicka S, 2000, LIVER, V20, P312, DOI 10.1034/j.1600-0676.2000.020004312.x; Leu JI, 2003, J CLIN INVEST, V111, P129, DOI 10.1172/JCI200316712; Melhuish TA, 2001, J BIOL CHEM, V276, P32109, DOI 10.1074/jbc.M103377200; Okabe H, 2001, CANCER RES, V61, P2129; Ostrowski J, 2000, BRIT J CANCER, V82, P1041; Ouyang XS, 2002, CARCINOGENESIS, V23, P721, DOI 10.1093/carcin/23.5.721; Ramljak D, 1998, CANCER RES, V58, P3590; Rescan C, 2001, MOL BIOL CELL, V12, P725, DOI 10.1091/mbc.12.3.725; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Tan JEL, 2001, J BIOL CHEM, V276, P20055, DOI 10.1074/jbc.M010800200; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; TONJES RR, 1995, ONCOGENE, V10, P765; Wang YP, 1999, HEPATOLOGY, V30, P682, DOI 10.1002/hep.510300318; Witz IP, 2000, J CELL BIOCHEM, P61; WU JC, 1994, CANCER RES, V54, P5964; YAMAGUCHI K, 1995, J SURG ONCOL, V58, P240	32	98	107	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1809	1819		10.1038/sj.onc.1208196	http://dx.doi.org/10.1038/sj.onc.1208196			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15674348				2022-12-17	WOS:000227542000001
J	Bren-Mattison, Y; Van Putten, V; Chan, D; Winn, R; Geraci, MW; Nemenoff, RA				Bren-Mattison, Y; Van Putten, V; Chan, D; Winn, R; Geraci, MW; Nemenoff, RA			Peroxisome proliferator-activated receptor-gamma (PPAR gamma) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC)	ONCOGENE			English	Article						PPAR gamma; non-small-cell lung cancer; metastasis; tumorigenesis; differentiation	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MACROPHAGE-GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; LIGAND TROGLITAZONE; COLORECTAL-CANCER; EPITHELIAL-CELL; BREAST-CANCER; COLON-CANCER; PHASE-II; DIFFERENTIATION	Pharmacological activators of peroxisome proliferatoractivated receptor-gamma (PPARgamma) have been shown to inhibit growth of lung tumors largely through growth inhibition and induction of apopotosis. However, since many of these agents engage other effectors, the role of PPARgamma in lung tumorigenesis remains poorly defined. To specifically examine PPARgamma-mediated events, non-small-cell lung cancer (NSCLC) cells overexpressing PPARgamma were established. Overexpression of PPARgamma in H2122 adenocarcinoma cells (H2122-PPARgamma) blocked anchorage-independent growth compared to cells transfected with empty vector (H2122-LNCX), but had no significant effect on cell proliferation or apoptosis under standard tissue culture conditions. Orthotopic implantation of H2122-PPARgamma cells into the lungs of nude rats inhibited tumor growth and metastasis in vivo and prolonged survival compared to implantation of H2122-LNCX cells. Consistent with these findings, H2122-PPARgamma cells had an impaired invasiveness as assessed in Transwell assays. In a three-dimensional culture system, H2122-PPARgamma cells formed polarized spheroid structures similar to those observed with normal lung epithelial cells. H2122-LNCX cells formed nonpolarized aggregate structures and did not show any of these epithelial properties. These data indicate that inhibitory effects of PPARgamma on lung tumorigenesis involve selective inhibition of invasive metastasis, and activation of pathways that promote a more differentiated epithelial phenotype.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Dis & Hypertens, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Nemenoff, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Dis & Hypertens, Box C-281,4200 E 9th Ave, Denver, CO 80262 USA.	raphael.nemenoff@uchsc.edu			NCI NIH HHS [CA58187, CA108610, CA103618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA103618, R01CA108610, P50CA058187] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; Bell-Parikh LC, 2003, J CLIN INVEST, V112, P945, DOI 10.1172/JCI200318012; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Burstein HJ, 2003, BREAST CANCER RES TR, V79, P391, DOI 10.1023/A:1024038127156; Chan DC, 2002, CLIN CANCER RES, V8, P904; Chang TH, 2000, CANCER RES, V60, P1129; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Cui Y, 2002, J BIOL CHEM, V277, P17830, DOI 10.1074/jbc.M200186200; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; Grommes C, 2004, LANCET ONCOL, V5, P419, DOI 10.1016/S1470-2045(04)01509-8; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kerr KM, 2001, J CLIN PATHOL, V54, P257, DOI 10.1136/jcp.54.4.257; Keshamouni VG, 2004, ONCOGENE, V23, P100, DOI 10.1038/sj.onc.1206885; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kulke MH, 2002, CANCER J, V8, P395, DOI 10.1097/00130404-200209000-00010; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; MALKINSON AM, 1979, TOXICOL APPL PHARM, V49, P551, DOI 10.1016/0041-008X(79)90457-5; March TH, 2001, VET PATHOL, V38, P483, DOI 10.1354/vp.38-5-483; Marx N, 1998, CIRC RES, V83, P1097, DOI 10.1161/01.RES.83.11.1097; Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; ROBERTS PE, 1990, AM J PHYSIOL, V259, pL415, DOI 10.1152/ajplung.1990.259.6.L415; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Sasaki H, 2002, LUNG CANCER-J IASLC, V36, P71, DOI 10.1016/S0169-5002(01)00449-4; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Theocharis S, 2002, LUNG CANCER, V36, P249, DOI 10.1016/S0169-5002(02)00013-2; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Whitehead CM, 2003, MOL CANCER THER, V2, P479; Wick M, 2002, MOL PHARMACOL, V62, P1207, DOI 10.1124/mol.62.5.1207; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291	49	98	99	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1412	1422		10.1038/sj.onc.1208333	http://dx.doi.org/10.1038/sj.onc.1208333			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608671				2022-12-17	WOS:000227092600011
J	Sinenko, SA; Mathey-Prevot, B				Sinenko, SA; Mathey-Prevot, B			Increased expression of Drosophila tetraspanin, Tsp68C, suppresses the abnormal proliferation of ytr-deficient and Ras/Raf-activated hemocytes	ONCOGENE			English	Article						tetraspanin; Tsp68C; yantar; Raf; hemocyte; Drosophila	DENDRITIC CELLS; EGF RECEPTOR; SUPERFAMILY; PROTEINS; ORGANIZERS; INTEGRINS; COMPLEXES; MIGRATION; RESPONSES; PATHWAY	Tetraspanins are evolutionary conserved transmembrane proteins thought to facilitate cell proliferation, movement or fusion by acting as organizers of different signaling events. Despite their prevalence and conservation, their specific role and functions remain largely elusive, as their redundancy in various. organisms has hindered loss of function studies. Here, we take a gain of function approach to study Drosophila tetraspanin Tsp68C and its effect on larval hemocytes. We recently characterized a lethal mutation in ytr, a conserved gene that encodes a nuclear arginine-rich protein of unknown function, which is accompanied by abnormal differentiation and proliferation of the larval hematopoietic tissue in flies. A hemolectin (hml)-Gal4 construct carried by hml-Gal4 transgenic flies was sufficient by itself to abrogate the hematopoietic defects in ytr mutant larvae. This rescue correlated with the overexpression of tsp68C, a tetraspanin gene nested in the hml promoter. The suppression of abnormal proliferation by the hml-Gal4 construct was not restricted to ytr-deficient hemocytes, but was also observed in hemocytes expressing the oncogenic forms of Raf or Ras proteins. However, it had no effect on overproliferation mediated by a constitutively active form of Jak. New hml-Gal4 lines, in which the tsp68C gene was silenced or deleted from the promoter, no longer rescued the hematopoietic defect in ytr mutants nor suppressed the activated Raf-induced overproliferation. Therefore, change in tetraspanin Tsp68C expression has a strong suppressor effect on abnormal proliferation and differentiation of hemocytes in the context of specific lesions, such as overactivation of the Ras/Raf/MAPK pathway.	Dana Farber Canc Inst, Div Pediat Oncol, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital	Sinenko, SA (corresponding author), Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, 621 Charles E Young Dr S,Life Sci Bldg 2204, Los Angeles, CA 90024 USA.	sinenko@mcdb.ucla.edu	Sinenko, Sergey A./C-3703-2016	Sinenko, Sergey A./0000-0001-5517-8218	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062434] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL62434] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anzai N, 2002, BLOOD, V99, P4413, DOI 10.1182/blood.V99.12.4413; Asha H, 2003, GENETICS, V163, P203; Bach EA, 2003, GENETICS, V165, P1149; Berditchevski F, 2001, J CELL SCI, V114, P4143; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Boucheix C., 2001, EXPERT REV MOL MED, V2001, P1; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; BRAND AH, 1993, DEVELOPMENT, V118, P401; Callus BA, 2002, ONCOGENE, V21, P4812, DOI 10.1038/sj.onc.1205618; Carloni V, 2004, ONCOGENE, V23, P1566, DOI 10.1038/sj.onc.1207287; Engering A, 2003, EUR J BIOCHEM, V270, P2412, DOI 10.1046/j.1432-1033.2003.03609.x; Fradkin LG, 2002, P NATL ACAD SCI USA, V99, P13663, DOI 10.1073/pnas.212511099; Goto A, 2001, BIOCHEM J, V359, P99, DOI 10.1042/0264-6021:3590099; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Hubner K, 2002, INT REV CYTOL, V214, P103; King R, 1999, AM J PATHOL, V155, P731, DOI 10.1016/S0002-9440(10)65172-3; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Mantegazza AR, 2004, BLOOD, V104, P1183, DOI 10.1182/blood-2004-01-0104; Miyazaki T, 1997, EMBO J, V16, P4217, DOI 10.1093/emboj/16.14.4217; Sawada S, 2003, J BIOL CHEM, V278, P26323, DOI 10.1074/jbc.C300210200; Scherberich A, 2002, THROMB HAEMOSTASIS, V87, P1043, DOI 10.1055/s-0037-1613130; Shi W, 2000, J CELL BIOL, V148, P591, DOI 10.1083/jcb.148.3.591; Sinenko SA, 2004, DEV BIOL, V273, P48, DOI 10.1016/j.ydbio.2004.05.022; Sorrentino RP, 2004, GENETICS, V166, P1343, DOI 10.1534/genetics.166.3.1343; Sorrentino RP, 2002, DEV BIOL, V243, P65, DOI 10.1006/dbio.2001.0542; Tarrant JA, 2002, MOL CELL BIOL, V22, P5006, DOI 10.1128/MCB.22.14.5006-5018.2002; Tarrant JM, 2003, TRENDS IMMUNOL, V24, P610, DOI 10.1016/j.it.2003.09.011; Todres E, 2000, INSECT MOL BIOL, V9, P581, DOI 10.1046/j.1365-2583.2000.00222.x; Xu H, 2004, EMBO J, V23, P811, DOI 10.1038/sj.emboj.7600112; Yunta M, 2003, CELL SIGNAL, V15, P559, DOI 10.1016/S0898-6568(02)00147-X; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	32	98	98	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	2004	23	56					9120	9128		10.1038/sj.onc.1208156	http://dx.doi.org/10.1038/sj.onc.1208156			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15480416				2022-12-17	WOS:000225492800013
J	Ku, JL; Kang, SB; Shin, YK; Kang, HC; Hong, SH; Kim, IJ; Shin, JH; Han, IO; Park, JG				Ku, JL; Kang, SB; Shin, YK; Kang, HC; Hong, SH; Kim, IJ; Shin, JH; Han, IO; Park, JG			Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines	ONCOGENE			English	Article						RUNX3; promoter; hypermethylation colorectal cancer	5'-CPG ISLAND METHYLATION; DNA METHYLATION; CHROMOSOME 1P; ALLELIC LOSS; DELETIONS; ESTABLISHMENT; MUTATIONS; GROWTH; LUNG; FHIT	It was recently reported that RUNX3 gene expression is significantly downregulated in human gastric cancer cells due to hypermethylation of its promoter region or hemizygous deletion ( Cell, 109, 2002). To verify the genetic alterations and methylation status of the RUNX3 gene in colorectal carcinogenesis, we analysed for mutations, loss of heterozygosity (LOH), and RUNX3 gene promoter hypermethylation, in 32 colorectal cancer cell lines. RT-PCR analysis showed undetectable or low RUNX3 expression in 16 cell lines, and no mutations were found in the RUNX3 gene by PCR-SSCP analysis. Of these 16 cell lines, hypermethylation of the RUNX3 promoter was confirmed in 12. The following observations were made: (i) RUNX3 was re-expressed after 5-aza-2'-deoxycytidine treatment, (ii) the RUNX3 promoter was found to be methylated by MS-PCR, and (iii) hypermethylation of the RUNX3 promoter was confirmed by direct sequencing analysis after sodium bisulfite modification in the above 12 cell lines. RUNX3 was neither methylated nor expressed in four cell lines. Of these four, microsatellite instability (MSI) at the RUNX3 locus was found in three, SNU-61 (D1S246), SNU-769A, and SNU-769B (D1S199). This study suggests that transcriptional repression of RUNX3 is caused by promoter hypermethylation of the RUNX3 CpG island in colorectal cancer cell lines, and the results of these experiments may contribute to an understanding of the role of RUNX3 inactivation in the pathogenesis of colorectal cancers.	Seoul Natl Univ, Coll Med, Canc Res Inst, Cell Biol Lab, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Canc Res Ctr, Korean Cell Line Bank, Seoul 110744, South Korea; Natl Canc Ctr, Res Inst & Hosp, Goyang 411764, Gyeonggi, South Korea	Seoul National University (SNU); Seoul National University (SNU); National Cancer Center - Korea (NCC)	Park, JG (corresponding author), Seoul Natl Univ, Coll Med, Canc Res Inst, Cell Biol Lab, 28 Yongon Dong, Seoul 110744, South Korea.	jgpark@plaza.snu.ac.kr	Ku, Ja-Lok/D-5736-2012; Kang, Sung-Bum/J-5361-2012; Park, Jae-Gahb/J-5494-2012; Shin, Joo-Ho/P-1417-2018					Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Di Vinci A, 1998, INT J CANCER, V75, P45, DOI 10.1002/(SICI)1097-0215(19980105)75:1<45::AID-IJC8>3.3.CO;2-0; Di Vinci A, 1998, CANCER-AM CANCER SOC, V83, P415; Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001; Ezaki T, 1996, BRIT J CANCER, V73, P424, DOI 10.1038/bjc.1996.76; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Ku JL, 2002, BRIT J CANCER, V87, P187, DOI 10.1038/sj.bjc.6600440; Ku JL, 1999, EUR J CANCER, V35, P1724, DOI 10.1016/S0959-8049(99)00206-3; Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Melki JR, 2000, BLOOD, V95, P3208; Nam S, 2002, MOL CELL BIOL, V22, P547, DOI 10.1128/MCB.22.2.547-554.2002; Ogunbiyi OA, 1997, GASTROENTEROLOGY, V113, P761, DOI 10.1016/S0016-5085(97)70169-0; Oh JH, 1999, INT J CANCER, V81, P902, DOI 10.1002/(SICI)1097-0215(19990611)81:6<902::AID-IJC11>3.0.CO;2-T; PARK JG, 1987, CANCER RES, V47, P6710; Paz MF, 2003, CANCER RES, V63, P1114; PRAML C, 1995, ONCOGENE, V11, P1357; Rini D, 2001, GENE, V273, P13, DOI 10.1016/S0378-1119(01)00579-0; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Song SH, 2001, CANCER RES, V61, P4628; Suh ER, 2002, J BIOL CHEM, V277, P35795, DOI 10.1074/jbc.M205567200; TANAKA K, 1993, ONCOGENE, V8, P2253; Trojan J, 2000, GUT, V47, P272, DOI 10.1136/gut.47.2.272; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Yang QF, 2002, CLIN CANCER RES, V8, P2890; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	29	98	112	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6736	6742		10.1038/sj.onc.1207731	http://dx.doi.org/10.1038/sj.onc.1207731			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273736				2022-12-17	WOS:000223653600005
J	Wang, WS; Chen, PM; Hsiao, HL; Wang, HS; Liang, WY; Su, Y				Wang, WS; Chen, PM; Hsiao, HL; Wang, HS; Liang, WY; Su, Y			Overexpression of the thymosin beta-4 gene is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma	ONCOGENE			English	Article						thymosin beta-4; colorectal carcinoma; beta-catenin; MMP-7; Fas; metastasis	BETA-CATENIN; FAS LIGAND; E-CADHERIN; MATRIX METALLOPROTEINASE-7; CANCER CELLS; MATRILYSIN EXPRESSION; TUMOR PROGRESSION; LIVER METASTASES; IMMUNE PRIVILEGE; BREAST-CANCER	Cell-matrix and cell-cell adhesive interactions play important roles in the normal organization and stabilization of the cell layer in epithelial tissue. Alterations in the expression and function of these adhesion systems that cause a switch to a migratory phenotype in tumor invasion and metastasis are critical for the malignant conversion of epithelial cells. Thymosin beta-4 (Tbeta-4) is the major actin-sequestering protein that has been shown to be upregulated in a wide variety of human carcinomas and has been implicated to be involved in altering the motility of certain tumors. We have recently demonstrated that the growth rate, colony formation in soft agar, and motility, all good indicators for malignant progression, of SW480 colon carcinoma cells are dramatically increased by enforced Tbeta-4 expression. To test the hypothesis that overexpression of this G- actin sequestering peptide also promotes tumor invasion, we examined not only the invasion capability of Tbeta-4-overexpressing SW480 cells, but also the expression levels of Tbeta-4 as well as several proteins that participate in different stages of tumor progression in matched samples of human primary colorectal adenocarcinoma and liver metastases from several patients. A marked increase on the invasiveness in Tbeta-4-overexpressing SW480 cells with increased levels and activity of matrix metalloproteinase-7 (MMP-7) was observed. Furthermore, the levels of Fas as well as the susceptibility to Fas ligand-mediated apoptosis in Tbeta-4-overexpressing cells were significantly decreased. Interestingly, the levels of Tbeta-4 mRNA, beta-catenin, c-Myc, and MMP-7 in metastatic liver lesions were relatively higher, whereas the levels of E-cadherin and Fas were significantly lower than those in the matched primary colorectal tumors. These results suggest that upregulation of Tbeta-4, by promoting the disruption of cell-cell adhesion and a consequential activation of the beta-catenin signaling, could be a key event in the acquisition of growth advantages as well as invasive phenotypes in human colorectal carcinomas.	Natl Yang Ming Univ, Coll Life Sci, Inst Biopharmaceut Sci, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Med, Inst Clin Med, Taipei 112, Taiwan; Taipei Vet Gen Hosp, Div Med Oncol, Taipei, Taiwan; Taipei Vet Gen Hosp, Dept Surg, Div Colorectal Surg, Taipei, Taiwan; Taipei Vet Gen Hosp, Dept Pathol, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; Taipei Veterans General Hospital; Taipei Veterans General Hospital	Su, Y (corresponding author), Natl Yang Ming Univ, Coll Life Sci, Inst Biopharmaceut Sci, Taipei 112, Taiwan.	yeusu@ym.edu.tw						Adachi Y, 2001, INT J CANCER, V95, P290, DOI 10.1002/1097-0215(20010920)95:5<290::AID-IJC1050>3.0.CO;2-I; ALBINI A, 1987, CANCER RES, V47, P3239; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; Califano D, 1998, CANCER RES, V58, P823; Cardi G, 1998, CANCER RES, V58, P2078; Cha HJ, 2003, J NATL CANCER I, V95, P1674, DOI 10.1093/jnci/djg100; Chopin D, 2003, AM J PATHOL, V162, P1139, DOI 10.1016/S0002-9440(10)63910-7; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Houghton JA, 1997, CLIN CANCER RES, V3, P2205; Ishikawa T, 1996, CANCER LETT, V107, P5, DOI 10.1016/0304-3835(96)04336-4; Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860; Kobayashi T, 2002, AM J PATHOL, V160, P869, DOI 10.1016/S0002-9440(10)64910-3; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314; MORI M, 1995, CANCER, V75, P1516, DOI 10.1002/1097-0142(19950315)75:6+<1516::AID-CNCR2820751522>3.0.CO;2-7; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; NETZELARNETT S, 1991, ANAL BIOCHEM, V195, P86, DOI 10.1016/0003-2697(91)90299-9; Noe V, 2001, J CELL SCI, V114, P111; O'Connell J, 1998, J PATHOL, V186, P240; O'Connell J, 2001, NAT MED, V7, P271, DOI 10.1038/85395; O'Connell J, 2000, ANN NY ACAD SCI, V910, P178; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; Sardi I, 2002, INT J MOL MED, V9, P541; Semb H, 1998, AM J HUM GENET, V63, P1588, DOI 10.1086/302173; Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; Su Y, 2000, MOL CELL BIOCHEM, V203, P163, DOI 10.1023/A:1007020619788; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Wang WS, 2003, ONCOGENE, V22, P3297, DOI 10.1038/sj.onc.1206404; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; Xie D, 2002, INT J ONCOL, V21, P499; Yamamoto H, 2003, J PATHOL, V199, P176, DOI 10.1002/path.1277; Zeng ZS, 2002, CLIN CANCER RES, V8, P144	41	98	105	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6666	6671		10.1038/sj.onc.1207888	http://dx.doi.org/10.1038/sj.onc.1207888			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15235586				2022-12-17	WOS:000223530800014
J	Boffetta, P				Boffetta, P			Epidemiology of environmental and occupational cancer	ONCOGENE			English	Review						air pollution; arsenic; environment; environmental tobacco smoke; neoplasms; occupation; radon	RESIDENTIAL RADON EXPOSURE; CHLORINATION BY-PRODUCTS; ARSENICAL AIR-POLLUTION; LUNG-CANCER; RESPIRATORY-CANCER; RISK-FACTORS; BLADDER-CANCER; NONOCCUPATIONAL EXPOSURE; ASBESTOS EXPOSURE; DRINKING-WATER	Environmental carcinogens, in a strict sense, include outdoor and indoor air pollutants, as well as soil and drinking water contaminants. An increased risk of mesothelioma has consistently been detected among individuals experiencing residential exposure to asbestos, while results for lung cancer are less consistent. Several good-quality studies have investigated lung cancer risk from outdoor air pollution based on measurement of specific agents. Their results tend to show an increased risk in the categories at highest exposure, with relative risks in the range 1.5. A causal association has been established between exposure to environmental tobacco smoke and lung cancer, with a relative risk in the order of 1.2. Radon is another carcinogen present in indoor air, with a relative risk in the order of 1.06 for exposure at 100 Bq/m(3). In several Asian populations, an increased risk of lung cancer results among women from indoor pollution from cooking and heating. There is strong evidence of an increased risk of bladder, skin and lung cancers following consumption of water with high arsenic contamination; results for other drinking water contaminants, including chlorination by-products, are inconclusive. A total of 29 occupational agents are established human carcinogens, and another 30 agents are suspected carcinogens. In addition, at least 12 exposure circumstances entail exposure to carcinogens. Exposure is still widespread for many important occupational carcinogens, such as asbestos, coal tar, arsenic and silica, in particular in developing countries. Although estimates of the global burden of occupational and environmental cancer result in figures in the order of 2% and less than 1%, respectively, these cancers concentrate in subgroups of the population; furthermore, exposure is involuntary and can, to a large extent, be avoided.	Int Agcy Res Canc, F-69008 Lyon, France; German Canc Res Ctr, D-69120 Heidelberg, Germany	World Health Organization; International Agency for Research on Cancer (IARC); Helmholtz Association; German Cancer Research Center (DKFZ)	Boffetta, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	boffetta@iarc.fr	Boffetta, Paolo/AAI-7767-2021	Boffetta, Paolo/0000-0002-3811-2791				Abbey DE, 1999, AM J RESP CRIT CARE, V159, P373, DOI 10.1164/ajrccm.159.2.9806020; Alavanja MCR, 1999, AM J PUBLIC HEALTH, V89, P1042, DOI 10.2105/AJPH.89.7.1042; [Anonymous], 1997, IARC Monogr Eval Carcinog Risks Hum, V68, P41; [Anonymous], 2000, IARC MON EV CARC RIS, V75; BARBONE F, 1995, AM J EPIDEMIOL, V141, P1161, DOI 10.1093/oxfordjournals.aje.a117389; Barros-Dios JM, 2002, AM J EPIDEMIOL, V156, P548, DOI 10.1093/aje/kwf070; BATES MN, 1995, AM J EPIDEMIOL, V141, P523, DOI 10.1093/oxfordjournals.aje.a117467; Beeson WL, 1998, ENVIRON HEALTH PERSP, V106, P813, DOI 10.2307/3434125; Bhopal RS, 1998, OCCUP ENVIRON MED, V55, P812, DOI 10.1136/oem.55.12.812; Biggeri A, 1996, ENVIRON HEALTH PERSP, V104, P750, DOI 10.2307/3433221; Blair A, 1997, CANCER CAUSE CONTROL, V8, P473, DOI 10.1023/A:1018417623867; BLOT WJ, 1975, LANCET, V2, P142; Boffetta, 1995, Int J Occup Environ Health, V1, P315; Boffetta P, 1997, CANCER CAUSE CONTROL, V8, P444, DOI 10.1023/A:1018465507029; Boffetta P, 2002, SCAND J WORK ENV HEA, V28, P30; BOND GG, 1992, SCAND J WORK ENV HEA, V18, P145, DOI 10.5271/sjweh.1594; BOTHA JL, 1986, AM J EPIDEMIOL, V123, P30, DOI 10.1093/oxfordjournals.aje.a114221; BROWN LM, 1984, ENVIRON RES, V34, P250, DOI 10.1016/0013-9351(84)90093-8; BROWNSON RC, 1987, AM J EPIDEMIOL, V125, P25, DOI 10.1093/oxfordjournals.aje.a114509; BUELL P, 1967, CANCER-AM CANCER SOC, V20, P2139, DOI 10.1002/1097-0142(196712)20:12<2139::AID-CNCR2820201212>3.0.CO;2-8; BUELL P, 1967, ARCH ENVIRON HEALTH, V15, P291, DOI 10.1080/00039896.1967.10664920; Camus M, 1998, NEW ENGL J MED, V338, P1565, DOI 10.1056/NEJM199805283382201; CANTOR KP, 1987, J NATL CANCER I, V79, P1269; Cantor KP, 1997, CANCER CAUSE CONTROL, V8, P292, DOI 10.1023/A:1018444902486; CARDIS E, 1994, LANCET, V344, P1039; CEDERLOF R, 1975, RELATIONSHIP SMOKING; CORDIER S, 1983, ENVIRON RES, V31, P311, DOI 10.1016/0013-9351(83)90009-9; COWLES SR, 1994, OCCUP ENVIRON MED, V51, P323, DOI 10.1136/oem.51.5.323; Dai XD, 1996, LUNG CANCER-J IASLC, V14, pS85, DOI 10.1016/S0169-5002(96)90213-5; Darby S, 1998, BRIT J CANCER, V78, P394, DOI 10.1038/bjc.1998.506; Darby S, 2001, ANN ONCOL, V12, P1341, DOI 10.1023/A:1012518223463; DEAN G, 1978, REPORT 2 RETROSPEC 2; DEAN G, 1977, REPORT 2 RETROSPEC 1; DEAN G, 1966, BMJ-BRIT MED J, V5502, P1506; Divine BJ, 1996, TOXICOLOGY, V113, P169, DOI 10.1016/0300-483X(96)03442-7; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; DU YX, 1996, LUNG CANCER S1, V14, P9; Engholm G, 1996, BRIT MED J, V312, P1259, DOI 10.1136/bmj.312.7041.1259; FROST F, 1987, ARCH ENVIRON HEALTH, V42, P148, DOI 10.1080/00039896.1987.9935813; Gailey F A, 1983, Ecol Dis, V2, P419; GAILEY FAY, 1986, ENVIRON HEALTH PERSP, V68, P187, DOI 10.2307/3430263; GAO YT, 1987, INT J CANCER, V40, P604, DOI 10.1002/ijc.2910400505; GOLDSMITH JR, 1980, J ENVIRON PATHOL TOX, V3, P205; Greaves W W, 1981, Am J Ind Med, V2, P15, DOI 10.1002/ajim.4700020105; Hackshaw AK, 1997, BMJ-BRIT MED J, V315, P980, DOI 10.1136/bmj.315.7114.980; HAENSZEL W, 1964, JNCI-J NATL CANCER I, V32, P803; HAENSZEL W, 1962, JNCI-J NATL CANCER I, V28, P947; HAMMOND E C, 1958, J Am Med Assoc, V166, P1159; Hammond E C, 1979, Ann N Y Acad Sci, V330, P417, DOI 10.1111/j.1749-6632.1979.tb18743.x; HAMMOND EC, 1958, JAMA-J AM MED ASSOC, V166, P1294, DOI 10.1001/jama.1958.02990110030007; HAMMOND EC, 1980, PREV MED, V9, P206, DOI 10.1016/0091-7435(80)90077-8; HAMMOND EC, 1972, ENV FACTORS RESPIRAT, P177; Hansen J, 1998, AM J RESP CRIT CARE, V157, P69, DOI 10.1164/ajrccm.157.1.96-11086; Hayes RB, 1997, CANCER CAUSE CONTROL, V8, P371, DOI 10.1023/A:1018457305212; HE XZ, 1991, ENVIRON HEALTH PERSP, V94, P9, DOI 10.2307/3431286; HITOSUGI M, 1968, Bulletin of the Institute of Public Health (Tokyo), V17, P237; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; HOLOWATY EJ, 1991, CAN J PUBLIC HEALTH, V82, P304; Howel D, 1997, OCCUP ENVIRON MED, V54, P403, DOI 10.1136/oem.54.6.403; HUGHES JM, 1994, LUNG BIOL HEALTH DIS, V74, P185; *IARC, 1992, IARC MON EV CARC RIS, V54, P41; IARC, 2004, IARC MON EV CARC RIS, V83; *IARC, 1972, IARC MON EV CARC RIS, V1; *IARC, 2001, IARC MON EV CARC RIS, V78; *IARC, 1998, IARC MON EV CARC RIS, V71, P109; *IARC, 1989, IARC MON EV CARC RIS, V46, P41; IARC (International Agency for Research on Cancer), 1987, IARC MON EV CARC R S; IARC (International Agency for Research on Cancer), 1991, IARC MON EV CARC RIS, V52; *INSERM, 1997, EFF SANT PRINC TYP E; INT AGCY RES CANC, 1990, IARC MONOG EVAL CARC, V49, P49; IPCS, 1998, ENV HLTH CRIT; JEDRYCHOWSKI W, 1990, J EPIDEMIOL COMMUN H, V44, P114, DOI 10.1136/jech.44.2.114; JOCKEL KH, 1992, INT J EPIDEMIOL, V21, P202, DOI 10.1093/ije/21.2.202; KATSOUYANNI K, 1991, PREV MED, V20, P271, DOI 10.1016/0091-7435(91)90026-Z; King WD, 1996, CANCER CAUSE CONTROL, V7, P596, DOI 10.1007/BF00051702; Ko YC, 1997, INT J EPIDEMIOL, V26, P24, DOI 10.1093/ije/26.1.24; Koo LC, 1996, LUNG CANCER, V14, pS47; Kurttio P, 1999, ENVIRON HEALTH PERSP, V107, P705, DOI 10.2307/3434654; Lagarde F, 1997, HEALTH PHYS, V72, P269, DOI 10.1097/00004032-199702000-00010; Lan Q, 2002, J NATL CANCER I, V94, P826, DOI 10.1093/jnci/94.11.826; Lan Qing, 1993, Biomedical and Environmental Sciences, V6, P112; LEVIN ML, 1960, J NATL CANCER I, V24, P1243; Liddell FDK, 2001, ANN OCCUP HYG, V45, P341, DOI 10.1093/annhyg/45.5.341; Lipsett M, 1999, AM J PUBLIC HEALTH, V89, P1009, DOI 10.2105/AJPH.89.7.1009; LLOYD OL, 1986, J SOC OCCUP MED, V36, P2; LLOYD OL, 1985, BRIT J IND MED, V42, P475; LLOYD OL, 1985, BRIT J IND MED, V42, P815; LLOYD OL, 1978, LANCET, V1, P318; Lubin JH, 1997, J NATL CANCER I, V89, P49, DOI 10.1093/jnci/89.1.49; LUBIN JH, 1995, J NATL CANCER I, V87, P817, DOI 10.1093/jnci/87.11.817; Luce D, 2000, AM J EPIDEMIOL, V151, P259, DOI 10.1093/oxfordjournals.aje.a010201; Luo S, 1998, Hua Xi Yi Ke Da Xue Xue Bao, V29, P63; LYON JL, 1977, LANCET, V2, P869; Macaluso M, 1996, TOXICOLOGY, V113, P190, DOI 10.1016/0300-483X(96)03444-0; MAGNANI C, 1995, OCCUP ENVIRON MED, V52, P362, DOI 10.1136/oem.52.6.362; Magnani C, 2001, ENVIRON HEALTH PERSP, V109, P915, DOI 10.2307/3454992; Magnani C, 2000, BRIT J CANCER, V83, P104; MARCOVECCHIO JE, 1993, ENVIRON MONIT ASSESS, V25, P119, DOI 10.1007/BF00549133; Marsh GM, 1997, ENVIRON RES, V75, P56, DOI 10.1006/enrs.1997.3768; Marsh GM, 1998, ARCH ENVIRON HEALTH, V53, P15, DOI 10.1080/00039899809605685; MATANOSKI GM, 1981, ENVIRON RES, V25, P8, DOI 10.1016/0013-9351(81)90076-1; McDonnell WF, 2000, J EXPO ANAL ENV EPID, V10, P427, DOI 10.1038/sj.jea.7500095; MCGEEHIN MA, 1993, AM J EPIDEMIOL, V138, P492, DOI 10.1093/oxfordjournals.aje.a116883; MILLS PK, 1991, ARCH ENVIRON HEALTH, V46, P271, DOI 10.1080/00039896.1991.9934387; MORRIS RD, 1992, AM J PUBLIC HEALTH, V82, P955, DOI 10.2105/AJPH.82.7.955; Mzileni O, 1999, TOB CONTROL, V8, P398, DOI 10.1136/tc.8.4.398; NEUBERGER M, 1984, ARCH ENVIRON HEALTH, V39, P261, DOI 10.1080/00039896.1984.10545846; NEWHOUSE ML, 1965, BRIT J IND MED, V22, P261; NEWMAN JA, 1976, ANN NY ACAD SCI, V271, P260, DOI 10.1111/j.1749-6632.1976.tb23120.x; Nyberg F, 2000, EPIDEMIOLOGY, V11, P487, DOI 10.1097/00001648-200009000-00002; Pawlega J, 1997, ACTA ONCOL, V36, P471, DOI 10.3109/02841869709001301; PERSHAGEN G, 1985, AM J EPIDEMIOL, V122, P684, DOI 10.1093/oxfordjournals.aje.a114147; PERSHAGEN G, 1977, ENVIRON HEALTH PERSP, V19, P133; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; Petrauskaite R, 2002, INT J CANCER, V99, P106, DOI 10.1002/ijc.10314; PIKE MC, 1979, ENERGY HLTH, P3; Pisa FE, 2001, ARCH ENVIRON HEALTH, V56, P208, DOI 10.1080/00039890109604444; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669, DOI 10.1164/ajrccm/151.3_Pt_1.669; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Pott P, 1775, CHIRURGICAL OBSERVAT; QING L, 1993, AM J EPIDEMIOL, V137, P145, DOI 10.1093/oxfordjournals.aje.a116654; ROM WN, 1982, BRIT J IND MED, V39, P269; SAMET JM, 1987, AM J EPIDEMIOL, V125, P800, DOI 10.1093/oxfordjournals.aje.a114597; Sathiakumar N, 1998, OCCUP ENVIRON MED, V55, P230, DOI 10.1136/oem.55.4.230; SHEAR CL, 1980, ARCH ENVIRON HEALTH, V35, P335; SMITH GH, 1987, BRIT J IND MED, V44, P795; SOBUE T, 1990, INT J EPIDEMIOL, V19, pS62, DOI 10.1093/ije/19.Supplement_1.S62; Steenland K, 2001, CANCER CAUSE CONTROL, V12, P773, DOI 10.1023/A:1012214102061; Steenland K, 1997, CANCER CAUSE CONTROL, V8, P491, DOI 10.1023/A:1018469607938; STOCKS P, 1955, BRIT MED J, V2, P923, DOI 10.1136/bmj.2.4945.923; SWAEN GMH, 1995, INT ARCH OCC ENV HEA, V67, P85; TENKANEN L, 1985, INT J CANCER, V35, P637, DOI 10.1002/ijc.2910350511; TENKANEN L, 1987, SCAND J SOC MED, V15, P67, DOI 10.1177/140349488701500203; TENKANEN L, 1993, CANCER CAUSE CONTROL, V4, P133, DOI 10.1007/BF00053154; THERIAULT GP, 1978, ARCH ENVIRON HEALTH, V33, P15, DOI 10.1080/00039896.1978.10667302; Tomasek L, 2001, SCI TOTAL ENVIRON, V272, P43, DOI 10.1016/S0048-9697(01)00663-5; TOMATIS L, 1990, IARC SCI PUBLICATION, V100; VENA JE, 1982, AM J EPIDEMIOL, V116, P42, DOI 10.1093/oxfordjournals.aje.a113401; Wang SY, 1996, LUNG CANCER-J IASLC, V14, pS99, DOI 10.1016/S0169-5002(96)90215-9; Wang ZY, 2002, AM J EPIDEMIOL, V155, P554, DOI 10.1093/aje/155.6.554; Ward EM, 1996, TOXICOLOGY, V113, P157, DOI 10.1016/0300-483X(96)03441-5; WILLIAMS FLR, 1988, PUBLIC HEALTH, V102, P531, DOI 10.1016/S0033-3506(88)80022-2; WUWILLIAMS AH, 1990, BRIT J CANCER, V62, P982, DOI 10.1038/bjc.1990.421; Xiao H P, 1985, Natl Cancer Inst Monogr, V69, P53; Xu Z Y, 1991, IARC Sci Publ, P460; Xu ZY, 1996, LUNG CANCER-J IASLC, V14, pS149, DOI 10.1016/S0169-5002(96)90220-2; XU ZY, 1989, J NATL CANCER I, V81, P1800, DOI 10.1093/jnci/81.23.1800; ZARIDZE DG, 1995, VESTN ROS AKAD MED, V4, P6; Zhong LJ, 1999, SCAND J WORK ENV HEA, V25, P309, DOI 10.5271/sjweh.440	150	98	100	1	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6392	6403		10.1038/sj.onc.1207715	http://dx.doi.org/10.1038/sj.onc.1207715			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322513				2022-12-17	WOS:000223468800007
J	Stupack, DG; Cheresh, DA				Stupack, DG; Cheresh, DA			Apoptotic cues from the extracellular matrix: regulators of angiogenesis	ONCOGENE			English	Article						angiogenesis; apoptosis; endothelial cell; extracellular matrix; integrin	ENDOTHELIAL GROWTH-FACTOR; FOCAL ADHESION KINASE; SURVIVAL FACTOR; CELL-SURVIVAL; BREAST-CANCER; TUMOR-GROWTH; IN-VIVO; GLANZMANN THROMBASTHENIA; INTEGRIN ALPHA(V)BETA(3); ALPHA-V-BETA-3	A variety of factors cooperate to regulate neovessel formation and persistence. Proangiogenic growth factors have remained an area of intense interest due to their capacity to promote endothelial cell (EC) proliferation and to initiate the angiogenic program. These growth factors are associated with increased cell survival, yet paradoxically, angiogenic ECs are more susceptible to apoptosis than quiescent ECs. Survival is regulated by cooperation between growth factor receptors and integrins, which are in turn governed by the composition of the local extracellular matrix (ECM). Integrin-mediated signaling is altered or disrupted by the presence of soluble, rather than matrix-bound ligands, thus providing a means by which ECM remodeling can influence both integrin- and growth factor-mediated events. Ultimately, the collaboration of these factors determines whether ECs survive or die, thereby regulating neovascularization.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Cheresh, DA (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	cheresh@scripps.edu			NCI NIH HHS [R01 CA107263] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abramovitch R, 1998, FEBS LETT, V425, P441, DOI 10.1016/S0014-5793(98)00283-X; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Biancone L, 1997, J EXP MED, V186, P147, DOI 10.1084/jem.186.1.147; Boudreau N, 1997, J CELL BIOL, V139, P257, DOI 10.1083/jcb.139.1.257; Bouvard D, 2001, CIRC RES, V89, P211, DOI 10.1161/hh1501.094874; Brassard DL, 1999, EXP CELL RES, V251, P33, DOI 10.1006/excr.1999.4559; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945-053X(00)00107-4; CHERESH DA, 1991, CANCER METAST REV, V10, P3, DOI 10.1007/BF00046839; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; COLLER BS, 1991, BLOOD, V77, P75; CRAFT PS, 1994, ANN ONCOL, V5, P305, DOI 10.1093/oxfordjournals.annonc.a058829; Dickson SE, 2001, J ENDOCRINOL, V168, P409, DOI 10.1677/joe.0.1680409; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Dor Y, 2002, EMBO J, V21, P1939, DOI 10.1093/emboj/21.8.1939; Eliceiri BP, 2001, CIRC RES, V89, P1104, DOI 10.1161/hh2401.101084; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1991, Princess Takamatsu Symp, V22, P339; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gasparini G, 1998, CLIN CANCER RES, V4, P2625; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; Hirschi K K, 1997, EXS, V79, P419; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Huang SL, 2001, CANCER RES, V61, P3373; ILLC D, 1995, NATURE, V377, P539; Ingber D E, 1992, Semin Cancer Biol, V3, P57; Ingber DE, 2002, CIRC RES, V91, P877, DOI 10.1161/01.RES.0000039537.73816.E5; Isik FF, 1998, J CELL PHYSIOL, V175, P149, DOI 10.1002/(SICI)1097-4652(199805)175:2<149::AID-JCP4>3.0.CO;2-O; Jones Peter Lloyd, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P137; Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509; Kerbel RS, 2000, EUR J CANCER, V36, P1248, DOI 10.1016/S0959-8049(00)00092-7; Keshet E, 1999, J CLIN INVEST, V104, P1497, DOI 10.1172/JCI8849; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Kim S, 2002, J CLIN INVEST, V110, P933, DOI 10.1172/JCI200214268; Klement G, 2002, CLIN CANCER RES, V8, P221; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li LM, 2002, MOL CELL BIOL, V22, P1203, DOI 10.1128/MCB.22.4.1203-1217.2002; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Maeshima Y, 2001, J BIOL CHEM, V276, P15240, DOI 10.1074/jbc.M007764200; Malyankar UM, 2000, J BIOL CHEM, V275, P20959, DOI 10.1074/jbc.C000290200; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Mitchell CA, 1998, DEV DYNAM, V213, P322, DOI 10.1002/(SICI)1097-0177(199811)213:3<322::AID-AJA8>3.0.CO;2-E; Mitsiades N, 2001, EXPERT OPIN INV DRUG, V10, P1075, DOI 10.1517/13543784.10.6.1075; Moldovan NI, 2003, ADV EXP MED BIOL, V522, P99; Myers C, 2002, AM J PATHOL, V161, P2099, DOI 10.1016/S0002-9440(10)64488-4; Myers C, 2000, J CELL BIOL, V148, P343, DOI 10.1083/jcb.148.2.343; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; OREILLY MS, 1994, COLD SPRING HARB SYM, V59, P471, DOI 10.1101/SQB.1994.059.01.052; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; Plath T, 2000, J CELL BIOL, V150, P1467, DOI 10.1083/jcb.150.6.1467; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Salven P, 2003, BLOOD, V101, P168, DOI 10.1182/blood-2002-03-0755; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Storgard CM, 1999, J CLIN INVEST, V103, P47, DOI 10.1172/JCI3756; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Stromblad S, 2002, J BIOL CHEM, V277, P13371, DOI 10.1074/jbc.C200044200; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349; Walsh DA, 2001, ARTHRITIS RES, V3, P147, DOI 10.1186/ar292; Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427; Yu K, 2001, ENDOCR-RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249	79	98	104	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2003	22	56					9022	9029		10.1038/sj.onc.1207110	http://dx.doi.org/10.1038/sj.onc.1207110			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	751GC	14663480				2022-12-17	WOS:000187043600005
J	Dolle, L; El Yazidi-Belkoura, I; Adriaenssens, E; Nurcombe, V; Hondermarck, H				Dolle, L; El Yazidi-Belkoura, I; Adriaenssens, E; Nurcombe, V; Hondermarck, H			Nerve growth factor overexpression and autocrine loop in breast cancer cells	ONCOGENE			English	Article						breast cancer; nerve growth factor; autocrine stimulation; cellular growth	STROMAL CELLS; RECEPTORS; EXPRESSION; PROLIFERATION; NEUROTROPHINS; SURVIVAL; RELEASE	We show here that nerve growth factor (NGF), the canonical neurotrophic factor, is synthesized and released by breast cancer cells. High levels of NGF transcript and protein were detected in breast cancer cells by reverse transcription-PCR, Western blotting, ELISA assay and immunohistochemistry. Conversely, NGF production could not be detected in normal breast epithelial cells at either the transcriptional or protein level. Confocal analysis indicated the presence of NGF within classical secretion vesicles. Breast cancer cell-produced NGF was biologically active, as demonstrated by its ability to induce the neuronal differentiation of embryonic neural precursor cells. Importantly, the constitutive growth of breast cancer cells was strongly inhibited by either NGF-neutralizing antibodies or K-252a, a pharmacological inhibitor of NGF receptor TrkA, indicating the existence of an NGF autocrine loop. Together, our data demonstrate the physiological relevance of NGF in breast cancer and its potential interest as a marker and therapeutic target.	Univ Sci & Technol Lille, UPRES EA 1033, F-59655 Villeneuve Dascq, France; Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia	Universite de Lille - ISITE; Universite de Lille; University of Queensland	Hondermarck, H (corresponding author), Univ Sci & Technol Lille, UPRES EA 1033, IFR 118,Batiment SN3, F-59655 Villeneuve Dascq, France.	hubert.hondermarck@univ-lille1.fr	El Yazidi-Belkoura, Ikram/AAE-8805-2022; Malwad, Govind V/F-4682-2010; Dollé, Laurent/H-4612-2014	EL YAZIDI-BELKOURA, IKRAM/0000-0002-5323-7509				Adriaenssens E, 1998, AM J PATHOL, V153, P1597, DOI 10.1016/S0002-9440(10)65748-3; ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; Bange J, 2001, NAT MED, V7, P548, DOI 10.1038/87872; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Bonini S, 1996, P NATL ACAD SCI USA, V93, P10955, DOI 10.1073/pnas.93.20.10955; Bourhis XFDL, 1997, INT J CANCER, V71, P42, DOI 10.1002/(SICI)1097-0215(19970328)71:1<42::AID-IJC9>3.0.CO;2-3; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; Chiarenza A, 2001, CANCER RES, V61, P3002; Clemow DB, 1998, AM J PHYSIOL-REG I, V275, pR1279, DOI 10.1152/ajpregu.1998.275.4.R1279; Colomer R, 2001, CANCER INVEST, V19, P49, DOI 10.1081/CNV-100000074; Dalal R, 1997, MOL CELL ENDOCRINOL, V134, P15, DOI 10.1016/S0303-7207(97)00165-2; Descamps S, 1998, J BIOL CHEM, V273, P16659, DOI 10.1074/jbc.273.27.16659; Descamps S, 2001, CANCER RES, V61, P4337; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; Dickson C, 2000, BREAST CANCER RES, V2, P191, DOI 10.1186/bcr53; DIMARCO E, 1993, J BIOL CHEM, V268, P22838; El Yazidi-Belkoura I, 2003, J BIOL CHEM, V278, P16952, DOI 10.1074/jbc.M300631200; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; Fawcett JP, 1997, J BIOL CHEM, V272, P8837; GRUETERS A, 1985, PEDIATR RES, V19, P934, DOI 10.1203/00006450-198509000-00014; HATTORI A, 1993, J BIOL CHEM, V268, P2577; KAUFFMAN RF, 1980, J BIOL CHEM, V255, P2735; KELLY R B, 1991, Current Opinion in Cell Biology, V3, P654, DOI 10.1016/0955-0674(91)90037-Y; Le Bourhis X., 2000, BREAST CANC RES TREA, V1722, P1; LEON A, 1994, P NATL ACAD SCI USA, V91, P3739, DOI 10.1073/pnas.91.9.3739; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LILLIEN LE, 1985, NATURE, V317, P632, DOI 10.1038/317632a0; LOSSING C, 1993, PLAST RECONSTR SURG, V91, P1277, DOI 10.1097/00006534-199306000-00014; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Moller JC, 1998, J NEUROSCI RES, V51, P463, DOI 10.1002/(SICI)1097-4547(19980215)51:4<463::AID-JNR6>3.0.CO;2-A; Nurcombe V, 2000, J BIOL CHEM, V275, P30009, DOI 10.1074/jbc.M003038200; SMALL DH, 1995, J NEUROSCI, V15, P144; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Tagliabue E, 2000, J BIOL CHEM, V275, P5388, DOI 10.1074/jbc.275.8.5388; Torcia M, 1996, CELL, V85, P345, DOI 10.1016/S0092-8674(00)81113-7; Wang XH, 1997, NEURON, V19, P825, DOI 10.1016/S0896-6273(00)80964-2; YAAR M, 1991, J CELL BIOL, V115, P821, DOI 10.1083/jcb.115.3.821	37	98	121	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5592	5601		10.1038/sj.onc.1206805	http://dx.doi.org/10.1038/sj.onc.1206805			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944907				2022-12-17	WOS:000184865900008
J	Ling, G; Ahmadian, A; Persson, A; Unden, AB; Afink, G; Williams, C; Uhlen, M; Toftgard, R; Lundeberg, J; Ponten, F				Ling, G; Ahmadian, A; Persson, A; Unden, AB; Afink, G; Williams, C; Uhlen, M; Toftgard, R; Lundeberg, J; Ponten, F			PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer	ONCOGENE			English	Article						BCC; p53; PATCHED; loss of heterozygosity; in situ hybridization; mutation	SKIN-CANCER; SUNLIGHT EXPOSURE; HUMAN HOMOLOG; MUTATIONS; CARCINOMA; KERATINOCYTES; ULTRAVIOLET; CLONES; CARCINOGENESIS; POLYMORPHISM	It is widely accepted that disruption of the hedgehog-patched pathway is a key event in development of basal cell cancer. In addition to patched gene alterations, p53 gene mutations are also frequent in basal cell cancer. We determined loss of heterozygosity in the patched and p53 loci as well as sequencing the p53 gene in tumors both from sporadic and hereditary cases. A total of 70 microdissected samples from tumor and adjacent skin were subjected to PCR followed by fragment analysis and DNA sequencing. We found allelic loss in the patched locus in 6/8 sporadic basal cell cancer and 17/19 hereditary tumors. All sporadic and 7/20 hereditary tumors showed p53 gene mutations. Loss of heterozygosity in the p53 locus was rare in both groups. The p53 mutations detected in hereditary tumors included rare single nucleotide deletions and unusual double-base substitutions compared to the typical ultraviolet light induced missense mutations found in sporadic tumors. Careful microdissection of individual tumors revealed genetically linked subclones with different p53 and/or patched genotype providing an insight on time sequence of genetic events. The high frequency and co-existence of genetic alterations in the patched and p53 genes suggest that both these genes are important in the development of basal cell cancer.	Univ Uppsala Hosp, Rudbeck Lab, Dept Genet & Pathol, S-75185 Uppsala, Sweden; Royal Inst Technol, Dept Biotechnol, S-10044 Stockholm, Sweden; Karolinska Inst, Dept Dermatol, S-17176 Stockholm, Sweden; Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden	Uppsala University; Uppsala University Hospital; Royal Institute of Technology; Karolinska Institutet; Karolinska Institutet	Ponten, F (corresponding author), Univ Uppsala Hosp, Rudbeck Lab, Dept Genet & Pathol, S-75185 Uppsala, Sweden.		Uhlen, Mathias/AAV-8746-2021; Afink, Gijs/A-2025-2009; Williams, Cecilia/A-6677-2009; Afink, Gijs/AAB-2832-2021; Uhlen, Mathias/B-3262-2016	Afink, Gijs/0000-0002-2155-725X; Williams, Cecilia/0000-0002-0602-2062; Uhlen, Mathias/0000-0002-4858-8056; Gao, Ling/0000-0001-7320-1442				Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; BERG C, 1995, CLIN CHEM, V41, P1461; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brash DE, 1998, CANCER SURV, V32, P69; D'Errico M, 2000, ONCOGENE, V19, P463, DOI 10.1038/sj.onc.1203313; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; Gailani MR, 1997, JNCI-J NATL CANCER I, V89, P1103, DOI 10.1093/jnci/89.15.1103; Gailani MR, 1996, J NATL CANCER I, V88, P349, DOI 10.1093/jnci/88.6.349; GALLAGHER RP, 1995, ARCH DERMATOL, V131, P157, DOI 10.1001/archderm.131.2.157; Green A, 1996, AM J EPIDEMIOL, V144, P1034, DOI 10.1093/oxfordjournals.aje.a008875; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Holmberg E, 1996, BRIT J CANCER, V74, P246, DOI 10.1038/bjc.1996.345; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; Kawanishi S, 2001, MUTAT RES-REV MUTAT, V488, P65, DOI 10.1016/S1383-5742(00)00059-4; KNUDSON AG, 1975, P NATL ACAD SCI USA, V72, P5116, DOI 10.1073/pnas.72.12.5116; Ling G, 2001, AM J PATHOL, V159, P1247, DOI 10.1016/S0002-9440(10)62511-4; MOLES JP, 1993, ONCOGENE, V8, P583; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Ponten F, 1997, ONCOGENE, V15, P1059, DOI 10.1038/sj.onc.1201435; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; Ratner D, 2001, J AM ACAD DERMATOL, V44, P293, DOI 10.1067/mjd.2001.112361; Rebel H, 2001, CANCER RES, V61, P977; Ren ZP, 1996, ONCOGENE, V12, P765; Ren ZP, 1997, AM J PATHOL, V150, P1791; Sarasin A, 1999, MUTAT RES-FUND MOL M, V428, P5, DOI 10.1016/S1383-5742(99)00025-3; Tabata H, 1999, J INVEST DERMATOL, V113, P972, DOI 10.1046/j.1523-1747.1999.00810.x; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Unden AB, 1997, CANCER RES, V57, P2336; Williams C, 1998, CANCER RES, V58, P2449; Zhang H, 2001, AM J PATHOL, V158, P381, DOI 10.1016/S0002-9440(10)63980-6; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	37	98	101	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2001	20	53					7770	7778		10.1038/sj.onc.1204946	http://dx.doi.org/10.1038/sj.onc.1204946			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753655				2022-12-17	WOS:000172161700008
J	Lu, WG; Chen, LH; Peng, YH; Chen, JD				Lu, WG; Chen, LH; Peng, YH; Chen, JD			Activation of p53 by roscovitine-mediated suppression of MDM2 expression	ONCOGENE			English	Article						roscovitine; p53; MDM2; cdk; transcription	CYCLIN-DEPENDENT KINASES; SOFT-TISSUE SARCOMAS; DNA-DAMAGE; SYNERGISTIC ACTIVATION; NUCLEAR EXCLUSION; HUMAN SKIN; IN-VIVO; PROTEIN; TRANSCRIPTION; INHIBITION	The p53 tumor suppressor is regulated by the MDM2 oncoprotein. Overexpression of MDM2 maintains p53 at low levels and contributes to the functional inactivation of p53 in a subset of tumors. We found that treatment with roscovitine and olomoucin, which were originally developed as cyclin-dependent kinase (CDK) inhibitors, can efficiently stabilize and activate nuclear p53 in tumor cells with MDM2 amplification or cytoplasmic p53. These inhibitors block the degradation of p53 without affecting p53-MDM2 binding and the nuclear shuttling function of p53 and MDM2. Roscovitine also induces stabilization of the p53 Ala-315 mutant, indicating that it does not act by regulating the CDK phosphorylation of serine 315, Roscovitine induces down-regulation of MDM2 expression at both protein and mRNA levels. Ectopic expression of MDM2 can abrogate the ability of roscovitine to induce p53 stabilization. Low concentrations of roscovitine cooperate with the DNA-damaging agent camptothecin to activate p53 in a synergistic fashion, These results show that the small molecule CDK inhibitors can be used to activate p53 through their potent inhibitory effect on MDM2 expression and may be useful as sensitizing agents for other DNA-damaging drugs.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute	Chen, JD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.							ADDISON C, 1990, ONCOGENE, V5, P423; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Blaydes JP, 2000, ONCOGENE, V19, P3829, DOI 10.1038/sj.onc.1203773; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Chang D, 1999, CELL GROWTH DIFFER, V10, P155; Chehab NH, 2000, GENE DEV, V14, P278; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; Chen LH, 1999, MOL MED, V5, P21, DOI 10.1007/BF03402136; CORDONCARDO C, 1994, CANCER RES, V54, P794; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hajduch M, 1999, ADV EXP MED BIOL, V457, P341; HALL PA, 1993, ONCOGENE, V8, P203; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Hietanen S, 2000, P NATL ACAD SCI USA, V97, P8501, DOI 10.1073/pnas.97.15.8501; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; LEACH FS, 1993, CANCER RES, V53, P2231; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Lu WG, 2000, ONCOGENE, V19, P232, DOI 10.1038/sj.onc.1203262; McMasters KM, 1996, ONCOGENE, V13, P1731; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meng RD, 1998, CLIN CANCER RES, V4, P251; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; O'Grady A, 1998, HUM PATHOL, V29, P559, DOI 10.1016/S0046-8177(98)80003-8; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sankrithi N, 1999, J NEUROCHEM, V72, P605, DOI 10.1046/j.1471-4159.1999.0720605.x; Schang LM, 1999, J VIROL, V73, P2161, DOI 10.1128/JVI.73.3.2161-2172.1999; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 2000, GENE DEV, V14, P289; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	47	98	101	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3206	3216		10.1038/sj.onc.1204412	http://dx.doi.org/10.1038/sj.onc.1204412			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423970				2022-12-17	WOS:000169163500004
J	Al-Obeidi, FA; Lam, KS				Al-Obeidi, FA; Lam, KS			Development of inhibitors for protein tyrosine kinases	ONCOGENE			English	Review						protein tyrosine kinase; inhibitors; preclinical studies; clinical studies; cancer therapy; drug development	GROWTH-FACTOR-RECEPTOR; STRUCTURE-BASED DESIGN; ATP-BINDING-SITE; IN-VIVO; C-SRC; PHASE-I; MONOCLONAL-ANTIBODY; SUBSTRATE-SPECIFICITY; SELECTIVE INHIBITOR; PEPTIDE INHIBITOR	In the last 5 years, through combinatorial chemistry, high-throughput screening, computational chemistry, and traditional medicinal chemistry, numerous inhibitors for various protein tyrosine kinases (PTKs) have been developed, The majority of these compounds are small molecules that compete at the ATP binding site of the catalytic domain of the enzymes, Some compounds such as pseudosubstrate-based peptide inhibitor binds to the peptide/protein substrate site of the catalytic domain. Some inhibitors, primarily monoclonal antibodies, bind to the extracellular domain of receptor tyrosine kinases, Some of these inhibitors are highly potent and selective, Several are currently undergoing clinical trials for a number of diseases such as cancer.	Univ Calif Davis, Ctr Canc, Div Hematol Oncol, Sacramento, CA 95817 USA; Univ Calif Davis, Dept Internal Med, Sacramento, CA 95817 USA; Selectide Corp, Tucson, AZ 85737 USA	University of California System; University of California Davis; University of California System; University of California Davis; Sanofi-Aventis	Lam, KS (corresponding author), Univ Calif Davis, Ctr Canc, Div Hematol Oncol, 4501 X St, Sacramento, CA 95817 USA.							AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Al-Obeidi FA, 1998, BIOPOLYMERS, V47, P197, DOI 10.1002/(SICI)1097-0282(1998)47:3<197::AID-BIP2>3.0.CO;2-H; Alfaro-Lopez J, 1998, J MED CHEM, V41, P2252, DOI 10.1021/jm9707885; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Baselga J, 1998, CANCER RES, V58, P2825; Ben-Bassat H, 1999, J PHARMACOL EXP THER, V290, P1442; Boschelli Diane H., 1999, Drugs of the Future, V24, P515, DOI 10.1358/dof.1999.024.05.858622; BOTFIELD MC, 1995, ANNU REP MED CHEM, V30, P227, DOI DOI 10.1016/S0065-7743(08)60937-9; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Braunwalder AF, 1996, ANAL BIOCHEM, V234, P23, DOI 10.1006/abio.1996.0044; Braunwalder AF, 1996, ANAL BIOCHEM, V238, P159, DOI 10.1006/abio.1996.0269; Bridges AJ, 1999, CURR MED CHEM, V6, P825; Bridges AJ, 1996, J MED CHEM, V39, P267, DOI 10.1021/jm9503613; Buchdunger E, 1996, CANCER RES, V56, P100; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; BURKE TR, 1993, J ORG CHEM, V58, P1336, DOI 10.1021/jo00058a009; Cassinelli G, 2000, BIOCHEM PHARMACOL, V59, P1539, DOI 10.1016/S0006-2952(00)00278-1; Chen CL, 1999, J CLIN PHARMACOL, V39, P1248, DOI 10.1177/00912709922012051; CIARDIELLO F, 2000, P AM ASSOC CANC RES, V41, P3075; Cohen P, 1999, CURR OPIN CHEM BIOL, V3, P459, DOI 10.1016/S1367-5931(99)80067-2; COOK PW, 1992, CANCER RES, V52, P3224; Demidem A, 1997, CANCER BIOTHER RADIO, V12, P177, DOI 10.1089/cbr.1997.12.177; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; DVIR A, 1991, J CELL BIOL, V113, P857, DOI 10.1083/jcb.113.4.857; Eckhardt SG, 1999, J CLIN ONCOL, V17, P1095, DOI 10.1200/JCO.1999.17.4.1095; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; FERAMISCO JR, 1978, J BIOL CHEM, V253, P8968; Ferry DR, 1996, CLIN CANCER RES, V2, P659; Floyd CD, 1999, PROGR MED CHEM, V36, P91, DOI 10.1016/S0079-6468(08)70046-8; Fong TAT, 1999, CANCER RES, V59, P99; FRY DW, 1994, PEPTIDES, V15, P951, DOI 10.1016/0196-9781(94)90057-4; Fry DW, 1996, ANNU REP MED CHEM, V31, P151, DOI 10.1016/S0065-7743(08)60455-8; GARCIA P, 1993, J BIOL CHEM, V268, P25146; Gazit A, 1996, J MED CHEM, V39, P4905, DOI 10.1021/jm960225d; GLOSSMANN H, 1981, N-S ARCH PHARMACOL, V317, P100, DOI 10.1007/BF00506266; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Hashimoto Koji, 1992, Journal of Dermatology (Tokyo), V19, P648; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Iwata K., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P633; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; Klohs Wayne D., 1997, Current Opinion in Oncology, V9, P562, DOI 10.1097/00001622-199711000-00012; Kolibaba KS, 1997, BBA-REV CANCER, V1333, pF217, DOI 10.1016/S0304-419X(97)00022-X; LAM KS, 1995, INT J PEPT PROT RES, V45, P587; Lam KS, 1997, ANTI-CANCER DRUG DES, V12, P145; Lee TR, 2000, J MED CHEM, V43, P1173, DOI 10.1021/jm990462r; Lei WD, 1999, ANTICANCER RES, V19, P221; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; Losiewicz MD, 1999, BIOCHEM PHARMACOL, V57, P281, DOI 10.1016/S0006-2952(98)00293-7; Lou Q, 1996, BIOORGAN MED CHEM, V4, P677, DOI 10.1016/0968-0896(96)00063-6; Lou Q, 1997, CANCER RES, V57, P1877; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; Lunney EA, 1997, J AM CHEM SOC, V119, P12471, DOI 10.1021/ja971794t; LUNNEY EA, 1997, Patent No. 9712903; Lydon NB, 1998, INT J CANCER, V76, P154, DOI 10.1002/(SICI)1097-0215(19980330)76:1<154::AID-IJC24>3.0.CO;2-B; McLeod HL, 1996, BRIT J CANCER, V74, P1714, DOI 10.1038/bjc.1996.620; Mendelsohn J, 1997, CLIN CANCER RES, V3, P2703; MILKIEWICZ KL, 2000, ACS NAT M WASH DC; Millauer B, 1996, CANCER RES, V56, P1615; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Niu JK, 1997, J BIOL CHEM, V272, P1493, DOI 10.1074/jbc.272.3.1493; Niu JK, 1997, J AM CHEM SOC, V119, P3844, DOI 10.1021/ja970037s; O'Donnell A, 1999, EUR J CANCER, V35, pS282, DOI 10.1016/S0959-8049(99)81554-8; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; PALMER BD, 1995, J MED CHEM, V38, P58, DOI 10.1021/jm00001a011; Palmer BD, 1997, J MED CHEM, V40, P1519, DOI 10.1021/jm960789h; PARKER YW, 1997, 3 ANN C SOC BIOM SCR; Patarca R, 1996, CRIT REV ONCOGENESIS, V7, P343, DOI 10.1615/CritRevOncog.v7.i5-6.20; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; PETRAKIS KS, 1987, J AM CHEM SOC, V109, P2831, DOI 10.1021/ja00243a050; Pietras RJ, 1998, ONCOGENE, V17, P2235, DOI 10.1038/sj.onc.1202132; POSNER I, 1994, MOL PHARMACOL, V45, P673; Powell TJ, 1999, BRIT J DERMATOL, V141, P802, DOI 10.1046/j.1365-2133.1999.03152.x; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Rewcastle GW, 1998, J MED CHEM, V41, P742, DOI 10.1021/jm970641d; Rewcastle GW, 1996, J MED CHEM, V39, P918, DOI 10.1021/jm950692f; Rice AB, 1999, AM J PATHOL, V155, P213, DOI 10.1016/S0002-9440(10)65115-2; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ruggeri BA, 1999, CURR MED CHEM, V6, P845; RUGGERI UT, 1989, TRENDS PHARMACOL SCI, V10, P218; Sausville EA, 1998, CANCER CHEMOTH PHARM, V42, pS54, DOI 10.1007/s002800051080; Sawyer TK, 1998, BIOPOLYMERS, V47, P243, DOI 10.1002/(SICI)1097-0282(1998)47:3<243::AID-BIP4>3.0.CO;2-P; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmitz R, 1996, J MOL BIOL, V260, P664, DOI 10.1006/jmbi.1996.0429; Seethalal R, 1997, ANAL BIOCHEM, V253, P210, DOI 10.1006/abio.1997.2365; Shakespeare W, 2000, P NATL ACAD SCI USA, V97, P9373, DOI 10.1073/pnas.97.17.9373; Showalter HDH, 1997, J MED CHEM, V40, P413, DOI 10.1021/jm960689b; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Smaill JB, 1999, J MED CHEM, V42, P1803, DOI 10.1021/jm9806603; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Stahura FL, 1999, J MOL GRAPH MODEL, V17, P1, DOI 10.1016/S1093-3263(99)00015-7; Stebbing J, 2000, CANCER TREAT REV, V26, P287, DOI 10.1053/ctrv.2000.0182; Strawn LM, 1996, CANCER RES, V56, P3540; Sun L, 1998, J MED CHEM, V41, P2588, DOI 10.1021/jm980123i; Sun L, 2000, J MED CHEM, V43, P2655, DOI 10.1021/jm9906116; Sun L, 2000, DRUG DISCOV TODAY, V5, P344, DOI 10.1016/S1359-6446(00)01534-8; Theodorescu D, 1998, INT J CANCER, V78, P775, DOI 10.1002/(SICI)1097-0215(19981209)78:6<775::AID-IJC16>3.0.CO;2-G; Toledo LM, 1999, CURR MED CHEM, V6, P775; Traxler P, 1999, J MED CHEM, V42, P1018, DOI 10.1021/jm980551o; Traxler PM, 1996, J MED CHEM, V39, P2285, DOI 10.1021/jm960118j; Twaddle GM, 1999, J SURG ONCOL, V70, P83, DOI 10.1002/(SICI)1096-9098(199902)70:2<83::AID-JSO4>3.0.CO;2-L; Uckun FM, 1999, CLIN CANCER RES, V5, P3906; UMEZAWA H, 1986, J ANTIBIOT, V39, P170, DOI 10.7164/antibiotics.39.170; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; Vincent P. W., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P117; WALSH DA, 1991, METHOD ENZYMOL, V201, P304; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698; WARD WHJ, 1994, BIOCHEM PHARMACOL, V48, P659, DOI 10.1016/0006-2952(94)90042-6; WEN X, 2000, P AM ASSOC CANC RES, V41, P2052; Woodburn J. R., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P633; WOODBURN JR, 2000, P AM ASSOC CANC RES, V41, P2552; Wu JJ, 1996, LETT PEPT SCI, V3, P309, DOI 10.1007/BF00127665; WU JJ, 1997, AM ASS CANC RES P, V38, P443; Wu JZJ, 1998, BIOORG MED CHEM LETT, V8, P2279, DOI 10.1016/S0960-894X(98)00413-2; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu XL, 1996, BIOCHEM PHARMACOL, V52, P527, DOI 10.1016/0006-2952(96)00303-6; YE F, 2000, ACS NAT M WASH DC; YUAN CJ, 1990, J BIOL CHEM, V265, P16205; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	125	98	107	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2000	19	49					5690	5701		10.1038/sj.onc.1203926	http://dx.doi.org/10.1038/sj.onc.1203926			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114749				2022-12-17	WOS:000165659300016
J	Boese, A; Sauter, M; Galli, U; Best, B; Herbst, H; Mayer, J; Kremmer, E; Roemer, K; Mueller-Lantzsch, N				Boese, A; Sauter, M; Galli, U; Best, B; Herbst, H; Mayer, J; Kremmer, E; Roemer, K; Mueller-Lantzsch, N			Human endogenous retrovirus protein cORF supports cell transformation and associates with the promyelocytic leukemia zinc finger protein	ONCOGENE			English	Article						endogenous retroviruses; germ cell tumor; spermatogenesis	ACID RECEPTOR-ALPHA; OPEN READING FRAMES; PLZF-RAR-ALPHA; RETINOIC ACID; GERM-CELL; HISTONE DEACETYLASE; TROPHOBLASTIC TUMORS; FUSION PARTNERS; HTDV/HERV-K; TRANSLOCATION	Human endogenous retrovirus sequences (HERVs) reside in the genomes of primates and humans for several million years, The majority of HERVs is non-coding but a limited set is intact and can express proteins, We have recently identified an almost intact HERV-K(HML-2) provirus on chromosome 7 and have documented that most patients with germ cell tumors (GCTs) display antibodies directed against proteins of HERV-K(HML-2), To address whether these proteins merely represent tumor markers or contribute to neoplastic transformation, we examined the transforming potential of various HERV sequences and studied physical interactions between HERV and cellular proteins by yeast two-hybrid and biochemical assays. cORF, a protein encoded by the C-terminal open reading frame within the cnv gene, supports tumor growth in nude mice and associates with the promyelocytic leukemia zinc finger protein (PLZF), The interaction domains map between amino acid residues 21 and 87 of cORF, and between residues 245 and 543 of PLZF, PLZF is critical for spermatogenesis in mice. Abnormal spermatogenesis or maturation of gonocytes is thought to predispose humans to the development of germ cell tumors. Thus, cORF of human endogenous retroviruses may contribute to tumor development by interfering,vith processes during spermatogenesis that involve PLZF.	Univ Saarland, Sch Med, Dept Virol, D-66421 Homburg, Germany; Gerhard Domagk Inst Pathol, D-48149 Munster, Germany; GSF Forschungszentrum Umwelt & Gesundheit, Inst Mol Immunol, D-81377 Munich, Germany	Saarland University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Mueller-Lantzsch, N (corresponding author), Univ Saarland, Sch Med, Dept Virol, Bldg 47, D-66421 Homburg, Germany.		Mayer, Jens/B-8506-2013; Mayer, Jens/P-4777-2019	Mayer, Jens/0000-0002-1090-5765; Mayer, Jens/0000-0002-1090-5765; Boese, Annette Sophia/0000-0002-5166-7425				Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Boese A, 2000, FEBS LETT, V468, P65, DOI 10.1016/S0014-5793(00)01197-2; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GUIDEZ F, 1994, LEUKEMIA, V8, P312; Hawe N., 1996, Blood, V88, p291A; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heimdal K, 1997, BRIT J CANCER, V75, P1084, DOI 10.1038/bjc.1997.185; Herbst H, 1998, APMIS, V106, P216, DOI 10.1111/j.1699-0463.1998.tb01338.x; Herbst H, 1996, AM J PATHOL, V149, P1727; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LOWER R, 1995, J VIROL, V69, P141; LOWER R, 1993, P NATL ACAD SCI USA, V90, P4480, DOI 10.1073/pnas.90.10.4480; Magin C, 1999, J VIROL, V73, P9496, DOI 10.1128/JVI.73.11.9496-9507.1999; Mangeney M, 1998, P NATL ACAD SCI USA, V95, P14920, DOI 10.1073/pnas.95.25.14920; Mayer J, 1999, NAT GENET, V21, P257, DOI 10.1038/6766; Mayer J, 1997, CYTOGENET CELL GENET, V78, P1, DOI 10.1159/000134614; Mayer J, 1997, CYTOGENET CELL GENET, V79, P157, DOI 10.1159/000134709; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MUELLERLANTZSCH N, 1993, AIDS RES HUM RETROV, V9, P343, DOI 10.1089/aid.1993.9.343; Ravnik SE, 1999, DEV BIOL, V207, P408, DOI 10.1006/dbio.1998.9156; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; SAUTER M, 1995, J VIROL, V69, P414, DOI 10.1128/JVI.69.1.414-421.1995; Sauter M, 1996, CANCER RES, V56, P4362; SKAKKEBAEK NE, 1972, LANCET, V2, P516; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Yang J, 1999, P NATL ACAD SCI USA, V96, P13404, DOI 10.1073/pnas.96.23.13404; YEE JK, 1994, METHOD CELL BIOL, V43, P99; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Zhang T, 1999, P NATL ACAD SCI USA, V96, P11422, DOI 10.1073/pnas.96.20.11422	41	98	103	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4328	4336		10.1038/sj.onc.1203794	http://dx.doi.org/10.1038/sj.onc.1203794			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980608				2022-12-17	WOS:000089271900003
J	Sanceau, J; Hiscott, J; Delattre, O; Wietzerbin, J				Sanceau, J; Hiscott, J; Delattre, O; Wietzerbin, J			IFN-beta induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7	ONCOGENE			English	Article						Ewing's sarcoma; interferon-beta; IRF-1; apoptosis; caspase-7	I INTERFERON RECEPTOR; NECROSIS-FACTOR-ALPHA; KINASE INHIBITOR P21; REGULATORY FACTOR-I; SIGNALING PATHWAY; TRANSCRIPTIONAL ACTIVATION; MOLECULAR-CLONING; GROWTH-INHIBITION; P53 MUTATIONS; HUMAN TUMORS	Four human cell lines derived from Ewing's sarcoma, EW-7, EW-1, COH and ORS, were investigated to establish the effects of human recombinant interferon-alpha 2a and human recombinant interferon-beta on cell proliferation and apoptosis, All four cell lines were much more sensitive to the antiproliferative effects of IFN-beta than of IFN-alpha. Analysis of the early signals triggered by IFN-alpha and IFN-beta demonstrated that the two IFNs were similarly effective in inducing tyrosine phosphorylation of the Jak-1 and Tyk-2 kinases and the transcription factors Stat-1 and Stat-2, Interestingly, an additional rapid phosphorylation of Stat-1 on serine was observed after IFN-beta treatment, with concomitant activation of p38 mitogen-activated protein kinase, In these cells, Stat-1 Ser727 phosphorylation in response to IFN-beta was found to be impaired by p38 MAPkinase inhibitor (SB203580). IFN-beta induced the formation of the Interferon Stimulated Gene Factor 3 complex more efficiently than IFN-alpha, as well as sustained induction of IRF-1, which may account for its greater induction of 2'5'oligo(A)synthetase and greater inhibition of cell proliferation. IFN-beta, but not IFN-alpha, induced apoptosis in wild-type p53 EW-7 and COH cell lines, but not in the mutated p53 EW-1 or ORS cell lines. The apoptosis induced by IFN-beta in EW-7 and COH cell lines appeared to be mediated by IRF-1 and involved the activation of caspase-7, Ectopic expression of IRF-1 induced apoptosis in all four cell lines which correlated with the activation of caspase-7 and,vith the downregulation of the Bcl-2 oncoprotein, as observed for IFN-beta-induced apoptosis in parental EW-7 and COH cell lines.	Inst Curie, INSERM, U365, Sect Rech, F-75248 Paris 05, France; McGill Univ, Lady Davis Inst Res, Montreal, PQ H3T 1E2, Canada; Inst Curie, INSERM, U509, Sect Rech, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Lady Davis Institute; McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Sanceau, J (corresponding author), Inst Curie, INSERM, U365, Sect Rech, 26 Rue Ulm, F-75248 Paris 05, France.			delattre, olivier/0000-0002-8730-2276				AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; Arriola EL, 1999, ONCOGENE, V18, P1457, DOI 10.1038/sj.onc.1202420; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; AURIAS A, 1983, NEW ENGL J MED, V309, P496; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; Borden, 1998, Oncologist, V3, P198; BRAILLY RA, 1993, MOL CELL BIOL, V14, P3230; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COLAMONICI OR, 1995, J BIOL CHEM, V270, P8188, DOI 10.1074/jbc.270.14.8188; Croze E, 1996, J BIOL CHEM, V271, P33165, DOI 10.1074/jbc.271.52.33165; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEMARCO F, 1995, J GEN VIROL, V76, P445, DOI 10.1099/0022-1317-76-2-445; Domanski P, 1998, J BIOL CHEM, V273, P3144, DOI 10.1074/jbc.273.6.3144; Domanski Paul, 1996, Cytokine and Growth Factor Reviews, V7, P143, DOI 10.1016/1359-6101(96)00017-2; DORR RT, 1993, DRUGS, V45, P177, DOI 10.2165/00003495-199345020-00003; EILERS A, 1995, MOL CELL BIOL, V15, P3579; Fizazi K, 1998, J CLIN ONCOL, V16, P3736, DOI 10.1200/JCO.1998.16.12.3736; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Giandomenico V, 1998, EUR CYTOKINE NETW, V9, P619; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Grander D, 1997, EUR J HAEMATOL, V59, P129; Grumbach IM, 1999, J INTERF CYTOK RES, V19, P797, DOI 10.1089/107999099313659; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Hadida F, 1999, HUM GENE THER, V10, P1803, DOI 10.1089/10430349950017482; HAMELIN R, 1994, INT J CANCER, V57, P336, DOI 10.1002/ijc.2910570308; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; Horowitz Marc E., 1997, P831; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Hotchkiss RS, 1999, J IMMUNOL, V162, P4148; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; Kimura T, 1996, GENES CELLS, V1, P115, DOI 10.1046/j.1365-2443.1996.08008.x; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Marcelli M, 1998, CANCER RES, V58, P76; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MICHALEVICZ R, 1988, LEUKEMIA RES, V12, P845, DOI 10.1016/0145-2126(88)90038-0; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; ROKLIN OW, 1996, CANCER RES, V58, P5870; Rosolen A, 1997, MODERN PATHOL, V10, P55; Runkel L, 1998, J BIOL CHEM, V273, P8003, DOI 10.1074/jbc.273.14.8003; Sacchi S, 1998, J CLIN ONCOL, V16, P882, DOI 10.1200/JCO.1998.16.3.882; Salmeron J, 1999, LIVER, V19, P275, DOI 10.1111/j.1478-3231.1999.tb00049.x; SALVESEN G, 1997, CELL, V91, P433; SANCEAU J, 1995, J BIOL CHEM, V270, P27920, DOI 10.1074/jbc.270.46.27920; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; Tanneberger S, 1996, J INTERF CYTOK RES, V16, P339, DOI 10.1089/jir.1996.16.339; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VANVALEN F, 1993, J CANCER RES CLIN, V119, P615, DOI 10.1007/BF01372725; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	70	98	101	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 13	2000	19	30					3372	3383		10.1038/sj.onc.1203670	http://dx.doi.org/10.1038/sj.onc.1203670			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918594				2022-12-17	WOS:000088198100005
J	Zisch, AH; Pazzagli, C; Freeman, AL; Schneller, M; Hadman, M; Smith, JW; Ruoslahti, E; Pasquale, EB				Zisch, AH; Pazzagli, C; Freeman, AL; Schneller, M; Hadman, M; Smith, JW; Ruoslahti, E; Pasquale, EB			Replacing two conserved tyrosines of the EphB2 receptor with glutamic acid prevents binding of SH2 domains without abrogating kinase activity and biological responses	ONCOGENE			English	Article						signaling pathways; tyrosine phosphorylation; actin cytoskeleton; cell adhesion; mitogen-activated protein kinases	ACTIN-BUNDLING PROTEIN; MAP KINASE; AUTOPHOSPHORYLATION SITE; INTEGRIN ACTIVATION; NEURAL DEVELOPMENT; LIGAND ACTIVATION; POINT MUTATION; CELL MOTILITY; IN-VITRO; FAMILY	Eph receptor tyrosine kinases play key roles in pattern formation during embryonic development, but little is known about the mechanisms by which they elicit specific biological responses in cells. Here, we investigate the role of tyrosines 605 and 611 in the juxtamembrane region of EphB2, because they are conserved Eph receptor autophosphorylation sites and demonstrated binding sites for the SH2 domains of multiple signaling proteins. Mutation of tyrosines 605 and 611 to phenylalanine impaired EphB2 kinase activity, complicating analysis of their function as SH2 domain binding sites and their contribution to EphB2-mediated signaling. In contrast, mutation to the negatively charged glutamic acid disrupted SH2 domain binding without reducing EphB2 kinase activity. By using a panel of EphB2 mutants, we found that kinase activity is required for the changes in cell-matrix and cell-cell adhesion, cytoskeletal organization, and activation of mitogen-activated protein (MAP) kinases elicited by EphB2 in transiently transfected cells, Instead, the two juxtamembrane SH2 domain binding sites were dispensable for these effects. These results suggest that phosphorylation of tyrosines 605 and 611 is critical for EphB2-mediated cellular responses because it regulates EphB2 kinase activity.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Pasquale, EB (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NICHD NIH HHS [HD26351, HD25938] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026351, P01HD025938, R01HD026351] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams JC, 1997, MOL BIOL CELL, V8, P2345, DOI 10.1091/mbc.8.11.2345; ADAMS JC, 1995, J CELL SCI, V108, P1977; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bruckner K, 1998, CURR OPIN NEUROBIOL, V8, P375, DOI 10.1016/S0959-4388(98)80064-0; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1991, CELL GROWTH DIFFER, V2, P483; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Drescher U, 1997, CURR BIOL, V7, pR799, DOI 10.1016/S0960-9822(06)00409-X; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Ellis C, 1996, ONCOGENE, V12, P1727; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; GANDINO L, 1994, J BIOL CHEM, V269, P1815; Giasson BI, 1997, J NEUROSCI, V17, P9466; Giasson BI, 1996, J BIOL CHEM, V271, P30404, DOI 10.1074/jbc.271.48.30404; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; Holash JA, 1997, DEV BIOL, V182, P256, DOI 10.1006/dbio.1996.8496; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Kalo MS, 1999, BIOCHEMISTRY-US, V38, P14396, DOI 10.1021/bi991628t; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lin XH, 1996, MOL BIOL CELL, V7, P1977, DOI 10.1091/mbc.7.12.1977; Luo LQ, 1997, CURR OPIN NEUROBIOL, V7, P81, DOI 10.1016/S0959-4388(97)80124-9; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; Meima L, 1997, MOL CELL NEUROSCI, V9, P314, DOI 10.1006/mcne.1997.0621; Meima L, 1997, EUR J NEUROSCI, V9, P177, DOI 10.1111/j.1460-9568.1997.tb01365.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Veeranna, 1998, J NEUROSCI, V18, P4008; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WITTEKIND M, 1989, BIOCHEMISTRY-US, V28, P9908, DOI 10.1021/bi00452a005; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823; Zisch AH, 1997, CELL TISSUE RES, V290, P217, DOI 10.1007/s004410050926; Zisch AH, 1997, J NEUROSCI RES, V47, P655, DOI 10.1002/(SICI)1097-4547(19970315)47:6<655::AID-JNR12>3.0.CO;2-U; ZOU JX, IN PRESS P NAT ACAD	74	98	98	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					177	187		10.1038/sj.onc.1203304	http://dx.doi.org/10.1038/sj.onc.1203304			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10644995				2022-12-17	WOS:000084844400002
J	Feldkamp, MM; Lau, N; Guha, A				Feldkamp, MM; Lau, N; Guha, A			Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects	ONCOGENE			English	Article						farnesyl transferase inhibitor, FTI; L-744,832; astrocytoma; glioma; Ras	RAS-TRANSFORMED-CELLS; HUMAN-BRAIN-TUMORS; NIH 3T3 CELLS; FARNESYLTRANSFERASE INHIBITORS; FACTOR RECEPTOR; PROTEIN TRANSFERASE; ACTIN CYTOSKELETON; TRANSGENIC MICE; KINASE-KINASE; ONCOGENIC RAS	While 25% of human cancers harbor oncogenic Ras mutations, such mutations are not found in astrocytomas. We have previously demonstrated that the activation of receptor tyrosine kinases expressed by malignant human astrocytoma cells and specimens results in functional upregulation of the Ras signalling pathway and increased levels of activated Ras GTP. Farnesyl transferase inhibitors (FTIs) are promising anti-cancer agents in early clinical trials, which may exert their effect through pharmacological inhibition of the Ras signalling pathway, In this study we establish the anti-tumorigenic properties of the FTI L-744,832 against a panel of malignant human astrocytoma cell Lines. Furthermore, we demonstrate the multiple mechanisms by which L744,832 exerts its effect. L-744,832 demonstrates both cytostatic and cytotoxic effects on astrocytoma cells, and cells expressing a truncated constitutively phosphorylated Epidermal Growth Factor Receptor common in high-grade astrocytomas (EGFRvIII/p140(EGF-R)) demonstrate increased sensitivity to the agent. L-744,832 is capable of inducing apoptosis in astrocytoma cells under anchorage-dependent conditions; this process occurs in a p53-independent manner and is associated with increased expression of Bax and Bak, L-744,832 also induces cell cycle arrest at both the G(1)/M and G(2)/S checkpoints; this process is also independent of p53 mutational status. Cell cycle arrest in drug-treated cells can be accompanied by induction of p21(WAF1/CIP1), but this induction is not necessary for the cell cycle inhibitory effects, nor is it dependent on functional p53, Finally, angiogenesis in astrocytomas has been shown to be dependent on secretion of Vascular Endothelial Growth Factor (VEGF) by tumour cells, particularly under hypoxic conditions, L-744,832 potently inhibits the secretion of VEGF under hypoxic conditions. These combinations of mechanisms suggest that these tumours, despite the absence of oncogenic Ras mutations, will be amenable to growth inhibition by FTIs, through a combination of anti-proliferative, pro-apoptotic, and anti-angiogenic effects.	Toronto Western Hosp, Univ Hlth Network, Div Neurosurg, Toronto, ON M5T 2S8, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Toronto, ON, Canada; Princess Margaret Hosp, Ontario Canc Inst, Dept Surg Oncol, Toronto, ON M4X 1K9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Guha, A (corresponding author), Toronto Western Hosp, Univ Hlth Network, Div Neurosurg, Toronto, ON M5T 2S8, Canada.							ASANO M, 1995, CANCER RES, V55, P5296; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; BOS JL, 1989, CANCER RES, V49, P4682; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; Du W, 1999, MOL CELL BIOL, V19, P1831; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Feldkamp MM, 1999, INT J CANCER, V81, P118, DOI 10.1002/(SICI)1097-0215(19990331)81:1<118::AID-IJC20>3.0.CO;2-5; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FLEMING TP, 1992, CANCER RES, V52, P4550; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GomezManzano C, 1996, CANCER RES, V56, P694; GOODWIN CJ, 1995, J IMMUNOL METHODS, V179, P95, DOI 10.1016/0022-1759(94)00277-4; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; GUHA A, 1995, J NEUROL NEUROSUR PS, V58, P711, DOI 10.1136/jnnp.58.6.711; Gutmann DH, 1996, ONCOGENE, V12, P2121; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Izawa I, 1996, FEBS LETT, V382, P53, DOI 10.1016/0014-5793(96)00137-8; James G, 1996, P NATL ACAD SCI USA, V93, P4454, DOI 10.1073/pnas.93.9.4454; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Law BK, 1999, J BIOL CHEM, V274, P4743, DOI 10.1074/jbc.274.8.4743; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lebowitz PF, 1997, CANCER RES, V57, P708; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LIBERMANN TA, 1984, CANCER RES, V44, P753; MANNE V, 1995, ONCOGENE, V10, P1763; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Melnyk O, 1996, CANCER RES, V56, P921; Millauer B, 1996, CANCER RES, V56, P1615; Miyake M, 1996, FEBS LETT, V378, P15, DOI 10.1016/0014-5793(95)01416-0; NAGASU T, 1995, CANCER RES, V55, P5310; NISTER M, 1988, CANCER RES, V48, P3910; Norgaard P, 1999, CLIN CANCER RES, V5, P35; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; RAK J, 1995, CANCER RES, V55, P4575; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Saleh M, 1996, CANCER RES, V56, P393; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Sepp-Lorenzino L, 1998, J BIOL CHEM, V273, P20243, DOI 10.1074/jbc.273.32.20243; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STECK PA, 1988, CANCER RES, V48, P5433; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; TUZI NL, 1991, BRIT J CANCER, V63, P227, DOI 10.1038/bjc.1991.54; Vogt A, 1996, ONCOGENE, V13, P1991; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; Zhang FL, 1997, J BIOL CHEM, V272, P10232; ZIMMERMA.HM, 1969, ANN NY ACAD SCI, V159, P337, DOI 10.1111/j.1749-6632.1969.tb48290.x	71	98	98	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7514	7526		10.1038/sj.onc.1203105	http://dx.doi.org/10.1038/sj.onc.1203105			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602510				2022-12-17	WOS:000084119600012
J	Hajra, KM; Ji, XD; Fearon, ER				Hajra, KM; Ji, XD; Fearon, ER			Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements	ONCOGENE			English	Article						E-cadherin; breast cancer; somatic cell hybrid; transcription factor; gene expression; E-box	INVASION-SUPPRESSOR GENE; CELL-LINES; GASTRIC-CANCER; UVOMORULIN; ADHESION; CARCINOMAS; MECHANISMS; MUTATIONS	Inactivation of the E-cadherin cell adhesion molecule is believed critical in the development and behavior of many epithelial cancers, though mutations in the E-cadherin gene account for inactivation in only a fraction of cases, In many breast cancer lines, E-cadherin transcription is extinguished, but the role and significance of alterations in trans-acting transcription factors, promoter hypermethylation, and chromatin changes remain unresolved, To gain further insights into mechanisms underlying E-cadherin in inactivation in breast cancer, we analysed somatic cell hybrids resulting from pairwise fusions between breast cancer lines with intact E-cadherin transcription (E-cad+) and lines lacking E-cadherin transcription (E-cad-), All hybrid lines failed to express E-cadherin transcripts and protein, despite the fact that E-cadherin alleles from E-cad+ lines were present in the hybrids, Elements in the proximal 108 bp of the E-cadherin promoter, when present in reporter gene constructs, mere sufficient to direct strong transcription in E-cad+ breast lines, but displayed weak activity in E-cad- parental lines and hybrids, E-cadherin expression could not be restored in E-cad- lines or hybrids by treatment with a DNA demethylating agent and/or a histone deacetylase inhibitor, Our findings suggest loss of E-cadherin expression in some breast cancers may be due to dominant repression of the trans-acting pathways that regulate E-cadherin transcription.	Univ Michigan, Sch Med, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Fearon, ER (corresponding author), Univ Michigan, Med Ctr, Div Med Genet, 1500 W Med Ctr Dr,4301 MSRB3, Ann Arbor, MI 48109 USA.				NATIONAL CANCER INSTITUTE [R01CA070097, T32CA009676] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA70097, 5 T32 CA09676-08] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BERX G, 1995, GENOMICS, V26, P281, DOI 10.1016/0888-7543(95)80212-5; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1284, DOI 10.1006/bbrc.1994.2321; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; FRESHNEY RI, 1994, CULTURE ANIMAL CELLS, P389; GAMALLO C, 1993, AM J PATHOL, V142, P987; Gayther SA, 1998, CANCER RES, V58, P4086; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAFF JR, 1995, CANCER RES, V55, P5195; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HENNIG G, 1995, ONCOGENE, V11, P475; Hiraguri S, 1998, CANCER RES, V58, P1972; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Keller G, 1999, AM J PATHOL, V155, P337, DOI 10.1016/S0002-9440(10)65129-2; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MANSOURI A, 1988, DIFFERENTIATION, V38, P67, DOI 10.1111/j.1432-0436.1988.tb00593.x; NATT E, 1989, CYTOGENET CELL GENET, V50, P145, DOI 10.1159/000132745; PIERCEALL WE, 1995, ONCOGENE, V11, P1319; Poola I, 1998, ANAL BIOCHEM, V258, P209, DOI 10.1006/abio.1998.2629; Siitonen SM, 1996, AM J CLIN PATHOL, V105, P394; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	28	98	100	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7274	7279		10.1038/sj.onc.1203336	http://dx.doi.org/10.1038/sj.onc.1203336			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602481				2022-12-17	WOS:000084119400011
J	Takahashi, T; Haruki, N; Nomoto, S; Masuda, A; Saji, S; Osada, H; Takahashi, T				Takahashi, T; Haruki, N; Nomoto, S; Masuda, A; Saji, S; Osada, H; Takahashi, T			Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung cancers	ONCOGENE			English	Article						mitotic checkpoint; lung cancer; hsMAD2; p55CDC; pseudogene	SPINDLE ASSEMBLY CHECKPOINT; BUDDING YEAST; ARREST; P53; PROTEIN; TARGET; CDC20	The mitotic checkpoint is thought to be essential for ensuring accurate chromosome segregation by implementing mitotic delay in response to a spindle defect. To date, however, very little data has become available on the defects of the mitotic checkpoint in human cancer cells, In the present study, impaired mitotic checkpoint was found in four (44%) of nine human lung cancer cell lines. To our knowledge, this is the first demonstration of frequent impairment of the mitotic checkpoint in this leading cause of cancer deaths. iis an initial step towards elucidation of the underlying mechanism, we further undertook a search for mutations in a key component of the mitotic checkpoint, known as hsMAD2, and its immediate downstream molecule, p55CDC, No such mutations were found, however, in either 21 lung cancer cell lines or 25 primary lung cancer cases, although we could identify silent polymorphisms and the transcribed and processed hsMAD2 pseudogene that was subsequently mapped at 14q21-q23, The present observations appear to warrant further investigations, such as search for alterations in other components, to better understand the molecular pathogenesis of this fatal disease, and warn against potential misinterpretation when performing mutational analyses for other cancer types based on cDNA templates.	Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Gifu Univ, Sch Med, Dept Surg 2, Gifu 5008705, Japan	Aichi Cancer Center; Aichi Cancer Center; Gifu University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Takahashi, Takashi/I-7262-2014; Osada, Hiroyuki/AAY-6254-2020	Takahashi, Takashi/0000-0003-0615-7001; 				Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Elledge SJ, 1998, SCIENCE, V279, P999, DOI 10.1126/science.279.5353.999; GOTOH K, 1999, IN PRESS CARCINOGENE; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; HIBI K, 1994, ONCOGENE, V9, P611; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; KONDO M, 1995, ONCOGENE, V10, P1193; Krishnan R, 1998, GENOMICS, V49, P475, DOI 10.1006/geno.1998.5233; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; *STAT INF DEP, 1998, VIT STAT JAP, V3, P384; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1986, CANCER RES, V46, P4770; TESTA JR, 1996, LUNG CANC PRINCIPLES, P55; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350	26	98	107	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4295	4300		10.1038/sj.onc.1202807	http://dx.doi.org/10.1038/sj.onc.1202807			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439037				2022-12-17	WOS:000081732700002
J	Weis, B; Giehl, K; Gana-Weisz, M; Egozi, Y; Ben-Baruch, G; Marciano, D; Gierschik, P; Kloog, Y				Weis, B; Giehl, K; Gana-Weisz, M; Egozi, Y; Ben-Baruch, G; Marciano, D; Gierschik, P; Kloog, Y			A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice	ONCOGENE			English	Article						Ras oncogenes; Ras antagonists; human pancreatic tumor; FTS; Panc-1; EGF; MAPK	DEPENDENT CELL-GROWTH; K-RAS; FARNESYLTRANSFERASE INHIBITORS; TRANSFORMED-CELLS; FACTOR RECEPTOR; FARNESYLTHIOSALICYLIC ACID; STRUCTURAL REQUIREMENTS; TRANSFERASE INHIBITORS; SIGNAL-TRANSDUCTION; HUMAN CANCER	Constitutively active Pas proteins, their regulatory components, and overexpressed tyrosine kinase receptors that activate Pas, are frequently associated with cell transformation in human tumors. This suggests that functional Pas antagonists may have anti-tumor activity. Studies in rodent fibroblasts have shown that S-trans, transfarnesylthiosalicylic acid (FTS) acts as a rather specific nontoxic Pas antagonist, dislodging Pas from its membrane anchorage domains and accelerating its degradation. FTS is not a farnesyltransferase inhibitor, and does not affect Pas maturation. Here we demonstrate that FTS also acts as a functional Pas antagonist in human pancreatic cell lines that express activated K-Ras (Panc-1 and MiaPaCa-2). In Panc-1 cells, FTS at a concentration of 25-100 mu M reduced the amount of Pas in a dose-dependent manner and interfered with serum-dependent and epidermal growth factor-stimulated ERK activation, thus inhibiting both anchorage-dependent and anchorage-independent growth of Panc-1 cells in vitro. FTS also inhibited tumor growth in Panc-1 xenografted nude mice, apparently without systemic toxicity. Daily FTS treatment (5 mg/kg intraperitoneallly) in mice with tumors (mean volume 0.07 cm(3)) markedly decreased tumor growth (after treatment for 18 days, tumor volume had increased by only 23+/-30-fold in the FTS-treated group and by 127+/-66-fold in controls). These findings suggest that FTS represents a new class of functional Pas antagonists with potential therapeutic value.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Univ Ulm, Dept Pharmacol & Toxicol, D-89069 Ulm, Germany; Chaim Sheba Med Ctr, Dept Obstet & Gynecol, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; Israel Inst Biol Res, IL-70450 Ness Ziona, Israel	Tel Aviv University; Ulm University; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Kloog, Y (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.							Aharonson Z, 1998, BBA-MOL BASIS DIS, V1406, P40, DOI 10.1016/S0925-4439(97)00077-X; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERROZPE G, 1994, INT J CANCER, V58, P185, DOI 10.1002/ijc.2910580207; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bos JL, 1997, BBA-REV CANCER, V1333, pM19, DOI 10.1016/S0304-419X(97)00015-2; BOS JL, 1995, EUR J CANCER, V31A, P1051, DOI 10.1016/0959-8049(95)00168-I; BOS JL, 1989, CANCER RES, V49, P4682; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN YF, 1990, PANCREAS, V5, P278, DOI 10.1097/00006676-199005000-00006; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; GanaWeisz ML, 1997, BIOCHEM BIOPH RES CO, V239, P900, DOI 10.1006/bbrc.1997.7582; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HUBRAN RH, 1993, AM J PATHOL, V143, P545; James G, 1996, P NATL ACAD SCI USA, V93, P4454, DOI 10.1073/pnas.93.9.4454; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kolibaba KS, 1997, BBA-REV CANCER, V1333, pF217, DOI 10.1016/S0304-419X(97)00022-X; KORC M, 1986, P NATL ACAD SCI USA, V83, P5141, DOI 10.1073/pnas.83.14.5141; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Lebowitz PF, 1997, CANCER RES, V57, P708; LEMOINE NR, 1992, J PATHOL, V166, P7, DOI 10.1002/path.1711660103; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; MANNE V, 1995, ONCOGENE, V10, P1763; MARCIANO D, 1995, J MED CHEM, V38, P1267, DOI 10.1021/jm00008a004; Marciano D, 1997, BIOORG MED CHEM LETT, V7, P1709, DOI 10.1016/S0960-894X(97)00294-1; MAROM M, 1995, J BIOL CHEM, V270, P22263, DOI 10.1074/jbc.270.38.22263; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MEIMBROOK DC, 1998, CURR OPIN CELL BIOL, V10, P284; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; NAGASU Y, 1995, CANCER RES, V55, P3510; PELLEGATA NS, 1994, CANCER RES, V54, P1556; Rall CJN, 1996, PANCREAS, V12, P10, DOI 10.1097/00006676-199601000-00002; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Siddiqui AA, 1998, J BIOL CHEM, V273, P3712, DOI 10.1074/jbc.273.6.3712; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SUN JZ, 1995, CANCER RES, V55, P4243; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459	65	98	100	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	1999	18	16					2579	2588		10.1038/sj.onc.1202602	http://dx.doi.org/10.1038/sj.onc.1202602			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353601				2022-12-17	WOS:000079907100005
J	Egan, C; Pang, A; Durda, D; Cheng, HC; Wang, JH; Fujita, DJ				Egan, C; Pang, A; Durda, D; Cheng, HC; Wang, JH; Fujita, DJ			Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530	ONCOGENE			English	Article						Src kinase; phosphotyrosyl phosphatase; breast cancer	EPIDERMAL-GROWTH-FACTOR; PP60C-SRC PROTEIN-KINASE; C-SRC; FACTOR RECEPTOR; MAMMARY-TUMORS; MITOGENIC RESPONSIVENESS; NEU PROTOONCOGENE; SH2 DOMAIN; EXPRESSION; PP60(C-SRC)	Elevated levels of Src kinase activity have been reported in a number of human cancers, including colon and breast cancer, We have analysed four human breast tumor cell lines that exhibit high levels of Src kinase activity, and have determined that these cell lines also exhibit a high level of a phosphotyrosine phosphatase activity that recognizes the Src carboxy-terminal P-Tyr530 negative regulatory site. Total Src kinase activity in these cell lines is elevated as much as 30-fold over activity in normal control cells and specific activity is elevated as much as 5.6-fold. When the breast tumor cells were grown in the presence of the tyrosine phosphatase inhibitor vanadate, Src kinase activity was reduced in all four breast tumor cell lines, suggesting that Src was being activated by a phosphatase which could recognize the Tyr530 negative regulatory site, In fractionated cell extracts from the breast tumor cells, we found elevated levels of a membrane associated tyrosine phosphatase activity that preferentially dephosphorylated a Src family carboxy-terminal phosphopeptide containing the regulatory tyrosine 530 site, Src was hypophosphorylated in vivo at tyrosine 530 in at least two of the tumor cell lines, further suggesting that Src was being activated by a phosphatase in these cells, In preliminary immunoprecipitation and antibody depletion experiments, we were unable to correlate the major portion of this phosphatase activity with several known phosphatases.	Univ Calgary, Med Ctr, Cell Regulat Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Med Ctr, Cell Regulat Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Med Ctr, Canc Biol Res Grp, Dept Biochem Med, Calgary, AB T2N 4N1, Canada; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Peoples R China	University of Calgary; University of Calgary; University of Calgary; Hong Kong University of Science & Technology	Fujita, DJ (corresponding author), Univ Calgary, Med Ctr, Cell Regulat Grp, Calgary, AB T2N 4N1, Canada.			Cheng, Heung-Chin/0000-0002-4965-7148				BERGER MS, 1988, CANCER RES, V48, P1238; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; JACOBS C, 1983, CANCER RES, V43, P1696; JANES PW, 1994, ONCOGENE, V9, P3601; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LITWIN CME, 1991, J BIOL CHEM, V266, P2557; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; OCONNOR TJ, 1995, CELL GROWTH DIFFER, V6, P123; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Pallen C J, 1993, Semin Cell Biol, V4, P403, DOI 10.1006/scel.1993.1048; PENG ZY, 1995, ONCOGENE, V11, P1955; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TANAKA A, 1990, ONCOGENE RES, V5, P305; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Uckun FM, 1996, J BIOL CHEM, V271, P6389, DOI 10.1074/jbc.271.11.6389; VARLEY JM, 1987, ONCOGENE, V1, P423; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; WEERNINK PAO, 1994, FEBS LETT, V352, P296, DOI 10.1016/0014-5793(94)00977-5; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; YUAN ZM, 1995, BIOCHEMISTRY-US, V34, P1058, DOI 10.1021/bi00003a041; ZHAI YF, 1993, CANCER RES, V53, P2272; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	46	98	103	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	1999	18	5					1227	1237		10.1038/sj.onc.1202233	http://dx.doi.org/10.1038/sj.onc.1202233			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022129				2022-12-17	WOS:000078510700012
J	Schmidt, T; Karsunky, H; Gau, E; Zevnik, B; Elsasser, HP; Moroy, T				Schmidt, T; Karsunky, H; Gau, E; Zevnik, B; Elsasser, HP; Moroy, T			Zinc finger protein GFI-1 has low oncogenic potential but cooperates strongly with pim and myc genes in T-cell lymphomagenesis	ONCOGENE			English	Article						oncogene cooperation; zinc finger	E-MU-MYC; TRANSGENIC MICE; N-MYC; C-MYC; ACTIVATION; TUMORS	The gfi-1 gene encodes a zinc finger containing protein that is specifically expressed in T-lymphocytes and is a frequent target of proviral insertion in T-cell lymphoma provoked by infection with MoMuLV-a non acute transforming retrovirus. Expression of a gfi-1 transgene targeted to T-cells by the lck proximal promoter provokes a reduction of peripheral CD4 and CD8 positive T-cells but nevertheless weakly predisposes transgenic animals for the development of T-cell lymphoma. Forced coexpression of the serine/threonine kinase Pim-1 can partially restore normal T-cell numbers in double pim-1/gfi-1 transgenic mice. Moreover, the combinatorial expression of Pim-1 and Gfi-1 leads to accelerated development of T-cell lymphoma with a mean latency period of 114 days. A similar accelerated rate of lymphoma development was observed when lck-gfi-1 mice were crossed with mice that carry a L-myc gene targeted to be expressed at high levels in T-cells. The results show that gfi-1 can act with low activity as a dominant oncogene when overexpressed but also demonstrate that it is most efficient only in the presence of a cooperative partner protein as for example Pim-1 or L-Myc. In addition, the results suggest that Pim-1 and Gfi-1 are acting synergistically in both T-cell lymphomagenesis and T-cell development.	Univ Essen Gesamthsch Klinikum, Inst Zellbiol Tumourforsch, IFZ, D-45122 Essen, Germany; Univ Marburg, Inst Zytobiol & Zytopathol, D-35033 Marburg, Germany	University of Duisburg Essen; Philipps University Marburg	Moroy, T (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Zellbiol Tumourforsch, IFZ, Virchowstr 173, D-45122 Essen, Germany.		Moroy, Tarik/D-9923-2011; Zevnik, Branko/AAB-7853-2020	Zevnik, Branko/0000-0001-7845-9522				BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HOGAN B, 1986, MANIPULATION MOUSE E; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MOROY T, 1991, ONCOGENE, V6, P1941; Sambrook J, 1989, MOL CLONING LAB MANU; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; Schmidt T, 1996, NUCLEIC ACIDS RES, V24, P2528, DOI 10.1093/nar/24.13.2528; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Zornig M, 1996, ONCOGENE, V12, P1789	15	98	100	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2661	2667		10.1038/sj.onc.1202191	http://dx.doi.org/10.1038/sj.onc.1202191			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840930				2022-12-17	WOS:000077058900014
J	Lutz, W; Fulda, S; Jeremias, I; Debatin, KM; Schwab, M				Lutz, W; Fulda, S; Jeremias, I; Debatin, KM; Schwab, M			MycN and IFN gamma cooperate in apoptosis of human neuroblastoma cells	ONCOGENE			English	Article						oncogenes; amplification; APO-1; FAS; cytokines; CD95	BCL-2 HOMOLOG BAK; C-MYC; N-MYC; ORNITHINE DECARBOXYLASE; DEATH; ALPHA; PROTEIN; GROWTH; EXPRESSION; INDUCTION	Neuroblastomas undergo spontaneous regression at an unusually high rate. The mechanisms are not clear, but apoptosis may be involved. A large proportion of neuroblastomas is characterized by amplification of MYCN. Using human neuroblastoma cells harbouring tetracycline controlled expression of MYCN we have analysed the role of the MycN protein and IFN gamma in cell death decision. Neither conditional expression of MYCN nor treatment with IFN gamma alone was sufficient to trigger cell death. However, when acting in concert MycN and IFN gamma efficiently triggered cell death, which was accompanied by DNA fragmentation and required caspase activity, two hallmarks of apoptosis, MycN and IFN gamma may cooperate along at least two different pathways. First, IFN gamma increased the CD95 cell surface expression while MycN enhanced the cellular susceptibility for the CD95 mediated death signal. Second, IFN gamma, treatment induced expression of BAK mRNA while MycN and IFN gamma in combination increased the amount of Bax protein, another activator of apoptosis, without a concomitant increase in BAX mRNA. MycN also increased cell death in response to TRAIL and TNF alpha, suggesting that enforced MYCN expression in general increases the susceptibility of neuroblastoma cells towards a variety of death stimuli.	German Canc Res Ctr, Dept Cytogenet 0825, D-69120 Heidelberg, Germany; Heidelberg Univ, Childrens Hosp, Div Hematol Oncol, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Mol Oncol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Schwab, M (corresponding author), German Canc Res Ctr, Dept Cytogenet 0825, Neuheimer Feld 280, D-69120 Heidelberg, Germany.		Fulda, Simone/D-5864-2011; Jeremias, Irmela/C-6090-2015; Jeremias, Irmela/Q-5934-2019; Debatin, Klaus-Michael/J-9704-2014	Jeremias, Irmela/0000-0003-1773-7677; Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				ASKEW DS, 1991, ONCOGENE, V6, P1915; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; BERTHOLD F, 1990, NEUROBLASTOMA TUMOR, P1; CASTLE VP, 1993, AM J PATHOL, V143, P1543; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1997, CANCER RES, V57, P3823; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Ikeda H, 1996, AM J SURG PATHOL, V20, P649, DOI 10.1097/00000478-199606000-00001; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LevyStrumpf N, 1997, MOL CELL BIOL, V17, P1615, DOI 10.1128/MCB.17.3.1615; Lutz W, 1996, ONCOGENE, V13, P803; MIYASHITA T, 1995, CELL, V80, P293; Montaldo PG, 1997, CELL DEATH DIFFER, V4, P150, DOI 10.1038/sj.cdd.4400215; Nakagawara A, 1997, CANCER RES, V57, P4578; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OITVAI ZN, 1993, CELL, V74, P609; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PONZONI M, 1992, CANCER RES, V52, P931; PRITCHARD J, 1994, LANCET, V344, P869, DOI 10.1016/S0140-6736(94)92834-7; Sato T, 1997, BRIT J HAEMATOL, V97, P356, DOI 10.1046/j.1365-2141.1997.562704.x; Schwab M, 1995, NEUROSCIENTIST, V1, P277; SCHWAB M, 1998, BIOESSAYS        JUN; Schwab M, 1997, PATHOLOGY GENETICS T, P117; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P7227, DOI 10.1073/pnas.94.14.7227; ZORNIG M, 1995, ONCOGENE, V11, P2165; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	55	98	102	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	1998	17	3					339	346		10.1038/sj.onc.1200201	http://dx.doi.org/10.1038/sj.onc.1200201			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690515				2022-12-17	WOS:000074947500008
J	Holmberg, C; Helin, K; Sehested, M; Karlstrom, O				Holmberg, C; Helin, K; Sehested, M; Karlstrom, O			E2F-1-induced p53-independent apoptosis in transgenic mice	ONCOGENE			English	Article						E2F; p53; apoptosis; testis; transgenic mice	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; S-PHASE ENTRY; UBIQUITIN-PROTEASOME PATHWAY; CELL-CYCLE REGULATION; TUMOR-SUPPRESSOR; BINDING PROTEIN; IN-VIVO; DEREGULATED EXPRESSION; FIBROBLASTS LEADS	The E2F transcription factors are keg targets for the retinoblastoma protein, pRB, By inactivation of E2Fs, PRE prevents progression to the S phase. To test proliferative functions of E2F, we generated transgenic mice expressing human E2F-1 and/or human DP-1. When the hydroxymethyl glutaryl coenzyme A reductase promoter was used to express DP-1, overexpression occurred in a variety of tissues and did not confer phenotypic changes. In contrast, expression of E2F-1 from the same promoter was obtained only in testicles, in which E2F-1 overexpression caused atrophy and sterility through a process involving increased apoptosis in the germinal epithelium. This effect was potentiated by simultaneous overexpression of DP-1. Testicular atrophy as a result of overexpression of E2F-1 and DP-1 is independent of functional p53, since p53-nullizygous transgenic mice overexpressing E2F-1 and DP-1 also suffered testicular atrophy.	Univ Copenhagen, Inst Mol Biol, Dept Mol Cell Biol, DK-1353 Copenhagen K, Denmark; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Rigshosp, Dept Pathol, DK-2100 Copenhagen O, Denmark	University of Copenhagen; IRCCS European Institute of Oncology (IEO); Rigshospitalet	Karlstrom, O (corresponding author), Univ Copenhagen, Inst Mol Biol, Dept Mol Cell Biol, Oster Farimagsgade 2A, DK-1353 Copenhagen K, Denmark.		Helin, Kristian/K-2526-2019; Helin, Kristian/HDM-8306-2022; Holmberg, Christian/L-8011-2014	Helin, Kristian/0000-0003-1975-6097; Holmberg, Christian/0000-0001-9224-0543				Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRADL M, 1991, P NATL ACAD SCI USA, V88, P6447, DOI 10.1073/pnas.88.15.6447; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; Dobie K, 1997, TRENDS GENET, V13, P127, DOI 10.1016/S0168-9525(97)01097-4; Dobie KW, 1996, P NATL ACAD SCI USA, V93, P6659, DOI 10.1073/pnas.93.13.6659; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GAUTIER C, 1989, NUCLEIC ACIDS RES, V17, P8389, DOI 10.1093/nar/17.20.8389; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Guy CT, 1996, MOL CELL BIOL, V16, P685; Harlow E LD, 1988, ANTIBODIES LAB MANUA; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hogan B., 1986, MANIPULATING MOUSE E; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KASTAN MB, 1991, CANCER RES, V51, P6304; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOWE SW, 1993, NATURE, V362, P2847; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MEHTALI M, 1990, GENE, V91, P179, DOI 10.1016/0378-1119(90)90086-7; MELLILO RM, 1994, MOL CELL BIOL, V14, P8241; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; PURDIE CA, 1994, ONCOGENE, V9, P603; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; ROBERTSON G, 1995, P NATL ACAD SCI USA, V92, P5371, DOI 10.1073/pnas.92.12.5371; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; Sambrook J, 1989, MOL CLONING LAB MANU; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	90	98	103	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					143	155		10.1038/sj.onc.1201915	http://dx.doi.org/10.1038/sj.onc.1201915			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674698				2022-12-17	WOS:000074706700002
J	Song, JS; Swann, PG; Szallasi, Z; Blank, U; Blumberg, PM; Rivera, J				Song, JS; Swann, PG; Szallasi, Z; Blank, U; Blumberg, PM; Rivera, J			Tyrosine phosphorylation-dependent and -independent associations of protein kinase C-delta with Src family kinases in the RBL-2H3 mast cell line: regulation of Src family kinase activity by protein kinase C-delta	ONCOGENE			English	Article						PKC-delta; Src; Lyn; mast cell; Fc epsilon RI	HIGH-AFFINITY RECEPTOR; FOCAL ADHESION KINASE; BASOPHILIC LEUKEMIA-CELLS; N-TERMINAL REGION; IGE-RECEPTOR; IMMUNOGLOBULIN-E; SIGNAL-TRANSDUCTION; INSULIN-RECEPTOR; CROSS-LINKING; GAMMA-CHAIN	Src kinases and protein kinase C (PKC) have been well studied for their role in oncogenic and normal cellular processes. Herein we report on a novel regulatory pathway mediated by the interaction of PKC-delta with p53/56(Lyn) (Lyn) and with p6o(Src) (Src) that results in the phosphorylation and increased activity of Lyn and Src, In the RBL-2H3 mast cell line, the interaction of PKC-delta with Lyn required the activation of the high affinity receptor for IgE (Fc epsilon RI) while the interaction with Src was constitutive. Increased complex formation of PKC-delta with Lyn or Src led to increased serine phosphorylation and activity of the Src family kinases, Conversely, Lyn was found to phosphorylate Lyn-associated and recombinant PKC-delta in vitro and the tyrosine 52 phosphorylated PKC-delta was recruited to associate with the Lyn SH2 domain. The constitutive association of PKC-delta with Src did not result in the tyrosine phosphorylation of PKC-delta prior to or after Fc epsilon RI engagement, However in cells over-expressing PKC-delta, Fc epsilon RI engagement resulted in the dramatic inhibition of Src activity and some inhibition of Lyn activity, Thus, the interaction and cross-talk of PKC-delta with Src family kinases suggests a novel and inter-dependent mechanism for regulation of enzymatic activity that may serve an important role in cellular responses.	NIAMS, Sect Chem Immunol, Bethesda, MD 20892 USA; NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; Inst Pasteur, F-75724 Paris 15, France	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Rivera, J (corresponding author), NIAMS, Sect Chem Immunol, Bethesda, MD 20892 USA.			Blank, Ulrich/0000-0002-2661-2983; Szallasi, Zoltan/0000-0001-5395-7509				ALEXANDER D R, 1990, New Biologist, V2, P1049; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CHACKALAPARAMPIL I, 1994, ONCOGENE, V9, P1947; Chang EY, 1997, J IMMUNOL, V159, P2624; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; DANIELSEN AG, 1995, J BIOL CHEM, V270, P21600, DOI 10.1074/jbc.270.37.21600; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Draberova L, 1996, IMMUNOLOGY, V87, P141; EISEMAN E, 1992, NATURE, V355, P78; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; FURUICHI K, 1984, J IMMUNOL, V133, P1513; Galron D, 1997, CELL IMMUNOL, V178, P141, DOI 10.1006/cimm.1997.1120; GERMANO P, 1994, J BIOL CHEM, V269, P23102; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HAMAWY MM, 1994, J IMMUNOL, V153, P4655; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HOLOWKA D, 1982, MOL IMMUNOL, V19, P219, DOI 10.1016/0161-5890(82)90334-0; Holowka D, 1996, ANNU REV BIOPH BIOM, V25, P79; JOUNG I, 1995, P NATL ACAD SCI USA, V92, P5778, DOI 10.1073/pnas.92.13.5778; Kawakami Y, 1996, IMMUNOL LETT, V54, P113, DOI 10.1016/S0165-2478(96)02659-4; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; LAROSE L, 1995, J BIOL CHEM, V270, P3858, DOI 10.1074/jbc.270.8.3858; Lee JE, 1997, J IMMUNOL, V159, P61; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; LIU F, 1994, BIOCHEM BIOPH RES CO, V200, P1570, DOI 10.1006/bbrc.1994.1630; LIU FT, 1980, J IMMUNOL, V124, P2728; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; MAO SY, 1995, BIOCHEMISTRY-US, V34, P1968, DOI 10.1021/bi00006a018; Mayer BJ, 1997, CURR BIOL, V7, pR295, DOI 10.1016/S0960-9822(06)00141-2; MIMNAUGH EG, 1995, J BIOL CHEM, V270, P28654, DOI 10.1074/jbc.270.48.28654; Moriya K, 1997, P NATL ACAD SCI USA, V94, P12539, DOI 10.1073/pnas.94.23.12539; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; OPPERMANN H, 1979, P NATL ACAD SCI USA, V76, P1804, DOI 10.1073/pnas.76.4.1804; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; Pathan NI, 1996, J BIOL CHEM, V271, P27517, DOI 10.1074/jbc.271.44.27517; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; PRIBLUDA VS, 1992, P NATL ACAD SCI USA, V89, P11446, DOI 10.1073/pnas.89.23.11446; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; SCHARENBERG AM, 1995, CHEM IMMUNOL, V61, P72; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; Singer WD, 1996, J BIOL CHEM, V271, P4504; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; Song JS, 1996, J BIOL CHEM, V271, P26962, DOI 10.1074/jbc.271.43.26962; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yuan ZM, 1996, ONCOGENE, V13, P939; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	65	98	100	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3357	3368		10.1038/sj.onc.1201886	http://dx.doi.org/10.1038/sj.onc.1201886			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692543				2022-12-17	WOS:000074544100002
J	Frizelle, SP; Grim, J; Zhou, J; Gupta, P; Curiel, DT; Geradts, J; Kratzke, RA				Frizelle, SP; Grim, J; Zhou, J; Gupta, P; Curiel, DT; Geradts, J; Kratzke, RA			Re-expression of p16(INK4a) in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression	ONCOGENE			English	Article						p16(INK4a); mesothelioma; tumor suppressor	RETINOBLASTOMA-SUSCEPTIBILITY GENE; LUNG-CANCER; MALIGNANT MESOTHELIOMA; FAMILIAL MELANOMA; WILD-TYPE; RB; MUTATIONS; PRODUCT; PROTEIN; LINES	Absence of expression of the p16(INK4a) gene product is commonly observed in mesothelioma tumors and cell lines, while wild-type pRB expression is maintained. We have examined the biologic and potential therapeutic role of re-expressing p16(INK4a) gene product in mesothelioma cells and tumors. Following transduction with a p16(INK4a) expressing adenovirus (Adp16), over-expression of p16(INK4a) in mesothelioma cells resulted in cell cycle arrest, inhibition of pRB phosphorylation, diminished cell growth, and eventual death of the transduced cells. Expression of p16(INK4a) protein was accompanied by decreased expression of pRB as detected by immunoblot and immunohistochemistry. Experiments in mesothelioma xenografts demonstrated inhibition of tumor formation, tumor growth arrest and diminished tumor size and spread. p16(INK4a) gene product expression was also demonstrated in intraperitoneal xenografts of human mesothelioma cells, These results demonstrate that p16(INK4a) gene transfer may play a therapeutic role in the treatment of mesothelioma.	Vet Affairs Med Ctr, Dept Med, Hematol Oncol Sect, Minneapolis, MN 55417 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55417 USA; Univ Alabama Birmingham, Gene Therapy Program, Birmingham, AL 35294 USA; Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of Alabama System; University of Alabama Birmingham; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Kratzke, RA (corresponding author), Vet Affairs Med Ctr, Dept Med, Hematol Oncol Sect, Minneapolis, MN 55417 USA.				NCI NIH HHS [1 R01 CA 68245-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068245] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antman KH, 1989, CANCER PRINCIPLES PR, P1399; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; BODNER SM, 1992, ONCOGENE, V7, P743; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; FUJIWARA T, 1994, J NATL CANCER I, V86, P1458, DOI 10.1093/jnci/86.19.1458; Geradts J, 1996, MODERN PATHOL, V9, P339; GERADTS J, 1995, CANCER RES, V55, P6006; GRIM J, 1997, IN PRESS CLIN CANC R; KRATZKE RA, 1995, J NATL CANCER I, V87, P1870, DOI 10.1093/jnci/87.24.1870; Kratzke RA, 1996, CANCER RES, V56, P3415; METCALF RA, 1992, CANCER RES, V52, P2610; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Parry D, 1996, MOL CELL BIOL, V16, P3844; PASS HI, 1995, ANN THORAC SURG, V59, P835, DOI 10.1016/0003-4975(95)00045-M; Pass HI, 1996, J CELL BIOCHEM, P142; Sakaguchi M, 1996, INT J CANCER, V65, P442, DOI 10.1002/(SICI)1097-0215(19960208)65:4<442::AID-IJC8>3.0.CO;2-X; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SEKIDO Y, 1995, CANCER RES, V55, P1227; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMYTHE WR, 1994, ANN THORAC SURG, V57, P1395, DOI 10.1016/0003-4975(94)90090-6; Treat J, 1996, HUM GENE THER, V7, P2047, DOI 10.1089/hum.1996.7.16-2047; Ueki K, 1996, CANCER RES, V56, P150; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	31	98	101	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	1998	16	24					3087	3095		10.1038/sj.onc.1201870	http://dx.doi.org/10.1038/sj.onc.1201870			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671387				2022-12-17	WOS:000074261300001
J	Cambier, N; Chopra, R; Strasser, A; Metcalf, D; Elefanty, AG				Cambier, N; Chopra, R; Strasser, A; Metcalf, D; Elefanty, AG			BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner	ONCOGENE			English	Article						BCR-ABL oncogene; apoptosis	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR P53; V-ABL; PHILADELPHIA-CHROMOSOME; PROGENITOR CELLS; CLONAL ANALYSIS; RAS ONCOGENE; BLAST CRISIS; DNA-DAMAGE	The hallmark of chronic myeloid leukemia (CML) is the chimeric tyrosine kinase oncogene bcp - abl. Since expression of bcr - abl mRNA frequently increases with disease progression and a duplication of the Philadelphia chromosome (harbouring the bcr - abl hybrid locus) represents the most frequent karyotypic abnormality in acute phase CML, we hypothesized that the level of BCR - ABL protein may affect the disease phenotype. Therefore, the biological effects of high and low levels of BCR - ABL expression were compared in growth factor-dependent and -independent myeloid and lymphoid cell lines. Our results demonstrated that low levels of BCR - ABL were sufficient to render these cell lines growth factor independent and tumorigenic, but higher levels were mandatory for additional protection against apoptotic stimuli. The provision of growth factor or an activated ras oncogene did not afford the same degree of protection as high levels of BCR - ABL and there were qualitative differences between the survival signals mediated by BCR - ABL and Bcl-2. These results have enabled us to establish a dose-dependent hierarchy of BCR - ABL induced biological effects, thus distinguishing the activation of pathways mediating protection from cytokine withdrawal from those protecting against other apoptotic stimuli.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute	Elefanty, AG (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, PO Royal Melbourne Hosp, Parkville, Vic 3050, Australia.		Elefanty, Andrew G/A-6066-2008; Strasser, Andreas/C-7581-2013	Strasser, Andreas/0000-0002-5020-4891; Elefanty, Andrew/0000-0001-6448-8314	NATIONAL CANCER INSTITUTE [R37CA022556, R01CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [CA22556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Albrecht T, 1996, BRIT J HAEMATOL, V95, P501, DOI 10.1046/j.1365-2141.1996.d01-1934.x; AMOS TAS, 1995, BRIT J HAEMATOL, V91, P387, DOI 10.1111/j.1365-2141.1995.tb05308.x; ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; ANDREWS DF, 1987, LEUKEMIA, V1, P718; ANTONIOU M, 1993, J CELL BIOL, V123, P1055, DOI 10.1083/jcb.123.5.1055; BAKER DA, 1994, LEUKEMIA, V8, P1970; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BOSWELL HS, 1990, EXP HEMATOL, V18, P452; CEROTTINI JC, 1974, J EXP MED, V140, P703, DOI 10.1084/jem.140.3.703; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; Cortez D, 1996, ONCOGENE, V13, P2589; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUMENIL D, 1994, EXP HEMATOL, V22, P178; ELEFANTY AG, 1992, BLOOD, V79, P1271; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GAIGER A, 1995, BLOOD, V86, P2371, DOI 10.1182/blood.V86.6.2371.bloodjournal8662371; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; GROFFEN J, 1987, CHRONIC MYELOID LEUK, P983; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hariharan I K, 1988, Oncogene Res, V3, P387; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Ihle JN, 1996, ADV CANCER RES, V68, P23, DOI 10.1016/S0065-230X(08)60351-6; JACOB MC, 1991, CYTOMETRY, V12, P550, DOI 10.1002/cyto.990120612; KANTARJIAN HM, 1987, AM J MED, V83, P445, DOI 10.1016/0002-9343(87)90754-6; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KEATING A, 1987, CHRONIC MYELOID LEUK, P1021; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KONOPKA JB, 1985, BIOCHIM BIOPHYS ACTA, V823, P1, DOI 10.1016/0304-419X(85)90012-5; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; METCALF D, 1988, LEUKEMIA, V2, P216; METCALF D, 1979, INT J CANCER, V24, P616, DOI 10.1002/ijc.2910240515; METCALF D, 1995, LEUKEMIA, V9, P1556; METCALF D, 1977, RECENT RESULTS CANC, V61, P120; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nishii K, 1996, ONCOGENE, V13, P2225; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; SAKAI N, 1994, EXP CELL RES, V215, P131, DOI 10.1006/excr.1994.1324; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YOUNG JC, 1991, MOL CELL BIOL, V11, P854, DOI 10.1128/MCB.11.2.854; Zhu JY, 1996, BLOOD, V87, P4368, DOI 10.1182/blood.V87.10.4368.bloodjournal87104368	74	98	101	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	1998	16	3					335	348		10.1038/sj.onc.1201490	http://dx.doi.org/10.1038/sj.onc.1201490			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467959				2022-12-17	WOS:000071582100006
J	Himelstein, BP; Lee, EJ; Sato, H; Seiki, M; Muschel, RJ				Himelstein, BP; Lee, EJ; Sato, H; Seiki, M; Muschel, RJ			Transcriptional activation of the matrix metalloproteinase-9 gene in an H-ras and v-myc transformed rat embryo cell line	ONCOGENE			English	Article						MMP-9; ras; transcription; purine-pyrimidine repeat	IV COLLAGENASE GENE; 5' FLANKING REGION; MESSENGER-RNA; COLON CANCER; EXPRESSION; LOCALIZATION; PROMOTER; HYBRIDIZATION; INHIBITORS; LYMPHOMAS	The 92 kd type IV collagenase/gelatinase (MMP-9) is important in mediating basement membrane and extracellular matrix degradation in metastasis. Because MMP-9 is made in tumor cells, but not in quiescent normal cells, we wished to identify the transcriptional elements responsible for its synthesis in tumor cells. We chose to characterize transcriptional regulation of the MMP-9 gene in a highly metastatic H-ras and v-myc transformed rat embryo cell line which overexpresses MMP-9. Using transient transfection of reporter gene constructs containing either 5'-deleted or mutated MMP-9 promoter fragments, as well as electrophoretic mobility shift assays, we have demonstrated that multiple transcription factor consensus binding motifs in the promoter, including those for NF kappa B, SP-1, Ets, AP-1, and a retinoblastoma binding element, participate in transcriptional regulation of MMP-9 expression in this cell line. Also, deletion of an alternating purine-pyrimidine tract in the downstream promoter was found to decrease transcriptional activity, suggesting that promoter conformation may be important in MMP-9 regulation. Thus multiple pathways leading to activation of NF kappa B, SP-1, Ets, AP-1, and retinoblastoma binding factors in tumor cells all may contribute to MMP-9 transcription and hence to metastasis.	KANAZAWA UNIV,CANC RES INST,DEPT MOL ONCOL & VIROL,KANAZAWA,ISHIKAWA 920,JAPAN; UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	Kanazawa University; University of Pennsylvania	Himelstein, BP (corresponding author), CHILDRENS HOSP,DIV ONCOL,ABRAMSON 902C,324 S 34TH ST,PHILADELPHIA,PA 19104, USA.		Seiki, Motoharu/K-9443-2015; SATO, Hiroshi/D-8454-2015		NCI NIH HHS [CA64805, CA63312, CA46830] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046830, K08CA063312, R01CA064805] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNHARD EJ, 1990, CANCER RES, V50, P3872; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; CANETESOLER R, 1994, AM J PATHOL, V144, P518; COTTAM DW, 1992, INVEST OPHTH VIS SCI, V33, P1923; DAVIES B, 1993, CANCER RES, V53, P5365; FINI ME, 1994, J BIOL CHEM, V269, P28620; GOLDBERG GI, 1991, REGULATORY MECHANISM, P421; GRESS TM, 1995, INT J CANCER, V62, P407, DOI 10.1002/ijc.2910620409; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; GUSTIN KE, 1993, BIOTECHNIQUES, V14, P22; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAMDY FC, 1994, BRIT J CANCER, V69, P177, DOI 10.1038/bjc.1994.30; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; HERRICK KR, 1993, GENE, V126, P203, DOI 10.1016/0378-1119(93)90368-D; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HIMELSTEIN BP, 1995, INVAS METAST, V14, P246; Hua J, 1996, CANCER RES, V56, P5279; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; KARELINA T, 1992, J INVEST DERMATOL, V100, P159; KOSSAKOWSKA AE, 1993, ONCOL RES, V5, P19; KOSSAKOWSKA AE, 1992, ONCOL RES, V4, P233; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MASURE S, 1993, EUR J BIOCHEM, V218, P129, DOI 10.1111/j.1432-1033.1993.tb18359.x; NERLOV C, 1991, ONCOGENE, V6, P1538; PYKE C, 1993, AM J PATHOL, V142, P359; PYKE C, 1992, CANCER RES, V52, P1336; RAO JS, 1993, CANCER RES, V53, P2208; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; TRIPATHI J, 1991, J BIOMOL STRUCT DYN, V9, P387, DOI 10.1080/07391102.1991.10507919; URBANSKI SJ, 1992, BRIT J CANCER, V66, P1188, DOI 10.1038/bjc.1992.434; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WU T, 1994, NUCLEIC ACIDS RES, V22, P5093, DOI 10.1093/nar/22.23.5093; Xia YY, 1996, FEBS LETT, V382, P285, DOI 10.1016/0014-5793(96)00185-8; YU M, 1995, ARCH BIOCHEM BIOPHYS, V316, P407, DOI 10.1006/abbi.1995.1054; ZUCKER S, 1993, CANCER RES, V53, P140	38	98	100	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 24	1997	14	16					1995	1998		10.1038/sj.onc.1201012	http://dx.doi.org/10.1038/sj.onc.1201012			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150367				2022-12-17	WOS:A1997WV80400013
J	Sangfelt, O; Erickson, S; Einhorn, S; Grander, D				Sangfelt, O; Erickson, S; Einhorn, S; Grander, D			Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-alpha in hematopoietic cell lines	ONCOGENE			English	Article						interferon; cell cycle; cyclin-dependent kinase; cyclin-dependent kinase inhibitors	TUMOR-SUPPRESSOR GENE; GROWTH-FACTOR-BETA; MUTANT P53; TGF-BETA; ARREST; EXPRESSION; LYMPHOMA; PROTEIN; P21; E2F	One prominent effect of IFNs is their cell growth inhibitory activity. The exact molecular mechanism behind this inhibition of proliferation remains to be elucidated. Possible effecters for IFN-induced growth inhibition are the recently discovered cyclin-dependent kinase inhibitors. The effect of IFN-alpha treatment on the members of the Ink4 and Cip/Kip families of Cdk inhibitors was investigated in three hematopoietic cell lines Daudi, U-266 and H9. Two of these cell lines, Daudi and U-266, respond to IFN-alpha by G(1) arrest, whereas the H9 cell line is not growth arrested by IFN-alpha. We show that a p53-independent upregulation of p21 mRNA occurs following IFN-alpha treatment in all three cell lines. In Daudi and U-266 cells, the mRNA induction is accompanied by an increase in p21 protein, followed by an increased binding of p21 to Cdk2 and a subsequent decrease in Cdk2 activity, temporally coinciding with G(1) arrest. In both these cell lines, there was also an increased binding of p21 to Cdk4. In contrast, p21 protein was not expressed in H9 cells, despite high levels of p21 mRNA following IFN-alpha treatment. In U-266 cells, IFN-alpha increased not only p21 but also p15 mRNA and protein levels, followed by an increased association of p15 with Cdk4, Furthermore, IFN-alpha treatment caused a four- to sixfold induction of the p16 E1 beta transcript in U-266 cells. Expression levels of the other Ink4 and Cip/Kip Cdk inhibitors mere not induced by IFN treatment in any of the cell lines. We conclude that IFN-alpha can act as a potent regulator of Cdk-inhibitor expression, correlating with decreased Cdk activity and cell growth inhibition, One mechanism for resistance to IFN may be loss of the ability of cells to upregulate these proteins.	KAROLINSKA HOSP & INST,RADIUMHEMMET,DEPT ONCOL PATHOL,S-17176 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital								Brandter LB, 1996, EUR J HAEMATOL, V56, P313; BRENNING G, 1985, SCAND J HAEMATOL, V35, P543; CASTRO J, 1993, CYTOMETRY, V14, P793, DOI 10.1002/cyto.990140712; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CORRADINI P, 1994, LEUKEMIA, V8, P758; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DEMAYER EM, 1988, INTERFERONS OTHER RE; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINKE J, 1987, J VIROL, V61, P3870, DOI 10.1128/JVI.61.12.3870-3878.1987; GRANA X, 1995, ONCOGENE, V11, P211; GRANDER D, 1990, LANCET, V336, P337, DOI 10.1016/0140-6736(90)91879-F; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Herman JG, 1996, CANCER RES, V56, P722; HEYMAN M, 1994, LEUKEMIA, V8, P425; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KIMCHI A, 1992, J CELL BIOCHEM, V50, P1, DOI 10.1002/jcb.240500102; KUNLIANG G, 1994, GENE DEV, V8, P2939; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MANN DL, 1989, AIDS RES HUM RETROV, V5, P253, DOI 10.1089/aid.1989.5.253; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUOKA MKJ, 1994, CELL, V79, P487; MAZARS GR, 1992, ONCOGENE, V7, P1015; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1995, CELL, V83, P993; RAMQVIST T, 1993, ONCOGENE, V8, P1495; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROOS G, 1984, CANCER RES, V44, P5358; Sangfelt O, 1996, INT J CANCER, V67, P106, DOI 10.1002/(SICI)1097-0215(19960703)67:1<106::AID-IJC18>3.0.CO;2-C; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIYANOV P, 1996, MOL CELL BIOL, V16, P734; SHUAI K, 1994, CURR OPIN CELL BIOL, V6, P253, DOI 10.1016/0955-0674(94)90144-9; TAYLORPAPADIMIT.J, 1985, INTERFERONS THEIR IM, P81; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WIMAN KG, 1991, ONCOGENE, V6, P1633; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG KR, 1994, BIOCHEM BIOPH RES CO, V200, P522, DOI 10.1006/bbrc.1994.1479; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	49	98	100	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					415	423		10.1038/sj.onc.1200832	http://dx.doi.org/10.1038/sj.onc.1200832			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053838				2022-12-17	WOS:A1997WE36400004
J	Hardiman, G; Rock, FL; Balasubramanian, S; Kastelein, RA; Bazan, JF				Hardiman, G; Rock, FL; Balasubramanian, S; Kastelein, RA; Bazan, JF			Molecular characterization and modular analysis of human MyD88	ONCOGENE			English	Article						MyD88; death domain; dendritic cells; interleukin-1 receptor; Toll; cloning	PROTEIN SECONDARY STRUCTURE; MESSENGER-RNA DEGRADATION; IMMEDIATE EARLY RESPONSE; DROSOPHILA TOLL PROTEIN; FACTOR TNF RECEPTOR; RESISTANCE GENE-N; DEATH DOMAIN; SIGNAL-TRANSDUCTION; CELL-DEATH; TERMINAL DIFFERENTIATION	MyD88 was first characterized as a myeloid differentiation primary response gene in mice, activated in M1 myeloleukemic cells following interleukin-6 (IL-6) induced growth arrest and terminal differentiation. Analysis of expressed sequence tags (ESTs) from activated dendritic cell libraries led to the indentification of cDNAs encoding the human homolog (hMyD88). The original description of MyD88 as a 243 aa protein may reflect a truncated mouse cDNA since the 2682 nt hMyD88 cDNA predicts a 296 aa cytoplasmic protein. Consistent with this proposal is the detection of a 33 kDa protein in human heart, kidney and liver tissue. The expression pattern of MyD88 is also more widespread than originally believed: a 2.6 kb hMyD88 mRNA species was found to be constitutively expressed in many adult human tissues; in addition MyD88 expression was observed in monocyte, T, B, NK and dendritic cells. The MyD88 protein has a modular structure composed of an N-terminal 'death domain' (DD) similar to the intracellular segments of TNF receptor 1 (TNFR1) and FAS and a C-terminal region related to the signaling domains of vertebrate interleukin-1 receptors (IL-1R) and the Drosophila morphogen Toll. This intriguing structural framework may endow MyD88 with unique signaling capabilities	DNAX RES INST MOL & CELLULAR BIOL INC,DEPT MOL BIOL,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Bazan, J. Fernando/B-4562-2010	Hardiman, Gary/0000-0003-4558-0400				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BARKER PA, 1994, J BIOL CHEM, V269, P30645; Bazan JF, 1996, PROTEINS, V24, P1; BOGUSKI MS, 1995, TRENDS BIOCHEM SCI, V20, P295, DOI 10.1016/S0968-0004(00)89051-9; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BROOKS JW, 1994, EUR CYTOKINE NETW, V5, P547; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CAOPONE MC, 1996, J IMMUNOL, V157, P969; CAUX C, 1995, J IMMUNOL, V155, P5427; CAUX C, 1995, IMMUNOL TODAY, V16, P2, DOI 10.1016/0167-5699(95)80061-1; CHIANG C, 1994, MECH DEVELOP, V47, P225; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; ELDON E, 1994, DEVELOPMENT, V120, P885; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; HARROCH S, 1995, NUCLEIC ACIDS RES, V23, P3539, DOI 10.1093/nar/23.17.3539; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; HULTMARK D, 1994, BIOCHEM BIOPH RES CO, V199, P144, DOI 10.1006/bbrc.1994.1206; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; ITOH N, 1993, J BIOL CHEM, V268, P10932; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAWRENCE GJ, 1995, PLANT CELL, V7, P1195, DOI 10.1105/tpc.7.8.1195; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, ONCOGENE, V5, P1095; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LOVENBERG TL, 1996, IN PRESS J NEUROIMMU; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; Parnet P, 1996, J BIOL CHEM, V271, P3967; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAMBROOK J, 1909, MOL CLONING LAB MANU; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; STINGL G, 1995, IMMUNOL TODAY, V16, P330, DOI 10.1016/0167-5699(95)80148-0; STJOHNSTON D, 1992, CELL, V68, P201; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Torcia M, 1996, CELL, V85, P345, DOI 10.1016/S0092-8674(00)81113-7; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; YAMAGATA M, 1994, GENE, V139, P223, DOI 10.1016/0378-1119(94)90760-9	63	98	109	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2467	2475						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957090				2022-12-17	WOS:A1996VX10800021
J	Fugazzola, L; Pierotti, MA; Vigano, E; Pacini, F; Vorontsova, TV; Bongarzone, I				Fugazzola, L; Pierotti, MA; Vigano, E; Pacini, F; Vorontsova, TV; Bongarzone, I			Molecular and biochemical analysis of RET/PTC4 a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer	ONCOGENE			English	Article						Chernobyl tumors; papillary thyroid carcinoma; RET arrangements; RET/PTC4	TRANSFORMING SEQUENCE; DNA REARRANGEMENT; ACTIVATION; PROTOONCOGENE; CARCINOMAS; CHILDREN; ACCIDENT; FUSION	A post-Chernobyl papillary thyroid cancer, displaying a novel ELE1/RET oncogenic rearrangement with an anomalous fusion transcript, was molecularly characterized, In spite of the presence of a normal breakpoint in exon 5 of the activating ELE1 gene, the sequence of the rearranged genomic DNA showed a previously unreported intra-exonic breakpoint in the RET proto-oncogene, As a consequence, a cDNA sequence 93 nucleotides larger than the regular one, and with the exon 5 of ELE1 joined to exon 11 instead of exon 12 of RET, is formed, To characterize the product of this new oncogenic ELE1/RET rearrangement, here designated as RET/PTC4, we performed an immunoprecipitation and Western blot analysis on cell extracts from NIH3T3 transfectants, The results showed the presence of two isoforms of the chimeric protein, displaying a constitutive tyrosine phosphorylation, As expected, the molecular weight of this protein was higher than that of RET/PTC3 protein (p80 and p85, instead of p76 and p81), Previous reports, from our and other laboratories, showed that post-Chernobyl papillary thyroid carcinomas are characterized by a high frequency (about 60%) of RET oncogenic rearrangements (Fugazzola et al., 1995; Klugbauer et al., 1995; Ito et al,, 1994), These events predominantly involve ELE1 activating sequence, thus producing RET/PTC3 oncogene (Fugazzola et al,, 1995; Klugbauer ef al., 1995), Hence, this elevated frequency of RET rearrangements could increase the probability of selecting unusual events as that here described, Alternatively, targeted radiation effects could be responsible for the atypical RET rearrangement producing RET/PTC4 oncogene.	IST NAZL TUMORI, DIV EXPT ONCOL A, I-20133 MILAN, ITALY; UNIV PISA, INST ENDOCRINOL, I-56018 PISA, ITALY; INST RADIAT MED, MINSK, BELARUS	Fondazione IRCCS Istituto Nazionale Tumori Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Pisa			Fugazzola, Laura/F-2846-2011; Bongarzone, Italia/B-9544-2017	Bongarzone, Italia/0000-0003-2530-9170; Pierotti, Marco Alessandro/0000-0002-7431-8332				Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ITO T, 1994, LANCET, V344, P259; Klugbauer S, 1995, ONCOGENE, V11, P2459; KUNIEDA T, 1991, GENE, V107, P323, DOI 10.1016/0378-1119(91)90334-8; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOZZI G, 1994, GENE CHROMOSOME CANC, V9, P244, DOI 10.1002/gcc.2870090404; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1	15	98	120	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	1996	13	5					1093	1097						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806699				2022-12-17	WOS:A1996VG76600023
J	Mehle, C; Piatyszek, MA; Ljungberg, B; Shay, JW; Roos, G				Mehle, C; Piatyszek, MA; Ljungberg, B; Shay, JW; Roos, G			Telomerase activity in human renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; telomerase; clinical course	TUMOR HETEROGENEITY	Telomeres have a vital role in maintaining chromosome stability and are essential for long term viability, Since the very ends of linear chromosomes cannot replicate, telomeres shorten in normal somatic cells eventually resulting in growth inhibition, However, most immortal cell lines maintain stable telomeres indicating that mechanisms exist to compensate for the end replication problem, Telomerase activity, leading to synthesis of telomeric DNA repeats, has been proposed to be an important step in the immortalization process of tumor cells, In the present study, 56 renal cell carcinomas were tested for telomerase activity using the sensitive TRAP (telomeric repeat amplification protocol), Forty of the analysed tumors (71%) were positive for telomerase activity, whereas none of the 56 corresponding normal kidney samples showed telomerase activity, All telomerase negative tumors had a reduction in mean telomere restriction fragment (TRF) length and a decrease in total telomere repeat hybridization signal, though cases were observed with an increase in peak TRF lengths, No obvious association between the presence of telomerase activity and clinicopathological parameters (histopathologic grade, DNA-ploidy, stage and clinical outcome) was found, The high frequency of detection of telomerase activity in the renal cell carcinomas indicates that this enzyme is likely to be an important factor involved in the evolution of this tumor type.	UMEA UNIV,DEPT UROL & ANDROL,S-90187 UMEA,SWEDEN; UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	Umea University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mehle, C (corresponding author), UMEA UNIV,DEPT PATHOL,S-90187 UMEA,SWEDEN.				NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER; NIA NIH HHS [AG07992] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BRYAN MT, 1995, EMBO J, V14, P4240; CHADENEAU C, 1995, CANCER RES, V55, P2533; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; HIYAMA E, 1995, CANCER RES, V55, P3258; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; HOLT SE, 1996, IN PRESS MOL CELL BI; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1995, TELOMERE, P1; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LANGFORD LA, 1995, LANCET, V346, P1267, DOI 10.1016/S0140-6736(95)91865-5; LARSSON P, 1993, INT J CANCER, V55, P566, DOI 10.1002/ijc.2910550408; LJUNGBERG B, 1985, CANCER, V56, P503, DOI 10.1002/1097-0142(19850801)56:3<503::AID-CNCR2820560316>3.0.CO;2-N; LJUNGBERG B, 1996, IN PRESS BR J CANC; MEHLE C, 1994, CANCER RES, V54, P236; MEHLE C, 1993, GENE CHROMOSOME CANC, V6, P86, DOI 10.1002/gcc.2870060204; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; NILSSON P, 1994, ONCOGENE, V9, P3043; NORDENSON I, 1988, CANCER GENET CYTOGEN, V32, P35, DOI 10.1016/0165-4608(88)90309-3; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; ROBSON CJ, 1969, J UROLOGY, V101, P239; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1995, MOL MED TODAY, V1, P378, DOI 10.1016/S1357-4310(95)93872-9; SKINNER DG, 1971, CANCER-AM CANCER SOC, V28, P1165, DOI 10.1002/1097-0142(1971)28:5<1165::AID-CNCR2820280513>3.0.CO;2-G; Sommerfeld HJ, 1996, CANCER RES, V56, P218; Strahl C, 1996, MOL CELL BIOL, V16, P53; TAHARA H, 1995, CANCER RES, V55, P2734; WHITAKER NJ, 1995, ONCOGENE, V11, P971; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794	40	98	105	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					161	166						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700542				2022-12-17	WOS:A1996UX31900018
J	Mujoo, K; Maneval, DC; Anderson, SC; Gutterman, JU				Mujoo, K; Maneval, DC; Anderson, SC; Gutterman, JU			Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma	ONCOGENE			English	Article						p53; adenoviral constructs; tumorigenicity; gene therapy	WILD-TYPE P53; CANCER CELLS; GROWTH; EXPRESSION; PROTEIN; MECHANISMS; MUTATIONS; APOPTOSIS	Mutations of p53 gene are reported in 50-60% of human cancers and reintroduction of wild-type p53 can suppress cell proliferation, In this study, replication deficient recombinant adenovirus encoding wild-type p53 (ACN53) under the control of the human cytomegalovirus (CMV) promoter was constructed. A specific incorporation of the p53 gene with ACN53 in SK-OV-3 (deleted p53 gene) cells was observed, ACN53 reduced the colony-forming ability of SK-OV-3 cells thereby supporting that 95-98% of cells are susceptible to infection by recombinant adenovirus. ACN53 inhibited the growth of 71-98% of SK-OV-3 cells 72-216 h after single infection, A highly aggressive ovarian xenograft model was established in which animals die between 25-45 days, A localization study with the adenovirus-containing beta galactosidase reporter gene showed effective gene transfer in the tumor tissues, Ex vivo treatment of SK-OV-3 cells with ACN53 followed by injection into nude mice, increased the survival of the p53 treated mice by more than 50% compared with control animals, Gene therapy with ACN53 in intraperitoneal model of SK-OV-3 cells in two independent experiments revealed that there were some long-term survivors in the group of mice [2/5 (66 and 120 days) and [2/8 (166 and 423 days)] treated with ACN53. These findings demonstrate the potential of the p53 tumor suppressor gene therapy in human ovarian carcinoma.	CANJI INC,SAN DIEGO,CA 92121		Mujoo, K (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOLEC ONCOL,HOUSTON,TX 77030, USA.		Mujoo, Kalpana/S-9933-2019	Mujoo, Kalpana/0000-0002-4275-1051				BACCHETTI S, 1993, INT J ONCOL, V3, P781; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTEK J, 1991, ONCOGENE, V6, P1699; BERCHUCK A, 1994, AM J OBSTET GYNECOL, V170, P246; Boente Matthew P., 1993, Current Opinion in Oncology, V5, P900, DOI 10.1097/00001622-199309000-00020; BOSARI S, 1993, HUM PATHOL, V24, P1175, DOI 10.1016/0046-8177(93)90212-Y; BRODY SL, 1994, ANN NY ACAD SCI, V716, P90, DOI 10.1111/j.1749-6632.1994.tb21705.x; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN YM, 1991, ONCOGENE, V6, P1799; CHENG J, 1992, CANCER RES, V52, P222; CLAYMAN GL, 1995, CANCER RES, V55, P1; GINSBERG HS, 1989, P NATL ACAD SCI USA, V86, P3823, DOI 10.1073/pnas.86.10.3823; GOODING LR, 1990, CRIT REV IMMUNOL, V10, P53; HOCK H, 1993, P NATL ACAD SCI USA, V90, P2774, DOI 10.1073/pnas.90.7.2774; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISAACS WB, 1991, CANCER RES, V51, P4716; JACOBS IJ, 1992, J NATL CANCER I, V84, P1793, DOI 10.1093/jnci/84.23.1793; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KEURBITZ SJ, 1992, P NATL ACAD SCI USA, V9, P7491; KOHLER MF, 1993, OBSTET GYNECOL, V81, P643; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIU TJ, 1994, CANCER RES, V54, P3662; OKAMOTO A, 1991, CANCER RES, V51, P5171; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROEMER K, 1994, ANN NY ACAD SCI, V716, P265, DOI 10.1111/j.1749-6632.1994.tb21718.x; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SIEGFRIED W, 1993, EXP CLIN ENDOCRINOL, V101, P7, DOI 10.1055/s-0029-1211201; TAKAHASHI T, 1992, CANCER RES, V52, P2340; WANG NP, 1993, ONCOGENE, V8, P279; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WILLS KN, 1994, HUM GENE THER, V5, P1079, DOI 10.1089/hum.1994.5.9-1079; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; YAGINUMA Y, 1992, CANCER RES, V52, P4196; ZHANG WW, 1994, CANCER GENE THER, V1, P1	39	98	104	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1617	1623						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622881				2022-12-17	WOS:A1996UG45800003
J	YU, DH; MATIN, A; XIA, WY; SORGI, F; HUANG, L; HUNG, MC				YU, DH; MATIN, A; XIA, WY; SORGI, F; HUANG, L; HUNG, MC			LIPOSOME-MEDIATED IN-VIVO E1A GENE-TRANSFER SUPPRESSED DISSEMINATION OF OVARIAN-CANCER CELLS THAT OVEREXPRESS HER-2/NEU	ONCOGENE			English	Note						C-ERBB-2; CATIONIC LIPOSOME; TUMOR SUPPRESSION; ADENOVIRUS-5 E1A; ONCOGENE	NATURAL-KILLER CELLS; BREAST-CANCER; NEU GENE; EXPRESSION; ADENOVIRUS; ONCOGENE; PROTOONCOGENE; PRODUCTS; AMPLIFICATION; METASTASIS	The HER-2/neu proto-oncogene is frequently amplified or overexpressed in many different types of human cancers, a phenomenon that has been shown to correlate with shorter survival time and lower survival rate in ovarian cancer patients, We previously reported that increased HER-2/neu expression led to more severe malignancy and increased metastatic potential in animal models and that the adenovirus 5 E1A gene repressed HER-2/nue gene expression at transcriptional level and was able to suppress tumor growth when stably transfected into human ovarian cancer SKOV-3 cells which overexpress HER-2/neu. To investigate whether the E1A gene may be used as a therapeutic agent for HER-2/neu-overexpressing human cancers in living hosts, we first developed tumor-bearing mice by injecting SKOV-3 cells that overexpress HER-2/neu intraperitonealy into female nu/nu mice, Five days later, rye used cationic liposomes to directly deliver the E1A gene into adenocarcinomas that developed in the peritoneal cavity and an the mesentery of the mice that received the SKOV-3 cell injection, We found that liposome-mediated E1A gene transfer significantly inhibited growth and dissemination of ovarian cancer cells that overexpress HER-2/neu in the treated mice; about 70% of these mice survived at least 365 days, whereas all the control mice that did not receive the gene therapy developed severe tumor symptoms and died within 160 days, The results suggest that liposome-mediated E1A gene transfer may serve as an effective therapy for human ovarian cancers that overexpress HER-2/neu by directly targeting the HER-2/neu oncogene.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT SURG ONCOL,HOUSTON,TX 77030; UNIV PITTSBURGH,DEPT PHARMACOL,PITTSBURGH,PA 15261	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381	NCI NIH HHS [CA60488, CA59327, CA64654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060488, P01CA059327, R29CA060488, R01CA064654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEAHRS OH, 1992, MANUAL STAGING CANCE; BERCHUCK A, 1990, CANCER RES, V50, P4087; BERGMANN CI, 1986, NATURE, V319, P226; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; COOK JL, 1984, SCIENCE, V224, P612, DOI 10.1126/science.6710160; COOK JL, 1989, J IMMUNOL, V142, P4527; CREASMAN WT, 1991, AM J OBSTET GYNECOL, V165, P7, DOI 10.1016/0002-9378(91)90213-B; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HSU SM, 1982, J HISTOCHEM CYTOCHEM, V29, P577; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PIVER MS, 1991, SEMIN ONCOL, V18, P177; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SAWADA Y, 1985, VIROLOGY, V147, P413, DOI 10.1016/0042-6822(85)90143-6; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEEG PS, 1988, CANCER RES, V48, P6550; TOIKKANEN S, 1992, J CLIN ONCOL, V10, P1044, DOI 10.1200/JCO.1992.10.7.1044; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEINER DB, 1990, CANCER RES, V50, P421; YAN DH, 1991, ONCOGENE, V6, P343; YU D, 1995, MOL BASIS ONCOLOGY, P131; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; ZHANG X, 1989, ONCOGENE, V4, P985	36	98	118	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1383	1388						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478560				2022-12-17	WOS:A1995RY96700020
J	CORVI, R; SAVELYEVA, L; BREIT, S; WENZEL, A; HANDGRETINGER, R; BARAK, J; OREN, M; AMLER, L; SCHWAB, M				CORVI, R; SAVELYEVA, L; BREIT, S; WENZEL, A; HANDGRETINGER, R; BARAK, J; OREN, M; AMLER, L; SCHWAB, M			NON-SYNTENIC AMPLIFICATION OF MDM2 AND MYCN IN HUMAN NEUROBLASTOMA	ONCOGENE			English	Article						ONCOGENES; REVERSE GENOMIC HYBRIDIZATION; TUMORIGENESIS; P53; PEDIATRIC CANCER	AMPLIFIED DNA-SEQUENCES; N-MYC; CELL-LINES; HUMAN SARCOMAS; P53 MUTATIONS; HUMAN CANCER; CDNA CLONES; C-MYC; GENE; TUMOR	Amplification of the MYCN gene is a well documented genetic alteration of aggressively growing human neuroblastomas. Through cytogenetic studies we have identified neuroblastoma cell lines which, in addition to amplified MYCN, carry amplified DNA not harbouring MYCN. In situ hybridization of biotinylated total genomic DNA to metaphase chromosomes of normal human lymphocytes by reverse genomic hybridization revealed the amplified DNA to be derived from chromosome 12 band q13-14, Subsequent filter analyses showed a 20- to 40-fold amplification of the MDM2 gene, located at 12q13-14, both in three cell lines and in an original tumor, in addition to amplified MYCN, As the apparent consequence of amplification abundant MDM2 protein was present, a part of which was complexed with p53.	GERMAN CANC RES CTR, DIV CYTOGENET, D-69120 HEIDELBERG, GERMANY; UNIV TUBINGEN, CHILDRENS CLIN, D-72070 TUBINGEN, GERMANY; WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL	Helmholtz Association; German Cancer Research Center (DKFZ); Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; Weizmann Institute of Science								ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; AMLER LC, 1989, MOL CELL BIOL, V9, P4903, DOI 10.1128/MCB.9.11.4903; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAM I, 1992, GENE CHROMOSOME CANC, V4, P314, DOI 10.1002/gcc.2870040407; BARKER PE, 1993, METHODS MOL GENETICS, V2, P129; Bertheir F., 1990, Computational Intelligence, II. Proceedings of the International Symposium `Computational Intelligence 89', P1; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; CORDONCARDO C, 1994, CANCER RES, V54, P794; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; COWELL JK, 1983, CANCER GENET CYTOGEN, V9, P273, DOI 10.1016/0165-4608(83)90011-0; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FUKUMOTO M, 1993, SOMAT CELL MOLEC GEN, V19, P21, DOI 10.1007/BF01233951; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARLOW E, 1981, J VIROL, V34, P752; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JANKOWSKI SA, 1994, ONCOGENE, V9, P1205; JOOS S, 1993, HUM GENET, V90, P584, DOI 10.1007/BF00202475; KHATIB ZA, 1993, CANCER RES, V53, P5535; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KOMURO H, 1993, CANCER RES, V53, P5284; LADANYI M, 1993, CANCER RES, V53, P16; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFAGE M, 1992, GENE CHROMOSOME CANC, V5, P40, DOI 10.1002/gcc.2870050107; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; LEACH FS, 1993, CANCER RES, V53, P2231; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; MALTZMAN W, 1981, VIROLOGY, V112, P145, DOI 10.1016/0042-6822(81)90620-6; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIBERT LM, 1994, GENE CHROMOSOME CANC, V9, P261; OHGAKI H, 1993, MOL CARCINOGEN, V8, P74, DOI 10.1002/mc.2940080203; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PEDEUTOUR F, 1994, GENE CHROMOSOME CANC, V10, P85, DOI 10.1002/gcc.2870100203; REIFENBERGER G, 1993, CANCER RES, V53, P2736; RUDOLPH G, 1991, HUM GENET, V86, P562; SCHNEIDER SS, 1992, MOL CELL BIOL, V12, P5563, DOI 10.1128/MCB.12.12.5563; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1993, SEMIN CANCER BIOL, V4, P13; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; VOGAN K, 1993, CANCER RES, V53, P5269; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	53	98	98	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	1995	10	6					1081	1086						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700632				2022-12-17	WOS:A1995QN35300007
J	NILSSON, P; MEHLE, C; REMES, K; ROOS, G				NILSSON, P; MEHLE, C; REMES, K; ROOS, G			TELOMERASE ACTIVITY IN-VIVO IN HUMAN-MALIGNANT HEMATOPOIETIC-CELLS	ONCOGENE			English	Note							TRANSFERASE-ACTIVITY; HUMAN FIBROBLASTS; IDENTIFICATION; REDUCTION; RNA	In somatic cells, each DNA replication round gives a shortening of the telomere ends as a consequence of incomplete lagging strand synthesis. Telomeres are essential for chromosomal integrity and extensive telomere length reduction is associated with increased instability of the genome. In germ line cells and in established cell lines, telomerase activity maintains the length of the telomeres by de novo synthesis of telomeric repeats, in humans (T(2)AG(3))(n). Recently, it was for the first time shown the existence of telomerase activity in human ovarian carcinomas. In the present study we show that telomerase activation can also occur in human hematopoietic tumor cells in vivo. Cell extracts from 19 cases with leukemia, lymphoma and myeloma were tested for telomerase activity using an in vitro assay with (T(2)AG(3))(3) or permutations of this sequence as primers. Eight cases demonstrated an RNAse A sensitive ability to add new nucleotides to the human telomere sequence. Nine acute leukemias were tested telomerase negative. Our data demonstrate that telomerase activation in vivo seems to be a common event in B cell neoplasias with a mature immunophenotype like non-Hodgkin's lymphoma and myeloma, in contrast to acute leukemias of B, T or myeloid cell origin. Telomere length evaluation indicated no marked differences between samples with or without telomerase activity which could argue for a telomere length independent mechanism for telomerase activation in at least some cases.	UMEA UNIV, DEPT PATHOL, S-90187 UMEA, SWEDEN	Umea University								ADAMSON DJA, 1992, CANCER GENET CYTOGEN, V61, P204, DOI 10.1016/0165-4608(92)90088-P; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Greider CW, 1991, CURR OPIN CELL BIOL, V3, P444, DOI 10.1016/0955-0674(91)90072-7; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MCCAFFREY R, 1975, NEW ENGL J MED, V292, P775, DOI 10.1056/NEJM197504102921504; MEHLE C, 1994, CANCER RES, V54, P236; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SMITH JK, 1992, AM J OBSTET GYNECOL, V167, P1883, DOI 10.1016/0002-9378(92)91791-8	20	98	104	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3043	3048						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084612				2022-12-17	WOS:A1994PG82200035
J	LEE, ST; STRUNK, KM; SPRITZ, RA				LEE, ST; STRUNK, KM; SPRITZ, RA			A SURVEY OF PROTEIN-TYROSINE KINASE MESSENGER-RNAS EXPRESSED IN NORMAL HUMAN MELANOCYTES	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; POLYMERASE CHAIN-REACTION; C-KIT; HUMAN PIEBALDISM; CATALYTIC DOMAIN; INSULIN-RECEPTOR; LEUKEMIA-CELLS; GENE; FAMILY; PROTOONCOGENE	We have used the reverse transcription-polymerase chain reaction to survey the repertoire of protein tyrosine kinases expressed in cultured normal human melanocytes, a differentiated cell type derived from the neural crest. We identified 25 different tyrosine kinase cDNAs among a total of 608 protein tyrosinase kinase-related cDNAs analyzed. Six encode receptor tyrosine kinases for known ligands, several of which have been implicated in controlling melanocyte proliferation in vitro. Two others encode apparent receptor tyrosine kinases for unknown ligands. Four encode known non-receptor tyrosine kinases and five encode previously identified anonymous protein tyrosine kinases. Of the eight other melanocyte-associated protein tyrosine kinases, most or all appear to be novel. These 25 protein tyrosine kinase genes exhibit distinct patterns of expression in cultured human melanocytes, human erythroleukemia cells, and a variety of normal human tissues. We mapped 16 of the corresponding protein tyrosine kinase genes to specific human chromosomes, identifying a total of 19 human genetic loci, some of which may constitute candidate genes for genetic disorders of mammalian development.	UNIV WISCONSIN, DEPT MED GENET, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT PEDIAT, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Lee, Seung-Taek/0000-0001-7300-9784	ACF HHS [AF-39892] Funding Source: Medline	ACF HHS		BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; DAURIOL L, 1988, HUM GENET, V78, P374, DOI 10.1007/BF00291740; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DEAN M, 1987, Genomics, V1, P167, DOI 10.1016/0888-7543(87)90009-7; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FLEISCHMAN RA, 1992, J CLIN INVEST, V89, P1713, DOI 10.1172/JCI115772; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FRANCKE U, 1986, COLD SPRING HARB SYM, V51, P855, DOI 10.1101/SQB.1986.051.01.099; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; GIEBEL LB, 1992, ONCOGENE, V7, P2207; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HALABAN R, 1992, ONCOGENE, V7, P2195; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; ISACCHI A, 1990, NUCLEIC ACIDS RES, V18, P1906, DOI 10.1093/nar/18.7.1906; JHANWAR SC, 1984, CYTOGENET CELL GENET, V38, P73, DOI 10.1159/000132033; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LYON MF, 1990, GENETIC VARIANTS STR; MANO H, 1993, ONCOGENE, V8, P417; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MORRIS C, 1990, CYTOGENET CELL GENET, V53, P196, DOI 10.1159/000132929; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PITTELKOW MR, 1989, J CELL PHYSIOL, V140, P565, DOI 10.1002/jcp.1041400323; POLVI A, 1993, IN PRESS GENE; PRITCHARD MA, 1992, MAMM GENOME, V3, P36, DOI 10.1007/BF00355839; RUTA M, 1988, ONCOGENE, V3, P9; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHISHIDO E, 1991, FEBS LETT, V289, P235, DOI 10.1016/0014-5793(91)81078-M; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; SPRITZ RA, 1992, AM J HUM GENET, V51, P1058; SPRITZ RA, 1992, AM J HUM GENET, V50, P261; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; TRASK B, 1993, GENOMICS, V15, P133, DOI 10.1006/geno.1993.1021; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; ULLRICH A, 1990, CELL, V61, P2003; VANDENBARK GR, 1992, ONCOGENE, V7, P1259; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YUE CC, 1991, MOL IMMUNOL, V28, P399	53	98	117	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3403	3410						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247543				2022-12-17	WOS:A1993MG78200025
J	JEGO, N; THOMAS, G; HAMELIN, R				JEGO, N; THOMAS, G; HAMELIN, R			SHORT DIRECT REPEATS FLANKING DELETIONS, AND DUPLICATING INSERTIONS IN P53 GENE IN HUMAN CANCERS	ONCOGENE			English	Note							HUMAN BREAST-CANCER; CELL-LINES; GASTRIC-CANCER; LUNG-CANCER; MUTATIONS; CARCINOMA; FREQUENT; LEUKEMIA; TUMORS; ABNORMALITIES	Compilation of 740 independent p53 mutations from a wide variety of human cancers was performed between 1989 and April 1992. Deletions or insertions were observed in 10% of the cases. Insertions ranged from 1 to 14 nucleotides. In 14 out of 16 cases, the inserted nucleotide(s) duplicated the sequence where it was inserted. The deletions ranged from one to 37 nucleotides. Twenty six cases were single nucleotide deletions and 19 of them were localized at iterated nucleotides. In all 26 deletions of two nucleotides or more, a direct repeat of 2-8 base pairs was present on the unaltered sequence in the close vicinity of the deletion. In 15 of these cases, the deletion removed a complete repeat and the entire region in between repeats. In the remaining cases, the deletion imperfectly removed one or both repeats and/or the intercalating sequence. Both p53 insertions and deletions can be explained by a slipped-mispairing mechanism as proposed for germinal mutations of a small number of eukaryotic genes. Less frequent than the deamination of 5-methyl cytosine in CpG dinucleotides, mutations resulting in loss or gain of nucleotide base pairs may represent the second highest endogenous mutagenic event for p53 gene in human cancers.	INST CURIE,GENET TUMEURS LAB,26 RUE ULM,F-75231 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie								BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BRACHMAN DG, 1991, CANCER RES, V51, P6393; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHIBA I, 1990, ONCOGENE, V5, P1603; CHUNG R, 1991, GENE CHROMOSOME CANC, V3, P323, DOI 10.1002/gcc.2870030502; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FENAUX P, 1991, BLOOD, V78, P1652; FRANKEL RH, 1992, CANCER RES, V52, P1427; FUJIMOTO K, 1992, CANCER RES, V52, P1393; FULTS D, 1992, CANCER RES, V52, P674; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HAN ES, 1992, GENE CHROMOSOME CANC, V4, P1; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; ISAACS WB, 1991, CANCER RES, V51, P4716; JONVEAUX P, 1991, ONCOGENE, V6, P2243; KIM JH, 1991, J NATL CANCER I, V83, P938, DOI 10.1093/jnci/83.13.938; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; KRAWCZAK M, 1991, HUM GENET, V86, P425; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MAZARS R, 1991, ONCOGENE, V6, P1685; MILLER CW, 1992, CANCER RES, V52, P1695; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MURAKAMI Y, 1991, CANCER RES, V51, P5520; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OHGAKI H, 1991, CANCER RES, V51, P6202; OKAMOTO A, 1991, CANCER RES, V51, P5171; OSBORNE RJ, 1991, CANCER RES, V51, P6194; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SATO T, 1992, CANCER RES, V52, P1643; SHIRASAWA S, 1991, CANCER RES, V51, P2874; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; SUGIMOTO K, 1991, BLOOD, V77, P1153; SUGITO S, 1991, INT J CANCER, V49, P880, DOI 10.1002/ijc.2910490614; SUZUKI H, 1992, CANCER RES, V52, P734; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAMURA G, 1991, CANCER RES, V51, P3056; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; TOMINAGA O, 1992, IN PRESS CRIT REV ON; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2; VARLEY JM, 1991, ONCOGENE, V6, P413; YAGINUMA Y, 1991, CANCER RES, V51, P6506; YAMADA Y, 1991, CANCER RES, V51, P5800	56	98	98	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					209	213						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380918				2022-12-17	WOS:A1993KN00500026
J	OKUDA, T; CLEVELAND, JL; DOWNING, JR				OKUDA, T; CLEVELAND, JL; DOWNING, JR			PCTAIRE-1 AND PCTAIRE-3, 2 MEMBERS OF A NOVEL CDC2/CDC28-RELATED PROTEIN-KINASE GENE FAMILY	ONCOGENE			English	Review							CELL-CYCLE CONTROL; SEA-URCHIN EGGS; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; TYROSINE PHOSPHORYLATION; SCHIZOSACCHAROMYCES-POMBE; M-PHASE; DIVISION CYCLE; CDC25 PROTEIN; MESSENGER-RNA	We have isolated two murine cDNAs designated PCTAIRE-1 and -3 which encode putative serine/threonine-specific protein kinases. The predicted products of PCTAIRE-1 and -3 are 65% homologous and are organized into a core 295-residue kinase domain flanked by unique 161 and 117 amino acid N-terminal and 40 and 39 amino acid C-terminal domains respectively. The kinase domains are approximately 50-55% homologous to members of the cdc2/CDC28 kinase gene family, and each contains a cysteine-for-serine substitution within the conserved PSTAIRE motif. PCTAIRE-1 was ubiquitously expressed as a predominant 3.0-kb transcript and a minor 2.2-kb mRNA resulting from differential polyadenylation. In contrast, PCTAIRE-3 exhibited a more restricted pattern of expression with a single 3.0-kb mRNA detected in brain, kidney and intestine. The PCTAIRE-1 and -3 products produced by in vitro transcription-translation failed to bind to p13suc1 but were precipitated by antibodies directed to Schizosaccharomyces pombe p34cdc2 or to the human PSTAIRE motif. Thus, PCTAIRE-1 and -3 are members of a novel subfamily of cdc2/CDC28-related protein kinases.	ST JUDE CHILDRENS RES HOSP, DEPT PATHOL, 575 ST JUDE PL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital			Downing, James R./N-8102-2018		NCI NIH HHS [CA-01429, CA-21765] Funding Source: Medline; NIDDK NIH HHS [DK-44158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, K08CA001429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; BUSTOS JG, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cleveland J L, 1988, Oncogene Res, V3, P357; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KIDD VJ, 1991, CELL GROWTH DIFFER, V2, P85; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LAPIDOTLIFSON Y, 1992, DEV BIOL, V89, P579; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1990, New Biologist, V2, P389; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; REED SI, 1980, GENETICS, V95, P561; REID BJ, 1977, J CELL BIOL, V75, P355, DOI 10.1083/jcb.75.2.355; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	104	98	103	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2249	2258						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437147				2022-12-17	WOS:A1992JW66500017
J	LAM, EWF; ROBINSON, C; WATSON, RJ				LAM, EWF; ROBINSON, C; WATSON, RJ			CHARACTERIZATION AND CELL CYCLE-REGULATED EXPRESSION OF MOUSE B-MYB	ONCOGENE			English	Article							DNA-POLYMERASE-ALPHA; MURINE ERYTHROLEUKEMIA-CELLS; HUMAN HEMATOPOIETIC-CELLS; C-MYB; GENE-EXPRESSION; ERYTHROID-DIFFERENTIATION; BINDING ACTIVITY; MESSENGER-RNA; A-MYB; PROLIFERATION	We have isolated a full-length mouse B-myb cDNA clone and used this to examine cell cycle-regulated expression of this gene. Mouse B-Myb was predicted to comprise 704 amino acids and to be 84% homologous with human B-Myb. There were three regions of extensive amino acid homology which may indicate functional domains: the first corresponded to the c-Myb DNA-binding domain, while the second had no counterpart in c-Myb but was instead homologous to a short segment of the related A-myb protein. The third region of homology is partially conserved in both c-Myb and A-Myb and may correspond to the c-Myb negative regulator domain. Stimulation of quiescent 3T3 fibroblasts with serum was found to result in induction of B-myb expression in late G1 and to lead to high levels of gene transcripts that persisted through S phase. Similarly, maximum B-myb mRNA levels were reached in G2/M synchronized cells prior to entry into S phase. These results are consistent with a role in G1/S transition as has been suggested for c-myb.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,NORFOLK PL,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research			Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576				BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; DENTE L, 1985, DNA CLONING PRACTICA, V1, P101; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; MCMAHON J, 1988, ONCOGENE, V3, P717; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RAMSAY RG, 1991, ONCOGENE, V6, P1875; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TERADA M, 1977, P NATL ACAD SCI USA, V74, P248, DOI 10.1073/pnas.74.1.248; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WATSON RJ, 1988, ONCOGENE, V2, P267; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x	30	98	100	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1885	1890						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501895				2022-12-17	WOS:A1992JJ37600027
J	MARTIN, P; CARRIERE, C; DOZIER, C; QUATANNENS, B; MIRABEL, MA; VANDENBUNDER, B; STEHELIN, D; SAULE, S				MARTIN, P; CARRIERE, C; DOZIER, C; QUATANNENS, B; MIRABEL, MA; VANDENBUNDER, B; STEHELIN, D; SAULE, S			CHARACTERIZATION OF A PAIRED BOX-CONTAINING AND HOMEOBOX-CONTAINING QUAIL GENE (PAX-QNR) EXPRESSED IN THE NEURORETINA	ONCOGENE			English	Article							DNA-BINDING DOMAIN; TRANSCRIPTION FACTOR; LEUKEMIA VIRUSES; MESSENGER-RNAS; TARGET-CELLS; NEURAL-TUBE; HOMEODOMAIN; PROTEIN; MYC; DIFFERENTIATION	The retina is an integral part of the central nervous system, and consists of two layers, the outer pigmented layer and the inner sensory layer or neuroretina (NR). The NR layer contains several strata of cells (glial and neuronal) derived from proliferating neuroectodermal precursors that differentiate after terminal mitosis. In vitro, NR cells can differentiate not only into neuronal and glial types, but also into pigment and lens cells. Quail (Coturnix coturnix japonica) NR cells (QNR) infected with MC29 transforming retrovirus become pigmented after several passages in vitro. In order to characterize the genes expressed in these pigmented MC29 QNR, a cDNA library was prepared from these cells. After differential screening we have isolated a cDNA clone which identifies an RNA expressed in NR but not in the pigmented layer of the retina. This cDNA encodes a protein related to that of Drosophila, mouse and zebrafish paired box- and homeobox-containing segmentation genes and is called Pax-QNR. The expression of Pax-QNR in the NR is confined to the ganglionic cell layer and to the lower part of the inner nuclear layer containing the amacrine or correlation neurones.	INST PASTEUR,CNRS,URA 1160,1 RUE CALMETTE,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			DOZIER, Christine/P-1539-2014					ALEMA S, 1985, MOL CELL BIOL, V5, P538, DOI 10.1128/MCB.5.3.538; ALLEN JD, 1991, GENE DEV, V5, P509, DOI 10.1101/gad.5.4.509; BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FAUQUET M, 1990, P NATL ACAD SCI USA, V87, P1546, DOI 10.1073/pnas.87.4.1546; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GAUZZI S, 1990, EMBO J, V9, P3631; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRAF T, 1981, EXP CELL RES, V131, P331, DOI 10.1016/0014-4827(81)90236-6; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUERMAH M, 1990, MOL CELL BIOL, V10, P3584, DOI 10.1128/MCB.10.7.3584; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JOSTES B, 1991, MECH DEVELOP, V33, P27; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; Maniatis T., 1982, MOL CLONING; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; Okada T.S., 1976, TESTS TERATOGENICITY, P91; QUEVA C, 1992, IN PRESS DEVELOPMENT, V114; ROMANOFF A, 1954, AVIAN EMBRYO, P382; ROSNER MH, 1991, CELL, V64, P1103, DOI 10.1016/0092-8674(91)90265-Z; SAULE S, 1981, J VIROL, V38, P409, DOI 10.1128/JVI.38.2.409-419.1981; SCOTT MP, 1987, CELL, V51, P689, DOI 10.1016/0092-8674(87)90092-4; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TREISMAN J, 1989, CELL, V59, P553; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; VENNSTROM B, 1981, J VIROL, V39, P625; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4	42	98	99	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1721	1728						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1354346				2022-12-17	WOS:A1992JJ37600007
J	DEVILEE, P; VANVLIET, M; KUIPERSDIJKSHOORN, N; PEARSON, PL; CORNELISSE, CJ				DEVILEE, P; VANVLIET, M; KUIPERSDIJKSHOORN, N; PEARSON, PL; CORNELISSE, CJ			SOMATIC GENETIC CHANGES ON CHROMOSOME-18 IN BREAST CARCINOMAS - IS THE DCC GENE INVOLVED	ONCOGENE			English	Article							COLORECTAL CARCINOMAS; RETINOBLASTOMA GENE; RECESSIVE MUTATION; CELL CARCINOMA; SHORT ARM; HETEROZYGOSITY; CANCER; TUMORS; EXPRESSION; DELETION	Recently, a gene has been isolated from the long arm of chromosome 18 which was shown to be frequently deleted in colorectal carcinomas and hence designated the DCC gene (Fearon et al., 1990). To explore the possible involvement of this gene in breast cancer, we have used 5 polymorphic DNA markers (one for 18p, and four for 18q) to examine the status of chromosome 18 in 49 primary breast carcinomas by comparing the genotypes of lymphocyte and tumour DNA samples. Imbalance of alleles, resulting in allelic loss or duplication, was observed in 17 cases (38% of informative cases). In 13 of these, this imbalance included the locus D18S8 located within the DCC gene region. In the remaining 4 cases this locus was not involved, with the affected chromosome region mapping proximally of D18S8 in 3 cases, and distally in 1 case. These results indicate that chromosome 18 is rearranged in breast cancer more frequently than is expected on the basis of cytogenetic data alone, and warrant a closer inspection of the DCC gene in this tumour.	LEIDEN UNIV,DEPT HUMAN GENET,2333 AL LEIDEN,NETHERLANDS; LEIDEN UNIV,DEPT PATHOL,2333 AL LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC			DEVILEE, PETER/ABR-2140-2022					BEERMAN H, 1990, INT J CANCER, V45, P34, DOI 10.1002/ijc.2910450108; BERGERHEIM U, 1989, CANCER RES, V49, P1390; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; DEVILEE P, 1990, CYTOGENET CELL GENET, V53, P52, DOI 10.1159/000132893; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DEVILEE P, 1991, IN PRESS CANCER RES; DEVILEE P, 1990, IN PRESS CANCER SURV; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GENDLER SJ, 1990, INT J CANCER, V45, P431, DOI 10.1002/ijc.2910450309; GENUARDI M, 1989, AM J HUM GENET, V45, P73; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KIDD KK, 1989, CYTOGEN CELL GENET, V51; Klein G, 1981, NATURE, V294, P313, DOI 10.1038/294313a0; KNUDSON AG, 1985, CANCER RES, V45, P1437; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MACKAY J, 1988, LANCET, V2, P1384; MITELMAN F, 1988, CATALOG CHROMOSOME A; MONPEZAT JP, 1988, INT J CANCER, V41, P404, DOI 10.1002/ijc.2910410315; MOTOMURA K, 1988, Genomics, V2, P180, DOI 10.1016/0888-7543(88)90101-2; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; TRENT JM, 1987, ONCOGENES HORMONES B, P142; VARLEY JM, 1989, ONCOGENE, V4, P725; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	32	98	100	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					311	315						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	2000224				2022-12-17	WOS:A1991FZ13400018
J	Witt, AE; Lee, CW; Lee, TI; Azzam, DJ; Wang, B; Caslini, C; Petrocca, F; Grosso, J; Jones, M; Cohick, EB; Gropper, AB; Wahlestedt, C; Richardson, AL; Shiekhattar, R; Young, RA; Ince, TA				Witt, A. E.; Lee, C-W; Lee, T. I.; Azzam, D. J.; Wang, B.; Caslini, C.; Petrocca, F.; Grosso, J.; Jones, M.; Cohick, E. B.; Gropper, A. B.; Wahlestedt, C.; Richardson, A. L.; Shiekhattar, R.; Young, R. A.; Ince, T. A.			Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer	ONCOGENE			English	Article							METASTASIS-ASSOCIATED PROTEIN-1; TUMOR-INITIATING CELLS; POOR-PROGNOSIS; EXPRESSION; DIFFERENTIATION; INHIBITOR; MIR-34A; BENZAMIDE; SIGNATURE; CARCINOMA	Tumours are comprised of a highly heterogeneous population of cells, of which only a small subset of stem-like cells possess the ability to regenerate tumours in vivo. These cancer stem cells (CSCs) represent a significant clinical challenge as they are resistant to conventional cancer therapies and play essential roles in metastasis and tumour relapse. Despite this realization and great interest in CSCs, it has been difficult to develop CSC-targeted treatments due to our limited understanding of CSC biology. Here, we present evidence that specific histone deacetylases (HDACs) play essential roles in the CSC phenotype. Utilizing a novel CSC model, we discovered that the HDACs, HDAC1 and HDAC7, are specifically over-expressed in CSCs when compared to non-stem-tumour-cells (nsTCs). Furthermore, we determine that HDAC1 and HDAC7 are necessary to maintain CSCs, and that over-expression of HDAC7 is sufficient to augment the CSC phenotype. We also demonstrate that clinically available HDAC inhibitors (HDACi) targeting HDAC1 and HDAC7 can be used to preferentially target CSCs. These results provide actionable insights that can be rapidly translated into CSC-specific therapies.	[Witt, A. E.; Wang, B.; Caslini, C.; Grosso, J.; Jones, M.; Ince, T. A.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr,Dept Pathol, Braman Family Breast Canc Inst,Interdisciplinary, Miami, FL 33136 USA; [Lee, C-W; Cohick, E. B.; Richardson, A. L.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA; [Lee, T. I.; Cohick, E. B.; Gropper, A. B.; Young, R. A.] Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA; [Azzam, D. J.; Wahlestedt, C.] Univ Miami, Miller Sch Med, Ctr Therapeut Innovat, Dept Psychiat & Behav Sci, Miami, FL 33136 USA; [Petrocca, F.] Harvard Med Sch, Dept Pediat, Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA; [Shiekhattar, R.] Univ Miami, Miller Sch Med, Dept Human Genet, Sylvester Comprehens Canc, Biomed Res Bldg, Miami, FL 33136 USA	University of Miami; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Miami; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; University of Miami	Ince, TA (corresponding author), Univ Miami, Miller Sch Med, Interdisciplinary Stem Cell Inst,Dept Pathol,TA I, Braman Family Breast Canc Inst,Sylvester Comprehe, Biomed Res Bldg BRB Room 907, Miami, FL 33136 USA.	TInce@med.miami.edu	Azzam, Diana/ABB-8342-2021; Caslini, Corrado/W-6123-2019; Young, Richard A/F-6495-2012	Azzam, Diana/0000-0002-2605-8855; Caslini, Corrado/0000-0001-8326-8368; Young, Richard A/0000-0001-8855-8647; Cohick, Evan/0000-0002-0824-9148; Ince, Tan/0000-0003-0315-6425	Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami; Breast Cancer Research Foundation, New York, NY; Women's Cancer Association; DoD-CDMRP Ovarian Cancer Research Program Resource Development Grant [W81XWH-14-1-0160, OC130649]; National Cancer Institute, Roadmap Epigenomics project [R01-CA146445-01]; NATIONAL CANCER INSTITUTE [R01CA146445, K22CA184244, P30CA010815] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM105754, R01GM078455] Funding Source: NIH RePORTER	Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami; Breast Cancer Research Foundation, New York, NY; Women's Cancer Association; DoD-CDMRP Ovarian Cancer Research Program Resource Development Grant; National Cancer Institute, Roadmap Epigenomics project; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was funded by grants from: (1) Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami (TAI); (2) Breast Cancer Research Foundation, New York, NY (TAI); (3) Women's Cancer Association (TAI); (4) DoD-CDMRP Ovarian Cancer Research Program (W81XWH-14-1-0160) Resource Development Grant OC130649 (TAI), and (5) National Cancer Institute, Roadmap Epigenomics project (R01-CA146445-01) to TAI, TIL and RAY. We thank Jayanta Debnath for his help with 3D morphogenesis assays, Dr Antonello Mai for providing MC1575, Chuck Harrell for help with mRNA expression array analysis, P.L. Guevara for help with FACs analysis, Noriyuki Kasahara and Sara Collins for transduction of OCI-P5x cell line with luciferase and F. Reinhardt for technical assistance.	Ablett MP, 2012, EUR J CANCER, V48, P2104, DOI 10.1016/j.ejca.2012.03.019; Azzam DJ, 2013, EMBO MOL MED, V5, P1502, DOI 10.1002/emmm.201302558; Beckers T, 2007, INT J CANCER, V121, P1138, DOI 10.1002/ijc.22751; Belsky DW, 2013, JAMA PSYCHIAT, V70, P534, DOI 10.1001/jamapsychiatry.2013.736; Boissinot M, 2012, LEUKEMIA RES, V36, P1304, DOI 10.1016/j.leukres.2012.07.002; Carrasco E, 2014, EUR J CLIN INVEST, V44, P678, DOI 10.1111/eci.12276; Chikamatsu K, 2013, CANCER SCI, V104, P1468, DOI 10.1111/cas.12271; Civenni G, 2011, CANCER RES, V71, P3098, DOI 10.1158/0008-5472.CAN-10-3997; Clocchiatti A, 2013, FASEB J, V27, P942, DOI 10.1096/fj.12-209346; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Debeb BG, 2012, STEM CELLS, V30, P2366, DOI 10.1002/stem.1219; Dokmanovic M, 2007, MOL CANCER THER, V6, P2525, DOI 10.1158/1535-7163.MCT-07-0251; Dovey OM, 2010, P NATL ACAD SCI USA, V107, P8242, DOI 10.1073/pnas.1000478107; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Galanis E, 2009, J CLIN ONCOL, V27, P2052, DOI 10.1200/JCO.2008.19.0694; Gao HF, 2013, J NEURO-ONCOL, V113, P221, DOI 10.1007/s11060-013-1119-1; Garcia-Manero G, 2008, BLOOD, V112, P981, DOI 10.1182/blood-2007-10-115873; Han ME, 2011, CELL MOL LIFE SCI, V68, P3589, DOI 10.1007/s00018-011-0672-z; Higashijima J, 2011, ONCOL REP, V26, P343, DOI 10.3892/or.2011.1312; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Ince TA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8419; Jiao J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042564; Karantzali E, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-4-r65; Kasler HG, 2011, J IMMUNOL, V186, P4782, DOI 10.4049/jimmunol.1001179; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Kidder BL, 2012, NUCLEIC ACIDS RES, V40, P2925, DOI 10.1093/nar/gkr1151; Kok M, 2009, J PATHOL, V218, P316, DOI 10.1002/path.2544; Leth-Larsen R, 2012, MOL MED, V18, P1109, DOI 10.2119/molmed.2012.00091; Liang J, 2008, NAT CELL BIOL, V10, P731, DOI 10.1038/ncb1736; McCool KW, 2007, J BIOL CHEM, V282, P6696, DOI 10.1074/jbc.M609519200; Merritt MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080314; Milde T, 2010, CLIN CANCER RES, V16, P3240, DOI 10.1158/1078-0432.CCR-10-0395; Minamiya Y, 2011, LUNG CANCER, V74, P300, DOI 10.1016/j.lungcan.2011.02.019; Miyake K, 2008, PANCREAS, V36, pE1, DOI 10.1097/MPA.0b013e31815f2c2a; Munster PN, 2001, CANCER RES, V61, P8492; Munz M, 2009, CANCER RES, V69, P5627, DOI 10.1158/0008-5472.CAN-09-0654; Pasto A, 2014, ONCOTARGET, V5, P4305, DOI 10.18632/oncotarget.2010; Petrocca F, 2013, CANCER CELL, V24, P182, DOI 10.1016/j.ccr.2013.07.008; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rowehl RA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099091; Salvador MA, 2013, CLIN CANCER RES, V19, P6520, DOI 10.1158/1078-0432.CCR-13-0877; Sauder CAM, 2014, BMC CELL BIOL, V15, DOI 10.1186/1471-2121-15-20; Schuettengruber B, 2003, MOL CELL BIOL, V23, P6993, DOI 10.1128/MCB.23.19.6993-7004.2003; Seto E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018713; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stuelten CH, 2010, STEM CELLS, V28, P649, DOI 10.1002/stem.324; Van Damme M, 2012, EPIGENETICS-US, V7, P1403, DOI 10.4161/epi.22674; Vincent A, 2012, BBA-REV CANCER, V1826, P83, DOI 10.1016/j.bbcan.2012.03.009; Wang Y, 2015, AM J TRANSL RES, V7, P111; Williams K, 2013, EXP BIOL MED, V238, P324, DOI 10.1177/1535370213480714; Wood TE, 2010, MOL CANCER THER, V9, P246, DOI 10.1158/1535-7163.MCT-09-0495; Wu MY, 2014, CANCER LETT, V354, P311, DOI 10.1016/j.canlet.2014.08.031; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; You JS, 2009, CANCER RES, V69, P5716, DOI 10.1158/0008-5472.CAN-08-4953; Zhang L, 2010, J BIOL CHEM, V285, P38463, DOI 10.1074/jbc.M110.153999; Zhu CH, 2011, J MOL MED, V89, P279, DOI 10.1007/s00109-010-0701-7	59	97	102	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1707	1720		10.1038/onc.2016.337	http://dx.doi.org/10.1038/onc.2016.337			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27694895	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000397460600010
J	Adapala, RK; Thoppil, RJ; Ghosh, K; Cappelli, HC; Dudley, AC; Paruchuri, S; Keshamouni, V; Klagsbrun, M; Meszaros, JG; Chilian, WM; Ingber, DE; Thodeti, CK				Adapala, R. K.; Thoppil, R. J.; Ghosh, K.; Cappelli, H. C.; Dudley, A. C.; Paruchuri, S.; Keshamouni, V.; Klagsbrun, M.; Meszaros, J. G.; Chilian, W. M.; Ingber, D. E.; Thodeti, C. K.			Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy	ONCOGENE			English	Article							RECEPTOR POTENTIAL VANILLOID-4; VESSEL NORMALIZATION; ANTI-ANGIOGENESIS; ENDOTHELIAL-CELLS; BLOOD-VESSELS; INTEGRIN; DELIVERY; RHO; DIFFERENTIATION; CHEMOTHERAPY	Tumor vessels are characterized by abnormal morphology and hyperpermeability that together cause inefficient delivery of chemotherapeutic agents. Although vascular endothelial growth factor has been established as a critical regulator of tumor angiogenesis, the role of mechanical signaling in the regulation of tumor vasculature or tumor endothelial cell (TEC) function is not known. Here we show that the mechanosensitive ion channel transient receptor potential vanilloid 4 (TRPV4) regulates tumor angiogenesis and tumor vessel maturation via modulation of TEC mechanosensitivity. We found that TECs exhibit reduced TRPV4 expression and function, which is correlated with aberrant mechanosensitivity towards extracellular matrix stiffness, increased migration and abnormal angiogenesis by TEC. Further, syngeneic tumor experiments revealed that the absence of TRPV4 induced increased vascular density, vessel diameter and reduced pericyte coverage resulting in enhanced tumor growth in TRPV4 knockout mice. Importantly, overexpression or pharmacological activation of TRPV4 restored aberrant TEC mechanosensitivity, migration and normalized abnormal angiogenesis in vitro by modulating Rho activity. Finally, a small molecule activator of TRPV4, GSK1016790A, in combination with anticancer drug cisplatin, significantly reduced tumor growth in wild-type mice by inducing vessel maturation. Our findings demonstrate TRPV4 channels to be critical regulators of tumor angiogenesis and represent a novel target for antiangiogenic and vascular normalization therapies.	[Adapala, R. K.; Thoppil, R. J.; Cappelli, H. C.; Meszaros, J. G.; Chilian, W. M.; Thodeti, C. K.] Northeast Ohio Med Univ, Dept Integrat Med Sci, Rootstown, OH 44272 USA; [Adapala, R. K.; Thoppil, R. J.; Cappelli, H. C.; Meszaros, J. G.; Chilian, W. M.; Thodeti, C. K.] Kent State Univ, Sch Biomed Sci, Kent, OH 44242 USA; [Ghosh, K.] Univ Calif Riverside, Dept Bioengn, Riverside, CA 92521 USA; [Ghosh, K.; Dudley, A. C.; Klagsbrun, M.; Ingber, D. E.; Thodeti, C. K.] Childrens Hosp, Vasc Biol Program, 300 Longwood Ave, Boston, MA 02115 USA; [Ghosh, K.; Dudley, A. C.; Klagsbrun, M.; Ingber, D. E.; Thodeti, C. K.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Dudley, A. C.] Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC USA; [Paruchuri, S.] Univ Akron, Dept Chem, Akron, OH 44325 USA; [Keshamouni, V.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Ingber, D. E.] Wyss Inst Biol Inspired Engn, Cambridge, MA USA; [Ingber, D. E.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA	Northeast Ohio Medical University (NEOMED); University System of Ohio; Kent State University; Kent State University Kent; Kent State University Salem; University of California System; University of California Riverside; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill; University System of Ohio; University of Akron; University of Michigan System; University of Michigan; Harvard University	Thodeti, CK (corresponding author), Northeast Ohio Med Univ, Dept Integrat Med Sci, Rootstown, OH 44272 USA.	cthodeti@neomed.edu	Adapala, Ravi kumar/AAD-1282-2020; Ingber, Donald E/AAC-5894-2019	Adapala, Ravi kumar/0000-0002-4082-5301; Keshamouni, Venkateshwar/0000-0003-1947-791X	NEOMED; AHA [14GRNT20380935]; NIH [CA55833, CA45548]; NATIONAL CANCER INSTITUTE [P30CA016086, R01CA055833, P01CA045548, R01CA177875] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R15HL106442, R01HL119705, R01HL115114] Funding Source: NIH RePORTER	NEOMED; AHA(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by the start-up funds from NEOMED and AHA (14GRNT20380935) (CKT) and NIH grants CA55833 and CA45548 (DI).	Abdollahi A, 2010, DRUG RESIST UPDATE, V13, P16, DOI 10.1016/j.drup.2009.12.001; Adapala RK, 2013, J MOL CELL CARDIOL, V54, P45, DOI 10.1016/j.yjmcc.2012.10.016; Adapala RK, 2011, AM J PHYSIOL-HEART C, V301, pH757, DOI 10.1152/ajpheart.00142.2011; Alessandri-Haber N, 2004, J NEUROSCI, V24, P4444, DOI 10.1523/JNEUROSCI.0242-04.2004; Alessandri-Haber N, 2008, J NEUROSCI, V28, P1046, DOI 10.1523/JNEUROSCI.4497-07.2008; Baylie RL, 2011, ACTA PHYSIOL, V203, P99, DOI 10.1111/j.1748-1716.2010.02217.x; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Brackenbury WJ, 2006, J PHYSIOL-LONDON, V573, P343, DOI 10.1113/jphysiol.2006.106906; Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; Chae SS, 2010, CLIN CANCER RES, V16, P3618, DOI 10.1158/1078-0432.CCR-09-3073; Chauhan VP, 2012, NAT NANOTECHNOL, V7, P383, DOI [10.1038/NNANO.2012.45, 10.1038/nnano.2012.45]; Cuevas I, 2009, ADV CANCER RES, V103, P25, DOI 10.1016/S0065-230X(09)03002-4; di Tomaso E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005123; Duda DG, 2007, TRENDS MOL MED, V13, P223, DOI 10.1016/j.molmed.2007.04.001; Dudley AC, 2008, CANCER CELL, V14, P201, DOI 10.1016/j.ccr.2008.06.017; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; Folkman J, 2003, CANCER BIOL THER, V2, pS127; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; Fraser SP, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0105; Fukumura D, 2008, APMIS, V116, P695, DOI 10.1111/j.1600-0463.2008.01148.x; Fukumura D, 2007, MICROVASC RES, V74, P72, DOI 10.1016/j.mvr.2007.05.003; Ghosh K, 2008, P NATL ACAD SCI USA, V105, P11305, DOI 10.1073/pnas.0800835105; Goel S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006486; Goel S, 2011, PHYSIOL REV, V91, P1071, DOI 10.1152/physrev.00038.2010; Gradilone SA, 2007, P NATL ACAD SCI USA, V104, P19138, DOI 10.1073/pnas.0705964104; Hartmannsgruber V, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000827; Hu F, 2013, ARCH ORAL BIOL, V58, P192, DOI 10.1016/j.archoralbio.2012.08.013; Ingber D E, 1997, Gravit Space Biol Bull, V10, P49; Ingber DE, 2002, CIRC RES, V91, P877, DOI 10.1161/01.RES.0000039537.73816.E5; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; Ingber DE, 1995, J BIOMECH, V28, P1471, DOI 10.1016/0021-9290(95)00095-X; Jain RK, 2008, SCI AM, V298, P56, DOI 10.1038/scientificamerican0108-56; Jain RK, 2012, CELL, V149, P1408, DOI 10.1016/j.cell.2012.05.025; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Lee HS, 2000, J BONE MINER RES, V15, P1501, DOI 10.1359/jbmr.2000.15.8.1501; Liedtke W, 2005, J PHYSIOL-LONDON, V567, P53, DOI 10.1113/jphysiol.2005.088963; Liu JQ, 2011, CLIN CANCER RES, V17, P3638, DOI 10.1158/1078-0432.CCR-10-2456; Mammoto A, 2009, NATURE, V457, P1103, DOI 10.1038/nature07765; Marnmoto A, 2008, CURR OPIN HEMATOL, V15, P228, DOI 10.1097/MOH.0b013e3282fa7445; Martinac B, 2004, J CELL SCI, V117, P2449, DOI 10.1242/jcs.01232; MATTHEWS BD, INTEGR BIOL CAMB, V2, P435; Mendoza SA, 2010, AM J PHYSIOL-HEART C, V298, pH466, DOI 10.1152/ajpheart.00854.2009; Paszek MJ, 2004, J MAMMARY GLAND BIOL, V9, P325, DOI 10.1007/s10911-004-1404-x; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Pla AF, 2012, ONCOGENE, V31, P200, DOI 10.1038/onc.2011.231; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Shakibael M, 2003, HISTOL HISTOPATHOL, V18, P343, DOI 10.14670/HH-18.343; Sukharev Sergei, 2004, Sci STKE, V2004, pre4, DOI 10.1126/stke.2192004re4; Thodeti CK, 2009, CIRC RES, V104, P1123, DOI 10.1161/CIRCRESAHA.108.192930; Thodeti CK, 2002, BIOCHEM J, V365, P157, DOI 10.1042/BJ20020248; Troidl C, 2009, J CELL MOL MED, V13, P2613, DOI 10.1111/j.1582-4934.2008.00579.x; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; Van der Veldt AAM, 2012, CANCER CELL, V21, P82, DOI 10.1016/j.ccr.2011.11.023; Wilson PD, 1999, LAB INVEST, V79, P1311; Xu HS, 2006, AM J PHYSIOL-RENAL, V290, pF1103, DOI 10.1152/ajprenal.00245.2005	57	97	104	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					314	322		10.1038/onc.2015.83	http://dx.doi.org/10.1038/onc.2015.83			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25867067	Green Accepted, Green Submitted			2022-12-17	WOS:000369055300005
J	Braeutigam, C; Rago, L; Rolke, A; Waldmeier, L; Christofori, G; Winter, J				Braeutigam, C.; Rago, L.; Rolke, A.; Waldmeier, L.; Christofori, G.; Winter, J.			The RNA-binding protein Rbfox2: an essential regulator of EMT-driven alternative splicing and a mediator of cellular invasion	ONCOGENE			English	Article						Rbfox2; epithelial-mesenchymal transition; EMT; alternative splicing	EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; IN-VIVO; CARCINOMA; MIGRATION; FOX-1; METASTASIS; EXPRESSION; DYNAMIN; CELLS	The epithelial-mesenchymal transition (EMT), a prerequisite for cancer progression and metastasis formation, is regulated not only at the transcriptional but also at the post-transcriptional level, including at the level of alternative pre-mRNA splicing. Several recent studies have highlighted the involvement of splicing factors, including epithelial splicing regulatory proteins (Esrps) and RNA-binding Fox protein 2 (Rbfox2), in this process. Esrps regulate epithelial-specific splicing, and their expression is downregulated during EMT. By contrast, the role of Rbfox2 is controversial because Rbfox2 regulates epithelial as well as mesenchymal splicing events. Here, we have used several established cell culture models to investigate the functions of Rbfox2 during EMT. We demonstrate that induction of an EMT upregulates the expression of Rbfox2, which correlates with an increase in Rbfox2-regulated splicing events in the cortactin (Cttn), Pard3 and dynamin 2 (Dnm2) transcripts. At the same time, however, the epithelial-specific ability to splice the Enah, Slk and Tsc2 transcripts is either reduced or lost completely by Rbfox2, which might be due, in part, to downregulation of the expression of the Esrps cooperative factors. Depletion of Rbfox2 during EMT did not prevent the activation of transforming growth factor-beta signaling, the upregulation of mesenchymal markers or changes in cell morphology toward a mesenchymal phenotype. In addition, this depletion did not influence cell migration. However, depletion of Rbfox2 in cells that have completed an EMT significantly reduced their invasive potential. Taken together, our results suggest that during an EMT, Rbfox2-regulated splicing shifts from epithelial-to mesenchymal-specific events, leading to a higher degree of tissue invasiveness.	[Braeutigam, C.; Rago, L.; Rolke, A.; Winter, J.] Max Planck Inst Immunobiol & Epigenet, Dept Mol Embryol, D-79108 Freiburg, Germany; [Waldmeier, L.; Christofori, G.] Univ Basel, Dept Biomed, Basel, Switzerland; [Winter, J.] Johannes Gutenberg Univ Mainz, Univ Med Ctr Johannes Gutenberg, Inst Human Genet, D-55122 Mainz, Germany	Max Planck Society; University of Basel; Johannes Gutenberg University of Mainz	Winter, J (corresponding author), Max Planck Inst Immunobiol & Epigenet, Dept Mol Embryol, Stuebeweg 51, D-79108 Freiburg, Germany.	winter@immunbio.mpg.de			Max-Planck Society	Max-Planck Society(Max Planck Society)	This work was supported by the Max-Planck Society. We are grateful to Rolf Kemler for helpful discussions.	Baraniak AP, 2006, MOL CELL BIOL, V26, P1209, DOI 10.1128/MCB.26.4.1209-1222.2006; Barnes EA, 2010, AM J RESP CELL MOL, V43, P617, DOI 10.1165/rcmb.2008-0335OC; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Biamonti G, 2012, CELL MOL LIFE SCI, V69, P2515, DOI 10.1007/s00018-012-0931-7; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Cheng CH, 2006, MOL CELL BIOL, V26, P362, DOI 10.1128/MCB.26.1.362-370.2006; Damianov A, 2010, RNA, V16, P405, DOI 10.1261/rna.1838210; Di Marcotullio L, 2011, ONCOGENE, V30, P65, DOI 10.1038/onc.2010.394; Dikshit B, 2013, ONCOGENE, V32, P3798, DOI 10.1038/onc.2012.393; Dow LE, 2008, ONCOGENE, V27, P5988, DOI 10.1038/onc.2008.219; Eppinga RD, 2012, ONCOGENE, V31, P1228, DOI 10.1038/onc.2011.329; Feng H, 2012, ONCOGENE, V31, P2691, DOI 10.1038/onc.2011.436; Ge XJ, 2005, GENOMICS, V86, P127, DOI 10.1016/j.ygeno.2005.04.008; Ghigna C, 2005, MOL CELL, V20, P881, DOI 10.1016/j.molcel.2005.10.026; Goswami S, 2009, CLIN EXP METASTAS, V26, P153, DOI 10.1007/s10585-008-9225-8; Guo M, 2012, CANCER RES, V72, P2017, DOI 10.1158/0008-5472.CAN-11-3985; Hidalgo-Carcedo C, 2011, NAT CELL BIOL, V13, P49, DOI 10.1038/ncb2133; Hirata E, 2012, J CELL SCI, V125, P858, DOI 10.1242/jcs.089995; Horiguchi K, 2012, ONCOGENE, V31, P3190, DOI 10.1038/onc.2011.493; HUH GS, 1994, GENE DEV, V8, P1561, DOI 10.1101/gad.8.13.1561; Jia YL, 2011, HEPATOLOGY, V54, P1808, DOI 10.1002/hep.24562; Jin Y, 2003, EMBO J, V22, P905, DOI 10.1093/emboj/cdg089; Kirkbride KC, 2011, CELL ADHES MIGR, V5, P187, DOI 10.4161/cam.5.2.14773; Kruchten AE, 2006, J CELL SCI, V119, P1683, DOI 10.1242/jcs.02963; Kuroyanagi H, 2009, CELL MOL LIFE SCI, V66, P3895, DOI 10.1007/s00018-009-0120-5; Lapuk A, 2010, MOL CANCER RES, V8, P961, DOI 10.1158/1541-7786.MCR-09-0528; Lehembre F, 2008, EMBO J, V27, P2603, DOI 10.1038/emboj.2008.178; LeMasters KE, 2012, BMC DEV BIOL, V12, DOI 10.1186/1471-213X-12-22; Liu H, 2006, P NATL ACAD SCI USA, V103, P4134, DOI 10.1073/pnas.0511342103; Massimi P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040279; Matsuda Yoko, 2012, Patholog Res Int, V2012, P574768, DOI 10.1155/2012/574768; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Modafferi EF, 1997, MOL CELL BIOL, V17, P6537, DOI 10.1128/MCB.17.11.6537; Moran-Jones K, 2009, CANCER RES, V69, P9219, DOI 10.1158/0008-5472.CAN-09-1852; Nakahata S, 2005, NUCLEIC ACIDS RES, V33, P2078, DOI 10.1093/nar/gki338; Nishikawa Y, 2011, ONCOL REP, V26, P587, DOI 10.3892/or.2011.1324; Oh S, 2012, BBA-REV CANCER, V1826, P1, DOI 10.1016/j.bbcan.2012.02.002; Philippar U, 2008, DEV CELL, V15, P813, DOI 10.1016/j.devcel.2008.09.003; Reed JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045877; Roovers K, 2009, ONCOGENE, V28, P2839, DOI 10.1038/onc.2009.146; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Underwood JG, 2005, MOL CELL BIOL, V25, P10005, DOI 10.1128/MCB.25.22.10005-10016.2005; Valacca C, 2010, J CELL BIOL, V191, P87, DOI 10.1083/jcb.201001073; Venables JP, 2006, BIOESSAYS, V28, P378, DOI 10.1002/bies.20390; Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608; Waldmeier L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048651; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Wesche J, 2011, BIOCHEM J, V437, P199, DOI 10.1042/BJ20101603; Winter J, 2004, HUM GENET, V114, P541, DOI 10.1007/s00439-004-1114-x; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yeo GW, 2009, NAT STRUCT MOL BIOL, V16, P130, DOI 10.1038/nsmb.1545; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Zhang CL, 2008, GENE DEV, V22, P2550, DOI 10.1101/gad.1703108	54	97	100	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1082	1092		10.1038/onc.2013.50	http://dx.doi.org/10.1038/onc.2013.50			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23435423				2022-12-17	WOS:000331933800002
J	Kesanakurti, D; Chetty, C; Maddirela, DR; Gujrati, M; Rao, JS				Kesanakurti, D.; Chetty, C.; Maddirela, D. Rajasekhar; Gujrati, M.; Rao, J. S.			Essential role of cooperative NF-kappa B and Stat3 recruitment to ICAM-1 intronic consensus elements in the regulation of radiation-induced invasion and migration in glioma	ONCOGENE			English	Article						chromatin immunoprecipitation (ChIP); glioma; GST pull-down; NF-kappa B; stat3; transactivation domain (TAD)	INTERCELLULAR-ADHESION MOLECULE-1; GENE-EXPRESSION; SIGNALING PATHWAYS; ENDOTHELIAL-CELLS; MALIGNANT GLIOMAS; MYELOID-LEUKEMIA; P65/RELA SUBUNIT; TUMOR PROMOTION; TRANSCRIPTION; INFLAMMATION	Although radiotherapy improves survival in patients, glioblastoma multiformes (GBMs) tend to relapse with augmented tumor migration and invasion even after ionizing radiation (IR). Aberrant nuclear factor-kappa B (NF-kappa B) and signal transducer and activator of transcription factor 3 (Stat3) activation and interaction have been suggested in several human tumors. However, possible NF-kappa B/Stat3 interaction and the role of Stat3 in maintenance of NF-kappa B nuclear retention in GBM still remain unknown. Stat3 and NF-kappa B (p65) physically interact with one another in the nucleus in glioma tumors. Most importantly, glutathione S-transferase pull-down assays identified that Stat3 binds to the p65 transactivation domain and is present in the NF-kappa B DNA-binding complex. Irradiation significantly elevated nuclear phospho-p65/phospho-Stat3 interaction in correlation with increased intercellular adhesion molecule-1 (ICAM-1) and soluble-ICAM-1 levels, migration and invasion in human glioma xenograft cell lines 4910 and 5310. Chromatin immunopreicipitation and promoter luciferase activity assays confirmed the critical role of adjacent NF-kappa B (+399) and Stat3 (+479) binding motifs in the proximal intron-1 in elevating IR-induced ICAM-1 expression. Specific inhibition of Stat3 or NF-kappa B with Stat3. siRNA or JSH-23 severely inhibited IR-induced p65 recruitment onto ICAM-1 intron-1 and suppressed migratory properties in both the cell lines. On the other hand, Stat3C- or IR-induced Stat3 promoter recruitment was significantly decreased in p65-knockdown cells, thereby suggesting the reciprocal regulation between p65 and Stat3. We also observed a significant increase in NF-kappa B enrichment on ICAM-1 intron-1 and ICAM-1 transactivation in Stat3C overexpressing cells. In in vivo orthotopic experiments, suppression of tumor growth in Stat3.si + IR-treated mice was associated with the inhibition of IR-induced p-p65/p-Stat3 nuclear colocalization and ICAM-1 levels. To our knowledge, this is the first study showing the crucial role of NF-kappa B/Stat3 nuclear association in IR-induced ICAM-1 regulation and implies that targeting NF-kappa B/Stat3 interaction may have future therapeutic significance in glioma treatment.	[Kesanakurti, D.; Chetty, C.; Maddirela, D. Rajasekhar; Rao, J. S.] Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA; [Gujrati, M.] Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA; [Rao, J. S.] Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA.	jsrao@uic.edu			National Institute of Neurological Disorders and Stroke [NS64535-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS064535] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Noorjehan Ali for technical assistance, Shelle Abraham for manuscript preparation, Diana Meister and Sushma Jasti for manuscript review. This research was supported by award NS64535-01A2 (to JSR) from the National Institute of Neurological Disorders and Stroke. Contents are solely the responsibility of the authors and do not necessarily represent the official views of NIH.	Anwar KN, 2004, J IMMUNOL, V173, P6965, DOI 10.4049/jimmunol.173.11.6965; Atkinson GP, 2010, EXPERT REV NEUROTHER, V10, P575, DOI 10.1586/ERN.10.21; Badiga AV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020614; Benezra M, 2003, J BIOL CHEM, V278, P26333, DOI 10.1074/jbc.M303076200; Berens Michael E., 1999, Neoplasia (New York), V1, P208, DOI 10.1038/sj.neo.7900034; Bollrath J, 2009, EMBO REP, V10, P1314, DOI 10.1038/embor.2009.243; Brantley EC, 2008, MOL CANCER RES, V6, P675, DOI 10.1158/1541-7786.MCR-07-2180; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burim RV, 2009, CLIN EXP MED, V9, P157, DOI 10.1007/s10238-009-0040-6; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Dutta J, 2008, J VIROL, V82, P10792, DOI 10.1128/JVI.00903-08; FINE HA, 1993, CANCER, V71, P2585, DOI 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S; Ghizzoni M, 2011, DRUG DISCOV TODAY, V16, P504, DOI 10.1016/j.drudis.2011.03.009; Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Han SS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-97; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; He GB, 2010, CANCER CELL, V17, P286, DOI 10.1016/j.ccr.2009.12.048; Jang HD, 2004, J BIOL CHEM, V279, P24873, DOI 10.1074/jbc.M313018200; Kargiotis O, 2010, J NEURO-ONCOL, V100, P323, DOI 10.1007/s11060-010-0199-4; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kesanakurti D, 2012, ONCOGENE, DOI [10.1038/onc.2012.52, DOI 10.1038/0NC.2012.52)]; Kesanakurti D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019341; Kesanakurti D, 2009, BIOCHEM BIOPH RES CO, V390, P427, DOI 10.1016/j.bbrc.2009.09.046; Lam LT, 2008, BLOOD, V111, P3701, DOI 10.1182/blood-2007-09-111948; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Lee H, 2011, CANCER RES, V71, P3772, DOI 10.1158/0008-5472.CAN-10-3304; Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015; Li T, 2011, CANCER GENE THER, V18, P617, DOI 10.1038/cgt.2011.29; Liu SJ, 2008, BLOOD, V111, P2364, DOI 10.1182/blood-2007-08-110171; Liu SJ, 2010, CANCER CELL, V17, P333, DOI 10.1016/j.ccr.2010.03.008; Louis DN, 2006, ANNU REV PATHOL-MECH, V1, P97, DOI 10.1146/annurev.pathol.1.110304.100043; Lowe JM, 2010, J BIOL CHEM, V285, P5249, DOI 10.1074/jbc.M109.034579; Maenpaa A, 1997, ACTA NEUROPATHOL, V94, P216, DOI 10.1007/s004010050696; Magne N, 2006, CANCER LETT, V231, P158, DOI 10.1016/j.canlet.2005.01.022; McDonald MW, 2011, INT J RADIAT ONCOL, V79, P130, DOI 10.1016/j.ijrobp.2009.10.048; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Rahman A, 2002, CIRC RES, V91, P398, DOI 10.1161/01.RES.0000033520.95242.A2; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Roebuck KA, 1999, INT J MOL MED, V4, P223; Roland CL, 2007, SURGERY, V141, P705, DOI 10.1016/j.surg.2007.01.016; Roy J, 2001, J BIOL CHEM, V276, P14553, DOI 10.1074/jbc.M005067200; Squarize CH, 2006, NEOPLASIA, V8, P733, DOI 10.1593/neo.06274; Strebovsky J, 2011, FASEB J, V25, P863, DOI 10.1096/fj.10-170597; Surh YJ, 2010, CANCER PREV RES, V3, P1379, DOI 10.1158/1940-6207.CAPR-10-0251; VORABERGER G, 1991, J IMMUNOL, V147, P2777; Wild-Bode C, 2001, CANCER RES, V61, P2744; Xue JP, 2009, PHYSIOL GENOMICS, V38, P42, DOI 10.1152/physiolgenomics.00012.2009	51	97	104	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2013	32	43					5144	5155		10.1038/onc.2012.546	http://dx.doi.org/10.1038/onc.2012.546			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240JY	23178493	Green Accepted			2022-12-17	WOS:000326093200002
J	Hsu, YL; Hou, MF; Kuo, PL; Huang, YF; Tsai, EM				Hsu, Y-L; Hou, M-F; Kuo, P-L; Huang, Y-F; Tsai, E-M			Breast tumor-associated osteoblast-derived CXCL5 increases cancer progression by ERK/MSK1/Elk-1/Snail signaling pathway	ONCOGENE			English	Article						breast cancer; osteoblasts; CXCL5; cancer progression	EPITHELIAL-MESENCHYMAL TRANSITIONS; ACTIVATED PROTEIN-KINASE; SNAIL; EXPRESSION; GROWTH; CELLS; MECHANISMS; DISEASE; GENE; MSK	The skeleton is the most common metastatic site for breast cancer, with bone metastasis causing pain as well as risk of pathological fractures. Interaction between tumors and the bone microenvironment creates a vicious cycle that accelerates both bone destruction and cancer progression. This study is the first to analyze the soluble factors secreted by breast tumor-associated osteoblasts (TAOBs), which are responsible for promoting cancer progression. The addition of CXCL5 (chemokine (C-X-C motif) ligand 5), present in large amounts in TAOB-condition medium (TAOB-CM), mimicked the inductive effect of TAOB-CM on breast cancer epithelial-mesenchymal transition, migration and invasion. In contrast, inhibition of CXCL5 in OBs decreased TAOB-mediated cancer progression. Inducement of MCF-7 and MDA-MB-231 cancer progression by TAOB-derived CXCL5 is associated with increased Raf/MEK/ERK activation, and mitogen-and stress-activated protein kinase 1 (MSK1) and Elk-1 phosphorylation, as well as Snail upregulation. Activation of Elk-1 facilitates recruitment of phosphorylated MSK1, which in turn enhances histone H3 acetylation and phosphorylation (serine 10) of Snail promoter, resulting in Snail enhancement and E-cadherin downregulation. Moreover, mice treated with anti-CXCL5 antibodies showed decreased metastasis of 4T1 breast cancer cells. Our study suggests that inhibition of CXCL5-mediated ERK/Snail signaling is an attractive therapeutic target for treating metastases in breast cancer patients.	[Hsu, Y-L; Tsai, E-M] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung 807, Taiwan; [Hou, M-F; Kuo, P-L; Huang, Y-F] Kaohsiung Med Univ, Coll Med, Inst Clin Med, Kaohsiung 807, Taiwan; [Hou, M-F; Kuo, P-L; Huang, Y-F] Kaohsiung Med Univ Hosp, Ctr Canc, Kaohsiung, Taiwan; [Kuo, P-L] Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan; [Tsai, E-M] Kaohsiung Med Univ Hosp, Dept Obstet & Gynecol, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Hsu, YL (corresponding author), Kaohsiung Med Univ, Coll Med, Grad Inst Med, 100 Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.	hsuyl326@gmail.com		Huang, Ya-Fang/0000-0002-7790-8071; Hou, Ming-Feng/0000-0001-6030-9702	National Science Council of Taiwan [NSC 99-2320-B-037-017-MY3]; Excellence for Cancer Research Center Grant, the Department of Health, Executive Yuan, Taipei, Taiwan [DOH101-TD-C-111-002]; Kaohsiung Medical University Hospital [KMUH 99-9I04]; Kaohsiung Medical University Research Foundation [KMUER008]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Excellence for Cancer Research Center Grant, the Department of Health, Executive Yuan, Taipei, Taiwan; Kaohsiung Medical University Hospital; Kaohsiung Medical University Research Foundation	This study is supported by grants from the National Science Council of Taiwan (NSC 99-2320-B-037-017-MY3), the Excellence for Cancer Research Center Grant, the Department of Health, Executive Yuan, Taipei, Taiwan (DOH101-TD-C-111-002), the Kaohsiung Medical University Hospital (KMUH 99-9I04) and the Kaohsiung Medical University Research Foundation (KMUER008).	Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Besnard A, 2011, J NEUROSCI, V31, P14296, DOI 10.1523/JNEUROSCI.2890-11.2011; Bieche I, 2007, ENDOCR-RELAT CANCER, V14, P1039, DOI 10.1677/erc.1.01301; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cassinat B, 2011, MOL CELL BIOL, V31, P1409, DOI 10.1128/MCB.00756-10; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Chen Y, 2011, J BIOL CHEM, V286, P42575, DOI 10.1074/jbc.M111.294595; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Coleman RE, 2010, CANCER TREAT REV, V36, P615, DOI 10.1016/j.ctrv.2010.04.003; Dunn KL, 2005, BIOCHEM CELL BIOL, V83, P1, DOI 10.1139/O04-121; Espino PS, 2006, CANCER RES, V66, P4610, DOI 10.1158/0008-5472.CAN-05-4251; Georges S, 2009, CYTOKINE GROWTH F R, V20, P29, DOI 10.1016/j.cytogfr.2008.11.005; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hsu YL, 2011, J BIOL CHEM, V286, P37335, DOI 10.1074/jbc.M111.256156; Jorda M, 2007, EXP CELL RES, V313, P2389, DOI 10.1016/j.yexcr.2007.04.001; Kuo PL, 2011, J CELL PHYSIOL, V226, P1224, DOI 10.1002/jcp.22445; Kuo PL, 2011, J IMMUNOL, V186, P1521, DOI 10.4049/jimmunol.1002940; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R; Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997; Onishi T, 2010, NAT REV CLIN ONCOL, V7, P641, DOI 10.1038/nrclinonc.2010.134; Pacheco-Rodriguez G, 2009, J IMMUNOL, V182, P1270, DOI 10.4049/jimmunol.182.3.1270; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Van't Veer LJ, 2003, NAT MED, V9, P999, DOI 10.1038/nm0803-999b; Vicent GP, 2006, MOL CELL, V24, P367, DOI 10.1016/j.molcel.2006.10.011; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yuen HF, 2011, J PATHOL, V224, P78, DOI 10.1002/path.2859; Zhang HM, 2008, NUCLEIC ACIDS RES, V36, P2594, DOI 10.1093/nar/gkn099	38	97	104	1	33	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2013	32	37					4436	4447		10.1038/onc.2012.444	http://dx.doi.org/10.1038/onc.2012.444			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23045282				2022-12-17	WOS:000324404200012
J	Ciechomska, IA; Gabrusiewicz, K; Szczepankiewicz, AA; Kaminska, B				Ciechomska, I. A.; Gabrusiewicz, K.; Szczepankiewicz, A. A.; Kaminska, B.			Endoplasmic reticulum stress triggers autophagy in malignant glioma cells undergoing cyclosporine A-induced cell death	ONCOGENE			English	Article						glioma; autophagy; endoplasmic reticulum stress; mTOR kinase	AP-1 TRANSCRIPTION FACTOR; IN-VIVO; INDUCED CYTOTOXICITY; SIGNALING PATHWAYS; ER STRESS; APOPTOSIS; THERAPY; INHIBITION; MECHANISMS; CANCER	Autophagy is a conserved, self-digestion process that is activated in response to nutrient limitation but acting also as an alternative death mechanism under certain conditions. It is accompanied by the progressive formation of vesicle structures from autophagosomes to autophagolysosomes orchestrated by autophagy effectors (Atg proteins) and modulators (that is, mTOR-mammalian target of rapamycin as a negative regulator). Malignant gliomas are highly resistant to current therapies that induce apoptosis, thus induction of the alternative cell death is an attractive strategy. We demonstrate that cyclosporine A (CsA, an immunophilin/calcineurin inhibitor) induces cell death with some apoptotic features but also accompanied by the appearance of numerous cytoplasmic vacuoles, immunostained for endoplasmic reticulum (ER) and autophagy markers. The induction of ER stress in glioma cells by CsA was evidenced by detection of unfolded protein response activation (phosphorylation of PERK, accumulation of IRE1 alpha) and accumulation of ER stress-associated proteins (BIP and CHOP). Formation of the acidic vesicular organelles, increase of autophagic vacuoles, GFP-LC3 punctation (microtubule-associated protein light chain 3) and LC3-II accumulation upon CsA treatment confirmed activation of autophagy. Decrease of phosphorylation of 4E-BP1, p70S6K1 and its downstream target S6 ribosomal protein demonstrate inhibition of mTOR signaling by CsA. Salubrinal and silencing of PERK and IRE1 alpha partially blocked CsA-induced accumulation of LC3-II. It suggests that ER stress precedes CsA-induced autophagy. Surprisingly, silencing of autophagy effectors ULK1, Atg5 or Atg7 increased the level of active caspases 3, 7 and PARP degradation in CsA-treated cells. Our results demonstrate that CsA induces both apoptosis and autophagy in malignant glioma cells via induction of ER stress and inhibition of mTOR/p70S6K1 pathway, however autophagy is cytoprotective in this context. Oncogene (2013) 32, 1518-1529; doi:10.1038/onc.2012.174; published online 14 May 2012	[Ciechomska, I. A.; Gabrusiewicz, K.; Kaminska, B.] Nencki Inst Expt Biol, Dept Cell Biol, Lab Transcript Regulat, PL-02093 Warsaw, Poland; [Szczepankiewicz, A. A.] Nencki Inst Expt Biol, Dept Neurophysiol, Lab Mol & Syst Neuromorphol, Warsaw, Poland	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Ciechomska, IA (corresponding author), Nencki Inst Expt Biol, Dept Cell Biol, Lab Transcript Regulat, 3 Pasteur Str, PL-02093 Warsaw, Poland.	jcjech@nencki.gov.pl	Kaminska, Bozena/H-4592-2011; Kaminska, Bozena/B-2915-2014; Ciechomksa, Iwona/R-4706-2016	Kaminska, Bozena/0000-0002-2642-4616; Ciechomksa, Iwona/0000-0002-8068-0020; Szczepankiewicz, Andrzej/0000-0002-1502-3147; Gabrusiewicz, Konrad/0000-0001-7857-8062	Polish Ministry of Science and Higher Education [N N301 092036]	Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland)	We are grateful to Aviva M. Tolkovsky for her critical review of the manuscript. This work was supported by a grant N N301 092036 from The Polish Ministry of Science and Higher Education (IC).	Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167; Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Ciechomska I, 2005, INT J CANCER, V117, P59, DOI 10.1002/ijc.21153; Ciechomska I, 2003, ONCOGENE, V22, P7617, DOI 10.1038/sj.onc.1207137; Ciechomska Iwona A., 2008, V445, P175, DOI 10.1007/978-1-59745-157-4_12; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Dunn IF, 2003, NEUROSURGERY, V52, P1411, DOI 10.1227/01.NEU.0000064808.27512.CF; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Ge PF, 2009, MED HYPOTHESES, V73, P45, DOI 10.1016/j.mehy.2008.11.047; Gijtenbeek JMM, 1999, J NEUROL, V246, P339, DOI 10.1007/s004150050360; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248; Iwamaru A, 2007, ONCOGENE, V26, P1840, DOI 10.1038/sj.onc.1209992; Jia WT, 2010, INT J BIOCHEM CELL B, V42, P2019, DOI 10.1016/j.biocel.2010.09.003; Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249; Kang CH, 2008, AUTOPHAGY, V4, P82, DOI 10.4161/auto.5154; Kanzawa T, 2003, CANCER RES, V63, P2103; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Lefranc F, 2007, ONCOLOGIST, V12, P1395, DOI 10.1634/theoncologist.12-12-1395; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Liu HY, 2009, J BIOL CHEM, V284, P31484, DOI 10.1074/jbc.M109.033936; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Mosieniak G, 1997, J NEUROCHEM, V68, P1142; Neufeld TP, 2010, CURR OPIN CELL BIOL, V22, P157, DOI 10.1016/j.ceb.2009.11.005; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Pallet N, 2008, AM J TRANSPLANT, V8, P2283, DOI 10.1111/j.1600-6143.2008.02396.x; Pallet N, 2008, AUTOPHAGY, V4, P783, DOI 10.4161/auto.6477; Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014; Pyrzynska B, 2000, J NEUROCHEM, V74, P42, DOI 10.1046/j.1471-4159.2000.0740042.x; Qadir MA, 2008, BREAST CANCER RES TR, V112, P389, DOI 10.1007/s10549-007-9873-4; Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027; Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030; Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008; Wang P, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-7-226; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Yoon Hye Eun, 2009, Korean Journal of Internal Medicine, V24, P81, DOI 10.3904/kjim.2009.24.2.81; Zupanska A, 2005, NEUROCHEM INT, V47, P430, DOI 10.1016/j.neuint.2005.05.010	48	97	103	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 21	2013	32	12					1518	1529		10.1038/onc.2012.174	http://dx.doi.org/10.1038/onc.2012.174			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22580614				2022-12-17	WOS:000316456000005
J	Liu, X; Yang, N; Figel, SA; Wilson, KE; Morrison, CD; Gelman, IH; Zhang, J				Liu, X.; Yang, N.; Figel, S. A.; Wilson, K. E.; Morrison, C. D.; Gelman, I. H.; Zhang, J.			PTPN14 interacts with and negatively regulates the oncogenic function of YAP	ONCOGENE			English	Article						epithelial-to-mesenchymal transition (EMT); Hippo pathway; PTPN14; tumor metastasis; YAP	PROTEIN-TYROSINE-PHOSPHATASE; HIPPO SIGNALING PATHWAY; CELL-PROLIFERATION; TUMOR-SUPPRESSOR; WW DOMAIN; TRANSCRIPTIONAL COACTIVATOR; COLORECTAL CANCERS; GROWTH-CONTROL; ALPHA-CATENIN; DROSOPHILA	The Hippo signaling pathway regulates cellular proliferation and survival, thus exerting profound effects on normal cell fate and tumorigenesis. The pivotal effector of this pathway is YAP, a transcriptional co-activator amplified in mouse and human cancers where it promotes epithelial-to-mesenchymal transition and malignant transformation. Here, we report a novel regulatory mechanism for the YAP oncogenic function via direct interaction with non-receptor tyrosine phosphatase 14 (PTPN14) through the WW domain of YAP and the PPxY domain of PTPN14. We also found that YAP is a direct substrate of PTPN14. In addition, luciferase reporter assay showed that the inhibition of the YAP transcriptional co-activator function by PTPN14 is mediated through their protein interactions and may result from an increase in the inactive cytoplasmic form of YAP. Last, knockdown of PTPN14 induces the nuclear retention of YAP and increases the YAP-dependent cell migration. In summary, our results indicate a potential regulatory role of PTPN14 on YAP and demonstrate a novel mechanism in YAP regulation. Oncogene (2013) 32, 1266-1273; doi:10.1038/onc.2012.147; published online 23 April 2012	[Liu, X.; Yang, N.; Figel, S. A.; Wilson, K. E.; Gelman, I. H.; Zhang, J.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; [Morrison, C. D.] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute	Zhang, J (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton Str, Buffalo, NY 14263 USA.	jianmin.zhang@roswellpark.org	Zhang, Jianmin/AAN-2931-2020		Roswell Park Cancer Institute; National Cancer Institute (NCI) [P30 CA016056]; NATIONAL CANCER INSTITUTE [R01CA094108, P30CA016056] Funding Source: NIH RePORTER	Roswell Park Cancer Institute; National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Kunliang Guan (University of California, San Diego) for generously sharing with us the 5 x UAS-luciferase reporter and Gal4-TEAD4 plasmids. We thank Dr Andrei V Bakin (RPCI) for his kind help with the microscopy technique and Dr Xinjiang Wang (RPCI) for assistance of phospohor-imaging analysis. We thank Ms Paula Jones for her kind assistance with the manuscript editing. This work was supported by Roswell Park Cancer Institute and National Cancer Institute (NCI) grant #P30 CA016056 (to JZ).	Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chan SW, 2011, J BIOL CHEM, V286, P7018, DOI 10.1074/jbc.C110.212621; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Lai ZC, 2005, CELL, V120, P675, DOI 10.1016/j.cell.2004.12.036; Mauviel A, 2012, ONCOGENE, V31, P1743, DOI 10.1038/onc.2011.363; Niedergethmann M, 2007, BRIT J CANCER, V97, P1432, DOI 10.1038/sj.bjc.6604031; Ogata M, 1999, J BIOL CHEM, V274, P12905, DOI 10.1074/jbc.274.18.12905; Ogata M, 1999, J BIOL CHEM, V274, P20717, DOI 10.1074/jbc.274.29.20717; Oka T, 2012, ONCOGENE, V31, P128, DOI 10.1038/onc.2011.216; Oka T, 2010, BIOCHEM J, V432, P461, DOI 10.1042/BJ20100870; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Poernbacher I, 2012, CURR BIOL, V22, P389, DOI 10.1016/j.cub.2012.01.019; SAWADA M, 1994, BIOCHEM BIOPH RES CO, V203, P479, DOI 10.1006/bbrc.1994.2207; Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031; Silvis MR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001823; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; SMITH AL, 1995, BIOCHEM BIOPH RES CO, V209, P959, DOI 10.1006/bbrc.1995.1591; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; SUDOL M, 1994, ONCOGENE, V9, P2145; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; Sudol M, 2010, TRENDS BIOCHEM SCI, V35, P627, DOI 10.1016/j.tibs.2010.05.010; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Varelas X, 2010, DEV CELL, V19, P831, DOI 10.1016/j.devcel.2010.11.012; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Wadham C, 2003, MOL BIOL CELL, V14, P2520, DOI 10.1091/mbc.E02-09-0577; Wadham C, 2000, J CELL SCI, V113, P3117; Wang WQ, 2011, J BIOL CHEM, V286, P4364, DOI 10.1074/jbc.C110.205401; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Wyatt L, 2008, CELL CYCLE, V7, P2290, DOI 10.4161/cc.6443; Xiao L, 2011, J BIOL CHEM, V286, P7788, DOI 10.1074/jbc.M110.173468; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073; Zhang JM, 2008, CANCER RES, V68, P2789, DOI 10.1158/0008-5472.CAN-07-6205; Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810	49	97	102	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 7	2013	32	10					1266	1273		10.1038/onc.2012.147	http://dx.doi.org/10.1038/onc.2012.147			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP		Green Accepted			2022-12-17	WOS:000316454500007
J	Zhang, H; Fagan, DH; Zeng, X; Freeman, KT; Sachdev, D; Yee, D				Zhang, H.; Fagan, D. H.; Zeng, X.; Freeman, K. T.; Sachdev, D.; Yee, D.			Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation	ONCOGENE			English	Article						insulin receptor; angiogenesis; lymphangiogenesis; metastasis	GROWTH-FACTOR-RECEPTOR; HUMAN-BREAST-CANCER; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; IGF-I RECEPTORS; M14 MELANOMA; VIVO; EXPRESSION; LINES; MICE; ACTIVATION	Insulin receptor (IR) and the type I IGF receptor (IGF1R) are structurally and functionally related. The function of IGF1R in cancer has been well documented and anti-IGF1R strategies to treat cancer have shown initial positive results. However, the role of IR in tumor biology, independent of IGF1R, is less clear. To address this issue, short hairpin RNA (shRNA) was used to specifically downregulate IR in two cancer cell lines, LCC6 and T47D. Cells with reduced IR showed reduced insulin-stimulated Akt activation, without affecting IGF1R activation. Cells with reduced IR formed fewer colonies in anchorage-independent conditions. LCC6 IR shRNA xenograft tumors in mice had reduced growth, angiogenesis and lymphangiogensis when compared with LCC6 wild-type cells. Accordingly, LCC6 IR shRNA clones produced less hypoxia-inducible factor-1 alpha, vascular endothelial growth factor (VEGF)-A and VEGF-D. Furthermore, LCC6 IR shRNA cells formed fewer pulmonary metastases when compared with LCC6 wild-type cells. Using in vivo luciferase imaging, we have shown that LCC6 IR shRNA cells have less seeding and colonization potential in the lung and liver of mice than LCC6 cells. In conclusion, downregulation of IR inhibited cancer cell proliferation, angiogenesis, lymphangiogenesis and metastasis. Our data argue that IR should also be targeted in cancer therapy. Oncogene (2010) 29, 2517-2527; doi:10.1038/onc.2010.17; published online 15 February 2010	[Zhang, H.; Freeman, K. T.; Sachdev, D.; Yee, D.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA; [Fagan, D. H.; Zeng, X.; Yee, D.] Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; [Sachdev, D.; Yee, D.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Yee, D (corresponding author), Univ Minnesota, Masonic Canc Ctr, MMC 806,420 Delaware St SE, Minneapolis, MN 55455 USA.	yeexx006@umn.edu		Yee, Douglas/0000-0002-3387-4009	Department of Defense [BC050548]; National Institutes of Health [R01CA74285]; National Cancer Institute Cancer Center [P30 077598]; NATIONAL CANCER INSTITUTE [P30CA077598, R01CA074285] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Colleen Forster for the technical service on immunohistochemistry staining of tumor and lung tissue. We thank Dr Ilze Matise from the Masonic Cancer Center Comparative Pathology Shared Resource for valuable advice. We thank Dr Yunfang Li and Dr Kalpna Gupta from Masonic Cancer Center for detailed protocol of LYVE-1 and CD31 staining in tumor samples. We appreciate Dr Minghai Shao and Dr Daniela E Matei from Indiana University School of Medicine for providing the retroviral vector expressing luciferase. We acknowledge the assistance of the Flow Cytometry Core Shared Resource of the Masonic Cancer Center. Animal imaging was performed at the Biomedical Image Processing laboratory at University of Minnesota. This work was supported by Department of Defense Breast Cancer Research Program post-doctoral Grant BC050548 to HZ, National Institutes of Health R01CA74285 to DY and National Cancer Institute Cancer Center Support Grant P30 077598.	Ademuyiwa FO, 2008, CLIN BREAST CANCER, V8, pS151, DOI 10.3816/CBC.2008.s.011; Avnet S, 2009, CANCER RES, V69, P2443, DOI 10.1158/0008-5472.CAN-08-2645; Bjorndahl M, 2005, P NATL ACAD SCI USA, V102, P15593, DOI 10.1073/pnas.0507865102; Byron SA, 2006, BRIT J CANCER, V95, P1220, DOI 10.1038/sj.bjc.6603354; Chambers AF, 2009, CANCER RES, V69, P5292, DOI 10.1158/0008-5472.CAN-09-1528; Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287; Dunn SE, 1998, CANCER RES, V58, P3353; Eccles S, 2007, CLIN EXP METASTAS, V24, P619, DOI 10.1007/s10585-007-9123-5; Feldser D, 1999, CANCER RES, V59, P3915; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Frasca Francesco, 2008, Archives of Physiology and Biochemistry, V114, P23, DOI [10.1080/13813450801969715, 10.1080/13813450801969715 ]; Frasca Francesco, 2003, Breast Dis, V17, P73; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Goodwin PJ, 2002, J CLIN ONCOL, V20, P42, DOI 10.1200/JCO.20.1.42; Haluska P, 2006, CANCER RES, V66, P362, DOI 10.1158/0008-5472.CAN-05-1107; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; HEUSON JC, 1972, CANCER RES, V32, P226; Hewish M, 2009, RECENT PAT ANTI-CANC, V4, P54, DOI 10.2174/157489209787002515; Ji QS, 2007, MOL CANCER THER, V6, P2158, DOI 10.1158/1535-7163.MCT-07-0070; KAREY KP, 1988, CANCER RES, V48, P4083; KASUYA J, 1993, BIOCHEMISTRY-US, V32, P13531, DOI 10.1021/bi00212a019; Leonessa F, 1996, BRIT J CANCER, V73, P154, DOI 10.1038/bjc.1996.29; Li JG, 2006, PHYSIOL GENOMICS, V25, P450, DOI 10.1152/physiolgenomics.00293.2005; Ma J, 2008, LANCET ONCOL, V9, P1039, DOI 10.1016/S1470-2045(08)70235-3; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; Novosyadlyy R, 2009, ONCOGENE, V28, P3477, DOI 10.1038/onc.2009.209; OSBORNE CK, 1976, P NATL ACAD SCI USA, V73, P4536, DOI 10.1073/pnas.73.12.4536; Pandini G, 1999, CLIN CANCER RES, V5, P1935; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Price JE, 1996, BREAST CANCER RES TR, V39, P93, DOI 10.1007/BF01806081; Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549-006-9392-8; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Sachdev D, 2004, J BIOL CHEM, V279, P5017, DOI 10.1074/jbc.M305403200; Sachdev D, 2003, CANCER RES, V63, P627; Sachdev D, 2006, J MAMMARY GLAND BIOL, V11, P27, DOI 10.1007/s10911-006-9010-8; Stoeltzing O, 2003, AM J PATHOL, V163, P1001, DOI 10.1016/S0002-9440(10)63460-8; Tang YC, 2003, CANCER RES, V63, P1166; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Wang JQ, 2006, BIOORG MED CHEM LETT, V16, P331, DOI 10.1016/j.bmcl.2005.09.082; Weroha S, 2008, J MAMMARY GLAND BIOL, V13, P471, DOI 10.1007/s10911-008-9104-6; Zhang H, 2007, CANCER RES, V67, P391, DOI 10.1158/0008-5472.CAN-06-1712; Zhang H, 2006, CLIN CANCER RES, V12, P6323, DOI 10.1158/1078-0432.CCR-06-1707	43	97	106	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2517	2527		10.1038/onc.2010.17	http://dx.doi.org/10.1038/onc.2010.17			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20154728	Green Accepted			2022-12-17	WOS:000277169400007
J	Kar, R; Singha, PK; Venkatachalam, MA; Saikumar, P				Kar, R.; Singha, P. K.; Venkatachalam, M. A.; Saikumar, P.			A novel role for MAP1 LC3 in nonautophagic cytoplasmic vacuolation death of cancer cells	ONCOGENE			English	Article						cell death; cytoplasmic vacuolation; LC3; ER stress; MAPK; 15d-PGJ2	15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); OXIDATIVE STRESS; INDUCE APOPTOSIS; DRUG-RESISTANCE; DNA-BINDING; AUTOPHAGY; ACTIVATION; MECHANISMS; PROTEASOME; INHIBITION	Thiol reactive cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ2), induced a novel, nonapoptotic and microtubule-associated protein 1 light chain 3 (MAP1 LC3) dependent but nonautophagic form of cell death in colon, breast and prostate cancer cell lines, characterized by extensive cytoplasmic vacuolation with dilatation of endoplasmic reticulum (ER). Disruption of sulfhydryl homeostasis, which resulted in ER stress, accumulation of ubiquitinated proteins and subsequent ER dilation, contributed to peroxisome proliferator-activated receptor gamma (PPAR gamma)-independent cell death by 15d-PGJ2. Absence of intracellular organelles in these vacuoles, shown by electron microscopy and unique fragmentation of lamin B, suggested this form of cell death to be different from autophagy and apoptosis. Cell death induced by 15d-PGJ2 is prevented by cycloheximide and actinomycin D, suggesting a requirement of new protein synthesis for death with cytoplasmic vacuolation. Here, we report for the. first time that upregulation and processing of autophagy marker LC3 is an important event in nonautophagic cytoplasmic vacuolation and cell death. Notably, knockdown of LC3 conferred significant protection against 15d-PGJ2-induced cytoplasmic vacuolation and cell death, suggesting a novel role of LC3 in a death process other than autophagy. Oncogene (2009) 28, 2556-2568; doi: 10.1038/onc.2009.118; published online 18 May 2009	[Kar, R.; Singha, P. K.; Venkatachalam, M. A.; Saikumar, P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Saikumar, P (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	saikumar@uthscsa.edu			National Institutes of Health [DK54472, DK37139]; Morrison Trust; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037139, R01DK054472, R37DK037139] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Morrison Trust; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Tamotsu Yoshimori of Osaka University, Japan, for LC3 antibody and GFP-LC3 construct and Drs Anthony J Valente and Robert A Clark of UTHSCSA, TX, for Calreticulin antibody. This work was supported by National Institutes of Health grant DK54472 and Morrison Trust Grant to PS and National Institutes of Health grant DK37139 to MAV.	Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223; Butler R, 2000, CELL GROWTH DIFFER, V11, P49; Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200; Chambers KT, 2007, AM J PHYSIOL-ENDOC M, V292, pE1052, DOI 10.1152/ajpendo.00274.2006; Chen SY, 2002, ANTI-CANCER DRUG, V13, P759, DOI 10.1097/00001813-200208000-00011; Chen YC, 2005, BBA-MOL CELL RES, V1743, P291, DOI 10.1016/j.bbamcr.2004.10.016; Cho WH, 2006, NEUROCHEM RES, V31, P1247, DOI 10.1007/s11064-006-9157-0; Ghribi O, 2001, MOL BRAIN RES, V96, P30, DOI 10.1016/S0169-328X(01)00256-X; Hashimoto K, 2004, PANCREAS, V28, P153, DOI 10.1097/00006676-200403000-00006; He H, 2003, J BIOL CHEM, V278, P29278, DOI 10.1074/jbc.M303800200; Huang WP, 2002, CELL STRUCT FUNCT, V27, P409, DOI 10.1247/csf.27.409; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; Ishii T, 2005, BIOCHEMISTRY-US, V44, P13893, DOI 10.1021/bi051336u; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kaufmann SH, 2003, ONCOGENE, V22, P7414, DOI 10.1038/sj.onc.1206945; Kimura H, 2008, NEPHROL DIAL TRANSPL, V23, P2496, DOI 10.1093/ndt/gfn139; Li LY, 2001, J BIOL CHEM, V276, P38152; Lin MS, 2007, J DIGEST DIS, V8, P82, DOI 10.1111/j.1443-9573.2007.00290.x; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706; MANN SS, 1994, J BIOL CHEM, V269, P11492; Mimnaugh EG, 2006, MOL CANCER RES, V4, P667, DOI 10.1158/1541-7786.MCR-06-0019; Morosetti R, 2004, INT J ONCOL, V25, P493; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Naito M, 2004, CANCER SCI, V95, P361, DOI 10.1111/j.1349-7006.2004.tb03216.x; Nawrocki ST, 2005, CANCER RES, V65, P11658, DOI 10.1158/0008-5472.CAN-05-2370; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Noda T, 2002, TRENDS CELL BIOL, V12, P231, DOI 10.1016/S0962-8924(02)02278-X; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Perez-Sala D, 2003, J BIOL CHEM, V278, P51251, DOI 10.1074/jbc.M309409200; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Proskuryakov SY, 2003, EXP CELL RES, V283, P1, DOI 10.1016/S0014-4827(02)00027-7; Pursiheimo JP, 2009, ONCOGENE, V28, P334, DOI 10.1038/onc.2008.392; Ray DM, 2006, J IMMUNOL, V177, P5068, DOI 10.4049/jimmunol.177.8.5068; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Saikumar P, 1998, ONCOGENE, V17, P3341, DOI 10.1038/sj.onc.1202579; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Wang ZY, 2006, J BIOL CHEM, V281, P21377, DOI 10.1074/jbc.M601201200	43	97	102	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2009	28	28					2556	2568		10.1038/onc.2009.118	http://dx.doi.org/10.1038/onc.2009.118			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	471LJ	19448671	Green Accepted			2022-12-17	WOS:000268058900002
J	Lee, SG; Jeon, HY; Su, ZZ; Richards, JE; Vozhilla, N; Sarkar, D; Van Maerken, T; Fisher, PB				Lee, S-G; Jeon, H-Y; Su, Z-Z; Richards, J. E.; Vozhilla, N.; Sarkar, D.; Van Maerken, T.; Fisher, P. B.			Astrocyte elevated gene-1 contributes to the pathogenesis of neuroblastoma	ONCOGENE			English	Article						neuroblastoma; AEG-1; MYCN; PI3K; Akt	RAPID SUBTRACTION HYBRIDIZATION; PHOSPHATIDYLINOSITOL 3-KINASE; N-MYC; C-MYC; CANCER PROGRESSION; TUMOR PROGRESSION; BREAST-CANCER; EXPRESSION; PATHWAY; CELLS	Neuroblastoma, derived from neural crest progenitor cells, is the most common extracranial solid tumor of childhood. Astrocyte elevated gene-1 (AEG-1) is a primary mediator of tumor progression and metastasis in several human cancers. In this study, we investigated the potential contribution of AEG-1 in human neuroblastoma pathogenesis. AEG-1 expression was significantly elevated in neuroblastoma patient-derived samples and neuroblastoma cell lines as compared with normal peripheral nerve tissues, normal astrocytes and immortalized melanocytes. Knockdown of AEG-1 by small interfering RNA reduced the tumorigenic properties of highly aggressive neuroblastoma cells. Conversely, over-expression of AEG-1 enhanced proliferation and expression of the transformed state in less aggressive neuroblastoma cells through activation of the phosphatidylinositol 3-kinase-Akt-signaling pathway and stabilization of MYCN. These provocative results indicate that AEG-1 may play a crucial role in the pathogenesis of neuroblastoma and could represent a potential target for therapeutic intervention. Oncogene (2009) 28, 2476-2484; doi:10.1038/onc.2009.93; published online 18 May 2009	[Lee, S-G; Jeon, H-Y; Su, Z-Z; Richards, J. E.; Vozhilla, N.; Sarkar, D.; Fisher, P. B.] Virginia Commonwealth Univ, Sch Med, Dept Human & Mol Genet, Richmond, VA 23298 USA; [Lee, S-G; Sarkar, D.; Fisher, P. B.] Virginia Commonwealth Univ, Sch Med, VCU Massey Canc Ctr, Richmond, VA 23298 USA; [Van Maerken, T.] Ghent Univ Hosp, Ctr Med Genet, B-9000 Ghent, Belgium; [Sarkar, D.; Fisher, P. B.] Virginia Commonwealth Univ, Sch Med, VCU Inst Mol Med, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Ghent University; Ghent University Hospital; Virginia Commonwealth University	Fisher, PB (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Human & Mol Genet, 1101 E Marshall St,Sanger Hall Bldg,Room 11-015, Richmond, VA 23298 USA.	sglee@vcu.edu; pbfisher@vcu.edu	Lee, Seok-Geun/B-3408-2011	Lee, Seok-Geun/0000-0002-0060-5777	NATIONAL CANCER INSTITUTE [R01CA035675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031492] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA035675] Funding Source: Medline; NINDS NIH HHS [P01 NS31492] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; Emdad L, 2006, CANCER RES, V66, P1509, DOI 10.1158/0008-5472.CAN-05-3029; Emdad L, 2007, PHARMACOL THERAPEUT, V114, P155, DOI 10.1016/j.pharmthera.2007.01.010; Fotsis T, 1999, EUR J BIOCHEM, V263, P757, DOI 10.1046/j.1432-1327.1999.00575.x; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hamada K, 2005, GENE DEV, V19, P2054, DOI 10.1101/gad.1308805; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; Ishola TA, 2007, BBA-GEN SUBJECTS, V1770, P927, DOI 10.1016/j.bbagen.2007.02.002; Kang DC, 2005, GENE, V353, P8, DOI [10.1016/j.gene.2005.04.006, 10.1016/j.gene.2005.04.005]; Kang J, 2008, ONCOGENE, V27, P3999, DOI 10.1038/onc.2008.15; Kikuno N, 2007, ONCOGENE, V26, P7647, DOI 10.1038/sj.onc.1210572; Lee SG, 2008, ONCOGENE, V27, P1114, DOI 10.1038/sj.onc.1210713; Lee SG, 2008, J BIOL CHEM, V283, P13116, DOI 10.1074/jbc.M707697200; Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103; Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Sagulenko V, 2008, CARCINOGENESIS, V29, P1869, DOI 10.1093/carcin/bgn147; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Sarkar D, 2008, CANCER RES, V68, P1478, DOI 10.1158/0008-5472.CAN-07-6164; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Su ZZ, 2003, GENE, V306, P67, DOI 10.1016/S0378-1119(03)00404-9; Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj.onc.1205445; Van Maerken T, 2006, CANCER RES, V66, P9646, DOI 10.1158/0008-5472.CAN-06-0792; Van Maerken T, 2009, J CELL PHYSIOL, V219, P707, DOI 10.1002/jcp.21719; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yaari S, 2005, CLIN CANCER RES, V11, P4321, DOI 10.1158/1078-0432.CCR-04-2071; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yoo BK, 2009, J CLIN INVEST, V119, P465, DOI 10.1172/JCI36460; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245	35	97	113	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	26					2476	2484		10.1038/onc.2009.93	http://dx.doi.org/10.1038/onc.2009.93			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465QH	19448665				2022-12-17	WOS:000267601400006
J	Smith, AP; Verrecchia, A; Faga, G; Doni, M; Perna, D; Martinato, F; Guccione, E; Amati, B				Smith, A. P.; Verrecchia, A.; Faga, G.; Doni, M.; Perna, D.; Martinato, F.; Guccione, E.; Amati, B.			A positive role for Myc in TGF beta-induced Snail transcription and epithelial-to-mesenchymal transition	ONCOGENE			English	Article						TGF beta; Myc; Snail; EMT	E-CADHERIN EXPRESSION; ACTIVATOR INHIBITOR-1 GENE; EMBRYONIC STEM-CELLS; BREAST-CANCER CELLS; C-MYC; SMAD PROTEINS; TARGET GENES; IN-VIVO; REPRESSION; P15(INK4B)	Myc and transforming growth factor-beta (TGF beta) signaling are mutually antagonistic, that is Myc suppresses the activation of TGF beta-induced genes, whereas TGF beta represses c-myc transcription. Here, we report a positive role for Myc in the TGF beta response, consisting in the induction of an epithelial-to-mesenchymal transition (EMT) and the activation of the EMT-associated gene Snail. Knockdown of either Myc or the TGF beta effectors SMAD3/4 in epithelial cells eliminated Snail induction by TGF beta. Both Myc and SMAD complexes targeted the Snail promoter in vivo, DNA binding occurring in a mutually independent manner. Myc was bound prior to TGF beta treatment, and was required for rapid Snail activation upon SMAD binding induced by TGF beta. On the other hand, c-myc downregulation by TGF beta was a slower event, occurring after Snail induction. The response of Snail to another cytokine, hepatocyte growth factor (HGF), also depended on Myc and SMAD4. Thus, contrary to their antagonistic effects on Cip1 and INK4b, Myc and SMADs cooperate in signal-dependent activation of Snail in epithelial cells. Although Myc also targeted the Snail promoter in serum-stimulated fibroblasts, it was dispensable for its activation in these conditions, further illustrating that the action of Myc in transcriptional regulation is context-dependent. Our findings suggest that Myc and TGF beta signaling may cooperate in promoting EMT and metastasis in carcinomas.	[Smith, A. P.; Verrecchia, A.; Faga, G.; Doni, M.; Perna, D.; Martinato, F.; Guccione, E.; Amati, B.] IFOM IEO Campus, European Inst Oncol IEO, Dept Expt Oncol, I-20139 Milan, Italy	IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO)	Amati, B (corresponding author), IFOM IEO Campus, European Inst Oncol IEO, Dept Expt Oncol, I-20139 Milan, Italy.	bruno.amati@ifom-ieo-campus.it	Verrecchia, Alessandro/AAQ-6454-2020; Amati, Bruno/AAM-3418-2020; Doni, Mirko/ABA-9174-2021; Faga, Giovanni/AAB-5540-2021; Doni, Mirko/AAN-6027-2020; guccione, ernesto/G-9874-2011	Verrecchia, Alessandro/0000-0002-8596-6650; Doni, Mirko/0000-0001-7099-2701; Amati, Bruno/0000-0002-2958-1799	Association for Cancer Research (AIRC); International Association for Cancer Research (AICR)	Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); International Association for Cancer Research (AICR)	We thank Gioacchino Natoli and Stefano Campaner for critical reading of the paper; all members of the Amati lab for discussion and feedback throughout this work; Giuseppina Giardina for help with lentiviruses; Gabriele Bucci for bioinformatic support; Peter ten Dijke, Thordur Oskarsson and Andreas Trumpp for cell lines; Pier Giuseppe Pelicci for his continuous support and enthusiasm. This work was supported by grants from the Italian Association for Cancer Research (AIRC) and the International Association for Cancer Research (AICR).	ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Cheng ASL, 2006, MOL CELL, V21, P393, DOI 10.1016/j.molcel.2005.12.016; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Dai CS, 2004, J AM SOC NEPHROL, V15, P1402, DOI 10.1097/01.ASN.0000130568.53923.FD; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Hurlin PJ, 2006, SEMIN CANCER BIOL, V16, P265, DOI 10.1016/j.semcancer.2006.07.009; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Kim J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001798; Kleine-Kohlbrecher D, 2006, CURR TOP MICROBIOL, V302, P51; Leung JY, 2008, ONCOGENE, V27, P4172, DOI 10.1038/onc.2008.55; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Phanish MK, 2006, BIOCHEM J, V393, P601, DOI 10.1042/BJ20051106; Piek E, 1999, J CELL SCI, V112, P4557; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Yang JW, 2005, J AM SOC NEPHROL, V16, P68, DOI 10.1681/ASN.2003090795; Yang JW, 2003, AM J PATHOL, V163, P621, DOI 10.1016/S0002-9440(10)63689-9; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zeller KI, 2001, J BIOL CHEM, V276, P48285, DOI 10.1074/jbc.M108506200; Zha YH, 2007, CELL BIOL INT, V31, P1089, DOI 10.1016/j.cellbi.2007.03.023	53	97	99	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					422	430		10.1038/onc.2008.395	http://dx.doi.org/10.1038/onc.2008.395			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18978814				2022-12-17	WOS:000262550300010
J	Vera, E; Canela, A; Fraga, MF; Esteller, M; Blasco, MA				Vera, E.; Canela, A.; Fraga, M. F.; Esteller, M.; Blasco, M. A.			Epigenetic regulation of telomeres in human cancer	ONCOGENE			English	Article						telomeres; subtelomeres; DNA methylation; epigenetic; telomerase; human cancer	RB FAMILY; LENGTH; RECOMBINATION; DNA; METHYLATION; CELLS; QUANTIFICATION; EXPRESSION; REPEATS	Hypomethylation of repeated elements in the genome is a common feature of human cancer, however, the direct consequences of this epigenetic defect for cancer biology are still largely unknown. Telomeres are specialized chromatin structures at the ends of eukaryotic chromosomes formed by tandem repeats of G-rich sequences and associated proteins, which have an essential role in chromosome end protection and genomic stability. Telomeric DNA repeats cannot be methylated, however, the adjacent subtelomeric DNA is heavily methylated in humans. Here, we show that the methylation status of subtelomeric DNA repeats negatively correlates with telomere length and telomere recombination in a large panel of human cancer cell lines. These findings suggest that tumor telomere length and integrity can be influenced by epigenetic factors. Finally, we show that treatment of human cancer cell lines with demethylating drugs results in hypomethylation of subtelomeric repeats and increased telomere recombination, which in turn may facilitate telomere elongation. All together, these findings suggest that tumor telomere length and integrity can be influenced by the epigenetic status of cancer cells. Oncogene (2008) 27, 6817-6833; doi: 10.1038/onc.2008.289; published online 1 September 2008	[Vera, E.; Canela, A.; Blasco, M. A.] Spanish Natl Canc Ctr CNIO, Telomeres & Telomerase Grp, Mol Oncol Program, E-28029 Madrid, Spain; [Fraga, M. F.; Esteller, M.] Spanish Natl Canc Ctr CNIO, Canc Epigenet Grp, Mol Pathol Program, E-28029 Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO)	Blasco, MA (corresponding author), Spanish Natl Canc Ctr CNIO, Telomeres & Telomerase Grp, Mol Oncol Program, 3 Melchor Fernandez Almagro, E-28029 Madrid, Spain.	mblasco@cnio.es	Esteller, Manel/L-5956-2014; Blasco, Maria A./M-1694-2014; Fraga, Mario F/H-7824-2017	Esteller, Manel/0000-0003-4490-6093; Blasco, Maria A./0000-0002-4211-233X; Fraga, Mario F/0000-0001-8450-2603	Spanish Ministry of Education and Science (MEC); MEC [SAF2005-00277, GEN2001-4856-C1308]; Regional Government of Madrid [GR/SAL/0597/2004]; European Union [TELOSENS FIGH-CT-2002-00217, INTACT LSHC-CT-2003-506803, ZINCAGE FOOD-CT-2003-506850, RISC-RAD FI6R-CT-2003-508842, MOL CANCER MED LSHC-CT-2004-502943]; Josef Steiner Cancer Research Award 2003	Spanish Ministry of Education and Science (MEC)(Spanish Government); MEC(European Commission); Regional Government of Madrid; European Union(European Commission); Josef Steiner Cancer Research Award 2003	EV is a predoctoral fellow of the Spanish Ministry of Education and Science (MEC). MA Blasco's Laboratory is funded by the MEC (SAF2005-00277, GEN2001-4856-C1308), by the Regional Government of Madrid (GR/SAL/0597/2004), European Union (TELOSENS FIGH-CT-2002-00217, INTACT LSHC-CT-2003-506803, ZINCAGE FOOD-CT-2003-506850, RISC-RAD FI6R-CT-2003-508842, MOL CANCER MED LSHC-CT-2004-502943) and the Josef Steiner Cancer Research Award 2003.	Bailey SM, 2004, NUCLEIC ACIDS RES, V32, P3743, DOI 10.1093/nar/gkh691; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Bechter OE, 2004, CANCER RES, V64, P3444, DOI 10.1158/0008-5472.CAN-04-0323; Benetti R, 2007, J CELL BIOL, V178, P925, DOI 10.1083/jcb.200703081; Benetti R, 2007, NAT GENET, V39, P243, DOI 10.1038/ng1952; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Blasco MA, 2004, CARCINOGENESIS, V25, P1083, DOI 10.1093/carcin/bgh185; Blasco MA, 2007, NAT REV GENET, V8, P299, DOI 10.1038/nrg2047; Canela A, 2007, P NATL ACAD SCI USA, V104, P5300, DOI 10.1073/pnas.0609367104; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Flores I, 2006, CURR OPIN CELL BIOL, V18, P254, DOI 10.1016/j.ceb.2006.03.003; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Fraga MF, 2002, ELECTROPHORESIS, V23, P1677, DOI 10.1002/1522-2683(200206)23:11&lt;1677::AID-ELPS1677&gt;3.0.CO;2-Z; Garcia-Aranda C, 2006, CANCER-AM CANCER SOC, V106, P541, DOI 10.1002/cncr.21625; Garcia-Cao M, 2004, NAT GENET, V36, P94, DOI 10.1038/ng1278; Garcia-Cao M, 2002, NAT GENET, V32, P415, DOI 10.1038/ng1011; Gonzalo S, 2006, NAT CELL BIOL, V8, P416, DOI 10.1038/ncb1386; Gonzalo S, 2005, CELL CYCLE, V4, P752, DOI 10.4161/cc.4.6.1720; Gonzalo S, 2005, NAT CELL BIOL, V7, P420, DOI 10.1038/ncb1235; Guilleret I, 2003, EXP CELL RES, V289, P326, DOI 10.1016/S0014-4827(03)00281-7; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Kitagawa Y, 2000, CLIN CANCER RES, V6, P2868; Kondo T, 2000, HUM MOL GENET, V9, P597, DOI 10.1093/hmg/9.4.597; Muntoni A, 2005, HUM MOL GENET, V14, pR191, DOI 10.1093/hmg/ddi266; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Shay JW, 2006, NAT REV DRUG DISCOV, V5, P577, DOI 10.1038/nrd2081; Steinert S, 2004, MOL CELL BIOL, V24, P4571, DOI 10.1128/MCB.24.10.4571-4580.2004	31	97	99	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2008	27	54					6817	6833		10.1038/onc.2008.289	http://dx.doi.org/10.1038/onc.2008.289			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IS	18762811				2022-12-17	WOS:000261108000003
J	Sureban, SM; Ramalingam, S; Natarajan, G; May, R; Subramaniam, D; Bishnupuri, KS; Morrison, AR; Dieckgraefe, BK; Brackett, DJ; Postier, RG; Houchen, CW; Anant, S				Sureban, S. M.; Ramalingam, S.; Natarajan, G.; May, R.; Subramaniam, D.; Bishnupuri, K. S.; Morrison, A. R.; Dieckgraefe, B. K.; Brackett, D. J.; Postier, R. G.; Houchen, C. W.; Anant, S.			Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe	ONCOGENE			English	Article						cyclooxygenase-2; RNA stability; transformation; mitosis; cell cycle	RNA-BINDING-PROTEIN; CYCLOOXYGENASE-2 GENE-EXPRESSION; COLON-CANCER CELLS; AU-RICH ELEMENTS; MESSENGER-RNA; PROSTAGLANDIN E-2; 3'-UNTRANSLATED REGION; OVARIAN-CARCINOMA; STABILITY FACTOR; CYCLE ARREST	RNA-binding proteins play a key role in post-transcriptional regulation of mRNA stability and translation. We have identified that RBM3, a translation regulatory protein, is significantly upregulated in human tumors, including a stage-dependent increase in colorectal tumors. Forced RBM3 overexpression in NIH3T3 mouse fibroblasts and SW480 human colon epithelial cells increases cell proliferation and development of compact multicellular spheroids in soft agar suggesting the ability to induce anchorage-independent growth. In contrast, down-regulating RBM3 in HCT116 colon cancer cells with specific siRNA decreases cell growth in culture, which was partially overcome when treated with prostaglandin E(2), a product of cyclooxygenase (COX)-2 enzyme activity. Knockdown also resulted in the growth arrest of tumor xenografts. We have also identified that RBM3 knockdown increases caspase-mediated apoptosis coupled with nuclear cyclin B1, and phosphorylated Cdc25c, Chk1 and Chk2 kinases, implying that under conditions of RBM3 downregulation, cells undergo mitotic catastrophe. RBM3 enhances COX-2, IL-8 and VEGF mRNA stability and translation. Conversely, RBM3 knockdown results in loss in the translation of these transcripts. These data demonstrate that the RNA stabilizing and translation regulatory protein RBM3 is a novel proto-oncogene that induces transformation when overexpressed and is essential for cells to progress through mitosis.	[Sureban, S. M.; Ramalingam, S.; Natarajan, G.; May, R.; Subramaniam, D.; Houchen, C. W.; Anant, S.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73126 USA; [Bishnupuri, K. S.; Morrison, A. R.; Dieckgraefe, B. K.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Brackett, D. J.; Postier, R. G.] Univ Oklahoma, Hlth Sci Ctr, Dept Surg, Oklahoma City, OK 73126 USA; [Brackett, D. J.; Postier, R. G.; Houchen, C. W.; Anant, S.] OU Canc Inst, Oklahoma City, OK USA; [Anant, S.] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73126 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Washington University (WUSTL); University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Anant, S (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Med, 970 Stanton L Young Blvd,WP1360, Oklahoma City, OK 73126 USA.	shrikant-anant@ouhsc.edu	Sureban, Sripathi/Q-8232-2019; Anant, Shrikant/AAF-8020-2020; Ramalingam, Satish/H-1577-2018	Ramalingam, Satish/0000-0002-3076-279X; Sureban, Sripathi/0000-0001-5476-9593	NCI NIH HHS [R01 CA135559, CA-109269, R01 CA109269, R01 CA109269-01A1] Funding Source: Medline; NIDDK NIH HHS [R01 DK062265-06, R01 DK062265, DK-62265] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA135559, R01CA109269] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062265] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREIS PG, 1981, EXP CELL RES, V134, P265, DOI 10.1016/0014-4827(81)90425-0; Blaxall BC, 2000, MOL CARCINOGEN, V28, P76; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Canman CE, 2001, CURR BIOL, V11, pR121, DOI 10.1016/S0960-9822(01)00057-4; Carpenter B, 2006, BRIT J CANCER, V95, P921, DOI 10.1038/sj.bjc.6603349; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen YQ, 1999, ONCOGENE, V18, P2747, DOI 10.1038/sj.onc.1202629; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Danno S, 1997, BIOCHEM BIOPH RES CO, V236, P804, DOI 10.1006/bbrc.1997.7059; de Silanes IL, 2003, ONCOGENE, V22, P7146, DOI 10.1038/sj.onc.1206862; Denkert C, 2004, CLIN CANCER RES, V10, P5580, DOI 10.1158/1078-0432.CCR-04-0070; Denkert C, 2006, MODERN PATHOL, V19, P1261, DOI 10.1038/modpathol.3800645; DERRY JMJ, 1995, HUM MOL GENET, V4, P2307, DOI 10.1093/hmg/4.12.2307; Deschenes-Furry J, 2005, J BIOL CHEM, V280, P25361, DOI 10.1074/jbc.M410929200; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI12973; Doree M, 2002, J CELL SCI, V115, P2461; Dresios J, 2005, P NATL ACAD SCI USA, V102, P1865, DOI 10.1073/pnas.0409764102; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Erkinheimo TL, 2005, GYNECOL ONCOL, V99, P14, DOI 10.1016/j.ygyno.2005.04.047; Erkinheimo TL, 2003, CANCER RES, V63, P7591; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Hacker S, 2004, J BIOL CHEM, V279, P5049, DOI 10.1074/jbc.C300522200; Heinonen M, 2005, CANCER RES, V65, P2157, DOI 10.1158/0008-5472.CAN-04-3765; Krysan K, 2005, CANCER RES, V65, P6275, DOI 10.1158/0008-5472.CAN-05-0216; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; Mukhopadhyay D, 2003, ANN NY ACAD SCI, V1010, P504, DOI 10.1196/annals.1299.093; Munkarah AR, 2002, J SOC GYNECOL INVEST, V9, P168, DOI 10.1016/S1071-5576(02)00141-7; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Nabors LB, 2001, CANCER RES, V61, P2154; Ning SC, 1999, RADIAT RES, V151, P659, DOI 10.2307/3580204; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; PinolRoma S, 1997, SEMIN CELL DEV BIOL, V8, P57, DOI 10.1006/scdb.1996.0122; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Shao JY, 2003, CANCER RES, V63, P5218; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; Smart F, 2007, J NEUROCHEM, V101, P1367, DOI 10.1111/j.1471-4159.2007.04521.x; Stark George R, 2004, Methods Mol Biol, V280, P51; Sureban SM, 2007, GASTROENTEROLOGY, V132, P1055, DOI 10.1053/j.gastro.2006.12.031; Sutherland LC, 2005, J CELL BIOCHEM, V94, P5, DOI 10.1002/jcb.20204; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Walworth NC, 2001, CURR OPIN GENET DEV, V11, P78, DOI 10.1016/S0959-437X(00)00160-X; Wang DZ, 2005, GASTROENTEROLOGY, V128, P1445, DOI 10.1053/j.gastro.2004.09.080; Wu Gaosong, 2005, J Huazhong Univ Sci Technolog Med Sci, V25, P42; Yamashita H, 2003, ANTICANCER RES, V23, P4671	56	97	109	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2008	27	33					4544	4556		10.1038/onc.2008.97	http://dx.doi.org/10.1038/onc.2008.97			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18427544	Green Accepted			2022-12-17	WOS:000258077300004
J	Arora, P; Cuevas, BD; Russo, A; Johnson, GL; Trejo, J				Arora, P.; Cuevas, B. D.; Russo, A.; Johnson, G. L.; Trejo, J.			Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion	ONCOGENE			English	Article						thrombin; GPCR; metalloprotease; MDA-MB-231; g protein	THROMBIN RECEPTOR; MONOCLONAL-ANTIBODY; CANCER; DESENSITIZATION; PROLIFERATION; CHEMOTHERAPY; MIGRATION; CLEAVAGE; REVEALS; FAMILY	Hyperactivation of ErbB signaling is implicated in metastatic breast cancer. However, the mechanisms that cause dysregulated ErbB signaling and promote breast carcinoma cell invasion remain poorly understood. One pathway leading to ErbB activation that remains unexplored in breast carcinoma cell invasion involves transactivation by G-protein-coupled receptors (GPCRs). Protease-activated receptor-1 (PAR1), a GPCR activated by extracellular proteases, is overexpressed in invasive breast cancer. PAR1 is also proposed to function in breast cancer invasion and metastasis, but how PAR1 contributes to these processes is not known. In this study, we report that proteolytic activation of PAR1 by thrombin induces persistent transactivation of EGFR and ErbB2/HER2 in invasive breast carcinoma, but not in normal mammary epithelial cells. PAR1-stimulated EGFR and ErbB2 transactivation leads to prolonged extracellular signal-regulated kinase-1 and -2 signaling and promotes breast carcinoma cell invasion. We also show that PAR1 signaling through G alpha(i/o) and metalloprotease activity is critical for ErbB transactivation and cellular invasion. Finally, we demonstrate that PAR1 expression in invasive breast carcinoma is essential for tumor growth in vivo assessed by mammary fat pad xenografts. These studies reveal a critical role for PAR1, a receptor activated by tumor-generated proteases, in hyperactivation of ErbB signaling that promotes breast carcinoma cell invasion.	[Arora, P.; Cuevas, B. D.; Russo, A.; Johnson, G. L.; Trejo, J.] Univ N Carolina, Sch Med, Lineberger Canc Res Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Trejo, J (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol, BSB 3018,9500 Gilman Dr, La Jolla, CA 92093 USA.	joann_trejo@med.unc.edu	, Pathology Services Core/CEZ-2246-2022	TREJO, JOANN/0000-0003-4405-6228	NHLBI NIH HHS [R01 HL073328, HL073328, R01 HL073328-06] Funding Source: Medline; NIDDK NIH HHS [R01 DK037871, DK37871] Funding Source: Medline; NIGMS NIH HHS [R01 GM030324, R37 GM030324, GM30324] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arora P, 2007, J CELL SCI, V120, P921, DOI 10.1242/jcs.03409; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bergmann S, 2006, ONCOL REP, V15, P889; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Booden MA, 2004, MOL CELL BIOL, V24, P1990, DOI 10.1128/MCB.24.5.1990-1999.2004; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Darmoul D, 2004, MOL CANCER RES, V2, P514; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Hart S, 2005, BIOL CHEM, V386, P845, DOI 10.1515/BC.2005.099; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Kuliopulos A, 1999, BIOCHEMISTRY-US, V38, P4572, DOI 10.1021/bi9824792; Lautrette A, 2005, NAT MED, V11, P867, DOI 10.1038/nm1275; Morris DR, 2006, CANCER RES, V66, P307, DOI 10.1158/0008-5472.CAN-05-1735; Nahta R, 2007, ONCOGENE, V26, P3637, DOI 10.1038/sj.onc.1210379; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Noma T, 2007, J CLIN INVEST, V117, P2445, DOI 10.1172/JCI31901; Ohtsu H, 2006, AM J PHYSIOL-CELL PH, V291, pC1, DOI 10.1152/ajpcell.00620.2005; Paing MM, 2006, MOL CELL BIOL, V26, P3231, DOI 10.1128/MCB.26.8.3231-3242.2006; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; PRICE JE, 1990, CANCER RES, V50, P717; Salah Z, 2007, MOL CANCER RES, V5, P229, DOI 10.1158/1541-7786.MCR-06-0261; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396	32	97	100	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4434	4445		10.1038/onc.2008.84	http://dx.doi.org/10.1038/onc.2008.84			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18372913	Green Accepted, Green Published			2022-12-17	WOS:000257881700006
J	Brookes, MJ; Boult, J; Roberts, K; Cooper, BT; Hotchin, NA; Matthews, G; Iqbal, T; Tselepis, C				Brookes, M. J.; Boult, J.; Roberts, K.; Cooper, B. T.; Hotchin, N. A.; Matthews, G.; Iqbal, T.; Tselepis, C.			A role for iron in Wnt signalling	ONCOGENE			English	Article						Wnt; E-cadherin; iron; colon	COLORECTAL-CANCER RISK; C-MYC; COLON-CANCER; E-CADHERIN; HEME IRON; CARCINOGENESIS; GENE; APC; IDENTIFICATION; ACTIVATION	There is an emerging body of evidence implicating iron in carcinogenesis and in particular colorectal cancer, but whether this involves Wnt signalling, a major oncogenic signalling pathway has not been studied. We aimed to determine the effect of iron loading on Wnt signalling using mutant APC (Caco-2 and SW480) and wild-type APC (HEK-293 and human primary. broblasts) containing cell lines. Elevating cellular iron levels in Caco-2 and SW480 cells caused increased Wnt signalling as indicated by increased TOPFLASH reporter activity, increased mRNA expression of two known targets, c-myc and Nkd1, and increased cellular proliferation. In contrast wild-type APC and beta-catenin-containing lines, HEK-293 and human primary. broblasts were not responsive to iron loading. This was verified in SW480 cells that no longer induced iron-mediated Wnt signalling when transfected with wild-type APC. The cell line LS174T, wild type for APC but mutant for beta-catenin, was also responsive suggesting that the role of iron is to regulate beta-catenin. Furthermore, we show that E-cadherin status has no influence on iron-mediated Wnt signalling. We thus speculate that excess iron could exacerbate tumorigenesis in the background of APC loss, a common finding in cancers.	[Brookes, M. J.; Boult, J.; Roberts, K.; Iqbal, T.; Tselepis, C.] Univ Birmingham, CRUK Inst Canc Studies, Birmingham B32 1NX, W Midlands, England; [Brookes, M. J.; Cooper, B. T.] City Hosp, Birmingham, W Midlands, England; [Hotchin, N. A.] Univ Birmingham, Sch Biosci, Birmingham B32 1NX, W Midlands, England; [Matthews, G.] Univ Birmingham, Dept Med Sci, Birmingham B32 1NX, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham	Tselepis, C (corresponding author), Univ Birmingham, CRUK Inst Canc Studies, Vincent Dr, Birmingham B32 1NX, W Midlands, England.	c.tselepis@bham.ac.uk	Brookes, Matthew/ABE-6952-2020	iqbal, tariq/0000-0002-6681-9882; Brookes, Matthew/0000-0002-8782-0292; Hotchin, Neil/0000-0002-1844-7607				Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Brookes MJ, 2006, GUT, V55, P1449, DOI 10.1136/gut.2006.094060; Chao A, 2005, JAMA-J AM MED ASSOC, V293, P172, DOI 10.1001/jama.293.2.172; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Habel ME, 2006, BIOCHEM BIOPH RES CO, V341, P1309, DOI 10.1016/j.bbrc.2006.01.097; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ilsley JNM, 2004, NUTR CANCER, V49, P162, DOI 10.1207/s15327914nc4902_7; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Latunde-Dada GO, 2006, TRENDS BIOCHEM SCI, V31, P182, DOI 10.1016/j.tibs.2006.01.005; Lee DH, 2004, JNCI-J NATL CANCER I, V96, P403, DOI 10.1093/jnci/djh047; Maines MD, 2005, BIOCHEM BIOPH RES CO, V338, P568, DOI 10.1016/j.bbrc.2005.08.121; Mainous AG, 2005, ANN FAM MED, V3, P131, DOI 10.1370/afm.283; Miranda E, 2006, BRIT J CANCER, V95, P1101, DOI 10.1038/sj.bjc.6603337; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Munro SB, 1995, EXP MOL PATHOL, V62, P118, DOI 10.1006/exmp.1995.1013; Nelson RL, 2001, NUTR REV, V59, P140, DOI 10.1111/j.1753-4887.2001.tb07002.x; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Norat T, 2005, J NATL CANCER I, V97, P906, DOI 10.1093/jnci/dji164; O'Donnell KA, 2006, MOL CELL BIOL, V26, P2373, DOI 10.1128/MCB.26.6.2373-2386.2006; Oates PS, 2006, WORLD J GASTROENTERO, V12, P4281, DOI 10.3748/wjg.v12.i27.4281; Orsulic S, 1999, J CELL SCI, V112, P1237; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Penman GA, 2005, J CELL SCI, V118, P4741, DOI 10.1242/jcs.02589; Pierre F, 2003, CARCINOGENESIS, V24, P1683, DOI 10.1093/carcin/bgg130; Rao AS, 2005, EUR J ENDOCRINOL, V153, P929, DOI 10.1530/eje.1.02038; Rouault TA, 2006, NAT CHEM BIOL, V2, P406, DOI 10.1038/nchembio807; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Seril DN, 2002, DIGEST DIS SCI, V47, P1266, DOI 10.1023/A:1015362228659; Shaheen NJ, 2003, JNCI-J NATL CANCER I, V95, P154, DOI 10.1093/jnci/95.2.154; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Toyokuni S, 1996, FREE RADICAL BIO MED, V20, P553, DOI 10.1016/0891-5849(95)02111-6; Uzel C, 1998, SEMIN HEMATOL, V35, P27; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; YOUNG GP, 1990, J GASTROEN HEPATOL, V5, P194, DOI 10.1111/j.1440-1746.1990.tb01824.x	38	97	100	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2008	27	7					966	975		10.1038/sj.onc.1210711	http://dx.doi.org/10.1038/sj.onc.1210711			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700530				2022-12-17	WOS:000252946300008
J	Saeki, N; Kim, DH; Usui, T; Aoyagi, K; Tatsuta, T; Aoki, K; Yanagihara, K; Tamura, M; Mizushima, H; Sakamoto, H; Ogawa, K; Ohki, M; Shiroishi, T; Yoshida, T; Sasaki, H				Saeki, N.; Kim, D. H.; Usui, T.; Aoyagi, K.; Tatsuta, T.; Aoki, K.; Yanagihara, K.; Tamura, M.; Mizushima, H.; Sakamoto, H.; Ogawa, K.; Ohki, M.; Shiroishi, T.; Yoshida, T.; Sasaki, H.			GASDERMIN, suppressed frequently in gastric cancer, is a target of LMO1 in TGF-beta-dependent apoptotic signalling	ONCOGENE			English	Article						gastric pit cells; apoptosis; LMO1; TGF-beta; GASDERMIN	MOUSE-CHROMOSOME 11; RUNX3 KNOCKOUTS; STOMACH-CANCER; CELL-LINES; NUDE-MICE; EXPRESSION; GENE; ESTABLISHMENT; CARCINOMA; EMBRYOGENESIS	Defining apoptosis-regulatory cascades of the epithelium is important for understanding carcinogenesis, since cancer cells are considered to arise as a result of the collapse of the cascades. We previously reported that a novel gene GASDERMIN (GSDM) is expressed in the stomach but suppressed in gastric cancer cell lines. Furthermore, in this study, we demonstrated that GSDM is expressed in the mucus-secreting pit cells of the gastric epithelium and frequently silenced in primary gastric cancers. We found that GSDM has a highly apoptotic activity and its expression is regulated by a transcription factor LIM domain only 1 (LMO1) through a sequence to which Runt-related transcription factor 3 (RUNX3) binds, in a GSDM promoter region. We observed coexpression of GSDM with LMO1, RUNX3 and type II transforming growth factor-beta receptor (TGF-beta RII) in the pit cells, and found that TGF-beta upregulates the LMO1- and GSDM-expression in the gastric epithelial cell line and induces apoptosis, which was confirmed by the finding that the apoptosis induction is inhibited by suppression of each LMO1-, RUNX3- and GSDM expression, respectively. The present data suggest that TGF-beta, LMO1, possibly RUNX3, and GSDM form a regulatory pathway for directing the pit cells to apoptosis.	Natl Canc Ctr, Res Inst, Div Genet, Chuo Ku, Tokyo 104, Japan; Natl Inst Canc Res, Ctr Med Genom, Chuo Ku, Tokyo, Japan; Tokyo Womens Med Univ, Sch Med, Med Ctr E, Tokyo, Japan; Natl Inst Canc Res, Sect Studies Host Immune Response, Chuo Ku, Tokyo, Japan; Natl Inst Canc Res, Cent Anim Lab, Chuo Ku, Tokyo, Japan; Natl Inst Genet, Genet Strains Res Ctr, Mammalian Genet Lab, Shizuoka, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Tokyo Women's Medical University; National Cancer Center - Japan; National Cancer Center - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Sasaki, H (corresponding author), Natl Canc Ctr, Res Inst, Div Genet, Chuo Ku, Tukiji 5-Chome, Tokyo 104, Japan.	hksasaki@gan2.res.ncc.go.jp	Tamura, Masaru/D-1416-2017	Tamura, Masaru/0000-0002-0311-8827				Aoyagi K, 2003, BIOCHEM BIOPH RES CO, V300, P915, DOI 10.1016/S0006-291X(02)02967-4; Bae SC, 2003, EMBO REP, V4, P538, DOI 10.1038/sj.embor.embor875; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; DEBOLOS C, 1995, GASTROENTEROLOGY, V109, P723, DOI 10.1016/0016-5085(95)90379-8; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; Fujihara T, 1998, CLIN EXP METASTAS, V16, P389; Fukaya M, 2006, GASTROENTEROLOGY, V131, P14, DOI 10.1053/j.gastro.2006.05.008; HO SB, 1995, GASTROENTEROLOGY, V109, P735, DOI 10.1016/0016-5085(95)90380-1; KARAM S, 1995, MICROSC RES TECHNIQ, V31, P93; Kenny DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/pnas.95.19.11257; Levanon D, 2003, EMBO REP, V4, P560, DOI 10.1038/sj.embor.embor868; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lunny DP, 2005, J INVEST DERMATOL, V124, P615, DOI 10.1111/j.0022-202X.2005.23623.x; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; Meyers S, 1996, ONCOGENE, V13, P303; Nishigaki M, 2005, CANCER RES, V65, P2115, DOI 10.1158/0008-5472.CAN-04-3340; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; Runkel F, 2004, GENOMICS, V84, P824, DOI 10.1016/j.ygeno.2004.07.003; Saeki N, 2000, MAMM GENOME, V11, P718, DOI 10.1007/s003350010138; Sato H, 1998, MAMM GENOME, V9, P20, DOI 10.1007/s003359900673; SEKIGUCHI M, 1978, JPN J EXP MED, V48, P61; Sekiguchi M., 1994, ATLAS HUMAN TUMOR CE, P287; Yanagihara K, 2004, CANCER SCI, V95, P575, DOI 10.1111/j.1349-7006.2004.tb02489.x; YANAGIHARA K, 1992, CANCER RES, V52, P4042	26	97	105	3	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	45					6488	6498		10.1038/sj.onc.1210475	http://dx.doi.org/10.1038/sj.onc.1210475			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17471240				2022-12-17	WOS:000249919800002
J	He, X; Pool, M; Darcy, KM; Lim, SB; Auersperg, N; Coon, JS; Beck, WT				He, X.; Pool, M.; Darcy, K. M.; Lim, S. B.; Auersperg, N.; Coon, J. S.; Beck, W. T.			Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro	ONCOGENE			English	Article						epithelial ovarian cancer; polypyrimidine tract-binding protein; RNA interference; tissue microarray; tumorigenesis	PERINUCLEOLAR COMPARTMENT; MESSENGER-RNA; HNRNP-I; CANCER; EXPRESSION; RESISTANCE; COMPLEX; ELEMENT; GENE	Polypyrimidine tract-binding protein (PTB) is an RNA-binding protein with multiple functions in the regulation of RNA processing and IRES-mediated translation. We report here overexpression of PTB in a majority of epithelial ovarian tumors revealed by immunoblotting and tissue microarray (TMA) staining. By western blotting, we found that PTB was overexpressed in 17 out of 19 ovarian tumor specimens compared to their matched-normal tissues. By TMA staining, we found PTB expression in 38 out of 44 ovarian cancer cases but only in two out of nine normal adjacent tissues. PTB is also overexpressed in SV40 large T-antigen immortalized ovarian epithelial cells compared to normal human ovarian epithelial cells. Using doxycycline-inducible small interfering RNA technology, we found that knockdown of PTB expression in the ovarian tumor cell line A2780 substantially impaired tumor cell proliferation, anchorageindependent growth and in vitro invasiveness. These results suggest that overexpression of PTB is an important component of the multistep process of tumorigenesis, and might be required for the development and maintenance of epithelial ovarian tumors. Moreover, because of its novel role in tumor cell growth and invasiveness, shown here for the. rst time, PTB may be a novel therapeutic target in the treatment of ovarian cancer.	Univ Illinois, GOG, Core Lab Mol Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Dept Biopharmaceut Sci, Coll Pharm, Chicago, IL 60607 USA; Univ Illinois, Ctr Canc, Chicago, IL 60607 USA; Rush Univ, Ctr Med, Dept Pathol, Chicago, IL USA; Roswell Pk Canc Inst, GOG Stat & Data Ctr, Buffalo, NY USA; Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC V5Z 1M9, Canada	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rush University; Roswell Park Cancer Institute; University of British Columbia	Beck, WT (corresponding author), Univ Illinois, Dept Biopharmaceut Sci, MC865, 833 S Wood St, Chicago, IL 60612 USA.	WTBeck@uic.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015482] Funding Source: NIH RePORTER; NCRR NIH HHS [C06 RR015482-01, C06RR15482, C06 RR015482] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bast RC, 2005, CLIN CANCER RES, V11, P6103, DOI 10.1158/1078-0432.CCR-04-2213; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; Bushell M, 2006, MOL CELL, V23, P401, DOI 10.1016/j.molcel.2006.06.012; Castelo-Branco P, 2004, MOL CELL BIOL, V24, P4174, DOI 10.1128/MCB.24.10.4174-4183.2004; Cornelis S, 2005, NUCLEIC ACIDS RES, V33, P3095, DOI 10.1093/nar/gki611; Cote CA, 1999, MOL CELL, V4, P431, DOI 10.1016/S1097-2765(00)80345-7; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; He XL, 2004, CLIN CANCER RES, V10, P4652, DOI 10.1158/1078-0432.CCR-03-0439; Huang S, 1997, J CELL BIOL, V137, P965, DOI 10.1083/jcb.137.5.965; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; JIN W, 1990, NUCLEIC ACIDS RES, V18, P5995, DOI 10.1093/nar/18.20.5995; Jin W, 2000, CANCER RES, V60, P1221; Jin W, 2003, CANCER RES, V63, P6154; Jin X, 2002, ANTICANCER RES, V22, P659; Kamath RV, 2005, CANCER RES, V65, P246; Kasper JS, 2005, J VIROL, V79, P11685, DOI 10.1128/JVI.79.18.11685-11692.2005; Knoch KP, 2004, NAT CELL BIOL, V6, P207, DOI 10.1038/ncb1099; Kosinski PA, 2003, J IMMUNOL, V170, P979, DOI 10.4049/jimmunol.170.2.979; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; MAINESBANDIERA SL, 1992, AM J OBSTET GYNECOL, V167, P729, DOI 10.1016/S0002-9378(11)91579-8; MATERA AG, 1995, J CELL BIOL, V129, P1181, DOI 10.1083/jcb.129.5.1181; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wang ZN, 2003, CANCER RES, V63, P655; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Wollerton MC, 2004, MOL CELL, V13, P91, DOI 10.1016/S1097-2765(03)00502-1; Xu Q, 2003, NUCLEIC ACIDS RES, V31, P5635, DOI 10.1093/nar/gkg786; Zang WQ, 2001, J VIROL, V75, P10779, DOI 10.1128/JVI.75.22.10779-10786.2001	32	97	103	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4961	4968		10.1038/sj.onc.1210307	http://dx.doi.org/10.1038/sj.onc.1210307			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310993	Green Accepted			2022-12-17	WOS:000248322500008
J	Chen, C; Sun, X; Guo, P; Dong, XY; Sethi, P; Zhou, W; Zhou, Z; Petros, J; Frierson, HF; Vessella, RL; Atfi, A; Dong, JT				Chen, C.; Sun, X.; Guo, P.; Dong, X-Y; Sethi, P.; Zhou, W.; Zhou, Z.; Petros, J.; Frierson, H. F., Jr.; Vessella, R. L.; Atfi, A.; Dong, J-T			Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer	ONCOGENE			English	Article						WWP1; amplification; overexpression; prostate cancer; KLF5; TGF beta	GROWTH-FACTOR-BETA; KLF5 TRANSCRIPTION FACTOR; TGF-BETA; EPITHELIAL-CELLS; NEDD4 FAMILY; EXPRESSION; DEGRADATION; GENE; CARCINOMA; PROTEIN	The gene for E3 ubiquitin ligase WWP1 is located at 8q21, a region frequently amplified in human cancers, including prostate cancer. Recent studies have shown that WWP1 negatively regulates the TGFb tumor suppressor pathway by inactivating its molecular components, including Smad2, Smad4 and T beta R1. These findings suggest an oncogenic role of WWP1 in carcinogenesis, but direct supporting evidence has been lacking. In this study, we examined WWP1 for gene dosage, mRNA expression, mutation and functions in a number of human prostate cancer samples. We found that the WWP1 gene had copy number gain in 15 of 34 (44%) xenografts and cell lines from prostate cancer and 15 of 49 (31%) clinical prostate cancer samples. Consistently, WWP1 was over-expressed in 60% of xenografts and cell lines from prostate cancer. Mutation of WWP1 occurred infrequently in prostate cancer. Functionally, WWP1 overexpression promoted colony formation in the 22Rv1 prostate cancer cell line. In PC-3 prostate cancer cells, WWP1 knockdown significantly suppressed cell proliferation and enhanced TGF beta-mediated growth inhibition. These findings suggest that WWP1 is an oncogene that undergoes genomic amplification at 8q21 in human prostate cancer, and WWP1 overexpression is a common mechanism involved in the inactivation of TGFb function in human cancer.	Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Hematol & Oncol, Atlanta, GA 30322 USA; Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Emory Univ, Sch Med, Dept Urol, Atlanta, GA USA; Atlanta VA Med Ctr, Decatur, GA USA; Univ Virginia, Hlth Syst, Dept Pathol, Charlottesville, VA USA; Univ Washington, Dept Urol, Seattle, WA 98195 USA; Hop St Antoine, INSERM, U482, Paris, France; Nankai Univ, Coll Life Sci, Dept Genet & Cell Biol, Tianjin, Peoples R China	Emory University; Emory University; Albany Medical College; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Atlanta VA Medical Center; University of Virginia; University of Washington; University of Washington Seattle; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Nankai University	Dong, JT (corresponding author), Emory Univ, Sch Med, Winship Canc Inst, 1365 Clifton Rd,Room C4080, Atlanta, GA 30322 USA.	jdong2@emory.edu	guo, peng/AAG-4052-2019; Guo, Peng/GWC-0572-2022	Dong, Jin-Tang/0000-0003-2349-5782	NATIONAL CANCER INSTITUTE [R01CA087921] Funding Source: NIH RePORTER; NCI NIH HHS [CA87921] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen C, 2003, PROSTATE, V55, P81, DOI 10.1002/pros.10205; Chen CS, 2005, J BIOL CHEM, V280, P41553, DOI 10.1074/jbc.M506183200; Chen CS, 2005, ONCOGENE, V24, P3319, DOI 10.1038/sj.onc.1208497; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Danielpour D, 2005, EUR J CANCER, V41, P846, DOI 10.1016/j.ejca.2004.12.027; Dong JT, 2000, CANCER RES, V60, P3880; Dong JT, 2006, J CELL BIOCHEM, V97, P433, DOI 10.1002/jcb.20696; Drobnjak M, 2003, CLIN CANCER RES, V9, P2613; Flasza M, 2002, BIOCHEM BIOPH RES CO, V290, P431, DOI 10.1006/bbrc.2001.6206; Gu ZN, 2005, CLIN CANCER RES, V11, P2237, DOI 10.1158/1078-0432.CCR-04-0356; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Kim IY, 1996, CANCER RES, V56, P44; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Leite KRM, 2001, MODERN PATHOL, V14, P428, DOI 10.1038/modpathol.3880330; Lu LF, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-22; Malbert-Colas L, 2003, PFLUG ARCH EUR J PHY, V447, P35, DOI 10.1007/s00424-003-1152-6; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Moren A, 2005, J BIOL CHEM, V280, P22115, DOI 10.1074/jbc.M414027200; Mu ZM, 2004, PROSTATE, V60, P187, DOI 10.1002/pros.20044; Nupponen NN, 1998, AM J PATHOL, V153, P141, DOI 10.1016/S0002-9440(10)65554-X; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Porkka K, 2002, LAB INVEST, V82, P629, DOI 10.1038/labinvest.3780457; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Rubin MA, 2004, CANCER RES, V64, P3814, DOI 10.1158/0008-5472.CAN-03-3881; Seo SR, 2004, EMBO J, V23, P3780, DOI 10.1038/sj.emboj.7600398; Sun SY, 1997, CANCER RES, V57, P4931; Sun XD, 2005, NAT GENET, V37, P407, DOI 10.1038/ng1528; van Dekken H, 2003, LAB INVEST, V83, P789, DOI 10.1097/01.LAB.0000074889.76221.49; Van der Poel HG, 2004, J UROLOGY, V172, P1333, DOI 10.1097/01.ju.0000138829.97838.19; Verdecia MA, 2003, MOL CELL, V11, P249, DOI 10.1016/S1097-2765(02)00774-8; Wang RX, 2004, CANCER RES, V64, P1589, DOI 10.1158/0008-5472.CAN-03-3331; Zhang XL, 2004, BIOCHEM BIOPH RES CO, V316, P139, DOI 10.1016/j.bbrc.2004.02.033; Zhang Z, 2003, P NATL ACAD SCI USA, V100, P11636, DOI 10.1073/pnas.1934692100; Zitzelsberger H, 1998, VIRCHOWS ARCH, V433, P297, DOI 10.1007/s004280050252	35	97	106	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2007	26	16					2386	2394		10.1038/sj.onc.1210021	http://dx.doi.org/10.1038/sj.onc.1210021			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016436				2022-12-17	WOS:000245466000015
J	Kamiyama, M; Pozzi, A; Yang, L; DeBusk, LM; Breyer, RM; Lin, PC				Kamiyama, M.; Pozzi, A.; Yang, L.; DeBusk, L. M.; Breyer, R. M.; Lin, P. C.			EP2, a receptor for PGE(2), regulates tumor angiogenesis through direct effects on endothelial cell motility and survival	ONCOGENE			English	Article						PGE2; EP2; endothelial cell; angiogenesis	PROSTANOID RECEPTORS; PROSTAGLANDIN; CYCLOOXYGENASE; EXPRESSION; CANCER; INHIBITION; SUBTYPE; PROTEIN; INFLAMMATION; MIGRATION	Prostaglandin E2 (PGE(2)), a major cyclooxygenase (COX) metabolite, plays important roles in tumor biology. We studied the role of EP2, a receptor for PGE2, in tumor angiogenesis using EP2 knockout mice. We found that deletion of the EP2 receptor impaired tumor angiogenesis and this finding was confirmed by an in vivo corneal angiogenesis model and an ex vivo aortic ring assay. To further characterize the cellular mechanisms of the EP2 receptor in angiogenesis, we isolated primary pulmonary endothelial cells (ECs) from wild-type (wt) and EP2(-/)-mice and observed that EP2(-/)-ECs exhibited defects in vascular branch formation when compared to wt ECs. In addition, EP2(-/)-ECs showed impaired cell motility on collagen-coated surface and they responded poorly to PGE(2)-induced cell migration compared to control cells. However, no difference in cell proliferation was observed between the EP2(-/)-and wt Ecs. In addition, EP2(-/)-ECs were more susceptible to apoptosis than wt cells under growth factor depletion conditions. Collectively, our data demonstrate that EP2 signaling in endothelium directly regulates tumor angiogenesis by contributing to cell survival and endothelial cell motility. Moreover, our finding suggests that EP2 is a major receptor in PGE(2)-mediated cell motility in ECs.	Vanderbilt Univ, Med Ctr, Dept Radiat Oncol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Lin, PC (corresponding author), Vanderbilt Univ, Med Ctr, Dept Radiat Oncol, Vanderbilt Ingram Canc Ctr, 338 PRB,2220 Pierce Ave, Nashville, TN 37232 USA.	charles.lin@vanderbilt.edu			NATIONAL CANCER INSTITUTE [P30CA068485, T32CA009592, R01CA108856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045888] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA009592, CA108856, CA68485] Funding Source: Medline; NINDS NIH HHS [NS45888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408; Bradbury D, 2005, J BIOL CHEM, V280, P29993, DOI 10.1074/jbc.M414530200; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Chang SH, 2005, PROSTAG OTH LIPID M, V76, P48, DOI 10.1016/j.prostaglandins.2004.12.001; Dormond O, 2002, J BIOL CHEM, V277, P45838, DOI 10.1074/jbc.M209213200; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Elder DJE, 2002, INT J CANCER, V99, P323, DOI 10.1002/ijc.10330; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Hida T, 1998, CANCER RES, V58, P3761; Huang LW, 1999, J BIOL CHEM, V274, P38183, DOI 10.1074/jbc.274.53.38183; Husain SS, 2001, LIFE SCI, V69, P3045, DOI 10.1016/S0024-3205(01)01411-4; Jiang HM, 2004, J BIOL CHEM, V279, P55905, DOI 10.1074/jbc.M406094200; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kennedy CRJ, 1999, NAT MED, V5, P217, DOI 10.1038/5583; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Klagsbrun M, 1999, CHEM BIOL, V6, pR217, DOI 10.1016/S1074-5521(99)80081-7; Kuwano T, 2004, FASEB J, V18, P300, DOI 10.1096/fj.03-0473com; Lin PN, 1997, J CLIN INVEST, V100, P2072, DOI 10.1172/JCI119740; Mutoh M, 2002, CANCER RES, V62, P28; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Rozic JG, 2001, INT J CANCER, V93, P497, DOI 10.1002/ijc.1376; SANO H, 1995, CANCER RES, V55, P3785; Seno H, 2002, CANCER RES, V62, P506; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Tilley SL, 2001, J CLIN INVEST, V108, P15, DOI 10.1172/JCI200113416; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Watanabe K, 1999, CANCER RES, V59, P5093; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yang L, 2003, J CLIN INVEST, V111, P727, DOI 10.1172/JCI200316492	34	97	100	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7019	7028		10.1038/sj.onc.1209694	http://dx.doi.org/10.1038/sj.onc.1209694			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16732324				2022-12-17	WOS:000241910500002
J	Patterson, SG; Wei, S; Chen, X; Sallman, DA; Gilvary, DL; Zhong, B; Pow-Sang, J; Yeatman, T; Djeu, JY				Patterson, S. G.; Wei, S.; Chen, X.; Sallman, D. A.; Gilvary, D. L.; Zhong, B.; Pow-Sang, J.; Yeatman, T.; Djeu, J. Y.			Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells	ONCOGENE			English	Article						stat1; clusterin; chemoresistance; prostate cancer; siRNA	CHEMOTHERAPY-INDUCED APOPTOSIS; CANCER-CELLS; IN-VITRO; CLUSTERIN/APOLIPOPROTEIN-J; ANDROGEN INDEPENDENCE; UP-REGULATION; NOBLE RAT; CLUSTERIN; EXPRESSION; PROTEINS	A major obstacle for clinicians in the treatment of advanced prostate cancer is the inevitable progression to chemoresistance, especially to docetaxel. It is essential to understand the molecular events that lead to docetaxel resistance in order to identify means to prevent or interfere with chemoresistance. In initial attempts to detect these events, we analysed genomic differences between non-resistant and docetaxel-resistant prostate tumor cells and, of the genes modulated by docetaxel treatment, we observed Stat1 and clusterin gene expression heightened in the resistant phenotype. In this study, we provide biochemical and biological evidence that these two gene products are related. Stat1 and clusterin protein expression was induced upon docetaxel treatment of DU145 cells and highly overexpressed in the docetaxel-resistant DU145 cells (DU145-DR). The increase in total Stat1 corresponded to an increase in phosphorylated Stat1. Interestingly, there was no detectable difference between DU145 and DU145-DR cells expression of total Stat3 and phosphorylated Stat3. Treatment of DU145-DR cells with small interfering RNA targeted for Stat1 not only resulted in the knockdown of Stat1 expression, but it also caused the inhibition of clusterin expression. Thus, Stat1 appears to play a key role in the regulation of clusterin. Remarkably, inhibition of Stat1 or clusterin expression resulted in the re-sensitization of DU145-DR cells to docetaxel. These results offer the first evidence that Stat1, and its subsequent regulation of clusterin, are essential for docetaxel resistance in prostate cancer. Targeting this pathway could be a potential therapeutic means for intervention of docetaxel resistance.	H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL USA; Genitourinary Oncol Program, Tampa, FL USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Djeu, JY (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, MRC-4 E,12902 Magnolia Dr, Tampa, FL 33612 USA.	djeu@moffitt.usf.edu			NCI NIH HHS [CA98080] Funding Source: Medline; NIAID NIH HHS [AI056213] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056213] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Assikis VJ, 2004, CLIN CANCER RES, V10, P6770, DOI 10.1158/1078-0432.CCR-04-0275; Barton BE, 2004, MOL CANCER THER, V3, P1183; Bettuzzi S, 2000, CANCER RES, V60, P1472; Cochet O, 2006, CELL SIGNAL, V18, P449, DOI 10.1016/j.cellsig.2005.05.010; Culine S, 2000, ANN ONCOL, V11, P1523, DOI 10.1023/A:1008394823889; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; De Marzo AM, 2004, J CELL BIOCHEM, V91, P459, DOI 10.1002/jcb.10747; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; DeMiguel F, 2002, PROSTATE, V52, P123, DOI 10.1002/pros.10110; Dhir R, 2002, PROSTATE, V51, P241, DOI 10.1002/pros.10079; El-Hashemite N, 2004, CANCER RES, V64, P3436, DOI 10.1158/0008-5472.CAN-03-3609; Geney R, 2002, CLIN CHEM LAB MED, V40, P918, DOI 10.1515/CCLM.2002.161; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Ho SM, 1998, AM J PATHOL, V153, P131, DOI 10.1016/S0002-9440(10)65553-8; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; July LV, 2004, MOL CANCER THER, V3, P223; Kominsky SL, 2000, CANCER RES, V60, P3904; Lacroix H, 1998, Expert Opin Investig Drugs, V7, P273, DOI 10.1517/13543784.7.2.273; Lee SO, 2004, PROSTATE, V60, P178, DOI 10.1002/pros.20045; Legrand A, 2004, LIVER INT, V24, P149, DOI 10.1111/j.1478-3231.2004.00899.x; Liu KB, 2005, CANCER RES, V65, P1045; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Makarovskiy AN, 2002, CELL MOL LIFE SCI, V59, P1198, DOI 10.1007/s00018-002-8498-3; Milbank AJ, 2002, UROLOGY, V60, P738, DOI 10.1016/S0090-4295(02)01867-8; Miller ML, 2001, CHEM REC, V1, P195, DOI 10.1002/tcr.1008; Miyake H, 2000, CLIN CANCER RES, V6, P1655; Miyake H, 2000, CANCER RES, V60, P170; Miyake H, 2003, ONCOL REP, V10, P469; Miyake H, 2000, CANCER RES, V60, P3058; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Nickerson T, 1999, CANCER RES, V59, P3392; O'Sullivan J, 2003, CELL DEATH DIFFER, V10, P914, DOI 10.1038/sj.cdd.4401254; Ouyang XS, 2001, CARCINOGENESIS, V22, P965, DOI 10.1093/carcin/22.6.965; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; Petrylak DP, 2005, UROLOGY, V65, P3, DOI 10.1016/j.urology.2005.03.053; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Pucci S, 2004, ONCOGENE, V23, P2298, DOI 10.1038/sj.onc.1207404; Stephanou A, 2003, INT J EXP PATHOL, V84, P239, DOI 10.1111/j.0959-9673.2003.00363.x; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Thomas M, 2004, CANCER RES, V64, P8357, DOI 10.1158/0008-5472.CAN-04-1864; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Trougakos IP, 2004, CANCER RES, V64, P1834, DOI 10.1158/0008-5472.CAN-03-2664; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Zellweger T, 2003, BJU INT, V92, P463, DOI 10.1046/j.1464-410X.2003.04349.x; Zellweger T, 2001, J PHARMACOL EXP THER, V298, P934	48	97	105	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6113	6122		10.1038/sj.onc.1209632	http://dx.doi.org/10.1038/sj.onc.1209632			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652143				2022-12-17	WOS:000241101200008
J	Peter, M; Rosty, C; Couturier, J; Radvanyi, F; Teshima, H; Sastre-Garau, X				Peter, M.; Rosty, C.; Couturier, J.; Radvanyi, F.; Teshima, H.; Sastre-Garau, X.			MYC activation associated with the integration of HPV DNA at the MYC locus in genital tumors	ONCOGENE			English	Article						MYC; HPV; integration; insertional mutagenesis; cervix	HUMAN-PAPILLOMAVIRUS TYPE-16; C-MYC; CERVICAL CARCINOMAS; HUMAN GENOME; PHYSICAL STATE; RAS GENE; SITES; AMPLIFICATION; SEQUENCES; ONCOGENES	To determine whether integration of human papillomavirus (HPV) DNA sequences could lead to the deregulation of genes implied in oncogenesis, we analysed the HPV integration sites in a series of nine cell lines derived from invasive genital carcinomas. Using in situ hybridization, HPV16 or 18 sequences were found at chromosome band 8q24, the localization of MYC, in IC1, IC2, IC3, IC6 and CAC-1 cells and at other sites in IC4, IC5, IC7 and IC8 cells. We then localized viral sequences at the molecular level and searched for alterations of MYC structure and expression in these cells. MYC genomic status and viral integration sites were also analysed in primary tumors from which IC1, IC2, IC3 and IC6 cells were derived. In IC1, IC2 and CAC-1 cells, HPV DNA was located within 58 kb of MYC, downstream, upstream, or within MYC. In IC3 and IC6 cells, HPV DNA was located 400-500 kb upstream of MYC. Amplification studies showed that, in IC1, IC2 and IC3, viral and MYC sequences were coamplified in an amplicon between less than 50 and 800 kb in size. MYC amplification was also observed in primary tumors, indicating that this genetic alteration, together with viral insertion at the MYC locus, had already taken place in vivo. MYC was not amplified in the other cell lines. MYC mRNA and protein overexpression was observed in the five cell lines in which the HPV DNA was inserted close to the MYC locus, but in none of the lines where the insertion had occurred at other sites. MYC activation, triggered by the insertion of HPV DNA sequences, can be an important genetic event in cervical oncogenesis.	Inst Curie, Serv Pathol, Dept Biol Tumeurs, F-75248 Paris 05, France; Inst Curie, UMR 144, CNRS, F-75248 Paris 05, France; Oita Prefectural Hosp, Dept Obstet & Gynaecol, Oita, Japan	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite	Sastre-Garau, X (corresponding author), Inst Curie, Serv Pathol, Dept Biol Tumeurs, 26 Rue Ulm, F-75248 Paris 05, France.	xavier.sastre@curie.net	Rosty, Christophe/F-1796-2010	Rosty, Christophe/0000-0001-7671-2651; Sastre-Garau, Xavier/0000-0001-5992-2083; Radvanyi, Francois/0000-0002-5696-6424				Alonso L, 2003, P NATL ACAD SCI USA, V100, P11830, DOI 10.1073/pnas.1734203100; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Bouallaga I, 2000, EMBO REP, V1, P422, DOI 10.1093/embo-reports/kvd091; Brink AATP, 2002, CANCER GENET CYTOGEN, V134, P145, DOI 10.1016/S0165-4608(01)00620-3; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; Dang CV, 1999, MOL CELL BIOL, V19, P1; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; Ferber MJ, 2003, ONCOGENE, V22, P7233, DOI 10.1038/sj.onc.1207006; Ferber MJ, 2003, ONCOGENE, V22, P3813, DOI 10.1038/sj.onc.1206528; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; Frye M, 2003, DEVELOPMENT, V130, P2793, DOI 10.1242/dev.00462; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAYAKAWA O, 1988, Sapporo Medical Journal, V57, P603; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; Herrick J, 2005, CANCER RES, V65, P1174, DOI 10.1158/0008-5472.CAN-04-2802; HORI T, 1991, JPN J CANCER RES, V82, P371, DOI 10.1111/j.1349-7006.1991.tb01857.x; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; JIKO K, 1994, INT J CANCER, V59, P601, DOI 10.1002/ijc.2910590505; JOOS S, 1992, CANCER RES, V52, P6547; Kalantari M, 2001, DIAGN MOL PATHOL, V10, P46, DOI 10.1097/00019606-200103000-00008; Klaes R, 1999, CANCER RES, V59, P6132; Klimov E, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-24; KRAUS I, 2005, 22 INT PAP C CLIN WO, V23, P157; LAZO PA, 1989, CANCER RES, V49, P4305; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lombard I, 1998, J CLIN ONCOL, V16, P2613, DOI 10.1200/JCO.1998.16.8.2613; Luft F, 2001, INT J CANCER, V92, P9, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1144>3.0.CO;2-L; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; NURNBERG W, 1995, CANCER RES, V55, P4432; PEI XF, 1993, VIROLOGY, V196, P855, DOI 10.1006/viro.1993.1546; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; POPESCU NC, 1987, CYTOGENET CELL GENET, V44, P58, DOI 10.1159/000132342; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; RIOU G, 1987, LANCET, V1, P761; RIOU G, 1988, ONCOGENE, V3, P329; Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177; ROSTY C, 2005, ONCOGENE; Rosty C, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-15; Sastre-Garau X, 2000, J GEN VIROL, V81, P1983, DOI 10.1099/0022-1317-81-8-1983; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Thorland EC, 2003, ONCOGENE, V22, P1225, DOI 10.1038/sj.onc.1206170; Thorland EC, 2000, CANCER RES, V60, P5916; Veldman T, 2003, P NATL ACAD SCI USA, V100, P8211, DOI 10.1073/pnas.1435900100; Waikel RL, 2001, NAT GENET, V28, P165, DOI 10.1038/88889; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wentzensen N, 2004, CANCER RES, V64, P3878, DOI 10.1158/0008-5472.CAN-04-0009; Wentzensen N, 2002, ONCOGENE, V21, P419, DOI 10.1038/sj.onc.1205104; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; ZEIDLER R, 1994, GENE CHROMOSOME CANC, V9, P282, DOI 10.1002/gcc.2870090408; Zhang A, 2002, INT J CANCER, V101, P427, DOI 10.1002/ijc.10627; Ziegert C, 2003, ONCOGENE, V22, P3977, DOI 10.1038/sj.onc.1206629	63	97	110	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2006	25	44					5985	5993		10.1038/sj.onc.1209625	http://dx.doi.org/10.1038/sj.onc.1209625			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16682952				2022-12-17	WOS:000240826300007
J	Donato, F; Gelatti, U; Limina, R; Fattovich, G				Donato, F.; Gelatti, U.; Limina, R. M.; Fattovich, G.			Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence	ONCOGENE			English	Review						hepatocellular carcinoma; risk factors; epidemiology; hepatitis B virus; hepatitis C virus; alcohol	HEPATITIS-C VIRUS; CHRONIC LIVER-DISEASE; GAMMA-GLUTAMYL-TRANSFERASE; HEPATOCELLULAR-CARCINOMA PATIENTS; NONALCOHOLIC FATTY LIVER; CHRONIC VIRAL-HEPATITIS; B SURFACE-ANTIGEN; CIGARETTE-SMOKING; RISK-FACTORS; NATURAL-HISTORY	Hepatitis B virus (HBV), hepatitis C virus (HCV) and alcohol consumption are major causes of hepatocellular carcinoma (HCC) worldwide. We performed a systematic review of epidemiologic studies carried out on HCC aetiology in Southern Europe, an area with an intermediate high prevalence of these agents as well as of putative risk factors such as tobacco smoking, diabetes and obesity. To retrieve the articles, we performed a Medline search for titles and abstracts of articles. After the Medline search, we reviewed the papers and reference lists to identify additional articles. A synergism between HCV infection and HBV infection, overt (hepatitis B virus antigen (HbsAg) positivity) or occult (HBsAg negativity with presence of HBV DNA in liver or serum), is suggested by the results of some studies. The pattern of the risk for HCC due to alcohol intake shows a continuous dose-effect curve without a definite threshold, although most studies found that HCC risk increased only for alcohol consumption above 40-60 g of ethanol per day. Some evidence supports a positive interaction of alcohol intake probably with HCV infection and possibly with HBV infection. A few studies found that coffee has a protective effect on HCC risk due to various risk factors. Some data also support a role of tobacco smoking, diabetes and obesity as single agents or preferably cofactors in causing HCC. In countries with a relatively high alcohol consumption and intermediate levels of HCV and HBV infections (1-3% of population infected by each virus), such as Mediterranean countries, the three main risk factors together account for about 85% of the total HCC cases, leaving little space to other known risk factors, such as haemochromatosis, and to new, still unrecognised, factors as independent causes of HCC.	Univ Brescia, Dipartimento Med Sperimentale & Applicata, Sez Igiene Epidemiol & Sanita Pubbl, Inst Hyg Epidemiol & Publ Hlth, I-25123 Brescia, Italy; Univ Verona, Dept Gastroenterol, I-37100 Verona, Italy	University of Brescia; University of Verona	Donato, F (corresponding author), Univ Brescia, Dipartimento Med Sperimentale & Applicata, Sez Igiene Epidemiol & Sanita Pubbl, Inst Hyg Epidemiol & Publ Hlth, Viale Europa 11, I-25123 Brescia, Italy.	donato@med.unibs.it	Donato, Francesco/AAQ-7477-2021; Fattovich, giovanna/AAC-7083-2020; Gelatti, Umberto/H-7719-2012	DONATO, Francesco/0000-0002-1402-1019				Adami HO, 1996, J NATL CANCER I, V88, P1472, DOI 10.1093/jnci/88.20.1472; ADAMI HO, 1992, INT J CANCER, V51, P898, DOI 10.1002/ijc.2910510611; Aizawa Y, 2000, CANCER, V89, P53, DOI 10.1002/1097-0142(20000701)89:1<53::AID-CNCR8>3.0.CO;2-6; Becker U, 2002, HEPATOLOGY, V35, P868, DOI 10.1053/jhep.2002.32101; Bedogni G, 2005, HEPATOLOGY, V42, P44, DOI 10.1002/hep.20734; Bellentani S, 1997, GUT, V41, P845, DOI 10.1136/gut.41.6.845; Bellentani S, 2001, J HEPATOL, V35, P531, DOI 10.1016/S0168-8278(01)00151-9; BELLENTANI S, 1994, HEPATOLOGY, V20, P1442, DOI 10.1002/hep.1840200611; Bellentani S, 1999, GUT, V44, P874, DOI 10.1136/gut.44.6.874; BENVEGNU L, 1994, CANCER, V74, P2442, DOI 10.1002/1097-0142(19941101)74:9<2442::AID-CNCR2820740909>3.0.CO;2-#; Benvegnu L, 2004, GUT, V53, P744, DOI 10.1136/gut.2003.020263; Bhattacharya R, 2003, J CLIN GASTROENTEROL, V36, P242, DOI 10.1097/00004836-200303000-00012; Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; Braga C, 1997, EUR J CANCER, V33, P629, DOI 10.1016/S0959-8049(96)00500-X; Brechot C, 2001, HEPATOLOGY, V34, P194, DOI 10.1053/jhep.2001.25172; Bugianesi E, 2005, ALIMENT PHARM THER, V22, P40, DOI 10.1111/j.1365-2036.2005.02594.x; Bugianesi E, 2002, GASTROENTEROLOGY, V123, P134, DOI 10.1053/gast.2002.34168; Cacciola I, 1999, NEW ENGL J MED, V341, P22, DOI 10.1056/NEJM199907013410104; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; CASIGLIA E, 1993, EUR J EPIDEMIOL, V9, P293, DOI 10.1007/BF00146266; Chan HLY, 2002, AM J GASTROENTEROL, V97, P1211, DOI 10.1111/j.1572-0241.2002.05706.x; CHEN CJ, 1991, HEPATOLOGY, V13, P398, DOI 10.1016/0270-9139(91)90289-8; Chen SY, 2002, INT J CANCER, V99, P14, DOI 10.1002/ijc.10291; Chen ZM, 2003, INT J CANCER, V107, P106, DOI 10.1002/ijc.11342; CHIARAMONTE M, 1998, CANCER, V85, P2132; Choudhury J, 2004, SEMIN LIVER DIS, V24, P349, DOI 10.1055/s-2004-860864; Corrao G, 2004, PREV MED, V38, P613, DOI 10.1016/j.ypmed.2003.11.027; Corrao G, 2001, ANN EPIDEMIOL, V11, P458, DOI 10.1016/S1047-2797(01)00223-X; Corrao G, 1997, J HEPATOL, V27, P470, DOI 10.1016/S0168-8278(97)80350-9; Corrao G, 1998, ALCOHOL ALCOHOLISM, V33, P381; CORRAO G, 1993, J CLIN EPIDEMIOL, V46, P601, DOI 10.1016/0895-4356(93)90032-V; Corrao G, 1998, J HEPATOL, V28, P608, DOI 10.1016/S0168-8278(98)80284-5; Corrao G, 1998, EUR J EPIDEMIOL, V14, P447, DOI 10.1023/A:1007411423766; Corrao G, 1998, HEPATOLOGY, V27, P914, DOI 10.1002/hep.510270404; Cotrim HP, 2000, AM J GASTROENTEROL, V95, P3018, DOI 10.1016/S0002-9270(00)02034-7; Coughlin SS, 2004, AM J EPIDEMIOL, V159, P1160, DOI 10.1093/aje/kwh161; Covolo L, 2005, CANCER CAUSE CONTROL, V16, P831, DOI 10.1007/s10552-005-2302-2; CRESPO J, 1994, AM J GASTROENTEROL, V89, P1147; Cuadrado A, 2005, OBES SURG, V15, P442, DOI 10.1381/0960892053576596; Davila JA, 2005, GUT, V54, P533, DOI 10.1136/gut.2004.052167; del Olmo JA, 1998, J CANCER RES CLIN, V124, P560, DOI 10.1007/s004320050215; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;347::AID-IJC4&gt;3.0.CO;2-2; Donato F, 2002, AM J EPIDEMIOL, V155, P323, DOI 10.1093/aje/155.4.323; Donato F, 1997, HEPATOLOGY, V26, P579, DOI 10.1002/hep.510260308; DONATO F, 2005, DIGEST LIVER DIS, V37, pA47; El-Serag HB, 2004, GASTROENTEROLOGY, V126, P460, DOI 10.1053/j.gastro.2003.10.065; Evans AA, 2002, CANCER EPIDEM BIOMAR, V11, P369; Falck-Ytter Y, 2001, SEMIN LIVER DIS, V21, P17, DOI 10.1055/s-2001-12926; Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gastro.2004.09.014; FONG TL, 1991, HEPATOLOGY, V14, P64, DOI 10.1002/hep.1840140111; Gallus S, 2002, BRIT J CANCER, V87, P956, DOI 10.1038/sj.bjc.6600582; Gallus S, 2002, ANN EPIDEMIOL, V12, P202, DOI 10.1016/S1047-2797(01)00304-0; Gelatti U, 2005, J HEPATOL, V42, P528, DOI 10.1016/j.jhep.2004.11.039; Gelatti U, 2005, INT J CANCER, V115, P301, DOI 10.1002/ijc.20895; GOODMAN MT, 1995, EPIDEMIOLOGY, V6, P36, DOI 10.1097/00001648-199501000-00008; HADZIYANNIS S, 1995, INT J CANCER, V60, P627, DOI 10.1002/ijc.2910600510; Harris DR, 2001, ANN INTERN MED, V134, P120, DOI 10.7326/0003-4819-134-2-200101160-00012; Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1; Hassan MM, 2002, HEPATOLOGY, V36, P1206, DOI 10.1053/jhep.2002.36780; Heathcote EJ, 2004, GASTROENTEROLOGY, V127, pS294, DOI 10.1053/j.gastro.2004.09.044; Hezode C, 2003, GUT, V52, P126, DOI 10.1136/gut.52.1.126; Honjo S, 2001, J CLIN EPIDEMIOL, V54, P823, DOI 10.1016/S0895-4356(01)00344-4; Honjo S, 1999, ANN EPIDEMIOL, V9, P325, DOI 10.1016/S1047-2797(99)00013-7; Hu KQ, 2002, J VIRAL HEPATITIS, V9, P243, DOI 10.1046/j.1365-2893.2002.00344.x; Hui JM, 2003, HEPATOLOGY, V38, P420, DOI 10.1053/jhep.2003.50320; *IARC, 1994, IARC MON EV CARC RIS, V59; *IARC, 1988, ALC DRINK IARC MON, V44; IARC, 1991, IARC MON EV CARC RIS, V51; Ikeda K, 1998, J HEPATOL, V28, P930, DOI 10.1016/S0168-8278(98)80339-5; Inoue M, 2005, J NATL CANCER I, V97, P293, DOI 10.1093/jnci/dji040; Jee SH, 2004, JNCI-J NATL CANCER I, V96, P1851, DOI 10.1093/jnci/djh334; Jee SH, 2005, JAMA-J AM MED ASSOC, V293, P194, DOI 10.1001/jama.293.2.194; Kamper-Jorgensen M, 2004, J HEPATOL, V41, P25, DOI 10.1016/j.jhep.2004.03.002; Klatsky A L, 1993, Ann Epidemiol, V3, P375, DOI 10.1016/1047-2797(93)90064-B; KLATSKY AL, 1992, AM J EPIDEMIOL, V136, P1248, DOI 10.1093/oxfordjournals.aje.a116433; KOIKE K, 1995, J MED VIROL, V45, P236, DOI 10.1002/jmv.1890450222; Kuper H, 2000, INT J CANCER, V85, P498, DOI 10.1002/(SICI)1097-0215(20000215)85:4&lt;498::AID-IJC9&gt;3.0.CO;2-F; Kuper H, 2001, HEPATOLOGY, V34, P714, DOI 10.1053/jhep.2001.28233; Kuper HE, 2000, CANCER CAUSE CONTROL, V11, P171, DOI 10.1023/A:1008951901148; Kuriyama S, 2005, INT J CANCER, V113, P148, DOI 10.1002/ijc.20529; Kurozawa Y, 2005, BRIT J CANCER, V93, P607, DOI 10.1038/sj.bjc.6602737; Lagiou P, 2000, J NATL CANCER I, V92, P1096, DOI 10.1093/jnci/92.13.1096; LaVecchia C, 1997, INT J CANCER, V73, P204, DOI 10.1002/(SICI)1097-0215(19971009)73:2<204::AID-IJC7>3.0.CO;2-#; Lecube A, 2004, DIABETES CARE, V27, P1171, DOI 10.2337/diacare.27.5.1171; Liaw KM, 1998, TOB CONTROL, V7, P141, DOI 10.1136/tc.7.2.141; LIAW YF, 1995, HEPATOLOGY, V22, P1101, DOI 10.1016/0270-9139(95)90615-0; Liu BQ, 1998, BMJ-BRIT MED J, V317, P1411, DOI 10.1136/bmj.317.7170.1411; Loguercio C, 2000, ALCOHOL ALCOHOLISM, V35, P296, DOI 10.1093/alcalc/35.3.296; Mandayam S, 2004, SEMIN LIVER DIS, V24, P217, DOI 10.1055/s-2004-832936; Manno M, 2004, GASTROENTEROLOGY, V127, P756, DOI 10.1053/j.gastro.2004.06.021; Marchesini G, 2005, ANN MED, V37, P333, DOI 10.1080/07853890510011445; Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161; Marrero JA, 2004, GASTROENTEROLOGY, V126, P347, DOI 10.1053/j.gastro.2003.11.021; Marrero JA, 2002, HEPATOLOGY, V36, P1349, DOI 10.1053/jhep.2002.36939; Mastrangelo G, 2004, ENVIRON HEALTH PERSP, V112, P1188, DOI 10.1289/ehp.6972; McGlynn KA, 2005, BEST PRACT RES CL GA, V19, P3, DOI 10.1016/j.bpg.2004.10.004; McKillop IH, 2005, ALCOHOL, V35, P195, DOI 10.1016/j.alcohol.2005.04.004; Mehta SH, 2003, HEPATOLOGY, V38, P50, DOI 10.1053/jhep.2003.50291; Mehta SH, 2001, EPIDEMIOL REV, V23, P302, DOI 10.1093/oxfordjournals.epirev.a000808; MENDENHALL CL, 1991, HEPATOLOGY, V14, P581; Mizoue T, 2000, INT J EPIDEMIOL, V29, P232, DOI 10.1093/ije/29.2.232; MOLLER H, 1994, EUR J CANCER, V30A, P344, DOI 10.1016/0959-8049(94)90254-2; Monto A, 2004, HEPATOLOGY, V39, P826, DOI 10.1002/hep.20127; Morgan TR, 2004, GASTROENTEROLOGY, V127, pS87, DOI 10.1053/j.gastro.2004.09.020; Mori M, 2000, AM J EPIDEMIOL, V151, P131, DOI 10.1093/oxfordjournals.aje.a010180; Nair S, 2002, HEPATOLOGY, V36, P150, DOI 10.1053/jhep.2002.33713; Neuschwander-Tetri BA, 2003, HEPATOLOGY, V37, P1202, DOI 10.1053/jhep.2003.50193; NKONTCHOU G, 2006, IN PRESS CLIN GASTRO; Pan SY, 2004, AM J EPIDEMIOL, V159, P259, DOI 10.1093/aje/kwh041; Pessione F, 2001, HEPATOLOGY, V34, P121, DOI 10.1053/jhep.2001.25385; Peters MG, 2002, HEPATOLOGY, V36, pS220, DOI 10.1053/jhep.2002.36811; Pintus F, 1996, EUR J EPIDEMIOL, V12, P71, DOI 10.1007/BF00144431; Poikolainen K, 1997, AM J EPIDEMIOL, V146, P1019, DOI 10.1093/oxfordjournals.aje.a009230; Pollicino T, 2004, GASTROENTEROLOGY, V126, P102, DOI 10.1053/j.gastro.2003.10.048; PONTISSO P, 1993, GASTROENTEROLOGY, V105, P1529, DOI 10.1016/0016-5085(93)90161-5; Poschl G, 2004, ALCOHOL ALCOHOLISM, V39, P155, DOI 10.1093/alcalc/agh057; POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Raimondo G, 2006, HEPATOLOGY, V43, P100, DOI 10.1002/hep.20944; Rapp K, 2005, BRIT J CANCER, V93, P1062, DOI 10.1038/sj.bjc.6602819; Ratziu V, 2005, ALIMENT PHARM THERAP, V22, P56, DOI 10.1111/j.1365-2036.2005.02598.x; Ratziu V, 2002, HEPATOLOGY, V35, P1485, DOI 10.1053/jhep.2002.33324; RATZIU V, 2005, FATTY LIVER DIS NASH, P263; Regev A, 1999, ALCOHOL CLIN EXP RES, V23, P1543, DOI 10.1111/j.1530-0277.1999.tb04679.x; Regimbeau Jean M, 2004, Liver Transpl, V10, pS69, DOI 10.1002/lt.20033; Rockhill B, 1998, AM J PUBLIC HEALTH, V88, P15, DOI 10.2105/AJPH.88.1.15; Rothman K, 1986, MODERN EPIDEMIOLOGY; RoudotThoraval F, 1997, HEPATOLOGY, V26, P485, DOI 10.1002/hep.510260233; Ruhl CE, 2005, GASTROENTEROLOGY, V129, P1928, DOI 10.1053/j.gastro.2005.08.056; Sagnelli E, 2005, J MED VIROL, V75, P522, DOI 10.1002/jmv.20313; Samanic C, 2004, CANCER CAUSE CONTROL, V15, P35, DOI 10.1023/B:CACO.0000016573.79453.ba; Sangiovanni A, 2004, GASTROENTEROLOGY, V126, P1005, DOI 10.1053/j.gastro.2003.12.049; Sharp DS, 1999, ANN EPIDEMIOL, V9, P391; Shi J, 2005, BRIT J CANCER, V92, P607, DOI 10.1038/sj.bjc.6602333; Shimada M, 2002, J HEPATOL, V37, P154, DOI 10.1016/S0168-8278(02)00099-5; Shintani Y, 2004, GASTROENTEROLOGY, V126, P840, DOI 10.1053/j.gastro.2003.11.056; Sorensen HT, 2003, J CLIN GASTROENTEROL, V36, P356, DOI 10.1097/00004836-200304000-00015; Sorensen HT, 1998, HEPATOLOGY, V28, P921, DOI 10.1002/hep.510280404; Squadrito G, 2006, CANCER-AM CANCER SOC, V106, P1326, DOI 10.1002/cncr.21702; Staretz ME, 1997, DRUG METAB DISPOS, V25, P154; STROFFOLINI T, 1992, J HEPATOL, V16, P360, DOI 10.1016/S0168-8278(05)80670-1; Stroffolini T, 2004, DIGEST LIVER DIS, V36, P56, DOI 10.1016/j.dld.2003.07.007; Sun CA, 2003, AM J EPIDEMIOL, V157, P674, DOI 10.1093/aje/kwg041; Sun ZT, 1999, HEPATOLOGY, V30, P379, DOI 10.1002/hep.510300204; Tanaka K, 1998, INT J EPIDEMIOL, V27, P438, DOI 10.1093/ije/27.3.438; TELI MR, 1995, LANCET, V346, P987, DOI 10.1016/S0140-6736(95)91685-7; Torbenson M, 2002, LANCET INFECT DIS, V2, P479, DOI 10.1016/S1473-3099(02)00345-6; Tverdal A, 2003, ANN EPIDEMIOL, V13, P419, DOI 10.1016/S1047-2797(02)00462-3; TZONOU A, 1991, INT J CANCER, V49, P377, DOI 10.1002/ijc.2910490311; VALLMAYANS M, 1990, INT J CANCER, V46, P378; Verlato G, 2003, DIABETES CARE, V26, P1047, DOI 10.2337/diacare.26.4.1047; Vineis P, 2004, JNCI-J NATL CANCER I, V96, P99, DOI 10.1093/jnci/djh014; Voigt Michael D, 2005, Clin Liver Dis, V9, P151, DOI 10.1016/j.cld.2004.10.003; Wang LY, 1998, AM J EPIDEMIOL, V147, P315; Wang LY, 2003, CANCER CAUSE CONTROL, V14, P241, DOI 10.1023/A:1023636619477; Wideroff L, 1997, J NATL CANCER I, V89, P1360, DOI 10.1093/jnci/89.18.1360; Wolk A, 2001, CANCER CAUSE CONTROL, V12, P13, DOI 10.1023/A:1008995217664; Wong RH, 2003, J OCCUP ENVIRON MED, V45, P379, DOI 10.1097/01.jom.0000063622.37065.fd; Yamanaka T, 2001, ANTICANCER RES, V21, P2937; YOSUYANAGI H, 2004, ALCOHOL CLIN EXP RES, V28, pS181; YU MC, 1991, JNCI-J NATL CANCER I, V83, P1820, DOI 10.1093/jnci/83.24.1820; Yu MC, 2004, GASTROENTEROLOGY, V127, pS72, DOI 10.1016/j.gastro.2004.09.018; Yu MW, 1997, AM J EPIDEMIOL, V145, P1039, DOI 10.1093/oxfordjournals.aje.a009060; Yuan JM, 2004, CANCER, V101, P1009, DOI 10.1002/cncr.20427; ZAVITSANOS X, 1992, CANCER RES, V52, P5364; Zen Y, 2001, PATHOL INT, V51, P127, DOI 10.1046/j.1440-1827.2001.01174.x; Zoli M, 1996, CANCER-AM CANCER SOC, V78, P977, DOI 10.1002/(SICI)1097-0142(19960901)78:5<977::AID-CNCR6>3.0.CO;2-9	168	97	100	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	27					3756	3770		10.1038/sj.onc.1209557	http://dx.doi.org/10.1038/sj.onc.1209557			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799617	Green Published			2022-12-17	WOS:000238559600003
J	Hatada, I; Fukasawa, M; Kimura, M; Morita, S; Yamada, K; Yoshikawa, T; Yamanaka, S; Endo, C; Sakurada, A; Sato, M; Kondo, T; Horii, A; Ushijima, T; Sasaki, H				Hatada, I.; Fukasawa, M.; Kimura, M.; Morita, S.; Yamada, K.; Yoshikawa, T.; Yamanaka, S.; Endo, C.; Sakurada, A.; Sato, M.; Kondo, T.; Horii, A.; Ushijima, T.; Sasaki, H.			Genome-wide profiling of promoter methylation in human	ONCOGENE			English	Article						DNA methylation; genome-wide profiling; epigenetics; microarray	DNA METHYLATION; CPG-ISLANDS	DNA methylation in the promoter region of a gene is associated with a loss of that gene's expression and plays an important role in gene silencing. The inactivation of tumor-suppressor genes by aberrant methylation in the promoter region is well recognized in carcinogenesis. However, there has been little study in this area when it comes to genome-wide profiling of the promoter methylation. Here, we developed a genome-wide profiling method called Microarray-based Integrated Analysis of Methylation by Isoschizomers to analyse the DNA methylation of promoter regions of 8091 human genes. With this method, resistance to both the methylation-sensitive restriction enzyme HpaII and the methylation-insensitive isoschizomer MspI was compared between samples by using a microarray with promoter regions of the 8091 genes. The reliability of the difference in HpaII resistance was judged using the difference in MspI resistance. We demonstrated the utility of this method by finding epigenetic mutations in cancer. Aberrant hypermethylation is known to inactivate tumour suppressor genes. Using this method, we found that frequency of the aberrant promoter hypermethylation in cancer is higher than previously hypothesized. Aberrant hypomethylation is known to induce activation of oncogenes in cancer. Genome-wide analysis of hypomethylated promoter sequences in cancer demonstrated low CG/GC ratio of these sequences, suggesting that CpG-poor genes are sensitive to demethylation activity in cancer.	Gunma Univ, Dept Mol & Cellular Biol, Lab Genome Sci, Biosignal Genome Resource Ctr, Maebashi, Gumma 3718512, Japan; PRESTO, JST, Kawaguchi, Japan; RIKEN, Brain Sci Inst, Lab Mol Psychiat, Wako, Saitama, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Thorac Surg, Sendai, Miyagi, Japan; Tohoku Univ, Sch Med, Dept Mol Pathol, Sendai, Miyagi, Japan; Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, Tokyo 104, Japan; Natl Inst Genet, Res Org Informat & Syst, Div Human Genet, Mishima, Shizuoka, Japan; Grad Univ Adv Studies, Sch Life Sci, Dept Genet, Mishima, Shizuoka, Japan	Gunma University; Japan Science & Technology Agency (JST); RIKEN; Tohoku University; Tohoku University; National Cancer Center - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan	Hatada, I (corresponding author), Gunma Univ, Dept Mol & Cellular Biol, Lab Genome Sci, Biosignal Genome Resource Ctr, 3-39-15 Showa Machi, Maebashi, Gumma 3718512, Japan.	ihatada@showa.gunma-u.ac.jp	Ushijima, Toshikazu/AAP-5742-2021; Horii, Akira/AAW-2839-2021; Yoshikawa, Takeo/F-9599-2019	Ushijima, Toshikazu/0000-0003-3405-7817; Horii, Akira/0000-0002-3967-3291; 				Abujiang P, 1998, ONCOGENE, V17, P3029, DOI 10.1038/sj.onc.1202230; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Baylin SB, 1998, ADV CANCER RES, V72, P141; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; Hatada I, 2002, J HUM GENET, V47, P448, DOI 10.1007/s100380200063; Heisler LE, 2005, NUCLEIC ACIDS RES, V33, P2952, DOI 10.1093/nar/gki582; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Jager AC, 1997, AM J HUM GENET, V61, P129, DOI 10.1086/513896; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Rozen S, 2000, Methods Mol Biol, V132, P365; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Yan PS, 2001, CANCER RES, V61, P8375	16	97	109	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3059	3064		10.1038/sj.onc.1209331	http://dx.doi.org/10.1038/sj.onc.1209331			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407832	Green Submitted			2022-12-17	WOS:000237950800010
J	Putz, G; Rosner, A; Nuesslein, I; Schmitz, N; Buchholz, F				Putz, G; Rosner, A; Nuesslein, I; Schmitz, N; Buchholz, F			AML1 deletion in adult mice causes splenomegaly and lymphomas	ONCOGENE			English	Article						AML1; conditional allele; hematopoiesis; splenomegaly; lymphoma	ACUTE MYELOID-LEUKEMIA; CORE-BINDING FACTOR; N-RAS ONCOGENE; MYELODYSPLASTIC SYNDROME; DEFINITIVE HEMATOPOIESIS; POINT MUTATIONS; RUNT DOMAIN; AML1/PEBP2-ALPHA-B GENE; ACQUIRED TRISOMY-21; EMBRYONIC LETHALITY	AML1 (RUNX1) encodes a DNA- binding subunit of the CBF transcription factor family and is required for the establishment of defi. nitive hematopoiesis. AML1 is one of the most frequently mutated genes associated with human acute leukemia, suggesting that genetic alterations of the gene contribute to leukemogenesis. Here, we report the analysis of mice e carrying conditional AML1 knockout alleles that were inactivated using the Cre/loxP system. AML1 was deleted in adult mice by inducing Cre activity to replicate AML1 deletions found in human MDS, familial platelet disorder and rare de novo human AML. At a latency of 2 months after induction, the thymus was reduced in size and frequently populated by immature double negative thymocytes, indicating defective T-lymphocyte maturation, resulting in lymphatic diseases with 50% penetrance, including atypical hyperplasia and thymic lymphoma. Metastatic lymphomas to the liver and the meninges were observed. Mice also developed splenomegaly with an expansion of the myeloid compartment. Increased Howell-Jolly body counts indicated splenic hypofunction. Thrombocytopenia occurred due to immaturity of mini-megakaryocytes in the bone marrow. Together with mild lymphocytopenia in the peripheral blood and increased fractions of immature cells in the bone marrow, AML1 deficient mice display features of a myelodysplastic syndrome, suggesting a preleukemic state.	Max Planck Inst Mol Cell Biol & Genet, Dresden, Germany; Tech Univ Dresden, Klin & Polklin Strahlentherapie & Radioonkol, Expt Zentrum, Med Fak Carl Gustav Carus, D-8027 Dresden, Germany	Max Planck Society; Technische Universitat Dresden; Carl Gustav Carus University Hospital	Buchholz, F (corresponding author), Pfotenhauer Str 108, D-01037 Dresden, Germany.	buchholz@mpi-cbg.de	Buchholz, Frank/B-4700-2017	Buchholz, Frank/0000-0002-4577-3344				Bourgeois E, 2001, LEUKEMIA, V15, P950, DOI 10.1038/sj.leu.2402129; Buchholz F, 2000, EMBO REP, V1, P133, DOI 10.1093/embo-reports/kvd027; Dunnick JK, 1997, TOXICOL PATHOL, V25, P533, DOI 10.1177/019262339702500601; Fredrickson TN, 2000, ATLAS MOUSE HEMATOPA; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; HIRAI H, 1988, BLOOD, V71, P256; HIRAI H, 1987, NATURE, V327, P430, DOI 10.1038/327430a0; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; LENNY N, 1995, ONCOGENE, V11, P1761; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Lorsbach RB, 2004, BLOOD, V103, P2522, DOI 10.1182/blood-2003-07-2439; Michaud J, 2003, CANCER INVEST, V21, P105, DOI 10.1081/CNV-120018821; Miller JD, 2001, BLOOD, V97, P2248, DOI 10.1182/blood.V97.8.2248; Morohashi K, 1999, BLOOD, V93, P1586; North T, 1999, DEVELOPMENT, V126, P2563; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Rhoades KL, 2000, BLOOD, V96, P2108; Roumier C, 2003, LEUKEMIA, V17, P9, DOI 10.1038/sj.leu.2402766; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Schiering A, 1999, ATHEROSCLEROSIS, V144, P73, DOI 10.1016/S0021-9150(99)00045-3; Silva FPG, 2003, ONCOGENE, V22, P538, DOI 10.1038/sj.onc.1206141; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Steensma DP, 2005, EUR J HAEMATOL, V74, P47, DOI 10.1111/j.1600-0609.2004.00363.x; Sun W, 2004, BLOOD, V104, P3565, DOI 10.1182/blood-2003-12-4349; Taketani T, 2003, GENE CHROMOSOME CANC, V38, P1, DOI 10.1002/gcc.10246; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298	41	97	99	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					929	939		10.1038/sj.onc.1209136	http://dx.doi.org/10.1038/sj.onc.1209136			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247465				2022-12-17	WOS:000235212700012
J	Kuphal, S; Wallner, S; Schimanski, CC; Bataille, F; Hofer, P; Strand, S; Strand, D; Bosserhoff, AK				Kuphal, S; Wallner, S; Schimanski, CC; Bataille, F; Hofer, P; Strand, S; Strand, D; Bosserhoff, AK			Expression of Hugl-1 is strongly reduced in malignant melanoma	ONCOGENE			English	Article						Lgl; Hugl; human; tumor; suppressor gene; malignant melanoma; cancer	TUMOR-SUPPRESSOR GENE; LETHAL-GIANT-LARVAE; II HEAVY-CHAIN; BREAST-CARCINOMA; CELL POLARITY; HUMAN HOMOLOG; IN-VIVO; DROSOPHILA; PROTEIN; CANCER	The human gene Hugl-1 (Llgl/Lgl1) has significant homology to the Drosophila tumor suppressor gene lethal(2) giant larvae (lgl). The lgl gene codes for a cortical cytoskeleton protein, Lgl, that is involved in maintaining cell polarity and epithelial integrity. We speculate that Hugl-1 might play a role in epithelial mesenchymal transition (EMT) and that loss of Hugl-1 expression plays a role in the development or progression of malignant melanoma. Thus, we evaluated melanoma cell lines and tissue samples of malignant melanoma for loss of Hugl-1 transcription. We found that Hugl-1 was downregulated or lost in all cell lines and in most of the tumor samples analysed, and that these losses were associated with advanced stage of the disease. Redu ced Hugl-1 expression occurred as early as in primary tumors detected by both immunohistochemical and reverse transcription-polymerase chain reaction (RT-PCR) analysis. Fun ctional assays with stable Hugl-1-transfected cell lines revealed that Hugl-1 expression increased cell adhesion and decreased cell migration. Further, downregulation of MMP2 and MMP14 (MT1- MMP) and re-expression of E-cadherin was found in the Hugl-1-expressing cell clones supporting a role of Hugl-1 in EMT. Our studies thus indicate that loss of Hugl-1 expression contributes to melanoma progression.	Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany; Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-6500 Mainz, Germany	University of Regensburg; Johannes Gutenberg University of Mainz	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Kuphal, Silke/AAW-2702-2020; Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				AGRAWAL N, 1995, DEV BIOL, V172, P218, DOI 10.1006/dbio.1995.0017; Behrmann I, 2003, AM J PATHOL, V163, P683, DOI 10.1016/S0002-9440(10)63695-4; Berking C, 2004, CANCER RES, V64, P807, DOI 10.1158/0008-5472.CAN-03-3438; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Borg JP, 2004, PATHOL BIOL, V52, P328, DOI 10.1016/j.patbio.2003.09.015; DANEN EHJ, 1995, CANCER SURV, V24, P43; Gilles C, 1997, LAB INVEST, V76, P651; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; Grifoni D, 2004, ONCOGENE, V23, P8688, DOI 10.1038/sj.onc.1208023; Haass NK, 2004, J MOL HISTOL, V35, P309; Hendrix MJC, 1996, CANCER METAST REV, V15, P507, DOI 10.1007/BF00054016; Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Hutterer A, 2004, DEV CELL, V6, P845, DOI 10.1016/j.devcel.2004.05.003; JACOB K, 1995, INT J CANCER, V60, P668, DOI 10.1002/ijc.2910600517; Jankowski JA, 1997, J CLIN PATHOL-MOL PA, V50, P289; Justice N, 2003, CURR BIOL, V13, P778, DOI 10.1016/S0960-9822(03)00288-4; Kalmes A, 1996, J CELL SCI, V109, P1359; Kuphal S, 2005, MELANOMA RES, V15, P305, DOI 10.1097/00008390-200508000-00012; Li G, 2004, EXP CELL RES, V297, P142, DOI 10.1016/j.yexcr.2004.03.012; Musch A, 2002, MOL BIOL CELL, V13, P158, DOI 10.1091/mbc.01-10-0496; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Pla P, 2001, J CELL PHYSIOL, V189, P121, DOI 10.1002/jcp.10008; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361; STRAND D, 1994, J CELL BIOL, V127, P1345, DOI 10.1083/jcb.127.5.1345; STRAND D, 1995, ONCOGENE, V11, P291; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Tester AM, 2001, CLIN EXP METASTAS, V18, P553, DOI 10.1023/A:1011953118186; TIMMONS L, 1993, DEV BIOL, V158, P364, DOI 10.1006/dbio.1993.1195; TOMOTSUNE D, 1993, NATURE, V365, P69, DOI 10.1038/365069a0; WOODHOUSE E, 1994, CELL GROWTH DIFFER, V5, P151; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6	35	97	106	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					103	110		10.1038/sj.onc.1209008	http://dx.doi.org/10.1038/sj.onc.1209008			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170365				2022-12-17	WOS:000234406400011
J	Wang, Q; Zhou, Y; Wang, X; Evers, BM				Wang, Q; Zhou, Y; Wang, X; Evers, BM			Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase	ONCOGENE			English	Article						GSK-3; MAPK; ERK; PKC delta; siRNA; colon cancer cells	NF-KAPPA-B; INTESTINAL-CELL DIFFERENTIATION; ACTIVATED PROTEIN-KINASES; TUMOR-NECROSIS-FACTOR; COLON-CANCER CELLS; C-DELTA; BETA-CATENIN; PHOSPHATIDYLINOSITOL 3-KINASE; INDUCED APOPTOSIS; DOWN-REGULATION	Glycogen-synthase kinase-3 (GSK- 3) and extracellular signal-regulated kinase (ERK) are critical downstream signaling proteins for the PI3-kinase/ Akt and Ras/Raf/ MEK-1 pathway, respectively, and regulate diverse cellular processes including embryonic development, cell differentiation and apoptosis. Here, we show that inhibition of GSK-3 using GSK- 3 inhibitors or RNA interference (RNAi) signifi. cantly induced the phosphorylation of ERK1/2 in human colon cancer cell lines HT29 and Caco-2. Pretreatment with the PKC delta-selective inhibitor rottlerin or transfection with PKC delta siRNA attenuated the phosphorylation of ERK1/2 induced by the GSK-3 inhibitor SB-216763 and, furthermore, treatment with SB-216763 or transfection with GSK-3 delta and GSK-3 beta siRNA increased PKCd activity, thus identifying a role for PKCd in the induction of ERK1/2 phosphorylation by GSK-3 inhibition. Treatment with SB-216763 increased expression of cyclooxygenase-2 (COX-2) and IL-8, which are downstream targets of ERK1/2 activation; this induction was abolished by MEK/ERK inhibition, suggesting GSK-3 inhibition induced COX-2 and IL-8 through ERK1/2 activation. The transcriptional induction of COX-2 and IL-8 by GSK- 3 inhibition was further demonstrated by the increased COX-2 and IL-8 promoter activity after SB-216763 treatment or transfection with GSK-3 alpha or GSK- 3b siRNA. Importantly, our. findings identify GSK-3, acting through PKCd, as a negative regulator of ERK1/2, thus revealing a novel crosstalk mechanism between these critical signaling pathways.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Evers, BM (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	mevers@utmb.edu			NIA NIH HHS [R37 AG010885, R37 AG10885] Funding Source: Medline; NIDDK NIH HHS [R01 DK048498, P01 DK35608, P01 DK035608, R01 DK48498] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035608, R01DK048498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG010885] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aikin R, 2004, ENDOCRINOLOGY, V145, P4522, DOI 10.1210/en.2004-0488; Akhtar M, 2003, FASEB J, V17, P1319, DOI 10.1096/fj.02-0950fje; Ali A, 2001, CHEM REV, V101, P2527, DOI 10.1021/cr000110o; Bancroft CC, 2001, CLIN CANCER RES, V7, P435; Brew R, 2000, CYTOKINE, V12, P78, DOI 10.1006/cyto.1999.0518; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Chen BC, 2004, J BIOL CHEM, V279, P20889, DOI 10.1074/jbc.M311279200; Choi JH, 2004, J BIOL CHEM, V279, P49430, DOI 10.1074/jbc.M402088200; Claria J, 2003, CURR PHARM DESIGN, V9, P2177, DOI 10.2174/1381612033454054; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ding QM, 2001, BIOCHEM BIOPH RES CO, V284, P282, DOI 10.1006/bbrc.2001.4969; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Eickholt BJ, 2002, J CELL BIOL, V157, P211, DOI 10.1083/jcb.200201098; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kim JW, 2003, J BIOL CHEM, V278, P13995, DOI 10.1074/jbc.M300253200; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Lee YJ, 2002, CELL GROWTH DIFFER, V13, P237; Levy L, 2002, J BIOL CHEM, V277, P42386, DOI 10.1074/jbc.M207418200; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Mazor M, 2004, ONCOGENE, V23, P7882, DOI 10.1038/sj.onc.1208068; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Murugappan S, 2004, J BIOL CHEM, V279, P2360, DOI 10.1074/jbc.M306960200; Pan ZZ, 2002, J BIOL CHEM, V277, P35050, DOI 10.1074/jbc.M201650200; Papadakis KA, 2000, ANNU REV MED, V51, P289, DOI 10.1146/annurev.med.51.1.289; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Rao R, 2004, J BIOL CHEM, V279, P3949, DOI 10.1074/jbc.M309325200; Remacle-Bonnet MM, 2000, CANCER RES, V60, P2007; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Takahashi-Yanaga F, 2004, BIOCHEM BIOPH RES CO, V316, P411, DOI 10.1016/j.bbrc.2004.02.061; Tang QB, 2001, CANCER RES, V61, P4329; Tominaga K, 2004, ALIMENT PHARM THER, V20, P143, DOI 10.1111/j.1365-2036.2004.01986.x; Tsujio I, 2000, FEBS LETT, V469, P111, DOI 10.1016/S0014-5793(00)01234-5; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Wang QD, 2001, GASTROENTEROLOGY, V120, P1381, DOI 10.1053/gast.2001.24044; Wang QD, 2000, ANTICANCER RES, V20, P75; Wang QD, 2003, J BIOL CHEM, V278, P51091, DOI 10.1074/jbc.M306541200; Wang YJ, 2004, J BIOL CHEM, V279, P31089, DOI 10.1074/jbc.M404170200; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Williams C, 1999, ANN NY ACAD SCI, V889, P72, DOI 10.1111/j.1749-6632.1999.tb08725.x; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; Zhao DZ, 2001, J BIOL CHEM, V276, P44464, DOI 10.1074/jbc.M104942200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	60	97	102	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					43	50		10.1038/sj.onc.1209004	http://dx.doi.org/10.1038/sj.onc.1209004			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16278684	Green Accepted			2022-12-17	WOS:000234406400005
J	Novoselov, SV; Calvisi, DF; Labunskyy, VM; Factor, VM; Carlson, BA; Fomenko, DE; Moustafa, ME; Hatfield, DL; Gladyshev, VN				Novoselov, SV; Calvisi, DF; Labunskyy, VM; Factor, VM; Carlson, BA; Fomenko, DE; Moustafa, ME; Hatfield, DL; Gladyshev, VN			Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic mice	ONCOGENE			English	Article						selenoprotein; selenocysteine; selenium; cancer prevention; redox regulation	GROWTH-FACTOR-ALPHA; CANCER PREVENTION; THIOREDOXIN REDUCTASE; MOUSE MODEL; ACCELERATED HEPATOCARCINOGENESIS; GLUTATHIONE PEROXIDASE-1; PROSTATE-CANCER; LIVER-CANCER; C-MYC; SELENOCYSTEINE	The micronutrient element selenium ( Se) has been shown to be effective in reducing the incidence of cancer in animal models and human clinical trials. Selenoproteins and low molecular weight Se compounds were implicated in the chemopreventive effect, but specific mechanisms are not clear. We examined the role of Se and selenoproteins in liver tumor formation in TGF alpha/c-Myc transgenic mice, which are characterized by disrupted redox homeostasis and develop liver cancer by 6 months of age. In these mice, both Se deficiency and high levels of Se compounds suppressed hepatocarcinogenesis. In addition, both treatments induced expression of detoxification genes, increased apoptosis and inhibited cell proliferation. Within low-to-optimal levels of dietary Se, tumor formation correlated with expression of most selenoproteins. These data suggest that changes in selenoprotein expression may either suppress or promote tumorigenesis depending on cell type and genotype. Since dietary Se may have opposing effects on cancer, it is important to identify the subjects who will benefit from Se supplementation as well as those who will not.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; NCI, Expt Carcinogenesis Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; NCI, Mol Biol Selenium Sect, Lab Canc Prevent, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	University of Nebraska System; University of Nebraska Lincoln; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gladyshev, VN (corresponding author), Univ Nebraska, Dept Biochem, N 151 Beadle Ctr,1901 Vine St, Lincoln, NE 68588 USA.	vgladyshev1@unl.edu	Gladyshev, Vadim N/A-9894-2013; Labunskyy, Vyacheslav/AAC-8489-2020; Moustafa, Mohamed E/E-9002-2018; Gladyshev, Vadim N/J-6187-2013; Moustafa, Mohamed/AAM-2211-2021	Gladyshev, Vadim/0000-0002-0372-7016; Novoselov, Sergey/0000-0003-0104-6492; Labunskyy, Vyacheslav/0000-0001-9317-1076; Moustafa, Mohamed/0000-0003-1308-6221	NATIONAL CANCER INSTITUTE [R01CA080946, Z01BC005317, ZIABC005317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021518] Funding Source: NIH RePORTER; NCI NIH HHS [CA080946] Funding Source: Medline; NIA NIH HHS [AG021518] Funding Source: Medline; NIGMS NIH HHS [GM061603] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Bock A, 2000, Biofactors, V11, P77; Burk Raymond F, 2002, Nutr Clin Care, V5, P75, DOI 10.1046/j.1523-5408.2002.00006.x; BURK RF, 1983, FUND APPL TOXICOL, V3, P218, DOI 10.1016/S0272-0590(83)80129-8; Calvisi DF, 2004, GASTROENTEROLOGY, V126, P1374, DOI 10.1053/j.gastro.2004.02.014; Carlson BA, 2004, J BIOL CHEM, V279, P8011, DOI 10.1074/jbc.M310470200; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Driscoll DM, 2003, ANNU REV NUTR, V23, P17, DOI 10.1146/annurev.nutr.23.011702.073318; El-Bayoumy K, 2004, MUTAT RES-FUND MOL M, V551, P181, DOI 10.1016/j.mrfmmm.2004.02.023; Factor VM, 2000, P NATL ACAD SCI USA, V97, P2196, DOI 10.1073/pnas.040428797; Factor VM, 1998, J BIOL CHEM, V273, P15846, DOI 10.1074/jbc.273.25.15846; Felix K, 2004, CANCER RES, V64, P2910, DOI 10.1158/0008-5472.CAN-03-2672; Fu YX, 2001, J BIOL CHEM, V276, P43004, DOI 10.1074/jbc.M106946200; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; Gladyshev VN, 1998, BIOCHEM BIOPH RES CO, V251, P488, DOI 10.1006/bbrc.1998.9495; Gouaze V, 2002, J BIOL CHEM, V277, P42867, DOI 10.1074/jbc.M203067200; Hatfield D. L., 2001, SELENIUM ITS MOL BIO; HILL KE, 1984, TOXICOL APPL PHARM, V72, P32, DOI 10.1016/0041-008X(84)90246-1; Hironaka K, 2003, LAB INVEST, V83, P643, DOI 10.1097/01.LAB.0000067483.89649.11; Ip C, 2002, CANCER METAST REV, V21, P281, DOI 10.1023/A:1021263027659; Ip C, 1998, ANTICANCER RES, V18, P9; Kim HY, 2004, MOL BIOL CELL, V15, P1055, DOI 10.1091/mbc.E03-08-0629; Klein EA, 2000, PROSTATE CANCER P D, V3, P145, DOI 10.1038/sj.pcan.4500412; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/S0968-0004(96)80016-8; Milner JA, 2001, NUTR CANCER, V41, P1, DOI 10.1207/S15327914NC41-1&amp;2_1; Moustafa ME, 2001, MOL CELL BIOL, V21, P3840, DOI 10.1128/MCB.21.11.3840-3852.2001; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; REITER R, 1984, BIOCHEM PHARMACOL, V33, P1923, DOI 10.1016/0006-2952(84)90548-3; SantoniRugiu E, 1996, AM J PATHOL, V149, P407; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Sunde R. A., 1994, Selenium in biology and human health., P45; Whanger PD, 2004, BRIT J NUTR, V91, P11, DOI 10.1079/BJN20031015; Yoshizawa K, 1998, JNCI-J NATL CANCER I, V90, P1219, DOI 10.1093/jnci/90.16.1219; Yu SY, 1997, BIOL TRACE ELEM RES, V56, P117, DOI 10.1007/BF02778987; Zhao HJ, 2004, MOL BIOL CELL, V15, P506, DOI 10.1091/mbc.E03-07-0501	36	97	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8003	8011		10.1038/sj.onc.1208940	http://dx.doi.org/10.1038/sj.onc.1208940			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16170372	hybrid			2022-12-17	WOS:000233656600007
J	Yoshida, M				Yoshida, M			Discovery of HTLV-1, the first human retrovirus, its unique regulatory mechanisms, and insights into pathogenesis	ONCOGENE			English	Article						HTLV-1; transcription; tumor-suppressor genes; cell cycle; epidemiology	T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEAT; TRANSCRIPTIONAL ACTIVATION; TAX ONCOPROTEIN; PROVIRUS GENOME; GENE-EXPRESSION; PROTEIN; LYMPHOMA; TYPE-1	I briefly review the discovery and characterization of the. first human retrovirus, human T-cell leukemia virus type 1, focusing on contributions from Japanese researchers. The unique regulatory mechanisms for the viral regulation with Tax and Rex, etiology of ATL and possible leukemogenic mechanism with Tax are also discussed briefly.	Banyu Pharmaceut Co Ltd, Banyu Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan	Merck & Company	Yoshida, M (corresponding author), Banyu Pharmaceut Co Ltd, Banyu Tsukuba Res Inst, 3 Ohkubo, Tsukuba, Ibaraki 3002611, Japan.	mitsuaki_yoshida@merck.com						Barmak K, 2003, VIROLOGY, V308, P1, DOI 10.1016/S0042-6822(02)00091-0; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; GESSAIN A, 1985, LANCET, V2, P407; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HINO S, 1994, LEUKEMIA S, V1, pS68; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HINUMA Y, 1981, INT J CANCER, V15, P631; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ISOBE M, 1990, CANCER RES, V50, P6171; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KIYOKAWA T, 1984, GANN, V75, P747; KORALNIK IJ, 1992, P NATL ACAD SCI USA, V89, P8813, DOI 10.1073/pnas.89.18.8813; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; MIYOSHI I, 1980, GANN, V71, P155; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; OSAME M, 1986, LANCET, V1, P1031; POEISZ BJ, 1980, P NATL ACAD SCI USA, V77, P7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; SEIKI M, 1982, P NATL ACAD SCI-BIOL, V79, P6899, DOI 10.1073/pnas.79.22.6899; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHIMOYAMA M, 1986, P NATL ACAD SCI USA, V83, P4524, DOI 10.1073/pnas.83.12.4524; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUGIYAMA H, 1986, J MED VIROL, V20, P253, DOI 10.1002/jmv.1890200307; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Suzuki T, 2000, VIROLOGY, V270, P291, DOI 10.1006/viro.2000.0266; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TAJIMA K, 1990, INT J CANCER, V45, P237, DOI 10.1002/ijc.2910450206; TAJIMA K, 1986, HEMATOL ONCOL, V4, P31, DOI 10.1002/hon.2900040106; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TEICH N, 1985, RNA TUMOR VIRUSES, P785; UCHIYAMA T, 1985, J CLIN INVEST, V76, P446, DOI 10.1172/JCI111992; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WATANABE T, 1984, VIROLOGY, V133, P238, DOI 10.1016/0042-6822(84)90446-X; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	45	97	104	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2005	24	39					5931	5937		10.1038/sj.onc.1208981	http://dx.doi.org/10.1038/sj.onc.1208981			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155600				2022-12-17	WOS:000231623400003
J	Nagayama, S; Fukukawa, C; Katagiri, T; Okamoto, T; Aoyama, T; Oyaizu, N; Imamura, M; Toguchida, J; Nakamura, Y				Nagayama, S; Fukukawa, C; Katagiri, T; Okamoto, T; Aoyama, T; Oyaizu, N; Imamura, M; Toguchida, J; Nakamura, Y			Therapeutic potential of antibodies against FZD10, a cell-surface protein, for synovial sarcomas	ONCOGENE			English	Article						synovial sarcoma; antibody-based therapy; FZD10; ADCC; xenograft	SOFT-TISSUE SARCOMAS; FRIZZLED GENE FAMILY; EPITHELIAL TRANSFORMATION; METANEPHRIC MESENCHYME; DEVELOPING KIDNEY; CHEMOTHERAPY; DOXORUBICIN; IFOSFAMIDE; SSX; SYT	Genome-wide expression pro. ling revealed overexpression of the gene encoding frizzled homologue 10 (FZD10), a cell-surface receptor for molecules in the Wnt pathway, as a potential contributor to synovial sarcomas (SS). Northern blotting and immunohistochemical staining confirmed that expression levels of FZD10 were very high in nearly all SS tumors and cell lines examined but absent in most normal organs or in some cancers arising in other tissues. Treatment of human SS cells with small-interfering RNA ( siRNA) to FZD10 decreased the amount of its product and suppressed growth of SS cells. Moreover, a polyclonal antibody specifically recognizing the extracellular domain (ECD) of FZD10 was markedly effective in mediating ADCC against FZD10-overexpressing synovial sarcoma cells in vitro. Injection of the antibody into SS xenografts in nude mice attenuated tumor growth, and TUNEL assays revealed clusters of apoptotic cells in antibody-treated xenografts. Taken together, these findings suggest that a humanized antibody against FZD10 might be a promising treatment for patients with tumors that over-express FZD10; minimal or no adverse reactions would be expected because FZD10 protein is not abundant in vital organs.	Univ Tokyo, Mol Med Lab, Human Genome Ctr, Inst Med Sci, Tokyo 1088639, Japan; Kyoto Univ, Dept Surg & Surg Basic Sci, Grad Sch Med, Kyoto 6068507, Japan; Kyoto Univ, Inst Frontier Med Sci, Kyoto 6068507, Japan; Kyoto Univ, Dept Orthopaed Surg, Grad Sch Med, Kyoto 6068507, Japan; Univ Tokyo, Dept Lab Med, Div Pathol, Hosp Inst Med Sci, Tokyo 1088639, Japan	University of Tokyo; Kyoto University; Kyoto University; Kyoto University; University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Mol Med Lab, Human Genome Ctr, Inst Med Sci, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Katagiri, Toyomasa/I-7344-2012					Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; ANTMAN K, 1993, J CLIN ONCOL, V11, P1276, DOI 10.1200/JCO.1993.11.7.1276; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Crist WM, 2001, J CLIN ONCOL, V19, P3091, DOI 10.1200/JCO.2001.19.12.3091; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; Edmonson JH, 2002, CANCER, V94, P786, DOI 10.1002/cncr.10259; FENDLY BM, 1990, CANCER RES, V50, P1550; Ferguson WS, 2001, CANCER INVEST, V19, P292, DOI 10.1081/CNV-100102557; Frustaci S, 2001, J CLIN ONCOL, V19, P1238, DOI 10.1200/JCO.2001.19.5.1238; Kaykas A, 2004, NAT CELL BIOL, V6, P52, DOI 10.1038/ncb1081; Kirikoshi H, 2001, INT J ONCOL, V19, P767; Kispert A, 1998, DEVELOPMENT, V125, P4225; Koike J, 1999, BIOCHEM BIOPH RES CO, V262, P39, DOI 10.1006/bbrc.1999.1161; Maloney DG, 1997, BLOOD, V90, P2188; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nagayama S, 2002, CANCER RES, V62, P5859; Patel SR, 1998, AM J CLIN ONCOL-CANC, V21, P317, DOI 10.1097/00000421-199806000-00025; Sato Y, 2002, J IMMUNOL, V169, P1611, DOI 10.4049/jimmunol.169.3.1611; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Terasaki H, 2002, INT J MOL MED, V9, P107; van de Rijn M, 1999, AM J CLIN PATHOL, V112, P43; Worley BS, 2001, CANCER RES, V61, P6868; Wunder JS, 1998, J BONE JOINT SURG AM, V80A, P1020, DOI 10.2106/00004623-199807000-00011	23	97	116	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6201	6212		10.1038/sj.onc.1208780	http://dx.doi.org/10.1038/sj.onc.1208780			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16007199				2022-12-17	WOS:000231877100001
J	Chen, M; O'Connor, KL				Chen, M; O'Connor, KL			Integrin alpha 6 beta 4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells	ONCOGENE			English	Article						integrin; chemotaxis; gene transcription; nuclear factor of activated T-cells ( NFAT)	LYSOPHOSPHOLIPASE-D ACTIVITY; LYSOPHOSPHATIDIC ACID; TRANSCRIPTIONAL REGULATION; CHEMOTACTIC MIGRATION; LAMELLAE FORMATION; CANCER CELLS; INVASION; RECEPTOR; PROTEIN; KINASE	In advanced breast carcinomas, the alpha 6 beta 4 integrin is associated with a migratory and invasive phenotype. In our current study, we show that expression of the a6b4 integrin in MDA- MB- 435 breast carcinoma cells leads to increased expression of the autocrine motility factor autotaxin, as determined by Affymetrix gene chip, realtime quantitative RT-PCR and immunoblot analyses. We further demonstrate that increased autotaxin secretion from integrin a6b4 expressing cells acts to enhance chemotaxis through its ability to convert lysophosphatidylcholine (LPC) to lysophosphatidic acid (LPA) and accounts for 80% of the motogenic activity of the conditioned medium. We determine that integrin alpha 6 beta 4dependent overexpression of autotaxin in MDA- MB- 435 cells is mediated by NFAT1, but not NFAT5, through the use of siRNAs that specifically target autotaxin, integrin beta 4, NFAT1 and NFAT5. Finally, we show by electrophoretic mobility shift assays that two consensus NFAT binding sites found in the autotaxin promoter strongly and specifically bind NFAT1 from integrin a6b4 expressing cells. In summary, we find that the a6b4 integrin potentiates autotaxin expression through the upregulation and activation of NFAT1. The se observations highlight for the first time a mechanism by which NFAT transcription factors can facilitate an invasive and motile phenotype downstream of integrin a6b4 signaling.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	O'Connor, KL (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	kloconno@utmb.edu	O'Connor, Kathleen L/H-2569-2013	O'Connor, Kathleen L/0000-0002-1088-9734				Bachelder RE, 2003, CANCER RES, V63, P5230; Bachelder RE, 2002, CANCER RES, V62, P7203; Black EJ, 2004, ONCOGENE, V23, P2357, DOI 10.1038/sj.onc.1207377; Chao C, 1996, CANCER RES, V56, P4811; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; FRIEDRICHS K, 1995, CANCER RES, V55, P901; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Jones JL, 1997, EXP CELL RES, V235, P325, DOI 10.1006/excr.1997.3662; Kawagoe H, 1997, CANCER RES, V57, P2516; Li J, 2004, J BIOL CHEM, V279, P28466, DOI 10.1074/jbc.M314307200; Lipscomb EA, 2003, CLIN EXP METASTAS, V20, P569, DOI 10.1023/A:1025819521707; Mainiero F, 2003, EUR J IMMUNOL, V33, P3038, DOI 10.1002/eji.200323931; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Mukhopadhyay R, 1999, CLIN EXP METASTAS, V17, P325; Nam SW, 2001, CANCER RES, V61, P6938; Nikolopoulos SN, 2004, CANCER CELL, V6, P471, DOI 10.1016/j.ccr.2004.09.029; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Tagliabue E, 1998, CLIN CANCER RES, V4, P407; Tani T, 1997, AM J PATHOL, V151, P1289; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Yang SY, 2002, CLIN EXP METASTAS, V19, P603, DOI 10.1023/A:1020950420196; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023	33	97	104	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5125	5130		10.1038/sj.onc.1208729	http://dx.doi.org/10.1038/sj.onc.1208729			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15897878				2022-12-17	WOS:000230816900012
J	O Flowers, L; Subramaniam, PS; Johnson, HM				O Flowers, L; Subramaniam, PS; Johnson, HM			A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; SOCS-1; IL-6; STAT3; complementary peptide	EPIDERMAL-GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAYS; ANDROGEN RECEPTOR; JAK/STAT PATHWAY; GENE-EXPRESSION; CARCINOMA-CELLS; CYCLIN D1; INTERLEUKIN-6; PROGRESSION; LINES	Prostate cancer is the second highest cause of cancer-related deaths of men in the US. Signal transducers and activators of transcription ( STATs) proteins are a small family of latent cytoplasmic transcription factors that act downstream of Janus kinase ( JAK) activation and mediate intracellular signaling from a wide variety of cytokines, growth factors, and hormones. Aberrant activation of STAT3 has been implicated in the progression of many human carcinomas, including prostate cancer. Previously, we have characterized a novel tyrosine kinase inhibitor peptide, Tkip, that is a mimetic of suppressor of cytokine signaling 1 (SOCS-1). Similar to SOCS-1, Tkip binds to the autophosphorylation site of JAK2 and inhibits phosphorylation of STAT1 alpha. In this study, we determined the inhibitory effects of Tkip on the human prostate cancer cell lines DU145 and LNCaP. Tkip inhibited cellular proliferation of both DU145 and LNCaP cells, with a slightly greater antiproliferative effect on DU145 cells. Cell cycle analysis using flow cytometry showed Tkip blockage of progression into the S phase of the cell cycle. Tkip also inhibited constitutive (DU145) and IL-6-induced (LNCaP) activation of STAT3, consistent with the fact that STAT3 activation is mediated by JAK2. Tkip also slightly reduced the levels of cyclin D1, an important regulator of cell cycle progression into S phase, in DU145 and LNCaP cancer cell lines. These data describe a potentially important therapeutic that targets both constitutive and IL-6-induced STAT3 activation in human prostate cancer cell lines.	Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA; Florida Atlantic Univ, Scripps Res Inst, Biomed Sci Ctr, Boca Raton, FL 33431 USA	State University System of Florida; University of Florida; Scripps Research Institute; State University System of Florida; Florida Atlantic University	Johnson, HM (corresponding author), Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA.	johnsonh@ufl.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056152, R56AI056152] Funding Source: NIH RePORTER; NIAID NIH HHS [AI56152] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Barton BE, 2004, MOL CANCER THER, V3, P11; Becker S, 1998, FEBS LETT, V441, P141, DOI 10.1016/S0014-5793(98)01543-9; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Chen TS, 2000, CANCER RES, V60, P2132; Chim CS, 2004, BLOOD, V103, P4630, DOI 10.1182/blood-2003-06-2007; Chung TDK, 1999, PROSTATE, V38, P199; Crawford ED, 2003, UROLOGY, V62, P3, DOI 10.1016/j.urology.2003.10.013; CULIG Z, 1994, CANCER RES, V54, P5474; de la Taille A, 2001, PROSTATE CANCER P D, V4, P204, DOI 10.1038/sj.pcan.4500534; Deutsch E, 2004, LANCET ONCOL, V5, P303, DOI 10.1016/S1470-2045(04)01468-8; Dhir R, 2002, PROSTATE, V51, P241, DOI 10.1002/pros.10079; Flowers LO, 2004, J IMMUNOL, V172, P7510, DOI 10.4049/jimmunol.172.12.7510; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; Gregory CW, 2004, J BIOL CHEM, V279, P7119, DOI 10.1074/jbc.M307649200; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hobeika AC, 1998, INT J CANCER, V77, P138, DOI 10.1002/(SICI)1097-0215(19980703)77:1<138::AID-IJC21>3.0.CO;2-9; Hobisch A, 1998, CANCER RES, V58, P4640; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Larsen L, 2002, APMIS, V110, P833, DOI 10.1034/j.1600-0463.2002.1101201.x; Lorenzo Giuseppe Di, 2003, Clin Prostate Cancer, V2, P50; Mora LB, 2002, CANCER RES, V62, P6659; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Okamoto M, 1997, CANCER RES, V57, P141; Petre-Draviam CE, 2003, CANCER RES, V63, P4903; Ritchie CK, 1997, ENDOCRINOLOGY, V138, P1145, DOI 10.1210/en.138.3.1145; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sgambato A, 2004, J CELL PHYSIOL, V201, P97, DOI 10.1002/jcp.20045; Shi XB, 2004, PROSTATE, V60, P257, DOI 10.1002/pros.20039; Smith PC, 2001, CYTOKINE GROWTH F R, V12, P33, DOI 10.1016/S1359-6101(00)00021-6; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; Szente BE, 1996, J INTERF CYTOK RES, V16, P813, DOI 10.1089/jir.1996.16.813; Thiam K, 1999, J MED CHEM, V42, P3732, DOI 10.1021/jm991025f; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; Xia L, 2002, J BIOL CHEM, V277, P30716, DOI 10.1074/jbc.M202823200; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675	39	97	104	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2114	2120		10.1038/sj.onc.1208437	http://dx.doi.org/10.1038/sj.onc.1208437			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688010				2022-12-17	WOS:000227681900017
J	He, Q; Huang, Y; Sheikh, MS				He, Q; Huang, Y; Sheikh, MS			Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells	ONCOGENE			English	Article						Apo2L/TRAIL; death receptor 5; caspases; Bax; proteasome inhibitor cytochrome c; Smac	TRAIL-INDUCED APOPTOSIS; DEPLETION-INDUCED APOPTOSIS; DECOY RECEPTORS; HUMAN COLON; IN-VIVO; AGENTS; FAMILY; LIGAND; DOMAIN; MITOCHONDRIAL	Apo2L/TRAIL (tumor necrosis factor-related apoptosis inducing ligand ( TRAIL), also known as Apo2L) is a potentially important anticancer agent awaiting clinical trials. Unfortunately, however, some cancer cells exhibit resistance to Apo2L/TRAIL, which could limit the use of this potentially promising anticancer agent. Although the molecular basis of the inherent or acquired resistance to Apo2L/TRAIL remains unclear, previous studies indicate that Bax deficiency can confer resistance to Apo2L/TRAIL. Proteasome inhibition is also emerging as a promising therapeutic strategy to manage human malignancies. Here, we report that proteasome inhibitor MG132 upregulates Apo2L/TRAIL death receptor 5 expression in both Bax-proficient and -deficient HCT116 cells. MG132 effectively cooperated with Apo2L/TRAIL to induce apoptosis in both Bax-proficient and -deficient cells that was coupled with caspases-8 and -3 activation and Bid cleavage. Although both agents in combination also induced cytochrome c and Smac release from mitochondria into cytosol and activated caspase-9 in Bax-proficient cells, their effects on these events were significantly diminished in Bax-deficient cells. These results suggest that Bax is not absolutely required for death receptor 5-dependent apoptotic signals and MG132 by upregulating DR5 effectively cooperates with Apo2L/TRAIL to overcome Bax deficiency-induced resistance to Apo2L/TRAIL. Our results have important clinical implications in that the use of Apo2L/TRAIL and proteasome inhibitors in combination could prove to be a novel therapeutic strategy to manage the Apo2L/TRAIL-resistant tumors.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	sheikhm@mail.upstate.edu			NCI NIH HHS [CA89043, CA86945] Funding Source: Medline; NIDDK NIH HHS [DK062136] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA089043, R01CA086945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK062136] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Adams J, 2000, ONCOGENE, V19, P6687, DOI 10.1038/sj.onc.1204088; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Burns TF, 2001, J BIOL CHEM, V276, P37879; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; He Q, 2003, ONCOGENE, V22, P2674, DOI 10.1038/sj.onc.1206363; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; He Q, 2002, ONCOGENE, V21, P2623, DOI 10.1038/sj.onc.1205345; Huang Y, 2001, CANCER RES, V61, P6918; Korsmeyer SJ, 1999, COLD SPRING HARB SYM, V64, P343, DOI 10.1101/sqb.1999.64.343; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lenz HJ, 2003, CANCER TREAT REV, V29, P41, DOI 10.1016/S0305-7372(03)00082-3; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagane M, 2000, CANCER RES, V60, P847; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Nimmanapalli R, 2001, CANCER RES, V61, P759; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Singh A, 1998, J INTERF CYTOK RES, V18, P439, DOI 10.1089/jir.1998.18.439; Verhagen AM, 2002, APOPTOSIS, V7, P163, DOI 10.1023/A:1014318615955; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yamaguchi H, 2003, CANCER RES, V63, P1483; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	41	97	108	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2554	2558		10.1038/sj.onc.1207351	http://dx.doi.org/10.1038/sj.onc.1207351			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14691451				2022-12-17	WOS:000220558000013
J	Ohta, T; Fukuda, M				Ohta, T; Fukuda, M			Ubiquitin and breast cancer	ONCOGENE			English	Review						breast cancer; ubiquitin; RING finger	ESTROGEN-RECEPTOR-ALPHA; GROWTH-FACTOR RECEPTOR; DNA-DAMAGE RESPONSE; CELL-CYCLE; C-CBL; TUMOR-SUPPRESSOR; LIGASE ACTIVITY; PROTEIN-LIGASE; RING FINGER; DEPENDENT UBIQUITINATION	The regulation of protein stability by the ubiquitin proteasome pathway is a critical issue central to the comprehension of the molecular basis of carcinogenesis. However, ubiquitin modi. cation of target substrates signals many cellular processes other than proteolysis that are also important for the development of cancer. It is noteworthy that many proteins studied by clinical breast cancer researchers are involved in these ubiquitin pathways. This review summarizes recent works on such proteins including cyclins, CDK inhibitors, and the SCF in cell cycle control; the breast and ovarian cancer suppressor BRCA1-BARD1; ErbB2/HER2/Neu and its ubiquitin ligase c-Cbl or CHIP; and the estrogen receptor and its downstream target Efp. Understanding these pathways may provide some hints toward developing diagnostic tools and treatments for breast cancer patients.	St Marianna Univ, Sch Med, Div Breast & Endocrine Surg, Kawasaki, Kanagawa 2168511, Japan	Saint Marianna University	Ohta, T (corresponding author), St Marianna Univ, Sch Med, Div Breast & Endocrine Surg, Kawasaki, Kanagawa 2168511, Japan.	to@marianna-u.ac.jp		Ohta, Tomohiko/0000-0002-9700-7342				Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chen LC, 1998, CANCER RES, V58, P3677; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; de Melker AA, 2001, J CELL SCI, V114, P2167; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hsu LC, 2001, CANCER RES, V61, P7713; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Klapper LN, 2000, CANCER RES, V60, P3384; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lee KB, 2002, P NATL ACAD SCI USA, V99, P4239, DOI 10.1073/pnas.072068399; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li BH, 2003, BLOOD, V101, P1769, DOI 10.1182/blood-2002-05-1517; Li BH, 2002, MOL CELL BIOL, V22, P4997, DOI 10.1128/MCB.22.14.4997-5005.2002; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; MCINTOSH GG, 1995, ONCOGENE, V11, P885; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; NIRMALA PB, 1995, BIOCHEM BIOPH RES CO, V213, P24, DOI 10.1006/bbrc.1995.2093; NISHIKAWA H, 2003, IN PRESS J BIOL CHEM; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Orimo A, 1999, P NATL ACAD SCI USA, V96, P12027, DOI 10.1073/pnas.96.21.12027; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Pearce ST, 2003, J BIOL CHEM, V278, P7630, DOI 10.1074/jbc.M211129200; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Preisler-Mashek MT, 2002, AM J PHYSIOL-ENDOC M, V282, pE891, DOI 10.1152/ajpendo.00353.2001; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Sivaraman L, 2000, BREAST CANCER RES TR, V62, P185, DOI 10.1023/A:1006410111706; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Subramaniam V, 2003, BRIT J CANCER, V89, P1538, DOI 10.1038/sj.bjc.6601301; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tan P, 1997, CANCER RES, V57, P1259; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vandenberg CJ, 2003, MOL CELL, V12, P247, DOI 10.1016/S1097-2765(03)00281-8; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wang Y, 2000, GENE DEV, V14, P927; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yun JH, 2003, MOL CELL BIOL, V23, P7305, DOI 10.1128/MCB.23.20.7305-7314.2003; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	99	97	105	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2079	2088		10.1038/sj.onc.1207371	http://dx.doi.org/10.1038/sj.onc.1207371			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021895				2022-12-17	WOS:000220213400012
J	Machwe, A; Xiao, LR; Orren, DK				Machwe, A; Xiao, LR; Orren, DK			TRF2 recruits the Werner syndrome (WRN) exonuclease for processing of telomeric DNA	ONCOGENE			English	Article						telomeres; Werner syndrome; RecQ helicases; cellular senescence; aging; cancer	SYNDROME PROTEIN; MAMMALIAN TELOMERES; SYNDROME CELLS; IN-VITRO; REPLICATION; BINDING; LENGTH; CANCER; MAINTENANCE; HELICASES	The cancer-prone and premature aging disease Werner syndrome is due to loss of WRN gene function. Cells lacking WRN demonstrate genomic instability, including telomeric abnormalities and undergo premature senescence, suggesting defects in telomere metabolism. This notion is strongly supported by our finding of physical and functional interactions between WRN and TRF2, a telomeric repeat binding factor essential for proper telomeric structure. TRF2 binds to DNA substrates containing telomeric repeats and facilitates their degradation specifically by WRN exonuclease activity. WRN and TRF2 also interact directly in the absence of DNA. These results suggest that TRF2 recruits WRN for accurate processing of telomeric structures in vivo. Thus, our findings link problems in telomere maintenance to both carcinogenesis and specific features of aging.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA	University of Kentucky	Orren, DK (corresponding author), Univ Kentucky, Grad Ctr Toxicol, 326 HSRB,800 Rose St, Lexington, KY 40536 USA.	dkorre2@pop.uky.edu						Ancelin K, 2002, MOL CELL BIOL, V22, P3474, DOI 10.1128/MCB.22.10.3474-3487.2002; Bianchi A, 1999, EMBO J, V18, P5735, DOI 10.1093/emboj/18.20.5735; Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lundblad V, 2002, ONCOGENE, V21, P522, DOI 10.1038/sj.onc.1205079; Machwe A, 2002, J BIOL CHEM, V277, P4492, DOI 10.1074/jbc.M108880200; MARTIN GM, 1970, LAB INVEST, V23, P86; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Orren DK, 2002, BIOCHEMISTRY-US, V41, P13483, DOI 10.1021/bi0266986; Oshima J, 2000, BIOESSAYS, V22, P894, DOI 10.1002/1521-1878(200010)22:10<894::AID-BIES4>3.0.CO;2-B; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Schulz VP, 1996, HUM GENET, V97, P750; Shay JW, 2001, RADIAT RES, V155, P188, DOI 10.1667/0033-7587(2001)155[0188:TATIFC]2.0.CO;2; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Stansel RM, 2001, EMBO J, V20, P5532; Tahara H, 1997, ONCOGENE, V15, P1911, DOI 10.1038/sj.onc.1201377; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630	32	97	99	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					149	156		10.1038/sj.onc.1206906	http://dx.doi.org/10.1038/sj.onc.1206906			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712220				2022-12-17	WOS:000187895300016
J	Rimoldi, V; Reversi, A; Taverna, E; Rosa, P; Francolini, M; Cassoni, P; Parenti, M; Chini, B				Rimoldi, V; Reversi, A; Taverna, E; Rosa, P; Francolini, M; Cassoni, P; Parenti, M; Chini, B			Oxytocin receptor elicits different EGFR/MAPK activation patterns depending on its localization in caveolin-1 enriched domains	ONCOGENE			English	Article						caveolin; oxytocin receptor; MAPK; EGFR; p21	GROWTH-FACTOR RECEPTOR; SIGNAL-TRANSDUCTION; LIPID RAFTS; PROTEIN-KINASE; CELL-GROWTH; TYROSINE KINASE; EGF RECEPTOR; INHIBITION; PATHWAY; ENDOCYTOSIS	We have recently shown that oxytocin inhibits cell proliferation when the vast majority of oxytocin receptors are excluded from caveolin-1-enriched microdomains, and that, on the contrary, it has a mitogenic effect when the receptors are targeted to these plasma membrane domains. In this study, we investigated whether the receptors located inside and outside caveolar microdomains initiate different signalling pathways and how this may lead to opposite effects on cell proliferation. Our data indicate that, depending on their localization, oxytocin receptors transactivate EGFR and activate ERK1/2 using different signalling intermediates. The final outcome is a different temporal pattern of EGFR and ERK1/2 phosphorylation, which is more persistent when the receptors are located outside caveolar microdomains and inhibit cell growth, and very transient when they are located in caveolar microdomains and stimulate cell growth. Finally, only the activation of receptors located outside caveolar microdomains correlates with the activation of the cell cycle inhibitor p21(WAF1/CIP1), thus suggesting that the antiproliferative OTR effects may, in this case, be achieved by a sustained activation of EGFR and MAPK leading to the induction of this cell cycle regulator.	CNR, Inst Neurosci, Cellular & Mol Pharmacol Sect, I-20129 Milan, Italy; Univ Milan, Dept Pharmacol, I-20122 Milan, Italy; Univ Turin, Dept Biomed Sci & Human Oncol, I-10124 Turin, Italy; Univ Milano Bicocca, Dept Expt & Environm Med & Med Biotechnol, Monza, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Turin; University of Milano-Bicocca	Chini, B (corresponding author), CNR, Inst Neurosci, Cellular & Mol Pharmacol Sect, Via Vanvitelli 32, I-20129 Milan, Italy.	B.Chini@csfic.mi.cnr.it	Cassoni, Paola/I-8544-2018; taverna, elena/O-8180-2014; Rimoldi, Valeria/AAB-4865-2020; Taverna, Elena/AFW-4935-2022	taverna, elena/0000-0002-2430-4725; Rimoldi, Valeria/0000-0002-5598-3986; Chini, Bice/0000-0002-1686-284X; FRANCOLINI, MAURA/0000-0002-3126-1575; Rosa, Patrizia/0000-0002-2590-6955; Reversi, Alessandra/0000-0002-9934-5636				Adachi T, 2002, J CELL PHYSIOL, V192, P151, DOI 10.1002/jcp.10124; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Breton C, 2002, J CLIN ENDOCR METAB, V87, P1415, DOI 10.1210/jc.87.3.1415; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Cassoni P, 2001, ENDOCRINOLOGY, V142, P1130, DOI 10.1210/en.142.3.1130; Copland JA, 1999, ENDOCRINOLOGY, V140, P4371, DOI 10.1210/en.140.9.4371; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dessy C, 2000, EMBO J, V19, P4272, DOI 10.1093/emboj/19.16.4272; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; Florio T, 1999, MOL ENDOCRINOL, V13, P24, DOI 10.1210/me.13.1.24; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Guzzi F, 2002, ONCOGENE, V21, P1658, DOI 10.1038/sj.onc.1205219; Jakus J, 1996, ONCOGENE, V12, P2369; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Johannessen LE, 1999, BIOCHEM J, V337, P599, DOI 10.1042/0264-6021:3370599; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; MOORE JJ, 1988, ENDOCRINOLOGY, V123, P1771, DOI 10.1210/endo-123-4-1771; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Paquin J, 2002, P NATL ACAD SCI USA, V99, P9550, DOI 10.1073/pnas.152302499; PHANEUF S, 1993, J ENDOCRINOL, V136, P497, DOI 10.1677/joe.0.1360497; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sanborn BM, 2001, EXP PHYSIOL, V86, P223, DOI 10.1113/eph8602179; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Strakova Z, 1997, AM J PHYSIOL-ENDOC M, V272, pE870, DOI 10.1152/ajpendo.1997.272.5.E870; Thibonnier M, 1999, ENDOCRINOLOGY, V140, P1301, DOI 10.1210/en.140.3.1301; USHIOFUKAI M, 2001, J BIOL CHEM, V3, P3; Volmat V, 2001, BIOL CELL, V93, P71, DOI 10.1016/S0248-4900(01)01129-7; Xie W, 1997, ANTICANCER RES, V17, P2627	44	97	100	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6054	6060		10.1038/sj.onc.1206612	http://dx.doi.org/10.1038/sj.onc.1206612			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955084				2022-12-17	WOS:000185137800014
J	Mulholland, DJ; Read, JT; Rennie, PS; Cox, ME; Nelson, CC				Mulholland, DJ; Read, JT; Rennie, PS; Cox, ME; Nelson, CC			Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis	ONCOGENE			English	Article						androgen receptor; prostate cancer; coactivator; Tcf signaling; beta-catenin	TRANSCRIPTIONAL ACTIVITY; PROSTATE-CANCER; HORMONE-RECEPTORS; ACTIVATION; PROTEIN; PATHWAY; COMPLEX; GROWTH; TRANSLOCATION; COACTIVATORS	Recent reports suggest that the beta-catenin-T-cell factor (Tcf) (BCT) signaling pathway is important in the progression of prostate cancer. Evidence suggests that the androgen receptor (AR) can repress BCT-mediated transcription both in prostate cancer and colon cancer cells (Chesire and Isaacs, 2002). In this study, we validate such findings and show that repression of BCT signaling is facilitated by competition between the AR and Tcf. Measurements of the Tcf transcriptional reporter (TOPFLASH) indicated that AR+DHT-mediated repression can inhibit BCT transcription in the presence of WT and exogenous activating beta-catenin (Delta1-130bp). Transient transfections in SW480 cells (APC(mut/mut)) showed that this mode of repression is functionally independent of APC-mediated beta-catenin ubiquitination. Using a recently developed red flourescent protein (HcRed), we demonstrate novel observations about the nuclear distribution of Tcf. Furthermore, with the use of red (HeRed-AR and HcRed-Tcf) and green fusion proteins (beta-catenin-EGFP), we provide morphological evidence of a reciprocal balance of nuclear beta-catenin-EGFP (BC-EGFP). By cotransfecting in LNCaP prostate tumor cells and using quantitative imaging software, we demonstrated a 62.0% colocalization of HcRed-AR and BC-EGFP in the presence of DHT and 63.3% colocalization of HcRed-Tcf/BC-EGFP in the absence of DHT. Costaining for activated RNA Pol II (phosphoserine 2) and HcRed-Tcf suggested that Tcf foci contain transcriptional 'hotspots' validating that these sites have the capacity for transcriptional activity. Given this apparent androgen-dependent competition for nuclear BC-EGFP, we chose to assess our hypothesis by in vivo and in vitro binding assays. SW480 cells transiently transfected with an AR expression construct, treated with DHT and immunoprecipitated for Tcf showed less associated beta-catenin when compared to Tcf precipitates from untreated cells. Furthermore, by treating cells with DHT+Casodex, we were able to abrogate the androgen-sensitive AR/beta-catenin interaction, in addition to relieving transcriptional repression of the TOPFLASH reporter. In vitro binding assays, with increasing amounts of AR(S35), resulted in decreased Tcf(S35) association with immunoprecipitated recombinant beta-catenin-HIS. These data suggest that in steady-state conditions, AR has the ability to compete out Tcf binding for beta-catenin. Finally, using SW480 cells, we show that AR-mediated repression of the BCT pathway has implications for cell cycle progression and in vitro growth. Using FACs analysis, we observed a 26.1% increase in accumulation of cells in the G1 phase of the cell cycle, while in vitro growth assays showed a 35% reduction in viable cells transfected with AR+DHT treatment. Together, our data strongly suggest that a reciprocal balance of nuclear beta-catenin facilitates AR-mediated repression of BCT-driven transcription and cell growth.	Jack Bell Res, Prostate Ctr, Vancouver, BC V6H 3Z6, Canada	University of British Columbia	Mulholland, DJ (corresponding author), Jack Bell Res, Prostate Ctr, Vancouver, BC V6H 3Z6, Canada.							Barker N, 2000, ADV CANCER RES, V77, P1; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Cairns P, 1997, CANCER RES, V57, P4997; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; Catalano MG, 2000, INT J CANCER, V86, P325, DOI 10.1002/(SICI)1097-0215(20000501)86:3<325::AID-IJC4>3.0.CO;2-G; Chen RH, 2001, CANCER RES, V61, P4445; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; Davies MA, 1999, CANCER RES, V59, P2551; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Giannini AL, 2000, EXP CELL RES, V255, P207, DOI 10.1006/excr.1999.4785; GLEAVE M, 1991, CANCER RES, V51, P3753; Helmbrecht K, 2001, ENDOCRINOLOGY, V142, P5261, DOI 10.1210/en.142.12.5261; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Janne OA, 2000, BIOCHEM SOC T, V28, P401, DOI 10.1042/0300-5127:0280401; Knop M, 2002, BIOTECHNIQUES, V33, P592, DOI 10.2144/02333rr02_11819a; Knudsen KE, 1999, CANCER RES, V59, P2297; Miller LD, 2001, MOL CELL BIOL, V21, P6626, DOI 10.1128/MCB.21.19.6626-6639.2001; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/edrv-16-3-271; Rivera OJ, 2003, MOL ENDOCRINOL, V17, P128, DOI 10.1210/me.2002-0165; Saitoh M, 2002, MOL ENDOCRINOL, V16, P694, DOI 10.1210/me.16.4.694; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; Shtutman Michael, 2002, Cancer Research, V62, P5947; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Snoek R, 1996, J STEROID BIOCHEM, V59, P243, DOI 10.1016/S0960-0760(96)00116-1; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; Truica CI, 2000, CANCER RES, V60, P4709; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yeh Shuyuan, 1999, Keio Journal of Medicine, V48, P87	37	97	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5602	5613		10.1038/sj.onc.1206802	http://dx.doi.org/10.1038/sj.onc.1206802			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944908				2022-12-17	WOS:000184865900009
J	Zalcenstein, A; Stambolsky, P; Weisz, L; Muller, M; Wallach, D; Goncharov, TM; Krammer, PH; Rotter, V; Oren, M				Zalcenstein, A; Stambolsky, P; Weisz, L; Muller, M; Wallach, D; Goncharov, TM; Krammer, PH; Rotter, V; Oren, M			Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants	ONCOGENE			English	Article						p53; apoptosis; CD 95; Fas/APO-1; repression	APO-1/FAS RECEPTOR/LIGAND SYSTEM; DRUG-INDUCED APOPTOSIS; WILD-TYPE; CD95 APO-1/FAS; IONIZING-RADIATION; OF-FUNCTION; HUMAN MDR1; ACTIVATION; SUPPRESSOR; FAS	Tumor-associated mutant forms of p53 can exert an antiapoptotic gain of function activity, which probably confers a selective advantage upon tumor cells harboring such mutations. We report that mutant p53 suppresses the expression of the CD95 (Fas/APO-1) gene, encoding a death receptor implicated in a variety of apoptotic responses. Moderate (40-50%) downregulation of CD95 mRNA and surface protein expression by mutant p53 correlates with partial protection against CD95-dependent cell death. Excess mutant p53 represses the transcriptional activity of the CD95 promoter, with the extent of repression varying among different tumor-associated p53 mutants. Furthermore, mutant p53 protein binds the CD95 promoter in vitro, in a region distinct from the one implicated in tight interactions of the CD95 gene with witd-type p53. Hence, the CD95 promoter is likely to be a direct target for downregulation by mutant p53. This activity of mutant p53 may contribute to its gain of function effects in oncogenesis.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Univ Hosp, Dept Internal Med 4, D-69115 Heidelberg, Germany; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; German Canc Res Ctr, Tumor Immunol Program, D-69120 Heidelberg, Germany	Weizmann Institute of Science; Ruprecht Karls University Heidelberg; Weizmann Institute of Science; Helmholtz Association; German Cancer Research Center (DKFZ)	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, POB 26, IL-76100 Rehovot, Israel.	moshe.oren@weizmann.ac.il	Martina, Mueller-Schilling/R-4162-2016	Oren, Moshe/0000-0003-4311-7172				Albor A, 1998, CANCER RES, V58, P2091; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Boldrini L, 2001, ONCOGENE, V20, P6632, DOI 10.1038/sj.onc.1204727; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Embree-Ku M, 2002, BIOL REPROD, V66, P1456, DOI 10.1095/biolreprod66.5.1456; Fanslow W C, 1994, Semin Immunol, V6, P267, DOI 10.1006/smim.1994.1035; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kremenetskaya OS, 1997, ONCOL RES, V9, P155; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; O'Connor L, 2000, CANCER RES, V60, P1217; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Peled A, 1996, CANCER RES, V56, P2148; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Shao RG, 2001, ONCOGENE, V20, P1852, DOI 10.1038/sj.onc.1204264; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; Spence CL, 2000, METHODS MOL BIOL, V147, P25; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; STRAUSS BE, 1995, BIOCHEM BIOPH RES CO, V217, P333, DOI 10.1006/bbrc.1995.2781; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Volkmann M, 2001, J MOL MED-JMM, V79, P594, DOI 10.1007/s001090100244; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Yang XL, 1999, ONCOGENE, V18, P4546, DOI 10.1038/sj.onc.1202843; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	55	97	101	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5667	5676		10.1038/sj.onc.1206724	http://dx.doi.org/10.1038/sj.onc.1206724			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944915				2022-12-17	WOS:000184865900016
J	Xin, H; Curry, J; Johnstone, RW; Nickoloff, BJ; Choubey, D				Xin, H; Curry, J; Johnstone, RW; Nickoloff, BJ; Choubey, D			Role of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence	ONCOGENE			English	Article						interferon-inducible IFI 16; prostate; senescence; p21(WAF1); E2F; Rb	NEGATIVE REGULATOR; RETINOBLASTOMA PROTEIN; GENE; EXPRESSION; CELLS; P202; TRANSCRIPTION; IDENTIFICATION; LOCALIZATION; INHIBITION	Recent studies have implicated interferon signaling in the regulation of cellular senescence. However, the role of specific interferon-inducible proteins in cellular senescence remains to be defined. Here we report that IFI 16, an interferon-inducible transcriptional modulator from the p200-protein family, contributes to cellular senescence of prostate epithelial cells. Normal human prostate epithelial cells (PrEC) in culture expressed detectable levels of IFI 16, and the levels increased more than fourfold when cells approached cellular senescence. Consistent with a role of IFI 16 in cellular senescence, human prostate cancer cell lines either did not express IFI 16 or expressed a variant form, which was primarily detected in the cytoplasm of prostate cancer cells and not in the nucleus. Moreover, overexpression of functional IFI 16 in human prostate cancer cell lines inhibited colony formation. Additionally, ectopic expression of IFI 16 in clonal prostate cancer cell lines was associated with a senescence-like phenotype, production of senescence-associated beta-galactosidase (a biochemical marker for cellular senescence), and reduction of S-phase cells in culture. Importantly, upregulation of p21(WAF1) and inhibition of E2F-stimulated transcription accompanied inhibition of cell growth by IFI 16 in prostate cancer cell lines. Collectively, our observations support the idea that increased levels of IFI 16 in PrECs contribute to senescence-associated irreversible cell growth arrest.	Loyola Univ, Stritch Sch Med, Dept Pathol, Med Ctr, Maywood, IL 60153 USA; Loyola Univ, Stritch Sch Med, Dept Radiat Oncol, Med Ctr, Maywood, IL 60153 USA; Peter MacCallum Canc Inst, Canc Immunol Program, Trescowthick Res Labs, Melbourne, Vic 3002, Australia	Loyola University Chicago; Loyola University Chicago; Peter Maccallum Cancer Center	Choubey, D (corresponding author), Loyola Univ, Stritch Sch Med, Dept Pathol, Med Ctr, 2160 S 1st Ave,Mail Code 114B, Maywood, IL 60153 USA.	dchoube@lumc.edu	Choubey, Divaker/A-4771-2008; Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237	NATIONAL CANCER INSTITUTE [R29CA069031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG022124] Funding Source: NIH RePORTER; NCI NIH HHS [CA69031] Funding Source: Medline; NIAMS NIH HHS [AR47307] Funding Source: Medline; NIA NIH HHS [AG022124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Borden EC, 2000, SEMIN CANCER BIOL, V10, P125, DOI 10.1006/scbi.2000.0315; Briggs LJ, 2001, BIOCHEM J, V353, P69, DOI 10.1042/bj3530069; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Castro P, 2003, PROSTATE, V55, P30, DOI 10.1002/pros.10204; Certa U, 2001, BRIT J CANCER, V85, P107, DOI 10.1054/bjoc.2001.1865; Choi J, 2000, UROLOGY, V56, P160, DOI 10.1016/S0090-4295(00)00538-0; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; Choubey D, 2002, FRONT BIOSCI-LANDMRK, V7, pE252, DOI 10.2741/choubey; Choubey D, 2000, J BIOL REG HOMEOS AG, V14, P187; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; DAWSON MJ, 1995, BIOCHEM BIOPH RES CO, V214, P152, DOI 10.1006/bbrc.1995.2269; Decesse JT, 2001, ONCOGENE, V20, P962, DOI 10.1038/sj.onc.1204169; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Gariglio M, 2002, J INTERF CYTOK RES, V22, P815, DOI 10.1089/107999002320271413; Garraway LA, 2003, PROSTATE, V55, P206, DOI 10.1002/pros.10244; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gribaudo G, 1999, FEBS LETT, V456, P31, DOI 10.1016/S0014-5793(99)00916-3; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Hertel L, 2000, ONCOGENE, V19, P3598, DOI 10.1038/sj.onc.1203697; Jarrard DF, 1999, CANCER RES, V59, P2957; Johnstone RW, 1998, BIOCHEMISTRY-US, V37, P11924, DOI 10.1021/bi981069a; Johnstone RW, 2000, ONCOGENE, V19, P6033, DOI 10.1038/sj.onc.1204005; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Jonasch E, 2001, ONCOLOGIST, V6, P34, DOI 10.1634/theoncologist.6-1-34; Karlsson C, 1996, CANCER RES, V56, P241; KINGSMORE SF, 1989, EMBO J, V8, P4073, DOI 10.1002/j.1460-2075.1989.tb08591.x; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; Landolfo S, 1998, BIOCHIMIE, V80, P721, DOI 10.1016/S0300-9084(99)80025-X; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Mori Y, 2001, CANCER RES, V61, P6046; Schlaak JF, 2002, J BIOL CHEM, V277, P49428, DOI 10.1074/jbc.M205571200; SEN GC, 1992, J BIOL CHEM, V267, P5017; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Staub E, 2001, TRENDS BIOCHEM SCI, V26, P83, DOI 10.1016/S0968-0004(00)01717-5; Untergasser G, 2002, CANCER RES, V62, P6255; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wang H, 1999, GENOMICS, V60, P281, DOI 10.1006/geno.1999.5923; Webber MM, 1997, PROSTATE, V30, P58; Wei W, 2003, HISTOCHEM CELL BIOL, V119, P45, DOI 10.1007/s00418-002-0485-0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xin H, 2001, ONCOGENE, V20, P6828, DOI 10.1038/sj.onc.1204844	51	97	100	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4831	4840		10.1038/sj.onc.1206754	http://dx.doi.org/10.1038/sj.onc.1206754			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894224				2022-12-17	WOS:000184344600006
J	Kim, TY; Jong, HS; Song, SH; Dimtchev, A; Jeong, SJ; Lee, JW; Kim, TY; Kim, NK; Jung, M; Bang, YJ				Kim, TY; Jong, HS; Song, SH; Dimtchev, A; Jeong, SJ; Lee, JW; Kim, TY; Kim, NK; Jung, M; Bang, YJ			Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells	ONCOGENE			English	Article						DLC-1; methylation; histone deacetylation; gastric cancer	HISTONE DEACETYLASE INHIBITOR; DNA METHYLATION; LUNG-CANCER; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; RECEPTOR GENE; SP1 SITES; ACTIVATION; CHROMATIN; PROMOTER	DLC-1 (deleted in liver cancer) gene is frequently deleted in hepatocellular carcinoma. However, little is known about the genetic status and the expression of this gene in gastric cancer. In this study, Northern and Southern analysis showed that seven of nine human gastric cancer cell lines did not express DLC-1 mRNA, but contained the DLC-1 gene. To identify the mechanism of the loss of DLC-1 mRNA expression in these cell lines, we investigated the methylation status of DLC-1 gene by using methylation-specific PCR (MSP) and Southern blot, and found that five of seven DLC-1 nonexpressing gastric cancer cell lines were methylated in the DLC-1 CpG island. Treatment with 5-aza-2'-deoxycytidine (5-Aza-dC) induced DLC-1 mRNA expression in the gastric cancer cell lines that have the methylated alleles. Studies using SNU-601 cell line with methylated DLC-1 alleles revealed that nearly all CpG sites within DLC-1 CpG island were methylated, and that the in vitro methylation of the DLC-1 promoter region is enough to repress DLC-1 mRNA expression, regardless of the presence of transcription factors capable of inducing this gene. In all, 29 of 97 (30%) primary gastric cancers were also shown to be methylated, demonstrating that methylation of the DLC-1 CpG island is not uncommon in gastric cancer. In addition, we demonstrated that DLC-1 mRNA expression was induced, and an increase in the level of acetylated H3 and H4 was detected by the treatment with trichostatin A (TSA) in two DLC-1 nonexpressing cell lines that have the unmethylated alleles. Taken together, the results of our study suggest that the transcriptional silencing of DLC-1, by epigenetic mechanism, may be involved in gastric carcinogenesis.	Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Natl Res Lab Canc Epigenet, Canc Res Inst, Seoul 110744, South Korea; Georgetown Univ, Med Ctr, Dept Radiat Med, Washington, DC 20007 USA	Seoul National University (SNU); Seoul National University (SNU); Georgetown University	Bang, YJ (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, 28 Yongon Dong, Seoul 110744, South Korea.	bangyj@plaza.snu.ac.kr	Lee, Jung Weon/F-9149-2012; Bang, Yung Jue/J-2759-2012; Kim, Tae-You/J-2750-2012; Lee, Jung Weon/AAC-1146-2020	Bang, Yung Jue/0000-0001-6000-4597; Lee, Jung Weon/0000-0003-2722-8200; KIM, TAI YOUNG/0000-0001-8086-2476				Baffa R, 2000, CLIN CANCER RES, V6, P1372; Burgers WA, 2002, TRENDS GENET, V18, P275, DOI 10.1016/S0168-9525(02)02667-7; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; EMI M, 1992, CANCER RES, V52, P5368; Euer N, 2002, ANTICANCER RES, V22, P733; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; Geiman TM, 2002, J CELL BIOCHEM, V87, P117, DOI 10.1002/jcb.10286; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jong HS, 1999, CANCER, V86, P559, DOI 10.1002/(SICI)1097-0142(19990815)86:4<559::AID-CNCR3>3.0.CO;2-4; Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146; Kikuchi T, 2002, INT J CANCER, V97, P272, DOI 10.1002/ijc.1612; Knosel T, 2002, VIRCHOWS ARCH, V440, P187, DOI 10.1007/s004280100493; Kurimoto F, 2001, INT J MOL MED, V8, P89; MORII N, 1993, J BIOL CHEM, V268, P27160; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng IOL, 2000, CANCER RES, V60, P6581; Pannell D, 2000, EMBO J, V19, P5884, DOI 10.1093/emboj/19.21.5884; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Satoh A, 2002, BRIT J CANCER, V86, P1817, DOI 10.1038/sj.bjc.6600319; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; Sliva D, 2000, BIOCHEM BIOPH RES CO, V268, P471, DOI 10.1006/bbrc.2000.2111; Sondak VK, 2001, CANCER GENET CYTOGEN, V131, P97, DOI 10.1016/S0165-4608(01)00539-8; Song SH, 2000, INT J CANCER, V87, P236, DOI 10.1002/1097-0215(20000715)87:2<236::AID-IJC14>3.0.CO;2-M; Song SH, 2001, CANCER RES, V61, P4628; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Stirzaker C, 1997, CANCER RES, V57, P2229; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Taniura S, 2002, J BIOL CHEM, V277, P16823, DOI 10.1074/jbc.M200527200; Tsutsumi S, 2002, CANCER RES, V62, P4484; VanLint C, 1996, GENE EXPRESSION, V5, P245; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wade PA, 1998, COLD SPRING HARB SYM, V63, P435, DOI 10.1101/sqb.1998.63.435; Wistuba II, 1999, CANCER RES, V59, P1973; YAREMKO ML, 1995, GENE CHROMOSOME CANC, V13, P186, DOI 10.1002/gcc.2870130308; Yuan BZ, 1998, CANCER RES, V58, P2196; Zhang Y, 2002, J BIOL CHEM, V277, P33431, DOI 10.1074/jbc.M204417200	48	97	108	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3943	3951		10.1038/sj.onc.1206573	http://dx.doi.org/10.1038/sj.onc.1206573			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813468				2022-12-17	WOS:000183612000014
J	Zhang, F; Li, C; Halfter, H; Liu, JW				Zhang, F; Li, C; Halfter, H; Liu, JW			Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells	ONCOGENE			English	Article						oncostatin M; STAT3; cell growth; cell migration; extracellular matrix	C-MYC-GENE; INDUCED GROWTH-INHIBITION; P53 TUMOR-SUPPRESSOR; BREAST-CANCER CELLS; INTERFERON-GAMMA; TRANSDUCER; INDUCTION; TRANSCRIPTION; BINDING; DIFFERENTIATION	A number of studies have demonstrated that the STAT pathway is an important signaling cascade utilized by the IL-6 cytokine family to regulate a variety of cell functions. However, the downstream target genes of STAT activation that mediate the cytokine-induced cellular responses are largely uncharacterized. The aims of the current study are to determine whether the STAT signaling pathway is critically involved in the oncostatin M (OM)-induced growth inhibition and morphological changes of MCF-7 cells and to identify STAT3-target genes that are utilized by OM to regulate cell growth and morphology. We show that expression of a dominant negative (DN) mutant of STAT3 in MCF-7 cells completely eliminated the antiproliferative activity of OM, whereas expression of DN STAT1 had no effect. The growth inhibition of breast cancer cells was achieved through a concerted action of OM on cell cycle components. We have identified four cell cycle regulators including c-myc, cyclin D1, c/EBPdelta, and p53 as downstream effectors of the OM-activated STAT3 signaling cascade. The expression of these genes is differentially regulated by OM in MCF-7 cells, but is unaffected by OM in MCF-7-dnStat3 stable clones. We also demonstrate that the OM-induced morphological changes are correlated with increased cell motility in a STAT3-dependent manner. Expression analysis of extracellular matrix (ECM) proteins leads to the identification of fibronectin as a novel OM-regulated ECM component. Our studies further reveal that STAT3 plays a key role in the robust induction of fibronectin expression by OM in MCF-7 and T47D cells. These new findings provide a molecular basis for the mechanistic understanding of the effects of OM on cell growth and migration.	VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; Univ Munster, Dept Neurol & Internal Med A Oncol, D-4400 Munster, Germany	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Munster	Liu, JW (corresponding author), VA Palo Alto Hlth Care Syst, 154P,3801 Miranda Ave, Palo Alto, CA 94304 USA.	jingwen.liu@med.va.gov			NCI NIH HHS [1R01CA83648-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Badache A, 2001, CANCER RES, V61, P383; Bamber B, 1998, J MOL MED-JMM, V76, P61, DOI 10.1007/s109-1998-8105-3; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BROWN TJ, 1987, J IMMUNOL, V139, P2977; Carroll JS, 2002, CANCER RES, V62, P3126; Catterall JB, 2001, ARTHRITIS RHEUM-US, V44, P2296, DOI 10.1002/1529-0131(200110)44:10<2296::AID-ART392>3.0.CO;2-9; Chang TLY, 2000, J BIOL CHEM, V275, P10212, DOI 10.1074/jbc.275.14.10212; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Douglas AM, 1998, INT J CANCER, V75, P64, DOI 10.1002/(SICI)1097-0215(19980105)75:1<64::AID-IJC11>3.0.CO;2-D; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; DUNCAN MR, 1995, J INVEST DERMATOL, V104, P128, DOI 10.1111/1523-1747.ep12613623; Grant SL, 2002, ONCOGENE, V21, P460, DOI 10.1038/sj.onc.1205100; GROVE RI, 1993, P NATL ACAD SCI USA, V90, P823, DOI 10.1073/pnas.90.3.823; GROVE RI, 1991, J LIPID RES, V32, P1889; Halfter H, 2000, J NEUROCHEM, V75, P973, DOI 10.1046/j.1471-4159.2000.0750973.x; Halfter H, 1998, GROWTH FACTORS, V15, P135, DOI 10.3109/08977199809117189; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; Hutt JA, 2000, J BIOL CHEM, V275, P29123, DOI 10.1074/jbc.M004476200; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Kerr C, 1999, J INTERF CYTOK RES, V19, P1195, DOI 10.1089/107999099313145; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Li C, 2001, BREAST CANCER RES TR, V66, P111, DOI 10.1023/A:1010614724664; Li C, 2001, ONCOGENE, V20, P8193, DOI 10.1038/sj.onc.1205046; LI W, 2002, J BIOL CHEM, V1, P1; Li WQ, 2001, J IMMUNOL, V166, P3491, DOI 10.4049/jimmunol.166.5.3491; Lin JY, 2002, CANCER RES, V62, P376; Liu HF, 1999, WORLD J GASTROENTERO, V5, P15; Liu JW, 1997, CELL GROWTH DIFFER, V8, P667; LIU JW, 1992, CELL GROWTH DIFFER, V3, P307; Mahboubi K, 2002, J BIOL CHEM, V277, P8012, DOI 10.1074/jbc.M107542200; Makogonenko E, 2002, BIOCHEMISTRY-US, V41, P7907, DOI 10.1021/bi025770x; MARSTERS P, 2002, BIOCHEM J, V1, P1; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Noda A, 2000, ONCOGENE, V19, P21, DOI 10.1038/sj.onc.1203230; Rayanade RJ, 1997, J BIOL CHEM, V272, P4659, DOI 10.1074/jbc.272.8.4659; Rayanade RJ, 1998, J IMMUNOL, V161, P325; Sauter ER, 2002, CANCER RES, V62, P3200; Schaefer LK, 2000, CYTOKINE, V12, P1647, DOI 10.1006/cyto.2000.0774; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Spence MJ, 1997, CANCER RES, V57, P2223; Strand K, 2000, J CELL BIOCHEM, V79, P239, DOI 10.1002/1097-4644(20001101)79:2<239::AID-JCB70>3.0.CO;2-2; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wahl AF, 2001, ANN RHEUM DIS, V60, pIII75; Yamada T, 1997, J BIOCHEM-TOKYO, V121, P731; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337	53	97	103	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					894	905		10.1038/sj.onc.1206158	http://dx.doi.org/10.1038/sj.onc.1206158			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584569				2022-12-17	WOS:000180864300012
J	Berkovich, E; Ginsberg, D				Berkovich, E; Ginsberg, D			ATM is a target for positive regulation by E2F-1	ONCOGENE			English	Article						E2F; ATM; oncogenic stress	TRANSCRIPTION FACTOR E2F-1; GENE-PRODUCT; DNA-REPLICATION; EXPRESSION; APOPTOSIS; PHOSPHORYLATION; P53; INDUCTION; FAMILY; REPAIR	The E2F-1 transcription factor is a critical downstream target of the tumor suppressor, RB. When activated, E2F-1 induces cell proliferation. In addition, deregulation of E2F-1 constitutes an oncogenic stress that can induce apoptosis. The protein kinase ATM is a pivotal mediator of the response to another type of stress, genotoxic stress. In response to ionizing radiation, ATM activates the tumor suppressor p53, a key player in the control of cell growth and viability. We show here that E2F-1 elevates ATM promoter activity and induces an increase in ATM mRNA and protein levels. This is accompanied by an E2F-nduced increase in p53 phosphorylation. Expression of the E7 protein of HPV16, which dissociates RB/E2F complexes, also induces the elevation of ATM levels and p53 phosphorylation, implicating endogenous E2F in these phenomena. These data demonstrate that ATM is transcriptionally regulated by E2F-1 and suggest that ATM serves as a novel, ARF-independent functional link between the RB/E2F pathway and p53.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Ginsberg, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	doron.ginsberg@weizmann.ac.il		ginsberg, doron/0000-0002-1257-4920				Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Berkovich E, 2001, J BIOL CHEM, V276, P42851, DOI 10.1074/jbc.M103596200; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Byrd PJ, 1996, HUM MOL GENET, V5, P1785, DOI 10.1093/hmg/5.11.1785; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Gottifredi V, 2001, MOL CELL BIOL, V21, P1066, DOI 10.1128/MCB.21.4.1066-1076.2001; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Imai T, 1996, GENOME RES, V6, P439, DOI 10.1101/gr.6.5.439; Imai T, 1997, GENOMICS, V42, P388, DOI 10.1006/geno.1997.4769; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; Lin WC, 2001, GENE DEV, V15, P1833; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Wang Y, 2000, GENE DEV, V14, P927; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	40	97	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					161	167		10.1038/sj.onc.1206144	http://dx.doi.org/10.1038/sj.onc.1206144			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527885				2022-12-17	WOS:000180322400001
J	Greider, C; Chattopadhyay, A; Parkhurst, C; Yang, E				Greider, C; Chattopadhyay, A; Parkhurst, C; Yang, E			BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases	ONCOGENE			English	Article						BCL2; BCL-x(L); cell cycle; p27; cdk; Myc	C-MYC; S-PHASE; EXPRESSION; APOPTOSIS; P27(KIP1); TRANSCRIPTION; GENE; PROGRESSION; DEATH; INDUCTION	The anti-apoptotic molecules BCL-X-L and BCL2 delay cell cycle entry from quiescence. We used serum induction and induction of a Myc-estrogen receptor fusion protein (MycER) in quiescent fibroblasts to investigate the mechanisms underlying the cell cycle activity of BCL-X-L and BCL2. We demonstrate for the first time that BCL-x(L) and BCL2 delayed serum-induced and Myc-induced, but not E2F-induced, cell cycle entry. The cyclin-dependent kinase inhibitor p27 was elevated during serum deprivation and cell cycle entry in BCL-X-L or BCL2-expressing NIH3T3 cells and a Rat1MycER cell line. Activation of cyclin-dependent kinase 2 (cdk2) and cyclin-dependent kinase 4 (cdk4) were delayed during progression to S phase, while the induction of cyclin 131 protein, as well as the levels of cyclin E, cdk2, and cdk4 were unaltered by BCL-X-L or BCL2. Inhibition of cyclin/cdk activities in BCL-X-L or BCL2 expressing cells was associated with excess p27 in the cyclin/cdk complexes. Neither BCL-X-L nor BCL2 delayed S phase entry in cells deficient in p27, thus p27 is required for the cell cycle function of BCL-X-L and BCL2. The cell cycle effects of BCL-X-L and BCL2 were more profound in Myc-induced than in serum-induced cell cycle entry. Our results suggest that one possible mechanism by which BCL-X-L and BCL2 delay cell cycle entry may be the inhibition of Myc activity through the elevation of p27.	Vanderbilt Univ, Ctr Med, Sch Med, Dept Pediat,Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Canc Biol, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Yang, E (corresponding author), Vanderbilt Univ, Ctr Med, Sch Med, Dept Pediat,Vanderbilt Ingram Canc Ctr, 397 PRB, Nashville, TN 37232 USA.	elizabeth.yang@vanderbilt.edu		Sansam, Courtney/0000-0002-0253-8643	NATIONAL CANCER INSTITUTE [T32CA009385, R01CA078443] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA78443, T32CA09385, CA58485] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Chattopadhyay A, 2001, ONCOGENE, V20, P4507, DOI 10.1038/sj.onc.1204584; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cory S, 1999, CANCER RES, V59, p1685S; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Hengstschlager M, 1999, ONCOGENE, V18, P843, DOI 10.1038/sj.onc.1202342; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lind EF, 1999, J IMMUNOL, V162, P5374; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; MARIN MC, 1995, EXP CELL RES, V217, P240, DOI 10.1006/excr.1995.1083; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TOMODA K, 2001, J BIOL CHEM, V9, P9; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; Vairo G, 1996, ONCOGENE, V13, P1511; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245	42	97	100	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7765	7775		10.1038/sj.onc.1205928	http://dx.doi.org/10.1038/sj.onc.1205928			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420213				2022-12-17	WOS:000178946000001
J	Kawai, H; Li, HC; Chun, P; Avraham, S; Avraham, HK				Kawai, H; Li, HC; Chun, P; Avraham, S; Avraham, HK			Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells	ONCOGENE			English	Article						VEGF; BRCA1; estrogen; estrogen receptors; breast cancer cells; transcriptional regulation	MAMMARY-CARCINOMA CELLS; EXON 7-ENCODED DOMAIN; TYROSINE KINASE; FACTOR GENE; MITOGENIC STIMULATION; EXTRACELLULAR-MATRIX; CYCLE PROGRESSION; OVARIAN-CANCER; TUMOR-CELLS; ANGIOGENESIS	Mutational inactivation of BRCA1 confers increased risk for breast cancer. However, the underlying basis for the breast tissue-restricted, tumor-suppressive properties of BRCA1 remains poorly defined. Here, we show that BRCA1 and the estrogen receptor alpha (ER-alpha) modulated vascular endothelial growth factor (VEGF) gene transcription and secretion in breast cancer cells. ER-alpha interacted in vitro and in vivo with BRCA1, and this interaction was mediated by the AF-2 domain of ER-alpha and two domains of BRCA1, the amino-acid residues 1-306 and 428-683. Endogenous interaction of ER-alpha with BRCA1 was observed in normal MCF-10A breast epithelial cells and in breast cancer cells (MCF-7 and T47D), and this interaction was significantly reduced in the presence of estrogen. Furthermore, ER-alpha induced activation of VEGF gene transcription, using human VEGF promoter-luciferase reporter constructs. The AF-2 domain of ER-alpha was also shown to induce VEGF gene transcription activation similar to that obtained with the full-length ER-alpha. However, in the presence of BRCA1, VEGF gene transcription activation and VEGF protein secretion were significantly inhibited in a dose-dependent manner. The BRCA1 domain of 1-683 amino acid residues was required for this inhibition of VEGF gene transcription activation. Three mutated forms of BRCA1 (A1708E, M1775R and Y1853X), that have been identified in familial breast cancers, failed to associate with ER-alpha and to suppress VEGF promoter activity and VEGF protein secretion. Overexpression of wild-type BRCA1 in HCC-1937 breast cancer cells that lack endogenous functional BRCA1 significantly reduced VEGF secretion in these cells. These results demonstrate a novel pathogenic mechanism whereby mutations in BRCA1, via their interaction with ER-alpha, could promote tumorigenesis through the hormonal regulation of mammary epithelial cell proliferation and impaired VEGF function, which may lead to cancer growth and angiogenesis.	Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Avraham, HK (corresponding author), Beth Israel Deaconess Med Ctr, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	havraham@caregroup.harvard.edu		Avraham, Hava/0000-0002-7545-3640	NATIONAL CANCER INSTITUTE [R01CA076226, R21CA087290] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA87290, CA76226] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali SH, 2000, CANCER RES, V60, P7094; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Altucci L, 1996, ONCOGENE, V12, P2315; Bachelder RE, 2001, CANCER RES, V61, P5736; BATTEGAY EJ, 1995, J MOL MED, V73, P333; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; GARRIDO C, 1993, GROWTH FACTORS, V8, P109, DOI 10.3109/08977199309046931; Gasparini G, 1997, ENDOCR-RELAT CANCER, V4, P423, DOI 10.1677/erc.0.0040423; Grunstein J, 1999, CANCER RES, V59, P1592; GUIDI AJ, 1995, J NATL CANCER I, V87, P1237, DOI 10.1093/jnci/87.16.1237; Hilakivi-Clarke L, 2000, CANCER RES, V60, P4993; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Hyder SM, 2000, CANCER RES, V60, P3183; Jordan VC, 2001, CANCER RES, V61, P5683; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937; Kranz A, 1999, INT J CANCER, V84, P293, DOI 10.1002/(SICI)1097-0215(19990621)84:3<293::AID-IJC16>3.0.CO;2-T; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levine AC, 1998, ENDOCRINOLOGY, V139, P4672, DOI 10.1210/en.139.11.4672; LIPPMAN M, 1976, CANCER RES, V36, P4595; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; Miralem T, 2001, ONCOGENE, V20, P5511, DOI 10.1038/sj.onc.1204753; Mueller MD, 2000, P NATL ACAD SCI USA, V97, P10972, DOI 10.1073/pnas.200377097; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; OSBORNE CK, 1983, CANCER RES, V43, P3583; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Santin AD, 1999, EUR J GYNAECOL ONCOL, V20, P177; SHIBUYA M, 1990, ONCOGENE, V5, P519; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; SUTHERLAND RL, 1983, CANCER RES, V43, P3998; TAYLOR IW, 1983, CANCER RES, V43, P4007; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Tomlinson GE, 1998, CANCER RES, V58, P3237; VANDERBURG B, 1988, J CELL PHYSIOL, V134, P101, DOI 10.1002/jcp.1041340112; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Weidner Noel, 1996, P167; Yoshida A, 1996, GROWTH FACTORS, V13, P57, DOI 10.3109/08977199609034566; Yoshiji H, 1997, CANCER RES, V57, P3924; Yoshiji H, 1996, CANCER RES, V56, P2013; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	61	97	108	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2002	21	50					7730	7739		10.1038/sj.onc.1205971	http://dx.doi.org/10.1038/sj.onc.1205971			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400015	Bronze			2022-12-17	WOS:000178756200012
J	Hertel, CB; Zhou, XG; Hamilton-Dutoit, SJ; Junker, S				Hertel, CB; Zhou, XG; Hamilton-Dutoit, SJ; Junker, S			Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma	ONCOGENE			English	Article						transcription factors; B cell markers; extinction; Hodgkin lymphoma	HEAVY-CHAIN; T-CELL; GENE-TRANSCRIPTION; ACTIVATOR PROTEIN; ENHANCER ACTIVITY; 3ALPHA ENHANCER; DOWN-REGULATION; TARGET GENES; NF-HB; EXPRESSION	In classical Hodgkin lymphoma the malignant Hodgkin/Reed-Sternberg (HRS) cells characteristically constitute only a small minority of the tumour load. Their origin has been debated for decades, but on the basis of rearrangement and somatic hypermutations of their immunoglubulin (Ig) genes, HRS cells are now ascribed to the B-cell lineage. Nevertheless, phenotypically HRS cells have lost their B cell identity: they usually lack common B cell-specific surface markers such as CD19 and CD79a as well as Ig gene transcripts. Here we demonstrate that Ig promoters as well as both intronic and 3' enhancer sequences are transcriptionally inactive in HRS cell lines. This inactivity correlates with either reduced levels or even a complete lack of several B cell-specific transcription factors required for their expression: Oct-2, OBF-1, PU.1, E47/E12, PAX-5 and EBF. Moreover, we demonstrate that PU.1 and PAX-5 are significantly down-regulated in HRS cells in pathological specimens from primary tumour tissues. However, forced expression of these transcription factors can activate regulatory sequences of silenced B cell marker genes, and in one instance also transcription from a silenced endogenous locus. Thus, HRS cells are dedifferentiated B cells with global down-regulation of B cell-specific genes.	Aarhus Univ, Inst Human Genet, DK-8000 Aarhus, Denmark; Aarhus Univ, Inst Pathol, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University	Junker, S (corresponding author), Aarhus Univ, Inst Human Genet, DK-8000 Aarhus, Denmark.	sjunker@biobase.dk	Dutoit, Stephen Hamilton/E-1815-2013	Hamilton-Dutoit, Stephen/0000-0003-2158-3885				Andersen AST, 1997, MOL IMMUNOL, V34, P97, DOI 10.1016/S0161-5890(97)00017-5; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; Birshtein BK, 1997, CURR TOP MICROBIOL, V224, P73; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Chang YF, 2000, J NONDESTRUCT EVAL, V19, P1, DOI 10.1023/A:1006671706818; CHEN HM, 1995, ONCOGENE, V11, P1549; Choi JK, 1996, EMBO J, V15, P5014, DOI 10.1002/j.1460-2075.1996.tb00881.x; Cossman J, 1999, BLOOD, V94, P411, DOI 10.1182/blood.V94.2.411; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; Drexler HG., 2001, LEUKEMIA LYMPHOMA CE, P2, DOI [10.1016/B978-012221970-2/50002-4, DOI 10.1016/B978-012221970-2/50002-4]; ERNST P, 1995, IMMUNITY, V2, P427, DOI 10.1016/1074-7613(95)90024-1; Foss HD, 1999, BLOOD, V94, P3108, DOI 10.1182/blood.V94.9.3108.421a21_3108_3113; Gisler R, 2000, BLOOD, V96, P1457, DOI 10.1182/blood.V96.4.1457.h8001457_1457_1464; Gisler R, 1999, MOL IMMUNOL, V36, P1067, DOI 10.1016/S0161-5890(99)00092-9; GRANT PA, 1992, NUCLEIC ACIDS RES, V20, P4401, DOI 10.1093/nar/20.17.4401; Horcher M, 2001, IMMUNITY, V14, P779, DOI 10.1016/S1074-7613(01)00153-4; Hsu PL, 1996, LAB INVEST, V74, P395; Jaffe ES, 2001, WHO CLASSIFICATION T; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Junker S, 1997, J CELL SCI, V110, P2579; JUNKER S, 1990, CELL, V61, P467, DOI 10.1016/0092-8674(90)90528-M; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; Krenacs L, 1998, BLOOD, V92, P1308, DOI 10.1182/blood.V92.4.1308.416k32_1308_1316; Kuppers R, 1998, ANNU REV IMMUNOL, V16, P471, DOI 10.1146/annurev.immunol.16.1.471; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; LIEBERMAN TA, 1991, HORMONAL CONTROL REG, P399; Maitra S, 2000, MOL CELL BIOL, V20, P1911, DOI 10.1128/MCB.20.6.1911-1922.2000; Marafioti T, 2000, BLOOD, V95, P1443, DOI 10.1182/blood.V95.4.1443.004k55_1443_1450; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; NEURATH MF, 1994, J IMMUNOL, V153, P730; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; O'Riordan M, 1999, IMMUNITY, V11, P21, DOI 10.1016/S1074-7613(00)80078-3; Odelberg SJ, 2000, CELL, V103, P1099, DOI 10.1016/S0092-8674(00)00212-9; Pettersson S, 1997, IMMUNOBIOLOGY, V198, P236, DOI 10.1016/S0171-2985(97)80044-7; Re D, 2001, CANCER RES, V61, P2080; Rothenberg EV, 2000, CURR OPIN GENET DEV, V10, P370, DOI 10.1016/S0959-437X(00)00098-8; Rudiger T, 1998, AM J SURG PATHOL, V22, P1184, DOI 10.1097/00000478-199810000-00003; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schubart K, 2001, NAT IMMUNOL, V2, P69, DOI 10.1038/83190; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Singh H, 1996, CURR OPIN IMMUNOL, V8, P160, DOI 10.1016/S0952-7915(96)80053-7; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; Stein H, 2001, BLOOD, V97, P496, DOI 10.1182/blood.V97.2.496; STEISHEN CP, 1945, MOL CELL BIOL, P15; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Sun L, 1999, CLIN CANCER RES, V5, P2112; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Theil J, 2001, BLOOD, V97, P3191, DOI 10.1182/blood.V97.10.3191; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Wallin JJ, 1998, SCIENCE, V279, P1961, DOI 10.1126/science.279.5358.1961; Watanabe K, 2000, HISTOPATHOLOGY, V36, P353; WESTON K, 1988, VIROLOGY, V162, P406, DOI 10.1016/0042-6822(88)90481-3	60	97	105	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2002	21	32					4908	4920		10.1038/sj.onc.1205629	http://dx.doi.org/10.1038/sj.onc.1205629			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118370				2022-12-17	WOS:000176874800006
J	Calvo, KR; Sykes, DB; Pasillas, MP; Kamps, MP				Calvo, KR; Sykes, DB; Pasillas, MP; Kamps, MP			Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1	ONCOGENE			English	Article						Hoxa9; Nup98-HoxA9; Meis1; leukaemia; AML	NUP98/HOXA9 FUSION TRANSCRIPT; CHRONIC MYELOGENOUS LEUKEMIA; HOMEOBOX GENE; DNA-BINDING; NUP98 GENE; T(7-11)(P15-P15); PROTEINS; CELLS; TRANSLOCATION; MICE	The association between acute myeloid leukaemia (AML) and the aberrant expression of Hoxa9 is evidenced by (1) proviral activation of Hoxa9 and Meis1 in BXH-2 murine AML, (2) formation of the chimeric Nup98-HoxA9 transactivator protein as a consequence of the t(7;11) translocation in human AML, and (3) the strong expression of HoxA9 and Meis1 in human AML. In mouse models, enforced retroviral expression of Hoxa9 alone in marrow is not sufficient to cause rapid AML, while co-expression of Meis1 and Hoxa9 induces rapid AML. In contrast, retroviral expression of Nup98-HoxA9 is sufficient to cause rapid AML in the absence of enforced Meis1 expression. Previously, we demonstrated that Hoxa9 could block the differentiation of murine marrow progenitors cultured in granulocyte-macrophage colony-simulating factor (GM-CSF). These progenitors lacked Meis1 expression, could not proliferate in stem cell factor (SCF), but could differentiate into neutrophils when switched into granulocyte colony-simulating factor (G-CSF). Ectopic expression of Meis1 in these Hoxa9 cells suppressed their G-CSF-induced differentiation, permitted proliferation in SCF, and therein offered a potential explanation of cooperative function. Because Meis1 binds N-terminal Hoxa9 sequences that are replaced by Nup98, we hypothesized that Nup98-HoxA9 might consolidate the biochemical functions of both Hoxa9 and MOO on target gene promoters and might evoke their same lymphokine-responsive profile in immortalized progenitors. Here we report that Nup98-HoxA9, indeed mimicks Hoxa9 plus Meis1 coexpression - it immortalizes myeloid progenitors, prevents differentiation in response to GM-CSF, IL-3, G-CSF, and permits proliferation in SCF. Unexpectedly, however, Nup98-Hoxa9 also enforced strong transcription of the cellular Hoxa9, Hoxa7 and Meis1 genes at levels similar to those found in mouse AML's generated by proviral activation of Hoxa9 and Meis1. Using Hoxa9(-/-) marrow, we demonstrate that expression of Hoxa9 is not required for myeloid immortalization by Nup98-HoxA9. Rapid leukaemogenesis by Nup98-HoxA9 may therefore result from both the intrinsic functions of Nup98-HoxA9, as well as of those of coexpressed HOX and MEIS1 genes.	Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Kamps, MP (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Calvo, Katherine/A-8109-2009	Calvo, Katherine/0000-0002-0771-4191	NATIONAL CANCER INSTITUTE [R01CA056876, P30CA023100, T32CA077109] Funding Source: NIH RePORTER; NCI NIH HHS [CA56876, CA77109-01, 5P0CA23100-16] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahuja HG, 2001, GENE CHROMOSOME CANC, V30, P410, DOI 10.1002/1098-2264(2001)9999:9999<::AID-GCC1108>3.0.CO;2-9; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Calvo KR, 2001, P NATL ACAD SCI USA, V98, P13120, DOI 10.1073/pnas.231115398; Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; Ferretti E, 2000, DEVELOPMENT, V127, P155; Fujino T, 2002, BLOOD, V99, P1428, DOI 10.1182/blood.V99.4.1428; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hatano Y, 1999, BRIT J HAEMATOL, V107, P600, DOI 10.1046/j.1365-2141.1999.01754.x; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Kawagoe H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/sj.leu.2401410; Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; Lawrence HJ, 1997, BLOOD, V89, P1922, DOI 10.1182/blood.V89.6.1922; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 1999, BLOOD, V94, P741, DOI 10.1182/blood.V94.2.741.414k04_741_747; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Nishiyama M, 1999, GENE CHROMOSOME CANC, V26, P215, DOI 10.1002/(SICI)1098-2264(199911)26:3<215::AID-GCC5>3.3.CO;2-T; Raza-Egilmez SZ, 1998, CANCER RES, V58, P4269; Rozovskaia T, 2001, ONCOGENE, V20, P874, DOI 10.1038/sj.onc.1204174; Schnabel CA, 2000, ONCOGENE, V19, P608, DOI 10.1038/sj.onc.1203371; Shanmugam K, 1999, MOL CELL BIOL, V19, P7577; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; Yamamoto K, 2000, BRIT J HAEMATOL, V109, P423, DOI 10.1046/j.1365-2141.2000.02003.x	28	97	104	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4247	4256		10.1038/sj.onc.1205516	http://dx.doi.org/10.1038/sj.onc.1205516			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082612				2022-12-17	WOS:000176174200007
J	Girard, PM; Riballo, E; Begg, AC; Waugh, A; Jeggo, PA				Girard, PM; Riballo, E; Begg, AC; Waugh, A; Jeggo, PA			Nbs1 promotes ATM dependent phosphorylation events including those required for G1/S arrest	ONCOGENE			English	Article						NBS; ATM; cell cycle checkpoint; ionizing radiation; kinase activity	NIJMEGEN-BREAKAGE-SYNDROME; ATAXIA-TELANGIECTASIA PATIENTS; LYMPHOBLASTOID CELL-LINES; REPLICATION PROTEIN-A; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; S-PHASE CHECKPOINT; IONIZING-RADIATION; HISTONE H2AX; REPAIR	Cell lines from Nijmegen Breakage Syndrome (NBS) and ataxia telangiectasia (A-T) patients show defective S phase checkpoint arrest. In contrast, only A-T but not NBS cells are significantly defective in radiation-induced G1/S arrest. Phosphorylation of some ATM substrates has been shown to occur in NBS cells. It has, therefore, been concluded that Nbs1 checkpoint function is S phase specific. Here, we have compared NBS with A-T cell lines (AT-5762ins137) that express a low level of normal ATM protein to evaluate the impact of residual Nbs1 function in NBS cells. The radiation-induced cell cycle response of these NBS and 'leaky' A-T cells is almost identical; normal G2/M arrest after 2 Gy, intermediate GI/S arrest depending on the dose and an A-T-like S phase checkpoint defect. Thus, the checkpoint assays differ in their sensitivity to low ATM activity. Radiation-induced phosphorylation of the ATM-dependent substrates Chk2, RPAp34 and p53-Sert5 are similarly impaired in AT-5762ins137 and NBS cells in a dose dependent manner. In contrast, NBS cells show normal ability to activate ATM kinase following irradiation in vitro and in vivo. We propose that Nbs1 facilitates ATM-dependent phosphorylation of multiple downstream substrates, including those required for GI/S arrest.	Univ Sussex, MRC, Cell Mutat Unit, Brighton BN1 9RR, E Sussex, England; Netherlands Canc Inst Antoni Van Leeuvenhoekhuis, Dept Expt Therapy, NL-1066 CX Amsterdam, Netherlands	University of Sussex; Netherlands Cancer Institute	Jeggo, PA (corresponding author), Univ Sussex, MRC, Cell Mutat Unit, Brighton BN1 9RR, E Sussex, England.	p.a.jeggo@sussex.ac.uk						Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Antoccia A, 1997, INT J RADIAT BIOL, V71, P41, DOI 10.1080/095530097144409; Antoccia A, 1999, INT J RADIAT BIOL, V75, P583; ARLETT CF, 1988, INT J RADIAT BIOL, V54, P911, DOI 10.1080/09553008814552321; Badie C, 1997, CANCER RES, V57, P4600; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BEGG AC, 1988, RADIOTHER ONCOL, V11, P337, DOI 10.1016/0167-8140(88)90205-8; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Featherstone C, 1998, CURR BIOL, V8, pR622, DOI 10.1016/S0960-9822(98)70392-6; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Girard PM, 2000, CANCER RES, V60, P4881; Grenon M, 2001, NAT CELL BIOL, V3, P844, DOI 10.1038/ncb0901-844; JASPERS NG, 1985, KROC F SERIES, P147; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; Lakin ND, 1996, ONCOGENE, V13, P2707; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; Matsuura K, 1998, BIOCHEM BIOPH RES CO, V242, P602, DOI 10.1006/bbrc.1997.7924; McConville CM, 1996, AM J HUM GENET, V59, P320; Modesti M, 2001, CURR BIOL, V11, pR229, DOI 10.1016/S0960-9822(01)00112-9; Morgan SE, 1997, CANCER RES, V57, P3386; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCOTT D, 1994, INT J RADIAT BIOL, V66, pS157, DOI 10.1080/09553009414551991; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stewart GS, 2001, J BIOL CHEM, V276, P30133, DOI 10.1074/jbc.M103160200; TAALMAN RDFM, 1989, AM J MED GENET, V32, P425, DOI 10.1002/ajmg.1320320332; Taylor A. M. R., 1996, P138; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Wegner RD, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P324; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Yamazaki V, 1998, CANCER RES, V58, P2316; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	44	97	102	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4191	4199		10.1038/sj.onc.1205596	http://dx.doi.org/10.1038/sj.onc.1205596			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082606				2022-12-17	WOS:000176174200001
J	Thornborrow, EC; Patel, S; Mastropietro, AE; Schwartzfarb, EM; Manfredi, JJ				Thornborrow, EC; Patel, S; Mastropietro, AE; Schwartzfarb, EM; Manfredi, JJ			A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes	ONCOGENE			English	Article						bax; p53; transcription; DNA-binding	TUMOR-SUPPRESSOR P53; CYTOCHROME-C; CELL-DEATH; IN-VIVO; BINDING-SITE; APOPTOSIS; SEQUENCE; PROMOTER; PROTEIN; OVEREXPRESSION	Both the human and the mouse bax promoters contain p53 binding sites which are sufficient to confer p53-dependent transcriptional activation in a heterologous setting. Nevertheless in the context of the bax promoter, these sites do not mediate a p53-dependent response, suggesting that bax may not be a direct transcriptional target of p53. Here, data are presented identifying a conserved p53 response element in the first intron of both the human and the murine bax genes. This element both in isolation and in the context of the first intron conferred p53-dependent transcriptional activation upon a minimal promoter. Electrophoretic mobility shift assays demonstrated that this sequence also is capable of mediating sequence specific binding to p53. p53 effectively activated transcription through both human and murine bax gene reporter constructs, whereas deletion of the intronic response element abrogated the p53-responsiveness of both reporters. Interestingly, tumor-derived mutants of p53 which are defective in inducing an apoptotic response retain the ability to activate transcription via the bax intronic p53 site. Since these mutants are transcriptionally inactive on the p53 site in the bax promoter, the ability of these mutants to up-regulating endogenous bax mRNA levels supports a role for the intronic element in p53-dependent up-regulation of bax expression. Taken together, these results show the requirement for a novel intronic element in the p53-dependent transcriptional activation of bax, and demonstrate that bax is indeed a direct and evolutionarily conserved transcriptional target of p53.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Manfredi, JJ (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130, New York, NY 10029 USA.				NATIONAL CANCER INSTITUTE [R29CA069161] Funding Source: NIH RePORTER; NCI NIH HHS [CA 69161] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Igata E, 1999, GENE, V238, P407, DOI 10.1016/S0378-1119(99)00348-0; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kim CN, 1997, CANCER RES, V57, P3115; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Schmidt T, 1999, CELL DEATH DIFFER, V6, P873, DOI 10.1038/sj.cdd.4400562; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	29	97	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					990	999		10.1038/sj.onc.1205069	http://dx.doi.org/10.1038/sj.onc.1205069			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850816				2022-12-17	WOS:000173580100002
J	Selaru, FM; Zou, T; Xu, Y; Shustova, V; Yin, J; Mori, Y; Sato, F; Wang, S; Olaru, A; Shibata, D; Greenwald, BD; Krasna, MJ; Abraham, JM; Meltzer, SJ				Selaru, FM; Zou, T; Xu, Y; Shustova, V; Yin, J; Mori, Y; Sato, F; Wang, S; Olaru, A; Shibata, D; Greenwald, BD; Krasna, MJ; Abraham, JM; Meltzer, SJ			Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarrays	ONCOGENE			English	Article						esophaegeal cancer; Barrett's esophagus; cDNA microassays; bioinformatics; cancer diagnosis	TRANSCRIPTIONAL PROGRAM; PATTERNS; TUMORS; YEAST	In order to identify and contrast global gene expression profiles defining the premalignant syndrome, Barrett's esophagus, as well as frank esophageal cancer, we utilized cDNA microarray technology in conjunction with bioinformatics tools. We hybridized microarrays, each containing 8000 cDNA clones, to RNAs extracted from 13 esophageal surgical or endoscopic biopsy specimens (seven Barrett's metaplasias and six esophageal carcinomas). Hierarchical cluster analysis was performed on these results and displayed using a color-coded graphic representation (Treeview). The esophageal samples clustered naturally into two principal groups, each possessing unique global gene expression profiles. After retrieving histologic reports for these tissues, we found that one main cluster contained all seven Barrett's samples, while the remaining principal cluster comprised the six esophageal cancers. The cancers also clustered according to histopathological subtype. Thus, squamous cell carcinomas (SCCAs) constituted one group, adenocarcinomas (ADCAs) clustered separately, and one signet-ring carcinoma was in its own cluster, distinct from the ADCA cluster. We conclude that cDNA microarrays and bioinformatics show promise in the classification of esophageal malignant and premalignant diseases, and that these methods can be applied to small biopsy samples.	Univ Maryland, Sch Med, Baltimore VA Hosp,Greenebaum Canc Ctr, Div Gastroenterol,Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med,Baltimore VA Hosp, Greenebaum Canc Ctr, Div Surg Oncol,Dept Surg, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Meltzer, SJ (corresponding author), Univ Maryland, Room N3W62,22 S Greene St, Baltimore, MD 21201 USA.			Selaru, Florin/0000-0001-7990-8238	NCI NIH HHS [CA77057, CA95323, CA85069] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095323, U01CA085069, R01CA077057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alizadeh A, 1998, J CLIN IMMUNOL, V18, P373, DOI 10.1023/A:1023293621057; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bassett DE, 1999, NAT GENET, V21, P51, DOI 10.1038/4478; Blot WJ, 1999, SEMIN ONCOL, V26, P2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Chu S, 1998, SCIENCE, V282, P1421; Daly JM, 2000, J AM COLL SURGEONS, V190, P562, DOI 10.1016/S1072-7515(00)00238-6; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Elek J, 2000, IN VIVO, V14, P173; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; PARKER EF, 1952, ANN SURG, V135, P697, DOI 10.1097/00000658-195205000-00013; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ransford RAJ, 2000, ACTA GASTRO-ENT BELG, V63, P18; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9	21	97	99	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					475	478		10.1038/sj.onc.1205111	http://dx.doi.org/10.1038/sj.onc.1205111			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821959				2022-12-17	WOS:000173311200015
J	Li, Q; Qi, B; Oka, K; Shimakage, M; Yoshioka, N; Inoue, H; Hakura, A; Kodama, K; Stanbridge, EJ; Yutsudo, M				Li, Q; Qi, B; Oka, K; Shimakage, M; Yoshioka, N; Inoue, H; Hakura, A; Kodama, K; Stanbridge, EJ; Yutsudo, M			Link of a new type of apoptosis-inducing gene ASY/Nogo-B to human cancer	ONCOGENE			English	Article						ASY; Nogo-B; apoptosis; cancer; endoplasmic reticulum	NEURITE OUTGROWTH; EXPRESSION; INHIBITOR; IDENTIFICATION; TRANSFORMATION; TRANSCRIPTS; CLONING; KINASE; GROWTH; DEATH	Although apoptosis plays an essential role in the embryogenesis and homeostasis of multicellular organisms, this mechanism has not yet been fully clarified. We isolated a novel human apoptosis-inducing gene, ASY, which encodes an endoplasmic reticulum-targeting protein without any known apoptosis-related motifs, This gene is identical to the Nogo-B, a splice variant of the Nogo-A which has recently been shown to be an inhibitor of neuronal regeneration in the central nervous system, Ectopic expression of the ASY gene led to extensive apoptosis, particularly in cancer cells. Furthermore, transcription of the ASY gene was suppressed in small cell lung cancer. These results suggest that a new type of apoptosis-inducing gene, namely, ASY, may be involved in the development of certain types of cancer.	Osaka Univ, Microbial Dis Res Inst, Dept Tumor Virol, Suita, Osaka 5650871, Japan; Wuhan Univ, Sch Life Sci, Virus Inst, Wuhan 430072, Hubei, Peoples R China; Osaka Natl Hosp, Clin Res Inst, Osaka 5400006, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Dept Thorac Surg, Osaka 5378511, Japan; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	Osaka University; Wuhan University; Osaka National Hospital; Osaka Medical Center for Cancer & Cardiovascular Diseases; University of California System; University of California Irvine	Yutsudo, M (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Tumor Virol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yutsudo@biken.osaka-u.ac.jp						Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BANERJEE A, 1992, CANCER RES, V52, P6297; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Oka K, 1999, GENE CHROMOSOME CANC, V26, P47, DOI 10.1002/(SICI)1098-2264(199909)26:1<47::AID-GCC7>3.0.CO;2-8; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; ROEBROEK AJM, 1993, J BIOL CHEM, V268, P13439; ROEBROEK AJM, 1989, CANCER RES, V49, P4154; Shimakage M, 1997, HUM PATHOL, V28, P1415, DOI 10.1016/S0046-8177(97)90232-X; STANBRIDGE EJ, 1982, SCIENCE, V215, P252, DOI 10.1126/science.7053574; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	28	97	113	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					3929	3936		10.1038/sj.onc.1204536	http://dx.doi.org/10.1038/sj.onc.1204536			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494121				2022-12-17	WOS:000169681500001
J	Nozaki, S; Sledge, GW; Nakshatri, H				Nozaki, S; Sledge, GW; Nakshatri, H			Repression of GADD153/CHOP by NF-kappa B: a possible cellular defense against endoplasmic reticulum stress-induced cell death	ONCOGENE			English	Article						NF-kappa B; GADD153/CHOP; apoptosis; transcription repression; endoplasmic reticulum stress	HUMAN BREAST-CANCER; DAMAGE-INDUCIBLE GENES; INDUCED APOPTOSIS; MESSENGER-RNA; C/EBP-BETA; GROWTH ARREST; MAMMARY-GLAND; BINDING-SITE; DNA-BINDING; NUDE-MICE	Exposure of mammalian cells to ultraviolet light, nutrient deprived culture media, hypoxia, environmental toxicants such as methyl mercury, methyl methanesulfonate, crocodilite asbestos or the agents that disrupt the function of endoplasmic reticulum (ER) leads to activation of the pro-apoptotic transcription factor GADD153/CHOP. Paradoxically, several of these agents also induce the anti-apoptotic transcription factor NF-kappaB. In this report, we demonstrate that NF-kappaB inhibits GADD153 activation in breast cancer cells exposed to nutrient deprived media, tunicamycin (which blocks protein folding in ER) or calcium ionopore (which depletes calcium stores in ER), Basal and calcium ionopore-induced GADD153 expression was more pronounced in fibroblasts obtained from mouse embryos lacking in p65 subunit of NF-kappaB compared to fibroblasts from wild type Littermate embryos. Moreover, p65-/-fibroblasts were killed more efficiently by calcium ionopore and tunicamycin but not hydrogen peroxide compared to wild type fibroblasts, We also show that parthenolide, a NF-kappaB inhibitor, sensitizes breast cancer tells to tunicamycin, Transient transfection assay revealed that the p65 subunit but not the p50 subunit of NF-kappaB represses GADD153 promoter activity, These results establish a correlation between repression of proapoptotic genes by NF-kappaB and increased cell survival during ER stress as well as identify a distinct NF-kappaB regulated cell survival pathway.	Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pathol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Nakshatri, H (corresponding author), Indiana Canc Res Inst, R4-202,1044 W Walnut St, Indianapolis, IN 46202 USA.			Nakshatri, Harikrishna/0000-0001-8876-0052				Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARTEK J, 1990, ONCOGENE, V5, P893; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Brickman JM, 1999, P NATL ACAD SCI USA, V96, P10679, DOI 10.1073/pnas.96.19.10679; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; CORNETTA K, 1994, CLIN EXP METASTAS, V12, P3, DOI 10.1007/BF01784328; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gately DP, 1996, J BIOL CHEM, V271, P20588, DOI 10.1074/jbc.271.34.20588; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Huang JD, 1995, GENE DEV, V9, P3177, DOI 10.1101/gad.9.24.3177; Huang QH, 1999, BIOCHEM J, V341, P225, DOI 10.1042/0264-6021:3410225; Johnson NF, 1997, ENVIRON HEALTH PERSP, V105, P913, DOI 10.2307/3433303; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kim R, 1999, ANTICANCER RES, V19, P1779; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LESOONWOOD LA, 1995, HUM GENE THER, V6, P395, DOI 10.1089/hum.1995.6.4-395; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; Los G, 1999, CLIN CANCER RES, V5, P1610; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; Ou YC, 1997, TOXICOL APPL PHARM, V147, P31, DOI 10.1006/taap.1997.8235; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Ravi R, 1998, CANCER RES, V58, P4531; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Schmitt-Ney M, 2000, J BIOL CHEM, V275, P40839, DOI 10.1074/jbc.M007440200; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; Summerton J, 1999, BBA-GENE STRUCT EXPR, V1489, P141, DOI 10.1016/S0167-4781(99)00150-5; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; Valentine SA, 1998, MOL CELL BIOL, V18, P6584, DOI 10.1128/MCB.18.11.6584; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	57	97	108	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2178	2185		10.1038/sj.onc.1204292	http://dx.doi.org/10.1038/sj.onc.1204292			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360202				2022-12-17	WOS:000168116700013
J	Zwerner, JP; May, WA				Zwerner, JP; May, WA			PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors	ONCOGENE			English	Article						Ewing's sarcoma; Ewing family tumors; PDGF-C; EWS/FLI	FUSION GENE; SARCOMA TRANSLOCATION; TRANSCRIPTION FACTOR; EXPRESSION CLONING; EWS GENE; CELLS; ONCOGENE; RECEPTOR; PROTEIN; BINDING	The aberrant transcription factors associated with many human malignancies function by deregulation of tumorigenic pathways, However, identification of these pathways has come slowly . Virtually all cases of Ewing's Sa;coma and peripheral Primitive, Neuroectodermal Tumor (PNET) are associated with aberrant transcription factors which fuse amino-terminal EWS with the DNA binding moiety of an ETS transcription factor (FLI-1 in 90% of cases), Attempts to identify the downstream targets of these chimeras in the Ewing Family Tumors (EFT) on the basis of differential gene regulation have produced little association with tumor biology, As an alternative approach, we have used highly efficient retroviral systems to biologically screen cDNA derived from cells transformed by EWS/FLI-1. We have identified the recently described PDGF-C as target of EWS/ETS transcriptional deregulation, This transcriptional deregulation is specific to EWS/FLI, PDGF-C possesses substantial biologic activity in vitro and in vivo. It is expressed in EFT cell lines and in primary tumors, Within these EFT cell lines, PDGF-C expression is dependent upon EWS/FLI activity. These results suggest that PDGF-C may be a significant mediator of EWS/FLI driven oncogenesis.	Univ Alabama, Dept Pediat, Birmingham, AL 35294 USA; Univ Alabama, Ctr Comprehens Canc, Birmingham, AL USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	May, WA (corresponding author), Univ Alabama, Dept Pediat, Birmingham, AL 35294 USA.				NATIONAL CANCER INSTITUTE [R01CA090666] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA090666] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Ding H, 2000, MECH DEVELOP, V96, P209, DOI 10.1016/S0925-4773(00)00425-1; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heldin Carl-Henrik, 1991, Critical Reviews in Oncogenesis, V2, P109; HELDIN CH, 1992, KIDNEY INT, V41, P571, DOI 10.1038/ki.1992.84; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Im YH, 2000, CANCER RES, V60, P1536; JEON IS, 1995, ONCOGENE, V10, P1229; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kristiansen M, 1999, J BIOL CHEM, V274, P20540, DOI 10.1074/jbc.274.29.20540; Lawlor ER, 1998, CANCER RES, V58, P2469; LESSNICK SL, 1995, ONCOGENE, V10, P423; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; May WA, 1997, CURR TOP MICROBIOL, V220, P143; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; Thompson AD, 1996, ONCOGENE, V13, P2649; Vogt PK, 1999, CELL GROWTH DIFFER, V10, P777; Vukmirovic OG, 2000, NATURE, V405, P820, DOI 10.1038/35015690; Welford SM, 1998, NUCLEIC ACIDS RES, V26, P3059, DOI 10.1093/nar/26.12.3059; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	40	97	105	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					626	633		10.1038/sj.onc.1204133	http://dx.doi.org/10.1038/sj.onc.1204133			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313995	Green Accepted			2022-12-17	WOS:000166755000010
J	Fleisher, AS; Esteller, M; Tamura, G; Rashid, A; Stine, OC; Yin, J; Zou, TT; Abraham, JM; Kong, DH; Nishizuka, S; James, SP; Wilson, KT; Herman, JG; Meltzer, SJ				Fleisher, AS; Esteller, M; Tamura, G; Rashid, A; Stine, OC; Yin, J; Zou, TT; Abraham, JM; Kong, DH; Nishizuka, S; James, SP; Wilson, KT; Herman, JG; Meltzer, SJ			Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia	ONCOGENE			English	Article						hypermethylation; hMLH1; microsatellite instability; mismatch repair; gastric cancer; gastric neoplasia	HELICOBACTER-PYLORI INFECTION; REPLICATION ERROR PHENOTYPE; DIFFERENTIATED TYPE; CANCER; METHYLATION; EXPRESSION; CARCINOMA; DNA; TUMORS; INACTIVATION	A significant portion of gastric cancers exhibit defective DNA mismatch repair, manifested as microsatellite instability (MSI). High-frequency MSI (MSI-H) is associated with hypermethylation of the human mut-L homologue 1 (hMLH1) mismatch repair gene promoter and diminished hMLH1 expression in advanced gastric cancers, However, the relationship between MSI and hMLH1 hypermethylation has not been studied in early gastric neoplasms, We therefore investigated hMLH1 hypermethylation, hMLH1 expression and MSI in a group of early gastric cancers and gastric adenomas, Sixty-four early gastric neoplasms mere evaluated, comprising 28 adenomas, 18 mucosal carcinomas, and 18 carcinomas with superficial submucosal invasion but clear margins, MSI was evaluated using multiplex fluorescent PCR to amplify loci D2S123, D5S346, D17S250, BAT 25 and BAT 26, Methylation-specific PCR was performed to determine the methylation status of hMLH1. In two hypermethylated MSI-H cancers, hMLH1 protein expression was also evaluated by immunohistochemistry. Six of sixty-four early gastric lesions were MSI-H, comprising 1 adenoma, 4 mucosal carcinomas, and 1 carcinoma with superficial submucosal invasion, Two lesions tone adenoma and one mucosal carcinoma) demonstrated low-frequency MSI (MSI-L), The remaining 56 neoplasms were MSI-stable (MSI-S), Six of six MSI-H, one of two MSI-L, and none of thirty MSI-S lesions showed hMLH1 hypermethylation (P < 0.001), Diminished hMLH1 protein expression was demonstrated by immunohistochemistry in two of two MSI-H hypermethylated lesions, hMLH1 promoter hypermethylation is significantly associated with MSI and diminished hMLH1 expression in early gastric neoplasms, MSI and hypermethylation-associated inactivation of hMLH1 are more prevalent in early gastric cancers than in gastric adenomas, Thus, hypermethylation-associated inactivation of the hMLH1 gene can occur early in gastric carcinogenesis.	Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, 22 S Greene St,Room N3W62, Baltimore, MD 21201 USA; Baltimore VA Hosp, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Genet Program, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Yamagata Univ, Sch Med, Dept Pathol, Yamagata 990, Japan; Univ Calif Irvine, Dept Mol Genet & Microbiol, Irvine, CA USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine; Yamagata University; University of California System; University of California Irvine	Meltzer, SJ (corresponding author), Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, 22 S Greene St,Room N3W62, Baltimore, MD 21201 USA.		Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093; Wilson, Keith/0000-0003-4421-1830	NATIONAL CANCER INSTITUTE [R01CA078843, U01CA085069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER; NCI NIH HHS [CA85069, CA78843] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Akiyama Y, 1996, JPN J CANCER RES, V87, P595, DOI 10.1111/j.1349-7006.1996.tb00265.x; BANKFALVI A, 1994, J PATHOL, V174, P223, DOI 10.1002/path.1711740312; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Boland CR, 1998, CANCER RES, V58, P5248; Claij N, 1999, EXP CELL RES, V246, P1, DOI 10.1006/excr.1998.4299; CORREA P, 1994, CANCER RES, V54, pS1941; CRAANEN ME, 1992, AM J GASTROENTEROL, V87, P572; Cunningham JM, 1998, CANCER RES, V58, P3455; DosSantos NR, 1996, GASTROENTEROLOGY, V110, P38, DOI 10.1053/gast.1996.v110.pm8536886; Driessen A, 1999, GASTROEN CLIN BIOL, V23, P747; ECKARDT VF, 1990, GASTROENTEROLOGY, V98, P708, DOI 10.1016/0016-5085(90)90292-9; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Esteller M, 2000, CANCER RES, V60, P129; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; Fleisher AS, 1999, CANCER RES, V59, P1090; FUKUTOMI H, 1984, JPN J CLIN ONCOL, V14, P169; Halling KC, 1999, AM J PATHOL, V155, P205, DOI 10.1016/S0002-9440(10)65114-0; HAN HJ, 1993, CANCER RES, V53, P5087; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hoang JM, 1997, CANCER RES, V57, P300; Iino H, 1999, J CLIN PATHOL, V52, P5, DOI 10.1136/jcp.52.1.5; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Isogaki J, 1999, CANCER DETECT PREV, V23, P204, DOI 10.1046/j.1525-1500.1999.99020.x; Kane MF, 1997, CANCER RES, V57, P808; Kang GH, 1999, LAB INVEST, V79, P903; Karran P, 1996, CANCER SURV, V28, P69; Keller G, 1998, AM J PATHOL, V152, P1281; Kuipers EJ, 1998, ALIMENT PHARM THER, V12, P25, DOI 10.1111/j.1365-2036.1998.00009.x; Leach FS, 1996, CANCER RES, V56, P235; Leung SY, 1999, CANCER RES, V59, P159; ORLOW I, 1994, CANCER RES, V54, P2848; Ottini L, 1997, CANCER RES, V57, P4523; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; RHYU MG, 1994, ONCOGENE, V9, P29; Sasaki I, 1999, CANCER, V85, P1719, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1719::AID-CNCR11>3.3.CO;2-M; SAVIDES C, 1999, TUMORS STOMACH, V1, P1500; Semba S, 1996, CANCER, V77, P1620, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1620::AID-CNCR30>3.3.CO;2-P; Suzuki H, 1999, INT J CANCER, V83, P309, DOI 10.1002/(SICI)1097-0215(19991029)83:3<309::AID-IJC4>3.0.CO;2-Z; SUZUKI H, 1994, CANCER RES, V54, P4841; Tamura G, 1996, PATHOL INT, V46, P834, DOI 10.1111/j.1440-1827.1996.tb03556.x; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thibodeau SN, 1996, CANCER RES, V56, P4836; TOMASULO J, 1971, CANCER-AM CANCER SOC, V27, P1346, DOI 10.1002/1097-0142(197106)27:6<1346::AID-CNCR2820270612>3.0.CO;2-V; Wu MS, 1997, J GASTROEN HEPATOL, V12, P425, DOI 10.1111/j.1440-1746.1997.tb00460.x; Yin J, 1997, HUM MUTAT, V10, P474, DOI 10.1002/(SICI)1098-1004(1997)10:6<474::AID-HUMU9>3.0.CO;2-D; Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4	50	97	104	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					329	335		10.1038/sj.onc.1204104	http://dx.doi.org/10.1038/sj.onc.1204104			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313962				2022-12-17	WOS:000166411000007
J	Tanaka, M; Koul, D; Davies, MA; Liebert, M; Steck, PA; Grossman, HB				Tanaka, M; Koul, D; Davies, MA; Liebert, M; Steck, PA; Grossman, HB			MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells	ONCOGENE			English	Article						MMAC1/PTEN; bladder cancer; growth suppression; doxorubicin; chemosensitization	TUMOR-SUPPRESSOR GENE; PROSTATE-CANCER; GERMLINE MUTATIONS; COWDEN-DISEASE; P53 GENE; GLIOBLASTOMA-MULTIFORME; MULTIDRUG-RESISTANCE; NATURAL-HISTORY; PTEN/MMAC1 GENE; PTEN	The development and progression of bladder cancer is associated with multiple alterations in the genome, including loss of chromosome 10. Recently, MMAC1/ PTEN, a phosphatidylinositol phosphatase, has been mapped to chromosome 10q23. We previously demonstrated that MMAC1/PTEN has tumor suppressive properties in glioblastoma and prostate cancer. To investigate the efficacy of gene therapy with MMAC1/ PTEN, we examined whether the exogenous introduction of MMAC1/PTEN via an adenoviral vector (Ad-MMAC) can inhibit tumor growth and reverse drug resistance to doxorubicin in human bladder cancer cells. Human bladder cancer cell lines UM-UC-3 and T24 were infected with Ad-MMAC to induce exogenous expression of MMAC1/PTEN. The cells were then analysed for cell growth and expression of phosphorylated protein kinase B (Akt/PKB) and MMAC1/PTEN. UM-UC-6dox, a doxorubicin resistant subline, was infected with Ad-MMAC to evaluate its role in reversing drug resistance to doxorubicin. We found that MMAC1/ PTEN suppressed tumor growth in UM-UC-3 and T24 cells with arrest in the G1 phase of the cell cycle. We also showed that gene therapy with MMAC1/PTEN abrogated phosphorylated Akt/PKB expression in UM-UC-3, T24 and UMUC-6dox cells, and restored doxorubicin sensitivity in UM-UC-6dox. These data demonstrate that MMAC1/PTEN can induce growth suppression and increase sensitivity to doxorubicin in bladder cancer cells and suggest that the MMAC1/ PTEN gene and its pathways can be therapeutic targets for bladder cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Grossman, HB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Urol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Davies, Michael/GWV-2527-2022		NCI NIH HHS [CA56973, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA056973, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN HJ, 1994, J UROLOGY, V151, P263, DOI 10.1016/S0022-5347(17)34929-7; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Aveyard JS, 1999, BRIT J CANCER, V80, P904, DOI 10.1038/sj.bjc.6690439; Cairns P, 1998, ONCOGENE, V16, P3215, DOI 10.1038/sj.onc.1201855; Cairns P, 1997, CANCER RES, V57, P4997; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; Cookson MS, 1997, J UROLOGY, V158, P62, DOI 10.1097/00005392-199707000-00017; Corral DA, 1997, WORLD J UROL, V15, P139, DOI 10.1007/BF02201986; Dahia PLM, 1997, CANCER RES, V57, P4710; Davies MA, 1999, CANCER RES, V59, P2551; Davies MA, 1998, CANCER RES, V58, P5285; FUJIWARA T, 1994, CANCER RES, V54, P2287; Guldberg P, 1997, CANCER RES, V57, P3660; Gurnani M, 1999, CANCER CHEMOTH PHARM, V44, P143, DOI 10.1007/s002800050959; Herr HW, 1997, WORLD J UROL, V15, P84, DOI 10.1007/BF02201977; KANAMARU H, 1989, UROL RES, V17, P259; Kim SK, 1998, ONCOGENE, V16, P89, DOI 10.1038/sj.onc.1201512; KIM WJ, 1995, JPN J CANCER RES, V86, P969, DOI 10.1111/j.1349-7006.1995.tb03009.x; Kozlowski J, 1999, J UROLOGY, V162, P1581, DOI 10.1016/S0022-5347(05)68170-0; KROFT SH, 1994, LAB INVEST, V71, P158; Levine RL, 1998, CANCER RES, V58, P3254; LI DM, 1997, CANCER RES, V57, P2130; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LIU J, 2000, IN PRESS MOL CARCINO; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Maxwell GL, 1998, CANCER RES, V58, P2500; NAITO S, 1995, JPN J CANCER RES, V86, P1112, DOI 10.1111/j.1349-7006.1995.tb03028.x; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Ogawa N, 1997, INT J CANCER, V73, P367, DOI 10.1002/(SICI)1097-0215(19971104)73:3<367::AID-IJC11>3.0.CO;2-A; Pu YS, 1996, J UROLOGY, V156, P271, DOI 10.1016/S0022-5347(01)66015-4; Rhei E, 1997, CANCER RES, V57, P3657; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; Sano T, 1999, CANCER RES, V59, P1820; SHINOHARA N, 1993, J UROLOGY, V150, P505, DOI 10.1016/S0022-5347(17)35536-2; STARINK TM, 1986, CLIN GENET, V29, P222; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki H, 1998, CANCER RES, V58, P204; TANAKA M, 1995, CANCER RES, V55, P3228; Tashiro H, 1997, CANCER RES, V57, P3935; Thakar M., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P633; USANSKY JI, 1991, SELECT CANCER THER, V7, P139, DOI 10.1089/sct.1991.7.139; Wang SI, 1997, CANCER RES, V57, P4183; Warde P, 1997, WORLD J UROL, V15, P125, DOI 10.1007/BF02201984; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246	46	97	107	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5406	5412		10.1038/sj.onc.1203918	http://dx.doi.org/10.1038/sj.onc.1203918			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103942				2022-12-17	WOS:000165302300012
J	Grothey, A; Hashizume, R; Ji, H; Tubb, BE; Patrick, CW; Yu, DH; Mooney, EE; McCrea, PD				Grothey, A; Hashizume, R; Ji, H; Tubb, BE; Patrick, CW; Yu, DH; Mooney, EE; McCrea, PD			C-erbB-2/HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines	ONCOGENE			English	Article						C-erbB-2; fascin; breast cancer; cell motility; actin	BETA-CATENIN; TYROSINE PHOSPHORYLATION; SELECTIVE-INHIBITION; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; NEU ONCOGENE; IN-VIVO; EXPRESSION; METASTASIS; KINASE	The over-expression of c-erbS-2/ HER-2, a receptor tyrosine kinase, correlates with poor prognosis in patients with breast and ovarian cancer. In the human breast cancer cell line, MDA-MB-435, c-erbB-2 overexpression results in increased chemoinvasion and higher metastatic properties in nude mice. I-ion ever, the mechanisms by which c-erbB-2 increases the malignant potential of cells remains unclear. We have determined that over-expression of c-erbB-2 in MDA-MB-435 cells, and in some additional breast cancer cell lines, is associated with graphic increases in mRNA and protein levels of the actin bundling protein fascin, Heightened fascin expression has been observed in other systems to result in greatly increased cell motility, and indeed, our work employing semi-automated time-lapse microscopy demonstrates that MDA-MB-435 cells over-expressing c-erbB-2 exhibit significantly heightened cellular dynamics and locomotion, while visualization of bundled microfilaments within fixed cells revealed enhanced formation of dendritic-like processes, microspikes and other dynamic actin based structures. To address the means by which c-erbB-2 over-expression might result in elevated fascin levels, we identified multiple perfect match TCF and NF-kappa B consensus sites in fascin's promoter and first intron,which appeared consistent with the greater endogenous transcriptional activities of TCF and NF-kappa B in c-erbB-2 over-expressing MDA-MB-435 cells. While such transcriptional modulation may occur in the context of the intact gene/chromatin, subsequent tests using reporter constructs did not support involvement of these signaling pathways. In conclusion, highly increased fascin levels were observed in MDA-MB-435 over-expressing c-erbB-2, likely contributing to these cells' altered actin dynamics, and increased cell motility and malignancy. Studies in progress aim to discern the means by which c-erbB-2 over-expression leads to transcriptional activation of the fascin gene.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Program Genes & Dev, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Plast Surg, Program Genes & Dev, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	McCrea, PD (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Program Genes & Dev, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Yu, Dihua/0000-0001-6231-9381	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052112] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 52112, R01 GM052112] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Adams JC, 1999, MOL BIOL CELL, V10, P4177, DOI 10.1091/mbc.10.12.4177; Aljada A, 1999, J CLIN ENDOCR METAB, V84, P3386, DOI 10.1210/jc.84.9.3386; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; CANO RJ, 1992, BIOTECHNIQUES, V12, P264; CROWELL PL, 1991, J BIOL CHEM, V266, P17679; DECORTE V, 1994, J CELL SCI, V107, P405; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; del Peso L, 1997, ONCOGENE, V15, P3047; DHALIWAL MK, 1990, ANTICANCER RES, V10, P113; DICKASON RR, 1995, J IMMUNOL METHODS, V185, P237, DOI 10.1016/0022-1759(95)00119-U; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; EDWARDS RA, 1995, CELL MOTIL CYTOSKEL, V32, P1, DOI 10.1002/cm.970320102; EDWARDS RA, 1995, J BIOL CHEM, V270, P10764, DOI 10.1074/jbc.270.18.10764; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GAFFNEY EV, 1982, CELL TISSUE RES, V227, P563, DOI 10.1007/BF00204786; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GROTHEY A, 2000, BR J CANC, V88; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Hung MC, 1999, SEMIN ONCOL, V26, P51; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Klapper LN, 2000, ADV CANCER RES, V77, P25; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kzhyshkowska JG, 1996, IMMUNOL LETT, V53, P101, DOI 10.1016/S0165-2478(96)02625-9; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Montross WT, 2000, J CELL SCI, V113, P1759; MOSIALOS G, 1994, J VIROL, V68, P7320, DOI 10.1128/JVI.68.11.7320-7328.1994; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; PELES E, 1992, J BIOL CHEM, V267, P12266; Pinkus GS, 1997, AM J PATHOL, V150, P543; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; SEGATTO O, 1993, ONCOGENE, V8, P2105; Shibata T, 1996, ONCOGENE, V13, P883; Tan M, 1999, CANCER RES, V59, P1620; Tan M, 1997, CANCER RES, V57, P1199; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; Tilney LG, 1998, J CELL BIOL, V143, P121, DOI 10.1083/jcb.143.1.121; VAN AD, 1996, SCIENCE, V274, P787; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wong V, 1999, J BIOL CHEM, V274, P5443, DOI 10.1074/jbc.274.9.5443; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260	51	97	114	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4864	4875		10.1038/sj.onc.1203838	http://dx.doi.org/10.1038/sj.onc.1203838			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039904				2022-12-17	WOS:000089757800009
J	Komarova, EA; Christov, K; Faerman, AI; Gudkov, AV				Komarova, EA; Christov, K; Faerman, AI; Gudkov, AV			Different impact of p53 and p21 on the radiation response of mouse tissues	ONCOGENE			English	Article						p53; p21; apoptosis; radiation; proliferation; mouse tissues	CELL-CYCLE ARREST; INDUCED APOPTOSIS; P53-DEFICIENT MICE; DISTINCT PATTERNS; P53-INDEPENDENT APOPTOSIS; INTESTINAL EPITHELIUM; IONIZING-RADIATION; GAMMA-IRRADIATION; HUMAN SKIN; IN-VIVO	Mammalian tissues differ dramatically in their sensitivity to genotoxic stress, although the mechanisms determining these differences remain largely unknown. To analyse the role of p53 and p21 in determination of tissue specificity to DNA damage in vivo, we compared the effects of gamma radiation on DNA synthesis on whole-body sections of wild type, p53-deficient and p21-deficient mice, ii dramatic reduction in C-14-thymidine incorporation after gamma irradiation was observed in the majority of rapidly proliferating tissues of wild type and p21(-/-) but not in p53(-/-) mice, confirming the key role of p53 in determination of tissue response to genotoxic stress vivo and suggesting that p53-mediated inhibition of DNA synthesis does not depend on p21, Rapid radiation induced p53-dependent apoptosis was mapped to the areas of high levels of p53 mRNA in radiation sensitive tissues analysed (white pulp in the spleen and bases of crypts in small intestine), indicating that p53 regulation at the mRNA level is a determinant of cellular sensitivity to genotoxic stress. High p53 mRNA expression is inherited as a recessive trait in cell-cell hybrids suggesting the involvement of a negative control mechanism in the regulation of p53 gene expression.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; Quark Biotech Inc, Ness Ziona, Israel	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gudkov, AV (corresponding author), Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA.			Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [CA75179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAMPBELL C, 1993, CANCER RES, V53, P2697; Christov KT, 1996, CARCINOGENESIS, V17, P1741, DOI 10.1093/carcin/17.8.1741; CLARKE AR, 1994, ONCOGENE, V9, P1767; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; Frenkel J, 1999, ONCOGENE, V18, P2901, DOI 10.1038/sj.onc.1202518; Gartel A L, 1998, Prog Mol Subcell Biol, V20, P43; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hasegawa M, 1998, RADIAT RES, V149, P263, DOI 10.2307/3579959; Hendry JH, 1997, RADIAT RES, V148, P254, DOI 10.2307/3579610; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MacCallum DE, 1996, ONCOGENE, V13, P2575; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MERRITT AJ, 1994, CANCER RES, V54, P614; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Reisman D, 1998, SEMIN CANCER BIOL, V8, P317, DOI 10.1006/scbi.1998.0094; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; Song SY, 1999, AM J PATHOL, V155, P1121, DOI 10.1016/S0002-9440(10)65215-7; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; Uberti D, 1999, EXP CELL RES, V252, P123, DOI 10.1006/excr.1999.4606; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Wilson JW, 1998, AM J PATHOL, V153, P899, DOI 10.1016/S0002-9440(10)65631-3	41	97	98	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3791	3798		10.1038/sj.onc.1203717	http://dx.doi.org/10.1038/sj.onc.1203717			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949934				2022-12-17	WOS:000088568400012
J	Dutertre, S; Ababou, M; Onclercq, R; Delic, J; Chatton, B; Jaulin, C; Amor-Gueret, M				Dutertre, S; Ababou, M; Onclercq, R; Delic, J; Chatton, B; Jaulin, C; Amor-Gueret, M			Cell cycle regulation of the endogenous wild type Bloom's syndrome DNA helicase	ONCOGENE			English	Article						Bloom's syndrome; RecQ 3 '-5 ' DNA helicase; cell cycle; post-translational modifications; cancer predisposition	UBIQUITIN-PROTEASOME PATHWAY; ESCHERICHIA-COLI RECQ; SYNDROME GENE-PRODUCT; BETA-CATENIN; REPLICATION; HOMOLOG; PROTEIN; CLONING; PHOSPHORYLATION; DEGRADATION	Bloom's syndrome (BS) is a rare human autosomal recessive disorder characterized by an increased risk to develop cancer of all types, BS cells are characterized by a generalized genetic instability including a high level of sister chromatid exchanges, BS arises through mutations in both alleles of the BLM gene which encodes a 3'-5' DNA helicase identified as a member of the RecQ family. We developed polyclonal antibodies specific for the NH2- and COOH-terminal region of BLM, Using these antibodies, we analysed BLM expression during the cell cycle and showed that the BLM protein accumulates to high levels in S phase, persists in G2/M and sharply declines in G1, strongly suggestive of degradation during mitosis, The BLM protein is subject to post-translational modifications in mitosis, as revealed by slow migrating forms of BLM found in both demecolcine-treated cells and in mitotic cells isolated from non-treated asynchronous populations. Phosphatase treatment indicated that phosphorylation events were solely responsible for the appearance of the retarded moieties, a possible signal for subsequent degradation. Together, these results are consistent with a role of BLM in a replicative (S phase) and/or post-replicative (G2 phase) process.	Inst Gustave Roussy, CNRS, UMR 1598, F-94805 Villejuif, France; Inst Curie, Lab Radiopathol, CEA, Lab Rech Correspondant,DSV,DRR, F-75005 Paris, France; ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, CU De Strasbour, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; CEA; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Amor-Gueret, M (corresponding author), Inst Gustave Roussy, CNRS, UMR 1598, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		CHATTON, Bruno/R-3813-2019; Jaulin, Christian/L-9126-2018	CHATTON, Bruno/0000-0003-4515-7119; ababou, mouna/0000-0003-4276-3754				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bahr A, 1998, ONCOGENE, V17, P2565, DOI 10.1038/sj.onc.1202389; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Chester N, 1998, GENE DEV, V12, P3382, DOI 10.1101/gad.12.21.3382; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; COUX O, 1996, ANNU REV BIOCHEM, V65, P80; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Frei C, 2000, GENE DEV, V14, P81; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; German J, 1997, CANCER GENET CYTOGEN, V93, P100, DOI 10.1016/S0165-4608(96)00336-6; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Gharibyan V, 1999, MOL CARCINOGEN, V26, P261, DOI 10.1002/(SICI)1098-2744(199912)26:4<261::AID-MC5>3.0.CO;2-A; GIANNELLI F, 1977, NATURE, V265, P466, DOI 10.1038/265466a0; HAND R, 1975, P NATL ACAD SCI USA, V72, P758, DOI 10.1073/pnas.72.2.758; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Kusano K, 1999, GENETICS, V151, P1027; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LEVENSON V, 1993, NUCLEIC ACIDS RES, V21, P3997, DOI 10.1093/nar/21.17.3997; LONN U, 1990, CANCER RES, V50, P3141; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; MULLER H, 1992, MUTAT RES, V284, P15, DOI 10.1016/0027-5107(92)90021-S; Murray JM, 1997, MOL CELL BIOL, V17, P6868, DOI 10.1128/MCB.17.12.6868; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RODMAN TC, 1980, CYTOGENET CELL GENET, V27, P98, DOI 10.1159/000131471; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; SKOOG L, 1971, EUR J BIOCHEM, V19, P81, DOI 10.1111/j.1432-1033.1971.tb01290.x; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; Walpita D, 1999, P NATL ACAD SCI USA, V96, P5622, DOI 10.1073/pnas.96.10.5622; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; ZHUO S, 1993, J BIOL CHEM, V268, P17754	41	97	100	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 25	2000	19	23					2731	2738		10.1038/sj.onc.1203595	http://dx.doi.org/10.1038/sj.onc.1203595			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851073				2022-12-17	WOS:000087318500001
J	Sheikh, MS; Fornace, AJ				Sheikh, MS; Fornace, AJ			Regulation of translation initiation following stress	ONCOGENE			English	Review						translation initiation; eIF2; eIF3; eIF5; eIF1(A121/SU11); translation checkpoints	ACTIVATED PROTEIN-KINASE; DAMAGE-INDUCIBLE TRANSCRIPTS; HERPES-SIMPLEX VIRUS; BJA-B CELLS; DNA-DAMAGE; INDUCED APOPTOSIS; PREMATURE SHUTOFF; GROWTH ARREST; ALPHA-SUBUNIT; RNA	Recent studies suggest that genotoxic and non-genotoxic stresses appear to invoke translational checkpoints in order,to inhibit protein synthesis. Depending on the stress and/or cell type, this downregulation of protein synthesis may either (i) protect against the deleterious effects of noxious agents and ensure the conservation of resources that are needed to survive under adverse conditions or (ii) activate apoptosis, In this article, we have reviewed several lines of evidence which support the notion that regulation of translation initiation is an important component of the cellular stress response. While the stress-induced post-translational regulation of translation initiation factors (eIFs) has been well documented, stress-induced regulation of eIFs at the mRNA levels, as review ed here, is only beginning to be elucidated. Thus, the stress-mediated regulation of eIFs occurs at multiple different levels involving, transcriptional, post-transcriptional and post-translational controls.	NCI, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sheikh, MS (corresponding author), NCI, Div Basic Sci, NIH, Bldg 37,Room 5CO9, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER HT, IN PRESS MOL CELL BI; Bulera SJ, 1996, HEPATOLOGY, V23, P1591; CASKEY CT, 1980, TRENDS BIOCHEM SCI, V5, P234, DOI 10.1016/S0968-0004(80)80809-7; CASTILHOVALAVICIUS B, 1990, GENETICS, V124, P483; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; CHOU J, 1995, P NATL ACAD SCI USA, V92, P10516, DOI 10.1073/pnas.92.23.10516; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; CLARK B, 1980, TRENDS BIOCHEM SCI, V5, P207, DOI 10.1016/S0968-0004(80)80009-0; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; Cui Y, 1998, MOL CELL BIOL, V18, P1506, DOI 10.1128/MCB.18.3.1506; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gil J, 1999, MOL CELL BIOL, V19, P4653; Haro CD, 1996, FASEB J, V10, P1378; HAYS JB, 1990, MOL CELL BIOL, V10, P3505, DOI 10.1128/MCB.10.7.3505; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; He B, 1996, J VIROL, V70, P84, DOI 10.1128/JVI.70.1.84-90.1996; Hershey JWB, 1996, TRANSLATIONAL CONTRO; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; Ishii H, 1997, INT J EXP PATHOL, V78, P123, DOI 10.1046/j.1365-2613.1997.170350.x; ISHII HH, 1995, IMMUNOL CELL BIOL, V73, P463, DOI 10.1038/icb.1995.72; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; Lewis JD, 1997, EUR J BIOCHEM, V247, P461, DOI 10.1111/j.1432-1033.1997.00461.x; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; Lian ZR, 1999, ONCOGENE, V18, P1677, DOI 10.1038/sj.onc.1202470; Liebermann DA, 1998, ONCOGENE, V17, P3319, DOI 10.1038/sj.onc.1202574; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; PATHAK VK, 1988, CELL, V54, P633, DOI 10.1016/S0092-8674(88)80007-2; Pellegata NS, 1996, P NATL ACAD SCI USA, V93, P15209, DOI 10.1073/pnas.93.26.15209; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SCHMEDT C, 1995, J MOL BIOL, V249, P29, DOI 10.1006/jmbi.1995.0278; Schulz JB, 1996, J NEUROSCI, V16, P4696; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; Sheikh MS, 1997, J BIOL CHEM, V272, P26720, DOI 10.1074/jbc.272.42.26720; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheikh MS, 1999, J BIOL CHEM, V274, P16487, DOI 10.1074/jbc.274.23.16487; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Viswanathan A, 1999, SCIENCE, V284, P159, DOI 10.1126/science.284.5411.159; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	57	97	97	2	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	1999	18	45			SI		6121	6128		10.1038/sj.onc.1203131	http://dx.doi.org/10.1038/sj.onc.1203131			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251LL	10557103				2022-12-17	WOS:000083447100006
J	Yang, JP; Hori, M; Takahashi, N; Kawabe, T; Kato, H; Okamoto, T				Yang, JP; Hori, M; Takahashi, N; Kawabe, T; Kato, H; Okamoto, T			NF-kappa B subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2	ONCOGENE			English	Article						53BP2; NF-kappa B; cell death; interaction	TUMOR-SUPPRESSOR P53; ANKYRIN REPEATS; SH3 DOMAINS; APOPTOSIS; PROTEIN; ACTIVATION; BCL-2; BAX; DNA; LOCALIZATION	Nuclear factor kappa B (NF-kappa B) is a transcription factor that controls the expression of many cellular and viral genes. The p65 (RelA) subunit plays a critical role as a transcriptional activator and recent observations have highlighted its role in the control of apoptosis, Here we report that 53BP2, a protein previously identified by interaction with wild type p53 and Bcl-2, also binds to p65 in a yeast two-hybrid system. This specific interaction was confirmed by pull-down assay in vitro and by a mammalian two-hybrid assay irt vivo. We observed that full-length 53BP2 fused to GFP had a punctate distribution in cytoplasm, predominantly in perinuclear region whereas the N-terminal 53BP2 localized in cytoplasm and C-terminal 53BP2 localized in the nucleus. Furthermore, we found that overexpression of GFP-53BP2 induced apoptosis in transiently transfected cells. Neither the N-terminal nor the C-terminal of 53BP2 fused to GFP induced cell death. Interestingly, co-transfection with a p65 expression plasmid significantly inhibited 53BP2-induced cell death. The previous findings that 53BP2 bound to p53 and Bcl-2 together with our present observations suggest that 53BP2 may play a central role in the regulation of apoptosis and cell growth.	Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Hokkaido Univ, Fac Pharmaceut Sci, Dept Mol Biol, Sapporo, Hokkaido 0608636, Japan	Nagoya City University; Hokkaido University	Okamoto, T (corresponding author), Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, Mizuho Cho, Nagoya, Aichi 4678601, Japan.							Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HARDIN JA, 1992, TOXICOL APPL PHARM, V117, P155, DOI 10.1016/0041-008X(92)90232-H; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Lippincott-Schwartz J, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, P243; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Okamoto T, 1997, CURR TOP CELL REGUL, V35, P149, DOI 10.1016/S0070-2137(97)80006-4; PINES J, 1995, TRENDS GENET, V11, P326, DOI 10.1016/S0168-9525(00)89092-7; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Sakurada S, 1996, INT IMMUNOL, V8, P1483, DOI 10.1093/intimm/8.10.1483; Sambrook J, 1989, MOL CLONING LAB MANU; Sato T, 1998, AIDS RES HUM RETROV, V14, P293, DOI 10.1089/aid.1998.14.293; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SIEBENLIST U, 1995, INDUCIBLE GENE EXPRE, V1, P93; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; WU HY, 1994, J BIOL CHEM, V269, P20067; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yamabhai M, 1997, ANAL BIOCHEM, V247, P143, DOI 10.1006/abio.1997.2040; Yang JP, 1997, CYTOGENET CELL GENET, V78, P61, DOI 10.1159/000134630	41	97	103	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5177	5186		10.1038/sj.onc.1202904	http://dx.doi.org/10.1038/sj.onc.1202904			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498867				2022-12-17	WOS:000082555700006
J	Wick, W; Furnari, FB; Naumann, U; Cavenee, WK; Weller, M				Wick, W; Furnari, FB; Naumann, U; Cavenee, WK; Weller, M			PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis	ONCOGENE			English	Article						PTEN; glioma; CD95; PKB; PI 3-kinase; irradiation	TUMOR-SUPPRESSOR; PROTEIN-KINASE; PHOSPHATASE; MUTATIONS; GROWTH; CELLS; ACTIVATION; PTEN/MMAC1; 3-KINASE; SURVIVAL	The tumor suppressor gene PTEN (MMAC1, TEP1) encodes a dual-specificity phosphatase and is considered a progression-associated target of genetic alterations in human gliomas. Recently, it has been reported that the introduction of wild type PTEN into glioma cells containing endogenous mutant PTEN alleles (U87MC;, LN-308), but not in those which retain wild-type PTEN (LN-18, LN-229), causes growth suppression and inhibits cellular migration, spreading and focal adhesion. Here, we show that PTEN gene transfer has no effect on the chemosensitivity of the four cell lines. Further, a correlational analysis of the endogenous PTEN status of 12 human glioma cell lines with their sensitivity to seven different cancer chemotherapy drugs reveals no link between PTEN and chemosensitivity, In contrast, ectopic expression of wild type PTEN, but not the PTENG129R mutant, in PTEN-mutant gliomas markedly sensitizes these cells to irradiation and to CD95-ligand (CD95L)-induced apoptosis. PTEN-mediated facilitation of CD95L-induced apoptosis is associated with enhanced CD95L-evoked caspase 3 activity, Protein kinase B (PKB/Akt), previously shown to inhibit CD95L-induced apoptosis in nonglial COS7 cells, is inactivated by dephosphorylation. Interestingly, both PTEN-mutant U87MG and PTEN-wild-type LN-229 cells contain phosphorylated PKB constitutively. Wild-type PTEN gene transfer promotes dephosphorylation of PKB specifically in U87MG cells but not in LN-229 cells, Sensitization of U87NG cells to CD95L-apoptosis by wild-type PTEN is blocked by insulin-like growth factor-1 (IGF-1). The protection by IGF-1 is inhibited by the phosphoinositide 3-OH (PI 3) kinase inhibitor, wort-mannin, Although PKB is a down-stream target of PI 3 kinase, the protection by IGF-1 was not associated with the reconstitution of PKB phosphorylation. Thus, PTEN may sensitize human malignant glioma cells to CD95L-induced apoptosis in a PI 3 kinase-dependent manner that may not require PKB phosphorylation.	Univ Tubingen, Dept Neurol, D-72076 Tubingen, Germany; Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	Eberhard Karls University of Tubingen; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Weller, M (corresponding author), Univ Tubingen, Dept Neurol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Wick, Wolfgang/AAA-2545-2020	Wick, Wolfgang/0000-0002-6171-634X; Weller, Michael/0000-0002-1748-174X; Furnari, Frank/0000-0003-1909-4361				BASERGA R, 1995, CANCER RES, V55, P249; Cheney IW, 1998, CANCER RES, V58, P2331; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu WG, 1997, CANCER RES, V57, P5254; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Rhei E, 1997, CANCER RES, V57, P3657; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; Schulz JB, 1997, J NEUROCHEM, V69, P2075; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Teng DHF, 1997, CANCER RES, V57, P5221; Wang SI, 1997, CANCER RES, V57, P4183; Weller M, 1997, NEUROL RES, V19, P459; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; WELLER M, 1998, INT J CANCER, V79, P1	24	97	103	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					3936	3943		10.1038/sj.onc.1202774	http://dx.doi.org/10.1038/sj.onc.1202774			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435616				2022-12-17	WOS:000081327800003
J	Kaltschmidt, B; Kaltschmidt, C; Hehner, SP; Droge, W; Schmitz, ML				Kaltschmidt, B; Kaltschmidt, C; Hehner, SP; Droge, W; Schmitz, ML			Repression of NF-kappa B impairs HeLa cell proliferation by functional interference with cell cycle checkpoint regulators	ONCOGENE			English	Article						cell cycle; NF-kappa B; G1/S transition; p53; c-Myc; apoptosis	TRANSCRIPTION FACTOR; C-MYC; PROTEIN-KINASE; ALPHA PROTEOLYSIS; BREAST-CANCER; DNA-BINDING; IN-VIVO; ACTIVATION; PHOSPHORYLATION; GROWTH	NF-kappa B is an inducible transcription factor, which is regulated by interaction with inhibitory I kappa B proteins. Previous studies linked the activity of NF-kappa B to the proliferative state of the cell, Here we have analysed the function of NF-kappa B in the cell cycle. Inhibition of NF-kappa B in HeLa cells by stable overexpression of a transdominant negative I kappa B-alpha protein reduced cell growth. A kinetic analysis of the cell cycle revealed a retarded G1/S transition. The I kappa B-alpha overexpressing cell clones show ed a decreased percentage of cells in the S phase and an impaired incorporation of bromodeoxyuridine (BrdU), The amounts of cyclins A, B1, D1, D3, and E were unchanged, but the G1-specific proteins cyclin D2 and cdk2 were strongly elevated in the I kappa B-alpha overexpressing cell clones. These cell clones also displayed an increase in cyclin D1-dependent kinase activity, pointing to a cell ca de arrest at the late G1 phase. I kappa B-alpha overexpression crosstalked to cell cycle checkpoints via a reduction of transcription factor p53 and elevation of p21(WAF). Surprisingly, the I kappa B-alpha overexpressing cells showed an enrichment of c-Myc in the nucleoli, although the total amount of c-Myc protein was unchanged. These experiments identify an important contribution of the NF-kappa B/I kappa B system for the growth of HeLa cells.	German Canc Res Ctr, Dept Immunochem, D-69120 Heidelberg, Germany; Univ Freiburg, Inst Anat, Mol Neurobiol Lab, D-79104 Freiburg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg	Schmitz, ML (corresponding author), German Canc Res Ctr, Dept Immunochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; COLIGAN JE, 1997, CURRENT PROTOCOLS IM, V1; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; DUCKETT CS, 1995, J BIOL CHEM, V270, P18836, DOI 10.1074/jbc.270.32.18836; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Gilmore TD, 1996, ONCOGENE, V13, P1367; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; KALTSCHMIDT C, 1995, BIOL CHEM H-S, V376, P9; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MICHIELI P, 1994, CANCER RES, V54, P3391; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; PAUL NL, 1990, J VIROL, V64, P5412, DOI 10.1128/JVI.64.11.5412-5419.1990; PERSSON H, 1986, MOL CELL BIOL, V6, P942, DOI 10.1128/MCB.6.3.942; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Scheidereit C, 1996, J MOL MED-JMM, V74, P707, DOI 10.1007/s001090050075; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Sharma HW, 1996, ANTICANCER RES, V16, P61; Siebenlist U., 1997, BIOCHIMICA BIOPHYSIC, V1332, P7; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; VRIZ S, 1992, MOL CELL BIOL, V12, P3548, DOI 10.1128/MCB.12.8.3548; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; WU HY, 1994, J BIOL CHEM, V269, P20067; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	65	97	98	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	1999	18	21					3213	3225		10.1038/sj.onc.1202657	http://dx.doi.org/10.1038/sj.onc.1202657			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359527				2022-12-17	WOS:000080523800004
J	Farina, A; Manni, I; Fontemaggi, G; Tiainen, M; Cenciarelli, C; Bellorini, M; Mantovani, R; Sacchi, A; Piaggio, G				Farina, A; Manni, I; Fontemaggi, G; Tiainen, M; Cenciarelli, C; Bellorini, M; Mantovani, R; Sacchi, A; Piaggio, G			Down-regulation of cyclin B1 gene transcription in terminally differentiated skeletal muscle cells is associated with loss of functional CCAAT-binding NF-Y complex	ONCOGENE			English	Article						cyclin B1 promoter; muscle differentiation; CCAAT-binding factor NF-Y	RNA POLYMERASE-II; DEPENDENT REGULATION; MAMMALIAN-CELLS; BREAST-CANCER; FISSION YEAST; S-PHASE; EXPRESSION; PROTEIN; PROMOTER; KINASE	The observation that cyclin B1 protein and mRNAs are down-regulated in terminally differentiated (TD) C2C12 cells, suggested us to investigate the transcriptional regulation of the cyclin B1 gene in these cells. Transfections of cyclin B1 promoter constructs indicate that two CCAAT boxes support ca clin BI promoter activity in proliferating cells. EMSAs demonstrate that both CCAAT boxes are recognized by the trimeric NF-Y complex in proliferating but not in TD cells. Transfecting a dominant-negative mutant of NF-YA me provide evidence that NF-Y is required for maximal promoter activity. Addition of recombinant NF-YA to TD C2C12 nuclear extracts restores binding activity in vitro, thus indicating that the loss of NF-YA in TD cells is responsible for the lack of the NF-Y binding to the CCAAT boxes, Consistent with this, we found that the IVF-YA protein is absent in TD C2C12 cells. In conclusion, our data demonstrate that NF-Y is required for cyclin B1 promoter activity. We also demonstrate that cyclin B1 expression is regulated at the transcriptional level in TD C2C12 cells and that the switch-off of cyclin B1 promoter activity in differentiated cells depends upon the loss of a functional NF-Y complex. In particular the loss of NF-YA protein is most likely responsible for its inactivation.	Ist Regina Elena, Ctr Ric Sperimentale, Lab Oncogenesi Mol, I-00158 Rome, Italy; Univ Milan, Dipartimento Genet & Biol Microganismi, I-20133 Milan, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Milan	Piaggio, G (corresponding author), Ist Regina Elena, Ctr Ric Sperimentale, Lab Oncogenesi Mol, Via Messi Oro 156, I-00158 Rome, Italy.		Piaggio, Giulia/J-7214-2018; Piaggio, Giulia/AAD-7336-2022; Manni, Isabella/ABH-6460-2020; Fontemaggi, Giulia/K-9702-2016; CENCIARELLI, CARLO/AAC-1603-2019	Piaggio, Giulia/0000-0003-2114-1892; Manni, Isabella/0000-0003-4823-0596; Fontemaggi, Giulia/0000-0001-8332-8842; CENCIARELLI, CARLO/0000-0001-7480-4608	Telethon [1035] Funding Source: Medline	Telethon(Fondazione Telethon)		Bellorini M, 1997, GENE, V193, P119, DOI 10.1016/S0378-1119(97)00109-1; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doerner P, 1996, NATURE, V380, P520, DOI 10.1038/380520a0; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; Farina A, 1996, ONCOGENE, V13, P1287; Fromm L, 1996, ONCOGENE, V12, P69; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANLEYHYDE J, 1992, GENOMICS, V13, P1018, DOI 10.1016/0888-7543(92)90015-K; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HWANG A, 1995, J BIOL CHEM, V270, P28419; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; MANTOVANI R, 1993, NUCLEIC ACIDS RES, V21, P4873, DOI 10.1093/nar/21.21.4873; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; OHKUBO Y, 1994, EXP CELL RES, V214, P270, DOI 10.1006/excr.1994.1258; OKAZAKI K, 1966, P NATL ACAD SCI USA, V56, P1484, DOI 10.1073/pnas.56.5.1484; Osada S, 1996, J BIOL CHEM, V271, P3891; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; PINES J, 1990, New Biologist, V2, P389; Sambrook J., MOL CLONING LAB MANU; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Tiainen M, 1996, CELL GROWTH DIFFER, V7, P1039; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZHAO JZ, 1995, NEUROSCI LETT, V190, P49, DOI 10.1016/0304-3940(95)11497-K; ZORBAS H, 1992, J BIOL CHEM, V267, P8478; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	45	97	98	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2818	2827		10.1038/sj.onc.1202472	http://dx.doi.org/10.1038/sj.onc.1202472			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362252				2022-12-17	WOS:000080125100004
J	Kawazoe, N; Watabe, M; Masuda, Y; Nakajo, S; Nakaya, K				Kawazoe, N; Watabe, M; Masuda, Y; Nakajo, S; Nakaya, K			Tiam1 is involved in the regulation of bufalin-induced apoptosis in human leukemia cells	ONCOGENE			English	Article						bufalin; apoptosis; Tiam1; leukemia	JNK/SAPK SIGNALING PATHWAY; PLECKSTRIN HOMOLOGY DOMAIN; HL-60 CELLS; KINASE ACTIVATION; ANTICANCER DRUGS; MAMMALIAN-CELLS; U937 CELLS; G-PROTEIN; DEATH; RAC	Bufalin, a component of the Chinese medicine chan'su, induces apoptosis in various lines of human tumor cells, such as leukemia HL60 and U937 cells, by altering the expression of apoptosis-related genes, for example, bcl-2 and c-myc. In this study, we characterized a gene that is involved in bufalin-induced apoptosis by the differential display (DD) technique, The partial nucleotide sequence of one of the differentially expressed clones obtained after treatment with bufalin was identical to that of the human gene for Tiam1, When U937 cells mere treated with 10(-7) M bufalin, expression of both Tiam1 mRNA and the protein was induced 1 h after the start of the treatment, The increase of Tiam1 mRNA was transient but the level of Tiam1 protein continued to increase at least for 6 h, In addition, the activities of Rad and p21-activated kinase (PAK) were also stimulated by bufalin treatment. To evaluate the role of Tiam1 in the apoptotic process, we examined the effects of the expression of sense and antisense RNA for Tiam1 in U937 cells, Apoptosis was strongly induced by bufalin in cells that expressed sense RNA for Tiam1 as compared to apoptosis in control cells treated with bufalin only, Cells expressing antisense RNA for Tiam1 were significantly more resistant than the control bufalin-treated cells to induction of DNA fragmentation in response to bufalin, Moreover, sense transformants had elevated activities of PAK and c-Jun NH2-terminal kinase (JNK). These results suggest that Tiam1 might play a critical role in bufalin-induced apoptosis through the activation of Rac1, PAK, and JNK pathway.	Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Shinagawa Ku, Tokyo 1428555, Japan	Showa University	Nakaya, K (corresponding author), Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.							BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BHALLA K, 1993, LEUKEMIA, V7, P563; Butterfield L, 1997, J BIOL CHEM, V272, P10110; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; DIDSBURY JR, 1987, FEBS LETT, V219, P259, DOI 10.1016/0014-5793(87)81228-0; Franklin CC, 1995, ONCOGENE, V11, P2365; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN JH, 1993, J BIOL CHEM, V268, P25009; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; JING YK, 1994, JPN J CANCER RES, V85, P645, DOI 10.1111/j.1349-7006.1994.tb02408.x; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MANIATIS T, 1982, MOL CLONING LABORATO, P188; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MASUDA Y, 1995, LEUKEMIA RES, V19, P549, DOI 10.1016/0145-2126(95)00031-I; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOGUCHI K, 1995, JPN J CANCER RES, V86, P217, DOI 10.1111/j.1349-7006.1995.tb03042.x; NUMAZAWA S, 1994, J CELL PHYSIOL, V160, P113, DOI 10.1002/jcp.1041600114; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; ONISHI Y, 1993, BIOCHIM BIOPHYS ACTA, V1175, P147, DOI 10.1016/0167-4889(93)90017-J; PIERCE GB, 1989, P NATL ACAD SCI USA, V86, P3654, DOI 10.1073/pnas.86.10.3654; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WALKER PR, 1991, CANCER RES, V51, P1078; Watabe M, 1996, J BIOL CHEM, V271, P14067, DOI 10.1074/jbc.271.24.14067; Watabe M, 1998, ONCOGENE, V16, P779, DOI 10.1038/sj.onc.1201592; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHANG L, 1991, BIOCHEM BIOPH RES CO, V178, P686, DOI 10.1016/0006-291X(91)90162-Z	56	97	105	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2413	2421		10.1038/sj.onc.1202555	http://dx.doi.org/10.1038/sj.onc.1202555			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229192				2022-12-17	WOS:000079703300001
J	Swanton, E; Savory, P; Cosulich, S; Clarke, P; Woodman, P				Swanton, E; Savory, P; Cosulich, S; Clarke, P; Woodman, P			Bcl-2 regulates a caspase-3/caspase-2 apoptotic cascade in cytosolic extracts	ONCOGENE			English	Article						ICH-1; caspase cleavage; cytochrome c; dATP	CELL-FREE SYSTEM; CYTOCHROME-C; INITIATES APOPTOSIS; DEATH DOMAIN; GRANZYME-B; PROTEIN; ACTIVATION; PROTEASES; CASPASES; INTERACTS	Apoptosis is accompanied by the activation of a number of apoptotic proteases (caspases) which selectively cleave specific cellular substrates. Caspases themselves are zymogens which are activated by proteolysis. It is widely believed that 'initiator' caspases are recruited to and activated within apoptotic signalling complexes, and then cleave and activate downstream 'effector' caspases, While activation of the effector caspase, caspase-3, has indeed been observed as distal to activation of several different initiator caspases, evidence for a further downstream proteolytic cascade is limited. In particular, there is little evidence that cellular levels of caspase-3 that are activated via one pathway are sufficient to cleave and activate other initiator caspases, To address this issue, the ability of caspase-3, activated upon addition to cytosolic extracts of cytochrome c, to cause cleavage of caspase-2 was investigated. It was demonstrated that cleavage of caspase-2 follows, and is dependent upon, activation of caspase-3, Moreover, the activation of both caspases was inhibited by Bcl-2, Together, these data indicate that Bcl-2 can protect cells from apoptosis by acting at a point downstream from release of mitochondrial cytochrome c, thereby preventing a caspase-3 dependent proteolytic cascade.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Woodman, P (corresponding author), Univ Manchester, Sch Biol Sci, Oxford Rd, Manchester M13 9PT, Lancs, England.		Clarke, Paul R./AAA-6803-2020; Clarke, Paul R/B-1684-2009	Clarke, Paul R/0000-0003-3525-2622; Swanton, Eileithyia/0000-0002-3299-4228				BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Pan GH, 1998, FEBS LETT, V426, P151, DOI 10.1016/S0014-5793(98)00330-5; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Polverino AJ, 1997, J BIOL CHEM, V272, P7013, DOI 10.1074/jbc.272.11.7013; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	29	97	128	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1781	1787		10.1038/sj.onc.1202490	http://dx.doi.org/10.1038/sj.onc.1202490			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086332				2022-12-17	WOS:000079090000001
J	Fritz, G; Kaina, B				Fritz, G; Kaina, B			Phosphorylation of the DNA repair protein APE/REF-1 by CKII affects redox regulation of AP-1	ONCOGENE			English	Article						apurinic endonuclease; phosphorylation; casein kinase; DNA repair; AP-1; stress response	CASEIN KINASE-II; C-FOS; TOPOISOMERASE-II; ENZYME HAP1; TRANSCRIPTIONAL ACTIVITY; ATAXIA-TELANGIECTASIA; XERODERMA-PIGMENTOSUM; CELLULAR-PROTECTION; BINDING ACTIVITY; ACTIVITY INVITRO	The DNA repair protein apurinic endonuclease (APE/Ref-1) exerts several physiological functions such as cleavage of apurinic/apyrimidinic sites and redox regulation of the transcription factor AP-1, whose activation is part of the cellular response to DNA damaging treatments. Here we demonstrate that APE/Ref-1 is phosphorylated by casein kinase II (CKII), This was shown for both the recombinant APE/Ref-1 protein (Km = 0.55 mM) and for APE/Ref-1 expressed in COS cells. Phosphorylation of APE/Ref-1 did not alter the repair activity of the enzyme, whereas it stimulated its redox capability towards AP-1, thus promoting DNA binding activity of AP-1, Inhibition of CKII mediated phosphorylation of APE/Ref-1 blocked mutagen-stimulated increase in AP-1 binding. It also abrogated the induction of c-Jun protein and rendered cells more sensitive to induced DNA damage. Thus, phosphorylation of APE/Ref-1 appears to be involved in regulating the different physiological activities of the enzyme, CKII mediated phosphorylation of APE/Ref-1 and concomitant increase in AP-1 binding activity appears to be a novel mechanism of cellular stress response, forcing transcription of AP-1 target gene(s) the product(s) of which may exert protective function.	Univ Mainz, Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Fritz, G (corresponding author), Univ Mainz, Inst Toxicol, Div Appl Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.							ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; BARZILAY G, 1995, NUCLEIC ACIDS RES, V23, P1544, DOI 10.1093/nar/23.9.1544; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COCHET C, 1982, BIOCHEM PHARMACOL, V31, P1357, DOI 10.1016/0006-2952(82)90028-4; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dosch J, 1996, ONCOGENE, V13, P1927; DUCEMAN BW, 1981, J BIOL CHEM, V256, P755; DURBAN E, 1985, EMBO J, V4, P2921, DOI 10.1002/j.1460-2075.1985.tb04024.x; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FRIEDBERG EC, 1995, DNA REPAIR MUTAGNESI; GRUNICKE H, 1994, ANN HEMATOL, V69, P1; GZUDER SN, 1994, NATURE, V369, P578; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; HAGIWARA M, 1988, BIOCHEM PHARMACOL, V37, P2987; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; ISSINGER OG, 1988, EMBO J, V7, P1621, DOI 10.1002/j.1460-2075.1988.tb02988.x; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JONES NJ, 1993, CARCINOGENESIS, V14, P2487, DOI 10.1093/carcin/14.12.2487; Kaina B, 1997, CANCER RES, V57, P2721; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE SK, 1984, J BIOL CHEM, V259, P4695; LEVIN JD, 1990, NUCLEIC ACIDS RES, V18, P5069, DOI 10.1093/nar/18.17.5069; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MATTER WF, 1992, BIOCHEM BIOPH RES CO, V186, P624, DOI 10.1016/0006-291X(92)90792-J; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; RITKE MK, 1995, MOL PHARMACOL, V48, P798; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHNEIDER HR, 1986, EUR J BIOCHEM, V161, P733, DOI 10.1111/j.1432-1033.1986.tb10501.x; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SMITH PJ, 1989, CANCER RES, V49, P1118; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; SRIVASTAVA AK, 1985, BIOCHEM BIOPH RES CO, V131, P1, DOI 10.1016/0006-291X(85)91761-9; STRYER L, 1998, BIOCHEMISTRY; TEITZ T, 1990, MUTAT RES, V236, P85, DOI 10.1016/0921-8777(90)90036-5; TUTEJA N, 1995, GENE, V160, P143, DOI 10.1016/0378-1119(95)00207-M; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Vassetzky YS, 1996, BRIT J CANCER, V73, P1201, DOI 10.1038/bjc.1996.231; Wada T, 1996, NUCLEIC ACIDS RES, V24, P876, DOI 10.1093/nar/24.5.876; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997	60	97	101	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1033	1040		10.1038/sj.onc.1202394	http://dx.doi.org/10.1038/sj.onc.1202394			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023679				2022-12-17	WOS:000078510600020
J	Hayette, S; Gadoux, M; Martel, S; Bertrand, S; Tigaud, I; Magaud, JP; Rimokh, R				Hayette, S; Gadoux, M; Martel, S; Bertrand, S; Tigaud, I; Magaud, JP; Rimokh, R			FLRG (follistatin-related gene), a new target of chromosomal rearrangement in malignant blood disorders	ONCOGENE			English	Article						FLRG; follistatin; chromosomal translocation; carcinogenesis	FOLLICLE-STIMULATING-HORMONE; ACTIVIN-BINDING PROTEIN; EXPRESSION; DIFFERENTIATION; RECEPTORS; LYMPHOMAS; LEUKEMIAS; FAMILY; AGRIN; SPARC	We report here the molecular study of t(11;19)(q13;p13) translocation observed in a case of B-cell chronic lymphocytic leukemia. This translocation leads to the juxtaposition of the CCND1 gene on chromosome 11 to a new transcriptionnal unit on chromosome 19. The cDNA of this new evolutionarily conserved gene (named FLRG for Follistatin-Related Gene) codes for a secreted glycoprotein of the follistatin-module-protein family. FLRG is expressed in a wide range of human and murine adult tissues and its expression seems to be tightly regulated during murine embryogenesis. Its transcripts could not be detected in hematopoietic cells from all lineages and in particular in cells from lymphoid B and T lineage except in the t(11;19)-carrying leukemia described here. A great variability of expression is observed among the other tumoral cell lines analysed. Besides the t(11;19)-carrying leukemia described in this work, structural rearrangements of the FLRG locus have been found in a non-Hodgkin lymphoma, suggesting that it may play a role in leukemogenesis.	Ctr Leon Berard, INSERM, U453, F-69373 Lyon 08, France; Hop Edouard Herriot, Lab Cytogenet Mol, F-69437 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; CHU Lyon	Rimokh, R (corresponding author), Ctr Leon Berard, INSERM, U453, F-69373 Lyon 08, France.		HAYETTE, sandrine/Z-2283-2019; Rimokh, Ruth/G-7506-2014					Besecke LM, 1996, ENDOCRINOLOGY, V137, P3667, DOI 10.1210/en.137.9.3667; Graham A, 1996, DEVELOPMENT, V122, P473; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HINO M, 1995, FEBS LETT, V374, P69, DOI 10.1016/0014-5793(95)01078-S; HOCH W, 1994, EMBO J, V13, P2814, DOI 10.1002/j.1460-2075.1994.tb06575.x; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; Mendis DB, 1996, BRAIN RES, V730, P95; MICHEL U, 1993, MOL CELL ENDOCRINOL, V91, P1, DOI 10.1016/0303-7207(93)90248-I; MOKOTURA T, 1991, NATURE, V350, P512; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; PATTHY L, 1993, TRENDS NEUROSCI, V16, P76, DOI 10.1016/0166-2236(93)90021-D; PIERANI A, 1995, MOL CELL BIOL, V15, P642; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RIMOKH R, 1994, BLOOD, V83, P3689; RIMOKH R, 1993, BLOOD, V81, P3063; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; TANIWAKI M, 1994, BLOOD, V84, P2283, DOI 10.1182/blood.V84.7.2283.bloodjournal8472283; UENO N, 1987, P NATL ACAD SCI USA, V84, P8282, DOI 10.1073/pnas.84.23.8282; YAMASHITA T, 1992, BLOOD, V79, P304	23	97	112	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 4	1998	16	22					2949	2954		10.1038/sj.onc.1201807	http://dx.doi.org/10.1038/sj.onc.1201807			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671416				2022-12-17	WOS:000073988200014
J	Meiners, S; Brinkmann, V; Naundorf, H; Birchmeier, W				Meiners, S; Brinkmann, V; Naundorf, H; Birchmeier, W			Role of morphogenetic factors in metastasis of mammary carcinoma cells	ONCOGENE			English	Review						HGF; neuregulin; E-cadherin; metastasis; morphogenesis; epithelial-mesenchymal transition	HEPATOCYTE GROWTH-FACTOR; E-CADHERIN EXPRESSION; C-MET RECEPTOR; HUMAN PANCREATIC-CANCER; HUMAN BREAST-CANCER; SCATTER FACTOR; BETA-CATENIN; EPITHELIAL-CELLS; TYROSINE KINASE; TUMOR PROGRESSION	We have analysed the role of the morphogenetic factors hepatocyte growth factor/scatter factor (HGF), neuregulin and E-cadherin in the process of metastasis and morphogenesis of mammary carcinoma cells. The cDNAs for HGF, neuregulin and E-cadherin were stably expressed in anaplastic human MDA MB 435 carcinoma cells. The altered cells were then injected into the mammary fat pads of nude mice, where they form tumors which can spontaneously metastasize to the lungs. We found that expression of HGF or neuregulin promoted metastasis whereas expression of the cell adhesion molecule E-cadherin was inhibitory. Moreover, expression of E-cadherin reconstituted the ability of the cells to form morphogenetic structures in matrigel cultures in response to HGF. These data demonstrate that HGF and neuregulin, which control branching or lobulo-alveolar morphogenesis of normal breast epithelium, do have metastasis-promoting effects on breast carcinoma cells. Moreover, our results suggest that the differential activities of the two factors can be explained by the degree of epithelial differentiation: induction of morphogenesis requires an intact epithelial adhesion and differentiation system, whereas induction of metastasis is observed when the cells have lost their epithelial characteristics.	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Birchmeier, W (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13122 Berlin, Germany.		Brinkmann, Volker/A-6015-2009					ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BECKER KF, 1994, CANCER RES, V54, P3845; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Boyer B, 1996, CURR TOP MICROBIOL, V213, P179; BRINGUIER PP, 1993, CANCER RES, V53, P3241; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; DANIEL CW, 1995, DEV BIOL, V169, P511, DOI 10.1006/dbio.1995.1165; DIRENZO MF, 1995, CANCER RES, V55, P1129; DORUDI S, 1993, AM J PATHOL, V142, P981; EBERT M, 1994, CANCER RES, V54, P5775; FERRACINI R, 1995, ONCOGENE, V10, P739; FIDLER IJ, 1990, CANCER RES, V50, P6130; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GAMALLO C, 1993, AM J PATHOL, V142, P987; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; Gunthert U, 1996, CURR TOP MICROBIOL, V213, P271; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; HUMPHREY PA, 1995, AM J PATHOL, V147, P386; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Jeffers M, 1996, ONCOGENE, V13, P853; JOSEPH A, 1995, J NATL CANCER I, V87, P372, DOI 10.1093/jnci/87.5.372; KANDA H, 1993, ONCOGENE, V8, P3047; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Krane IM, 1996, ONCOGENE, V12, P1781; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LEONE A, 1993, ONCOGENE, V8, P2325; LIOTTA LA, 1988, CANCER SURV, V7, P631; MAYER B, 1993, CANCER RES, V53, P1690; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MOLL R, 1993, AM J PATHOL, V143, P1731; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAIDU YM, 1994, P NATL ACAD SCI USA, V91, P5281, DOI 10.1073/pnas.91.12.5281; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; NIEMANN C, 1997, UNPUB J CELL BIOL; OTTO T, 1994, CANCER RES, V54, P3120; OYAMA T, 1994, CANCER RES, V54, P6282; PARK JB, 1989, CANCER RES, V49, P6605; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Powell WC, 1996, CURR TOP MICROBIOL, V213, P1; PRESS MF, 1994, CANCER RES, V54, P5675; PRICE JE, 1990, CANCER RES, V50, P717; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; REICHMANN E, 1994, SEMIN CANCER BIOL, V5, P157; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; RONG S, 1995, CANCER RES, V55, P1963; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; Silletti S, 1996, CURR TOP MICROBIOL, V213, P137; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SORIANO JV, 1995, J CELL SCI, V108, P413; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; UMBAS R, 1994, CANCER RES, V54, P3929; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YAMASHITA J, 1994, CANCER RES, V54, P1630; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Zschiesche W, 1997, ANTICANCER RES, V17, P561	105	97	106	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	1998	16	1					9	20		10.1038/sj.onc.1201486	http://dx.doi.org/10.1038/sj.onc.1201486			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467938				2022-12-17	WOS:000071236800002
J	PROSCHEL, C; BLOUIN, MJ; GUTOWSKI, NJ; LUDWIG, R; NOBLE, M				PROSCHEL, C; BLOUIN, MJ; GUTOWSKI, NJ; LUDWIG, R; NOBLE, M			LIMK1 IS PREDOMINANTLY EXPRESSED IN NEURAL TISSUES AND PHOSPHORYLATES SERINE, THREONINE AND TYROSINE RESIDUES IN-VITRO	ONCOGENE			English	Article						LIMK1; LIM-DOMAIN; PROTEIN KINASE; CHROMOSOME 5; MOUSE	CYSTEINE-RICH PROTEIN; POLYMERASE CHAIN-REACTION; ZINC-FINGER MOTIF; T-CELL ONCOGENE; KINASE FAMILY; DEVELOPMENTAL REGULATION; CONSERVED FEATURES; POINT MUTATIONS; INSULIN GENE; KIT RECEPTOR	We have isolated the murine Limk1 gene, which is a single copy gene located at the distal end of mouse chromosome 5. Limk1 exhibits a 95% homology to the human homologue, LIMK, which contains two LIM domains and a putative protein kinase domain. Although Limk1 and LIMK contain all motifs found in catalytic kinase domains, amino acids previously described to be diagnostic of either serine/threonine- or tyrosine-kinases are not present. It is demonstrated that GST-Limk1-fusion protein can autophosphorylate on serine, tyrosine and threonine residues in vitro and that mutation of residue D460 within the IHRDL motif abolishes kinase activity. Northern blot showed preferential expression of a 3.5 kb message in adult spinal cord and brain. In situ hybridisation confirmed high expression levels in the nervous system, particularly in the spinal cord and the cranial nerve and dorsal root ganglia. Limk1 also contains two tandem LIM-domains. These zinc-finger like domains can mediate protein-protein interactions and have been described in nuclear and cytoskeletal proteins. The combination of LIM- and kinase domains may provide a novel route by which intracellular signalling can be integrated.			PROSCHEL, C (corresponding author), LUDWIG INST CANC RES, 91 RIDING HOUSE ST, LONDON W1P 8BT, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; ARCHER VEV, 1994, P NATL ACAD SCI USA, V91, P316, DOI 10.1073/pnas.91.1.316; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; DAVIES AH, 1993, BIO-TECHNOL, V11, P933, DOI 10.1038/nbt0893-933; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONG JL, 1991, MOL ENDOCRINOL, V5, P1633, DOI 10.1210/mend-5-11-1633; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FISCH P, 1992, ONCOGENE, V7, P2389; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEVIN DE, 1987, P NATL ACAD SCI USA, V84, P6035, DOI 10.1073/pnas.84.17.6035; LI PM, 1991, P NATL ACAD SCI USA, V88, P9210, DOI 10.1073/pnas.88.20.9210; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MICHELSEN JW, 1994, J BIOL CHEM, V269, P11108; MIZUNO K, 1994, ONCOGENE, V9, P1605; MORAN MF, 1988, ONCOGENE, V3, P665; NADEAU JH, 1984, P NATL ACAD SCI-BIOL, V81, P814, DOI 10.1073/pnas.81.3.814; NORNES HO, 1974, BRAIN RES, V73, P121, DOI 10.1016/0006-8993(74)91011-7; OKANO I, 1993, FEBS LETT, V333, P51, DOI 10.1016/0014-5793(93)80373-3; ORKIN SH, 1992, BLOOD, V80, P575; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; PEREZALVARADO GC, 1994, STRUCT BIOL, V1, P388; PLACZEK M, 1991, DEVELOPMENT, P105; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REITH AD, 1993, ONCOGENE, V8, P45; ROWE LB, 1994, MAMMALIAN GENOME, V5; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SAMBROOK KJ, 1989, MOL CLONING LABORATO; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Scott J D, 1992, Curr Opin Neurobiol, V2, P289, DOI 10.1016/0959-4388(92)90117-4; TAIRA M, 1993, DEV BIOL, V159, P245, DOI 10.1006/dbio.1993.1237; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; TAYLOR SS, 1992, CURR OPIN STRUC BIOL, V2, P743; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; TURNER CE, 1994, J CELL SCI, V107, P1583; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEISKIRCHEN R, 1993, ONCOGENE, V8, P2317; WILKINSON DG, 1992, IN SITU HYBRIDSATION; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; WOODGETT JR, 1989, RECEPTORS PRACTICAL, P133; WU RY, 1994, J BIOL CHEM, V269, P25085; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	82	97	99	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1271	1281						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478547				2022-12-17	WOS:A1995RY96700007
J	LIU, L; LASSAM, NJ; SLINGERLAND, JM; BAILEY, D; COLE, D; JENKINS, R; HOGG, D				LIU, L; LASSAM, NJ; SLINGERLAND, JM; BAILEY, D; COLE, D; JENKINS, R; HOGG, D			GERMLINE P16(INK4A) MUTATION AND PROTEIN DYSFUNCTION IN A FAMILY WITH INHERITED MELANOMA	ONCOGENE			English	Article						CDK INHIBITORS; P16(INK4A); MELANOMA	WILD-TYPE P53; GROWTH; SUPPRESSION; GENE; ONCOGENE; LOCUS; CELLS; MLM	The gene encoding the cell cycle inhibitor p16(INK4A) (also known as p16, MTS1, CDKN2 and INK4) has been mapped to human chromosome band 9p21, a region that also contains a putative melanoma susceptibility gene. Although germline mutations in the coding region of the p16(INK4A) gene have been detected in some families with inherited melanoma, many other families show no evidence of such mutations and hence the role of p16(INK4A) in the development of this tumor is still unclear. In this report, we describe a family with inherited melanoma in which a novel mutation in exon 2 of the p16(INK4A) gene segregates with the disease. The mutant gene encodes a protein with an in-frame deletion of two amino acids (Asp96 and Leu97). We show that the mutant protein is functionally abnormal: it is unable to bind cdk4 in vitro and does not inhibit colony formation in tertiary passage rat embryo fibroblasts. Moreover, in a metastatic lesion from one patient the wild type p16(INK4A) allele was deleted and the mutant allele retained. We conclude that family members carrying this germline mutation in the p16(INK4A) gene are predisposed to melanoma. By extension, these findings implicate the p16(INK4A) gene in the development of some cases of familial melanoma.	TORONTO GEN HOSP,DIV ONCOL RES,TORONTO,ON M5G 2C4,CANADA; TORONTO GEN HOSP,DEPT PATHOL,TORONTO,ON M5G 2C4,CANADA; TORONTO GEN HOSP,DEPT CLIN BIOCHEM,TORONTO,ON M5G 2C4,CANADA; TORONTO SUNNYBROOK REG CANC CTR,DIV MED ONCOL,TORONTO,ON M4N 3M5,CANADA; TORONTO SUNNYBROOK REG CANC CTR,DIV CANC BIOL RES,TORONTO,ON M4N 3M5,CANADA; MAYO CLIN & MAYO FDN,DIV LAB GENET,ROCHESTER,MN 55905	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Mayo Clinic								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BATTISTUTTA D, 1994, LANCET, V344, P1607, DOI 10.1016/S0140-6736(94)90408-1; BONETTA L, 1994, NATURE, V370, P180, DOI 10.1038/370180a0; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CANNONALBRIGHT LA, 1994, CANCER RES, V54, P6041; CANNONALBRIGHT LA, 1994, GENOMICS, V23, P265, DOI 10.1006/geno.1994.1491; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; COLEMAN A, 1994, CANCER RES, V54, P344; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUIS NA, 1995, IN PRESS AM J PATH, V146; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KAUFMAN DK, 1993, NEUROLOGY, V43, P1728, DOI 10.1212/WNL.43.9.1728; LIU L, 1995, IN PRESS ONCOGENE; MACGEOCH C, 1994, HUM MOL GENET, V3, P2195, DOI 10.1093/hmg/3.12.2195; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MYERSON M, 1994, MOL CELL BIOL, V14, P2077; NANCARROW DJ, 1992, GENOMICS, V12, P18, DOI 10.1016/0888-7543(92)90401-D; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHTA M, 1994, CANCER RES, V54, P5269; PENG HQ, 1993, CANCER RES, V53, P3574; ROVINSKI B, 1988, ONCOGENE, V2, P445; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SPRUCK CH, 1994, NATURE, V265, P183; WAINWRIGHT B, 1994, NAT GENET, V8, P3, DOI 10.1038/ng0994-3; WALKER GJ, 1994, ONCOGENE, V9, P819; XU L, 1994, CANCER RES, V54, P5262	42	97	99	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					405	412						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624155				2022-12-17	WOS:A1995RK95700022
J	GARDNER, HAR; BERSE, B; SENGER, DR				GARDNER, HAR; BERSE, B; SENGER, DR			SPECIFIC REDUCTION IN OSTEOPONTIN SYNTHESIS BY ANTISENSE RNA INHIBITS THE TUMORIGENICITY OF TRANSFORMED RAT1 FIBROBLASTS	ONCOGENE			English	Article							NEOPLASTIC TRANSFORMATION; SECRETED PHOSPHOPROTEIN; BONE SIALOPROTEIN; MESSENGER-RNA; DEVELOPMENTAL EXPRESSION; ALPHA-V-BETA-3 INTEGRIN; BINDING-PROPERTIES; TUMOR PROGRESSION; GENE-EXPRESSION; CELL-ADHESION	Osteopontin (OPN) is a secreted phosphoglycoprotein abundant in secretory luminal epithelia (Brown et al., 1992) and in bone (Reinholt et al., 1990). It contains a functional gly-arg-gly-asp-ser (GRGDS) integrin binding domain (Oldberg ct al., 1986), promotes the adhesion of a variety of cell types (Somerman et al., 1989; Brown et al., 1992) and is a ligand for the vitronectin binding integrin alpha v beta 3 (Miyauchi et al., 1991). Elevated expression of OPN correlates with tumorigenic transformation in a great variety of stromal and epithelial cell lines (Senger et al., 1980, 1983, 1989; Craig et al., 1988; Chambers et al., 1992; Chang and Prince, 1993). The protein is also present in excess in the blood of patients with metastatic disease (Senger et al., 1988). To find whether OPN contributes significantly to the tumorigenic phenotype, we expressed antisense mRNA to OPN in high OPN producing malignant B77-Rat1 fibroblasts. This caused a reduction in their OPN secretion and reduced their ability to form both lung tumors in nude mice after intravenous injection, and colonies in soft agar. Antisense transfectants also showed increased spreading on vitronectin. These observations suggest that OPN overproduction is advantageous to the metastatic phenotype, possibly by altering adhesion via, or signal transduction from, vitronectin receptors.	BETH ISRAEL HOSP,DEPT PATHOL,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center				Berse, Brygida/0000-0002-0735-2792	NCI NIH HHS [CA 34025] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R23CA034025, R01CA034025] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1990, CANCER RES, V50, P6757; BEHREND EI, 1994, CANCER RES, V54, P832; BOUKERCHE H, 1989, BLOOD, V74, P909; BROWN LF, 1992, MOL BIOL CELL, V3, P1169, DOI 10.1091/mbc.3.10.1169; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; CHANG PL, 1993, CANCER RES, V53, P2217; CHEN JK, 1993, MATRIX, V13, P113, DOI 10.1016/S0934-8832(11)80070-3; CHEN Y, 1992, J BIOL CHEM, V267, P24871; CRAIG AM, 1988, BIOCHEM BIOPH RES CO, V157, P166, DOI 10.1016/S0006-291X(88)80028-7; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; HART IR, 1991, CANCER METAST REV, V10, P115, DOI 10.1007/BF00049409; HWANG S, 1994, J BIOL CHEM, V269, P711; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOHRI K, 1993, J BIOL CHEM, V268, P15180; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MCDONNELL S, 1990, CANCER METAST REV, V9, P305; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SENGER DR, 1983, NATURE, V302, P714, DOI 10.1038/302714a0; SENGER DR, 1980, NATURE, V286, P619, DOI 10.1038/286619a0; SENGER DR, 1985, CANCER RES, V45, P5818; SENGER DR, 1988, CANCER RES, V48, P5770; SENGER DR, 1989, ANTICANCER RES, V9, P1291; SINGH K, 1993, J BIOCHEM-TOKYO, V114, P702, DOI 10.1093/oxfordjournals.jbchem.a124240; SOMERMAN MJ, 1989, MATRIX, V9, P49, DOI 10.1016/S0934-8832(89)80018-6; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269	34	97	99	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2321	2326						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036014				2022-12-17	WOS:A1994NX62900025
J	HIMES, SR; COLES, LS; KATSIKEROS, R; LANG, RK; SHANNON, MF				HIMES, SR; COLES, LS; KATSIKEROS, R; LANG, RK; SHANNON, MF			HTLV-1 TAX ACTIVATION OF THE GM-CSF AND G-CSF PROMOTERS REQUIRES THE INTERACTION OF NF-KB WITH OTHER TRANSCRIPTION FACTOR FAMILIES	ONCOGENE			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; COLONY-STIMULATING FACTOR; TUMOR NECROSIS FACTOR; LONG TERMINAL REPEAT; KAPPA-B; FACTOR GENE; TRANS-ACTIVATION; INTERLEUKIN-2 RECEPTOR; NUCLEAR FACTOR	The trans-activator protein, tax, from the human T leukemia virus type 1 (HTLV-1) trans-activates both viral and cellular genes. It has previously been shown that granulocyte macrophage-colony stimulating factor (GM-CSF) is constitutively expressed in HTLV-1 infected cells and in cells artificially expressing tax. We show here that the GM-CSF promoter is tax responsive in fibroblasts and T cells, whereas the granulocyte (G)-CSF promoter is tax responsive only in fibroblasts. The tax protein can activate cellular genes through at least two families of transcription factors; the NF-kB/rel and CREB/ATF families. We have used mutant tax proteins to show that the activation of NF-kB proteins is essential for tax trans-activation of both the GM-CSF and G-CSF promoters. The ability of tax to activate CREB/ATF proteins is also essential for GM-CSF trans-activation. We have identified a 44 bp region of the GM-CSF promoter that contains tax responsive elements. This region contains a classical NF-kB site, a CK-1 element that can bind the NF-kB p65 protein, as well as a putative ATF binding site. The tax response of the G-CSF promoter requires not only the conserved CK-1 sequence but also an adjacent NF-IL6 binding site that may explain the cell restricted function of the G-CSF promoter.	INST MED & VET SCI,HANSON CTR CANC RES,DIV HUMAN IMMUNOL,ADELAIDE,SA 5000,AUSTRALIA	Institute Medical & Veterinary Science Australia								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALEXANDRE C, 1991, ONCOGENE, V6, P1851; AZIZUKI S, 1987, LANCET, V1, P156; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GREEN JE, 1989, MOL CELL BIOL, V9, P4731, DOI 10.1128/MCB.9.11.4731; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3653, DOI 10.1073/pnas.84.11.3653; JACOBSON S, 1988, NATURE, V331, P540, DOI 10.1038/331540a0; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; KOEFFLER HP, 1988, MOL CELL BIOL, V8, P3432, DOI 10.1128/MCB.8.8.3432; KUCZEK ES, 1991, J IMMUNOL, V146, P2426; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NIMER SD, 1989, ONCOGENE, V4, P671; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PICCARDO P, 1988, ANN NEUROL S, V23, P156; ROONEY RJ, 1990, MOL CELL BIOL, V10, P5138, DOI 10.1128/MCB.10.10.5138; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; Shannon MF, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046923; SHANNON MF, 1988, P NATL ACAD SCI USA, V85, P674, DOI 10.1073/pnas.85.3.674; SHANNON MF, 1990, MOL CELL BIOL, V10, P2950, DOI 10.1128/MCB.10.6.2950; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUGIMOTO K, 1990, INT IMMUNOL, V2, P787, DOI 10.1093/intimm/2.8.787; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TAN TH, 1989, MOL CELL BIOL, V9, P1733, DOI 10.1128/MCB.9.4.1733; WACHSMAN W, 1986, SEMIN HEMATOL, V23, P246; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WOOD KV, 1991, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P543; XU YL, 1990, J BIOL CHEM, V265, P20285; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	46	97	98	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3189	3197						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	7504230				2022-12-17	WOS:A1993MG78200001
J	REID, RL; LINDHOLM, PF; MIRESKANDARI, A; DITTMER, J; BRADY, JN				REID, RL; LINDHOLM, PF; MIRESKANDARI, A; DITTMER, J; BRADY, JN			STABILIZATION OF WILD-TYPE P53 IN HUMAN T-LYMPHOCYTES TRANSFORMED BY HTLV-I	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; VIRUS TYPE-I; HUMAN PAPILLOMAVIRUS TYPE-16; CORD BLOOD-LYMPHOCYTES; MONOCLONAL-ANTIBODIES; LEUKEMIA LYMPHOMA; SV40-TRANSFORMED CELLS; ACTIVATING MUTATIONS; INCREASED EXPRESSION; MOLECULAR-CLONING	Adult T-cell leukemia/lymphoma is an aggressive malignancy associated with infection by the human T-lymphotropic virus type-I (HTLV-1). We now demonstrate that p53 expression is elevated in the HTLV-1-transformed T-lymphocyte lines C81, MT-2, MT-4 and HUT 102. In pulse-chase experiments, the p53 protein demonstrated a prolonged half-life of 2 to 8 h in HTLV-1-transformed cells compared with 0.5 to 1.0 h for wild-type p53 in primary human and murine fibroblasts, or human peripheral blood lymphocytes. In cell lines C81 and HUT 102, which exhibited the longest p53 protein half-life, the wild-type-related PAb1620 epitope was detected at reduced levels. The PAb240 mutant-related p53 epitope was not detected in any of the transformed cell lines. By direct sequence analysis of RT-PCR products, the entire p53 cDNA coding sequence was determined to be wild-type in all four cell lines. Stabilization of wild-type p53 may represent its functional inactivation and contribute to lymphocyte transformation by HTLV-I.	NCI,MOLEC VIROL LAB,BLDG 41,ROOM B602,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Dittmer, Juergen/G-1160-2011					BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIECOBIANCHI L, 1988, LEUKEMIA, V2, pS223; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; KONDO T, 1987, LANCET, V2, P159; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUBBERT M, 1989, ONCOGENE, V4, P643; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MARUYAMA K, 1990, CANCER RES, V50, pS5697; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER J, 1992, ONCOGENE, V7, P661; NAGAI H, 1991, JPN J CANCER RES, V82, P1421, DOI 10.1111/j.1349-7006.1991.tb01815.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROWLEY JD, 1984, HUMAN T CELL LEUKEMI, P85; SAKASHITA A, 1992, BLOOD, V79, P477; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SANADA I, 1985, BLOOD, V65, P649; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEIKI M, 1982, P NATL ACAD SCI-BIOL, V79, P6899, DOI 10.1073/pnas.79.22.6899; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; SOUSSI T, 1990, ONCOGENE, V5, P945; SQUIRES J, 1988, P AM ASSOC CANC RES, V29, P454; SUGITO S, 1991, INT J CANCER, V49, P880, DOI 10.1002/ijc.2910490614; TOKUDOME S, 1989, CANCER RES, V49, P226; UESHIMA Y, 1981, BLOOD, V58, P420; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; YEARGIN J, 1992, LEUKEMIA, V6, pS85; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	73	97	98	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3029	3036						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414503				2022-12-17	WOS:A1993MC09300017
J	ZHANG, W; FUNK, WD; WRIGHT, WE; SHAY, JW; DEISSEROTH, AB				ZHANG, W; FUNK, WD; WRIGHT, WE; SHAY, JW; DEISSEROTH, AB			NOVEL DNA-BINDING OF P53 MUTANTS AND THEIR ROLE IN TRANSCRIPTIONAL ACTIVATION	ONCOGENE			English	Note							WILD-TYPE P53; ACUTE MYELOGENOUS LEUKEMIA; MONOCLONAL-ANTIBODIES; GENE AMPLIFICATION; PROTEIN; EXPRESSION; CELLS; SITE; WILD-TYPE-P53; ELEMENT	The protein product of the normal p53 gene binds to the DNA p53CON element (GGACATGCCCGGGCATGTCC, Funk et al., 1992), thereby activating transcription from adjacent promoters. Two mutants, 248 (Arg-->Trp) and 281 (Asp-->Gly), failed to bind p53CON and to activate transcription. However, in contrast to previous reports that all p53 mutants fail to bind to the other p53 binding elements, two p53 mutants, 143 (Val-->Ala) and 273 (Arg-->His), retained both p53CON binding and transcriptional activation functions. A third mutant 175 (Arg-->His) bound to the p53CON but did not activate transcription. These data suggest that the DNA binding and transcriptional activation functions of p53 mutants in tumor cells are dependent on the specific missense mutations acquired in the p53 gene and the target sequences of p53 in the genome.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,BOX 24,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; UNIV TEXAS,SW MED CTR DALLAS,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Shay, Jerry W/F-7878-2011		NATIONAL CANCER INSTITUTE [P01CA055164, R01CA050195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER; NCI NIH HHS [CA50195, P01 CA55164] Funding Source: Medline; NIA NIH HHS [AG07992] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARTWELL L, 1992, CELL, V71, P542; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HU GY, 1992, BRIT J HAEMATOL, V81, P489, DOI 10.1111/j.1365-2141.1992.tb02979.x; HUPP TP, 1992, CELL, V27, P875; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SOUSSI T, 1990, ONCOGENE, V5, P945; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1992, P NATL ACAD SCI USA, V89, P3952, DOI 10.1073/pnas.89.9.3952; ZHANG W, 1992, ONCOGENE, V7, P1645; ZHANG W, 1992, GENE, V117, P271, DOI 10.1016/0378-1119(92)90738-B; ZHANG W, 1993, IN PRESS CANCER RES	34	97	97	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2555	2559						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361764				2022-12-17	WOS:A1993LT36800028
J	MONTENARH, M				MONTENARH, M			BIOCHEMICAL-PROPERTIES OF THE GROWTH SUPPRESSOR ONCOPROTEIN P53	ONCOGENE			English	Review							LARGE-T-ANTIGEN; CELLULAR TUMOR-ANTIGEN; TRANSFORMATION-RELATED PROTEIN; HEAT-SHOCK PROTEINS; WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; VIRUS 40-TRANSFORMED CELLS; AMINO-ACID-SEQUENCE; SIMIAN VIRUS-40; MUTANT P53	The cellular p53 protein is so called because of its molecular weight as determined by SDS-polyacrylamide gel electrophoresis. It was originally classified as a nuclear oncogene product when it was shown by DNA transfection experiments that p53 is able to extend the lifespan of primary rodent cell cultures and to cooperate with an activated ras oncogene to achieve complete transformation of primary cells. However, there is now conclusive evidence that loss of normal p53 expression may be an important step in cell transformation and tumorigenesis. Furthermore, it has been shown that mutant p53 was used for the experiments demonstrating the immortalizing and transforming capacity of p53. Wild-type p53 seems to negatively regulate cell growth and division. So far, the basic function of p53 is not known. Biochemical variability seems to be a key feature of p53 and an understanding of biochemical variations in the p53 protein may contribute to an understanding of how p53 is regulated or how p53 may regulate cell proliferation. Thus, the present review will focus on the biochemical properties of p53.			MONTENARH, M (corresponding author), UNIV SAARLAND,BLDG 44,W-6650 HOMBURG,GERMANY.							ADDISON C, 1990, ONCOGENE, V5, P423; Anderson CW., 1986, CANC CELLS, V4, P395; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BENCHIMOL S, 1985, SOMAT CELL MOLEC GEN, V11, P505, DOI 10.1007/BF01534845; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BENDORI R, 1983, FEBS LETT, V162, P384; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLAIR ZM, 1988, ONCOGENE, V2, P579; BRAITHWAITE AW, 1991, ONCOGENE, V6, P781; CARROLL RB, 1982, J VIROL, V44, P565, DOI 10.1128/JVI.44.2.565-573.1982; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; COULIER F, 1985, EMBO J, V4, P3413, DOI 10.1002/j.1460-2075.1985.tb04098.x; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; CROOK T, 1991, ONCOGENE, V6, P1251; CZOSNEK HH, 1984, MOL CELL BIOL, V4, P1638, DOI 10.1128/MCB.4.8.1638; DANG CV, 1989, J BIOL CHEM, V264, P18019; DEFROMENTEL CC, 1992, GENE, V112, P241, DOI 10.1016/0378-1119(92)90383-Z; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EHRHART JC, 1988, ONCOGENE, V3, P595; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FANNING E, 1981, J GEN VIROL, V55, P367, DOI 10.1099/0022-1317-55-2-367; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FREED MI, 1983, J VIROL, V46, P1061, DOI 10.1128/JVI.46.3.1061-1065.1983; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; IGUCHIARIGA SMM, 1988, ONCOGENE, V3, P509; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JAY G, 1981, P NATL ACAD SCI-BIOL, V78, P2932, DOI 10.1073/pnas.78.5.2932; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JENKINS JR, 1988, ONCOGENE HDB, P403; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KRAISS S, 1992, BIOCHIM BIOPHYS ACTA, V1119, P11, DOI 10.1016/0167-4838(92)90227-5; KRAISS S, 1990, ONCOGENE, V5, P845; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; KRAISS S, 1990, LEUKEMIA RES, V14, P1041, DOI 10.1016/0145-2126(90)90118-S; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEPPARD K, 1983, EMBO J, V2, P1457, DOI 10.1002/j.1460-2075.1983.tb01608.x; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1990, VIROLOGY, V176, P302, DOI 10.1016/0042-6822(90)90258-S; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MCCORMICK F, 1980, J VIROL, V34, P213, DOI 10.1128/JVI.34.1.213-224.1980; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1986, MOL CELL BIOL, V6, P3531, DOI 10.1128/MCB.6.10.3531; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; MILNER J, 1989, ONCOGENE, V4, P665; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1985, VIROLOGY, V147, P206, DOI 10.1016/0042-6822(85)90240-5; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1986, VIROLOGY, V150, P265, DOI 10.1016/0042-6822(86)90286-2; MILNER J, 1990, ONCOGENE, V5, P1683; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MONTENARH M, 1987, J VIROL, V61, P940, DOI 10.1128/JVI.61.3.940-944.1987; MONTENARH M, 1985, EMBO J, V4, P2941, DOI 10.1002/j.1460-2075.1985.tb04027.x; MONTENARH M, 1986, J VIROL, V60, P761, DOI 10.1128/JVI.60.2.761-764.1986; MONTENARH M, 1989, ONCOGENE, V4, P379; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; OREN M, 1983, P NATL ACAD SCI-BIOL, V80, P56, DOI 10.1073/pnas.80.1.56; OREN M, 1992, MOL CELL BIOL, V7, P661; ORTTER V, 1991, ADV CANCER RES, V57, P257; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PUVION E, 1988, EXP CELL RES, V177, P73, DOI 10.1016/0014-4827(88)90026-2; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REIHSAUS E, 1990, ONCOGENE, V5, P137; RIGAUDY P, 1989, NUCLEIC ACIDS RES, V17, P8375, DOI 10.1093/nar/17.20.8375; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROMANO JW, 1989, ONCOGENE, V4, P1483; ROTTER V, 1984, MOL CELL BIOL, V4, P383, DOI 10.1128/MCB.4.2.383; ROTTER V, 1983, J IMMUNOL, V131, P329; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; ROTTER V, 1983, P NATL ACAD SCI-BIOL, V80, P2613, DOI 10.1073/pnas.80.9.2613; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; ROVINSKI B, 1988, ONCOGENE, V2, P445; SAMAD A, 1991, MOL CELL BIOL, V11, P1598, DOI 10.1128/MCB.11.3.1598; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SANTOS M, 1984, J VIROL, V49, P50, DOI 10.1128/JVI.49.1.50-56.1984; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SCHMIEG FI, 1984, J VIROL, V52, P350, DOI 10.1128/JVI.52.2.350-355.1984; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHOHAT O, 1987, ONCOGENE, V1, P277; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1987, VIROLOGY, V160, P445; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; SYMONDS H, 1991, J VIROL, V65, P5417, DOI 10.1128/JVI.65.10.5417-5424.1991; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; THOMAS R, 1983, VIROLOGY, V131, P502, DOI 10.1016/0042-6822(83)90516-0; VANROY F, 1984, MOL CELL BIOL, V4, P232, DOI 10.1128/MCB.4.2.232; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILLIAMS NW, 1989, EXP CELL RES, V184, P316, DOI 10.1016/0014-4827(89)90331-5; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	156	97	100	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1673	1680						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501881				2022-12-17	WOS:A1992JJ37600001
J	CHEN, JD; TOBIN, GJ; PIPAS, JM; VANDYKE, T				CHEN, JD; TOBIN, GJ; PIPAS, JM; VANDYKE, T			T-ANTIGEN MUTANT ACTIVITIES INVIVO - ROLES OF P53-BINDING AND PRB-BINDING IN TUMORIGENESIS OF THE CHOROID-PLEXUS	ONCOGENE			English	Article							SV40 LARGE-T; RETINOBLASTOMA SUSCEPTIBILITY GENE; LARGE TUMOR-ANTIGEN; RAT EMBRYO FIBROBLASTS; SIMIAN VIRUS-40; TRANSGENIC MICE; SV40-TRANSFORMED CELLS; HYDROPHOBIC REGION; P53 GENE; TRANSFORMATION	To study the mechanism by which SV40 large T antigen transforms cells under physiological conditions, we analysed several mutant forms of T antigen for their ability to induce cell proliferation and tumorigenesis in transgenic mice. These mutant proteins, which differ in their ability to form complexes with the tumor suppressors pRB and p53, were analysed under conditions in which wild-type T antigen induces choroid plexus papillomas as a result of uniform proliferation of the entire choroid plexus epithelium. The results presented here show that binding of T antigen to p53 is not required for induction of choroid plexus tumors. However, tumorigenesis does appear to require the binding of T antigen to pRB/p107. An additional activity, resident in the amino-terminal one-fifth of the protein, may also play a role. These experiments indicate the importance of whole-animal assays in determining the molecular basis of transformation, since each of these mutants possessed similar transformation phenotypes in culture but showed distinct phenotypes in the choroid plexus of the animal.			VANDYKE, T (corresponding author), UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260, USA.			Tobin, Gregory/0000-0002-8396-0466	NATIONAL CANCER INSTITUTE [R01CA040586, R37CA040586, R01CA046283] Funding Source: NIH RePORTER; NCI NIH HHS [CA-46283, CA40586] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASSELIN C, 1985, J VIROL, V56, P958, DOI 10.1128/JVI.56.3.958-968.1985; CHEN J, 1991, IN PRESS MOL CELL BI, V11; CHEN JD, 1989, J VIROL, V63, P2204, DOI 10.1128/JVI.63.5.2204-2214.1989; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; CLARK R, 1983, MOL CELL BIOL, V3, P220, DOI 10.1128/MCB.3.2.220; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; ERSELIUS JR, 1990, J VIROL, V64, P1657, DOI 10.1128/JVI.64.4.1657-1666.1990; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; JENKINS JR, 1988, ONCOGENE HDB, P403; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MANFREDI JJ, 1990, J VIROL, V64, P5250, DOI 10.1128/JVI.64.11.5250-5259.1990; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MICHALOVITZ D, 1987, J VIROL, V61, P2648, DOI 10.1128/JVI.61.8.2648-2654.1987; MOLE SE, 1987, PHILOS T ROY SOC B, V317, P455, DOI 10.1098/rstb.1987.0072; MONIER R, 1986, PAPOVAVIRIDAE; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PAWLITA M, 1984, CURR TOP MICROBIOL, V113, P26; PEDEN KWC, 1990, J VIROL, V64, P2912, DOI 10.1128/JVI.64.6.2912-2921.1990; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PINKERT CA, 1987, VIROLOGY, V160, P169, DOI 10.1016/0042-6822(87)90057-2; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SOMPAYRAC L, 1988, VIROLOGY, V163, P391, DOI 10.1016/0042-6822(88)90279-6; SOMPAYRAC L, 1991, VIROLOGY, V181, P412, DOI 10.1016/0042-6822(91)90516-E; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; TEITELMAN G, 1988, CELL, V52, P97, DOI 10.1016/0092-8674(88)90534-X; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; [No title captured]	51	97	101	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1167	1175						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1317542				2022-12-17	WOS:A1992HU64200014
J	MAZARS, GR; PORTIER, M; ZHANG, XG; JOURDAN, M; BATAILLE, R; THEILLET, C; KLEIN, B				MAZARS, GR; PORTIER, M; ZHANG, XG; JOURDAN, M; BATAILLE, R; THEILLET, C; KLEIN, B			MUTATIONS OF THE P53 GENE IN HUMAN MYELOMA CELL-LINES	ONCOGENE			English	Note							MULTIPLE-MYELOMA; GROWTH; INTERLEUKIN-6; EVOLUTION; LEUKEMIA; PROTEIN	Mutations affecting the p53 gene have been found associated with many human malignancies, but little is as yet known about multile myeloma. We investigated p53 gene alterations in 10 human myeloma cell lines (HMCL), half of these being dependent upon exogenous interleukin 6(IL-6) for in vitro growth, similar to freshly explanted myeloma cells. Using a polymerase chain reaction - single-strand conformation polymorphism (PCR-SSCP) approach, eight of the 10 HMCL were found to bear a mutated p53 gene. All the mutations were single base substitutions with a predominance of G:C to A:T transitions. There was no apparent relation between the presence of a mutation and IL-6 requirement of the cell line. Interestingly, in two cell lines (XG-2 and XG-4) the SSCP pattern showed the presence of both the wild-type and the mutated allele and, upon reverse PCR on RNA, both alleles were found to be concomitantly expressed at the RNA level. Moreover, three freshly explanted tumor samples had the same p53 gene status (mutated versus wild type) as the HMCL that were derived from them. These results show that p53 mutations are frequent in HMCL. Although no apparent relation could be evidenced with the loss of exogenous IL-6 requirement, it may prove interesting to investigate further potential relations between the presence of a mutated p53 allele and gradual autonomy for cell growth.	INSERM,U291,99 RUE PUECH VILLA,F-34100 MONTPELLIER,FRANCE; UNIV MONTPELLIER 2,GENET MOLEC LAB,CNRS,UA 1191,F-34094 MONTPELLIER 5,FRANCE; HOP ST ELOI,CTR GUI DE CHAULIAC,CONSULAT IMMUNORHUMATOL,F-34059 MONTPELLIER,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier			Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759				AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; DURIE BGM, 1985, BLOOD, V66, P548; ELIYAHU D, 1988, ONCOGENE, V3, P313; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HAMILTON MS, 1990, BRIT J HAEMATOL, V75, P378, DOI 10.1111/j.1365-2141.1990.tb04352.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKSON N, 1989, CLIN EXP IMMUNOL, V75, P93; JOURDAN M, 1991, J IMMUNOL, V147, P4402; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Klein B, 1990, Eur Cytokine Netw, V1, P193; KLEIN B, 1989, BLOOD, V73, P517; KLEIN B, 1991, BLOOD, V78, P1198; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOORE GE, 1968, NEW YORK STATE J MED, V68, P2054; NILSSON K, 1970, CLIN EXP IMMUNOL, V7, P447; PALUMBO AP, 1989, CANCER RES, V49, P4701; PORTIER M, 1991, EUR J IMMUNOL, V21, P1759, DOI 10.1002/eji.1830210727; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Sambrook J., 1989, MOL CLONING; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SLINGERLAND JM, 1991, BLOOD, V77, P1500; SNATHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605; SOUSSI T, 1990, ONCOGENE, V5, P945; SUGIMOTO K, 1991, BLOOD, V77, P1153; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG XG, 1989, BLOOD, V74, P11	30	97	98	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					1015	1018						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373872				2022-12-17	WOS:A1992HP64200024
J	CROOK, T; WREDE, D; TIDY, J; SCHOLEFIELD, J; CRAWFORD, L; VOUSDEN, KH				CROOK, T; WREDE, D; TIDY, J; SCHOLEFIELD, J; CRAWFORD, L; VOUSDEN, KH			STATUS OF C-MYC, P53 AND RETINOBLASTOMA GENES IN HUMAN PAPILLOMAVIRUS POSITIVE AND NEGATIVE SQUAMOUS-CELL CARCINOMAS OF THE ANUS	ONCOGENE			English	Article								We have examined a series of squamous cell carcinomas (SCC) of the anus, anal intraepithelial neoplasia grade III (AINIII) lesions and haemorrhoids for the presence of sequences from transforming human papillomavirus (HPV) types by polymerase chain reaction (PCR)/Southern blotting. In addition, the same DNAs have been analysed for abnormalities in the c-myc, p53 and retinoblastoma (Rb-1) gene loci by Southern blotting. HPV16 sequences were detected in a total of 38 of 50 (76%) and HPV18 sequences in 4 of the 50 cancers (8%). Of 12 haemorrhoids examined, none contained HPV16 or HPV18 sequences. Amplification of c-myc was demonstrated in 15 of the 50 cancers (30%), of which 13 were HPV16 positive, and one also positive for HPV18. Amplification of c-myc was not observed in the 5 AINIII or any of the 41 haemorrhoid DNAs analysed. Rearrangement of c-myc was not seen in any of the DNAs. Gross rearrangement, or loss of p53 or Rb-1 loci was not observed in any normal or tumour tissue. However, in preliminary analysis of p53 sequence, three tumours negative for HPV were heterozygous for p53 point mutation whereas six HPV positive tumours and two haemorrhoids were wild-type sequence throughout exons four to ten.	ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, NORFOLK PL, LONDON WC2, ENGLAND; SAMARITAN HOSP WOMEN, DEPT GYNAECOL, LONDON NW1, ENGLAND; UNIV CAMBRIDGE, DEPT PATHOL, IMPERIAL CANCER RES FUND, TUMOUR VIRUS GRP, CAMBRIDGE CB2 1QP, ENGLAND; UNIV SHEFFIELD, NO GEN HOSP, CTR CLIN SCI, SURG UNIT, SHEFFIELD S5 7AU, ENGLAND	Ludwig Institute for Cancer Research; University of Cambridge; Northern General Hospital; University of Sheffield	VOUSDEN, KH (corresponding author), ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, NORFOLK PL, LONDON WC2, ENGLAND.							Austin D F, 1982, Natl Cancer Inst Monogr, V62, P89; BARTEK J, 1990, ONCOGENE, V5, P893; BECKMANN AM, 1989, INT J CANCER, V43, P1042, DOI 10.1002/ijc.2910430615; CHIBA I, 1990, ONCOGENE, V5, P1603; CROOK T, 1990, ONCOGENE, V5, P619; CROOK T, 1989, MOL CARCINOGEN, V2, P308, DOI 10.1002/mc.2940020605; CROOK T, 1991, IN PRESS J VIROL; CROOK T, 1991, IN PRESS ONCOGENE; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; DARLING SM, 1986, P NATL ACAD SCI USA, V83, P135, DOI 10.1073/pnas.83.1.135; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HAUSEN HZ, 1988, MOL CARCINOGEN, V1, P147, DOI 10.1002/mc.2940010302; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KONDOLEON S, 1987, NUCLEIC ACIDS RES, V15, P10605, DOI 10.1093/nar/15.24.10605; MORI N, 1990, ONCOGENE, V5, P1713; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OCADIZ R, 1987, CANCER RES, V47, P4173; PALMER JG, 1987, LANCET, V2, P42; PALMER JG, 1989, DIS COLON RECTUM, V32, P1016, DOI 10.1007/BF02553872; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; REISSMANN PT, 1989, ONCOGENE, V4, P839; RIOU G, 1987, LANCET, V1, P761; RIOU G, 1990, LANCET, V335, P1171; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCHEURLEN W, 1986, INT J CANCER, V38, P671, DOI 10.1002/ijc.2910380509; SCHOLEFIELD JH, 1989, LANCET, V2, P765; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TUCK SP, 1989, ONCOGENE RES, V4, P81; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YOUNG LS, 1989, BRIT MED J, V298, P14, DOI 10.1136/bmj.298.6665.14	37	97	98	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1991	6	7					1251	1257						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650445				2022-12-17	WOS:A1991GV26000022
J	SITHANANDAM, G; KOLCH, W; DUH, FM; RAPP, UR				SITHANANDAM, G; KOLCH, W; DUH, FM; RAPP, UR			COMPLETE CODING SEQUENCE OF A HUMAN B-RAF CDNA AND DETECTION OF B-RAF PROTEIN-KINASE WITH ISOZYME SPECIFIC ANTIBODIES	ONCOGENE			English	Article							SIGNAL TRANSDUCTION; BIOLOGICAL-ACTIVITY; FISSION YEAST; A-RAF; V-RAF; ONCOGENE; GENES; MIL; PHOSPHORYLATION; REQUIREMENT	A 2.2kb cDNA clone which presumably includes the complete human B-raf coding sequence was isolated from a human testes cDNA library. Sequence analysis showed the presence of all three conserved regions CR1, CR2 and CR3 previously identified in raf protein kinases. The cDNA was expressed in E. coli yielding a B-raf fusion protein which reacts with antibodies specific for B-raf raised against the C-terminal peptide as well as with monoclonal antibodies which map into the kinase domain.	NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Kolch, Walter/ABF-2102-2021	Kolch, Walter/0000-0001-5777-5016				BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BECK TW, 1990, MOL CELL BIOL, V10, P3325, DOI 10.1128/MCB.10.7.3325; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOZIER C, 1988, MOL CELL BIOL, V8, P1835, DOI 10.1128/MCB.8.4.1835; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HEIDECKER G, 1989, GENES SIGNAL TRANSDU, P339; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KOLCH W, 1990, ONCOGENE, V5, P713; LEE M, 1988, TRENDS GENET, V4, P287, DOI 10.1016/0168-9525(88)90171-0; MALLER JL, 1989, J CELL SCI S, V12, P53; MIHALY A, 1990, NEUROSCI LETT, V116, P45, DOI 10.1016/0304-3940(90)90384-L; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1988, HDB ONCOGENES, P213; SCHULTZ AM, 1988, ONCOGENE, V2, P187; SITHANANDAM G, 1989, ONCOGENE, V4, P451; SITHANANDAM G, 1989, MOL DIAGNOSTICS HUMA, P171; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STORM SM, 1990, ONCOGENE, V5, P345; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2	32	97	116	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1990	5	12					1775	1780						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET436	2284096				2022-12-17	WOS:A1990ET43600006
J	CLEMENTI, E; MALGARETTI, N; MELDOLESI, J; TARAMELLI, R				CLEMENTI, E; MALGARETTI, N; MELDOLESI, J; TARAMELLI, R			A NEW CONSTITUTIVELY ACTIVATING MUTATION OF THE GS PROTEIN ALPHA-SUBUNIT-GSP ONCOGENE IS FOUND IN HUMAN PITUITARY-TUMORS	ONCOGENE			English	Note									UNIV MILANO,DEPT GENET & BIOL MICROORGANISMS,I-20132 MILAN,ITALY	University of Milan	CLEMENTI, E (corresponding author), UNIV MILANO,SCI INST S RAFFAELE,CNR,CTR CYTOPHARMACOL,DEPT PHARMACOL,VIA OLGETTINA 60,I-20132 MILAN,ITALY.							BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SPADA A, 1984, ENDOCRINOLOGY, V115, P1203, DOI 10.1210/endo-115-3-1203; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0	18	97	99	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					1059	1061						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	2115641				2022-12-17	WOS:A1990DP41500016
J	WEINER, DB; KOKAI, Y; WADA, T; COHEN, JA; WILLIAMS, WV; GREENE, MI				WEINER, DB; KOKAI, Y; WADA, T; COHEN, JA; WILLIAMS, WV; GREENE, MI			LINKAGE OF TYROSINE KINASE-ACTIVITY WITH TRANSFORMING ABILITY OF THE P185NEU ONCOPROTEIN	ONCOGENE			English	Article									UNIV PENN,SCH MED,DEPT NEUROL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	WEINER, DB (corresponding author), UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,571 MALONEY BLDG,3600 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		Weiner, David B/H-8579-2014	Williams, William/0000-0003-3611-9284				BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BELL JC, 1987, NATURE, V325, P552, DOI 10.1038/325552a0; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COHEN JC, 1989, ONCOGENE, V4, P67; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DANIEL TO, 1985, PNAS, V82, P2084; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAULTON GN, 1986, J IMMUNOL, V136, P2470; GILMORE T, 1985, CELL, V40, P609, DOI 10.1016/0092-8674(85)90209-0; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Maniatis T., 1982, MOL CLONING; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; NICHOLS EJ, 1985, MOL CELL BIOL, V5, P3467, DOI 10.1128/MCB.5.12.3467; PADHY LC, 1982, CELL, V28, P365; RUSSO MW, 1985, J BIOL CHEM, V260, P5205; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1984, FEBS LETT, V175, P387, DOI 10.1016/0014-5793(84)80774-7; STREBHARDT K, 1987, P NATL ACAD SCI USA, V84, P8778, DOI 10.1073/pnas.84.24.8778; WEINER BD, 1988, PNAS, V85, P6077; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEINMASTER G, 1986, EMBO J, V5, P69, DOI 10.1002/j.1460-2075.1986.tb04179.x; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZICK Y, 1984, BIOCHEM BIOPH RES CO, V119, P6, DOI 10.1016/0006-291X(84)91610-3	56	97	103	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1989	4	10					1175	1183						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2571965				2022-12-17	WOS:A1989AU50800003
J	GELINAS, C; TEMIN, HM				GELINAS, C; TEMIN, HM			THE V-REL ONCOGENE ENCODES A CELL-SPECIFIC TRANSCRIPTIONAL ACTIVATOR OF CERTAIN PROMOTERS	ONCOGENE			English	Article									UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [P01CA022443, P30CA007175] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22443, CA-07175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ASSELIN C, 1986, J VIROL, V57, P165, DOI 10.1128/JVI.57.1.165-172.1986; BERK AJ, 1978, P NATL ACAD SCI USA, V75, P1274, DOI 10.1073/pnas.75.3.1274; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; EMBRETSON JE, 1986, J VIROL, V60, P662, DOI 10.1128/JVI.60.2.662-668.1986; FRANKLIN RB, 1974, INTERVIROLOGY, V3, P342, DOI 10.1159/000149771; GARSON K, 1986, BIOCHEM BIOPH RES CO, V134, P716, DOI 10.1016/S0006-291X(86)80479-X; GELINAS C, 1985, VIROLOGY, V146, P233, DOI 10.1016/0042-6822(85)90007-8; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; NEVINS JR, 1986, ADV CANCER RES, V47, P283, DOI 10.1016/S0065-230X(08)60202-X; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; ROSS J, 1976, J MOL BIOL, V106, P403, DOI 10.1016/0022-2836(76)90093-0; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SHIBUYA T, 1982, CANCER RES, V42, P2722; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; THEILEN GH, 1966, J NATL CANCER I, V37, P731; TOOZE J, 1980, MOL BIOL TUMOR VIRUS, V2; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WEAVER RF, 1979, NUCLEIC ACIDS RES, V7, P1175, DOI 10.1093/nar/7.5.1175	38	97	98	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					349	355						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	2856247				2022-12-17	WOS:A1988Q773900001
J	Gallagher, EJ; Zelenko, Z; Neel, BA; Antoniou, IM; Rajan, L; Kase, N; LeRoith, D				Gallagher, E. J.; Zelenko, Z.; Neel, B. A.; Antoniou, I. M.; Rajan, L.; Kase, N.; LeRoith, D.			Elevated tumor LDLR expression accelerates LDL cholesterol-mediated breast cancer growth in mouse models of hyperlipidemia	ONCOGENE			English	Article							MESSENGER-RNA; CELL-GROWTH; RECEPTOR; DENSITY; MICE; HYPERCHOLESTEROLEMIA; ATHEROSCLEROSIS; SURVIVAL; GENE; PROGRESSION	Obesity is associated with an increase in cancer-specific mortality in women with breast cancer. Elevated cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), is frequently seen in obese women. Here, we aimed to determine the importance of elevated circulating LDL, and LDL receptor (LDLR) expression in tumor cells, on the growth of breast cancer using mouse models of hyperlipidemia. We describe two novel immunodeficient mouse models of hyperlipidemia (Rag1(-/-)/LDLR-/- and Rag1(-/-)/ApoE (apolipoprotein E)(-/-) mice) in addition to established immunocompetent LDLR-/- and ApoE(-/-) mice. The mice were used to study the effects of elevated LDL-C in human triple-negative (MDA-MB-231) and mouse Her2/Neu-overexpressing (MCNeuA) breast cancers. Tumors derived from MCNeuA and MDA-MB-231 cells had high LDLR expression and formed larger tumors in mice with high circulating LDL-C concentrations than in mice with lower LDL-C. Silencing the LDLR in the tumor cells led to decreased growth of Her2/Neu-overexpressing tumors in LDLR-/- and ApoE(-/-) mice, with increased Caspase 3 cleavage. Additionally, in vitro, silencing the LDLR led to decreased cell survival in serum-starved conditions, associated with Caspase 3 cleavage. Examining publically available human data sets, we found that high LDLR expression in human breast cancers was associated with decreased recurrence-free survival, particularly in patients treated with systemic therapies. Overall, our results highlight the importance of the LDLR in the growth of triple-negative and HER2-overexpressing breast cancers in the setting of elevated circulating LDL-C, which may be important contributing factors to the increased recurrence and mortality in obese women with breast cancer.	[Gallagher, E. J.; Zelenko, Z.; Neel, B. A.; Antoniou, I. M.; Rajan, L.; Kase, N.; LeRoith, D.] Icahn Sch Med Mt Sinai, Div Endocrinol Diabet & Bone Dis, Dept Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Gallagher, EJ (corresponding author), Icahn Sch Med Mt Sinai, Div Endocrinol Diabet & Bone Dis, Dept Med, New York, NY 10029 USA.	Emily.Gallagher@mssm.edu			NCI/NIH [K08 CA190779, R01 CA200553]; Tisch Cancer Institute at Mount Sinai Junior Scientist Award; NATIONAL CANCER INSTITUTE [R01CA190779, K08CA190770, R01CA200553] Funding Source: NIH RePORTER	NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Tisch Cancer Institute at Mount Sinai Junior Scientist Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research in this study was funded by NCI/NIH K08 CA190779 to EJG, NCI/NIH R01 CA200553 to DLR and Tisch Cancer Institute at Mount Sinai Junior Scientist Award to EJG. We would like to acknowledge the Icahn School of Medicine at Mount Sinai Mouse Genetics and Gene Targeting Core Facility, Translational and Molecular Imaging Core facility and the Biorepository and Pathology Core Facility.	Alberti KGMM, 2006, DIABETIC MED, V23, P469, DOI 10.1111/j.1464-5491.2006.01858.x; Alikhani N, 2013, ONCOGENE, V32, P961, DOI 10.1038/onc.2012.113; Antalis CJ, 2011, CLIN EXP METASTAS, V28, P733, DOI 10.1007/s10585-011-9405-9; Badana A, 2016, J BREAST CANCER, V19, P372, DOI 10.4048/jbc.2016.19.4.372; Bahl M, 2005, BREAST CANCER RES TR, V94, P135, DOI 10.1007/s10549-005-6654-9; Bieghs V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030668; BROWN MS, 1974, SCIENCE, V185, P61, DOI 10.1126/science.185.4145.61; Buffa FM, 2011, CANCER RES, V71, P5635, DOI 10.1158/0008-5472.CAN-11-0489; Campbell MJ, 2002, IN VITRO CELL DEV-AN, V38, P326; Chahil TJ, 2006, ENDOCRIN METAB CLIN, V35, P491, DOI 10.1016/j.ecl.2006.06.002; Chanrion M, 2008, CLIN CANCER RES, V14, P1744, DOI 10.1158/1078-0432.CCR-07-1833; Choudhury RP, 2004, ARTERIOSCL THROM VAS, V24, P1904, DOI 10.1161/01.ATV.0000142808.34602.25; Dansky HM, 1999, ARTERIOSCL THROM VAS, V19, P1960, DOI 10.1161/01.ATV.19.8.1960; de Gonzalo-Calvo D, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1469-5; Demark-Wahnefried W, 2012, CANCER EPIDEM BIOMAR, V21, P1244, DOI 10.1158/1055-9965.EPI-12-0485; dos Santos CR, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-132; Ferguson RD, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3089; Goswami Chirayu Pankaj, 2013, J Clin Bioinforma, V3, P22, DOI 10.1186/2043-9113-3-22; Grossmann ME, 2008, BRIT J CANCER, V98, P370, DOI 10.1038/sj.bjc.6604166; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hogarth CA, 2003, COMP BIOCHEM PHYS B, V135, P219, DOI 10.1016/S1096-4959(03)00046-0; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Kuzu OF, 2016, CANCER RES, V76, P2063, DOI 10.1158/0008-5472.CAN-15-2613; Lamas B, 2015, MOL CARCINOGEN, V54, P58, DOI 10.1002/mc.22074; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Liu J, 2013, ONCOTARGET, V4, P1804, DOI 10.18632/oncotarget.1364; Liu X, 2015, INT J OBESITY, V39, P1548, DOI 10.1038/ijo.2015.93; Llaverias G, 2011, AM J PATHOL, V178, P402, DOI 10.1016/j.ajpath.2010.11.005; Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239; Mansourian M, 2016, J PHARM PHARM SCI, V19, P72, DOI 10.18433/J3202B; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Mulder M, 2007, NEUROSCI RES, V59, P251, DOI 10.1016/j.neures.2007.07.004; Nelson ER, 2013, SCIENCE, V342, P1094, DOI 10.1126/science.1241908; Pelton K, 2014, AM J PATHOL, V184, P2099, DOI 10.1016/j.ajpath.2014.03.006; Pires LA, 2012, BRAZ J MED BIOL RES, V45, P557, DOI 10.1590/S0100-879X2012007500068; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Ribas V, 2016, CLIN TRANSL MED, V5, DOI 10.1186/s40169-016-0106-5; RUDLING MJ, 1986, BRIT MED J, V292, P580, DOI 10.1136/bmj.292.6520.580; Stranzl A, 1997, BREAST CANCER RES TR, V42, P195, DOI 10.1023/A:1005754026205; Suarez Y, 2004, CARDIOVASC RES, V64, P346, DOI 10.1016/j.cardiores.2004.06.024; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Teupser D, 2003, ARTERIOSCL THROM VAS, V23, P1907, DOI 10.1161/01.ATV.0000090126.34881.B1; Wang SH, 2014, LIPIDS HEALTH DIS, V13, DOI 10.1186/1476-511X-13-175; Weitman ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070703; Winer S, 2009, NAT MED, V15, P921, DOI 10.1038/nm.2001; Yin W, 2012, J LIPID RES, V53, P51, DOI 10.1194/jlr.M019927; Zelenko Z, 2017, ONCOGENE, V36, P1394, DOI 10.1038/onc.2016.305; Zeng XK, 2009, CLIN CANCER RES, V15, P2840, DOI 10.1158/1078-0432.CCR-08-1401; Zhao WN, 2016, CANCER RES, V76, P2037, DOI 10.1158/0008-5472.CAN-15-1970	49	96	101	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6462	6471		10.1038/onc.2017.247	http://dx.doi.org/10.1038/onc.2017.247			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28759039	Green Accepted			2022-12-17	WOS:000415622900009
J	Jia, L; Zhou, Z; Liang, H; Wu, J; Shi, P; Li, F; Wang, Z; Wang, C; Chen, W; Zhang, H; Wang, Y; Liu, R; Feng, J; Chen, C				Jia, L.; Zhou, Z.; Liang, H.; Wu, J.; Shi, P.; Li, F.; Wang, Z.; Wang, C.; Chen, W.; Zhang, H.; Wang, Y.; Liu, R.; Feng, J.; Chen, C.			KLF5 promotes breast cancer proliferation, migration and invasion in part by upregulating the transcription of TNFAIP2	ONCOGENE			English	Article							NECROSIS-FACTOR-ALPHA; PRIMARY RESPONSE GENE; KRUPPEL-LIKE FACTOR-5; CELL-PROLIFERATION; TUNNELING NANOTUBES; EPITHELIAL-CELLS; PROGNOSTIC-FACTOR; BINDING-PROTEIN; ANIMAL-CELLS; RHO-GTPASES	The Kruppel-like factor 5 (KLF5) transcription factor is highly expressed in high-grade and basal-like breast cancers. However, the mechanism by which KLF5 promotes cell migration and invasion is still not completely understood. In this study, we demonstrate that TNFAIP2, a tumor necrosis factor-alpha (TNF alpha)-induced gene, is a direct KLF5 target gene. The expression of TNFAIP2 is highly correlated with the expression of KLF5 in breast cancers. The manipulation of KLF5 expression positively alters TNFAIP2 expression levels. KLF5 directly binds to the TNFAIP2 gene promoter and activates its transcription. Functionally, KLF5 promotes cancer cell proliferation, migration and invasion in part through TNFAIP2. TNFAIP2 interacts with the two small GTPases Rac1 and Cdc42, thereby increasing their activities to change actin cytoskeleton and cell morphology. These findings collectively suggest that TNFAIP2 is a direct KLF5 target gene, and both KLF5 and TNFAIP2 promote breast cancer cell proliferation, migration and invasion through Rac1 and Cdc42.	[Jia, L.; Zhou, Z.; Liang, H.; Wu, J.; Shi, P.; Li, F.; Wang, Z.; Wang, C.; Zhang, H.; Liu, R.; Chen, C.] Chinese Acad Sci, Kunming Inst Zool, Chinese Acad Sci & Yunnan Prov, Key Lab Anim Models & Human Dis Mech, 32 Jiaochang East Rd, Kunming 650223, Yunnan, Peoples R China; [Jia, L.] Yuxi Normal Univ, Dept Biol, Yuxi, Peoples R China; [Jia, L.; Wu, J.; Wang, C.] Univ Chinese Acad Sci, Beijing, Peoples R China; [Wu, J.] Kunming Med Univ, Dept Biochem & Mol Biol, Kunming, Peoples R China; [Wang, C.] Kunming Med Univ, Dept Pathol, Affiliated Hosp 1, Kunming, Peoples R China; [Chen, W.; Wang, Y.] Kunming Med Univ, Canc Hosp, Kunming, Peoples R China; [Feng, J.] Southern Med Univ, Affiliated Fengxian Hosp, Dept Lab Med, Shanghai 201499, Peoples R China; [Feng, J.] Southern Med Univ, Affiliated Fengxian Hosp, Cent Lab, Shanghai 201499, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Zoology; Yuxi Normal University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Kunming Medical University; Kunming Medical University; Kunming Medical University; Southern Medical University - China; Southern Medical University - China	Chen, C (corresponding author), Chinese Acad Sci, Kunming Inst Zool, Chinese Acad Sci & Yunnan Prov, Key Lab Anim Models & Human Dis Mech, 32 Jiaochang East Rd, Kunming 650223, Yunnan, Peoples R China.; Feng, J (corresponding author), Southern Med Univ, Affiliated Fengxian Hosp, Dept Lab Med, Shanghai 201499, Peoples R China.; Feng, J (corresponding author), Southern Med Univ, Affiliated Fengxian Hosp, Cent Lab, Shanghai 201499, Peoples R China.	fengjing8801530@163.com; chenc@mail.kiz.ac.cn	Wang, Zehua/I-6452-2018	Wang, Zehua/0000-0002-0769-8865; wang, zhengbo/0000-0002-4717-5137	Strategic Priority Research Program of the Chinese Academy of Sciences, Stem Cell and Regenerative Medicine Research [XDA01040406]; National Natural Science Foundation of China [81120108019, 81325016, U1132605, 81322038, 81272930]; West Light Foundation of Chinese Academy of Sciences; Shanghai Health System outstanding academic leader training program [XBR2013114]	Strategic Priority Research Program of the Chinese Academy of Sciences, Stem Cell and Regenerative Medicine Research; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); West Light Foundation of Chinese Academy of Sciences(Chinese Academy of Sciences); Shanghai Health System outstanding academic leader training program	We thank Professor Jun Zhou at Nankai University for providing reagents and Professor Ping Wang from Tongji University for bioinformatics analysis. This study was supported by the Strategic Priority Research Program of the Chinese Academy of Sciences, Stem Cell and Regenerative Medicine Research (XDA01040406) and the National Natural Science Foundation of China (81120108019, 81325016, U1132605, 81322038 and 81272930) West Light Foundation of Chinese Academy of Sciences (to RL) and Shanghai Health System outstanding academic leader training program (XBR2013114 to JF).	Abounit S, 2012, J CELL SCI, V125, P1089, DOI 10.1242/jcs.083279; Aizawa K, 2004, J BIOL CHEM, V279, P70, DOI 10.1074/jbc.M306621200; Bafford R, 2006, SURGERY, V140, P289, DOI 10.1016/j.surg.2006.04.004; Bateman NW, 2004, J BIOL CHEM, V279, P12093, DOI 10.1074/jbc.M311532200; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Chanchevalap S, 2006, NUCLEIC ACIDS RES, V34, P1216, DOI 10.1093/nar/gkl014; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen CS, 2007, INT J CANCER, V121, P80, DOI 10.1002/ijc.22653; Chen CH, 2006, INT J CANCER, V118, P1346, DOI 10.1002/ijc.21533; Chen CJ, 2012, PATHOL ONCOL RES, V18, P161, DOI 10.1007/s12253-011-9422-7; Chen CS, 2005, ONCOGENE, V24, P3319, DOI 10.1038/sj.onc.1208497; Chen LC, 2011, MODERN PATHOL, V24, P175, DOI 10.1038/modpathol.2010.193; Chevrier N, 2011, CELL, V147, P853, DOI 10.1016/j.cell.2011.10.022; Davis DM, 2008, NAT REV MOL CELL BIO, V9, P431, DOI 10.1038/nrm2399; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Dong JT, 2009, CELL MOL LIFE SCI, V66, P2691, DOI 10.1007/s00018-009-0045-z; Gerdes HH, 2007, FEBS LETT, V581, P2194, DOI 10.1016/j.febslet.2007.03.071; Haffty BG, 2006, J CLIN ONCOL, V24, P5652, DOI 10.1200/JCO.2006.06.5664; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hase K, 2009, NAT CELL BIOL, V11, P1427, DOI 10.1038/ncb1990; He M, 2009, J BIOCHEM, V146, P683, DOI 10.1093/jb/mvp115; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Kimura S, 2012, EXP CELL RES, V318, P1699, DOI 10.1016/j.yexcr.2012.05.013; Kojima S, 1997, J BIOCHEM, V121, P389; Liu R, 2011, MOL ENDOCRINOL, V25, P1137, DOI 10.1210/me.2010-0497; Ma Y, 2003, ONCOGENE, V22, P4924, DOI 10.1038/sj.onc.1206728; Maxmen A, 2012, NATURE, V485, pS50, DOI 10.1038/485S50a; McConnell BB, 2009, CANCER RES, V69, P4125, DOI 10.1158/0008-5472.CAN-08-4402; Mori A, 2009, MOL CANCER RES, V7, P1390, DOI 10.1158/1541-7786.MCR-08-0525; Ohno Hiroshi, 2010, Commun Integr Biol, V3, P231; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; SARMA V, 1992, J IMMUNOL, V148, P3302; Schiller C, 2013, J CELL SCI, V126, P767, DOI 10.1242/jcs.114033; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Shi XJ, 2012, CELL CYCLE, V11, P1554, DOI 10.4161/cc.19954; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; Sur I, 2002, EUR J CELL BIOL, V81, P323, DOI 10.1078/0171-9335-00257; Suzuki T, 2009, J BIOL CHEM, V284, P9549, DOI 10.1074/jbc.M806230200; Takagi K, 2012, ENDOCR-RELAT CANCER, V19, P741, DOI 10.1530/ERC-12-0017; Tong D, 2006, CLIN CANCER RES, V12, P2442, DOI 10.1158/1078-0432.CCR-05-0964; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Wang C, 2015, ONCOTARGET; WOLF FW, 1994, J BIOL CHEM, V269, P3633; Xia HJ, 2013, J BIOL CHEM, V288, P26731, DOI 10.1074/jbc.M113.483958; Yang YZ, 2008, J BIOL CHEM, V283, P18812, DOI 10.1074/jbc.M801384200; Zhao D, 2012, CARCINOGENESIS, V33, P59, DOI 10.1093/carcin/bgr242; Zhao D, 2010, CANCER RES, V70, P4728, DOI 10.1158/0008-5472.CAN-10-0040; Zheng HQ, 2009, ONCOGENE, V28, P3702, DOI 10.1038/onc.2009.235; Zhu NX, 2006, J BIOL CHEM, V281, P14711, DOI 10.1074/jbc.M513810200	50	96	104	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2040	2051		10.1038/onc.2015.263	http://dx.doi.org/10.1038/onc.2015.263			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26189798				2022-12-17	WOS:000374505600004
J	Gibaja, V; Shen, F; Harari, J; Korn, J; Ruddy, D; Saenz-Vash, V; Zhai, H; Rejtar, T; Paris, CG; Yu, Z; Lira, M; King, D; Qi, W; Keen, N; Hassan, AQ; Chan, HM				Gibaja, V.; Shen, F.; Harari, J.; Korn, J.; Ruddy, D.; Saenz-Vash, V.; Zhai, H.; Rejtar, T.; Paris, C. G.; Yu, Z.; Lira, M.; King, D.; Qi, W.; Keen, N.; Hassan, A. Q.; Chan, H. M.			Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors	ONCOGENE			English	Article							EMBRYONIC STEM-CELLS; SELECTIVE-INHIBITION; LYSINE 27; LYMPHOMA; METHYLTRANSFERASE; METHYLATION; POLYCOMB; CANCER; EPIGENETICS; REGULATORS	The histone methyltransferase Enhancer of Zeste Homolog 2 (EZH2) is frequently dysregulated in cancers, and gain-of-function (GOF) EZH2 mutations have been identified in non-Hodgkin lymphomas. Small-molecule inhibitors against EZH2 demonstrated anti-tumor activity in EZH2-mutated lymphomas and entered clinical trials. Here, we developed models of acquired resistance to EZH2 inhibitor EI1 with EZH2-mutated lymphoma cells. Resistance was generated by secondary mutations in both wild-type (WT) and GOF Y641N EZH2 alleles. These EZH2 mutants retained the substrate specificity of their predecessor complexes but became refractory to biochemical inhibition by EZH2 inhibitors. Resistant cells were able to maintain a high level of H3K27Me3 in the presence of inhibitors. Interestingly, mutation of EZH2 WT alone generated an intermediate resistance phenotype, which is consistent with a previously proposed model of cooperation between EZH2 WT and Y641N mutants to promote tumorigenesis. In addition, the findings presented here have implications for the clinical translation of EZH2 inhibitors and underscore the need to develop novel EZH2 inhibitors to target potential resistance emerging in clinical settings.	[Gibaja, V.; Shen, F.; Harari, J.; Korn, J.; Ruddy, D.; Saenz-Vash, V.; Zhai, H.; Rejtar, T.; Paris, C. G.; Lira, M.; King, D.; Keen, N.; Hassan, A. Q.; Chan, H. M.] Novartis Inst BioMed Res, 250 Mass Ave, Cambridge, MA 02139 USA; [Yu, Z.; Qi, W.] China Novartis Inst BioMed Res, Shanghai, Peoples R China	Novartis; Novartis	Hassan, AQ; Chan, HM (corresponding author), Novartis Inst BioMed Res, 250 Mass Ave, Cambridge, MA 02139 USA.	quamrul.hassan@novartis.com; homan.chan@novartis.com		Qi, Wei/0000-0003-0813-5316				Antonysamy S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084147; Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Beguelin W, 2013, CANCER CELL, V23, P677, DOI 10.1016/j.ccr.2013.04.011; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Ferguson AD, 2011, STRUCTURE, V19, P1262, DOI 10.1016/j.str.2011.06.011; Garapaty-Rao S, 2013, CHEM BIOL, V20, P1329, DOI 10.1016/j.chembiol.2013.09.013; Helin K, 2013, NATURE, V502, P480, DOI 10.1038/nature12751; Hoffman GR, 2014, P NATL ACAD SCI USA, V111, P3128, DOI 10.1073/pnas.1316793111; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Jaffe JD, 2013, NAT GENET, V45, P1386, DOI 10.1038/ng.2777; Kim W, 2013, NAT CHEM BIOL, V9, P643, DOI [10.1038/NCHEMBIO.1331, 10.1038/nchembio.1331]; Kipp DR, 2013, BIOCHEMISTRY-US, V52, P6866, DOI 10.1021/bi400805w; Knutson SK, 2014, MOL CANCER THER, V13, P842, DOI 10.1158/1535-7163.MCT-13-0773; Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; Korpal M, 2013, CANCER DISCOV, V3, P1030, DOI 10.1158/2159-8290.CD-13-0142; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Mack SC, 2014, NATURE, V506, P445, DOI 10.1038/nature13108; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Qi W, 2012, P NATL ACAD SCI USA, V109, P21360, DOI 10.1073/pnas.1210371110; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107; Vedadi M, 2011, NAT CHEM BIOL, V7, P566, DOI [10.1038/NCHEMBIO.599, 10.1038/nchembio.599]; Wehrle J, 2014, RECENT RESULTS CANC, V201, P99, DOI 10.1007/978-3-642-54490-3_5; Wu HY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013316; Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208	31	96	100	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					558	566		10.1038/onc.2015.114	http://dx.doi.org/10.1038/onc.2015.114			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25893294	hybrid, Green Published			2022-12-17	WOS:000369548800003
J	Vassallo, I; Zinn, P; Lai, M; Rajakannu, P; Hamou, MF; Hegi, ME				Vassallo, I.; Zinn, P.; Lai, M.; Rajakannu, P.; Hamou, M-F; Hegi, M. E.			WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1	ONCOGENE			English	Article							TYROSINE KINASE ROR2; GLIOMA-CELL LINES; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; COLON-CANCER; SELF-RENEWAL; BETA-CATENIN; STEM-CELLS; EXPRESSION; PATHWAY	Glioblastoma is the most aggressive primary brain tumor in adults and due to the invasive nature cannot be completely removed. The WNT inhibitory factor 1 (WIF1), a secreted inhibitor of WNTs, is systematically downregulated in glioblastoma and acts as strong tumor suppressor. The aim of this study was the dissection of WIF1-associated tumor-suppressing effects mediated by canonical and non-canonical WNT signaling. We found that WIF1 besides inhibiting the canonical WNT pathway selectively downregulates the WNT/calcium pathway associated with significant reduction of p38-MAPK (p38-mitogen-activated protein kinase) phosphorylation. Knockdown of WNT5A, the only WNT ligand overexpressed in glioblastoma, phenocopied this inhibitory effect. WIF1 expression inhibited cell migration in vitro and in an orthotopic brain tumor model, in accordance with the known regulatory function of the WNT/Ca2+ pathway on migration and invasion. In search of a mediator for this function differential gene expression profiles of WIF1-expressing cells were performed. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), a long non-coding RNA and key positive regulator of invasion, emerged as the top downregulated gene. Indeed, knockdown of MALAT1 reduced migration in glioblastoma cells, without effect on proliferation. Hence, loss of WIF1 enhances the migratory potential of glioblastoma through WNT5A that activates the WNT/Ca2+ pathway and MALAT1. These data suggest the involvement of canonical and non-canonical WNT pathways in glioblastoma promoting key features associated with this deadly disease, proliferation on one hand and invasion on the other. Successful targeting will require a dual strategy affecting both canonical and non-canonical WNT pathways.	[Vassallo, I.; Rajakannu, P.; Hamou, M-F; Hegi, M. E.] Lausanne Univ Hosp CHUV, Neurosurg NCH, Lausanne, Switzerland; [Vassallo, I.; Rajakannu, P.; Hamou, M-F; Hegi, M. E.] Lausanne Univ Hosp CHUV, Neurosci Res Ctr CRN, Dept Clin Neurosci, CH-1066 Epalinges, Switzerland; [Zinn, P.] Baylor Coll Med, Dept Neurol Surg, Houston, TX 77030 USA; [Lai, M.] Ecole Polytech Fed Lausanne, Lab Funct & Metab Imaging LIFMET, Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Baylor College of Medicine; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Hegi, ME (corresponding author), Lausanne Univ Hosp CHUV, Neurosci Res Ctr CRN, Dept Clin Neurosci, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	Monika.Hegi@chuv.ch	Hegi, Monika/O-4796-2015	Hegi, Monika/0000-0003-0855-6495	Swiss National Science Foundation [31003A_138116/1]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	The presented work was supported by the Swiss National Science Foundation (31003A_138116/1). The results published here are in part based on data generated by The Cancer TCGA Genome Atlas pilot project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions who constitute the TCGA research network can be found at http://cancergenome.nih.gov/.	Andreeff M, 2008, LEUKEMIA, V22, P2041, DOI 10.1038/leu.2008.198; Bady P, 2012, NEURO-ONCOLOGY, V14, P701, DOI 10.1093/neuonc/nos072; Besson A, 2001, ONCOGENE, V20, P7398, DOI 10.1038/sj.onc.1204899; Bitler BG, 2011, CANCER RES, V71, P6184, DOI 10.1158/0008-5472.CAN-11-1341; Boerboom D, 2006, CANCER RES, V66, P1964, DOI 10.1158/0008-5472.CAN-05-3493; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Cawthorne Christopher, 2007, J Biomol Tech, V18, P120; Cheng RF, 2014, J CELL PHYSIOL, V229, P1908, DOI 10.1002/jcp.24566; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chuderland Dana, 2008, Commun Integr Biol, V1, P4; De A, 2011, ACTA BIOCH BIOPH SIN, V43, P745, DOI 10.1093/abbs/gmr079; Demuth T, 2007, MOL CANCER THER, V6, P1212, DOI 10.1158/1535-7163.MCT-06-0711; Enomoto M, 2009, ONCOGENE, V28, P3197, DOI 10.1038/onc.2009.175; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gotze S, 2010, INT J CANCER, V126, P2584, DOI 10.1002/ijc.24981; Gong AH, 2012, CANCER RES, V72, P5658, DOI 10.1158/0008-5472.CAN-12-0953; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Greenberg AK, 2002, AM J RESP CELL MOL, V26, P558, DOI 10.1165/ajrcmb.26.5.4689; Habu M, 2014, J BIOCHEM, V156, P29, DOI 10.1093/jb/mvu015; Hutchinson JN, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-39; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Kamino M, 2011, CANCER SCI, V102, P540, DOI 10.1111/j.1349-7006.2010.01815.x; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kremenevskaja N, 2005, ONCOGENE, V24, P2144, DOI 10.1038/sj.onc.1208370; Lal M, 2008, HUM MOL GENET, V17, P3105, DOI 10.1093/hmg/ddn208; Lambiv WL, 2011, NEURO-ONCOLOGY, V13, P736, DOI 10.1093/neuonc/nor036; Li GB, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/780521; Li XY, 2013, MOL PHARMACEUT, V10, P307, DOI 10.1021/mp300445a; Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X; Ma L, 2007, J BIOL CHEM, V282, P28980, DOI 10.1074/jbc.M702840200; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Morris LGT, 2013, NAT GENET, V45, P253, DOI 10.1038/ng.2538; Murat A, 2008, J CLIN ONCOL, V26, P3015, DOI 10.1200/JCO.2007.15.7164; Nishita M, 2006, J CELL BIOL, V175, P555, DOI 10.1083/jcb.200607127; O'Connell MP, 2009, J INVEST DERMATOL, V129, P1782, DOI 10.1038/jid.2008.433; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Petrova TV, 2008, CANCER CELL, V13, P407, DOI 10.1016/j.ccr.2008.02.020; Polakis P, 2012, COLD SPRING HARB PER, V4; Pulvirenti T, 2011, CANCER RES, V71, P7280, DOI 10.1158/0008-5472.CAN-11-1531; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Sciuscio D, 2011, CLIN CANCER RES, V17, P255, DOI 10.1158/1078-0432.CCR-10-1931; Semenov MV, 2007, CELL, V131, DOI 10.1016/j.cell.2007.12.011; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tano K, 2010, FEBS LETT, V584, P4575, DOI 10.1016/j.febslet.2010.10.008; Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011; Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Voloshanenko O, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3610; Wang Y, 2012, CANC LETT, V331, P139; Wick W, 2008, NEURO-ONCOLOGY, V10, P1019, DOI 10.1215/15228517-2008-058; Xu CA, 2011, INT J ONCOL, V39, P169, DOI 10.3892/ijo.2011.1007; Yamamoto H, 2010, ONCOGENE, V29, P2036, DOI 10.1038/onc.2009.496; Ying JM, 2008, CLIN CANCER RES, V14, P55, DOI 10.1158/1078-0432.CCR-07-1644; Yu JM, 2007, CANCER LETT, V257, P172, DOI 10.1016/j.canlet.2007.07.011; Zhang ZN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090318	59	96	98	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					12	21		10.1038/onc.2015.61	http://dx.doi.org/10.1038/onc.2015.61			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25772239	Green Submitted, Green Accepted			2022-12-17	WOS:000367812400002
J	Sleire, L; Skeie, BS; Netland, IA; Forde, HE; Dodoo, E; Selheim, F; Leiss, L; Heggdal, JI; Pedersen, PH; Wang, J; Enger, PO				Sleire, L.; Skeie, B. S.; Netland, I. A.; Forde, H. E.; Dodoo, E.; Selheim, F.; Leiss, L.; Heggdal, J. I.; Pedersen, P-H; Wang, J.; Enger, P. O.			Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc(-), leading to glutathione depletion	ONCOGENE			English	Article							FACTOR-KAPPA-B; GLUTAMATE TRANSPORTERS; CELLS; GROWTH; GLIOBLASTOMA; INHIBITION; SULPHASALAZINE; RADIOTHERAPY; TEMOZOLOMIDE; ACTIVATION	Glioblastomas (GBMs) are aggressive brain tumors that always recur after radiotherapy. Cystine, mainly provided by the system X-c(-) antiporter, is a requirement for glioma cell synthesis of glutathione (GSH) which has a critical role in scavenging free radicals, for example, after radiotherapy. Thus, we hypothesized that the X-c(-) inhibitor sulfasalazine (SAS) could potentiate the efficacy of radiotherapy against gliomas. Here, we show that the catalytic subunit of system X-c(,)- xCT, was uniformly expressed in a panel of 30 human GBM biopsies. SAS treatment significantly reduced cystine uptake and GSH levels, whereas it significantly increased the levels of reactive oxygen species (ROS) in glioma cells in vitro. Furthermore, SAS and radiation synergistically increased DNA double-strand breaks and increased glioma cell death, whereas adding the antioxidant N-acetyl-L-cysteine (NAC) reversed cell death. Moreover, SAS and gamma knife radiosurgery (GKRS) synergistically prolonged survival in nude rats harboring human GBM xenografts, compared with controls or either treatment alone. In conclusion, SAS effectively blocks cystine uptake in glioma cells in vitro, leading to GSH depletion and increased ROS levels, DNA damage and cell death. Moreover, it potentiates the anti-tumor efficacy of GKRS in rats with human GBM xenografts, providing a survival benefit. Thus, SAS may have a role as a radiosensitizer to enhance the efficacy of current radiotherapies for glioma patients.	[Sleire, L.; Netland, I. A.; Forde, H. E.; Leiss, L.; Wang, J.; Enger, P. O.] Univ Bergen, Oncomatrix Res Lab, Dept Biomed, N-5020 Bergen, Norway; [Skeie, B. S.; Pedersen, P-H] Univ Bergen, Dept Clin Med, N-5020 Bergen, Norway; [Skeie, B. S.; Pedersen, P-H; Enger, P. O.] Haukeland Hosp, Dept Neurosurg, N-5021 Bergen, Norway; [Dodoo, E.] Karolinska Univ Hosp, Dept Neurosurg, Stockholm, Sweden; [Selheim, F.] Univ Bergen, Prote Unit PROBE, Dept Biomed, N-5020 Bergen, Norway; [Leiss, L.] Haukeland Hosp, Neuro Clin, N-5021 Bergen, Norway; [Heggdal, J. I.] Haukeland Hosp, Dept Oncol & Med Phys, N-5021 Bergen, Norway	University of Bergen; University of Bergen; University of Bergen; Haukeland University Hospital; Karolinska Institutet; Karolinska University Hospital; University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital	Enger, PO (corresponding author), Univ Bergen, Oncomatrix Res Lab, Dept Biomed, Jonas Lies Vei 91, N-5020 Bergen, Norway.	per.enger@biomed.uib.no		Skeie, Bente Sandvei/0000-0001-9876-5826				AKSLEN LA, 1988, ANTICANCER RES, V8, P797; ALLALUNISTURNER MJ, 1991, J NEURO-ONCOL, V11, P157, DOI 10.1007/BF02390175; ARCHIBALD YM, 1994, J NEUROSURG, V80, P247, DOI 10.3171/jns.1994.80.2.0247; BANNAI S, 1980, J BIOL CHEM, V255, P2372; BJERKVIG R, 1990, J NEUROSURG, V72, P463, DOI 10.3171/jns.1990.72.3.0463; Buckingham SC, 2011, NAT MED, V17, P1269, DOI 10.1038/nm.2453; BUMP EA, 1982, SCIENCE, V217, P544, DOI 10.1126/science.7089580; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chung WJ, 2005, J NEUROSCI, V25, P7101, DOI 10.1523/JNEUROSCI.5258-04.2005; DICK AP, 1964, GUT, V5, P437, DOI 10.1136/gut.5.5.437; Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082; Gout PW, 2001, LEUKEMIA, V15, P1633, DOI 10.1038/sj.leu.2402238; Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008; Hsieh PC, 2005, NEUROSURGERY, V57, P684, DOI 10.1227/01.NEU.0000175550.96901.A3; KATO S, 1992, NEUROSCIENCE, V48, P903, DOI 10.1016/0306-4522(92)90278-A; Kim JY, 2001, BBA-BIOMEMBRANES, V1512, P335, DOI 10.1016/S0005-2736(01)00338-8; Lluis JM, 2007, CANCER RES, V67, P7368, DOI 10.1158/0008-5472.CAN-07-0515; Lyons SA, 2007, CANCER RES, V67, P9463, DOI 10.1158/0008-5472.CAN-07-2034; McDonald JT, 2010, CANCER RES, V70, P8886, DOI 10.1158/0008-5472.CAN-10-0171; Narang VS, 2007, CHEMOTHERAPY, V53, P210, DOI 10.1159/000100812; NEUMANN VC, 1984, J ROY SOC MED, V77, P169, DOI 10.1177/014107688407700301; Ogunrinu TA, 2010, J BIOL CHEM, V285, P37716, DOI 10.1074/jbc.M110.161190; Rey M, 1996, NEUROCHIRURGIE, V42, P289; Robe PA, 2004, CLIN CANCER RES, V10, P5595, DOI 10.1158/1078-0432.CCR-03-0392; Robe PA, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-372; Robert SM, 2014, CELL MOL LIFE SCI, V71, P1839, DOI 10.1007/s00018-013-1521-z; Rothstein JD, 2001, NAT MED, V7, P994, DOI 10.1038/nm0901-994; Sakariassen PO, 2006, P NATL ACAD SCI USA, V103, P16466, DOI 10.1073/pnas.0607668103; SALCMAN M, 1980, NEUROSURGERY, V7, P435, DOI 10.1227/00006123-198011000-00001; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Skeie BS, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/139674; Skeie BS, 2012, WORLD NEUROSURG, V78, P658, DOI 10.1016/j.wneu.2012.03.024; Soffietti R, 2013, J CLIN ONCOL, V31, P65, DOI 10.1200/JCO.2011.41.0639; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Takeuchi S, 2014, NEUROL INDIA, V62, P42, DOI 10.4103/0028-3886.128280; Takeuchi S, 2013, NEUROSURGERY, V72, P33, DOI 10.1227/NEU.0b013e318276b2de; Towner RA, 2013, BBA-MOL BASIS DIS, V1832, P2153, DOI 10.1016/j.bbadis.2013.08.004; Wang J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-465; Wegener J, 2000, EXP CELL RES, V259, P158, DOI 10.1006/excr.2000.4919; Ye ZC, 1999, J NEUROSCI, V19, P10767, DOI 10.1523/JNEUROSCI.19-24-10767.1999	40	96	102	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2015	34	49					5951	5959		10.1038/onc.2015.60	http://dx.doi.org/10.1038/onc.2015.60			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RO	25798841				2022-12-17	WOS:000366113500002
J	Que, T; Song, Y; Liu, Z; Zheng, S; Long, H; Li, Z; Liu, Y; Wang, G; Liu, Y; Zhou, J; Zhang, X; Fang, W; Qi, S				Que, T.; Song, Y.; Liu, Z.; Zheng, S.; Long, H.; Li, Z.; Liu, Y.; Wang, G.; Liu, Y.; Zhou, J.; Zhang, X.; Fang, W.; Qi, S.			Decreased miRNA-637 is an unfavorable prognosis marker and promotes glioma cell growth, migration and invasion via direct targeting Akt1	ONCOGENE			English	Article							HUMAN GLIOBLASTOMA-MULTIFORME; MALIGNANT GLIOMA; NASOPHARYNGEAL CARCINOMA; TUMOR-SUPPRESSOR; EXPRESSION; MICRORNAS; PROLIFERATION; PAKT	Although increasing evidence indicated that the deregulation of microRNAs (miRNAs) contributes to tumorigenesis and invasion, little is known about the role of miR-637 in human gliomas. In the present study, we found that the expression level of miR-637 was significantly reduced in clinical glioma tissues compared with normal brain tissues. Moreover, we revealed that the introduction of miR-637 dramatically suppressed glioma cell growth, migration and invasion in vitro and in vivo. Further studies revealed that Akt1 is a direct target gene of miR-637. Silencing of Akt1 inhibited the growth and invasion of glioma cells by decreasing phosphorylated Akt, beta-catenin, phosphorylated Foxo1 and Cyclin D1 and inducing the expression of Foxo1, which was consistent with the effect of miR-637 overexpression. Suppressed expression of miR-637 and increased Akt1 protein levels were correlated with unfavorable progression and poor prognosis, respectively, and a negative relationship between the miR-637 expression and Akt1 protein levels was observed in gliomas. Our findings provide new insights into the role of miR-637 in the development of gliomas, and implicate the potential application of miR-637 in cancer therapy.	[Que, T.; Song, Y.; Zheng, S.; Long, H.; Li, Z.; Liu, Y.; Wang, G.; Liu, Y.; Zhang, X.; Qi, S.] Southern Med Univ, Nanfang Hosp, Dept Neurosurg, Guangzhou 510515, Guangdong, Peoples R China; [Que, T.; Liu, Z.; Fang, W.] Southern Med Univ, Canc Res Inst, Guangzhou 510515, Guangdong, Peoples R China; [Liu, Z.] Guangzhou Med Univ, Basic Sch, Dept Pathol, Guangzhou, Guangdong, Peoples R China; [Zhou, J.] Luzhou Med Coll, Affiliated Hosp, Dept Neurosurg, Luzhou, Sichuan, Peoples R China; [Fang, W.] Southern Med Univ, TCM Integrated Hosp, Canc Ctr, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China; Guangzhou Medical University; Southwest Medical University; Southern Medical University - China	Qi, S (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Neurosurg, 1838,North Guangzhou Ave, Guangzhou 510515, Guangdong, Peoples R China.	zhang-xi-an@hotmail.com; fangweiyi1975@163.com; qisongtaosjwk@163.com		Que, Tianshi/0000-0002-3838-8253; Wang, Gang/0000-0003-3827-2653	National Nature Science Fund of China [81372692]; Natural Science Fund of Guangdong Province [S2013010014886]; Medical Scientific Research Fund of Guangdong Province [B2013238]; Scientific Research Initiative Project Fund of Southern Medical University [B1012032]; President Fund of Nanfang Hospital [2011C007, 2012C011]; Science Fund of the Affiliated Hospital of Luzhou Medical College [2013-60]; Science and Technology Project of Luzhou [3-S-48]	National Nature Science Fund of China(National Natural Science Foundation of China (NSFC)); Natural Science Fund of Guangdong Province(National Natural Science Foundation of Guangdong Province); Medical Scientific Research Fund of Guangdong Province; Scientific Research Initiative Project Fund of Southern Medical University; President Fund of Nanfang Hospital; Science Fund of the Affiliated Hospital of Luzhou Medical College; Science and Technology Project of Luzhou	This study was supported by the National Nature Science Fund of China (NO. 81372692; http://www.nsfc.gov.cn), the Natural Science Fund of Guangdong Province (NO. S2013010014886; http://www.gdstc.gov.cn), the Medical Scientific Research Fund of Guangdong Province (NO. B2013238; http://www.medste.gd.cn), the Scientific Research Initiative Project Fund of Southern Medical University (NO. B1012032; http://www.fimmu.com), the President Fund of Nanfang Hospital (2011C007, 2012C011; http://www.nfyy.com), the Science Fund of the Affiliated Hospital of Luzhou Medical College (2013-60) and Science and Technology Project of Luzhou (3-S-48). The funders had no role in study design, data collection, data analysis, decision to publish, or preparation of the manuscript.	Al-Harthi L, 2012, J NEUROIMMUNE PHARM, V7, P725, DOI 10.1007/s11481-012-9412-x; Antonelli M, 2012, NEUROPATHOLOGY, V32, P133, DOI 10.1111/j.1440-1789.2011.01252.x; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Besse A, 2013, TUMOR BIOL, V34, P1969, DOI 10.1007/s13277-013-0772-5; Cai N, 2013, RNA, V19, P85, DOI 10.1261/rna.035295.112; Dontula Ranadheer, 2013, Genes Cancer, V4, P285, DOI 10.1177/1947601913500141; Emdad L, 2012, FUTURE ONCOL, V8, P343, DOI [10.2217/FON.12.16, 10.2217/fon.12.16]; Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465; Guo P, 2013, ONCOL REP, V30, P870, DOI 10.3892/or.2013.2526; Hobert O, 2007, CELL, V131, P22, DOI 10.1016/j.cell.2007.09.031; Jansen M, 2010, LANCET NEUROL, V9, P717, DOI 10.1016/S1474-4422(10)70105-8; Kim KH, 2013, NEURO-ONCOLOGY, V15, P161, DOI 10.1093/neuonc/nos299; Lefranc F, 2005, J CLIN ONCOL, V23, P2411, DOI 10.1200/JCO.2005.03.089; Leivonen SK, 2014, MOL ONCOL, V8, P93, DOI 10.1016/j.molonc.2013.10.001; Li GQ, 2013, MOL CELL BIOCHEM, V372, P221, DOI 10.1007/s11010-012-1463-z; Li T, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-263; Liu Z, 2011, INT J CANCER, V128, P2562, DOI 10.1002/ijc.25595; Liu Z, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-270; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Nan Y, 2010, BRAIN RES, V1359, P14, DOI 10.1016/j.brainres.2010.08.074; Pan SJ, 2012, INT J IMMUNOPATH PH, V25, P871, DOI 10.1177/039463201202500405; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Qi ST, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038842; Quintavalle C, 2012, ONCOGENE, V31, P858, DOI 10.1038/onc.2011.280; Rodriguez EF, 2011, ACTA NEUROPATHOL, V121, P407, DOI 10.1007/s00401-010-0784-9; Schlegel J, 2000, CANCER LETT, V158, P103, DOI 10.1016/S0304-3835(00)00515-2; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Stokowy T, 2014, HORM METAB RES, V46, P171, DOI 10.1055/s-0033-1363264; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Suzuki Y, 2010, J RADIAT RES, V51, P343, DOI 10.1269/jrr.09109; Wang YY, 2012, J NEURO-ONCOL, V106, P217, DOI 10.1007/s11060-011-0679-1; Wlodarski P, 2006, FOLIA NEUROPATHOL, V44, P214; Wu S, 2012, ONCOGENE, V31, P3866, DOI 10.1038/onc.2011.551; Yin D, 2013, ONCOGENE, V32, P1155, DOI 10.1038/onc.2012.132; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhang JF, 2011, HEPATOLOGY, V54, P2137, DOI 10.1002/hep.24595	36	96	100	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2015	34	38					4952	4963		10.1038/onc.2014.419	http://dx.doi.org/10.1038/onc.2014.419			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9QZ	25597410				2022-12-17	WOS:000361693000005
J	Vincent, EE; Coelho, PP; Blagih, J; Griss, T; Viollet, B; Jones, RG				Vincent, E. E.; Coelho, P. P.; Blagih, J.; Griss, T.; Viollet, B.; Jones, R. G.			Differential effects of AMPK agonists on cell growth and metabolism	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; LKB1-AMPK PATHWAY; CANCER-CELLS; MITOCHONDRIAL DYSFUNCTION; LUNG-CANCER; METFORMIN; LKB1; PHOSPHORYLATION; SURVIVAL; INHIBITION	As a sensor of cellular energy status, the AMP-activated protein kinase (AMPK) is believed to act in opposition to the metabolic phenotypes favored by proliferating tumor cells. Consequently, compounds known to activate AMPK have been proposed as cancer therapeutics. However, the extent to which the anti-neoplastic properties of these agonists are mediated by AMPK is unclear. Here we examined the AMPK dependence of six commonly used AMPK agonists (metformin, phenformin, 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), 2-deoxy-D-glucose (2DG), salicylate and A-769662) and their influence on cellular processes often deregulated in tumor cells. We demonstrate that the majority of these agonists display AMPK-independent effects on cell proliferation and metabolism with only the synthetic activator, A-769662, exerting AMPK-dependent effects on these processes. We find that A-769662 promotes an AMPK-dependent increase in mitochondrial spare respiratory capacity. Finally, contrary to the view of AMPK activity being tumor suppressive, we find that A-769662 confers a selective proliferative advantage to tumor cells growing under nutrient deprivation. Our results indicate that many of the antigrowth properties of these agonists cannot be attributed to AMPK activity in cells, and thus any observed effects using these agonists should be confirmed using AMPK-deficient cells. Ultimately, our data urge caution not only regarding the type of AMPK agonist proposed for cancer treatment but also the context in which they are used.	[Vincent, E. E.; Coelho, P. P.; Blagih, J.; Griss, T.; Jones, R. G.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3G 1Y6, Canada; [Vincent, E. E.; Coelho, P. P.; Blagih, J.; Griss, T.; Jones, R. G.] McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada; [Viollet, B.] INSERM, Inst Cochin, U1016, Paris, France; [Viollet, B.] CNRS, UMR 8104, Paris, France; [Viollet, B.] Univ Paris 05, Sorbonne Paris Cite, Paris, France	McGill University; McGill University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Jones, RG (corresponding author), McGill Univ, Dept Physiol, Goodman Canc Res Ctr, 3655 Promenade Sir William Osler,Room 705, Montreal, PQ H3G 1Y6, Canada.	russell.jones@mcgill.ca	Viollet, Benoit/O-6927-2017; Viollet, Benoit/N-2397-2019; Jones, Russell/AAC-2861-2022; Jones, Russell Graham/ABD-5261-2021	Viollet, Benoit/0000-0002-0121-0224; Viollet, Benoit/0000-0002-0121-0224; Jones, Russell Graham/0000-0003-2250-4675; Vincent, Emma/0000-0002-8917-7384	McGill Integrated Cancer Research Training Program (MICRTP); Fonds de researche Sante Quebec; Canadian Institute Health Research (CIHR) [MOP-93799]; Canadian Cancer Society [2010-700586]; Terry Fox Research Foundation [TEF-116128]	McGill Integrated Cancer Research Training Program (MICRTP); Fonds de researche Sante Quebec; Canadian Institute Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society(Canadian Cancer Society (CCS)); Terry Fox Research Foundation	We acknowledge Douglas Elder and Nicole Beauchemin, and members of the Jones Laboratory for critical reading of this manuscript. EEV, PPC and TG were funded by the McGill Integrated Cancer Research Training Program (MICRTP) and JB was funded by Fonds de researche Sante Quebec. This work was supported by grants to RGJ from the Canadian Institute Health Research (CIHR) (MOP-93799), Canadian Cancer Society (2010-700586) and Terry Fox Research Foundation (TEF-116128). This work is dedicated to the memory of Rosalind Goodman.	Appleyard MVCL, 2012, BRIT J CANCER, V106, P1117, DOI 10.1038/bjc.2012.56; Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162; BRODY TM, 1956, J PHARMACOL EXP THER, V117, P39; Bungard D, 2010, SCIENCE, V329, P1201, DOI 10.1126/science.1191241; Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Chhipa RR, 2010, CELL SIGNAL, V22, P1554, DOI 10.1016/j.cellsig.2010.05.024; Cool B, 2006, CELL METAB, V3, P403, DOI 10.1016/j.cmet.2006.05.005; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.tb20498.x; CRISSMAN HA, 1973, J CELL BIOL, V59, P766, DOI 10.1083/jcb.59.3.766; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; DeCensi A, 2010, CANCER PREV RES, V3, P1451, DOI 10.1158/1940-6207.CAPR-10-0157; Dupuy F, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-18; Dykens JA, 2008, TOXICOL APPL PHARM, V233, P203, DOI 10.1016/j.taap.2008.08.013; El-Masry OS, 2012, ONCOL LETT, V3, P224, DOI 10.3892/ol.2011.458; El-Mir MY, 2000, J BIOL CHEM, V275, P223, DOI 10.1074/jbc.275.1.223; Elder DJE, 1996, CANCER RES, V56, P2273; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Faubert B., 2014, CANC LETT; Faubert B, 2014, P NATL ACAD SCI USA, V111, P2554, DOI 10.1073/pnas.1312570111; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Garber K, 2006, SCIENCE, V312, P1158, DOI 10.1126/science.312.5777.1158; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Godlewski J, 2010, MOL CELL, V37, P620, DOI 10.1016/j.molcel.2010.02.018; Goransson O, 2007, J BIOL CHEM, V282, P32549, DOI 10.1074/jbc.M706536200; Guigas B, 2006, DIABETES, V55, P865, DOI 10.2337/diabetes.55.04.06.db05-1178; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hardie DG, 2013, DIABETES, V62, P2164, DOI 10.2337/db13-0368; Hardie DG, 2011, BIOCHEM SOC T, V39, P1, DOI 10.1042/BST0390001; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hawley SA, 2012, SCIENCE, V336, P918, DOI 10.1126/science.1215327; Hearle N, 2006, CLIN CANCER RES, V12, P3209, DOI 10.1158/1078-0432.CCR-06-0083; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Huang X, 2008, BIOCHEM J, V412, P211, DOI 10.1042/BJ20080557; Imamura K, 2001, BIOCHEM BIOPH RES CO, V287, P562, DOI 10.1006/bbrc.2001.5627; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014; Kim IY, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00175; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Liang JY, 2013, CANCER RES, V73, P2929, DOI 10.1158/0008-5472.CAN-12-3876; Morita M, 2013, CELL METAB, V18, P698, DOI 10.1016/j.cmet.2013.10.001; Nicholls DG, 2009, BIOCHEM SOC T, V37, P1385, DOI 10.1042/BST0371385; Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607; PACHMAN LM, 1971, J CLIN INVEST, V50, P226, DOI 10.1172/JCI106478; Pollak M, 2013, J CLIN INVEST, V123, P3693, DOI 10.1172/JCI67232; Rosilio C, 2013, CANCER LETT, V336, P114, DOI 10.1016/j.canlet.2013.04.015; Sanchez-Cespedes M, 2007, ONCOGENE, V26, P7825, DOI 10.1038/sj.onc.1210594; Shackelford DB, 2013, CANCER CELL, V23, P143, DOI 10.1016/j.ccr.2012.12.008; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shackelford DB, 2009, P NATL ACAD SCI USA, V106, P11137, DOI 10.1073/pnas.0900465106; Shu Y, 2007, J CLIN INVEST, V117, P1422, DOI 10.1172/JCI30558; Suter M, 2006, J BIOL CHEM, V281, P32207, DOI 10.1074/jbc.M606357200; Vincent EE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066963; VINCENT MF, 1992, BIOCHEM J, V281, P267, DOI 10.1042/bj2810267; Wu N, 2011, NEOPLASMA, V58, P482, DOI 10.4149/neo_2011_06_482; Zadra G, 2014, EMBO MOL MED, V6, P519, DOI 10.1002/emmm.201302734; Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500; Zannella VE, 2011, RADIOTHER ONCOL, V99, P293, DOI 10.1016/j.radonc.2011.05.049	63	96	98	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3627	3639		10.1038/onc.2014.301	http://dx.doi.org/10.1038/onc.2014.301			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25241895	Green Accepted			2022-12-17	WOS:000357679100002
J	Rodriguez-Paredes, M; de Paz, AM; Simo-Riudalbas, L; Sayols, S; Moutinho, C; Moran, S; Villanueva, A; Vazquez-Cedeira, M; Lazo, PA; Carneiro, F; Moura, CS; Vieira, J; Teixeira, MR; Esteller, M				Rodriguez-Paredes, M.; Martinez de Paz, A.; Simo-Riudalbas, L.; Sayols, S.; Moutinho, C.; Moran, S.; Villanueva, A.; Vazquez-Cedeira, M.; Lazo, P. A.; Carneiro, F.; Moura, C. S.; Vieira, J.; Teixeira, M. R.; Esteller, M.			Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis	ONCOGENE			English	Article						SETDB1; gene amplification; overexpression; lung cancer; histone methyltransferase; chemotherapy	COMPARATIVE GENOMIC HYBRIDIZATION; GROUP PROTEIN EZH2; PROSTATE-CANCER; LYSINE METHYLTRANSFERASES; BREAST-CANCER; C-MYC; LEUKEMIA; CELLS; EXPRESSION; POLYCOMB	Disruption of the histone modification patterns is one of the most common features of human tumors. However, few genetic alterations in the histone modifier genes have been described in tumorigenesis. Herein we show that the histone methyltransferase SETDB1 undergoes gene amplification in non-small and small lung cancer cell lines and primary tumors. The existence of additional copies of the SETDB1 gene in these transformed cells is associated with higher levels of the corresponding mRNA and protein. From a functional standpoint, the depletion of SETDB1 expression in amplified cells reduces cancer growth in cell culture and nude mice models, whereas its overexpression increases the tumor invasiveness. The increased gene dosage of SETDB1 is also associated with enhanced sensitivity to the growth inhibitory effect mediated by the SETDB1-interfering drug mithramycin. Overall, the findings identify SETDB1 as a bona fide oncogene undergoing gene amplification-associated activation in lung cancer and suggest its potential for new therapeutic strategies.	[Rodriguez-Paredes, M.; Martinez de Paz, A.; Simo-Riudalbas, L.; Sayols, S.; Moutinho, C.; Moran, S.; Esteller, M.] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Progrm PEBC, Barcelona, Spain; [Villanueva, A.] Inst Catala Oncol, IDIBELL, Translat Res Lab, Barcelona, Spain; [Vazquez-Cedeira, M.; Lazo, P. A.] Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Expt Therapeut & Translat Oncol Program, E-37008 Salamanca, Spain; [Vazquez-Cedeira, M.; Lazo, P. A.] Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain; [Carneiro, F.; Moura, C. S.] Univ Porto IPATIMPU, Ctr Hosp Sao Joao, Fac Med, Dept Pathol, P-4100 Oporto, Portugal; [Carneiro, F.; Moura, C. S.] Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, Oporto, Portugal; [Vieira, J.; Teixeira, M. R.] Univ Porto, Portuguese Oncol Inst, Dept Genet, P-4100 Oporto, Portugal; [Vieira, J.; Teixeira, M. R.] Univ Porto, Biomed Sci Inst ICBAS, P-4100 Oporto, Portugal; [Esteller, M.] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Spain; [Esteller, M.] ICREA, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); Sao Joao Hospital; Universidade do Porto; Universidade do Porto; Portuguese Institute of Oncology; Universidade do Porto; Universidade do Porto; University of Barcelona; ICREA	Esteller, M (corresponding author), Hosp Duran & Reynals, Canc Epigenet & Biol Program PEBC, 3rd Floor,Ave Gran Via 199-203, Barcelona 08907, Spain.	mesteller@idibell.cat	Lazo, Pedro A./M-6435-2014; Carneiro, Fatima/AAV-8677-2021; Esteller, Manel/L-5956-2014; Teixeira, Manuel AC/AAZ-7251-2020; Moran, Sebastian/G-5293-2013; Rodríguez Paredes, Manuel/B-1480-2019; Teixeira, Manuel António Rodrigues/E-4885-2011; Rodríguez, Manuel/N-2708-2019; Carneiro, Fatima/J-6432-2013	Lazo, Pedro A./0000-0001-8997-3025; Carneiro, Fatima/0000-0002-1964-1006; Esteller, Manel/0000-0003-4490-6093; Teixeira, Manuel AC/0000-0002-1959-0624; Moran, Sebastian/0000-0003-4192-8983; Rodríguez Paredes, Manuel/0000-0001-5471-4277; Teixeira, Manuel António Rodrigues/0000-0002-4896-5982; Carneiro, Fatima/0000-0002-1964-1006; Vieira, Joana/0000-0002-0608-2137; Sayols, Sergi/0000-0002-3877-4170	European Community - CURELUNG project [HEALTH-F2-2010-258677]; Institute of Health Carlos III [(ISCIII)-PI10/02992]; Ministerio de Educacion, Ciencia e Innovacion [SAF2010-14935]; Kutxa-Fundacion INBIOMED; Health and Science Departments of the Catalan Government (Generalitat de Catalunya); ICREA Funding Source: Custom	European Community - CURELUNG project; Institute of Health Carlos III(Instituto de Salud Carlos III); Ministerio de Educacion, Ciencia e Innovacion; Kutxa-Fundacion INBIOMED; Health and Science Departments of the Catalan Government (Generalitat de Catalunya); ICREA(ICREA)	This work was supported by the European Community's Seventh Framework Programme (FP7/2007-2013) under Grant agreement number HEALTH-F2-2010-258677-CURELUNG project, the Institute of Health Carlos III (ISCIII)-PI10/02992, Ministerio de Educacion, Ciencia e Innovacion Grant SAF2010-14935, Kutxa-Fundacion INBIOMED and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya). ME is an ICREA Research Professor.	Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Balsara BR, 1997, CANCER RES, V57, P2116; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Beke L, 2007, ONCOGENE, V26, P4590, DOI 10.1038/sj.onc.1210248; Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Berdasco M, 2009, P NATL ACAD SCI USA, V106, P21830, DOI 10.1073/pnas.0906831106; Bilodeau S, 2009, GENE DEV, V23, P2484, DOI 10.1101/gad.1837309; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Canaani E, 2004, BRIT J CANCER, V90, P756, DOI 10.1038/sj.bjc.6601639; Ceol CJ, 2011, NATURE, V471, P513, DOI 10.1038/nature09806; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; Cho S, 2011, J BIOL CHEM, V286, P41115, DOI 10.1074/jbc.M111.248534; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Esteller M, 2006, BRIT J CANCER, V94, P179, DOI 10.1038/sj.bjc.6602918; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Fullgrabe J, 2011, ONCOGENE, V30, P3391, DOI 10.1038/onc.2011.121; Goeze A, 2002, J PATHOL, V196, P8, DOI 10.1002/path.1009; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hayashi M, 2005, ONCOL REP, V14, P1429; JONES DE, 1995, ONCOGENE, V10, P2323; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Karimi MM, 2011, CELL STEM CELL, V8, P676, DOI 10.1016/j.stem.2011.04.004; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Li HW, 2006, J BIOL CHEM, V281, P19489, DOI 10.1074/jbc.M513249200; Luk C, 2001, CANCER GENET CYTOGEN, V125, P87, DOI 10.1016/S0165-4608(00)00363-0; MacGregor S, 2011, NAT GENET, V43, P1114, DOI 10.1038/ng.958; Matsui T, 2010, NATURE, V464, P927, DOI 10.1038/nature08858; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Ryu H, 2006, P NATL ACAD SCI USA, V103, P19176, DOI 10.1073/pnas.0606373103; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Sun P, 2009, STEM CELLS, V27, P1473, DOI 10.1002/stem.89; Sy SMH, 2004, EUR J CANCER, V40, P1082, DOI 10.1016/j.ejca.2004.01.012; Taniguchi H, 2012, ONCOGENE, V31, P1988, DOI 10.1038/onc.2011.387; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Watanabe H, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-15; Wilkerson MD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036530; Yakut T, 2006, LUNG CANCER, V54, P293, DOI 10.1016/j.lungcan.2006.08.011; Yang L, 2002, ONCOGENE, V21, P148, DOI 10.1038/sj.onc.1204998; Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208; Yoshimi A, 2011, J CELL BIOCHEM, V112, P415, DOI 10.1002/jcb.22972; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	49	96	100	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2807	2813		10.1038/onc.2013.239	http://dx.doi.org/10.1038/onc.2013.239			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23770855	Green Published, hybrid			2022-12-17	WOS:000337231700014
J	Jin, S; Mutvei, AP; Chivukula, IV; Andersson, ER; Ramskold, D; Sandberg, R; Lee, KL; Kronqvist, P; Mamaeva, V; Ostling, P; Mpindi, JP; Kallioniemi, O; Screpanti, I; Poellinger, L; Sahlgren, C; Lendahl, U				Jin, S.; Mutvei, A. P.; Chivukula, I. V.; Andersson, E. R.; Ramskold, D.; Sandberg, R.; Lee, K. L.; Kronqvist, P.; Mamaeva, V.; Ostling, P.; Mpindi, J-P; Kallioniemi, O.; Screpanti, I.; Poellinger, L.; Sahlgren, C.; Lendahl, U.			Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKK alpha/IKKb	ONCOGENE			English	Article						cytokine; inflammation; tumor stroma; estrogen receptor; breast cancer; BCL	ESTROGEN-RECEPTOR; CROSS-TALK; CANCER; EXPRESSION; PATHWAY; BINDING; KINASE; REPRESSION; SUPPRESSOR; INHIBITOR	Notch signaling is frequently hyperactivated in breast cancer, but how the enhanced signaling contributes to the tumor process is less well understood. In this report, we identify the proinflammatory cytokine interleukin-6 (IL-6) as a novel Notch target in breast tumor cells. Enhanced Notch signaling upregulated IL-6 expression, leading to activation of autocrine and paracrine Janus kinase/signal transducers and activators of transcription signaling. IL-6 upregulation was mediated by non-canonical Notch signaling, as it could be effectuated by a cytoplasmically localized Notch intracellular domain and was independent of the DNA-binding protein CSL. Instead, Notch-mediated IL-6 upregulation was controlled by two proteins in the nuclear factor (NF)-kappa B signaling cascade, IK kappa alpha and IKKb (inhibitor of nuclear factor kappa-B kinase subunit alpha and beta, respectively), as well as by p53. Activation of IL-6 by Notch required IKKa/IKKb function, but interestingly, did not engage canonical NF-kB signaling, in contrast to IL-6 activation by inflammatory agents such as lipopolysaccharide. With regard to p53 status, IL-6 expression was upregulated by Notch when p53 was mutated or lost, and restoring wild-type p53 into p53-mutated or -deficient cells abrogated the IL-6 upregulation. Furthermore, Notch-induced transcriptomes from p53 wild-type and -mutated breast tumor cell lines differed extensively, and for a subset of genes upregulated by Notch in a p53-mutant cell line, this upregulation was reduced by wild-type p53. In conclusion, we identify IL-6 as a novel non-canonical Notch target gene, and reveal roles for p53 and IKKa/IKKb in noncanonical Notch signaling in breast cancer and in the generation of cell context-dependent diversity in the Notch signaling output.	[Jin, S.; Mutvei, A. P.; Chivukula, I. V.; Andersson, E. R.; Ramskold, D.; Sandberg, R.; Poellinger, L.; Lendahl, U.] Karolinska Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden; [Ramskold, D.; Sandberg, R.] Ludwig Inst Canc Res, S-10401 Stockholm, Sweden; [Lee, K. L.; Poellinger, L.] Natl Univ Singapore, Singapore 117548, Singapore; [Kronqvist, P.] Univ Turku, Dept Pathol, Turku, Finland; [Mamaeva, V.; Sahlgren, C.] Univ Turku, Turku Ctr Biotechnol, Turku, Finland; [Mamaeva, V.; Sahlgren, C.] Abo Akad Univ, Turku, Finland; [Ostling, P.; Mpindi, J-P; Kallioniemi, O.] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland; [Screpanti, I.] Univ Roma La Sapienza, Dept Mol Med, Rome, Italy	Karolinska Institutet; Ludwig Institute for Cancer Research; National University of Singapore; University of Turku; University of Turku; Abo Akademi University; University of Helsinki; Sapienza University Rome	Lendahl, U (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Box 285,Eulers Vag 3, SE-17177 Stockholm, Sweden.	Urban.Lendahl@ki.se	Andersson, Emma R/J-4236-2012; Kallioniemi, Olli P/H-5111-2011; LEE, Kian Leong/E-3584-2013; Andersson, Emma/AAB-8532-2019	Andersson, Emma R/0000-0002-8608-625X; Kallioniemi, Olli P/0000-0002-3231-0332; LEE, Kian Leong/0000-0002-0443-2746; Andersson, Emma/0000-0002-8608-625X; Ramskold, Daniel/0000-0003-2892-673X; Ostling, Paivi/0000-0001-5501-466X; Sandberg, Rickard/0000-0001-6473-1740; Lendahl, Urban/0000-0001-9543-8141; Chivukula, Indira/0000-0003-4416-3808; MUTVEI, ANDERS/0000-0002-2498-5225	Swedish Cancer Society; Swedish Research Council; EC; EuroSyStem and NotchIT; Karolinska Institutet (BRECT, Theme Center in Regenerative Medicine and a Distinguished Professor Award)	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); EC(European CommissionEuropean Commission Joint Research Centre); EuroSyStem and NotchIT; Karolinska Institutet (BRECT, Theme Center in Regenerative Medicine and a Distinguished Professor Award)	This work was financially supported by the Swedish Cancer Society, the Swedish Research Council (DBRM and Project Grant), the EC projects EuroSyStem and NotchIT, Karolinska Institutet (BRECT, Theme Center in Regenerative Medicine and a Distinguished Professor Award). We are grateful to Susanne Bergstedt, Rasmus Niemi and Sinikka Kollanus for technical assistance.	Ak P, 2010, FASEB J, V24, P3643, DOI 10.1096/fj.10-160549; Andersson ER, 2011, DEVELOPMENT, V138, P3593, DOI 10.1242/dev.063610; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Botcheva K, 2011, CELL CYCLE, V10, P4237, DOI 10.4161/cc.10.24.18383; Chapman G, 2006, J CELL BIOL, V175, P535, DOI 10.1083/jcb.200602009; Chua SW, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl024; CHUNG CN, 1994, NUCLEIC ACIDS RES, V22, P2938, DOI 10.1093/nar/22.15.2938; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heitzler P, 2010, CURR TOP DEV BIOL, V92, P457, DOI 10.1016/S0070-2153(10)92014-0; Johnston DA, 2009, GENE, V435, P36, DOI 10.1016/j.gene.2009.01.003; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Kovall RA, 2010, CURR TOP DEV BIOL, V92, P31, DOI 10.1016/S0070-2153(10)92002-4; Landor SKJ, 2011, P NATL ACAD SCI USA, V108, P18814, DOI 10.1073/pnas.1104943108; Main H, 2010, EXP CELL RES, V316, P1610, DOI 10.1016/j.yexcr.2009.12.012; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Meier-Stiegen F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011481; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Muggerud AA, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-26; Murphy SH, 2011, P NATL ACAD SCI USA, V108, P17117, DOI 10.1073/pnas.1114420108; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Osipo C, 2008, LAB INVEST, V88, P11, DOI 10.1038/labinvest.3700700; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140; Perumalsamy LR, 2009, CELL DEATH DIFFER, V16, P879, DOI 10.1038/cdd.2009.20; Perumalsamy LR, 2010, P NATL ACAD SCI USA, V107, P6882, DOI 10.1073/pnas.0910060107; Podolin PL, 2005, J PHARMACOL EXP THER, V312, P373, DOI 10.1124/jpet.104.074484; Raafat A, 2009, ONCOGENE, V28, P219, DOI 10.1038/onc.2008.379; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Rizzo P, 2008, CANCER RES, V68, P5226, DOI 10.1158/0008-5472.CAN-07-5744; Robinson DR, 2011, NAT MED, V17, P1646, DOI 10.1038/nm.2580; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Schneider G, 2011, BBA-REV CANCER, V1815, P90, DOI 10.1016/j.bbcan.2010.10.003; Schroeder T, 2000, EMBO J, V19, P2558, DOI 10.1093/emboj/19.11.2558; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022; Song LL, 2008, ONCOGENE, V27, P5833, DOI 10.1038/onc.2008.190; Speiser J, 2012, INT J SURG PATHOL, V20, P139, DOI 10.1177/1066896911427035; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Sun Y, 2011, J CELL SCI, V124, P1067, DOI 10.1242/jcs.068965; Tao LW, 2011, STEM CELLS, V29, P119, DOI 10.1002/stem.552; Turkson J, 2004, EXPERT OPIN THER TAR, V8, P409, DOI 10.1517/14728222.8.5.409; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vilimas T, 2007, NAT MED, V13, P70, DOI 10.1038/nm1524; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wang YA, 2008, INT J CANCER, V123, P1536, DOI 10.1002/ijc.23671; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wongchana W, 2012, CELL MOL IMMUNOL, V9, P155, DOI 10.1038/cmi.2011.36; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zeng B, 2008, CANCER RES, V68, P5397, DOI 10.1158/0008-5472.CAN-07-6792	53	96	99	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4892	4902		10.1038/onc.2012.517	http://dx.doi.org/10.1038/onc.2012.517			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23178494	Green Published, hybrid			2022-12-17	WOS:000325717800005
J	Hudson, RS; Yi, M; Esposito, D; Glynn, SA; Starks, AM; Yang, Y; Schetter, AJ; Watkins, SK; Hurwitz, AA; Dorsey, TH; Stephens, RM; Croce, CM; Ambs, S				Hudson, R. S.; Yi, M.; Esposito, D.; Glynn, S. A.; Starks, A. M.; Yang, Y.; Schetter, A. J.; Watkins, S. K.; Hurwitz, A. A.; Dorsey, T. H.; Stephens, R. M.; Croce, C. M.; Ambs, S.			MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer	ONCOGENE			English	Article						prostate cancer; microRNA; apoptosis; disease outcome	MICRORNAS; OVEREXPRESSION; APOPTOSIS; PROFILE; GROWTH; LEADS; MCM7; BIM	The miR-106b-25 microRNA (miRNA) cluster is a candidate oncogene in human prostate cancer. Here, we report that miRNAs encoded by miR-106b-25 are upregulated in both primary tumors and distant metastasis. Moreover, increased tumor miR-106b expression was associated with disease recurrence and the combination of high miR-106b and low CASP7 (caspase-7) expressions in primary tumors was an independent predictor of early disease recurrence (adjusted hazard ratio = 4.1; 95% confidence interval: 1.6-12.3). To identify yet unknown oncogenic functions of miR-106b, we overexpressed it in LNCaP human prostate cancer cells to examine miR-106b-induced global expression changes among protein-coding genes. The approach revealed that CASP7 is a direct target of miR-106b, which was confirmed by western blot analysis and a 3'-untranslated region reporter assay. Moreover, selected phenotypes induced by miR-106b knockdown in DU145 human prostate cancer cells did not develop when both miR-106b and CASP7 expression were inhibited. Further analyses showed that CASP7 is downregulated in primary prostate tumors and metastatic lesions across multiple data sets and is by itself associated with disease recurrence and disease-specific survival. Using bioinformatics, we also observed that miR-106b-25 may specifically influence focal adhesion-related pathways. This observation was experimentally examined using miR-106b-25-transduced 22Rv1 human prostate cancer cells. After infection with a miR-106b-25 lentiviral expression construct, 22Rv1 cells showed increased adhesion to basement membrane-and bone matrix-related filaments and enhanced soft agar growth. In summary, miR-106b-25 was found to be associated with prostate cancer progression and disease outcome and may do so by altering apoptosis-and focal adhesion-related pathways.	[Hudson, R. S.; Glynn, S. A.; Starks, A. M.; Yang, Y.; Schetter, A. J.; Dorsey, T. H.; Ambs, S.] NCI, Human Carcinogenesis Lab, Ctr Canc Res CRC, NIH, Bethesda, MD 20892 USA; [Yi, M.; Stephens, R. M.] NCI, Adv Biomed Comp Ctr, SAIC Frederick Inc, Frederick, MD 21701 USA; [Esposito, D.] NCI, Protein Express Lab, Adv Technol Program, SAIC Frederick Inc, Frederick, MD 21701 USA; [Watkins, S. K.; Hurwitz, A. A.] NCI, Mol Immunoregulat Lab, Frederick, MD 21701 USA; [Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Ambs, S (corresponding author), NCI, Human Carcinogenesis Lab, Ctr Canc Res CRC, Bldg 37 Room 3050B, Bethesda, MD 20892 USA.	ambss@mail.nih.gov	Young, Richard A/F-6495-2012; Glynn, Sharon A/D-7136-2013	Young, Richard A/0000-0001-8855-8647; Glynn, Sharon A/0000-0003-1459-2580; Ambs, Stefan/0000-0001-7651-9309; Starks, Adrienne/0000-0002-2640-6928; Esposito, Dominic/0000-0002-9987-1687; Yi, Ming/0000-0001-9098-1364	NIH, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [U01CA152758, ZIABC010499, ZIABC010954, ZIABC010886] Funding Source: NIH RePORTER	NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Barbara J Taylor at the NCI FACS Core Laboratory for technical help. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.	Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Catto JWF, 2011, EUR UROL, V59, P671, DOI 10.1016/j.eururo.2011.01.044; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465; Ghavami S, 2009, J MED GENET, V46, P497, DOI 10.1136/jmg.2009.066944; Gocek E, 2011, CANCER RES, V71, P6230, DOI 10.1158/0008-5472.CAN-11-1717; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Jalava SE, 2012, ONCOGENE, V31, P4460, DOI 10.1038/onc.2011.624; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kan T, 2009, GASTROENTEROLOGY, V136, P1689, DOI 10.1053/j.gastro.2009.02.002; Li BQ, 2011, PROSTATE, V71, P567, DOI 10.1002/pros.21272; Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x; Martens-Uzunova ES, 2012, ONCOGENE, V31, P978, DOI 10.1038/onc.2011.304; Petrocca F, 2008, CANCER RES, V68, P8191, DOI 10.1158/0008-5472.CAN-08-1768; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Poliseno L, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000594; Prueitt RL, 2008, PROSTATE, V68, P1152, DOI 10.1002/pros.20786; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Ren B, 2006, ONCOGENE, V25, P1090, DOI 10.1038/sj.onc.1209134; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Sboner A, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-8; Smith AL, 2012, ONCOGENE, V31, P5162, DOI 10.1038/onc.2012.11; Szczyrba J, 2010, MOL CANCER RES, V8, P529, DOI 10.1158/1541-7786.MCR-09-0443; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Trompeter HI, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016138; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Yu J, 2006, BIOCHEM BIOPH RES CO, V349, P59, DOI 10.1016/j.bbrc.2006.07.207; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103	35	96	99	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2013	32	35					4139	4147		10.1038/onc.2012.424	http://dx.doi.org/10.1038/onc.2012.424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	22986525	Green Accepted			2022-12-17	WOS:000323748500009
J	Fedorenko, IV; Gibney, GT; Smalley, KSM				Fedorenko, I. V.; Gibney, G. T.; Smalley, K. S. M.			NRAS mutant melanoma: biological behavior and future strategies for therapeutic management	ONCOGENE			English	Review						melanoma; Ras; targeted therapy	INHIBITOR AZD6244 ARRY-142886; BRAF MUTATIONS; ACQUIRED-RESISTANCE; RAS MUTATIONS; MEDIATES RESISTANCE; SIGNALING PATHWAYS; CLINICAL-RESPONSE; IMPROVED SURVIVAL; KINASE INHIBITOR; TYROSINE KINASE	The recent years have seen a significant shift in the expectations for the therapeutic management of disseminated melanoma. The clinical success of BRAF targeted therapy suggests that long-term disease control may one day be a reality for genetically defined subgroups of melanoma patients. Despite this progress, few advances have been made in developing targeted therapeutic strategies for the 50% of patients whose melanomas are BRAF wild-type. The most well-characterized subgroup of BRAF wild-type tumors is the 15-20% of all melanomas that harbor activating NRAS (Neuroblastoma Rat Sarcoma Virus) mutations. Emerging preclinical and clinical evidence suggests that NRAS mutant melanomas have patterns of signal transduction and biological behavior that is distinct from BRAF mutant melanomas. This overview will discuss the unique clinical and prognostic behavior of NRAS mutant melanoma and will summarize the emerging data on how NRAS-driven signaling networks can be translated into novel therapeutic strategies.	[Fedorenko, I. V.; Smalley, K. S. M.] Dept Mol Oncol, Tampa, FL USA; [Fedorenko, I. V.; Gibney, G. T.; Smalley, K. S. M.] Univ S Florida, H Lee Moffitt Canc Ctr, Comprehens Melanoma Res Ctr, Tampa, FL 33612 USA; [Gibney, G. T.; Smalley, K. S. M.] Dept Cutaneous Oncol, Tampa, FL USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Smalley, KSM (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Comprehens Melanoma Res Ctr, Dept Mol Oncol,SRB, 12902 Magnolia Dr, Tampa, FL 33612 USA.	keiran.smalley@moffitt.org	Smalley, Inna/G-9016-2015; Smalley, Inna/AAR-8638-2021	Smalley, Inna/0000-0002-6796-9145; Smalley, Inna/0000-0002-6796-9145; Smalley, Keiran/0000-0003-1089-9307	National Institutes of Health, The Harry Lloyd Trust [U54 CA143970-01, R01 CA161107-01]; State of Florida [09BN-14]; NATIONAL CANCER INSTITUTE [R01CA161107, U54CA143970] Funding Source: NIH RePORTER	National Institutes of Health, The Harry Lloyd Trust(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); State of Florida; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Work in the Smalley lab is supported by Grants U54 CA143970-01 and R01 CA161107-01 from the National Institutes of Health, The Harry Lloyd Trust and the State of Florida (09BN-14).	Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956; ALBINO AP, 1984, NATURE, V308, P69, DOI 10.1038/308069a0; Ascierto PA, 2012, J CLIN ONCOL, V30; Atefi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028973; Atkins MB, 1997, ROLE CYTOTOXIC CHEMO, P219; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bastian BC, 2000, AM J PATHOL, V157, P967, DOI 10.1016/S0002-9440(10)64609-3; Bauer J, 2007, J INVEST DERMATOL, V127, P179, DOI 10.1038/sj.jid.5700490; Bedard P, 2012, J CLIN ONCOL, V30; Bhatt KV, 2005, ONCOGENE, V24, P3459, DOI 10.1038/sj.onc.1208544; Boisvert-Adamo K, 2008, ONCOGENE, V27, P3301, DOI 10.1038/sj.onc.1211003; BOS JL, 1989, CANCER RES, V49, P4682; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Chandarlapaty S, 2012, CANCER DISCOV, V2, P311, DOI 10.1158/2159-8290.CD-12-0018; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cheung M, 2008, CANCER RES, V68, P3429, DOI 10.1158/0008-5472.CAN-07-5867; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Cho KJ, 2012, CURR BIOL, V22, P945, DOI 10.1016/j.cub.2012.03.067; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davies MA, 2008, BRIT J CANCER, V99, P1265, DOI 10.1038/sj.bjc.6604637; Davies MA, 2009, CLIN CANCER RES, V15, P7538, DOI 10.1158/1078-0432.CCR-09-1985; Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956; De Ruiter ND, 2001, MOL CELL BIOL, V21, P8225, DOI 10.1128/MCB.21.23.8225-8235.2001; Devitt B, 2011, PIGM CELL MELANOMA R, V24, P666, DOI 10.1111/j.1755-148X.2011.00873.x; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Duensing S, 2010, BIOCHEM PHARMACOL, V80, P575, DOI 10.1016/j.bcp.2010.04.006; Dumaz N, 2002, MOL CELL BIOL, V22, P3717, DOI 10.1128/MCB.22.11.3717-3728.2002; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Dumaz Nicolas, 2011, Small GTPases, V2, P289; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Ebi H, 2011, J CLIN INVEST, V121, P4311, DOI 10.1172/JCI57909; Ellerhorst JA, 2011, CLIN CANCER RES, V17, P229, DOI 10.1158/1078-0432.CCR-10-2276; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Eskandarpour M, 2009, INT J CANCER, V124, P16, DOI 10.1002/ijc.23876; Fedorenko IV, 2011, BIOCHEM PHARMACOL, V82, P201, DOI 10.1016/j.bcp.2011.05.015; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Gilmartin AG, 2011, CLIN CANCER RES, V17, P989, DOI 10.1158/1078-0432.CCR-10-2200; Gopal YNV, 2010, CANCER RES, V70, P8736, DOI 10.1158/0008-5472.CAN-10-0902; Gowrishankar K, 2012, J INVEST DERMATOL, V132, P1850, DOI 10.1038/jid.2012.63; Greger JG, 2012, MOL CANCER THER, V11, P909, DOI 10.1158/1535-7163.MCT-11-0989; Haass NK, 2008, CLIN CANCER RES, V14, P230, DOI 10.1158/1078-0432.CCR-07-1440; Halaban R, 2010, PIGM CELL MELANOMA R, V23, P190, DOI 10.1111/j.1755-148X.2010.00685.x; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Jaiswal BS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005717; Jakob JA, 2012, CANCER-AM CANCER SOC, V118, P4014, DOI 10.1002/cncr.26724; Jonsson A, 2010, J INVEST DERMATOL, V130, P2809, DOI 10.1038/jid.2010.216; Joseph RW, 2012, J IMMUNOTHER, V35, P66, DOI 10.1097/CJI.0b013e3182372636; Jovanovic B, 2010, J INVEST DERMATOL, V130, P618, DOI 10.1038/jid.2009.287; Kaplan FM, 2011, ONCOGENE, V30, P366, DOI 10.1038/onc.2010.408; Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300; Konstantinopoulos PA, 2007, NAT REV DRUG DISCOV, V6, P540, DOI 10.1038/nrd2221; Li A, 2012, J INVEST DERMATOL, V132, P2610, DOI 10.1038/jid.2012.186; Lin WM, 2008, CANCER RES, V68, P664, DOI 10.1158/0008-5472.CAN-07-2615; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Madhunapantula SV, 2009, PIGM CELL MELANOMA R, V22, P400, DOI 10.1111/j.1755-148X.2009.00585.x; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Marquette A, 2011, NAT STRUCT MOL BIOL, V18, P584, DOI 10.1038/nsmb.2022; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; Means-Powell JA, 2012, J CLIN ONCOL, V30; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Milagre C, 2010, CANCER RES, V70, P5549, DOI 10.1158/0008-5472.CAN-09-4254; Mishra PJ, 2010, ONCOGENE, V29, P2449, DOI 10.1038/onc.2009.521; Molhoek KR, 2011, MELANOMA RES, V21, P274, DOI 10.1097/CMR.0b013e328343a1d6; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Niessner H, 2011, J INVEST DERMATOL, V131, P468, DOI 10.1038/jid.2010.297; Oberholzer PA, 2012, J CLIN ONCOL, V30, P316, DOI 10.1200/JCO.2011.36.7680; Omholt K, 2007, MELANOMA RES, V17, P410, DOI 10.1097/CMR.0b013e3282ef4178; Paraiso KHT, 2012, CLIN CANCER RES, V18, P2502, DOI 10.1158/1078-0432.CCR-11-2612; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Robert C, 2012, J CLIN ONCOL, V30, DOI 10.1200/jco.2012.30.18_suppl.lba8509; Sensi M, 2006, ONCOGENE, V25, P3357, DOI 10.1038/sj.onc.1209379; Sensi M, 2011, J INVEST DERMATOL, V131, P2448, DOI 10.1038/jid.2011.218; Shahabi V, 2012, CANCER IMMUNOL IMMUN, V61, P733, DOI 10.1007/s00262-012-1227-3; Shakhova O, 2012, NAT CELL BIOL, V14, P882, DOI 10.1038/ncb2535; Shao YP, 2010, CANCER RES, V70, P6670, DOI 10.1158/0008-5472.CAN-09-4471; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Smalley KSM, 2009, ONCOGENE, V28, P85, DOI 10.1038/onc.2008.362; Smalley Keiran S M, 2012, Pigment Cell Melanoma Res, V25, pE1, DOI 10.1111/j.1755-148X.2011.00943.x; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Smalley KSM, 2003, INT J CANCER, V105, P165, DOI 10.1002/ijc.11064; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Su F, 2012, CANCER RES, V72, P969, DOI 10.1158/0008-5472.CAN-11-1875; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Su YJ, 2012, CLIN CANCER RES, V18, P2184, DOI 10.1158/1078-0432.CCR-11-1122; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Tworkoski K, 2011, MOL CANCER RES, V9, P801, DOI 10.1158/1541-7786.MCR-10-0512; Viros A, 2008, PLOS MED, V5, P941, DOI 10.1371/journal.pmed.0050120; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Whitwam T, 2007, ONCOGENE, V26, P4563, DOI 10.1038/sj.onc.1210239; Wu M, 2000, GENE DEV, V14, P301; Zimmer L, 2012, J CLIN ONCOL, V30, P2375, DOI 10.1200/JCO.2011.41.1660; Zipfel PA, 2010, ONCOGENE, V29, P4859, DOI 10.1038/onc.2010.224	111	96	105	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2013	32	25					3009	3018		10.1038/onc.2012.453	http://dx.doi.org/10.1038/onc.2012.453			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	168KX	23069660	Green Accepted			2022-12-17	WOS:000320705700001
J	Shi, G; DiRenzo, D; Qu, C; Barney, D; Miley, D; Konieczny, SF				Shi, G.; DiRenzo, D.; Qu, C.; Barney, D.; Miley, D.; Konieczny, S. F.			Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia	ONCOGENE			English	Article						Mist1; pancreatic cancer; lineage tracing; signaling pathways; 3D tissue culture	TRANSCRIPTION FACTOR MIST1; PANCREATIC INTRAEPITHELIAL NEOPLASIA; K-RAS ONCOGENE; CANCER; MICE; INDUCTION; ADENOCARCINOMA; PROGRESSION; TRANSDIFFERENTIATION; TRANSFORMATION	Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers owing to a number of characteristics including difficulty in establishing early diagnosis and the absence of effective therapeutic regimens. A large number of genetic alterations have been ascribed to PDAC with mutations in the KRAS2 proto-oncogene thought to be an early event in the progression of disease. Recent lineage-tracing studies have shown that acinar cells expressing mutant Kras(G12D) are induced to transdifferentiate, generating duct-like cells through a process known as acinar-ductal metaplasia (ADM). ADM lesions then convert to precancerous pancreatic intraepithelial neoplasia (PanIN) that progresses to PDAC over time. Thus, understanding the earliest events involved in ADM/PanIN formation would provide much needed information on the molecular pathways that are instrumental in initiating this disease. As studying the transition of acinar cells to metaplastic ductal cells in vivo is complicated by analysis of the entire organ, an in vitro three dimensional (3D) culture system was used to model ADM outside the animal. Kras(G12D)-expressing acinar cells rapidly underwent ADM in 3D culture, forming ductal cysts that silenced acinar genes and activated duct genes, characteristics associated with in vivo ADM/PanIN lesions. Analysis of downstream KRAS signaling events established a critical importance for the Raf/MEK/ERK pathway in ADM induction. In addition, forced expression of the acinar-restricted transcription factor Mist1, which is critical to acinar cell organization, significantly attenuated Kras(G12D)-induced ADM/PanIN formation. These results suggest that maintaining MIST1 activity in Kras(G12D)-expressing acinar cells can partially mitigate the transformation activity of oncogenic KRAS. Future therapeutics that target both the MAPK pathway and Mist1 transcriptional networks may show promising efficacy in combating this deadly disease. Oncogene (2013) 32, 1950-1958; doi:10.1038/onc.2012.210; published online 4 June 2012	[Konieczny, S. F.] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; [Konieczny, S. F.] Purdue Univ, Purdue Ctr Canc Res, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Konieczny, SF (corresponding author), Purdue Univ, Dept Biol Sci, Hansen Life Sci Res Bldg,201 South Univ St, W Lafayette, IN 47907 USA.	sfk@purdue.edu	Shi, Guanglu/G-1641-2013	Shi, Guanglu/0000-0001-5562-111X	NIH [CA124586, DK55489]; CTSI Predoctoral Fellowship; Phi Beta Psi Sorority for Cancer Research; NATIONAL CANCER INSTITUTE [R01CA124586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055489] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CTSI Predoctoral Fellowship; Phi Beta Psi Sorority for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Judy Hallett of the Purdue Center for Cancer Research Transgenic Mouse Core Facility for generating the transgenic mouse strains used in this study and David Hess and Anju Karki for critical reading of the manuscript. This work was supported by grants to SFK (NIH CA124586, NIH DK55489 and the Phi Beta Psi Sorority for Cancer Research) and to DD (CTSI Predoctoral Fellowship).	ARAKI K, 1995, P NATL ACAD SCI USA, V92, P160, DOI 10.1073/pnas.92.1.160; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; Brembeck FH, 2003, CANCER RES, V63, P2005; Brune K, 2006, AM J SURG PATHOL, V30, P1067; Calhoun ES, 2003, AM J PATHOL, V163, P1255, DOI 10.1016/S0002-9440(10)63485-2; Carriere C, 2007, P NATL ACAD SCI USA, V104, P4437, DOI 10.1073/pnas.0701117104; Carriere C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027725; Carriere C, 2009, BIOCHEM BIOPH RES CO, V382, P561, DOI 10.1016/j.bbrc.2009.03.068; De Corte V, 2002, EMBO J, V21, P6781, DOI 10.1093/emboj/cdf680; Detlefsen S, 2005, VIRCHOWS ARCH, V447, P800, DOI 10.1007/s00428-005-0032-1; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Friedlander SYG, 2009, CANCER CELL, V16, P379, DOI 10.1016/j.ccr.2009.09.027; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Habbe N, 2008, P NATL ACAD SCI USA, V105, P18913, DOI 10.1073/pnas.0810097105; Heid I, 2011, GASTROENTEROLOGY, V141, P719, DOI 10.1053/j.gastro.2011.04.043; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Houbracken I, 2011, GASTROENTEROLOGY, V141, P731, DOI 10.1053/j.gastro.2011.04.050; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Jean-Paul D, 2008, P NATL ACAD SCI USA, V105, P18907, DOI 10.1073/pnas.0810111105; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jensen JN, 2005, GASTROENTEROLOGY, V128, P728, DOI 10.1053/j.gastro.2004.12.008; Kowalik AS, 2007, AM J PHYSIOL-GASTR L, V292, pG1123, DOI 10.1152/ajpgi.00512.2006; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Maitra A, 2005, ADV ANAT PATHOL, V12, P81, DOI 10.1097/01.pap.0000155055.14238.25; Malka D, 2002, GUT, V51, P849, DOI 10.1136/gut.51.6.849; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Means AL, 2005, DEVELOPMENT, V132, P3767, DOI 10.1242/dev.01925; Morris JP, 2010, J CLIN INVEST, V120, P508, DOI 10.1172/JCI40045; Pin CL, 2001, J CELL BIOL, V155, P519, DOI 10.1083/jcb.200105060; Ramsey VG, 2007, DEVELOPMENT, V134, P211, DOI 10.1242/dev.02700; Ray KC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016786; Rovira M, 2008, GASTROENTEROLOGY, V135, P1301, DOI 10.1053/j.gastro.2008.06.049; Sakai K, 1997, BIOCHEM BIOPH RES CO, V237, P318, DOI 10.1006/bbrc.1997.7111; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Schreiber FS, 2004, GASTROENTEROLOGY, V127, P250, DOI 10.1053/j.gastro.2004.03.058; Shi CJ, 2009, MOL CANCER RES, V7, P230, DOI 10.1158/1541-7786.MCR-08-0206; Shi GL, 2009, GASTROENTEROLOGY, V136, P1368, DOI 10.1053/j.gastro.2008.12.066; Siveke JT, 2007, CANCER CELL, V12, P266, DOI 10.1016/j.ccr.2007.08.002; Strobel O, 2007, GASTROENTEROLOGY, V133, P1999, DOI 10.1053/j.gastro.2007.09.009; Tuveson DA, 2006, CANCER RES, V66, P242, DOI 10.1158/0008-5472.CAN-05-2305; Wagner M, 1998, GASTROENTEROLOGY, V115, P1254, DOI 10.1016/S0016-5085(98)70098-8; Zhu LQ, 2007, AM J PATHOL, V171, P263, DOI 10.2353/ajpath.2007.061176; Zhu LQ, 2004, MOL CELL BIOL, V24, P2673, DOI 10.1128/MCB.24.7.2673-2681.2004	47	96	97	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2013	32	15					1950	1958		10.1038/onc.2012.210	http://dx.doi.org/10.1038/onc.2012.210			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22665051	Green Accepted			2022-12-17	WOS:000317599900009
J	Urbanucci, A; Sahu, B; Seppala, J; Larjo, A; Latonen, LM; Waltering, KK; Tammela, TLJ; Vessella, RL; Lahdesmaki, H; Janne, OA; Visakorpi, T				Urbanucci, A.; Sahu, B.; Seppala, J.; Larjo, A.; Latonen, L. M.; Waltering, K. K.; Tammela, T. L. J.; Vessella, R. L.; Lahdesmaki, H.; Janne, O. A.; Visakorpi, T.			Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer	ONCOGENE			English	Article						prostatic neoplasia; AR; ChIP-seq; FEN1; SKP2; ZWINT	RESPONSE ELEMENT; TRANSCRIPTION; GENE; PROLIFERATION; AMPLIFICATION; ANTIANDROGEN; PROGRESSION; EXPRESSION; CASTRATION; NETWORK	Androgen receptor (AR) is overexpressed in the majority of castration-resistant prostate cancers (CRPCs). Our goal was to study the effect of AR overexpression on the chromatin binding of the receptor and to identify AR target genes that may be important in the emergence of CRPC. We have established two sublines of LNCaP prostate cancer (PC) cell line, one overexpressing AR 2-3-fold and the other 4-5-fold compared with the control cells. We used chromatin immunoprecipitation (ChIP) and deep-sequencing (seq) to identify AR-binding sites (ARBSs). We found that the number of ARBSs and the AR-binding strength were positively associated with the level of AR when cells were stimulated with low concentrations of androgens. In cells overexpressing AR, the chromatin binding of the receptor took place in 100-fold lower concentration of the ligand than in control cells. We confirmed the association of AR level and chromatin binding in two PC xenografts, one containing AR gene amplification with high AR expression, and the other with low expression. By combining the ChIP-seq and expression profiling, we identified AR target genes that are upregulated in PC. Of them, the expression of ZWINT, SKP2 (S-phase kinase-associated protein 2 (p45)) and FEN1 (flap structure-specific endonuclease 1) was demonstrated to be increased in CRPC, while the expression of SNAI2 was decreased in both PC and CRPC. FEN1 protein expression was also associated with poor prognosis in prostatectomy-treated patients. Finally, the knock-down of FEN1 with small interfering RNA inhibited the growth of LNCaP cells. Our data demonstrate that the overexpression of AR sensitizes the receptor binding to chromatin, thus, explaining how AR signaling pathway is reactivated in CRPC cells. Oncogene (2012) 31, 2153-2163; doi:10.1038/onc.2011.401; published online 12 September 2011	[Urbanucci, A.; Latonen, L. M.; Waltering, K. K.; Visakorpi, T.] Univ Tampere, Inst Biomed Technol, FIN-33014 Tampere, Finland; [Urbanucci, A.; Latonen, L. M.; Waltering, K. K.; Tammela, T. L. J.; Visakorpi, T.] Tampere Univ Hosp, Tampere, Finland; [Sahu, B.; Janne, O. A.] Univ Helsinki, Inst Biomed Physiol, Biomedicum Helsinki, Helsinki, Finland; [Seppala, J.; Larjo, A.] Tampere Univ Technol, Dept Signal Proc, FIN-33101 Tampere, Finland; [Tammela, T. L. J.] Univ Tampere, Dept Urol, FIN-33014 Tampere, Finland; [Vessella, R. L.] Univ Washington, Med Ctr, Dept Urol, NE Pacific, Seattle, WA 98195 USA; [Lahdesmaki, H.] Aalto Univ, Sch Sci & Technol, Dept Informat & Comp Sci, Helsinki, Finland	Tampere University; Tampere University; Tampere University Hospital; University of Helsinki; Tampere University; Tampere University; University of Washington; University of Washington Seattle; Aalto University	Visakorpi, T (corresponding author), Univ Tampere, Inst Biomed Technol, Biokatu 6, FIN-33014 Tampere, Finland.	tapio.visakorpi@uta.fi	Urbanucci, Alfonso/S-4450-2019; Latonen, Leena/C-8787-2016; Sahu, Biswajyoti/U-6724-2017	Urbanucci, Alfonso/0000-0003-2931-3652; Latonen, Leena/0000-0003-4502-2193; Sahu, Biswajyoti/0000-0001-6576-5440; Visakorpi, Tapio/0000-0002-5004-0364	European Union [MEST-CT-2005-020970]; Academy of Finland; Cancer Society of Finland; Reino Lahtikari Foundation; Sigrid Juselius Foundation; Tampere University Hospital	European Union(European Commission); Academy of Finland(Academy of Finland); Cancer Society of Finland; Reino Lahtikari Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Tampere University Hospital	We wish to thank Ms Mariitta Vakkuri, Ms Paivi Martikainen and Mr Rolle Rahikainen for the skillful technical assistance. The research leading to these results has received funding from the European Union FP6, CANCURE Programme (contract number: MEST-CT-2005-020970). In addition, grant support has been received from Academy of Finland, Cancer Society of Finland, Reino Lahtikari Foundation, Sigrid Juselius Foundation, and the Medical Research Fund of Tampere University Hospital.	Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Andriole GL, 2010, NEW ENGL J MED, V362, P1192, DOI 10.1056/NEJMoa0908127; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Huggins C, 2002, J UROLOGY, V168, P9, DOI 10.1016/S0022-5347(05)64820-3; ISAACS JT, 1994, VITAM HORM, V49, P433; Jia L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003645; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Karvonen U, 1997, J BIOL CHEM, V272, P15973, DOI 10.1074/jbc.272.25.15973; Kasowski M, 2010, SCIENCE, V328, P232, DOI 10.1126/science.1183621; Keller A, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-552; Kokontis JM, 1998, MOL ENDOCRINOL, V12, P941, DOI 10.1210/me.12.7.941; Kops GJPL, 2005, J CELL BIOL, V169, P49, DOI 10.1083/jcb.200411118; Lam JS, 2006, BJU INT, V98, P445, DOI 10.1111/j.1464-410X.2006.06224.x; Leinonen KA, 2010, CLIN CANCER RES, V16, P2845, DOI 10.1158/1078-0432.CCR-09-2505; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lin YT, 2006, ONCOGENE, V25, P6901, DOI 10.1038/sj.onc.1209687; Linja MJ, 2001, CANCER RES, V61, P3550; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Massie CE, 2007, EMBO REP, V8, P871, DOI 10.1038/sj.embor.7401046; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nguyen PL, 2011, UROL ONCOL-SEMIN ORI, V29, P302, DOI 10.1016/j.urolonc.2009.03.022; Obuse C, 2004, NAT CELL BIOL, V6, P1135, DOI 10.1038/ncb1187; Reid AHM, 2010, J CLIN ONCOL, V28, P1489, DOI 10.1200/JCO.2009.24.6819; Roudier Martine P, 2004, Cancer Treat Res, V118, P311; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Seruga B, 2011, NAT REV CLIN ONCOL, V8, P12, DOI 10.1038/nrclinonc.2010.136; Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239; Starr DA, 2000, J CELL SCI, V113, P1939; Takayama K, 2011, ONCOGENE, V30, P619, DOI 10.1038/onc.2010.436; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; Thompson J, 2006, EMBO J, V25, P2757, DOI 10.1038/sj.emboj.7601161; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Urbanucci A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-219; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Waltering KK, 2011, PROSTATE, V71, P604, DOI 10.1002/pros.21276; Waltering KK, 2009, CANCER RES, V69, P8141, DOI 10.1158/0008-5472.CAN-09-0919; Waltregny D, 2001, MOL ENDOCRINOL, V15, P765, DOI 10.1210/me.15.5.765; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Wei GH, 2010, EMBO J, V29, P2147, DOI 10.1038/emboj.2010.106; Xu H, 2011, ONCOGENE, V30, P1072, DOI 10.1038/onc.2010.482; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zheng L, 2007, NAT MED, V13, P812, DOI 10.1038/nm1599; Zheng L, 2011, NUCLEIC ACIDS RES, V39, P781, DOI 10.1093/nar/gkq884; Zinzen RP, 2009, NATURE, V462, P65, DOI 10.1038/nature08531	53	96	100	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	17					2153	2163		10.1038/onc.2011.401	http://dx.doi.org/10.1038/onc.2011.401			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21909140	Bronze			2022-12-17	WOS:000303415900004
J	de la Cruz-Morcillo, MA; Valero, MLL; Callejas-Valera, JL; Arias-Gonzalez, L; Melgar-Rojas, P; Galan-Moya, EM; Garcia-Gil, E; Garcia-Cano, J; Sanchez-Prieto, R				de la Cruz-Morcillo, M. A.; Valero, M. L. L.; Callejas-Valera, J. L.; Arias-Gonzalez, L.; Melgar-Rojas, P.; Galan-Moya, E. M.; Garcia-Gil, E.; Garcia-Cano, J.; Sanchez-Prieto, R.			P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance	ONCOGENE			English	Article						5-fluorouracil; p38MAPK; autophagy; resistance; p53; apoptosis	ACTIVATED PROTEIN-KINASE; P38 MAP KINASE; COLORECTAL-CANCER CELLS; CISPLATIN-BASED THERAPY; DNA-DAMAGE; GENE-EXPRESSION; COLON-CANCER; CHEMOTHERAPEUTIC-AGENTS; P53-DEPENDENT APOPTOSIS; THYMIDYLATE SYNTHASE	5-Fluorouracil (5-FU), together with other drugs such as oxaliplatin, is one of the most important pharmacological agents in the treatment of colorectal cancer. Although mitogen-activated protein kinases (MAPKs) have been extensively connected with resistance to platinum compounds, no role has been established in 5-FU resistance. Here we demonstrate that p38MAPK activation is a key determinant in the cellular response to 5-FU. Thus, inhibition of p38MAPK alpha by SB203580 compound or by short-hairpin RNA interference-specific knockdown correlates with a decrease in the 5-FU-associated apoptosis and chemical resistance in both HaCaT and HCT116 cells. Activation of p38MAPK by 5-FU was dependent on canonical MAP2K, MAPK kinase (MKK)-3 and MKK6. In addition, ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3 related (ATR) showed a redundancy of function for the final activation of p38MAPK. Resistance associated with p38MAPK inhibition correlates with an autophagic response that was mediated by a decrease in p53-driven apoptosis, without effect onto p53-dependent autophagy. Moreover, the results with colorectal cancer-derived cell lines with different p53 status and patterns of resistance to 5-FU suggest that de novo and acquired resistance was controlled by similar mechanisms. In summary, our data demonstrate a critical role for the p38MAPK signaling pathway in the cellular response to 5-FU by controlling the balance between apoptosis and autophagy. Oncogene (2012) 31, 1073-1085; doi:10.1038/onc.2011.321; published online 15 August 2011	[de la Cruz-Morcillo, M. A.; Valero, M. L. L.; Callejas-Valera, J. L.; Arias-Gonzalez, L.; Melgar-Rojas, P.; Galan-Moya, E. M.; Garcia-Gil, E.; Garcia-Cano, J.; Sanchez-Prieto, R.] UCLM, Oncol Mol Lab, CRIB, PCYTA, Albacete 02006, Spain	Universidad de Castilla-La Mancha	Sanchez-Prieto, R (corresponding author), UCLM, Oncol Mol Lab, CRIB, PCYTA, C Almansa 14, Albacete 02006, Spain.	ricardo.sanchez@uclm.es	Garcia, Elena/GWR-0291-2022; Sanchez-Prieto, Ricardo/B-6877-2008; Prieto, Ricardo/AAZ-7221-2021; Arias-González, Laura/D-9517-2016; Romo, José A./J-3024-2012; Galan-Moya, Eva M/I-2912-2015; García-Cano, Jesús/AAA-9257-2020; Sanchez-Prieto, Ricardo/AAY-4271-2021	Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Arias-González, Laura/0000-0003-2132-9350; Romo, José A./0000-0003-2907-580X; Galan-Moya, Eva M/0000-0001-5758-7592; García-Cano, Jesús/0000-0002-8312-2622; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Garcia Gil, Elena/0000-0002-8952-0306; de la Cruz-Morcillo, Miguel Angel/0000-0002-6674-1333	Fundacion Leticia Castillejo Castillo; Ministerio de Ciencia e Innovacion [SAF2009-07329]; European Community	Fundacion Leticia Castillejo Castillo; Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); European Community(European Commission)	This work was supported by grants from Fundacion Leticia Castillejo Castillo and Ministerio de Ciencia e Innovacion (SAF2009-07329) to RSP. RSP Research Institute, and the work carried out in his laboratory, received support from the European Community through the regional development funding program (FEDER). We appreciate the comments and suggestions of Drs G Almazan, E de la Casa-Esperon, S Gutkind, D Arango, A Cuenda, A Vazquez, I Sanchez and D Garcia-Olmo.	Ariumi Y, 2005, J VIROL, V79, P2973, DOI 10.1128/JVI.79.5.2973-2978.2005; Bensaad K, 2009, EMBO J, V28, P3015, DOI 10.1038/emboj.2009.242; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Callejas-Valera JL, 2008, J BIOL CHEM, V283, P13450, DOI 10.1074/jbc.M709230200; Chan A, 2009, EUR J CANCER, V45, P2253, DOI 10.1016/j.ejca.2009.04.031; Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003; Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Crighton D, 2007, CELL DEATH DIFFER, V14, P1071, DOI 10.1038/sj.cdd.4402108; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Cuadrado A, 2007, EMBO J, V26, P2115, DOI 10.1038/sj.emboj.7601657; Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323; Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002; Elsea CR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002355; Ewald B, 2008, ONCOGENE, V27, P6522, DOI 10.1038/onc.2008.316; Ewald B, 2008, CANCER RES, V68, P7947, DOI 10.1158/0008-5472.CAN-08-0971; Fedier A, 2003, ANN ONCOL, V14, P938, DOI 10.1093/annonc/mdg240; Galan-Moya EM, 2008, INT J CANCER, V122, P289, DOI 10.1002/ijc.23063; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Habiro A, 2004, BIOCHEM BIOPH RES CO, V316, P71, DOI 10.1016/j.bbrc.2004.02.017; Hector S, 2009, BBA-REV CANCER, V1795, P117, DOI 10.1016/j.bbcan.2008.12.002; Im JS, 2008, J BIOL CHEM, V283, P25171, DOI 10.1074/jbc.M802851200; Jardim MJ, 2009, MOL BIOL CELL, V20, P3801, DOI 10.1091/mbc.E09-04-0303; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; Kennedy AS, 2000, INT J CANCER, V90, P175, DOI 10.1002/1097-0215(20000820)90:4<175::AID-IJC1>3.0.CO;2-W; Koizumi K, 2005, ANTICANCER RES, V25, P3347; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Lafarga V, 2009, MOL CELL BIOL, V29, P4341, DOI 10.1128/MCB.00210-09; Lau A, 2005, NAT CELL BIOL, V7, P493, DOI 10.1038/ncb1250; Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021; Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0; Li Y, 2010, MOL CANCER THER, V9, P113, DOI 10.1158/1535-7163.MCT-08-1189; Liu A, 2008, J CELL BIOCHEM, V105, P245, DOI 10.1002/jcb.21824; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Longley DB, 2002, CANCER RES, V62, P2644; Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001; Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498; Mariadason JM, 2003, CANCER RES, V63, P8791; McClung JM, 2010, AM J PHYSIOL-CELL PH, V298, pC542, DOI 10.1152/ajpcell.00192.2009; McDonald GT, 2010, EXP CELL RES, V316, P3197, DOI 10.1016/j.yexcr.2010.08.007; Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823; NABEYA Y, 1995, INT J CANCER, V64, P37, DOI 10.1002/ijc.2910640109; O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066; OConnor PM, 1997, CANCER RES, V57, P4285; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Perfettini JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002458; Peters GJ, 2002, BBA-MOL BASIS DIS, V1587, P194, DOI 10.1016/S0925-4439(02)00082-0; Raftery L, 2008, SEMIN ONCOL, V35, P561, DOI 10.1053/j.seminoncol.2008.08.004; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Reinhardt HC, 2010, MOL CELL, V40, P34, DOI 10.1016/j.molcel.2010.09.018; Sanchez-Arevalo LV, 2005, BIOCH J 1, V387, P231; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; Specenier P, 2010, CURR OPIN ONCOL, V22, P200, DOI 10.1097/CCO.0b013e3283376e15; Tanida I, 2008, AUTOPHAGY, V4, P131, DOI 10.4161/auto.5233; Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Tominaga T, 2010, INT J CANCER, V126, P1691, DOI 10.1002/ijc.24929; Viniegra JG, 2005, J BIOL CHEM, V280, P4029, DOI 10.1074/jbc.M410344200; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Webber JL, 2010, EMBO J, V29, P27, DOI 10.1038/emboj.2009.321; Wilsker D, 2007, MOL CANCER THER, V6, P1406, DOI 10.1158/1535-7163.MCT-06-0679; Wyatt MD, 2009, CELL MOL LIFE SCI, V66, P788, DOI 10.1007/s00018-008-8557-5; Xiong HY, 2010, CANCER LETT, V288, P68, DOI 10.1016/j.canlet.2009.06.039; Zeng XH, 2010, CELL RES, V20, P665, DOI 10.1038/cr.2010.40; Zhao HY, 2008, CANCER RES, V68, P7035, DOI 10.1158/0008-5472.CAN-07-6496; Zheng MH, 1999, J CANCER RES CLIN, V125, P357, DOI 10.1007/s004320050286	74	96	96	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	9					1073	1085		10.1038/onc.2011.321	http://dx.doi.org/10.1038/onc.2011.321			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21841826				2022-12-17	WOS:000300945900001
J	Aziz, MH; Shen, H; Maki, CG				Aziz, M. H.; Shen, H.; Maki, C. G.			Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3	ONCOGENE			English	Article						p53; Nutlin; resistance	TUMOR-CELLS; MUTANT P53; OVARIAN-CANCER; APOPTOSIS; MDM2; THERAPY; PATHWAY; PROTEIN; GENE; CHEMOSENSITIVITY	Wild-type p53 is a stress-responsive tumor suppressor and potent growth inhibitor. Genotoxic stresses (for example, ionizing and ultraviolet radiation or chemotherapeutic drug treatment) can activate p53, but also induce mutations in the P53 gene, and thus select for p53-mutated cells. Nutlin-3a (Nutlin) is pre-clinical drug that activates p53 in a non-genotoxic manner. Nutlin occupies the p53-binding pocket of murine double minute 2 (MDM2), activating p53 by blocking the p53-MDM2 interaction. Because Nutlin neither binds p53 directly nor introduces DNA damage, we hypothesized Nutlin would not induce P53 mutations, and, therefore, not select for p53-mutated cells. To test this, populations of SJSA-1 (p53 wild-type) cancer cells were expanded that survived repeated Nutlin exposures, and individual clones were isolated. Group 1 clones were resistant to Nutlin-induced apoptosis, but still underwent growth arrest. Surprisingly, while some Group 1 clones retained wild-type p53, others acquired a heterozygous p53 mutation. Apoptosis resistance in Group 1 clones was associated with decreased PUMA induction and decreased caspase 3/7 activation. Group 2 clones were resistant to both apoptosis and growth arrest induced by Nutlin. Group 2 clones had acquired mutations in the p53-DNA-binding domain and expressed only mutant p53s that were induced by Nutlin treatment, but were unable to bind the P21 and PUMA gene promoters, and unable to activate transcription. These results demonstrate that non-genotoxic p53 activation (for example, by Nutlin treatment) can lead to the acquisition of somatic mutations in p53 and select for p53-mutated cells. These findings have implications for the potential clinical use of Nutlin and other small molecule MDM2 antagonists. Oncogene (2011) 30, 4678-4686; doi:10.1038/onc.2011.185; published online 6 June 2011	[Aziz, M. H.; Shen, H.; Maki, C. G.] Rush Univ, Dept Anat & Cell Biol, Med Ctr, Chicago, IL 60612 USA	Rush University	Maki, CG (corresponding author), Rush Univ, Dept Anat & Cell Biol, Med Ctr, 1653 W Congress Pkwy,Jelke 1306,900 S Paulina,AcF, Chicago, IL 60612 USA.	Carl_Maki@rush.edu			National Cancer Institute [1RO1CA137598-01A1]; NATIONAL CANCER INSTITUTE [R01CA137598] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Cancer Institute grant 1RO1CA137598-01A1 to CGM.	Ahmed AA, 2010, J PATHOL, V221, P49, DOI 10.1002/path.2696; Ashkenazi A, 2008, CYTOKINE GROWTH F R, V19, P325, DOI 10.1016/j.cytogfr.2008.04.001; Blagosklonny MV, 2005, CELL DEATH DIFFER, V12, P592, DOI 10.1038/sj.cdd.4401610; Blagosklonny MV, 2002, NAT REV CANCER, V2, P221, DOI 10.1038/nrc743; Brown L, 2007, CRIT REV EUKAR GENE, V17, P73, DOI 10.1615/CritRevEukarGeneExpr.v17.i1.50; Christiansen DH, 2001, J CLIN ONCOL, V19, P1405, DOI 10.1200/JCO.2001.19.5.1405; DeBenedetti VMG, 1996, CANCER EPIDEM BIOMAR, V5, P93; Drakos E, 2007, CLIN CANCER RES, V13, P3380, DOI 10.1158/1078-0432.CCR-06-2581; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; Gaitonde SV, 2000, ONCOGENE, V19, P4042, DOI 10.1038/sj.onc.1203756; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kumamoto K, 2008, CANCER RES, V68, P3193, DOI 10.1158/0008-5472.CAN-07-2780; Leonard DGB, 2002, CLIN CANCER RES, V8, P973; Lovric MM, 2010, ONCOGENE, V29, P5048, DOI 10.1038/onc.2010.242; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Mayelzadeh F, 2007, ONCOGENE, V26, P2955, DOI 10.1038/sj.onc.1210110; McDermott U, 2005, CANCER RES, V65, P8951, DOI 10.1158/0008-5472.CAN-05-0961; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Pietenpol JA, 1996, P NATL ACAD SCI USA, V93, P8390, DOI 10.1073/pnas.93.16.8390; Pinyol M, 2000, AM J PATHOL, V156, P1987, DOI 10.1016/S0002-9440(10)65071-7; Shen H, 2008, CANCER RES, V68, P8260, DOI 10.1158/0008-5472.CAN-08-1901; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Vaseva AV, 2009, CELL CYCLE, V8, P1711, DOI 10.4161/cc.8.11.8596; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wu GS, 1996, CLIN CANCER RES, V2, P623; Wu GS, 2002, ONCOGENE, V21, P1, DOI 10.1038/sj.onc.1205020	36	96	96	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2011	30	46					4678	4686		10.1038/onc.2011.185	http://dx.doi.org/10.1038/onc.2011.185			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	851EV	21643018	Green Accepted			2022-12-17	WOS:000297252100007
J	Garofalo, C; Manara, MC; Nicoletti, G; Marino, MT; Lollini, PL; Astolfi, A; Pandini, G; Lopez-Guerrero, JA; Schaefer, KL; Belfiore, A; Picci, P; Scotlandi, K				Garofalo, C.; Manara, M. C.; Nicoletti, G.; Marino, M. T.; Lollini, P-L; Astolfi, A.; Pandini, G.; Lopez-Guerrero, J. A.; Schaefer, K-L; Belfiore, A.; Picci, P.; Scotlandi, K.			Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling	ONCOGENE			English	Article						sarcomas; IGF-1R; insulin signaling; drug resistance	FACTOR-I RECEPTOR; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; INHIBITOR BMS-536924; DOWN-REGULATION; CELL-LINES; BREAST; SENSITIVITY; PATHWAY; GENE	Identification of patient selection criteria and understanding of the potential mechanisms involved in the development of resistance are crucial for an appropriate and successful design of clinical trials with anti-insulinlike growth factor (IGF)-1R therapies. Few Ewing's sarcomas are highly sensitive to IGF-1R targeting and understanding the reason why, may hold the secret to improve successful treatments. In this paper, we show that a major mechanism of resistance to highly specific inhibitors of IGF-1R, either antibodies or tyrosine kinase inhibitors may involve enhanced insulin receptor (IR)-A homodimer formation and IGF-2 production. Resistant cells are able to switch from IGF-1/IGF-1R to IGF-2/IRA dependency to maintain sustained activation of AKT and ERK1/2, proliferation, migration and metastasis. These cells also showed higher proliferative response to insulin, in keeping with a switch towards insulin pathways sustaining proliferation and malignancy, rather than metabolism. Our findings demonstrate a role for IR-A in eliciting intrinsic and adaptive resistance to anti-IGF-1R therapies. Thus, we indicate that tumors with low IGF1R: IR ratio are unlikely to greatly benefit from anti-IGF1R therapies and that the efficacy of anti-IGF-1R therapies should be evaluated in relationship to the IRA: IGF-1R ratio in cancer cells. Moreover, we provide evidences supporting IR-A as an important target in sarcoma therapy. Oncogene (2011) 30, 2730-2740; doi: 10.1038/onc.2010.640; published online 31 January 2011	[Scotlandi, K.] Ist Ortoped Rizzoli, CRS Dev Biomol Therapies, I-40136 Bologna, Italy; [Garofalo, C.; Manara, M. C.; Nicoletti, G.; Marino, M. T.; Picci, P.; Scotlandi, K.] Ist Ortoped Rizzoli, Expt Oncol Lab, I-40136 Bologna, Italy; [Lollini, P-L] Univ Bologna, Dept Hematol & Oncol Sci LA Seragnoli, St Orsola Malpighi Hosp, Bologna, Italy; [Astolfi, A.] Univ Bologna, G Prodi Canc Res Ctr, Bologna, Italy; [Pandini, G.] Univ Catania, Dept Internal Med & Med Specialties, Catania, Italy; [Lopez-Guerrero, J. A.] Fdn Inst Valenciano Oncol, Mol Biol Lab, Valencia, Spain; [Schaefer, K-L] Univ Med Ctr, Inst Pathol, Dusseldorf, Germany; [Belfiore, A.] Univ Catanzaro, Dept Clin & Expt Med, Catanzaro, Italy	IRCCS Istituto Ortopedico Rizzoli; IRCCS Istituto Ortopedico Rizzoli; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; University of Bologna; University of Catania; Instituto Valenciano De Oncologia; Magna Graecia University of Catanzaro	Scotlandi, K (corresponding author), Ist Ortoped Rizzoli, CRS Dev Biomol Therapies, Via Barbiano 1-10, I-40136 Bologna, Italy.	katia.scotlandi@ior.it	Belfiore, Antonino/B-4652-2011; Guerrero, Jose Antonio Lopez/Z-2413-2019; Astolfi, Annalisa/K-3034-2016; Pandini, Giuseppe/AAB-9650-2019; Manara, Maria Cristina/K-3366-2018; Garofalo, Cecilia/B-3834-2017; Scotlandi, Katia/J-9009-2016; Lollini, Pier Luigi/A-7644-2008; Picci, Piero/J-5979-2016	Belfiore, Antonino/0000-0002-6181-4193; Guerrero, Jose Antonio Lopez/0000-0002-7369-8388; Astolfi, Annalisa/0000-0002-2732-0747; Pandini, Giuseppe/0000-0003-3747-7649; Manara, Maria Cristina/0000-0001-5686-720X; Garofalo, Cecilia/0000-0001-5334-8930; Scotlandi, Katia/0000-0001-6114-9499; Lollini, Pier Luigi/0000-0003-1702-4108; Picci, Piero/0000-0002-8519-4101	Italian Association for Cancer Research; Italian Ministry of Health [RFPS-2006-3-340280]; Italian Ministry of Research and Instruction; EU [018814]	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy); Italian Ministry of Research and Instruction; EU(European Commission)	We thank Cristina Ghinelli and Alba Balladelli for their help in editing the manuscript. Studies are supported by grants from the Italian Association for Cancer Research (KS and AB), the Italian Ministry of Health (Strategico Oncologia RFPS-2006-3-340280; RF2008 to KS); the Italian Ministry of Research and Instruction (PRIN 2009) and the EU project Eurobonet (#018814).	Avnet S, 2009, CANCER RES, V69, P2443, DOI 10.1158/0008-5472.CAN-08-2645; Belfiore A, 2009, ENDOCR REV, V30, P586, DOI 10.1210/er.2008-0047; Benini S, 1999, INT J CANCER, V80, P581, DOI 10.1002/(SICI)1097-0215(19990209)80:4<581::AID-IJC16>3.3.CO;2-F; Brierley GV, 2010, ENDOCRINOLOGY, V151, P1418, DOI 10.1210/en.2009-1006; Buck E, 2010, MOL CANCER THER, V9, P2652, DOI 10.1158/1535-7163.MCT-10-0318; Cao L, 2008, CANCER RES, V68, P8039, DOI 10.1158/0008-5472.CAN-08-1712; Carboni JM, 2009, MOL CANCER THER, V8, P3341, DOI 10.1158/1535-7163.MCT-09-0499; Casa AJ, 2008, FRONT BIOSCI-LANDMRK, V13, P3273, DOI 10.2741/2925; Chitnis MM, 2008, CLIN CANCER RES, V14, P6364, DOI 10.1158/1078-0432.CCR-07-4879; Cironi L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002634; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; Desbois-Mouthon C, 2009, CLIN CANCER RES, V15, P5445, DOI 10.1158/1078-0432.CCR-08-2980; Dinchuk JE, 2010, ENDOCRINOLOGY, V151, P4123, DOI 10.1210/en.2010-0032; FORSAYETH JR, 1987, J BIOL CHEM, V262, P4134; GANDERTON RH, 1992, BIOCHEM J, V288, P195, DOI 10.1042/bj2880195; Ginzinger DG, 2002, EXP HEMATOL, V30, P503, DOI 10.1016/S0301-472X(02)00806-8; Gualberto A, 2010, CLIN CANCER RES, V16, P4654, DOI 10.1158/1078-0432.CCR-10-0089; Hendrickson AEW, 2009, CANCER RES, V69, P7635, DOI 10.1158/0008-5472.CAN-09-0511; Huang F, 2009, CANCER RES, V69, P161, DOI 10.1158/0008-5472.CAN-08-0835; Kolb EA, 2008, PEDIATR BLOOD CANCER, V50, P1190, DOI 10.1002/pbc.21450; KULL FC, 1983, J BIOL CHEM, V258, P6561; Machado I, 2009, DIAGN MOL PATHOL, V18, P189, DOI 10.1097/PDM.0b013e3181a06f66; Maloney EK, 2003, CANCER RES, V63, P5073; Manara MC, 2010, CLIN CANCER RES, V16, P530, DOI 10.1158/1078-0432.CCR-09-0816; Mukohara T, 2009, CANCER LETT, V282, P14, DOI 10.1016/j.canlet.2009.02.056; Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717; Pandini G, 1999, CLIN CANCER RES, V5, P1935; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Sachdev D, 2006, CANCER RES, V66, P2391, DOI 10.1158/0008-5472.CAN-05-3126; Sciacca L, 2002, ONCOGENE, V21, P8240, DOI 10.1038/sj.onc.1206058; Scotlandi K, 2005, CANCER RES, V65, P3868, DOI 10.1158/0008-5472.CAN-04-3192; Scotlandi K, 1996, CANCER RES, V56, P4570; Scotlandi K, 2008, CURR OPIN ONCOL, V20, P419, DOI 10.1097/CCO.0b013e328302edab; SOOS MA, 1992, J BIOL CHEM, V267, P12955; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Ulanet DB, 2010, P NATL ACAD SCI USA, V107, P10791, DOI 10.1073/pnas.0914076107; Zha JP, 2009, MOL CANCER THER, V8, P2110, DOI 10.1158/1535-7163.MCT-09-0381; Zhang H, 2010, ONCOGENE, V29, P2517, DOI 10.1038/onc.2010.17; Zhang H, 2007, CANCER RES, V67, P391, DOI 10.1158/0008-5472.CAN-06-1712; Zhou QL, 2004, BIOCHEM SOC T, V32, P817, DOI 10.1042/BST0320817	41	96	102	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	24					2730	2740		10.1038/onc.2010.640	http://dx.doi.org/10.1038/onc.2010.640			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778DB	21278796				2022-12-17	WOS:000291678500004
J	Yeung, CLA; Tsang, TY; Yau, PL; Kwok, TT				Yeung, C. L. Au; Tsang, T. Y.; Yau, P. L.; Kwok, T. T.			Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway	ONCOGENE			English	Article						HPV-16 E6; p53; miR-23b; uPA; cervical cancer	DIFFERENTIAL REGULATION; MICRORNA EXPRESSION; GENE-EXPRESSION; UROKINASE; CARCINOMA; MIR-34A; P53; TRANSCRIPTION; LESIONS; SYSTEM	Deregulation of microRNA (miRNA or miR) expression in human cervical cancer is associated frequently with human papillomavirus (HPV) integration. miR-23b is often downregulated in HPV-associated cervical cancer. Interestingly, urokinase-type plasminogen activator (uPA), the miR-23b target, is detected in cervical cancer, but not in normal cervical tissues. Thus, the importance of miR-23b and uPA in HPV-associated cervical cancer development is investigated. In this study, the high-risk subtype HPV-16 E6 oncoprotein was found to decrease the expression of miR-23b, increase the expression of uPA, and thus induce the migration of human cervical carcinoma SiHa and CaSki cells. uPA is the target gene for miR-23b as the miR repressed uPA expression and interacted with the 30-untranslated region of uPA mRNA. The tumor suppressor p53 is known to be inactivated by HPV-16 E6. A consensus p53 binding site is detected in the promoter region of miR-23b, whereas p53 trans-activated and also interacted with the miR's promoter. Therefore, p53 is believed to mediate the HPV-16 E6 downregulation of miR-23b. From the above, miR-23b/uPA are confirmed to be involved in HPV-16 E6-associated cervical cancer development. Oncogene (2011) 30, 2401-2410; doi:10.1038/onc.2010.613; published online 17 January 2011	[Yeung, C. L. Au; Tsang, T. Y.; Yau, P. L.; Kwok, T. T.] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Ctr Sci, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong	Kwok, TT (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Ctr Sci, Room 177, Shatin, Hong Kong, Peoples R China.	kwok2020@cuhk.edu.hk			Hong Kong Research Grants; Council Earmarked [466908, 467609]	Hong Kong Research Grants(Hong Kong Research Grants Council); Council Earmarked	The study is supported by grants from Hong Kong Research Grants and Council Earmarked Grants 466908, 467609.	Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Ass K, 2008, CANCER TREAT REV, V34, P122, DOI 10.1016/j.ctrv.2007.10.005; Bai L, 2006, INT J GYNECOL CANCER, V16, P718, DOI 10.1111/j.1525-1438.2006.00380.x; Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Davis BN, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-18; Diederichs S, 2006, CANCER RES, V66, P6097, DOI 10.1158/0008-5472.CAN-06-0537; Duffy MJ, 1999, J SURG ONCOL, V71, P130, DOI 10.1002/(SICI)1096-9098(199906)71:2<130::AID-JSO14>3.0.CO;2-9; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Garzon R, 2006, TRENDS MOL MED, V12, P580, DOI 10.1016/j.molmed.2006.10.006; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; Lee JW, 2008, CLIN CANCER RES, V14, P2535, DOI 10.1158/1078-0432.CCR-07-1231; Lui WO, 2007, CANCER RES, V67, P6031, DOI 10.1158/0008-5472.CAN-06-0561; Martinez I, 2008, ONCOGENE, V27, P2575, DOI 10.1038/sj.onc.1210919; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Muralidhar B, 2007, J PATHOL, V212, P368, DOI 10.1002/path.2179; Riethdorf L, 1999, J PATHOL, V189, P245, DOI 10.1002/(SICI)1096-9896(199910)189:2<245::AID-PATH427>3.0.CO;2-Z; Salvi A, 2009, FEBS J, V276, P2966, DOI 10.1111/j.1742-4658.2009.07014.x; Scaria V, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-82; Shetty P, 2008, AM J RESP CELL MOL, V39, P364, DOI 10.1165/rcmb.2007-0406OC; Soliman PT, 2004, DRUG DISCOV TODAY, V1, P253; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; TURNER MA, 1995, CLIN EXP METASTAS, V13, P260, DOI 10.1007/BF00133481; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wang X, 2009, RNA, V15, P637, DOI 10.1261/rna.1442309; Wu W, 2006, MOL ENDOCRINOL, V20, P2304, DOI 10.1210/me.2006-0131; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zuna RE, 2004, MODERN PATHOL, V17, P1314, DOI 10.1038/modpathol.3800223; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	33	96	98	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	21					2401	2410		10.1038/onc.2010.613	http://dx.doi.org/10.1038/onc.2010.613			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	769JF	21242962				2022-12-17	WOS:000291008000002
J	Mestdagh, P; Fredlund, E; Pattyn, F; Schulte, JH; Muth, D; Vermeulen, J; Kumps, C; Schlierf, S; De Preter, K; Van Roy, N; Noguera, R; Laureys, G; Schramm, A; Eggert, A; Westermann, F; Speleman, F; Vandesompele, J				Mestdagh, P.; Fredlund, E.; Pattyn, F.; Schulte, J. H.; Muth, D.; Vermeulen, J.; Kumps, C.; Schlierf, S.; De Preter, K.; Van Roy, N.; Noguera, R.; Laureys, G.; Schramm, A.; Eggert, A.; Westermann, F.; Speleman, F.; Vandesompele, J.			MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors	ONCOGENE			English	Article						MYCN; c-MYC; microRNA; neuroblastoma	B-CELL LYMPHOMAS; C-MYC; N-MYC; TRANSCRIPTIONAL REPRESSION; EXPRESSION SIGNATURES; PATHWAY DEREGULATION; NEUROBLASTOMA; DIFFERENTIATION; TARGET; GROWTH	Increased activity of MYC protein-family members is a common feature in many cancers. Using neuroblastoma as a tumor model, we established a microRNA (miRNA) signature for activated MYCN/c-MYC signaling in two independent primary neuroblastoma tumor cohorts and provide evidence that c-MYC and MYCN have overlapping functions. On the basis of an integrated approach including miRNA and messenger RNA (mRNA) gene expression data we show that miRNA activation contributes to widespread mRNA repression, both in c-MYC- and MYCN-activated tumors. c-MYC/MYCN-induced miRNA activation was shown to be dependent on c-MYC/MYCN promoter binding as evidenced by chromatin immunoprecipitation. Finally, we show that pathways, repressed through c-MYC/MYCN miRNA activation, are highly correlated to tumor aggressiveness and are conserved across different tumor entities suggesting that c-MYC/MYCN activate a core set of miRNAs for cooperative repression of common transcriptional programs related to disease aggressiveness. Our results uncover a widespread correlation between miRNA activation and c-MYC/MYCN-mediated coding gene expression modulation and further substantiate the overlapping functions of c-MYC and MYCN in the process of tumorigenesis. Oncogene (2010) 29, 1394-1404; doi:10.1038/onc.2009.429; published online 30 November 2009	[Vandesompele, J.] Ghent Univ Hosp, Ctr Med Genet, MRB, B-9000 Ghent, Belgium; [Schulte, J. H.; Schlierf, S.; Schramm, A.; Eggert, A.] Univ Childrens Hosp, Essen, Germany; [Muth, D.; Westermann, F.] German Canc Res Ctr, Dept Tumour Genet, D-6900 Heidelberg, Germany; [Noguera, R.] Med Sch Valencia, Valencia, Spain	Ghent University; Ghent University Hospital; University of Duisburg Essen; University of Hamburg; University Medical Center Hamburg-Eppendorf; Helmholtz Association; German Cancer Research Center (DKFZ)	Vandesompele, J (corresponding author), Ghent Univ Hosp, Ctr Med Genet, MRB, Pintelaan 185, B-9000 Ghent, Belgium.	Joke.Vandesompele@UGent.be	Westermann, Frank/F-7509-2013; Pattyn, Filip/A-4164-2015; Schulte, Johannes H./V-2474-2018; De Preter, Katleen/I-7135-2013; speleman, frank/AAR-5184-2020; Eggert, Angelika/AAE-6907-2022; Schramm, Alexander/G-5688-2010; laureys, genevieve/AAG-2390-2021; Vandesompele, Jo/W-3411-2018; Schulte, Johannes H/G-3981-2010	Pattyn, Filip/0000-0003-0858-6651; De Preter, Katleen/0000-0002-7726-5096; speleman, frank/0000-0002-6628-8559; Eggert, Angelika/0000-0003-3476-8184; Schramm, Alexander/0000-0001-7670-7529; Vandesompele, Jo/0000-0001-6274-0184; Schulte, Johannes Hubertus/0000-0003-0671-1201; Mestdagh, Pieter/0000-0001-7821-9684	Gent University [BOF 01D31406, BOF 01F07207, BOF 01Z09407]; Fondation pour la recherche Nuovo-Soldati; RTICC/ISCIII [RD06/0020/0102]; Fund for Scientific Research [G.0198.08, 31511809]; Belgian Kid's Fund; Stichting tegen Kanker; European Community [037260]	Gent University; Fondation pour la recherche Nuovo-Soldati(Fondation pour la Recherche Medicale); RTICC/ISCIII(Instituto de Salud Carlos III); Fund for Scientific Research; Belgian Kid's Fund; Stichting tegen Kanker; European Community(European Commission)	We acknowledge Q Wang and J Maris for providing the neuroblastoma microarray data set. This research was funded by the Gent University Research Fund (BOF 01D31406 to PM, BOF 01F07207 to FP, BOF 01Z09407 to J Vandesompele), the Fondation pour la recherche Nuovo-Soldati (J Vermeulen), RD06/0020/0102 from RTICC/ISCIII to RN, the Fund for Scientific Research (grant number: G.0198.08 and 31511809), the Belgian Kid's Fund and the Stichting tegen Kanker. KDP is a post-doctoral researcher with the Fund for Scientific Research-Flanders. We acknowledge the support of the European Community under the FP6 (project: STREP: EET-pipeline, number: 037260).	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Cappellen D, 2007, EMBO REP, V8, P70, DOI 10.1038/sj.embor.7400849; Chang CC, 2000, AM J CLIN PATHOL, V113, P512, DOI 10.1309/YHFE-R65B-D3LK-3GGV; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen YX, 2007, CANCER RES, V67, P976, DOI 10.1158/0008-5472.CAN-06-3667; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; Fredlund E, 2008, P NATL ACAD SCI USA, V105, P14094, DOI 10.1073/pnas.0804455105; Gartel AL, 2006, ONCOGENE, V25, P1989, DOI 10.1038/sj.onc.1209101; Jiang MR, 2008, BBA-MOL CELL RES, V1783, P1055, DOI 10.1016/j.bbamcr.2008.02.007; Kleine-Kohlbrecher D, 2006, CURR TOP MICROBIOL, V302, P51; Kramer MHH, 1998, BLOOD, V92, P3152, DOI 10.1182/blood.V92.9.3152.421a07_3152_3162; Landais S, 2007, CANCER RES, V67, P5699, DOI 10.1158/0008-5472.CAN-06-4478; Lee Y, 2008, NAT NEUROSCI, V11, P1137, DOI 10.1038/nn.2183; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Liu YC, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r77; Malynn BA, 2000, GENE DEV, V14, P1390; Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64; Mestdagh P, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn725; Northcott PA, 2009, CANCER RES, V69, P3249, DOI 10.1158/0008-5472.CAN-08-4710; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Park DS, 2001, BIOCHEMISTRY-US, V40, P3354, DOI 10.1021/bi002787b; Peterson S, 2004, ONCOGENE, V23, P213, DOI 10.1038/sj.onc.1206980; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645; Schulte JH, 2008, INT J CANCER, V122, P699, DOI 10.1002/ijc.23153; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun Y, 2009, BREAST CANCER RES TR, V118, P185, DOI 10.1007/s10549-008-0171-6; Tan LP, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp715; Van Roy N, 2006, GENE CHROMOSOME CANC, V45, P107, DOI 10.1002/gcc.20272; Vandesompele J, 2003, ONCOGENE, V22, P456, DOI 10.1038/sj.onc.1206148; VANROY N, 1994, GENE CHROMOSOME CANC, V10, P103, DOI 10.1002/gcc.2870100205; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Watters JW, 2006, MOL CANCER THER, V5, P2444, DOI 10.1158/1535-7163.MCT-06-0340; Westermann F, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r150; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	45	96	98	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1394	1404		10.1038/onc.2009.429	http://dx.doi.org/10.1038/onc.2009.429			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19946337				2022-12-17	WOS:000275170600014
J	Davidson, L; Maccario, H; Perera, NM; Yang, X; Spinelli, L; Tibarewal, P; Glancy, B; Gray, A; Weijer, CJ; Downes, CP; Leslie, NR				Davidson, L.; Maccario, H.; Perera, N. M.; Yang, X.; Spinelli, L.; Tibarewal, P.; Glancy, B.; Gray, A.; Weijer, C. J.; Downes, C. P.; Leslie, N. R.			Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN	ONCOGENE			English	Article						PTEN; PI3 kinase; phosphoinositide; cancer; TPIP; Akt	TUMOR-SUPPRESSOR; GLIOMA-CELLS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; GLIOBLASTOMA CELLS; BINDING MOTIF; NUCLEAR PTEN; GROWTH; ACTIVATION; MIGRATION; EXPRESSION	PTEN is a tumour suppressor with phosphatase activity in vitro against both lipids and proteins and other potential non-enzymatic mechanisms of action. Although the importance of PTEN's lipid phosphatase activity in regulating the PI3K signalling pathway is recognized, the significance of PTEN's other mechanisms of action is currently unclear. In this study, we describe the systematic identification of a PTEN mutant, PTEN Y138L, with activity against lipid, but not soluble substrates. Using this mutant, we provide evidence for the interfacial activation of PTEN against lipid substrates. We also show that when re-expressed at physiological levels in PTEN null U87MG glioblastoma cells, the protein phosphatase activity of PTEN is not required to regulate cellular PtdInsP(3) levels or the downstream protein kinase Akt/PKB. Finally, in three-dimensional Matrigel cultures of U87MG cells similarly re-expressing PTEN mutants, both the protein and lipid phosphatase activities were required to inhibit invasion, but either activity alone significantly inhibited proliferation, albeit only weakly for the protein phosphatase activity. Our data provide a novel tool to address the significance of PTEN's separable lipid and protein phosphatase activities and suggest that both activities suppress proliferation and together suppress invasion. Oncogene (2010) 29, 687-697; doi: 10.1038/onc.2009.384; published online 16 November 2009	[Davidson, L.; Maccario, H.; Perera, N. M.; Spinelli, L.; Tibarewal, P.; Glancy, B.; Gray, A.; Downes, C. P.; Leslie, N. R.] Univ Dundee, Div Mol Physiol, Coll Life Sci, Dundee DD1 5EH, Scotland; [Yang, X.; Weijer, C. J.] Univ Dundee, Div Cell & Dev Biol, Coll Life Sci, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Leslie, NR (corresponding author), Univ Dundee, Div Mol Physiol, Coll Life Sci, Dow St, Dundee DD1 5EH, Scotland.	n.r.leslie@dundee.ac.uk	Leslie, Nicholas/D-2699-2009; weijer, cornelis j/I-4538-2012	LESLIE, Nicholas/0000-0001-5131-0541; Tibarewal, Priyanka/0000-0003-3510-8428; Gray, Alexander/0000-0001-9227-0363; Weijer, Cornelis/0000-0003-2192-8150; Spinelli, Laura/0000-0002-5801-6297	Medical Research Council; Association for International Cancer Research; DSTT consortium; MRC [G0801865, G9403619] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [G18071] Funding Source: researchfish; Medical Research Council [G0801865, G9403619] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Association for International Cancer Research; DSTT consortium; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Sam Swift and Paul Appleton from the Dundee Light Microscopy Facility for their help with image acquisition and analysis. We thank Hilary McLauchlan, James Hastie and their staff in the DSTT (University of Dundee) for provision of purified antibodies and recombinant protein kinases and Steven Hubbard for advice regarding data analysis. NL is an RCUK Academic Fellow. Work in the Inositol Lipid Signalling laboratory was funded by the Medical Research Council, the Association for International Cancer Research and the pharmaceutical companies of the DSTT consortium (Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck KGaA and Pfizer).	Campbell RB, 2003, J BIOL CHEM, V278, P33617, DOI 10.1074/jbc.C300296200; Cheney IW, 1998, CANCER RES, V58, P2331; Chow LML, 2006, CANCER LETT, V241, P184, DOI 10.1016/j.canlet.2005.11.042; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Davies MA, 1998, CANCER RES, V58, P5285; de Bouard S, 2002, J NEUROSURG, V97, P169, DOI 10.3171/jns.2002.97.1.0169; Deleu S, 2006, CELL SIGNAL, V18, P488, DOI 10.1016/j.cellsig.2005.05.017; Dey N, 2008, CANCER RES, V68, P1862, DOI 10.1158/0008-5472.CAN-07-1182; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Gil A, 2007, CELL DEATH DIFFER, V14, P395, DOI 10.1038/sj.cdd.4402073; Gildea JJ, 2004, ONCOGENE, V23, P6788, DOI 10.1038/sj.onc.1207599; Goldbrunner RH, 1998, MICROSC RES TECHNIQ, V43, P250, DOI 10.1002/(SICI)1097-0029(19981101)43:3<250::AID-JEMT7>3.0.CO;2-C; Gray A, 2003, ANAL BIOCHEM, V313, P234, DOI 10.1016/S0003-2697(02)00607-3; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Hjelmeland AB, 2005, CANCER RES, V65, P11276, DOI 10.1158/0008-5472.CAN-05-3016; Iijima M, 2004, J BIOL CHEM, V279, P16606, DOI 10.1074/jbc.M312098200; Ikeda Y, 2003, NAT BIOTECHNOL, V21, P569, DOI 10.1038/nbt815; Ji SP, 2006, NAT MED, V12, P324, DOI 10.1038/nm1349; Keniry M, 2008, ONCOGENE, V27, P5477, DOI 10.1038/onc.2008.248; Lackey J, 2007, ONCOGENE, V26, P7132, DOI 10.1038/sj.onc.1210520; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2008, ONCOGENE, V27, P5464, DOI 10.1038/onc.2008.243; Leslie NR, 2007, CURR BIOL, V17, P115, DOI 10.1016/j.cub.2006.12.026; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maccario H, 2007, BIOCHEM J, V405, P439, DOI 10.1042/BJ20061837; Mahimainathan L, 2004, J BIOL CHEM, V279, P15258, DOI 10.1074/jbc.M314328200; McConnachie G, 2003, BIOCHEM J, V371, P947, DOI 10.1042/BJ20021848; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Ning K, 2006, EMBO J, V25, P2377, DOI 10.1038/sj.emboj.7601118; Okumura K, 2005, P NATL ACAD SCI USA, V102, P2703, DOI 10.1073/pnas.0409370102; Orchiston EA, 2004, J BIOL CHEM, V279, P1116, DOI 10.1074/jbc.M310933200; Park MJ, 2002, CANCER RES, V62, P6318; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Redfern RE, 2008, BIOCHEMISTRY-US, V47, P2162, DOI 10.1021/bi702114w; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Suzuki A, 2008, CANCER SCI, V99, P209, DOI 10.1111/j.1349-7006.2007.00670.x; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tapparel C, 2003, GENE, V323, P189, DOI 10.1016/j.gene.2003.09.038; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Vogelmann R, 2005, J CELL SCI, V118, P4901, DOI 10.1242/jcs.02594; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839; Walker SM, 2001, BIOCHEM J, V360, P277, DOI 10.1042/0264-6021:3600277; Yang XS, 2002, DEV CELL, V3, P425, DOI 10.1016/S1534-5807(02)00256-3	49	96	100	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					687	697		10.1038/onc.2009.384	http://dx.doi.org/10.1038/onc.2009.384			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19915616	Green Accepted			2022-12-17	WOS:000274223700006
J	Yang, SL; Cao, Q; Zhou, KC; Feng, YJ; Wang, YZ				Yang, S. L.; Cao, Q.; Zhou, K. C.; Feng, Y. J.; Wang, Y. Z.			Transient receptor potential channel C3 contributes to the progression of human ovarian cancer	ONCOGENE			English	Article						TRPC channels; ovarian epithelium cancer; proliferation; Ca2+/calmodulin-dependent kinase II; M phase	CAPACITATIVE CA2+ ENTRY; PROTEIN KINASE-II; CELL-PROLIFERATION; MAMMALIAN-CELLS; TRPC3 CHANNELS; CYTOSTATIC FACTOR; EPITHELIAL-CELLS; CALCIUM; EXPRESSION; ACTIVATION	Ovarian cancer (OC) is the leading cause of death from gynecological malignancy. However, the mechanism by which OC develops remains largely unknown. Increases in cytosolic free Ca2+ ([Ca2+](i)) can result in different physiological changes including cell growth, differentiation and death. The transient receptor potential (TRP) C channels are nonselective cation channels with permeability to Ca2(+). Here we report that TRPC3 channels promote human OC growth. The TRPC3 protein levels in human OC specimens were greatly increased than those in normal ovarian specimens. Downregulating TRPC3 expression in SKOV3 cells, a human OC cell line, led to reduction of proliferation, suppression in epidermal growth factor-induced Ca2+ in flux, dephosphorylation of Cdc2 and CaMKII alpha and prolonged progression through M phase of these cells. Further, decreased the expression of TRPC3 suppressed the tumor formation generated by injecting SKOV3 cells in nude mice. Together, our results suggest that increased activity of TRPC3 channels is necessary for the development of OCs. Oncogene (2009) 28, 1320-1328; doi:10.1038/onc.2008.475; published online 19 January 2009	[Yang, S. L.; Zhou, K. C.; Wang, Y. Z.] Shanghai Inst Biol Sci, Inst Neurosci, Lab Neural Signal Transduct, State Key Lab Neurosci, Shanghai 200031, Peoples R China; [Yang, S. L.; Zhou, K. C.; Wang, Y. Z.] Chinese Acad Sci, Grad Sch, Shanghai, Peoples R China; [Cao, Q.; Feng, Y. J.] Fudan Univ, Med Ctr, Obstet & Gynecol Hosp, Shanghai 200433, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Fudan University	Wang, YZ (corresponding author), Shanghai Inst Biol Sci, Inst Neurosci, Lab Neural Signal Transduct, State Key Lab Neurosci, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	yzwang@ion.ac.cn			973 Program [2006CB806600]; National Natural Science Foundation of China [30711120566, 30621062, U0632006]	973 Program(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Q Hu and HL Yao for technical support and B Shen for reading the article. This work was supported by grants from the 973 Program (2006CB806600), projects 30711120566, 30621062, U0632006 from the National Natural Science Foundation of China and project B117 from Shanghai Leading Academic Discipline Project.	Auersperg N, 1998, SEMIN ONCOL, V25, P281; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Cook SJ, 2006, CELL CALCIUM, V39, P101, DOI 10.1016/j.ceca.2005.10.014; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Dietrich A, 2005, MOL CELL BIOL, V25, P6980, DOI 10.1128/MCB.25.16.6980-6989.2005; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Eder P, 2005, PFLUG ARCH EUR J PHY, V451, P99, DOI 10.1007/s00424-005-1434-2; El Boustany C, 2008, HEPATOLOGY, V47, P2068, DOI 10.1002/hep.22263; FONG YL, 1989, J BIOL CHEM, V264, P16759; Hansen DV, 2006, P NATL ACAD SCI USA, V103, P608, DOI 10.1073/pnas.0509549102; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; Hussain MM, 2003, J CLIN ONCOL, V21, P4356, DOI 10.1200/JCO.2003.04.136; Jia YC, 2007, NAT NEUROSCI, V10, P559, DOI 10.1038/nn1870; Kahl CR, 2003, ENDOCR REV, V24, P719, DOI 10.1210/er.2003-0008; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; Kohn EC, 1996, CANCER RES, V56, P569; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Liu JJ, 2005, CURR BIOL, V15, P1458, DOI 10.1016/j.cub.2005.07.030; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; Maihle N J, 2002, Cancer Treat Res, V107, P247; Minaguchi T, 2006, CANCER RES, V66, P11677, DOI 10.1158/0008-5472.CAN-06-2240; Mochida S, 2007, NATURE, V449, P336, DOI 10.1038/nature06121; Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171; Nicosia SV, 2003, HEMATOL ONCOL CLIN N, V17, P927, DOI 10.1016/S0889-8588(03)00056-X; Odell AF, 2005, J BIOL CHEM, V280, P37974, DOI 10.1074/jbc.M503646200; POPPER LD, 1993, CELL CALCIUM, V14, P209, DOI 10.1016/0143-4160(93)90068-H; Psyrri A, 2005, CLIN CANCER RES, V11, P8637, DOI 10.1158/1078-0432.CCR-05-1436; Rauh NR, 2005, NATURE, V437, P1048, DOI 10.1038/nature04093; Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374; Rosenberg P, 2004, P NATL ACAD SCI USA, V101, P9387, DOI 10.1073/pnas.0308179101; Rosker C, 2004, J BIOL CHEM, V279, P13696, DOI 10.1074/jbc.M308108200; Schultze-Mosgau A, 2000, MOL HUM REPROD, V6, P435, DOI 10.1093/molehr/6.5.435; Smyth JT, 2006, J BIOL CHEM, V281, P11712, DOI 10.1074/jbc.M510541200; Thebault S, 2006, CANCER RES, V66, P2038, DOI 10.1158/0008-5472.CAN-05-0376; Thebault S, 2005, J CELL PHYSIOL, V204, P320, DOI 10.1002/jcp.20301; TOMBES RM, 1989, J CELL BIOL, V109, P627, DOI 10.1083/jcb.109.2.627; Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819; Xu NH, 2003, BIOCHEM BIOPH RES CO, V306, P737, DOI 10.1016/S0006-291X(03)01061-1; Yang H, 2005, J BIOL CHEM, V280, P32230, DOI 10.1074/jbc.M504553200; Yu Y, 2004, P NATL ACAD SCI USA, V101, P13861, DOI 10.1073/pnas.0405908101; Yu Y, 2003, AM J PHYSIOL-CELL PH, V284, pC316, DOI 10.1152/ajpcell.00125.2002; Zagranichnaya TK, 2005, J BIOL CHEM, V280, P29559, DOI 10.1074/jbc.M505842200; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	49	96	101	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1320	1328		10.1038/onc.2008.475	http://dx.doi.org/10.1038/onc.2008.475			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19151765				2022-12-17	WOS:000264116000004
J	Smith, JR; Clarke, PA; de Billy, E; Workman, P				Smith, J. R.; Clarke, P. A.; de Billy, E.; Workman, P.			Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors	ONCOGENE			English	Article						CDC37; cochaperone; HSP90; client; 17-AAG	SHOCK-PROTEIN 90; MOLECULAR CHAPERONE; SIGNAL-TRANSDUCTION; TARGETING SUBUNIT; QUALITY-CONTROL; ATPASE ACTIVITY; BREAST-CANCER; GROWTH ARREST; IN-VITRO; COMPLEX	The cochaperone CDC37 promotes the association of HSP90 with the protein kinase subset of client proteins to maintain their stability and signalling functions. HSP90 inhibitors induce depletion of clients, which include several oncogenic kinases. We hypothesized that the targeting of CDC37 using siRNAs would compromise the maturation of these clients and increase the sensitivity of cancer cells to HSP90 inhibitors. Here, we show that silencing of CDC37 in human colon cancer cells diminished the association of kinase clients with HSP90 and reduced levels of the clients ERBB2, CRAF, CDK4 and CDK6, as well as phosphorylated AKT. CDC37 silencing promoted the proteasome-mediated degradation of kinase clients, suggesting a degradation pathway independent from HSP90 binding. Decreased cell signalling through kinase clients was also demonstrated by reduced phosphorylation of downstream substrates and colon cancer cell proliferation was subsequently reduced by the inhibition of the G1/S-phase transition. Furthermore, combining CDC37 silencing with the HSP90 inhibitor 17-AAG induced more extensive and sustained depletion of kinase clients and potentiated cell cycle arrest and apoptosis. These results support an essential role for CDC37 in concert with HSP90 in maintaining oncogenic protein kinase clients and endorse the therapeutic potential of targeting CDC37 in cancer.	[Smith, J. R.; Clarke, P. A.; de Billy, E.; Workman, P.] Inst Canc Res, Haddow Labs, Signal Transduct & Mol Pharmacol Team, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England	Cancer Research UK; University of London; Institute of Cancer Research - UK	Workman, P (corresponding author), Inst Canc Res, Haddow Labs, Signal Transduct & Mol Pharmacol Team, Canc Res UK Ctr Canc Therapeut, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	paul.workman@icr.ac.uk	de billy, emmanuel/AAA-6095-2020	Clarke, Paul/0000-0001-9342-1290; de Crespin de Billy, emmanuel/0000-0002-3610-7083	Cancer Research UK [CUK] [C309/A8274]; Institute of Cancer Research	Cancer Research UK [CUK](Cancer Research UK); Institute of Cancer Research	We thank our colleagues in the Signal Transduction and Molecular Pharmacology Team and Chaperone Project Team for helpful discussions. Our work is supported by Cancer Research UK [CUK] Programme Grant number C309/A8274. JRS is the recipient of a studentship from The Institute of Cancer Research. PW is a Cancer Research UK Life Fellow.	Banerji U, 2005, J CLIN ONCOL, V23, P4152, DOI 10.1200/JCO.2005.00.612; Banerji U, 2008, MOL CANCER THER, V7, P737, DOI 10.1158/1535-7163.MCT-08-0145; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Caplan AJ, 2007, TRENDS CELL BIOL, V17, P87, DOI 10.1016/j.tcb.2006.12.002; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Clarke PA, 2000, ONCOGENE, V19, P4125, DOI 10.1038/sj.onc.1203753; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Dias SD, 2005, CANCER RES, V65, P10686, DOI 10.1158/0008-5472.CAN-05-2632; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; Ghatak S, 2005, J BIOL CHEM, V280, P8875, DOI 10.1074/jbc.M410882200; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Gray PJ, 2008, NAT REV CANCER, V8, P491, DOI 10.1038/nrc2420; Gray PJ, 2007, CANCER RES, V67, P11942, DOI 10.1158/0008-5472.CAN-07-3162; Grbovic OM, 2006, P NATL ACAD SCI USA, V103, P57, DOI 10.1073/pnas.0609973103; Guo F, 2005, CANCER RES, V65, P10536, DOI 10.1158/0008-5472.CAN-05-1799; Hartson SD, 2000, BIOCHEMISTRY-US, V39, P7631, DOI 10.1021/bi000315r; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Holford J, 1998, BRIT J CANCER, V77, P366, DOI 10.1038/bjc.1998.59; Holmes JL, 2008, CANCER RES, V68, P1187, DOI 10.1158/0008-5472.CAN-07-3268; Hostein I, 2001, CANCER RES, V61, P4003; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Lamphere L, 1997, ONCOGENE, V14, P1999, DOI 10.1038/sj.onc.1201036; Lavictoire SJ, 2003, J BIOL CHEM, V278, P5292, DOI 10.1074/jbc.M209494200; Lee P, 2002, J CELL BIOL, V159, P1051, DOI 10.1083/jcb.200210121; MacLean M, 2003, CELL STRESS CHAPERON, V8, P114, DOI 10.1379/1466-1268(2003)008<0114:CGBHAK>2.0.CO;2; Maloney A, 2002, EXPERT OPIN BIOL TH, V2, P3, DOI 10.1517/14712598.2.1.3; Mandal AK, 2007, J CELL BIOL, V176, P319, DOI 10.1083/jcb.200604106; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; McDonald E, 2006, CURR TOP MED CHEM, V6, P1091, DOI 10.2174/156802606777812004; Modi S, 2007, J CLIN ONCOL, V25, P5410, DOI 10.1200/JCO.2007.11.7960; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Pacey S, 2006, HANDB EXP PHARM, V172, P331; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; Pearl LH, 2008, BIOCHEM J, V410, P439, DOI 10.1042/BJ20071640; Pearl LH, 2006, ANNU REV BIOCHEM, V75, P271, DOI 10.1146/annurev.biochem.75.103004.142738; Pearl LH, 2005, CURR OPIN GENET DEV, V15, P55, DOI 10.1016/j.gde.2004.12.011; Powers MV, 2008, CANCER CELL, V14, P250, DOI 10.1016/j.ccr.2008.08.002; Raynaud FI, 2007, CANCER RES, V67, P5840, DOI 10.1158/0008-5472.CAN-06-4615; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schwarze SR, 2003, CANCER RES, V63, P4614; Sharp SY, 2007, MOL CANCER THER, V6, P1198, DOI 10.1158/1535-7163.MCT-07-0149; Siligardi G, 2004, J BIOL CHEM, V279, P51989, DOI 10.1074/jbc.M410562200; Siligardi G, 2002, J BIOL CHEM, V277, P20151, DOI 10.1074/jbc.M201287200; Smith J.R., 2007, DRUG DISCOV TODAY TH, V4, P219, DOI [10.1016/j.ddstr.2008.02.005, DOI 10.1016/J.DDSTR.2008.02.005]; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Stepanova L, 2000, ONCOGENE, V19, P2186, DOI 10.1038/sj.onc.1203561; Stepanova L, 1997, METHOD ENZYMOL, V283, P220; Stepanova L, 2000, MOL CELL BIOL, V20, P4462, DOI 10.1128/MCB.20.12.4462-4473.2000; Turnbull EL, 2005, FEBS J, V272, P4129, DOI 10.1111/j.1742-4658.2005.04825.x; Vaughan CK, 2006, MOL CELL, V23, P697, DOI 10.1016/j.molcel.2006.07.016; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Westerheide SD, 2004, J BIOL CHEM, V279, P56053, DOI 10.1074/jbc.M409267200; Workman P, 2004, CANCER LETT, V206, P149, DOI 10.1016/j.canlet.2003.08.032; Workman P, 2007, ANN NY ACAD SCI, V1113, P202, DOI 10.1196/annals.1391.012; Xu WP, 2003, CANCER RES, V63, P7777; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Yang HJ, 2006, CANCER RES, V66, P4758, DOI 10.1158/0008-5472.CAN-05-4529; Yun BG, 2005, EXP CELL RES, V307, P212, DOI 10.1016/j.yexcr.2005.03.003; Zhang T, 2008, MOL CANCER THER, V7, P162, DOI 10.1158/1535-7163.MCT-07-0484; Zhang W, 2004, J MOL BIOL, V340, P891, DOI 10.1016/j.jmb.2004.05.007	62	96	98	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					157	169		10.1038/onc.2008.380	http://dx.doi.org/10.1038/onc.2008.380			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18931700	Green Accepted			2022-12-17	WOS:000262501100001
J	Bartkova, J; Horejsi, Z; Sehested, M; Nesland, JM; Rajpert-De Meyts, E; Skakkebaek, NE; Stucki, M; Jackson, S; Lukas, J; Bartek, J				Bartkova, J.; Horejsi, Z.; Sehested, M.; Nesland, J. M.; Rajpert-De Meyts, E.; Skakkebaek, N. E.; Stucki, M.; Jackson, S.; Lukas, J.; Bartek, J.			DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours	ONCOGENE			English	Article						DNA damage response; breast cancer; lung cancer; testicular cancer; MDC1 and 53BP1 defects; tumour suppressors	ONCOGENE-INDUCED SENESCENCE; CARCINOMA IN-SITU; GENOMIC INSTABILITY; CYCLE CHECKPOINTS; ATM ACTIVATION; PROTEIN; P53; CHK1; DIFFERENTIATION; TUMORIGENESIS	MDC1 and 53BP1 are critical components of the DNA damage response (DDR) machinery that protects genome integrity and guards against cancer, yet the tissue expression patterns and involvement of these two DDR adaptors/mediators in human tumours remain largely unknown. Here we optimized immunohistochemical analyses of human 53BP1 and MDC1 proteins in situ and identified their virtually ubiquitous expression, both in proliferating and quiescent, differentiated tissues. Focus formation by 53BP1 and/or MDC1 in human spermatogenesis and subsets of breast and lung carcinomas indicated physiological and 'pathological' activation of the DDR, respectively. Furthermore, aberrant reduction or lack of either protein in significant proportions of carcinomas supported the candidacy of 53BP1 and MDC1 for tumour suppressors. Contrary to carcinomas, almost no activation or loss of MDC1 or 53BP1 were found among testicular germ-cell tumours (TGCTs), a tumour type with unique biology and exceptionally low incidence of p53 mutations. Such concomitant presence ( in carcinomas) or absence ( in TGCTs) of DDR activation and DDR aberrations supports the roles of MDC1 and 53BP1 within the ATM/ATR-regulated checkpoint network which, when activated, provides an early anticancer barrier the pressure of which selects for DDR defects such as p53 mutations or loss of 53BP1/MDC1 during cancer progression.	Danish Canc Soc, Ctr Genotox Stress Res, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Acad Sci Czech Republ, Inst Mol Genet, Prague, Czech Republic; Copenhagen Univ Hosp, Dept Pathol, Copenhagen, Denmark; Univ Oslo, Norwegian Radium Hosp, Dept Pathol, Oslo, Norway; Univ Copenhagen Hosp, Dept Growth & Reproduct, DK-2100 Copenhagen, Denmark; Univ Zurich, Inst Vet Biochem & Mol Biol, Zurich, Switzerland; Gurdon Inst, Cambridge, England	Danish Cancer Society; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; University of Copenhagen; University of Oslo; University of Copenhagen; University of Zurich	Bartek, J (corresponding author), Danish Canc Soc, Ctr Genotox Stress Res, Inst Canc Biol, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.	jb@cancer.dk	Rajpert-De Meyts, Ewa/H-6526-2019; Dry, Kate/I-2328-2014; Bartek, Jiri/G-5870-2014; Stucki, Manuel/H-4739-2017; Jackson, Stephen Philip/R-4548-2019	Rajpert-De Meyts, Ewa/0000-0002-5946-7559; Jackson, Stephen Philip/0000-0001-9317-7937; Licenikova Horejsi, Zuzana/0000-0002-9943-1649; Lukas, Jiri/0000-0001-9087-506X				Albanell J, 1999, J NATL CANCER I, V91, P1321, DOI 10.1093/jnci/91.15.1321; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bartek J, 2006, CELL, V124, P888, DOI 10.1016/j.cell.2006.02.029; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Bartkova J, 2003, APMIS, V111, P252, DOI 10.1034/j.1600-0463.2003.1110129.x; Bartkova J, 2005, CELL CYCLE, V4, P838, DOI 10.4161/cc.4.6.1742; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bassing CH, 2004, DNA REPAIR, V3, P781, DOI 10.1016/j.dnarep.2004.06.001; Bekker-Jensen S, 2005, J CELL BIOL, V170, P201, DOI 10.1083/jcb.200503043; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Horejsi Z, 2004, ONCOGENE, V23, P3122, DOI 10.1038/sj.onc.1207447; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(05)00092-4; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Latella L, 2004, MOL CELL BIOL, V24, P6350, DOI 10.1128/MCB.24.14.6350-6361.2004; Liu S, 2006, MOL CELL BIOL, V26, P6056, DOI 10.1128/MCB.00492-06; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Lukas C, 2004, EMBO J, V23, P2674, DOI 10.1038/sj.emboj.7600269; Lukas C, 2001, CANCER RES, V61, P4990; Lukas J, 2004, DNA REPAIR, V3, P997, DOI 10.1016/j.dnarep.2004.03.006; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Mochan TA, 2004, DNA REPAIR, V3, P945, DOI 10.1016/j.dnarep.2004.03.017; Mochan TA, 2003, CANCER RES, V63, P8586; Morales JC, 2006, P NATL ACAD SCI USA, V103, P3310, DOI 10.1073/pnas.0511259103; Nevanlinna H, 2006, ONCOGENE, V25, P5912, DOI 10.1038/sj.onc.1209877; Nowak R, 2000, ONCOGENE, V19, P4075, DOI 10.1038/sj.onc.1203746; Oosterhuis JW, 2005, NAT REV CANCER, V5, P210, DOI 10.1038/nrc1568; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; Pusapati RV, 2006, P NATL ACAD SCI USA, V103, P1446, DOI 10.1073/pnas.0507367103; Rajpert-de Meyts E, 2003, APMIS, V111, P267, DOI 10.1034/j.1600-0463.2003.11101301.x; Rajpert-De Meyts E, 2006, HUM REPROD UPDATE, V12, P303, DOI 10.1093/humupd/dmk006; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stucki M, 2006, DNA REPAIR, V5, P534, DOI 10.1016/j.dnarep.2006.01.012; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tort F, 2006, CANCER RES, V66, P10258, DOI 10.1158/0008-5472.CAN-06-2178; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Ward IM, 2005, MOL CELL BIOL, V25, P10079, DOI 10.1128/MCB.25.22.10079-10086.2005; Xu XZ, 2003, FASEB J, V17, P1842, DOI 10.1096/fj.03-0310com	50	96	108	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2007	26	53					7414	7422		10.1038/sj.onc.1210553	http://dx.doi.org/10.1038/sj.onc.1210553			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17546051				2022-12-17	WOS:000251282000003
J	Robb, L				Robb, L.			Cytokine receptors and hematopoietic differentiation	ONCOGENE			English	Review						hematopoietin receptor; hematopoiesis; lineage commitment	COLONY-STIMULATING FACTOR; ERYTHROPOIETIN RECEPTOR; MICE LACKING; DEFICIENT MICE; C-MPL; TARGETED DISRUPTION; GROWTH-FACTORS; G-CSF; SIGNAL-TRANSDUCTION; LINEAGE COMMITMENT	Colony- stimulating factors and other cytokines signal via their cognate receptors to regulate hematopoiesis. In many developmental systems, inductive signalling determines cell fate and, by analogy with this, it has been postulated that cytokines, signalling via their cognate receptors, may play an instructive role in lineage specification in hematopoiesis. An alternative to this instructive hypothesis is the stochastic or permissive hypothesis. The latter proposes that commitment to a particular hematopoietic lineage is an event that occurs independently of extrinsic signals. It predicts that the role of cytokines is to provide nonspecific survival and proliferation signals. In this review, we look at the role of cytokine receptor signalling in hematopoiesis and consider the evidence for both hypotheses. Data from experiments that genetically manipulate receptor gene expression in vitro or in vivo are reviewed. Experiments in which cytokine receptors were installed in multipotential cells showed that, in some cases, stimulation with the cognate ligand could lead to alterations in lineage output. The creation of genetically manipulated mouse strains demonstrated that cytokine receptors are required for expansion and survival of single lineages but did not reveal a role in lineage commitment. We conclude that hematopoietic differentiation involves mainly stochastic events, but that cytokine receptors also have some instructive role.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Robb, L (corresponding author), Walter & Eliza Hall Inst Med Res, IG Royal Parade, Melbourne, Vic 3050, Australia.	robb@wehi.edu.au			NCI NIH HHS [CA-22556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA022556, R01CA022556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; Barner M, 1998, CURR BIOL, V8, P669, DOI 10.1016/S0960-9822(98)70256-8; Behrmann I, 2004, J BIOL CHEM, V279, P35486, DOI 10.1074/jbc.M404202200; Betz UAK, 1998, J EXP MED, V188, P1955, DOI 10.1084/jem.188.10.1955; Cantor AB, 2001, CURR OPIN GENET DEV, V11, P513, DOI 10.1016/S0959-437X(00)00226-4; CarverMoore K, 1996, BLOOD, V88, P803; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; DANDREA AD, 1994, CURR OPIN CELL BIOL, V6, P804, DOI 10.1016/0955-0674(94)90048-5; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; Evans CA, 1999, BLOOD, V94, P1504, DOI 10.1182/blood.V94.5.1504.417a27_1504_1514; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; Fox N, 2002, J CLIN INVEST, V110, P389, DOI 10.1172/JCI200215430; Frohlich A, 2007, BLOOD, V109, P2023, DOI 10.1182/blood-2006-05-021600; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; Gainsford T, 2000, BLOOD, V95, P528, DOI 10.1182/blood.V95.2.528; Goldsmith MA, 1998, P NATL ACAD SCI USA, V95, P7006, DOI 10.1073/pnas.95.12.7006; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; Hisakawa H, 2001, BLOOD, V98, P3618, DOI 10.1182/blood.V98.13.3618; Horan T, 1996, BIOCHEMISTRY-US, V35, P4886, DOI 10.1021/bi9525841; Howard M, 1994, GUIDEBOOK CYTOKINES; ICHIHARA M, 1995, EMBO J, V14, P939, DOI 10.1002/j.1460-2075.1995.tb07075.x; Iwasaki-Arai J, 2003, J EXP MED, V197, P1311, DOI 10.1084/jem.20021843; Jegalian AG, 2002, BLOOD, V99, P2603, DOI 10.1182/blood.V99.7.2603; JUST U, 1991, CELL, V64, P1163, DOI 10.1016/0092-8674(91)90271-Y; Kaushansky K, 2002, BLOOD, V99, P3573, DOI 10.1182/blood.V99.10.3573; Kaushansky K, 2006, NEW ENGL J MED, V354, P2034, DOI 10.1056/NEJMra052706; Kertesz N, 2004, DEV BIOL, V276, P101, DOI 10.1016/j.ydbio.2004.08.025; Kieran MW, 1996, P NATL ACAD SCI USA, V93, P9126, DOI 10.1073/pnas.93.17.9126; Kirby SL, 1996, P NATL ACAD SCI USA, V93, P9402, DOI 10.1073/pnas.93.18.9402; Kondo M, 2000, NATURE, V407, P383, DOI 10.1038/35030112; Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092-8674(00)80290-1; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Liu FL, 1996, IMMUNITY, V5, P491, DOI 10.1016/S1074-7613(00)80504-X; Liu FL, 1997, BLOOD, V90, P2583, DOI 10.1182/blood.V90.7.2583.2583_2583_2590; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Maki K, 1996, P NATL ACAD SCI USA, V93, P7172, DOI 10.1073/pnas.93.14.7172; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; MCARTHUR GA, 1994, BLOOD, V83, P972; McKinstry WJ, 1997, BLOOD, V89, P65, DOI 10.1182/blood.V89.1.65.65_65_71; METCALF D, 1982, J CELL PHYSIOL, V111, P275, DOI 10.1002/jcp.1041110308; Metcalf D, 1999, STEM CELLS, V17, P1, DOI 10.1002/stem.170001; Metcalf D, 1984, CLONAL CULTURE HEMOP; Nandurkar HH, 1997, BLOOD, V90, P2148; NICOLA M, 1996, SCI TECHNOL ENV PROT, V3, P3; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; NISHINAKAMURA R, 1995, IMMUNITY, V2, P211, DOI 10.1016/1074-7613(95)90046-2; Orkin SH, 2000, NAT REV GENET, V1, P57, DOI 10.1038/35049577; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; PHARR PN, 1994, P NATL ACAD SCI USA, V91, P7482, DOI 10.1073/pnas.91.16.7482; Porteu F, 1996, MOL CELL BIOL, V16, P2473; Richards MK, 2003, BLOOD, V102, P3562, DOI 10.1182/blood-2003-02-0593; Robb L, 1998, NAT MED, V4, P303, DOI 10.1038/nm0398-303; ROBB L, 1995, P NATL ACAD SCI USA, V92, P9565, DOI 10.1073/pnas.92.21.9565; Scott CL, 2000, EXP HEMATOL, V28, P1001, DOI 10.1016/S0301-472X(00)00504-X; Semerad CL, 2002, IMMUNITY, V17, P413, DOI 10.1016/S1074-7613(02)00424-7; Semerad CL, 1999, IMMUNITY, V11, P153, DOI 10.1016/S1074-7613(00)80090-4; Seymour JF, 1997, BLOOD, V90, P3037, DOI 10.1182/blood.V90.8.3037; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; Solar GP, 1998, BLOOD, V92, P4, DOI 10.1182/blood.V92.1.4.413k38_4_10; STANLEY E, 1994, P NATL ACAD SCI USA, V91, P5592, DOI 10.1073/pnas.91.12.5592; Stoffel R, 1999, P NATL ACAD SCI USA, V96, P698, DOI 10.1073/pnas.96.2.698; Suzuki H, 1997, J EXP MED, V185, P499, DOI 10.1084/jem.185.3.499; Tamada T, 2006, P NATL ACAD SCI USA, V103, P3135, DOI 10.1073/pnas.0511264103; Tanaka M, 2003, BLOOD, V102, P3154, DOI 10.1182/blood-2003-02-0367; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; WARE CB, 1995, DEVELOPMENT, V121, P1283; Watowich SS, 1996, ANNU REV CELL DEV BI, V12, P91, DOI 10.1146/annurev.cellbio.12.1.91; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200; Wu H, 1999, DEVELOPMENT, V126, P3597; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Yoshida T, 1996, IMMUNITY, V4, P483, DOI 10.1016/S1074-7613(00)80414-8	84	96	98	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6715	6723		10.1038/sj.onc.1210756	http://dx.doi.org/10.1038/sj.onc.1210756			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934480	Bronze			2022-12-17	WOS:000250147000004
J	Wood, VHJ; O'Neil, JD; Wei, W; Stewart, SE; Dawson, CW; Young, LS				Wood, V. H. J.; O'Neil, J. D.; Wei, W.; Stewart, S. E.; Dawson, C. W.; Young, L. S.			Epstein-Barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGF beta signaling pathways	ONCOGENE			English	Article						EBV; EBNA1; STAT1; TGF beta 1; SMAD2	GROWTH-FACTOR-BETA; NUCLEAR ANTIGEN 1; NASOPHARYNGEAL CARCINOMA; KAPOSIS-SARCOMA; LYMPHOMA-CELLS; KAPPA-B; EXPRESSION; CANCER; PROTEIN; PROMOTER	The Epstein-Barr virus (EBV)-encoded EBNA1 protein is expressed in all virus-associated tumors where it plays an essential role in the maintenance, replication and transcription of the EBV genome. Transcriptional pro. ling of EBNA1-expressing carcinoma cells demonstrated that EBNA1 also influences the expression of a range of cellular genes including those involved in translation, transcription and cell signaling. Of particular interest was the ability of EBNA1 to enhance expression of STAT1 and sensitize cells to interferon-induced STAT1 activation with resultant enhancement of major histocompatibility complex expression. A negative effect of EBNA1 on the expression of TGF beta 1-responsive beta ig-h3 and PAI-1 genes was confirmed at the protein level in EBV-infected carcinoma cells. This effect resulted from the ability of EBNA1 to repress TGFb1-induced transcription via a reduction in the interaction of SMAD2 with SMAD4. More detailed analysis revealed that EBNA1 induces a lower steady-state level of SMAD2 protein as a consequence of increased protein turnover. These data show that EBNA1 can influence cellular gene transcription resulting in effects that may contribute to the development of EBV-associated tumors.	Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	Cancer Research UK; University of Birmingham	Young, LS (corresponding author), Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.	L.S.Young@bham.ac.uk	Young, Lawrence S/B-7213-2009	Young, Lawrence S/0000-0003-3919-4298; Wei, Wenbin/0000-0003-1288-6999				AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Baumforth KRN, 2005, BLOOD, V106, P2138, DOI 10.1182/blood-2005-02-0471; Cao WP, 2006, BLOOD, V107, P2777, DOI 10.1182/blood-2005-05-1803; Chen HL, 2003, J VIROL, V77, P4139, DOI 10.1128/JVI.77.7.4139-4148.2003; Chen HL, 1999, P NATL ACAD SCI USA, V96, P9339, DOI 10.1073/pnas.96.16.9339; Chen HL, 2001, J VIROL, V75, P2929, DOI 10.1128/JVI.75.6.2929-2937.2001; Choi SH, 2006, J BIOL CHEM, V281, P7468, DOI 10.1074/jbc.M512438200; Chow LSN, 2006, ONCOGENE, V25, P310, DOI 10.1038/sj.onc.1209001; Chuang TC, 2002, FEBS LETT, V532, P135, DOI 10.1016/S0014-5793(02)03658-X; Debonneville C, 2004, MOL CELL BIOL, V24, P2397, DOI 10.1128/MCB.24.6.2397-2409.2004; Fakhari FD, 2006, J CLIN INVEST, V116, P735, DOI 10.1172/JCI26190; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829; Fukuda M, 2004, J VIROL, V78, P1697, DOI 10.1128/JVI.78.4.1697-1705.2004; Gupta A, 2006, NATURE, V442, P82, DOI 10.1038/nature04836; Haider AS, 2006, J INVEST DERMATOL, V126, P869, DOI 10.1038/sj.jid.5700157; Harn HJ, 2002, ORAL ONCOL, V38, P23, DOI 10.1016/S1368-8375(01)00008-2; Holowaty MN, 2003, J BIOL CHEM, V278, P29987, DOI 10.1074/jbc.M303977200; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Humme S, 2003, P NATL ACAD SCI USA, V100, P10989, DOI 10.1073/pnas.1832776100; Kang MS, 2005, P NATL ACAD SCI USA, V102, P820, DOI 10.1073/pnas.0408774102; Kang MS, 2001, P NATL ACAD SCI USA, V98, P15233, DOI 10.1073/pnas.211556598; Kennedy G, 2003, P NATL ACAD SCI USA, V100, P14269, DOI 10.1073/pnas.2336099100; Kieff E, 2001, FIELDS VIROLOGY, V2, P2511; Komano J, 1998, J VIROL, V72, P9150, DOI 10.1128/JVI.72.11.9150-9156.1998; Kovacic B, 2006, CANCER CELL, V10, P77, DOI 10.1016/j.ccr.2006.05.025; Kube D, 1999, J VIROL, V73, P1630, DOI 10.1128/JVI.73.2.1630-1636.1999; Kuratomi G, 2005, BIOCHEM J, V386, P461, DOI 10.1042/BJ20040738; Lee CY, 2004, IEEE T EVOLUT COMPUT, V8, P1, DOI 10.1109/TEVC.2003.816583; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Liang CL, 2000, VIROLOGY, V277, P184, DOI 10.1006/viro.2000.0582; Liang CL, 2002, J BIOL CHEM, V277, P23345, DOI 10.1074/jbc.M107420200; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Mori N, 2003, INT J CANCER, V105, P661, DOI 10.1002/ijc.11146; Munier FL, 1997, NAT GENET, V15, P247, DOI 10.1038/ng0397-247; Nam JO, 2005, CANCER RES, V65, P4153, DOI 10.1158/0008-5472.CAN-04-2705; Oh JE, 2005, J BIOL CHEM, V280, P21629, DOI 10.1074/jbc.m412293200; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Raab-Traub N, 2002, SEMIN CANCER BIOL, V12, P431, DOI 10.1016/S1044579X0200086X; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Renne C, 2006, AM J PATHOL, V169, P655, DOI 10.2353/ajpath.2006.060020; Ruf IK, 2000, J VIROL, V74, P10223, DOI 10.1128/JVI.74.21.10223-10228.2000; Saridakis V, 2005, MOL CELL, V18, P25, DOI 10.1016/j.molcel.2005.02.029; Seo TG, 2005, CANCER RES, V65, P1738, DOI 10.1158/0008-5472.CAN-04-2374; Shao GZ, 2006, CANCER RES, V66, P4566, DOI 10.1158/0008-5472.CAN-05-2130; Sheng Y, 2006, NAT STRUCT MOL BIOL, V13, P285, DOI 10.1038/nsmb1067; Sheu LF, 1996, J PATHOL, V180, P243, DOI 10.1002/(SICI)1096-9896(199611)180:3<243::AID-PATH655>3.0.CO;2-7; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; SRINIVAS SK, 1995, J VIROL, V69, P8155, DOI 10.1128/JVI.69.12.8155-8158.1995; Stewart S, 2004, P NATL ACAD SCI USA, V101, P15730, DOI 10.1073/pnas.0402135101; Tellam J, 2004, J EXP MED, V199, P1421, DOI 10.1084/jem.20040191; Tsimbouri P, 2002, ONCOGENE, V21, P5182, DOI 10.1038/sj.onc.1205490; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Voo KS, 2004, J EXP MED, V199, P459, DOI 10.1084/jem.20031219; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; Xi SC, 2006, JNCI-J NATL CANCER I, V98, P181, DOI 10.1093/jnci/djj020; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	60	96	103	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4135	4147		10.1038/sj.onc.1210496	http://dx.doi.org/10.1038/sj.onc.1210496			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17486072				2022-12-17	WOS:000247252700009
J	Akiyama, T; Kawasaki, Y				Akiyama, T.; Kawasaki, Y.			Wnt signalling and the actin cytoskeleton	ONCOGENE			English	Review						tumour suppressor; colon tumour; APC; cytoskeleton; kinesin-2; Asef	ADENOMATOUS POLYPOSIS-COLI; CELL-CELL ADHESION; TUMOR-SUPPRESSOR PROTEIN; APC PROTEIN; EPITHELIAL-CELLS; IN-VIVO; MICROTUBULES; CDC42; ASSOCIATION; MIGRATION	The tumour suppressor adenomatous polyposis coli (APC) is mutated in sporadic and familial colorectal tumours. APC binds to beta-catenin, a key component of the Wnt signalling pathway, and induces its degradation. In addition to this role, there is increasing evidence for additional roles of APC, including the organization of cytoskeletal networks. APC interacts with microtubules and accumulates at their plus ends in membrane protrusions. Also, it has been reported that APC is associated with the plasma membrane in an actin-dependent manner. Moreover, APC interacts with IQGAP1, an effector of Rac1 and Cdc42, and APC-stimulated guanine nucleotide exchange factor (Asef), a Rac1-specific guanine nucleotide exchange factor (GEF). IQGAP1 mediates association of APC with cortical actin in the leading edge of migrating cell and both proteins are required for cell polarization and directional migration. APC interacts with Asef and stimulates its activity, thereby regulating the actin cytoskeletal network, cell morphology, adhesion and migration. Truncated mutant APCs present in colorectal tumour cells activate Asef constitutively and contribute to their aberrant migratory properties, which may be important for adenoma formation as well as tumour progression to invasive malignancy.	Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	akiyama@imcbns.iam.u-tokyo.ac.jp						Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bienz M, 2004, CURR OPIN CELL BIOL, V16, P528, DOI 10.1016/j.ceb.2004.08.001; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Braga VMM, 2000, MOL BIOL CELL, V11, P3703, DOI 10.1091/mbc.11.11.3703; Briggs MW, 2003, FEBS LETT, V542, P7, DOI 10.1016/S0014-5793(03)00333-8; Brocardo M, 2005, EMBO REP, V6, P184, DOI 10.1038/sj.embor.7400329; CADIGAN KM, 1997, GENE DEV, V11, P3052; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Faux MC, 2004, J CELL SCI, V117, P427, DOI 10.1242/jcs.00862; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Langford KJ, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-3; Mateer SC, 2003, CELL MOTIL CYTOSKEL, V55, P147, DOI 10.1002/cm.10118; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; McCartney BM, 2000, NAT CELL BIOL, V2, pE58, DOI 10.1038/35008685; McCartney BM, 2006, DEVELOPMENT, V133, P2407, DOI 10.1242/dev.02398; Miki H, 2005, TRENDS CELL BIOL, V15, P467, DOI 10.1016/j.tcb.2005.07.006; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; MIYASHIRO I, 1995, ONCOGENE, V11, P89; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Oshima H, 1997, CANCER RES, V57, P1644; Polakis P, 2000, GENE DEV, V14, P1837; Reilein A, 2005, NAT CELL BIOL, V7, P463, DOI 10.1038/ncb1248; Rosin-Arbesfeld R, 2001, EMBO J, V20, P5929, DOI 10.1093/emboj/20.21.5929; Samowitz WS, 1999, CANCER RES, V59, P1442; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Scholey JM, 1996, J CELL BIOL, V133, P1, DOI 10.1083/jcb.133.1.1; Sharma M, 2006, J BIOL CHEM, V281, P17140, DOI 10.1074/jbc.M513027200; SU LK, 1995, CANCER RES, V55, P2972; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Wen Y, 2004, NAT CELL BIOL, V6, P820, DOI 10.1038/ncb1160; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	45	96	97	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2006	25	57					7538	7544		10.1038/sj.onc.1210063	http://dx.doi.org/10.1038/sj.onc.1210063			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143298				2022-12-17	WOS:000242514900012
J	Wang, M; Kirk, JS; Venkataraman, S; Domann, FE; Zhang, HJ; Schafer, FQ; Flanagan, SW; Weydert, CJ; Spitz, DR; Buettner, GR; Oberley, LW				Wang, M; Kirk, JS; Venkataraman, S; Domann, FE; Zhang, HJ; Schafer, FQ; Flanagan, SW; Weydert, CJ; Spitz, DR; Buettner, GR; Oberley, LW			Manganese superoxide dismutase suppresses hypoxic induction of hypoxia-inducible factor-1 alpha and vascular endothelial growth factor	ONCOGENE			English	Article						HIF-1; VEGF; angiogenesis; hypoxia; MnSOD	INDUCIBLE FACTOR-I; NF-KAPPA-B; LINDAU TUMOR-SUPPRESSOR; REDOX REGULATION; GLUTATHIONE-PEROXIDASE; INDUCED ANGIOGENESIS; ANTIOXIDANT ENZYMES; CELL PHENOTYPE; NITRIC-OXIDE; CANCER CELLS	Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that governs cellular responses to reduced O-2 availability by mediating crucial homeostatic processes. HIF-1 is composed of an HIF-1 alpha subunit and an HIF-1 beta subunit. HIF-1 alpha is degraded following enzyme-dependent hydroxylation of prolines of HIF-1 alpha in the presence of molecular oxygen, Fe2+, alpha-ketoglutarate, and ascorbate. These cofactors contribute to the redox environment of cells. The antioxidant enzyme manganese superoxide dismutase (MnSOD) also modulates the cellular redox environment. Here we show that MnSOD suppressed hypoxic accumulation of HIF-1 alpha protein in human breast carcinoma MCF-7 cells. This suppression was biphasic depending on MnSOD activity. At low levels of MnSOD activity, HIF-1 alpha protein accumulated under hypoxic conditions. At moderate levels of MnSOD activity (two-to six-fold increase compared to parent cells), these accumulations were blocked. However, at higher levels of MnSOD activity (> 6-fold increase), accumulation of HIF-1 alpha protein was again observed. This biphasic modulation was observed under both 1 and 4% O-2. Coexpression of mitochondrial hydrogen peroxide-removing proteins prevented the accumulation of HIF-1 alpha protein in cells with high levels of MnSOD; this effect demonstrates that the restabilization of HIF-1 alpha observed in high MnSOD overexpressors is probably due to hydrogen peroxide, most likely produced from MnSOD. Hypoxic induction of vascular endothelial growth factor ( VEGF) protein was also suppressed by elevated MnSOD activity and its levels reflected HIF-1 alpha protein levels. These observations demonstrated that HIF-1 alpha accumulation and VEGF expression could be modulated by the antioxidant enzyme MnSOD.	Univ Iowa, Holden Comprehens Canc Ctr, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA	University of Iowa	Oberley, LW (corresponding author), Univ Iowa, Holden Comprehens Canc Ctr, Dept Radiat Oncol, Free Rad & Radiat Biol Program, B180 Med Labs, Iowa City, IA 52242 USA.	larry-oberley@uiowa.edu		Domann, Frederick/0000-0002-0489-2179; Buettner, Garry/0000-0002-5594-1903; Spitz, Douglas/0000-0002-1254-8765	NATIONAL CANCER INSTITUTE [P01CA066081, R01CA081090] Funding Source: NIH RePORTER; NCI NIH HHS [CA81090, CA66081] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [DOI 10.1016/0003-2697(71)90370-8, 10.1016/0003-2697(71)90370-8]; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; BROWN LF, 1997, EXS, V79, P233; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Choi KS, 2003, J BIOCHEM MOL BIOL, V36, P120; Collingridge DR, 1997, RADIAT RES, V147, P329, DOI 10.2307/3579340; DARR D, 1986, BIOCHEM PHARMACOL, V35, P3642, DOI 10.1016/0006-2952(86)90639-8; DEWHIRST MW, 1989, INT J RADIAT ONCOL, V17, P91, DOI 10.1016/0360-3016(89)90375-1; DVORAK HF, 1995, INT ARCH ALLERGY IMM, V107, P233, DOI 10.1159/000236988; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Hockel M, 1996, CANCER RES, V56, P4509; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kelley MR, 2001, ANTIOXID REDOX SIGN, V3, P671, DOI 10.1089/15230860152543014; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; Li JJ, 1998, FASEB J, V12, P1713, DOI 10.1096/fasebj.12.15.1713; Li N, 1998, PROSTATE, V35, P221, DOI 10.1002/(SICI)1097-0045(19980515)35:3<221::AID-PROS8>3.0.CO;2-J; Li Q, 2001, ANTIOXID REDOX SIGN, V3, P415, DOI 10.1089/15230860152409068; Li SJ, 2000, CANCER RES, V60, P3927; Liu RG, 1997, HUM GENE THER, V8, P585, DOI 10.1089/hum.1997.8.5-585; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Mateo J, 2003, BIOCHEM J, V376, P537, DOI 10.1042/BJ20031155; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McNeill LA, 2002, BIOORG MED CHEM LETT, V12, P1547, DOI 10.1016/S0960-894X(02)00219-6; MOULDER JE, 1984, RADIAT RES, V98, P536, DOI 10.2307/3576486; Nagy JA, 2002, J EXP MED, V196, P1497, DOI 10.1084/jem.20021244; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; OBERLEY LW, 1984, METHOD ENZYMOL, V105, P457; OBERLEY LW, 1988, MOL CELL BIOCHEM, V84, P147, DOI 10.1007/BF00421049; OBERLEY LW, 1979, CANCER RES, V39, P1141; OBERLEY LW, 1989, FREE RADICAL BIO MED, V6, P379, DOI 10.1016/0891-5849(89)90083-X; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P473, DOI 10.1016/0891-5849(90)90124-2; Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182; Park JH, 2003, CLIN CANCER RES, V9, P433; Powis G, 1997, Adv Pharmacol, V38, P329; Pugh CW, 2003, SEMIN CANCER BIOL, V13, P83, DOI 10.1016/S1044-579X(02)00103-7; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Rodriguez AM, 2000, FREE RADICAL BIO MED, V29, P801, DOI 10.1016/S0891-5849(00)00362-2; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schroedl C, 2002, AM J PHYSIOL-LUNG C, V283, pL922, DOI 10.1152/ajplung.00014.2002; Semenza GL, 1998, CHEST, V114, p40S, DOI 10.1378/chest.114.1_Supplement.40S; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2001, J CLIN INVEST, V108, P39, DOI 10.1172/JCI13374; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 1999, ANN NY ACAD SCI, V874, P262, DOI 10.1111/j.1749-6632.1999.tb09241.x; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; SHAHYUKICH AA, 1988, LAB INVEST, V58, P236; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; SUN Y, 1988, FREE RADICAL RES COM, V5, P67, DOI 10.3109/10715768809066913; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Thomas DD, 2004, P NATL ACAD SCI USA, V101, P8894, DOI 10.1073/pnas.0400453101; TULCHIN N, 1976, ANAL BIOCHEM, V72, P485, DOI 10.1016/0003-2697(76)90558-3; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, J BIOL CHEM, V268, P21513; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; Wheeler MD, 2003, MOL CANCER RES, V1, P871; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W; Zhang HJ, 2002, J BIOL CHEM, V277, P20919, DOI 10.1074/jbc.M109801200; Zhang HJ, 1999, CANCER RES, V59, P6276; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698	68	96	103	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8154	8166		10.1038/sj.onc.1208986	http://dx.doi.org/10.1038/sj.onc.1208986			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16170370				2022-12-17	WOS:000233809400007
J	Iwakiri, D; Sheen, TS; Chen, JY; Huang, DP; Takada, K				Iwakiri, D; Sheen, TS; Chen, JY; Huang, DP; Takada, K			Epstein-Barr virus-encoded small RNA induces insulin-like growth factor 1 and supports growth of nasopharyngeal carcinoma-derived cell lines	ONCOGENE			English	Article						EBV; IGF-1; nasopharyngeal carcinoma; EBER	BURKITTS-LYMPHOMA; INFECTION; CANCER	To assess the role of insulin-like growth factor 1 (IGF-1) in the growth of nasopharyngeal carcinoma (NPC), three NPC-derived cell lines, C666-1, CNE1 and HONE1, were examined. C666-1 cells maintained NPC phenotype of Epstein-Barr virus (EBV) expression and were positive for IGF-1 secretion, and their growth was strikingly inhibited by treatment with an anti-IGF-1 antibody under low serum condition. On the other hand, CNE1 and HONE1 cells were EBV-negative and did not secrete IGF-1. Although they could not grow under low serum condition, addition of recombinant IGF-1 made them grow. EBV conversion of CNE1 and HONE1 cells reproduced NPC phenotype of EBV expression and accompanied IGF-1 expression. Although they could grow under low serum condition, their growth was strikingly inhibited by treatment with the anti-IGF-1 antibody. These results suggest that EBV infection induces IGF-1 in NPC cell lines, and that the secreted IGF-1 acts as an autocrine growth factor. These findings seem to be operative in vivo, as NPC biopsies consistently express IGF-1. Further studies demonstrated that increased IGF-1 expression reflected transcriptional activation, and EBV-encoded small RNA ( EBER) was responsible for IGF-1 induction. EBER is invariably expressed in EBV-associated malignancies, including NPC. The present findings strongly suggest that EBER directly affects the pathogenesis of NPC.	Hokkaido Univ, Inst Med Genet, Dept Tumor Virol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Natl Taiwan Univ, Coll Med, Dept Otolaryngol, Taipei 10764, Taiwan; Natl Taiwan Univ, Coll Med, Dept Microbiol, Taipei 10764, Taiwan; Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China	Hokkaido University; National Taiwan University; National Taiwan University; Chinese University of Hong Kong	Takada, K (corresponding author), Hokkaido Univ, Inst Med Genet, Dept Tumor Virol, Kita Ku, N15 W7, Sapporo, Hokkaido 0600815, Japan.	kentaka@igm.hokudai.ac.jp	Takada, Kenzo/A-6666-2012; Chen, Jen-Yang/D-2085-2010					Cheung ST, 1999, INT J CANCER, V83, P121, DOI 10.1002/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO;2-F; Furstenberger G, 2002, LANCET ONCOL, V3, P298, DOI 10.1016/S1470-2045(02)00731-3; Imai S, 1998, J VIROL, V72, P4371, DOI 10.1128/JVI.72.5.4371-4378.1998; Iwakiri D, 2003, CANCER RES, V63, P7062; KIEFF E, 2002, FIELDS VIROLOGY, P2511; Kitagawa N, 2000, EMBO J, V19, P6742, DOI 10.1093/emboj/19.24.6742; Komano J, 1999, J VIROL, V73, P9827, DOI 10.1128/JVI.73.12.9827-9831.1999; Maruo S, 2001, J GEN VIROL, V82, P2373, DOI 10.1099/0022-1317-82-10-2373; Nanbo A, 2002, EMBO J, V21, P954, DOI 10.1093/emboj/21.5.954; RICKINSON AB, 2002, FIELDS VIROLOGY, P2575; SHARP TV, 1993, NUCLEIC ACIDS RES, V21, P4483, DOI 10.1093/nar/21.19.4483; Yamamoto N, 2000, FEBS LETT, V484, P153, DOI 10.1016/S0014-5793(00)02145-1; YAO K, 1990, INT J CANCER, V45, P83, DOI 10.1002/ijc.2910450116; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; ZHANG S, 1982, HEREDITAS, V97, P23, DOI 10.1111/j.1601-5223.1982.tb00706.x	15	96	104	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1767	1773		10.1038/sj.onc.1208357	http://dx.doi.org/10.1038/sj.onc.1208357			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15608666				2022-12-17	WOS:000227345100012
J	Massimi, P; Gammoh, N; Thomas, M; Banks, L				Massimi, P; Gammoh, N; Thomas, M; Banks, L			HPV E6 specifically targets different cellular pools of its PDZ domain-containing tumour suppressor substrates for proteasome-mediated degradation	ONCOGENE			English	Article						transformation; human papillomavirus; E6; PDZ domains	HUMAN HOMOLOG; PROTEINS TARGET; CANCER-CELLS; RECOGNITION; INDUCTION; POLARITY; BINDING; GROWTH; APC	The high-risk HPV E6 proteins have been shown to directthe degradation of a variety of cellular proteins that contain PDZ domains. Although some of these proteins are involved in regulating processes of cell growth and polarity in Drosophila, little is known about their function in higher eukaryotic epithelial cells. In HPV-containing cells derived from cervical tumours, we find that the patterns of expression of the E6 targets hDlg (discs large), hScrib (Scribble), and MUPP1 are consistent with their being substrates for E6-induced degradation. It is also clear that, in the case of hDlg, E6 is specifically targeting nuclear pools of the protein rather than membrane-bound forms. We have also analysed the activity of a subset of E6 target proteins in the suppression of oncogene-induced cell transformation. Interestingly, Dlg, MAGI-1 and MUPP1 efficiently suppressed cell transformation, while MAGI-2 and MAGI-3 were ineffective in this assay. These results suggest that in the context of HPV-induced transformation Dlg, MAGI-1 and MUPP1 can function as tumour suppressors.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org						Alvarez-Salas LM, 1998, P NATL ACAD SCI USA, V95, P1189, DOI 10.1073/pnas.95.3.1189; Banks L, 2003, TRENDS BIOCHEM SCI, V28, P452, DOI 10.1016/S0968-0004(03)00141-5; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Caruana G, 2001, MOL CELL BIOL, V21, P1475, DOI 10.1128/MCB.21.5.1475-1483.2001; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2002, J GEN VIROL, V83, P283, DOI 10.1099/0022-1317-83-2-283; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Mantovani F, 2003, J BIOL CHEM, V278, P42477, DOI 10.1074/jbc.M302799200; Mantovani F, 2001, J CELL SCI, V114, P4285; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; McLaughlin M, 2002, J BIOL CHEM, V277, P6406, DOI 10.1074/jbc.M108724200; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Reuver SM, 1998, J CELL SCI, V111, P1071; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; VONKNEBEL M, 1992, INT J CANCER, V51, P831, DOI 10.1002/ijc.2910510527; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yoshinouchi M, 2003, MOL THER, V8, P762, DOI 10.1016/j.ymthe.2003.08.004; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	36	96	106	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8033	8039		10.1038/sj.onc.1207977	http://dx.doi.org/10.1038/sj.onc.1207977			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15378012				2022-12-17	WOS:000224692500001
J	Ludes-Meyers, JH; Kil, H; Bednarek, AK; Drake, J; Bedford, MT; Aldaz, CM				Ludes-Meyers, JH; Kil, H; Bednarek, AK; Drake, J; Bedford, MT; Aldaz, CM			WWOX binds the specific proline-rich ligand PPXY: identification of candidate interacting proteins	ONCOGENE			English	Article						tumor suppressors; WW domain; protein-protein interaction	DOMAIN-CONTAINING OXIDOREDUCTASE; FRA16D; COMMON; GENES; MOTIF	WWOX, the gene that maps to common chromosomal fragile site FRA16D, is frequently affected by aberrations in multiple types of cancers. WWOX encodes a 46 kDa protein that contains two WW domains and a short-chain oxidoreductase (SDR) domain. We recently demonstrated that ectopic expression of WWOX inhibits xenograft tumor growth of tumorigenic breast cancer cells. Little is known of the biochemical function(s) of WWOX. The SDR domain is predicted to be involved in sex-steroid metabolism and the WW domains are likely involved in protein-protein interactions. In this report, we identify the specific proline-rich ligand for WWOX as PPXY and show that the amino-terminal WW domain is responsible for this interaction. Using the WWOX WW domains as a probe, we screened high-density protein arrays and identified five candidate-binding partners. The binding to one of these candidates, small membrane protein of the lysosome/late endosome (SIMPLE), was further analysed, and we observed that a specific PPSY motif in the SIMPLE amino-acid sequence was required to interact with the amino-terminal WW domain of WWOX. In addition, immunofluorescence staining demonstrated that endogenous WWOX and SIMPLE co-localize to perinuclear compartments of MCF-7 human breast cancer cells. These studies demonstrate that WWOX contains a Group I WW domain that binds known cellular proteins containing the specific ligand PPXY. Identification and characterization of WWOX interacting proteins will lead to an understanding of the biological functions of WWOX in normal and tumor cells.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; Med Univ Lodz, IPh&B Dept Med Biochem, PL-92215 Lodz, Poland	University of Texas System; UTMD Anderson Cancer Center; Medical University Lodz	Aldaz, CM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, POB 389, Smithville, TX 78957 USA.	maldaz@odin.mdacc.tmc.edu	Aldaz, C. Marcelo/E-7868-2011; Bedford, Mark T/E-7856-2011; Bednarek, Andrzej K./S-9664-2016	Aldaz, C. Marcelo/0000-0002-2453-2939; Bednarek, Andrzej K./0000-0002-4570-4154	NATIONAL CANCER INSTITUTE [R01CA102444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102444-04, R01 CA102444-03, R01 CA 102 444, R01 CA102444-07, R01 CA102444-01, R01 CA102444-06A1, R01 CA102444-02, R01 CA102444, R01 CA102444-05] Funding Source: Medline; NIEHS NIH HHS [P30 ES007784, ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Bussow K, 1998, NUCLEIC ACIDS RES, V26, P5007, DOI 10.1093/nar/26.21.5007; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Chang NS, 2003, J BIOL CHEM, V278, P9195, DOI 10.1074/jbc.M208373200; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Kallberg Y, 2002, PROTEIN SCI, V11, P636, DOI 10.1110/ps.26902; Kasanov J, 2001, CHEM BIOL, V8, P231, DOI 10.1016/S1074-5521(01)00005-9; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Ludes-Meyers JH, 2003, CYTOGENET GENOME RES, V100, P101, DOI 10.1159/000072844; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; Moriwaki Y, 2001, J BIOL CHEM, V276, P23065, DOI 10.1074/jbc.M011660200; Otte L, 2003, PROTEIN SCI, V12, P491, DOI 10.1110/ps.0233203; Sambrook J, 2001, MOL CLONING LAB MANU; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Winfield SL, 1997, GENOME RES, V7, P1020, DOI 10.1101/gr.7.10.1020	21	96	102	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5049	5055		10.1038/sj.onc.1207680	http://dx.doi.org/10.1038/sj.onc.1207680			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15064722	Green Accepted			2022-12-17	WOS:000222237300011
J	Lee, JH; Park, SJ; Abraham, SC; Seo, JS; Nam, JH; Choi, C; Juhng, SW; Rashid, A; Hamilton, SR; Wu, TT				Lee, JH; Park, SJ; Abraham, SC; Seo, JS; Nam, JH; Choi, C; Juhng, SW; Rashid, A; Hamilton, SR; Wu, TT			Frequent CpG island methylation in precursor lesions and early gastric adenocarcinomas	ONCOGENE			English	Article						gastric neoplasms; precursor lesions; CpG island methylation	HMLH1 GENE PROMOTER; DNA HYPERMETHYLATION; APC GENE; CLINICOPATHOLOGICAL FEATURES; MICROSATELLITE INSTABILITY; MALIGNANT TRANSFORMATION; ABERRANT METHYLATION; SOMATIC MUTATIONS; MULTIPLE GENES; E-CADHERIN	Gastric carcinogenesis involves multiple genetic and epigenetic alterations. Epigenetic silencing of tumor-related genes due to CpG island methylation (CIM) has been recently reported in gastric cancer, but the role in precursor lesions is not well understood. We analysed the methylation status of the tumor suppressor gene p16, the DNA mismatch repair gene hMLH1, and four CpG islands (MINT1, MINT2, MINT25, and MINT31) using methylation-specific polymerase chain reaction in 35 polypoid adenomas and 46 flat dysplasias unassociated with carcinoma, 34 early adenocarcinomas (T1N0M0) and associated adenomas/dysplasias, and corresponding adjacent non-neoplastic mucosa. The extent of CIM was defined by the fraction of methylated loci (methylation index), and compared with previously characterized genetic alterations (microsatellite instability (MSI) and APC gene mutation). We found that methylation of p16 was more frequent in adenocarcinoma-associated dysplasias/adenomas (29%) and adenocarcinomas (44%) as compared to flat dysplasias (4%) and adenomas (18%) unassociated with adenocarcinorna (P = 0.001). The mean methylation index increased from normal/chronic gastritis (CG) mucosa (0.09) to intestinal metaplasia (IM) (0.16), flat dysplasias (0.40) or polypoid adenomas (0.41) unassociated with carcinoma, dysplasias/adenomas associated with carcinoma (0.44), and adenocarcinomas (0.44). There was no difference in frequencies of high-level CpG island methylation (CIM-H, methylation index greater than or equal to0.5) among flat dysplasias (50%) and polypoid adenomas (51%) unassociated with carcinoma, dysplasias/adenomas associated with adenocarcinoma (47%), and adenocarcinoma (47%). CIM-H was present in 15% of IM, but not in normal/CG mucosa. There was a significant correlation between methylation of hMLH1 and high-level of microsatellite instability (MSI-H): methylation of hMLH1 was present in 71% of MSI-H tumors, but only 8% of MSI-low tumors and 13% of microsatellite-stable tumors (P=0.0001). There was no statistical difference between methylation index and APC mutation. Our results indicate that concurrent promoter methylation is an early and frequent event in gastric tumorigenesis, including both MSI-H and microsatellite-stable neoplasms. Methylation of the p16 gene may contribute to the malignant transformation of gastric precursor lesions.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Chonnam Natl Univ, Sch Med, Kwangju 501190, South Korea	University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic; Chonnam National University	Wu, TT (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, G1-3595C,Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.	twu@mdanderson.org	Seo, Jeong-Sun/J-2763-2012					Akiyama Y, 1996, JPN J CANCER RES, V87, P595, DOI 10.1111/j.1349-7006.1996.tb00265.x; BANKFALVI A, 1994, J PATHOL, V174, P223, DOI 10.1002/path.1711740312; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BECKER KF, 1994, CANCER RES, V54, P3845; CORREA P, 1994, CANCER RES, V54, pS1941; CORREA P, 1992, CANCER RES, V52, P6735; Eads CA, 2001, CANCER RES, V61, P3410; Eads CA, 2000, CANCER RES, V60, P5021; Endoh Y, 2000, AM J PATHOL, V157, P717, DOI 10.1016/S0002-9440(10)64584-1; Fleisher AS, 1999, CANCER RES, V59, P1090; Fleisher AS, 2001, ONCOGENE, V20, P329, DOI 10.1038/sj.onc.1204104; Fujimoto J, 2000, CANCER LETT, V149, P125, DOI 10.1016/S0304-3835(99)00349-3; Gunther T, 1998, PATHOL RES PRACT, V194, P809, DOI 10.1016/S0344-0338(98)80082-4; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; IIDA S, 2002, INT J CANCER, V87, P654; Jang TJ, 2001, INT J CANCER, V93, P629, DOI 10.1002/ijc.1394; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KAMIYA T, 1982, CANCER, V50, P2496, DOI 10.1002/1097-0142(19821201)50:11<2496::AID-CNCR2820501140>3.0.CO;2-1; Kanai Y, 1998, CANCER LETT, V122, P135, DOI 10.1016/S0304-3835(97)00380-7; Kang GH, 2003, LAB INVEST, V83, P519, DOI 10.1097/01.LAB.0000064704.53132.65; Kang GH, 2001, CANCER RES, V61, P2847; Kang YH, 2002, LAB INVEST, V82, P285, DOI 10.1038/labinvest.3780422; KIHANA T, 1991, JPN J CANCER RES, V82, P308, DOI 10.1111/j.1349-7006.1991.tb01847.x; KOLODZIEJCZYK P, 1994, CANCER-AM CANCER SOC, V74, P2896, DOI 10.1002/1097-0142(19941201)74:11<2896::AID-CNCR2820741103>3.0.CO;2-P; Kwong J, 2002, CLIN CANCER RES, V8, P131; Lee JH, 2002, AM J PATHOL, V161, P611, DOI 10.1016/S0002-9440(10)64216-2; Lee S, 2002, AM J PATHOL, V161, P1015, DOI 10.1016/S0002-9440(10)64262-9; Leung WK, 2001, CANCER-AM CANCER SOC, V91, P2294; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MAESAWA C, 1995, J PATHOL, V176, P249, DOI 10.1002/path.1711760307; Maruyama R, 2001, CANCER RES, V61, P8659; Maruyama R, 2002, CLIN CANCER RES, V8, P514; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; Moskaluk CA, 1997, AM J PATHOL, V150, P1547; NAKATSURU S, 1993, HUM MOL GENET, V2, P1463, DOI 10.1093/hmg/2.9.1463; ORLOWSKA J, 1995, AM J GASTROENTEROL, V90, P2152; Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1; Park WS, 1999, CANCER RES, V59, P4257; RHYU MG, 1994, GASTROENTEROLOGY, V106, P1584, DOI 10.1016/0016-5085(94)90414-6; Stadtlander CTKH, 1999, CARCINOGENESIS, V20, P2195, DOI 10.1093/carcin/20.12.2195; TAMURA G, 1994, CANCER RES, V54, P1149; Toyota M, 2000, ELECTROPHORESIS, V21, P329, DOI 10.1002/(SICI)1522-2683(20000101)21:2<329::AID-ELPS329>3.0.CO;2-9; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P5438; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Ueki T, 2001, CANCER RES, V61, P8540; Virmani AK, 2001, CLIN CANCER RES, V7, P584; Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003; Waki T, 2002, AM J PATHOL, V161, P399, DOI 10.1016/S0002-9440(10)64195-8	49	96	105	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4646	4654		10.1038/sj.onc.1207588	http://dx.doi.org/10.1038/sj.onc.1207588			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064707				2022-12-17	WOS:000221799000015
J	Rosenwald, IB				Rosenwald, IB			The role of translation in neoplastic transformation from a pathologist's point of view	ONCOGENE			English	Review						translation; translation factors; protein synthesis; ribosomes; cancer; neoplastic transformation	INITIATION-FACTOR 4E; CAP-BINDING-PROTEIN; CYCLIN D1 EXPRESSION; GROWTH-FACTOR-BETA; POLYMERASE-I TRANSCRIPTION; NF-KAPPA-B; SQUAMOUS-CELL CARCINOMAS; CHRONIC MYELOID-LEUKEMIA; C-MYC TRANSCRIPTION; MESSENGER-RNA	Increased cell proliferation, which is a hallmark of aggressive malignant neoplasms, requires a general increase in protein synthesis and a specific increase in the synthesis of replication-promoting proteins. Transient increase in the general protein synthesis rate, as well as preferential translation of specific mRNAs coding for growth promoting proteins (e.g. cyclin D1), takes place during normal mitogenic response. A number of extensively studied growth signal transduction pathways (Ras, PI3K, MAPK, mTOR-dependent pathways) activate the function and expression of various components of the translational machinery. In abnormal situations, constitutive activation of signal transduction pathways (e.g. oncogenic activation of Ras or Myc) leads to continuous upregulation of key elements of translational machinery. On the other hand, tumor suppressor genes (p53, pRb) downregulate ribosomal and tRNA synthesis, and their inactivation results in uncontrolled production of these translational components. During recent years, a significant effort has been dedicated to determining whether expression of translation factors is increased in human tumors using clinical biopsy specimens. The results of these studies indicate that expression of particular translation initiation factors is not always increased in human neoplasms. The pattern of expression is characteristic for a particular tumor type. For example, eIF-4E is usually increased in bronchioloalveolar carcinomas but not in squamous cell carcinomas of the lung. Interestingly, in certain highly proliferative and aggressive neoplasms (e.g. squamous cell carcinoma of the lung, melanoma), the expression of eIF-4E is barely detectable. These findings suggest that mechanisms for increasing general protein synthesis in various neoplasms differ significantly. Finally, the possibility of qualitative alterations in the translational machinery, rather than a simple increase in the activity of its components, is discussed along with the possibility of targeting those qualitative differences for tumor therapy.	Univ New Mexico, Dept Pathol, Div Hematopathol, Albuquerque, NM 87131 USA	University of New Mexico	Rosenwald, IB (corresponding author), Univ New Mexico, Dept Pathol, Div Hematopathol, BRF Bldg,Room 323 B,MSC08 4640, Albuquerque, NM 87131 USA.	irozenvald@salud.unm.edu						Abid MR, 1999, J BIOL CHEM, V274, P35991, DOI 10.1074/jbc.274.50.35991; Abou-Jawde R, 2003, CLIN THER, V25, P2121, DOI 10.1016/S0149-2918(03)80209-6; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Ali IK, 2001, EMBO J, V20, P4233, DOI 10.1093/emboj/20.15.4233; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bauer C, 2002, INT J CANCER, V98, P181, DOI 10.1002/ijc.10180; Berkel HJ, 2001, CANCER EPIDEM BIOMAR, V10, P663; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Cai DX, 2001, AM J CLIN PATHOL, V115, P213; Caraglia M, 2000, EUR J BIOCHEM, V267, P3919, DOI 10.1046/j.1432-1327.2000.01465.x; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Ciarmatori S, 2001, MOL CELL BIOL, V21, P5806, DOI 10.1128/MCB.21.17.5806-5814.2001; Clemens MJ, 2001, PROG MOLEC, V27, P57; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; Cohen N, 2001, EMBO J, V20, P4547, DOI 10.1093/emboj/20.16.4547; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Crew JP, 2000, BRIT J CANCER, V82, P161; Crighton D, 2003, EMBO J, V22, P2810, DOI 10.1093/emboj/cdg265; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Dang CV, 1999, MOL CELL BIOL, V19, P1; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DeFatta RJ, 2000, LARYNGOSCOPE, V110, P928, DOI 10.1097/00005537-200006000-00007; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Epifanova O I, 1977, Int Rev Cytol Suppl, P303; Erickson FL, 2001, GENETICS, V158, P123; Felton-Edkins ZA, 2003, EMBO J, V22, P2422, DOI 10.1093/emboj/cdg240; Felton-Edkins ZA, 2003, CELL CYCLE, V2, P181, DOI 10.4161/cc.2.3.375; Frater JL, 2003, AM J CLIN PATHOL, V119, P833, DOI 10.1309/A4RGP4LF12GGH8MW; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Gao MX, 1998, J BIOL CHEM, V273, P4622, DOI 10.1074/jbc.273.8.4622; Grady WM, 1998, CANCER RES, V58, P3101; GRAFF JR, 1995, INT J CANCER, V60, P255; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harrison CJ, 2001, BLOOD REV, V15, P49, DOI 10.1054/blre.2001.0150; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; HAUMEDER E, 1933, L KREBSFORSCH, V40, P105; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEIM S, 1995, CANC CYTOGENETICS, P180; HERSHKO A, 1971, NATURE-NEW BIOL, V232, P206, DOI 10.1038/newbio232206a0; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hochhaus A, 2003, SEMIN HEMATOL, V40, P69, DOI 10.1053/shem.2003.50045; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/ng0501-53; Hughes TP, 2003, NEW ENGL J MED, V349, P1423, DOI 10.1056/NEJMoa030513; Iborra FJ, 2002, CURR OPIN CELL BIOL, V14, P780, DOI 10.1016/S0955-0674(02)00386-1; Iborra FJ, 2001, SCIENCE, V293, P1139, DOI 10.1126/science.1061216; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jones RM, 1996, MOL CELL BIOL, V16, P4754; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; Kim S, 2000, P NATL ACAD SCI USA, V97, P11198, DOI 10.1073/pnas.200372597; Kim SH, 2002, ONCOGENE, V21, P8741, DOI 10.1038/sj.onc.1205987; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSS LG, 1982, ANAL QUANT CYTOL, V4, P251; Lamlum H, 2000, P NATL ACAD SCI USA, V97, P2225, DOI 10.1073/pnas.040564697; Larminie CGC, 1998, J MOL MED, V76, P94, DOI 10.1007/s001090050196; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; Li BDL, 2002, ANN SURG, V235, P732, DOI 10.1097/00000658-200205000-00016; Li BDL, 1997, CANCER-AM CANCER SOC, V79, P2385; LI C, 2003, CANCER RES, V63, P5716; Lobo MVT, 2000, HISTOCHEM J, V32, P139, DOI 10.1023/A:1004091122351; Marin D, 2003, LANCET, V362, P617, DOI 10.1016/S0140-6736(03)14182-7; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz S, 2000, BBA-REV CANCER, V1470, pM13, DOI 10.1016/S0304-419X(99)00031-1; Martin ME, 2000, INT J BIOCHEM CELL B, V32, P633, DOI 10.1016/S1357-2725(00)00007-8; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4; MELHEM MF, 1992, CANCER RES, V52, P5853; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Meric F, 2002, MOL CANCER THER, V1, P971; Morley SJ, 2001, PROG MOLEC, V27, P1; MORRIS DR, 1995, PROG NUCLEIC ACID RE, V51, P339, DOI 10.1016/S0079-6603(08)60883-1; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MULDER KM, 1988, INT J CANCER, V42, P64, DOI 10.1002/ijc.2910420113; MULDER KM, 1990, CANCER RES, V50, P7581; MUNGER K, 1992, CANCER SURV, V12, P197; Nathan CAO, 1997, ONCOGENE, V15, P579, DOI 10.1038/sj.onc.1201216; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nika J, 2001, J BIOL CHEM, V276, P1051, DOI 10.1074/jbc.M007398200; Nupponen NN, 1999, AM J PATHOL, V154, P1777, DOI 10.1016/S0002-9440(10)65433-8; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; Rosenwald IB, 1996, BIOESSAYS, V18, P243, DOI 10.1002/bies.950180312; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; Rosenwald IB, 2003, CANCER-AM CANCER SOC, V98, P1080, DOI 10.1002/cncr.11619; Rosenwald IB, 2001, CANCER-AM CANCER SOC, V92, P2164, DOI 10.1002/1097-0142(20011015)92:8<2164::AID-CNCR1559>3.0.CO;2-A; Rosenwald IB, 2001, THROMB HAEMOSTASIS, V85, P142; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RUECKERT RR, 1960, CANCER RES, V20, P1584; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sanchez-Beato M, 2003, BLOOD, V101, P1220, DOI 10.1182/blood-2002-07-2009; Saramaki O, 2001, AM J PATHOL, V159, P2089, DOI 10.1016/S0002-9440(10)63060-X; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Seki N, 2002, CLIN CANCER RES, V8, P3046; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shantz LM, 1996, CANCER RES, V56, P3265; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SINGH C, 1995, TUMOR BIOL, V16, P281, DOI 10.1159/000217945; Sirri V, 2002, J CELL BIOL, V156, P969, DOI 10.1083/jcb.200201024; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Sorrells DL, 1999, J ORAL MAXIL SURG, V57, P294, DOI 10.1016/S0278-2391(99)90676-6; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; STANNERS CP, 1979, J CELL PHYSIOL, V100, P127, DOI 10.1002/jcp.1041000113; Strudwick S, 2002, DIFFERENTIATION, V70, P10, DOI 10.1046/j.1432-0436.2002.700102.x; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Sun YL, 1997, CANCER RES, V57, P18; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; Thomas G, 2002, BIOL RES, V35, P305, DOI 10.4067/S0716-97602002000200022; Thornton S, 2003, J MOL MED, V81, P536, DOI 10.1007/s00109-003-0461-8; Topisirovic I, 2003, EMBO J, V22, P689, DOI 10.1093/emboj/cdg069; TUAZON PT, 1990, J BIOL CHEM, V265, P10617; Tuhackova Z, 1999, ONCOL REP, V6, P827; Voit R, 1999, EMBO J, V18, P1891, DOI 10.1093/emboj/18.7.1891; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; VOLM M, 1992, ANTICANCER RES, V12, P11; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; Wang Q, 2001, GENE, V263, P205, DOI 10.1016/S0378-1119(00)00570-9; Wang ST, 1999, AM J PATHOL, V155, P247, DOI 10.1016/S0002-9440(10)65118-8; Wang ST, 2001, THYROID, V11, P1101, DOI 10.1089/10507250152740939; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; Yang Yu-Jie, 2003, Ai Zheng, V22, P1023; ZETTERBERG A, 1991, COLD SH Q B, V56, P137; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0; Zhao J, 2003, MOL CELL, V11, P405, DOI 10.1016/S1097-2765(03)00036-4	177	96	109	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3230	3247		10.1038/sj.onc.1207552	http://dx.doi.org/10.1038/sj.onc.1207552			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094773				2022-12-17	WOS:000220879700012
J	Ro, TB; Holt, RU; Brenne, AT; Hjorth-Hansen, H; Waage, A; Hjertner, O; Sundan, A; Borset, M				Ro, TB; Holt, RU; Brenne, AT; Hjorth-Hansen, H; Waage, A; Hjertner, O; Sundan, A; Borset, M			Bone morphogenetic protein-5,-6 and-7 inhibit growth and induce apoptosis in human myeloma cells	ONCOGENE			English	Article						BMP-5; BMP-6; BMP-7; myeloma; apoptosis	HEMATOPOIETIC STEM-CELLS; MULTIPLE-MYELOMA; OSTEOGENIC PROTEIN-1; SERINE/THREONINE KINASE; SIGNALING PATHWAYS; I RECEPTORS; ACTIVIN; DIFFERENTIATION; EXPRESSION; CANDIDATE	Previously, bone morphogenetic protein (BMP)-2 and -4 have been shown to inhibit proliferation and induce apoptosis in human myeloma cells. BMP-2 and -4 belong to a subgroup of BMPs using the BMP receptors Alk-3 or -6. In this study, we examined the effects on human myeloma cells of BMP-6 and -7, members of a different BMP subgroup, which mainly utilize Alk-2 as their receptor. All cell lines examined expressed mRNA for the BMP-6 and -7 receptor Alk-2. We did not detect transcripts for the BMP-2 and -4 receptors Alk-3 or Alk-6 in INA-6 and RPMI-8226 cells by RT-PCR. Accordingly, the intracellular signalling molecules Smad-1, -5 and -8 were not phosphorylated by BMP-4 in INA-6 and RPMI-8226 cells. The expression patterns of various BMP receptors in the myeloma cell lines explained the differences in responses to the various BMPs. Alk-2-expressing cell lines responded with growth inhibition and apoptosis to BMP-6 and -7, whereas cell lines lacking both Alk-3 and -6 were resistant to BMP-4. Soluble Alk-3 and -6 were able to neutralize the BMP-4 effects in BMP-4-responsive cell lines. All BMPs reduced viability in more than 70% of purified primary myeloma cell samples. BMPs have intriguing antitumor effects in vitro. Importantly, myeloma cells not responsive to BMP-2 and -4 may still be sensitive to BMP-6 or -7. It is possible that therapeutic use of BMP or BMP analogues could have an impact on both myeloma bone disease and myeloma cell growth.	Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, MTFS, N-7489 Trondheim, Norway; St Olavs Hosp, Dept Hematol, N-7005 Trondheim, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU)	Ro, TB (corresponding author), Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, MTFS, N-7489 Trondheim, Norway.	torstein.ro@medisin.ntnu.no	Waage, Anders/D-7705-2013; Borset, Magne/AAY-1713-2021; Rø, Torstein/I-2340-2013	Ro, Torstein/0000-0002-5258-500X; Borset, Magne/0000-0001-5179-2835				Beck HN, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-12; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; BORSET M, 1994, EUR J HAEMATOL, V53, P31; Borset M, 1996, BLOOD, V88, P3998, DOI 10.1182/blood.V88.10.3998.bloodjournal88103998; Brenne AT, 2002, BLOOD, V99, P3756, DOI 10.1182/blood.V99.10.3756; Chang CF, 2003, STROKE, V34, P558, DOI 10.1161/01.STR.0000051507.64423.00; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; Ebisawa T, 1999, J CELL SCI, V112, P3519; Franzen A, 2001, BIOCHEM BIOPH RES CO, V285, P773; Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS151; Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501; Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hallahan AR, 2003, NAT MED, V9, P1033, DOI 10.1038/nm904; Hjertner O, 2001, BLOOD, V97, P516, DOI 10.1182/blood.V97.2.516; JACKSON N, 1989, CLIN EXP IMMUNOL, V75, P93; JERNBERGWIKLUND H, 1991, EUR J HAEMATOL, V46, P231; Kawamura C, 2000, BLOOD, V96, P2005, DOI 10.1182/blood.V96.6.2005.h8002005a_2005_2011; Kim IY, 2000, CANCER RES, V60, P2840; NISHIHARA T, 1993, BIOCHEM BIOPH RES CO, V197, P985, DOI 10.1006/bbrc.1993.2576; Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200; Paine-Saunders S, 2002, J BIOL CHEM, V277, P2089, DOI 10.1074/jbc.M109151200; Rodriguez-Leon J, 1999, NAT CELL BIOL, V1, P125, DOI 10.1038/10098; Seidel C, 2000, BLOOD, V95, P388, DOI 10.1182/blood.V95.2.388; SHIMA Y, 1995, BLOOD, V85, P757, DOI 10.1182/blood.V85.3.757.bloodjournal853757; Tarte K, 2003, BLOOD, V102, P592, DOI 10.1182/blood-2002-10-3161; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Tsuchida K, 1996, MOL CELL NEUROSCI, V7, P467, DOI 10.1006/mcne.1996.0034; Urashima M, 1996, BLOOD, V87, P1928; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Wach S, 2001, ONCOGENE, V20, P7761, DOI 10.1038/sj.onc.1204962; Wozney J M, 1989, Prog Growth Factor Res, V1, P267, DOI 10.1016/0955-2235(89)90015-X; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Zavadil J, 1997, LEUKEMIA, V11, P1187, DOI 10.1038/sj.leu.2400750; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	36	96	104	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3024	3032		10.1038/sj.onc.1207386	http://dx.doi.org/10.1038/sj.onc.1207386			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14691444				2022-12-17	WOS:000220845200006
J	McJilton, MA; Van Sikes, C; Wescott, GG; Wu, DQ; Foreman, TL; Gregory, CW; Weidner, DA; Ford, OH; Lasater, AM; Mohler, JL; Terrian, DM				McJilton, MA; Van Sikes, C; Wescott, GG; Wu, DQ; Foreman, TL; Gregory, CW; Weidner, DA; Ford, OH; Lasater, AM; Mohler, JL; Terrian, DM			Protein kinase C epsilon interacts with Bax and promotes survival of human prostate cancer cells	ONCOGENE			English	Article						apoptosis; LNCaP; CWR22; recurrent prostate cancer; phorbol ester; Bcl-2	ESTER-INDUCED APOPTOSIS; N-TERMINAL KINASE; PHORBOL ESTER; 12-O-TETRADECANOYLPHORBOL-13-ACETATE-INDUCED APOPTOSIS; SIGNALING COMPLEXES; EPITHELIAL-CELLS; LINE LNCAP; ANDROGEN; ACTIVATION; EXPRESSION	Prostatic glandular epithelial cells express protein kinase Cepsilon (PKCepsilon), an oncoprotein that coordinately disrupts the reactivation of the tumor suppressor Rb, derepressess transcriptional elongation of the c-myc oncogene, and propagates survival signals in LNCaP cells. Since the activation of such a program may contribute to the progression of human prostate cancer, a proteomic analysis was performed to gain a more global perspective on the signaling network that PKCepsilon might be capable of engaging in prostate cancer cells. Using CWR22 xenografts, we identified at least 18 different structural, signaling, and stress-related proteins that associated with PKCepsilon, including an interaction with the proapoptotic protein Bax that was novel to recurrent CWR22 tumors. An investigation into the biological significance of the PKCepsilon association with Bax provided the first evidence of an inverse relationship between endogenous levels of PKCepsilon and susceptibility of prostate cancer cells to the apoptotic effects of phorbol esters. Western blot and antisense experiments demonstrated that CWR-R1 cells expressed moderate levels of PKCepsilon and relied on this protein to survive in the presence of phorbol esters, while the apoptosis normally induced by phorbol esters in PKCepsilon-deficient LNCaP cells was dependent on the presence of Bax. Forced expression of PKCepsilon in LNCaP cells was sufficient to confer a significant resistance to phorbol esters and this resistance was associated with an inhibition of phorbol ester-induced Bax conformational rearrangements that are important for Bax oligomerization, mitochondrial integration, and cytochrome c release. Considered in their entirety, our data suggest that an association of PKCepsilon with Bax may neutralize apoptotic signals propagated through a mitochondrial death-signaling pathway.	E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Leo W Jenkins Canc Ctr, Greenville, NC 27858 USA; Univ N Carolina, Dept Lab Med & Pathol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Surg, Div Urol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Terrian, DM (corresponding author), E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, 600 Moye Blvd, Greenville, NC 27858 USA.			Weidner, Douglas/0000-0003-1397-1757	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD035041] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA077739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008397] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA77739] Funding Source: Medline; NICHD NIH HHS [U54 HD35041] Funding Source: Medline; NIEHS NIH HHS [ES8397] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Antonsson B, 2001, CELL TISSUE RES, V306, P347, DOI 10.1007/s00441-001-0472-0; Basu A, 2002, J BIOL CHEM, V277, P41850, DOI 10.1074/jbc.M205997200; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Cornford P, 1999, AM J PATHOL, V154, P137, DOI 10.1016/S0002-9440(10)65260-1; DAY ML, 1994, CELL GROWTH DIFFER, V5, P735; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; Dibbert B, 1999, P NATL ACAD SCI USA, V96, P13330, DOI 10.1073/pnas.96.23.13330; Ding L, 2002, J BIOL CHEM, V277, P35305, DOI 10.1074/jbc.M201460200; Edmondson RD, 2002, MOL CELL PROTEOMICS, V1, P421, DOI 10.1074/mcp.M100036-MCP200; Engedal N, 2002, ONCOGENE, V21, P1017, DOI 10.1038/sj.onc.1205167; Engedal N, 2001, PROSTATE, V46, P289, DOI 10.1002/1097-0045(20010301)46:4<289::AID-PROS1035>3.0.CO;2-K; Fribourg AF, 2000, CELL GROWTH DIFFER, V11, P361; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Gao WH, 2001, J CELL SCI, V114, P2855; Garcia-Bermejo ML, 2002, J BIOL CHEM, V277, P645, DOI 10.1074/jbc.M107639200; Garzotto M, 1998, CANCER RES, V58, P2260; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Gregory CW, 1999, ENDOCRINOLOGY, V140, P2372, DOI 10.1210/en.140.5.2372; Gregory CW, 2001, J ANDROL, V22, P537; Gregory CW, 1998, CANCER RES, V58, P5718; Gregory CW, 2001, CANCER RES, V61, P2892; Gschwend JE, 2000, MOL PHARMACOL, V57, P1224; Henttu P, 1998, BIOCHEM BIOPH RES CO, V244, P167, DOI 10.1006/bbrc.1998.8238; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Metcalfe AD, 1999, J CELL SCI, V112, P1771; Montalvo L, 2002, LIFE SCI, V71, P2257, DOI 10.1016/S0024-3205(02)02016-7; Mousses S, 2001, ONCOGENE, V20, P6718, DOI 10.1038/sj.onc.1204889; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Ochoa WF, 2001, J MOL BIOL, V311, P837, DOI 10.1006/jmbi.2001.4910; Ping PP, 2001, CIRC RES, V88, P59, DOI 10.1161/01.RES.88.1.59; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; Prekeris R, 1998, J BIOL CHEM, V273, P26790, DOI 10.1074/jbc.273.41.26790; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Qiao LX, 2001, BIOORG MED CHEM LETT, V11, P955, DOI 10.1016/S0960-894X(01)00097-X; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Song CX, 2002, AM J PHYSIOL-HEART C, V282, pH1166, DOI 10.1152/ajpheart.00830.2001; Sumitomo M, 2002, J CLIN INVEST, V109, P827, DOI 10.1172/JCI200214146; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Wu DQ, 2002, J BIOL CHEM, V277, P40449, DOI 10.1074/jbc.M206270200; Wu DQ, 2002, CANCER RES, V62, P2423; YOUNG CYF, 1994, ONCOL RES, V6, P203; Zhao X, 2001, UROLOGY, V57, P860, DOI 10.1016/S0090-4295(01)00946-3; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751	46	96	112	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7958	7968		10.1038/sj.onc.1206795	http://dx.doi.org/10.1038/sj.onc.1206795			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970744				2022-12-17	WOS:000185388200011
J	Schmidt-Ullrich, RK; Contessa, JN; Lammering, G; Amorino, G; Lin, PS				Schmidt-Ullrich, RK; Contessa, JN; Lammering, G; Amorino, G; Lin, PS			ERBB receptor tyrosine kinases and cellular radiation responses	ONCOGENE			English	Article						ERBB receptors; IGF-IR; proliferation; apoptosis; DNA repair; signal transduction	EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER CELLS; FACTOR-I RECEPTOR; MAMMARY-CARCINOMA CELLS; IONIZING-RADIATION; EGF RECEPTOR; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; ZD1839 IRESSA; INTACT-CELLS	Ionizing radiation induces in autocrine growth-regulated carcinoma and malignant glioma cells powerful cytoprotective responses that confer relative resistance to consecutive radiation exposures. Understanding the mechanisms of these responses should provide new molecular targets for tumor radiosensitization. ERBB and other receptor Tyr kinases have been identified as immediate early response gene products that are activated by radiation within minutes, as by their physiological growth factor ligands, and induce secondary stimulation of cytoplasmic protein kinase cascades. The simultaneous activation of all receptor Tyr kinases and nonreceptor Tyr kinases leads to complex cytoprotective responses including increased cell proliferation, reduced apoptosis and enhanced DNA repair. Since these responses contribute to cellular radioresistance, ERBB1, the most extensively studied ERBB receptor, is examined as a target for tumor cell radiosensitization. The three methods of ERBB1 inhibition include blockade of growth factor binding by monoclonal antibody against the ligand-binding domain, inhibition of the receptor Tyr kinase-mediating receptor activation, and overexpression of a dominant-negative epidermal growth factor receptor-CD533 that lacks the COOH-terminal 533 amino acids and forms nonfunctional heterodimeric complexes with wild-type receptors. All the three approaches enhance radiation toxicity in vitro and in vivo. The different mechanisms of inhibition have contributed to the understanding of cellular responses to radiation, vary in relative effectiveness and pose different challenges for translation.	Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23284 USA; Univ Dusseldorf, Dept Radiat Oncol, Dusseldorf, Germany	Virginia Commonwealth University; Heinrich Heine University Dusseldorf	Schmidt-Ullrich, RK (corresponding author), Virginia Commonwealth Univ, Dept Radiat Oncol, Med Coll Virginia Campus, Richmond, VA 23284 USA.	rullrich@hsc.vcu.edu			NCI NIH HHS [R01CA65896, P01CA72955] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065896, P01CA072955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akimoto T, 1999, CLIN CANCER RES, V5, P2884; Allen LF, 2002, SEMIN ONCOL, V29, P11, DOI 10.1053/sonc.2002.34049; Amorino GP, 2002, MOL BIOL CELL, V13, P2233, DOI 10.1091/mbc.01-12-0572; AMORINO GP, 2003, UNPUB J BIOL CHEM; Ang KK, 2002, CANCER RES, V62, P7350; BASERGA R, 1995, CANCER RES, V55, P249; BENTZEN SM, 1991, RADIOTHER ONCOL, V22, P161, DOI 10.1016/0167-8140(91)90019-D; Bernhard EJ, 1998, CANCER RES, V58, P1754; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bonner JA, 2000, J CLIN ONCOL, V18, p47S; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Chakravarti A, 2002, CANCER RES, V62, P200; Chou JL, 1999, BREAST CANCER RES TR, V55, P267, DOI 10.1023/A:1006217413089; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; Contessa JN, 2002, ONCOGENE, V21, P4032, DOI 10.1038/sj.onc.1205500; Contessa JN, 1999, CLIN CANCER RES, V5, P405; Craggs G, 2001, J BIOL CHEM, V276, P23719, DOI 10.1074/jbc.M102846200; DENEKAMP J, 1973, BRIT J RADIOL, V46, P381, DOI 10.1259/0007-1285-46-545-381; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Durand, 1993, Semin Radiat Oncol, V3, P105, DOI 10.1016/S1053-4296(05)80086-4; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; Emlet DR, 1997, J BIOL CHEM, V272, P4079, DOI 10.1074/jbc.272.7.4079; FERTIL B, 1984, RADIAT RES, V99, P73, DOI 10.2307/3576448; FOWLER JF, 1991, RADIOTHER ONCOL, V22, P156, DOI 10.1016/0167-8140(91)90017-B; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Harari PM, 2001, SEMIN RADIAT ONCOL, V11, P281, DOI 10.1053/srao.2001.26027; Huang SM, 2002, CANCER RES, V62, P4300; Huang SM, 2000, CLIN CANCER RES, V6, P2166; Huang SM, 1999, CANCER RES, V59, P1935; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; Kasid U, 2003, ONCOGENE, V22, P5876, DOI 10.1038/sj.onc.1206700; Kavanagh BD, 1995, CLIN CANCER RES, V1, P1557; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; Kuan CT, 1999, CLIN CANCER RES, V5, P1539; Lammering G, 2001, INT J RADIAT ONCOL, V51, P775, DOI 10.1016/S0360-3016(01)01714-X; Lammering G, 2001, J NATL CANCER I, V93, P921, DOI 10.1093/jnci/93.12.921; Lammering G, 2001, CLIN CANCER RES, V7, P682; LAMMERING G, 2003, IN PRESS ONCOGENE; Leach JK, 2002, J BIOL CHEM, V277, P15400, DOI 10.1074/jbc.M110309200; Leach JK, 2001, CANCER RES, V61, P3894; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levitzki A, 1997, MED ONCOL, V14, P83, DOI 10.1007/BF02990952; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; McKenna WG, 2003, ONCOGENE, V22, P5866, DOI 10.1038/sj.onc.1206699; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; MIKKELSEN RB, 2003, IN PRESS ONCOGENE RE; Milas L, 2000, CLIN CANCER RES, V6, P701; Nelson JM, 2001, J BIOL CHEM, V276, P14842, DOI 10.1074/jbc.M008786200; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; O'Rourke DM, 1998, P NATL ACAD SCI USA, V95, P10842, DOI 10.1073/pnas.95.18.10842; Park BW, 2000, NAT BIOTECHNOL, V18, P194, DOI 10.1038/72651; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Pietras RJ, 1999, CANCER RES, V59, P1347; Rao GS, 2000, INT J RADIAT ONCOL, V48, P1519, DOI 10.1016/S0360-3016(00)01358-4; Reardon DB, 1999, ONCOGENE, V18, P4756, DOI 10.1038/sj.onc.1202849; Rojas M, 1996, J BIOL CHEM, V271, P27456, DOI 10.1074/jbc.271.44.27456; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Schmidt-Ullrich RK, 1999, RADIAT ONCOL INVESTI, V7, P321, DOI 10.1002/(SICI)1520-6823(1999)7:6<321::AID-ROI2>3.0.CO;2-Q; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; SCHMIDTULLRICH RK, 1994, INT J RADIAT ONCOL, V29, P813, DOI 10.1016/0360-3016(94)90570-3; SHAH BH, 2003, UNPUB J BIOL CHEM; Shtiegman K, 2003, SEMIN CANCER BIOL, V13, P29, DOI 10.1016/S1044-579X(02)00097-4; Solomon B, 2003, INT J RADIAT ONCOL, V55, P713, DOI 10.1016/S0360-3016(02)04357-2; Swantek JL, 1999, ENDOCRINOLOGY, V140, P3163, DOI 10.1210/en.140.7.3163; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; Tiganis T, 2002, IUBMB LIFE, V53, P3, DOI 10.1080/15216540210811; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Turner BC, 1997, CANCER RES, V57, P3079; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; Wen B, 2001, BRIT J CANCER, V85, P2017, DOI 10.1054/bjoc.2001.2171; Wikstrand CJ, 1997, CANCER RES, V57, P4130; Wilkinson JC, 2002, BIOCHEMISTRY-US, V41, P8, DOI 10.1021/bi015839l; WITHERS HR, 1988, ACTA ONCOL, V27, P131, DOI 10.3109/02841868809090333; Yacoub A, 2003, RADIAT RES, V159, P439, DOI 10.1667/0033-7587(2003)159[0439:EGFAIR]2.0.CO;2	81	96	99	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5855	5865		10.1038/sj.onc.1206698	http://dx.doi.org/10.1038/sj.onc.1206698			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947392				2022-12-17	WOS:000185086100012
J	Park, WY; Hwang, CI; Im, CN; Kang, MJ; Woo, JH; Kim, JH; Kim, YS; Kim, JH; Kim, H; Kim, KA; Yu, HJ; Lee, SJ; Lee, YS; Seo, JS				Park, WY; Hwang, CI; Im, CN; Kang, MJ; Woo, JH; Kim, JH; Kim, YS; Kim, JH; Kim, H; Kim, KA; Yu, HJ; Lee, SJ; Lee, YS; Seo, JS			Identification of radiation-specific responses from gene expression profile	ONCOGENE			English	Article						gamma-irradiation; cDNA microarray; p53; cytoplasmic epoxide hydrolase; phospholipase C gamma 2	T-CELL RECEPTOR; IONIZING-RADIATION; GENOTOXIC STRESS; DNA-DAMAGE; KAPPA-B; IN-VITRO; P53; APOPTOSIS; IRRADIATION; CANCER	The responses to ionizing radiation (IR) in tumors are dependent on cellular context. We investigated radiation-related expression patterns in Jurkat T cells with nonsense mutation in p53 using cDNA microarray. Expression of 2400 genes in gamma-irradiated cells was distinct from other stimulations like anti-CD3, phetohemagglutinin (PHA) and concanavalin A (ConA) in unsupervised clustering analysis. Among them, 384 genes were selected for their IR-specific changes to make 'RadChip'. In spite of p53 status, every type of cells showed similar patterns in expression of these genes upon gamma-radiation. Moreover, radiation-induced responses were clearly separated from the responses to other genotoxic stress like UV radiation, cisplatin and doxorubicin. We focused on two IR-related genes, phospholipase Cgamma2 (PLCG2) and cytosolic epoxide hydrolase (EPHX2), which were increased at 12 h after gamma-radiation in RT-PCR. TPCK could suppress the induction of these two genes in either of Jurkat T cells and PBMCs, which might suggest the transcriptional regulation of PLCG2 and EPHX2 by NF-gammaB upon gamma-radiation. From these results, we could identify the IR-specific genes from expression profiling, which can be used as radiation biomarkers to screen radiation exposure as well as probing the mechanism of cellular responses to ionizing radiation.	Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Chongnogu, Seoul 110799, South Korea; Seoul Natl Univ, Ilchun Mol Med Inst, Seoul, South Korea; Seoul Natl Univ, Dept Internal Med, Seoul, South Korea; Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea; Seoul Natl Univ, Grad Sch Publ Hlth, Dept Biostat, Seoul, South Korea; Macrogen Inc, Seoul, South Korea; Korea Canc Ctr Hosp, Lab Radiat Effect, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Macrogen, Inc.; National Cancer Center - Korea (NCC)	Seo, JS (corresponding author), Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Chongnogu, 28 Yongondong, Seoul 110799, South Korea.		Kim, Ho/AAS-2402-2021; park, woongyang/D-5727-2012; Kim, Ju Han/E-5983-2012; Seo, Jeong-Sun/J-2763-2012; Kim, Yon Su/J-2743-2012	Kim, Ho/0000-0001-7472-3752; Hwang, Chang-il/0000-0002-5710-7672; Im, Chang-Nim/0000-0002-7566-7075				Abraham RT, 2000, IMMUNOL RES, V22, P95, DOI 10.1385/IR:22:2-3:95; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Amundson SA, 2001, COMP BIOCHEM PHYS B, V129, P703, DOI 10.1016/S1096-4959(01)00389-X; Backlund MG, 2001, CANCER RES, V61, P6577; Cemerski S, 2002, J BIOL CHEM, V277, P19585, DOI 10.1074/jbc.M111451200; DENEKAMP J, 1973, BRIT J RADIOL, V46, P381, DOI 10.1259/0007-1285-46-545-381; DENT P, 1995, MOL CELL BIOL, V15, P4125; Dysvik B, 2001, BIOINFORMATICS, V17, P369, DOI 10.1093/bioinformatics/17.4.369; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FUKS Z, 1993, RADIAT ONCOL INVEST, V1, P81; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Gong BD, 2000, CANCER RES, V60, P5754; Green JA, 2001, LANCET, V358, P781, DOI 10.1016/S0140-6736(01)05965-7; Iwamoto KS, 1996, CANCER RES, V56, P3862; Kang JS, 1996, FEBS LETT, V399, P14, DOI 10.1016/S0014-5793(96)01276-8; Kavanagh BD, 1995, CLIN CANCER RES, V1, P1557; Kawabe T, 2002, ONCOGENE, V21, P1717, DOI 10.1038/sj.onc.1205229; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim SG, 1997, MOL PHARMACOL, V51, P225, DOI 10.1124/mol.51.2.225; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LuHesselmann J, 1997, RADIAT RES, V148, P531, DOI 10.2307/3579728; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; MORETTA A, 1987, P NATL ACAD SCI USA, V84, P1654, DOI 10.1073/pnas.84.6.1654; NOGAMI M, 1994, RADIAT RES, V139, P47, DOI 10.2307/3578731; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park WY, 2001, BIOCHEM BIOPH RES CO, V282, P934, DOI 10.1006/bbrc.2001.4632; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; Roth JA, 2001, ACTA ONCOL, V40, P739; Safwat A, 2000, RADIAT RES, V153, P599, DOI 10.1667/0033-7587(2000)153[0599:TIOLDT]2.0.CO;2; SALLY AA, 1999, ONCOGENE, V18, P3666; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Seidegard J, 1997, ENVIRON HEALTH PERSP, V105, P791, DOI 10.1289/ehp.97105s4791; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Vigorito E, 1999, HEMATOL CELL THER, V41, P153, DOI 10.1007/s00282-999-0153-0; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Zhan QM, 1996, ONCOGENE, V13, P2287	41	96	104	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8521	8528		10.1038/sj.onc.1205977	http://dx.doi.org/10.1038/sj.onc.1205977			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466973				2022-12-17	WOS:000179480100016
J	Pandey, A; Dan, I; Kristiansen, TZ; Watanabe, NM; Voldby, J; Kajikawa, E; Khosravi-Far, R; Blagoev, B; Mann, M				Pandey, A; Dan, I; Kristiansen, TZ; Watanabe, NM; Voldby, J; Kajikawa, E; Khosravi-Far, R; Blagoev, B; Mann, M			Cloning and characterization of PAK5, a novel member of mammalian p21-activated kinase-II subfamily that is predominantly expressed in brain	ONCOGENE			English	Article						p2l-activated kinase; Ste20; CDC42; JNK; brain	ACTIVATED PROTEIN-KINASE; FAMILY; CELLS; APOPTOSIS; ACTIN; DEATH; RAS	The p21-activated kinase (PAK) family of protein kinases has recently attracted considerable attention as an effector of Rho family of small G proteins and as an upstream regulator of MAPK signalling pathways during cellular events such as re-arrangement of the cytoskeleton and apoptosis. We have cloned a novel human PAK family kinase that has been designated as PAK5. PAK5 contains a CDC42/Rac1 interactive binding (CRIB) motif at the N-terminus and a Ste20-like kinase domain at the C-terminus. PAK5 is structurally most related to PAK4 and PAK6 to make up the PAK-II subfamily. We have shown that PAK5 preferentially binds to CDC42 in the presence of GTP and that CRIB motif is essential for this interaction. PAK5 is a functional protein kinase but unlike PAK-I family kinases (PAKI, 2, and 3), the kinase activity of PAK5 does not seem to require the binding of CDC42. Overexpression of PAK5 activates the JNK kinase pathway but not p38 or ERK pathways. PAK5 transcript is predominantly expressed in brain as revealed by Northern blot and in situ hybridization. The expression pattern of PAK5 is distinct from that of PAK4 and PAK6, suggesting a functional division among PAK-11 subfamily kinases based on differential tissue distribution.	Univ So Denmark, Ctr Expt Bioinformat, DK-5230 Odense M, Denmark; Harvard Med Ctr, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA; Nagoya Univ, Grad Sch Sci, Dept Biol Sci,ERATO, JST,Kusumi Membrane Organizer Project,Chikusa Ku, Nagoya, Aichi 4648602, Japan	University of Southern Denmark; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Japan Science & Technology Agency (JST); Nagoya University	Mann, M (corresponding author), Univ So Denmark, Ctr Expt Bioinformat, Campusvej 55, DK-5230 Odense M, Denmark.		Mann, Matthias/A-3454-2013; Khosravi-Far, Roya/C-3789-2008; Dan, Ippeita/F-9179-2011; Pandey, Akhilesh/B-4127-2009	Mann, Matthias/0000-0003-1292-4799; Dan, Ippeita/0000-0002-1779-9205; Pandey, Akhilesh/0000-0001-9943-6127; Blagoev, Blagoy/0000-0002-3596-0066	NCI NIH HHS [CA 75447] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA075447] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Cau J, 2001, J CELL BIOL, V155, P1029, DOI 10.1083/jcb.200104123; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Dieffenbach C.W., 1995, PCR PRIMER LAB MANUA; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Melzig J, 1998, CURR BIOL, V8, P1223, DOI 10.1016/S0960-9822(07)00514-3; Nagase T, 1999, DNA Res, V6, P337, DOI 10.1093/dnares/6.5.337; Peri S, 2001, TRENDS GENET, V17, P685, DOI 10.1016/S0168-9525(01)02493-3; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	23	96	109	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3939	3948		10.1038/sj.onc.1205478	http://dx.doi.org/10.1038/sj.onc.1205478			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032833				2022-12-17	WOS:000175847200014
J	Seo, YR; Sweeney, C; Smith, ML				Seo, YR; Sweeney, C; Smith, ML			Selenomethionine induction of DNA repair response in human fibroblasts	ONCOGENE			English	Article						cancer-chemoprevention; selenium; nutrition; DNA-repair	NUCLEOTIDE EXCISION-REPAIR; SELENIUM-COMPOUNDS; CANCER PREVENTION; MAMMARY-CANCER; TRIPHENYLSELENONIUM CHLORIDE; CHEMOPREVENTION; GROWTH; P53; SUPPLEMENTATION; SELENOPROTEINS	Selenium compounds have a long history in chemoprevention of mammary and colon cancers in rodent models. Selenium compounds are in current clinical trials, having shown promise in prevention of prostate and other human cancers. In human tissues, it has been estimated that each cell sustains approximately 10 000 potentially mutagenic (if not repaired) lesions per day due to endogenous DNA damage. Almost no studies have addressed the potential for selenium compounds to induce DNA repair, a potential mechanism for their cancer-preventive actions. We show that selenium in the form of selenomethionine induces a DNA repair response in normal human fibroblasts in vitro, and protects cells from DNA damage. We show a possible mechanism for the inducible DNA repair response, in which enhanced repair complex formation was observed in selenomethionine-treated cells.	Indiana Univ, Ctr Canc, Dept Microbiol, Walther Oncol Ctr,Sch Med, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Hematol Oncol Sect, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis	Smith, ML (corresponding author), Indiana Univ, Ctr Canc, Dept Microbiol, Walther Oncol Ctr,Sch Med, 1044 W Walnut,Room 155, Indianapolis, IN 46202 USA.	marlsmit@iupui.edu						ABOUSSEKHRA A, 1995, EXP CELL RES, V221, P326, DOI 10.1006/excr.1995.1382; Allan CB, 1999, ANNU REV NUTR, V19, P1, DOI 10.1146/annurev.nutr.19.1.1; Ames BN, 1997, ENVIRON HEALTH PERSP, V105, P865, DOI 10.2307/3433296; Baines AT, 2000, CANCER LETT, V160, P193, DOI 10.1016/S0304-3835(00)00585-1; Berggren MM, 1999, BIOCHEM PHARMACOL, V57, P187, DOI 10.1016/S0006-2952(98)00283-4; Cheo DL, 1999, CANCER RES, V59, P771; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; COLLINS AR, 1995, MUTAT RES-DNA REPAIR, V336, P69, DOI 10.1016/0921-8777(94)00043-6; Combs G F Jr, 1997, Biomed Environ Sci, V10, P356; DOETSCH PW, 1995, BIOCHEMISTRY-US, V34, P737, DOI 10.1021/bi00003a005; Ganesan AK, 1999, MUTAT RES-DNA REPAIR, V433, P117, DOI 10.1016/S0921-8777(98)00070-6; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gniadecki R, 2000, J CELL BIOCHEM, V80, P216; Grossman L, 1997, ENVIRON HEALTH PERSP, V105, P927, DOI 10.2307/3433305; He ZG, 1997, NUCLEIC ACIDS RES, V25, P1136, DOI 10.1093/nar/25.6.1136; Ip C, 1999, ANTICANCER RES, V19, P2875; IP C, 1981, CANCER RES, V41, P4386; Ip C, 1998, ANTICANCER RES, V18, P9; IP C, 1994, CARCINOGENESIS, V15, P187, DOI 10.1093/carcin/15.2.187; IP C, 1994, CARCINOGENESIS, V15, P2879, DOI 10.1093/carcin/15.12.2879; Karmakar P, 2001, MUTAGENESIS, V16, P225, DOI 10.1093/mutage/16.3.225; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LU JX, 1995, BIOCHEM PHARMACOL, V50, P213, DOI 10.1016/0006-2952(95)00119-K; Morris EJ, 1999, BIOTECHNIQUES, V26, P282, DOI 10.2144/99262st02; Parshad R, 1996, BRIT J CANCER, V74, P1, DOI 10.1038/bjc.1996.307; Patterson BH, 1997, CANCER EPIDEM BIOMAR, V6, P63; Redman C, 1998, CANCER LETT, V125, P103, DOI 10.1016/S0304-3835(97)00497-7; SATOH MS, 1993, P NATL ACAD SCI USA, V90, P6335, DOI 10.1073/pnas.90.13.6335; Seo YR, 2002, ONCOGENE, V21, P731, DOI 10.1038/sj.onc.1205129; Sinha R, 1996, CANCER LETT, V107, P277, DOI 10.1016/0304-3835(96)04373-X; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Stewart MS, 1999, FREE RADICAL BIO MED, V26, P42, DOI 10.1016/S0891-5849(98)00147-6; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001	38	96	102	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3663	3669		10.1038/sj.onc.1205468	http://dx.doi.org/10.1038/sj.onc.1205468			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032834				2022-12-17	WOS:000175676000001
J	Boyer, B; Bourgeois, Y; Poupon, MF				Boyer, B; Bourgeois, Y; Poupon, MF			Src kinase contributes to the metastatic spread of carcinoma cells	ONCOGENE			English	Article						epithelium-mesenchyme transition; cell scattering; tumor cells; cell differentiation; tyrosine phosphorylation	PROTEIN-TYROSINE KINASES; FIBROBLAST-GROWTH-FACTOR; FOCAL ADHESION KINASE; HUMAN BREAST-CANCER; C-SRC; V-SRC; PP60C-SRC ACTIVITY; CATALYTIC-ACTIVITY; TRANSFORMED CELLS; TUMOR-GROWTH	The involvement of Src kinase during carcinoma metastasis has been explored by using the NBT-II rat carcinoma cell line, which can be induced to scatter in vitro through Src activity. Here we show that Src activity was not required for growth of tumors derived from NBT-II cells injected into nude mice. In contrast, the presence of micrometastases was strictly dependent on Src, since the percentage of mice bearing metastases was dramatically reduced by the expression of a dominant-negative mutant of Src (SrcK(-)) or of Csk, the natural inhibitor of Src. Furthermore, metastatic cells originating from NBT-II cells displayed a Src activity higher than the parental cells, confirming that Src gives a selective advantage during the metastatic process. Finally, anatomopathological analysis of the primary tumors arising from NBT-II cells expressing Csk or SrcK(-) constructs revealed a highly differentiated epithelial phenotype contrasting with the poor differentiation of tumors derived from parental cells. The differentiated phenotype correlated with the presence of desmosomes at the cell periphery and the absence of vimentin intermediate filaments. Altogether, these data demonstrate that Src activity correlates with the loss of epithelial differentiation concomitantly with the increase of the metastatic potential of carcinoma cells.	Ctr Univ Paris Sud, Inst Curie, CNRS, UMR 146,Sect Rech, F-91405 Orsay, France; Inst Curie, CNRS, UMR 147, Sech Rech, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite	Boyer, B (corresponding author), Ctr Univ Paris Sud, Inst Curie, CNRS, UMR 146,Sect Rech, Batiment 110, F-91405 Orsay, France.	Brigitte.Boyer@curie.u-psud.fr						BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Birchmeier C, 1996, ACTA ANAT, V156, P217; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; Cary LA, 1996, J CELL SCI, V109, P1787; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; CUPRITI S, 2000, EMBO J, V19, P4614; Daigo Y, 1999, CANCER RES, V59, P4222; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Duband JL, 1995, ACTA ANAT, V154, P63; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; Faraldo MM, 2001, EMBO REP, V2, P431, DOI 10.1093/embo-reports/kve086; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; FURUTA Y, 1995, ONCOGENE, V11, P1989; GAVRILOVIC J, 1990, CELL REGUL, V1, P1003, DOI 10.1091/mbc.1.13.1003; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GREENBERG JM, 1989, ADV SPACE RES, V9, P3; GUARINO M, 1995, HISTOL HISTOPATHOL, V10, P171; Hall CL, 1996, ONCOGENE, V13, P2213; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Hay ED, 1995, ACTA ANAT, V154, P8; Ilic D, 1996, EXP CELL RES, V222, P298, DOI 10.1006/excr.1996.0038; ILLC D, 1995, NATURE, V377, P539; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Irby R, 1997, CELL GROWTH DIFFER, V8, P1287; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JOUANNEAU J, 1994, P NATL ACAD SCI USA, V91, P286, DOI 10.1073/pnas.91.1.286; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KELLIE S, 1991, J CELL SCI, V99, P207; Kirschmann DA, 1999, BREAST CANCER RES TR, V55, P127; KOPFMAIER P, 1991, CELL TISSUE RES, V264, P563, DOI 10.1007/BF00319046; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAREEL MM, 1993, CRIT REV ONCOGENESIS, V4, P559; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Mayer K, 1996, ANTICANCER RES, V16, P1733; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Morse-Gaudio M, 1998, INT J ONCOL, V12, P1349; MUTHUSWAMY SK, 1994, ADV CANCER RES, V64, P111, DOI 10.1016/S0065-230X(08)60836-2; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; PENA SV, 1995, GASTROENTEROLOGY, V108, P117, DOI 10.1016/0016-5085(95)90015-2; POUPON MF, 1993, J NATL CANCER I, V85, P2023, DOI 10.1093/jnci/85.24.2023; Putz E, 1999, CANCER RES, V59, P241; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; Rodina A, 1999, FEBS LETT, V455, P145, DOI 10.1016/S0014-5793(99)00794-2; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Sim SJ, 1999, MODERN PATHOL, V12, P351; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; TAKAYAMA T, 1993, INT J CANCER, V54, P875, DOI 10.1002/ijc.2910540525; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Tatsuka M, 1996, MOL CARCINOGEN, V15, P300, DOI 10.1002/(SICI)1098-2744(199604)15:4<300::AID-MC7>3.0.CO;2-J; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; Tsukamoto T, 1999, J BIOL CHEM, V274, P24579, DOI 10.1074/jbc.274.35.24579; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; Viebahn C, 1995, ACTA ANAT, V154, P79; VOLBERG T, 1991, CELL REGUL, V2, P105, DOI 10.1091/mbc.2.2.105; WARREN SL, 1988, MOL CELL BIOL, V8, P632, DOI 10.1128/MCB.8.2.632; WEBER TK, 1992, J CLIN INVEST, V90, P815, DOI 10.1172/JCI115956; Wiener JR, 1999, CLIN CANCER RES, V5, P2164; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113	72	96	101	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2347	2356		10.1038/sj.onc.1205298	http://dx.doi.org/10.1038/sj.onc.1205298			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948418				2022-12-17	WOS:000174635600007
J	Plumb, JA; Bilsland, A; Kakani, R; Zhao, JQ; Glasspool, RM; Knox, RJ; Evans, TRJ; Keith, WN				Plumb, JA; Bilsland, A; Kakani, R; Zhao, JQ; Glasspool, RM; Knox, RJ; Evans, TRJ; Keith, WN			Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954	ONCOGENE			English	Article						telomerase; hTERT; hTR; gene therapy; nitroreductase; GDEPT	ESCHERICHIA-COLI NITROREDUCTASE; IN-SITU HYBRIDIZATION; CATALYTIC SUBUNIT; RNA COMPONENT; PROMOTER SEQUENCES; HTERT GENE; ACTIVATION; STRATEGIES; IDENTIFICATION; CLONING	Telomerase activation is considered to be a critical step in cancer progression due to its role in cellular immortalization. The prevalence of telomerase expression in human cancers makes it an attractive candidate for new mechanism-based targets for cancer therapy. The selective killing of cancer cells can be achieved by gene-directed enzyme pro-drug therapy (GDEPT). In this study we have tested the feasibility of using the transcriptional regulatory sequences from the hTERT and hTR genes to regulate expression of the bacterial nitroreductase enzyme in combination with the pro-drug CB1954 in a suicide gene therapy strategy. hTERT and hTR promoter activity was compared in a panel of 10 cell lines and showed a wide distribution in activity; low activity was observed in normal cells and telomerase-negative immortal ALT cell lines, with up to 300-fold higher activity observed in telomerase positive cancer lines. Placing the nitroreductase gene under the control of the telomerase gene promoters sensitized cancer cells in tissue culture to the pro-drug CB1954 and promoter activity was predictive of sensitization to the pro-drug (2-20-fold sensitization), with cell death restricted to lines exhibiting high levels of promoter activity. The in vivo relevance of these data was tested using two xenograft models (C33a and GLC4 cells). Significant tumour reduction was seen with both telomerase promoters and the promoter-specific patterns of sensitization observed in tissue culture were retained in xenograft models. Thus, telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954.	Univ Glasgow, CRC, Dept Med Oncol, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Enact Pharma Plc, Salisbury SP4 0JQ, Wilts, England	Beatson Institute; University of Glasgow	Keith, WN (corresponding author), Univ Glasgow, CRC, Dept Med Oncol, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.		Keith, Nicol/D-3325-2009; Bilsland, Alan/G-2629-2010	Keith, Nicol/0000-0001-7862-3580; Zhao, Jiangqin/0000-0003-4672-0735; Glasspool, Rosalind/0000-0002-5000-1680; Bilsland, Alan/0000-0003-0957-3908				Abdul-Ghani R, 2000, MOL THER, V2, P539, DOI 10.1006/mthe.2000.0196; Bailey SM, 1996, GENE THER, V3, P1143; Bailey SM, 1997, GENE THER, V4, P80, DOI 10.1038/sj.gt.3300400; Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969; Greco O, 2001, J CELL PHYSIOL, V187, P22, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1060>3.0.CO;2-H; Gu J, 2000, CANCER RES, V60, P5359; Gunes C, 2000, CANCER RES, V60, P2116; Harrington KJ, 2000, ADV DRUG DELIVER REV, V44, P167, DOI 10.1016/S0169-409X(00)00093-4; Heine B, 1998, J PATHOL, V185, P139, DOI 10.1002/(SICI)1096-9896(199806)185:2<139::AID-PATH79>3.0.CO;2-L; Hiyama E, 2001, NEOPLASIA, V3, P17, DOI 10.1038/sj.neo.7900134; Hiyama T, 1999, VIRCHOWS ARCH, V434, P483, DOI 10.1007/s004280050372; Hoare SF, 2001, CANCER RES, V61, P27; Koga S, 2000, HUM GENE THER, V11, P1397, DOI 10.1089/10430340050057477; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Maitra A, 1999, CANCER-AM CANCER SOC, V85, P741, DOI 10.1002/(SICI)1097-0142(19990201)85:3<741::AID-CNCR25>3.0.CO;2-6; Majumdar AS, 2001, GENE THER, V8, P568, DOI 10.1038/sj.gt.3301421; Mistry P, 2001, CANCER RES, V61, P749; Nettelbeck DM, 2000, TRENDS GENET, V16, P174, DOI 10.1016/S0168-9525(99)01950-2; Nowak R, 1998, CANCER J SCI AM, V4, P148; Park TW, 1999, INT J CANCER, V84, P426, DOI 10.1002/(SICI)1097-0215(19990820)84:4<426::AID-IJC17>3.3.CO;2-T; Plumb JA, 2000, CANCER RES, V60, P6039; Sarvesvaran J, 1999, CARCINOGENESIS, V20, P1649, DOI 10.1093/carcin/20.8.1649; Sharma S, 1997, ANN ONCOL, V8, P1063, DOI 10.1023/A:1008206420505; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; Soder AI, 1998, ONCOGENE, V16, P979, DOI 10.1038/sj.onc.1201620; Stanta G, 1999, FEBS LETT, V460, P285, DOI 10.1016/S0014-5793(99)01357-5; Takakura M, 1999, CANCER RES, V59, P551; Urquidi V, 1998, ANN MED, V30, P419, DOI 10.3109/07853899809002483; Vile RG, 1998, MOL MED TODAY, V4, P84, DOI 10.1016/S1357-4310(97)01157-X; Weedon SJ, 2000, INT J CANCER, V86, P848, DOI 10.1002/(SICI)1097-0215(20000615)86:6<848::AID-IJC14>3.0.CO;2-B; Weng NP, 1997, J IMMUNOL, V158, P3215; White LK, 2001, TRENDS BIOTECHNOL, V19, P114, DOI 10.1016/S0167-7799(00)01541-9; Wisman GBA, 2000, HUM PATHOL, V31, P1304, DOI 10.1053/hupa.2000.19299; Yashima K, 1998, CELL GROWTH DIFFER, V9, P805; Yi XM, 1999, MOL CELL BIOL, V19, P3989; Zhao JQ, 1998, ONCOGENE, V16, P1345, DOI 10.1038/sj.onc.1201892; Zhao JQ, 2000, NEOPLASIA, V2, P531, DOI 10.1038/sj.neo.7900114	37	96	101	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2001	20	53					7797	7803		10.1038/sj.onc.1204954	http://dx.doi.org/10.1038/sj.onc.1204954			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753658				2022-12-17	WOS:000172161700011
J	Zhu, WG; Dai, ZY; Ding, HM; Srinivasan, K; Hall, J; Duan, WR; Villalona-Calero, MA; Plass, C; Otterson, GA				Zhu, WG; Dai, ZY; Ding, HM; Srinivasan, K; Hall, J; Duan, WR; Villalona-Calero, MA; Plass, C; Otterson, GA			Increased expression of unmethylated CDKN2D by 5-aza-2 '-deoxycytidine in human lung cancer cells	ONCOGENE			English	Article						DNA methylation; histone acetylation; CDKN2D; p16(INK4a); p19(INK4d)	CPG-ISLAND METHYLATION; DNA METHYLATION; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; IMPRINTED EXPRESSION; PROMOTER SEQUENCES; GENE; HYPERMETHYLATION; PROTEIN; COMPLEX	DNA hypermethylation of CpG islands in the promoter region of genes is associated with transcriptional silencing. Treatment with hypo-methylating agents can lead to expression of these silenced genes. However, whether inhibition of DNA methylation influences the expression of unmethylated genes has not been extensively studied. We analysed the methylation status of CDKN2A and CDKN2D in human lung cancer cell lines and demonstrated that the CDKN2A CpG island is methylated, whereas CDKN2D is unmethylated. Treatment of cells with 5-aza-2 ' -deoxycytidine (5-Aza-CdR), an inhibitor of DNA methyltransferase 1, induced a dose and duration dependent increased expression of both p16(INK4a) and p19(INK4d), the products of CDKN2A and CDKN2D, respectively. These data indicate that global DNA demethylation not only influences the expression of methylated genes but also of unmethylated genes. Histone acetylation is linked to methylation induced transcriptional silencing. Depsipeptide, an inhibitor of histone deacetylase, acts synergistically with 5-Aza-CdR in inducing expression of p16(INK4a) and p19(INK4d). However, when cells were treated with higher concentrations of 5-Aza-CdR and depsipeptide, p16(INK4a) expression was decreased together with significant suppression of cell growth. Interestingly, p19(INK4d) expression was enhanced even more by the higher concentrations of 5-Aza-CdR and depsipeptide. Our data suggest that p19(INK4d) plays a distinct role from other INK4 family members in response to the cytotoxicity induced by inhibition of DNA methylation and histone deacetylation.	Ohio State Univ, Dept Internal Med, Div Hematol & Oncol, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Otterson, GA (corresponding author), Ohio State Univ, Dept Internal Med, Div Hematol & Oncol, Ctr Comprehens Canc, Room B415,Starling Loving Hall,320 W 10th Ave, Columbus, OH 43210 USA.	otterson-1@medctr.osu.edu	zhu, wei-guo/E-1334-2012; Plass, Christoph/H-7192-2014	Zhu, Wei-Guo/0000-0001-8385-6581; duan, wenrui/0000-0001-6512-7350	NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA16058] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chan MF, 2000, CURR TOP MICROBIOL, V249, P75; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Elson DA, 1997, MOL CELL BIOL, V17, P309, DOI 10.1128/MCB.17.1.309; Evron E, 2001, CANCER RES, V61, P2782; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; Glenn CC, 1996, AM J HUM GENET, V58, P335; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Knudsen S, 1999, BIOINFORMATICS, V15, P356, DOI 10.1093/bioinformatics/15.5.356; Kumar KS, 2000, WIND STRUCT, V3, P1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Loeb DM, 2001, CANCER RES, V61, P921; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Ohler U, 2000, Pac Symp Biocomput, P380; OKUDA T, 1995, GENOMICS, V29, P623, DOI 10.1006/geno.1995.9957; OTTERSON GA, 1995, ONCOGENE, V11, P1211; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; STAIGER D, 1989, P NATL ACAD SCI USA, V86, P6930, DOI 10.1073/pnas.86.18.6930; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707; Zhu WG, 2001, CANCER RES, V61, P1327	51	96	98	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2001	20	53					7787	7796		10.1038/sj.onc.1204970	http://dx.doi.org/10.1038/sj.onc.1204970			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753657				2022-12-17	WOS:000172161700010
J	Falck, J; Lukas, C; Protopopova, M; Lukas, J; Selivanova, G; Bartek, J				Falck, J; Lukas, C; Protopopova, M; Lukas, J; Selivanova, G; Bartek, J			Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway	ONCOGENE			English	Article						DNA damage; cell cycle checkpoints; Chk2; p53; tumour suppressor	DNA-DAMAGE; S-PHASE; PRB/E2F PATHWAY; CELL-LINES; P53; CHECKPOINT; ATM; ACTIVATION; CANCER; PHOSPHORYLATION	Recent evidence identified a genetic and functional link between Chk2 kinase and p53 as a candidate genome integrity checkpoint and a tumour suppressor pathway. Here we report that in human cells, Chk2 and p53 form protein-protein complexes whose abundance increased upon DNA damage, and whose formation was abrogated through cancer associated mutations in the FHA domain of Chk2, or mutations in the tetramerization domain of p53. Whereas among Li-Fraumeni syndrome families mutations of Chk2 or p53 occur in a mutually exclusive manner, we document that the colon cancer cell line HCT-15 concomitantly lacks functions of both Chk2 and p53, the latter demonstrated by a non-invasive reporter assay monitoring p53-dependent transactivation in live cells. Despite the preserved ability of common cancer-derived mutant p53 proteins to bind and potentially 'titrate' activated Chk2, the integrity of the S phase checkpoint response to ionizing radiation remained largely intact and dependent on Chk2 in cells with wild-type, mutant, or no p53. These results provide new mechanistic insights into the Chk2-p53 interplay, suggest how mutations in Chk2 may abrogate its tumour suppressor function, and indicate that compared with individual defects in either Chk2 or p53, concomitant mutations in both of these cell cycle checkpoint regulators may provide some additional selective advantage to tumour cells.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen O, Denmark; Karolinska Inst, Canc Ctr Karolinska R8 04, Dept Oncol Pathol, S-17176 Stockholm, Sweden	Danish Cancer Society; Karolinska Institutet	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen O, Denmark.		Bartek, Jiri/G-5870-2014	Selivanova, Galina/0000-0002-8698-4332; Lukas, Claudia/0000-0001-7169-6883; Lukas, Jiri/0000-0001-9087-506X				Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; BARTEK J, 1990, ONCOGENE, V5, P893; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Carr AM, 2000, SCIENCE, V287, P1765, DOI 10.1126/science.287.5459.1765; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Haruki N, 2000, CANCER RES, V60, P4689; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Meek DW, 2000, PATHOL BIOL, V48, P246; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; OConnor PM, 1997, CANCER RES, V57, P4285; Petrini JHJ, 2000, NAT GENET, V26, P257, DOI 10.1038/81529; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 2000, GENE DEV, V14, P289; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	31	96	97	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5503	5510		10.1038/sj.onc.1204811	http://dx.doi.org/10.1038/sj.onc.1204811			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571648				2022-12-17	WOS:000170781100011
J	Munshi, A; Pappas, G; Honda, T; McDonnell, TJ; Younes, A; Li, Y; Meyn, RE				Munshi, A; Pappas, G; Honda, T; McDonnell, TJ; Younes, A; Li, Y; Meyn, RE			TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2	ONCOGENE			English	Article						apoptosis; TRAIL; bcl-2; cycloheximide; prostate	CYTOTOXIC LIGAND TRAIL; CYTOCHROME-C RELEASE; MEDIATED APOPTOSIS; DEATH DOMAIN; PROTEIN EXPRESSION; MELANOMA-CELLS; MYELOMA CELLS; FAS; RECEPTOR; TNF	To determine if TRAIL-induced apoptosis in human prostate tumor cells was suppressed by bcl-2, we compared the levels of apoptosis induced by recombinant human TRAIL in pairs of isogenic cell lines that do or do not express bcl-2, Three human prostate tumor cell lines (PC3, DU145 and LNCaP) and their bcl-2-expressing counterparts were tested for their susceptibility to TRAIL, Cells were exposed to TRAIL in the presence of cycloheximide which acted as a sensitizer. Apoptosis was induced rapidly in PC3 and DU145 neo-control transfected cells, whereas induction in LNCaP required 24 h, All three cell line variants expressing bcl-2 were resistant to the apoptotic effects of TRAIL. Caspase 3 and 8 activation was also detected in the neo control cells after treatment with TRAIL, demonstrating the rapid activation of the caspase cascade similar to that seen with other death receptors, Bcl-2 overexpression in these cells blocked activation of these caspases, suggesting that bcl-2 expression of human cancer cells may be a critical factor in the therapeutic efficacy of TRAIL.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma & Leukemia, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Meyn, RE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd,Box 066, Houston, TX 77030 USA.				NCI NIH HHS [P30 CA16672, R01 CA69003, P01 CA06294] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA069003, P01CA006294] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Bonavida B, 1999, INT J ONCOL, V15, P793; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Fulda S, 2000, CANCER RES, V60, P3947; Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501; Gazitt Y, 1999, CYTOKINE, V11, P1010, DOI 10.1006/cyto.1999.0536; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1993, J IMMUNOL, V151, P621; JAATTELA M, 1995, ONCOGENE, V10, P2297; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; KORSMEYER SJ, 1992, BLOOD, V80, P879; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; MARIANI SM, 1997, J CELL BIOL, V37, P211; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MIYASHITA T, 1993, BLOOD, V81, P151; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SELLINS KS, 1987, J IMMUNOL, V139, P3199; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Snell V, 1997, BRIT J HAEMATOL, V99, P618, DOI 10.1046/j.1365-2141.1997.4393250.x; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; TANG C, 1994, LEUKEMIA, V8, P1960; Thomas WD, 1998, J IMMUNOL, V161, P2195; TSUCHIDA H, 1995, J IMMUNOL, V154, P2403; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; WALLACH D, 1984, J IMMUNOL, V132, P2464; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yamada K, 1999, DIABETES, V48, P478, DOI 10.2337/diabetes.48.3.478; Yu R, 2000, CANCER RES, V60, P2384; Zhang XD, 1999, CANCER RES, V59, P2747	48	96	99	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3757	3765		10.1038/sj.onc.1204504	http://dx.doi.org/10.1038/sj.onc.1204504			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439339				2022-12-17	WOS:000169494700001
J	Liu, BL; Fang, M; Lu, Y; Mendelsohn, J; Fan, Z				Liu, BL; Fang, M; Lu, Y; Mendelsohn, J; Fan, Z			Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody	ONCOGENE			English	Article						EGF receptor; monoclonal antibody; apoptosis; cell cycle arrest; bFGF; IGF-1	PROTEIN-KINASE PATHWAY; EPITHELIAL-CELLS; G(1) ARREST; BAD PHOSPHORYLATION; CARCINOMA-CELLS; INHIBITION; ACTIVATION; SURVIVAL; ALPHA; AKT	DiFi human colon carcinoma cells are stimulated by the transforming growth factor-alpha (TGF-alpha)/epidermal growth factor (EGF) receptor autocrine loop. Exposure of DiFi cells to monoclonal antibody (mAb) 225, which blocks ligand-induced activation of the EGF receptor, induces G1 arrest and subsequent cell death via apoptosis, We investigated the signal pathways by which basic fibroblast growth factor (bFGF) and insulin-like growth factor-1 (IGF-1) modulate mAb 225-induced G1 arrest and apoptosis in DiFi cells. Both bFGF and IGF-1 activated the mitogen-activated protein kinase (MAPK) kinase (MEK) pathway in DiFi cells, Additionally, IGF-1 activated the phosphoinositide 3-kinase (PI-3K)/Akt pathway. Both bFGF and IGF-1 inhibited mAb 225-induced apoptosis; however, bFGF provided sustained protection against apoptosis, while the protection by IGF-1 was only temporary. Also, bFGF reversed the mAb 225-induced increase in the p27(Kip1) level, inhibition of cyclin-dependent kinase-2 (CDK-2) activity, dephosphorylation of the retinoblastoma (Rb) protein and the resultant G1 arrest of the cells. In contrast, IGF-1 did not reverse such effects by mAb 225, The prevention of mAb 225-induced G1 arrest and apoptosis in DiFi cells by bFGF was sensitive to the MEK/MAPK inhibitor PD98059 but not to the PI-3K inhibitor LY294002. In contrast, inhibition of apoptosis by IGF-1 in DiFi cells was sensitive only to LY294002 and not to PD98059, These results further our understanding of how mAb 225 induces apoptosis in DiFi cells.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Box 36,1515 Holcombe Blvd, Houston, TX 77030 USA.			Liu, Bolin/0000-0003-0150-8650				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Baselga J, 1996, J BIOL CHEM, V271, P3279, DOI 10.1074/jbc.271.6.3279; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Caraglia M, 1999, CELL DEATH DIFFER, V6, P773, DOI 10.1038/sj.cdd.4400550; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chou JL, 1999, BREAST CANCER RES TR, V55, P267, DOI 10.1023/A:1006217413089; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Fan Z, 1997, CLIN CANCER RES, V3, P1943; FAN Z, 1993, CANCER RES, V53, P4322; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FAN Z, 1994, J BIOL CHEM, V269, P27595; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; GILL GN, 1984, J BIOL CHEM, V259, P7755; GROSS ME, 1991, CANCER RES, V51, P1452; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; Lan L, 1999, FEBS LETT, V444, P90, DOI 10.1016/S0014-5793(99)00032-0; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Liu B, 2000, BRIT J CANCER, V82, P1991; McClellan M, 1999, EXP CELL RES, V246, P471, DOI 10.1006/excr.1998.4328; OLIVE M, 1993, IN VITRO CELL DEV-AN, V29A, P239; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Payne SG, 1999, J CELL PHYSIOL, V180, P263, DOI 10.1002/(SICI)1097-4652(199908)180:2<263::AID-JCP14>3.0.CO;2-H; Peng D, 1996, CANCER RES, V56, P3666; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; Sato J D, 1983, Mol Biol Med, V1, P511; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; ULLRICH A, 1990, CELL, V61, P303; UNTAWALE S, 1993, CANCER RES, V53, P1630; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; Wu XP, 1996, ONCOGENE, V12, P1397; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	39	96	103	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2001	20	15					1913	1922		10.1038/sj.onc.1204277	http://dx.doi.org/10.1038/sj.onc.1204277			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313939				2022-12-17	WOS:000167908400012
J	Iwashita, T; Kato, M; Murakami, H; Asai, N; Ishiguro, Y; Ito, S; Iwata, Y; Kawai, K; Asai, M; Kurokawa, K; Kajita, H; Takahashi, M				Iwashita, T; Kato, M; Murakami, H; Asai, N; Ishiguro, Y; Ito, S; Iwata, Y; Kawai, K; Asai, M; Kurokawa, K; Kajita, H; Takahashi, M			Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma	ONCOGENE			English	Article						Ret; tyrosine kinase; MEN 2A; MEN 2B; FMTC	DISEASE PHENOTYPE; TYROSINE KINASE; MEN 2A; TRANSFORMING ACTIVITY; POINT MUTATION; PROTOONCOGENE; ACTIVATION; FMTC; SHC; CODON-883	Several mutations were identified in the kinase domain of the RET proto-oncogene in patients with multiple endocrine neoplasia (MEN) 2B, familial medullary thyroid carcinoma (FMTC) or sporadic medullary thyroid carcinoma. We introduced seven mutations (glutamic acid 768-->aspartic acid (E768D), valine 804-->leucine (V804L), alanine 883-->phenylalanine (A1883F), serine 891-->alanine (S891A), methionine 918 -->threonine (M918T), alanine 919-->proline (A919P) and E768D/A919P) into the short and long isoforms of RET cDNA and transfected the mutant cDNAs into NIH3T3 cells, The transforming activity of the long isoform of Ret with each mutation was much higher that that of its short isoform, Based on the levels of the transforming activity, these mutant RET genes were classified into two groups; a group with high transforming activity (A883F, M918T and E768D/A919P) and a group with low transforming activity (E768D, V804L, S891A and A919P) (designated high group and low group). Interestingly, the level of transforming activity correlated with clinical phenotypes; high group Bet with the A883F or M918T mutation and low group Ret with the E768D, V804L or S891A mutation were associated with the development of MEN 2B and FMTC, respectively. in addition, we found that substitution of phenylalanine for tyrosine 905 present in the kinase domain abolished both transforming and autophosphorylation activities of low group Ret whereas it did not affect the activities of high group Ret.	Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Immunol, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University	Takahashi, M (corresponding author), Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai-cho, Nagoya, Aichi 4668550, Japan.		Takahashi, Masahide/AAN-4770-2020; KATO, Masashi/I-7250-2014; ASAI, Naoya/I-7377-2014; Kumi, Kawai/I-6275-2014; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; Kumi, Kawai/0000-0002-7772-2605; 				Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BOLINO A, 1995, ONCOGENE, V10, P2415; Borrello MG, 1995, ONCOGENE, V11, P2419; Carlomagno F, 1997, CANCER RES, V57, P391; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; ENG C, 1995, ONCOGENE, V10, P509; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Gimm O, 1997, J CLIN ENDOCR METAB, V82, P3902, DOI 10.1210/jc.82.11.3902; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hofstra RMW, 1997, J CLIN ENDOCR METAB, V82, P4176, DOI 10.1210/jc.82.12.4176; Ito S, 1997, CANCER RES, V57, P2870; Iwashita T, 1996, ONCOGENE, V12, P481; LIPS CJM, 1994, NEW ENGL J MED, V331, P828, DOI 10.1056/NEJM199409293311302; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Miyauchi A, 1997, JPN J CANCER RES, V88, P527, DOI 10.1111/j.1349-7006.1997.tb00414.x; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; Nozaki C, 1998, ONCOGENE, V16, P293, DOI 10.1038/sj.onc.1201548; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Smith DP, 1997, ONCOGENE, V15, P1213, DOI 10.1038/sj.onc.1201481; TAHIRA T, 1990, ONCOGENE, V5, P97	28	96	102	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3919	3922		10.1038/sj.onc.1202742	http://dx.doi.org/10.1038/sj.onc.1202742			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445857				2022-12-17	WOS:000081171700015
J	Guldberg, P; Straten, PT; Ahrenkiel, V; Seremet, T; Kirkin, AF; Zeuthen, J				Guldberg, P; Straten, PT; Ahrenkiel, V; Seremet, T; Kirkin, AF; Zeuthen, J			Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma	ONCOGENE			English	Article						STK11; LKB1; tumour suppressor; malignant melanoma; Peutz-Jeghers syndrome; serine/threonine kinase	CUTANEOUS MELANOMA; CELL-LINES; CANCER; IDENTIFICATION; BREAST; PTEN	Mutations in LKB1/STK11, a gene mapping to chromosome 19p13.3 and encoding a widely expressed serine/threonine kinase, were recently identified as the cause of Peutz-Jeghers syndrome. Despite the hamartomatous polyps and increased cancer risk associated with this syndrome, somatic alterations in LKB1/STK11 have not been identified in human tumours. Prompted by another feature of the syndrome, lentigines of the lips and oral mucosa, we evaluated the status of LKB1/STK11 expression, deletion, and mutation in cell lines and tumour samples from 35 patients with sporadic malignant melanoma, Two somatic mutations were identified, a nonsense mutation (Glu170Stop) causing exon skipping and intron retention, and a missense mutation (Asp194Tyr) affecting an invariant residue in the catalytic subunit of LKB1/STK11. Our data suggest that LKB1/STK11 may contribute to tumorigenesis in a small fraction of malignant melanomas.	Danish Canc Soc, Inst Canc Biol, Dept Tumor Cell Biol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Guldberg, P (corresponding author), Danish Canc Soc, Inst Canc Biol, Dept Tumor Cell Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.							ABRAMS ES, 1992, METHOD ENZYMOL, V212, P71; Albino Anthony P., 1995, Current Opinion in Oncology, V7, P162, DOI 10.1097/00001622-199503000-00012; Avizienyte E, 1998, CANCER RES, V58, P2087; Bartkova J, 1996, CANCER RES, V56, P5475; Bignell GR, 1998, CANCER RES, V58, P1384; BRAITMAN M, 1979, CUTIS, V23, P617; Castellano M, 1997, CANCER RES, V57, P4868; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; Guldberg P, 1997, CANCER RES, V57, P3660; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Healy E, 1996, CANCER RES, V56, P589; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hoffmeyer S, 1998, AM J HUM GENET, V62, P269, DOI 10.1086/301715; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; KAMP A, 1994, SCIENCE, V264, P436; KOH HK, 1991, NEW ENGL J MED, V325, P171, DOI 10.1056/NEJM199107183250306; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; PARMITER AH, 1986, CANCER RES, V46, P1526; Ray ME, 1997, P NATL ACAD SCI USA, V94, P3229, DOI 10.1073/pnas.94.7.3229; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Teng DHF, 1997, CANCER RES, V57, P5221; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Walker GJ, 1998, GENE CHROMOSOME CANC, V22, P157, DOI 10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N; Welch DR, 1997, PATHOBIOLOGY, V65, P311, DOI 10.1159/000164143; Wong SS, 1996, BRIT J DERMATOL, V135, P439, DOI 10.1046/j.1365-2133.1996.d01-1017.x	28	96	97	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	1999	18	9					1777	1780		10.1038/sj.onc.1202486	http://dx.doi.org/10.1038/sj.onc.1202486			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208439				2022-12-17	WOS:000079025000013
J	Blankenship, C; Naglich, JG; Whaley, JM; Seizinger, B; Kley, N				Blankenship, C; Naglich, JG; Whaley, JM; Seizinger, B; Kley, N			Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity	ONCOGENE			English	Article						pVHL; VEGF; elongins; Hs-CUL2	ENDOTHELIAL GROWTH-FACTOR; RENAL-CARCINOMA; MESSENGER-RNA; SOMATIC MUTATIONS; HUMAN TISSUES; PROTEIN; TRANSLATION; EXPRESSION; BINDING; HEMANGIOBLASTOMAS	The VHL tumor suppressor gene has previously been reported to encode a protein of 213 amino acid residues. Here we report the identification of a second major VHL gene product with an apparent molecular weight of 18 kD, pVHL18, which appears to arise from alternate translation initiation at a second AUG codon (codon 54) within the VHL open reading frame. In vitro and in vivo studies indicate that the internal codon in the VHL mRNA is necessary and sufficient for production of pVHL18. pVHL18 can bind to elongin B, elongin C, and Hs-CUL2, When reintroduced into renal carcinoma cells that lack a wild-type VHL allele, pVHL18 suppresses basal levels of VEGF expression, restores hypoxia-inducibility of VEGF expression, and inhibits tumor formation in nude mice. These data strongly support the existence of two distinct VHL gene products in VHL tumor suppression.	Genome Therapeut Corp, Dept Funct Genom, Waltham, MA 02154 USA; Bristol Myers Squibb Pharmaceut Res Inst, Dept Oncol, Princeton, NJ 08540 USA; Bristol Myers Squibb Pharmaceut Res Inst, Dept Metab Dis, Princeton, NJ 08540 USA	Bristol-Myers Squibb; Bristol-Myers Squibb	Kley, N (corresponding author), Genome Therapeut Corp, Dept Funct Genom, 100 Beaver St, Waltham, MA 02154 USA.							ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Corless CL, 1997, HUM PATHOL, V28, P459, DOI 10.1016/S0046-8177(97)90035-6; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; GAO JZ, 1995, CANCER RES, V55, P743; GILLMAN EC, 1991, MOL CELL BIOL, V11, P2382, DOI 10.1128/MCB.11.5.2382; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Iizuka N, 1995, CURR TOP MICROBIOL, V203, P155; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; KANNO H, 1994, CANCER RES, V54, P4845; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KISHIDA T, 1995, CANCER RES, V55, P4544; Knebelmann B, 1998, CANCER RES, V58, P226; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Los M, 1996, LAB INVEST, V75, P231; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; SHUIN T, 1994, CANCER RES, V54, P2852; Siemeister G, 1996, CANCER RES, V56, P2299; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WHALEY JM, 1994, AM J HUM GENET, V55, P1092; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; Zbar Berton, 1995, V25, P219	33	96	100	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	1999	18	8					1529	1535		10.1038/sj.onc.1202473	http://dx.doi.org/10.1038/sj.onc.1202473			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102622				2022-12-17	WOS:000078770700002
J	Rickert, P; Corden, JL; Lees, E				Rickert, P; Corden, JL; Lees, E			Cyclin C CDK8 and cyclin H CDK7 p36 are biochemically distinct CTD kinases	ONCOGENE			English	Article						cyclin C; CDK8; CTD; RNA polymerase II	RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; TRANSCRIPTION FACTOR TFIIH; PRE-MESSENGER-RNA; LARGEST SUBUNIT; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; ACTIVATING KINASE; REPEAT DOMAIN; DEPENDENT KINASES	Phosphorylation of the carboxyl-terminal domain (CTD) of RNA polymerase IT is important for basal transcriptional processes in vivo and for cell viability. Several kinases, including certain cyclin-dependent kinases, can phosphorylate this substrate in vitro. It has been proposed that differential CTD phosphorylation by different kinases may regulate distinct transcriptional processes. We have found that two of these kinases, cyclin C/CDK8 and cyclin H/CDK7/p36, can specifically phosphorylate distinct residues in recombinant CTD substrates, This difference in specificity may be largely due to their varying ability to phosphorylate lysine-substituted heptapeptide repeats within the CTD, since they phosphorylate the same residue in CTD consensus heptapeptide repeats. Furthermore, this substrate specificity is reflected in vivo where cyclin C/CDK8 and cyclin H/CDK7/p36 can differentially phosphorylate an endogenous RNA polymerase II substrate, Several small-molecule kinase inhibitors have different specificities for these related kinases, indicating that these enzymes have diverse active-site conformations. These results suggest that cyclin C/CDK8 and cyclin H/CDK7/p36 are physically distinct enzymes that may have unique roles in transcriptional regulation mediated by their phosphorylation of specific sites on RNA polymerase II.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, Palo Alto, CA 94304 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21209 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Stanford University; Johns Hopkins University	Lees, E (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, 901 Calif Ave, Palo Alto, CA 94304 USA.							ABRAHAM RT, 1995, BIOL CELL, V83, P105, DOI 10.1016/0248-4900(96)81298-6; AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; Baskaran R, 1997, J BIOL CHEM, V272, P18905, DOI 10.1074/jbc.272.30.18905; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Bellier S, 1997, MOL CELL BIOL, V17, P1434, DOI 10.1128/MCB.17.3.1434; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CAGAS PM, 1995, PROTEINS, V21, P149, DOI 10.1002/prot.340210209; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; CHAPMAN AB, 1994, J BIOL CHEM, V269, P4754; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORDEN JL, 1993, CURR OPIN GENET DEV, V3, P213, DOI 10.1016/0959-437X(93)90025-K; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DAHMUS ME, 1981, J BIOL CHEM, V256, P3332; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; Dubois MF, 1997, NUCLEIC ACIDS RES, V25, P694, DOI 10.1093/nar/25.4.694; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; DUBOIS MF, 1994, EMBO J, V13, P4787, DOI 10.1002/j.1460-2075.1994.tb06804.x; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Gebara MM, 1997, J CELL BIOCHEM, V64, P390; GIESECKE H, 1991, BIOCHEM BIOPH RES CO, V180, P1350, DOI 10.1016/S0006-291X(05)81344-0; GLAB N, 1994, FEBS LETT, V353, P207, DOI 10.1016/0014-5793(94)01035-8; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; JIANG Y, 1994, NUCLEIC ACIDS RES, V22, P4958, DOI 10.1093/nar/22.23.4958; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; Lee JM, 1997, J BIOL CHEM, V272, P10990; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; MISTELI T, 1995, J CELL SCI, V108, P2715; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PAYNE JM, 1993, J BIOL CHEM, V268, P80; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; RICE SA, 1994, J VIROL, V68, P988, DOI 10.1128/JVI.68.2.988-1001.1994; Rickert P, 1996, ONCOGENE, V12, P2631; RICKERT P, 1997, THESIS STANFORD U; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SAMBROOK J, CLONIONG LAB MANUAL; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; SEHGAL PB, 1976, CELL, V9, P473, DOI 10.1016/0092-8674(76)90092-1; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Shilatifard A, 1997, CURR OPIN GENET DEV, V7, P199, DOI 10.1016/S0959-437X(97)80129-3; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; Song CZ, 1996, BIOCHEM BIOPH RES CO, V229, P810, DOI 10.1006/bbrc.1996.1885; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; STEVENS A, 1989, BIOCHEM BIOPH RES CO, V159, P508, DOI 10.1016/0006-291X(89)90022-3; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587; VENETIANER A, 1995, EUR J BIOCHEM, V233, P83, DOI 10.1111/j.1432-1033.1995.083_1.x; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WEST ML, 1995, GENETICS, V140, P1223; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; Yuryev A, 1996, GENETICS, V143, P661; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	82	96	99	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					1093	1102		10.1038/sj.onc.1202399	http://dx.doi.org/10.1038/sj.onc.1202399			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023686				2022-12-17	WOS:000078510600027
J	Callaghan, MJ; Russell, AJ; Woollatt, E; Sutherland, GR; Sutherland, RL; Watts, CKW				Callaghan, MJ; Russell, AJ; Woollatt, E; Sutherland, GR; Sutherland, RL; Watts, CKW			Identification of a human HECT family protein with homology to the Drosophila tumor suppressor gene hyperplastic discs	ONCOGENE			English	Article						ubiquitination; tumor suppressor; progestin; breast cancer	HUMAN-BREAST-CANCER; UBIQUITIN-DEPENDENT DEGRADATION; SQUAMOUS-CELL CARCINOMA; NF-KAPPA-B; PROTEASOME PATHWAY; CYCLE PROGRESSION; ANGELMAN SYNDROME; GROWTH-FACTOR; C-JUN; EXPRESSION	Use of the differential display technique to isolate progestin-regulated genes in T-47D human breast cancer cells led to identification of a novel gene, EDD, The cDNA sequence contains a 2799 amino acid open reading frame sharing 40% identity with the predicted 2894 amino acid product of the Drosophila melanogaster tumor suppressor gene hyperplastic discs, while the carboxy-terminal 889 amino acids show 96% identity to a rat 100 kDa HECT domain protein. EDD mRNA was progestin-induced in T-47D cells and was highly abundant in testes and expressed at moderately high le,els in other tissues, suggesting a broad role for EDD, Anti-EDD antibodies immunoprecipitated an approximately 300 kDa protein from T-47D cell lysates, HECT family proteins function as E3 ubiquitin-protein ligases, targeting specific proteins for ubiquitin-mediated proteolysis. EDD is likely to function as an E3 as irt vitro translated protein hound ubiquitin reversibly through a conserved HECT domain cysteine residue. EDD was localized by FISH to chromosome 8q22, a locus disrupted in a variety of cancers. Given the homology between EDD and the hyperplastic discs protein, which is required for control of imaginal disc growth in Drosophila, EDD potentially has a role in regulation of cell proliferation or differentiation.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; Womens & Childrens Hosp, Dept Cytogenet & Mol Genet, Ctr Genet Med, Adelaide, SA 5006, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Womens & Childrens Hospital Australia	Watts, CKW (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia.		Sutherland, Robert L/A-8378-2008; henderson, Michelle/G-6657-2012; Sutherland, Grant Robert/D-2606-2012					ALEXANDER IE, 1989, MOL ENDOCRINOL, V3, P1377, DOI 10.1210/mend-3-9-1377; Benito J, 1998, EMBO J, V17, P482, DOI 10.1093/emboj/17.2.482; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; CHAN YL, 1984, J BIOL CHEM, V259, P224; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; CLARKE RA, 1995, AM J HUM GENET, V57, P1364; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ElRifai W, 1996, CANCER RES, V56, P3230; ERICKSON P, 1992, BLOOD, V80, P1825; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; GU J, 1994, MOL BRAIN RES, V24, P77, DOI 10.1016/0169-328X(94)90120-1; HALL RE, 1990, INT J CANCER, V46, P1081, DOI 10.1002/ijc.2910460622; Hamilton JA, 1997, MOL ENDOCRINOL, V11, P490, DOI 10.1210/me.11.4.490; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P5249, DOI 10.1073/pnas.92.11.5249-a; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; LAIDLAW IJ, 1995, ENDOCRINOLOGY, V136, P164, DOI 10.1210/en.136.1.164; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MANSFIELD E, 1994, DEV BIOL, V165, P507, DOI 10.1006/dbio.1994.1271; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; MULLER D, 1992, NUCLEIC ACIDS RES, V20, P1471, DOI 10.1093/nar/20.7.1471; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; MUSGROVE EA, 1991, MOL CELL BIOL, V11, P5032, DOI 10.1128/MCB.11.10.5032; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; NAWROZ H, 1994, CANCER RES, V54, P1152; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.3.CO;2-#; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; SATO S, 1994, CANCER RES, V54, P5652; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Sutherland RL, 1998, J MAMMARY GLAND BIOL, V3, P63, DOI 10.1023/A:1018774302092; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x	56	96	103	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3479	3491		10.1038/sj.onc.1202249	http://dx.doi.org/10.1038/sj.onc.1202249			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030672				2022-12-17	WOS:000078086200009
J	Tamir, I; Cambier, JC				Tamir, I; Cambier, JC			Antigen receptor signaling: integration of protein tyrosine kinase functions	ONCOGENE			English	Review						signal transduction; antigen receptors; protein tyrosine kinases	T-CELL-RECEPTOR; B-LYMPHOCYTE DEVELOPMENT; X-LINKED AGAMMAGLOBULINEMIA; PHOSPHORYLATED IG-ALPHA; SEVERE COMBINED IMMUNODEFICIENCY; PLECKSTRIN HOMOLOGY DOMAINS; PROTOONCOGENE C-CBL; BETA-GAMMA-SUBUNITS; SRC FAMILY KINASES; FC-EPSILON-RI	Antigen receptors on T and B cells function to transduce signals leading to a variety of biologic responses minimally including antigen receptor editing, apoptotic death, developmental progression, cell activation, proliferation and survival. The response to antigen depends upon antigen affinity and valence, involvement of coreceptors in signaling and differentiative stage of the responding cell. The requirement that these receptors integrate signals that drive an array of responses may explain their evolved structural complexity. Antigen receptors are composed of multiple subunits compartmentalized to provide antigen recognition and signal transduction function. In lieu of on-board enzymatic activity these receptors rely on associated Protein Tyrosine Kinases (PTKs) for their signaling function. By aggregating the receptors, and hence their appended PTKs, antigens induce PTK transphosphorylation, activating them to phosphorylate the receptor within conserved motifs termed Immunoreceptor Tyrosine-based Activation Motifs (ITAMs) found in transducer subunits, The tyrosyl phosphorylated ITAMs then interact with Src Homology 2 (SH2) domains within the PTKs leading to their further activation. As receptor phosphorylation is amplified, other effecters, such as Shc, dock by virtue of SH2 binding, and serve, in-turn, as substrates for these PTKs, This sequence of events not only provides a signal amplification mechanism by combining multiple consecutive steps with positive feedback, but also allows for signal diversification by differential recruitment of effecters that provide access to distinct parallel downstream signaling pathways. The subject of antigen receptor signaling has been recently reviewed in depth (DeFranco, 1997; Kurosaki, 1997), Here we discuss the biochemical basis of antigen receptor signal transduction, using the B cell receptor (BCR) as a paradigm, with specific emphasis on the involved PTKs, We review several specific mechanisms by which responses through these receptors are propagated and modified by accessory molecules, and discuss how signal amplification and diversification are achieved.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA	National Jewish Health	Cambier, JC (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, 1400 Jackson St, Denver, CO 80206 USA.			Cambier, John/0000-0002-7803-242X				Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; AOKI Y, 1995, J BIOL CHEM, V270, P15658, DOI 10.1074/jbc.270.26.15658; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; Benatar T, 1996, J EXP MED, V183, P329, DOI 10.1084/jem.183.1.329; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BonnefoyBerard N, 1996, STEM CELLS, V14, P250, DOI 10.1002/stem.140250; BRAESCHANDERSEN S, 1994, J BIOL CHEM, V269, P11783; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BROWN VK, 1994, J BIOL CHEM, V269, P17238; BU JY, 1995, P NATL ACAD SCI USA, V92, P5106, DOI 10.1073/pnas.92.11.5106; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; Buhl AM, 1997, J EXP MED, V186, P1897, DOI 10.1084/jem.186.11.1897; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CARRERA AC, 1992, J IMMUNOL, V149, P3142; Carter RH, 1997, J IMMUNOL, V158, P3062; CHALUPNY NJ, 1993, EMBO J, V12, P2691, DOI 10.1002/j.1460-2075.1993.tb05930.x; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Cheng AM, 1997, P NATL ACAD SCI USA, V94, P9797, DOI 10.1073/pnas.94.18.9797; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; Couture C, 1997, EUR J BIOCHEM, V246, P447, DOI 10.1111/j.1432-1033.1997.00447.x; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; Couture C, 1996, J BIOL CHEM, V271, P24294, DOI 10.1074/jbc.271.39.24294; Cyster JG, 1997, IMMUNITY, V6, P509, DOI 10.1016/S1074-7613(00)80339-8; DAmbrosio D, 1996, EUR J IMMUNOL, V26, P1960, DOI 10.1002/eji.1830260842; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Desiderio S, 1997, CURR OPIN IMMUNOL, V9, P534, DOI 10.1016/S0952-7915(97)80107-0; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; ElHillal O, 1997, P NATL ACAD SCI USA, V94, P1919, DOI 10.1073/pnas.94.5.1919; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; FitzerAttas CJ, 1997, J BIOL CHEM, V272, P8551, DOI 10.1074/jbc.272.13.8551; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Furlong MT, 1997, BBA-MOL CELL RES, V1355, P177, DOI 10.1016/S0167-4889(96)00131-0; Garcia KC, 1996, NATURE, V384, P577, DOI 10.1038/384577a0; Gauen LKT, 1996, J CELL BIOL, V133, P1007, DOI 10.1083/jcb.133.5.1007; GOLD MR, 1994, J IMMUNOL, V153, P2369; GOLD MR, 1994, ADV IMMUNOL, V55, P221; GOLD MR, 1992, J IMMUNOL, V148, P2012; Gong Q, 1997, IMMUNITY, V7, P369, DOI 10.1016/S1074-7613(00)80358-1; Graef IA, 1997, EMBO J, V16, P5618, DOI 10.1093/emboj/16.18.5618; HANASAKI K, 1995, J BIOL CHEM, V270, P7543, DOI 10.1074/jbc.270.13.7543; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; HATA A, 1994, MOL CELL BIOL, V14, P7306, DOI 10.1128/MCB.14.11.7306; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; Itano A, 1996, J EXP MED, V183, P731, DOI 10.1084/jem.183.3.731; JabrilCuenod B, 1996, J BIOL CHEM, V271, P16268, DOI 10.1074/jbc.271.27.16268; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JOHNSON SA, 1995, J IMMUNOL, V155, P4596; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; Justement LB, 1997, ADV IMMUNOL, V66, P1, DOI 10.1016/S0065-2776(08)60595-7; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KAWAUCHI K, 1994, J IMMUNOL, V152, P3306; Keshvara LM, 1997, J BIOL CHEM, V272, P10377; KIESEL S, 1988, IMMUNOLOGY, V64, P445; KILLEEN N, 1993, NATURE, V364, P729, DOI 10.1038/364729a0; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; Koretzky GA, 1997, IMMUNOL TODAY, V18, P401, DOI 10.1016/S0167-5699(97)01088-8; Krop I, 1996, J IMMUNOL, V157, P48; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Kurosaki T, 1997, J BIOL CHEM, V272, P15595, DOI 10.1074/jbc.272.25.15595; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; Latour S, 1997, MOL CELL BIOL, V17, P4434, DOI 10.1128/MCB.17.8.4434; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Law CL, 1996, MOL CELL BIOL, V16, P1305; LAW CL, 1994, IMMUNOL TODAY, V15, P442, DOI 10.1016/0167-5699(94)90275-5; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; Li TJ, 1997, ONCOGENE, V15, P1375, DOI 10.1038/sj.onc.1201308; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Li XL, 1997, J IMMUNOL, V158, P5649; LIN JJ, 1992, J IMMUNOL, V149, P1548; LINDSBERG ML, 1991, J IMMUNOL, V147, P3774; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; Mayer BJ, 1997, CURR BIOL, V7, pR295, DOI 10.1016/S0960-9822(06)00141-2; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J IMMUNOL, V159, P1639; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; Nagata K, 1997, IMMUNITY, V7, P559, DOI 10.1016/S1074-7613(00)80377-5; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Pao LI, 1998, J IMMUNOL, V160, P3305; Pao LI, 1997, J IMMUNOL, V158, P2663; Pao LI, 1997, J IMMUNOL, V158, P1116; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PESANDO JM, 1989, J EXP MED, V170, P2159, DOI 10.1084/jem.170.6.2159; Peters JD, 1996, J BIOL CHEM, V271, P4755; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; PLEIMAN CM, 1994, J IMMUNOL, V152, P2837; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Qian DP, 1996, J EXP MED, V183, P611, DOI 10.1084/jem.183.2.611; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; Razi N, 1997, BLOOD, V90, P2022; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Richards JD, 1996, J BIOL CHEM, V271, P6458, DOI 10.1074/jbc.271.11.6458; RIGLEY KP, 1989, EUR J IMMUNOL, V19, P2081, DOI 10.1002/eji.1830191117; ROIFMAN CM, 1993, BIOCHEM BIOPH RES CO, V194, P222, DOI 10.1006/bbrc.1993.1807; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; Sato S, 1997, J IMMUNOL, V159, P3278; Sato S, 1997, P NATL ACAD SCI USA, V94, P13158, DOI 10.1073/pnas.94.24.13158; Sato S, 1997, J IMMUNOL, V158, P4662; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; SAXTON TM, 1994, J IMMUNOL, V153, P623; Schmitz R, 1996, J MOL BIOL, V260, P664, DOI 10.1006/jmbi.1996.0429; Sgroi D, 1996, J BIOL CHEM, V271, P18803, DOI 10.1074/jbc.271.31.18803; SHINKAI Y, 1995, IMMUNITY, V2, P401; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SHORES EW, 1994, SCIENCE, V266, P1047, DOI 10.1126/science.7526464; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SILLMAN AL, 1995, J BIOL CHEM, V270, P11806, DOI 10.1074/jbc.270.20.11806; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SMIT L, 1994, J BIOL CHEM, V269, P20209; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TEDDER TF, 1989, J IMMUNOL, V143, P712; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; Tooze RM, 1997, IMMUNITY, V7, P59, DOI 10.1016/S1074-7613(00)80510-5; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Tuscano JM, 1996, EUR J IMMUNOL, V26, P1246, DOI 10.1002/eji.1830260610; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Wahl MI, 1997, P NATL ACAD SCI USA, V94, P11526, DOI 10.1073/pnas.94.21.11526; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; WECHSLER RJ, 1995, J IMMUNOL, V154, P3234; Weiser P, 1997, SCIENCE, V276, P407, DOI 10.1126/science.276.5311.407; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Wiest DL, 1997, IMMUNITY, V6, P663, DOI 10.1016/S1074-7613(00)80442-2; Wu J, 1997, J EXP MED, V185, P1877, DOI 10.1084/jem.185.10.1877; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YAMADA H, 1993, J EXP MED, V177, P1613, DOI 10.1084/jem.177.6.1613; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YANG WY, 1995, J BIOL CHEM, V270, P20832, DOI 10.1074/jbc.270.35.20832; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	203	96	96	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1353	1364		10.1038/sj.onc.1202187	http://dx.doi.org/10.1038/sj.onc.1202187			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779983				2022-12-17	WOS:000076161900004
J	Amendt, C; Schirmacher, P; Weber, H; Blessing, M				Amendt, C; Schirmacher, P; Weber, H; Blessing, M			Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development	ONCOGENE			English	Article						TGF-beta; receptor; skin; carcinogenesis; growth control	GROWTH-FACTOR-BETA; TRANSGENIC MICE; TRANSFORMING GROWTH-FACTOR-BETA-1; MALIGNANT CONVERSION; KERATIN-5 GENE; HIGH-RISK; RAS GENE; HA-RAS; CELLS; CARCINOGENESIS	The role of Transforming growth factor beta (TGF-beta) in carcinogenesis is complex. There are reports on both tumor inhibition and tumor promotion by TGF-beta. To elucidate the complex role of TGF-beta in epithelial carcinogenesis, we generated transgenic mice overexpressing a dominant negative type II TGF-beta receptor in the basal cell compartment and in follicular cells of the skin, Despite the reduced responsiveness of transgenic keratinocytes to TGF-beta, both proliferation and differentiation were normal in non-irritated epidermis of these transgenic mice, Thus, interruption of signaling of all three isoforms of TGF-beta in basal and follicular cells does not disturb tissue homeostasis. However, during tumor promotion transgenic mice showed an elevated level of proliferation in the epidermis. This hyperproliferation correlated with a very early onset of carcinoma development and a malignant conversion frequency of 30% from benign papillomas to carcinomas. By comparison, the conversion frequency in wild-type mice of this strain has previously been reported as 5.5%, Even without induction of hyperproliferation by tumor promoters, transgenic mice developed far more carcinomas as controls when treated with a carcinogen. This result indicates that there is a synergistic effect between loss of TGF-beta responsiveness and mutations caused by initiation with a carcinogen leading to an endogeneous tumor promotion in initiated cells only.	Johannes Gutenberg Univ Mainz, Dept Med 1, Boehringer Ingelheim Res Grp, D-55131 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Pathol, D-55101 Mainz, Germany	Boehringer Ingelheim; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Blessing, M (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med 1, Boehringer Ingelheim Res Grp, SFB-311,Obere Zahlbacher Str 63, D-55131 Mainz, Germany.							AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BLESSING M, 1993, GENE DEV, V7, P204, DOI 10.1101/gad.7.2.204; Bottinger EP, 1997, CANCER RES, V57, P5564; BRAND T, 1993, J BIOL CHEM, V268, P11500; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHOI Y, 1990, CELL REGUL, V1, P791, DOI 10.1091/mbc.1.11.791; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COFFEY RJ, 1988, CANCER RES, V48, P1596; CUI W, 1995, GENE DEV, V9, P945, DOI 10.1101/gad.9.8.945; CUI W, 1994, CANCER RES, V54, P5831; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DIGIOVANNI J, 1991, PROG EXP TUMOR RES, V33, P192; DROZDOFF V, 1993, J CELL BIOL, V123, P909, DOI 10.1083/jcb.123.4.909; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ESHERICK JS, 1993, CANCER RES, V53, P5517; FAFEUR V, 1993, MOL BIOL CELL, V4, P135, DOI 10.1091/mbc.4.2.135; Fowlis DJ, 1996, CELL GROWTH DIFFER, V7, P679; FURSTENBERGER G, 1989, INT J CANCER, V43, P915; GITELMAN SE, 1997, CALCIFIED TISSUE INT, V60, P283; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; HADDOW S, 1991, ONCOGENE, V6, P1465; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; HENNINGS H, 1993, CARCINOGENESIS, V14, P2353, DOI 10.1093/carcin/14.11.2353; Hogan B., 1986, MANIPULATING MOUSE E; JORCANO JL, 1984, J MOL BIOL, V179, P257, DOI 10.1016/0022-2836(84)90468-6; JORCANO JL, 1984, DIFFERENTIATION, V28, P155, DOI 10.1111/j.1432-0436.1984.tb00278.x; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KITANO Y, 1983, BRIT J DERMATOL, V108, P555, DOI 10.1111/j.1365-2133.1983.tb01056.x; Knaus PI, 1996, MOL CELL BIOL, V16, P3480; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MANSBRIDGE JN, 1988, J INVEST DERMATOL, V90, P336, DOI 10.1111/1523-1747.ep12456286; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MILLER SJ, 1993, J INVEST DERMATOL, V101, P591, DOI 10.1111/1523-1747.ep12366045; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P9613, DOI 10.1073/pnas.88.21.9613; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; SANKAR S, 1995, J BIOL CHEM, V270, P13567, DOI 10.1074/jbc.270.22.13567; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhao Y, 1996, J BIOL CHEM, V271, P2369, DOI 10.1074/jbc.271.5.2369	64	96	100	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	1998	17	1					25	34		10.1038/sj.onc.1202161	http://dx.doi.org/10.1038/sj.onc.1202161			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671311				2022-12-17	WOS:000074677800004
J	Dahl, R; Wani, B; Hayman, MJ				Dahl, R; Wani, B; Hayman, MJ			The Ski oncoprotein interacts with Skip, the human homolog of Drosophila Bx42	ONCOGENE			English	Article						Ski oncogene	HIGH-EFFICIENCY TRANSFORMATION; CEREVISIAE CHROMOSOME-I; V-SKI; MOLECULAR ANALYSIS; ESCHERICHIA-COLI; CDNA CLONES; SGS-4 GENE; ONCOGENE; CELLS; DNA	The v-Ski avian retroviral oncogene is postulated to act as a transcription factor. Since protein-protein interactions have been shown to play an important role in the transcription process, we attempted to identify Ski protein partners with the yeast two-hybrid system, Using v-Ski sequence as bait, the human gene skip (Ski Interacting Protein) was identified as encoding a protein which interacts with both the cellular and viral forms of Ski in the two-hybrid system, Skip is highly homologous to the Drosophila melanogaster protein Bx42 which is found associated with chromatin in transcriptionally active puffs of salivary glands, The Ski-Skip interaction is potentially important in Ski's transforming activity since Skip was demonstrated to interact with a highly conserved region of Ski required for transforming activity, Like Ski, Skip is expressed in multiple tissue types and is localized to the cell nucleus.	SUNY Stony Brook, Dept Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hayman, MJ (corresponding author), SUNY Stony Brook, Dept Microbiol, Stony Brook, NY 11794 USA.			Dahl, Richard/0000-0002-6341-5604	NATIONAL CANCER INSTITUTE [R01CA042573] Funding Source: NIH RePORTER; NCI NIH HHS [CA42573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARKAS AE, 1986, VIROLOGY, V151, P131, DOI 10.1016/0042-6822(86)90111-X; BARTEL PL, 1993, CELL INTERACTIONS DE; BEUG H, 1995, ONCOGENE, V11, P59; BOGUSKI MS, 1995, TRENDS BIOCHEM SCI, V20, P295, DOI 10.1016/S0968-0004(00)89051-9; BOYER PL, 1993, ONCOGENE, V8, P457; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Colmenares C, 1990, Semin Cancer Biol, V1, P383; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; DIEHL BE, 1991, GENETICS, V127, P287; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ENGERT JC, 1995, NUCLEIC ACIDS RES, V23, P2988, DOI 10.1093/nar/23.15.2988; Folk P, 1996, GENE, V181, P229, DOI 10.1016/S0378-1119(96)00483-0; FRASCH M, 1989, CHROMOSOMA, V97, P272, DOI 10.1007/BF00371966; HARRIS SD, 1992, J MOL BIOL, V225, P53, DOI 10.1016/0022-2836(92)91025-K; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; KAUFMAN RJ, 1985, MOL CELL BIOL, V5, P1750, DOI 10.1128/MCB.5.7.1750; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LARSEN J, 1992, ONCOGENE, V7, P1903; LEHMANN M, 1995, EMBO J, V14, P716, DOI 10.1002/j.1460-2075.1995.tb07050.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; NAGASE T, 1993, J BIOL CHEM, V268, P13710; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Park CY, 1996, GENE, V177, P93, DOI 10.1016/0378-1119(96)00278-8; Romero F, 1996, MOL CELL BIOL, V16, P37; Sambrook J, 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUMWEBER H, 1990, CHROMOSOMA, V99, P52, DOI 10.1007/BF01737289; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SLEEMAN JP, 1993, ONCOGENE, V8, P67; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831	43	96	111	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1579	1586		10.1038/sj.onc.1201687	http://dx.doi.org/10.1038/sj.onc.1201687			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569025				2022-12-17	WOS:000072743200008
J	Martin, M; Vozenin, MC; Gault, N; Crechet, F; Pfarr, CM; Lefaix, JL				Martin, M; Vozenin, MC; Gault, N; Crechet, F; Pfarr, CM; Lefaix, JL			Coactivation of AP-1 activity and TGF-beta 1 gene expression in the stress response of normal skin cells to ionizing radiation	ONCOGENE			English	Article						AP-1; fos; jun; TGF-beta 1; skin; gamma-irradiation	TRANSFORMING GROWTH FACTOR-BETA-1; IMMEDIATE-EARLY GENES; C-FOS; FACTOR-BETA; PIG SKIN; FIBROBLAST GROWTH; MUSCULAR FIBROSIS; BINDING-PROTEINS; GAMMA-RAYS; JUN	Activation of the AP-1 transcription factor and TGF-beta 1 growth factor by ionizing radiation was studied both in vivo in pig skin, and in vitro in human fibroblasts and keratinocytes, Three and 6h after irradiation, the Fos and Jun proteins and their binding activity to an AP-1 consensus sequence were strongly induced by high doses of gamma-rays, c-Fos, c-Jun and JunB proteins were found to be present in gel-shift complexes by probing with specific antibodies, Both keratinocytes and fibroblasts exhibited heightened AP-1 activity following irradiation, As we previously found that TGF-beta 1 is involved in the development of skin lesions induced by radiation, TGF-beta 1 gene expression was also examined, Two and 6h after irradiation, the levels of TGF-beta 1 transcripts were increased in skin, By immunostaining, TGF-beta 1 protein levels were found to be increased in fibroblasts, keratinocytes and endothelial cells, As promoter contains AP-1 binding sites, between AP-1 activity and TGF-beta 1 induction was addressed, The -365 TGF-beta 1 promoter fragment, which contains a high affinity AP-1 site, exhibited increased binding to Jun and Fos proteins following irradiation, These results suggest that stress-inducible TGF-beta 1 expression is mediated by the activation of AP-1 transcription factor.	INST PASTEUR,UNITE VIRUS ONCOGENES,CNRS,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	Martin, M (corresponding author), CEA,LAB RADIOBIOL & ETUDE GENOME,DVS,F-91191 GIF SUR YVETTE,FRANCE.		Vozenin, Marie-Catherine/AAR-2268-2021; Martin, Michele T/C-5554-2008; Pfarr, Curt/HHD-1410-2022	Vozenin, Marie-Catherine/0000-0002-2109-8073; Martin, Michele T/0000-0003-0530-6466; Gault, Nathalie/0000-0001-6233-1946				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ASIEDU CK, 1994, BBA-GENE STRUCT EXPR, V1219, P55, DOI 10.1016/0167-4781(94)90246-1; BARCELLOSHOFF MH, 1993, CANCER RES, V53, P3880; BASSETSEGUIN N, 1994, ONCOGENE, V9, P765; COLLART FR, 1995, RADIAT RES, V142, P18; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; Fan GS, 1996, ONCOGENE, V12, P1909; FINKELSTEIN JN, 1994, INT J RADIAT ONCOL, V28, P621, DOI 10.1016/0360-3016(94)90187-2; GILLARDON F, 1995, NEUROREPORT, V6, P1766, DOI 10.1097/00001756-199509000-00014; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; GUBITS RM, 1993, INT J RADIAT ONCOL, V27, P637, DOI 10.1016/0360-3016(93)90390-H; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Hsing AY, 1996, CANCER RES, V56, P5146; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1989, J BIOL CHEM, V264, P7041; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YJ, 1995, J BIOL CHEM, V270, P28790, DOI 10.1074/jbc.270.48.28790; LEFAIX JL, 1993, BRIT J RADIOL, V66, P537, DOI 10.1259/0007-1285-66-786-537; MARTIN M, 1993, CANCER RES, V53, P3246; MARTIN M, 1993, RADIAT RES, V134, P63, DOI 10.2307/3578502; MARTIN M, 1989, J INVEST DERMATOL, V93, P497, DOI 10.1111/1523-1747.ep12284053; MASSAGUE J, 1990, CELL BIOL, V6, P597; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RANDALL K, 1995, INT J RADIAT BIOL, V68, P301, DOI 10.1080/09553009514551231; RAYNAL S, 1995, INT J ONCOL, V7, P337; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; RUBIN P, 1995, INT J RADIAT ONCOL, V33, P99, DOI 10.1016/0360-3016(95)00095-G; SAHIJDAK WM, 1994, RADIAT RES, V138, pS47, DOI 10.2307/3578760; Saltis J, 1996, MOL CELL ENDOCRINOL, V116, P227, DOI 10.1016/0303-7207(95)03721-7; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; VOZENIN MC, 1997, IN PRESS CYTOTECHNOL; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WEICHSELBAUM R, 1993, MOL BIOL ONCOLOGISTS, P213; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; Welter JF, 1995, ONCOGENE, V11, P2681; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2	42	96	101	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					981	989		10.1038/sj.onc.1201433	http://dx.doi.org/10.1038/sj.onc.1201433			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285693				2022-12-17	WOS:A1997XR76700011
J	Pim, D; Massimi, P; Banks, L				Pim, D; Massimi, P; Banks, L			Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth	ONCOGENE			English	Article						HPV; E6; p53; transformation	HUMAN PAPILLOMAVIRUS TYPE-16; FULL-LENGTH E6; MESSENGER-RNA; HUMAN KERATINOCYTES; EARLY GENES; E7; EXPRESSION; DNA; IDENTIFICATION; TRANSCRIPTION	The E6 proteins originating from the tumour-associated Human Papillomavirus (HPV) types 16 and 18 have been shown to bind to and target the tumour suppressor protein, p53, for ubiquitin-mediated degradation. However, in cell lines derived from cervical neoplasias, the predominant early region transcripts are spliced and encode truncated forms of E6, termed E6*. We report here that HPV-18 E6* protein will interact both with the full-length E6 proteins from HPV-16 and HPV-18 and also with E6-AP, and subsequently blocks the association of full length E6 protein with p53. We also show that, as a result of this block, E6* can inhibit E6-mediated degradation of p53 both in vitro and in vivo. The biological consequences of this are increased transcriptional activity on p53-responsive promoters and an inhibition of cell growth in cells transfected with E6*. This is the first report of a potential biological function for this polypeptide and may represent a means by which HPV is able to modulate the activity of the full-length E6 protein with respect to p53 during viral infection.			Pim, D (corresponding author), INT CTR GENET ENGN & BIOTECHNOL,PADRICIANO 99,I-34012 TRIESTE,ITALY.							ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BOHM S, 1993, INT J CANCER, V55, P791, DOI 10.1002/ijc.2910550517; BUTZ K, 1995, ONCOGENE, V10, P927; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; CHOW LT, 1987, J VIROL, V61, P2581, DOI 10.1128/JVI.61.8.2581-2588.1987; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOORBAR J, 1990, VIROLOGY, V178, P254, DOI 10.1016/0042-6822(90)90401-C; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Grassmann K, 1996, J VIROL, V70, P2339, DOI 10.1128/JVI.70.4.2339-2349.1996; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Massimi P, 1996, ONCOGENE, V12, P2325; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MUNGER K, 1989, J VIROL, V63, P4417; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIM D, 1994, ONCOGENE, V9, P1869; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHNEIDERGADICKE A, 1988, CANCER RES, V48, P2969; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; Shally M, 1996, VIRUS RES, V42, P81, DOI 10.1016/0168-1702(96)01301-9; SHIRASAWA H, 1994, VIROLOGY, V203, P36, DOI 10.1006/viro.1994.1452; SMOTKIN D, 1989, J VIROL, V63, P1441, DOI 10.1128/JVI.63.3.1441-1447.1989; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STACEY SN, 1995, J VIROL, V69, P7023, DOI 10.1128/JVI.69.11.7023-7031.1995; STOREY A, 1995, J GEN VIROL, V76, P819, DOI 10.1099/0022-1317-76-4-819; THOMAS M, 1995, ONCOGENE, V10, P261; Thomas M, 1996, ONCOGENE, V13, P265; Thomas M, 1996, ONCOGENE, V13, P471; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; ZURHAUSEN H, 1987, PAPOVAVIRIDAE PAPILL, P245	44	96	101	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					257	264		10.1038/sj.onc.1201202	http://dx.doi.org/10.1038/sj.onc.1201202			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233760				2022-12-17	WOS:A1997XK99900002
J	Wienecke, R; Maize, JC; Shoarinejad, F; Vass, WC; Reed, J; Bonifacino, JS; Resau, JH; deGunzburg, J; Yeung, RS; DeClue, JE				Wienecke, R; Maize, JC; Shoarinejad, F; Vass, WC; Reed, J; Bonifacino, JS; Resau, JH; deGunzburg, J; Yeung, RS; DeClue, JE			Co-localization of the TSC2 product tuberin with its target Rap1 in the golgi apparatus	ONCOGENE			English	Article						tuberous sclerosis; tuberin; localization Rap1; Golgi apparatus	EKER RAT MODEL; DOMINANTLY INHERITED CANCER; SCLEROSIS TSC2; CYTOPLASMIC DOMAIN; HUMAN NEUTROPHILS; PLASMA-MEMBRANE; MANNOSIDASE-II; GENE-PRODUCT; PROTEINS; COMPLEX	Tuberin is the protein product of the tuberous sclerosis-2 (TSC2) gene, which is associated with tuberous sclerosis (TSC), a human genetic syndrome characterized by the development of tumors in a variety of tissues, We have previously shown that tuberin is a widely expressed 180 kDa protein which exhibits specific GTPase activating activity in vitro towards the Ras-related Rap1 study we have used affinity-purified antibodies against tuberin to analyse its expression in human and rat tissues and to examine its subcellular localization, Tuberin expression was detected in all adult human tissues tested, with the highest levels found in brain, heart and kidney, organs that are commonly affected in TSC patients, By contrast, in adult rats the highest levels of tuberin were found in brain, liver and testis, Indirect immunofluorescence of tuberin in various cultured cell lines revealed a punctate, mostly perinuclear staining pattern, Double-indirect immunofluorescence analysis sera and anti-tuberin sera and antisera against known Golgi markers (mannosidase-II and furin) revealed that the staining of tuberin was consistent with its localization in the stacks of the Golgi apparatus, In support of this, treatment of cells with brefeldin A, a drug known to cause disassembly of the Golgi apparatus: abolished the perinuclear staining of tuberin, Moreover, conventional and confocal immunofluorescence demonstrated co-localization of tuberin with Rap1, which has previously been localized to the Golgi apparatus, The colocalization of tuberin and Rap1 in vivo strengthens the likelihood that the in vitro catalytic activity of tuberin toward Rap1 plays a physiologically relevant role in the tumor suppressor function of tuberin.	NCI, CELLULAR ONCOL LAB, BETHESDA, MD 20892 USA; FOX CHASE CANC CTR, DIV MED SCI, PHILADELPHIA, PA 19111 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, DEPT DERMATOPATHOL, NEW YORK, NY 10021 USA; NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA; NCI, FREDERICK CANC RES & DEV CTR, ADV BIOSCI LABS, BASIS RES PROGRAM, FREDERICK, MD 21702 USA; INST CURIE, SECT RECH, F-74231 PARIS 05, FRANCE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fox Chase Cancer Center; Cornell University; NewYork-Presbyterian Hospital; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie				Bonifacino, Juan S./0000-0002-5673-6370				BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; Carbonara C, 1996, GENE CHROMOSOME CANC, V15, P18, DOI 10.1002/(SICI)1098-2264(199601)15:1<18::AID-GCC3>3.0.CO;2-7; COHEN BD, 1993, J VIROL, V67, P5303, DOI 10.1128/JVI.67.9.5303-5311.1993; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GEIST RT, 1995, CELL GROWTH DIFFER, V6, P1477; Givol I, 1995, ONCOGENE, V11, P2609; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; Gomez MR, 1988, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HENSKE EP, 1995, GENE CHROMOSOME CANC, V13, P295, DOI 10.1002/gcc.2870130411; HINO O, 1995, MOL CARCINOGEN, V14, P23, DOI 10.1002/mc.2940140106; JANSSEN B, 1994, HUM GENET, V94, P437, DOI 10.1007/BF00201608; JIN F, 1996, IN PRESS P NATL ACAD; KAMEYAMA Y, 1994, LIFE SCI, V55, P213, DOI 10.1016/0024-3205(94)00882-5; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOBAYASHI T, 1995, NUCLEIC ACIDS RES, V23, P2608, DOI 10.1093/nar/23.14.2608; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; KUMAR A, 1995, HUM MOL GENET, V4, P1471, DOI 10.1093/hmg/4.8.1471; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MOLLINEDO F, 1993, FEBS LETT, V326, P209, DOI 10.1016/0014-5793(93)81792-X; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NELLIST M, 1993, CELL, V75, P1305; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NOVIKOFF PM, 1983, P NATL ACAD SCI-BIOL, V80, P4364, DOI 10.1073/pnas.80.14.4364; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1994, J CELL SCI, V107, P1661; QUARCK R, 1994, FEBS LETT, V342, P159, DOI 10.1016/0014-5793(94)80492-3; Tsuchiya H, 1996, CANCER RES, V56, P429; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; Wilson PJ, 1996, HUM MOL GENET, V5, P249, DOI 10.1093/hmg/5.2.249; XIAO GH, 1995, ONCOGENE, V11, P81; XIAO GH, 1995, CELL GROWTH DIFFER, V6, P1185; XU L, 1995, GENOMICS, V27, P475, DOI 10.1006/geno.1995.1079; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; YEUNG RS, 1995, MOL CARCINOGEN, V14, P28, DOI 10.1002/mc.2940140107; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	49	96	96	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	1996	13	5					913	923						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806680				2022-12-17	WOS:A1996VG76600004
J	Distelhorst, CW; Lam, M; McCormick, TS				Distelhorst, CW; Lam, M; McCormick, TS			Bcl-2 inhibits hydrogen peroxide-induced ER Ca2+ pool depletion	ONCOGENE			English	Article						Bcl-2; oxygen radical; apoptosis; programmed cell death; calcium; thapsigargin	PROGRAMMED CELL-DEATH; INTRACELLULAR CALCIUM HOMEOSTASIS; C-FOS; ENDOPLASMIC-RETICULUM; MEMBRANE PROTEIN; CIS-FOS; EXPRESSION; TRANSLOCATION; APOPTOSIS; DNA	The mechanism by which Bcl-2 inhibits apoptosis is unknown, The Bcl-2 protein is localized to intracellular membranes, including the endoplasmic reticulum (ER), The ER is the major intracellular reservoir of Ca2+ in non-muscle cells, sequestering Ca2+ for use in intracellular signaling, and is a prime target of oxidative damage, Because of the recent suggestion that Bcl-2 acts in an antioxidant pathway, we wondered whether Bcl-2 might protect the ER Ca2+ pool in cells exposed to reactive oxygen species. To test this hypothesis, we assessed the effect of hydrogen peroxide (H2O2) treatment on the ER Ca2+ pool in WEH17.2 cells, which do not express Bcl-2, and two stable transfectants, W.Hb13 and W.Hb12, The Bcl-2 level by Western blotting is 4-fold higher in W.Hb12 cells compared to W.Hb13 cells, The ER Ca2+ pool in H2O2-treated and untreated cells was measured according to the amount of Ca2+ mobilized from the ER lumen into the cytoplasm by thapsigargin (TG), a selective inhibitor of the ER Ca2+-ATPase, H2O2 treatment produced a significant reduction in the TG-mobilizable Ca2+ pool in WEH17.2 and W.Hb13 cells, but not in W.Hb12 cells, indicating that overexpression of Bcl-2 preserves the integrity of the ER Ca2+ pool in cells exposed to reactive oxygen species.	CASE WESTERN RESERVE UNIV, DEPT PHARMACOL, CLEVELAND, OH 44106 USA	Case Western Reserve University	Distelhorst, CW (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT MED, BRB329, 10900 EUCLID AVE, CLEVELAND, OH 44106 USA.			McCormick, Thomas/0000-0002-3294-0326	NCI NIH HHS [T32 CA59366, R01 CA42755-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042755, T32CA059366] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; CRAWFORD D, 1988, ONCOGENE, V3, P27; DUBYAK GR, 1986, ARCH BIOCHEM BIOPHYS, V245, P84, DOI 10.1016/0003-9861(86)90192-X; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; JONES DP, 1983, J BIOL CHEM, V258, P6390; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LODISH HF, 1992, J BIOL CHEM, V267, P12753; MIYASHITA T, 1992, CANCER RES, V52, P5407; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MUSCHEL RJ, 1995, CANCER RES, V55, P995; ORRENIUS S, 1992, ANN NEUROL, V32, pS33, DOI 10.1002/ana.410320708; REED DJ, 1990, CHEM RES TOXICOL, V3, P495, DOI 10.1021/tx00018a002; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SHIBANUMA M, 1988, ONCOGENE, V3, P17; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WERLEN G, 1993, J BIOL CHEM, V268, P16596; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	44	96	101	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	1996	12	10					2051	2055						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668330				2022-12-17	WOS:A1996UP28300003
J	Holland, EA; Beaton, SC; Becker, TM; Grulet, OMC; Peters, BA; Rizos, H; Kefford, RF; Mann, GJ				Holland, EA; Beaton, SC; Becker, TM; Grulet, OMC; Peters, BA; Rizos, H; Kefford, RF; Mann, GJ			Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds	ONCOGENE			English	Article						p16; CDKN2; familial melanoma; mutation linkage; cyclin dependent kinase inhibitor	FAMILIAL MELANOMA; LINKAGE ANALYSIS; LOCUS	CDKN2 has been implicated as a melanoma susceptibility gene in some kindreds with a family history of this disease, Mutation analysis of CDKN2 in 17 familial melanoma Australian kindreds revealed a paucity of exon mutations and none of the previously described disease-related mutations, One novel germline mutation was found in exon one, Arg24Pro, which segregates with melanoma in 1/17 kindreds, Two previously described polymorphisms, A1a148Thr and a base change at nucleotide 540 were detected and one novel polymorphism in the untranslated region of exon 3 (nucleotide 580) was also found, Together with other recent reports, these findings provide support for CDKN2 as a susceptibility locus for familial melanoma but suggest that other loci are involved in some hereditary melanoma kindreds.			Holland, EA (corresponding author), UNIV SYDNEY,WESTMEAD HOSP,DEPT MED ONCOL,WESTMEAD,NSW 2145,AUSTRALIA.		; Mann, Graham/G-4758-2014	Kefford, Richard/0000-0001-9251-9229; Becker, Therese/0000-0002-5636-9902; Rizos, Helen/0000-0002-2094-9198; Mann, Graham/0000-0003-1301-405X				CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CANNONALBRIGHT LA, 1994, GENOMICS, V23, P265, DOI 10.1006/geno.1994.1491; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GRUIS NA, 1995, AM J PATHOL, V146, P1199; GRUIS NA, 1993, MELANOMA RES, V3, P271; HOLLAND EA, 1994, ONCOGENE, V9, P1361; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KEFFORD RF, 1991, CANCER GENET CYTOGEN, V51, P45, DOI 10.1016/0165-4608(91)90007-H; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MACGEOCH C, 1994, HUM MOL GENET, V3, P2195, DOI 10.1093/hmg/3.12.2195; MAMELKA PM, 1993, PEDIGREE DRAW VERSIO; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Ott J., 1991, ANAL HUMAN GENETIC L; PETTY EM, 1993, AM J HUM GENET, V53, P96; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; Sambrook J., 1989, MOL CLONING LAB MANU; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; WALKER GJ, 1994, ONCOGENE, V9, P819; WALKER GJ, 1995, 7TH LORN CANC C LORN; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563; XU L, 1994, CANCER RES, V54, P5262	34	96	97	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2289	2294						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570179				2022-12-17	WOS:A1995TK70200012
J	HSU, B; MARIN, MC; ELNAGGAR, AK; STEPHENS, LC; BRISBAY, S; MCDONNELL, TJ				HSU, B; MARIN, MC; ELNAGGAR, AK; STEPHENS, LC; BRISBAY, S; MCDONNELL, TJ			EVIDENCE THAT C-MYC MEDIATED APOPTOSIS DOES NOT REQUIRE WILD-TYPE P53 DURING LYMPHOMAGENESIS	ONCOGENE			English	Article						APOPTOSIS; ONCOGENE; C-MYC; P53; LYMPHOMA	CELL-CYCLE ARREST; BURKITT-LYMPHOMA; PROTEIN; GENE; DEATH; MICE; FIBROBLASTS; EXPRESSION; INDUCTION; LINE	Deregulation of c-myc, frequently implicated in oncogenesis, is associated with increased cell proliferation and also cell death. Similarly, the p53 tumor suppressor gene commonly mutated in human tumors, is known to induce apoptosis or cell cycle arrest in its wild-type conformation. Genetically altered mice simultaneously overexpressing c-myc and possessing a disrupted p53 gene were used to investigate whether c-myc mediated apoptosis requires wild-type p53, The accelerated development of malignant lymphomas in these mice was found to be a consequence of enhanced proliferation and not reduced apoptosis resulting from the synergistic effect of c-myc overexpression and p53 inactivation.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT VET MED & SURG,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Marín Vieira, María del Carmen/B-8108-2015; Marin, Maria C/G-1040-2010	Marín Vieira, María del Carmen/0000-0002-7149-287X; Marin, Maria C/0000-0002-7149-287X	NCI NIH HHS [CA09255, CA16672, CA62597] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062597, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1991, ONCOGENE, V6, P1915; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELDIERY WS, 1994, CANCER RES, V54, P1169; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P4279; KASTAN MB, 1991, CANCER RES, V53, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MARIN MC, 1995, EXP CELL RES, V217, P240, DOI 10.1006/excr.1995.1083; MCDONNELL TJ, 1993, MOL CARCINOGEN, V8, P209, DOI 10.1002/mc.2940080402; MILNER AE, 1993, ONCOGENE, V8, P3385; OCONNOR PM, 1993, CANCER RES, V53, P4776; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; WAFIK S, 1994, CANCER RES, V54, P1169; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WATERS CM, 1991, ONCOGENE, V6, P797; XIONG Y, 1993, NATURE, V336, P701; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	32	96	100	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					175	179						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624125				2022-12-17	WOS:A1995RJ29500020
J	RODRIGUES, GA; PARK, M				RODRIGUES, GA; PARK, M			AUTOPHOSPHORYLATION MODULATES THE KINASE-ACTIVITY AND ONCOGENIC POTENTIAL OF THE MET RECEPTOR TYROSINE KINASE	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; ATP-BINDING-SITE; FUJINAMI SARCOMA-VIRUS; INSULIN-RECEPTOR; BETA-SUBUNIT; PROTEIN-KINASE; EGF-RECEPTOR; PHOSPHORYLATION SITE; SIGNAL TRANSDUCTION	The met oncogene is activated by a genomic rearrangement that generates a hybrid protein containing tpr sequences at its amino terminus fused directly to the met (hepatocyte growth factor/scatter factor) receptor tyrosine kinase domain. The resultant p65(Tpr-Met) hybrid protein possesses tyrosine kinase activity and is constitutively phosphorylated on tyrosine in vivo. A substitution of the conserved lysine in the catalytic domain abolished kinase activity and the transforming potential of Tpr-Met demonstrating the requirement for kinase activity for transformation. To study the role of autophosphorylation at particular tyrosine residues on the transforming activity of Tpr-Met, the major autophosphorylation sites were identified by two dimensional phosphopeptide mapping. Two tyrosine residues in the catalytic domain, tyrosine 365 and tyrosine 366, were found to be the major autophosphorylation sites both in vitro and in vivo. Mutation of these sites singly or together modulates the biochemical and biological properties of Tpr-Met. Compared with the wild-type Tpr-Met, mutants have a reduced in vitro kinase activity when measured by levels of autophosphorylation and by their ability to phosphorylate an exogenous substrate and have little or no transforming activity. These results indicate that autophosphorylation at critical tyrosine residues is required for activation of the kinase activity of Tpr-Met and for cell transformation by this oncogene.	MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT ONCOL, MOLEC ONCOL GRP, MONTREAL H3A 1A1, PQ, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT MED, MONTREAL H3A 1A1, PQ, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT BIOCHEM, MONTREAL H3A 1A1, PQ, CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital								ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DICKENS M, 1992, BIOCHEM BIOPH RES CO, V186, P244, DOI 10.1016/S0006-291X(05)80799-5; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Kriegler M., 1990, GENE TRANSFER EXPRES; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MECKLINGHANSEN K, 1987, EMBO J, V6, P659, DOI 10.1002/j.1460-2075.1987.tb04805.x; MITRA G, 1991, ONCOGENE, V6, P2237; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RODRIGUES GA, 1993, HEPATOCYTE GROWTH FA, P167; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONSIN C, 1993, ONCOGENE, V8, P1195; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI N, 1985, J BIOL CHEM, V260, P9793; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; YU KT, 1984, J BIOL CHEM, V259, P5277; YU KT, 1986, J BIOL CHEM, V261, P1341; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZHO H, 1994, CELL GROWTH DIFFER, V5, P1	64	96	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					2019	2027						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208547				2022-12-17	WOS:A1994NR68500026
J	ZAKUT, R; PERLIS, R; ELIYAHU, S; YARDEN, Y; GIVOL, D; LYMAN, SD; HALABAN, R				ZAKUT, R; PERLIS, R; ELIYAHU, S; YARDEN, Y; GIVOL, D; LYMAN, SD; HALABAN, R			KIT-LIGAND (MAST-CELL GROWTH-FACTOR) INHIBITS THE GROWTH OF KIT-EXPRESSING MELANOMA-CELLS	ONCOGENE			English	Article							FACTOR RECEPTOR PROTOONCOGENE; TYROSINE KINASE RECEPTOR; ACTIVATED PROTEIN-KINASE; CYTOMETRIC DNA ANALYSIS; W-MUTANT MICE; C-KIT; SI-LOCUS; SIGNAL TRANSDUCTION; FUNCTION MUTATIONS; HUMAN MELANOCYTES	Previous studies in vivo and in vitro show that KIT kinase promotes normal melanocyte development and growth. However, the role of the KIT proto-oncogene in neoplastic melanocytes is not certain. We therefore examined KIT expression and function in human melanomas. Our results show that KIT mRNA was expressed in 12 of 28 melanoma cell lines (approximately 40%), mainly in those originating from pigmented tumors. Surprisingly, activation of KIT with mast cell growth factor (MGF) in melanoma cells produced biological responses opposite to those elicited in normal melanocytes. MGF inhibited rather than stimulated the growth of metastatic melanoma cell lines. The opposite effects may be due to aberrant signal transduction by KIT in melanoma cells in response to MGF. The in vitro inhibition of melanoma cells by MGF suggests that growth in vivo of this tumor is not promoted by KIT kinase activation, but rather that transformed melanocytes might regress when MGF is expressed in their immediate environment.	IMMUNEX RES & DEV CORP,SEATTLE,WA 98103; YALE UNIV,SCH MED,DEPT DERMATOL,NEW HAVEN,CT 06510; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Yale University; Weizmann Institute of Science	ZAKUT, R (corresponding author), NCI,SURG BRANCH,BETHESDA,MD 20892, USA.		YARDEN, YOSEF/K-1467-2012		NATIONAL CANCER INSTITUTE [R29CA044542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039848] Funding Source: NIH RePORTER; NCI NIH HHS [5-R29-CA44542] Funding Source: Medline; NIAMS NIH HHS [1RO1-AR39848] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CARROW CE, 1991, BLOOD, V78, P2216; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; Coppock D L, 1991, Cancer Treat Res, V54, P67; Cowan J M, 1991, Cancer Treat Res, V54, P3; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FLEISCHMAN RA, 1992, J CLIN INVEST, V89, P1713, DOI 10.1172/JCI115772; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P10885, DOI 10.1073/pnas.88.23.10885; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; HALABAN R, 1992, ONCOGENE, V7, P2195; HALABAN R, 1991, Critical Reviews in Oncogenesis, V2, P247; HALABAN R, 1991, ANN NY ACAD SCI, V638, P232, DOI 10.1111/j.1749-6632.1991.tb49034.x; HENDRIE PC, 1991, EXP HEMATOL, V19, P1031; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; Kock A, 1991, Cancer Treat Res, V54, P41; Kriegler M., 1990, GENE TRANSFER EXPRES; LASSAM N, 1992, ONCOGENE, V7, P51; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MCNIECE IK, 1991, J IMMUNOL, V146, P3785; MIGLIACCIO G, 1991, P NATL ACAD SCI USA, V88, P7420, DOI 10.1073/pnas.88.16.7420; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; NATALI PG, 1992, INT J CANCER, V52, P197, DOI 10.1002/ijc.2910520207; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; QUI F, 1988, EMBO J, V7, P1003; RATAJCZAK M, 1991, CLIN RES, V39, pA190; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P1710, DOI 10.1073/pnas.89.5.1710; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Sambrook J., 1989, MOL CLONING LAB MANU; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SPRITZ RA, 1992, AM J HUM GENET, V50, P261; SZEBO KM, 1990, CELL, V63, P195; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; VINDELOV LL, 1983, CYTOMETRY, V3, P328, DOI 10.1002/cyto.990030504; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WELHAM MJ, 1991, MOL CELL BIOL, V11, P2901, DOI 10.1128/MCB.11.5.2901; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1987, EMBO J, V6, P3342; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	58	96	97	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2221	2229						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	7687762				2022-12-17	WOS:A1993LP17100023
J	FAZIOLI, F; WONG, WT; ULLRICH, SJ; SAKAGUCHI, K; APPELLA, E; DIFIORE, PP				FAZIOLI, F; WONG, WT; ULLRICH, SJ; SAKAGUCHI, K; APPELLA, E; DIFIORE, PP			THE EZRIN-LIKE FAMILY OF TYROSINE KINASE SUBSTRATES - RECEPTOR-SPECIFIC PATTERN OF TYROSINE PHOSPHORYLATION AND RELATIONSHIP TO MALIGNANT TRANSFORMATION	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; ROUS-SARCOMA VIRUS; GTPASE-ACTIVATING PROTEIN; SIGNAL TRANSDUCTION; CDNA CLONING; MONOCLONAL-ANTIBODIES; MEMBRANE SKELETON; CELLULAR PROTEINS	A method for the isolation of tyrosine kinases substrates was developed. The method takes advantage of immunoaffinity purification of an entire set of proteins phosphorylated by tyrosine kinases, followed by generation of antisera against the purified protein pool and immunological screening of bacterial expression libraries with these antisera. By applying this methodology to the study of the phosphorylation events triggered by activation of the epidermal growth factor receptors, we have isolated several cDNAs encoding novel putative tyrosine kinase substrates. One of these cDNAs encodes radixin, a protein belonging to the band 4.1 family of proteins and highly related to ezrin and moesin. We demonstrated that, despite a high degree of relatedness, these three proteins exhibit a distinct receptor-specific pattern of phosphorylation, raising the possibility that they might mediate receptor-specific cellular changes. In addition the generation of antibodies specific for either radixin, ezrin or moesin allowed us to show that a previously described tumor transplantation antigen is indeed ezrin, thus implicating this protein in the determination of the biological phenotype of certain tumors.	NCI, MOLEC & CELLULAR BIOL LAB, BLDG 37, ROOM 1D23, BETHESDA, MD 20892 USA; NCI, CELL BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950; Sakaguchi, Kazuyasu/0000-0002-8434-4171				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; BASSIRI RM, 1972, ENDOCRINOLOGY, V90, P722, DOI 10.1210/endo-90-3-722; BENNETT V, 1989, BIOCHIM BIOPHYS ACTA, V988, P107, DOI 10.1016/0304-4157(89)90006-3; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; BRETSCHER A, 1986, METHOD ENZYMOL, V134, P24; BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; COOPER JA, 1983, J VIROL, V48, P752, DOI 10.1128/JVI.48.3.752-764.1983; COOPER JA, 1982, CELL, V31, P263, DOI 10.1016/0092-8674(82)90426-3; CORREAS I, 1986, J BIOL CHEM, V261, P3362; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DUBOIS GC, 1982, P NATL ACAD SCI-BIOL, V79, P7669, DOI 10.1073/pnas.79.24.7669; DUBOIS GC, 1980, CANCER RES, V40, P4204; EGERTON M, 1992, J IMMUNOL, V149, P1847; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GLENNEY JR, 1991, METHOD ENZYMOL, V201, P92; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KELLIE S, 1988, BIOESSAYS, V8, P25, DOI 10.1002/bies.950080107; KRIEG J, 1992, J BIOL CHEM, V267, P19258; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LANKES W, 1988, BIOCHEM J, V251, P831, DOI 10.1042/bj2510831; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LETO TL, 1986, MEMBRANE SKELETONS C, P201; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Luna EJ, 1991, CURR OPIN CELL BIOL, V3, P120, DOI 10.1016/0955-0674(91)90174-W; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAMBROOK J, 1989, MOL BIOL LABORATORY; SATO N, 1991, J CELL BIOL, V113, P321, DOI 10.1083/jcb.113.2.321; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TURUNEN O, 1989, J BIOL CHEM, V264, P16727; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH SJ, 1986, MOL IMMUNOL, V23, P545, DOI 10.1016/0161-5890(86)90118-5; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	67	96	103	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1335	1345						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479753				2022-12-17	WOS:A1993KY32800027
J	BALENTIEN, E; MUFSON, BE; SHATTUCK, RL; DERYNCK, R; RICHMOND, A				BALENTIEN, E; MUFSON, BE; SHATTUCK, RL; DERYNCK, R; RICHMOND, A			EFFECTS OF MGSA GRO-ALPHA ON MELANOCYTE TRANSFORMATION	ONCOGENE			English	Article							SIMIAN SARCOMA-VIRUS; STIMULATORY ACTIVITY; CELL-LINES; MONOCLONAL-ANTIBODY; MURINE MELANOCYTES; MALIGNANT-MELANOMA; TUMOR PROGRESSION; AUTOCRINE GROWTH; TRANSGENIC MICE; FACTOR CDNA	In the work described here we demonstrate that the clonal cell line Mel-a-6, produced by transfection of mouse Melan-a cells with human MGSA, had an increased ability to form large colonies in soft agar and increased ability to form tumors when injected into nude mice as compared to cells transfected with the neomycin resistance gene alone. This effect appeared to be dependent on the levels of MGSA produced since another transfected clone, Mel-a-l, produced only a low level of MGSA transgene mRNA, formed only minimal large colonies in soft agar and had a tumorigenic rate equal to that of neomycin resistant controls. The histology of the Mel-a-6 tumors is compatible with features normally exhibited by melanoma tumors. The cells do not stain for melanin, and they are positive for the neural crest marker protein S-100 as well as the HMB 45 melanoma specific antigen. Immunohistochemical studies revealed expression of the human MGSA in tumor cells from tissues, excised from animals injected with cells from clone Mel-a-6. Whereas DNA ploidy analysis suggests that in vitro the Mel-a parent cell line, control Mel-a-neo, Mel-a-1 and Mel-a-6 cells show no evidence of aneuploidy, the nuclei isolated from the tumors from animals injected with Mel-a-6 do exhibit aneuploidy. These data suggest that over-expression of MGSA in immortalized melanocytes contributes to transformation.	VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37240; DEPT VET AFFAIRS,NASHVILLE,TN; GENENTECH INC,DEPT DEV BIOL,S SAN FRANCISCO,CA; EMORY UNIV,DEPT PATHOL,ATLANTA,GA 30322; EMORY UNIV,DEPT MED,ATLANTA,GA 30322; VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37240	Vanderbilt University; Roche Holding; Genentech; Emory University; Emory University; Vanderbilt University	RICHMOND, A (corresponding author), VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37240, USA.		Richmond, Ann/A-3048-2014	RICHMOND, ANN/0000-0002-9580-900X				ALBINO AP, 1981, J EXP MED, V154, P1764, DOI 10.1084/jem.154.6.1764; ANZANO MA, 1985, MOL CELL BIOL, V5, P242, DOI 10.1128/MCB.5.1.242; BAKER N, 1990, NUCLEIC ACIDS RES, V18, P21; BALENTIEN F, 1990, BIOCHEM, V29, P10225; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BORDONI R, 1990, J CELL BIOCHEM, V44, P207, DOI 10.1002/jcb.240440403; BOWENPOPE DF, 1984, P NATL ACAD SCI-BIOL, V81, P2396, DOI 10.1073/pnas.81.8.2396; CHENEVIXTRENCH G, 1990, ONCOGENE, V5, P1187; DERYNCK R, 1987, CANCER RES, V47, P707; DICKER P, 1981, EXP CELL RES, V135, P221, DOI 10.1016/0014-4827(81)90314-1; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; ERISMAN MD, 1982, P NATL ACAD SCI-BIOL, V79, P2379, DOI 10.1073/pnas.79.7.2379; FINZI E, 1990, J INVEST DERMATOL, V95, P382, DOI 10.1111/1523-1747.ep12555464; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; GATTUSO P, 1990, SURGERY, V108, P702; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GIANGASPERO F, 1987, CANCER, V60, P59, DOI 10.1002/1097-0142(19870701)60:1<59::AID-CNCR2820600111>3.0.CO;2-4; GOWN AM, 1986, AM J PATHOL, V123, P195; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; HERLYN M, 1987, LAB INVEST, V56, P461; HUANG JS, 1984, CELL, V39, P79, DOI 10.1016/0092-8674(84)90193-4; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JOHNSSON A, 1985, NATURE, V317, P438, DOI 10.1038/317438a0; KHEIR S M, 1988, Annals of Surgery, V207, P455, DOI 10.1097/00000658-198804000-00014; LAWSON DH, 1987, J CELL BIOCHEM, V34, P169, DOI 10.1002/jcb.240340304; LINDGREN V, 1989, P NATL ACAD SCI USA, V86, P5025, DOI 10.1073/pnas.86.13.5025; MANIATIS T, 1987, MOL CLONING; Masson P, 1928, AM J PATHOL, V4, P181; MOODY TW, 1981, SCIENCE, V214, P1246, DOI 10.1126/science.6272398; MOSCATELLI D, 1986, J CELL PHYSIOL, V129, P273, DOI 10.1002/jcp.1041290220; NAKAJIMA T, 1982, CANCER, V50, P912, DOI 10.1002/1097-0142(19820901)50:5<912::AID-CNCR2820500519>3.0.CO;2-U; NAKANISHI Y, 1988, EXP CELL BIOL, V56, P74; ORDONEZ NG, 1988, AM J CLIN PATHOL, V90, P385, DOI 10.1093/ajcp/90.4.385; RICHMOND A, 1988, J CELL BIOCHEM, V36, P185, DOI 10.1002/jcb.240360209; RICHMOND A, 1986, J INVEST DERMATOL, V86, P295, DOI 10.1111/1523-1747.ep12285452; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; RICHMOND A, 1985, CANCER RES, V45, P6390; RICHMOND A, 1982, COLD SPRING HARBOR C, V9, P885; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SCHRODER JM, 1990, J EXP MED, V171, P1091, DOI 10.1084/jem.171.4.1091; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SIPPOLATHIELE M, 1989, MOL CELL BIOL, V9, P925, DOI 10.1128/MCB.9.3.925; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; TODARO GJ, 1977, NATURE, V267, P526, DOI 10.1038/267526a0; WESTERMARK B, 1986, P NATL ACAD SCI USA, V83, P7197, DOI 10.1073/pnas.83.19.7197; WILSON RE, 1989, CANCER RES, V49, P711	47	96	100	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1115	1124						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861861				2022-12-17	WOS:A1991GV26000004
J	STORK, P; LODA, M; BOSARI, S; WILEY, B; POPPENHUSEN, K; WOLFE, H				STORK, P; LODA, M; BOSARI, S; WILEY, B; POPPENHUSEN, K; WOLFE, H			DETECTION OF K-RAS MUTATIONS IN PANCREATIC AND HEPATIC NEOPLASMS BY NONISOTOPIC MISMATCHED POLYMERASE CHAIN-REACTION	ONCOGENE			English	Article							HUMAN-COLON; ENZYMATIC AMPLIFICATION; POINT MUTATIONS; TRANSGENIC MICE; GENE-MUTATIONS; ONCOGENES; DNA; ACTIVATION; TUMORIGENESIS; CARCINOMAS	Mutations within codon 12 leading to activation of Kirsten-ras (K-ras) genes occur in a wide variety of human tumors, but have been reported most frequently in pancreatic carcinomas. We studied twenty-four paraffin-embedded pancreatic and hepatic tumors and two colon carcinoma cell lines with a rapid and simple approach that exploits allele-specific amplification of genomic DNA in a polymerase chain reaction (PCR). We extend the utility of this technique, which is dependent on an exact match at the 3' nucleotide between synthetic oligonucleotides and template DNA, to analyse paraffin-embedded tumor samples for the presence of point mutations at the first and second base of codon 12 of the K-ras gene. The PCR mismatch amplification technique demonstrated a 66% incidence of K-ras mutations at codon 12 in the group of pancreatic neoplasms as a whole. The percentage of mutations varied only slightly in the pancreatic cancer subcategories: 75% in ampullary, 66% in bile duct and 57% in the ductal adenocarcinomas. One islet cell carcinoma and normal tissues adjacent to the tumors revealed wild-type alleles only. One hepatoblastoma and one of six hepatocellular carcinomas also had codon 12 mutations. The PCR mismatch is a sensitive and rapid method that may be useful in screening neoplasms for K-ras point mutation and can be applied to archival material. This application allows a retrospective analyses of a wide range of pathological specimens to determine the role of K-ras mutations in human tumorigenesis.	NEW ENGLAND MED CTR HOSP, DEPT PATHOL, 171 HARRISON AVE, BOSTON, MA 02111 USA	Tufts Medical Center	WOLFE, H (corresponding author), NEW ENGLAND MED CTR HOSP, DEPT PATHOL, 171 HARRISON AVE, BOSTON, MA 02111 USA.		Bosari, Silvano/K-7744-2016	Bosari, Silvano/0000-0002-9744-6951				ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CHEHAB FF, 1989, P NATL ACAD SCI USA, V86, P9178, DOI 10.1073/pnas.86.23.9178; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; EHLEN T, 1989, BIOCHEM BIOPH RES CO, V160, P441, DOI 10.1016/0006-291X(89)92452-2; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GRUNEWALD K, 1989, INT J CANCER, V43, P1037, DOI 10.1002/ijc.2910430614; GU JR, 1986, J CELL PHYSIOL, P13; JIANG W, 1989, ONCOGENE, V4, P923; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; OKAYAMA H, 1989, J LAB CLIN MED, V114, P105; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RODENHUIS S, 1988, CANCER RES, V48, P5738; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; TADA M, 1990, CANCER RES, V50, P1121; WATATANI M, 1989, CANCER RES, V49, P1103; WU DY, 1989, P NATL ACAD SCI USA, V86, P2757, DOI 10.1073/pnas.86.8.2757	28	96	103	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1991	6	5					857	862						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1646989				2022-12-17	WOS:A1991GT82500023
J	KOUZARIDES, T; PACKHAM, G; COOK, A; FARRELL, PJ				KOUZARIDES, T; PACKHAM, G; COOK, A; FARRELL, PJ			THE BZLF1 PROTEIN OF EBV HAS A COILED COIL DIMERIZATION DOMAIN WITHOUT A HEPTAD LEUCINE REPEAT BUT WITH HOMOLOGY TO THE C/EBP LEUCINE ZIPPER	ONCOGENE			English	Article							DNA-BINDING SPECIFICITY; LIVER NUCLEAR-PROTEIN; EPSTEIN-BARR VIRUSES; FOS-JUN INTERACTION; SWITCH GENE BZLF1; DIMERIZATION SPECIFICITY; ZTA TRANSACTIVATOR; MESSENGER-RNAS; EARLY PROMOTER; C-FOS	The EBV transactivator protein BZLF1 can bind many sites in EBV genome, most of which have homology to a consensus AP-1 site, the binding site for the fos/jun family of transcription factors. Here we present evidence that BZLF1 can also recognise the binding site for the CCAAT/enhancer binding protein C/EBP and that a BZLF1 binding site within the BZLF1 promoter is recognised by the C/EBP protein. Analysis of the BZLF1 DNA binding domain suggests that the BZLF1 protein binds to DNA as a dimer using sequences adjacent to a basic DNA binding motif. The BZLF1 dimerisation domain does not have a hepatad repeat of leucine residues common to leucine zipper proteins but does not have characteristics of a coiled coil structure, as judged by site directed mutagenesis. We therefore propose that the dimerisation domain of BZLF1 is structurally related to the coiled coil structure of leucine zippers but lacks the highly conserved leucine repeat. We show that the PZLF1 dimerisation domain has residues in common with the C/EBP leucine zipper and discuss the possible implications of this relationship.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research	KOUZARIDES, T (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT PATHOL,DIV VIROL,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND.			Kouzarides, Tony/0000-0002-8918-4162; Farrell, Paul/0000-0002-6754-9351				AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BENBROOK DM, 1990, ONCOGENE, V5, P295; BIGGIN M, 1987, J VIROL, V61, P3120, DOI 10.1128/JVI.61.10.3120-3132.1987; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; CHAVRIER P, 1989, J VIROL, V63, P607, DOI 10.1128/JVI.63.2.607-614.1989; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; COHEN DR, 1990, ONCOGENE, V5, P929; COUNTRYMAN J, 1987, J VIROL, V61, P3672, DOI 10.1128/JVI.61.12.3672-3679.1987; COUNTRYMAN J, 1985, P NATL ACAD SCI USA, V82, P4085, DOI 10.1073/pnas.82.12.4085; COX MA, 1990, J VIROL, V64, P313, DOI 10.1128/JVI.64.1.313-321.1990; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FLEMINGTON E, 1990, J VIROL, V64, P1217, DOI 10.1128/JVI.64.3.1217-1226.1990; FLEMINGTON E, 1990, J VIROL, V64, P1227, DOI 10.1128/JVI.64.3.1227-1232.1990; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KENNEY S, 1989, J VIROL, V63, P1729, DOI 10.1128/JVI.63.4.1729-1736.1989; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIEBERMAN PM, 1990, J VIROL, V64, P1143, DOI 10.1128/JVI.64.3.1143-1155.1990; LIEBERMAN PM, 1989, J VIROL, V63, P3040, DOI 10.1128/JVI.63.7.3040-3050.1989; LIEBERMAN PM, 1990, J VIROL, V64, P2560, DOI 10.1128/JVI.64.6.2560-2568.1990; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MANET E, 1989, EMBO J, V8, P1819, DOI 10.1002/j.1460-2075.1989.tb03576.x; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; PACKHAM G, 1990, J VIROL, V64, P2110, DOI 10.1128/JVI.64.5.2110-2116.1990; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROONEY CM, 1989, J VIROL, V63, P3109, DOI 10.1128/JVI.63.7.3109-3116.1989; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SELLERS JW, 1989, NATURE, V341, P74, DOI 10.1038/341074a0; TAKADA K, 1989, J VIROL, V63, P445, DOI 10.1128/JVI.63.1.445-449.1989; TAYLOR N, 1989, J VIROL, V63, P1721, DOI 10.1128/JVI.63.4.1721-1728.1989; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; URIER G, 1989, EMBO J, V8, P1447, DOI 10.1002/j.1460-2075.1989.tb03527.x; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088	47	96	98	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					195	204						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1847997				2022-12-17	WOS:A1991FZ13400003
J	COHN, SL; SALWEN, H; QUASNEY, MW; IKEGAKI, N; COWAN, JM; HERST, CV; KENNETT, RH; ROSEN, ST; DIGIUSEPPE, JA; BRODEUR, GM				COHN, SL; SALWEN, H; QUASNEY, MW; IKEGAKI, N; COWAN, JM; HERST, CV; KENNETT, RH; ROSEN, ST; DIGIUSEPPE, JA; BRODEUR, GM			PROLONGED N-MYC PROTEIN HALF-LIFE IN A NEUROBLASTOMA CELL-LINE LACKING N-MYC AMPLIFICATION	ONCOGENE			English	Article							HUMAN NEURO-BLASTOMA; ONCOGENE EXPRESSION; TUMORS; GENE; DNA; IDENTIFICATION; CHROMOSOME-1; DEFINITION	Genomic amplification of the oncogene N-myc is associated with rapid tumor progression and poor prognosis in patients with neuroblastoma (NB). However, 40% of NBs which lack N-myc amplification are also clinically aggressive. Factors other than N-myc copy number must therefore play a role in determining tumor progression in these NBs. We have established an unusual human NB cell line (NBL-S) from the primary tumor of a patient with rapidly progressive disease which lacks N-myc amplification. The doubling time in vitro (48 h) and the time from injection of 2 x 10(7) cells to detectable tumors in nude mice (46 days) is similar to NB cell lines with amplified N-myc. However, karyotype analysis reveals no evidence of double minutes (DMs), homogeneously staining regions (HSRs), or chromosome 1p deletions, features commonly seen in NB cell lines. The cells have the cell surface phenotype typical of N-myc amplified NB (HLA-A,B,C negative and HSAN 1.2 positive), and similar to other NB cell lines, N-myc RNA and protein are expressed. Interestingly, the half-life of the N-myc protein in NBL-S is prolonged (approximately 100 min) compared to the short N-myc protein half-life previously described in N-myc amplified NB cell lines (approximately 30 min). Because N-myc protein is thought to have a regulatory role, prolongation of the half-life of this protein may be an important factor in the regulation of growth in NBs which lack N-myc amplification and rapidly progress.	NORTHWESTERN UNIV,MED CTR,DEPT PEDIAT,CHICAGO,IL 60614; NORTHWESTERN UNIV,MED CTR,DEPT MED,CHICAGO,IL 60614; UNIV PENN,SCH MED,DEPT HUMAN GENET,PHILADELPHIA,PA 19104; UNIV CHICAGO,MED CTR,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60637; ONCORE ANALYT,HOUSTON,TX 77008; WASHINGTON UNIV,MED CTR,DEPT PEDIAT,ST LOUIS,MO 63110	Northwestern University; Northwestern University; University of Pennsylvania; University of Chicago; University of Chicago Medical Center; Washington University (WUSTL)			Cohn, Susan/AAB-6010-2021; DiGiuseppe, Joseph/AAD-1935-2019	Cohn, Susan/0000-0001-5749-7650	NATIONAL CANCER INSTITUTE [R01CA039771, K04CA001027] Funding Source: NIH RePORTER; NCI NIH HHS [CA-01027, CA-39771] Funding Source: Medline; NCRR NIH HHS [RR-05730] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BARTRAM CR, 1987, EUR J PEDIATR, V146, P162, DOI 10.1007/BF02343225; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Brodeur G M, 1988, Prog Clin Biol Res, V271, P3; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1981, CANCER RES, V41, P4678; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIECHANOVER A, 1990, IN PRESS P NATL ACAD; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLLINS SJ, 1987, BLOOD, V70, P1233; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FRANCKE U, 1978, HUM GENET, V45, P137, DOI 10.1007/BF00286957; GILBERT F, 1984, CANCER RES, V44, P5444; GRADYLEOPARDI EF, 1986, CANCER RES, V46, P3196; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; MAKELA TP, 1989, MOL CELL BIOL, V9, P1545; MANIATIS T., 1982, MOL CLONING LABORATO, P382; MICHITSCH RW, 1984, MOL CELL BIOL, V4, P2370, DOI 10.1128/MCB.4.11.2370; NISEN PD, 1988, J NATL CANCER I, V80, P1633, DOI 10.1093/jnci/80.20.1633; PARHAM P, 1979, J IMMUNOL, V123, P342; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; Reynolds C P, 1988, Prog Clin Biol Res, V271, P291; ROSS RA, 1983, J NATL CANCER I, V71, P741; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; Seeger R C, 1988, Prog Clin Biol Res, V271, P41; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SLAMON DJ, 1986, SCIENCE, V232, P768, DOI 10.1126/science.3008339; SLAVC I, 1990, CANCER RES, V50, P1459; SMITH RG, 1987, DIAGN CLIN IMMUNOL, V5, P209; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; VENNSTROM B, 1981, J VIROL, V39, P625; Wada R K, 1988, Prog Clin Biol Res, V271, P57; WHANGPENG J, 1986, CANCER GENET CYTOGEN, V21, P185, DOI 10.1016/0165-4608(86)90001-4; YOUNG JL, 1975, J PEDIATR-US, V86, P254, DOI 10.1016/S0022-3476(75)80484-7	43	96	96	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1990	5	12					1821	1827						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET436	2284101				2022-12-17	WOS:A1990ET43600012
J	KUMAR, R; BARBACID, M				KUMAR, R; BARBACID, M			ONCOGENE DETECTION AT THE SINGLE CELL LEVEL	ONCOGENE			English	Article											KUMAR, R (corresponding author), NCI, FREDERICK CANC RES FACIL, DEV ONCOL SECT, BASIC RES PROGRAM, FREDERICK, MD 21701 USA.				OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; DUCNGUYEN H, 1966, J BACTERIOL, V92, P1133, DOI 10.1128/JB.92.4.1133-1140.1966; ENGELKE DR, 1988, P NATL ACAD SCI USA, V85, P544, DOI 10.1073/pnas.85.2.544; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; KWOK S, 1987, J VIROL, V61, P1690, DOI 10.1128/JVI.61.5.1690-1694.1987; LEE MS, 1987, SCIENCE, V237, P175, DOI 10.1126/science.3110950; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; MCMAHON G, 1987, P NATL ACAD SCI USA, V84, P4974, DOI 10.1073/pnas.84.14.4974; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225; STOFLET ES, 1988, SCIENCE, V239, P491, DOI 10.1126/science.3340835; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	25	96	104	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1988	3	6					647	651						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R6460	2578002				2022-12-17	WOS:A1988R646000004
J	Ippolito, L; Morandi, A; Taddei, ML; Parri, M; Comito, G; Iscaro, A; Raspollini, MR; Magherini, F; Rapizzi, E; Masquelier, J; Muccioli, GG; Sonveaux, P; Chiarugi, P; Giannoni, E				Ippolito, Luigi; Morandi, Andrea; Taddei, Maria Letizia; Parri, Matteo; Comito, Giuseppina; Iscaro, Alessandra; Raspollini, Maria Rosaria; Magherini, Francesca; Rapizzi, Elena; Masquelier, Julien; Muccioli, Giulio G.; Sonveaux, Pierre; Chiarugi, Paola; Giannoni, Elisa			Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer	ONCOGENE			English	Article							TUMOR MICROENVIRONMENT; LACTATE METABOLISM; CELLS; PGC-1-ALPHA; MUSCLE; HOMEOSTASIS; SUPEROXIDE; ACTIVATION; SIRTUINS; KINASE	Cancer-associated fibroblasts (CAFs) are the major cellular stromal component of many solid tumors. In prostate cancer (PCa), CAFs establish a metabolic symbiosis with PCa cells, contributing to cancer aggressiveness through lactate shuttle. In this study, we report that lactate uptake alters the NAD(+)/NADH ratio in the cancer cells, which culminates with SIRT1-dependent PGC-1 alpha activation and subsequent enhancement of mitochondrial mass and activity. The high exploitation of mitochondria results in tricarboxylic acid cycle deregulation, accumulation of oncometabolites and in the altered expression of mitochondrial complexes, responsible for superoxide generation. Additionally, cancer cells hijack CAF-derived functional mitochondria through the formation of cellular bridges, a phenomenon that we observed in both in vitro and in vivo PCa models. Our work reveals a crucial function of tumor mitochondria as the energy sensors and transducers of CAF-dependent metabolic reprogramming and underscores the reliance of PCa cells on CAF catabolic activity and mitochondria trading.	[Ippolito, Luigi; Morandi, Andrea; Parri, Matteo; Comito, Giuseppina; Iscaro, Alessandra; Magherini, Francesca; Chiarugi, Paola; Giannoni, Elisa] Univ Florence, Dept Expt & Clin Biomed Sci, I-50134 Florence, Italy; [Taddei, Maria Letizia; Rapizzi, Elena] Univ Florence, Dept Expt & Clin Med, I-50134 Florence, Italy; [Raspollini, Maria Rosaria] Univ Hosp Careggi, Histopathol & Mol Diagnost, Largo Brambilla 3, I-50134 Florence, Italy; [Masquelier, Julien; Muccioli, Giulio G.] UCL, LDRI, Bioanal & Pharmacol Bioact Lipids Res Grp, B-1200 Brussels, Belgium; [Sonveaux, Pierre] UCL, IREC, Pole Pharmacol, B-1200 Brussels, Belgium; [Chiarugi, Paola] Tuscany Tumour Inst ITT, Florence, Italy; [Chiarugi, Paola] Excellence Ctr Res Transfer & High Educ DenoTHE, Florence, Italy	University of Florence; University of Florence; University of Florence; Azienda Ospedaliero Universitaria Careggi; Universite Catholique Louvain; Universite Catholique Louvain	Chiarugi, P; Giannoni, E (corresponding author), Univ Florence, Dept Expt & Clin Biomed Sci, I-50134 Florence, Italy.; Chiarugi, P (corresponding author), Tuscany Tumour Inst ITT, Florence, Italy.; Chiarugi, P (corresponding author), Excellence Ctr Res Transfer & High Educ DenoTHE, Florence, Italy.	paola.chiarugi@unifi.it; elisa.giannoni@unifi.it	Giannoni, Elisa/AAE-2092-2020; Morandi, Andrea/AAC-1901-2022; Chiarugi, Paola/CDD-7988-2022	Morandi, Andrea/0000-0002-9222-5332; Ippolito, Luigi/0000-0001-7927-8555; Muccioli, Giulio/0000-0002-1600-9259; Chiarugi, Paola/0000-0001-7655-2969	Fondazione Umberto Veronesi; Associazione Italiana Ricerca sul Cancro (AIRC) [8797]; AIRC; Fondazione Cassa di Risparmio di Firenze [19515]; Istituto Toscano Tumori [0203607]; Interuniversity Attraction Pole from Belspo [UP7-03]; Action de Recherche Concertee from the Communaute Francaise de Belgique [ARC 14/19-058]; Belgian Fonds National de la Recherche Scientifique (F.R.S. FNRS); Programma operativo regionale Obiettivo "Competitivita regionale e occupazione" della Regione Toscana cofinanziato dal Fondo europeo di sviluppo regionale 2007-2013 (POR CReO FESR 2007-2013)	Fondazione Umberto Veronesi(Fondazione Umberto Veronesi); Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro); Fondazione Cassa di Risparmio di Firenze(Fondazione Cassa Risparmio Firenze); Istituto Toscano Tumori; Interuniversity Attraction Pole from Belspo; Action de Recherche Concertee from the Communaute Francaise de Belgique; Belgian Fonds National de la Recherche Scientifique (F.R.S. FNRS)(Fonds de la Recherche Scientifique - FNRS); Programma operativo regionale Obiettivo "Competitivita regionale e occupazione" della Regione Toscana cofinanziato dal Fondo europeo di sviluppo regionale 2007-2013 (POR CReO FESR 2007-2013)	The work was supported by Fondazione Umberto Veronesi to AM, Associazione Italiana Ricerca sul Cancro (AIRC) (grant 8797 to PC), AIRC and Fondazione Cassa di Risparmio di Firenze (grant 19515 to PC and AM), Istituto Toscano Tumori (grant 0203607 to PC), Programma operativo regionale Obiettivo "Competitivita regionale e occupazione" della Regione Toscana cofinanziato dal Fondo europeo di sviluppo regionale 2007-2013 (POR CReO FESR 2007-2013, grant to PC), Interuniversity Attraction Pole from Belspo (grant #UP7-03 to PS), an Action de Recherche Concertee from the Communaute Francaise de Belgique (ARC 14/19-058 to PS), and the Belgian Fonds National de la Recherche Scientifique (F.R.S. FNRS, to PS). The authors thank: Dr Paolo E. Porporato (University of Turin, Italy) for providing mitochondria-targeted plasmids mt-HA-eGFP, AT-F001-D and mtDsRed, AT-F002-D (Aequotech srl); Dr Andrea Rasola (University of Padua, Italy) for providing pLJM1-EGFP plasmid for lentiviral infection; Dr Barbara Stecca (Istituto Toscano Tumori, Florence, Italy) for providing pCMV-dR8.91 packaging plasmid and pMD2G envelope plasmid; Dr. Nicla Lorito and Dr. Lavinia Ferrone for technical support. PS is a F.R.S.-FNRS Senior Research Associate. The MASSMET platform (https://www.uclouvain.be/en-massmet.html) is acknowledged for the access to the HLPC-MS.	Andrzejewski S, 2017, CELL METAB, V26, P778, DOI 10.1016/j.cmet.2017.09.006; Aspuria PJP, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-21; Benton CR, 2008, PHYSIOL GENOMICS, V35, P45, DOI 10.1152/physiolgenomics.90217.2008; Brauer HA, 2013, CLIN CANCER RES, V19, P571, DOI 10.1158/1078-0432.CCR-12-2123; Caicedo A, 2015, SCI REP-UK, V5, DOI 10.1038/srep09073; Cannito S, 2010, ANTIOXID REDOX SIGN, V12, P1383, DOI 10.1089/ars.2009.2737; Chandel NS, 2015, CELL METAB, V22, P204, DOI 10.1016/j.cmet.2015.05.013; Chen EI, 2007, CANCER RES, V67, P1472, DOI 10.1158/0008-5472.CAN-06-3137; Chen YJ, 2016, NAT CHEM BIOL, V12, P937, DOI [10.1038/NCHEMBIO.2172, 10.1038/nchembio.2172]; Dikalova AE, 2010, CIRC RES, V107, P106, DOI 10.1161/CIRCRESAHA.109.214601; Dong LF, 2017, ELIFE, V6, DOI 10.7554/eLife.22187; Faubert B, 2017, CELL, V171, P358, DOI 10.1016/j.cell.2017.09.019; Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949; Frezza C, 2007, NAT PROTOC, V2, P287, DOI 10.1038/nprot.2006.478; Gambini J, 2011, ARCH BIOCHEM BIOPHYS, V512, P24, DOI 10.1016/j.abb.2011.04.020; Giannoni E, 2005, MOL CELL BIOL, V25, P6391, DOI 10.1128/MCB.25.15.6391-6403.2005; Giannoni E, 2009, ONCOGENE, V28, P2074, DOI 10.1038/onc.2009.77; Giannoni E, 2015, ONCOTARGET, V6, P24061, DOI 10.18632/oncotarget.4448; Giannoni E, 2011, ANTIOXID REDOX SIGN, V14, P2361, DOI 10.1089/ars.2010.3727; Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008-5472.CAN-10-0785; Guarente L, 2013, GENE DEV, V27, P2072, DOI 10.1101/gad.227439.113; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Ippolito L, 2016, ONCOTARGET, V7, P61890, DOI 10.18632/oncotarget.11301; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Kong XX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011707; Le Gal K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad3740; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; Lou E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033093; MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06; Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3515, DOI 10.4161/cc.9.17.12928; Morandi A, 2016, TRENDS CANCER, V2, P736, DOI 10.1016/j.trecan.2016.11.001; Nazarewicz RR, 2013, ANTIOXID REDOX SIGN, V19, P344, DOI 10.1089/ars.2013.5185; Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200; Pasquier J, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-94; Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238; Pittelli M, 2011, MOL PHARMACOL, V80, P1136, DOI 10.1124/mol.111.073916; Porporato PE, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.968043; Porporato PE, 2014, CELL REP, V8, P754, DOI 10.1016/j.celrep.2014.06.043; Rabinovitch RC, 2017, CELL REP, V21, P1, DOI 10.1016/j.celrep.2017.09.026; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rogers RS, 2013, PHYSIOLOGY, V28, P414, DOI 10.1152/physiol.00032.2013; Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133; Salem AF, 2012, CELL CYCLE, V11, P2545, DOI 10.4161/cc.20920; Santi A, 2015, BBA-MOL CELL RES, V1853, P3211, DOI 10.1016/j.bbamcr.2015.09.013; Sciacovelli M, 2016, NATURE, V537, P544, DOI 10.1038/nature19353; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Spees JL, 2006, P NATL ACAD SCI USA, V103, P1283, DOI 10.1073/pnas.0510511103; Summermatter S, 2013, P NATL ACAD SCI USA, V110, P8738, DOI 10.1073/pnas.1212976110; Tan AS, 2015, CELL METAB, V21, P81, DOI 10.1016/j.cmet.2014.12.003; Torrano V, 2016, NAT CELL BIOL, V18, P645, DOI 10.1038/ncb3357; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Weinberg F, 2009, ANN NY ACAD SCI, V1177, P66, DOI 10.1111/j.1749-6632.2009.05039.x	53	95	97	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5339	5355		10.1038/s41388-019-0805-7	http://dx.doi.org/10.1038/s41388-019-0805-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30936458	Green Submitted			2022-12-17	WOS:000473842500001
J	Yochum, ZA; Cades, J; Wang, HL; Chatterjee, S; Simons, BW; O'Brien, JP; Khetarpal, SK; Lemtiri-Chlieh, G; Myers, KV; Huang, EHB; Rudin, CM; Tran, PT; Burns, TF				Yochum, Zachary A.; Cades, Jessica; Wang, Hailun; Chatterjee, Suman; Simons, Brian W.; O'Brien, James P.; Khetarpal, Susheel K.; Lemtiri-Chlieh, Ghali; Myers, Kayla V.; Huang, Eric H. -B.; Rudin, Charles M.; Tran, Phuoc T.; Burns, Timothy F.			Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer	ONCOGENE			English	Article							BIM DELETION POLYMORPHISM; ACQUIRED-RESISTANCE; MESENCHYMAL TRANSITION; CONFERS RESISTANCE; AZD9291; OSIMERTINIB; ACTIVATION; EXPRESSION; SENSITIVITY; MECHANISMS	Patients with EGFR-mutant non-small-cell lung cancer (NSCLC) have significantly benefited from the use of EGFR tyrosine kinase inhibitors (TKIs). However, long-term efficacy of these therapies is limited due to de novo resistance (similar to 30%) as well as acquired resistance. Epithelial-mesenchymal transition transcription factors (EMT-TFs), have been identified as drivers of EMTmediated resistance to EGFR TKIs, however, strategies to target EMT-TFs are lacking. As the third generation EGFR TKI, osimertinib, has now been adopted in the first-line setting, the frequency of T790M mutations will significantly decrease in the acquired resistance setting. Previously less common mechanisms of acquired resistance to first generation EGFR TKIs including EMT are now being observed at an increased frequency after osimertinib. Importantly, there are no other FDA approved targeted therapies after progression on osimertinib. Here, we investigated a novel strategy to overcome EGFR TKI resistance through targeting the EMT-TF, TWIST1, in EGFR-mutant NSCLC. We demonstrated that genetic silencing of TWIST1 or treatment with the TWIST1 inhibitor, harmine, resulted in growth inhibition and apoptosis in EGFR-mutant NSCLC. TWIST1 overexpression resulted in erlotinib and osimertinib resistance in EGFR-mutant NSCLC cells. Conversely, genetic and pharmacological inhibition of TWIST1 in EGFR TKI-resistant EGFR-mutant cells increased sensitivity to EGFR TKIs. TWIST1-mediated EGFR TKI resistance was due in part to TWIST1 suppression of transcription of the pro-apoptotic BH3-only gene, BCL2L11 (BIM), by directly binding to BCL2L11 intronic regions and promoter. As such, pan-BCL2 inhibitor treatment overcame TWIST1mediated EGFR TKI resistance and were more effective in the setting of TWIST1 overexpression. Finally, in a mouse model of autochthonous EGFR-mutant lung cancer, Twist1 overexpression resulted in erlotinib resistance and suppression of erlotinibinduced apoptosis. These studies establish TWIST1 as a driver of resistance to EGFR TKIs and provide rationale for use of TWIST1 inhibitors or BCL2 inhibitors as means to overcome EMT-mediated resistance to EGFR TKIs.	[Yochum, Zachary A.; Burns, Timothy F.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA; [Yochum, Zachary A.; Chatterjee, Suman; O'Brien, James P.; Khetarpal, Susheel K.; Myers, Kayla V.; Huang, Eric H. -B.; Burns, Timothy F.] UPMC Hillman Canc Ctr, Div Hematol Oncol, Dept Med, Pittsburgh, PA 15232 USA; [Cades, Jessica] Johns Hopkins Univ, Sch Med, Dept Pharmacol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; [Wang, Hailun; Lemtiri-Chlieh, Ghali; Tran, Phuoc T.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA; [Cades, Jessica; Tran, Phuoc T.] Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; [Rudin, Charles M.] Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, 1275 York Ave, New York, NY 10021 USA; [Simons, Brian W.; Tran, Phuoc T.] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21205 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Memorial Sloan Kettering Cancer Center; Johns Hopkins University	Burns, TF (corresponding author), Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA.; Burns, TF (corresponding author), UPMC Hillman Canc Ctr, Div Hematol Oncol, Dept Med, Pittsburgh, PA 15232 USA.; Tran, PT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA.; Tran, PT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA.; Tran, PT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21205 USA.	tranp@jhmi.edu; burnstf@upmc.edu	Tran, Phuoc/W-2084-2019; Wang, Hailun/T-5696-2019; Rudin, Charles/R-2530-2019; Simons, Brian/G-7352-2015	Tran, Phuoc/0000-0002-0147-0376; Rudin, Charles/0000-0001-5204-3465; Myers, Kayla/0000-0002-0748-1092; Simons, Brian/0000-0003-0644-211X; Wang, Hailun/0000-0001-8651-2856	Uniting Against Lung Cancer Foundation; V Foundation Scholar Award; American Lung Association Award [LCD 257864]; Sidney Kimmel Foundation [SKF-15-099, SKF-13-021]; Doris Duke Charitable Foundation Clinical Scientist Award [2015097]; Pittsburgh LUNG SPORE CDA [P50CA090440]; We Wish Foundation; Howard Hughes Medical Institute Medical Fellowship [T32GM008421-22, 1F30CA213765-01]; Nesbitt Family; Movember-Prostate Cancer Foundation; American Lung Association [LCD-339465]; Commonwealth Foundation; ACS [122688-RSG-12-196-01-TBG]; DoD [W81XWH-13-1-0182]; NIH/NCI [R01CA166348];  [P30CA047904]; NATIONAL CANCER INSTITUTE [F30CA213765, U01CA212007, R01CA166348, P30CA008748, P30CA047904, P50CA090440] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008424] Funding Source: NIH RePORTER	Uniting Against Lung Cancer Foundation; V Foundation Scholar Award; American Lung Association Award; Sidney Kimmel Foundation; Doris Duke Charitable Foundation Clinical Scientist Award(Doris Duke Charitable Foundation (DDCF)); Pittsburgh LUNG SPORE CDA; We Wish Foundation; Howard Hughes Medical Institute Medical Fellowship; Nesbitt Family; Movember-Prostate Cancer Foundation; American Lung Association; Commonwealth Foundation; ACS(American Cancer Society); DoD(United States Department of Defense); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the following funding sources: HW has received research funding from the Uniting Against Lung Cancer Foundation. TFB was supported for this project from a V Foundation Scholar Award, American Lung Association Award (LCD 257864), Sidney Kimmel Foundation (SKF-15-099) and a Doris Duke Charitable Foundation Clinical Scientist Award (2015097), a Pittsburgh LUNG SPORE CDA P50CA090440 and generous support from the We Wish Foundation. This project used the Hillman Cancer Center Animal, Flow Cytometry and Biostatistics Facilities that are supported in part by award P30CA047904. ZAY has received research funding for this project from the Howard Hughes Medical Institute Medical Fellowship, T32GM008421-22 and a 1F30CA213765-01. PTT has received research funding for this project from the Nesbitt Family; Movember-Prostate Cancer Foundation; Uniting Against Lung Cancer Foundation; American Lung Association (LCD-339465); Commonwealth Foundation; Sidney Kimmel Foundation (SKF-13-021); ACS (122688-RSG-12-196-01-TBG); DoD (W81XWH-13-1-0182); NIH/NCI (R01CA166348). We Laura Stabile, PhD, James G. Herman, MD, and Frank P. Vendetti PhD at the University of Pittsburgh for the discussion, advice regarding experimental design and supply of reagents when applicable. In addition, we would like to acknowledge the helpful discussion and comments provided by the Burns, Rudin, and Tran laboratory members.	Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Burns TF, 2013, MOL CANCER RES, V11, P329, DOI 10.1158/1541-7786.MCR-12-0456; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Chang AT, 2015, GENE DEV, V29, P603, DOI 10.1101/gad.242842.114; Chang TH, 2011, AM J RESP CRIT CARE, V183, P1071, DOI 10.1164/rccm.201009-1440OC; Chen YT, 2007, GENESIS, V45, P588, DOI 10.1002/dvg.20332; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315; Deng J, 2007, CANCER RES, V67, P11867, DOI 10.1158/0008-5472.CAN-07-1961; Eberlein CA, 2015, CANCER RES, V75, P2489, DOI 10.1158/0008-5472.CAN-14-3167; Faber AC, 2011, CANCER DISCOV, V1, P352, DOI 10.1158/2159-8290.CD-11-0106; Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8; Hwang W, 2017, CANCER RES, V77, P3013, DOI 10.1158/0008-5472.CAN-16-3168; Izumchenko E, 2014, CANCER RES, V74, P3995, DOI 10.1158/0008-5472.CAN-14-0110; Jacqueroud L, 2016, NEOPLASIA, V18, P317, DOI 10.1016/j.neo.2016.03.007; Jakobsen KR, 2016, TRANSL LUNG CANCER R, V5, P172, DOI 10.21037/tlcr.2016.04.07; Jin HO, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.63; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim TM, 2015, J THORAC ONCOL, V10, P1736, DOI 10.1097/JTO.0000000000000688; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Li L, 2017, ONCOTARGET, V8, P18609, DOI 10.18632/oncotarget.14506; McGowan Marc, 2017, Genes Cancer, V8, P497, DOI 10.18632/genesandcancer.136; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Moloudizargari Milad, 2013, Pharmacogn Rev, V7, P199, DOI 10.4103/0973-7847.120524; Ohashi K, 2012, P NATL ACAD SCI USA, V109, pE2127, DOI 10.1073/pnas.1203530109; Ou SHI, 2016, LUNG CANCER, V98, P59, DOI 10.1016/j.lungcan.2016.05.015; Pan DN, 2009, CELL, V137, P73, DOI 10.1016/j.cell.2009.01.051; Pham CG, 2007, MOL CELL BIOL, V27, P3920, DOI 10.1128/MCB.01219-06; Planchard D, 2015, ANN ONCOL, V26, P2073, DOI 10.1093/annonc/mdv319; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; Ramalingam SS, 2018, J CLIN ONCOL, V36, P841, DOI 10.1200/JCO.2017.74.7576; Ricordel Charles, 2017, J Thorac Oncol, V12, pe184, DOI 10.1016/j.jtho.2017.07.019; Roberts CM, 2016, SCI REP-UK, V6, DOI 10.1038/srep37652; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Rosell R, 2011, CLIN CANCER RES, V17, P1160, DOI 10.1158/1078-0432.CCR-10-2158; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shi PY, 2017, CLIN CANCER RES, V23, P6567, DOI 10.1158/1078-0432.CCR-17-1574; Sionov RV, 2015, ONCOTARGET, V6, P23058, DOI 10.18632/oncotarget.5492; Soh SX, 2017, ONCOTARGET, V8, P41474, DOI 10.18632/oncotarget.17102; Song KA, 2018, CLIN CANCER RES, V24, P197, DOI 10.1158/1078-0432.CCR-17-1577; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Sos ML, 2009, CANCER RES, V69, P3256, DOI 10.1158/0008-5472.CAN-08-4055; Suda K, 2011, J THORAC ONCOL, V6, P1152, DOI 10.1097/JTO.0b013e318216ee52; Tanimoto A, 2017, CLIN CANCER RES, V23, P3139, DOI 10.1158/1078-0432.CCR-16-2271; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tran PT, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002650; Tran PT, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002018; Vazquez-Martin A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02560; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yochum ZA, 2017, MOL CANCER RES, V15, P1764, DOI 10.1158/1541-7786.MCR-17-0298; Yochum ZA, 2016, J THORAC DIS, V8, pE1528, DOI 10.21037/jtd.2016.11.59; Yoshida T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147344; Zhang T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12231; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330; Zheng H, 2014, ONCOGENE, V33, P1755, DOI 10.1038/onc.2013.128; Zhuo WL, 2008, BIOCHEM BIOPH RES CO, V369, P1098, DOI 10.1016/j.bbrc.2008.02.143	60	95	99	2	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					656	670		10.1038/s41388-018-0482-y	http://dx.doi.org/10.1038/s41388-018-0482-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30171258	Green Accepted			2022-12-17	WOS:000457300300004
J	Qiao, Y; Zhang, C; Li, A; Wang, D; Luo, Z; Ping, Y; Zhou, B; Liu, S; Li, H; Yue, D; Zhang, Z; Chen, X; Shen, Z; Lian, J; Li, Y; Wang, S; Li, F; Huang, L; Wang, L; Zhang, B; Yu, J; Qin, Z; Zhang, Y				Qiao, Y.; Zhang, C.; Li, A.; Wang, D.; Luo, Z.; Ping, Y.; Zhou, B.; Liu, S.; Li, H.; Yue, D.; Zhang, Z.; Chen, X.; Shen, Z.; Lian, J.; Li, Y.; Wang, S.; Li, F.; Huang, L.; Wang, L.; Zhang, B.; Yu, J.; Qin, Z.; Zhang, Y.			IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma	ONCOGENE			English	Article							BREAST-CANCER; CHEMOKINE RECEPTOR; DRUG-RESISTANCE; MYELOMA CELLS; TUMOR-GROWTH; IN-VIVO; MICROENVIRONMENT; METASTASIS; EXPRESSION; SURVIVAL	Various factors and cellular components in the tumor microenvironment are key drivers associated with drug resistance in many cancers. Here, we analyzed the factors and molecular mechanisms involved in chemoresistance in patients with esophageal squamous cell carcinoma (ESCC). We found that interleukin 6 (IL6) derived mainly from cancer-associated fibroblasts played the most important role in chemoresistance by upregulating C-X-C motif chemokine receptor 7 (CXCR7) expression through signal transducer and activator of transcription 3/nuclear factor-kappa B pathway. CXCR7 knockdown resulted in the inhibition of IL6-induced proliferation and chemoresistance. In addition, CXCR7 silencing significantly decreased gene expression associated with stemness, chemoresistance and epithelial-mesenchymal transition and suppressed the proliferation ability of ESCC cells in three-dimensional culture systems and angiogenesis assay. In clinical samples, ESCC patients with high expression of CXCR7 and IL6 presented a significantly worse overall survival and progression-free survival upon receiving cisplatin after operation. These results suggest that the IL6-CXCR7 axis may provide a promising target for the treatment of ESCC.	[Qiao, Y.; Zhang, C.; Li, A.; Wang, D.; Luo, Z.; Ping, Y.; Zhou, B.; Liu, S.; Li, H.; Yue, D.; Zhang, Z.; Chen, X.; Shen, Z.; Lian, J.; Li, Y.; Wang, S.; Li, F.; Huang, L.; Zhang, Y.] Zhengzhou Univ, Affiliated Hosp 1, Biotherapy Ctr, Zhengzhou 450052, Henan, Peoples R China; [Qiao, Y.; Zhang, C.; Li, A.; Wang, D.; Luo, Z.; Yue, D.; Chen, X.; Shen, Z.; Wang, S.; Wang, L.; Zhang, Y.] Zhengzhou Univ, Affiliated Hosp 1, Canc Ctr, Zhengzhou, Henan, Peoples R China; [Zhou, B.; Liu, S.; Lian, J.; Li, Y.; Zhang, Y.] Zhengzhou Univ, Sch Life Sci, Zhengzhou, Henan, Peoples R China; [Zhang, B.] Northwestern Univ, Sch Med, Dept Hematol Oncol, Chicago, IL USA; [Yu, J.] Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH USA; [Qin, Z.] Zhengzhou Univ, Affiliated Hosp 1, Med Res Ctr, Zhengzhou, Henan, Peoples R China; [Zhang, Y.] Key Lab Tumor Immunol & Biotherapy Henan Prov, Zhengzhou, Henan, Peoples R China	Zhengzhou University; Zhengzhou University; Zhengzhou University; Northwestern University; University System of Ohio; University of Cincinnati; Zhengzhou University	Zhang, Y (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Biotherapy Ctr, Zhengzhou 450052, Henan, Peoples R China.	yizhang@zzu.edu.cn		Zhang, Yi/0000-0001-9861-4681	National Natural Science Foundation of China [81171986]; Research Grant from the Ministry of Public Health [201501004]; Basic and Advanced Technology Research Foundation from Science and Technology Department of Henan Province [112300410153, 122300410155]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Grant from the Ministry of Public Health; Basic and Advanced Technology Research Foundation from Science and Technology Department of Henan Province	This study was supported by grants from the National Natural Science Foundation of China (Grant No. 81171986), Research Grant from the Ministry of Public Health (Grant No. 201501004) and the Basic and Advanced Technology Research Foundation from Science and Technology Department of Henan Province (Grant Nos. 112300410153 and 122300410155).	Alas S, 2001, CLIN CANCER RES, V7, P709; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Balkwill FR, 2012, J PATHOL, V226, P148, DOI 10.1002/path.3029; Bid HK, 2013, CLIN CANCER RES, V19, P6716, DOI 10.1158/1078-0432.CCR-13-0842; Calinescu AA, 2017, CLIN CANCER RES, V23, P1250, DOI 10.1158/1078-0432.CCR-15-2888; Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje; Demeester SR, 2005, GUT, V54, P440; Duda DG, 2011, CLIN CANCER RES, V17, P2074, DOI 10.1158/1078-0432.CCR-10-2636; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Gil M, 2013, P NATL ACAD SCI USA, V110, pE1291, DOI 10.1073/pnas.1220580110; Goto M, 2017, ANN SURG ONCOL, V24, P832, DOI 10.1245/s10434-015-4974-5; Hartmann TN, 2005, ONCOGENE, V24, P4462, DOI 10.1038/sj.onc.1208621; Hattermann K, 2010, CANCER RES, V70, P3299, DOI 10.1158/0008-5472.CAN-09-3642; Heinecke JL, 2014, P NATL ACAD SCI USA, V111, P6323, DOI 10.1073/pnas.1401799111; Hinton CV, 2010, CLIN EXP METASTAS, V27, P97, DOI 10.1007/s10585-008-9210-2; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Jin Z, 2009, INT J CANCER, V125, P2229, DOI 10.1002/ijc.24612; Kerdivel G, 2013, BIOCHEM BIOPH RES CO, V431, P729, DOI 10.1016/j.bbrc.2013.01.050; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Korkaya H, 2011, CLIN CANCER RES, V17, P6125, DOI 10.1158/1078-0432.CCR-10-2743; Lin L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.392; Lippitz BE, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1093722; Liu FY, 2011, ONCOL REP, V25, P383, DOI 10.3892/or.2010.1090; Liu JQ, 2011, CLIN CANCER RES, V17, P3638, DOI 10.1158/1078-0432.CCR-10-2456; McMillin DW, 2013, NAT REV DRUG DISCOV, V12, P217, DOI 10.1038/nrd3870; Miao Z, 2007, P NATL ACAD SCI USA, V104, P15735, DOI 10.1073/pnas.0610444104; Morin PJ, 2003, DRUG RESIST UPDATE, V6, P169, DOI 10.1016/S1368-7646(03)00059-1; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Park YH, 2009, CLIN CANCER RES, V15, P2107, DOI 10.1158/1078-0432.CCR-08-1588; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Schweigert M, 2013, NAT REV GASTRO HEPAT, V10, P230, DOI 10.1038/nrgastro.2012.236; Shi WJ, 2016, WORLD J GASTRO ONCOL, V8, P673, DOI 10.4251/wjgo.v8.i9.673; Sierro F, 2007, P NATL ACAD SCI USA, V104, P14759, DOI 10.1073/pnas.0702229104; Smith MR, 1998, BRIT J HAEMATOL, V102, P1090, DOI 10.1046/j.1365-2141.1998.00850.x; Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x; Tachezy M, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-238; Tarnowski M, 2010, EUR J HAEMATOL, V85, P472, DOI 10.1111/j.1600-0609.2010.01531.x; Tarnowski M, 2010, MOL CANCER RES, V8, P1, DOI 10.1158/1541-7786.MCR-09-0259; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Vandercappellen J, 2008, CANCER LETT, V267, P226, DOI 10.1016/j.canlet.2008.04.050; Velaei K, 2016, BREAST, V30, P92, DOI 10.1016/j.breast.2016.09.002; Villanueva M Teresa, 2012, Nat Rev Clin Oncol, V9, P490, DOI 10.1038/nrclinonc.2012.129; Wang LH, 2004, IMMUNITY, V20, P205, DOI 10.1016/S1074-7613(04)00030-5; Wilson BJ, 2014, CANCER RES, V74, P4196, DOI 10.1158/0008-5472.CAN-14-0582; Wu K, 2016, AM J TRANSL RES, V8, P3398; Wu YC, 2016, ONCOGENE, V35, P2123, DOI 10.1038/onc.2015.274; ZHANG L, 2013, J TRANSL MED, V11; Zhao S, 2014, TRANSL ONCOL, V7, P429, DOI 10.1016/j.tranon.2014.04.001	48	95	96	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					873	883		10.1038/onc.2017.387	http://dx.doi.org/10.1038/onc.2017.387			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059160				2022-12-17	WOS:000425281800005
J	Harrod, A; Fulton, J; Nguyen, VTM; Periyasamy, M; Ramos-Garcia, L; Lai, CF; Metodieva, G; de Giorgio, A; Williams, RL; Santos, DB; Gomez, PJ; Lin, ML; Metodiev, MV; Stebbing, J; Castellano, L; Magnani, L; Coombes, RC; Buluwela, L; Ali, S				Harrod, A.; Fulton, J.; Nguyen, V. T. M.; Periyasamy, M.; Ramos-Garcia, L.; Lai, C-F; Metodieva, G.; de Giorgio, A.; Williams, R. L.; Santos, D. B.; Gomez, P. J.; Lin, M-L; Metodiev, M. V.; Stebbing, J.; Castellano, L.; Magnani, L.; Coombes, R. C.; Buluwela, L.; Ali, S.			Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; LIGAND-BINDING DOMAIN; ER-ALPHA; ENDOCRINE RESISTANCE; POSTMENOPAUSAL WOMEN; GENE-EXPRESSION; RETINOIC ACID; TYROSINE 537; PHOSPHORYLATION; TRANSCRIPTION	Drugs that inhibit estrogen receptor-a (ER) activity have been highly successful in treating and reducing breast cancer progression in ER-positive disease. However, resistance to these therapies presents a major clinical problem. Recent genetic studies have shown that mutations in the ER gene are found in > 20% of tumours that progress on endocrine therapies. Remarkably, the great majority of these mutations localize to just a few amino acids within or near the critical helix 12 region of the ER hormone binding domain, where they are likely to be single allele mutations. Understanding how these mutations impact on ER function is a prerequisite for identifying methods to treat breast cancer patients featuring such mutations. Towards this end, we used CRISPR-Cas9 genome editing to make a single allele knock-in of the most commonly mutated amino acid residue, tyrosine 537, in the estrogen-responsive MCF7 breast cancer cell line. Genomic analyses using RNA-seq and ER ChIP-seq demonstrated that the Y537S mutation promotes constitutive ER activity globally, resulting in estrogen-independent growth. MCF7-Y537S cells were resistant to the antiestrogen tamoxifen and fulvestrant. Further, we show that the basal transcription factor TFIIH is constitutively recruited by ER-Y537S, resulting in ligand-independent phosphorylation of Serine 118 (Ser118) by the TFIIH kinase, cyclin-dependent kinase (CDK)7. The CDK7 inhibitor, THZ1 prevented Ser118 phosphorylation and inhibited growth of MCF7-Y537S cells. These studies confirm the functional importance of ER mutations in endocrine resistance, demonstrate the utility of knock-in mutational models for investigating alternative therapeutic approaches and highlight CDK7 inhibition as a potential therapy for endocrine-resistant breast cancer mediated by ER mutations.	[Harrod, A.; Fulton, J.; Nguyen, V. T. M.; Periyasamy, M.; Ramos-Garcia, L.; Lai, C-F; de Giorgio, A.; Williams, R. L.; Santos, D. B.; Gomez, P. J.; Lin, M-L; Stebbing, J.; Castellano, L.; Magnani, L.; Coombes, R. C.; Buluwela, L.; Ali, S.] Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England; [Metodieva, G.; Metodiev, M. V.] Univ Essex, Sch Biol Sci, Wivenhoe Pk, Colchester, Essex, England	Imperial College London; University of Essex	Buluwela, L; Ali, S (corresponding author), Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	l.buluwela@imperial.ac.uk; simak.ali@imperial.ac.uk	periyasamy, manikandan/AAB-7924-2020; Periyasamy, Manikandan/AAL-6211-2020; Castellano, Leandro/AAE-1366-2021; magnani, luca/N-1094-2015; Ali, Simak/M-6912-2018	Harrod, Alison/0000-0002-3977-2791; Nguyen, Thuy Mai Van/0000-0002-5898-0043; magnani, luca/0000-0002-7534-0785; Castellano, Leandro/0000-0002-3059-4829; Coombes, Raoul Charles/0000-0002-4811-1100; Periyasamy, Manikandan/0000-0001-7626-2531; Ali, Simak/0000-0002-1320-0816; Stebbing, Justin/0000-0002-1117-6947	Breast Cancer Now [2014MayPR234]; Cancer Research UK [C37/A18784]; Cancer Research UK Imperial Centre; Cancer Research UK [12011, 18784, 14549] Funding Source: researchfish	Breast Cancer Now; Cancer Research UK(Cancer Research UK); Cancer Research UK Imperial Centre; Cancer Research UK(Cancer Research UK)	This work was funded by grants from Breast Cancer Now (2014MayPR234) and Cancer Research UK (C37/A18784). AH is supported by a PhD studentship from the Cancer Research UK Imperial Centre. We thank M Jones and L Game, MRC CSC Genomics Facility, Imperial College London. This study is dedicated to the memory of Professor Susan Malcolm.	Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Ali S, 2011, ANNU REV MED, V62, P217, DOI 10.1146/annurev-med-052209-100305; Ali S, 2009, CANCER RES, V69, P6208, DOI 10.1158/0008-5472.CAN-09-0301; Anghel SI, 2000, J BIOL CHEM, V275, P20867, DOI 10.1074/jbc.M002098200; Arnold SF, 1997, MOL ENDOCRINOL, V11, P48, DOI 10.1210/me.11.1.48; ARNOLD SF, 1995, J BIOL CHEM, V270, P30205; Chen DS, 2002, ONCOGENE, V21, P4921, DOI 10.1038/sj.onc.1205420; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Cuzick J, 2010, LANCET ONCOL, V11, P1135, DOI 10.1016/S1470-2045(10)70257-6; Eng FCS, 1997, MOL CELL BIOL, V17, P4644, DOI 10.1128/MCB.17.8.4644; Eng FCS, 1998, J BIOL CHEM, V273, P28371, DOI 10.1074/jbc.273.43.28371; Fanning Sean W, 2016, Elife, V5, DOI 10.7554/eLife.12792; Fisher RP, 2005, J CELL SCI, V118, P5171, DOI 10.1242/jcs.02718; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Garner F, 2015, ANTI-CANCER DRUG, V26, P948, DOI 10.1097/CAD.0000000000000271; Guttery DS, 2015, CLIN CHEM, V61, P974, DOI 10.1373/clinchem.2015.238717; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Herynk MH, 2004, ENDOCR REV, V25, P869, DOI 10.1210/er.2003-0010; Hua SJ, 2009, CELL, V137, P1259, DOI 10.1016/j.cell.2009.04.043; Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483; Jeselsohn R, 2014, CLIN CANCER RES, V20, P1757, DOI 10.1158/1078-0432.CCR-13-2332; Johnston SRD, 2003, NAT REV CANCER, V3, P821, DOI 10.1038/nrc1211; Jozwik KM, 2012, NAT REV CANCER, V12, P381, DOI 10.1038/nrc3263; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Lai A, 2015, J MED CHEM, V58, P4888, DOI 10.1021/acs.jmedchem.5b00054; Lai CF, 2013, NUCLEIC ACIDS RES, V41, P10228, DOI 10.1093/nar/gkt827; Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liu YW, 2014, BIOINFORMATICS, V30, P301, DOI 10.1093/bioinformatics/btt688; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mali P, 2013, NAT METHODS, V10, P957, DOI [10.1038/NMETH.2649, 10.1038/nmeth.2649]; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; McCormack P, 2008, CLIN BREAST CANCER, V8, P347, DOI 10.3816/CBC.2008.n.040; Merenbakh-Lamin K, 2013, CANCER RES, V73, P6856, DOI 10.1158/0008-5472.CAN-13-1197; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Mohammed H, 2015, NATURE, V523, P313, DOI 10.1038/nature14583; Nguyen VTM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10044; Oesterreich S, 2013, NAT GENET, V45, P1415, DOI 10.1038/ng.2831; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Periyasamy M, 2015, CELL REP, V13, P108, DOI 10.1016/j.celrep.2015.08.066; Piccart M., 2013, ANN ONCOL, V24, P25; Pritchard KI, 2010, BREAST CANCER RES TR, V123, P453, DOI 10.1007/s10549-010-1022-9; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Ross-Innes CS, 2010, GENE DEV, V24, P171, DOI 10.1101/gad.552910; Sarwar N, 2006, ENDOCR-RELAT CANCER, V13, P851, DOI 10.1677/erc.1.01123; Schiavon G, 2015, SCI TRANSL MED; Segal CV, 2014, CLIN CANCER RES, V20, P1724, DOI 10.1158/1078-0432.CCR-14-0067; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Skliris GP, 2010, ENDOCR-RELAT CANCER, V17, P589, DOI 10.1677/ERC-10-0030; Tharun IM, 2015, ACS CHEM BIOL, V10, P475, DOI 10.1021/cb5007097; Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Valley CC, 2005, MOL CELL BIOL, V25, P5417, DOI 10.1128/MCB.25.13.5417-5428.2005; Wang PL, 2016, CLIN CANCER RES, V22, P1130, DOI 10.1158/1078-0432.CCR-15-1534; Wang S, 2013, NAT PROTOC, V8, P2502, DOI 10.1038/nprot.2013.150; Weir HM, 2016, CANCER RES, V76, P3307, DOI 10.1158/0008-5472.CAN-15-2357; Weis KE, 1996, MOL ENDOCRINOL, V10, P1388, DOI 10.1210/me.10.11.1388; White R, 1997, EMBO J, V16, P1427, DOI 10.1093/emboj/16.6.1427; Wittmann BM, 2007, CANCER RES, V67, P9549, DOI 10.1158/0008-5472.CAN-07-1590; Yudt MR, 1999, BIOCHEMISTRY-US, V38, P14146, DOI 10.1021/bi9911132; Zhang QX, 1997, CANCER RES, V57, P1244; Zhao CQ, 2003, J BIOL CHEM, V278, P27278, DOI 10.1074/jbc.M303840200	64	95	98	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2286	2296		10.1038/onc.2016.382	http://dx.doi.org/10.1038/onc.2016.382			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27748765	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000399782700009
J	Xu, Y; Qin, L; Sun, T; Wu, H; He, T; Yang, Z; Mo, Q; Liao, L; Xu, J				Xu, Y.; Qin, L.; Sun, T.; Wu, H.; He, T.; Yang, Z.; Mo, Q.; Liao, L.; Xu, J.			Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN-RECEPTOR-ALPHA; TUMOR-METASTASIS; LUMINAL SUBTYPE; ER-ALPHA; GENE; CELLS; TARGET; MICE; MORPHOGENESIS	The heterogeneous breast cancers can be classified into different subtypes according to their histopathological characteristics and molecular signatures. Foxa1 expression is linked with luminal breast cancer (LBC) with good prognosis, whereas Twist1 expression is associated with basal-like breast cancer (BLBC) with poor prognosis owing to its role in promoting epithelial-to-mesenchymal transition (EMT), invasiveness and metastasis. However, the regulatory and functional relationships between Twist1 and Foxa1 in breast cancer progression are unknown. In this study, we demonstrate that in the estrogen receptor (ERa)-positive LBC cells Twist1 silences Foxa1 expression, which has an essential role in relieving Foxa1-arrested migration, invasion and metastasis of breast cancer cells. Mechanistically, Twist1 binds to Foxa1 proximal promoter and recruits the NuRD transcriptional repressor complex to de-acetylate H3K9 and repress RNA polymerase II recruitment. Twist1 also silences Foxa1 promoter by inhibiting AP-1 recruitment. Twist1 expression in MCF7 cells silenced Foxa1 expression, which was concurrent with the induction of EMT, migration, invasion and metastasis of these cells. Importantly, restored Foxa1 expression in these cells largely inhibited Twist1-promoted migration, invasion and metastasis. Restored Foxa1 expression did not change the Twist1-induced mesenchymal cellular morphology and the expression of Twist1-regulated E-cadherin, beta-catenin, vimentin and Slug, but it partially rescued Twist1-silenced ERa and cytokeratin 8 expression and reduced Twist1-induced integrin alpha 5, integrin beta 1 and MMP9 expression. In a xenografted mouse model, restored Foxa1 also increased Twist1-repressed LBC markers and decreased Twist1-induced BLBC markers. Furthermore, Twist1 expression is negatively correlated with Foxa1 in the human breast tumors. The tumors with high Twist1 and low Foxa1 expressions are associated with poor distant metastasis-free survival. These results demonstrate that Twist1's silencing effect on Foxa1 expression is largely responsible for Twist1-induced migration, invasion and metastasis, but less responsible for Twist1-induced mesenchymal morphogenesis and expression of certain EMT markers.	[Xu, Y.; Qin, L.; Sun, T.; Wu, H.; Liao, L.; Xu, J.] Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Mol & Cell Biol, Houston, TX 77030 USA; [Xu, Y.; He, T.; Yang, Z.; Xu, J.] Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX USA; [He, T.; Yang, Z.; Xu, J.] Southwest Med Univ, Inst Canc Med, Luzhou, Peoples R China; [Mo, Q.] Southwest Med Univ, Coll Basic Med Sci, Luzhou, Peoples R China; Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Med Hematol Oncol, Houston, TX USA	Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Southwest Medical University; Southwest Medical University; Baylor College of Medicine	Xu, J (corresponding author), Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Mol & Cell Biol, Houston, TX 77030 USA.	jxu@bcm.edu	xu, yixiang/J-4297-2017	xu, yixiang/0000-0001-5793-7783; Qin, Li/0000-0003-0099-4992	National Institutes of Health (NIH) at Baylor College of Medicine [P30CA125123]; NIH [CA112403, CA193455]; Cancer Prevention and Research Institute of Texas [RP120732-P5, RP150197]; National Natural Science Foundation of China [81572619]; Sichuan Education Department research [15TD0020]; NATIONAL CANCER INSTITUTE [R01CA193455, P30CA125123, R01CA112403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK059820] Funding Source: NIH RePORTER	National Institutes of Health (NIH) at Baylor College of Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sichuan Education Department research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Yuqing Xiong for assisting with manuscript preparation and the Genetically Engineered Mouse Core (GEMC) partially supported by the National Institutes of Health (NIH) grant P30CA125123 at Baylor College of Medicine for assisting with mouse models. This study is supported by NIH grants CA112403 and CA193455 and Cancer Prevention and Research Institute of Texas grants RP120732-P5 and RP150197. This study is also partially supported by National Natural Science Foundation of China grants 81572619 and Sichuan Education Department research grant 15TD0020.	Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Badve S, 2007, CLIN CANCER RES, V13, P4415, DOI 10.1158/1078-0432.CCR-07-0122; Banerjee S, 2006, J CLIN PATHOL, V59, P729, DOI 10.1136/jcp.2005.033043; Bernardo GM, 2013, ONCOGENE, V32, P554, DOI 10.1038/onc.2012.62; Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299; Brenton JD, 2005, J CLIN ONCOL, V23, P7350, DOI 10.1200/JCO.2005.03.3845; Carroll JS, 2006, MOL ENDOCRINOL, V20, P1707, DOI 10.1210/me.2005-0334; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Chen HF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5697; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Cheng GZ, 2008, CANCER RES, V68, P957, DOI 10.1158/0008-5472.CAN-07-5067; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; Fu JJ, 2012, INT J BIOL SCI, V8, P522, DOI 10.7150/ijbs.4164; Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118; Gupta SK, 2013, ONCOGENE, V32, P141, DOI 10.1038/onc.2012.41; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108; Hsu RYC, 2011, CANCER RES, V71, P1989, DOI 10.1158/0008-5472.CAN-10-2833; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Kuang SQ, 2004, CANCER RES, V64, P1875, DOI 10.1158/0008-5472.CAN-03-3745; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lee DK, 2014, INT J BIOL SCI, V10, P1007, DOI 10.7150/ijbs.9997; Longo PA, 2013, METHOD ENZYMOL, V529, P227, DOI 10.1016/B978-0-12-418687-3.00018-5; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; McCune K, 2010, ONCOL REP, V24, P1233, DOI 10.3892/or_00000977; Mitra AK, 2011, ONCOGENE, V30, P1566, DOI 10.1038/onc.2010.532; Naderi A, 2012, NEOPLASIA, V14, P283, DOI 10.1593/neo.12294; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Qin L, 2008, MOL CELL BIOL, V28, P5937, DOI 10.1128/MCB.00579-08; Qin L, 2014, CANCER RES, V74, P3477, DOI 10.1158/0008-5472.CAN-13-2639; Qin L, 2009, CANCER RES, V69, P3819, DOI 10.1158/0008-5472.CAN-08-4389; Qin Q, 2012, CELL RES, V22, P90, DOI 10.1038/cr.2011.144; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Song Y, 2010, CANCER RES, V70, P2115, DOI 10.1158/0008-5472.CAN-09-2979; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sottnik JL, 2013, CLIN EXP METASTAS, V30, P569, DOI 10.1007/s10585-012-9561-6; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thorat MA, 2008, J CLIN PATHOL, V61, P327, DOI 10.1136/jcp.2007.052431; Tien JCY, 2014, INT J BIOL SCI, V10, P1116, DOI 10.7150/ijbs.10236; Vesuna F, 2012, ONCOGENE, V31, P3223, DOI 10.1038/onc.2011.483; Wang S, 2009, P NATL ACAD SCI USA, V106, P151, DOI 10.1073/pnas.0808703105; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Xu Y, 2013, AM J PATHOL, V183, P1281, DOI 10.1016/j.ajpath.2013.06.021; Xue GD, 2012, CANCER DISCOV, V2, P248, DOI 10.1158/2159-8290.CD-11-0270; Yang F, 2012, EMBO J, V31, P110, DOI 10.1038/emboj.2011.364; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099	55	95	100	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1157	1166		10.1038/onc.2016.286	http://dx.doi.org/10.1038/onc.2016.286			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27524420	Green Accepted			2022-12-17	WOS:000395371500013
J	Zhang, Q; Liu, S; Parajuli, KR; Zhang, W; Zhang, K; Mo, Z; Liu, J; Chen, Z; Yang, S; Wang, A; Myers, L; You, Z				Zhang, Q.; Liu, S.; Parajuli, K. R.; Zhang, W.; Zhang, K.; Mo, Z.; Liu, J.; Chen, Z.; Yang, S.; Wang, A. R.; Myers, L.; You, Z.			Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition	ONCOGENE			English	Article							VASCULAR ENDOTHELIAL-CELLS; TUMOR-GROWTH; INTESTINAL TUMORIGENESIS; MATRIX-METALLOPROTEINASE; E-CADHERIN; IL-17; INFLAMMATION; MATRILYSIN; EXPRESSION; MICE	Chronic inflammation has been associated with a variety of human cancers including prostate cancer. Interleukin-17 (IL-17) is a critical pro-inflammatory cytokine, which has been demonstrated to promote development of prostate cancer, colon cancer, skin cancer, breast cancer, lung cancer and pancreas cancer. IL-17 promotes prostate adenocarcinoma with a concurrent increase of matrix metalloproteinase 7 (MMP7) expression in mouse prostate. Whether MMP7 mediates IL-17's action and the underlying mechanisms remain unknown. We generated Mmp7 and Pten double knockout (KO) (Mmp7 (-/-)) mouse model and demonstrated that MMP7 promotes prostate adenocarcinoma through induction of epithelial-to-mesenchymal transition (EMT) in Pten-null mice. MMP7 disrupted E-cadherin/beta-catenin complex to upregulate EMT transcription factors in mouse prostate tumors. IL-17 receptor C and Pten double KO mice rcapitulated the weak EMT characteristics observed in Mmp7 (-/-) mice. IL-17 induced MMP7 and EMT in human prostate cancer LNCaP, C4-2B and PC-3 cell lines, while small interfering RNA knockdown of MMP7 inhibited IL-17-induced EMT. Compound III, a selective MMP7 inhibitor, decreased development of invasive prostate cancer in Pten single KO mice. In human normal prostates and prostate tumors, IL-17 mRNA levels were positively correlated with MMP7 mRNA levels. These findings demonstrate that MMP7 mediates IL-17's function in promoting prostate carcinogenesis through induction of EMT, indicating IL-17-MMP7-EMT axis as a potential target for developing new strategies in the prevention and treatment of prostate cancer.	[Zhang, Q.; Liu, S.; Parajuli, K. R.; Mo, Z.; Liu, J.; Chen, Z.; Yang, S.; You, Z.] Tulane Univ, Sch Med, Dept Struct & Cellular Biol, 1430 Tulane Ave Mailbox 8649, New Orleans, LA 70112 USA; [Zhang, W.; Zhang, K.] Xavier Univ Louisiana, Dept Comp Sci, New Orleans, LA USA; [Zhang, W.; Zhang, K.] Xavier Univ Louisiana, Biostat Facil, RCMI Canc Res Ctr, New Orleans, LA USA; [Mo, Z.; Liu, J.] Shijiazhuang Maternal & Child Hlth Care Hosp, Dept Obstet & Gynecol, Shijiazhuang, Peoples R China; [Chen, Z.] North China Univ Sci & Technol, Dept Thorac Surg, Affiliated Hosp, Tangshan, Peoples R China; [Yang, S.] Hebei Med Univ, Dept Urol, Hosp 3, Shijiazhuang, Peoples R China; [Wang, A. R.] Tulane Univ, Dept Pathol & Lab Med, New Orleans, LA 70118 USA; [Myers, L.] Tulane Univ, Dept Biostat & Bioinformat, New Orleans, LA 70118 USA; [You, Z.] Tulane Univ, Dept Orthopaed Surg, New Orleans, LA USA; [You, Z.] Tulane Univ, Tulane Canc Ctr, New Orleans, LA 70118 USA; [You, Z.] Tulane Univ, Louisiana Canc Res Consortium, New Orleans, LA 70118 USA; [You, Z.] Tulane Univ, Tulane Ctr Stem Cell Res & Regenerat Med, New Orleans, LA 70118 USA; [You, Z.] Tulane Univ, Tulane Ctr Aging, New Orleans, LA 70118 USA	Tulane University; Xavier University of Louisiana; Xavier University of Louisiana; North China University of Science & Technology; Hebei Medical University; Tulane University; Tulane University; Tulane University; Tulane University; Tulane University; Tulane University; Tulane University	You, Z (corresponding author), Tulane Univ, Sch Med, Dept Struct & Cellular Biol, 1430 Tulane Ave Mailbox 8649, New Orleans, LA 70112 USA.	zyou@tulane.edu			National Institutes of Health [R01CA174714, P20GM103518]; Department of Defense [W81XWH-14-1-0050, W81XWH-14-1-0149, W81XWH-14-1-0458, W81XWH-15-1-0444]; Developmental Fund of Tulane Cancer Center (TCC); Louisiana Cancer Research Consortium (LCRC) Fund; Tulane's Institute of Integrated Engineering for Health and Medicine (TI2EHM); National Institute on Minority Health and Health Disparities [5G12MD007595]; NATIONAL CANCER INSTITUTE [R01CA174714] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103518] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [G12MD007595] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Developmental Fund of Tulane Cancer Center (TCC); Louisiana Cancer Research Consortium (LCRC) Fund; Tulane's Institute of Integrated Engineering for Health and Medicine (TI2EHM); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	ZY was partially supported by the National Institutes of Health (R01CA174714 and P20GM103518), Department of Defense (W81XWH-14-1-0050, W81XWH-14-1-0149, W81XWH-14-1-0458 (PI: Feng Chen; Co-I: ZY), and W81XWH-15-1-0444), the Developmental Fund of Tulane Cancer Center (TCC), Louisiana Cancer Research Consortium (LCRC) Fund and Tulane's Institute of Integrated Engineering for Health and Medicine (TI2EHM). WZ and KZ were partially supported by the National Institute on Minority Health and Health Disparities (5G12MD007595, PIs: Gene D'Amour and Guangdi Wang).	Benchetrit F, 2002, BLOOD, V99, P2114, DOI 10.1182/blood.V99.6.2114; Chae WJ, 2011, BIOCHEM BIOPH RES CO, V414, P31, DOI 10.1016/j.bbrc.2011.09.016; Chae WJ, 2010, P NATL ACAD SCI USA, V107, P5540, DOI 10.1073/pnas.0912675107; Chang SH, 2014, P NATL ACAD SCI USA, V111, P5664, DOI 10.1073/pnas.1319051111; Chen C, 2015, PROSTATE, V75, P883, DOI 10.1002/pros.22971; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cunningham David, 2015, J Biol Methods, V2; Davies G, 2001, CLIN CANCER RES, V7, P3289; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Debelec-Butuner B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109868; Easwaran V, 2003, CANCER RES, V63, P3145; Edman K, 2011, CHEMMEDCHEM, V6, P769, DOI 10.1002/cmdc.201000550; Gerstenbluth RE, 2002, J UROLOGY, V167, P2267, DOI 10.1016/S0022-5347(05)65140-3; GILLES C, 1994, INT J CANCER, V59, P661, DOI 10.1002/ijc.2910590514; Gu K, 2015, AM J CANCER RES, V5, P1169; Hirahara N, 2001, ONCOLOGY-BASEL, V61, P79, DOI 10.1159/000055357; Huo N, 2002, CANCER LETT, V177, P95, DOI 10.1016/S0304-3835(01)00772-8; Hyun YS, 2012, CARCINOGENESIS, V33, P931, DOI 10.1093/carcin/bgs106; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Knox JD, 1996, MOL CARCINOGEN, V15, P57; Kryczek I, 2009, BLOOD, V114, P357, DOI 10.1182/blood-2008-09-177360; Li B, 2010, BIOINFORMATICS, V26, P493, DOI 10.1093/bioinformatics/btp692; Li QL, 2013, DRUG DES DEV THER, V7, P635, DOI 10.2147/DDDT.S49197; Liu CN, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000382; Liu S, 2016, ONCOTARGET, V7, P13651, DOI 10.18632/oncotarget.7296; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Martin-Orozco N, 2009, CURR OPIN INVEST DR, V10, P543; McAleer JP, 2014, IMMUNOL REV, V260, P129, DOI 10.1111/imr.12183; McAllister F, 2014, CANCER CELL, V25, P621, DOI 10.1016/j.ccr.2014.03.014; Nishizuka I, 2001, CANCER LETT, V173, P175, DOI 10.1016/S0304-3835(01)00634-6; Noe V, 2001, J CELL SCI, V114, P111; Novitskiy SV, 2011, CANCER DISCOV, V1, P430, DOI 10.1158/2159-8290.CD-11-0100; Numasaki M, 2003, BLOOD, V101, P2620, DOI 10.1182/blood-2002-05-1461; Onishi RM, 2010, IMMUNOLOGY, V129, P311, DOI 10.1111/j.1365-2567.2009.03240.x; PAJOUH MS, 1991, J CANCER RES CLIN, V117, P144, DOI 10.1007/BF01613138; Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552; Schatteman PHF, 2000, EUR UROL, V37, P404, DOI 10.1159/000020161; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Sutcliffe S, 2007, UROL ONCOL-SEMIN ORI, V25, P242, DOI 10.1016/j.urolonc.2006.09.014; Tartour E, 1999, CANCER RES, V59, P3698; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq622; Wang L, 2010, CANCER RES, V70, P10112, DOI 10.1158/0008-5472.CAN-10-0775; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Wang LX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108060; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wilson CL, 1996, INT J BIOCHEM CELL B, V28, P123, DOI 10.1016/1357-2725(95)00121-2; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Wu SG, 1998, P NATL ACAD SCI USA, V95, P14979, DOI 10.1073/pnas.95.25.14979; Wu SG, 2003, GASTROENTEROLOGY, V124, P392, DOI 10.1053/gast.2003.50047; Wu SG, 2009, NAT MED, V15, P1016, DOI 10.1038/nm.2015; Xiao MJ, 2009, CANCER RES, V69, P2010, DOI 10.1158/0008-5472.CAN-08-3479; Xu BB, 2014, AM J PHYSIOL-LUNG C, V307, pL497, DOI 10.1152/ajplung.00125.2014; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110; Zhang QY, 2014, PROSTATE, V74, P869, DOI 10.1002/pros.22805; Zhang QY, 2012, CANCER RES, V72, P2589, DOI 10.1158/0008-5472.CAN-11-3795; Zou WP, 2010, NAT REV IMMUNOL, V10, P248, DOI 10.1038/nri2742	62	95	100	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					687	699		10.1038/onc.2016.240	http://dx.doi.org/10.1038/onc.2016.240			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27375020	Green Accepted			2022-12-17	WOS:000394167700010
J	Zhao, L; Guo, H; Zhou, B; Feng, J; Li, Y; Han, T; Liu, L; Li, L; Zhang, S; Liu, Y; Shi, J; Zheng, D				Zhao, L.; Guo, H.; Zhou, B.; Feng, J.; Li, Y.; Han, T.; Liu, L.; Li, L.; Zhang, S.; Liu, Y.; Shi, J.; Zheng, D.			Long non-coding RNA SNHG5 suppresses gastric cancer progression by trapping MTA2 in the cytosol	ONCOGENE			English	Article							SNORNA U50; EXPRESSION; PROTEIN; GAS5; PROLIFERATION; CARCINOMA; APOPTOSIS; GROWTH; GENES	Recently, intriguing new roles for some small nucleolar RNA host genes (SNHGs) in cancer have emerged. In the present study, a panel of SNHGs was profiled to detect aberrantly expressed SNHGs in gastric cancer (GC). The expression of SNHG5 was significantly downregulated in GC and was significantly associated with the formation of a tumor embolus and with the tumor, node and metastasis stage. SNHG5 was a long non-coding RNA, which was a class of non-coding RNA transcripts longer than 200 nucleotides. SNHG5 suppressed GC cell proliferation and metastasis in vitro and in vivo. Furthermore, SNHG5 exerted its function through interacting with MTA2, preventing the translocation of MTA2 from the cytoplasm into the nucleus. SNHG5 overexpression led to significant increases in the acetylation levels of histone H3 and p53, indicating that SNHG5 might affect acetylation by trapping MTA2 in the cytosol, thereby interfering with the formation of the nucleosome remodeling and histone deacetylation complex. This study is the first to demonstrate that SNHG5 is a critical and powerful regulator that is involved in GC progression through trapping MTA2 in the cytosol. These results imply that SNHG5 may be a novel therapeutic target for the treatment of GC.	[Zhao, L.; Guo, H.; Li, Y.; Han, T.; Li, L.; Zhang, S.; Liu, Y.; Shi, J.; Zheng, D.] Chinese Acad Med Sci, Inst Basic Med Sci, State Key Lab Med Mol Biol, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China; [Zhao, L.; Guo, H.; Li, Y.; Han, T.; Li, L.; Zhang, S.; Liu, Y.; Shi, J.; Zheng, D.] Peking Union Med Coll, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China; [Zhao, L.; Liu, L.] Hebei Med Univ, Hosp 4, Res Ctr, Shijiazhuang, Peoples R China; [Zhou, B.] Harbin Med Univ, Affiliated Hosp 1, Dept Gen Surg, Harbin, Heilongjiang, Peoples R China; [Feng, J.] Chinese PLA, Bethune Int Peace Hosp, Dept Gastroenterol, Shijiazhuang, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Hebei Medical University; Harbin Medical University	Shi, J; Zheng, D (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, State Key Lab Med Mol Biol, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China.; Shi, J; Zheng, D (corresponding author), Peking Union Med Coll, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China.	shijuantt@163.com; zhengdx@pumc.edu.cn		Guo, Hui/0000-0003-3901-6336	State Key Basic Research Program of China [2013CB530805]; Natural Science Foundation of China [81372200, 81572755]; PUMC Youth Fund; Fundamental Research Funds for Central Universities [3332013055, 3332014007]	State Key Basic Research Program of China(National Basic Research Program of China); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); PUMC Youth Fund; Fundamental Research Funds for Central Universities(Fundamental Research Funds for the Central Universities)	This work was partially supported by the State Key Basic Research Program of China (Grant No. 2013CB530805, to J Shi and D Zheng), the Natural Science Foundation of China (Grant No. 81372200, 81572755, to J Shi), the PUMC Youth Fund and the Fundamental Research Funds for the Central Universities (Grant No. 3332013055 and 3332014007, to J Shi).	Askarian-Amiri ME, 2011, RNA, V17, P878, DOI 10.1261/rna.2528811; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Cao WJ, 2013, WORLD J GASTROENTERO, V19, P3658, DOI 10.3748/wjg.v19.i23.3658; Chaudhry MA, 2013, INT J MOL SCI, V14, P9099, DOI 10.3390/ijms14059099; Covington KR, 2013, BREAST CANCER RES TR, V141, P375, DOI 10.1007/s10549-013-2709-5; Dong XY, 2008, HUM MOL GENET, V17, P1031, DOI 10.1093/hmg/ddm375; Dong XY, 2009, J GENET GENOMICS, V36, P447, DOI 10.1016/S1673-8527(08)60134-4; Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118; Gee HE, 2011, BRIT J CANCER, V104, P1168, DOI 10.1038/sj.bjc.6606076; Hudson WH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6395; Kino T, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000568; Lee H, 2009, J GASTROEN HEPATOL, V24, P1445, DOI 10.1111/j.1440-1746.2009.05965.x; Li JM, 2014, PROTEIN CELL, V5, P457, DOI 10.1007/s13238-014-0055-y; Liao JP, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-198; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Martens-Uzunova ES, 2012, ONCOGENE, V31, P978, DOI 10.1038/onc.2011.304; Mizrahi I, 2015, J CANCER, V6, P105, DOI 10.7150/jca.10568; Mourtada-Maarabouni M, 2009, ONCOGENE, V28, P195, DOI 10.1038/onc.2008.373; Nagini S, 2012, WORLD J GASTRO ONCOL, V4, P156, DOI 10.4251/wjgo.v4.i7.156; Okugawa Y, 2017, GUT, V66, P107, DOI 10.1136/gutjnl-2015-309359; Okugawa Y, 2014, CARCINOGENESIS, V35, P2731, DOI 10.1093/carcin/bgu200; Scarpino S, 2013, THYROID, V23, P1127, DOI 10.1089/thy.2011.0421; Siprashvili Z, 2016, NAT GENET, V48, P53, DOI 10.1038/ng.3452; Sun M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-319; Tanaka R, 2000, GENES CELLS, V5, P277, DOI 10.1046/j.1365-2443.2000.00325.x; Williams GT, 2006, GENE THER MOL BIOL, V10B, P255; Wu M, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-1; Yang F, 2012, FEBS J, V279, P3159, DOI 10.1111/j.1742-4658.2012.08694.x; Zhou CF, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-102	29	95	102	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5770	5780		10.1038/onc.2016.110	http://dx.doi.org/10.1038/onc.2016.110			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27065326				2022-12-17	WOS:000386998400008
J	Tigan, AS; Bellutti, F; Kollmann, K; Tebb, G; Sexl, V				Tigan, A-S; Bellutti, F.; Kollmann, K.; Tebb, G.; Sexl, V.			CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation	ONCOGENE			English	Review							NF-KAPPA-B; DEPENDENT KINASE 6; HEMATOPOIETIC STEM-CELLS; ARF TUMOR-SUPPRESSOR; DNA-DAMAGE RESPONSE; THERAPEUTIC CDK4/6 INHIBITION; MEDIATED DOWN-REGULATION; GENE-EXPRESSION; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE	The G1 cell-cycle kinase CDK6 has long been thought of as a redundant homolog of CDK4. Although the two kinases have very similar roles in cell-cycle progression, it has recently become apparent that they differ in tissue-specific functions and contribute differently to tumor development. CDK6 is directly involved in transcription in tumor cells and in hematopoietic stem cells. These functions point to a role of CDK6 in tissue homeostasis and differentiation that is partially independent of CDK6's kinase activity and is not shared with CDK4. We review the literature on the contribution of CDK6 to transcription in an attempt to link the new findings on CDK6's transcriptional activity to cell-cycle progression. Finally, we note that anticancer therapies based on the inhibition of CDK6 kinase activity fail to take into account its kinase-independent role in tumor development.	[Tigan, A-S; Bellutti, F.; Kollmann, K.; Sexl, V.] Univ Vet Med, Inst Pharmacol & Toxicol, Vet Pl 1, A-1210 Vienna, Austria; [Kollmann, K.] Univ Cambridge, Cambridge Inst Med Res, Wellcome Trust MRC Stem Cell Inst, Cambridge, England; [Kollmann, K.] Univ Cambridge, Dept Haematol, Cambridge, England; [Tebb, G.] Univ Vet Med, Vienna, Austria	University of Veterinary Medicine Vienna; University of Cambridge; University of Cambridge; University of Veterinary Medicine Vienna	Sexl, V (corresponding author), Univ Vet Med, Inst Pharmacol & Toxicol, Vet Pl 1, A-1210 Vienna, Austria.	veronika.sexl@vetmeduni.ac.at	; Sexl, Veronika/B-8657-2016	Kollmann, Karoline/0000-0002-7937-4245; Bellutti, Florian/0000-0003-2095-4971; Sexl, Veronika/0000-0001-9363-0412; Tebb, Graham/0000-0002-1294-2025	Austrian Science Foundation (FWF) [SFB F47, P24297-B23]; Austrian Science Fund (FWF) [P 24297] Funding Source: researchfish	Austrian Science Foundation (FWF)(Austrian Science Fund (FWF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We are grateful to Peter Alexander Martinek for technical help in the generation of figures. This work was supported by the Austrian Science Foundation (FWF) via grants to VS (SFB F47 and P24297-B23).	AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; Aggarwal P, 2010, CANCER CELL, V18, P329, DOI 10.1016/j.ccr.2010.08.012; Aleem E, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00016; Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Antony-Debre I, 2014, BLOOD, V124, P5, DOI 10.1182/blood-2014-05-572917; Baker GL, 2005, CELL CYCLE, V4, P330; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; BATES S, 1994, ONCOGENE, V9, P71; Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Benzeno S, 2006, ONCOGENE, V25, P6291, DOI 10.1038/sj.onc.1209644; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bienvenu F, 2005, MOL BIOL CELL, V16, P1850, DOI 10.1091/mbc.e04-08-0654; Bienvenu F, 2010, NATURE, V463, P374, DOI 10.1038/nature08684; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Bourgo RJ, 2011, MOL CELL, V43, P663, DOI 10.1016/j.molcel.2011.06.029; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brito-Babapulle V, 2002, HAEMATOLOGICA, V87, P357; Brower V, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju221; Burke JR, 2014, J MOL BIOL, V426, P245, DOI 10.1016/j.jmb.2013.09.031; Burke JR, 2010, J BIOL CHEM, V285, P16286, DOI 10.1074/jbc.M110.108167; Buss H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051847; Casimiro MC, 2015, AGING-US, V7, P455, DOI 10.18632/aging.100773; Casimiro MC, 2015, ONCOTARGET, V6, P8525, DOI 10.18632/oncotarget.3267; Casimiro MC, 2012, ONCOTARGET, V3, P224; Cerqueira A, 2014, MOL CELL BIOL, V34, P1452, DOI 10.1128/MCB.01163-13; Chavey C., 2013, PHYSL PHYSIOPATHOLOG, P17; Chen D, 2009, AM J SURG PATHOL, V33, P720, DOI 10.1097/PAS.0b013e3181934244; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Chilosi M, 1998, AM J PATHOL, V152, P209; Choe KS, 2010, J BIOL CHEM, V285, DOI 10.1074/jbc.M109.077727; Choi YJ, 2014, ONCOGENE, V33, P1890, DOI 10.1038/onc.2013.137; Choi YJ, 2013, ONCOTARGET, V4, P176, DOI 10.18632/oncotarget.912; Choi YJ, 2012, CANCER CELL, V22, P438, DOI 10.1016/j.ccr.2012.09.015; Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154; Dean JL, 2012, J BIOL CHEM, V287, P29075, DOI 10.1074/jbc.M112.365494; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Dong F, 1998, MOL BIOL CELL, V9, P2081, DOI 10.1091/mbc.9.8.2081; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ecker A, 2009, FRONT BIOSCI-LANDMRK, V14, P2944, DOI 10.2741/3425; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Fu MF, 2005, J BIOL CHEM, V280, P16934, DOI 10.1074/jbc.M500403200; Fu MF, 2005, J BIOL CHEM, V280, P29728, DOI 10.1074/jbc.M503188200; Fujimoto T, 2007, EMBO J, V26, P2361, DOI 10.1038/sj.emboj.7601675; Gallagher SJ, 2006, INT J BIOCHEM CELL B, V38, P1637, DOI 10.1016/j.biocel.2006.02.008; Gordon GM, 2011, PROTEIN CELL, V2, P864, DOI 10.1007/s13238-011-1117-z; Guzman ML, 2015, BLOOD, V125, P7, DOI 10.1182/blood-2014-11-609230; Handschick K, 2014, MOL CELL, V53, P193, DOI 10.1016/j.molcel.2013.12.002; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hayette S, 2003, BLOOD, V102, P1549, DOI 10.1182/blood-2003-04-1220; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Hu MG, 2011, BLOOD, V117, P6120, DOI 10.1182/blood-2010-08-300517; Hu MG, 2009, CANCER RES, V69, P810, DOI 10.1158/0008-5472.CAN-08-2473; Huberts DHEW, 2010, BBA-MOL CELL RES, V1803, P520, DOI 10.1016/j.bbamcr.2010.01.022; Hussain MS, 2013, HUM MOL GENET, V22, P5199, DOI 10.1093/hmg/ddt374; Inoue K, 2007, ONCOGENE, V26, P4329, DOI 10.1038/sj.onc.1210226; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Jares P, 2007, NAT REV CANCER, V7, P750, DOI 10.1038/nrc2230; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; Jing H, 2011, GENE DEV, V25, P2137, DOI 10.1101/gad.17620611; Jirawatnotai S, 2012, CANCER RES, V72, P4289, DOI 10.1158/0008-5472.CAN-11-3549; Jirawatnotai S, 2011, NATURE, V474, P230, DOI 10.1038/nature10155; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Knudsen KE, 1999, CANCER RES, V59, P2297; Kohrt D, 2014, CELL CYCLE, V13, P62, DOI 10.4161/cc.26755; Kollmann K, 2013, ONCOTARGET, V4, P1858, DOI 10.18632/oncotarget.1541; Kollmann K, 2013, CANCER CELL, V24, P167, DOI 10.1016/j.ccr.2013.07.012; Konecny GE, 2011, CLIN CANCER RES, V17, P1591, DOI 10.1158/1078-0432.CCR-10-2307; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Lapenna S, 2009, NAT REV DRUG DISCOV, V8, P547, DOI 10.1038/nrd2907; Laurenti E, 2015, CELL STEM CELL, V16, P302, DOI 10.1016/j.stem.2015.01.017; Lazaro JB, 2002, GENE DEV, V16, P1792, DOI 10.1101/gad.U-9988R; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee YJ, 2014, NATURE, V510, P547, DOI 10.1038/nature13267; Li Y, 2015, CANCER DISCOV, V5, P288, DOI 10.1158/2159-8290.CD-14-0625; Li ZP, 2010, CANCER RES, V70, P8802, DOI 10.1158/0008-5472.CAN-10-0312; Lien HC, 2000, LAB INVEST, V80, P893, DOI 10.1038/labinvest.3780093; Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744; LUCAS JJ, 1995, J IMMUNOL, V154, P6275; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Malinkova V, 2015, EXPERT OPIN THER PAT, P1; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Malumbres M, 2009, NAT CELL BIOL, V11, P1275, DOI 10.1038/ncb1109-1275; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Matushansky I, 2003, ONCOGENE, V22, P4143, DOI 10.1038/sj.onc.1206484; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Michaud K, 2010, CANCER RES, V70, P3228, DOI 10.1158/0008-5472.CAN-09-4559; Min IM, 2008, CELL STEM CELL, V2, P380, DOI 10.1016/j.stem.2008.01.015; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nagel S, 2008, LEUKEMIA, V22, P387, DOI 10.1038/sj.leu.2405028; Nakajima K, 2011, DEVELOPMENT, V138, P1771, DOI 10.1242/dev.059295; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Ogasawara T, 2004, MOL CELL BIOL, V24, P6560, DOI 10.1128/mcb.24.15.6560-6568.2004; Ogasawara T, 2004, J BONE MINER RES, V19, P1128, DOI 10.1359/jbmr.2004.19.7.1128; Parry D, 1999, MOL CELL BIOL, V19, P1775; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pauls E, 2014, J IMMUNOL, V193, P1988, DOI 10.4049/jimmunol.1400873; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Pestell RG, 2013, AM J PATHOL, V183, P3, DOI 10.1016/j.ajpath.2013.03.001; Placke T, 2014, BLOOD, V124, P13, DOI 10.1182/blood-2014-02-558114; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Puyol M, 2010, CANCER CELL, V18, P63, DOI 10.1016/j.ccr.2010.05.025; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Reddy HKDL, 2005, CANCER RES, V65, P10174, DOI 10.1158/0008-5472.CAN-05-2639; Resemann HK, 2014, MOL CELL ENDOCRINOL, V382, P603, DOI 10.1016/j.mce.2013.06.029; Ressler S, 2006, AGING CELL, V5, P379, DOI 10.1111/j.1474-9726.2006.00231.x; Rodriguez-Diez E, 2014, BLOOD, V124, P2380, DOI 10.1182/blood-2014-02-555292; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Rubin SM, 2005, CELL, V123, P1093, DOI 10.1016/j.cell.2005.09.044; Rubio MF, 2012, BBA-MOL CELL RES, V1823, P1119, DOI 10.1016/j.bbamcr.2012.01.009; Ruiz A, 2015, CELL CYCLE, V14, P1657, DOI 10.1080/15384101.2015.1030558; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sanchez-Martinez C, 2015, BIOORG MED CHEM LETT, V25, P3420, DOI 10.1016/j.bmcl.2015.05.100; Saporita AJ, 2007, CURR MED CHEM, V14, P1815; Sawai CM, 2012, CANCER CELL, V22, P452, DOI 10.1016/j.ccr.2012.09.016; Scheicher R, 2015, BLOOD, V125, P90, DOI 10.1182/blood-2014-06-584417; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Schmitz R, 2012, NATURE, V490, P116, DOI 10.1038/nature11378; Schwartz R, 2006, P NATL ACAD SCI USA, V103, P9976, DOI 10.1073/pnas.0603728103; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shen R, 2006, J BIOL CHEM, V281, P16347, DOI 10.1074/jbc.M603439200; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Singh AM, 2013, STEM CELL REP, V1, P532, DOI 10.1016/j.stemcr.2013.10.009; Sugimoto M, 2002, ONCOGENE, V21, P8067, DOI 10.1038/sj.onc.1206019; Sulli G, 2012, NAT REV CANCER, V12, DOI 10.1038/nrc3344; Talluri S, 2012, CELL CYCLE, V11, P3189, DOI 10.4161/cc.21263; TAM SW, 1994, CANCER RES, V54, P5816; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; van der Linden MH, 2014, CELL CYCLE, V13, P834, DOI 10.4161/cc.27757; van der Velden PA, 2001, CANCER RES, V61, P5303; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vanden Bush T.J., 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019468; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Wiedemeyer WR, 2010, P NATL ACAD SCI USA, V107, P11501, DOI 10.1073/pnas.1001613107; Wierstra I, 2007, BIOL CHEM, V388, P1257, DOI 10.1515/BC.2007.159; Wierstra I, 2013, ADV CANCER RES, V118, P97, DOI 10.1016/B978-0-12-407173-5.00004-2; Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048; Witkiewicz AK, 2011, CELL CYCLE, V10, P2497, DOI 10.4161/cc.10.15.16776; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Zacharek SJ, 2005, CANCER RES, V65, P11354, DOI 10.1158/0008-5472.CAN-05-2236; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang LS, 2008, BLOOD, V111, P1193, DOI 10.1182/blood-2007-08-109702; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	174	95	96	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3083	3091		10.1038/onc.2015.407	http://dx.doi.org/10.1038/onc.2015.407			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26500059				2022-12-17	WOS:000378092700001
J	Sanchez-Lopez, E; Flashner-Abramson, E; Shalapour, S; Zhong, Z; Taniguchi, K; Levitzki, A; Karin, M				Sanchez-Lopez, E.; Flashner-Abramson, E.; Shalapour, S.; Zhong, Z.; Taniguchi, K.; Levitzki, A.; Karin, M.			Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling	ONCOGENE			English	Article							FACTOR-I RECEPTOR; COLITIS-ASSOCIATED CANCER; ADENOMATOUS POLYPS; CIRCULATING LEVELS; MOUSE MODEL; GROWTH; TUMORIGENESIS; METASTASIS; ACTIVATION; CELLS	The tumor microenvironment (TME) exerts critical pro-tumorigenic effects through cytokines and growth factors that support cancer cell proliferation, survival, motility and invasion. Insulin-like growth factor-1 (IGF-1) and signal transducer and activator of transcription 3 (STAT3) stimulate colorectal cancer development and progression via cell autonomous and microenvironmental effects. Using a unique inhibitor, NT157, which targets both IGF-1 receptor (IGF-1R) and STAT3, we show that these pathways regulate many TME functions associated with sporadic colonic tumorigenesis in CPC-APC mice, in which cancer development is driven by loss of the Apc tumor suppressor gene. NT157 causes a substantial reduction in tumor burden by affecting cancer cells, cancer-associated fibroblasts (CAF) and myeloid cells. Decreased cancer cell proliferation and increased apoptosis were accompanied by inhibition of CAF activation and decreased inflammation. Furthermore, NT157 inhibited expression of protumorigenic cytokines, chemokines and growth factors, including IL-6, IL-11 and IL-23 as well as CCL2, CCL5, CXCL7, CXCL5, ICAM1 and TGF beta; decreased cancer cell migratory activity and reduced their proliferation in the liver. NT157 represents a new class of anticancer drugs that affect both the malignant cell and its supportive microenvironment.	[Sanchez-Lopez, E.; Shalapour, S.; Zhong, Z.; Taniguchi, K.; Karin, M.] Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA; [Sanchez-Lopez, E.; Shalapour, S.; Zhong, Z.; Taniguchi, K.; Karin, M.] Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA; [Flashner-Abramson, E.; Levitzki, A.] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel; [Taniguchi, K.] Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo, Japan	University of California System; University of California San Diego; University of California System; University of California San Diego; Hebrew University of Jerusalem; Keio University	Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.; Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu	Sanchez-Lopez, Elsa/A-7131-2017	Sanchez-Lopez, Elsa/0000-0002-4236-1985; Zhong, Zhenyu/0000-0002-9441-7645	Sara Borrell fellowship ISCIII/MICINN program; ERC Advanced Grant [249898]; NIH grants [AI043477, CA118165]; NATIONAL CANCER INSTITUTE [R01CA118165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043477] Funding Source: NIH RePORTER	Sara Borrell fellowship ISCIII/MICINN program; ERC Advanced Grant(European Research Council (ERC)); NIH grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	ESL was supported by Sara Borrell fellowship ISCIII/MICINN program. SS and ZZ are CRI Irvington postdoctoral fellows. KT is Uehara Memorial Foundation Fellow. AL and EFA were supported by ERC Advanced Grant (249898) to AL. Research was supported by NIH grants (AI043477 and CA118165) to MK, who is an American Cancer Society Research Professor and holds the Ben and Wanda Hildyard Chair for Mitochondrial and Metabolic Diseases.	Albanell J, 2001, JNCI-J NATL CANCER I, V93, P1830, DOI 10.1093/jnci/93.24.1830; Arber N, 2006, NEW ENGL J MED, V355, P885, DOI 10.1056/NEJMoa061652; Bonapace L, 2014, NATURE, V515, DOI 10.1038/nature13862; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Chan B, 2008, J MAMMARY GLAND BIOL, V13, P415, DOI 10.1007/s10911-008-9101-9; Chang Q, 2002, CANCER RES, V62, P6035; Esposito DL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036190; Feng QY, 2014, WORLD J GASTROENTERO, V20, P4263, DOI 10.3748/wjg.v20.i15.4263; Giovannucci E, 2001, J NUTR, V131, p3109S, DOI 10.1093/jn/131.11.3109S; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Grivennikov SI, 2011, ANN RHEUM DIS, V70, pI104, DOI 10.1136/ard.2010.140145; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Heron-Milhavet L, 2002, J BIOL CHEM, V277, P15600, DOI 10.1074/jbc.M111142200; Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735; Huang F, 2012, CLIN CANCER RES, V18, P1156, DOI 10.1158/1078-0432.CCR-11-1135; Jones HE, 2004, ENDOCR-RELAT CANCER, V11, P793, DOI 10.1677/erc.1.00799; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Lee J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103551; Lee KW, 2015, CANCER RES, V75, P73, DOI 10.1158/0008-5472.CAN-14-0350; Maeda S, 2009, HEPATOLOGY, V50, P1851, DOI 10.1002/hep.23199; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Ollberding NJ, 2012, CANCER EPIDEM BIOMAR, V21, P810, DOI 10.1158/1055-9965.EPI-11-1105; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; Prager GW, 2012, HAMOSTASEOLOGIE, V32, P105, DOI 10.5482/ha-1163; Putoczki TL, 2013, CANCER CELL, V24, P257, DOI 10.1016/j.ccr.2013.06.017; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Ramocki NM, 2008, ENDOCRINOLOGY, V149, P261, DOI 10.1210/en.2007-0869; Reuveni H, 2013, CANCER RES, V73, P4383, DOI 10.1158/0008-5472.CAN-12-3385; Rojas A, 2011, ONCOGENE, V30, P2345, DOI 10.1038/onc.2010.605; Ryan PD, 2008, ONCOLOGIST, V13, P16, DOI 10.1634/theoncologist.2007-0199; Schlussel AT, 2014, J GASTROINTEST ONCOL, V5, P326, DOI 10.3978/j.issn.2078-6891.2014.069; Shiratsuchi I, 2011, ANTICANCER RES, V31, P2541; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Soubry A, 2012, INT J CANCER, V131, P512, DOI 10.1002/ijc.26393; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Surmacz E, 2003, ONCOGENE, V22, P6589, DOI 10.1038/sj.onc.1206772; Tang Z, 2008, AM J SURG, V196, P690, DOI 10.1016/j.amjsurg.2008.08.001; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang KP, 2014, IMMUNITY, V41, P1052, DOI 10.1016/j.immuni.2014.11.009; Woodson K, 2004, JNCI-J NATL CANCER I, V96, P407, DOI 10.1093/jnci/djh042; Xiong H, 2014, INT J CANCER, V134, P2030, DOI 10.1002/ijc.28539; Zhang WZ, 2006, MOL CELL BIOL, V26, P413, DOI 10.1128/MCB.26.2.413-424.2006; Zhou SL, 2014, CARCINOGENESIS, V35, P597, DOI 10.1093/carcin/bgt397; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	50	95	103	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2634	2644		10.1038/onc.2015.326	http://dx.doi.org/10.1038/onc.2015.326			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26364612	Green Submitted, Green Accepted			2022-12-17	WOS:000376165700010
J	Wang, JY; Sun, J; Huang, MY; Wang, YS; Hou, MF; Sun, Y; He, H; Krishna, N; Chiu, SJ; Lin, S; Yang, S; Chang, WC				Wang, J-Y; Sun, J.; Huang, M-Y; Wang, Y-S; Hou, M-F; Sun, Y.; He, H.; Krishna, N.; Chiu, S-J; Lin, S.; Yang, S.; Chang, W-C			STIM1 overexpression promotes colorectal cancer progression, cell motility and COX-2 expression	ONCOGENE			English	Article							OPERATED CALCIUM INFLUX; GENE ACTIVATION; CA2+ INFLUX; GROWTH; PROLIFERATION; MIGRATION; CHANNELS; FASCIN; ORAI1; INVOLVEMENT	Tumor metastasis is the major cause of death among cancer patients, with >90% of cancer-related death attributable to the spreading of metastatic cells to secondary organs. Store-operated Ca2+ entry (SOCE) is the predominant Ca2+ entry mechanism in most cancer cells, and stromal interaction molecule 1 (STIM1) is the endoplasmic reticulum (ER) Ca2+ sensor for store-operated channels. Here we reported that the STIM1 was overexpressed in colorectal cancer (CRC) patients. STIM1 overexpression in CRC was significantly associated with tumor size, depth of invasion, lymph node metastasis status and serum levels of carcinoembryonic antigen. Furthermore, ectopic expression of STIM1 promoted CRC cell motility, while depletion of STIM1 with short hairpin RNA inhibited CRC cell migration. Our data further suggested that STIM1 promoted CRC cell migration through increasing the expression of cyclooxygenase-2 (COX-2) and production of prostaglandin E2 (PGE2). Importantly, ectopically expressed COX-2 or exogenous PGE2 were able to rescue migration defect in STIM1 knockdown CRC cells, and inhibition of COX-2 with ibuprofen and indomethacin abrogated STIM1-mediated CRC cell motility. In short, our data provided clinicopathological significance for STIM1 and SOCE in CRC progression, and implicated a role for COX-2 in STIM1-mediated CRC metastasis. Our studies also suggested a new approach to inhibit STIM1-mediated metastasis with COX-2 inhibitors.	[Wang, J-Y; Huang, M-Y; Hou, M-F; Chiu, S-J; Chang, W-C] Kaohsiung Med Univ Hosp, Ctr Canc, Kaohsiung, Taiwan; [Wang, J-Y] Kaohsiung Med Univ Hosp, Div Gastrointestinal & Gen Surg, Kaohsiung, Taiwan; [Wang, J-Y] Kaohsiung Med Univ, Coll Med, Grad Inst Clin Med, Dept Surg, Kaohsiung, Taiwan; [Wang, J-Y] Kaohsiung Med Univ, Ctr Biomarkers & Biotech Drugs, Kaohsiung, Taiwan; [Sun, J.; He, H.; Krishna, N.; Lin, S.; Yang, S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Comprehens Melanoma Res Ctr,Dept Tumor Biol, Tampa, FL 33612 USA; [Huang, M-Y; Hou, M-F] Kaohsiung Med Univ Hosp, Dept Radiat Oncol, Kaohsiung, Taiwan; [Huang, M-Y; Hou, M-F] Kaohsiung Med Univ, Fac Med, Dept Radiat Oncol, Kaohsiung, Taiwan; [Wang, Y-S] Kaohsiung Med Univ, Fac Med, Dept Genom Med, Kaohsiung, Taiwan; [Hou, M-F] Kaohsiung Municipal Tatung Hosp, Kaohsiung, Taiwan; [Sun, Y.] Tianjin Med Univ, Canc Inst & Hosp, Dept Pathol, Tianjin, Peoples R China; [Chiu, S-J; Chang, W-C] Taipei Med Univ, Sch Pharm, Master Program Clin Pharmacogen & Pharmacoprote, Taipei, Taiwan; [Chang, W-C] Taipei Med Univ, Sch Pharm, Dept Clin Pharm, Taipei 110, Taiwan; [Chang, W-C] Taipei Med Univ, Wanfang Hosp, Dept Pharm, Taipei 110, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Municipal Ta-Tung Hospital; Tianjin Medical University; Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital	Yang, S (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Biol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	shengyu.yang@moffitt.org; wcc@tmu.edu.tw	Huang, Ming-Yii/AAS-8132-2021; Lin, Shengchen/T-3529-2018	Lin, Shengchen/0000-0003-1488-8680; Chang, Wei-Chiao/0000-0002-8573-5924; Wang, Yu-Shiuan/0000-0001-7204-1256; Hou, Ming-Feng/0000-0001-6030-9702	Health and welfare surcharge of tobacco products, Taiwan [DOH102-TD-C-111-002]; National Science Council, Taiwan [NSC98-2320-B-037-028, NSC101-2320-B-038-029-MY3]; Center for Biomarkers and Biotech Drugs, Kaohsiung Medical Universit, Aim for the Top Universities Grant [KMU-TP103C00, KMU-TP103C03]; NIH grant [R01CA175741]; NATIONAL CANCER INSTITUTE [R01CA175741] Funding Source: NIH RePORTER	Health and welfare surcharge of tobacco products, Taiwan; National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Center for Biomarkers and Biotech Drugs, Kaohsiung Medical Universit, Aim for the Top Universities Grant; NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Minjung Kim for assistance with IHC staining and we are grateful to Professor Yun Yen (City of Hope National Medical Center) for reading this paper and providing comments. This study was partly supported by funding from Health and welfare surcharge of tobacco products, Taiwan (Grant no. DOH102-TD-C-111-002), National Science Council, Taiwan (Grant no. NSC98-2320-B-037-028; NSC101-2320-B-038-029-MY3) and Center for Biomarkers and Biotech Drugs, Kaohsiung Medical Universit, Aim for the Top Universities Grant (KMU-TP103C00, KMU-TP103C03) WCC; and an NIH grant R01CA175741 to SY.	Aytes A, 2012, MOL CARCINOGEN, V51, P746, DOI 10.1002/mc.20843; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berry PA, 2011, PROSTATE, V71, P1646, DOI 10.1002/pros.21384; Brandman O, 2007, CELL, V131, P1327, DOI 10.1016/j.cell.2007.11.039; Chantome A, 2013, CANCER RES, V73, P4852, DOI 10.1158/0008-5472.CAN-12-4572; Chen L, 2010, NATURE, V464, P1062, DOI 10.1038/nature08978; Chen YF, 2011, P NATL ACAD SCI USA, V108, P15225, DOI 10.1073/pnas.1103315108; Fedida-Metula S, 2012, CARCINOGENESIS, V33, P740, DOI 10.1093/carcin/bgs021; Feng MY, 2010, CELL, V143, P84, DOI 10.1016/j.cell.2010.08.040; Feng ZY, 2009, BIOORGAN MED CHEM, V17, P2147, DOI 10.1016/j.bmc.2008.10.074; Hogan PG, 2010, ANNU REV IMMUNOL, V28, P491, DOI 10.1146/annurev.immunol.021908.132550; Hou MF, 2011, BBA-GEN SUBJECTS, V1810, P1278, DOI 10.1016/j.bbagen.2011.07.001; Hsu WL, 2012, CELL CALCIUM, V52, P161, DOI 10.1016/j.ceca.2012.05.007; Hu JJ, 2011, BIOCHEM BIOPH RES CO, V411, P786, DOI 10.1016/j.bbrc.2011.07.025; Huang WC, 2011, CELL CALCIUM, V50, P27, DOI 10.1016/j.ceca.2011.04.004; Jans R, 2013, J INVEST DERMATOL, V133, P793, DOI 10.1038/jid.2012.370; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; McAndrew D, 2011, MOL CANCER THER, V10, P448, DOI 10.1158/1535-7163.MCT-10-0923; McGarrigle D, 2006, J BIOL CHEM, V281, P10583, DOI 10.1074/jbc.M513002200; Munoz E, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.198952; Parkin DM, 2005, CA CANC J CLIN, V55, P74; Potier M, 2009, FASEB J, V23, P2425, DOI 10.1096/fj.09-131128; Prevarskaya N, 2011, NAT REV CANCER, V11, P609, DOI 10.1038/nrc3105; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Ryu S, 2013, CANCER CELL, V23, P63, DOI 10.1016/j.ccr.2012.11.019; Schulz RA, 2004, DEV BIOL, V266, P1, DOI 10.1016/j.ydbio.2003.10.008; Shin DH, 2011, J PHARMACOL SCI, V115, P144, DOI 10.1254/jphs.10209FP; Sun JW, 2013, J BIOL CHEM, V288, P36971, DOI 10.1074/jbc.M113.506535; Sun JW, 2011, J BIOL CHEM, V286, P38865, DOI 10.1074/jbc.M111.270413; Wang DZ, 2013, ANNU REV MED, V64, P131, DOI 10.1146/annurev-med-112211-154330; Wang JY, 2012, CELL SIGNAL, V24, P162, DOI 10.1016/j.cellsig.2011.08.017; WOLMARK N, 1984, ANN SURG, V199, P375, DOI 10.1097/00000658-198404000-00001; Yang IH, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-41; Yang N, 2013, CANCER LETT, V330, P163, DOI 10.1016/j.canlet.2012.11.040; Yang Shengyu, 2012, Methods Mol Biol, V928, P221, DOI 10.1007/978-1-62703-008-3_17; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Yang SY, 2005, J BIOL CHEM, V280, P27130, DOI 10.1074/jbc.M501625200; Yoshida J, 2012, BIOCHEM PHARMACOL, V84, P1592, DOI 10.1016/j.bcp.2012.09.021	38	95	97	0	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4358	4367		10.1038/onc.2014.366	http://dx.doi.org/10.1038/onc.2014.366			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25381814	Green Accepted			2022-12-17	WOS:000359494400007
J	Aprelikova, O; Palla, J; Hibler, B; Yu, X; Greer, YE; Yi, M; Stephens, R; Maxwell, GL; Jazaeri, A; Risinger, JI; Rubin, JS; Niederhuber, J				Aprelikova, O.; Palla, J.; Hibler, B.; Yu, X.; Greer, Y. E.; Yi, M.; Stephens, R.; Maxwell, G. L.; Jazaeri, A.; Risinger, J. I.; Rubin, J. S.; Niederhuber, J.			Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility	ONCOGENE			English	Article						cancer-associated fibroblasts; endometrial cancer; microRNA; miR-148a; WNT10B	NUCLEAR BETA-CATENIN; STROMAL CELLS; HUMAN BREAST; GASTRIC-CANCER; ENDOMETRIAL; MICRORNAS; DNA; CARCINOMAS; EXPRESSION; ABNORMALITIES	The tumor microenvironment has an important role in cancer progression. Here we show that miR-148a is downregulated in 15 out of 16 samples (94%) of cancer-associated fibroblasts (CAFs) compared with matched normal tissue fibroblasts (NFs) established from patients with endometrial cancer. Laser-capture microdissection of stromal cells from normal tissue and endometrial cancer confirmed this observation. Treatment of cells with 5-aza-deoxycytidine stimulated the expression of miR-148a in the majority of CAFs implicating DNA methylation in the regulation of miR-148a expression. Investigation of miR-148a function in fibroblasts demonstrated that conditioned media (CM) from CAFs overexpressing miR-148a significantly impaired the migration of five endometrial cancer cell lines without affecting their growth rates in co-culture experiments. Among predicted miR-148a target genes are two WNT family members, WNT1 and WNT10B. Activation of the WNT/b-catenin pathway in CAFs was confirmed by microarray analysis of gene expression and increased activity of the SuperTOPFlash luciferase reporter. We found elevated levels of WNT10B protein in CAFs and its level decreased when miR-148a was re-introduced by lentiviral infection. The 3'-UTR of WNT10B, cloned downstream of luciferase cDNA, suppressed luciferase activity when co-expressed with miR-148a indicating that WNT10B is a direct target of miR-148a. In contrast to the effect of miR-148a, WNT10B stimulated migration of endometrial cancer cell lines. Our findings have defined a molecular mechanism in the tumor microenvironment that is a novel target for cancer therapy.	[Aprelikova, O.; Palla, J.; Hibler, B.; Yu, X.; Niederhuber, J.] Canc & Cell Biol Branch, Bethesda, MD USA; [Greer, Y. E.; Rubin, J. S.] NCI, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA; [Yi, M.; Stephens, R.] SAIC Inc, Frederick, MD USA; [Maxwell, G. L.] Walter Reed Army Med Ctr, US Mil Canc Inst, Washington, DC 20307 USA; [Jazaeri, A.] Univ Virginia, Charlottesville, VA USA; [Risinger, J. I.] Michigan State Univ, Coll Human Med, Dept Obstet Gynecol & Reprod Biol, Grand Rapids, MI USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; University of Virginia; Michigan State University; Michigan State University College of Human Medicine	Aprelikova, O (corresponding author), NCI, Bldg 37,Rm 1042,9000 Rockville Pike, Bethesda, MD 20892 USA.	apreliko@mail.nih.gov; rubinj@mail.nih.gov	Jazaeri, Amir/I-3458-2015; Greer, Yoshimi/K-2155-2019	Jazaeri, Amir/0000-0003-4335-4151; Yi, Ming/0000-0001-9098-1364	Intramural Research Program of National Institutes of Health; National Cancer Institute; Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010251] Funding Source: NIH RePORTER	Intramural Research Program of National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Julie Oliver, Tracy Litzi, and Shelley Hoover for help with laser capture microdissection, Dr Xin Wei Wang (NCI) for the WNT10B expression vector and Dr Randall Moon (University of Washington) for the SuperTOPFlash and SuperFOPFlash constructs. This work was supported by the Intramural Research Program of National Institutes of Health, National Cancer Institute, and Center for Cancer Research.	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X; Aprelikova O, 2010, CELL CYCLE, V9, P4387, DOI 10.4161/cc.9.21.13674; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160; Cardone A, 1997, PANMINERVA MED, V39, P174; Carmon KS, 2008, MOL CANCER RES, V6, P1017, DOI 10.1158/1541-7786.MCR-08-0039; Chen K, 2008, PEDIATR BLOOD CANCER, V51, P349, DOI 10.1002/pbc.21595; Di Leva G, 2010, TRENDS MOL MED, V16, P257, DOI 10.1016/j.molmed.2010.04.001; Endo Y, 2005, J BIOL CHEM, V280, P777, DOI 10.1074/jbc.M406391200; Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508; Hanoun N, 2010, CLIN CHEM, V56, P1107, DOI 10.1373/clinchem.2010.144709; Hecht JL, 2006, J CLIN ONCOL, V24, P4783, DOI 10.1200/JCO.2006.06.7173; Hill R, 2005, CELL, V123, P1001, DOI 10.1016/j.cell.2005.09.030; Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596; Jiang L, 2008, CANCER RES, V68, P9900, DOI 10.1158/0008-5472.CAN-08-1319; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kellermann MG, 2008, ORAL ONCOL, V44, P509, DOI 10.1016/j.oraloncology.2007.07.001; Kiaris H, 2005, CANCER RES, V65, P1627, DOI 10.1158/0008-5472.CAN-04-3791; Kikuchi A, 2008, CANCER SCI, V99, P202, DOI 10.1111/j.1349-7006.2007.00675.x; Klapholz-Brown Z, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000945; Konopka B, 2007, J CANCER RES CLIN, V133, P361, DOI 10.1007/s00432-006-0179-4; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Moreno-Bueno G, 2002, ONCOGENE, V21, P7981, DOI 10.1038/sj.onc.1205924; Nagendra DC, MOL CARCINOG, DOI DOI 10.1002/MC.20850); Olson P, 2009, GENE DEV, V23, P2152, DOI 10.1101/gad.1820109; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Patocs A, 2007, NEW ENGL J MED, V357, P2543, DOI 10.1056/NEJMoa071825; Polyak K, 2009, TRENDS GENET, V25, P30, DOI 10.1016/j.tig.2008.10.012; Qin LM, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-320; Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117; Risinger JI, 2005, CANCER RES, V65, P5031, DOI 10.1158/0008-5472.CAN-04-0850; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Saegusa M, 2001, J PATHOL, V194, P59, DOI 10.1002/path.856; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Scholten AN, 2003, J PATHOL, V201, P460, DOI 10.1002/path.1402; Sneddon JB, 2006, P NATL ACAD SCI USA, V103, P14842, DOI 10.1073/pnas.0606857103; Song YX, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-1; Tchemitsa O, 2010, J PATHOL, V222, P310, DOI 10.1002/path.2759; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Walter K, 2008, CANCER BIOL THER, V7, P882, DOI 10.4161/cbt.7.6.5869; Wei J, 2011, ARTHRITIS RHEUM-US, V63, P1707, DOI 10.1002/art.30312; Yi M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003288; Yoshikawa H, 2007, MOL BIOL CELL, V18, P4292, DOI 10.1091/mbc.E06-10-0889; Zheng BQ, 2011, CLIN CANCER RES, V17, P7574, DOI 10.1158/1078-0432.CCR-11-1714	50	95	100	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2013	32	27					3246	3253		10.1038/onc.2012.351	http://dx.doi.org/10.1038/onc.2012.351			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	22890324	Green Accepted			2022-12-17	WOS:000321301600004
J	Qiu, X; Dong, S; Qiao, F; Lu, S; Song, Y; Lao, Y; Li, Y; Zeng, T; Hu, J; Zhang, L; Zhang, L; Fan, H				Qiu, X.; Dong, S.; Qiao, F.; Lu, S.; Song, Y.; Lao, Y.; Li, Y.; Zeng, T.; Hu, J.; Zhang, L.; Zhang, L.; Fan, H.			HBx-mediated miR-21 upregulation represses tumor-suppressor function of PDCD4 in hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; hepatitis B virus X protein; PDCD4; miR-21	VIRUS-X-PROTEIN; HEPATITIS-B; GENE-EXPRESSION; CDNA MICROARRAY; DOWN-REGULATION; KAPPA-B; ACTIVATION; TRANSLATION; HEPATOCARCINOGENESIS; DEGRADATION	The hepatitis B virus (HBV) X protein (HBx) has a key role in the molecular pathogenesis of HBV-related hepatocellular carcinoma (HCC). However, the mechanism of HBx-mediated hepatocarcinogenesis remains to be elucidated. In this study, we aimed to better understand the effects of HBx on gene-expression profiles that participate in hepatocarcinogenesis and the mechanism by which HBx regulates these genes. Differentially expressed genes between L02-HBx and L02-Vector control cells were identified by microarray and validated using quantitative real-time PCR. HBx upregulates 456 genes and downregulates 843 genes, including programmed cell death 4 (PDCD4). PDCD4 was downregulated in clinical HCC specimens and the downregulation of PDCD4 in HCC is correlated with HBx. Furthermore, overexpression experiments in HCC cells proved that PDCD4 has strong tumor-suppressive effects both in vitro and in vivo, and may induce cell apoptosis to suppress the development of HCC. HBx induces expression of DNA methyltransferases (DNMTs), but failed to change the methylation status of the PDCD4 promoter. HBx downregulates PDCD4 expression at least partially through miR-21. Taken together, this study reported for the first time that HBx downregulates PDCD4 and upregulates miR-21 expression. The overexpression of PDCD4 could suppress tumorigenicity. The deregulation of PDCD4 by HBx through miR-21 represents a potential novel mechanism of the downregulation of PDCD4 in HBV-related HCC and provides new insights into HCC development.	[Qiu, X.; Qiao, F.; Song, Y.; Lao, Y.; Hu, J.; Fan, H.] Southeast Univ, Dept Med Genet & Dev Biol, Sch Med, Key Lab Dev Genes & Human Dis,Minist Educ, Nanjing 210009, Jiangsu, Peoples R China; [Dong, S.] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; [Lu, S.] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China; [Li, Y.; Zeng, T.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol Southern China, Guangzhou 510275, Guangdong, Peoples R China; [Zhang, L.] Shandong Univ, Sch Med, Dept Immunol, Jinan 250100, Peoples R China; [Zhang, L.] Southeast Univ, Affiliated Zhongda Hosp, Nanjing 210009, Jiangsu, Peoples R China	Southeast University - China; University of Hong Kong; Nanjing Medical University; State Key Lab Oncology South China; Sun Yat Sen University; Shandong University; Southeast University - China	Fan, H (corresponding author), Southeast Univ, Dept Med Genet & Dev Biol, Sch Med, Key Lab Dev Genes & Human Dis,Minist Educ, 87 Dingjiaqiao Rd, Nanjing 210009, Jiangsu, Peoples R China.	fanh@seu.edu.cn			National Natural Science Foundation of China [30470950, 91229107]; National 973 Basic Research Program of China [2013CB911302]; Innovative Scientific Research Projects for College Graduates of Jiangsu Province [CXZZ_0137]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National 973 Basic Research Program of China(National Basic Research Program of China); Innovative Scientific Research Projects for College Graduates of Jiangsu Province	This work was supported by The National Natural Science Foundation of China, no. 30470950, National 973 Basic Research Program of China 2013CB911302, National Natural Science Foundation of China, no. 91229107 and in part by Innovative Scientific Research Projects for College Graduates of Jiangsu Province, no. CXZZ_0137. We thank Professor Guan Xinyuan in the Univrsity of Hong Kong for providing the HBx construct, Dr Olubunmi Afonja in New York University for providing the PDCD4 construct and Dr Heike Allgayer in the University of Heidelberg for providing the PDCD4 promoter constructs.	Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Fan H, 2007, EUR J GASTROEN HEPAT, V19, P952, DOI 10.1097/MEG.0b013e3282c3a89e; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Gao F, 2009, J CELL MOL MED, V13, P4257, DOI 10.1111/j.1582-4934.2008.00497.x; Hajjou M, 2005, J MED VIROL, V77, P57, DOI 10.1002/jmv.20427; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hilliard A, 2006, J IMMUNOL, V177, P8095, DOI 10.4049/jimmunol.177.11.8095; Huang JZ, 2003, WORLD J GASTROENTERO, V9, P84, DOI 10.3748/wjg.v9.i1.84; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Kong GY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019518; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Ladeiro Y, 2008, HEPATOLOGY, V47, P1955, DOI 10.1002/hep.22256; Lankat-Buttgereit B, 2003, BIOL CELL, V95, P515, DOI 10.1016/j.biolcel.2003.09.003; Lee JO, 2005, ONCOGENE, V24, P6617, DOI 10.1038/sj.onc.1208827; Leupold JH, 2012, BIOSCIENCE REP, V32, P281, DOI 10.1042/BSR20110045; Li J, 2010, BMC EVOL BIOL, V10, DOI [10.1186/1471-2148-10-68, 10.1186/1471-2407-10-354]; Lok AS, 2001, GASTROENTEROLOGY, V120, P1828, DOI 10.1053/gast.2001.24839; LUBER B, 1993, RES VIROLOGY, V144, P311, DOI 10.1016/S0923-2516(06)80047-6; Lupberger J, 2007, WORLD J GASTROENTERO, V13, P74, DOI 10.3748/wjg.v13.i1.74; Matsuhashi Sachiko, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P109; Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283; Okabe H, 2001, CANCER RES, V61, P2129; Ozaki I, 2000, CANCER RES, V60, P6519; Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113; Park IY, 2007, GASTROENTEROLOGY, V132, P1476, DOI 10.1053/j.gastro.2007.01.034; Schmid T, 2008, CANCER RES, V68, P1254, DOI 10.1158/0008-5472.CAN-07-1719; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Soejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510; Talotta F, 2009, ONCOGENE, V28, P73, DOI 10.1038/onc.2008.370; Tan A, 2008, LIVER INT, V28, P175, DOI 10.1111/j.1478-3231.2007.01652.x; Tanaka Y, 2006, ONCOGENE, V25, P633, DOI 10.1038/sj.onc.1209093; Tsai CN, 2002, P NATL ACAD SCI USA, V99, P10084, DOI 10.1073/pnas.152059399; Wang Q, 2008, ONCOGENE, V27, P1527, DOI 10.1038/sj.onc.1210793; Wang YL, 2004, HEPATOLOGY, V39, P318, DOI 10.1002/hep.20076; Wang Y, 2010, J HEPATOL, V53, P57, DOI 10.1016/j.jhep.2009.12.043; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yoshinaga H, 1999, PATHOL INT, V49, P1067, DOI 10.1046/j.1440-1827.1999.00995.x; YU MW, 1994, CRIT REV ONCOL HEMAT, V17, P71, DOI 10.1016/1040-8428(94)90020-5; Zhang H, 2006, ONCOGENE, V25, P6101, DOI 10.1038/sj.onc.1209634; Zhang S, 2009, J EXP CLIN CANC RES, V28, P1; Zhang X, 2010, CANCER SCI, V101, P2163, DOI 10.1111/j.1349-7006.2010.01664.x; Zhang XY, 2009, HEPATOLOGY, V50, P490, DOI 10.1002/hep.23008; Zheng DL, 2009, J HEPATOL, V50, P377, DOI 10.1016/j.jhep.2008.10.019	47	95	105	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2013	32	27					3296	3305		10.1038/onc.2013.150	http://dx.doi.org/10.1038/onc.2013.150			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	23604124				2022-12-17	WOS:000321301600009
J	Ezponda, T; Popovic, R; Shah, MY; Martinez-Garcia, E; Zheng, Y; Min, DJ; Will, C; Neri, A; Kelleher, NL; Yu, J; Licht, JD				Ezponda, T.; Popovic, R.; Shah, M. Y.; Martinez-Garcia, E.; Zheng, Y.; Min, D-J; Will, C.; Neri, A.; Kelleher, N. L.; Yu, J.; Licht, J. D.			The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer	ONCOGENE			English	Article						MMSET; histone methylation; epithelial-mesenchymal transition; invasion; prostate cancer	MULTIPLE-MYELOMA; GENE-EXPRESSION; MODIFICATION PATTERNS; UP-REGULATION; PREDICT RISK; MMSET; PROTEIN; CLASSIFICATION; IDENTIFICATION; CHARACTERIZES	Epigenetic deregulation of gene expression has a role in the initiation and progression of prostate cancer (PCa). The histone methyltransferase MMSET/WHSC1 (Multiple Myeloma SET domain) is overexpressed in a number of metastatic tumors, but its mechanism of action has not been defined. In this work, we found that PCa cell lines expressed significantly higher levels of MMSET compared with immortalized, non-transformed prostate cells. Knockdown experiments showed that, in metastatic PCa cell lines, dimethylation of lysine 36 and trimethylation of lysine 27 on histone H3 (H3K36me2 and H3K27me3, respectively) depended on MMSET expression, whereas depletion of MMSET in benign prostatic cells did not affect chromatin modifications. Knockdown of MMSET in DU145 and PC-3 tumor cells decreased cell proliferation, colony formation in soft agar and strikingly diminished cell migration and invasion. Conversely, overexpression of MMSET in immortalized, non-transformed RWPE-1 cells promoted cell migration and invasion, accompanied by an epithelial-mesenchymal transition (EMT). Among a panel of EMT-promoting genes analyzed, TWIST1 expression was strongly activated in response to MMSET. Chromatin immunoprecipitation analysis demonstrated that MMSET binds to the TWIST1 locus and leads to an increase in H3K36me2, suggesting a direct role of MMSET in the regulation of this gene. Depletion of TWIST1 in MMSET-overexpressing RWPE-1 cells blocked cell invasion and EMT, indicating that TWIST1 was a critical target of MMSET, responsible for the acquisition of an invasive phenotype. Collectively, these data suggest that MMSET has a role in PCa pathogenesis and progression through epigenetic regulation of metastasis-related genes.	[Ezponda, T.; Popovic, R.; Shah, M. Y.; Martinez-Garcia, E.; Min, D-J; Will, C.; Kelleher, N. L.; Yu, J.; Licht, J. D.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA; [Zheng, Y.; Kelleher, N. L.] Northwestern Univ, Dept Chem, Dept Mol Biosci, Evanston, IL USA; [Zheng, Y.; Kelleher, N. L.] Northwestern Univ, Chem Life Proc Inst, Evanston, IL USA; [Neri, A.] Univ Milan, Dept Med Sci, Fdn Ist Ricovero & Cura Carattere Sci Policlin, Hematol Ctr Trapianti Midollo Osseo 1, Milan, Italy	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Northwestern University; University of Milan	Licht, JD (corresponding author), Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Feinberg Sch Med, Lurie 5-123,303 E Super St, Chicago, IL 60611 USA.	j-licht@northwestern.edu	Neri, Antonino/I-9690-2014; Licht, Jonathan/AAL-9184-2020; Ezponda, Teresa/AAA-5040-2020; Zheng, Yupeng/B-3782-2014; Licht, Jonathan/L-4239-2019	Neri, Antonino/0000-0001-9047-5912; Licht, Jonathan/0000-0002-3942-1369; Ezponda, Teresa/0000-0003-3682-7125; Zheng, Yupeng/0000-0002-3351-5161	Fundacion Alfonso Martin Escudero fellowship; Ruth Kirschstein National Research Service Award [F32HL099177]; Associazione Italiana Ricerca sul Cancro (AIRC); NIH [K99/R00CA129565]; U.S. Department of Defense [W81XWH-09-1-0193]; American Cancer Society [RSG-12-085-01, R01GM067193, RO1CA123204]; Leukemia and Lymphoma Society Specialized Center of Research Award; Physical Sciences Oncology Center grant [U54CA143869]; NATIONAL CANCER INSTITUTE [R01CA123204, U54CA143869, K99CA129565, P30CA060553] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL099177] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067193] Funding Source: NIH RePORTER	Fundacion Alfonso Martin Escudero fellowship; Ruth Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Defense(United States Department of Defense); American Cancer Society(American Cancer Society); Leukemia and Lymphoma Society Specialized Center of Research Award(Leukemia and Lymphoma Society); Physical Sciences Oncology Center grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by a Fundacion Alfonso Martin Escudero fellowship (T.E.), a Ruth Kirschstein National Research Service Award F32HL099177 (R.P.), the Associazione Italiana Ricerca sul Cancro (AIRC) (A.N.), NIH K99/R00CA129565 (J.Y.), the U.S. Department of Defense W81XWH-09-1-0193 (J.Y.), a Research Scholar Award RSG-12-085-01 from the American Cancer Society (J.Y.), R01GM067193 (N.L.K.), RO1CA123204 (J.D.L.) a Leukemia and Lymphoma Society Specialized Center of Research Award (J.D.L.) and Physical Sciences Oncology Center grant U54CA143869 (J.D.L. and N.L.K.).	Agnelli L, 2005, J CLIN ONCOL, V23, P7296, DOI 10.1200/JCO.2005.01.3870; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Bergsagel PL, 2005, J CLIN ONCOL, V23, P6333, DOI 10.1200/JCO.2005.05.021; Bianco-Miotto T, CANC EPIDEMIOL BIOMA, V19, P2611; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Brito JLR, 2009, HAEMATOL-HEMATOL J, V94, P78, DOI 10.3324/haematol.13426; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Daigle SR, CANC CELL, V20, P53; Garcia BA, 2007, NAT PROTOC, V2, P933, DOI 10.1038/nprot.2007.106; Garlisi CG, 2001, AM J RESP CELL MOL, V24, P90, DOI 10.1165/ajrcmb.24.1.4224; Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022; Hudlebusch HR, CLIN CANC RES, V17, P2919; Hudlebusch HR, CANC RES, V71, P4226; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jeronimo C, 2011, EUR UROL, V60, P753, DOI 10.1016/j.eururo.2011.06.035; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Kassambara A, 2009, BIOCHEM BIOPH RES CO, V379, P840, DOI 10.1016/j.bbrc.2008.12.093; Keats JJ, 2005, BLOOD, V105, P4060, DOI 10.1182/blood-2004-09-3704; Kim JY, 2008, MOL CELL BIOL, V28, P2023, DOI 10.1128/MCB.02130-07; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lauring J, 2008, BLOOD, V111, P856, DOI 10.1182/blood-2007-05-088674; Lennartsson A, 2009, BBA-GEN SUBJECTS, V1790, P863, DOI 10.1016/j.bbagen.2008.12.006; Li J, 2008, NEURO-ONCOLOGY, V10, P45, DOI 10.1215/15228517-2007-036; Li Y, 2009, J BIOL CHEM, V284, P34283, DOI 10.1074/jbc.M109.034462; Lombardi L, 2007, GENE CHROMOSOME CANC, V46, P226, DOI 10.1002/gcc.20404; MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054; Marango J, 2008, BLOOD, V111, P3145, DOI 10.1182/blood-2007-06-092122; Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349; Mellor J, 2005, MOL CELL, V19, P147, DOI 10.1016/j.molcel.2005.06.023; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Morishita M, 2011, BBA-REV CANCER, V1816, P158, DOI 10.1016/j.bbcan.2011.05.004; Okabe H, 2001, CANCER RES, V61, P2129; Perry AS, 2010, NAT REV UROL, V7, P668, DOI 10.1038/nrurol.2010.185; Schulz WA, 2006, J CELL MOL MED, V10, P100, DOI 10.1111/j.1582-4934.2006.tb00293.x; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Toyokawa G, 2011, NEOPLASIA, V13, P887, DOI 10.1593/neo.11048; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vedadi M, 2011, NAT CHEM BIOL, V7, P566, DOI [10.1038/NCHEMBIO.599, 10.1038/nchembio.599]; Volkel P, 2007, BIOCHIMIE, V89, P1, DOI 10.1016/j.biochi.2006.07.009; Wang GG, 2007, NAT CELL BIOL, V9, P804, DOI 10.1038/ncb1608; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yegnasubramanian S, 2004, CANCER RES, V64, P1975, DOI 10.1158/0008-5472.CAN-03-3972; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zhuo WL, 2008, BIOCHEM BIOPH RES CO, V369, P1098, DOI 10.1016/j.bbrc.2008.02.143	52	95	103	1	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2013	32	23					2882	2890		10.1038/onc.2012.297	http://dx.doi.org/10.1038/onc.2012.297			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WR	22797064	Green Accepted			2022-12-17	WOS:000320369100008
J	Galeano, F; Rossetti, C; Tomaselli, S; Cifaldi, L; Lezzerini, M; Pezzullo, M; Boldrini, R; Massimi, L; Di Rocco, CM; Locatelli, F; Gallo, A				Galeano, F.; Rossetti, C.; Tomaselli, S.; Cifaldi, L.; Lezzerini, M.; Pezzullo, M.; Boldrini, R.; Massimi, L.; Di Rocco, C. M.; Locatelli, F.; Gallo, A.			ADAR2-editing activity inhibits glioblastoma growth through the modulation of the CDC14B/Skp2/p21/p27 axis	ONCOGENE			English	Article						RNA editing; ADAR2; GBM; cell cycle; CDC14B	TO-INOSINE RNA; MESSENGER-RNA; DOWN-REGULATION; EDITING SITES; CELL-CYCLE; SKP2; ENZYME; P21; IDENTIFICATION; HYBRIDIZATION	Grade IV astrocytoma or glioblastoma multiforme (GBM) is one of the most aggressive and lethal tumors affecting humans. ADAR2-mediated A-to-I RNA editing, an essential post-transcriptional modification event in brain, is impaired in GBMs and astrocytoma cell lines. However, the role of ADAR2 editing in astrocytomas remains to be defined. Here, we show that ADAR2 editing rescue in astrocytomas prevents tumor growth in vivo and modulates an important cell cycle pathway involving the Skp2/p21/p27 proteins, often altered in glioblastoma. We demonstrate that ADAR2 deaminase activity is essential to inhibit tumor growth. Indeed, we identify the phosphatase CDC14B, which acts upstream of the Skp2/p21/p27 pathway, as a novel and critical ADAR2 target gene involved in glioblastonna growth. Specifically, ADAR2-mediated editing on CDC14B pre-mRNA increases its expression with a consequent reduction of the Skp2 target protein, as shown both in vitro and in vivo. We found that, compared to normal brain, both CDC14B editing and expression are progressively impaired in astrocytomas from grade I to IV, being very low in GBMs. These findings (1) demonstrate that post-transcriptional A-to-I RNA editing might be crucial for glioblastoma pathogenesis, (2) identify ADAR2-editing enzyme as a novel candidate tumor suppressor gene and (3) provide proof of principle that ADAR2 or its substrates may represent a suitable target(s) for possible novel, more effective and less toxic approaches to the treatment of GBMs. Oncogene (2013) 32, 998-1009; doi:10.1038/onc.2012.125; published online 23 April 2012	[Galeano, F.; Rossetti, C.; Tomaselli, S.; Cifaldi, L.; Lezzerini, M.; Pezzullo, M.; Boldrini, R.; Locatelli, F.; Gallo, A.] IRCCS, Osped Pediat Bambino Gesu, Oncohaematol Dept, Lab RNA Editing, I-00165 Rome, Italy; [Massimi, L.; Di Rocco, C. M.] Policlin Gemelli, Pediat Neurosurg Dept, Rome, Italy; [Locatelli, F.] Univ Pavia, Oncohaematol Dept, I-27100 Pavia, Italy	IRCCS Bambino Gesu; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Pavia	Gallo, A (corresponding author), IRCCS, Osped Pediat Bambino Gesu, Oncohaematol Dept, Lab RNA Editing, Piazza S Onofrio 4, I-00165 Rome, Italy.	angela.gallo@opbg.net	Gallo, Angela/E-7837-2011; Gallo, Angela/AAA-5003-2020; Pezzullo, Marco/AAI-2404-2019; Cifaldi, Loredana/AAI-1972-2019	Gallo, Angela/0000-0003-0297-1807; Gallo, Angela/0000-0003-0297-1807; Cifaldi, Loredana/0000-0001-5014-430X	Associazione Italiana per la Ricerca sul Cancro (AIRC, Milan, Italy); AIRC	Associazione Italiana per la Ricerca sul Cancro (AIRC, Milan, Italy)(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro)	This study was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC, Milan, Italy) grant to A Gallo and a special project 5 x 1000 AIRC grant to F Locatelli. The authors are grateful to Genevieve Rodier for the CDC14B clones, to Alekos Athanasiadis and to Ernesto Picardi for bioinformatics support and to Mattia Locatelli for statistical analysis.	Abukhdeir Abde M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000744; Athanasiadis A, 2004, PLOS BIOL, V2, P2144, DOI 10.1371/journal.pbio.0020391; BASILIO C, 1962, P NATL ACAD SCI USA, V48, P613, DOI 10.1073/pnas.48.4.613; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; Bassermann F, 2008, CELL, V134, P256, DOI 10.1016/j.cell.2008.05.043; Cenci C, 2008, J BIOL CHEM, V283, P7251, DOI 10.1074/jbc.M708316200; Chen LL, 2008, CELL CYCLE, V7, P3294, DOI 10.4161/cc.7.21.6927; Chiarle R, 2002, AM J PATHOL, V160, P1457, DOI 10.1016/S0002-9440(10)62571-0; Chiesa M, 2011, CELL CYCLE, V10, P1607, DOI 10.4161/cc.10.10.15566; Colman H, 2010, NEURO-ONCOLOGY, V12, P49, DOI 10.1093/neuonc/nop007; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dominissini D, 2011, CARCINOGENESIS, V32, P1569, DOI 10.1093/carcin/bgr124; Farajollahi S, 2010, TRENDS GENET, V26, P221, DOI 10.1016/j.tig.2010.02.001; Galeano F, 2010, INT J CANCER, V127, P127, DOI 10.1002/ijc.25022; Gallo A, 2003, EMBO J, V22, P3421, DOI 10.1093/emboj/cdg327; Gallo A, 2011, BIOL REV CAMB PHILOS, V87, P95, DOI DOI 10.1111/J.1469-185X.2011.00186.X; Greenberger S, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-608; Greger IH, 2002, NEURON, V34, P759, DOI 10.1016/S0896-6273(02)00693-1; Halfter H, 2006, CANCER RES, V66, P6530, DOI 10.1158/0008-5472.CAN-04-3734; Heale BSE, 2009, EMBO J, V28, P3145, DOI 10.1038/emboj.2009.244; Hershko DD, 2008, CANCER-AM CANCER SOC, V112, P1415, DOI 10.1002/cncr.23317; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; Ishiuchi S, 2002, NAT MED, V8, P971, DOI 10.1038/nm746; Jackson RJ, 2003, CANCER RES, V63, P3021; Keegan LP, 2001, NAT REV GENET, V2, P869, DOI 10.1038/35098584; Kiran A, 2010, BIOINFORMATICS, V26, P1772, DOI 10.1093/bioinformatics/btq285; Kitagawa K, 2009, CANCER SCI, V100, P1374, DOI 10.1111/j.1349-7006.2009.01196.x; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; Kwon CH, 2008, CANCER RES, V68, P3286, DOI 10.1158/0008-5472.CAN-07-6867; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; Lee SH, 2005, J MOL MED, V83, P296, DOI 10.1007/s00109-004-0611-7; Levanon EY, 2004, NAT BIOTECHNOL, V22, P1001, DOI 10.1038/nbt996; Li JB, 2009, SCIENCE, V324, P1210, DOI 10.1126/science.1170995; Maas S, 2001, P NATL ACAD SCI USA, V98, P14687, DOI 10.1073/pnas.251531398; Macbeth MR, 2005, SCIENCE, V309, P1534, DOI 10.1126/science.1113150; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Martin-Caballero J, 2004, ONCOGENE, V23, P8231, DOI 10.1038/sj.onc.1207863; Nakayama KI, 2005, SEMIN CELL DEV BIOL, V16, P323, DOI 10.1016/j.semcdb.2005.02.010; Nishikura K, 2004, NAT BIOTECHNOL, V22, P962, DOI 10.1038/nbt0804-962; Nishikura K, 2006, NAT REV MOL CELL BIO, V7, P919, DOI 10.1038/nrm2061; Nishikura K, 2010, ANNU REV BIOCHEM, V79, P321, DOI 10.1146/annurev-biochem-060208-105251; Ohlson J, 2007, RNA, V13, P698, DOI 10.1261/rna.349107; Paul MS, 1998, EMBO J, V17, P1120, DOI 10.1093/emboj/17.4.1120; Paz N, 2007, GENOME RES, V17, P1586, DOI 10.1101/gr.6493107; Picardi E, 2011, BIOINFORMATICS, V27, P1311, DOI 10.1093/bioinformatics/btr117; Rodier G, 2008, EMBO J, V27, P679, DOI 10.1038/emboj.2008.6; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; Saigusa K, 2005, CANCER SCI, V96, P676, DOI 10.1111/j.1349-7006.2005.00099.x; Schiffer D, 2002, NEUROSCI LETT, V328, P125, DOI 10.1016/S0304-3940(02)00483-4; Seeburg PH, 1998, BRAIN RES REV, V26, P217, DOI 10.1016/S0165-0173(97)00062-3; Seeburg PH, 2002, NEURON, V35, P17, DOI 10.1016/S0896-6273(02)00760-2; Stupp Roger, 2005, Curr Neurol Neurosci Rep, V5, P198, DOI 10.1007/s11910-005-0047-7; Tumurbaatar I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014711; Wahlstedt H, 2009, GENOME RES, V19, P978, DOI 10.1101/gr.089409.108; Yang L, 2010, FASEB J, V24, P3720, DOI 10.1096/fj.09-152363; Zhu Y, 2005, CANCER CELL, V8, P119, DOI 10.1016/j.ccr.2005.07.004; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	59	95	100	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2013	32	8					998	1009		10.1038/onc.2012.125	http://dx.doi.org/10.1038/onc.2012.125			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22525274	Green Published, hybrid			2022-12-17	WOS:000316523200007
J	Serrano, I; McDonald, PC; Lock, FE; Dedhar, S				Serrano, I.; McDonald, P. C.; Lock, F. E.; Dedhar, S.			Role of the integrin-linked kinase (ILK)/Rictor complex in TGF beta-1-induced epithelial-mesenchymal transition (EMT)	ONCOGENE			English	Article						integrin-linked kinase; breast epithelial cells; ILK/Rictor complex; EMT; Rictor; cancer	GLYCOGEN-SYNTHASE KINASE-3; E-CADHERIN REPRESSOR; BREAST-CANCER CELLS; TGF-BETA; MAMMALIAN TARGET; EXPRESSION; RICTOR; SNAIL; PHOSPHORYLATION; ACTIVATION	Epithelial-to-mesenchymal transition (EMT) causes fibrosis, cancer progression and metastasis. Integrin-linked kinase (ILK) is a focal adhesion adaptor and a serine/threonine protein kinase that regulates cell proliferation, survival and EMT. Elucidating the molecular mechanisms necessary for development and progression of human malignancies is critical to predict the most appropriate targets for cancer therapy. Here, we used transforming growth factor beta-1 (TGF beta-1) to promote EMT and migration in mammary epithelial cells. We demonstrate a requirement of ILK activity for TGF beta-1-mediated EMT in mammary epithelial cells. In addition to nuclear translocation of Snail and Slug, TGF beta-1 treatment also induced expression of the mammalian target of rapamycin complex 2 component Rictor and its phosphorylation on Thr1135. Interestingly, TGF beta-1 treatment also induced an interaction between ILK and Rictor. All of these TGF beta-1-induced processes were significantly suppressed by inhibiting ILK activity or by disrupting the ILK/Rictor complex using small-interfering RNA-mediated knockdown. Furthermore, we identified ILK/Rictor complex formation in cancer but not in normal cell types, and this was accompanied by ILK-dependent phosphorylation of Rictor on residue Thr1135. Inhibition of ILK partially reversed the basal mesenchymal phenotype of MDA-MB-231 cells and prevented EMT in MCF10A cells after TGF beta-1 treatment. These data demonstrate a requirement for ILK function in TGF beta-1-induced EMT in mammary epithelial cells and identify the ILK/Rictor complex as a potential molecular target for preventing/reversing EMT. Oncogene (2013) 32, 50-60; doi:10.1038/onc.2012.30; published online 6 February 2012	[Dedhar, S.] Univ British Columbia, BC Canc Res Ctr, Inst Life Sci, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1L3, Canada; [Serrano, I.; McDonald, P. C.; Lock, F. E.; Dedhar, S.] BC Canc Agcy, British Columbia Canc Res Ctr, Dept Integrat Oncol, Vancouver, BC, Canada	British Columbia Cancer Agency; University of British Columbia; British Columbia Cancer Agency	Dedhar, S (corresponding author), Univ British Columbia, BC Canc Res Ctr, Inst Life Sci, Dept Biochem & Mol Biol, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	sdedhar@bccrc.ca		Dedhar, Shoukat/0000-0003-4355-1657	Canadian Cancer Society Research Institute (CCSRI); Canadian Institutes for Health Research (CIHR)	Canadian Cancer Society Research Institute (CCSRI)(Canadian Cancer Society (CCS)); Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	This study was supported by grants to SD from the Canadian Cancer Society Research Institute (CCSRI) and the Canadian Institutes for Health Research (CIHR). We thank Quadra Logic Technology Inc (QLT Inc), Vancouver, BC, for supplying QLT-0267.	Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Boulbes D, 2010, MOL CANCER RES, V8, P896, DOI 10.1158/1541-7786.MCR-09-0409; Garcia SAD, 2011, CANCER MICROENVIRON, V4, P33, DOI 10.1007/s12307-010-0059-y; Dibble CC, 2009, MOL CELL BIOL, V29, P5657, DOI 10.1128/MCB.00735-09; Doble BW, 2007, CELLS TISSUES ORGANS, V185, P73, DOI 10.1159/000101306; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Dzwonek J, 2009, MOL CANCER RES, V7, P1342, DOI 10.1158/1541-7786.MCR-08-0558; Fielding AB, 2008, CELL CYCLE, V7, P1899, DOI 10.4161/cc.7.13.6204; Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003; Futterman MA, 2011, DEV DYNAM, V240, P1502, DOI 10.1002/dvdy.22607; Gao H, 2012, CELL BIOL INT, V36, P155, DOI 10.1042/CBI20100240; Garcia G, 2009, J MED CHEM, V52, P7220, DOI 10.1021/jm9003957; Gil D, 2011, ADV ENZYME REGUL, V51, P195, DOI 10.1016/j.advenzreg.2010.09.005; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hong-Brown LQ, 2011, ALCOHOL CLIN EXP RES, V35, P1445, DOI 10.1111/j.1530-0277.2011.01480.x; Jing YY, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-29; Jo M, 2009, J BIOL CHEM, V284, P22825, DOI 10.1074/jbc.M109.023960; Julien LA, 2010, MOL CELL BIOL, V30, P908, DOI 10.1128/MCB.00601-09; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kavvadas P, 2010, VIRCHOWS ARCH, V457, P563, DOI 10.1007/s00428-010-0976-7; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Lee YI, 2004, BIOCHEM BIOPH RES CO, V316, P997, DOI 10.1016/j.bbrc.2004.02.150; Li YJ, 2009, J AM SOC NEPHROL, V20, P1907, DOI 10.1681/ASN.2008090930; Margadant C, 2010, EMBO REP, V11, P97, DOI 10.1038/embor.2009.276; Matsui Y, 2012, INT J CANCER, V130, P521, DOI 10.1002/ijc.26008; McDonald PC, 2008, J CELL SCI, V121, P3121, DOI 10.1242/jcs.017996; McDonald PC, 2008, CANCER RES, V68, P1618, DOI 10.1158/0008-5472.CAN-07-5869; McPhee TR, 2008, DEV DYNAM, V237, P2737, DOI 10.1002/dvdy.21685; Mikami S, 2011, LAB INVEST, V91, P1443, DOI 10.1038/labinvest.2011.111; Oh JS, 2002, NEOPLASIA, V4, P204, DOI 10.1038/sj.neo.7900229; Papanikolaou S, 2010, HISTOPATHOLOGY, V56, P799, DOI 10.1111/j.1365-2559.2010.03556.x; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Piek E, 1999, J CELL SCI, V112, P4557; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110; Somasiri A, 2001, J CELL SCI, V114, P1125; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Treins C, 2010, ONCOGENE, V29, P1003, DOI 10.1038/onc.2009.401; Troussard AA, 2006, CANCER RES, V66, P393, DOI 10.1158/0008-5472.CAN-05-2304; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhao JH, 2011, CANCER INVEST, V29, P377, DOI 10.3109/07357907.2010.512595; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	49	95	109	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					50	60		10.1038/onc.2012.30	http://dx.doi.org/10.1038/onc.2012.30			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22310280				2022-12-17	WOS:000313029500005
J	Lakshmanan, I; Ponnusamy, MP; Das, S; Chakraborty, S; Haridas, D; Mukhopadhyay, P; Lele, SM; Batra, SK				Lakshmanan, I.; Ponnusamy, M. P.; Das, S.; Chakraborty, S.; Haridas, D.; Mukhopadhyay, P.; Lele, S. M.; Batra, S. K.			MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells	ONCOGENE			English	Article						MUC16; JNK; Aurora kinase; Cyclin B1; G2/M arrest and breast cancer	N-TERMINAL DOMAIN; AURORA-A; C-JUN; TRANSCRIPTION FACTORS; CYCLE INHIBITORS; EPITHELIAL-CELLS; TYROSINE KINASE; MITOTIC ENTRY; DNA-DAMAGE; PHOSPHORYLATION	MUC16/CA125 is a tumor marker currently used in clinics for the follow-up of patients with ovarian cancer. However, MUC16 expression is not entirely restricted to ovarian malignancies and has been reported in other cancers including breast cancer. Although it is well established as a biomarker, function of MUC16 in cancer remains to be elucidated. In the present study, we investigated the role of MUC16 in breast cancer and its underlying mechanisms. Interestingly, our results showed that MUC16 is overexpressed in breast cancer tissues whereas not expressed in non-neoplastic ducts. Further, stable knockdown of MUC16 in breast cancer cells (MDA MB 231 and HBL100) resulted in significant decrease in the rate of cell growth, tumorigenicity and increased apoptosis. In search of a mechanism for breast cancer cell proliferation we found that MUC16 interacts with the ezrin/radixin/moesin domain-containing protein of Janus kinase ( JAK2) as demonstrated by the reciprocal immunoprecipitation method. These interactions mediate phosphorylation of STAT3 (Tyr705), which might be a potential mechanism for MUC16-induced proliferation of breast cancer cells by a subsequent co-transactivation of transcription factor c-Jun. Furthermore, silencing of MUC16 induced G2/M arrest in breast cancer cells through downregulation of Cyclin B1 and decreased phosphorylation of Aurora kinase A. This in turn led to enhanced apoptosis in the MUC16-knockdown breast cancer cells through Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated extrinsic apoptotic pathway with the help of c-Jun N-terminal kinase signaling. Collectively, our results suggest that MUC16 has a dual role in breast cancer cell proliferation by interacting with JAK2 and by inhibiting the apoptotic process through downregulation of TRAIL. Oncogene (2012) 31, 805-817; doi: 10.1038/onc.2011.297; published online 25 July 2011	[Batra, S. K.] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Lele, S. M.; Batra, S. K.] Univ Nebraska, Med Ctr, Dept Pathol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	sbatra@unmc.edu		Mukhopadhyay, Partha/0000-0001-5817-0174; lakshmanan, Imayavaramban/0000-0003-1733-2223; Palanimuthu Ponnusamy, Moorthy/0000-0001-5744-193X	National Institutes of Health [CA78590, CA111294, CA133774, CA131944]; Department of Defense [BC101014]; NATIONAL CANCER INSTITUTE [R01CA133774, R01CA078590, R01CA131944, U01CA111294] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are supported by grants from the National Institutes of Health (CA78590, CA111294, CA133774 and CA131944) and Department of Defense (BC101014). We thank Dr Jessica Mercer, Editorial Grants Associate at UNMC, for carefully editing this manuscript. We also acknowledge Erik Moore and Kavita Mallya for their technical support. We also thank Janice A Tayor and James R Talaska of the confocal laser scanning microscope core facility at UNMC for their support.	Bafna S, 2008, CANCER RES, V68, P9231, DOI 10.1158/0008-5472.CAN-08-3135; Bast RC, 1998, INT J BIOL MARKER, V13, P179, DOI 10.1177/172460089801300402; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Blalock TD, 2007, INVEST OPHTH VIS SCI, V48, P4509, DOI 10.1167/iovs.07-0430; Bode AM, 2007, MOL CARCINOGEN, V46, P591, DOI 10.1002/mc.20348; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Chaturvedi P, 2008, CANCER RES, V68, P2065, DOI 10.1158/0008-5472.CAN-07-6041; Chen M, 1997, P NATL ACAD SCI USA, V94, P6910, DOI 10.1073/pnas.94.13.6910; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fendrick JL, 1997, TUMOR BIOL, V18, P278, DOI 10.1159/000218041; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; Fujimoto K, 1999, INT J CANCER, V81, P637, DOI 10.1002/(SICI)1097-0215(19990517)81:4<637::AID-IJC21>3.0.CO;2-4; Gamet-Payrastre L, 2000, CANCER RES, V60, P1426; Ginsberg M, 2007, MOL CELL BIOL, V27, P6300, DOI 10.1128/MCB.00613-07; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hattrup CL, 2008, ANNU REV PHYSIOL, V70, P431, DOI 10.1146/annurev.physiol.70.113006.100659; He LL, 2008, J BIOL CHEM, V283, P31012, DOI 10.1074/jbc.M803547200; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Huang YL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005397; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Korgun ET, 2006, HISTOCHEM CELL BIOL, V125, P615, DOI 10.1007/s00418-006-0160-y; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li GC, 2003, DEV CELL, V4, P865, DOI 10.1016/S1534-5807(03)00159-X; Lin HH, 2007, INT J CANCER, V120, P2306, DOI 10.1002/ijc.22571; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Moritani S, 2008, HUM PATHOL, V39, P666, DOI 10.1016/j.humpath.2007.09.009; Munoz-Pinedo C, 2006, P NATL ACAD SCI USA, V103, P11573, DOI 10.1073/pnas.0603007103; Munro EG, 2009, INT J GYNECOL PATHOL, V28, P127, DOI 10.1097/PGP.0b013e318184f3e0; O'Brien TJ, 2002, TUMOR BIOL, V23, P154, DOI 10.1159/000064032; Orren DK, 1997, MOL BIOL CELL, V8, P1129, DOI 10.1091/mbc.8.6.1129; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Perez BH, 2008, EXP EYE RES, V87, P400, DOI 10.1016/j.exer.2007.12.008; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Rahman M, 2009, BREAST CANCER RES TR, V113, P217, DOI 10.1007/s10549-008-9924-5; Rakha EA, 2005, MODERN PATHOL, V18, P1295, DOI 10.1038/modpathol.3800445; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Singh PK, 2007, CANCER RES, V67, P5201, DOI 10.1158/0008-5472.CAN-06-4647; Tanaka H, 2002, J CELL BIOL, V158, P321, DOI 10.1083/jcb.200202071; Tong W, 1999, MOL CELL BIOL, V19, P2251; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Watson CJ, 2001, J MAMMARY GLAND BIOL, V6, P115, DOI 10.1023/A:1009524817155; Wu YM, 2009, J PROTEOME RES, V8, P1876, DOI 10.1021/pr8008379; Yin BWT, 2002, INT J CANCER, V98, P737, DOI 10.1002/ijc.10250; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Yue P, 2009, EXPERT OPIN INV DRUG, V18, P45, DOI [10.1517/13543780802565791, 10.1517/13543780802565791 ]; Zenz R, 2003, DEV CELL, V4, P879, DOI 10.1016/S1534-5807(03)00161-8; Zhao LQ, 2010, BIOCHEM J, V426, P91, DOI 10.1042/BJ20090615	59	95	105	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	7					805	817		10.1038/onc.2011.297	http://dx.doi.org/10.1038/onc.2011.297			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21785467	Green Accepted			2022-12-17	WOS:000300615800001
J	King, CE; Wang, L; Winograd, R; Madison, BB; Mongroo, PS; Johnstone, CN; Rustgi, AK				King, C. E.; Wang, L.; Winograd, R.; Madison, B. B.; Mongroo, P. S.; Johnstone, C. N.; Rustgi, A. K.			LIN28B fosters colon cancer migration, invasion and transformation through let-7-dependent and -independent mechanisms	ONCOGENE			English	Article						LIN28B; LIN28; Let-7; colon cancer; LGR5; PROM1	LET-7 MICRORNA; C-MYC; STEM-CELLS; EXPRESSION; IDENTIFICATION; LIN-28; CONSERVATION; ASSOCIATION; SUPPRESSOR; MATURATION	Lin28b is an RNA-binding protein that inhibits biogenesis of let-7 microRNAs. LIN28B is overexpressed in diverse cancers, yet a specific role in the molecular pathogenesis of colon cancer has to be elucidated. We have determined that human colon tumors exhibit decreased levels of mature let-7 isoforms and increased expression of LIN28B. To determine LIN28B's mechanistic role in colon cancer, we expressed LIN28B in immortalized colonic epithelial cells and human colon cancer cell lines. We found that LIN28B promotes cell migration, invasion and transforms immortalized colonic epithelial cells. In addition, constitutive LIN28B expression increases expression of intestinal stem cell markers LGR5 and PROM1 in the presence of let-7 restoration. This may occur as a result of Lin28b protein binding LGR5 and PROM1 mRNA, suggesting that a subset of LIN28B functions is independent of its ability to repress let-7. Our findings establish a new role for LIN28B in human colon cancer pathogenesis, and suggest LIN28B post-transcriptionally regulates LGR5 and PROM1 through a let-7-independent mechanism. Oncogene (2011) 30, 4185-4193; doi:10.1038/onc.2011.131; published online 30 May 2011	[Rustgi, A. K.] Univ Penn, Dept Med, Dept Genet, Div Gastroenterol,Abramson Canc Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Rustgi, AK (corresponding author), Univ Penn, Dept Med, Dept Genet, Div Gastroenterol,Abramson Canc Ctr, 415 Curie Blvd,600 CRB, Philadelphia, PA 19104 USA.	anil2@mail.med.upenn.edu			Pfizer; NIH/NIDDK Center for Molecular Studies in Digestive and Liver Diseases [P30-DK050306]; NIH [U01-DK085551]; NIH ARRA [NIH P30 DK050306];  [R01-DK056645]; NATIONAL CANCER INSTITUTE [P30CA016520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306, R01DK056645, U01DK085551] Funding Source: NIH RePORTER	Pfizer(Pfizer); NIH/NIDDK Center for Molecular Studies in Digestive and Liver Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH ARRA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by R01-DK056645 (AR, CK and PM). Hauser Foundation, National Colon Cancer Research Alliance (EIF) and American Cancer Society Research Professorship (AR). Catrina King is a Pfizer Animal Health scholarship recipient, a doctoral candidate in Biomedical Graduate Studies, and a student of the School of Veterinary Medicine at the University of Pennsylvania. We thank Dr Joshua Mendell for gifts of LIN28B expression vectors, as well as Ben Rhoades and Mark Bowser for technical assistance. We also acknowledge help from the NIH/NIDDK P30-DK050306 Center for Molecular Studies in Digestive and Liver Diseases and its Molecular Biology and Cell Culture Core Facilities and NIH U01-DK085551. Louise Wang was supported by an NIH ARRA student fellowship through the NIH P30 DK050306.	Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903; Balzer E, 2010, DEVELOPMENT, V137, P891, DOI 10.1242/dev.042895; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Boyerinas B, 2008, CANCER RES, V68, P2587, DOI 10.1158/0008-5472.CAN-08-0264; Chang TC, 2009, P NATL ACAD SCI USA, V106, P3384, DOI 10.1073/pnas.0808300106; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; FLINT N, 1991, BIOCHEM J, V280, P331, DOI 10.1042/bj2800331; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Guo YQ, 2006, GENE, V384, P51, DOI 10.1016/j.gene.2006.07.011; Hafner Markus, 2010, J Vis Exp, DOI 10.3791/2034; Hagan JP, 2009, NAT STRUCT MOL BIOL, V16, P1021, DOI 10.1038/nsmb.1676; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heo I, 2008, MOL CELL, V32, P276, DOI 10.1016/j.molcel.2008.09.014; Heo I, 2009, CELL, V138, P696, DOI 10.1016/j.cell.2009.08.002; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Keene JD, 2006, NAT PROTOC, V1, P302, DOI 10.1038/nprot.2006.47; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Moss EG, 2003, DEV BIOL, V258, P432, DOI 10.1016/S0012-1606(03)00126-X; Park SM, 2007, CELL CYCLE, V6, P2585, DOI 10.4161/cc.6.21.4845; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065; Polesskaya A, 2007, GENE DEV, V21, P1125, DOI 10.1101/gad.415007; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Shell S, 2007, P NATL ACAD SCI USA, V104, P11400, DOI 10.1073/pnas.0704372104; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; Snippert HJ, 2009, GASTROENTEROLOGY, V136, P2187, DOI 10.1053/j.gastro.2009.03.002; STEWART J, 1986, BRIT J CANCER, V53, P1, DOI 10.1038/bjc.1986.1; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Uchida H, 2010, CANCER SCI, V101, P1731, DOI 10.1111/j.1349-7006.2010.01571.x; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhao YC, 2011, BREAST CANCER RES TR, V127, P69, DOI 10.1007/s10549-010-0972-2; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589	40	95	104	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	40					4185	4193		10.1038/onc.2011.131	http://dx.doi.org/10.1038/onc.2011.131			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	833ZK	21625210	Green Accepted			2022-12-17	WOS:000295924600005
J	Standiford, TJ; Kuick, R; Bhan, U; Chen, J; Newstead, M; Keshamouni, VG				Standiford, T. J.; Kuick, R.; Bhan, U.; Chen, J.; Newstead, M.; Keshamouni, V. G.			TGF-beta-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth	ONCOGENE			English	Article						IRAK-M; TGF-beta; lung cancer; tumor-associated macrophages; Toll-like receptors	TOLL-LIKE RECEPTORS; TRANSFORMING GROWTH-FACTOR-BETA-1 LEVEL; NEGATIVE REGULATOR; SIGNALING PATHWAY; IMMUNE-RESPONSES; INNATE IMMUNITY; HUMAN MONOCYTES; EARLY-STAGE; CANCER; ADENOCARCINOMA	Tumor-associated macrophages (TAMs) constitute a major component of the immune cell infiltrate observed in the tumor microenvironment (TME). Factors present in the TME, including tumor growth factor-beta (TGF-beta), allow tumors to circumvent host-mediated immune responses to promote tumor progression. However, the molecular mechanism(s) involved are not clear. Toll-like receptors (TLRs) are important mediators of innate immune responses by immune cells, whose activation triggers the production of molecules required for antitumoral responses. Interleukin (IL) receptor-associated kinase (IRAK)-M is an inactive serine/threonine kinase, predominantly expressed in macrophages and is a potent negative regulator of TLR signaling. In this study, we show that TAMs express significantly higher levels of IRAK-M compared with peritoneal macrophages in a syngeneic mouse model of lung cancer. Subcutaneous implantation of Lewis lung carcinoma cells in IRAK-M-/- mice resulted in a five-fold reduction in tumor growth as compared with tumors in wild-type (WT) animals. Furthermore, compared with WT TAMs, TAMs isolated from IRAK-M-/- mice displayed features of a classically activated (M1) rather than alternatively activated (M2) phenotype, as manifest by greater expression of IL-12, interferon-gamma (IFN-gamma) and inducible nitric oxide synthase. Human lung cancer cells induced IRAK-M expression in human peripheral blood mononuclear cells (PBMCs) when co-cultured together. Tumor cell-induced expression of IRAK-M was dependent on the activation of TGF-beta pathway. Similarly, treatment of human PBMCs or mouse macrophage cell line, RAW 264.4, with TGF-beta, induced IRAK-M expression. Interestingly, IRAK-M gene expression in 439 human lung adenocarcinoma tumors correlated with poor survival in patients with lung cancer. Together, our data demonstrates that TGF-beta-dependent induction of IRAK-M expression is an important, clinically relevant mechanism by which tumors may circumvent anti-tumor responses of macrophages. Oncogene (2011) 30, 2475-2484; doi:10.1038/onc.2010.619; published online 31 January 2011	[Standiford, T. J.; Bhan, U.; Chen, J.; Newstead, M.; Keshamouni, V. G.] Univ Michigan, Med Ctr, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA; [Kuick, R.; Keshamouni, V. G.] Univ Michigan, Med Ctr, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Keshamouni, VG (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Pulm & Crit Care Med, 4062 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	vkeshamo@med.umich.edu		Keshamouni, Venkateshwar/0000-0003-1947-791X	NIH/NCI [R01 CA132571-01]; American Cancer Society [RSG-CSM-116801]; NIH/NHLBI [HL25243, HL097564]; NATIONAL CANCER INSTITUTE [R01CA132571] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL097564] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This research is funded by the NIH/NCI (R01 CA132571-01), and the American Cancer Society (RSG-CSM-116801) grants to VGK, and NIH/NHLBI HL25243 and HL097564 to TJS.	Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Ben-Baruch A, 2006, SEMIN CANCER BIOL, V16, P38, DOI 10.1016/j.semcancer.2005.07.006; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; de Vos AF, 2009, J IMMUNOL, V183, P533, DOI 10.4049/jimmunol.0802189; del Fresno C, 2005, J IMMUNOL, V174, P3032, DOI 10.4049/jimmunol.174.5.3032; Deng JC, 2006, J CLIN INVEST, V116, P2532, DOI 10.1172/JCI28054; Edwards BK, 2005, JNCI-J NATL CANCER I, V97, P1407, DOI 10.1093/jnci/dji289; Elgert KD, 1998, J LEUKOCYTE BIOL, V64, P275, DOI 10.1002/jlb.64.3.275; Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Hasegawa Y, 2001, CANCER-AM CANCER SOC, V91, P964, DOI 10.1002/1097-0142(20010301)91:5<964::AID-CNCR1086>3.0.CO;2-O; JACOBSEN SEW, 1991, BLOOD, V78, P2239, DOI 10.1182/blood.V78.9.2239.bloodjournal7892239; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Johnson SK, 2000, LUNG CANCER-J IASLC, V27, P27, DOI 10.1016/S0169-5002(99)00095-1; Kim WS, 1999, ANTICANCER RES, V19, P301; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kong FM, 1999, CANCER-AM CANCER SOC, V86, P1712, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1712::AID-CNCR12>3.0.CO;2-V; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; McCartney-Francis N, 2004, J IMMUNOL, V172, P3814, DOI 10.4049/jimmunol.172.6.3814; Moustakas A, 2003, GENE DEV, V17, P2855, DOI 10.1101/gad.1161403; Mytar B, 2003, J LEUKOCYTE BIOL, V74, P1094, DOI 10.1189/jlb.0403140; Naiki Y, 2005, J BIOL CHEM, V280, P5491, DOI 10.1074/jbc.C400503200; Pan HJ, 2010, J IMMUNOL, V184, P5502, DOI 10.4049/jimmunol.0901601; Pardoll D, 2003, ANNU REV IMMUNOL, V21, P807, DOI 10.1146/annurev.immunol.21.120601.141135; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Reddy RC, 2004, AM J PHYSIOL-LUNG C, V286, pL613, DOI 10.1152/ajplung.00206.2003; Rosati O, 2002, BIOCHEM BIOPH RES CO, V293, P1472, DOI 10.1016/S0006-291X(02)00411-4; Scagliotti G, 2003, LUNG CANCER-J IASLC, V42, pS47, DOI 10.1016/S0169-5002(03)00304-0; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Seya T, 2003, ANTICANCER RES, V23, P4369; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Souquet PJ, 2001, LUNG CANCER-J IASLC, V34, pS155, DOI 10.1016/S0169-5002(01)00361-0; Toonkel RL, 2010, J THORAC ONCOL, V5, P153, DOI 10.1097/JTO.0b013e3181c8cc0c; van 't Veer C, 2007, J IMMUNOL, V179, P7110, DOI 10.4049/jimmunol.179.10.7110; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Xiao CC, 2003, GENE DEV, V17, P2933, DOI 10.1101/gad.1145603; Xie QF, 2007, MOL IMMUNOL, V44, P3453, DOI 10.1016/j.molimm.2007.03.018; Yamaguchi H, 2006, EUR J CELL BIOL, V85, P213, DOI 10.1016/j.ejcb.2005.10.004	44	95	101	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	21					2475	2484		10.1038/onc.2010.619	http://dx.doi.org/10.1038/onc.2010.619			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	769JF	21278795	Green Accepted			2022-12-17	WOS:000291008000009
J	Jin, Z; Selaru, FM; Cheng, Y; Kan, T; Agarwal, R; Mori, Y; Olaru, AV; Yang, J; David, S; Hamilton, JP; Abraham, JM; Harmon, J; Duncan, M; Montgomery, EA; Meltzer, SJ				Jin, Z.; Selaru, F. M.; Cheng, Y.; Kan, T.; Agarwal, R.; Mori, Y.; Olaru, A. V.; Yang, J.; David, S.; Hamilton, J. P.; Abraham, J. M.; Harmon, J.; Duncan, M.; Montgomery, E. A.; Meltzer, S. J.			MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro	ONCOGENE			English	Article						microRNA-192 and-215; gastric cancer; ALCAM	CELL-ADHESION MOLECULE; TUMOR PROGRESSION; GENE-EXPRESSION; MESSENGER-RNAS; CYCLE ARREST; METASTASIS; INVOLVEMENT; STATISTICS; MECHANISM; INVASION	The dismal outcome of gastric cancer patients highlights the need for diagnostic biomarkers and effective therapeutic targets, such as microRNAs. We sought to discover microRNAs involved in gastric cancer, and to elucidate their downstream target mechanisms. Both cultured gastric epithelial cells (HFE145 and NCI-N87) and primary human gastric tissues (31 non-neoplastic stomach (NS) and 25 gastric carcinomas (GC)) were studied. MicroRNA microarrays and quantitative RT-PCR were applied to discover and verify differentially expressed microRNAs. in vitro cell migration and invasion, cell proliferation, cell cycle and apoptosis assays were executed to elucidate biological effects of microRNA-192 and -215. Western blotting and luciferase assays were performed to confirm direct messenger RNA targeting by microRNA-192 and -215. MicroRNA microarray analyses revealed that 25 and 20 microRNAs were upregulated and downregulated in GC vs NS, respectively. Expression levels of both microRNA-192 and -215 were significantly higher in GC than in NS (P < 0.05). Luciferase assays suggested that microRNA-215 inhibits activated leukocyte cell adhesion molecule (ALCAM) expression at the posttranscriptional level. In addition, expression levels of ALCAM were significantly lower in GC than in NS. Mimics and inhibitors, respectively, of microRNA-192 or -215 exerted no effect on cell cycle or apoptosis in the immortalized normal gastric cell line HFE145 or the gastric cancer cell line NCI-N87. However, mimics of microRNA-192 or -215 significantly increased growth rates in HFE145 cells, whereas inhibitors of microRNA-192 or -215 caused significant decreases in growth rates in NCI-N87 cells. ALCAM knockdown by an ALCAM-specific siRNA significantly increased cell growth in HFE145 cells. Both transfection of mimics of microRNA-192 or -215 and ALCAM knockdown by an ALCAM-specific siRNA significantly increased the migration of HFE145 cells. In conclusion, in gastric cancer, both microRNA-192 and 215 are overexpressed in vivo and exert cell growth and migration-promoting effects in vitro, thus representing potential microRNAs with a role in cancer in the human stomach. Oncogene (2011) 30, 1577-1585; doi: 10.1038/onc.2010.534; published online 29 November 2010	[Jin, Z.; Selaru, F. M.; Cheng, Y.; Kan, T.; Agarwal, R.; Mori, Y.; Olaru, A. V.; Yang, J.; David, S.; Hamilton, J. P.; Abraham, J. M.; Meltzer, S. J.] Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21287 USA; [Harmon, J.; Duncan, M.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21287 USA; [Montgomery, E. A.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA; [Meltzer, S. J.] Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Jin, Z (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, 1503 E Jefferson St,Rm 101A, Baltimore, MD 21287 USA.	zjin1@jhmi.edu		Selaru, Florin/0000-0001-7990-8238	NCI NIH HHS [P30 CA006973] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adiseshaiah P, 2007, CANCER RES, V67, P6204, DOI 10.1158/0008-5472.CAN-06-4687; Agarwal R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008002; Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Georges SA, 2008, CANCER RES, V68, P10105, DOI 10.1158/0008-5472.CAN-08-1846; Guo JM, 2009, J GASTROEN HEPATOL, V24, P652, DOI 10.1111/j.1440-1746.2008.05666.x; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jezierska A, 2006, MED SCI MONITOR, V12, pBR245; Jezierska A, 2009, MED SCI MONITOR, V15, pRA32; Khushalani NI, 2008, MAYO CLIN PROC, V83, P712; KIM JH, 1991, J NATL CANCER I, V83, P938, DOI 10.1093/jnci/83.13.938; Kim YK, 2009, NUCLEIC ACIDS RES, V37, P1672, DOI 10.1093/nar/gkp002; Kimura Y, 2004, MODERN PATHOL, V17, P1328, DOI 10.1038/modpathol.3800180; Kristiansen G, 2003, PROSTATE, V54, P34, DOI 10.1002/pros.10161; Li ZR, 2006, BIOCHEM BIOPH RES CO, V348, P229, DOI 10.1016/j.bbrc.2006.07.043; Lytle JR, 2007, P NATL ACAD SCI USA, V104, P9667, DOI 10.1073/pnas.0703820104; Motoyama K, 2008, CLIN CANCER RES, V14, P2334, DOI 10.1158/1078-0432.CCR-07-4667; Noguchi T, 2001, AM J CLIN PATHOL, V115, P828; Ofori-Acquah SF, 2008, TRANSL RES, V151, P122, DOI 10.1016/j.trsl.2007.09.006; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Rosso O, 2007, MOL CANCER RES, V5, P1246, DOI 10.1158/1541-7786.MCR-07-0060; Shi XB, 2008, CELL CYCLE, V7, P1529, DOI 10.4161/cc.7.11.5977; Song B, 2008, CLIN CANCER RES, V14, P8080, DOI 10.1158/1078-0432.CCR-08-1422; Swart GWM, 2002, EUR J CELL BIOL, V81, P313, DOI 10.1078/0171-9335-00256; Tsai NP, 2009, BIOCHEM J, V424, P411, DOI 10.1042/BJ20090915; Tsukamoto Y, 2008, J PATHOL, V216, P471, DOI 10.1002/path.2424; van Kempen LCLT, 2004, J INVEST DERMATOL, V122, P1293, DOI 10.1111/j.0022-202X.2004.22531.x; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang Z, 2008, INT J CANCER, V123, P1439, DOI 10.1002/ijc.23643; Xia L, 2008, INT J CANCER, V123, P372, DOI 10.1002/ijc.23501; Zhou X, 2009, GENETICA, V137, P159, DOI 10.1007/s10709-009-9378-7	35	95	107	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	13					1577	1585		10.1038/onc.2010.534	http://dx.doi.org/10.1038/onc.2010.534			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21119604	Green Accepted			2022-12-17	WOS:000288998300008
J	Sengupta, S; Mantha, AK; Mitra, S; Bhakat, KK				Sengupta, S.; Mantha, A. K.; Mitra, S.; Bhakat, K. K.			Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1	ONCOGENE			English	Article						APE1; acetylation; YB-1/p300; RNA pol II; MDR1	BASE EXCISION-REPAIR; DNA-BINDING ACTIVITY; KINASE-C-ALPHA; APURINIC/APYRIMIDINIC ENDONUCLEASE; OXIDATIVE STRESS; P-GLYCOPROTEIN; HUMAN AP-ENDONUCLEASE-1; ANTICANCER AGENTS; ALTERED EXPRESSION; ELECTRON-TRANSFER	The overexpression of human apurinic/apyrimidinic (AP) endonuclease 1 (APE1/Ref-1), a key enzyme in the DNA base excision repair (BER) pathway, is often associated with tumor cell resistance to various anticancer drugs. In this study, we examined the molecular basis of transcriptional regulatory (nonrepair) function of APE1 in promoting resistance to certain types of drugs. We have recently shown that APE1 stably interacts with Y-box-binding protein 1 (YB-1), and acts as its coactivator for the expression of multidrug resistance gene MDR1, thereby causing drug resistance. In this study, we show, to the best of our knowledge, for the first time that APE1 is stably associated with the basic transcription factor RNA polymerase II (RNA pol II) and the coactivator p300 on the endogenous MDR1 promoter. The depletion of APE1 significantly reduces YB-1-p300 recruitment to the promoter, resulting in reduced RNA pol II loading. Drug-induced APE1 acetylation, which is mediated by p300, enhances formation of acetylated APE1 (AcAPE1)-YB-1-p300 complex on the MDR1 promoter. Enhanced recruitment of this complex increases MDR1 promoter-dependent luciferase activity and its endogenous expression. Using APE1-downregulated cells and cells overexpressing wild-type APE1 or its nonacetylable mutant, we have demonstrated that the loss of APE1's acetylation impaired MDR1 activation and sensitizes the cells to cisplatin or etoposide. We have thus established the basis for APE1's acetylation-dependent regulatory function in inducing MDR1-mediated drug resistance. Oncogene (2011) 30, 482-493; doi: 10.1038/onc.2010.435; published online 20 September 2010	[Sengupta, S.; Mantha, A. K.; Mitra, S.; Bhakat, K. K.] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; [Mitra, S.; Bhakat, K. K.] Univ Texas Med Branch, Sealy Ctr Mol Med, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Bhakat, KK (corresponding author), Univ Texas Med Branch, Dept Biochem & Mol Biol, 6-136 Med Res Bldg, Galveston, TX 77555 USA.	kkbhakat@utmb.edu	Sengupta, Shiladitya/L-5951-2015; Mantha, Anil/AAM-5035-2021; Bhakat, Kishor/C-8072-2012	Sengupta, Shiladitya/0000-0001-9558-2741	 [RO1 ESO8457];  [RO1 CA53791];  [P50 ES66076]; NATIONAL CANCER INSTITUTE [R01CA053791] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008457] Funding Source: NIH RePORTER	; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We acknowledge the help of Dr Gianluca Tell, University of Udine, Italy for the APE1 siRNA construct, Larry J Bellot, University of Texas Medical Branch, Galveston and Dr Ranajay Chattopadhyay, University of Virginia, Charlottesville in this study. This study was supported by Grants: RO1 ESO8457, RO1 CA53791 and P50 ES66076 to SM.	AHMAD S, 1993, MOL PHARMACOL, V43, P858; AHMAD S, 1994, BIOCHEMISTRY-US, V33, P10313, DOI 10.1021/bi00200a011; Ambudkar SV, 2005, TRENDS PHARMACOL SCI, V26, P385, DOI 10.1016/j.tips.2005.06.001; Ando K, 2008, NUCLEIC ACIDS RES, V36, P4327, DOI 10.1093/nar/gkn416; Bapat A, 2009, ANTIOXID REDOX SIGN, V11, P651, DOI [10.1089/ars.2008.2218, 10.1089/ARS.2008.2218]; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Bhakat KK, 2009, ANTIOXID REDOX SIGN, V11, P621, DOI [10.1089/ars.2008.2198, 10.1089/ARS.2008.2198]; Bhakat KK, 2006, MOL CELL BIOL, V26, P1654, DOI 10.1128/MCB.26.5.1654-1665.2006; Bhakat KK, 2003, METHOD ENZYMOL, V371, P292; Bhakat KK, 2003, EMBO J, V22, P6299, DOI 10.1093/emboj/cdg595; Bhakat KK, 2000, J BIOL CHEM, V275, P34197, DOI 10.1074/jbc.M005447200; Bhattacharyya A, 2009, GASTROENTEROLOGY, V136, P2258, DOI 10.1053/j.gastro.2009.02.014; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Bobola MS, 2005, CLIN CANCER RES, V11, P7405, DOI 10.1158/1078-0432.CCR-05-1068; Busso CS, 2009, ONCOGENE, V28, P1616, DOI 10.1038/onc.2009.5; Chattopadhyay R, 2008, MOL CELL BIOL, V28, P7066, DOI 10.1128/MCB.00244-08; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Curtis CD, 2009, MOL ENDOCRINOL, V23, P1346, DOI 10.1210/me.2009-0093; Das S, 2007, J BIOL CHEM, V282, P28474, DOI 10.1074/jbc.M704672200; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fan JS, 2005, FREE RADICAL BIO MED, V38, P1121, DOI 10.1016/j.freeradbiomed.2005.01.012; Fantini D, 2008, FREE RADICAL RES, V42, P20, DOI 10.1080/10715760701765616; Fishel ML, 2007, MOL ASPECTS MED, V28, P375, DOI 10.1016/j.mam.2007.04.005; Fuchs S, 2003, J HYPERTENS, V21, P327, DOI 10.1097/00004872-200302000-00024; Germann UA, 1998, CYTOTECHNOLOGY, V27, P31, DOI 10.1023/A:1008023629269; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Higashi K, 2003, J BIOL CHEM, V278, P43470, DOI 10.1074/jbc.M302339200; Izumi T, 2005, P NATL ACAD SCI USA, V102, P5739, DOI 10.1073/pnas.0500986102; Izumi T, 2003, TOXICOLOGY, V193, P43, DOI 10.1016/S0300-483X(03)00289-0; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jiang YL, 2008, CANCER RES, V68, P6425, DOI 10.1158/0008-5472.CAN-08-1173; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kaina B, 2002, INT J CLIN PHARM TH, V40, P354; Kaina B, 2001, PROG NUCLEIC ACID RE, V68, P41; Kelley MR, 2001, CLIN CANCER RES, V7, P824; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; KOHNO K, 1989, BIOCHEM BIOPH RES CO, V165, P1415, DOI 10.1016/0006-291X(89)92761-7; KOHNO K, 1994, J BIOL CHEM, V269, P20503; Kovacic P, 2000, CURR PHARM DESIGN, V6, P277, DOI 10.2174/1381612003401046; Kovacic P, 2007, MED HYPOTHESES, V69, P510, DOI 10.1016/j.mehy.2006.08.046; Kuninger DT, 2002, NUCLEIC ACIDS RES, V30, P823, DOI 10.1093/nar/30.3.823; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; Mantha AK, 2008, J MOL BIOL, V379, P28, DOI 10.1016/j.jmb.2008.03.052; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; McNeill DR, 2009, MOL CANCER RES, V7, P897, DOI 10.1158/1541-7786.MCR-08-0519; Mitra S, 2002, FREE RADICAL BIO MED, V33, P15, DOI 10.1016/S0891-5849(02)00819-5; Mujtaba S, 2002, MOL CELL, V9, P575, DOI 10.1016/S1097-2765(02)00483-5; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; Okamura H, 2004, INT J ONCOL, V25, P1031; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; Ordway JM, 2003, MOL CELL BIOL, V23, P4257, DOI 10.1128/MCB.23.12.4257-4266.2003; Pajic M, 2009, CANCER RES, V69, P6396, DOI 10.1158/0008-5472.CAN-09-0041; Rahman I, 2002, BIOCHEM PHARMACOL, V64, P935, DOI 10.1016/S0006-2952(02)01153-X; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Robertson KA, 1997, CELL GROWTH DIFFER, V8, P443; Robertson KA, 2001, CANCER RES, V61, P2220; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Tell G, 2009, ANTIOXID REDOX SIGN, V11, P601, DOI 10.1089/ars.2008.2194; Vascotto C, 2009, PROTEOMICS, V9, P1058, DOI 10.1002/pmic.200800638; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; Wang D, 2004, MOL CANCER THER, V3, P679; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Xu Y, 1997, ANTICANCER RES, V17, P3713; Yamamori T, 2010, NUCLEIC ACIDS RES, V38, P832, DOI 10.1093/nar/gkp1039; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YU G, 1991, CANCER COMMUN, V3, P181, DOI 10.3727/095535491820873263	73	95	97	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2011	30	4					482	493		10.1038/onc.2010.435	http://dx.doi.org/10.1038/onc.2010.435			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20856196	Green Accepted			2022-12-17	WOS:000286621600010
J	Li, L; Wei, XH; Pan, YP; Li, HC; Yang, H; He, QH; Pang, Y; Shan, Y; Xiong, FX; Shao, GZ; Zhou, RL				Li, L.; Wei, X. H.; Pan, Y. P.; Li, H. C.; Yang, H.; He, Q. H.; Pang, Y.; Shan, Y.; Xiong, F. X.; Shao, G. Z.; Zhou, R. L.			LAPTM4B: A novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling	ONCOGENE			English	Article						LAPTM4B; multidrug resistance; drug efflux; PI3K-AKT signaling	P-GLYCOPROTEIN; TETRATRANSMEMBRANE PROTEIN; MEMBRANE-PROTEIN; DRUG-RESISTANCE; EXPRESSION; OVEREXPRESSION; MECHANISMS; INHIBITOR; MARKER; GROWTH	LAPTM4B (lysosomal protein transmembrane 4 beta) is a newly identified cancer-associated gene. Both of its mRNA and the encoded LAPTM4B-35 protein are significantly upregulated with more than 70% frequency in a wide variety of cancers. The LAPTM4B-35 level in cancer is evidenced to be an independent prognostic factor and its upregulation promotes cell proliferation, migration and invasion, as well as tumorigenesis in nude mice. In contrary, knockdown of LAPTM4B-35 expression by RNA interference (RNAi) reverses all of the above malignant phenotypes. We herein reveal a new role of LAPTM4B-35 in promoting multidrug resistance of cancer cells. Upregulation of LAPTM4B-35 motivates multidrug resistance by enhancement of efflux from cancer cells of a variety of chemodrugs with variant structures and properties, including doxorubicin, paclitaxel and cisplatin through colocalization and interaction of LAPTM4B-35 with multidrug resistance (MDR) 1 (P-glycoprotein, P-gp), and also by activation of PI3K/AKT signaling pathway through interaction of PPRP motif contained in the N-terminus of LAPTM4B-35 with the p85 alpha regulatory subunit of PI3K. The specific inhibitors of PI3K and knockdown of LAPTM4B-35 expression by RNAi eliminate the multidrug resistance effect motivated by upregulation of LAPTM4B-35. In conclusion, LAPTM4B-35 motivates multidrug resistance of cancer cells by promoting drug efflux through colocalization and interaction with P-gp, and anti-apoptosis by activating PI3K/AKT signaling. These findings provide a promising novel strategy for sensitizing chemical therapy of cancers and increasing the chemotherapeutic efficacy through knockdown LAPTM4B-35 expression by RNAi. Oncogene (2010) 29, 5785-5795; doi: 10.1038/onc.2010.303; published online 16 August 2010	[Li, L.; Wei, X. H.; Pan, Y. P.; Li, H. C.; Yang, H.; He, Q. H.; Pang, Y.; Shan, Y.; Xiong, F. X.; Shao, G. Z.; Zhou, R. L.] Peking Univ, Sch Basic Med Sci, Dept Cell Biol, Beijing 100191, Peoples R China	Peking University	Zhou, RL (corresponding author), Peking Univ, Sch Basic Med Sci, Dept Cell Biol, 38 Xue Yuan Rd, Beijing 100191, Peoples R China.	rlzhou@bjmu.edu.cn	Shan, Yi/E-3862-2016	Li, Li/0000-0002-8630-3699	211 and 985 Foundation of Peking University; National High-tech R&D Program (863 Program) [2006AA02A305]; 248 major R&D program of Beijing [H020220020310]; NNSFC [90408018]	211 and 985 Foundation of Peking University; National High-tech R&D Program (863 Program)(National High Technology Research and Development Program of China); 248 major R&D program of Beijing; NNSFC(National Natural Science Foundation of China (NSFC))	This work was supported by grants from 211 and 985 Foundation of Peking University, National High-tech R&D Program (863 Program) (2006AA02A305), 248 major R&D program of Beijing (H020220020310) and NNSFC (90408018).	Abdul-Ghani R, 2006, ONCOGENE, V25, P1743, DOI 10.1038/sj.onc.1209201; Ambudkar SV, 2003, ONCOGENE, V22, P7468, DOI 10.1038/sj.onc.1206948; Barancik M, 2006, EUR J PHARM SCI, V29, P426, DOI 10.1016/j.ejps.2006.08.006; Cabrita MA, 1999, CANCER RES, V59, P4890; Choi BH, 2008, CANCER LETT, V259, P111, DOI 10.1016/j.canlet.2007.10.003; Duvvuri M, 2005, BIOCHEMISTRY-US, V44, P15743, DOI 10.1021/bi051759w; Fu D, 2007, AM J PHYSIOL-CELL PH, V292, pC1543, DOI 10.1152/ajpcell.00068.2006; GARCIA MG, 2008, LEUKEMIA RES, V33, P288; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; He Jing, 2003, Beijing Da Xue Xue Bao Yi Xue Ban, V35, P348; Hogue DL, 1996, J BIOL CHEM, V271, P9801, DOI 10.1074/jbc.271.16.9801; Hogue DL, 1999, J BIOL CHEM, V274, P12877, DOI 10.1074/jbc.274.18.12877; Kasper G, 2005, CANCER LETT, V224, P93, DOI 10.1016/j.canlet.2004.10.004; Kim H, 1997, AM J PHYSIOL-CELL PH, V273, pC687, DOI 10.1152/ajpcell.1997.273.2.C687; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Larsen AK, 2000, PHARMACOL THERAPEUT, V85, P217, DOI 10.1016/S0163-7258(99)00073-X; Lee JT, 2004, CANCER RES, V64, P8397, DOI 10.1158/0008-5472.CAN-04-1612; Liu XR, 2004, WORLD J GASTROENTERO, V10, P1555, DOI 10.3748/wjg.v10.i11.1555; Liu XR, 2009, CANCER SCI, V100, P2335, DOI 10.1111/j.1349-7006.2009.01346.x; Morris DG, 2005, EUR J ENDOCRINOL, V153, P143, DOI 10.1530/eje.1.01937; Peng C, 2005, WORLD J GASTROENTERO, V11, P2704, DOI 10.3748/wjg.v11.i18.2704; Shao GZ, 2003, ONCOGENE, V22, P5060, DOI 10.1038/sj.onc.1206832; Tazzari PL, 2007, LEUKEMIA, V21, P427, DOI 10.1038/sj.leu.2404523; Tsuruo T, 2003, CANCER SCI, V94, P15, DOI 10.1111/j.1349-7006.2003.tb01345.x; Yang H, 2010, CANCER LETT, V294, P236, DOI 10.1016/j.canlet.2010.02.006; Yang H, 2010, J CANCER RES CLIN, V136, P275, DOI 10.1007/s00432-009-0659-4; Yang TT, 1996, ANAL BIOCHEM, V241, P103, DOI 10.1006/abio.1996.0383; Yang Y, 2008, ONCOL REP, V20, P1077, DOI 10.3892/or_00000112; Zhang XY, 2008, EUR J OBSTET GYN R B, V139, P237, DOI 10.1016/j.ejogrb.2007.12.021; Zhou L, 2008, CANCER LETT, V264, P209, DOI 10.1016/j.canlet.2008.01.025; Zhou L, 2007, EUR J CANCER, V43, P809, DOI 10.1016/j.ejca.2006.10.025	31	95	105	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	43					5785	5795		10.1038/onc.2010.303	http://dx.doi.org/10.1038/onc.2010.303			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20711237				2022-12-17	WOS:000283586200004
J	Crusio, KM; King, B; Reavie, LB; Aifantis, I				Crusio, K. M.; King, B.; Reavie, L. B.; Aifantis, I.			The ubiquitous nature of cancer: the role of the SCFFbw7 complex in development and transformation	ONCOGENE			English	Review						Fbw7; ubiquitin-proteasome system; GSK-3 beta; p53	F-BOX PROTEIN; PHOSPHORYLATION-DEPENDENT DEGRADATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-DAMAGE-RESPONSE; CELL SELF-RENEWAL; C-MYC PROTEIN; TUMOR-SUPPRESSOR; CYCLIN-E; CHROMOSOMAL INSTABILITY; FBXW7 ACTS	The ubiquitin-proteasome system (UPS) is a multi-subunit pathway that allows for ubiquitin modification of proteins and leads to either degradation or other non-proteolytic processes such as trafficking or transcriptional activation. Given its role as a regulator of cellular homeostasis it is not surprising that members of the UPS are frequently aberrantly expressed in a number of disease states including cancer. This review will focus on one member of the UPS, the F-box protein, Fbw7 (also known as Sel-10, Ago, hCDC4) and mechanisms by which Fbw7 interacts with its substrates in the context of development and tumorigenesis will be discussed. In addition, antagonists of this pathway as well as current and future therapeutics for the UPS will be examined. Oncogene (2010) 29, 4865-4873; doi: 10.1038/onc.2010.222; published online 14 June 2010	[Crusio, K. M.; King, B.; Reavie, L. B.; Aifantis, I.] NYU, Sch Med, Howard Hughes Med Inst, Dept Pathol, New York, NY 10016 USA; [Crusio, K. M.; King, B.; Reavie, L. B.; Aifantis, I.] NYU, Sch Med, NYU Canc Inst, New York, NY 10016 USA; [Crusio, K. M.; King, B.; Reavie, L. B.; Aifantis, I.] NYU, Sch Med, Helen & Martin S Kimmel Stem Cell Ctr, New York, NY 10016 USA	Howard Hughes Medical Institute; New York University; New York University; New York University	Aifantis, I (corresponding author), NYU, Sch Med, Howard Hughes Med Inst, Dept Pathol, 550 1st Ave,MSB 504, New York, NY 10016 USA.	iannis.aifantis@nyumc.org			National Institutes of Health [RO1CA133379, RO1CA105129, R21CA141399, RO1CA149655, P30CA016087]; American Cancer Society [RSG0806801]; Edward Mallinckrodt Jr Foundation; Irma T Hirschl Trust; Alex's Lemonade Stand Foundation; NYU [5T32CA009161]; NATIONAL CANCER INSTITUTE [R01CA133379, T32CA009161, R21CA141399, R01CA149655, R01CA105129, P30CA016087] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Edward Mallinckrodt Jr Foundation; Irma T Hirschl Trust; Alex's Lemonade Stand Foundation; NYU; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the members of the Aifantis Lab for advice and illuminating discussions. Supported by the National Institutes of Health (RO1CA133379, RO1CA105129, R21CA141399, RO1CA149655 and P30CA016087), the American Cancer Society (RSG0806801), the Edward Mallinckrodt Jr Foundation, the Irma T Hirschl Trust, the Alex's Lemonade Stand Foundation (all to IA), NYU Molecular Oncology and Immunology/Ruth L Kirchstein Institutional Training Grant (5T32CA009161 to KC), NYU Cell and Molecular Biology/Ruth L Kirchstein Institutional Traning Grant (BK). IA is a Leukemia & Lymphoma Society Scholar and an Early Career Scientist at the Howard Hughes Medical Institute.	Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Barr AR, 2007, J CELL SCI, V120, P2987, DOI 10.1242/jcs.013136; Bassermann F, 2008, CELL, V134, P256, DOI 10.1016/j.cell.2008.05.043; Bechard M, 2009, MOL CELL BIOL, V29, P2092, DOI 10.1128/MCB.01405-08; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Ferrando Adolfo A, 2009, Hematology Am Soc Hematol Educ Program, P353, DOI 10.1182/asheducation-2009.1.353; Finkin S, 2008, ONCOGENE, V27, P4411, DOI 10.1038/onc.2008.77; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hao B, 2007, MOL CELL, V26, P131, DOI 10.1016/j.molcel.2007.02.022; HARTWELL LH, 1973, GENETICS, V74, P267; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Ishikawa Y, 2008, ONCOGENE, V27, P6164, DOI 10.1038/onc.2008.216; Kane RC, 2003, ONCOLOGIST, V8, P508, DOI 10.1634/theoncologist.8-6-508; Kane RC, 2007, CLIN CANCER RES, V13, P5291, DOI 10.1158/1078-0432.CCR-07-0871; Kanei-Ishii C, 2008, J BIOL CHEM, V283, P30540, DOI 10.1074/jbc.M804340200; Kitagawa K, 2009, ONCOGENE, V28, P2393, DOI 10.1038/onc.2009.111; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Li JH, 2002, J NEUROCHEM, V82, P1540, DOI 10.1046/j.1471-4159.2002.01105.x; Loeb KR, 2005, CANCER CELL, V8, P35, DOI 10.1016/j.ccr.2005.06.010; Love KR, 2007, NAT CHEM BIOL, V3, P697, DOI 10.1038/nchembio.2007.43; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Mao JH, 2008, SCIENCE, V321, P1499, DOI 10.1126/science.1162981; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; Masuda K, 2010, ONCOGENE, V29, P1798, DOI 10.1038/onc.2009.469; Matsuoka S, 2008, GENE DEV, V22, P986, DOI 10.1101/gad.1621808; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Onoyama I, 2007, J EXP MED, V204, P2875, DOI 10.1084/jem.20062299; Palomero T, 2006, BLOOD, V108, P986, DOI 10.1182/blood-2005-08-3482; Petroski MD, 2008, BMC BIOCHEM, V9, DOI 10.1186/1471-2091-9-S1-S7; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Popov N, 2007, CELL CYCLE, V6, P2327, DOI 10.4161/cc.6.19.4804; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Reavie L, 2010, NAT IMMUNOL, V11, P207, DOI 10.1038/ni.1839; Schwartz AL, 2009, ANNU REV PHARMACOL, V49, P73, DOI 10.1146/annurev.pharmtox.051208.165340; Schwickart M, 2010, NATURE, V463, P103, DOI 10.1038/nature08646; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SIEGERT W, 1990, EUR J CANCER, V26, P733, DOI 10.1016/0277-5379(90)90130-L; Skaar JR, 2009, CURR OPIN CELL BIOL, V21, P816, DOI 10.1016/j.ceb.2009.08.004; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; Smith APL, 2006, ONCOGENE, V25, P7245, DOI 10.1038/sj.onc.1209713; Song L, 2008, CURR OPIN CELL BIOL, V20, P156, DOI 10.1016/j.ceb.2008.01.012; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Tan YM, 2008, CANCER LETT, V271, P1, DOI 10.1016/j.canlet.2008.04.036; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; Thompson BJ, 2008, J EXP MED, V205, P1395, DOI 10.1084/jem.20080277; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Tsunematsu R, 2004, J BIOL CHEM, V279, P9417, DOI 10.1074/jbc.M312337200; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Welcker M, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-7; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; YANO T, 1993, ONCOGENE, V8, P2741; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	80	95	106	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	35					4865	4873		10.1038/onc.2010.222	http://dx.doi.org/10.1038/onc.2010.222			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20543859	Green Accepted			2022-12-17	WOS:000281578700001
J	Mollinedo, F; de la Iglesia-Vicente, J; Gajate, C; de Mendoza, AEH; Villa-Pulgarin, JA; Campanero, MA; Blanco-Prieto, MJ				Mollinedo, F.; de la Iglesia-Vicente, J.; Gajate, C.; Estella-Hermoso de Mendoza, A.; Villa-Pulgarin, J. A.; Campanero, M. A.; Blanco-Prieto, M. J.			Lipid raft-targeted therapy in multiple myeloma	ONCOGENE			English	Article						lipid raft; cholesterol; phospholipid ether; edelfosine; apoptosis; MM	ETHER PHOSPHOLIPID EDELFOSINE; ET-18-OCH3 EDELFOSINE; CANCER-CELLS; DEATH RECEPTOR; TUMOR-TISSUES; APOPTOSIS; CHOLESTEROL; FAS/CD95; FAS; INVOLVEMENT	Despite recent advances in treatment, multiple myeloma (MM) remains an incurable malignancy. By using in vitro, ex vivo and in vivo approaches, we have identified here that lipid rafts constitute a new target in MM. We have found that the phospholipid ether edelfosine targets and accumulates in MM cell membrane rafts, inducing apoptosis through co-clustering of rafts and death receptors. Raft disruption by cholesterol depletion inhibited drug uptake by tumor cells as well as cell killing. Cholesterol replenishment restored MM cell ability to take up edelfosine and to undergo drug-induced apoptosis. Ceramide addition displaced cholesterol from rafts, and inhibited edelfosine-induced apoptosis. In an MM animal model, edelfosine oral administration showed a potent in vivo antimyeloma activity, and the drug accumulated preferentially and dramatically in the tumor. A decrease in tumor cell cholesterol, a major raft component, inhibited the in vivo antimyeloma action of edelfosine and reduced drug uptake by the tumor. The results reported here provide the proof-of-principle and rationale for further clinical evaluation of edelfosine and for this raft-targeted therapy to improve patient outcome in MM. Our data reveal cholesterol-containing lipid rafts as a novel and efficient therapeutic target in MM, opening a new avenue in cancer treatment. Oncogene (2010) 29, 3748-3757; doi: 10.1038/onc.2010.131; published online 26 April 2010	[Mollinedo, F.; de la Iglesia-Vicente, J.; Gajate, C.; Villa-Pulgarin, J. A.] Univ Salamanca, CSIC, Ctr Invest Canc, Inst Biol Mol & Celular Canc, E-37007 Salamanca, Spain; [Gajate, C.] Hosp Univ Salamanca, Unidad Invest, E-37007 Salamanca, Spain; [Estella-Hermoso de Mendoza, A.; Blanco-Prieto, M. J.] Univ Navarra, Fac Farm, Dept Farm & Tecnol Farmaceut, E-31080 Pamplona, Spain; [Campanero, M. A.] Clin Univ, Serv Farmacol Clin, Pamplona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Navarra; University of Navarra	Mollinedo, F (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Inst Biol Mol & Celular Canc, Campus Miguel Unamuno, E-37007 Salamanca, Spain.	fmollin@usal.es; cgajate@usal.es	Villa-Pulgarin, Janny A/AAW-4592-2020; Maria, Blanco-Prieto/E-6665-2017; IBSAL, Secretaría/H-3719-2011; Estella-Hermoso de Mendoza, Ander/E-9201-2011; Estella-Hermoso de Mendoza, Ander/M-7194-2016	Villa-Pulgarin, Janny A/0000-0002-9916-5977; Maria, Blanco-Prieto/0000-0003-0710-899X; Estella-Hermoso de Mendoza, Ander/0000-0001-9855-4527; Gajate, Consuelo/0000-0003-0604-6459	Ministerio de Ciencia e Innovacion [SAF2007-61261, SAF2008-02251, PCT-0901002007-27, RD06/0020/1037]; Fondo de Investigacion Sanitaria; European Commission [FIS-FEDER 06/0813, PS09/01915]; Junta de Castilla y Leon; Caja Navarra Foundation; Department of Health of the Navarra Government; Department of Education of the Basque Government [BF106.37]	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Fondo de Investigacion Sanitaria(Instituto de Salud Carlos III); European Commission(European CommissionEuropean Commission Joint Research Centre); Junta de Castilla y Leon(Junta de Castilla y Leon); Caja Navarra Foundation; Department of Health of the Navarra Government; Department of Education of the Basque Government	This work was supported by grants from Ministerio de Ciencia e Innovacion (SAF2007-61261, SAF2008-02251, PCT-0901002007-27, RD06/0020/1037 from Red Tematica de Investigacion Cooperativa en Cancer, Instituto de Salud Carlos III), Fondo de Investigacion Sanitaria and European Commission (FIS-FEDER 06/0813, PS09/01915), Junta de Castilla y Leon (GR15-Experimental Therapeutics and Translational Oncology Program, and Biomedicine Project 2009) and Caja Navarra Foundation, Department of Health of the Navarra Government ('Ortiz de Landazuri, 2009' project). CG is supported by the Ramon y Cajal Program from the Ministerio de Ciencia e Innovacion of Spain. AEHdM is supported by a research grant (BF106.37) from the Department of Education of the Basque Government.	Auer J, 2002, CURR MED CHEM, V9, P1831, DOI 10.2174/0929867023369024; Ausili A, 2008, J PHYS CHEM B, V112, P11643, DOI 10.1021/jp802165n; Barnes K, 2004, BIOCHEM J, V378, P343, DOI 10.1042/BJ20031186; Blanco-Prieto MJ, 2004, J CHROMATOGR B, V810, P85, DOI 10.1016/j.jchromb.2004.07.013; Busto Jon V, 2008, J Chem Biol, V1, P89, DOI 10.1007/s12154-008-0009-z; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Christian AE, 1997, J LIPID RES, V38, P2264; DESSI S, 1994, CANCER, V73, P253, DOI 10.1002/1097-0142(19940115)73:2<253::AID-CNCR2820730204>3.0.CO;2-F; Dimberg LY, 2005, BLOOD, V106, P1346, DOI 10.1182/blood-2004-04-1322; Elahi MM, 2008, HYPERTENSION, V51, P939, DOI 10.1161/HYPERTENSIONAHA.107.100982; de Mendoza AEH, 2009, CLIN CANCER RES, V15, P858, DOI 10.1158/1078-0432.CCR-08-1654; Freeman MR, 2004, J CELL BIOCHEM, V91, P54, DOI 10.1002/jcb.10724; Gajate C, 2000, INT J CANCER, V85, P674, DOI 10.1002/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO;2-Z; Gajate C, 2005, J BIOL CHEM, V280, P11641, DOI 10.1074/jbc.M411781200; Gajate C, 2004, J EXP MED, V200, P353, DOI 10.1084/jem.20040213; Gajate C, 2000, INT J CANCER, V86, P208, DOI 10.1002/(SICI)1097-0215(20000415)86:2<208::AID-IJC10>3.0.CO;2-E; Gajate C, 2002, CURR DRUG METAB, V3, P491, DOI 10.2174/1389200023337225; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Gajate C, 2007, BLOOD, V109, P711, DOI 10.1182/blood-2006-04-016824; Gajate C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005044; Gajate C, 2009, BIOCHEM BIOPH RES CO, V380, P780, DOI 10.1016/j.bbrc.2009.01.147; Grassme H, 2003, ONCOGENE, V22, P5457, DOI 10.1038/sj.onc.1206540; Hanson PK, 2003, J BIOL CHEM, V278, P36041, DOI 10.1074/jbc.M305263200; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; Hussein MA, 2002, CURR OPIN ONCOL, V14, P31, DOI 10.1097/00001622-200201000-00006; Jasinska M, 2007, PHARMACOL REP, V59, P483; Karasavvas N, 1996, EUR J BIOCHEM, V236, P729, DOI 10.1111/j.1432-1033.1996.00729.x; KOGA T, 1990, BIOCHIM BIOPHYS ACTA, V1045, P115, DOI 10.1016/0005-2760(90)90139-O; Kolanjiappan K, 2003, CLIN BIOCHEM, V36, P61, DOI 10.1016/S0009-9120(02)00421-6; Li YC, 2006, AM J PATHOL, V168, P1107, DOI 10.2353/ajpath.2006.050959; MEGHA LE, 2004, J BIOL CHEM, V279, P9997; Mihelic R, 2007, LEUKEMIA, V21, P1150, DOI 10.1038/sj.leu.2404633; Mollinedo F, 1997, CANCER RES, V57, P1320; Mollinedo F, 2004, CURR MED CHEM, V11, P3163, DOI 10.2174/0929867043363703; Mollinedo F, 2007, EXPERT OPIN THER PAT, V17, P385, DOI 10.1517/13543776.17.4.385; Mollinedo F, 2006, DRUG RESIST UPDATE, V9, P51, DOI 10.1016/j.drup.2006.04.002; Mollinedo F, 2008, CONTEMP HEMATOL, P393; Mollinedo F, 2009, J PHARMACOL EXP THER, V329, P439, DOI 10.1124/jpet.108.148254; Mollinedo Faustino, 2006, P13; Nieto-Miguel T, 2006, J BIOL CHEM, V281, P14833, DOI 10.1074/jbc.M511251200; Nybond S, 2005, BBA-BIOMEMBRANES, V1718, P61, DOI 10.1016/j.bbamem.2005.10.009; PEREZSALA D, 1994, BIOCHEM BIOPH RES CO, V199, P1209, DOI 10.1006/bbrc.1994.1359; PEREZSALA D, 1995, J BIOL CHEM, V270, P6235, DOI 10.1074/jbc.270.11.6235; Quesada E, 2004, J MED CHEM, V47, P5333, DOI 10.1021/jm049808a; Rouquette-Jazdanian AK, 2007, CELL SIGNAL, V19, P1404, DOI 10.1016/j.cellsig.2007.01.015; SCHON A, 1989, BIOCHEMISTRY-US, V28, P5019, DOI 10.1021/bi00438a017; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Tosi MR, 2005, CLIN CHIM ACTA, V359, P27, DOI 10.1016/j.cccn.2005.04.003; Zerp SF, 2008, ANTI-CANCER DRUG, V19, P65, DOI 10.1097/CAD.0b013e3282f16d36; Zhuang LY, 2005, J CLIN INVEST, V115, P959	51	95	97	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2010	29	26					3748	3757		10.1038/onc.2010.131	http://dx.doi.org/10.1038/onc.2010.131			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20418917				2022-12-17	WOS:000279385200003
J	Kim, KW; Moretti, L; Mitchell, LR; Jung, DK; Lu, B				Kim, K. W.; Moretti, L.; Mitchell, L. R.; Jung, D. K.; Lu, B.			Endoplasmic reticulum stress mediates radiation-induced autophagy by perk-eIF2 alpha in caspase-3/7-deficient cells	ONCOGENE			English	Article						autophagy; cancer; ER stress; PERK; radiation	INDUCED APOPTOSIS; MAMMALIAN TARGET; DOWN-REGULATION; CASPASE-3; CANCER; DEATH; INHIBITION; TRANSLATION; RAPAMYCIN; CHAPERONE	As apoptosis defects limit efficacy of anticancer agents, autophagy has been proposed as a novel strategy for radiotherapy enhancement. We previously showed that caspase-3/7 inhibition induces autophagy and promotes radiosensitivity in vitro and in vivo. Therefore, we further investigated the mechanism by which radiation triggers autophagy in caspase-3/7-deficient cells, and found the involvement of endoplasmic reticulum (ER) stress. The ER activates a survival pathway, the unfolded protein response, which involves ER-localized transmembrane proteins such as protein kinase-like ER kinase (PERK), inositol-requiring enzyme-1 and activating transcription factor-6. In this study, we found that PERK is essential for radiation-induced autophagy and radiosensitivity in caspase-3/7 double-knockout cells. Irradiation of these cells increased expression of phosphorylated-eIF2 alpha. Similar results were seen after administration of tunicamycin (TM), a well-known ER stressor. Importantly, we found that the administration of TM with radiation in MCF-7 breast cancer cells, which are lacking functional caspase-3 and relatively resistant to many anticancer agents, enhances radiation sensitivity. Our findings reveal ER stress as a novel potential mechanism of radiation-induced autophagy in caspase-3/7-deficient cells and as a potential strategy to maximize efficiency of radiation therapy in breast cancer. Oncogene (2010) 29, 3241-3251; doi: 10.1038/onc.2010.74; published online 29 March 2010	[Lu, B.] Vanderbilt Univ, Dept Radiat Oncol, Vanderbilt Clin B 902, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University	Lu, B (corresponding author), Vanderbilt Univ, Dept Radiat Oncol, Vanderbilt Clin B 902, Vanderbilt Ingram Canc Ctr, 1301 22nd Ave S, Nashville, TN 37232 USA.	bo.lu@vanderbilt.edu	lu, bo/G-4573-2010		NCI [1R01 CA125842-01A1]; DOD [BC030542]; NATIONAL CANCER INSTITUTE [R01CA125842] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by NCI 1R01 CA125842-01A1 and DOD BC030542.	Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423; Cao C, 2006, CANCER RES, V66, P10040, DOI 10.1158/0008-5472.CAN-06-0802; Dahmer MK, 2005, J NEUROSCI RES, V80, P576, DOI 10.1002/jnr.20471; Daido S, 2005, CANCER RES, V65, P4368, DOI 10.1158/0008-5472.CAN-04-4202; Delom F, 2007, CELL DEATH DIFFER, V14, P586, DOI 10.1038/sj.cdd.4402012; Delom F, 2007, APOPTOSIS, V12, P293, DOI 10.1007/s10495-006-0625-4; Devarajan E, 2002, ONCOGENE, V21, P8843, DOI 10.1038/sj.onc.1206044; Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200; Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; Essmann F, 2004, CANCER RES, V64, P7065, DOI 10.1158/0008-5472.CAN-04-1082; Gelebart P, 2005, INT J BIOCHEM CELL B, V37, P260, DOI 10.1016/j.biocel.2004.02.030; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hitomi J, 2004, NEUROSCI LETT, V357, P127, DOI 10.1016/j.neulet.2003.12.080; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Kim I, 2009, J BIOL CHEM, V284, P1593, DOI 10.1074/jbc.M807308200; Kim KW, 2008, AUTOPHAGY, V4, P659, DOI 10.4161/auto.6058; Kim KW, 2006, J BIOL CHEM, V281, P36883, DOI 10.1074/jbc.M607094200; Kim KW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002275; Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984; Lai ED, 2007, PHYSIOLOGY, V22, P193, DOI 10.1152/physiol.00050.2006; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Marissen WE, 2000, J BIOL CHEM, V275, P9314, DOI 10.1074/jbc.275.13.9314; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Ostenfeld MS, 2005, CANCER RES, V65, P8975, DOI 10.1158/0008-5472.CAN-05-0269; Paglin S, 2001, CANCER RES, V61, P439; Palmerini F, 2001, HUM PATHOL, V32, P461, DOI 10.1053/hupa.2001.24328; Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606; Satoh S, 1999, BIOCHEM J, V342, P65, DOI 10.1042/0264-6021:3420065; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Ullman E, 2008, CELL DEATH DIFFER, V15, P422, DOI 10.1038/sj.cdd.4402234; Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200	39	95	106	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2010	29	22					3241	3251		10.1038/onc.2010.74	http://dx.doi.org/10.1038/onc.2010.74			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20348950	Green Accepted			2022-12-17	WOS:000278321100007
J	Abedini, MR; Muller, EJ; Bergeron, R; Gray, DA; Tsang, BK				Abedini, M. R.; Muller, E. J.; Bergeron, R.; Gray, D. A.; Tsang, B. K.			Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein	ONCOGENE			English	Article						FLIP; Akt; p53; chemoresistance; ovarian cancer	X-LINKED INHIBITOR; FAS-MEDIATED APOPTOSIS; TRAIL-INDUCED APOPTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; DOWN-REGULATION; UP-REGULATION; CELLULAR FLIP; PATHWAY; P53; RESISTANCE	Although Akt is a determinant of cisplatin (cis-diaminedi-chloroplatinum (CDDP)) resistance in ovarian cancer cells, which is related in part to its inhibitory action on p53 activation, precisely how Akt confers CDDP resistance is unclear. In this study, we show that CDDP induced p53-dependent Fas-associated death domain-like interleukin-1 beta-converting enzyme (FLICE)-like inhibitory protein (FLIP) degradation in chemosensitive ovarian cancer cells but not their resistant counterparts. CDDP induced FLIP-p53-Itch interaction, colocalization and FLIP ubiquitination in chemosensitive but not chemoresistant ovarian cancer cells. Moreover, although activated Akt inhibited CDDP-induced FLIP degradation and apoptosis in sensitive cells, these responses were facilitated by dominant-negative Akt expression in chemoresistant cells. Inhibition of Akt function also facilitated p53-FLIP interaction and FLIP ubiquitination, which were attenuated by p53 silencing. These results suggest that Akt confers resistance, in part, by modulating CDDP-induced, p53-dependent FLIP ubiquitination. Understanding the precise etiology of chemoresistance may improve treatment for ovarian cancer.	[Tsang, B. K.] Ottawa Hosp Res Inst, Chron Dis Program, Ottawa, ON K1Y 4E9, Canada; [Abedini, M. R.; Muller, E. J.; Bergeron, R.; Tsang, B. K.] Univ Ottawa, Dept Cellular, Ottawa, ON, Canada; [Abedini, M. R.; Muller, E. J.; Bergeron, R.; Tsang, B. K.] Univ Ottawa, Dept Mol Med, Ottawa, ON, Canada; [Abedini, M. R.] Birjand Univ Med Sci, Dept Physiol & Pharmacol, Birjand, Iran; [Muller, E. J.; Bergeron, R.] Ottawa Hosp Res Inst, Neurosci Program, Ottawa, ON K1Y 4E9, Canada; [Bergeron, R.] Univ Ottawa, Dept Psychiat, Ottawa, ON K1N 6N5, Canada; [Gray, D. A.] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Gray, D. A.] Univ Ottawa, Dept Biochem, Ottawa, ON, Canada; [Gray, D. A.] Univ Ottawa, Dept Microbiol, Ottawa, ON, Canada; [Gray, D. A.] Univ Ottawa, Dept Immunol, Ottawa, ON, Canada; [Gray, D. A.] Ottawa Hosp Res Inst, Canc Therapeut Program, Ottawa, ON K1Y 4E9, Canada; [Tsang, B. K.] Univ Ottawa, Dept Obstet, Ottawa, ON, Canada; [Tsang, B. K.] Univ Ottawa, Dept Gynaecol, Ottawa, ON, Canada; [Tsang, B. K.] Seoul Natl Univ, World Class Univ Major Biomodulat, Dept Agr Biotechnol, Coll Agr & Life Sci, Seoul, South Korea	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; Seoul National University (SNU)	Tsang, BK (corresponding author), Ottawa Hosp Res Inst, Chron Dis Program, 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.	btsang@ohri.ca	Darmian, Faezeh Vahedi/AAF-7755-2019; amiri, omolbanin/G-4425-2017; /U-3554-2018	amiri, omolbanin/0000-0002-3815-5716; /0000-0002-8634-4984; Bergeron, Richard/0000-0002-5632-750X; Tsang, Benjamin K./0000-0003-1213-3946	Cancer Research Society [11181]; Canadian Institutes of Health Research [MOP-79360]; National Research Foundation of Korea [R31-10056]; Ministry of Health and Medical Education Scholarship, Iran; H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA [A2780s-AAkt2, A2780s-PHM6]	Cancer Research Society; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Health and Medical Education Scholarship, Iran; H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA	This work was supported by grants from the Cancer Research Society (# 11181 to BKT) and the Canadian Institutes of Health Research (# MOP-79360 to RB), the WCU (World Class University) program through the Korea Science and Engineering Foundation funded by the National Research Foundation of Korea (R31-10056) and a New Investigator Award to RB. MRA was the recipient of a Ministry of Health and Medical Education Scholarship, Iran. We thank Dr Qiao Li (University of Ottawa, Canada) and Dr Kenneth Walsh (St Elizabeth's Medical Centre, Boston, MA, USA) for providing HA-tagged ubiquitin and adenoviral HA-tagged DN-Akt, respectively. A2780s-AAkt2 and A2780s-PHM6 cells were generously provided by Dr Jin Cheng (H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA).	Abedini MR, 2008, CANCER RES, V68, P4511, DOI 10.1158/0008-5472.CAN-08-0673; Abedini MR, 2004, ONCOGENE, V23, P6997, DOI 10.1038/sj.onc.1207925; Alladina SJ, 2005, J VASC RES, V42, P337, DOI 10.1159/000086599; Buttitta F, 1997, BRIT J CANCER, V75, P230, DOI 10.1038/bjc.1997.38; Chandrasekaran Y, 2006, BIOL REPROD, V74, P560, DOI 10.1095/biolreprod.105.045146; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen SZ, 2007, MOL PHARMACOL, V72, P1269, DOI 10.1124/mol.107.037465; Cheng JQ, 2002, DRUG RESIST UPDATE, V5, P131, DOI 10.1016/S1368-7646(02)00003-1; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Fraser M, 2003, CANCER RES, V63, P7081; Fraser M, 2008, INT J CANCER, V122, P534, DOI 10.1002/ijc.23086; Fukazawa T, 2001, ONCOGENE, V20, P5225, DOI 10.1038/sj.onc.1204673; Hagopian GS, 1999, CLIN CANCER RES, V5, P655; Kamarajan P, 2003, BIOCHEM J, V376, P253, DOI 10.1042/BJ20030659; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Li JL, 2000, BIOL SIGNAL RECEPT, V9, P122; Mansouri A, 2003, ONCOL RES, V13, P399; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meinander A, 2007, J IMMUNOL, V178, P3944, DOI 10.4049/jimmunol.178.6.3944; Milne D, 2004, FEBS LETT, V577, P270, DOI 10.1016/j.febslet.2004.09.081; Moriyama H, 2007, IMMUNOL LETT, V109, P36, DOI 10.1016/j.imlet.2006.12.009; Moumen A, 2007, HEPATOLOGY, V45, P1210, DOI 10.1002/hep.21604; Muller E, 2004, EUR J NEUROSCI, V20, P3286, DOI 10.1111/j.1460-9568.2004.03785.x; Nam SY, 2003, CANCER SCI, V94, P1066, DOI 10.1111/j.1349-7006.2003.tb01402.x; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Poukkula M, 2005, J BIOL CHEM, V280, P27345, DOI 10.1074/jbc.M504019200; Sasaki H, 2000, CANCER RES, V60, P5659; Schneiderman D, 1999, APOPTOSIS, V4, P271, DOI 10.1023/A:1008186323178; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shim E, 2007, BIOTECHNOL LETT, V29, P141, DOI 10.1007/s10529-006-9213-5; Skurk C, 2004, J BIOL CHEM, V279, P1513, DOI 10.1074/jbc.M304736200; Starck L, 2005, EUR J IMMUNOL, V35, P1257, DOI 10.1002/eji.200425686; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Yang XK, 2006, CANCER RES, V66, P3126, DOI 10.1158/0008-5472.CAN-05-0425; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zou W, 2007, CANCER BIOL THER, V6, P1614, DOI 10.4161/cbt.6.10.4763	38	95	100	5	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					11	25		10.1038/onc.2009.300	http://dx.doi.org/10.1038/onc.2009.300			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19802016				2022-12-17	WOS:000273373500002
J	Lallemand, D; Manent, J; Couvelard, A; Watilliaux, A; Siena, M; Chareyre, F; Lampin, A; Niwa-Kawakita, M; Kalamarides, M; Giovannini, M				Lallemand, D.; Manent, J.; Couvelard, A.; Watilliaux, A.; Siena, M.; Chareyre, F.; Lampin, A.; Niwa-Kawakita, M.; Kalamarides, M.; Giovannini, M.			Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas	ONCOGENE			English	Article						neurofibromatosis type 2; growth factor receptors; trafficking; Schwann cells; proliferation; schwannoma	NF2 TUMOR-SUPPRESSOR; GROWTH-FACTOR; NEUROFIBROMATOSIS TYPE-2; CELLULAR SENESCENCE; TYROSINE KINASES; ERBB RECEPTORS; ACTIVATION; TUMORIGENESIS; SURVIVAL; TRANSPORT	The NF2 gene product, merlin/schwannomin, is a cytoskeleton organizer with unique growth-inhibiting activity in specific cell types. A narrow spectrum of tumors is associated with NF2 deficiency, mainly schwannomas and meningiomas, suggesting cell-specific mechanisms of growth control. We have investigated merlin function in mouse Schwann cells (SCs). We found that merlin regulates contact inhibition of proliferation by limiting the delivery of several growth factor receptors at the plasma membrane of primary SCs. Notably, upon cell-to-cell contact, merlin downregulates the membrane levels of ErbB2 and ErbB3, thus inhibiting the activity of the downstream mitogenic signaling pathways protein kinase B and mitogen-activated protein kinase. Consequently, loss of merlin activity is associated with elevated levels of ErbB receptors in primary SCs. We also observed accumulation of growth factor receptors such as ErbB2 and 3, insulin-like growth factor 1 receptor and platelet-derived growth factor receptor in peripheral nerves of Nf2-mutant mice and in human NF2 schwannomas, suggesting that this mechanism could play an important role in tumorigenesis.	[Lallemand, D.; Manent, J.; Watilliaux, A.; Siena, M.; Chareyre, F.; Lampin, A.; Niwa-Kawakita, M.; Kalamarides, M.; Giovannini, M.] INSERM, U674, Paris, France; [Lallemand, D.; Manent, J.; Watilliaux, A.; Siena, M.; Chareyre, F.; Lampin, A.; Niwa-Kawakita, M.; Kalamarides, M.; Giovannini, M.] Univ Paris 07, Inst Univ Hematol, Paris, France; [Couvelard, A.] Hop Beaujon, APHP, Serv Anat & Cytol Pathol, Clichy, France; [Kalamarides, M.] Hop Beaujon, APHP, Serv Neurochirurg, Clichy, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Giovannini, M (corresponding author), House Ear Res Inst, Ctr Neural Tumor Res, 2100W 3rd St, Los Angeles, CA 90057 USA.	mgiovannini@hei.org	lallemand, dominique/O-7445-2017	lallemand, dominique/0000-0002-0212-7342; Kawakita, Michiko/0000-0002-9450-583X; Anne, Couvelard/0000-0002-6316-1210; Manent, Jan/0000-0001-9152-5459	US Department of Defense [W81XWH-05-10265]; Association Neurofibromatoses et Recklinghausen; Canceropole Ile-de France; Institut National du Cancer; ANR; INSERM	US Department of Defense(United States Department of Defense); Association Neurofibromatoses et Recklinghausen; Canceropole Ile-de France(Region Ile-de-France); Institut National du Cancer(Institut National du Cancer (INCA) France); ANR(French National Research Agency (ANR)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	We thank J Lippincott-Schwartz for the kind gift of the VSV-GFP construct, Z-Y Han for assistance with mouse genotyping, all members of the U674 lab for helpful discussions and support, L Goutebroze B Goud and O Hanemann for helpful suggestions, A McClatchey for many stimulating discussions, M Pla (Departement d'Experimentation Animale-Institut Universitaire d'Hematologie) and the Centre de Distribution, Typage et Archivage animal for mouse housing. DL personally thanks F Mechta-Grigoriou for helpful advice and discussions and continuous support and Odette Mariani for careful reading of the manuscript. This work was supported by Grants from the US Department of Defense (W81XWH-05-10265), Association Neurofibromatoses et Recklinghausen, Canceropole Ile-de France, Institut National du Cancer, ANR and INSERM.	Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Buzard GS, 1999, J CANCER RES CLIN, V125, P653, DOI 10.1007/s004320050330; Cheng HL, 2000, MOL CELL ENDOCRINOL, V170, P211, DOI 10.1016/S0303-7207(00)00324-5; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Deretic D, 2004, MOL BIOL CELL, V15, P359, DOI 10.1091/mbc.e03-04-0203; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; Fraenzer JT, 2003, INT J ONCOL, V23, P1493; Giovannini M, 2000, GENE DEV, V14, P1617; Giovannini M, 1999, GENE DEV, V13, P978, DOI 10.1101/gad.13.8.978; Hansen MR, 2004, OTOL NEUROTOL, V25, P155, DOI 10.1097/00129492-200403000-00013; HARDY M, 1992, J NEUROSCI RES, V31, P254, DOI 10.1002/jnr.490310206; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Hyun TS, 2004, TRENDS MOL MED, V10, P194, DOI 10.1016/j.molmed.2004.02.003; Itahana K, 2004, BIOGERONTOLOGY, V5, P1, DOI 10.1023/B:BGEN.0000017682.96395.10; Jones KA, 2004, EXP CELL RES, V295, P512, DOI 10.1016/j.yexcr.2004.01.022; Jozwiak J, 2006, INT J CANCER, V118, P1, DOI 10.1002/ijc.21542; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Lim JY, 2003, BIOCHEM BIOPH RES CO, V302, P238, DOI 10.1016/S0006-291X(03)00124-4; Lobsiger CS, 2000, GLIA, V30, P290, DOI 10.1002/(SICI)1098-1136(200005)30:3<290::AID-GLIA8>3.0.CO;2-6; Maitra S, 2006, CURR BIOL, V16, P702, DOI 10.1016/j.cub.2006.02.063; Manent J, 2003, J NEUROSCI METH, V123, P167, DOI 10.1016/S0165-0270(02)00349-7; Mary S, 2002, MOL BIOL CELL, V13, P285, DOI 10.1091/mbc.01-07-0337; McClatchey AI, 2005, GENE DEV, V19, P2265, DOI 10.1101/gad.1335605; Miyake K, 2001, J CELL SCI, V114, P3487; Morrison H, 2007, CANCER RES, V67, P520, DOI 10.1158/0008-5472.CAN-06-1608; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; Perrais M, 2007, MOL BIOL CELL, V18, P2013, DOI 10.1091/mbc.E06-04-0348; Polo S, 2004, CURR OPIN CELL BIOL, V16, P156, DOI 10.1016/j.ceb.2004.02.003; Pujuguet P, 2003, MOL BIOL CELL, V14, P2181, DOI 10.1091/mbc.E02-07-0410; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Rao DS, 2002, J CLIN INVEST, V110, P351, DOI 10.1172/JCI200215529; Sherman L, 1999, ONCOGENE, V18, P6692, DOI 10.1038/sj.onc.1203055; Siskova Z, 2006, MOL CELL NEUROSCI, V33, P150, DOI 10.1016/j.mcn.2006.07.001; Stanasila L, 2006, J BIOL CHEM, V281, P4354, DOI 10.1074/jbc.M511989200; Stonecypher MS, 2006, J NEUROPATH EXP NEUR, V65, P162, DOI 10.1097/01.jnen.0000199575.93794.2f; Syroid DE, 1999, J NEUROSCI, V19, P2059; Tamma G, 2005, J CELL SCI, V118, P3623, DOI 10.1242/jcs.02495	42	95	99	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					854	865		10.1038/onc.2008.427	http://dx.doi.org/10.1038/onc.2008.427			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19029950	Bronze			2022-12-17	WOS:000263320000008
J	Takagi, Y; Kobayashi, T; Shiono, M; Wang, L; Piao, X; Sun, G; Zhang, D; Abe, M; Hagiwara, Y; Takahashi, K; Hino, O				Takagi, Y.; Kobayashi, T.; Shiono, M.; Wang, L.; Piao, X.; Sun, G.; Zhang, D.; Abe, M.; Hagiwara, Y.; Takahashi, K.; Hino, O.			Interaction of folliculin (Birt-Hogg-Dube gene product) with a novel Fnip1-like (FnipL/Fnip2) protein	ONCOGENE			English	Article						BHD; S6K1; AMPK; FnipL/Fnip2; Fnip1	NIHON RAT MODEL; UNIDENTIFIED HUMAN GENES; BHD GENE; RENAL CARCINOGENESIS; COMPLETE SEQUENCES; CODING SEQUENCES; NATURAL-HISTORY; CDNA-CLONES; CANCER; MTOR	Birt-Hogg-Dube (BHD) syndrome is characterized by the development of pneumothorax, hair folliculomas and renal tumors and the responsible BHD gene is thought to be a tumor suppressor. The function of folliculin (Flcn), encoded by BHD, is totally unknown, although its interaction with Fnip1 has been reported. In this study, we identified a novel protein binding to Flcn, which is highly homologous to Fnip1, and which we named FnipL (recently reported in an independent study as Fnip2). The interaction between FnipL/Fnip2 and Flcn may be mediated mainly by the C-terminal domains of each protein as is the case for the Flcn-Fnip1 interaction. FnipL/Fnip2 and Flcn were located together in the cytoplasm in a reticular pattern, although solely expressed Flcn was found mainly in the nucleus. Cytoplasmic retention of Flcn was canceled with C-terminal truncation of FnipL/Fnip2, suggesting that FnipL/Fnip2 regulates Flcn distribution through their complex formation. By the employment of siRNA, we observed a decrease in S6K1 phosphorylation in the BHD-suppressed cell. We also observed a decrease in S6K1 phosphorylation in FNIP1- and, to a lesser extent, in FNIPL/FNIP2-suppressed cells. These results suggest that Flcn-FnipL/Fnip2 and Flcn-Fnip1 complexes positively regulate S6K1 phosphorylation and that FnipL/Fnip2 provides an important clue to elucidating the function of Flcn and the pathogenesis of BHD.	[Takagi, Y.; Kobayashi, T.; Shiono, M.; Wang, L.; Piao, X.; Sun, G.; Zhang, D.; Abe, M.; Hagiwara, Y.; Hino, O.] Juntendo Univ, Sch Med, Dept Pathol & Oncol, Bunkyo Ku, Tokyo 1138421, Japan; [Hagiwara, Y.] Immunobiol Labs Co Ltd, Div Mfg Res & Dev, Fujioka, Gunma, Japan	Juntendo University; Immuno-Biological Laboratories Co. Ltd.	Hino, O (corresponding author), Juntendo Univ, Sch Med, Dept Pathol & Oncol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	ohino@juntendo.ac.jp			Japan Society for the Promotion of Science (JSPS); Ministry of Education, Culture, Sports and Technology of Japan; Ministry of Health, Labour and Welfare of Japan	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	We thank Drs Fujii H, Tsurui H, Matsuoka S, Wakiya M, Kajino K, Mr Sasahara K and Mr Takagaki T in the Department of Pathology and Oncology for helpful discussions and technical supports. We also thank Ms Ochiai K and Mr Matsunami K in the Division of Radioisotope Research for expert support. We appreciate Dr Maeda M (IBL) for production of antibodies, and Drs Okimoto K, Matsumoto I and Kouchi M (Dainippon-Sumitomo Pharma) and Dr Maeda T (Tokyo University) for helpful discussions. We also thank Kazusa DNA Research Institute for cDNA clones. This study was supported by the grants from the Japan Society for the Promotion of Science (JSPS), from the Ministry of Education, Culture, Sports and Technology of Japan, and from the Ministry of Health, Labour and Welfare of Japan.	Baba M, 2008, JNCI-J NATL CANCER I, V100, P140, DOI 10.1093/jnci/djm288; Baba M, 2006, P NATL ACAD SCI USA, V103, P15552, DOI 10.1073/pnas.0603781103; BIRT AR, 1977, ARCH DERMATOL, V113, P1674, DOI 10.1001/archderm.113.12.1674; Fukuda T, 2000, ANAL BIOCHEM, V285, P274, DOI 10.1006/abio.2000.4787; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hasumi H, 2008, GENE, V415, P60, DOI 10.1016/j.gene.2008.02.022; Hino O, 2003, CANCER SCI, V94, P142, DOI 10.1111/j.1349-7006.2003.tb01410.x; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Kouchi M, 2006, VIRCHOWS ARCH, V448, P463, DOI 10.1007/s00428-005-0142-9; Lingaas F, 2003, HUM MOL GENET, V12, P3043, DOI 10.1093/hmg/ddg336; Nagase T, 2000, DNA RES, V7, P143, DOI 10.1093/dnares/7.2.143; Nagase T, 2001, DNA RES, V8, P319, DOI 10.1093/dnares/8.6.319; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Okimoto K, 2004, CURR MOL MED, V4, P887, DOI 10.2174/1566524043359737; Okimoto K, 2004, P NATL ACAD SCI USA, V101, P2023, DOI 10.1073/pnas.0308071100; Okimoto K, 2000, JPN J CANCER RES, V91, P1096, DOI 10.1111/j.1349-7006.2000.tb00890.x; Roberg KJ, 1997, GENETICS, V147, P1569; Schmidt LS, 2001, AM J HUM GENET, V69, P876, DOI 10.1086/323744; Singh SR, 2006, ONCOGENE, V25, P5933, DOI 10.1038/sj.onc.1209593; Togashi Y, 2006, ONCOGENE, V25, P2885, DOI 10.1038/sj.onc.1209317; van Slegtenhorst M, 2007, J BIOL CHEM, V282, P24583, DOI 10.1074/jbc.M700857200; Vocke CD, 2005, J NATL CANCER I, V97, P931, DOI 10.1093/jnci/dji154	23	95	99	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2008	27	40					5339	5347		10.1038/onc.2008.261	http://dx.doi.org/10.1038/onc.2008.261			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	346UW	18663353				2022-12-17	WOS:000259096100006
J	Vecchi, M; Confalonieri, S; Nuciforo, P; Vigano, MA; Capra, M; Bianchi, M; Nicosia, D; Bianchi, F; Galimberti, V; Viale, G; Palermo, G; Riccardi, A; Campanini, R; Daidone, MG; Pierotti, MA; Pece, S; Di Fiore, P				Vecchi, M.; Confalonieri, S.; Nuciforo, P.; Vigano, M. A.; Capra, M.; Bianchi, M.; Nicosia, D.; Bianchi, F.; Galimberti, V.; Viale, G.; Palermo, G.; Riccardi, A.; Campanini, R.; Daidone, M. G.; Pierotti, M. A.; Pece, S.; Di Fiore, P. P.			Breast cancer metastases are molecularly distinct from their primary tumors	ONCOGENE			English	Article						gene profiling; breast cancer; metastases	LYMPH-NODE METASTASES; GENE-EXPRESSION; LUNG METASTASIS; SOLID TUMORS; CELLS; MASPIN; GROWTH; MICROENVIRONMENT; PROGRESSION; LACTOFERRIN	Metastases have been widely thought to arise from rare, selected, mutation-bearing cells in the primary tumor. Recently, however, it has been proposed that breast tumors are imprinted ab initio with metastatic ability. Thus, there is a debate over whether 'phenotypic' disease progression is really associated with 'molecular' progression. We pro. led 26 matched primary breast tumors and lymph node metastases and identified 270 probesets that could discriminate between the two categories. We then used an independent cohort of breast tumors (81 samples) and unmatched distant metastases (32 samples) to validate and re. ne this list down to a 126-probeset list. A representative subset of these genes was subjected to analysis by in situ hybridization, on a third independent cohort (57 primary breast tumors and matched lymph node metastases). This not only confirmed the expression pro. le data, but also allowed us to establish the cellular origin of the signals. One-third of the analysed representative genes (4 of 11) were expressed by the epithelial component. The four epithelial genes alone were able to discriminate primary breast tumors from their metastases. Finally, engineered alterations in the expression of two of the epithelial genes (SERPINB5 and LTF) modified cell motility in vitro, in accordance with a possible causal role in metastasis. Our results show that breast cancer metastases are molecularly distinct from their primary tumors.	[Vecchi, M.; Confalonieri, S.; Nuciforo, P.; Vigano, M. A.; Capra, M.; Bianchi, M.; Nicosia, D.; Bianchi, F.; Galimberti, V.; Viale, G.; Pierotti, M. A.; Pece, S.; Di Fiore, P. P.] Ist Europeo Oncol, Fdn Ist FIRC Oncol Mol, IFOM, I-20139 Milan, Italy; [Viale, G.; Pece, S.; Di Fiore, P. P.] Univ Milan, Dipartimento Med Chirurg Odontoiatria, I-20122 Milan, Italy; [Palermo, G.; Riccardi, A.; Campanini, R.] Univ Bologna, Dept Phys, I-40126 Bologna, Italy; [Daidone, M. G.; Pierotti, M. A.] Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy	IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); University of Milan; University of Bologna; Fondazione IRCCS Istituto Nazionale Tumori Milan	Di Fiore, P (corresponding author), Ist Europeo Oncol, Fdn Ist FIRC Oncol Mol, IFOM, Via Adamello 16, I-20139 Milan, Italy.	pierpaolo.difiore@ifom-ieo-campus.it	Pierotti, Marco Alessandro/AAC-4728-2022; Di Fiore, Pier Paolo/K-2130-2012; GALIMBERTI, Viviana Enrica/AAS-3963-2020; Capra, Maria/AAM-8054-2020; Bianchi, Fabrizio/W-7037-2019; Viale, Giuseppe/AAE-8921-2019; Nuciforo, Paolo/Q-2885-2019; Vecchi, Manuela/L-3502-2017; Bianchi, Fabrizio/B-5995-2017; Confalonieri, Stefano/AAQ-6786-2020; Daidone, Maria Grazia/E-9232-2017; Pece, Salvatore/B-9609-2013	Pierotti, Marco Alessandro/0000-0002-7431-8332; Di Fiore, Pier Paolo/0000-0002-2252-0950; GALIMBERTI, Viviana Enrica/0000-0002-5036-7439; Bianchi, Fabrizio/0000-0001-7412-8638; Vecchi, Manuela/0000-0002-2750-9160; Bianchi, Fabrizio/0000-0001-7412-8638; Confalonieri, Stefano/0000-0001-6886-9851; Daidone, Maria Grazia/0000-0002-4786-1321; Pece, Salvatore/0000-0003-1764-3929; vigano, maria alessandra/0000-0003-2009-0384; Nuciforo, Paolo/0000-0003-1380-0990	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Beltran A, 2007, ONCOGENE, V26, P2791, DOI 10.1038/sj.onc.1210072; BEZAULT J, 1994, CANCER RES, V54, P2310; Capra M, 2006, CANCER RES, V66, P8147, DOI 10.1158/0008-5472.CAN-05-3489; Dave SS, 2004, NEW ENGL J MED, V351, P2159, DOI 10.1056/NEJMoa041869; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; Feng YM, 2007, BREAST CANCER RES TR, V103, P319, DOI 10.1007/s10549-006-9385-7; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; Gangnus R, 2004, CLIN CANCER RES, V10, P3457, DOI 10.1158/1078-0432.CCR-03-0818; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hao XS, 2004, CANCER-AM CANCER SOC, V100, P1110, DOI 10.1002/cncr.20095; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Lamelas M L, 2000, Int J Surg Investig, V2, P285; Luo JL, 2007, NATURE, V446, P690, DOI 10.1038/nature05656; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Reddy KB, 2001, ONCOGENE, V20, P6538, DOI 10.1038/sj.onc.1204796; Rolli M, 2003, P NATL ACAD SCI USA, V100, P9482, DOI 10.1073/pnas.1633689100; Schedin P, 2004, BREAST CANCER RES, V6, P93, DOI 10.1186/bcr772; Schmidt-Kittler O, 2003, P NATL ACAD SCI USA, V100, P7737, DOI 10.1073/pnas.1331931100; Shi HY, 2001, CANCER RES, V61, P6945; Suzuki M, 2007, MOL ONCOL, V1, P172, DOI 10.1016/j.molonc.2007.03.005; Ushida Y, 1998, CANCER LETT, V134, P141, DOI 10.1016/S0304-3835(98)00249-3; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Weigelt B, 2003, P NATL ACAD SCI USA, V100, P15901, DOI 10.1073/pnas.2634067100; Weigelt B, 2005, BRIT J CANCER, V93, P924, DOI 10.1038/sj.bjc.6602794; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	41	95	98	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2008	27	15					2148	2158		10.1038/sj.onc.1210858	http://dx.doi.org/10.1038/sj.onc.1210858			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17952122				2022-12-17	WOS:000254621300005
J	Galie, M; Konstantinidou, G; Peroni, D; Scambi, I; Marchini, C; Lisi, V; Krampera, M; Magnani, P; Merigo, F; Montani, M; Boschi, F; Marzola, P; Orru, R; Farace, P; Sbarbati, A; Amici, A				Galie, M.; Konstantinidou, G.; Peroni, D.; Scambi, I.; Marchini, C.; Lisi, V.; Krampera, M.; Magnani, P.; Merigo, F.; Montani, M.; Boschi, F.; Marzola, P.; Orru, R.; Farace, P.; Sbarbati, A.; Amici, A.			Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice	ONCOGENE			English	Article						mammary carcinoma; reactive stromal cells; mesenchymal stem cells; angiogenesis; molecular signature; HER-2/neu	HUMAN ADIPOSE-TISSUE; ACUTE MYELOID-LEUKEMIA; BREAST-CANCER CELLS; POSTNATAL NEOVASCULARIZATION; STROMAL FIBROBLASTS; ENDOTHELIAL-CELLS; BONE-MARROW; IN-VITRO; ANGIOGENESIS; IDENTIFICATION	Tumor microenvironment in carcinomas recruits mesenchymal cells with an abnormal proangiogenic and invasive phenotype. It is not clear whether mesenchymal tumor cells (MTCs) derive from the activation of mature fibroblasts or from their stem cell precursors. However, stromal cell activation in tumors resembles in several aspects the mesenchymal rearrangement which normally occurs during reparative processes such as wound healing. Mesenchymal stem cells (MSCs) play a crucial role in developmental and reparative processes and have extraordinary proangiogenic potential, on the basis of which they are thought to show great promise for the treatment of ischemic disorders. Here, we show that MTCs have proangiogenic potential and that they share the transcriptional expression of the best-known proangiogenic factors with MSCs. We also found that MTCs and MSCs have the same molecular signature for stemness-related genes, and that when co-implanted with cancer cells in syngeneic animals MSCs determine early tumor appearance, probably by favoring the angiogenic switch. Our data (1) reveal crucial aspects of the proangiogenic phenotype of MTCs, (2) strongly suggest their stem origin and (3) signal the risk of therapeutic use of MSCs in tumor-promoting conditions.	[Galie, M.; Peroni, D.; Scambi, I.; Magnani, P.; Merigo, F.; Boschi, F.; Marzola, P.; Farace, P.; Sbarbati, A.] Univ Verona, Dept Morphol & Biomed Sci, Anat & Histol Sect, I-37134 Verona, Italy; [Konstantinidou, G.; Marchini, C.; Montani, M.; Orru, R.; Amici, A.] Univ Camerino, Genet Immunizat Lab, Dept Mol Cellular & Anim Biol, Camerino, Macerata, Italy; [Lisi, V.; Krampera, M.] Univ Verona, Dept Clin & Expt Med, Haematol Sect, I-37134 Verona, Italy	University of Verona; University of Camerino; University of Verona	Galie, M (corresponding author), Univ Verona, Dept Morphol & Biomed Sci, Anat & Histol Sect, Via Grazie 8, I-37134 Verona, Italy.	mirco@anatomy.univr.it	Konstantinidou, Georgia/O-9192-2016; Farace, Paolo/AAK-4072-2020; KRAMPERA, MAURO/K-5596-2018	Konstantinidou, Georgia/0000-0001-9513-0286; Farace, Paolo/0000-0002-6051-2345; GALIE', Mirco/0000-0002-6441-8313; Peroni, Daniele/0000-0002-0862-266X; Amici, Augusto/0000-0002-4634-1500; KRAMPERA, Mauro/0000-0002-7280-2040; Marchini, Cristina/0000-0001-7692-8428; MARZOLA, Pasquina/0000-0001-6936-8901				Al Sayed AD, 2006, ACTA ONCOL, V45, P188, DOI 10.1080/02841860500513235; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Burns JS, 2005, CANCER RES, V65, P3126, DOI 10.1158/0008-5472.CAN-04-2218; Cao Y, 2005, BIOCHEM BIOPH RES CO, V332, P370, DOI 10.1016/j.bbrc.2005.04.135; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Dingli D, 2006, STEM CELLS, V24, P2603, DOI 10.1634/stemcells.2006-0136; Direkze NC, 2004, CANCER RES, V64, P8492, DOI 10.1158/0008-5472.CAN-04-1708; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Galie M, 2005, CARCINOGENESIS, V26, P1868, DOI 10.1093/carcin/bgi158; Galie M, 2005, NEOPLASIA, V7, P528, DOI 10.1593/neo.04730; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Hayward SW, 2001, CANCER RES, V61, P8135; Hill R, 2005, CELL, V123, P1001, DOI 10.1016/j.cell.2005.09.030; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596; Hung SC, 2005, CLIN CANCER RES, V11, P7749, DOI 10.1158/1078-0432.CCR-05-0876; Keith WN, 2004, ONCOGENE, V23, P5092, DOI 10.1038/sj.onc.1207762; Knutson KL, 2006, J IMMUNOL, V177, P1526, DOI 10.4049/jimmunol.177.3.1526; Krampera M, 2007, BONE, V40, P382, DOI 10.1016/j.bone.2006.09.006; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; McAlhany SJ, 2003, CANCER RES, V63, P5859; Miranville A, 2004, CIRCULATION, V110, P349, DOI 10.1161/01.CIR.0000135466.16823.D0; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Naumov GN, 2006, CELL CYCLE, V5, P1779, DOI 10.4161/cc.5.16.3018; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Petersen OW, 2001, BREAST CANCER RES, V3, P213; Planat-Benard V, 2004, CIRCULATION, V109, P656, DOI 10.1161/01.CIR.0000114522.38265.61; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rigotti G, 2007, PLAST RECONSTR SURG, V119, P1409, DOI 10.1097/01.prs.0000256047.47909.71; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Rubio D, 2005, CANCER RES, V65, P3035, DOI 10.1158/0008-5472.CAN-04-4194; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Wolf D, 2005, JNCI-J NATL CANCER I, V97, P540, DOI 10.1093/jnci/dji088; Yang F, 2005, CANCER RES, V65, P8887, DOI 10.1158/0008-5472.CAN-05-1702; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105	46	95	103	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2008	27	18					2542	2551		10.1038/sj.onc.1210920	http://dx.doi.org/10.1038/sj.onc.1210920			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17998939				2022-12-17	WOS:000255057000004
J	Cordes, N; Frickz, S; Brunner, TB; Pilarsky, C; Grutzmann, R; Siposs, B; Kloppels, G; McKenna, WG; Bernhard, EJ				Cordes, N.; Frickz, S.; Brunner, T. B.; Pilarsky, C.; Gruetzmann, R.; Siposs, B.; Kloeppels, G.; McKenna, W. G.; Bernhard, E. J.			Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1	ONCOGENE			English	Article						caveolin-1; ionizing radiation; beta 1-integrin; FAK; pancreatic cancer	LUNG-CANCER CELLS; INDUCED GENOTOXIC INJURY; P42/44 MAP KINASE; EXTRACELLULAR-MATRIX; DOWN-REGULATION; DUCTAL ADENOCARCINOMA; EXPRESSION; SURVIVAL; ADHESION; GROWTH	Caveolin-1 (Cav-1) is an integral transmembrane protein and a critical component in interactions of integrin receptors with cytoskeleton-associated and signaling molecules. Since integrin-mediated cell adhesion generates signals conferring radiation resistance, we examined the effects of small interfering RNA-mediated knockdown of Cav-1 alone or in combination with beta 1-integrin or focal adhesion kinase (FAK) on radiation survival and proliferation of pancreatic carcinoma cell lines. Irradiation induced Cav-1 expression in PATU8902, MiaPaCa2 and Panel cell lines. The cell lines showed significant radio-sensitization after knockdown of Cav-1, beta 1-integrin or FAK and cholesterol depletion by beta-cyclodextrin relative to nonspecific controls. Under knockdown conditions, proliferation of non-irradiated and irradiated cells was significantly attenuated relative to controls. These findings correlated with changes in expression or phosphorylation of Akt, glycogen synthase kinase 3 beta, Paxillin, Src, c-Jun N-terminal kinase and mitogen-activated protein kinase. Analysis of DNA microarray data revealed a Cav-1 overexpression in a subset of pancreatic ductal adenocarcinoma samples. The data presented show, for the first time, that disruption of interactions of Cav-1 with beta 1-integrin or FAK affects radiation survival and proliferation of pancreatic carcinoma cells and suggest that Cav-1 is critical to these processes.. These results indicate that strategies targeting Cav-1 may be useful as an approach to improve conventional therapies, including radiotherapy, for pancreatic cancer.	Tech Univ Dresden, Med Fac Carl Gustav Carus, OncoRay Ctr Radiat Res Oncol, D-01307 Dresden, Germany; Bundeswehr Inst Radiobiol, Munich, Germany; Univ Erlangen Nurnberg, Erlangen, Germany; Univ Hosp Dresden, Dept Visceral Thorac, Dresden, Germany; Univ Hosp Dresden, Dept Vasc Surg, Dresden, Germany; Univ Hosp Kiel, Dept Pathol, Kiel, Germany; Univ Oxford, Churchill Hosp, Radiobiol Res Inst, Oxford, England	Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Erlangen Nuremberg; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Oxford	Cordes, N (corresponding author), Tech Univ Dresden, Med Fac Carl Gustav Carus, OncoRay Ctr Radiat Res Oncol, Fetscherstasse 74-PF, D-01307 Dresden, Germany.	nils.cordes@oncoray.de		Cordes, Nils/0000-0001-5684-629X; Pilarsky, Christian/0000-0002-7968-3283	Medical Research Council [G0700730] Funding Source: Medline; NCI NIH HHS [R01 CA73820] Funding Source: Medline; MRC [G0700730] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [R01CA073820] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belanger MM, 2004, CANCER BIOL THER, V3, P954, DOI 10.4161/cbt.3.10.1112; Buttery RC, 2004, INT J BIOCHEM CELL B, V36, P1154, DOI 10.1016/S1357-2725(03)00261-9; Carver LA, 2003, NAT REV CANCER, V3, P571, DOI 10.1038/nrc1146; Cherubini A, 2005, MOL BIOL CELL, V16, P2972, DOI 10.1091/mbc.E04-10-0940; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V284, pC457, DOI 10.1152/ajpcell.00380.2002; Cordes N, 2006, ONCOGENE, V25, P1378, DOI 10.1038/sj.onc.1209164; Cordes N, 2004, CANCER RES, V64, P5683, DOI 10.1158/0008-5472.CAN-04-1056; Cordes N, 2003, STRAHLENTHER ONKOL, V179, P337, DOI 10.1007/s00066-003-1074-4; Eke I, 2006, RADIOTHER ONCOL, V80, P178, DOI 10.1016/j.radonc.2006.07.028; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Estrugo D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000269; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Fritz G, 2003, INT J RADIAT BIOL, V79, P601, DOI 10.1080/09553000310001609233; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gonzalez E, 2004, J BIOL CHEM, V279, P40659, DOI 10.1074/jbc.M407051200; Grutzmann R, 2004, NEOPLASIA, V6, P611, DOI 10.1593/neo.04295; Grutzmann R, 2005, ONCOGENE, V24, P5079, DOI 10.1038/sj.onc.1208696; Grutzmann R, 2003, VIRCHOWS ARCH, V443, P508, DOI 10.1007/s00428-003-0884-1; Hailstones D, 1998, J LIPID RES, V39, P369; Hayashi K, 2001, CANCER RES, V61, P2361; Hehlgans S, 2007, BBA-REV CANCER, V1775, P163, DOI 10.1016/j.bbcan.2006.09.001; Hess F, 2007, ONCOGENE, V26, P1372, DOI 10.1038/sj.onc.1209947; Hodkinson PS, 2006, CELL DEATH DIFFER, V13, P1776, DOI 10.1038/sj.cdd.4401849; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Iliakis G, 1997, SEMIN ONCOL, V24, P602; Kasahara T, 2002, ANTIOXID REDOX SIGN, V4, P491, DOI 10.1089/15230860260196290; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li JW, 2005, CELL CYCLE, V4, P1817, DOI 10.4161/cc.4.12.2199; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Regina A, 2004, J NEUROSCI RES, V75, P291, DOI 10.1002/jnr.10865; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shatz M, 2004, LEUKEMIA RES, V28, P907, DOI 10.1016/j.leukres.2004.03.013; Sunaga N, 2004, CANCER RES, V64, P4277, DOI 10.1158/0008-5472.CAN-03-3941; Suzuoki M, 2002, BRIT J CANCER, V87, P1140, DOI 10.1038/sj.bjc.6600619; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Willcox M, 2004, TRA HERB, V4, P279; Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004; Yacoub A, 2007, MOL PHARMACOL, V71, P259, DOI 10.1124/mol.106.031153	43	95	100	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2007	26	48					6851	6862		10.1038/sj.onc.1210498	http://dx.doi.org/10.1038/sj.onc.1210498			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17471232				2022-12-17	WOS:000250188400001
J	Vogler, M; Durr, K; Jovanovic, M; Debatin, KM; Fulda, S				Vogler, M.; Duerr, K.; Jovanovic, M.; Debatin, K-M; Fulda, S.			Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells	ONCOGENE			English	Article						apoptosis; TRAIL; pancreatic cancer; XIAP; resistance	X-LINKED INHIBITOR; DRUG-INDUCED APOPTOSIS; DOWN-REGULATION; CANCER-CELLS; EXPRESSION; PROTEINS; DEATH; BCL-2; REGRESSION; RESISTANT	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising candidate for cancer therapy because of its relative tumor selectivity. However, many cancers including pancreatic cancer remain resistant towards TRAIL. To develop TRAIL for cancer therapy of pancreatic carcinoma, it will therefore be pivotal to elucidate the molecular mechanisms of TRAIL resistance. Here, we identify X-linked inhibitor of apoptosis (XIAP) as a regulator of TRAIL sensitivity in pancreatic carcinoma cells. Full activation of effector caspases, loss of mitochondrial membrane potential and cytochrome c release following TRAIL treatment were markedly impaired in pancreatic carcinoma cell lines, which poorly responded to TRAIL (PaTuII, PancTu1, ASPC1, DanG), compared to TRAIL-sensitive Colo357 pancreatic carcinoma cells. Stable downregulation of XIAP by RNA interference significantly reduced survival and enhanced TRAIL-induced apoptosis in pancreatic carcinoma cells. Also, downregulation of XIAP significantly increased CD95-induced cell death. Importantly, knockdown of XIAP strongly inhibited clonogenicity of pancreatic cancer cells treated with TRAIL indicating that XIAP promotes clonogenic survival of pancreatic carcinoma cells. Thus, our findings for the first time indicate that targeting XIAP represents a promising strategy to enhance the antitumor activity of TRAIL in pancreatic cancer, which has important clinical implications.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany	Ulm University	Fulda, S (corresponding author), Univ Ulm, Childrens Hosp, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de	Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014; Duerr, Katharina/A-6975-2015	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417; Vogler, Meike/0000-0003-2650-586X; Duerr, Katharina/0000-0002-3245-4088				Amantana A, 2004, MOL CANCER THER, V3, P699; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Burstein E, 2004, EMBO J, V23, P244, DOI 10.1038/sj.emboj.7600031; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Fulda S, 2004, CURR CANCER DRUG TAR, V4, P569, DOI 10.2174/1568009043332763; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2004, VITAM HORM, V67, P275; Gerhard MC, 2002, BRIT J CANCER, V86, P893, DOI 10.1038/sj.bjc.6600171; Hao YY, 2004, NAT CELL BIOL, V6, P849, DOI 10.1038/ncb1159; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Ibrahim SM, 2001, PANCREAS, V23, P72, DOI 10.1097/00006676-200107000-00011; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lima RT, 2004, CANCER GENE THER, V11, P309, DOI 10.1038/sj.cgt.7700706; McManus DC, 2004, ONCOGENE, V23, P8105, DOI 10.1038/sj.onc.1207967; Mohr A, 2004, CELL DEATH DIFFER, V11, P1153, DOI 10.1038/sj.cdd.4401480; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sasaki H, 2000, CANCER RES, V60, P5659; Satoh K, 2001, PANCREAS, V23, P251, DOI 10.1097/00006676-200110000-00005; Schneider G, 2005, GASTROENTEROLOGY, V128, P1606, DOI 10.1053/j.gastro.2005.04.001; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; Trauzold A, 2003, BRIT J CANCER, V89, P1714, DOI 10.1038/sj.bjc.6601330; Vischioni B, 2006, HUM PATHOL, V37, P78, DOI 10.1016/j.humpath.2005.09.022; Westphal Sabine, 2003, Mol Cancer, V2, P6, DOI 10.1186/1476-4598-2-6; Wolff RA, 2000, INVEST NEW DRUG, V18, P43, DOI 10.1023/A:1006383831045; Yang L, 2003, CANCER RES, V63, P6815	38	95	97	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					248	257		10.1038/sj.onc.1209776	http://dx.doi.org/10.1038/sj.onc.1209776			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16832350				2022-12-17	WOS:000243398300008
J	Hill, A; McFarlane, S; Mulligan, K; Gillespie, H; Draffin, JE; Trimble, A; Ouhtit, A; Johnston, PG; Harkin, DP; McCormick, D; Waugh, DJJ				Hill, A.; McFarlane, S.; Mulligan, K.; Gillespie, H.; Draffin, J. E.; Trimble, A.; Ouhtit, A.; Johnston, P. G.; Harkin, D. P.; McCormick, D.; Waugh, D. J. J.			Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrowendothelial cells	ONCOGENE			English	Article						CD44; cortactin; breast cancer; metastasis; invasion	CYTOSKELETON FUNCTION; EXTRACELLULAR-MATRIX; CD44 INTERACTION; PROMOTES; HYALURONAN; KINASE; CARCINOMA; MIGRATION; EMS1; IDENTIFICATION	Using a validated tetracycline (tet)-regulated MCF7-founder (MCF7F) expression system to modulate expression of CD44 standard form (CD44s), we report the functional importance of CD44s and that of a novel transcriptional target of hyaluronan (HA)/CD44s signaling, EMS1/cortactin, in underpinning breast cancer metastasis. In functional experiments, tet-regulated induction of CD44s potentiated the migration and invasion of MCF7F cells through HA-supplemented Matrigel. EMS1/cortactin was identified by expression profiling as a novel transcriptional target of HA/CD44 signaling, an association validated by quantitative PCR and immunoblotting experiments in a range of breast cancer cell lines. The mechanistic basis underpinning CD44-promoted transcription of EMS1/cortactin was shown to be dependent upon a NF kappa B mechanism, since pharmacological inhibition of I kappa Kinase-2 or suppression of p65 Rel A expression attenuated CD44-induced increases in cortactin mRNA transcript levels. Overexpression of a c-myc tagged murine cortactin construct in the weakly invasive, CD44-deficient MCF7F and T47D cells potentiated their invasion. Furthermore, the functional importance of cortactin to CD44s-promoted metastasis was demonstrated by selective suppression of cortactin in CD44-expressing MCF7F-B5 and MDA-MB-231 breast cancer cells using RNAi, which was shown to result in attenuated CD44-promoted invasion and CD44-promoted adhesion to bone marrow endothelial cells (BMECs).	Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast City Hosp, Belfast BT9 7AB, Antrim, North Ireland	Belfast City Hospital; Queens University Belfast	Waugh, DJJ (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast City Hosp, Univ Floor,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	d.waugh@qub.ac.uk		WAUGH, DAVID/0000-0002-4022-3765	MRC [G0200103] Funding Source: UKRI; Medical Research Council [G0200103] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Arderiu G, 2002, BIOCHEM J, V364, P65, DOI 10.1042/bj3640065; Auvinen P, 2000, AM J PATHOL, V156, P529, DOI 10.1016/S0002-9440(10)64757-8; Berner HS, 2001, BREAST CANCER RES TR, V65, P23, DOI 10.1023/A:1006417412046; Bourguignon LYW, 2004, J BIOL CHEM, V279, P29654, DOI 10.1074/jbc.M403608200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Bryce NS, 2005, CURR BIOL, V15, P1276, DOI 10.1016/j.cub.2005.06.043; Draffin JE, 2004, CANCER RES, V64, P5702, DOI 10.1158/0008-5472.CAN-04-0389; Fitzgerald KA, 2000, J IMMUNOL, V164, P2053, DOI 10.4049/jimmunol.164.4.2053; Herrera-Gayol A, 2001, INT J EXP PATHOL, V82, P193, DOI 10.1111/j.1365-2613.2001.iep196.x; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hui R, 1997, ONCOGENE, V15, P1617, DOI 10.1038/sj.onc.1201311; Isacke CM, 2002, INT J BIOCHEM CELL B, V34, P718, DOI 10.1016/S1357-2725(01)00166-2; Kinoshita J, 1999, BREAST CANCER RES TR, V53, P177, DOI 10.1023/A:1006130601575; Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911-005-5399-8; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; Li YS, 2001, CANCER RES, V61, P6906; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Monaghan M, 2000, J PATHOL, V192, P519; Mullins RD, 2000, CURR OPIN CELL BIOL, V12, P91, DOI 10.1016/S0955-0674(99)00061-7; Oliferenko S, 2000, J CELL BIOL, V148, P1159, DOI 10.1083/jcb.148.6.1159; Rodrigo JP, 2000, CLIN CANCER RES, V6, P3177; SAYEGH TY, 2005, MOL BIOL CELL, V12, P5514; SCHUURING E, 1992, ONCOGENE, V7, P355; Tilghman RW, 2002, FASEB J, V16, P1257, DOI 10.1096/fj.01-0969fje; Timpson P, 2005, CANCER RES, V65, P3273, DOI 10.1158/0008-5472.CAN-04-2118; Toole BP, 2002, GLYCOBIOLOGY, V12, p37R, DOI 10.1093/glycob/12.3.37R; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; van Rossum AGSH, 2005, BREAST CANCER RES, V7, P235, DOI 10.1186/bcr1316; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Weber GF, 2002, CANCER RES, V62, P2281; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Zhu D, 1998, CELL MOTIL CYTOSKEL, V39, P209, DOI 10.1002/(SICI)1097-0169(1998)39:3<209::AID-CM4>3.0.CO;2-#	39	95	97	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6079	6091		10.1038/sj.onc.1209628	http://dx.doi.org/10.1038/sj.onc.1209628			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652145				2022-12-17	WOS:000241101200005
J	Clement, G; Braunschweig, R; Pasquier, N; Bosman, FT; Benhattar, J				Clement, G.; Braunschweig, R.; Pasquier, N.; Bosman, F. T.; Benhattar, J.			Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus	ONCOGENE			English	Article						Barrett's esophagus; Wnt pathway; DNA methylation; APC; SFRP	BETA-CATENIN EXPRESSION; FREQUENT UP-REGULATION; PRIMARY GASTRIC-CANCER; APC GENE; HUMAN MESOTHELIOMA; COLORECTAL-CANCER; DNA METHYLATION; COLON-CANCER; E-CADHERIN; ADENOCARCINOMA	Aberrant activation of the Wnt signaling pathway has been reported during neoplastic progression in Barrett's esophagus (BE). However, mutations in APC and CTNNB1 genes were rarely observed. In this study, expression pattern of Wnt ligands, Frizzled receptors and APC, as well as the methylation status of the APC, SFRP1 and SFRP2 promoter genes were investigated in normal esophageal mucosa and in preneoplastic and neoplastic lesions of BE patients. Promoter methylation of APC was found in all BE samples and in 95% of esophageal adenocarcinomas (EAC). Full methylation of APC correlated with lack of expression. In EAC, nuclear translocation of ss-catenin was observed regardless of the expression of APC. WNT2 expression was higher in dysplasia and EAC than in BE, with 20/26 (77%) of the EAC showing high expression of WNT2. SFRP1 methylation occurred in all BE samples and in 96% of EAC, while SFRP2 was methylated in 73% of the normal squamous esophageal mucosa samples. In conclusion, (1) alterations of key regulators of the Wnt signaling are frequent in the pathogenesis of BE; (2) the APC and SFRP1 genes are inactivated by promoter methylation in BE; (3) the WNT2 gene is upregulated along the progression from low-grade dysplasia to EAC.	CHU Vaudois, Inst Pathol, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Benhattar, J (corresponding author), CHU Vaudois, Inst Pathol, Bugnon 25, CH-1011 Lausanne, Switzerland.	Jean.Benhattar@chuv.hospvd.ch						Baisse B, 2000, BIOTECHNIQUES, V28, P856; Benhattar Jean, 2004, Methods Mol Biol, V287, P181; Bian YS, 2000, AM J CLIN PATHOL, V114, P583, DOI 10.1309/3QLC-5MF1-JYXU-A5XX; Bian YS, 2001, BIOTECHNIQUES, V30, P66, DOI 10.2144/01301st02; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BLASBAND A, 1992, ONCOGENE, V7, P153; Blot WJ, 1999, SEMIN ONCOL, V26, P2; Brabender J, 2004, ONCOGENE, V23, P4780, DOI 10.1038/sj.onc.1207663; Bui TD, 1997, BRIT J CANCER, V75, P1131, DOI 10.1038/bjc.1997.195; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Clement G, 2004, CANCER RES, V64, P6867, DOI 10.1158/0008-5472.CAN-03-2503; Clement G, 2005, J CLIN PATHOL, V58, P155, DOI 10.1136/jcp.2004.021147; Falk GW, 2002, GASTROENTEROLOGY, V122, P1569, DOI 10.1053/gast.2002.33427; Flejou JF, 2005, GUT, V54, pI6, DOI 10.1136/gut.2004.041525; Gonzalez MV, 1997, J CLIN PATHOL, V50, P212, DOI 10.1136/jcp.50.3.212; Guillou L, 2001, HUM PATHOL, V32, P105, DOI 10.1053/hupa.2001.21130; He B, 2005, CANCER RES, V65, P743; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; HORII A, 1993, HUM MOL GENET, V2, P283, DOI 10.1093/hmg/2.3.283; Howng SL, 2002, CANCER LETT, V183, P95, DOI 10.1016/S0304-3835(02)00085-X; Jenkins GJS, 2002, BRIT J SURG, V89, P824, DOI 10.1046/j.1365-2168.2002.02107.x; Katoh M, 2001, INT J ONCOL, V19, P1003; Katoh M, 2003, INT J MOL MED, V12, P811; Katoh M, 2001, INT J MOL MED, V8, P657; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kitadai Y, 1998, CLIN CANCER RES, V4, P2195; Kobayashi K, 2002, GENE, V282, P151, DOI 10.1016/S0378-1119(01)00838-1; Koppert LB, 2004, BRIT J CANCER, V90, P892, DOI 10.1038/sj.bjc.6601589; Le Floch N, 2004, FASEB J, V18, P144, DOI 10.1096/fj.04-2373fje; Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; McManus DT, 2004, CANCER RES, V64, P1561, DOI 10.1158/0008-5472.CAN-03-2438; Metzger R, 2004, ONKOLOGIE, V27, P200, DOI 10.1159/000076913; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Osterheld MC, 2002, AM J CLIN PATHOL, V117, P451; Pham K, 2003, J CLIN PATHOL-MOL PA, V56, P280, DOI 10.1136/mp.56.5.280; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920; Ricken A, 2002, ENDOCRINOLOGY, V143, P2741, DOI 10.1210/en.143.7.2741; Rockett JC, 1997, BRIT J CANCER, V75, P258, DOI 10.1038/bjc.1997.42; Saitoh T, 2002, INT J MOL MED, V9, P515; Seery JP, 1999, ACTA ONCOL, V38, P945, DOI 10.1080/028418699432635; Shih IM, 2000, CANCER RES, V60, P1671; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Verma UN, 2003, CLIN CANCER RES, V9, P1291; Worm J, 2004, ONCOGENE, V23, P5215, DOI 10.1038/sj.onc.1207647	51	95	102	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3084	3092		10.1038/sj.onc.1209338	http://dx.doi.org/10.1038/sj.onc.1209338			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407829				2022-12-17	WOS:000237950800014
J	Suzuki, M; Yamada, T; Kihara-Negishi, F; Sakurai, T; Hara, E; Tenen, DG; Hozumi, N; Oikawa, T				Suzuki, M; Yamada, T; Kihara-Negishi, F; Sakurai, T; Hara, E; Tenen, DG; Hozumi, N; Oikawa, T			Site-specific DNA methylation by a complex of PU.1 and Dnmt3a/b	ONCOGENE			English	Article						PU.1; DNA methyltransferase; epigenetic transcriptional repression; p16(INK4a)	TRANSCRIPTION FACTOR PU.1; ETS FAMILY; EXPRESSION; DNMT1; DIFFERENTIATION; ASSOCIATION; PROTEINS; BINDS; METHYLTRANSFERASES; LOCALIZATION	The Ets transcription factor PU.1 is a hematopoietic master regulator essential for the development of myeloid and B-cell lineages. As we previously reported, PU.1 sometimes represses transcription on forming a complex with mSin3A-histone deacetyl transferase-MeCP2. Here, we show an interaction between PU.1 and DNA methyltransferases, DNA methyltransferase (Dnmt)3a and Dnmt3b (Dnmt3s). Glutathione-S-transferase pulldown assay revealed that PU.1 directly interacted with the ATRX domain of Dnmt3s through the ETS domain. Dnmt3s repressed the transcriptional activity of PU.1 on a reporter construct with trimerized PU.1-binding sites. The repression was recovered by addition of 5-aza-deoxycitidine, a DNA methyltransferase inhibitor, but not trichostatin A, a histone deacetylase inhibitor. Bisulfite sequence analysis revealed that several CpG sites in the promoter region neighboring the PU.1-binding sites were methylated when Dnmt3s were coexpressed with PU.1. We also showed that the CpG sites in the p16(INK4A) promoter were methylated by overexpression of PU.1 in NIH3T3 cells, accompanied by a downregulation of p16(INK4A) gene expression. These results suggest that PU.1 may downregulate its target genes through an epigenetic modi. cation such as DNA methylation.	Sasaki Inst, Dept Cell Genet, Chiyoda Ku, Tokyo 1010062, Japan; Tokyo Univ Sci, Res Inst Biol Sci, Chiba, Japan; Univ Tokushima, Inst Genome Res, Tokushima, Japan; Beth Israel Hosp, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Tokyo University of Science; Tokushima University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Oikawa, T (corresponding author), Sasaki Inst, Dept Cell Genet, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.	oikawa@sasaki.or.jp		Tenen, Daniel/0000-0002-6423-3888				Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Datta J, 2003, J CELL BIOCHEM, V88, P855, DOI 10.1002/jcb.10457; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Hara E, 1996, MOL CELL BIOL, V16, P859; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hwang CK, 2004, J BIOL CHEM, V279, P19764, DOI 10.1074/jbc.M400755200; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Konishi Y, 1999, ONCOGENE, V18, P6795, DOI 10.1038/sj.onc.1203118; Linderson Y, 2004, EMBO REP, V5, P291, DOI 10.1038/sj.embor.7400089; Majumder S, 2002, J BIOL CHEM, V277, P16048, DOI 10.1074/jbc.M111662200; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1997, BIOCHIM BIOPHYS ACTA, V1198, P149; Mueller BU, 2002, BLOOD, V100, P998, DOI 10.1182/blood.V100.3.998; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; Suzuki M, 2003, ONCOGENE, V22, P8688, DOI 10.1038/sj.onc.1207182; Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	44	95	100	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2477	2488		10.1038/sj.onc.1209272	http://dx.doi.org/10.1038/sj.onc.1209272			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16331260				2022-12-17	WOS:000236948000006
J	Ballester, B; Ramuz, O; Gisselbrecht, C; Doucet, G; Loi, L; Loriod, B; Bertucci, F; Bouabdallah, R; Devilard, E; Carbuccia, N; Mozziconacci, MJ; Birnbaum, D; Brousset, P; Berger, F; Salles, G; Briere, J; Houlgatte, R; Gaulard, P; Xerri, L				Ballester, B; Ramuz, O; Gisselbrecht, C; Doucet, G; Loi, L; Loriod, B; Bertucci, F; Bouabdallah, R; Devilard, E; Carbuccia, N; Mozziconacci, MJ; Birnbaum, D; Brousset, P; Berger, F; Salles, G; Briere, J; Houlgatte, R; Gaulard, P; Xerri, L			Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas	ONCOGENE			English	Article						T-cell lymphoma; gene expression profiling; microarray	DNA MICROARRAYS; KAPPA-B; CLASSIFICATION; PREDICTION; SURVIVAL; PROTEIN; DISTINCT; LINES; OVEREXPRESSION; CHEMOTHERAPY	The classification of peripheral T-cell lymphomas (PTCL) is still a matter of debate. To establish a molecular classification of PTCL, we analysed 59 primary nodal T-cell lymphomas using cDNA microarrays, including 56 PTCL and three T-lymphoblastic lymphoma (T-LBL). The expression profiles could discriminate angioimmunoblastic lymphoma, anaplastic large-cell lymphoma and T-LBL. In contrast, cases belonging to the broad category of 'PTCL, unspecified' (PTCL-U) did not share a single molecular pro. le. Using a multiclass predictor, we could separate PTCL-U into three molecular subgroups called U1, U2 and U3. The U1 gene expression signature included genes known to be associated with poor outcome in other tumors, such as CCND2. The U2 subgroup was associated with overexpression of genes involved in T-cell activation and apoptosis, including NFKB1 and BCL-2. The U3 subgroup was mainly defined by overexpression of genes involved in the IFN/JAK/STAT pathway. It comprised a majority of histiocyte-rich PTCL samples. Gene Ontology annotations revealed different functional pro. le for each subgroup. These results suggest the existence of distinct subtypes of PTCL-U with specific molecular profiles, and thus provide a basis to improve their classification and to develop new therapeutic targets.	Inst J Paoli I Calmettes, Dept Biopathol, F-13273 Marseille 9, France; INSERM, TAGC, ERM206, Marseille, France; Univ Mediterranee, Marseille, France; CHU St Louis, Dept Hematopathol, Paris, France; Hop St Louis, Inst Hematol, Grp Etud Lymphomes Adulte, F-75010 Paris, France; Inst J Paoli I Calmettes, Dept Mol Oncol, F-13009 Marseille, France; CHU Purpan, Dept Pathol, F-31052 Toulouse, France; CHU Lyon, Dept Pathol, Lyon, France; CHU Lyon, Dept Hematol, Lyon, France; Hop Henri Mondor, Dept Pathol, INSERM U 617, AP HP, F-94010 Creteil, France	UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Institut Paoli-Calmette (IPC); CHU de Toulouse; CHU Lyon; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Xerri, L (corresponding author), Inst J Paoli I Calmettes, Dept Biopathol, F-13273 Marseille 9, France.	xerril@marseille.fnclcc.fr	Doucet, Gaelle/H-9367-2019; Salles, Gilles/Z-2336-2019; loriod, beatrice/L-2948-2016; Ballester, Benoit/N-6127-2016	Doucet, Gaelle/0000-0003-4120-0474; Salles, Gilles/0000-0002-9541-8666; loriod, beatrice/0000-0001-5801-2264; Ballester, Benoit/0000-0002-0834-7135; gaulard, philippe/0000-0002-4243-905X				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bertucci F, 2004, CANCER RES, V64, P8558, DOI 10.1158/0008-5472.CAN-04-2696; Bertucci F, 1999, HUM MOL GENET, V8, P1715, DOI 10.1093/hmg/8.9.1715; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Chan WC, 1997, BLOOD, V89, P3909; Chauhan D, 2003, BLOOD, V101, P3606, DOI 10.1182/blood-2002-10-3146; Dogan A, 2003, BRIT J HAEMATOL, V121, P681, DOI 10.1046/j.1365-2141.2003.04335.x; Fillmore GC, 2002, FEBS LETT, V522, P183, DOI 10.1016/S0014-5793(02)02914-9; Ginestier C, 2002, AM J PATHOL, V161, P1223, DOI 10.1016/S0002-9440(10)64399-4; Gisselbrecht C, 1998, BLOOD, V92, P76; HARRIS NL, 1994, BLOOD, V84, P1361; Hiroi M, 2003, BIOCHEM J, V376, P393, DOI 10.1042/BJ20030842; Hiroi M, 2003, J BIOL CHEM, V278, P651, DOI 10.1074/jbc.M204544200; Hisaoka M, 2004, CANCER GENET CYTOGEN, V152, P101, DOI 10.1016/j.cancergencyto.2003.11.011; Ihaka R., 1996, J COMPUT GRAPH STAT, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Kagami Y, 1999, AM J SURG PATHOL, V23, P1184, DOI 10.1097/00000478-199910000-00003; Kari L, 2003, J EXP MED, V197, P1477, DOI 10.1084/jem.20021726; Li SY, 2001, AM J PATHOL, V158, P1231, DOI 10.1016/S0002-9440(10)64073-4; Lopez F, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-38; Lossos IS, 2004, NEW ENGL J MED, V350, P1828, DOI 10.1056/NEJMoa032520; Mao X, 2003, BLOOD, V101, P1513, DOI 10.1182/blood-2002-08-2434; Martinez-Delgado B, 2004, CLIN CANCER RES, V10, P4971, DOI 10.1158/1078-0432.CCR-04-0269; Munshi NC, 2004, BLOOD, V103, P1799, DOI 10.1182/blood-2003-02-0402; Petit B, 2001, HUM PATHOL, V32, P196, DOI 10.1053/hupa.2001.21569; Pinet F, 2004, FASEB J, V18, P585, DOI 10.1096/fj.03-0939fje; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Rassidakis GZ, 2002, AM J PATHOL, V160, P2309, DOI 10.1016/S0002-9440(10)61178-9; Rassidakis GZ, 2003, J PATHOL, V200, P240, DOI 10.1002/path.1346; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Shi GX, 2004, J IMMUNOL, V172, P5175, DOI 10.4049/jimmunol.172.9.5175; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; SUCHI T, 1987, J CLIN PATHOL, V40, P995, DOI 10.1136/jcp.40.9.995; Thieblemont C, 2004, BLOOD, V103, P2727, DOI 10.1182/blood-2003-06-2160; Tracey L, 2003, BLOOD, V102, P1042, DOI 10.1182/blood-2002-11-3574; Tsuchiya T, 2004, BLOOD, V103, P236, DOI 10.1182/blood-2002-05-1352; Villalva C, 2002, BRIT J HAEMATOL, V118, P791, DOI 10.1046/j.1365-2141.2002.03671.x; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28	42	95	102	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1560	1570		10.1038/sj.onc.1209178	http://dx.doi.org/10.1038/sj.onc.1209178			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16288225				2022-12-17	WOS:000235890400013
J	Matei, D; Emerson, RE; Lai, YC; Baldridge, LA; Rao, J; Yiannoutsos, C; Donner, DB				Matei, D; Emerson, RE; Lai, YC; Baldridge, LA; Rao, J; Yiannoutsos, C; Donner, DB			Autocrine activation of PDGFR alpha promotes the progression of ovarian cancer	ONCOGENE			English	Article						ovarian epithelial cancer; platelet-derived growth factor receptor; autocrine	GROWTH-FACTOR-RECEPTOR; PROGNOSTIC-SIGNIFICANCE; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL-3 KINASE; C-KIT; BETA; CARCINOMA; CELLS; MUTATIONS; RECURRENT	Platelet-derived growth factor receptor ( PDGFR) a expression was found in ovarian cancer cells and tumors by microarray hybridization. This led us to test whether ovarian cancers also produce ligands for this receptor, as this would demonstrate that such malignancies support their own growth and spread through autocrine activation. We assayed the expression of ligands for the PDGFR in ovarian tumors, cell lines and peritoneal fluid using RT-PCR, immunohistochemistry (IHC) and ELISA. We detected strong mRNA expression for the PDGFR alpha ligands in most ovarian tumors. Receptor and ligand expressions (PDGFR alpha and PDGF AB) were also detected by IHC in, respectively, 34 and 32 of 47 ovarian tumors. The stainings for PDGFR alpha and PDGF AB were strongly correlated (P-value = 0.014), suggesting that an autocrine loop is functional in ovarian cancer. PDGF AA and BB were quantified in peritoneal fluid by ELISA. Both ligands are secreted at higher levels in ovarian cancer ascites specimens (n = 54) than in fluid from nonmalignant disorders (n = 8). PDGF was detected in media conditioned by ovarian cancer cells. Such conditioned media induced activation of the PDGFR, Akt and MAPK and stimulated cell proliferation. A neutralizing PDGF antibody blocked these effects. Specific PDGFR inhibition by siRNA or a neutralizing antibody to the receptor inhibited PDGF-stimulated receptor activation and cell proliferation, suggesting that receptor targeting has a role in ovarian cancer treatment.	Indiana Univ, Sch Med, Div Hematol Oncol, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Ctr Canc, Indianapolis, IN USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN USA; Indiana Univ, Sch Med, Dept Pathol & Lab Med, Indianapolis, IN USA; Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA USA; Indiana Univ, Sch Med, Dept Biostat, Indianapolis, IN USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Matei, D (corresponding author), Indiana Univ, Sch Med, Div Hematol Oncol, Dept Med, RT-457,535 Barnhill Dr, Indianapolis, IN 46202 USA.	dmatei@iupui.edu		Matei, Daniela/0000-0003-2169-5035				Aase K, 2002, MECH DEVELOP, V110, P187, DOI 10.1016/S0925-4773(01)00560-3; Bookman MA, 2003, J CLIN ONCOL, V21, P283, DOI 10.1200/JCO.2003.10.104; Dong JY, 2004, EMBO J, V23, P2800, DOI 10.1038/sj.emboj.7600289; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FRANKLIN WA, 1990, CANCER RES, V50, P6344; Gillan L, 2002, CANCER RES, V62, P5358; Gordon AN, 2001, J CLIN ONCOL, V19, P3312, DOI 10.1200/JCO.2001.19.14.3312; GREENHALGH DG, 1990, AM J PATHOL, V136, P1235; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HENRIKSEN R, 1993, CANCER RES, V53, P4550; Hu YH, 1998, FASEB J, V12, P1135, DOI 10.1096/fasebj.12.12.1135; HUANG JS, 1984, CELL, V39, P79, DOI 10.1016/0092-8674(84)90193-4; Ikeda K, 2003, INT J GYNECOL CANCER, V13, P776, DOI 10.1111/j.1525-1438.2003.13381.x; Ismail RS, 2000, CANCER RES, V60, P6744; JENSEN RA, 1992, BIOCHEMISTRY-US, V31, P10887, DOI 10.1021/bi00159a032; KARLAN BY, 1995, GYNECOL ONCOL, V59, P67, DOI 10.1006/gyno.1995.1269; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Lassus H, 2004, BRIT J CANCER, V91, P2048, DOI 10.1038/sj.bjc.6602252; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Loizos N, 2005, MOL CANCER THER, V4, P369; Lokker NA, 2002, CANCER RES, V62, P3729; Matei D, 2004, CLIN CANCER RES, V10, P681, DOI 10.1158/1078-0432.CCR-0754-03; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; OZOLS RF, 1997, CANC PRINCIPLES PRAC, V1, P1502; Pietras K, 2002, CANCER RES, V62, P5476; Schmandt RE, 2003, CANCER-AM CANCER SOC, V98, P758, DOI 10.1002/cncr.11561; Sihto H, 2005, J CLIN ONCOL, V23, P49, DOI 10.1200/JCO.2005.02.093; Spentzos D, 2004, J CLIN ONCOL, V22, P4700, DOI 10.1200/JCO.2004.04.070; UREN A, 1994, BIOCHEM BIOPH RES CO, V204, P628, DOI 10.1006/bbrc.1994.2505; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VERSNEL MA, 1994, CANCER GENET CYTOGEN, V73, P60, DOI 10.1016/0165-4608(94)90183-X; Wilczynski SP, 2005, HUM PATHOL, V36, P242, DOI 10.1016/j.humpath.2004.11.009; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YU JC, 1994, J BIOL CHEM, V269, P10668; Yu JH, 2001, BIOCHEM BIOPH RES CO, V282, P697, DOI 10.1006/bbrc.2001.4622; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	40	95	102	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2060	2069		10.1038/sj.onc.1209232	http://dx.doi.org/10.1038/sj.onc.1209232			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16331269				2022-12-17	WOS:000236359700009
J	Li, J; Zou, C; Bai, Y; Wazer, DE; Band, V; Gao, Q				Li, J; Zou, C; Bai, Y; Wazer, DE; Band, V; Gao, Q			DSS1 is required for the stability of BRCA2	ONCOGENE			English	Article						DSS1; BRCA2; DNA damage repair; tumor; suppressor gene; protein degradation; breast cancer	BREAST-CANCER SUSCEPTIBILITY; MAMMARY EPITHELIAL-CELLS; DNA-REPAIR; GENE BRCA2; RADIATION HYPERSENSITIVITY; SACCHAROMYCES-CEREVISIAE; CANDIDATE GENE; PROTEIN; RAD51; RECOMBINATION	DSS1 is an evolutionarily conserved acidic protein that binds to BRCA2. However, study of the function of DSS1 in mammalian cells has been hampered because endogenous DSS1 has not been detectable by Western blotting. Here, we developed a modified Western blotting protocol that detects endogenous DSS1 protein, and used it to study the function of DSS1 and its interaction with BRCA2 in mammalian cells. We found that essentially all BRCA2 in human cell lines is associated with DSS1. Importantly, we found that RNAi knockdown of DSS1 in human cell lines led to dramatic loss of BRCA2 protein, mainly due to its increased degradation. Furthermore, the stability of BRCA2 mutant devoid of the DSS1-binding domain is unaffected by the depletion of DSS1. Most notably, like BRCA2 depletion, DSS1 depletion also led to hypersensitivity to DNA damage. These results demonstrated that the stability of BRCA2 protein in mammalian cells depends on the presence of DSS1. Deletion or mutation of DSS1 or suppression of its expression by other mechanisms are therefore potential causative mechanisms for human breast and ovarian cancer. Such mechanisms may be relevant to sporadic as well as familiar breast cancer where BRCA1 and BRCA2 mutations are not present.	Northwestern Univ, Feinberg Sch Med, Div Canc Biol, Dept Med,Evanston Northwestern Healthcare Res Ins, Evanston, IL 60201 USA; Tufts Univ, Sch Med, Dept Radiat Oncol, New England Med Ctr, Boston, MA 02111 USA	Northwestern University; Feinberg School of Medicine; Tufts Medical Center; Tufts University	Gao, Q (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Canc Biol, Dept Med,Evanston Northwestern Healthcare Res Ins, 1001 Univ Pl, Evanston, IL 60201 USA.	Q-GAO@Northwestern.edu			NCI NIH HHS [R01 CA096986-03, R01 CA096986-02, R01 CA096986-05, R01 CA095221-04, R01 CA095221-03, R01 CA096986-01A1, R01 CA095221-02, R01 CA095221-01A1, R01 CA095221-05, R01 CA096986-04] Funding Source: Medline; NIAID NIH HHS [1 R01 CA96986-01AI, 1 R01 CA095221-01AI] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095221, R01CA096986] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; Brody LC, 1998, MEDICINE, V77, P208, DOI 10.1097/00005792-199805000-00006; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Gudmundsdottir K, 2004, EMBO REP, V5, P989, DOI 10.1038/sj.embor.7400255; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; Isono E, 2004, J BIOL CHEM, V279, P27168, DOI 10.1074/jbc.M314231200; Jantti J, 1999, P NATL ACAD SCI USA, V96, P909, DOI 10.1073/pnas.96.3.909; Kojic M, 2003, MOL CELL, V12, P1043, DOI 10.1016/S1097-2765(03)00367-8; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Ratsch SB, 2001, RADIAT RES, V155, P143, DOI 10.1667/0033-7587(2001)155[0143:MGCARF]2.0.CO;2; Sharan SK, 2004, DEVELOPMENT, V131, P131, DOI 10.1242/dev.00888; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shin S, 2003, P NATL ACAD SCI USA, V100, P7201, DOI 10.1073/pnas.1132020100; Sone T, 2004, J BIOL CHEM, V279, P28807, DOI 10.1074/jbc.M403165200; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Tian XX, 2005, CANCER RES, V65, P4747, DOI 10.1158/0008-5472.CAN-05-0018; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Wang SC, 2002, CANCER RES, V62, P1311; Wang SC, 2001, CANCER RES, V61, P2838; Wei SJ, 2003, J BIOL CHEM, V278, P1758, DOI 10.1074/jbc.M206328200; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837	40	95	99	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1186	1194		10.1038/sj.onc.1209153	http://dx.doi.org/10.1038/sj.onc.1209153			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16205630	Bronze			2022-12-17	WOS:000235537500006
J	Goncalves, A; Esterni, B; Bertucci, F; Sauvan, R; Chabannon, C; Cubizolles, M; Bardou, VJ; Houvenaegel, G; Jacquemier, J; Granjeaud, S; Meng, XY; Fung, ET; Birnbaum, D; Maraninchi, D; Viens, P; Borg, JP				Goncalves, A; Esterni, B; Bertucci, F; Sauvan, R; Chabannon, C; Cubizolles, M; Bardou, VJ; Houvenaegel, G; Jacquemier, J; Granjeaud, S; Meng, XY; Fung, ET; Birnbaum, D; Maraninchi, D; Viens, P; Borg, JP			Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy	ONCOGENE			English	Article						proteomics; breast cancer; prognosis; chemotherapy; SELDI-TOF MS; serum profiling	PARTIAL LEAST-SQUARES; TUMOR CLASSIFICATION; CELL-MIGRATION; BIOMARKERS; GROWTH; IDENTIFICATION; HAPTOGLOBIN; DISCOVERY; DIAGNOSIS; VARIANTS	A total of 30 - 50% of early breast cancer ( EBC) patients considered as high risk using standard prognostic factors develop metastatic recurrence despite standard adjuvant systemic treatment. A means to better predict clinical outcome is needed to optimize and individualize therapeutic decisions. To identify a protein signature correlating with metastatic relapse, we performed surface-enhanced laser desorption/ionization-time of flight mass spectrometry profiling of early postoperative serum from 81 high-risk EBC patients. Denatured and fractionated serum samples were incubated with IMAC30 and CM10 ProteinChip arrays. Several protein peaks were differentially expressed according to clinical outcome. By combining partial least squares and logistic regression methods, we built a multiprotein model that correctly predicted outcome in 83% of patients. The 5-year metastasis-free survival in 'good prognosis' and 'poor prognosis' patients as defined using the multiprotein index were strikingly different ( 83 and 22%, respectively; P < 0.0001, log-rank test). In a multivariate Cox regression including conventional pathological factors and multiprotein index, the latter retained the strongest independent prognostic significance for metastatic relapse. Major components of the multiprotein index included haptoglobin, C3a complement fraction, transferrin, apolipoprotein C1 and apolipoprotein A1. Therefore, postoperative serum protein pattern may have an important prognostic value in high-risk EBC.	Inst J Paoli I Calmettes, Dept Med Oncol, INSERM, UMR599, F-13273 Marseille 9, France; Inst J Paoli I Calmettes, Dept Mol Pharmacol, UMR599, INSERM, F-13009 Marseille, France; Univ Mediterranee, UFR Med, Marseille, France; Inst J Paoli I Calmettes, Dept Biostat, UMR599, INSERM, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Mol Oncol, UMR599, INSERM, F-13009 Marseille, France; Inst J Paoli I Calmettes, Biol Resource Ctr, UMR599, INSERM, F-13009 Marseille, France; Ciphergen Biosyst, Fremont, CA USA; Inst J Paoli I Calmettes, Dept Pathol, UMR599, INSERM, F-13009 Marseille, France; INSERM, ERM 206, TAGC, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Goncalves, A (corresponding author), Inst J Paoli I Calmettes, Dept Med Oncol, INSERM, UMR599, 273 Blvd St Marguerite, F-13273 Marseille 9, France.	goncalvesa@marseille.fnclcc.fr	Borg, Jean-Paul/AAX-8096-2020; Cubizolles, Myriam/AAZ-7719-2021; Granjeaud, Samuel/AAE-6488-2022	Borg, Jean-Paul/0000-0001-8418-3382; Granjeaud, Samuel/0000-0001-9245-1535				Abe O, 1998, LANCET, V352, P930; Adam BL, 2002, CANCER RES, V62, P3609; Ahmed N, 2004, BRIT J CANCER, V91, P129, DOI 10.1038/sj.bjc.6601882; Antoniadis A, 2003, BIOINFORMATICS, V19, P563, DOI 10.1093/bioinformatics/btg062; Bertucci F, 2005, CANCER RES, V65, P2170, DOI 10.1158/0008-5472.CAN-04-4115; Bertucci F, 2002, HUM MOL GENET, V11, P863, DOI 10.1093/hmg/11.8.863; Bharti A, 2004, ANTICANCER RES, V24, P1031; BONADONNA G, 1995, JAMA-J AM MED ASSOC, V273, P542; Carlevaro MF, 1997, J CELL BIOL, V136, P1375, DOI 10.1083/jcb.136.6.1375; Cavanaugh PG, 1998, J CELL PHYSIOL, V174, P48, DOI 10.1002/(SICI)1097-4652(199801)174:1<48::AID-JCP6>3.0.CO;2-G; Cavanaugh PG, 1999, BREAST CANCER RES TR, V56, P203; CID MC, 1993, J CLIN INVEST, V91, P977, DOI 10.1172/JCI116319; Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; COX DR, 1972, J R STAT SOC B, V34, P187; de Kleijn DPV, 2002, FASEB J, V16, P1123, DOI 10.1096/fj.02-0019fje; Demicheli R, 1997, ANN ONCOL, V8, P1075, DOI 10.1023/A:1008263116022; Diamandis EP, 2004, J NATL CANCER I, V96, P353, DOI 10.1093/jnci/djh056; Eifel P, 2001, JNCI-J NATL CANCER I, V93, P979; FISHER B, 1989, CANCER RES, V49, P1996; Fung ET, 2005, INT J CANCER, V115, P783, DOI 10.1002/ijc.20928; Fung ET, 2001, CURR OPIN BIOTECH, V12, P65, DOI 10.1016/S0958-1669(00)00167-1; Goldhirsch A, 2003, J CLIN ONCOL, V21, P3357, DOI 10.1200/JCO.2003.04.576; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Heimann R, 2000, EUR J CANCER, V36, P1631, DOI 10.1016/S0959-8049(00)00151-9; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; INOUE T, 1993, J CELL PHYSIOL, V156, P212, DOI 10.1002/jcp.1041560128; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Koopmann J, 2004, CLIN CANCER RES, V10, P860, DOI 10.1158/1078-0432.CCR-1167-3; Kozak KR, 2003, P NATL ACAD SCI USA, V100, P12343, DOI 10.1073/pnas.2033602100; Kwak JY, 2004, EXP HEMATOL, V32, P836, DOI 10.1016/j.exphem.2004.06.006; NABHOLTZ JM, 2002, P ASCO, V21, P141; Nguyen DV, 2002, BIOINFORMATICS, V18, P1216, DOI 10.1093/bioinformatics/18.9.1216; Nguyen DV, 2002, BIOINFORMATICS, V18, P39, DOI 10.1093/bioinformatics/18.1.39; NICOLSON GL, 1992, J NATL CANCER I MONO, V13, P153; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Paradis V, 2005, HEPATOLOGY, V41, P40, DOI 10.1002/hep.20505; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Petricoin EF, 2002, J NATL CANCER I, V94, P1576; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142; Rozanov DV, 2004, J BIOL CHEM, V279, P46551, DOI 10.1074/jbc.M405284200; Steel LF, 2003, PROTEOMICS, V3, P601, DOI 10.1002/pmic.200300399; Tagliabue E, 2003, LANCET, V362, P527, DOI 10.1016/S0140-6736(03)14112-8; Tolson J, 2004, LAB INVEST, V84, P845, DOI 10.1038/labinvest.3700097; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van 't Veer LJ, 2003, BREAST CANCER RES, V5, P57, DOI 10.1186/bcr562; Vlahou Antonia, 2003, Clin Breast Cancer, V4, P203, DOI 10.3816/CBC.2003.n.026; Wadsworth JT, 2004, CLIN CANCER RES, V10, P1625, DOI 10.1158/1078-0432.CCR-0297-3; Zhang Z, 2004, CANCER RES, V64, P5882, DOI 10.1158/0008-5472.CAN-04-0746	50	95	112	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					981	989		10.1038/sj.onc.1209131	http://dx.doi.org/10.1038/sj.onc.1209131			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16186794				2022-12-17	WOS:000235361000003
J	Bandyopadhyay, S; Pai, SK; Watabe, M; Gross, SC; Hirota, S; Hosobe, S; Tsukada, T; Miura, K; Saito, K; Markwell, SJ; Wang, Y; Huggenvik, J; Pauza, ME; Iiizumi, M; Watabe, K				Bandyopadhyay, S; Pai, SK; Watabe, M; Gross, SC; Hirota, S; Hosobe, S; Tsukada, T; Miura, K; Saito, K; Markwell, SJ; Wang, Y; Huggenvik, J; Pauza, ME; Iiizumi, M; Watabe, K			FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis	ONCOGENE			English	Article						PTEN; PI3-K; FAS; siRNA; apoptosis	FATTY-ACID SYNTHASE; TUMOR-SUPPRESSOR GENE; BREAST-CARCINOMA; PROGRESSION; PATHWAY; ACTIVATION; PREDICTOR; OA-519; CELLS; OVEREXPRESSION	Fatty acid synthase (FAS), a key enzyme of the fatty acid biosynthetic pathway, has been shown to be overexpressed in various types of human cancer and is, therefore, considered to be an attractive target for anticancer therapy. However, the exact mechanism of overexpression of the FAS gene in tumor cells is not well understood. In this report, we demonstrate that the expression of the tumor suppressor gene PTEN has a significant inverse correlation with FAS expression in the case of prostate cancer in the clinical setting, and inhibition of the PTEN gene leads to the overexpression of FAS in vitro. We also found that the combination of the expression status of these two genes is a better prognostic marker than either gene alone. Furthermore, our results indicate that the specific inhibition of FAS gene by siRNA leads to apoptosis of prostate tumor cells, and inhibition of PI 3-kinase pathway synergizes with FAS siRNA to enhance tumor cell death. These results provide a strong rationale for exploring the therapeutic use of an inhibitor of the PTEN signaling pathway in conjunction with the FAS siRNA to inhibit prostate tumor growth.	So Illinois Univ, Sch Med, Dept Med Microbiol & Immunol, Springfield, IL 62702 USA; Akita Red Cross Hosp, Aichi, Japan; So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA	Southern Illinois University System; Southern Illinois University; Akita Red Cross Hospital; Southern Illinois University System; Southern Illinois University	Watabe, K (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol & Immunol, 801 N Rutledge St, Springfield, IL 62702 USA.	kwatabe@siumed.edu			NCI NIH HHS [5R01CA89438] Funding Source: Medline; PHS HHS [1R15V50079473] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089438] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Clegg DJ, 2002, DIABETES, V51, P3196, DOI 10.2337/diabetes.51.11.3196; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; De Schrijver E, 2003, CANCER RES, V63, P3799; EPSTEIN JI, 1995, UROLOGY, V45, P81, DOI 10.1016/S0090-4295(95)96904-7; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; Heemers H, 2001, MOL ENDOCRINOL, V15, P1817, DOI 10.1210/me.15.10.1817; Innocenzi D, 2003, J CUTAN PATHOL, V30, P23, DOI 10.1034/j.1600-0560.2003.300104.x; JOCHEN AL, 1995, BBA-LIPID LIPID MET, V1259, P65, DOI 10.1016/0005-2760(95)00147-5; Kridel SJ, 2004, CANCER RES, V64, P2070, DOI 10.1158/0008-5472.CAN-03-3645; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Kusakabe T, 2002, HISTOPATHOLOGY, V40, P71, DOI 10.1046/j.1365-2559.2002.01289.x; Li JN, 2001, CANCER RES, V61, P1493; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; MALVOISIN E, 1990, BIOCHIM BIOPHYS ACTA, V1042, P359, DOI 10.1016/0005-2760(90)90165-T; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Pflug BR, 2003, PROSTATE, V57, P245, DOI 10.1002/pros.10297; Piyathilake CJ, 2000, HUM PATHOL, V31, P1068, DOI 10.1053/hupa.2000.9842; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 2001, PROSTATE, V47, P102, DOI 10.1002/pros.1052; Rashid A, 1997, AM J PATHOL, V150, P201; Sebastiani V, 2004, GYNECOL ONCOL, V92, P101, DOI 10.1016/j.ygyno.2003.10.027; Shurbaji MS, 1996, HUM PATHOL, V27, P917, DOI 10.1016/S0046-8177(96)90218-X; Su HS, 2000, J NUTR, V130, p315S, DOI 10.1093/jn/130.2.315S; Suzuki H, 1998, CANCER RES, V58, P204; Swinnen JV, 2000, ONCOGENE, V19, P5173, DOI 10.1038/sj.onc.1203889; Swinnen JV, 2002, INT J CANCER, V98, P19, DOI 10.1002/ijc.10127; Takahashi KA, 2004, ENDOCRINOLOGY, V145, P184, DOI 10.1210/en.2003-0337; Van de Sande T, 2002, CANCER RES, V62, P642; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Woessmann Willi, 2003, Rev Clin Exp Hematol, V7, P270; Yang YA, 2002, EXP CELL RES, V279, P80, DOI 10.1006/excr.2002.5600	33	95	108	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5389	5395		10.1038/sj.onc.1208555	http://dx.doi.org/10.1038/sj.onc.1208555			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	15897909				2022-12-17	WOS:000231158500013
J	Park, S; Yeung, ML; Beach, S; Shields, JM; Yeung, KC				Park, S; Yeung, ML; Beach, S; Shields, JM; Yeung, KC			RKIP downregulates B-Raf kinase activity in melanoma cancer cells	ONCOGENE			English	Article						B-Raf; melanomas; RKIP	RNA INTERFERENCE; TRANSFORMATION; SUPPRESSION; ACTIVATION; MUTATIONS; ONCOGENE; PATHWAY; BRAF; APOPTOSIS; MECHANISM	The Raf-MEK-ERK protein kinase cascade is a highly conserved signaling pathway that is pivotal in relaying environmental cues from the cell surface to the nucleus. Three Raf isoforms, which share great sequence and structure similarities, have been identified in mammalian cells. We have previously identified Raf kinase inhibitor protein (RKIP) as a negative regulator of the Raf-MEK-ERK signaling pathway by specifically binding to the Raf-1 isoform. We show here that RKIP also antagonizes kinase activity of the B-Raf isoform. Yeast two-hybrid and coimmunoprecipitation experiments indicated that RKIP specifically interacted with B-Raf. Ectopic expression of RKIP antagonized the kinase activity of B-Raf. We showed that the effects of RKIP on B-Raf functions were independent of its known inhibitory action on Raf-1. The expression levels of RKIP in melanoma cancer cell lines are low relative to primary melanocytes. Forced expression of RKIP partially reverted the oncogenic B-Raf kinase-transformed melanoma cancer cell line SK-Mel-28. The low expression of RKIP and its antagonistic action on B-Raf suggests that RKIP may play an important role in melanoma turmorgenesis.	Med Coll Ohio, Dept Biochem & Canc Biol, Toledo, OH 43614 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Yeung, KC (corresponding author), Med Coll Ohio, Dept Biochem & Canc Biol, BHSB Rm 469,3035 Arlington Ave, Toledo, OH 43614 USA.	kyeung@mco.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064767] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM64767] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARR J, 1994, BRIT J DERMATOL, V131, P72, DOI 10.1111/j.1365-2133.1994.tb08460.x; Chatterjee D, 2004, J BIOL CHEM, V279, P17515, DOI 10.1074/jbc.M313816200; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hingorani SR, 2003, CANCER RES, V63, P5198; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Mercer K, 2002, ONCOGENE, V21, P347, DOI 10.1038/sj.onc.1205101; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Weber CK, 2001, CANCER RES, V61, P3595; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429	20	95	111	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3535	3540		10.1038/sj.onc.1208435	http://dx.doi.org/10.1038/sj.onc.1208435			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15782137				2022-12-17	WOS:000229038800015
J	Suzuki, H; Yagi, K; Kondo, M; Kato, M; Miyazono, K; Miyazawa, K				Suzuki, H; Yagi, K; Kondo, M; Kato, M; Miyazono, K; Miyazawa, K			c-Ski inhibits the TGF-beta signaling pathway through stabilization of inactive Smad complexes on Smad-binding elements	ONCOGENE			English	Article						Ski; Smad; TGF-beta; Smad-binding element	TGF-BETA-1 INHIBITION; MEDIATED REPRESSION; ONCOPROTEIN SKI; CELL-MEMBRANE; GROWTH; MYC; PROTEINS; PROMOTER; SNON; TRANSCRIPTION	c-Ski inhibits transforming growth factor-beta (TGF-beta) signaling through interaction with Smad proteins. c-Ski represses Smad-mediated transcriptional activation, probably through its action as a transcriptional co-repressor. c-Ski also inhibits TGF-beta-induced downregulation of genes such as c-myc. How ever, mechanisms for transcriptional regulation of target genes by c-Ski have not been fully determined. In this study, we examined how c-Ski inhibits both TGF-beta-induced transcriptional activation and repression. DNA-affinity precipitation analysis revealed that c-Ski enhances the binding of Smad2 and 4, and to a lesser extent Smad3, to both CAGA and TGF-beta1 inhibitory element probes. A c-Ski mutant, which is unable to interact with Smad4, failed to enhance the binding of Smad complex on these probes and to inhibit the Smad-responsive promoter. These results suggest that stabilization of inactive Smad complexes on DNA is a critical event in c-Ski-mediated inhibition of TGF-beta signaling.	Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan.	miyazono-ind@umin.ac.jp	MIYAZAWA, KEIJI/I-9713-2014					Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Mizuide M, 2003, J BIOL CHEM, V278, P531, DOI 10.1074/jbc.C200596200; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Prunier C, 2003, J BIOL CHEM, V278, P26249, DOI 10.1074/jbc.M304459200; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Suzuki H, 2001, ONCOGENE, V20, P5779, DOI 10.1038/sj.onc.1204742; Takeda M, 2004, MOL BIOL CELL, V15, P963, DOI 10.1091/mbc.E03-07-0478; Ueki N, 2003, J BIOL CHEM, V278, P32489, DOI 10.1074/jbc.C300276200; Ueki N, 2003, J BIOL CHEM, V278, P24858, DOI 10.1074/jbc.M303447200; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Yagi K, 2002, J BIOL CHEM, V277, P854, DOI 10.1074/jbc.M104170200; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703	33	95	108	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5068	5076		10.1038/sj.onc.1207690	http://dx.doi.org/10.1038/sj.onc.1207690			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15107821				2022-12-17	WOS:000222237300013
J	Strand, S; Vollmer, P; van den Abeelen, L; Gottfried, D; Alla, V; Heid, H; Kuball, J; Theobald, M; Galle, PR; Strand, D				Strand, S; Vollmer, P; van den Abeelen, L; Gottfried, D; Alla, V; Heid, H; Kuball, J; Theobald, M; Galle, PR; Strand, D			Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells	ONCOGENE			English	Article						CD95; MMP-7; apoptosis; immune evasion	FAS LIGAND; SOLUBLE FAS; IN-VIVO; SERUM; ESCAPE; KILL	The ability of tumour cells to resist apoptosis-inducing signals by cytotoxic T cells may decide the success or failure of tumour elimination. An important effector of apoptosis is the CD95/CD95 ligand system (APO-1/Fas) that mediates perforin-independent cytotoxic T-cell killing of tumour cells. We propose a new strategy by which tumour cells can resist CD95-induced apoptosis. We identified matrix metalloproteinase-7, MMP-7 (Martilysin), as the first physiologically relevant protease that can specifically cleave CD95. MMP-7 is of unique importance because it is produced by the tumour cells themselves at early stages of tumour development. Microsequencing of the positions in CD95 cleaved by MMP-7 revealed two sites in the N-terminal extracellular domain of CD95, important for preligand assembly of CD95. MMP-7 cleavage of CD95 results in reduced CD95 surface expression and decreased CD95-mediated apoptosis sensitivity of tumour cells. Treatment of MMP-7-positive HT-29 tumour cells with MMP-7-antisense oligonucleotides led to an increase in CD95-mediated apoptosis sensitivity. Finally, specific cytotoxic T-cell killing was reduced in the presence of MMP-7. Thus, MMP-7 expression in tumour cells may contribute to an apoptosis-resistant phenotype, which ultimately promotes immune escape. This activity may account for the well-established role of MMP-7 in early tumour development.	Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-55101 Mainz, Germany; German Canc Res Ctr, Dept Cell Biol, D-69120 Heidelberg, Germany; Johannes Gutenberg Univ Mainz, Dept Hematol & Oncol, D-55101 Mainz, Germany	Johannes Gutenberg University of Mainz; Helmholtz Association; German Cancer Research Center (DKFZ); Johannes Gutenberg University of Mainz	Strand, D (corresponding author), Johannes Gutenberg Univ Mainz, Dept Internal Med 1, Obere Zahlbacherstr 63, D-55101 Mainz, Germany.	sstrand@mail.uni-mainz.de	Galle, Peter R/T-5292-2018; Galle, Peter/ABE-2872-2021	Galle, Peter R/0000-0001-8294-0992; Galle, Peter/0000-0001-8294-0992				Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fingleton B, 2001, NEOPLASIA, V3, P459, DOI 10.1038/sj.neo.7900190; Galle PR, 1998, SEMIN LIVER DIS, V18, P141, DOI 10.1055/s-2007-1007150; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Lustgarten J, 1997, HUM IMMUNOL, V52, P109, DOI 10.1016/S0198-8859(96)00292-3; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Mitsiades N, 2001, CANCER RES, V61, P577; Mizutani Y, 2001, CANCER, V92, P287, DOI 10.1002/1097-0142(20010715)92:2<287::AID-CNCR1321>3.0.CO;2-4; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nonomura N, 2000, UROLOGY, V55, P151, DOI 10.1016/S0090-4295(99)00379-9; Osorio LM, 2001, EUR J HAEMATOL, V66, P342, DOI 10.1034/j.1600-0609.2001.066005342.x; Pikul S, 1998, J MED CHEM, V41, P3568, DOI 10.1021/jm980253r; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Rosenberg SA, 1999, IMMUNITY, V10, P281, DOI 10.1016/S1074-7613(00)80028-X; Rudolph-Owen LA, 1998, CANCER RES, V58, P5500; Seki N, 2002, J IMMUNOL, V168, P3484, DOI 10.4049/jimmunol.168.7.3484; Shresta S, 1998, CURR OPIN IMMUNOL, V10, P581, DOI 10.1016/S0952-7915(98)80227-6; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Strand S, 1998, NAT MED, V4, P588, DOI 10.1038/nm0598-588; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Theobald M, 1995, P NATL ACAD SCI USA, V92, P11993, DOI 10.1073/pnas.92.26.11993; Ugurel S, 2001, CLIN CANCER RES, V7, P1282; Vargo-Gogola T, 2002, CANCER RES, V62, P5559; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Woessner J.F., 2000, PROTEIN PROFILE SER	30	95	104	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3732	3736		10.1038/sj.onc.1207387	http://dx.doi.org/10.1038/sj.onc.1207387			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077180				2022-12-17	WOS:000221101700027
J	Wan, XL; Helman, LJ				Wan, XL; Helman, LJ			Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cells	ONCOGENE			English	Article						Akt; phosphorylation; PTEN	TUMOR-SUPPRESSOR PTEN; GROWTH-FACTOR-II; INTEGRIN-LINKED KINASE; SIGNAL-TRANSDUCTION; PROSTATE-CANCER; GLIOMA-CELLS; ACTIVATION; INSULIN; INHIBITION; EXPRESSION	Constitutive activation of Akt has been found in many types of human cancer, and is believed to promote proliferation and increased cell survival thereby contributing to cancer progression. In this study, we examined Akt phosphorylation on Ser473 and Thr308 in seven IGF-II-overexpressing rhabdomyosarcomas (RMS) cells. All the RMS cell lines tested had high levels of Akt phosphorylation on Thr308, whereas three cell lines (Rh5, Rh18, and CTR) had a much lower level of Akt phosphorylation on Ser473. To determine whether the difference in Akt phosphorylation on Ser473, but not on Thr308, observed among cell lines is a cell-specific phenomenon or due to other factors, which possibly downregulate Akt phosphorylation, we examined expression of PTEN protein, which acts as a negative regulator of the PI3K/Akt signaling pathway through its ability to dephosphorylate phosphatidylinositol 3,4,5-triphosphate (PIP3). The levels of PTEN expression inversely correlate with Akt phosphorylation on Ser473, but not on Thr308. Consistent with this finding, transfection of wild-type PTEN into RMS and mouse myoblast C2C12 cells resulted in reduced Akt phosphorylation on Ser473, but not on Thr308. Our data suggest that Ser473 may be a key target residue for PTEN to modulate the effects of IGF-II on activating the PI3K/Akt pathway in RMS cells. A better understanding of the pathway in RMS will likely contribute to insights into the biology of the RMS tumorigenesis and hopefully lead to novel therapeutic options.	NCI, Mol Oncol Sect, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Helman, LJ (corresponding author), NCI, Mol Oncol Sect, Pediat Oncol Branch, NIH, Bldg 10,Rm 13N240, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [Z01SC006892, ZIASC006892] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brodbeck D, 2001, J BIOL CHEM, V276, P29550, DOI 10.1074/jbc.M104633200; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Davies MA, 1998, CANCER RES, V58, P5285; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; ELBADRY OM, 1991, J CLIN INVEST, V87, P648, DOI 10.1172/JCI115042; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Ghosh AK, 1999, GENE, V235, P85, DOI 10.1016/S0378-1119(99)00206-1; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Kroner C, 2000, J BIOL CHEM, V275, P27790, DOI 10.1074/jbc.M000540200; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; Tsatsanis C, 2000, INT J MOL MED, V5, P583; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Wan XL, 2002, NEOPLASIA, V4, P400, DOI 10.1038/sj.neo.7900242; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598	53	95	95	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8205	8211		10.1038/sj.onc.1206878	http://dx.doi.org/10.1038/sj.onc.1206878			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603261				2022-12-17	WOS:000186403400015
J	Motiwala, T; Ghoshal, K; Das, A; Majumder, S; Weichenhan, D; Wu, YZ; Holman, K; James, SJ; Jacob, ST; Plass, C				Motiwala, T; Ghoshal, K; Das, A; Majumder, S; Weichenhan, D; Wu, YZ; Holman, K; James, SJ; Jacob, ST; Plass, C			Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas	ONCOGENE			English	Article						DNA methylation; DNA amplification; folate deficiency; hepatocellular carcinoma; PTPRO; 5-azacytidine	ACUTE MYELOID-LEUKEMIA; RNA POLYMERASE-I; RAT HEPATOMA; P53 GENE; DNA; CANCER; EXPRESSION; DEFICIENT; FOLATE; METHYLTRANSFERASE	A diet lacking folic acid and choline and low in methionine (folate/methyl deficient diet, FMD diet) fed to rats is known to produce preneoplastic nodules (PNNs) after 36 weeks and hepatocellular carcinomas (tumors) after 54 weeks. FMD diet-induced tumors exhibit global hypomethylation and regional hypermethylation. Restriction landmark genome scanning analysis with methylation-sensitive enzyme NotI (RLGS-M) of genomic DNA isolated from control livers, PNNs and tumor tissues was performed to identify the genes that are differentially methylated or amplified during multistage hepatocarcinogenesis. Out of the 1250 genes analysed, 2 to 5 genes were methylated in the PNNs, whereas 5 to 45 genes were partially or completely methylated in the tumors. This analysis also showed amplification of 3 to 12 genes in the primary tumors. As a first step towards identifying the genes methylated in the PNNs and primary hepatomas, we generated a rat NotI-EcoRV genomic library in the pBluescriptKS vector. Here, we describe identification of one methylated and downregulated gene as the rat protein tyrosine phosphatase receptor type O ( PTPRO) and one amplified gene as rat C-MYC. Methylation of PTPRO at the NotI site located immediate upstream of the trancription start site in the PNNs and tumors, and amplification of C-MYC gene in the tumors were confirmed by Southern blot analyses. Bisulfite genomic sequencing of the CpG island encompassing exon 1 of the PTPRO gene revealed dense methylation in the PNNs and tumors, whereas it was methylation free in the livers of animals on normal diet. Reverse transcription-polymerase chain reaction (RT-PCR) analysis showed significant decrease in the expression of PTPRO in the tumors and in a transplanted rat hepatoma. The expression of PTPRO mRNA in the transplanted hepatoma after demethylation with 5-azacytidine, a potent inhibitor of DNA methyltransferases, further confirmed the role of methylation in PTPRO gene expression. These results demonstrate alteration in methylation pro. le and expression of specific genes during tumor progression in the livers of rats in response to folate/methyl deficiency, and further implicate the potential role of PTPRO as a novel growth regulatory gene at least in the hepatocellular carcinomas.	Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Med Univ Lubeck, Inst Biol, D-23538 Lubeck, Germany; Ohio State Univ, Coll Med, Div Human Canc Genet, Columbus, OH 43210 USA; US FDA, Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA	University System of Ohio; Ohio State University; University of Lubeck; University System of Ohio; Ohio State University; US Food & Drug Administration (FDA)	Jacob, ST (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.	jacob.42@osu.edu	Motiwala, Tasneem/AAB-9067-2021; Das, Anindita/K-8003-2013; Plass, Christoph/H-7192-2014; Jacob, Samson/H-3135-2011	Das, Anindita/0000-0003-4422-7277; 	NCI NIH HHS [CA86978, R01 CA086978-01A2, R01 CA086978] Funding Source: Medline; NIEHS NIH HHS [ES10874, R01 ES010874-01, R01 ES010874] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aguiar RCT, 1999, BLOOD, V94, P2403, DOI 10.1182/blood.V94.7.2403.419k39_2403_2413; BUTTERWORTH C, 1991, AM J CLIN NUTR, V94, P2; Canzian F, 1996, CANCER RES, V56, P3331; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; CAVE H, 1995, BLOOD, V86, P3869, DOI 10.1182/blood.V86.10.3869.bloodjournal86103869; Chen YQ, 2002, CARCINOGENESIS, V23, P1811, DOI 10.1093/carcin/23.11.1811; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Choi SW, 2000, J NUTR, V130, P129, DOI 10.1093/jn/130.2.129; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; CRAVO ML, 1992, CANCER RES, V52, P5002; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; DUCEMAN BW, 1981, J BIOL CHEM, V256, P755; Duthie SJ, 1999, BRIT MED BULL, V55, P578, DOI 10.1258/0007142991902646; GHOSHAL AK, 1987, CANCER LETT, V36, P289, DOI 10.1016/0304-3835(87)90022-X; Ghoshal K, 2000, J BIOL CHEM, V275, P539, DOI 10.1074/jbc.275.1.539; Glynn SA, 1996, CANCER CAUSE CONTROL, V7, P214, DOI 10.1007/BF00051297; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gray JW, 2000, CARCINOGENESIS, V21, P443, DOI 10.1093/carcin/21.3.443; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; HAYASHI K, 1984, JPN J CANCER RES, V75, P475; HAYASHIZAKI Y, 1993, ELECTROPHORESIS, V14, P251, DOI 10.1002/elps.1150140145; HAYASHIZAKI Y, 1992, GENOMICS, V14, P733, DOI 10.1016/S0888-7543(05)80176-4; Hirao T, 2002, CARCINOGENESIS, V23, P1127, DOI 10.1093/carcin/23.7.1127; JAMES SJ, 1989, CARCINOGENESIS, V10, P1209, DOI 10.1093/carcin/10.7.1209; JAMES SJ, 1992, CARCINOGENESIS, V13, P2471, DOI 10.1093/carcin/13.12.2471; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kibel AS, 2000, J UROLOGY, V164, P192, DOI 10.1016/S0022-5347(05)67493-9; LASHNER BA, 1989, GASTROENTEROLOGY, V97, P255, DOI 10.1016/0016-5085(89)90058-9; Majumder S, 1999, J BIOL CHEM, V274, P28584, DOI 10.1074/jbc.274.40.28584; Majumder S, 1999, ONCOGENE, V18, P6287, DOI 10.1038/sj.onc.1203004; Majumder S, 2002, J BIOL CHEM, V277, P16048, DOI 10.1074/jbc.M111662200; Matter WF, 2001, BIOCHEM BIOPH RES CO, V283, P1061, DOI 10.1006/bbrc.2001.4881; MCKEEVER MP, 1991, CLIN SCI, V81, P551, DOI 10.1042/cs0810551; Melnyk S, 1999, CANCER LETT, V146, P35, DOI 10.1016/S0304-3835(99)00213-X; MIKOL YB, 1983, CARCINOGENESIS, V4, P1619, DOI 10.1093/carcin/4.12.1619; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; OKAZAKI Y, 1995, ELECTROPHORESIS, V16, P197, DOI 10.1002/elps.1150160134; Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187; POGRIBNY IP, 1995, CANCER RES, V55, P1894; Pogribny IP, 1997, CANCER LETT, V115, P31, DOI 10.1016/S0304-3835(97)04708-3; ROGERS AE, 1993, CARCINOGENESIS, V14, P2205, DOI 10.1093/carcin/14.11.2205; Roman-Gomez J, 2002, BLOOD, V99, P2291, DOI 10.1182/blood.V99.7.2291; ROSE KM, 1981, J BIOL CHEM, V256, P7468; ROSE KM, 1981, P NATL ACAD SCI-BIOL, V78, P2833, DOI 10.1073/pnas.78.5.2833; ROSENBERG IH, 1989, GASTROENTEROLOGY, V97, P502, DOI 10.1016/0016-5085(89)90091-7; Rush LJ, 2002, BLOOD, V99, P1874, DOI 10.1182/blood.V99.5.1874; Rush LJ, 2001, BLOOD, V97, P3226, DOI 10.1182/blood.V97.10.3226; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; SEIMIYA H, 1995, ONCOGENE, V10, P1731; Seimiya H, 1998, J BIOL CHEM, V273, P21187, DOI 10.1074/jbc.273.33.21187; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; SUCHY BK, 1989, CANCER RES, V49, P6781; Tagawa M, 1997, BIOCHEM J, V321, P865, DOI 10.1042/bj3210865; Takeuchi S, 1996, CANCER RES, V56, P738; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; Van den Veyver IB, 2002, ANNU REV NUTR, V22, P255, DOI 10.1146/annurev.nutr.22.010402.102932; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WAINFAN E, 1992, CANCER RES, V52, pS2071; WAINFAN E, 1988, CARCINOGENESIS, V9, P861, DOI 10.1093/carcin/9.5.861; WAINFAN E, 1989, CANCER RES, V49, P4094; Watanabe T, 2001, ACTA NEUROPATHOL, V101, P185; Weng LP, 1998, CURR BIOL, V8, P247, DOI 10.1016/S0960-9822(98)70106-X; WIGGINS RC, 1995, GENOMICS, V27, P174, DOI 10.1006/geno.1995.1021; Wilkens L, 2000, AM J CLIN PATHOL, V114, P867, DOI 10.1309/BMTT-JBPD-D13H-1UVD; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	70	95	104	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6319	6331		10.1038/sj.onc.1206750	http://dx.doi.org/10.1038/sj.onc.1206750			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508512	Green Accepted			2022-12-17	WOS:000185535300002
J	Goueli, BS; Janknecht, R				Goueli, BS; Janknecht, R			Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor	ONCOGENE			English	Article						E-box; human telomerase reverse transcriptase (hTERT); Myc; transcription; upstream regulatory factor (USF)	FACTOR USF; C-MYC; MEDIATED REGULATION; CATALYTIC SUBUNIT; ACTIVATION; PROMOTER; HTERT; PROTEIN; KINASE; CELLS	Upregulation of human telomerase reverse transcriptase (hTERT) transcription accounts for the immortalization of greater than 85% of all human tumor cells. However, the mechanism whereby hTERT expression is activated remains unresolved. Specifically, recent data challenging the role of Myc/Max in E-box-dependent activation of hTERT expression suggests that other E-box-binding proteins regulate hTERT transcription. Indeed, we now demonstrate that two such proteins, upstream stimulatory factor (USF) 1 and 2, readily associate with two E-boxes in the hTERT promoter in vitro and in vivo primarily as heterodimers, whereas Myc/Max does not. The avid binding of USF1/2 heterodimers to these E-boxes occurs in both hTERT-positive and -negative cells. In contrast, USF1/2 activates the hTERT promoter exclusively in hTERT-positive cells in a manner that is enhanced by the coactivator p300 and attenuated upon inhibiting p38-MAP kinase, a known modulator of USF activity. Collectively, our data indicate that USF binding to the hTERT promoter may be transcriptionally neutral, or even repressive, in nonimmortalized hTERT-negative somatic cells, but stimulatory in hTERT-positive cells where USF1/2 contributes to the acquisition and maintenance of immortality.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Janknecht, R (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.			Janknecht, Ralf/0000-0003-1741-1562				Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; BredemeierErnst I, 1997, FEBS LETT, V408, P47, DOI 10.1016/S0014-5793(97)00387-6; Breen GAM, 1999, BBA-GEN SUBJECTS, V1428, P169, DOI 10.1016/S0304-4165(99)00061-6; Dhaene K, 2000, J PATHOL, V190, P80; Dillner NB, 2002, J BIOL CHEM, V277, P33890, DOI 10.1074/jbc.M204399200; Drissi R, 2001, J BIOL CHEM, V276, P29994, DOI 10.1074/jbc.M101899200; Ducrest AL, 2002, ONCOGENE, V21, P541, DOI 10.1038/sj.onc.1205081; Ducrest AL, 2001, CANCER RES, V61, P7594; Galibert MD, 2001, EMBO J, V20, P5022, DOI 10.1093/emboj/20.17.5022; Goodman RH, 2000, GENE DEV, V14, P1553; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Heckert LL, 2001, MOL ENDOCRINOL, V15, P704, DOI 10.1210/me.15.5.704; Hiyama E, 2002, ONCOGENE, V21, P643, DOI 10.1038/sj.onc.1205070; Horikawa I, 2002, MOL BIOL CELL, V13, P2585, DOI 10.1091/mbc.E01-11-0107; HORIUCHI K, 1981, CANCER RES, V41, P1488; Janknecht R, 2002, HISTOL HISTOPATHOL, V17, P657, DOI 10.14670/HH-17.657; Kumari D, 2001, J BIOL CHEM, V276, P4357, DOI 10.1074/jbc.M009629200; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liu SL, 2000, ONCOGENE, V19, P3352, DOI 10.1038/sj.onc.1203675; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; Pearson KL, 1999, BBA-GENE STRUCT EXPR, V1489, P354, DOI 10.1016/S0167-4781(99)00166-9; Poole JC, 2001, GENE, V269, P1, DOI 10.1016/S0378-1119(01)00440-1; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Won JJ, 2002, FASEB J, V16, P1943, DOI 10.1096/fj.02-0311fje; Yago M, 2002, FEBS LETT, V520, P40, DOI 10.1016/S0014-5793(02)02757-6	32	95	98	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					8042	8047		10.1038/sj.onc.1206847	http://dx.doi.org/10.1038/sj.onc.1206847			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970752				2022-12-17	WOS:000185388200019
J	West, JT; Wood, C				West, JT; Wood, C			The role of Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 regulator of transcription activation (RTA) in control of gene expression	ONCOGENE			English	Review						Kaposi's sarcoma; KSHV; HHV-8; herpesvirus; transcriptional control; RTA	PRIMARY-EFFUSION LYMPHOMA; READING FRAME 50; PROTEIN-COUPLED RECEPTOR; IMMEDIATE-EARLY GENE; BARR-VIRUS EBV; POLYADENYLATED NUCLEAR-RNA; CREB-BINDING PROTEIN; LYTIC SWITCH PROTEIN; JAK-STAT PATHWAY; RBP-J-KAPPA	The mechanisms that control the replication state, latency versus lytic, of human herpesviruses have been under intense investigations. Here we summarize some of the recent findings that help define such mechanisms for Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8 (KSHV/HHV-8). For HHV-8, the viral regulator of transcription activation (RTA) is a key mediator of the switch from latency to lytic gene expression in infected cells. RTA is necessary and sufficient to drive HHV-8 lytic replication and the production of viral progeny. The RTA is an immediate-early gene product, it is the initial activator of expression of a multitude of viral and cellular genes that have been implicated in the replication of HHV-8 and pathogenesis of KS. Interactions of RTA with a number of viral promoters, and with a number of transcription factors or transcriptional co-activators are highlighted. Modulation of transactivation, through alternate RTA-protein, or RTA-promoter interactions, is hypothesisized to participate in the selective tissue tropism and differential pathogenesis observed in KS.	Univ Nebraska, Sch Biol Sci, Nebraska Ctr Virol, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Wood, C (corresponding author), Univ Nebraska, Sch Biol Sci, Nebraska Ctr Virol, 1901 Vine St,E249 Beadle Ctr, Lincoln, NE 68588 USA.	cwood1@unl.edu	Wood, Charles/AAH-4536-2021	Wood, Charles/0000-0002-4256-1530	NATIONAL CANCER INSTITUTE [R01CA075903, R01CA076958] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NCI NIH HHS [CA76958, CA75903] Funding Source: Medline; NCRR NIH HHS [RR15635] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abrink M, 2001, P NATL ACAD SCI USA, V98, P1422, DOI 10.1073/pnas.041616998; Alkan S, 1997, BRIT J HAEMATOL, V96, P412, DOI 10.1046/j.1365-2141.1997.d01-2040.x; AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; An JB, 2002, BLOOD, V99, P649, DOI 10.1182/blood.V99.2.649; Aoki Y, 2000, BLOOD, V96, P1599, DOI 10.1182/blood.V96.4.1599.h8001599_1599_1601; Aoki Y, 1999, BLOOD, V93, P4034, DOI 10.1182/blood.V93.12.4034.412k38_4034_4043; Aoki Y, 2001, BLOOD, V98, P3042, DOI 10.1182/blood.V98.10.3042; Aoki Y, 2000, J HEMATOTH STEM CELL, V9, P137, DOI 10.1089/152581600319351; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAINES JD, 1994, J VIROL, V68, P8118, DOI 10.1128/JVI.68.12.8118-8124.1994; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bornkamm GW, 2001, PHILOS T R SOC B, V356, P437, DOI 10.1098/rstb.2000.0781; Boshoff C, 1997, SCIENCE, V278, P290, DOI 10.1126/science.278.5336.290; Boshoff C, 2001, ANNU REV MED, V52, P453, DOI 10.1146/annurev.med.52.1.453; BOSHOFF C, 1995, LANCET, V345, P1043; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Buonaguro FM, 1996, INT J CANCER, V65, P25, DOI 10.1002/(SICI)1097-0215(19960103)65:1&lt;25::AID-IJC5&gt;3.0.CO;2-3; Burysek L, 2001, J VIROL, V75, P2345, DOI 10.1128/JVI.75.5.2345-2352.2001; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chandran B, 1998, VIROLOGY, V249, P140, DOI 10.1006/viro.1998.9316; Chang PJ, 2002, J VIROL, V76, P3168, DOI 10.1128/JVI.76.7.3168-3178.2002; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, INFECT AGENT DIS, V5, P215; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; Chen J, 2001, P NATL ACAD SCI USA, V98, P4119, DOI 10.1073/pnas.051004198; Cohrs RJ, 2001, BRAIN PATHOL, V11, P465, DOI 10.1111/j.1750-3639.2001.tb00415.x; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Deng HY, 2000, J GEN VIROL, V81, P3043, DOI 10.1099/0022-1317-81-12-3043; Deng HY, 2002, BLOOD, V100, P1919, DOI 10.1182/blood-2002-01-0015; Deng HY, 2002, J VIROL, V76, P8252, DOI 10.1128/JVI.76.16.8252-8264.2002; DeWire SM, 2002, J VIROL, V76, P9819, DOI 10.1128/JVI.76.19.9819-9831.2002; Dittmer D, 1998, J VIROL, V72, P8309, DOI 10.1128/JVI.72.10.8309-8315.1998; Duan W, 2001, ARCH VIROL, V146, P403, DOI 10.1007/s007050170185; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; Fickenscher H, 2001, PHILOS T R SOC B, V356, P545, DOI 10.1098/rstb.2000.0780; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gebelein B, 2001, MOL CELL BIOL, V21, P928, DOI 10.1128/MCB.21.3.928-939.2001; Giles RH, 1998, TRENDS GENET, V14, P214, DOI 10.1016/S0168-9525(98)01500-5; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gradoville L, 2000, J VIROL, V74, P6207, DOI 10.1128/JVI.74.13.6207-6212.2000; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; GRUFFAT H, 1990, NUCLEIC ACIDS RES, V18, P6835, DOI 10.1093/nar/18.23.6835; GRUFFAT H, 1994, NUCLEIC ACIDS RES, V22, P1172, DOI 10.1093/nar/22.7.1172; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gugasyan R, 2000, IMMUNOL REV, V176, P134; Gwack Y, 2002, J BIOL CHEM, V277, P6438, DOI 10.1074/jbc.M108289200; Gwack Y, 2001, J VIROL, V75, P6245, DOI 10.1128/JVI.75.13.6245-6248.2001; Gwack Y, 2001, J VIROL, V75, P1909, DOI 10.1128/JVI.75.4.1909-1917.2001; Hall KT, 1999, J VIROL, V73, P9756, DOI 10.1128/JVI.73.12.9756-9763.1999; HARDWICK JM, 1992, J VIROL, V66, P5500, DOI 10.1128/JVI.66.9.5500-5508.1992; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; Hwang S, 2001, J VIROL, V75, P9509, DOI 10.1128/JVI.75.19.9509-9516.2001; Jenner RG, 2002, BBA-REV CANCER, V1602, P1, DOI 10.1016/S0304-419X(01)00040-3; Johannsen E, 1996, J VIROL, V70, P4179, DOI 10.1128/JVI.70.6.4179-4183.1996; JOHANNSEN E, 1995, J VIROL, V69, P253, DOI 10.1128/JVI.69.1.253-262.1995; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kedda MA, 1996, CLIN TRANSPLANT, V10, P429; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kedes DH, 1997, JAMA-J AM MED ASSOC, V277, P478, DOI 10.1001/jama.277.6.478; KENNEY S, 1989, J VIROL, V63, P3870, DOI 10.1128/JVI.63.9.3870-3877.1989; KENNEY S, 1989, J VIROL, V63, P3878, DOI 10.1128/JVI.63.9.3878-3883.1989; Kirshner JR, 1999, J VIROL, V73, P6006, DOI 10.1128/JVI.73.7.6006-6014.1999; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lefrere JJ, 1996, J INFECT DIS, V174, P283, DOI 10.1093/infdis/174.2.283; Li H, 2001, J VIROL, V75, P3325, DOI 10.1128/JVI.75.7.3325-3334.2001; Li MT, 1999, J VIROL, V73, P1341, DOI 10.1128/JVI.73.2.1341-1349.1999; Liang YY, 2002, GENE DEV, V16, P1977, DOI 10.1101/gad.996502; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu CQ, 2001, J VIROL, V75, P10933, DOI 10.1128/JVI.75.22.10933-10940.2001; Lukac DM, 1998, VIROLOGY, V252, P304, DOI 10.1006/viro.1998.9486; Lukac DM, 2001, J VIROL, V75, P6786, DOI 10.1128/JVI.75.15.6786-6799.2001; Lukac DM, 1999, J VIROL, V73, P9348, DOI 10.1128/JVI.73.11.9348-9361.1999; MANET E, 1991, NUCLEIC ACIDS RES, V19, P2661, DOI 10.1093/nar/19.10.2661; Manteuffel-Cymborowska M, 1999, ACTA BIOCHIM POL, V46, P77, DOI 10.18388/abp.1999_4185; Martin DF, 1999, NEW ENGL J MED, V340, P1063, DOI 10.1056/NEJM199904083401402; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Masumi A, 1999, MOL CELL BIOL, V19, P1810; Memar OM, 1995, J MOL MED-JMM, V73, P603; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Molden J, 1997, J BIOL CHEM, V272, P19625, DOI 10.1074/jbc.272.31.19625; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Moore PS, 2001, PHILOS T R SOC B, V356, P499, DOI 10.1098/rstb.2000.0777; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Muralidhar S, 1998, J VIROL, V72, P4980, DOI 10.1128/JVI.72.6.4980-4988.1998; Nan XS, 1996, MOL CELL BIOL, V16, P414; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Neipel F, 1998, J Natl Cancer Inst Monogr, P73; Neipel F, 1997, J VIROL, V71, P4187, DOI 10.1128/JVI.71.6.4187-4192.1997; Nicholas J, 1998, J Natl Cancer Inst Monogr, P79; Nicholas J, 1997, J VIROL, V71, P1963, DOI 10.1128/JVI.71.3.1963-1974.1997; NICHOLAS J, 1988, J VIROL, V62, P3250, DOI 10.1128/JVI.62.9.3250-3257.1988; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Olsen SJ, 1998, AIDS, V12, P1921, DOI 10.1097/00002030-199814000-00024; Osborne J, 1999, HUM IMMUNOL, V60, P921, DOI 10.1016/S0198-8859(99)00083-X; Parravicini C, 2000, AM J PATHOL, V156, P743, DOI 10.1016/S0002-9440(10)64940-1; QUINLIVAN EB, 1993, NUCLEIC ACIDS RES, V21, P1999, DOI 10.1093/nar/21.8.1999; Raab MS, 1998, J VIROL, V72, P6725, DOI 10.1128/JVI.72.8.6725-6731.1998; RADY PL, 1995, LANCET, V345, P1339, DOI 10.1016/S0140-6736(95)92538-4; Ragoczy T, 1999, J VIROL, V73, P9858, DOI 10.1128/JVI.73.12.9858-9866.1999; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Reed JA, 1998, BLOOD, V91, P3825, DOI 10.1182/blood.V91.10.3825.3825_3825_3832; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Roan F, 2002, VIROLOGY, V301, P293, DOI 10.1006/viro.2002.1582; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sadler R, 1999, J VIROL, V73, P5722, DOI 10.1128/JVI.73.7.5722-5730.1999; Sakakibara S, 2001, J VIROL, V75, P6894, DOI 10.1128/JVI.75.15.6894-6900.2001; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; Saveliev AK, 2002, VIROLOGY, V299, P301, DOI 10.1006/viro.2002.1561; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schulz TF, 1998, J GEN VIROL, V79, P1573, DOI 10.1099/0022-1317-79-7-1573; Schumann G, 1999, J NEUROCHEM, V73, P2009; Seaman WT, 1999, VIROLOGY, V263, P436, DOI 10.1006/viro.1999.9963; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Smith PD, 1998, BIOCHEM J, V331, P381, DOI 10.1042/bj3310381; Snowden AW, 1998, BIOCHEM PHARMACOL, V55, P1947, DOI 10.1016/S0006-2952(98)00020-3; Song MJ, 2002, J VIROL, V76, P5000, DOI 10.1128/JVI.76.10.5000-5013.2002; Song MJ, 2001, J VIROL, V75, P3129, DOI 10.1128/JVI.75.7.3129-3140.2001; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Staskus KA, 1999, J VIROL, V73, P4181, DOI 10.1128/JVI.73.5.4181-4187.1999; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Sun R, 1998, P NATL ACAD SCI USA, V95, P10866, DOI 10.1073/pnas.95.18.10866; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; Sun R, 1996, P NATL ACAD SCI USA, V93, P11883, DOI 10.1073/pnas.93.21.11883; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TAKADA K, 1986, J VIROL, V57, P1016, DOI 10.1128/JVI.57.3.1016-1022.1986; Taylor TJ, 2002, FRONT BIOSCI-LANDMRK, V7, pD752, DOI 10.2741/taylor; TELFORD EAR, 1995, J MOL BIOL, V249, P520, DOI 10.1006/jmbi.1995.0314; Virgin HW, 1997, J VIROL, V71, P5894, DOI 10.1128/JVI.71.8.5894-5904.1997; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Waltzer L, 1996, J VIROL, V70, P5909, DOI 10.1128/JVI.70.9.5909-5915.1996; Wan XY, 1999, J VIROL, V73, P8268, DOI 10.1128/JVI.73.10.8268-8278.1999; Wang S, 2001, ARCH VIROL, V146, P1415, DOI 10.1007/s007050170102; Wang SZ, 2001, J VIROL, V75, P11961, DOI 10.1128/JVI.75.24.11961-11973.2001; Weber-Nordt RM, 1998, LEUKEMIA LYMPHOMA, V28, P459, DOI 10.3109/10428199809058353; WeberNordt RM, 1996, BLOOD, V88, P809; Weinmaster G, 2000, CURR OPIN GENET DEV, V10, P363, DOI 10.1016/S0959-437X(00)00097-6; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Whitby D, 1998, J NATL CANCER I, V90, P395, DOI 10.1093/jnci/90.5.395; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; Whitehouse A, 1998, J VIROL, V72, P857, DOI 10.1128/JVI.72.1.857-861.1998; Whitehouse A, 1997, J VIROL, V71, P2550, DOI 10.1128/JVI.71.3.2550-2554.1997; Whitehouse A, 1998, J VIROL, V72, P1967, DOI 10.1128/JVI.72.3.1967-1973.1998; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Wu TT, 2000, J VIROL, V74, P3659, DOI 10.1128/JVI.74.8.3659-3667.2000; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yu YM, 1999, J GEN VIROL, V80, P83, DOI 10.1099/0022-1317-80-1-83; Zalani S, 1996, P NATL ACAD SCI USA, V93, P9194, DOI 10.1073/pnas.93.17.9194; Zhang T, 2000, MOL CELL BIOL, V20, P7132, DOI 10.1128/MCB.20.19.7132-7139.2000; Zhao B, 1996, J VIROL, V70, P4228, DOI 10.1128/JVI.70.7.4228-4236.1996; Zhong WD, 1996, P NATL ACAD SCI USA, V93, P6641, DOI 10.1073/pnas.93.13.6641; Zhu FX, 1999, J VIROL, V73, P5556, DOI 10.1128/JVI.73.7.5556-5567.1999	169	95	99	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2003	22	33					5150	5163		10.1038/sj.onc.1206555	http://dx.doi.org/10.1038/sj.onc.1206555			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910252				2022-12-17	WOS:000184615100006
J	Polsky, D; Cordon-Cardo, C				Polsky, D; Cordon-Cardo, C			Oncogenes in melanoma	ONCOGENE			English	Article						melanoma; oncogenes; review; proliferation; transformation	CUTANEOUS MALIGNANT-MELANOMA; HDM2 PROTEIN OVEREXPRESSION; GENE AMPLIFICATION; C-MYC; N-RAS; GERMLINE MUTATIONS; GROWTH-FACTORS; IN-VIVO; CDK4; EXPRESSION	Transformation of normal melanocytes into melanoma cells is accomplished by the activation of growth stimulatory pathways, typically leading to cellular proliferation, and the inactivation of apoptotic and tumor suppressor pathways. Small molecule inhibitors of proteins in the growth stimulatory pathways are under active investigation, and their application to melanoma patients would represent a new treatement strategy to inhibit cell proliferation or induce cell death. We provide a general overview of the mechanisms of oncogene activation and the functions of oncogenes. Lastly, we review oncogenic events in melanoma.	NYU, Med Ctr, Dept Dermatol, Skin & Canc Unit,Oncol Sect, New York, NY 10016 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, Div Mol Pathol, New York, NY 10021 USA	New York University; Memorial Sloan Kettering Cancer Center	Polsky, D (corresponding author), NYU, Med Ctr, Dept Dermatol, Skin & Canc Unit,Oncol Sect, 550 1St Ave, New York, NY 10016 USA.		Polsky, David/AAO-6254-2020	Polsky, David/0000-0001-9554-5289				Bastian BC, 2000, AM J PATHOL, V157, P967, DOI 10.1016/S0002-9440(10)64609-3; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Berking C, 2001, CANCER RES, V61, P8306; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Boni R, 1998, DERMATOLOGY, V196, P288, DOI 10.1159/000017922; Chana JS, 2001, ANN PLAS SURG, V47, P172, DOI 10.1097/00000637-200108000-00011; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Demunter A, 2001, J INVEST DERMATOL, V117, P1483, DOI 10.1046/j.0022-202x.2001.01601.x; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Halaban R, 1996, SEMIN ONCOL, V23, P673; HALABAN R, 1991, CANCER METAST REV, V10, P129, DOI 10.1007/BF00049410; Hayashi S, 1997, J CLIN INVEST, V99, P2581, DOI 10.1172/JCI119446; HODGSON SV, 1997, PRACTICAL GUIDE HUMA; Innominato PF, 2001, J PATHOL, V194, P95, DOI 10.1002/path.861; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kraehn GM, 2001, BRIT J CANCER, V84, P72, DOI 10.1054/bjoc.2000.1535; Leiter U, 2000, ARCH DERMATOL RES, V292, P225, DOI 10.1007/s004030050479; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Mertens F, 1997, CANCER RES, V57, P2765; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; OOI A, 1994, INT J ONCOL, V4, P85; Owen JD, 1997, INT J CANCER, V73, P94, DOI 10.1002/(SICI)1097-0215(19970926)73:1<94::AID-IJC15>3.0.CO;2-5; Papp T, 1999, J MED GENET, V36, P610; PASTERNAK JJ, 1999, INTRO HUMAN MOL GENE; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Polsky D, 2002, J NATL CANCER I, V94, P1803; Polsky D, 2001, CANCER RES, V61, P7642; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; RICHMOND A, 1983, CANCER RES, V43, P2106; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Rubie H, 1997, J CLIN ONCOL, V15, P1171, DOI 10.1200/JCO.1997.15.3.1171; Satyamoorthy K, 2002, CANCER BIOL THER, V1, P14, DOI 10.4161/cbt.1.1.32; Satyamoorthy K, 2001, CANCER RES, V61, P7318; Sauter ER, 2002, CANCER RES, V62, P3200; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; vanElsas A, 1996, AM J PATHOL, V149, P883; VARMUS HE, 1985, CANCER-AM CANCER SOC, V55, P2324, DOI 10.1002/1097-0142(19850515)55:10<2324::AID-CNCR2820551004>3.0.CO;2-A; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Willis R.A., 1952, SPREAD TUMORS HUMAN; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	48	95	96	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 19	2003	22	20					3087	3091		10.1038/sj.onc.1206449	http://dx.doi.org/10.1038/sj.onc.1206449			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789285				2022-12-17	WOS:000183096600010
J	Lin, TY; Huang, XF; Gu, J; Zhang, LD; Roth, JA; Xiong, MM; Curley, SA; Yu, YH; Hunt, KK; Fang, BL				Lin, TY; Huang, XF; Gu, J; Zhang, LD; Roth, JA; Xiong, MM; Curley, SA; Yu, YH; Hunt, KK; Fang, BL			Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells	ONCOGENE			English	Article						apoptosis; drug-resistance; telomerase; doxorubicin; gene therapy	TRANSGENE EXPRESSION; TELOMERASE ACTIVITY; APOPTOSIS; CHEMOTHERAPY	We evaluated anti-tumor activity and toxic effect of an adenoviral vector expressing the GFP/TRAIL fusion gene from the hTERT promoter (designated Ad/gTRAIL) on human breast cancer cell tines and on normal human breast cells. Treatment with Ad/gTRAIL elicited high levels of transgene expression and apoptosis in a variety of breast cancer cell lines. Furthermore, treatment with Ad/gTRAIL was effective in killing breast cancer lines resistant to doxorubicin or soluble TRAIL protein. In contrast, only minimal transgene expression and toxicity was detected in normal human primary mammary epithelial cells after treatment with this vector. An in vivo study further showed that the intralesional administration of Ad/gTRAIL effectively suppressed the growth of human tumor xenografts derived from both doxorubicin-sensitive and doxorubicin-resistant breast cancer lines. Specifically, about 50% of animals bearing doxorubicin-sensitive and doxorubicin-resistant breast cancer xenografts showed complete tumor regression and remained tumor-free for over 5 months. These results suggest that the adenovirus encoding the GFP/TRAIL gene driven by the hTERT promoter has potential application in cancer therapy.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Ctr Human Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fang, BL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Unit 445,1515 Holcombe Blvd, Houston, TX 77030 USA.		Gu, Jian/Q-4780-2018; Yu, Yan/GYV-4514-2022	Gu, Jian/0000-0003-3499-0973; 	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		de Jong S, 2001, CANCER METAST REV, V20, P51, DOI 10.1023/A:1013112624971; Griffith TS, 2000, J IMMUNOL, V165, P2886, DOI 10.4049/jimmunol.165.5.2886; Gu J, 2000, CANCER RES, V60, P5359; Gu J, 2002, ONCOGENE, V21, P4757, DOI 10.1038/sj.onc.1205582; Jazirehi AR, 2001, CLIN CANCER RES, V7, P3874; Kagawa S, 2001, CANCER RES, V61, P3330; Keane MM, 1999, CANCER RES, V59, P734; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klement G, 2002, CLIN CANCER RES, V8, P221; Koch PE, 2001, MOL THER, V3, P278, DOI 10.1006/mthe.2001.0273; Lebwohl DE, 1999, ANN ONCOL, V10, P139, DOI 10.1023/A:1008318725670; Levine MN, 1998, J CLIN ONCOL, V16, P2651, DOI 10.1200/JCO.1998.16.8.2651; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; Nguyen T, 2001, CLIN CANCER RES, V7, p966S; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Seth P, 1997, CANCER GENE THER, V4, P383; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Stampfer M R, 1994, Cancer Treat Res, V71, P29; STEWART CF, 2001, PRINCIPLES PRACTICE, P425; Voelkel-Johnson C, 2002, CANCER GENE THER, V9, P164, DOI 10.1038/sj.cgt.7700420; ZHANG L, 2002, IN PRESS GENE THER	21	95	103	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 14	2002	21	52					8020	8028		10.1038/sj.onc.1205926	http://dx.doi.org/10.1038/sj.onc.1205926			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439752				2022-12-17	WOS:000179097200011
J	Chang, BY; Harte, RA; Cartwright, CA				Chang, BY; Harte, RA; Cartwright, CA			RACK1: a novel substrate for the Src protein-tyrosine kinase	ONCOGENE			English	Article						Src; RACK1; PKC; signal transduction	MIDDLE TUMOR-ANTIGEN; SIGNAL-TRANSDUCTION; MONOCLONAL-ANTIBODIES; SH2 DOMAIN; C-SRC; PHOSPHORYLATION; PP60C-SRC; ACTIVATION; FAMILY; CELLS	RACK1 is one of a group of PKC-interacting proteins collectively called RACKs (Receptors for Activated C-Kinases). Previously, we showed that RACK1 also interacts with the Src tyrosine kinase, and is an inhibitor of Src activity and cell growth. PKC activation induces the intracellular movement and co-localization of RACK1 and Src, and the tyrosine phosphorylation of RACK1. To determine whether RACK1 is a Src substrate, we assessed phosphorylation of RACK1 by various tyrosine kinases in vitro, and by kinase-active and inactive mutants of Src in vivo. We found that RACK1 is a Src substrate. Moreover, Src activity is necessary for both the tyrosine phosphorylation of RACK1 and the binding of RACK1 to Src's SH2 domain that occur following PKC activation. To identify the tyrosine(s) on RACK1 that is phosphorylated by Src, we generated and tested a series of RACK1 mutants. We found that Src phosphorylates RACK1 on Tyr 228 and/or Tyr 246, highly-conserved tyrosines located in the sixth WD repeat that interact with Src's SH2 domain. We think that RACK1 is an important Src substrate that signals downstream of growth factor receptor tyrosine kinases and is involved in the regulation of Src function and cell growth.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University	Cartwright, CA (corresponding author), Stanford Univ, Sch Med, Dept Med, CCSR Bldg,Room 3115-C,269 Campus Dr, Stanford, CA 94305 USA.				NATIONAL CANCER INSTITUTE [F32CA069810] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043743] Funding Source: NIH RePORTER; NCI NIH HHS [CA69810] Funding Source: Medline; NIDDK NIH HHS [R01 DK43743] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1985, MOL CELL BIOL, V5, P2647, DOI 10.1128/MCB.5.10.2647; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Lou Q, 1996, BIOORGAN MED CHEM, V4, P677, DOI 10.1016/0968-0896(96)00063-6; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Mochly-Rosen D, 1998, ADV PHARMACOL, V44, P91, DOI 10.1016/S1054-3589(08)60126-X; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; PARK J, 1995, MOL CELL BIOL, V15, P2374; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schmitz R, 1996, J MOL BIOL, V260, P664, DOI 10.1006/jmbi.1996.0429; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Zhou Songyang, 1995, Nature (London), V373, P536	30	95	105	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7619	7629		10.1038/sj.onc.1206002	http://dx.doi.org/10.1038/sj.onc.1206002			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400005				2022-12-17	WOS:000178756200002
J	Winn, RA; Bremnes, RM; Bemis, L; Franklin, WA; Miller, YE; Cool, C; Heasley, LE				Winn, RA; Bremnes, RM; Bemis, L; Franklin, WA; Miller, YE; Cool, C; Heasley, LE			gamma-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth	ONCOGENE			English	Article						lung cancer; NSCLC; gamma-catenin; tumor suppressor; cell transformation	BETA-CATENIN; MALIGNANT-MELANOMA; COLORECTAL-CANCER; CARCINOMA-CELLS; FACTOR RECEPTOR; ALPHA-CATENIN; N-CADHERIN; CYCLIN D1; PLAKOGLOBIN; MUTATIONS	Lung cancer is a heterogeneous disease categorized into multiple subtypes of cancers which likely arise from distinct patterns of genetic alterations and disruptions. Precedent exists for a role of beta-catenin, a downstream component of the Writ signaling pathway that serves as a transcriptional co-activator with TCF/LEF, in several human cancers including colon carcinomas. In this study, we observed that beta-catenin was highly and uniformly expressed in a panel of NSCLC cell lines and primary lung tumors. By contrast gamma-catenin was weakly expressed or absent in several NSCLC cell lines and immunohistochemical analysis of primary NSCLC tumors revealed negligible to weak gamma-catenin staining in similar to30% of the specimens. Treatment of NSCLC cells expressing reduced gamma-catenin protein with 5-aza-2'-deoxycytidine (5aza2dc), a DNA methylation inhibitor, or trichostatin A (TSA), a histone deacetylase inhibitor, increased gamma-catenin protein content in NSCLC cells with low gamma-catenin expression. Significantly, the activity of a beta-catenin/TCF-dependent luciferase reporter was markedly elevated in the NSCLC cell lines that underexpressed gamma-catenin relative to those lines that highly expressed gamma-catenin. Moreover, transfection of these cells with gamma-catenin expression plasmid reduced the elevated TCF activity by 85% and strongly inhibited cell growth on tissue culture plastic as well as anchorage-independent growth in soft agar. This study shows that gamma-catenin can function as an inhibitor of beta-catenin/TCFdependent gene transcription and highlights gamma-catenin as a potentially novel tumor suppressor protein in a subset of human NSCLC cancers.	Univ Colorado, Hlth Sci Ctr, Div Pulm & Crit Care, Dept Med, Denver, CO 80262 USA; Vet Adm Med Ctr, Denver, CO 80220 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Winn, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Pulm & Crit Care, Dept Med, C272,4200 E 9th Ave, Denver, CO 80262 USA.			Bemis, Lynne/0000-0001-9986-7154	NATIONAL CANCER INSTITUTE [P50CA058187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58187] Funding Source: Medline; NIDDK NIH HHS [DK 19928] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; Beekman A, 1998, CANCER RES, V58, P910; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Calvo R, 2000, P NATL ACAD SCI USA, V97, P12776, DOI 10.1073/pnas.97.23.12776; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Fukuchi T, 1998, CANCER RES, V58, P3526; Graziano SL, 1999, J CLIN ONCOL, V17, P668, DOI 10.1200/JCO.1999.17.2.668; Green DR, 2000, NAT IMMUNOL, V1, P15, DOI 10.1038/76868; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Howe LR, 2001, ENDOCR-RELAT CANCER, V8, P97, DOI 10.1677/erc.0.0080097; Hsieh ETK, 2000, LUNG CANCER, V29, P151, DOI 10.1016/S0169-5002(00)00116-1; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; IMRAVET S, 2002, J BIOL CHEM, V277, P1884; KARNOVSKY A, 1995, P NATL ACAD SCI USA, V92, P4522, DOI 10.1073/pnas.92.10.4522; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kolligs FT, 2000, GENE DEV, V14, P1319; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NICHOLSON RI, 2001, EUR J CANC S4, V3, P9; Ohsaki Y, 2000, ONCOL REP, V7, P603; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Pantel K, 1998, J CLIN ONCOL, V16, P1407, DOI 10.1200/JCO.1998.16.4.1407; Parker HR, 1998, CELL MOTIL CYTOSKEL, V40, P87, DOI 10.1002/(SICI)1097-0169(1998)40:1<87::AID-CM8>3.0.CO;2-C; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Pirinen RT, 2001, J CLIN PATHOL, V54, P391, DOI 10.1136/jcp.54.5.391; Polakis P, 2000, GENE DEV, V14, P1837; Potter E, 2001, EUR J ENDOCRINOL, V145, P625, DOI 10.1530/eje.0.1450625; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Toyoyama H, 1999, ONCOL REP, V6, P81; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Westra WH, 1996, CANCER RES, V56, P2224; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	41	95	100	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7497	7506		10.1038/sj.onc.1205963	http://dx.doi.org/10.1038/sj.onc.1205963			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386812				2022-12-17	WOS:000178618200005
J	Briggs, J; Chamboredon, S; Castellazzi, M; Kerry, JA; Bos, TJ				Briggs, J; Chamboredon, S; Castellazzi, M; Kerry, JA; Bos, TJ			Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells	ONCOGENE			English	Article						SPARC; osteonectin; c-Jun; target genes	EXTRACELLULAR-MATRIX PROTEIN; CHICKEN-EMBRYO FIBROBLASTS; GENE-EXPRESSION; GLUCOCORTICOID RECEPTOR; V-JUN; NEOPLASTIC PROGRESSION; FUNCTIONAL ANTAGONISM; OVARIAN-CANCER; FAMILY MEMBERS; HUMAN-MELANOMA	Overexpression of the c-Jun proto-oncogene in MCF7 breast cancer cells results in a variety of phenotype changes related to malignant progression including increased motility and invasion. Concurrent with these phenotypic effects are changes in the expression of multiple gene targets. We previously demonstrated that expression of the SPARC/osteonectin gene, while undetectable in the MCF7 cell line, is highly induced in response to stable c-Jun overexpression (c-Jun/MCF7). Because the SPARC gene product is associated with tumor cell invasion in a variety of different cancers, we have examined its role in mediating the phenotypic changes induced by c-Jun in MCF7 cells. We found that antisense mediated suppression of SPARC dramatically inhibits both motility and invasion in this c-Jun/MCF7 model. In contrast, stable overexpression of SPARC in the parental MCF7 cell line is not sufficient to stimulate cell motility or invasion. Examination of the promoter region of the human SPARC gene reveals three non-canonical AP-1 sites. We demonstrate that one of these sites binds c-Jun/Fra1 heterodimers in vitro, but that this and the other AP-1 like sites are dispensable with respect to c-Jun stimulated SPARC promoter activation. Deletion analysis identified a region between -120 and -70 as a c-Jun responsive element sufficient to induce maximal promoter activation. This region does not contain any AP-1 sites but does mediate binding by SP1 'like' complexes. Furthermore, this region is necessary for SP1/SP3 responsiveness in Drosophila SL2 cells. These results demonstrate that SPARC plays an important role in stimulating motility and the invasive behavior of c-Jun/MCF7 cells and that SPARC promoter activation by c-Jun appears to occur through an indirect mechanism.	Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23501 USA; Ecole Normale Super Lyon, INSERM, Unite Virol Humaine, U412, F-69364 Lyon 07, France	Eastern Virginia Medical School; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Bos, TJ (corresponding author), Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, POB 1980, Norfolk, VA 23501 USA.				NATIONAL CANCER INSTITUTE [R01CA051982] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA51982] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bamberger AM, 1999, INT J CANCER, V84, P533, DOI 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J; Basso J, 2000, ONCOGENE, V19, P4876, DOI 10.1038/sj.onc.1203863; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Bos TJ, 1999, INT J CANCER, V81, P404, DOI 10.1002/(SICI)1097-0215(19990505)81:3<404::AID-IJC14>3.0.CO;2-I; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Brekken Rolf A., 2001, Matrix Biology, V19, P816; Brown TJ, 1999, GYNECOL ONCOL, V75, P25, DOI 10.1006/gyno.1999.5552; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; COLOMBO MP, 1991, EUR J CANCER, V27, P58, DOI 10.1016/0277-5379(91)90062-I; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DECESARE D, 1995, ONCOGENE, V11, P365; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; GEE JMW, 1995, INT J CANCER, V64, P269, DOI 10.1002/ijc.2910640410; Gee JMW, 2000, INT J CANCER, V89, P177, DOI 10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0; Gilles C, 1998, CANCER RES, V58, P5529; Graham JD, 1997, EUR J CANCER, V33, P1654, DOI 10.1016/S0959-8049(97)00182-2; Greenwood JA, 1998, MICROSC RES TECHNIQ, V43, P420, DOI 10.1002/(SICI)1097-0029(19981201)43:5<420::AID-JEMT8>3.0.CO;2-B; HADMAN M, 1993, ONCOGENE, V8, P1895; Hadman M, 1996, ONCOGENE, V12, P135; Horne GM, 1996, BRIT J CANCER, V73, P29, DOI 10.1038/bjc.1996.6; Jacob K, 1999, CANCER RES, V59, P4453; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kato Yasumasa, 2000, Pathology Oncology and Research, V6, P24; Kim Youn Wha, 1998, Journal of Korean Medical Science, V13, P652; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; Kraemer M, 1999, CELL GROWTH DIFFER, V10, P193; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R; Mok SC, 1996, ONCOGENE, V12, P1895; Motamed K, 1999, INT J BIOCHEM CELL B, V31, P1363, DOI 10.1016/S1357-2725(99)00090-4; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; Porte H, 1998, CLIN CANCER RES, V4, P1375; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; PORTER PL, 1995, J HISTOCHEM CYTOCHEM, V43, P791, DOI 10.1177/43.8.7622842; Reed MJ, 1996, CURR TOP MICROBIOL, V213, P81; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; Rosenblatt S, 1997, BIOCHEM J, V324, P311, DOI 10.1042/bj3240311; RYSECK RP, 1991, ONCOGENE, V6, P533; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Sturm RA, 2002, CANCER RES, V62, P226; Thomas R, 2000, CLIN CANCER RES, V6, P1140; TINIAKOS DG, 1994, J PATHOL, V172, P19, DOI 10.1002/path.1711720106; TOURAY M, 1991, ONCOGENE, V6, P1227; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Yamanaka M, 2001, J UROLOGY, V166, P2495, DOI 10.1016/S0022-5347(05)65623-6; Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4; Zajchowski DA, 2001, CANCER RES, V61, P5168	68	95	102	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7077	7091		10.1038/sj.onc.1205857	http://dx.doi.org/10.1038/sj.onc.1205857			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370830				2022-12-17	WOS:000178424900011
J	Araujo, FD; Pierce, AJ; Stark, JM; Jasin, M				Araujo, FD; Pierce, AJ; Stark, JM; Jasin, M			Variant XRCC3 implicated in cancer is functional in homology-directed repair of double-strand breaks	ONCOGENE			English	Article						homologous recombination; DNA double-strand break repair; XRCC3; RAD51; polymorphism	DNA-REPAIR; CHROMOSOME STABILITY; GENES; POLYMORPHISMS	Polymorphisms in DNA repair genes, including double-strand break (DSB) repair genes, are postulated to confer increased cancer risk. A variant of the XRCC3 gene, which is involved in DSB repair, has been associated with increased risk of malignant skin melanoma and bladder cancer. We tested the hypothesis that this variant, Thr241Met, may affect cancer risk by disrupting a critical function of XRCC3, i.e., promoting homology-directed repair (HDR) of chromosomal DSBs. Using a quantitative fluorescence assay, we find that the variant XRCC3 protein is functionally active for HDR, complementing the HDR defects of an XRCC3 mutant cell line as well as the wild-type protein. We also examined cells expressing this variant for sensitivity to the interstrand cross-linking agent, mitomycin C (MMC), as HDR mutant cell lines, including the XRCC3 mutant, have been found to be hypersensitive to this DNA damaging agent. Cells expressing the variant protein were found to be no more sensitive than cells expressing the wild-type protein. These results suggest that the increased cancer risk associated with this variant may not be due to an intrinsic HDR defect.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Jasin, M (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.	m-jasin@ski.mskcc.org		Pierce, Andrew/0000-0001-9062-0307	NIGMS NIH HHS [GM54688] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Brenneman MA, 2000, MUTAT RES-DNA REPAIR, V459, P89, DOI 10.1016/S0921-8777(00)00002-1; Butkiewicz D, 2001, CARCINOGENESIS, V22, P593, DOI 10.1093/carcin/22.4.593; Cui X, 1999, MUTAT RES-DNA REPAIR, V434, P75, DOI 10.1016/S0921-8777(99)00010-5; David-Beabes GL, 2001, CANCER EPIDEM BIOMAR, V10, P911; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; Kurumizaka H, 2001, P NATL ACAD SCI USA, V98, P5538, DOI 10.1073/pnas.091603098; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Masson JY, 2001, P NATL ACAD SCI USA, V98, P8440, DOI 10.1073/pnas.111005698; Matullo G, 2001, INT J CANCER, V92, P562, DOI 10.1002/ijc.1228; MIYAZAKI J, 1989, GENE, V79, P269; Moynahan ME, 2001, CANCER RES, V61, P4842; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Schild D, 2000, J BIOL CHEM, V275, P16443, DOI 10.1074/jbc.M001473200; Shen MR, 1998, CANCER RES, V58, P604; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; Vogelstein B., 1998, GENETIC BASIS HUMAN; Winsey SL, 2000, CANCER RES, V60, P5612	20	95	96	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2002	21	26					4176	4180		10.1038/sj.onc.1205539	http://dx.doi.org/10.1038/sj.onc.1205539			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037675				2022-12-17	WOS:000176186000013
J	Hemmati, PG; Gillissen, B; von Haefen, C; Wendt, J; Starck, L; Guner, D; Dorken, B; Daniel, PT				Hemmati, PG; Gillissen, B; von Haefen, C; Wendt, J; Starck, L; Guner, D; Dorken, B; Daniel, PT			Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis	ONCOGENE			English	Article						p14(ARF); p53; Bax; mitochondria; apoptosis	DRUG-INDUCED APOPTOSIS; P19(ARF) TUMOR-SUPPRESSOR; CELL-CYCLE ARREST; HUMAN ARF PROTEIN; BREAST-CANCER; CYTOCHROME-C; INK4A LOCUS; P53-DEPENDENT APOPTOSIS; METASTATIC MELANOMA; BCL-2 PROTEIN	The human INK4a gene locus encodes two structurally unrelated tumor suppressor proteins, p16(INK4a) and p14(ARF), which are frequently inactivated in human cancer. Whereas p16(INK4a) acts through engagement of the Rb-cdk4/6-cyclin D pathway, both the pro-apoptotic and cell cycle-regulatory functions of p14(ARF) were shown to be primarily dependent on the presence of functional p53. Recent reports have also implicated p14(ARF) in p53-independent mechanisms of cell cycle regulation and apoptosis induction, respectively. To further explore the pro-apoptotic function of p14(ARF) in relation to functional cellular p53, we constructed a replication-deficient adenoviral vector for overexpression of p14(ARF) (Ad-p14(ARF)). As expected, Ad-p14(ARF) efficiently induced apoptosis in p53/Rb wild-type U-2OS osteosarcoma cells at low multiplicities of infection. Interestingly, Ad-p14(ARF) also induced apoptosis in both p53-deleted SAOS-2 osteosarcoma cells and HCT116 colon cancer cells with a bi-allelic knock-out of p53 (HCT116-p53(-/-)). Similarly, adenovirus-mediated overexpression of p14(ARF) induced apoptosis in p53/Bax-mutated DU145 prostate cancer cells as well as in HCT116 cells devoid of functional Bax (HCT116-Bax(-/-)). Restoration of Bax expression by retroviral gene transfer in DU145 cells did not further enhance p14(ARF)-triggered cell death. Infection with Ad-p14(ARF) induced activation of mitochondrial permeability shift transition, caspase activation and apoptotic DNA fragmentation irrespective of the presence or absence of either Bax or functional cellular p53. Nevertheless, overexpression of the anti-apoptotic Bcl-2 homolog Bcl-x(L) markedly inhibited p14(ARF)-induced apoptosis. This may indicate that p14(ARF) triggers a so far unknown activator of mitochondrial apoptosis which can be inhibited by Bcl-2 but which acts either independently or downstream of Bax. Taken together, this report demonstrates the participation of signaling pathways apart from the p53/Mdm-2 rheostat and Bax in p14(ARF)-mediated apoptosis.	Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, Charite, D-13125 Berlin, Germany; Charite, Dept Radiat Oncol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Daniel, PT (corresponding author), Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, Charite, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.			Gillissen, Bernhard/0000-0002-1815-2091				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Anderson RD, 2000, GENE THER, V7, P1034, DOI 10.1038/sj.gt.3301197; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; BOSANQUET, 2002, IN PRESS LEUKEMIA, V16; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; Daniel PT, 1999, BLOOD, V94, P1100, DOI 10.1182/blood.V94.3.1100.415a16_1100_1107; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Fatyol K, 2001, J BIOL CHEM, V276, P28421, DOI 10.1074/jbc.M102847200; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Groth A, 2000, J BIOL CHEM, V275, P27473; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hermann S, 2001, INT J CANCER, V92, P805, DOI 10.1002/ijc.1284; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Iida S, 2000, INT J CANCER, V87, P654, DOI 10.1002/1097-0215(20000901)87:5<654::AID-IJC6>3.0.CO;2-P; Inoue R, 1999, ANTICANCER RES, V19, P2939; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Karayan L, 2001, ONCOGENE, V20, P836, DOI 10.1038/sj.onc.1204170; Krajewska M, 1996, CANCER RES, V56, P2422; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MAO L, 1995, CANCER RES, V55, P2995; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Nakamura M, 2001, BRAIN PATHOL, V11, P159; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Poppe M, 2001, J NEUROSCI, V21, P4551, DOI 10.1523/JNEUROSCI.21-13-04551.2001; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sherr CJ, 2000, CANCER RES, V60, P3689; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sturm I, 2000, INT J CANCER, V87, P517, DOI 10.1002/1097-0215(20000815)87:4<517::AID-IJC9>3.0.CO;2-B; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Vivo M, 2001, J BIOL CHEM, V276, P14161, DOI 10.1074/jbc.M006845200; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Weinmann P, 1997, EUR J IMMUNOL, V27, P2466, DOI 10.1002/eji.1830270947; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Yang CT, 2000, J NATL CANCER I, V92, P636, DOI 10.1093/jnci/92.8.636; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	64	95	98	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3149	3161		10.1038/sj.onc.1205458	http://dx.doi.org/10.1038/sj.onc.1205458			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082630				2022-12-17	WOS:000175373600006
J	Caballero, OL; Resto, V; Patturajan, M; Meerzaman, D; Guo, MZ; Engles, J; Yochem, R; Ratovitski, E; Sidransky, D; Jen, J				Caballero, OL; Resto, V; Patturajan, M; Meerzaman, D; Guo, MZ; Engles, J; Yochem, R; Ratovitski, E; Sidransky, D; Jen, J			Interaction and colocalization of PGP9.5 with JAB1 and p27(Kip1)	ONCOGENE			English	Article						PGP9.5/UCH-L1; JAB1; p27(Kip1); lung cancer; nuclear localization; yeast two-hybrid system	DEUBIQUITINATING ENZYMES; CELL-CYCLE; CDK INHIBITOR; PROTEIN; P27; DEGRADATION; SPECIFICITY; EXPRESSION; PREDICTOR; COMPLEX	PGP9.5 (UCH-L1) is a member of the ubiquitin C-terminal hydrolase (UCH) family of proteins that is expressed in neuronal tissues. Our previous studies have shown that PGP9.5 was highly expressed in primary lung cancers and lung cancer cell lines. Additionally, the frequency of PGP9.5 over expression increases with tumor stage, indicating that PGP9.5 may play a role in lung cancer tumorigenesis. We used the yeast two-hybrid system to identify proteins that interact with PGP9.5. We show that PGP9.5 interacts with at least three proteins, one of which is JAB1, a Jun activation domain binding protein that can bind to p27(Kip1) and is involved in the cytoplasmic transportation of p27(Kip1) for its degradation. We also show that PGP9.5 is associated with JAB1 in vitro and in vivo; and that both proteins can be a part of a heteromeric complex containing p27(Kip1) in the nucleus in lung cancer cells. Furthermore, under serum-restimulation, nuclear translocation of both PGP9.5 and JAB1 coincides with a reduced level of P27(Kip1) in the nucleus. In contrast, when cells are contact inhibited, both PGP9.5 and JAB1 became more perinuclear and cytoplasmic in localization while p27(Kip1) was present only in the nucleus. Therefore, PGP9.5 may contribute to p27(Kip1) degradation via its interaction and nuclear translocation with JAB1.	NCI, Lab Populat Genet, Ctr Canc Res, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University	Jen, J (corresponding author), NCI, Lab Populat Genet, Ctr Canc Res, Bldg 41,Rm D702,41 Lib Dr, Bethesda, MD 20892 USA.	jenj@mail.nih.gov	Resto, Vicente/D-9891-2014		NATIONAL CANCER INSTITUTE [P50CA058184] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; Ciechanover A, 2000, J CELL BIOCHEM, P40; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hibi K, 1999, AM J PATHOL, V155, P711, DOI 10.1016/S0002-9440(10)65169-3; Hibi K, 1998, CANCER RES, V58, P5690; Hirano K, 2000, CANCER DETECT PREV, V24, P343; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Hommura F, 2000, CLIN CANCER RES, V6, P4073; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; James P, 1996, GENETICS, V144, P1425; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; Li SH, 2000, J BIOL CHEM, V275, P13386, DOI 10.1074/jbc.275.18.13386; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Nicol SM, 2000, EXP CELL RES, V257, P272, DOI 10.1006/excr.2000.4886; Nishitani H, 2001, GENE, V272, P25, DOI 10.1016/S0378-1119(01)00553-4; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Wada H, 1998, BIOCHEM BIOPH RES CO, V251, P688, DOI 10.1006/bbrc.1998.9532; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yao J, 2000, INT J CANCER, V89, P213, DOI 10.1002/1097-0215(20000520)89:3<213::AID-IJC1>3.0.CO;2-L	33	95	105	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3003	3010		10.1038/sj.onc.1205390	http://dx.doi.org/10.1038/sj.onc.1205390			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082530	Bronze			2022-12-17	WOS:000175262700007
J	Ramirez de Molina, A; Penalva, V; Lucas, L; Lacal, JC				Ramirez de Molina, A; Penalva, V; Lucas, L; Lacal, JC			Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K	ONCOGENE			English	Article						ras; oncogenes; choline kinase; Ras effectors; Raf; Ral-GDS; PI3K	PHOSPHOLIPASE-D; PHOSPHOINOSITIDE 3-KINASE; STRUCTURAL REQUIREMENTS; NIH 3T3-CELLS; CELL-CYCLE; V-SRC; ACTIVATION; CANCER; TRANSFORMATION; PROLIFERATION	Ras proteins are molecular switches that control signaling pathways critical in the onset of a variety of human cancers. The signaling pathways activated by Ras proteins are those controlled by its direct effectors such as the serine-threonine protein kinase Raf-1, the exchange factor for other GTPases Ral-GDS, and the lipid kinase PI3K. As a consequence of Ras activation, a number of additional enzymes are affected, including several members of the serine-threonine intracellular proteins kinases as well as enzymes related to phospholipid metabolism regulation such as phospholipases A2 and D, and choline kinase. The precise mechanisms by which ras oncogenes impinge into these later molecules and their relevance to the onset of the carcinogenic process is still not fully understood. Here we have investigated the mechanism of regulation of choline kinase by Ras proteins and found no direct link between PLD and choline kinase activation. We provide evidence that Ras proteins regulate the activity of choline kinase through its direct effectors Ral-GDS and PI3K, while the Raf pathways seems to be not relevant in this process. The importance of Ras-dependent activation of choline kinase is discussed.	CSIC, Inst Invest Biomed, Madrid 28049, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, Madrid 28049, Spain.		Lacal, Juan Carlos/AAL-2235-2020; de Molina, Ana Ramirez/AAA-3848-2019; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777				Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; Baldassare JJ, 1997, J BIOL CHEM, V272, P4911, DOI 10.1074/jbc.272.8.4911; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBADELLI A, 1999, ONCOGENE, V18, P1139; BERNHARED EJ, 2000, CANCER RES, V60, P6577; Bhakoo KK, 1996, CANCER RES, V56, P4630; BOS JL, 1989, CANCER RES, V49, P4682; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; CUADRADO A, 1993, ONCOGENE, V8, P2959; de Molina AR, 2001, BIOCHEM BIOPH RES CO, V285, P873, DOI 10.1006/bbrc.2001.5250; De molina AR, 2001, INT J ONCOL, V19, P5; DECERTAINES JD, 1993, NMR BIOMED, V6, P345, DOI 10.1002/nbm.1940060602; Exton JH, 2000, ANN NY ACAD SCI, V905, P61; FRIEDMAN SL, 1994, J BIOL CHEM, V269, P10551; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; GRATAS C, 1993, ANTICANCER RES, V13, P1239; Guillemain I, 1998, BBA-MOL CELL RES, V1405, P161, DOI 10.1016/S0167-4889(98)00107-4; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; Hernandez-Alcoceba R, 2000, CELL MOL LIFE SCI, V57, P65, DOI 10.1007/s000180050499; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kerkhoff E, 2000, CELL GROWTH DIFFER, V11, P185; Lacal J C, 2001, IDrugs, V4, P419; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; Lucas L, 2001, ONCOGENE, V20, P1110, DOI 10.1038/sj.onc.1204216; Lucas L, 2000, ONCOGENE, V19, P431, DOI 10.1038/sj.onc.1203323; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MALUMBRES M, 1999, REV ONCOLOGIA, V1, P66; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; MOODIE SA, 1995, ONCOGENE, V11, P447; Moore SM, 1998, CANCER RES, V58, P5239; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Muller SM, 2000, BIOCHEM BIOPH RES CO, V270, P892, DOI 10.1006/bbrc.2000.2531; Nakagami K, 1999, JPN J CANCER RES, V90, P419, DOI 10.1111/j.1349-7006.1999.tb00764.x; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; RATNAM S, 1995, ARCH BIOCHEM BIOPHYS, V323, P313, DOI 10.1006/abbi.1995.9959; REICH R, 1995, CLIN EXP METASTAS, V13, P134, DOI 10.1007/BF00133618; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RUIZCABELLO J, 1992, NMR BIOMED, V5, P226, DOI 10.1002/nbm.1940050506; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH TAD, 1993, NMR BIOMED, V6, P318, DOI 10.1002/nbm.1940060506; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SRIVASTAVA SK, 1989, MOL CELL BIOL, V9, P1779, DOI 10.1128/MCB.9.4.1779; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	55	95	99	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					937	946		10.1038/sj.onc.1205144	http://dx.doi.org/10.1038/sj.onc.1205144			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840339				2022-12-17	WOS:000173427100009
J	McKay, BC; Becerril, C; Ljungman, M				McKay, BC; Becerril, C; Ljungman, M			P53 plays a protective role against UV- and cisplatin-induced apoptosis in transcription-coupled repair proficient fibroblasts	ONCOGENE			English	Article						apoptosis; DNA repair; p53; ultraviolet	RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; IRRADIATED HUMAN FIBROBLASTS; LIGHT-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR P53; LI-FRAUMENI SYNDROME; ULTRAVIOLET-LIGHT; DNA-DAMAGE; HUMAN-CELLS; INHIBITION	We previously reported that transcription-coupled repair (TCR)-deficient human fibroblasts are extremely sensitive to UV-induced apoptosis and this sensitivity correlated with the induction of the p53 tumour suppressor. However, we have also found that p53 can be protective against UV-induced apoptosis. Thus, prior to this study, it was not clear whether the induction of p53 in TCR-deficient fibroblasts contributed to their death. To address this issue, we have expressed human papillomavirus E6 (HPV-E6) in primary fibroblasts derived from patients affected with xeroderma pigmentosum (complementation groups A, B and C) and Cockayne syndrome (complementation group B). We found that TCR-deficient (XP-A, XP-B and CS-B) fibroblasts were more sensitive than TCR-proficient cells (XP-C and normal) to both UV light and cisplatin treatment and this increase in sensitivity was not p53 dependent. Importantly, HPV-E6 expression increased the sensitivity of TCR-proficient normal and XP-C fibroblasts to UV- and cisplatin-induced apoptosis. This increase in sensitivity correlated with a decrease in the capacity of HPV-E6 expressing cells to recover mRNA synthesis following UV-irradiation. Therefore, we propose that p53 protects against UV- and cisplatin-induced apoptosis in a TCR-dependent manner and that p53 does not contribute strongly to the induction of apoptosis. in TCR-deficient fibroblasts.	Ottawa Reg Canc Ctr, Ctr Canc Therapeut, Ottawa, ON K1H 1C4, Canada; Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Michigan System; University of Michigan	McKay, BC (corresponding author), Ottawa Reg Canc Ctr, Ctr Canc Therapeut, 503 Smyth Rd,3rd Floor, Ottawa, ON K1H 1C4, Canada.		McKay, Bruce C/I-4081-2013	McKay, Bruce C/0000-0002-7921-1331	NCI NIH HHS [CA 82376-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082376] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; Barley RDC, 1998, ONCOGENE, V17, P533, DOI 10.1038/sj.onc.1202271; Conforti G, 2000, ONCOGENE, V19, P2714, DOI 10.1038/sj.onc.1203583; Cullinane C, 1999, BIOCHEMISTRY-US, V38, P6204, DOI 10.1021/bi982685+; El-Mahdy MA, 2000, MUTAT RES-DNA REPAIR, V459, P135, DOI 10.1016/S0921-8777(99)00066-X; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; Lackinger D, 2001, MUTAGENESIS, V16, P233, DOI 10.1093/mutage/16.3.233; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MAY A, 1993, J BIOL CHEM, V268, P1650; McKay BC, 1997, PHOTOCHEM PHOTOBIOL, V66, P659, DOI 10.1111/j.1751-1097.1997.tb03203.x; McKay BC, 2000, MOL BIOL CELL, V11, P2543, DOI 10.1091/mbc.11.8.2543; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; McKay BC, 1999, CARCINOGENESIS, V20, P1389, DOI 10.1093/carcin/20.8.1389; McKay BC, 2001, MUTAT RES-DNA REPAIR, V485, P93, DOI 10.1016/S0921-8777(00)00064-1; McKay BC, 1997, CARCINOGENESIS, V18, P245, DOI 10.1093/carcin/18.2.245; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; MELLO JA, 1995, BIOCHEMISTRY-US, V34, P14783, DOI 10.1021/bi00045a020; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 1996, AM J PATHOL, V148, P1019; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; Therrien JP, 1999, P NATL ACAD SCI USA, V96, P15038, DOI 10.1073/pnas.96.26.15038; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wani MA, 1999, CARCINOGENESIS, V20, P765, DOI 10.1093/carcin/20.5.765; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775	36	95	95	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6805	6808		10.1038/sj.onc.1204901	http://dx.doi.org/10.1038/sj.onc.1204901			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709715				2022-12-17	WOS:000171551600017
J	Finzer, P; Kuntzen, C; Soto, U; Zur Hausen, H; Rosl, F				Finzer, P; Kuntzen, C; Soto, U; Zur Hausen, H; Rosl, F			Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression	ONCOGENE			English	Article						p21; p27; p45(SKP2); E7; apoptosis; therapy	RETINOBLASTOMA GENE-PRODUCT; DEPENDENT-KINASE INHIBITOR; S-PHASE; TRANSCRIPTIONAL REGULATION; REPRESS TRANSCRIPTION; ECTOPIC EXPRESSION; POTENTIAL MEDIATOR; E7 ONCOPROTEIN; PROTEIN; DEGRADATION	Histone deacetylase (HDAC) inhibitors sodium butyrate and trichostatin A arrest human papillomavirus (HPV)positive carcinoma cells in G1 to S transition of the cell cycle, which is paralleled by an up-regulation of the cyclin-dependent kinase inhibitors (CKIs) p21(CIP1) and p27(KIP1) as well as the complete loss of cdk2 activity. Although HPV expression was hitherto thought to be required to maintain a proliferative phenotype of these cells, cdk2 suppression is achieved even in the presence of ongoing viral transcription. While CKIs normally cannot exert their cdk2-inhibitory function in the presence of the viral oncoprotein E7, co-immunoprecipitation experiments revealed that E7 binding is prevented. Increase of p27(KIP1) correlates with down-regulation of p45(SKP2), a component of the ubiquitin-protein ligase SCFSKP2 controlling the half-life of regulatory proteins during the cell cycle. HDAC inhibition also triggered an E7-dependent degradation of pRb, while the levels of E2F remained unaffected. The presence of free intracellular E2F and the concomitant up-regulation of CKIs during G1 arrest results in a 'conflicting growth situation', which finally renders the cells to undergo apoptosis. These data provide novel molecular insights into how the transforming potential of HPV can be bypassed and open new therapeutical perspectives for the treatment of cervical cancer.	Deutsch Krebsforschungszentrum, Forschungsschwerpunkt Angew Tumorvirol, Abt Tumorvirus Immunol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Rosl, F (corresponding author), Deutsch Krebsforschungszentrum, Forschungsschwerpunkt Angew Tumorvirol, Abt Tumorvirus Immunol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.							ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Carnero A, 1998, CURR TOP MICROBIOL, V227, P43; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Finzer P, 2000, ONCOGENE, V19, P3235, DOI 10.1038/sj.onc.1203643; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Janson W, 1997, ONCOGENE, V15, P1395, DOI 10.1038/sj.onc.1201304; Jones DL, 1996, SEMIN CANCER BIOL, V7, P327, DOI 10.1006/scbi.1996.0042; Lallemand F, 1996, BIOCHEM BIOPH RES CO, V229, P163, DOI 10.1006/bbrc.1996.1774; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; NEWMARK HL, 1994, CANCER LETT, V78, P1, DOI 10.1016/0304-3835(94)90023-X; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; ROSL F, 1999, POSSIBLE ROLE CHEMOK, P207; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Siavoshian S, 1997, BIOCHEM BIOPH RES CO, V232, P169, DOI 10.1006/bbrc.1997.6255; STOEHR M, 1978, STAIN TECHNOL, V55, P205; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TOMMASINO M, 1993, ONCOGENE, V8, P195; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	53	95	97	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4768	4776		10.1038/sj.onc.1204652	http://dx.doi.org/10.1038/sj.onc.1204652			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521189				2022-12-17	WOS:000170271800002
J	Turton, NJ; Judah, DJ; Riley, J; Davies, R; Lipson, D; Styles, JA; Smith, AG; Gant, TW				Turton, NJ; Judah, DJ; Riley, J; Davies, R; Lipson, D; Styles, JA; Smith, AG; Gant, TW			Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance	ONCOGENE			English	Article						multidrug resistance; cDNA microarrays; differential gene expression; genomic amplification; doxorubicin resistance; breast cancer	CANCER-CELLS; P-GLYCOPROTEIN; PATTERNS; OVEREXPRESSION; METASTASIS; INVASION; ANTIGEN; DISPLAY; LINES	The multidrug resistance (MDR) phenotype is a major cause of cancer treatment failure. Here the expressions of 4224 genes were analysed for association with intrinsic or acquired doxorubicin (DOX) resistance. A cluster of overexpressed genes related to DOX resistance was observed. Included in this cluster was ABCB1 the P-glycoprotein transporter protein gene and MMPI (Matrix Metalloproteinase 1), indicative of the invasive nature of resistant cells, and the oxytocin receptor (OXTR), a potential new therapeutic target. Overexpression of genes associated with xenobiotic transformation, cell transformation, cell signalling and lymphocyte activation was also associated with DOX resistance as was estrogen receptor negativity, In all carcinoma cells, compared with HBL100 a putatively normal breast epithelial cell line, a cluster of overexpressed genes was identified which included several keratins, in particular keratins 8 and 18 which are regulated through the ras signalling pathway. Analysis of genomic amplifications and deletions revealed specific genetic alterations common to both intrinsic and acquired DOX resistance including ABCB1, PGY3 (ABCB4) and BAK, The findings shown here indicate new possibilities for the diagnosis of DOX resistance using gene expression, and potential novel therapeutic targets for pharmacological intervention.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Technion Israel Inst Technol, IL-32000 Haifa, Israel	University of Leicester; Technion Israel Institute of Technology	Gant, TW (corresponding author), Univ Leicester, MRC, Toxicol Unit, Lancaster Rd, Leicester LE1 9HN, Leics, England.			Gant, Timothy/0000-0001-9057-4937				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bamberger AM, 1999, INT J CANCER, V84, P533, DOI 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J; BATIST G, 1986, J BIOL CHEM, V261, P5544; Benbow U, 1999, J BIOL CHEM, V274, P25371, DOI 10.1074/jbc.274.36.25371; Blatchford DR, 1999, J CELL PHYSIOL, V181, P304, DOI 10.1002/(SICI)1097-4652(199911)181:2<304::AID-JCP12>3.0.CO;2-5; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; Cassoni P, 1997, INT J CANCER, V72, P340, DOI 10.1002/(SICI)1097-0215(19970717)72:2<340::AID-IJC23>3.0.CO;2-I; Cassoni P, 2000, J PATHOL, V190, P470, DOI 10.1002/(SICI)1096-9896(200003)190:4<470::AID-PATH550>3.0.CO;2-G; Chang K, 1996, P NATL ACAD SCI USA, V93, P136, DOI 10.1073/pnas.93.1.136; CHEN G, 1994, CANCER RES, V54, P4980; Davies R, 1996, BRIT J CANCER, V73, P307, DOI 10.1038/bjc.1996.54; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; EISEN MB, 1999, DNA ARRAYS ANAL GENE, P179; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jones JL, 1997, INT J ONCOL, V11, P609; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Lala P, 2000, J BIOL CHEM, V275, P6246, DOI 10.1074/jbc.275.9.6246; Martin K, 2000, CANCER RES, V60, P2232; Oshima RG, 1996, CANCER METAST REV, V15, P445, DOI 10.1007/BF00054012; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Robinson LJ, 1997, BIOCHEMISTRY-US, V36, P11169, DOI 10.1021/bi9627830; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; Stephen R, 1998, J MOL ENDOCRINOL, V20, P375, DOI 10.1677/jme.0.0200375; VANDERBLIEK AM, 1988, CANCER RES, V48, P5927; Vasudevan S, 1998, J BIOL CHEM, V273, P25413, DOI 10.1074/jbc.273.39.25413; WEINSTEIN RS, 1991, CANCER RES, V51, P2720	31	95	106	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 15	2001	20	11					1300	1306		10.1038/sj.onc.1204235	http://dx.doi.org/10.1038/sj.onc.1204235			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313874				2022-12-17	WOS:000167495000004
J	Champagne, N; Pelletier, N; Yang, XJ				Champagne, N; Pelletier, N; Yang, XJ			The monocytic leukemia zinc finger protein MOZ is is histone acetyltransferase	ONCOGENE			English	Article						histone acetyltransferase; MYST; MOZ; MORF; leukemia	ACUTE MYELOID-LEUKEMIA; CREB-BINDING-PROTEIN; HUMAN GENES; CBP; YEAST; FUSION; MLL; TRANSCRIPTION; TRANSLOCATION; COACTIVATOR	The monocytic leukemia zinc finger protein (MOZ) gene is rearranged in t(8;16)(p11;p13), t(8;22)(p11;q13) and inv(8)(p11q13) associated with acute myeloid leukemia. The other fusion partners involved are CBP, p300 and TIF2, transcriptional coactivators with known or potential histone acetyltransferase (HAT) activity. MOZ itself is a 2004-residue protein containing a putative acetyl CoA-binding motif, so it was hypothesized that MOZ is a HAT. Here we present direct evidence that MOZ has intrinsic HAT activity. Moreover, MOZ possesses a transcriptional repression domain at its N-terminal part and an activation domain at its C-terminal part. The activation domain does not show sequence similarity to any yeast proteins, but when tethered, it is able to activate transcription in yeast. Therefore, MOZ is a HAT with characteristics of a transcriptional coregulator, supporting the hypothesis that aberrant acetylation by abnormal MOZ proteins leads to leukemogenesis.	McGill Univ, Ctr Hlth, Dept Med, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada	McGill University	Yang, XJ (corresponding author), McGill Univ, Ctr Hlth, Dept Med, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada.							Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Carapeti M, 1999, CANCER GENET CYTOGEN, V113, P70, DOI 10.1016/S0165-4608(99)00007-2; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Chaffanet M, 1999, GENE CHROMOSOME CANC, V26, P161, DOI 10.1002/(SICI)1098-2264(199910)26:2<161::AID-GCC8>3.3.CO;2-Y; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jacobson S, 1999, CURR OPIN GENET DEV, V9, P175, DOI 10.1016/S0959-437X(99)80027-6; John S, 2000, GENE DEV, V14, P1196; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Liang J, 1998, BLOOD, V92, P2118, DOI 10.1182/blood.V92.6.2118.418k09_2118_2122; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Neal KC, 2000, BBA-GENE STRUCT EXPR, V1490, P170, DOI 10.1016/S0167-4781(99)00211-0; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Rowley JD, 1997, BLOOD, V90, P535; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Takechi S, 1999, BIOCHEM BIOPH RES CO, V266, P405, DOI 10.1006/bbrc.1999.1836; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Thomas T, 2000, DEVELOPMENT, V127, P2537; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; Wolffe AP, 1997, GENES CELLS, V2, P291, DOI 10.1046/j.1365-2443.1997.1260323.x; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	46	95	98	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					404	409		10.1038/sj.onc.1204114	http://dx.doi.org/10.1038/sj.onc.1204114			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313971				2022-12-17	WOS:000166411000016
J	Kong, FM; Anscher, MS; Washington, MK; Killian, JK; Jirtle, RL				Kong, FM; Anscher, MS; Washington, MK; Killian, JK; Jirtle, RL			M6P/IGF2R is mutated in squamous cell carcinoma of the lung	ONCOGENE			English	Article						M6P/IGF2R; loss of heterozygosity; lung cancer; mutation; tumor suppressor	FACTOR-II RECEPTOR; MANNOSE 6-PHOSPHATE RECEPTOR; TUMOR-SUPPRESSOR GENE; GROWTH-FACTOR-BETA; BINDING-SITE; IGF-II; MANNOSE-6-PHOSPHATE RECEPTOR; MICROSATELLITE INSTABILITY; MOLECULAR PATHOGENESIS; LIVER CARCINOGENESIS	In addition to the intracellular sorting of lysosomal enzymes, the mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) plays a critical role in regulating the bioavailability of extracellular proteolytic enzymes and growth factors. It has also been shown to be mutated in a number of human cancers, and to suppress cancer cell growth. The purpose of this study was to determine if the M6P/IGF2R is mutated in lung cancer, a leading cause of cancer death worldwide. Archival pathology specimens were obtained on 22 patients with newly diagnosed, untreated squamous cell carcinoma of the lung. Two polymorphisms in the 3'-untranslated region of the M6P/IGF2R were used to screen lung tumors for loss of heterozygosity (LOH) by PCR amplification of DNA, Nineteen of 22 (86%) patients were informative (heterozygous), and 11/19 (58%) squamous cell carcinomas of the lung had LOH at the M6P/IGF2R locus, The remaining allele in 6/11 (55%) LOH patients contained mutations in either the mannose 6-phosphate or the IGF2 binding domain of the M6P/ IGF2R. Thus, the M6P/IGF2R is mutated frequently in squamous cell carcinoma of the lung, providing further support for its function as a tumor suppressor.	Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA	Duke University; Vanderbilt University	Jirtle, RL (corresponding author), Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA.		Wang, Weili/D-1546-2011; Kong, Feng-Ming/Y-2825-2019	Kong, Feng-Ming/0000-0003-2652-098X; Anscher, Mitchell/0000-0003-4480-111X	NATIONAL CANCER INSTITUTE [R01CA025951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008823] Funding Source: NIH RePORTER; NCI NIH HHS [CA25951] Funding Source: Medline; NIEHS NIH HHS [ES08823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; Bepler G, 1995, CANCER GENET CYTOGEN, V84, P39, DOI 10.1016/0165-4608(95)00063-1; Byrd JC, 1999, J BIOL CHEM, V274, P24408, DOI 10.1074/jbc.274.34.24408; Chappell SA, 1997, BRIT J CANCER, V76, P1558, DOI 10.1038/bjc.1997.596; CZECH MP, 1989, CIBA F SYMP, V145, P27; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1994, J BIOL CHEM, V269, P3802; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DESOUZA AT, 1995, ONCOGENE, V10, P1725; deSouza AT, 1997, FASEB J, V11, P60, DOI 10.1096/fasebj.11.1.9034167; Devi GR, 1998, MOL ENDOCRINOL, V12, P1661, DOI 10.1210/me.12.11.1661; Devi GR, 1999, CANCER RES, V59, P4314; Falls JG, 1999, AM J PATHOL, V154, P635, DOI 10.1016/S0002-9440(10)65309-6; Fong KM, 1995, PATHOLOGY, V27, P295, DOI 10.1080/00313029500169173; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Garmroudi F, 1996, MOL ENDOCRINOL, V10, P642, DOI 10.1210/me.10.6.642; Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559; GINSBERG RJ, 1997, PRINCIPLES PRACTICE, P858; Gotoh K, 1999, CARCINOGENESIS, V20, P499, DOI 10.1093/carcin/20.3.499; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hankins GR, 1996, ONCOGENE, V12, P2003; Hol F. A., 1992, Human Molecular Genetics, V1, P347, DOI 10.1093/hmg/1.5.347; JIRTLE RL, 1994, CARCINOGENESIS, V15, P1473, DOI 10.1093/carcin/15.8.1473; Jirtle RL, 1999, EXP CELL RES, V248, P18, DOI 10.1006/excr.1999.4453; JIRTLE RL, 1999, ENCY MOL BIOL, P1441; Kang JX, 1997, P NATL ACAD SCI USA, V94, P13671, DOI 10.1073/pnas.94.25.13671; Kang JX, 1999, CELL GROWTH DIFFER, V10, P591; Killian JK, 1999, MAMM GENOME, V10, P74, DOI 10.1007/s003359900947; KORNER C, 1995, J BIOL CHEM, V270, P287, DOI 10.1074/jbc.270.1.287; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Leung SY, 1998, AM J PATHOL, V153, P1181, DOI 10.1016/S0002-9440(10)65662-3; LOBEL P, 1988, J BIOL CHEM, V263, P2563; Mills JJ, 1998, ONCOGENE, V16, P2797, DOI 10.1038/sj.onc.1201801; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; O'Gorman DB, 1999, CANCER RES, V59, P5692; Ouyang H, 1997, CANCER RES, V57, P1851; Petersen I, 1997, CANCER RES, V57, P2331; RIMER BK, 1997, PRINCIPLES PRACTICE, P619; Roberts DL, 1998, CELL, V93, P639, DOI 10.1016/S0092-8674(00)81192-7; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; SCOTT CD, 1987, ENDOCRINOLOGY, V120, P1; Sekido Y, 1998, BBA-REV CANCER, V1378, pF21, DOI 10.1016/S0304-419X(98)00010-9; Souza RF, 1999, ONCOGENE, V18, P4063, DOI 10.1038/sj.onc.1202768; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366; Xu YQ, 1997, ONCOGENE, V14, P1041, DOI 10.1038/sj.onc.1200926; Yamada T, 1997, P NATL ACAD SCI USA, V94, P10351, DOI 10.1073/pnas.94.19.10351; ZHOU M, 1995, P NATL ACAD SCI USA, V92, P9762, DOI 10.1073/pnas.92.21.9762	55	95	102	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	2000	19	12					1572	1578		10.1038/sj.onc.1203437	http://dx.doi.org/10.1038/sj.onc.1203437			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734317				2022-12-17	WOS:000086108100010
J	Nesbit, M; Nesbit, HKE; Bennett, J; Andl, T; Hsu, MY; Dejesus, E; McBrian, M; Gupta, AR; Eck, SL; Herlyn, M				Nesbit, M; Nesbit, HKE; Bennett, J; Andl, T; Hsu, MY; Dejesus, E; McBrian, M; Gupta, AR; Eck, SL; Herlyn, M			Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes	ONCOGENE			English	Article						melanocytes; bFGF; adenovirus; transformation	FACTOR MESSENGER-RNA; MELANOMA CELL-LINES; MALIGNANT-MELANOMA; FACTOR RECEPTORS; 3T3 CELLS; EXPRESSION; BFGF; GENE; FGF; PROLIFERATION	Basic fibroblast growth factor (bFGF or FGF-2) is produced by nearly all melanomas in vitro and in viva but not by normal melanocytes, which require exogenous bFGF for growth, In this study, we transduced normal human melanocytes to overexpress two forms of bFGF: (bFGF-Long and bFGF-Short) using replication-deficient adenovirus 5 vectors. bFGF-Long induced the 17.8, 22.5, 23.1 and 24.2 kDa forms of bFGF, whereas bFGF-Short induced only the 17.8 kDa mature form. Growth of cultured melanocytes transduced with either vector was similar to that of nevus and melanoma cells and was independent of exogenous bFGF and of insulin/insulin-like growth factor 1, and cyclic AMP enhancers, requiring only phorbol ester as an exogenous mitogen, Like primary melanoma cells, transduced normal melanocytes grew anchorage independently in soft agar, When injected into the dermis of human skin grafted to mice, bFGF-transduced melanocytes proliferated for at least 20 days, whereas cells from control cultures showed poor survival and no proliferation. These results demonstrate that bFGF upregulation is a component in melanoma progression.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.			Hsu, Mei-Yu/0000-0002-4628-0808; Andl, Thomas/0000-0002-5555-468X	NCI NIH HHS [CA25874, CA47159, CA76674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA025874, R01CA047159, R01CA076674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELMALEK Z, 1992, J CELL PHYSIOL, V150, P416, DOI 10.1002/jcp.1041500226; Ahmed NU, 1997, MELANOMA RES, V7, P299, DOI 10.1097/00008390-199708000-00004; AlAlousi S, 1996, J CUTAN PATHOL, V23, P506, DOI 10.1111/j.1600-0560.1996.tb01442.x; AlAlousi S, 1996, J CUTAN PATHOL, V23, P118, DOI 10.1111/j.1600-0560.1996.tb01284.x; ALBINO AP, 1991, CANCER RES, V51, P4815; AMALRIC F, 1994, BIOCHEM PHARMACOL, V47, P111, DOI 10.1016/0006-2952(94)90443-X; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BECKER D, 1992, ONCOGENE, V7, P2303; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BOUCHE G, 1994, CELL MOL BIOL RES, V40, P547; Care A, 1996, MOL CELL BIOL, V16, P4842; CohenJonathan E, 1997, CANCER RES, V57, P1364; Coleman AB, 1998, J INVEST DERMATOL, V110, P793, DOI 10.1046/j.1523-1747.1998.00166.x; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; DAVOL P, 1995, J INVEST DERMATOL, V104, P916, DOI 10.1111/1523-1747.ep12606193; DELUCA M, 1993, J CELL SCI, V105, P1079; deOliveira AR, 1996, BRAZ J MED BIOL RES, V29, P1743; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; GUALANDRIS A, 1994, J CELL PHYSIOL, V161, P149, DOI 10.1002/jcp.1041610118; HALABAN R, 1988, ONCOGENE RES, V3, P177; HERLYN M, 1988, EXP CELL RES, V179, P322, DOI 10.1016/0014-4827(88)90271-6; HERLYN M, 1994, PIGM CELL RES, V7, P81, DOI 10.1111/j.1600-0749.1994.tb00025.x; HERLYN M, 1994, CANCER RES, V45, P5670; Horikawa T, 1996, PIGM CELL RES, V9, P58, DOI 10.1111/j.1600-0749.1996.tb00089.x; Hsu MY, 1999, HUMAN CELL CULTURE, V1, P259; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; JUHASZ I, 1993, AM J PATHOL, V143, P528; KOZARSKY KF, 1993, CURR OPIN GENET DEV, V3, P499, DOI 10.1016/0959-437X(93)90126-A; MANCIANTI ML, 1993, J INVEST DERMATOL, V100, pS281, DOI 10.1111/1523-1747.ep12470161; Nakazawa K, 1996, PIGM CELL RES, V9, P28, DOI 10.1111/j.1600-0749.1996.tb00083.x; Nelson JE, 1997, J VIROL, V71, P8902, DOI 10.1128/JVI.71.11.8902-8907.1997; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; QUARTO N, 1989, ONCOGENE RES, V5, P101; REED JA, 1994, AM J PATHOL, V144, P329; RODECK U, 1987, INT J CANCER, V40, P687, DOI 10.1002/ijc.2910400520; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; SATYAMOORTHY K, 1996, IMMUNOLOGY HUMAN MEL, P71; SCOTT G, 1991, J INVEST DERMATOL, V96, P318, DOI 10.1111/1523-1747.ep12465203; Seno M, 1998, CYTOKINE, V10, P290, DOI 10.1006/cyto.1997.0286; UEDA M, 1994, BRIT J DERMATOL, V130, P320, DOI 10.1111/j.1365-2133.1994.tb02927.x; VALYINAGY IT, 1993, LAB INVEST, V69, P152; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; WEITZMAN MD, 1995, CNAC THERAPEUTICS; YAN HC, 1993, J CLIN INVEST, V91, P986, DOI 10.1172/JCI116320; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159	48	95	100	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6469	6476		10.1038/sj.onc.1203066	http://dx.doi.org/10.1038/sj.onc.1203066			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597249				2022-12-17	WOS:000083709200009
J	Perrem, K; Bryan, TM; Englezou, A; Hackl, T; Moy, EL; Reddel, RR				Perrem, K; Bryan, TM; Englezou, A; Hackl, T; Moy, EL; Reddel, RR			Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids	ONCOGENE			English	Article						alternative lengthening of telomeres; immortalization; senescence; somatic cell hybridization; telomerase	HUMAN FIBROBLASTS; INDEFINITE DIVISION; IMMORTAL CELLS; DYNAMICS; COMPLEMENTATION; CANCER; LINES; IDENTIFICATION; CHROMOSOME-7; SENESCENCE	Some immortalized cell lines maintain their telomeres in the absence of detectable telomerase activity by an alternative (ALT) mechanism. To study how telomere maintenance is controlled in ALT cells, we have fused an ALT cell Line GM847 (SV40 immortalized human skin fibroblasts) with normal fibroblasts or with telomerase positive immortal human cell lines and have examined their proliferative potential and telomere dynamics. The telomeres in ALT cells are characteristically very heterogeneous in length, ranging from very short to very long, The ALT x normal hybrids underwent a rapid reduction in telomeric DIVA and entered a senescence-like state. Immortal segregants rapidly reverted to the ALT telomere phenotype. Fusion of ALT cells to telomerase-positive immortal cells in the same immortalization complementation group resulted in hybrids that appeared immortal and also exhibited repression of the ALT telomere phenotype. In these hybrids, which were all telomerase-positive, we observed an initial rapid loss of most long telomeres, followed either by gradual loss of the remaining long telomeres at a rate similar to the rate of telomere shortening in normal telomerase-negative cells, or by maintenance of shortened telomeres. These data indicate the existence of a mechanism of rapid telomere deletion in human cells. They also demonstrate that normal cells and at least some telomerase-positive immortal cells contain repressors of the ALT telomere phenotype.	Childrens Med Res Inst, Canc Res Grp, Sydney, NSW 2145, Australia	Children's Medical Research Institute - Australia; University of Sydney	Reddel, RR (corresponding author), Childrens Med Res Inst, Canc Res Grp, 214 Hawkesbury Rd, Sydney, NSW 2145, Australia.		Reddel, Roger R/A-6635-2014; Bryan, Tracy M/B-8468-2014	Reddel, Roger R/0000-0002-6302-6107; Bryan, Tracy/0000-0002-7990-5501				ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; BACCHETTI S, 1995, INT J ONCOL, V7, P423; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bryan TM, 1998, EXP CELL RES, V239, P370, DOI 10.1006/excr.1997.3907; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; BUNN CL, 1980, EXP CELL RES, V127, P385, DOI 10.1016/0014-4827(80)90443-7; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Jones CJ, 1998, EXP CELL RES, V240, P333, DOI 10.1006/excr.1998.3944; Katoh M, 1998, MOL CARCINOGEN, V21, P17, DOI 10.1002/(SICI)1098-2744(199801)21:1<17::AID-MC4>3.0.CO;2-M; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Li BB, 1996, GENE DEV, V10, P1310, DOI 10.1101/gad.10.11.1310; LINDSEY J, 1991, MUTAT RES, V256, P45, DOI 10.1016/0921-8734(91)90032-7; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; Moy EL, 1997, EXP GERONTOL, V32, P663, DOI 10.1016/S0531-5565(97)00092-2; MUGGLETONHARRIS AL, 1980, SOMAT CELL GENET, V6, P689, DOI 10.1007/BF01538968; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Nakabayashi K, 1997, EXP CELL RES, V235, P345, DOI 10.1006/excr.1997.3678; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; OGATA T, 1995, JPN J CANCER RES, V86, P35, DOI 10.1111/j.1349-7006.1995.tb02985.x; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Reddel RR, 1998, BIOESSAYS, V20, P977, DOI 10.1002/(SICI)1521-1878(199812)20:12<977::AID-BIES3>3.0.CO;2-E; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Shore D, 1997, TRENDS BIOCHEM SCI, V22, P233, DOI 10.1016/S0968-0004(97)01082-7; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WHITAKER NJ, 1995, ONCOGENE, V11, P971	38	95	102	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3383	3390		10.1038/sj.onc.1202752	http://dx.doi.org/10.1038/sj.onc.1202752			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362359				2022-12-17	WOS:000080589300009
J	Lipsick, JS; Wang, DM				Lipsick, JS; Wang, DM			Transformation by v-Myb	ONCOGENE			English	Review						myb; oncogene; transcription	AVIAN-MYELOBLASTOSIS VIRUS; DNA-BINDING DOMAIN; E26 LEUKEMIA-VIRUS; CHICKEN C-MYB; MURINE HEMATOPOIETIC-CELLS; LONG TERMINAL REPEATS; ACID RECEPTOR-ALPHA; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION	The v-myb oncogene of the avian myeloblastosis virus (AMV) is unique among known oncogenes in that it causes only acute leukemia in animals and transforms only hematopoietic cells in culture, AMV was discovered in the 1930s as a virus that caused a disease in chickens that is similar to acute myelogenous leukemia in humans (Hall et al,, 1941), This avian retrovirus played an important role in the history of cancer research for two reasons, First, AMV was used to demonstrate that all oncogenic viruses did not contain a single cancer-causing principle, In particular, although both Rous sarcoma virus (RSV) and AMV could replicate in cultures of either embryonic fibroblasts or hematopoietic cells, RSV could transform only fibroblasts whereas AMV could transform only hematopoietic cells (Baluda, 1963; Durban and Boettiger, 1981a), Second, chickens infected with AMV develop remarkably high white counts and therefore their peripheral blood contains remarkably large quantities of viral particles (Beard, 1963), For this reason AMV was often used as a prototypic retrovirus in order to study viral assembly and later to produce large amounts of reverse transcriptase for both research and commercial purposes, Following the discovery of the v-src oncogene of RSV and the demonstration that it arose from the normal c-src proto-oncogene, a number of acute leukemia viruses were analysed by similar techniques and found to also contain viral oncogenes of cellular origin (Roussel et al,, 1979), In the case of AMV, it was shown that almost the entire retroviral env gene had been replaced by a sequence of cellular origin (initially called mab or amy, but later renamed v-myb) (Duesberg et al,, 1980; Souza et al., 1980). Remarkably, sequences contained in this myb oncogene were shared between AMV and the avian E26 leukemia virus, but were not contained in any other acutely transforming retroviruses. In addition, the E26 virus contained a second sequence of cellular origin (ets) that was unique, The E26 leukemia virus was first described in the 1960s and causes an acute erythroblastosis in chickens, more reminiscent of the disease caused by avian erythroblastosis virus (AEV) than by AMV (Ivanov et al,, 1962).	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University	Lipsick, JS (corresponding author), Stanford Univ, Sch Med, Dept Pathol, 300 Pasteur Dr, Stanford, CA 94305 USA.				NATIONAL CANCER INSTITUTE [T32CA009151] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09151] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Badiani PA, 1996, ONCOGENE, V13, P2205; BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BALUDA MA, 1994, ONCOGENE, V9, P2761; BALUDA MA, 1962, COLD SPRING HARB SYM, V27, P415, DOI 10.1101/SQB.1962.027.001.039; Bartunek P, 1997, ONCOGENE, V15, P2939, DOI 10.1038/sj.onc.1201457; BEARD JW, 1963, ADV CANCER RES, V7, P1, DOI 10.1016/S0065-230X(08)60982-3; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIZUB D, 1984, J VIROL, V49, P557, DOI 10.1128/JVI.49.2.557-565.1984; BOETTIGER D, 1984, J VIROL, V49, P841, DOI 10.1128/JVI.49.3.841-847.1984; BORTNER DM, 1991, NUCLEIC ACIDS RES, V19, P1533, DOI 10.1093/nar/19.7.1533; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; CHEN JH, 1980, J VIROL, V36, P162, DOI 10.1128/JVI.36.1.162-170.1980; CHEN RH, 1995, ONCOGENE, V11, P1771; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUESBERG PH, 1980, P NATL ACAD SCI-BIOL, V77, P5120, DOI 10.1073/pnas.77.9.5120; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; DURBAN EM, 1981, P NATL ACAD SCI-BIOL, V78, P3600, DOI 10.1073/pnas.78.6.3600; DURBAN EM, 1981, J VIROL, V37, P488, DOI 10.1128/JVI.37.1.488-492.1981; ENGELKE U, 1994, J VIROL, V68, P2752, DOI 10.1128/JVI.68.4.2752-2755.1994; ENGELKE U, 1995, VIROLOGY, V208, P467, DOI 10.1006/viro.1995.1177; Engelke U, 1997, J VIROL, V71, P3760, DOI 10.1128/JVI.71.5.3760-3766.1997; FAVIER D, 1994, ONCOGENE, V9, P305; FERRAO P, 1995, ONCOGENE, V11, P1631; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Frykberg L, 1988, Oncogene Res, V3, P313; Fu SL, 1996, J VIROL, V70, P5600, DOI 10.1128/JVI.70.8.5600-5610.1996; Fu SL, 1997, CELL GROWTH DIFFER, V8, P35; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Ganter B, 1997, ONCOGENE, V15, P193, DOI 10.1038/sj.onc.1201173; GANTER B, 1999, IN PRESS ADV CANC RE; GARCIA A, 1991, ONCOGENE, V6, P265; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GAZZOLO L, 1975, VIROLOGY, V67, P553, DOI 10.1016/0042-6822(75)90455-9; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GRAF T, 1981, EXP CELL RES, V131, P331, DOI 10.1016/0014-4827(81)90236-6; GRAF T, 1979, VIROLOGY, V99, P431, DOI 10.1016/0042-6822(79)90024-2; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GRASSER FA, 1992, ONCOGENE, V7, P1005; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HALL W. J., 1941, AMER JOUR VET RES, V2, P272; HATEBOER G, 1995, EMBO J, V14, P3159, DOI 10.1002/j.1460-2075.1995.tb07318.x; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1988, J VIROL, V62, P4398, DOI 10.1128/JVI.62.11.4398-4402.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; Ivanov X, 1962, B I PATHOL COMP ANIM, V9, P5; Jiang WP, 1997, J VIROL, V71, P6526, DOI 10.1128/JVI.71.9.6526-6533.1997; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; Kiewitz A, 1997, FEBS LETT, V415, P258, DOI 10.1016/S0014-5793(97)01134-4; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1983, J VIROL, V48, P565, DOI 10.1128/JVI.48.3.565-572.1983; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LeRouzic E, 1996, J VIROL, V70, P7414, DOI 10.1128/JVI.70.11.7414-7423.1996; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; LIPSICK JS, 1987, J VIROL, V61, P933, DOI 10.1128/JVI.61.3.933-936.1987; LIPSICK JS, 1987, J VIROL, V61, P3284, DOI 10.1128/JVI.61.10.3284-3287.1987; Lipsick JS, 1996, ONCOGENE, V13, P223; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; McNagny KM, 1996, CURR TOP MICROBIOL, V212, P143; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; METZ T, 1991, EMBO J, V10, P837, DOI 10.1002/j.1460-2075.1991.tb08016.x; MIZUGUCHI G, 1995, J BIOL CHEM, V270, P9384, DOI 10.1074/jbc.270.16.9384; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MOSCOVICI C, 1975, VIROLOGY, V68, P173, DOI 10.1016/0042-6822(75)90159-2; MOSCOVICI C, 1985, RETROVIRUSES HUMAN P, P177; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MOSCOVICI MG, 1983, P NATL ACAD SCI-BIOL, V80, P1421, DOI 10.1073/pnas.80.5.1421; MOSCOVICI MG, 1983, VIROLOGY, V124, P185, DOI 10.1016/0042-6822(83)90303-3; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NUNN M, 1984, VIROLOGY, V139, P330, DOI 10.1016/0042-6822(84)90378-7; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PERBAL B, 1985, J VIROL, V56, P240, DOI 10.1128/JVI.56.1.240-244.1985; PESSANO S, 1979, MICROBIOLOGICA, V2, P379; PRESS RD, 1994, MOL CELL BIOL, V14, P2278, DOI 10.1128/MCB.14.4.2278; PRESS RD, 1992, J VIROL, V66, P5373, DOI 10.1128/JVI.66.9.5373-5383.1992; QUEVA C, 1992, DEVELOPMENT, V114, P125; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAMSAY RG, 1992, CELL GROWTH DIFFER, V3, P723; RAMSAY RG, 1991, ONCOGENE, V6, P1875; RAVELCHAPUIS P, 1991, J VIROL, V65, P3928, DOI 10.1128/JVI.65.7.3928-3931.1991; Rossi F, 1996, EMBO J, V15, P1894, DOI 10.1002/j.1460-2075.1996.tb00540.x; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; RUSHLOW KE, 1982, J VIROL, V42, P840, DOI 10.1128/JVI.42.3.840-846.1982; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Saville MK, 1998, ADV CANCER RES, V72, P109; SCHIRM S, 1990, J VIROL, V64, P767, DOI 10.1128/JVI.64.2.767-773.1990; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SENECA S, 1993, ONCOGENE, V8, P2335; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; Sitzmann J, 1995, ONCOGENE, V11, P2273; SMARDA J, 1995, MOL CELL BIOL, V15, P2474; SMARDA J, 1994, ONCOGENE, V9, P237; SOUZA LM, 1980, P NATL ACAD SCI-BIOL, V77, P3004, DOI 10.1073/pnas.77.5.3004; STOBERGRASSER U, 1988, J VIROL, V62, P1093; SYMONDS G, 1984, MOL CELL BIOL, V4, P1627, DOI 10.1128/MCB.4.8.1627; SYMONDS G, 1984, MOL CELL BIOL, V4, P2587, DOI 10.1128/MCB.4.12.2587; Tanaka Y, 1997, FEBS LETT, V413, P162, DOI 10.1016/S0014-5793(97)00900-9; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1987, CANCER RES, V47, P5266; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Worpenberg S, 1997, ONCOGENE, V15, P213, DOI 10.1038/sj.onc.1201179; Zemanova K, 1998, BLOOD CELL MOL DIS, V24, P239, DOI 10.1006/bcmd.1998.0189	145	95	100	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	1999	18	19					3047	3055		10.1038/sj.onc.1202745	http://dx.doi.org/10.1038/sj.onc.1202745			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378700				2022-12-17	WOS:000080387800014
J	Dejardin, E; Deregowski, V; Chapelier, M; Jacobs, N; Gielen, J; Merville, MP; Bours, V				Dejardin, E; Deregowski, V; Chapelier, M; Jacobs, N; Gielen, J; Merville, MP; Bours, V			Regulation of NF-kappa B activity by I kappa B-related proteins in adenocarcinoma cells	ONCOGENE			English	Article						NF-kappa B; I kappa B; cancer; adenocarcinoma	UBIQUITIN-PROTEASOME PATHWAY; CANDIDATE ONCOPROTEIN BCL-3; LEUKEMIA-VIRUS TYPE-1; BREAST-CANCER CELLS; DNA-BINDING; TAX-PROTEIN; SPLENIC MICROARCHITECTURE; CONSTITUTIVE ACTIVATION; ALPHA PROTEOLYSIS; ESTROGEN-RECEPTOR	Constitutive NF-kappa B activity varies widely among cancer cell lines. In this report, we studied the expression and the role of different I kappa B inhibitors in adenocarcinoma cell lines. High constitutive NF-kappa B activity and low I kappa B-alpha expression was found in a number of these cell lines. Moreover, some of these cells showed a high p100 expression, responsible for the cytoplasmic sequestration of most of p65 complexes. Treatment of these cells with TNF-alpha or other NF-kappa B activating agents induced only weakly nuclear NF-kappa B activity without significant p100 processing and led to a very weak transcription of NF-kappa B-dependent reporter gene. Induction of NF-kappa B activity can be restored by expression of the Tax protein or by treatment with antisense p100 oligonucleotides. In MCF7 A/Z cells stably transfected with a p100 expression vector, p65 complexes were sequestered in the cytoplasm by p100. These cells showed a reduced nuclear NF-KB induction and NF-kappa B-dependent gene transcription following TNF-x stimulation. As a consequence of a competition between I kappa B-alpha and p100, cells expressing high levels of p100 respond poorly to NF-kappa B activating stimuli as TNF-alpha.	Univ Liege, Lab Med Oncol & Med Chem, B-4000 Liege, Belgium; Univ Liege, Dept Pathol, B-4000 Liege, Belgium	University of Liege; University of Liege	Bours, V (corresponding author), Univ Liege, Lab Med Oncol & Med Chem, B-4000 Liege, Belgium.		Dejardin, Emmanuel/AAE-9076-2021	Jacobs, Nathalie/0000-0002-9895-8465				ABMAYR SM, 1990, CURR PROTOCOL MOL BI; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Betts JC, 1996, MOL CELL BIOL, V16, P6363; BITAR R, 1995, CELL GROWTH DIFFER, V6, P965; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1994, ONCOGENE, V9, P1699; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Dejardin E, 1998, ONCOGENE, V16, P3299, DOI 10.1038/sj.onc.1201879; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DOBRZANSKI P, 1995, ONCOGENE, V10, P1003; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HISCOTT J, 1995, VIROLOGY, V214, P3, DOI 10.1006/viro.1995.9960; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; KANNO T, 1994, P NATL ACAD SCI USA, V91, P12634, DOI 10.1073/pnas.91.26.12634; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Klement JF, 1996, MOL CELL BIOL, V16, P2341; LENARDO M, 1994, IMMUNOL TODAY, V15, P145, DOI 10.1016/0167-5699(94)90308-5; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RAY A, 1994, J BIOL CHEM, V269, P12940; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; Siebenlist U, 1997, BBA-REV CANCER, V1332, pR7, DOI 10.1016/S0304-419X(96)00038-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEIN B, 1995, MOL CELL BIOL, V15, P4971; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Weil R, 1997, J BIOL CHEM, V272, P9942; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	77	95	106	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2567	2577		10.1038/sj.onc.1202599	http://dx.doi.org/10.1038/sj.onc.1202599			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353600				2022-12-17	WOS:000079907100004
J	Hornigold, N; Devlin, J; Davies, AM; Aveyard, JS; Habuchi, T; Knowles, MA				Hornigold, N; Devlin, J; Davies, AM; Aveyard, JS; Habuchi, T; Knowles, MA			Mutation of the 9q34 gene TSC1 in sporadic bladder cancer	ONCOGENE			English	Article						TSC1; bladder cancer; loss of heterozygosity; 9q34	TUMOR-SUPPRESSOR LOCI; TUBEROUS SCLEROSIS; CANDIDATE REGION; CHROMOSOME-9; CARCINOMA; FREQUENT; DELETION; HETEROZYGOSITY; IDENTIFICATION; NEOPLASIA	Deletions involving chromosome 9 occur in more than 50% of human bladder cancers of all grades and stages. Most involve loss of the whole chromosome or of an entire chromosome arm but some small deletions are found which can be used to define critical regions which may contain tumour suppressor genes. We have localized such a critical region of deletion at 9q34 between the markers D9S149 and D9S66, an interval which contains the Tuberous Sclerosis gene TSC1. Single strand conformation polymorphism (SSCP) and sequence analysis of TSC1 in bladder tumours and cell lines with 9q34 loss of heterozygosity (LOH) has identified five mutations in retained TSC1 alleles. Our results support the hypothesis that TSC1 can act as a bladder tumour suppressor gene.	St James Univ Hosp, ICRF Canc Med Res Unit, Leeds LS9 7TF, W Yorkshire, England; Kyoto Univ, Grad Sch Med, Dept Urol, Sakyo Ku, Kyoto 606, Japan	Saint James's University Hospital; Kyoto University	Knowles, MA (corresponding author), St James Univ Hosp, ICRF Canc Med Res Unit, Beckett St, Leeds LS9 7TF, W Yorkshire, England.			Knowles, Margaret/0000-0002-9363-8657				Baylin SB, 1998, ADV CANCER RES, V72, P141; Bjornsson J, 1996, AM J PATHOL, V149, P1201; CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1991, ONCOGENE, V6, P2305; CARBONARA C, 1994, HUM MOL GENET, V3, P1829, DOI 10.1093/hmg/3.10.1829; DEVLIN J, 1994, ONCOGENE, V9, P2757; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Henske EP, 1996, AM J HUM GENET, V59, P400; Hornigold N, 1997, GENOMICS, V41, P385, DOI 10.1006/geno.1997.4681; ISHIBASHI Y, 1991, ANN NY ACAD SCI, V615, P228; Jones AC, 1997, HUM MOL GENET, V6, P2155, DOI 10.1093/hmg/6.12.2155; KEEN AJ, 1994, ONCOGENE, V9, P2083; Knowles MA, 1998, CANCER SURV, V31, P49; ORLOW I, 1994, CANCER RES, V54, P2848; Pajak L, 1997, AM J PHYSIOL-HEART C, V273, pH1619, DOI 10.1152/ajpheart.1997.273.3.H1619; Pea M, 1998, AM J SURG PATHOL, V22, P180, DOI 10.1097/00000478-199802000-00005; POVEY S, 1994, ANN HUM GENET, V58, P177, DOI 10.1111/j.1469-1809.1994.tb01887.x; SCAPPATICCI S, 1988, HUM GENET, V79, P151, DOI 10.1007/BF00280555; SCHULTZ DC, 1995, CANCER RES, V55, P2150; Simoneau AR, 1996, CANCER RES, V56, P5039; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wolfe J, 1997, ANN HUM GENET, V61, P401; YOUNG JM, 1998, IN PRESS ANN HUM GEN	27	95	99	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	1999	18	16					2657	2661		10.1038/sj.onc.1202854	http://dx.doi.org/10.1038/sj.onc.1202854			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353610				2022-12-17	WOS:000079907100014
J	Bartsch, D; Hahn, SA; Danichevski, KD; Ramaswamy, A; Bastian, D; Galehdari, H; Barth, P; Schmiegel, W; Simon, B; Rothmund, M				Bartsch, D; Hahn, SA; Danichevski, KD; Ramaswamy, A; Bastian, D; Galehdari, H; Barth, P; Schmiegel, W; Simon, B; Rothmund, M			Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors	ONCOGENE			English	Article						non-functioning neuroendocrine pancreatic; carcinoma; gastrinoma; insulinoma; DPC4/Smad4; tumor-suppressor genes	DPC4 GENE; SUPPRESSOR GENE; IN-VIVO; GASTRINOMAS; ADENOCARCINOMA; CARCINOMA; NEOPLASIA; 18Q21.1; CANCERS; MEN1	Tumors of the endocrine pancreas are extremely rare, and molecular mechanisms leading to their development are not well understood, ii candidate tumor suppressor gene, DPC4, located at 18q21, has recently been shown to be inactivated in half of pancreatic adenocarcinoma xenografts, The close anatomical relationship of the exocrine and endocrine pancreas prompted us to determine the role of DPC4 in the tumorigenesis of 25 pancreatic islet cell tumors (II insulinomas, nine nonfunctioning endocrine carcinomas, three gastrinomas, two vipomas). A mutation screening of the highly conserved COOH-terminal domain of DPC4 (exons 8-11) was performed by single-strand conformational variant (SSCP) analysis and a PCR-based deletion assay. Five of nine (55%) non-functioning endocrine pancreatic carcinomas revealed either point mutations, small intragenic deletions or homozygous deletion of DPC4 sequences compared to none of the insulinomas, gastrinomas or vipomas, These results suggest that DPC4 is an important target gene promoting tumorigenesis of non-functioning neuroendocrine pancreatic carcinomas.	Univ Marburg, Dept Surg, D-35043 Marburg, Germany; Univ Marburg, Dept Pathol, D-35043 Marburg, Germany; Univ Marburg, Dept Internal Med, D-35043 Marburg, Germany; Setchenov Med Acad, Moscow 109507, Russia; Ruhr Univ Bochum, Dept Internal Med, D-44892 Bochum, Germany	Philipps University Marburg; Philipps University Marburg; Philipps University Marburg; Ruhr University Bochum	Bartsch, D (corresponding author), Univ Marburg, Dept Surg, Baldringerstr, D-35043 Marburg, Germany.		Hahn, Stephan A./AAV-6062-2021; Hahn, Stephan/E-3880-2010	Hahn, Stephan A./0000-0003-0855-9741; Hahn, Stephan/0000-0003-0855-9741				Barrett MT, 1996, CANCER RES, V56, P4351; BARTSCH D, 1995, GENE CHROMOSOME CANC, V14, P189, DOI 10.1002/gcc.2870140306; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; EDIS AJ, 1984, MANUAL ENDOCRINE SUR; EVERS BM, 1994, ANN SURG, V219, P596, DOI 10.1097/00000658-199406000-00002; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; Hahn SA, 1996, CANCER RES, V56, P490; HAHN SA, 1995, CANCER RES, V55, P4670; Hoque ATMS, 1997, GUT, V40, P120, DOI 10.1136/gut.40.1.120; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Kim SK, 1996, CANCER RES, V56, P2519; Kong XT, 1997, CANCER RES, V57, P3772; Lei JY, 1996, ONCOGENE, V13, P2459; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; McGrogan D, 1997, ONCOGENE, V15, P1111; Muscarella P, 1998, CANCER RES, V58, P237; Nagatake M, 1996, CANCER RES, V56, P2718; Schutte M, 1996, CANCER RES, V56, P2527; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; THIAGALINGAM S, 1996, NAT GENET, V13, P342; Trump D, 1996, QJM-INT J MED, V89, P653; YASHIRO T, 1993, SURGERY, V114, P758; YOSHIMOTO K, 1992, CANCER RES, V53, P1057; Zhuang ZP, 1997, CANCER RES, V57, P4682	25	95	99	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2367	2371		10.1038/sj.onc.1202585	http://dx.doi.org/10.1038/sj.onc.1202585			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327057				2022-12-17	WOS:000079595500009
J	Liu, SK; McGlade, CJ				Liu, SK; McGlade, CJ			Gads is a novel SH2 and SH3 domain-containing adaptor protein that binds to tyrosine-phosphorylated Shc	ONCOGENE			English	Article						adaptor protein; SH2 domain; SH3 domain; Shc; Bcr-Abl	NUCLEOTIDE EXCHANGE FACTOR; EPIDERMAL GROWTH-FACTOR; C-CBL PROTOONCOGENE; SIGNAL TRANSDUCTION; HEMATOPOIETIC-CELLS; RAS PATHWAY; GRB2; RECEPTOR; TRANSFORMATION; KINASE	Shc proteins are important substrates of receptor and cytoplasmic tyrosine kinases that couple activated receptors to downstream signaling enzymes. Phosphorylation of Shc tyrosine residues 239 and 317 leads to recruitment of the Grb2-Sos complex, thus linking Shc phosphorylation to Ras activation. We have used phosphorylated peptides corresponding to the regions spanning tyrosine 239/240 and 317 of Shc in an expression library screen to identify additional downstream targets of Shc. Here we report the identification of Gads, a novel adaptor protein most similar to Grb2 and Grap that contains amino and carboxy terminal SH3 domains flanking a central SH2 domain and a 120 amino acid unique region. Gads is most highly expressed in the thymus and spleen of adult animals and in human leukemic cell lines, The binding specificity of the Gads SH2 domain is similar to Grb2 and mediates the interaction of Gads with Shc, Bcr-Abl and c-kit, Gads does not interact with Sos, Cbl or Sam68, although the isolated carboxy terminal Gads SH3 domain is able to bind these molecules in vitro. Our results suggest that the unique structure of Gads regulates its interaction with downstream SH3 domain-binding proteins and that Gads may function to couple tyrosine-phosphorylated proteins such as Shc, Bcr-Abl and activated receptor tyrosine kinases to downstream effectors distinct from Sos and Ras.	Univ Toronto, Ontario Canc Inst, AMGEN Inst, Dept Med Biophys, Toronto, ON M5G 2C1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	McGlade, CJ (corresponding author), Univ Toronto, Ontario Canc Inst, AMGEN Inst, Dept Med Biophys, 60 Univ Ave,Suite 706, Toronto, ON M5G 2C1, Canada.			Liu, Stanley/0000-0001-6851-0857				Anafi M, 1996, J BIOL CHEM, V271, P21365, DOI 10.1074/jbc.271.35.21365; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALDARI CT, 1995, ONCOGENE, V10, P1141; Benson DA, 1998, NUCLEIC ACIDS RES, V26, P1, DOI 10.1093/nar/26.1.1; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/0968-0004(96)10033-5; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CROWE AJ, 1994, ONCOGENE, V9, P537; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; Gotoh A, 1997, Curr Opin Hematol, V4, P3; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; LI N, 1993, NATURE, V363, P88; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PULL L, 1994, EMBO J, V13, P764; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	46	95	97	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 17	1998	17	24					3073	3082		10.1038/sj.onc.1202337	http://dx.doi.org/10.1038/sj.onc.1202337			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872323				2022-12-17	WOS:000077517400001
J	Wu, GF; Fan, RS; Li, WH; Ko, TC; Brattain, MG				Wu, GF; Fan, RS; Li, WH; Ko, TC; Brattain, MG			Modulation of cell cycle control by vitamin D-3 and its analogue, EB1089, in human breast cancer cells	ONCOGENE			English	Article						breast cancer; vitamin D-3; EB1089; p21(WAF-1)/(CIP-1); inactivation of Cdk2 activity	DEPENDENT KINASE INHIBITOR; GROWTH-FACTOR-BETA; DNA-REPLICATION; MCF-7 CELLS; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; CDK INHIBITOR; P21; P27(KIP1); PHASE	Examination of a panel of ER positive breast cancer cell lines showed that they were differentially growth inhibited by vitamin D-3 and its analogue EB1089. EB1089 treatment of the breast cancer cell lines MCF-7 E, BT20, T47D, and ZR75 demonstrated a correlation between a reduction in Cdk2 kinase activity towards phosphorylation of histone H1 and a decrease in DNA synthesis, while no modulation of Cdk2 activity was observed in the vitamin D-3 and EB1089 resistant cell line MCF-7 L. This was accompanied by a time dependent decrease in the percentage of S phase cells in the responsive lines. Characterization of the expression levels of Cdk2 and its related cell cycle proteins in MCF-7 E cells showed that after EB1089 treatment, there was a concentration and time dependent up-regulation of p21 as well as a decrease in cyclin A proteins. Paradoxically, cyclin E levels were increased as a function of treatment. Analysis of cyclin-Cdk2-Cdki complex formation showed that in EB1089 treated MCF-7 E cells, Cdk2, cyclin A and cyclin E immunoprecipitates contained an increased abundance of p21. In contrast to MCF-7 E cells, increases in both p21 and p27 as well as their complex formation with Cdk2 were observed in BT20 and ZR75 cells. These findings indicate that up-regulation of p21 as well as p27 in some cell types mag account for the inactivation of Cdk2 activity and a G(1) block of the cell cycle following EB1089 treatment.	MED COLL OHIO,DEPT BIOCHEM & MOL BIOL,TOLEDO,OH 43699; UNIV TEXAS,MED BRANCH,DEPT SURG,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston					NCI NIH HHS [CA72001, CA50457, CA38173] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA038173, R01CA038173, R01CA050457, R01CA072001] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE J, 1991, ENDOCRINOLOGY, V129, P832, DOI 10.1210/endo-129-2-832; ABE J, 1986, CANCER RES, V46, P6316; BERGER U, 1987, CANCER RES, V47, P6793; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Brattain MG, 1996, J MAMMARY GLAND BIOL, V1, P365, DOI 10.1007/BF02017392; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHOUVET C, 1986, J STEROID BIOCHEM, V24, P373, DOI 10.1016/0022-4731(86)90085-3; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COLSTON KW, 1992, BIOCHEM PHARMACOL, V44, P2273, DOI 10.1016/0006-2952(92)90669-A; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EISMAN JA, 1986, CANCER RES, V46, P5406; EISMAN JA, 1989, J CELL PHYSIOL, V138, P611, DOI 10.1002/jcp.1041380323; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1993, CELL, V75, P815; ELSTNER E, 1995, CANCER RES, V55, P2822; FELDMAN D, 1980, J CLIN ENDOCR METAB, V51, P1463, DOI 10.1210/jcem-51-6-1463; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fotedar R, 1996, ONCOGENE, V12, P2155; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Gorospe M, 1996, CANCER RES, V56, P475; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MAZARS P, 1995, FEBS LETT, V362, P295, DOI 10.1016/0014-5793(95)00247-7; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RIGBY WFC, 1985, J IMMUNOL, V135, P2279; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang QM, 1996, CANCER RES, V56, P264; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	55	95	96	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1555	1563		10.1038/sj.onc.1201329	http://dx.doi.org/10.1038/sj.onc.1201329			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380407				2022-12-17	WOS:A1997XX36900006
J	Berns, K; Hijmans, EM; Bernards, R				Berns, K; Hijmans, EM; Bernards, R			Repression of c-Myc responsive genes in cycling cells causes G(1) arrest through reduction of cyclin E CDK2 kinase activity	ONCOGENE			English	Article						c-Myc; cell cycle; cyclin; CDK	ORNITHINE DECARBOXYLASE GENE; RETINOBLASTOMA-PROTEIN; DEPENDENT KINASES; EPIDERMAL DIFFERENTIATION; TRANSCRIPTIONAL REPRESSOR; ONCOGENIC ACTIVITY; MESSENGER-RNA; IN-VIVO; S-PHASE; MAX	The c-myc gene encodes a sequence-specific DNA binding protein involved in proliferation and oncogenesis. Activation of c-myc expression in quiescent cells is sufficient to mediate cell cycle entry, whereas inhibition of c-myc expression causes cycling cells to withdraw from the cell cycle. To search for components of the cell cycle machinery that are targets of c-Myc, we have made a mutant c-Myc protein, named MadMyc, that actively represses c-myc target genes. Expression of MadMyc in cycling NIH3T3 cells causes a significant accumulation of cells in G(1). The MadMyc-induced G(1) arrest is rescued by ectopic expression of cyclin E/CDK2 and cyclin D1/ CDK4, but not by Cdc25A, a known cell cycle target of c-Myc. The MadMyc G(1) arrest does not require the presence of a functional retinoblastoma protein and is associated with a strong reduction in cyclin E/CDK2 kinase activity in arrested cells. MadMyc does not cause alterations in the expression levels of cyclin E, CDK2, p27(kip1), cyclin DI or CDK4 in G(1)-arrested cells. These data indicate that inhibition of c-Myc activity in exponentially growing cells leads to G(1) arrest through loss of cyclin E-associated kinase activity.	NETHERLANDS CANC INST,DIV MOL CARCINOGENESIS,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Bernards, Rene/0000-0001-8677-3423				ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; CERNI C, 1995, ONCOGENE, V11, P587; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GORUPPI S, 1994, ONCOGENE, V9, P1537; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1995, ONCOGENE, V11, P1409; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KELLY K, 1983, CELL, V35, P600; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1994, ONCOGENE, V9, P1247; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Marhin WW, 1996, ONCOGENE, V12, P43; Mayol X, 1996, ONCOGENE, V13, P237; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SOLOMON DLC, 1995, ONCOGENE, V11, P1893; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; THOMPSON CR, 1986, NATURE, V314, P363; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wu SJ, 1996, ONCOGENE, V12, P621; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	67	95	97	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1347	1356		10.1038/sj.onc.1201280	http://dx.doi.org/10.1038/sj.onc.1201280			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315103	Green Published			2022-12-17	WOS:A1997XV84500013
J	Nakamura, T; Jenkins, NA; Copeland, NG				Nakamura, T; Jenkins, NA; Copeland, NG			Identification of a new family of Pbx-related homeobox genes	ONCOGENE			English	Article						Meis; Pbx; Hox; homeobox; transcription	HUMAN PROTOONCOGENE PBX1; DNA-BINDING SPECIFICITY; TRANSLOCATION PROTEIN; MYELOID-LEUKEMIA; LINKAGE MAP; PRE-B; EXTRADENTICLE; MOUSE; MICE; ARABIDOPSIS	The expression of Meis1 (a novel Pbx-related homeobox gene) and either Hoxa7 or Hoxa9 are coactivated by retroviral integration in BXH2 murine myeloid leukemias (T Nakamura, DA Largaespada, JD Shaughnessy Jr, NA Jenkins and NG Copeland (1996) Nature Genet. 12: 149-153). As Pbx proteins are Hox cofactors, which cooperatively bind DNA with Hox proteins to modulate the otherwise similar DNA bind specificities of Hox proteins, these results suggested that Meis1 may function as a cofactor for Hoxa7 and Hoxa9 in the induction of murine myeloid leukemias. By DNA cross-hybridization we have identified two Meis1-related genes, Meis2 and Meis3. Sequence analysis revealed extensive amino acid similarity among the three Meis proteins both within and outside of the homeodomain. Phylogenetic analysis showed that the Meis genes belong to a distinct family of Pbx-related genes. Chromosome mapping studies indicated that Meis2 and Meis3 are unlinked to Meis1 and map to mouse chromosome 2 and 7, respectively. The Meis genes displayed distinct but overlapping patterns of expression in normal tissues and were expressed in some cases of murine myeloid leukemia. The identification of two additional Meis genes identifies a new family of potential Hox cofactors as well as two new potential disease genes.	NCI,FREDERICK CANC RES & DEV CTR,MAMMALIAN GENET LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								Beckler G S, 1995, Methods Mol Biol, V37, P215; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; CHENCHIK A, 1995, CLONTECHNIQUES, V10, P5; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKINSON ME, 1990, GENOMICS, V6, P505, DOI 10.1016/0888-7543(90)90480-I; DOCKX J, 1995, PLANT MOL BIOL, V28, P723, DOI 10.1007/BF00021196; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Goudet J., 2001, CLADISTICS; Green EL, 1981, GENETICS PROBABILITY, P77; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HURST HC, 1995, PROTEIN PROFILE, V2, P131; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; JENKINS NA, 1982, J VIROL, V42, P379, DOI 10.1128/JVI.42.2.379-388.1982; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LARGAESPADA DA, 1995, J VIROL, V69, P5095, DOI 10.1128/JVI.69.8.5095-5102.1995; LAWLER J, 1991, GENOMICS, V11, P587, DOI 10.1016/0888-7543(91)90066-N; Lu Q, 1996, MOL CELL BIOL, V16, P1632; LU QA, 1995, MOL CELL BIOL, V15, P3786; MA HC, 1994, PLANT MOL BIOL, V24, P465, DOI 10.1007/BF00024114; MANAK JR, 1994, DEVELOPMENT, P61; MATSUOKA M, 1993, PLANT CELL, V5, P1039, DOI 10.1105/tpc.5.9.1039; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MITELMAN F, 1994, CATALOG CHROMOSOME A; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MOSCOW JJ, 1995, MOL CELL BIOL, V15, P5434; MUELLER KJ, 1995, NATURE, V347, P727; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PHELAN ML, 1995, MOL CELL BIOL, V15, P3786; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; QUAEDVLIEG N, 1995, PLANT CELL, V7, P117, DOI 10.1105/tpc.7.1.117; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; REISER L, 1995, CELL, V83, P735, DOI 10.1016/0092-8674(95)90186-8; SIRACUSA LD, 1991, GENETICS, V127, P169; SIRACUSA LD, 1991, GENETICS, V128, P813; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VOLLBRECHT E, 1991, NATURE, V350, P241, DOI 10.1038/350241a0; WYMORE RS, 1994, GENOMICS, V20, P191, DOI 10.1006/geno.1994.1153	52	95	97	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2235	2242						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950991				2022-12-17	WOS:A1996VV14500021
J	Okuda, K; Golub, TR; Gilliland, DG; Griffin, JD				Okuda, K; Golub, TR; Gilliland, DG; Griffin, JD			p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell Lines	ONCOGENE			English	Article						leukemia; signal transduction; BCR/ABL	BCR-ABL ONCOGENE; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; TYROSINE KINASE; ADAPTER PROTEIN; TEL GENE; C-ABL; FUSION; PHOSPHORYLATION; TRANSFORMATION	The Philadelphia chromosome translocation generates a chimeric oncogene, BCR/ABL which causes chronic myelogenous leukemia, Two different fusion proteins can be produced, p190BCR/ABL and p210BCR/ABL, depending on the location of the breakpoint in BCR, Although the ABL tyrosine kinase activity of the resulting oncoprotein is essential for transformation, the exact functional contribution of BCR to transformation is unclear, A novel oncogene containing ABL is formed by the (9;12) translocation which fuses part of the ets-family member TEL to c-ABL in patients with acute leukemia, In an effort to compare the biological effects of various ABL oncogenes, rye transformed two different factor-dependent murine hematopoietic cell Lines with cDNA's encoding p210 BCR/ABL, p190 BCR/ABL, or TEL/ABL, Transfection of each of the three activated ABL oncogenes resulted in rapid emergence of growth factor-independence, and 2-4 sublines from each cell line with each oncogene were further studied, Each oncogene induced an increase in the tyrosine phosphorylation of cellular proteins and autophosphorylation of the oncoprotein itself, Overall, the pattern of increased tyrosine phosphorylation was similar in the cell lines, suggesting that many of the major substrates were identical, We specifically examined a series of proteins known to be p210 BCR/ABL substrates, including rasGAP, Shc, SH-PTP2, SH-PTP1, CRK-L, CBL, paxillin, and STATs, and found that each were also tyrosine phosphorylated in response to p190 BCR/ABL and TEL/ABL. These results suggest that the function of BCR can be largely replaced by the unrelated protein TEL with regards to transformation of murine hematopoietic cell lines to factor-independence, and support the hypothesis that a major contribution of both fusion partners is to activate the ABL tyrosine kinase.	DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115; DANA FARBER CANC INST,DEPT PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL CANCER INSTITUTE [P01CA066996] Funding Source: NIH RePORTER; NCI NIH HHS [CA66996] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BUIJS A, 1995, ONCOGENE, V10, P1511; CAMPBELL ML, 1990, ONCOGENE, V5, P773; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DRUKER B, 1992, BLOOD, V79, P2215; FRANK DA, 1995, P NATL ACAD SCI USA, V92, P7779, DOI 10.1073/pnas.92.17.7779; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GOLUB TR, 1996, IN PRESS MOL CELL BI; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JANSSEN JWG, 1995, BRIT J HAEMATOL, V90, P222, DOI 10.1111/j.1365-2141.1995.tb03407.x; LANEUVILLE P, 1992, BLOOD, V80, P1788; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; ODA T, 1994, J BIOL CHEM, V269, P22925; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RON D, 1991, NEW BIOL, V3, P372; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SETH A, 1990, ONCOGENE, V5, P1761; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	44	95	101	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1147	1152						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808688				2022-12-17	WOS:A1996VJ20200005
J	Jiang, MC; YangYen, HF; Lin, JK; Yen, JJY				Jiang, MC; YangYen, HF; Lin, JK; Yen, JJY			Differential regulation of p53, c-Myc, Bcl-2 and Bax protein expression during apoptosis induced by widely divergent stimuli in human hepatoblastoma cells	ONCOGENE			English	Article						apoptosis; p53; c-Myc; Bcl-2; Bax; hepatoma	WILD-TYPE P53; MYELOID LEUKEMIC-CELLS; HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; CYCLE ARREST; IN-VIVO; HEPATOMA-CELLS; CURCUMA-LONGA; DNA-BINDING; DEATH	Apoptosis of HepG2 cells triggered by various agents is characterized in an attempt to delineate the common apoptosis signaling pathway in human hepatoma cells. Several hallmarks of apoptosis, including DNA laddering, chromatin condensation and fragmentation, and an apoptosis specific cleavage of 28S and 18S ribosomal RNA were observed after treatment with curcumin. Curcumin treatment however did not alter the expression levels of Bcl-2 and Bax proteins, p53 protein accumulated slowly and decreased abruptly after reaching the maximum. Conversely, c-Myc protein decreased initially and subsequently increased preceding the onset of apoptosis. The accumulation of p53 protein is not due to increased levels of p53 mRNA and does not result in growth arrest. Staurosporine, quinacrine, ultraviolet irradiation, hydrogen peroxide, and cyclohexamide are all capable of triggering apoptosis in HepG2 cells. While most of these agents affect the expression levels of p53 and c-Myc similarly, none of them altered the expression levels of the Bcl-2 and Bax proteins. In conclusion, these data suggest that p53 and c-Myc may play a more important role in the apoptosis signaling pathway in HepG2 cells, than the bcl-2 gene family.	ACAD SINICA, INST BIOMED SCI, TAIPEI 11529, TAIWAN; ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN; NATL TAIWAN UNIV, SCH MED, INST BIOCHEM, TAIPEI 10764, TAIWAN	Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Taiwan University			Yen, Jeffrey Jong-Young/Q-5134-2018; Yang-Yen, Hsin-Fang/ABA-5808-2021	Yen, Jeffrey Jong-Young/0000-0001-6299-1995; Yang-Yen, Hsin-Fang/0000-0001-9048-4800				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004; ASKEW DS, 1991, ONCOGENE, V6, P1915; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CAMPOS L, 1993, BLOOD, V81, P3091; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLOMBEL M, 1992, CANCER RES, V52, P4313; DEFORGE LE, 1993, J BIOL CHEM, V268, P25568; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; ERAY M, 1994, INT IMMUNOL, V6, P1817, DOI 10.1093/intimm/6.12.1817; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FUJIMOTO Y, 1994, CANCER RES, V54, P281; GILLARDON F, 1994, ONCOGENE, V9, P3219; GOVINDARAJAN VS, 1980, CRC CR REV FOOD SCI, V12, P199, DOI 10.1080/10408398009527278; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOSONO S, 1993, ONCOGENE, V8, P491; HOUGE G, 1995, MOL CELL BIOL, V15, P2051; HOUGE G, 1993, FEBS LETT, V315, P16, DOI 10.1016/0014-5793(93)81123-H; HUBER BE, 1987, CANCER RES, V47, P3414; ITO N, 1990, JPN J CANCER RES, V81, P216, DOI 10.1111/j.1349-7006.1990.tb02552.x; JIANG MC, 1996, IN PRESS NUTR CANC; KANEKO Y, 1992, CANCER LETT, V66, P155, DOI 10.1016/0304-3835(92)90228-N; KASTAN MB, 1991, CANCER RES, V51, P6304; KUTTAN R, 1985, CANCER LETT, V29, P197, DOI 10.1016/0304-3835(85)90159-4; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAKINO R, 1984, BIOCHEM BIOPH RES CO, V119, P1096, DOI 10.1016/0006-291X(84)90887-8; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; NERENSTONE SR, 1988, CANCER TREAT REV, V15, P1, DOI 10.1016/0305-7372(88)90007-2; OCONNOR PM, 1993, CANCER RES, V53, P4776; OLAH E, 1990, CANCER BIOCHEM BIOPH, V11, P107; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; ROH M S, 1990, Current Opinion in Oncology, V2, P725; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SAITO H, 1991, INT J CANCER, V48, P291, DOI 10.1002/ijc.2910480223; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHEU JC, 1992, CANCER RES, V52, P6098; STRANGE R, 1992, DEVELOPMENT, V115, P49; TAKEDA T, 1991, BIOCHEM BIOPH RES CO, V178, P378, DOI 10.1016/0006-291X(91)91824-V; TELFORD WG, 1992, CYTOMETRY, V13, P137, DOI 10.1002/cyto.990130205; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; TISHLER RB, 1993, CANCER RES, V53, P2212; VENOOK AP, 1994, J CLIN ONCOL, V12, P1323, DOI 10.1200/JCO.1994.12.6.1323; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAP EPH, 1993, LANCET, V341, P251, DOI 10.1016/0140-6736(93)90124-Y; YEN JJY, 1995, J IMMUNOL, V154, P2144; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHANG XK, 1990, ONCOGENE, V5, P909	63	95	106	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	1996	13	3					609	616						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760302				2022-12-17	WOS:A1996VB32800018
J	HERMEKING, H; FUNK, JO; REICHERT, M; ELLWART, JW; EICK, D				HERMEKING, H; FUNK, JO; REICHERT, M; ELLWART, JW; EICK, D			ABROGATION OF P53-INDUCED CELL-CYCLE ARREST BY C-MYC - EVIDENCE FOR AN INHIBITOR OF P21(WAF1/CIP1/SDI1)	ONCOGENE			English	Article						C-MYC; P53; P21; CDK2; CYCLINS; CELL CYCLE	PROTEIN; APOPTOSIS; TRANSCRIPTION; KINASES; GENE; P53	The tumour-suppressor p53 inhibits cell cycle progression by direct transactivation of the p21(WAF1/CIP1/SD11) gene, which encodes a universal inhibitor of cyclin dependent kinases (cdk). The proto-oncogene product c-Myc induces cell cycle progression and, in the absence of survival factors, apoptosis. However, a direct link between the cell cycle machinery and c-Myc has not yet been established, We show that c-Myc abrogates a p53-induced G1-arrest without elevating the expression of cdks or cyclins involved in the G1/S-transition, Instead, the results suggest that c-Myc interferes with the inhibitory action of p21 on cdk/cyclin-complexes by inducing a heat-labile inhibitor of p21, The inactivation of p21 and related cdk-inhibitors may explain several of the oncogenic actions of c-Myc, including the induction of proliferation, immortalisation and the inhibition of differentiation. Modulation of cdk activity by the induction of an inhibitor of cdk-inhibitors represents a novel mechanism of cell cycle regulation in mammalian cells.	GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT GMBH,INST EXPTL HAMATOL,D-81377 MUNICH,GERMANY; UNIV MUNICH,DERMATOL KLIN & POLIKLIN,MOLEK PATHOL ABT,D-80337 MUNICH,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	HERMEKING, H (corresponding author), GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT GMBH,INST KLIN MOLEK BIOL & TUMORGENET,D-81377 MUNICH,GERMANY.							ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ELDEIRY WS, 1993, CELL, V75, P8817; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; HHERMEKING H, 1994, SCIENCE, V265, P2091; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KIESER A, 1994, ONCOGENE, V9, P963; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, IN PRESS NATURE; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MICHIELI P, 1994, CANCER RES, V54, P3391; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RAGIMOV N, 1993, ONCOGENE, V8, P1183; SAMBROCK J, 1989, MOL CLONING LABORATO; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WOLF DA, 1995, ONCOGENE, V10, P2067; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	39	95	96	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1409	1415						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478565				2022-12-17	WOS:A1995RY96700025
J	MIYASHIRO, I; SENDA, T; MATSUMINE, A; BAEG, GH; KURODA, T; SHIMANO, T; MIURA, S; NODA, T; KOBAYASHI, S; MONDEN, M; TOYOSHIMA, K; AKIYAMA, T				MIYASHIRO, I; SENDA, T; MATSUMINE, A; BAEG, GH; KURODA, T; SHIMANO, T; MIURA, S; NODA, T; KOBAYASHI, S; MONDEN, M; TOYOSHIMA, K; AKIYAMA, T			SUBCELLULAR-LOCALIZATION OF THE APC PROTEIN - IMMUNOELECTRON MICROSCOPIC STUDY OF THE ASSOCIATION OF THE APC PROTEIN WITH CATENIN	ONCOGENE			English	Article						TUMOR SUPPRESSOR GENE; APC; FAP; CATENIN; COLORECTAL TUMOR	FAMILIAL ADENOMATOUS POLYPOSIS; MULTIPLE INTESTINAL NEOPLASIA; CANCER CELL-LINE; GENE-PRODUCT; MUTATIONS; CHROMOSOME-5Q21; IDENTIFICATION; EXPRESSION; FAP	Mutations in the APC gene are linked to the development of sporadic colorectal tumors as well as to familial adenomatous polyposis, Recently, the APC protein was reported to associate with catenins, proteins that bind to the cell adhesion molecule E-cadherin, In the present study, we examined the distribution and localization of the APC protein and alpha-catenin in the normal mouse intestine by light and immunoelectron microscopy using specific antibodies, The APC protein was found to be localized in microvilli and in the apical and lateral cytoplasm of the epithelial cells, whereas alpha-catenin was detected only in the lateral cytoplasm. Double-labeling immunoelectron microscopy showed colocalization of the APC protein with alpha-catenin in the lateral cytoplasm, especially along the lateral plasma membrane, although a certain portion of the APC protein in this region was distributed independently of alpha-catenin. These results suggest that a portion of the APC protein localized in the lateral cytoplasm of intestinal epithelial cells functions in cooperation with catenins, whereas the APC protein in microvilli and in the apical cytoplasm has other functions independent of catenins.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT ONCOGENSE RES,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT SURG 2,SUITA,OSAKA 565,JAPAN; NAGOYA UNIV,SCH MED,DEPT ANAT 1,SHOWA KU,NAGOYA,AICHI 466,JAPAN; UNIV TOKYO,INST MED SCI,DEPT PATHOL,MINATO KU,TOKYO 108,JAPAN; JAPANESE FDN CANC RES,INST CANC,DEPT CELL BIOL,TOSHIMA KU,TOKYO 170,JAPAN	Osaka University; Osaka University; Nagoya University; University of Tokyo; Japanese Foundation for Cancer Research			Baeg, Gyeong-Hun/A-2951-2008; Noda, Tetsuo/B-1667-2016	Kuroda, Toshihiko/0000-0001-6660-8930				BHAT RV, 1994, J NEUROSCI, V14, P3059; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; GARDNER EJ, 1953, AM J HUM GENET, V5, P139; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MUNEMITSU S, 1994, CANCER RES, V54, P3676; NAGAFUCHI A, 1994, DEV GROWTH DIFFER, V36, P59; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; ODA T, 1993, BIOCHEM BIOPH RES CO, V193, P897, DOI 10.1006/bbrc.1993.1710; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SENDA T, 1991, HISTOCHEMISTRY, V96, P25, DOI 10.1007/BF00266757; SHIBATA T, 1994, BIOCHEM BIOPH RES CO, V203, P519, DOI 10.1006/bbrc.1994.2213; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SMITH KJ, 1994, CANCER RES, V54, P3672; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1993, CANCER RES, V53, P2728; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z	30	95	96	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					89	96						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624136				2022-12-17	WOS:A1995RJ29500011
J	MOYRET, C; THEILLET, C; PUIG, PL; MOLES, JP; THOMAS, G; HAMELIN, R				MOYRET, C; THEILLET, C; PUIG, PL; MOLES, JP; THOMAS, G; HAMELIN, R			RELATIVE EFFICIENCY OF DENATURING GRADIENT GEL-ELECTROPHORESIS AND SINGLE-STRAND CONFORMATION POLYMORPHISM IN THE DETECTION OF MUTATIONS IN EXON-5 TO EXON-8 OF THE P53 GENE	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; LI-FRAUMENI SYNDROME; POINT MUTATIONS; DNA FRAGMENTS; BREAST-CANCER; LUNG-CANCER; OCCUR; SUBSTITUTIONS; EXPRESSION; DELETIONS	p53 is the most commonly mutated gene in a large variety of human tumors including familial cancers. Because p53 mutations have in a number of human cancer types, been related to a negative outcome of the disease and the importance of pre-symptomatic diagnosis in cancer-prone families, screening for p53 mutations is becoming more and more widely used. In order to avoid sequencing of the complete coding sequence, several prescreening methods have been developed and applied to the p53 gene. Among them, Single Strand Conformation Polymorphism (SSCP) and Denaturing Gradient Gel Electrophoresis (DGGE) appear to be highly sensitive. In this work, we used 52 different p53 variants to compare the two methods. In our conditions, DGGE is more sensitive than SSCP since 100% of the variants were detected. SSCP detected 90% of the variants, but efficiency of the method can still be improved by additional optimization experiments.	INST CURIE,GENET TUMEURS LAB,F-75231 PARIS,FRANCE; INST GENET MOLEC MONTPELLIER,CNRS,F-34033 MONTPELLIER 01,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS)			Theillet, Charles/O-7634-2018; Molès, Jean-Pierre/M-2286-2017	Molès, Jean-Pierre/0000-0002-6863-6350; Theillet, Charles/0000-0001-5555-2759				BAKER SJ, 1990, CANCER RES, V50, P7717; CONDIE A, 1993, HUM MUTAT, V2, P58, DOI 10.1002/humu.1380020111; FISCHER SG, 1983, P NATL ACAD SCI-BIOL, V80, P1579, DOI 10.1073/pnas.80.6.1579; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; HAMELIN R, 1993, ONCOGENE, V8, P2213; HAMELIN R, 1994, INT J CANCER, V57; HORIO Y, 1993, CANCER RES, V53, P1; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTIN HM, 1992, INT J CANCER, V50, P859, DOI 10.1002/ijc.2910500604; MAZARS GR, 1992, ONCOGENE, V7, P1015; MAZARS R, 1992, CANCER RES, V52, P3918; MAZARS R, 1991, ONCOGENE, V6, P1685; MOLES JP, 1993, ONCOGENE, V8, P583; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PORTIER M, 1992, ONCOGENE, V7, P2539; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SPINARDI L, 1991, NUCLEIC ACIDS RES, V19, P4009, DOI 10.1093/nar/19.14.4009; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TOMINAGA O, 1993, ONCOGENE, V8, P2653	25	95	96	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1739	1743						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183571				2022-12-17	WOS:A1994NL81500028
J	SORKIN, A; DIFIORE, PP; CARPENTER, G				SORKIN, A; DIFIORE, PP; CARPENTER, G			THE CARBOXYL-TERMINUS OF EPIDERMAL GROWTH-FACTOR RECEPTOR/ERBB-2 CHIMERAE IS INTERNALIZATION IMPAIRED	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; EGF RECEPTOR; DOWN-REGULATION; A431 CELLS; HUMAN-FIBROBLASTS; ENDOCYTIC SYSTEM; CARCINOMA-CELLS; NEU ONCOGENE; GENE; PROTEIN	The endocytosis of gp185erbB-2 was studied using chimeric receptors in which the intracellular domain of erbB-2, or subdomains thereof, was substituted for the corresponding regions of the epidermal growth factor (EGF) receptor. Chimeric and wild-type EGF or erbB-2 receptors were expressed in mouse NIH3T3 or NR6 fibroblasts and in a human mammary adenocarcinoma cell line, MDAMB-134. The rate of EGF-induced internalization for the chimera consisting of the extracellular EGF receptor domain and intracellular erbB-2 domain was reduced three- to fourfold compared with the wild-type EGF receptor. The low rate of internalization of the chimeric receptor resulted in impaired down-regulation and degradation of the receptor. Substitution of the carboxyl terminus of erhB-2 for the corresponding region of the EGF receptor caused a similar decrease of receptor endocytosis, whereas substitution of the erhB-2 tyrosine kinase domain did not affect internalization and down-regulation. Since the tyrosine kinase of the internalization-defective chimeric receptors could be activated by EGF, kinase activity and autophosphorylation of erhB-2 do not appear to be sufficient for a maximum rapid internalization of the chimeric receptors. These results suggest that the carboxyl terminus of erhB-2 either does not possess all the signals required for the rapid internalization or contains an inhibitory signal for rapid internalization.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA	Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SORKIN, A (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA.		Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950; Sorkin, Alexander/0000-0002-4446-1920	NATIONAL CANCER INSTITUTE [R01CA024071] Funding Source: NIH RePORTER; NCI NIH HHS [CA24071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; CARPENTER G, 1976, J CELL PHYSIOL, V88, P227, DOI 10.1002/jcp.1040880212; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIFIORE PP, 1992, GENES ONCOGENES HORM, P139; DUNN WA, 1984, J CELL BIOL, V98, P2148, DOI 10.1083/jcb.98.6.2148; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HELIN K, 1991, J BIOL CHEM, V266, P8363; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; Lehtola L, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000256; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LONARDO F, 1990, New Biologist, V2, P992; LOTTI LV, 1990, NEW BIOL, V2, P992; LUND KA, 1990, J BIOL CHEM, V265, P15713; MAIER LA, 1991, CANCER RES, V51, P5361; MILLER K, 1986, J CELL BIOL, V102, P500, DOI 10.1083/jcb.102.2.500; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SEGATTO O, 1992, ONCOGENE, V7, P1339; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, 1991, J CELL BIOL, V112, P55, DOI 10.1083/jcb.112.1.55; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; STOSCHECK CM, 1984, J CELL PHYSIOL, V120, P296, DOI 10.1002/jcp.1041200306; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VAUX D, 1992, Trends in Cell Biology, V2, P189, DOI 10.1016/0962-8924(92)90232-C; WATERS CM, 1992, J CELL PHYSIOL, V152, P253, DOI 10.1002/jcp.1041520206; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1991, J BIOL CHEM, V266, P11083; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	47	95	96	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					3021	3028						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8105439				2022-12-17	WOS:A1993MC09300016
J	HAMELIN, R; JEGO, N; LAURENTPUIG, P; VIDAUD, M; THOMAS, G				HAMELIN, R; JEGO, N; LAURENTPUIG, P; VIDAUD, M; THOMAS, G			EFFICIENT SCREENING OF P53 MUTATIONS BY DENATURING GRADIENT GEL-ELECTROPHORESIS IN COLORECTAL TUMORS	ONCOGENE			English	Article							SINGLE BASE SUBSTITUTIONS; POLYMERASE CHAIN-REACTION; CANCER CELL-LINES; SUPPRESSOR GENE; BREAST-CANCER; DNA FRAGMENTS; LUNG-CANCER; GC-CLAMP; POINT MUTATIONS; KI-RAS	Alterations in exons 5-8 of the p53 gene have been found in the vast majority of human tumors. Although some specific codons have been revealed as preferential mutational sites in defined tumor types, mutations are generally so scattered within this region that various screening methods for their detection have been widely used. However, the capacity of these techniques to detect exhaustively all mutations has not been evaluated. In this report, conditions for analysing exons 5-8 of the p53 gene by denaturing gradient gel electrophoresis (DGGE) have been elaborated using the Melt87 and SQHTX computer programs. The procedure requires five different amplifications. The screening of 90 colorectal tumors revealed 56 amplification products demonstrating abnormal DGGE behavior. Direct sequencing of these amplification products after asymmetric polymerase chain reaction (PCR) showed, besides polymorphism, 49 somatically mutated DNA samples (54.4%) corresponding to 38 different p53 variants. Moreover, 25 additional p53 variants identified in other tumor types were also detectable with our conditions. Thus, altogether the procedure has been successfully used in the detection of 63 different p53 variants. The experimental differences in migration between the wild-type homoduplex DNA molecule and the heteroduplex(es) containing one mismatch were systematically compared with those calculated by the SQHTX program. The computer program was found to be reliably predictive. This DGGE procedure appears thus to be effective and reliable for detecting mutations in exons 5-8 of the p53 gene.	INST CURIE,GENET TUMEURS LAB,26 RUE ULM,F-75231 PARIS 05,FRANCE; FAC SCI PHARMACEUT & BIOL PARIS,BIOL MOLEC LAB,F-75006 PARIS,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Cite			laurent-puig, pierre/B-2226-2013; Vidaud, Michel/O-7346-2017; Laurent-Puig, Pierre/K-3641-2019	laurent-puig, pierre/0000-0001-8475-5459; Laurent-Puig, Pierre/0000-0001-8475-5459				ABRAMS ES, 1990, GENOMICS, V7, P463, DOI 10.1016/0888-7543(90)90188-Z; BAKER SJ, 1990, CANCER RES, V50, P7717; BARTEK J, 1990, ONCOGENE, V5, P893; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CARBONE D, 1991, ONCOGENE, V6, P1691; CHIBA I, 1990, ONCOGENE, V5, P1603; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; DAMICO D, 1992, ONCOGENE, V7, P339; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; FISCHER SG, 1983, P NATL ACAD SCI-BIOL, V80, P1579, DOI 10.1073/pnas.80.6.1579; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISHIOKA C, 1991, BIOCHEM BIOPH RES CO, V177, P901, DOI 10.1016/0006-291X(91)90623-F; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JEGO N, 1993, ONCOGENE, V8, P209; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; KRAWCZAK M, 1991, HUM GENET, V86, P425; LAW JC, 1991, CANCER RES, V51, P6385; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; LOTHE RA, 1992, J NATL CANCER I, V84, P1100, DOI 10.1093/jnci/84.14.1100; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MAZARS GR, 1992, ONCOGENE, V7, P781; MAZARS GR, 1992, ONCOGENE, V7, P1015; MAZARS R, 1992, CANCER RES, V52, P3918; MAZARS R, 1991, ONCOGENE, V6, P1685; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3131, DOI 10.1093/nar/13.9.3131; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OSBORNE RJ, 1991, CANCER RES, V51, P6194; PORTIER M, 1992, ONCOGENE, V7, P2539; PROSSER J, 1990, ONCOGENE, V5, P1573; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Sambrook J., 1989, MOL CLONING LABORATO, P31; SHAW P, 1991, ONCOGENE, V6, P2121; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SHIRASAWA S, 1991, CANCER RES, V51, P2874; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THEOPHILUS BDM, 1989, NUCLEIC ACIDS RES, V17, P7707, DOI 10.1093/nar/17.19.7707; TOMINAGA O, 1992, Critical Reviews in Oncogenesis, V3, P257; TOMNAGA O, 1993, IN PRESS ONCOGENE; WINTER E, 1985, P NATL ACAD SCI USA, V82, P7575, DOI 10.1073/pnas.82.22.7575	47	95	97	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2213	2220						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336944				2022-12-17	WOS:A1993LP17100022
J	SETH, A; ROBINSON, L; THOMPSON, DM; WATSON, DK; PAPAS, TS				SETH, A; ROBINSON, L; THOMPSON, DM; WATSON, DK; PAPAS, TS			TRANSACTIVATION OF GATA-1 PROMOTER WITH ETS1, ETS2 AND ERGB/HU-FLI-1 PROTEINS - STABILIZATION OF THE ETS1 PROTEIN-BINDING ON GATA-1 PROMOTER SEQUENCES BY MONOCLONAL-ANTIBODY	ONCOGENE			English	Article							ERYTHROID TRANSCRIPTION FACTOR; LONG TERMINAL REPEAT; C-ETS-1 PROTOONCOGENE; GENE; EXPRESSION; INDUCTION; COOPERATE; ONCOGENE; LINEAGES; VIRUS	Ets family proteins activate transcription via binding to the GGAA core sequence located in the promoter/ enhancer elements of many cellular and viral genes. GATA-1 is an erythroid-specific transcription factor. The promoter of the chicken GATA-1 gene contains multiple ets binding sites (EBS), two of them are present in palindromic form. The GATA-1 promoter has been shown to be activated by the E26 virus. In this study, we have analysed whether the palidromic EBS of the chicken GATA-1 promoter is a target for binding and activation by members of the cellular ets gene family products. The results herein indicate that both EBS in the palindrome are required for DNA-binding because mutations in either site reduces the activity by at least 95%. Moreover, DNA binding of ETS1 to the EBS palindrome is dramatically stabilized in the presence of a specific monoclonal antibody whose epitope maps between amino acid positions 240-260. Although each of the single sites bind, the efficiency of binding is extremely low. Furthermore, for efficient binding the two sites must be in an inverted configuration because of the fact that the oligonucleotide containing the left and right EBS in the same orientation binds 10-fold less than the oligonucleotide containing the EBS palindrome. Additionally, we show that the transcription of a reporter gene (CAT) either linked to the GATA-1 EBS palindrome or GATA-1 promoter can be activated by cotransfection with ETS1, alternatively-spliced ETS1, ETS2 or ERGB/Hu-FLI-1 expression vectors.	PROGRAM RESOURCES INC,DYNCORP,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	SETH, A (corresponding author), NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702, USA.							ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ASCIONE R, 1992, INT J ONCOL, V1, P631; AURIGEMMA RE, 1992, J VIROL, V66, P3056, DOI 10.1128/JVI.66.5.3056-3061.1992; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HODGE DR, IN PRESS ADV GENE TE; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOIZUMI S, 1990, ONCOGENE, V5, P675; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; NERLOV C, 1991, ONCOGENE, V6, P1583; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OKA T, 1991, ONCOGENE, V6, P2077; PANAYIOTAKIS A, IN PRESS J VIRAL DIS; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; RUSCETTI S, 1992, J VIROL, V66, P20, DOI 10.1128/JVI.66.1.20-26.1992; SETH A, 1989, ONCOGENE RES, V5, P61; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1990, ONCOGENE, V5, P1761; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WERNERT N, 1992, AM J PATHOL, V140, P119; YUAN CC, 1989, J VIROL, V61, P205	38	95	96	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1783	1790						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510925				2022-12-17	WOS:A1993LG68200009
J	ZIEGLER, SF; BIRD, TA; SCHNERINGER, JA; SCHOOLEY, KA; BAUM, PR				ZIEGLER, SF; BIRD, TA; SCHNERINGER, JA; SCHOOLEY, KA; BAUM, PR			MOLECULAR-CLONING AND CHARACTERIZATION OF A NOVEL RECEPTOR PROTEIN TYROSINE KINASE FROM HUMAN PLACENTA	ONCOGENE			English	Article							EGF-LIKE REPEATS; LEUKEMIA-CELLS; GENE-PRODUCT; DOMAINS; ENCODES; FAMILY; NOTCH; IMMUNOGLOBULIN; FIBRONECTIN; HOMOLOGY	Using a polymerase chain reaction-based approach we have isolated and characterized a cDNA (HPK-6) from human placental RNA encoding a novel receptor protein tvrosine kinase. This receptor tyrosine kinase has a unique extracellular domain, with an immunoglobulin-like domain at the amino terminus followed by three EGF-like cysteine repeats and three fibronectin type III repeats, giving the HPK-6 gene extracellular domain a novel combination of structural motifs. A comparison of the HPK-6 sequence with other receptor tyrosine kinases shows that the HPK-6 gene is the human homolog of the murine tek gene and very closely related to the recently described receptor tyrosine kinase tie. The HPK-6 gene is expressed predominantly in placenta and lung, with a lower level in umbilical vein endothelial cells, brain and kidney. The HPK-6 cDNA, when transfected into COS-7 cells, encodes a 140-kDa protein with in vitro kinase activity.			ZIEGLER, SF (corresponding author), IMMUNEX CORP,51 UNIV ST,SEATTLE,WA 98101, USA.							APRELIKOVA O, 1992, CANCER RES, V52, P746; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CHAN J, 1991, ONCOGENE, V6, P1057; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS C G, 1990, New Biologist, V2, P410; DUMONT DJ, 1992, ONCOGENE, V7, P1471; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P233, DOI 10.1093/oxfordjournals.jbchem.a131053; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SASAKI M, 1988, J BIOL CHEM, V263, P1653; SCHROEDER HW, 1987, SCIENCE, V238, P791, DOI 10.1126/science.3118465; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1990, CELL, V61, P243; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	35	95	108	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					663	670						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382358				2022-12-17	WOS:A1993KN00800017
J	ECCLES, DM; RUSSELL, SEH; HAITES, NE; ATKINSON, R; BELL, DW; GRUBER, L; HICKEY, I; KELLY, K; KITCHENER, H; LEONARD, R; LESSELLS, A; LOWRY, S; MILLER, I; MILNER, B; STEEL, M				ECCLES, DM; RUSSELL, SEH; HAITES, NE; ATKINSON, R; BELL, DW; GRUBER, L; HICKEY, I; KELLY, K; KITCHENER, H; LEONARD, R; LESSELLS, A; LOWRY, S; MILLER, I; MILNER, B; STEEL, M			EARLY LOSS OF HETEROZYGOSITY ON 17Q IN OVARIAN-CANCER	ONCOGENE			English	Note							P53 GENE; BREAST-CANCER; ALLELE LOSS; CHROMOSOME-17; TRANSMISSION; MUTATIONS; CARCINOMA; TUMORS; FAMILY	We have studied 146 ovarian tumours (94 carcinomas, 22 tumours of low malignant potential and 30 benign tumours) for evidence of allele loss on chromosome 17p and 17q sufficient to imply the proximity of a tumour-suppressor gene. We have examined two polymorphic loci (YNZ22.2 and BHP53) on 17p13 and one on chromosome 17q (17q23-qter). Loss of heterozygosity (LOH) was detected in 34/63 (54%) informative malignant tumours at YNZ22.2 and 22/47 (47%) at BHP53; on 17q, 45/64 (70%) had LOH. Allele loss was detected in a small number of benign and borderline tumours. There was a statistically significant difference between the patterns of allele loss in serous and endometrioid groups of tumours, and allele loss occurred with significantly greater frequency on 17q than on 17p. Comparison of all malignant tumours presenting with either localized (FIGO stage I/II) or widespread (FIGO stage III/IV) disease showed that, particularly on 17q, allele loss increases in the more advanced stages. The p53 tumour-suppressor gene is implicated in ovarian carcinogenesis, and our findings suggest that an important tumour-suppressor gene may be located in the region 17q23-qter. Loss of function in this gene may be responsible for the frequently observed rapid progression of serous-type adenocarcinomas to an advanced stage.	QUEENS UNIV BELFAST,DEPT ONCOL,97 LISBURN RD,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND; UNIV ABERDEEN,SCH MED,DEPT MED GENET,ABERDEEN AB9 22D,SCOTLAND; QUEENS UNIV BELFAST,DIV GENET ENGN,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND; WESTERN GEN HOSP,ICRF MED ONCOL UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	Queens University Belfast; University of Aberdeen; Queens University Belfast; University of Edinburgh; University of Edinburgh			Eccles, Diana/K-6327-2019	Eccles, Diana/0000-0002-9935-3169				Anderson MC, 1990, OVARIAN CANCER BIOL, P187; BAAK JPA, 1986, J CLIN PATHOL, V39, P1340, DOI 10.1136/jcp.39.12.1340; BAKER SJ, 1990, CANCER RES, V50, P7717; CAMPBELL S, 1989, BMJ-BRIT MED J, V299, P1363, DOI 10.1136/bmj.299.6712.1363; DELACALLEMARTIN O, 1990, NUCLEIC ACIDS RES, V18, P4963, DOI 10.1093/nar/18.16.4963; ECCLES DM, 1990, ONCOGENE, V5, P1599; FOULKES W, 1991, LANCET, V338, P444, DOI 10.1016/0140-6736(91)91065-3; FOX H, 1990, OVARIAN CANC BIOL TH, P185; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HARLOW BL, 1989, AM J EPIDEMIOL, V130, P1071, DOI 10.1093/oxfordjournals.aje.a115414; JACOBS I, 1988, LANCET, V1, P268; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOCH M, 1989, INT J EPIDEMIOL, V18, P782, DOI 10.1093/ije/18.4.782; LEE JH, 1990, CANCER RES, V50, P2724; LYNCH HT, 1991, CANCER, V67, P1460, DOI 10.1002/1097-0142(19910301)67:5<1460::AID-CNCR2820670534>3.0.CO;2-S; LYNCH HT, 1986, AM J MED, V81, P1073, DOI 10.1016/0002-9343(86)90411-0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; NAROD SA, 1991, LANCET, V338, P82; PANANI A, 1985, CANCER GENET CYTOGEN, V16, P65, DOI 10.1016/0165-4608(85)90078-0; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SATO T, 1991, CANCER RES, V51, P5118; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STENBACK F, 1981, PATHOL RES PRACT, V172, P58, DOI 10.1016/S0344-0338(81)80123-9; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0	27	95	96	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2069	2072						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408149				2022-12-17	WOS:A1992JP42400023
J	TAKAYAMA, H; SUZUKI, T; MUGISHIMA, H; FUJISAWA, T; OOKUNI, M; SCHWAB, M; GEHRING, M; NAKAMURA, Y; SUGIMURA, T; TERADA, M; YOKOTA, J				TAKAYAMA, H; SUZUKI, T; MUGISHIMA, H; FUJISAWA, T; OOKUNI, M; SCHWAB, M; GEHRING, M; NAKAMURA, Y; SUGIMURA, T; TERADA, M; YOKOTA, J			DELETION MAPPING OF CHROMOSOME-14Q AND CHROMOSOME-1P IN HUMAN NEUROBLASTOMA	ONCOGENE			English	Article							N-MYC AMPLIFICATION; NEURO-BLASTOMA; CELL CARCINOMA; HETEROZYGOSITY; CANCER; TUMOR; GENES; DNA; ADENOCARCINOMA; ABNORMALITIES	It has been suggested that loss of heterozygosity (LOH) on the short arm of chromosome 1 is a critical event for the development of neuroblastoma, and we have previously shown frequent LOH on chromosome 14 in neuroblastoma. To pursue these observations, especially to define further the regions which are commonly deleted in the tumor, we examined for allelic losses in 27 cases of neuroblastomas by using a number of polymorphic DNA markers for chromosomes 14q and 1p. LOH was observed in 10 out of the 25 informative cases (40%) on chromosome 14q and in eight out of the 21 informative cases (38%) on 1p. The commonly deleted regions were distal to the D14S13 locus (14q32-qter) on chromosome 14 and distal to the D1S112 locus (1p36.1-pter) on chromosome 1. These results strongly suggest that tumor-suppressor genes important in the pathogenesis of human neuroblastoma are located on the distal part of both chromosomes 14q and 1p.	NATL CANC CTR,RES INST,1-1 TSUKIJI,5-CHOME,TOKYO 104,JAPAN; NIHON UNIV,SCH MED,DEPT PEDIAT,ITABASHI KU,TOKYO 173,JAPAN; GERMAN CANC RES CTR,INST EXPTL PATHOL,W-6900 HEIDELBERG 1,GERMANY; JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOKYO 170,JAPAN	National Cancer Center - Japan; Nihon University; Helmholtz Association; German Cancer Research Center (DKFZ); Japanese Foundation for Cancer Research				Licka, Manuela/0000-0002-5270-5294				BRODEUR GM, 1981, CANCER RES, V41, P4678; DEVILEE P, 1991, CANCER RES, V51, P1020; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FLEJTER WL, 1989, GENE CHROMOSOME CANC, V1, P148, DOI 10.1002/gcc.2870010207; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GILBERT F, 1984, CANCER RES, V44, P5444; HOFKER MH, 1990, GENOMICS, V6, P33, DOI 10.1016/0888-7543(90)90445-Z; KEATS BJB, 1990, CYTOGENET CELL GENET, V55, P387, DOI 10.1159/000133023; KIDD KK, 1989, CYTOGENET CELL GENET, V51, P622, DOI 10.1159/000132810; KOVACS G, 1989, CANCER RES, V49, P651; LEISTER I, 1990, CANCER RES, V50, P7232; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; NAKAMURA Y, 1989, GENOMICS, V4, P76, DOI 10.1016/0888-7543(89)90317-0; SASAKI M, 1989, CANCER RES, V49, P4402; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SIMON D, 1991, ONCOGENE, V6, P765; SUZUKI T, 1989, CANCER RES, V49, P1095; TSAI YC, 1990, CANCER RES, V50, P44; TSUDA T, 1987, CANCER, V60, P820, DOI 10.1002/1097-0142(19870815)60:4<820::AID-CNCR2820600418>3.0.CO;2-Y; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; YAMADA H, 1986, JPN J CANCER RES, V77, P370; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; ZHANG WD, 1990, JPN J CANCER RES, V81, P108, DOI 10.1111/j.1349-7006.1990.tb02534.x	29	95	95	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1185	1189						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594247				2022-12-17	WOS:A1992HU64200016
J	Bonci, D; Coppola, V; Patrizii, M; Addario, A; Cannistraci, A; Francescangeli, F; Pecci, R; Muto, G; Collura, D; Bedini, R; Zeuner, A; Valtieri, M; Sentinelli, S; Benassi, MS; Gallucci, M; Carlini, P; Piccolo, S; De Maria, R				Bonci, D.; Coppola, V.; Patrizii, M.; Addario, A.; Cannistraci, A.; Francescangeli, F.; Pecci, R.; Muto, G.; Collura, D.; Bedini, R.; Zeuner, A.; Valtieri, M.; Sentinelli, S.; Benassi, M. S.; Gallucci, M.; Carlini, P.; Piccolo, S.; De Maria, R.			A microRNA code for prostate cancer metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR-BETA; TGF-BETA; BREAST-CANCER; STEM-CELLS; BONE-METASTASIS; SELF-RENEWAL; TUMOR; RAS; PROGRESSION	Although the development of bone metastasis is a major detrimental event in prostate cancer, the molecular mechanisms responsible for bone homing and destruction remain largely unknown. Here we show that loss of miR-15 and miR-16 in cooperation with increased miR-21 expression promote prostate cancer spreading and bone lesions. This combination of microRNA endows bone-metastatic potential to prostate cancer cells. Concomitant loss of miR-15/miR-16 and gain of miR-21 aberrantly activate TGF-beta and Hedgehog signaling, that mediate local invasion, distant bone marrow colonization and osteolysis by prostate cancer cells. These findings establish a new molecular circuitry for prostate cancer metastasis that was validated in patients' cohorts. Our data indicate a network of biomarkers and druggable pathways to improve patient treatment.	[Bonci, D.; Coppola, V.; Patrizii, M.; Addario, A.; Cannistraci, A.; Francescangeli, F.; Zeuner, A.; Valtieri, M.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy; [Bonci, D.; Sentinelli, S.; Gallucci, M.; Carlini, P.; De Maria, R.] Regina Elena Inst Canc Res, Sci Directorate, Rome, Italy; [Pecci, R.; Bedini, R.] Ist Super Sanita, Dept Technol & Hlth, Viale Regina Elena 299, I-00161 Rome, Italy; [Muto, G.; Collura, D.] S Giovanni Bosco Hosp, Dept Urol, Turin, Italy; [Muto, G.] Campus Biomed Univ, Dept Urol, Rome, Italy; [Benassi, M. S.] Ist Ortoped Rizzoli, Lab Expt Oncol, Bologna, Italy; [Piccolo, S.] Univ Padua, Sch Med, Dept Mol Med, Padua, Italy	Istituto Superiore di Sanita (ISS); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Istituto Superiore di Sanita (ISS); University Campus Bio-Medico - Rome Italy; IRCCS Istituto Ortopedico Rizzoli; University of Padua	Bonci, D; De Maria, R (corresponding author), IRE, Regina Elena Canc Inst, Italian Natl Canc Inst Regina Elena, Viale Elio Chianesi 53, I-00144 Rome, Italy.	desiree.bonci@iss.it; demaria@ifo.it	Francescangeli, Federica/K-6500-2016; Bedini, Rossella/B-2465-2013; De Maria, Ruggero/S-6385-2019; Zeuner, Ann/K-8607-2016; Bonci, Desiree/K-6488-2016; Addario, Antonio/AAC-4707-2022; valtieri, mauro/H-1044-2016; Coppola, Valeria/K-5120-2016; Zeuner, Ann/A-8529-2010; Gallucci, Michele/K-9600-2016	Francescangeli, Federica/0000-0002-1086-5265; De Maria, Ruggero/0000-0003-2255-0583; Bonci, Desiree/0000-0002-2472-5140; Addario, Antonio/0000-0001-8527-8738; valtieri, mauro/0000-0002-9139-6754; Coppola, Valeria/0000-0002-5745-2572; collura, devis/0000-0002-8964-5248; Bedini, Rossella/0000-0002-0830-6632; Zeuner, Ann/0000-0002-8295-3715; PICCOLO, STEFANO/0000-0002-2037-0004; Gallucci, Michele/0000-0002-3637-6531; Muto, Giovanni/0000-0003-3593-6450; Pecci, Raffaella/0000-0002-6500-9124	National Ministry of Health; Italy-USA microRNA program; Italian Association for Cancer Research (AIRC); Fondazione Roma	National Ministry of Health; Italy-USA microRNA program; Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Roma(Fondazione RomaEuropean Commission)	We thank Giuseppe Loreto, Tania Merlino, Laura De Salvo and Roberto Giaconella for their technical support. We thank Michelangelo Cordenonsi, Maria Musumeci and Marcello Maugeri-Sacca for manuscript discussion. This manuscript has been supported by National Ministry of Health, Under-forty researcher and Italy-USA microRNA program to DB and the Italian Association for Cancer Research (AIRC) and Fondazione Roma funding to RDM.	Aqeilan RI, 2010, CELL DEATH DIFFER, V17, P215, DOI 10.1038/cdd.2009.69; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bhattacharya R, 2009, CANCER RES, V69, P9090, DOI 10.1158/0008-5472.CAN-09-2552; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chan E, 2011, TRENDS MOL MED, V17, P235, DOI 10.1016/j.molmed.2011.01.008; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011; Coppola V, 2013, ONCOGENE, V32, P1843, DOI 10.1038/onc.2012.194; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Cortez MA, 2011, NAT REV CLIN ONCOL, V8, P467, DOI 10.1038/nrclinonc.2011.76; Das S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034374; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Frezzetti D, 2011, ONCOGENE, V30, P275, DOI 10.1038/onc.2010.416; Grusch M, 2010, CURR CANCER DRUG TAR, V10, P849, DOI 10.2174/156800910793357943; Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Javelaud D, 2012, FEBS LETT, V586, P2016, DOI 10.1016/j.febslet.2012.05.011; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Karaa ZS, 2009, RNA, V15, P249, DOI 10.1261/rna.1301109; Kim C, 2010, NAT REV CLIN ONCOL, V7, P340, DOI 10.1038/nrclinonc.2010.61; Klein U, 2010, CANCER CELL, V17, P28, DOI 10.1016/j.ccr.2009.11.019; Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x; Lawrence MG, 2011, PROSTATE, V71, P1198, DOI 10.1002/pros.21335; Liu G, 2010, J EXP MED, V207, P1589, DOI 10.1084/jem.20100035; Liu Q, 2008, NUCLEIC ACIDS RES, V36, P5391, DOI 10.1093/nar/gkn522; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; Lukacs RU, 2010, CELL STEM CELL, V7, P682, DOI 10.1016/j.stem.2010.11.013; Luo J, 2002, CANCER RES, V62, P2220; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martello G, 2007, NATURE, V449, P183, DOI 10.1038/nature06100; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mishra S, 2011, PROSTATE, V71, P1441, DOI 10.1002/pros.21361; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Musumeci M, 2011, ONCOGENE, V30, P4231, DOI 10.1038/onc.2011.140; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Perrot CY, 2013, PHARMACOL THERAPEUT, V137, P183, DOI 10.1016/j.pharmthera.2012.10.002; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Pratap J, 2006, CANCER METAST REV, V25, P589, DOI 10.1007/s10555-006-9032-0; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Sanchez P, 2005, CANCER RES, V65, P2990, DOI 10.1158/0008-5472.CAN-05-0439; Shariat SF, 2004, CLIN CANCER RES, V10, P1992, DOI 10.1158/1078-0432.CCR-0768-03; Shi L, 2014, CANCER RES, V74, P532, DOI 10.1158/0008-5472.CAN-13-2203; Shirakihara T, 2011, EMBO J, V30, P783, DOI 10.1038/emboj.2010.351; Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140-6736(11)61226-9; Sorrentino A, 2008, EXP HEMATOL, V36, P1035, DOI 10.1016/j.exphem.2008.03.004; Stinchfield MJ, 2012, DEVELOPMENT, V139, P2721, DOI 10.1242/dev.077206; Sturge J, 2011, NAT REV CLIN ONCOL, V8, P357, DOI 10.1038/nrclinonc.2011.67; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Talotta F, 2009, ONCOGENE, V28, P73, DOI 10.1038/onc.2008.370; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Teicher BA, 2001, CANCER METAST REV, V20, P133, DOI 10.1023/A:1013177011767; Valtieri M, 2008, J CELL PHYSIOL, V217, P296, DOI 10.1002/jcp.21521; Vo BT, 2011, PROSTATE, V71, P1084, DOI 10.1002/pros.21326; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Watabe T, 2009, CELL RES, V19, P103, DOI 10.1038/cr.2008.323; Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006; Zhang HL, 2011, PROSTATE, V71, P326, DOI 10.1002/pros.21246	66	94	100	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1180	1192		10.1038/onc.2015.176	http://dx.doi.org/10.1038/onc.2015.176			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	26073083	hybrid, Green Published			2022-12-17	WOS:000371351700012
J	Yang-Hartwich, Y; Soteras, MG; Lin, ZP; Holmberg, J; Sumi, N; Craveiro, V; Liang, M; Romanoff, E; Bingham, J; Garofalo, F; Alvero, A; Mor, G				Yang-Hartwich, Y.; Soteras, M. G.; Lin, Z. P.; Holmberg, J.; Sumi, N.; Craveiro, V.; Liang, M.; Romanoff, E.; Bingham, J.; Garofalo, F.; Alvero, A.; Mor, G.			p53 protein aggregation promotes platinum resistance in ovarian cancer	ONCOGENE			English	Article							MUTANT P53; WILD-TYPE; AMYLOID FORMATION; STABILIZES P53; BREAST-CANCER; MDM2; MECHANISMS; DISEASES; BINDING; CELLS	High-grade serous ovarian carcinoma (HGSOC), the most lethal gynecological cancer, often leads to chemoresistant diseases. The p53 protein is a key transcriptional factor regulating cellular homeostasis. A majority of HGSOCs have inactive p53 because of genetic mutations. However, genetic mutation is not the only cause of p53 inactivation. The aggregation of p53 protein has been discovered in different types of cancers and may be responsible for impairing the normal transcriptional activation and pro-apoptotic functions of p53. We demonstrated that in a unique population of HGSOC cancer cells with cancer stem cell properties, p53 protein aggregation is associated with p53 inactivation and platinum resistance. When these cancer stem cells differentiated into their chemosensitive progeny, they lost tumor-initiating capacity and p53 aggregates. In addition to the association of p53 aggregation and chemoresistance in HGSOC cells, we further demonstrated that the overexpression of a p53-positive regulator, p14ARF, inhibited MDM2-mediated p53 degradation and led to the imbalance of p53 turnover that promoted the formation of p53 aggregates. With in vitro and in vivo models, we demonstrated that the inhibition of p14ARF could suppress p53 aggregation and sensitize cancer cells to platinum treatment. Moreover, by two-dimensional gel electrophoresis and mass spectrometry we discovered that the aggregated p53 may function uniquely by interacting with proteins that are critical for cancer cell survival and tumor progression. Our findings help us understand the poor chemoresponse of a subset of HGSOC patients and suggest p53 aggregation as a new marker for chemoresistance. Our findings also suggest that inhibiting p53 aggregation can reactivate p53 pro-apoptotic function. Therefore, p53 aggregation is a potential therapeutic target for reversing chemoresistance. This is paramount for improving ovarian cancer patients' responses to chemotherapy, and thus increasing their survival rate.	[Yang-Hartwich, Y.; Soteras, M. G.; Holmberg, J.; Sumi, N.; Craveiro, V.; Liang, M.; Romanoff, E.; Bingham, J.; Garofalo, F.; Alvero, A.; Mor, G.] Yale Univ, Sch Med, Dept Obstet & Gynecol, New Haven, CT 06520 USA; [Lin, Z. P.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University; Yale University	Mor, G (corresponding author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, Div Reprod Sci, 333 Cedar St,LSOG 305A, New Haven, CT 06520 USA.	gil.mor@yale.edu		Alvero, Ayesha/0000-0002-6593-3595; Holmberg, Jennie/0000-0002-1106-4718	NIH [RO1CA118678, RO1CA127913]; Sands Family Foundation; Discovery to Cure Program; NATIONAL CANCER INSTITUTE [R01CA127913, R01CA118678] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sands Family Foundation; Discovery to Cure Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH Grants RO1CA118678 and RO1CA127913, Sands Family Foundation and Discovery to Cure Program. We thank Drs Alice Soragni and David Eisenberg of UCLA for their suggestion that aggregated p53 could act as a potential therapeutic target.	Aguzzi A, 2010, NAT REV DRUG DISCOV, V9, P237, DOI 10.1038/nrd3050; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Albor A, 1998, CANCER RES, V58, P2091; Alvero AB, 2009, STEM CELLS, V27, P2405, DOI 10.1002/stem.191; Alvero AB, 2009, CELL CYCLE, V8, P158, DOI 10.4161/cc.8.1.7533; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Biancalana M, 2010, BBA-PROTEINS PROTEOM, V1804, P1405, DOI 10.1016/j.bbapap.2010.04.001; Bom APDA, 2012, J BIOL CHEM, V287, P28152, DOI 10.1074/jbc.M112.340638; Butler JS, 2003, BIOCHEMISTRY-US, V42, P2396, DOI 10.1021/bi026635n; Chen R, 2008, ONCOGENE, V27, P4712, DOI 10.1038/onc.2008.112; Ciechanover A, 2006, NEUROLOGY, V66, pS7, DOI 10.1212/01.wnl.0000192261.02023.b8; Clarke-Pearson DL, 2009, NEW ENGL J MED, V361, P170, DOI 10.1056/NEJMcp0901926; Craveiro V, 2013, CANCER MED-US, V2, P751, DOI 10.1002/cam4.115; Dieguez-Acuna F, 2010, INT J BIOCHEM CELL B, V42, P1651, DOI 10.1016/j.biocel.2009.12.001; Erica Golemis PDA, 2002, PROT PROT INT MOL CL; Forget KJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069242; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Higashimoto Y, 2006, BIOCHEMISTRY-US, V45, P1608, DOI 10.1021/bi051192j; Houben R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022096; Ishimaru D, 2004, BIOPHYS J, V87, P2691, DOI 10.1529/biophysj.104.044685; Ishimaru D, 2003, BIOCHEMISTRY-US, V42, P9022, DOI 10.1021/bi034218k; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Kamsteeg M, 2003, ONCOGENE, V22, P2611, DOI 10.1038/sj.onc.1206422; Kayed R, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-18; Kayed R, 2006, METHOD ENZYMOL, V413, P326, DOI 10.1016/S0076-6879(06)13017-7; Klump B, 2003, CLIN CANCER RES, V9, P1773; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; Lasagna-Reeves CA, 2013, BIOCHEM BIOPH RES CO, V430, P963, DOI 10.1016/j.bbrc.2012.11.130; Levy CB, 2011, INT J BIOCHEM CELL B, V43, P60, DOI 10.1016/j.biocel.2010.10.017; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Olzscha H, 2011, CELL, V144, P67, DOI 10.1016/j.cell.2010.11.050; Peng S, 2010, ONCOGENE, V29, P2153, DOI 10.1038/onc.2009.500; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636; Richardson GD, 2004, J CELL SCI, V117, P3539, DOI 10.1242/jcs.01222; Rigacci S, 2008, BIOPHYS J, V94, P3635, DOI 10.1529/biophysj.107.122283; Rizzo S, 2011, MOL CANCER THER, V10, P325, DOI 10.1158/1535-7163.MCT-10-0788; Shih IM, 2009, FUTURE ONCOL, V5, P1641, DOI [10.2217/fon.09.126, 10.2217/FON.09.126]; Silva JL, 2014, TRENDS BIOCHEM SCI, V39, P260, DOI 10.1016/j.tibs.2014.04.001; Silva JL, 2013, BIOSCIENCE REP, V33, P593, DOI 10.1042/BSR20130065; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Steg AD, 2012, CLIN CANCER RES, V18, P869, DOI 10.1158/1078-0432.CCR-11-2188; Szybka M, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-278; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37; TOMINAGA O, 1993, ONCOGENE, V8, P2653; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Wilcken R, 2012, P NATL ACAD SCI USA, V109, P13584, DOI 10.1073/pnas.1211550109; Wong E, 2010, NAT NEUROSCI, V13, P805, DOI 10.1038/nn.2575; Wong KK, 2013, GYNECOL ONCOL, V130, P565, DOI 10.1016/j.ygyno.2013.06.016; Wu Terence L., 2006, V328, P71; Xu J, 2011, NAT CHEM BIOL, V7, P285, DOI 10.1038/nchembio.546; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zheng SC, 2000, CARCINOGENESIS, V21, P2057, DOI 10.1093/carcin/21.11.2057	56	94	98	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3605	3616		10.1038/onc.2014.296	http://dx.doi.org/10.1038/onc.2014.296			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25263447				2022-12-17	WOS:000357434900012
J	Zeilstra, J; Joosten, SPJ; van Andel, H; Tolg, C; Berns, A; Snoek, M; van de Wetering, MV; Spaargaren, M; Clevers, H; Pals, ST				Zeilstra, J.; Joosten, S. P. J.; van Andel, H.; Tolg, C.; Berns, A.; Snoek, M.; van de Wetering, M.; Spaargaren, M.; Clevers, H.; Pals, S. T.			Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling	ONCOGENE			English	Article						CD44; colorectal cancer; stem cell; Wnt signaling	HUMAN COLORECTAL-CANCER; PROTEOGLYCAN FORMS; BETA-CATENIN; COLON-CANCER; C-MET; EXPRESSION; APC; DIFFERENTIATION; PROGRESSION; METASTASIS	A gene signature specific for intestinal stem cells (ISCs) has recently been shown to predict relapse in colorectal cancer (CRC) but the tumorigenic role of individual signature genes remains poorly defined. A prominent ISC-signature gene is the cancer stem cell marker CD44, which encodes various splice variants comprising a diverse repertoire of adhesion and signaling molecules. Using Lgr5 as ISC marker, we have fluorescence-activated cell sorting-purified ISCs to define their CD44 repertoire. ISCs display a specific set of CD44 variant isoforms (CD44v), but remarkably lack the CD44 standard (CD44s) isoform. These CD44v also stand-out in transformed human ISCs isolated from microadenomas of familial adenomatous polyposis patients. By employing knock-in mice expressing either CD44v4-10 or CD44s, we demonstrate that the CD44v isoform, but not CD44s, promotes adenoma initiation in Apc(Min/+) mice. Our data identify CD44v as component of the ISCs program critical for tumor initiation, and as potential treatment target in CRC.	[Zeilstra, J.; Joosten, S. P. J.; van Andel, H.; Spaargaren, M.; Pals, S. T.] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; [Tolg, C.; Berns, A.; Snoek, M.] Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; [van de Wetering, M.; Clevers, H.] Hubrecht Inst, Utrecht, Netherlands; [van de Wetering, M.; Clevers, H.] Univ Med Ctr Utrecht, Utrecht, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Netherlands Cancer Institute; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center	Pals, ST (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Pathol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	s.t.pals@amc.uva.nl	Spaargaren, Marcel/AAU-1298-2021	Spaargaren, Marcel/0000-0002-3135-5109; Pals, Steven/0000-0002-1419-0939; Joosten, Sander/0000-0002-6699-3717	Dutch Cancer Society	Dutch Cancer Society(KWF Kankerbestrijding)	This work was supported by a grant from the Dutch Cancer Society. The authors declare no competing financial interests.	Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; BENNETT KL, 1995, J CELL BIOL, V131, P1623, DOI 10.1083/jcb.131.6.1623; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094; Boon EMJ, 2002, CANCER RES, V62, P5126; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; McCart AE, 2008, PATHOL RES PRACT, V204, P479, DOI 10.1016/j.prp.2008.03.004; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MULDER JWR, 1994, LANCET, V344, P1470, DOI 10.1016/S0140-6736(94)90290-9; Noah TK, 2011, EXP CELL RES, V317, P2702, DOI 10.1016/j.yexcr.2011.09.006; Nusse R, 2008, CELL RES, V18, P523, DOI 10.1038/cr.2008.47; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031; van der Voort R, 1999, J BIOL CHEM, V274, P6499, DOI 10.1074/jbc.274.10.6499; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; VANDERVOORT R, 1995, BIOCHEM BIOPH RES CO, V214, P137, DOI 10.1006/bbrc.1995.2267; VANWEERING DHJ, 1993, PCR METH APPL, V3, P100; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; WIELENGA VJM, 1993, CANCER RES, V53, P4754; Wielenga VJM, 2000, ADV CANCER RES, V77, P169; Wielenga VJM, 2000, AM J PATHOL, V157, P1563, DOI 10.1016/S0002-9440(10)64793-1; Zeilstra J, 2008, CANCER RES, V68, P3655, DOI 10.1158/0008-5472.CAN-07-2940; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	39	94	94	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					665	670		10.1038/onc.2012.611	http://dx.doi.org/10.1038/onc.2012.611			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23318432				2022-12-17	WOS:000331125100014
J	Chimge, NO; Frenkel, B				Chimge, N-O; Frenkel, B.			The RUNX family in breast cancer: relationships with estrogen signaling	ONCOGENE			English	Review						RUNX1; RUNX2; RUNX3; tumor suppressor; oncogene; ER alpha	TRANSCRIPTION FACTOR RUNX2; ACUTE MYELOID-LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; BONE MORPHOGENETIC PROTEIN-7; TO-MESENCHYMAL TRANSITION; MAMMARY EPITHELIAL-CELLS; TUMOR-SUPPRESSOR RUNX3; PROSTATE-CANCER; AML1 GENE	The three RUNX family members are lineage specific master regulators, which also have important, context-dependent roles in carcinogenesis as either tumor suppressors or oncogenes. Here we review evidence for such roles in breast cancer (BCa). RUNX1, the predominant RUNX family member in breast epithelial cells, has a tumor suppressor role reflected by many somatic mutations found in primary tumor biopsies. The classical tumor suppressor gene RUNX3 does not consist of such a mutation hot spot, but it too seems to inhibit BCa; it is often inactivated in human BCa tumors and its haploinsufficiency in mice leads to spontaneous BCa development. The tumor suppressor activities of RUNX1 and RUNX3 are mediated in part by antagonism of estrogen signaling, a feature recently attributed to RUNX2 as well. Paradoxically, however RUNX2, a master osteoblast regulator, has been implicated in various aspects of metastasis in general and bone metastasis in particular. Reciprocating the anti-estrogenic tumor suppressor activity of RUNX proteins, inhibition of RUNX2 by estrogens may help explain their context-dependent anti-metastatic roles. Such roles are reserved to non-osseous metastasis, because ER alpha is associated with increased, not decreased skeletal dissemination of BCa cells. Finally, based on diverse expression patterns in BCa subtypes, the successful use of future RUNX-based therapies will most likely require careful patient selection. Oncogene (2013) 32, 2121-2130; doi:10.1038/onc.2012.328; published online 8 October 2012	[Chimge, N-O; Frenkel, B.] Univ So Calif, Dept Biochem & Mol Biol, Inst Med Genet, Keck Sch Med, Los Angeles, CA 90033 USA; [Frenkel, B.] Univ So Calif, Dept Orthopaed Surg, Inst Med Genet, Keck Sch Med, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Chimge, NO (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, Inst Med Genet, 2250 Alcazar St,CSC 240, Los Angeles, CA 90033 USA.	chimgee@usc.edu; frenkel@usc.edu			NIH grant from the National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK071122]	NIH grant from the National Institute of Diabetes and Digestive and Kidney Diseases	We thank Gerhard A Coetzee, Debu Tripathy, Gillian H Little (University of Southern California) and Andre van Wijnen (University of Massachusetts Medical School) for carefully reading the manuscript and providing critical comments. We are particularly thankful to Charles Perou (University of North Carolina), Dan Koboldt and Matthew Ellis (Washington University), who also shared, analyzed and edited data for this review. This work was supported by NIH grant R01 DK071122 from the National Institute of Diabetes and Digestive and Kidney Diseases to BF, who holds the J Harold and Edna L LaBriola Chair in Genetic Orthopaedic Research at USC.	Ahlquist T, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-94; Akech J, 2010, ONCOGENE, V29, P811, DOI 10.1038/onc.2009.389; Alarmo EL, 2009, CANCER LETT, V275, P35, DOI 10.1016/j.canlet.2008.09.028; Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Bae SC, 1999, HISTOL HISTOPATHOL, V14, P1213, DOI 10.14670/HH-14.1213; Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095; Baniwal SK, 2012, OSTEOPOROSIS INT, V23, P1399, DOI 10.1007/s00198-011-1728-5; Baniwal SK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-258; Baniwal SK, 2009, MOL ENDOCRINOL, V23, P1203, DOI 10.1210/me.2008-0470; Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008-5472.CAN-03-3851; Barnes GL, 2003, CANCER RES, V63, P2631; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; BELLAHCENE A, 1994, CANCER RES, V54, P2823; Blyth K, 2006, CANCER RES, V66, P2195, DOI 10.1158/0008-5472.CAN-05-3558; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Blyth K, 2010, BLOOD CELL MOL DIS, V45, P117, DOI 10.1016/j.bcmd.2010.05.007; Blyth K, 2009, BLOOD CELL MOL DIS, V43, P12, DOI 10.1016/j.bcmd.2009.01.013; Boonstra JJ, 2012, GENE CHROMOSOME CANC, V51, P272, DOI 10.1002/gcc.20952; Brady G, 2009, J VIROL, V83, P6909, DOI 10.1128/JVI.00216-09; Brubaker KD, 2003, PROSTATE, V56, P13, DOI 10.1002/pros.10233; Cameron ER, 2003, BLOOD CELL MOL DIS, V30, P194, DOI 10.1016/S1079-9796(03)00031-7; Carlinfante G, 2003, CLIN EXP METASTAS, V20, P437, DOI 10.1023/A:1025419708343; Chen G, 2006, CANCER-AM CANCER SOC, V107, P289, DOI 10.1002/cncr.21978; Chen LF, 2012, J CELL BIOCHEM, V113, P1470, DOI 10.1002/jcb.24074; Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547; Chimge NO, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3073; Chimge NO, 2012, CLIN CANCER RES, V18, P901, DOI 10.1158/1078-0432.CCR-11-1530; Chuang LSH, 2010, ONCOGENE, V29, P2605, DOI 10.1038/onc.2010.88; Cicatiello L, 2010, AM J PATHOL, V176, P2113, DOI 10.2353/ajpath.2010.090837; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; Cross SS, 2006, J CLIN PATHOL, V59, P716, DOI 10.1136/jcp.2005.030031; Das K, 2009, EUR J CANCER, V45, P2239, DOI 10.1016/j.ejca.2009.06.021; De Braekeleer E, 2008, CANCER GENET CYTOGEN, V185, P47, DOI 10.1016/j.cancergencyto.2008.04.011; De Braekeleer E, 2009, ANTICANCER RES, V29, P1031; Dicker F, 2010, LEUKEMIA, V24, P1528, DOI 10.1038/leu.2010.124; Doll A, 2009, INT J CANCER, V125, P257, DOI 10.1002/ijc.24330; Douet-Guilbert N, 2003, CANCER GENET CYTOGEN, V144, P143, DOI 10.1016/S0165-4608(02)00932-9; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Dupuy AJ, 2005, NATURE, V436, P221, DOI 10.1038/nature03691; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Ellis MJ, 2009, JAMA-J AM MED ASSOC, V302, P774, DOI 10.1001/jama.2009.1204; Endo T, 2008, J CLIN ENDOCR METAB, V93, P2409, DOI 10.1210/jc.2007-2805; Fijneman RJA, 2012, CANCER SCI, V103, P593, DOI 10.1111/j.1349-7006.2011.02189.x; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P15, DOI 10.1002/gcc.2870140104; Frenkel B, 2010, J CELL PHYSIOL, V224, P305, DOI 10.1002/jcp.22159; Fukamachi H, 2004, ONCOGENE, V23, P4330, DOI 10.1038/sj.onc.1207121; Gaidzik VI, 2011, J CLIN ONCOL, V29, P1364, DOI 10.1200/JCO.2010.30.7926; Galindo M, 2005, J BIOL CHEM, V280, P20274, DOI 10.1074/jbc.M413665200; Gao F, 2009, J CANCER RES CLIN, V135, P739, DOI 10.1007/s00432-008-0508-x; Gelsi-Boyer V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-299; Geoffroy V, 2002, MOL CELL BIOL, V22, P6222, DOI 10.1128/MCB.22.17.6222-6233.2002; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Han YX, 2012, INT J ONCOL, V40, P673, DOI 10.3892/ijo.2011.1249; Harada H, 2004, BLOOD, V103, P2316, DOI 10.1182/blood-2003-09-3074; Harada H, 2003, BLOOD, V101, P673, DOI 10.1182/blood-2002-04-1010; Harewood L, 2003, LEUKEMIA, V17, P547, DOI 10.1038/sj.leu.2402849; He L, 2012, PLOS ONE, V7, P3; He N, 2011, J CELL BIOCHEM, V112, P653, DOI 10.1002/jcb.22968; Hess KR, 2003, BREAST CANCER RES TR, V78, P105, DOI 10.1023/A:1022166517963; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Hoi CSL, 2010, MOL CELL BIOL, V30, P2518, DOI 10.1128/MCB.01308-09; Hromas R, 2000, BLOOD, V95, P4011; Hsu YL, 2011, J BIOL CHEM, V286, P37335, DOI 10.1074/jbc.M111.256156; Huang B, 2012, ONCOGENE, V31, P527, DOI 10.1038/onc.2011.252; Huang SP, 2011, BJU INT, V107, P486, DOI 10.1111/j.1464-410X.2010.09512.x; Hwang KT, 2007, J KOREAN MED SCI, V22, pS24, DOI 10.3346/jkms.2007.22.S.S24; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; Inman CK, 2003, J BIOL CHEM, V278, P48684, DOI 10.1074/jbc.M308001200; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004; Janes KA, 2011, CELL CYCLE, V10, P3461, DOI 10.4161/cc.10.20.18029; Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102; Jiang Y, 2008, PATHOBIOLOGY, V75, P244, DOI 10.1159/000132385; Kadota M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009201; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kayed H, 2007, BRIT J CANCER, V97, P1106, DOI 10.1038/sj.bjc.6603984; Khalid O, 2008, ENDOCRINOLOGY, V149, P5984, DOI 10.1210/en.2008-0680; Kim TY, 2004, LAB INVEST, V84, P479, DOI 10.1038/labinvest.3700060; Kim WJ, 2005, CANCER RES, V65, P9347, DOI 10.1158/0008-5472.CAN-05-1647; Koeneman KS, 1999, PROSTATE, V39, P246; Kohlmann A, 2010, J CLIN ONCOL, V28, P3858, DOI 10.1200/JCO.2009.27.1361; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441-009-0832-8; Kouros-Mehr H, 2006, DEV DYNAM, V235, P3404, DOI 10.1002/dvdy.20978; Kuo MC, 2009, LEUKEMIA, V23, P1426, DOI 10.1038/leu.2009.48; Kuo YH, 2009, BLOOD, V113, P3323, DOI 10.1182/blood-2008-06-162248; Lam K, 2012, FRONT BIOSCI-LANDMRK, V17, P1120, DOI 10.2741/3977; Lau CC, 2004, GENE CHROMOSOME CANC, V39, P11, DOI 10.1002/gcc.10291; Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369; Lee SH, 2009, ONCOGENE, V28, P184, DOI 10.1038/onc.2008.377; Leong DT, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2762; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li DL, 2007, J BIOL CHEM, V282, P13542, DOI 10.1074/jbc.M700074200; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lim M, 2010, LAB INVEST, V90, P222, DOI 10.1038/labinvest.2009.128; Little GH, 2012, NUCLEIC ACIDS RES, V40, P3538, DOI 10.1093/nar/gkr1219; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991; Mangan James K., 2011, Critical Reviews in Oncogenesis, V16, P77; Martin J. W., 2011, Sarcoma, V2011, P282745, DOI 10.1155/2011/282745; Maruyama Z, 2007, DEV DYNAM, V236, P1876, DOI 10.1002/dvdy.21187; Maynadier M, 2008, FASEB J, V22, P671, DOI 10.1096/fj.07-9322com; Mendoza-Villanueva D, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3048; Mendoza-Villanueva D, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-171; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Miething C, 2007, P NATL ACAD SCI USA, V104, P4594, DOI 10.1073/pnas.0604716104; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Morrissey C, 2010, NEOPLASIA, V12, P192, DOI 10.1593/neo.91836; Mueller W, 2007, ONCOGENE, V26, P583, DOI 10.1038/sj.onc.1209805; Mundlos S, 1999, J MED GENET, V36, P177; Network TCGA, NATURE IN PRESS; Nevadunsky NS, 2009, GYNECOL ONCOL, V112, P325, DOI 10.1016/j.ygyno.2008.09.006; Niini T, 2000, HAEMATOLOGICA, V85, P362; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1993, BLOOD, V81, P2728; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; NUCIFORA G, 1995, BLOOD, V86, P1; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Onodera Y, 2010, CANCER SCI, V101, P2670, DOI 10.1111/j.1349-7006.2010.01742.x; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Oshimo Y, 2004, PATHOBIOLOGY, V71, P137, DOI 10.1159/000076468; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Patani N, 2008, ANTICANCER RES, V28, P4105; Pencovich N, 2011, BLOOD, V117, pE1, DOI 10.1182/blood-2010-07-295113; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Planaguma J, 2004, CANCER RES, V64, P8846, DOI 10.1158/0008-5472.CAN-04-2066; Planaguma J, 2011, HUM PATHOL, V42, P57, DOI 10.1016/j.humpath.2010.01.025; Platet N, 2000, MOL ENDOCRINOL, V14, P999, DOI 10.1210/me.14.7.999; Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581-8591.2005; Pratap J, 2003, CANCER RES, V63, P5357; Pratap J, 2008, CANCER RES, V68, P7795, DOI 10.1158/0008-5472.CAN-08-1078; Pratap J, 2011, BONE, V48, P30, DOI 10.1016/j.bone.2010.05.035; Pratap J, 2009, CANCER RES, V69, P6807, DOI 10.1158/0008-5472.CAN-09-1471; Radtke I, 2009, P NATL ACAD SCI USA, V106, P12944, DOI 10.1073/pnas.0903142106; Rahrmann EP, 2009, CANCER RES, V69, P4388, DOI 10.1158/0008-5472.CAN-08-3901; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Richiardi L, 2009, J CLIN ONCOL, V27, P3161, DOI 10.1200/JCO.2008.18.2485; Robinson HM, 2003, LEUKEMIA, V17, P2249, DOI 10.1038/sj.leu.2403140; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Roulston D, 1998, BLOOD, V92, P2879, DOI 10.1182/blood.V92.8.2879.420k22_2879_2885; ROWLEY JD, 1973, ANN GENET-PARIS, V16, P109; Sakakura C, 2005, INT J CANCER, V113, P221, DOI 10.1002/ijc.20551; Salto-Tellez M, 2006, ONCOGENE, V25, P7646, DOI 10.1038/sj.onc.1209739; Sase T, 2012, INT J CANCER, V131, P2284, DOI 10.1002/ijc.27525; Sato K, 2006, ONCOL REP, V15, P129; Shiraha H, 2011, J CELL BIOCHEM, V112, P745, DOI 10.1002/jcb.22973; Shore P, 2005, J CELL BIOCHEM, V96, P484, DOI 10.1002/jcb.20557; Silva FPG, 2003, ONCOGENE, V22, P538, DOI 10.1038/sj.onc.1206141; Slattery ML, 2011, CARCINOGENESIS, V32, P318, DOI 10.1093/carcin/bgq245; Smith N, 2005, J CELL PHYSIOL, V203, P133, DOI 10.1002/jcp.20210; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Soong R, 2009, BRIT J CANCER, V100, P676, DOI 10.1038/sj.bjc.6604899; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Spender LC, 2005, ONCOGENE, V24, P1873, DOI 10.1038/sj.onc.1208404; Steensma DP, 2005, EUR J HAEMATOL, V74, P47, DOI 10.1111/j.1600-0609.2004.00363.x; Stender JD, 2010, MOL CELL BIOL, V30, P3943, DOI 10.1128/MCB.00118-10; Stewart M, 2002, J VIROL, V76, P4364, DOI 10.1128/JVI.76.9.4364-4369.2002; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Subramaniam MM, 2009, AM J GASTROENTEROL, V104, P426, DOI 10.1038/ajg.2008.141; Subramaniam MM, 2009, BREAST CANCER RES TR, V113, P113, DOI 10.1007/s10549-008-9917-4; Suzuki M, 2005, BRIT J CANCER, V93, P1029, DOI 10.1038/sj.bjc.6602837; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tan SH, 2007, ONCOL REP, V18, P1225; Tang JL, 2009, BLOOD, V114, P5352, DOI 10.1182/blood-2009-05-223784; Thalmann GN, 1999, CLIN CANCER RES, V5, P2271; Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187; Tsoli E, 2007, J CLIN PATHOL, V60, P261, DOI 10.1136/jcp.2006.037887; Tsunematsu T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005892; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; van der Deen M, 2012, J BIOL CHEM, V287, P4503, DOI 10.1074/jbc.M111.287771; Vasko V, 2007, P NATL ACAD SCI USA, V104, P2803, DOI 10.1073/pnas.0610733104; Wada M, 2004, ONCOGENE, V23, P2401, DOI 10.1038/sj.onc.1207395; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang LX, 2011, P NATL ACAD SCI USA, V108, pE803, DOI 10.1073/pnas.1103423108; Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055; Wolff EM, 2008, CANCER RES, V68, P6208, DOI 10.1158/0008-5472.CAN-07-6616; Wotton S, 2008, ONCOGENE, V27, P5856, DOI 10.1038/onc.2008.195; Wu C, 2011, NAT GENET, V43, P679, DOI 10.1038/ng.849; Yan C, 2012, J SURG ONCOL, V105, P425, DOI 10.1002/jso.22087; Yang SX, 2006, CANCER RES, V66, P4285, DOI 10.1158/0008-5472.CAN-05-4456; Ye Y, 2010, ONCOGENE, V29, P1451, DOI 10.1038/onc.2009.433; Yeon S, 2012, MODERN PATHOL, V25, P185, DOI 10.1038/modpathol.2011.160; Young DW, 2007, NATURE, V445, P442, DOI 10.1038/nature05473; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	192	94	98	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2121	2130		10.1038/onc.2012.328	http://dx.doi.org/10.1038/onc.2012.328			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	23045283	Green Accepted			2022-12-17	WOS:000318062800001
J	Mamo, A; Cavallone, L; Tuzmen, S; Chabot, C; Ferrario, C; Hassan, S; Edgren, H; Kallioniemi, O; Aleynikova, O; Przybytkowski, E; Malcolm, K; Mousses, S; Tonin, PN; Basik, M				Mamo, A.; Cavallone, L.; Tuzmen, S.; Chabot, C.; Ferrario, C.; Hassan, S.; Edgren, H.; Kallioniemi, O.; Aleynikova, O.; Przybytkowski, E.; Malcolm, K.; Mousses, S.; Tonin, P. N.; Basik, M.			An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer	ONCOGENE			English	Article						ARID1A; nonsense-mediated mRNA decay; tumor-suppressor gene; breast cancer	CHROMATIN REMODELING COMPLEXES; SWI/SNF-RELATED COMPLEXES; DNA-BINDING PROPERTIES; CELL-CYCLE ARREST; TRANSCRIPTIONAL ACTIVATORS; SACCHAROMYCES-CEREVISIAE; FAMILY PROTEINS; IN-VIVO; MUTATIONS; EXPRESSION	Tumor-suppressor genes (TSGs) have been classically defined as genes whose loss of function in tumor cells contributes to the formation and/or maintenance of the tumor phenotype. TSGs containing nonsense mutations may not be expressed because of nonsense-mediated RNA decay (NMD). We combined inhibition of the NMD process, which clears transcripts that contain nonsense mutations, with the application of high-density single-nucleotide polymorphism arrays analysis to discriminate allelic content in order to identify candidate TSGs in five breast cancer cell lines. We identified ARID1A as a target of NMD in the T47D breast cancer cell line, likely as a consequence of a mutation in exon-9, which introduces a premature stop codon at position Q944. ARID1A encodes a human homolog of yeast SWI1, which is an integral member of the hSWI/SNF complex, an ATP-dependent, chromatin-remodeling, multiple-subunit enzyme. Although we did not find any somatic mutations in 11 breast tumors, which show DNA copy-number loss at the 1p36 locus adjacent to ARID1A, we show that low ARID1A RNA or nuclear protein expression is associated with more aggressive breast cancer phenotypes, such as high tumor grade, in two independent cohorts of over 200 human breast cancer cases each. We also found that low ARID1A nuclear expression becomes more prevalent during the later stages of breast tumor progression. Finally, we found that ARID1A re-expression in the T47D cell line results in significant inhibition of colony formation in soft agar. These results suggest that ARID1A may be a candidate TSG in breast cancer. Oncogene (2012) 31, 2090-2100; doi: 10.1038/onc.2011.386; published online 5 September 2011	[Mamo, A.; Chabot, C.; Ferrario, C.; Hassan, S.; Przybytkowski, E.; Malcolm, K.; Basik, M.] McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst, Dept Oncol, Montreal, PQ H3T 1E2, Canada; [Cavallone, L.; Tonin, P. N.] McGill Univ, Dept Human Genet, Montreal, PQ H3T 1E2, Canada; [Tuzmen, S.; Mousses, S.] Translat Genom Res Inst, Pharmaceut Genom Div, Scottsdale, AZ USA; [Edgren, H.; Kallioniemi, O.] Univ Helsinki, Inst Mol Med FIMM, Helsinki, Finland; [Edgren, H.; Kallioniemi, O.] VTT Tech Res Ctr Finland, Turku, Finland; [Edgren, H.; Kallioniemi, O.] Univ Turku, Turku, Finland; [Aleynikova, O.] McGill Univ, Jewish Gen Hosp, Dept Pathol, Montreal, PQ H3T 1E2, Canada; [Tonin, P. N.] McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; [Tonin, P. N.] McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; Translational Genomics Research Institute; University of Helsinki; VTT Technical Research Center Finland; University of Turku; McGill University; McGill University; McGill University	Basik, M (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst, Dept Oncol, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	markbasik@gmail.com	Kallioniemi, Olli P/H-5111-2011; Tuzmen, Sukru/I-5663-2013; Tüzmen, Şükrü/AAH-9916-2021	Kallioniemi, Olli P/0000-0002-3231-0332; Tuzmen, Sukru/0000-0003-4822-396X; Tüzmen, Şükrü/0000-0003-4822-396X; Hassan, Saima/0000-0003-0232-2807	Quebec Breast Cancer Foundation; McGill Integrated Cancer Research Training Program; Fonds de Recherche en Sante du Quebec (FRSQ) through the Reseau de Cancer-Axe cancer du sein et de l'ovaire	Quebec Breast Cancer Foundation; McGill Integrated Cancer Research Training Program; Fonds de Recherche en Sante du Quebec (FRSQ) through the Reseau de Cancer-Axe cancer du sein et de l'ovaire	This study was supported by a grant from the Quebec Breast Cancer Foundation to Mark Basik and Patricia N Tonin. EP is supported by the McGill Integrated Cancer Research Training Program. The tumor bank was supported by the Fonds de Recherche en Sante du Quebec (FRSQ) through the Reseau de Cancer-Axe cancer du sein et de l'ovaire to MB.	Adler HT, 1999, MOL CELL BIOL, V19, P7050; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129; Biegel Jaclyn A, 2004, Curr Oncol Rep, V6, P445, DOI 10.1007/s11912-004-0075-5; Campeau PM, 2008, HUM GENET, V124, P31, DOI 10.1007/s00439-008-0529-1; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; Dallas PB, 2000, MOL CELL BIOL, V20, P3137, DOI 10.1128/MCB.20.9.3137-3146.2000; Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007; Forbes SA, 2010, NUCLEIC ACIDS RES, V38, pD652, DOI 10.1093/nar/gkp995; Grand F, 1999, CANCER RES, V59, P3870; Hassan S, 2008, CLIN CANCER RES, V14, P446, DOI 10.1158/1078-0432.CCR-07-1189; Hassan S, 2009, AM J PATHOL, V175, P66, DOI 10.2353/ajpath.2009.080948; HIRSCHHORN JN, 1995, MOL CELL BIOL, V15, P1999; Hosein AN, 2010, CANCER RES, V70, P5770, DOI 10.1158/0008-5472.CAN-10-0673; Huang JM, 2007, GENE CHROMOSOME CANC, V46, P745, DOI 10.1002/gcc.20459; Huusko P, 2004, NAT GENET, V36, P979, DOI 10.1038/ng1408; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; Li XS, 2010, MOL CELL BIOL, V30, P1673, DOI 10.1128/MCB.00540-09; Medina PP, 2008, EPIGENETICS-US, V3, P64, DOI 10.4161/epi.3.2.6153; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Nagl NG, 2006, CANCER RES, V66, P1289, DOI 10.1158/0008-5472.CAN-05-3427; Nagl NG, 2005, CANCER RES, V65, P9236, DOI 10.1158/0008-5472.CAN-05-1225; Nagl NG, 2007, EMBO J, V26, P752, DOI 10.1038/sj.emboj.7601541; Noensie EN, 2001, NAT BIOTECHNOL, V19, P434, DOI 10.1038/88099; Orlando FA, 2009, ANN SURG ONCOL, V16, P2270, DOI 10.1245/s10434-009-0500-y; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Patsialou A, 2005, NUCLEIC ACIDS RES, V33, P66, DOI 10.1093/nar/gki145; Presneau N, 2003, CURR MOL MED, V3, P605, DOI 10.2174/1566524033479500; Roberts CWM, 2009, CANCER BIOL THER, V8, P412, DOI 10.4161/cbt.8.5.8019; Rodriguez-Nieto S, 2009, CARCINOGENESIS, V30, P547, DOI 10.1093/carcin/bgp035; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Staden R, 2000, Methods Mol Biol, V132, P115; Strumane K, 2004, HANDB EXP PHARM, V165, P69, DOI 10.1007/978-3-540-68170-0_4; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; Takeuchi T, 1997, GENE, V204, P71, DOI 10.1016/S0378-1119(97)00525-8; Takeuchi T, 1998, GENE, V213, P189, DOI 10.1016/S0378-1119(98)00194-2; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Van Rechem C, 2009, BIOCHEM BIOPH RES CO, V385, P586, DOI 10.1016/j.bbrc.2009.05.115; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang XM, 2004, BIOCHEM J, V383, P319, DOI 10.1042/BJ20040524; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wilsker D, 2004, NUCLEIC ACIDS RES, V32, P1345, DOI 10.1093/nar/gkh277; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Yuge M, 2000, CANCER GENET CYTOGEN, V122, P37, DOI 10.1016/S0165-4608(00)00274-0; Zhang B, 2007, ONCOGENE, V26, P7153, DOI 10.1038/sj.onc.1210509	49	94	99	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	16					2090	2100		10.1038/onc.2011.386	http://dx.doi.org/10.1038/onc.2011.386			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21892209				2022-12-17	WOS:000303008600009
J	Zheng, YS; Zhang, H; Zhang, XJ; Feng, DD; Luo, XQ; Zeng, CW; Lin, KY; Zhou, H; Qu, LH; Zhang, P; Chen, YQ				Zheng, Y-S; Zhang, H.; Zhang, X-J; Feng, D-D; Luo, X-Q; Zeng, C-W; Lin, K-Y; Zhou, H.; Qu, L-H; Zhang, P.; Chen, Y-Q			MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia	ONCOGENE			English	Article						microRNA; acute myeloblastic leukemia; granulocyte/monocyte differentiation; RBSP3-pRB-E2F1 pathway	RETINOBLASTOMA PROTEIN PATHWAY; FREQUENT ALTERATIONS; BINDING PROTEIN; CANCER; MICRORNAS; CYCLE; E2F1; KARYOTYPE; APOPTOSIS; PATTERNS	Acute myeloblastic leukemia (AML) is characterized by the accumulation of abnormal myeloblasts (mainly granulocyte or monocyte precursors) in the bone marrow and blood. Though great progress has been made for improvement in clinical treatment during the past decades, only minority with AML achieve long-term survival. Therefore, further understanding mechanisms of leukemogenesis and exploring novel therapeutic strategies are still crucial for improving disease outcome. MicroRNA-100 (miR-100), a small non-coding RNA molecule, has been reported as a frequent event aberrantly expressed in patients with AML; however, the molecular basis for this phenotype and the statuses of its downstream targets have not yet been elucidated. In the present study, we found that the expression level of miR-100 in vivo was related to the stage of the maturation block underlying the subtypes of myeloid leukemia. In vitro experiments further demonstrated that miR-100 was required to promote the cell proliferation of promyelocytic blasts and arrest them differentiated to granulocyte/monocyte lineages. Significantly, we identified RBSP3, a phosphatase-like tumor suppressor, as a bona fide target of miR-100 and validated that RBSP3 was involved in cell differentiation and survival in AML. Moreover, we revealed a new pathway that miR-100 regulates G1/S transition and S-phase entry and blocks the terminal differentiation by targeting RBSP3, which partly in turn modulates the cell cycle effectors pRB/E2F1 in AML. These events promoted cell proliferation and blocked granulocyte/monocyte differentiation. Our data highlight an important role of miR-100 in the molecular etiology of AML, and implicate the potential application of miR-100 in cancer therapy. Oncogene (2012) 31, 80-92; doi: 10.1038/onc.2011.208; published online 6 June 2011	[Chen, Y-Q] Sun Yat Sen Univ, Minist Educ, Biotechnol Res Ctr, Key Lab Gene Engn,State Key Lab Biocontrol, Guangzhou 510275, Guangdong, Peoples R China; [Zheng, Y-S] Hainan Univ, Dept Biotechnol, Hainan, Peoples R China; [Luo, X-Q] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China; [Zhang, P.] Third Mil Med Univ, Southwest Hosp, Inst Pathol, Chongqing, Peoples R China; [Zhang, P.] Third Mil Med Univ, Southwest Hosp, SW Canc Ctr, Chongqing, Peoples R China	Sun Yat Sen University; Hainan University; Sun Yat Sen University; Army Medical University; Army Medical University	Chen, YQ (corresponding author), Sun Yat Sen Univ, Minist Educ, Biotechnol Res Ctr, Key Lab Gene Engn,State Key Lab Biocontrol, Guangzhou 510275, Guangdong, Peoples R China.	lsscyq@mail.sysu.edu.cn	Zhang, Hua/AAF-3999-2020; Zhang, Hua/AAA-2164-2022; Lin, Kangyu/I-8050-2016; Zeng, Chengwu/AAA-8920-2019	Zhang, Hua/0000-0001-9731-2737; Lin, Kangyu/0000-0003-0140-2557; Zeng, Chengwu/0000-0002-1333-3918; Zhang, Xingju/0000-0003-0717-2510; Zhou, Hui/0000-0001-9157-3792	National Science and Technology Department [2011CBA01105, 2011CB811301, 2009ZX09103-641]; National Natural Science Foundation of China [30872784, 81070440]; Fundamental Research Funds for the Central Universities	National Science and Technology Department; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	We thank the following investigators and hospitals that provided samples for the analysis: Dr Hai-Xia Guo at the Second Affiliated Hospital of Sun Yat-sen University; Li-Bing Huang at the First Affiliated Hospital of Sun Yat-sen University; This work was supported by National Science and Technology Department (2011CBA01105, 2011CB811301 and 2009ZX09103-641) and the funds from National Natural Science Foundation of China (No 30872784 and 81070440), as well as supported by 'the Fundamental Research Funds for the Central Universities'. We thank Nature Publishing Group Language Editing, LLC for editing the text of the manuscript.	Anedchenko EA, 2008, MOL BIOL+, V42, P859, DOI 10.1134/S0026893308060058; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bousquet M, 2008, J EXP MED, V205, P2499, DOI 10.1084/jem.20080285; Careccia S, 2009, ONCOGENE, V28, P4034, DOI 10.1038/onc.2009.255; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; Dixon-McIver A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002141; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Estey E, 2007, J CLIN ONCOL, V25, P1908, DOI 10.1200/JCO.2006.10.2731; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Farag SS, 2005, J CLIN ONCOL, V23, P482, DOI 10.1200/JCO.2005.06.090; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Fontana L, 2007, NAT CELL BIOL, V9, P775, DOI 10.1038/ncb1613; Garzon R, 2009, BLOOD, V114, P5331, DOI 10.1182/blood-2009-03-211938; Ghosh A, 2010, CANCER SCI, V101, P1511, DOI 10.1111/j.1349-7006.2010.01551.x; Guo XB, 2010, BIOCHEM BIOPH RES CO, V398, P1, DOI 10.1016/j.bbrc.2010.05.082; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Han YC, 2010, J EXP MED, V207, P475, DOI 10.1084/jem.20090831; Ji Y, 2004, CANCER RES, V64, P370, DOI 10.1158/0008-5472.CAN-03-3029; Jiang JM, 2005, NUCLEIC ACIDS RES, V33, P5394, DOI 10.1093/nar/gki863; Jongen-Lavrencic M, 2008, BLOOD, V111, P5078, DOI 10.1182/blood-2008-01-133355; Kashuba VI, 2004, P NATL ACAD SCI USA, V101, P4906, DOI 10.1073/pnas.0401238101; Kashuba VI, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005231; Lee KH, 2009, ONCOGENE, V28, P3360, DOI 10.1038/onc.2009.192; Leite KR, 2009, UROL ONCOL, V29, P265; Li ZJ, 2008, P NATL ACAD SCI USA, V105, P15535, DOI 10.1073/pnas.0808266105; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lin RJ, 2010, MOL CARCINOGEN, V49, P719, DOI 10.1002/mc.20647; Liu SJ, 2010, CANCER CELL, V17, P333, DOI 10.1016/j.ccr.2010.03.008; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Nagaraja AK, 2010, MOL ENDOCRINOL, V24, P447, DOI 10.1210/me.2009-0295; Pigazzi M, 2009, CANCER RES, V69, P2471, DOI 10.1158/0008-5472.CAN-08-3404; Pulikkan JA, 2010, BLOOD, V115, P1768, DOI 10.1182/blood-2009-08-240101; Rosa A, 2007, P NATL ACAD SCI USA, V104, P19849, DOI 10.1073/pnas.0706963104; Senchenko VN, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-75; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shi W, 2010, INT J CANCER, V126, P2036, DOI 10.1002/ijc.24880; Sinha S, 2008, CANCER SCI, V99, P1984, DOI 10.1111/j.1349-7006.2008.00952.x; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; Strom DK, 1998, CELL GROWTH DIFFER, V9, P59; Varnholt H, 2008, HEPATOLOGY, V47, P1223, DOI 10.1002/hep.22158; Wang JR, 2009, EUR J CELL BIOL, V88, P103, DOI 10.1016/j.ejcb.2008.05.003; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhang H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007826	48	94	107	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	1					80	92		10.1038/onc.2011.208	http://dx.doi.org/10.1038/onc.2011.208			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21643017	Green Published, hybrid			2022-12-17	WOS:000299176200008
J	Fujii, S; Tokita, K; Wada, N; Ito, K; Yamauchi, C; Ito, Y; Ochiai, A				Fujii, S.; Tokita, K.; Wada, N.; Ito, K.; Yamauchi, C.; Ito, Y.; Ochiai, A.			MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes	ONCOGENE			English	Article						EZH2/MEK-ERK pathway; histone; triple negative; breast cancer; ERBB2-overexpressing breast cancer	H3 LYSINE-27 METHYLATION; GENE-EXPRESSION; GASTRIC-CANCER; POLYCOMB; CELLS; CARCINOMAS; HER-2/NEU; PHENOTYPE; PROSTATE; ENHANCER	EZH2 overexpression occurs in various malignancies and is associated with a poor outcome. We have so far demonstrated that EZH2 downregulates the important genes such as E-cadherin and RUNX3 by increasing histone H3K27 trimethylation. However, the mechanism of EZH2 overexpression in various cancer cells remains unclear. In this study we carried out a promoter analysis of the EZH2 gene and investigated whether a survival signal that is upregulated in cancer cells is related to overexpression at the transcription level. We also explored the clinical relevance of the signaling pathway that leads to EZH2 overexpression in breast cancer and demonstrated that MEK-ERK1/2-Elk-1 pathway leads to EZH2 overexpression. The triple-negative and ERBB2-overexpressing subtypes of breast cancer are known to contain more rapidly proliferating breast cancer cells. The signaling pathway connected to EZH2 overexpression was associated with both aggressive subtypes of breast cancer. We show the significance that overexpression of histone modifier protein EZH2 in cancer cells and our study could pave the way for EZH2 inhibition to become an efficient treatment for more aggressive breast cancers. Oncogene (2011) 30, 4118-4128; doi:10.1038/onc.2011.118; published online 18 April 2011	[Fujii, S.; Tokita, K.; Yamauchi, C.; Ochiai, A.] Natl Canc Ctr Kashiwa, Div Pathol, Res Ctr Innovat Oncol, Chiba 2778577, Japan; [Wada, N.] Natl Canc Ctr Hosp E, Breast Surg Div, Chiba, Japan; [Ito, K.] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 852, Japan; [Ito, Y.] Canc Sci Inst Singapore, Proteos, Singapore	National Cancer Center - Japan; National Cancer Center - Japan; Nagasaki University	Ochiai, A (corresponding author), Natl Canc Ctr Kashiwa, Div Pathol, Res Ctr Innovat Oncol, 6-5-1 Kashiwanoha, Chiba 2778577, Japan.	aochiai@east.ncc.go.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan [21590453]; Grants-in-Aid for Scientific Research [21590453] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We wish to acknowledge the assistance of Ms Hiroko Hashimoto for cell culture support and the assistance of Mr Shinya Yanagi for making paraffin-embedded thin sections for immunohistochemistry. The research described in this report has been funded by a grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan (21590453), to SF. Individual contributions of each author; Study concept and design; SF, AO, Acquisition of data; SF, KT, Analysis and interpretation of data; SF, KT, NW, Drafting the manuscript; SF, Critical revision of the manuscript for important intellectual content; SF, KI, YI, AO. Statistical analysis; SF, KT, NW Obtained funding; SF, Material support; NW, KI, YI, CY, Study supervision; SF.	Arai A, 2002, ONCOGENE, V21, P2641, DOI 10.1038/sj.onc.1205346; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cleator S, 2007, LANCET ONCOL, V8, P235, DOI 10.1016/S1470-2045(07)70074-8; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Foulkes WD, 2004, CANCER RES, V64, P830, DOI 10.1158/0008-5472.CAN-03-2970; Fujii S, 2003, HUM MOL GENET, V12, P1791, DOI 10.1093/hmg/ddg204; Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200; Fujii S, 2008, CANCER SCI, V99, P738, DOI 10.1111/j.1349-7006.2008.00743.x; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Hollestelle A, 2010, BREAST CANCER RES TR, V121, P53, DOI 10.1007/s10549-009-0460-8; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Konecny G, 2003, J NATL CANCER I, V95, P142, DOI 10.1093/jnci/95.2.142; Korsching E, 2008, J CLIN PATHOL, V61, P553, DOI 10.1136/jcp.2008.055475; Morris DP, 2005, J BIOL CHEM, V280, P31368, DOI 10.1074/jbc.M501546200; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Puppe J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2354; Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395	28	94	99	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	39					4118	4128		10.1038/onc.2011.118	http://dx.doi.org/10.1038/onc.2011.118			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	826ME	21499305				2022-12-17	WOS:000295357500007
J	Patel, JB; Appaiah, HN; Burnett, RM; Bhat-Nakshatri, P; Wang, G; Mehta, R; Badve, S; Thomson, MJ; Hammond, S; Steeg, P; Liu, Y; Nakshatri, H				Patel, J. B.; Appaiah, H. N.; Burnett, R. M.; Bhat-Nakshatri, P.; Wang, G.; Mehta, R.; Badve, S.; Thomson, M. J.; Hammond, S.; Steeg, P.; Liu, Y.; Nakshatri, H.			Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22	ONCOGENE			English	Article						breast cancer; metastasis; microRNA; miR-22; let-7	GENE-EXPRESSION; SIGNATURE; REPRESSION; MIGRATION; INSIGHTS; ESCAPE; LEADS	Metastasis in breast cancer carries a disproportionately worse prognosis than localized primary disease. To identify microRNAs (miRNA) involved in metastasis, the expression of 254 miRNAs was measured across the following cell lines using microarray analysis: MDA-MB-231 breast cancer cells, cells that grew as a tumor in the mammary fat pad of nude mice (TMD-231), metastatic disease to the lungs (LMD-231), bone (BMD-231) and adrenal gland (ADMD-231). A brain-seeking variant of this cell line (231-BR) was used additionally in validation studies. Twenty miRNAs were upregulated and seven were downregulated in metastatic cancer cells compared with TMD-231 cells. The expression of the tumor suppressor miRNAs let-7 and miR-22 was consistently downregulated in metastatic cancer cells. These metastatic cells expressed higher levels of putative/proven miR-22 target oncogenes ERBB3, CDC25C and EVI-1. Introduction of miR-22 into cancer cells reduced the levels of ERBB3 and EVI-1 as well as phospho-AKT, an EVI-1 downstream target. The miR-22 primary transcript is located in the 50-untranslated region of an open reading frame C17orf91, and the promoter/enhancer of C17orf91 drives miR-22 expression. We observed elevated C17orf91 expression in non-basal subtype compared with basal subtype breast cancers. In contrast, elevated expression of EVI-1 was observed in basal subtype and was associated with poor outcome in estrogen receptor-negative breast cancer patients. These results suggest that metastatic cancer cells increase specific oncogenic signaling proteins through downregulation of miRNAs. Identifying such metastasis-specific oncogenic pathways may help to manipulate tumor behavior and aid in the design of more effective targeted therapies. Oncogene (2011) 30, 1290-1301; doi:10.1038/onc.2010.510; published online 8 November 2010	[Patel, J. B.; Appaiah, H. N.; Bhat-Nakshatri, P.; Nakshatri, H.] Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA; [Wang, G.; Liu, Y.] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; [Mehta, R.; Badve, S.] Indiana Univ, Sch Med, Dept Pathol, Indianapolis, IN 46202 USA; [Thomson, M. J.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA; [Hammond, S.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; [Steeg, P.] NCI, Mol Pharmacol Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Nakshatri, H.] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Vanderbilt University; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Indiana University System; Indiana University-Purdue University Indianapolis	Nakshatri, H (corresponding author), Indiana Univ, Sch Med, Dept Surg, 980 W Walnut St C218E, Indianapolis, IN 46202 USA.	hnakshat@iupui.edu	Wang, Guohua/GLR-7939-2022; Xie, Huangming/B-2260-2012; Mehta, Rutika/S-2052-2016; Nidumanda, HITESH/B-5744-2015	Mehta, Rutika/0000-0003-4277-0153; Nakshatri, Harikrishna/0000-0001-8876-0052; Badve, Sunil/0000-0001-8861-9980	Indiana University Simon Cancer Center; Komen for Cure [BCTR0601111]; National Institutes of Health [T32 DK07519, T32 CA111198]; NATIONAL CANCER INSTITUTE [T32CA111198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007519] Funding Source: NIH RePORTER	Indiana University Simon Cancer Center; Komen for Cure(Susan G. Komen Breast Cancer Foundation); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work is supported by Indiana University Simon Cancer Center Pilot grant and by Komen for Cure grant BCTR0601111 to HN. JBP and RMB are supported by National Institutes of Health Training Grants T32 DK07519 and T32 CA111198, respectively. HN is Marian J Morrison Professor of Breast Cancer Research.	Bhat-Nakshatri P, 2004, BRIT J CANCER, V90, P853, DOI 10.1038/sj.bjc.6601541; Bhat-Nakshatri P, 2009, NUCLEIC ACIDS RES, V37, P4850, DOI 10.1093/nar/gkp500; Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214; Campbell MR, 2010, CLIN CANCER RES, V16, P1373, DOI 10.1158/1078-0432.CCR-09-1218; Castellano L, 2009, P NATL ACAD SCI USA, V106, P15732, DOI 10.1073/pnas.0906947106; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Goyama S, 2010, LEUKEMIA, V24, P81, DOI 10.1038/leu.2009.202; Gril B, 2008, JNCI-J NATL CANCER I, V100, P1092, DOI 10.1093/jnci/djn216; Gupta GP, 2005, COLD SH Q B, V70, P149, DOI 10.1101/sqb.2005.70.018; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Hoser M, 2007, J NEUROSCI, V27, P5495, DOI 10.1523/JNEUROSCI.1384-07.2007; Hurst DR, 2009, CANCER RES, V69, P7495, DOI 10.1158/0008-5472.CAN-09-2111; Ibarra I, 2007, GENE DEV, V21, P3238, DOI 10.1101/gad.1616307; Iliopoulos D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003740; Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Koshiol J, 2010, CANCER EPIDEM BIOMAR, V19, P907, DOI 10.1158/1055-9965.EPI-10-0071; Kumano K, 2010, J CELL PHYSIOL, V222, P282, DOI 10.1002/jcp.21953; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liu Y, 2006, ONCOGENE, V25, P3565, DOI 10.1038/sj.onc.1209403; Maillot G, 2009, CANCER RES, V69, P8332, DOI 10.1158/0008-5472.CAN-09-2206; Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Nagaraja AK, 2010, MOL ENDOCRINOL, V24, P447, DOI 10.1210/me.2009-0295; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; O'Day E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2484; Pandey DP, 2009, MOL CELL BIOL, V29, P3783, DOI 10.1128/MCB.01875-08; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Shimabe M, 2009, ONCOGENE, V28, P4364, DOI 10.1038/onc.2009.288; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Sun M, 2008, MOL CANCER THER, V7, P464, DOI 10.1158/1535-7163.MCT-07-2272; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wieser R, 2007, GENE, V396, P346, DOI 10.1016/j.gene.2007.04.012; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526	48	94	101	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	11					1290	1301		10.1038/onc.2010.510	http://dx.doi.org/10.1038/onc.2010.510			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21057539				2022-12-17	WOS:000288492100004
J	Tabaries, S; Dong, Z; Annis, MG; Omeroglu, A; Pepin, F; Ouellet, V; Russo, C; Hassanain, M; Metrakos, P; Diaz, Z; Basik, M; Bertos, N; Park, M; Guettier, C; Adam, R; Hallett, M; Siegel, PM				Tabaries, S.; Dong, Z.; Annis, M. G.; Omeroglu, A.; Pepin, F.; Ouellet, V.; Russo, C.; Hassanain, M.; Metrakos, P.; Diaz, Z.; Basik, M.; Bertos, N.; Park, M.; Guettier, C.; Adam, R.; Hallett, M.; Siegel, P. M.			Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes	ONCOGENE			English	Article						breast cancer; liver metastasis; claudins; extracellular matrix; adhesion; integrins	SINUSOIDAL ENDOTHELIAL-CELLS; TO-MESENCHYMAL TRANSITION; PROGNOSTIC-FACTORS; COLORECTAL-CANCER; CARCINOMA CELLS; GENE-EXPRESSION; POOR-PROGNOSIS; 1ST RECURRENCE; ADHESION; TETRASPANINS	The liver represents the third most frequent site of metastasis in patients with breast cancer. We performed in vivo selection using 4T1 breast cancer cells to identify genes associated with the liver metastatic phenotype. Coincident with the loss of numerous tight-junctional proteins, we observe claudin-2 overexpression, specifically in liver-aggressive breast cancer cells. We further demonstrate that claudin-2 is both necessary and sufficient for the ability of 4T1 breast cancer cells to colonize and grow in the liver. The liver-aggressive breast cancer cells display a claudin-2-mediated increase in their ability to adhere to extracellular matrix (ECM) components, such as fibronectin and type IV collagen. Claudin-2 facilitates these cell/matrix interactions by increasing the cell surface expression of alpha(2)beta(1)- and alpha(5)beta(1)-integrin complexes in breast cancer cells. Indeed, claudin-2-mediated adhesion to fibronectin and type IV collagen can be blocked with neutralizing antibodies that target alpha(5)beta(1) and alpha(2)beta(1) complexes, respectively. Immunohistochemical analyses reveal that claudin-2, although weakly expressed in primary human breast cancers, is readily detected in all liver metastasis samples examined to date. Together, these results uncover novel roles for claudin-2 in promoting breast cancer adhesion to the ECM and define its importance during breast cancer metastasis to the liver. Oncogene (2011) 30, 1318-1328; doi:10.1038/onc.2010.518; published online 15 November 2010	[Tabaries, S.; Dong, Z.; Annis, M. G.; Pepin, F.; Ouellet, V.; Russo, C.; Bertos, N.; Park, M.; Hallett, M.; Siegel, P. M.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [Tabaries, S.; Dong, Z.; Annis, M. G.; Ouellet, V.; Russo, C.; Bertos, N.; Park, M.; Siegel, P. M.] McGill Univ, Dept Med, Montreal, PQ H3A 1A3, Canada; [Omeroglu, A.; Park, M.; Siegel, P. M.] McGill Univ, Dept Pathol, Ctr Hlth, Montreal, PQ H3A 1A3, Canada; [Pepin, F.; Hallett, M.] McGill Univ, Dept Biochem, Montreal, PQ H3A 1A3, Canada; [Pepin, F.] McGill Univ, McGill Ctr Bioinformat, Montreal, PQ H3A 1A3, Canada; [Hassanain, M.; Metrakos, P.] McGill Univ, Dept Hepatopancreatobiliary Surg, Ctr Hlth, Montreal, PQ H3A 1A3, Canada; [Hassanain, M.; Metrakos, P.] King Saud Univ, Coll Med, Dept Surg, Riyadh 11461, Saudi Arabia; [Diaz, Z.; Basik, M.] Sir Mortimer B Davis Jewish Hosp, Segal Canc Ctr, Montreal, PQ, Canada; [Guettier, C.; Adam, R.] Hop Paul Brousse, AP HP, Unite Chronotherapie,Dept Cancerol, Ctr Hepatobiliaire,Serv Anat Pathol, Villejuif, France; [Guettier, C.; Adam, R.] Hop Paul Brousse, AP HP, Serv Biochim, Villejuif, France	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University; King Saud University; McGill University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP	Tabaries, S (corresponding author), McGill Univ, Goodman Canc Res Ctr, 1160 Pine Ave W,Room 513, Montreal, PQ H3A 1A3, Canada.	peter.siegel@mcgill.ca	Hassanain, Mazen/C-7256-2011; metrakos, peter/D-3726-2013	Hassanain, Mazen/0000-0002-2441-5142; Hallett, Michael/0000-0001-6738-6786; Diaz, Zuanel/0000-0002-4866-9614; Annis, Matthew/0000-0002-8776-004X	Terry Fox Foundation [020002]; Banque de tissu et de donnees of the Reseau de la recherche sur le cancer (RR Cancer) of the Fonds de recherche en sante du Quebec (FRSQ); McGill University Department of Medicine; US Department of Defense; Fonds de la Recherche en Sante du Quebec (FRSQ); Canadian Cancer Society	Terry Fox Foundation; Banque de tissu et de donnees of the Reseau de la recherche sur le cancer (RR Cancer) of the Fonds de recherche en sante du Quebec (FRSQ)(Fonds de la Recherche en Sante du Quebec); McGill University Department of Medicine; US Department of Defense(United States Department of Defense); Fonds de la Recherche en Sante du Quebec (FRSQ)(Fonds de la Recherche en Sante du Quebec); Canadian Cancer Society(Canadian Cancer Society (CCS))	We acknowledge the McGill Centre for Bone and Periodontal Research and the Goodman Cancer Research Centre for routine histological services. We thank Dr Jeanine Quillard for her invaluable assistance in identifying the liver resection specimens analyzed in this study. We thank J Ursini-Siegel and members of the Siegel laboratory for thoughtful discussions and critical reading of the manuscript. This work was supported by a program project grant from the Terry Fox Foundation (Grant #020002) (to PMS and MP) and by a grant from the Banque de tissu et de donnees of the Reseau de la recherche sur le cancer (RR Cancer) of the Fonds de recherche en sante du Quebec (FRSQ) (to MP). ST acknowledges support from the McGill University Department of Medicine, FP was the recipient of a Breast Cancer Pre-doctoral Traineeship Award from the US Department of Defense, VO is supported by a Fellowship from the Fonds de la Recherche en Sante du Quebec (FRSQ) and PMS was a research scientist supported by the Canadian Cancer Society and is currently a Chercheur-Junior2 of the FRSQ.	Aung PP, 2006, VIRCHOWS ARCH, V448, P428, DOI 10.1007/s00428-005-0120-2; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Berditchevski F, 2002, J BIOL CHEM, V277, P36991, DOI 10.1074/jbc.M205265200; Berkowitz N, 2000, Value Health, V3, P23, DOI 10.1046/j.1524-4733.2000.31003.x; Blanchard AA, 2009, VIRCHOWS ARCH, V454, P647, DOI 10.1007/s00428-009-0770-6; Braet Filip, 2002, Comp Hepatol, V1, P1, DOI 10.1186/1476-5926-1-1; Braet F, 2009, LIVER INT, V29, P603, DOI 10.1111/j.1478-3231.2008.01836.x; Buchert M, 2010, P NATL ACAD SCI USA, V107, P2628, DOI 10.1073/pnas.0903747107; CLARK GM, 1987, J CLIN ONCOL, V5, P55, DOI 10.1200/JCO.1987.5.1.55; Creighton CJ, 2010, J MAMMARY GLAND BIOL, V15, P253, DOI 10.1007/s10911-010-9173-1; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Diamond JR, 2009, LANCET ONCOL, V10, P615, DOI 10.1016/S1470-2045(09)70029-4; Eichbaum MHR, 2006, BREAST CANCER RES TR, V96, P53, DOI 10.1007/s10549-005-9039-1; Enns AE, 2004, J GASTROINTEST SURG, V8, P1049, DOI 10.1016/j.gassur.2004.08.016; Er O, 2008, CANCER J, V14, P62, DOI 10.1097/PPO.0b013e3181629a7b; Erin N, 2009, INT J CANCER, V124, P1503, DOI 10.1002/ijc.24131; FIDLER IJ, 1986, CANCER METAST REV, V5, P29, DOI 10.1007/BF00049529; Friedrichs J, 2008, J BIOL CHEM, V283, P32264, DOI 10.1074/jbc.M803634200; GIAVAZZI R, 1986, J NATL CANCER I, V77, P1303; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Insa A, 1999, BREAST CANCER RES TR, V56, P67, DOI 10.1023/A:1006285726561; KEMPERMAN H, 1995, CANCER SURV, V24, P67; Kim TH, 2008, HISTOPATHOLOGY, V53, P48, DOI 10.1111/j.1365-2559.2008.03052.x; Kinugasa T, 2007, ANTICANCER RES, V27, P3729; Kominsky SL, 2004, AM J PATHOL, V164, P1627, DOI 10.1016/S0002-9440(10)63721-2; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; Kramer F, 2000, HUM GENET, V107, P249, DOI 10.1007/s004390000375; Kuhn S, 2007, MOL CANCER RES, V5, P553, DOI 10.1158/1541-7786.MCR-06-0384; Kulka J, 2009, PATHOL ONCOL RES, V15, P59, DOI 10.1007/s12253-008-9089-x; Lanigan F, 2009, INT J CANCER, V124, P2088, DOI 10.1002/ijc.24159; Lazo PA, 2007, CANCER SCI, V98, P1666, DOI 10.1111/j.1349-7006.2007.00584.x; Magro Gaetano, 1997, General and Diagnostic Pathology, V143, P203; Martin TA, 2004, EUR J CANCER, V40, P2717, DOI 10.1016/j.ejca.2004.08.008; Martin TA, 2009, BBA-BIOMEMBRANES, V1788, P872, DOI 10.1016/j.bbamem.2008.11.005; MARTINEZHERNANDEZ A, 1993, VIRCHOWS ARCH A, V423, P1, DOI 10.1007/BF01606425; Mima S, 2008, CARCINOGENESIS, V29, P1994, DOI 10.1093/carcin/bgn134; Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782; Mourskaia AA, 2009, ONCOGENE, V28, P1005, DOI 10.1038/onc.2008.454; Naik MU, 2008, CANCER RES, V68, P2194, DOI 10.1158/0008-5472.CAN-07-3057; Northey JJ, 2008, MOL CELL BIOL, V28, P3162, DOI 10.1128/MCB.01734-07; Osanai M, 2007, CANCER SCI, V98, P1557, DOI 10.1111/j.1349-7006.2007.00569.x; Osanai M, 2006, CANCER RES, V66, P9125, DOI 10.1158/0008-5472.CAN-06-1864; Penas PF, 2000, J INVEST DERMATOL, V114, P1126, DOI 10.1046/j.1523-1747.2000.00998.x; Pentheroudakis G, 2006, BREAST CANCER RES TR, V97, P237, DOI 10.1007/s10549-005-9117-4; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rose AAN, 2007, MOL CANCER RES, V5, P1001, DOI 10.1158/1541-7786.MCR-07-0119; Rosenow Felix, 2008, Neoplasia, V10, P168, DOI 10.1593/neo.07898; Sauer T, 2005, CYTOPATHOLOGY, V16, P193, DOI 10.1111/j.1365-2303.2005.00257.x; Schluter K, 2006, AM J PATHOL, V169, P1064, DOI 10.2353/ajpath.2006.050566; Selzner M, 2000, SURGERY, V127, P383, DOI 10.1067/msy.2000.103883; Soini Y, 2004, HUM PATHOL, V35, P1531, DOI 10.1016/j.humpath.2004.09.015; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thakur A, 2008, CLIN CANCER RES, V14, P4427, DOI 10.1158/1078-0432.CCR-08-0458; Tiwari-Woodruff SK, 2001, J CELL BIOL, V153, P295, DOI 10.1083/jcb.153.2.295; Tokes AM, 2005, PATHOL RES PRACT, V201, P537, DOI 10.1016/j.prp.2005.05.005; Turksen K, 2004, J CELL SCI, V117, P2435, DOI 10.1242/jcs.01235; Ugnat AM, 2004, BRIT J CANCER, V90, P1138, DOI 10.1038/sj.bjc.6601662; Ura H, 1998, SURG TODAY, V28, P1001, DOI 10.1007/BF02483952; Wisse E, 2008, GENE THER, V15, P1193, DOI 10.1038/gt.2008.60; Yanez-Mo M, 2001, J CELL SCI, V114, P577; Yokomori H, 2008, MED MOL MORPHOL, V41, P1, DOI 10.1007/s00795-007-0390-7; Yoshimura K, 2009, CANCER RES, V69, P7320, DOI 10.1158/0008-5472.CAN-09-0315	64	94	99	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	11					1318	1328		10.1038/onc.2010.518	http://dx.doi.org/10.1038/onc.2010.518			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21076473				2022-12-17	WOS:000288492100006
J	Martin-Montalvo, A; Villalba, JM; Navas, P; de Cabo, R				Martin-Montalvo, A.; Villalba, J. M.; Navas, P.; de Cabo, R.			NRF2, cancer and calorie restriction	ONCOGENE			English	Review						calorie restriction; carcinogenesis; NRF2; phytochemicals	ANTIOXIDANT-RESPONSE ELEMENT; TRANSCRIPTION FACTOR NRF2; GLUTATHIONE-S-TRANSFERASE; DIETARY ENERGY RESTRICTION; SKIN TUMOR PROMOTION; SMALL MAF PROTEINS; CHEMICALLY-INDUCED MAMMARY; TRANSGENIC MOUSE MODEL; CENTRAL-NERVOUS-SYSTEM; CUL3-BASED E3 LIGASE	The transcription factor NF-E2-related factor (NRF2) is a key regulator of several enzymatic pathways, including cytoprotective enzymes in highly metabolic organs. In this review, we summarize the ongoing research related to NRF2 activity in cancer development, focusing on in vivo studies using NRF2 knockout (KO) mice, which have helped in defining the crucial role of NRF2 in chemoprevention. The lower cancer protection observed in NRF2 KO mice under calorie restriction (CR) suggests that most of the beneficial effects of CR on the carcinogenesis process are likely mediated by NRF2. We propose that future interventions in cancer treatment would be carried out through the activation of NRF2 in somatic cells, which will lead to a delay or prevention of the onset of some forms of human cancers, and subsequently an extension of health-and lifespan. Oncogene (2011) 30, 505-520; doi: 10.1038/onc.2010.492; published online 8 November 2010	[Martin-Montalvo, A.; de Cabo, R.] NIA, Aging Metab & Nutr Unit, Lab Expt Gerontol, NIH, Baltimore, MD 21224 USA; [Villalba, J. M.] Univ Cordoba, Dept Biol Celular Fisiol & Inmunol, Cordoba, Spain; [Navas, P.] Univ Pablo Olavide, CSIC, Ctr Andaluz Biol Desarrollo, Seville, Spain; [Navas, P.] ISCIII, Ctr Biomed Res Rare Dis CIBERER, Seville, Spain	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Universidad de Cordoba; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; CSIC - Andalusian Center for Developmental Biology (CABD); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Instituto de Salud Carlos III	de Cabo, R (corresponding author), NIA, Aging Metab & Nutr Unit, Lab Expt Gerontol, NIH, Baltimore, MD 21224 USA.	decabora@mail.nih.gov	NAVAS, PLACIDO/R-5943-2019; de Cabo, Rafael/E-7996-2010; Martin-Montalvo, Alejandro/C-2031-2017; de Cabo, Rafael Carlos/J-5230-2016; de Cabo, Rafael/J-5230-2016	NAVAS, PLACIDO/0000-0002-4115-7966; de Cabo, Rafael/0000-0003-2830-5693; Martin-Montalvo, Alejandro/0000-0002-3886-5355; de Cabo, Rafael Carlos/0000-0003-2830-5693; Villalba Montoro, Jose Manuel/0000-0001-8554-3802; de Cabo, Rafael/0000-0002-3354-2442	National Institute on Aging, National Institutes of Health; Junta de Andalucia [CVI 4887, CVI-276]; NIH [1R01AG028125-01A1]; Ministry of Health, Spain [PI080500]; NATIONAL INSTITUTE ON AGING [ZIAAG000361, ZIAAG000368, R01AG028125] Funding Source: NIH RePORTER	National Institute on Aging, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Junta de Andalucia(Junta de Andalucia); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Health, Spain(Spanish Government); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	AM-M and RdC are supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health. The work was partially supported by Junta de Andalucia International Projects, CVI 4887 and CVI-276, NIH Grant 1R01AG028125-01A1 and FIS Grant PI080500 of the Ministry of Health, Spain. We thank Alex Sossong and Andrew Levette for critiquing the manuscript.	Alam ZI, 1997, J NEUROCHEM, V69, P1326; Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; Aleksunes LM, 2010, J PHARMACOL EXP THER, V333, P140, DOI 10.1124/jpet.109.162271; ANDREOU KK, 1981, ARCH ORAL BIOL, V26, P525, DOI 10.1016/0003-9969(81)90011-X; ANSHER SS, 1986, FOOD CHEM TOXICOL, V24, P405, DOI 10.1016/0278-6915(86)90205-X; Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; Bae SY, 2006, CANCER SCI, V97, P774, DOI 10.1111/j.1349-7006.2006.00241.x; Baguley BC, 2010, MOL BIOTECHNOL, V46, P308, DOI 10.1007/s12033-010-9321-2; Banning A, 2008, CANCER RES, V68, P9746, DOI 10.1158/0008-5472.CAN-08-1321; Bartke Andrzej, 2007, V35, P69; Birt DF, 1999, J NUTR, V129, p571S, DOI 10.1093/jn/129.2.571S; Birt DF, 2004, J CELL BIOCHEM, V91, P258, DOI 10.1002/jcb.10741; BIRT DF, 1993, CANCER RES, V53, P27; Birt DF, 1998, NUTR CANCER, V31, P119, DOI 10.1080/01635589809514690; BIRT DF, 1991, CANCER RES, V51, P1851; Bishop NA, 2007, NATURE, V447, P545, DOI 10.1038/nature05904; Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; BOISSONNEAULT GA, 1986, J NATL CANCER I, V76, P335; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; BREESE CR, 1991, J GERONTOL, V46, pB180, DOI 10.1093/geronj/46.5.B180; Brigelius-Flohe R, 2006, FREE RADICAL RES, V40, P775, DOI 10.1080/10715760600722643; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Burton NC, 2006, NEUROTOXICOLOGY, V27, P1094, DOI 10.1016/j.neuro.2006.07.019; Butt AJ, 2002, ENDOCRINOLOGY, V143, P2693, DOI 10.1210/en.143.7.2693; CABRAL JRP, 1983, CANCER LETT, V19, P125, DOI 10.1016/0304-3835(83)90146-5; Cakatay U, 2001, EXP GERONTOL, V36, P221, DOI 10.1016/S0531-5565(00)00197-2; Calkins MJ, 2005, P NATL ACAD SCI USA, V102, P244, DOI 10.1073/pnas.0408487101; Campbell JK, 2004, J NUTR, V134, p3486S, DOI 10.1093/jn/134.12.3486S; Cao JX, 2009, EMBO J, V28, P1505, DOI 10.1038/emboj.2009.101; Castello L, 2010, FREE RADICAL BIO MED, V48, P47, DOI 10.1016/j.freeradbiomed.2009.10.003; Chan JM, 2001, EPIDEMIOL REV, V23, P82, DOI 10.1093/oxfordjournals.epirev.a000799; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; CHANDRASEKAR B, 1995, CLIN IMMUNOL IMMUNOP, V76, P291, DOI 10.1006/clin.1995.1128; Chang XZ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1789; Chartoumpekis D, 2010, BIOCHEM BIOPH RES CO, V396, P463, DOI 10.1016/j.bbrc.2010.04.117; Chen C, 2000, ARCH PHARM RES, V23, P605, DOI 10.1007/BF02975249; Chen XL, 2003, J BIOL CHEM, V278, P703, DOI 10.1074/jbc.M203161200; CHENEY KE, 1983, J GERONTOL, V38, P420, DOI 10.1093/geronj/38.4.420; Chiao JW, 2004, CARCINOGENESIS, V25, P1403, DOI 10.1093/carcin/bgh136; Clinton SK, 1996, CANCER EPIDEM BIOMAR, V5, P823; COHEN ND, 1974, CANCER RES, V34, P3245; Collins AR, 2009, CIRC RES, V104, pe42, DOI 10.1161/CIRCRESAHA.108.188771; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Dai G, 2007, CIRC RES, V101, P723, DOI 10.1161/CIRCRESAHA.107.152942; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; De Cabo R, 2004, EXP GERONTOL, V39, P297, DOI 10.1016/j.exger.2003.12.003; Derjuga A, 2004, MOL CELL BIOL, V24, P3286, DOI 10.1128/MCB.24.8.3286-3294.2004; Devling TWP, 2005, P NATL ACAD SCI USA, V102, P7280, DOI 10.1073/pnas.0501475102; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; Ding Y, 2008, AM J PATHOL, V172, P1529, DOI 10.2353/ajpath.2008.070429; Dinikova-Kostova AT, 2004, METHOD ENZYMOL, V382, P423; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198; DJURIC Z, 1993, MUTAT RES, V295, P181, DOI 10.1016/0921-8734(93)90019-Y; Duan WS, 2009, IN VITRO CELL DEV-AN, V45, P388, DOI 10.1007/s11626-009-9194-5; Efferth T, 2005, IN VIVO, V19, P225; Eggler AL, 2005, P NATL ACAD SCI USA, V102, P10070, DOI 10.1073/pnas.0502402102; Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; Fialka F, 2008, ORAL ONCOL, V44, P941, DOI 10.1016/j.oraloncology.2007.10.011; Fields WR, 1999, CARCINOGENESIS, V20, P1121, DOI 10.1093/carcin/20.6.1121; Fitzmaurice PS, 1996, MUSCLE NERVE, V19, P797; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; GARCEA R, 1988, CARCINOGENESIS, V9, P931, DOI 10.1093/carcin/9.6.931; Gerhauser C, 1997, CANCER RES, V57, P272; GIOVANNUCCI E, 1995, J NATL CANCER I, V87, P1767, DOI 10.1093/jnci/87.23.1767; GORDON GB, 1987, ADV ENZYME REGUL, V26, P355, DOI 10.1016/0065-2571(87)90023-9; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; GROSS L, 1986, P NATL ACAD SCI USA, V83, P7928, DOI 10.1073/pnas.83.20.7928; Guo ZM, 2002, MECH AGEING DEV, V123, P1121, DOI 10.1016/S0047-6374(02)00008-8; Halagappa VKM, 2007, NEUROBIOL DIS, V26, P212, DOI 10.1016/j.nbd.2006.12.019; Halliwell B, 1996, FREE RADICAL RES, V25, P57, DOI 10.3109/10715769609145656; Halliwell B, 1996, BIOCHEM SOC T, V24, P1023, DOI 10.1042/bst0241023; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HANSEN BC, 1995, OBES RES, V3, pS199, DOI 10.1002/j.1550-8528.1995.tb00464.x; Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033; Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008; HECHT SS, 1995, CANCER EPIDEM BIOMAR, V4, P877; Heiss E, 2001, J BIOL CHEM, V276, P32008, DOI 10.1074/jbc.M104794200; Henderson CJ, 1998, P NATL ACAD SCI USA, V95, P5275, DOI 10.1073/pnas.95.9.5275; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Holloszy JO, 2007, EXP GERONTOL, V42, P709, DOI 10.1016/j.exger.2007.03.009; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; HOWELL TH, 1987, AGE AGEING, V16, P194; Hu R, 2006, CANCER LETT, V243, P170, DOI 10.1016/j.canlet.2005.11.050; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; HURSTING SD, 1994, P NATL ACAD SCI USA, V91, P7036, DOI 10.1073/pnas.91.15.7036; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Hyer ML, 2005, CANCER RES, V65, P4799, DOI 10.1158/0008-5472.CAN-04-3319; Hyun DH, 2007, J NEUROCHEM, V100, P1364, DOI 10.1111/j.1471-4159.2006.04411.x; Hyun DH, 2006, P NATL ACAD SCI USA, V103, P19908, DOI 10.1073/pnas.0608008103; Iida K, 2004, CANCER RES, V64, P6424, DOI 10.1158/0008-5472.CAN-04-1906; INGRAM DK, 1990, J GERONTOL, V45, pB148, DOI 10.1093/geronj/45.5.B148; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Jakel RJ, 2007, BRAIN RES, V1144, P192, DOI 10.1016/j.brainres.2007.01.131; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jiang T, 2010, DIABETES, V59, P850, DOI 10.2337/db09-1342; Jimenez-Hidalgo M, 2009, AGING CELL, V8, P140, DOI 10.1111/j.1474-9726.2009.00461.x; Johnson JB, 2007, FREE RADICAL BIO MED, V42, P665, DOI 10.1016/j.freeradbiomed.2006.12.005; Juge N, 2007, CELL MOL LIFE SCI, V64, P1105, DOI 10.1007/s00018-007-6484-5; Jung KJ, 2009, INFLAMM RES, V58, P143, DOI 10.1007/s00011-008-7227-2; Kalaany NY, 2009, NATURE, V458, P725, DOI 10.1038/nature07782; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Kanninen K, 2009, P NATL ACAD SCI USA, V106, P16505, DOI 10.1073/pnas.0908397106; Keller UAD, 2006, MOL CELL BIOL, V26, P3773, DOI 10.1128/MCB.26.10.3773-3784.2006; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; KENSLER TW, 1995, J CELL BIOCHEM, P101; KENSLER TW, 1987, CANCER RES, V47, P4271; Khor TO, 2008, PLANTA MED, V74, P1540, DOI 10.1055/s-0028-1088303; Khor TO, 2006, CANCER RES, V66, P11580, DOI 10.1158/0008-5472.CAN-06-3562; Kiritoshi S, 2003, DIABETES, V52, P2570, DOI 10.2337/diabetes.52.10.2570; Kitamura Y, 2007, CANCER SCI, V98, P19, DOI 10.1111/j.1349-7006.2006.00352.x; Klaassen CD, 2005, CURR DRUG METAB, V6, P309, DOI 10.2174/1389200054633826; KLURFELD DM, 1987, CANCER RES, V47, P2759; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kobayashi A, 2004, METHOD ENZYMOL, V378, P273; Kobayashi M, 2002, GENES CELLS, V7, P807, DOI 10.1046/j.1365-2443.2002.00561.x; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; KRITCHEVSKY D, 1984, CANCER RES, V44, P3174; Kritchevsky D, 2001, J NUTR SCI VITAMINOL, V47, P13, DOI 10.3177/jnsv.47.13; Kwak MK, 2003, MOL CELL BIOL, V23, P8786, DOI 10.1128/MCB.23.23.8786-8794.2003; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; LAGOPOULOS L, 1987, CARCINOGENESIS, V8, P33, DOI 10.1093/carcin/8.1.33; Lal S, 2008, CANCER SCI, V99, P2045, DOI 10.1111/j.1349-7006.2008.00903.x; Lapillonne H, 2003, CANCER RES, V63, P5926; Lee HH, 2010, ARCH BIOCHEM BIOPHYS, V501, P142, DOI 10.1016/j.abb.2010.06.011; Lee JM, 2005, FASEB J, V19, P1061, DOI 10.1096/fj.04-2591hyp; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Lee KW, 2005, J BIOL CHEM, V280, P16942, DOI 10.1074/jbc.M412757200; Lee SK, 2010, LIFE SCI, V86, P107, DOI 10.1016/j.lfs.2009.11.013; Leifert WR, 2008, NUTR RES, V28, P729, DOI 10.1016/j.nutres.2008.09.001; Leonard MO, 2006, FASEB J, V20, P2624, DOI 10.1096/fj.06-5097fje; LI Y, 1992, J BIOL CHEM, V267, P15097; Lii CK, 2010, J NUTR, V140, P885, DOI 10.3945/jn.110.121418; Liu XM, 2007, CARDIOVASC RES, V75, P381, DOI 10.1016/j.cardiores.2007.03.004; LOK E, 1988, CANCER LETT, V38, P249, DOI 10.1016/0304-3835(88)90016-X; Love R, 2005, LANCET NEUROL, V4, P84, DOI 10.1016/S1474-4422(05)00985-3; Maher J, 2010, TOXICOL APPL PHARM, V244, P4, DOI 10.1016/j.taap.2010.01.011; Mandlekar S, 2006, CURR DRUG METAB, V7, P661, DOI 10.2174/138920006778017795; MANJGALADZE M, 1993, MUTAT RES, V295, P201, DOI 10.1016/0921-8734(93)90021-T; Marzetti E, 2009, BIOFACTORS, V35, P28, DOI 10.1002/biof.5; MASORO EJ, 1995, OBES RES, V3, pS241, DOI 10.1002/j.1550-8528.1995.tb00470.x; Mattison Julie A., 2007, V35, P137; Mattson MP, 2003, NEUROLOGY, V60, P690, DOI 10.1212/01.WNL.0000042785.02850.11; Mattson MP, 2001, MECH AGEING DEV, V122, pIII; McKiernan S, 2004, FASEB J, V18, P580, DOI 10.1096/fj.03-0667fje; McMahon M, 2001, CANCER RES, V61, P3299; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; McMahon M, 2004, J BIOL CHEM, V279, P31556, DOI 10.1074/jbc.M403061200; Miller EC, 2002, UROL CLIN N AM, V29, P83, DOI 10.1016/S0094-0143(02)00020-4; Mitra A, 2009, CLIN EXP METASTAS, V26, P559, DOI 10.1007/s10585-009-9255-x; Miyagi S, 2003, Asia Pac J Public Health, V15 Suppl, pS3, DOI 10.1177/101053950301500S03; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moreschi C., 1909, Z IMMUNITATSFORSCH, V2, P661; Mostoslavsky R, 2006, CELL, V124, P315, DOI [10.1016/j.cell.2005.11.044, 10.1016/J.CEL.2005.11.044]; Motohashi H, 2004, P NATL ACAD SCI USA, V101, P6379, DOI 10.1073/pnas.0305902101; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Muguruma M, 2006, TOXICOLOGY, V228, P178, DOI 10.1016/j.tox.2006.08.029; MULCAHY RT, 1995, BIOCHEM BIOPH RES CO, V209, P227, DOI 10.1006/bbrc.1995.1493; Murakami S, 1996, GENETICS, V143, P1207; Muto A, 1998, EMBO J, V17, P5734, DOI 10.1093/emboj/17.19.5734; Nagaraj S, 2010, CLIN CANCER RES, V16, P1812, DOI 10.1158/1078-0432.CCR-09-3272; Nair S, 2006, PHARM RES-DORDR, V23, P2621, DOI 10.1007/s11095-006-9099-x; Nguyen T, 2004, FREE RADICAL BIO MED, V37, P433, DOI 10.1016/j.freeradbiomed.2004.04.033; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nguyen TV, 2009, ONCOL RES, V18, P349, DOI 10.3727/096504010X12626118080064; Nioi P, 2007, BIOCHEM BIOPH RES CO, V362, P816, DOI 10.1016/j.bbrc.2007.08.051; Nolan KA, 2010, BIOCHEM PHARMACOL, V80, P977, DOI 10.1016/j.bcp.2010.06.024; Numazawa S, 2003, AM J PHYSIOL-CELL PH, V285, pC334, DOI 10.1152/ajpcell.00043.2003; Okawa H, 2006, BIOCHEM BIOPH RES CO, V339, P79, DOI 10.1016/j.bbrc.2005.10.185; Onken B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008758; Osburn WO, 2008, TOXICOL SCI, V104, P218, DOI 10.1093/toxsci/kfn079; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Palli D, 2000, INT J CANCER, V87, P444, DOI 10.1002/1097-0215(20000801)87:3&lt;444::AID-IJC21&gt;3.0.CO;2-#; PASHKO LL, 1991, CARCINOGENESIS, V12, P2189, DOI 10.1093/carcin/12.11.2189; PASHKO LL, 1992, CARCINOGENESIS, V13, P1925, DOI 10.1093/carcin/13.10.1925; Patel M, 2008, LUNG CANCER, V59, P340, DOI 10.1016/j.lungcan.2007.08.033; Pearson KJ, 2008, P NATL ACAD SCI USA, V105, P2325, DOI 10.1073/pnas.0712162105; Philip M, 2004, SEMIN CANCER BIOL, V14, P433, DOI 10.1016/j.semcancer.2004.06.006; Pietsch EC, 2003, J BIOL CHEM, V278, P2361, DOI 10.1074/jbc.M210664200; Pollak M, 2009, CANCER PREV RES, V2, P698, DOI 10.1158/1940-6207.CAPR-09-0134; POLLARD M, 1984, CANCER TREAT REP, V68, P405; Pratico D, 2000, AM J MED, V109, P577, DOI 10.1016/S0002-9343(00)00547-7; PRESTERA T, 1995, MOL MED, V1, P827, DOI 10.1007/BF03401897; Pugh TD, 1999, CANCER RES, V59, P1642; Qin WP, 2008, ANN NY ACAD SCI, V1147, P335, DOI 10.1196/annals.1427.024; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Ramos-Gomez M, 2003, CARCINOGENESIS, V24, P461, DOI 10.1093/carcin/24.3.461; Ramsey JJ, 2000, EXP GERONTOL, V35, P1131, DOI 10.1016/S0531-5565(00)00166-2; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; REINHART J, 1993, ARCH BIOCHEM BIOPHYS, V303, P383, DOI 10.1006/abbi.1993.1299; Rous P, 1914, J EXP MED, V20, P433, DOI 10.1084/jem.20.5.433; RUGGERI BA, 1989, CANCER RES, V49, P4130; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; Sell C, 2003, HORM METAB RES, V35, P705, DOI 10.1055/s-2004-814156; SHANTZ LM, 1989, P NATL ACAD SCI USA, V86, P3852, DOI 10.1073/pnas.86.10.3852; SHAW PJ, 1995, ANN NEUROL, V38, P691, DOI 10.1002/ana.410380424; Shen GX, 2006, MOL CANCER THER, V5, P39, DOI 10.1158/1535-7163.MCT-05-0293; Shibata T, 2008, GASTROENTEROLOGY, V135, P1358, DOI 10.1053/j.gastro.2008.06.082; Shih AY, 2005, J BIOL CHEM, V280, P22925, DOI 10.1074/jbc.M414635200; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; Shih PH, 2007, BIOGERONTOLOGY, V8, P71, DOI 10.1007/s10522-006-9033-y; SHIMOKAWA I, 1991, J GERONTOL, V46, pB228, DOI 10.1093/geronj/46.6.B228; Shou M, 2001, J BIOL CHEM, V276, P2256, DOI 10.1074/jbc.M008799200; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Stack C, 2010, FREE RADICAL BIO MED, V49, P147, DOI 10.1016/j.freeradbiomed.2010.03.017; Stadtman ER, 1998, DRUG METAB REV, V30, P225, DOI 10.3109/03602539808996310; Stewart JW, 2005, CARCINOGENESIS, V26, P1077, DOI 10.1093/carcin/bgi051; Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101; Suzuki M, 2001, Nihon Ronen Igakkai Zasshi, V38, P163; Suzuki T, 2005, BIOCHEM J, V388, P65, DOI 10.1042/BJ20041860; Sykiotis GP, 2008, DEV CELL, V14, P76, DOI 10.1016/j.devcel.2007.12.002; TANNENBAUM A, 1949, CANCER RES, V9, P162; TANNENBAUM A, 1953, ADV CANCER RES, V1, P451, DOI 10.1016/S0065-230X(08)60009-3; TAUB R, 1987, J BIOL CHEM, V262, P10893; Thatcher Gregory R. J., 2005, Current Alzheimer Research, V2, P171, DOI 10.2174/1567205053585945; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Thompson HJ, 2003, J MAMMARY GLAND BIOL, V8, P133, DOI 10.1023/A:1025743607445; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024; Tong KI, 2006, MOL CELL BIOL, V26, P2887, DOI 10.1128/MCB.26.8.2887-2900.2006; Tong KI, 2006, BIOL CHEM, V387, P1311, DOI 10.1515/BC.2006.164; Tullet JMA, 2008, CELL, V132, P1025, DOI 10.1016/j.cell.2008.01.030; Udenigwe CC, 2008, NUTR REV, V66, P445, DOI 10.1111/j.1753-4887.2008.00076.x; Ungvari Z, 2008, CIRC RES, V102, P519, DOI 10.1161/CIRCRESAHA.107.168369; Volchegorskii I A, 2004, Neurosci Behav Physiol, V34, P303, DOI 10.1023/B:NEAB.0000018736.84877.4f; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Wang HJ, 2010, J HUAZHONG U SCI-MED, V30, P415, DOI 10.1007/s11596-010-0441-5; Warabi E, 2007, FREE RADICAL BIO MED, V42, P260, DOI 10.1016/j.freeradbiomed.2006.10.043; Warita H, 2001, MOL BRAIN RES, V89, P147, DOI 10.1016/S0169-328X(01)00029-8; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; WATTENBERG LW, 1972, JNCI-J NATL CANCER I, V48, P1425; Weed JL, 1997, PHYSIOL BEHAV, V62, P97, DOI 10.1016/S0031-9384(97)00147-9; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; Westerbeek ZW, 2008, J GERONTOL A-BIOL, V63, P1131, DOI 10.1093/gerona/63.11.1131; Willcox BJ, 2007, ANN NY ACAD SCI, V1114, P434, DOI 10.1196/annals.1396.037; Williams KV, 1998, DIABETES CARE, V21, P2, DOI 10.2337/diacare.21.1.2; Wilson LA, 2005, FASEB J, V19, P2085, DOI 10.1096/fj.05-4401fje; Xu CJ, 2006, CANCER RES, V66, P8293, DOI 10.1158/0008-5472.CAN-06-0300; Xue MZ, 2008, DIABETES, V57, P2809, DOI 10.2337/db06-1003; Yamamoto T, 2006, GENES CELLS, V11, P575, DOI 10.1111/j.1365-2443.2006.00965.x; Yang H, 2004, J GERONTOL A-BIOL, V59, P316; Yates MS, 2007, MOL CANCER THER, V6, P154, DOI 10.1158/1535-7163.MCT-06-0516; Ye G, 2004, DIABETES, V53, P1336, DOI 10.2337/diabetes.53.5.1336; Yu X, 2005, MUTAT RES-FUND MOL M, V591, P93, DOI 10.1016/j.mrfmmm.2005.04.017; Zakkar M, 2009, ARTERIOSCL THROM VAS, V29, P1851, DOI 10.1161/ATVBAHA.109.193375; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; ZHANG YS, 1994, P NATL ACAD SCI USA, V91, P3147, DOI 10.1073/pnas.91.8.3147	263	94	97	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	5					505	520		10.1038/onc.2010.492	http://dx.doi.org/10.1038/onc.2010.492			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	21057541	Green Accepted, Green Submitted			2022-12-17	WOS:000286922300001
J	Martin, F; Ladoire, S; Mignot, G; Apetoh, L; Ghiringhelli, F				Martin, F.; Ladoire, S.; Mignot, G.; Apetoh, L.; Ghiringhelli, F.			Human FOXP3 and cancer	ONCOGENE			English	Review						Foxp3; regulatory T cells; tumor immunity; tolerance; tumor suppressor gene	REGULATORY T-CELLS; TRANSCRIPTION FACTOR FOXP3; EFFECTOR FUNCTIONS; PERIPHERAL-BLOOD; CARCINOMA CELLS; DENDRITIC CELLS; TUMOR-IMMUNITY; CUTTING EDGE; EXPRESSION; SURVIVAL	FOXP3 is a transcription factor necessary and sufficient for induction of the immunosuppressive functions in regulatory T lymphocytes. Its expression was first considered as specific of this cell type, but FOXP3 can also be transiently expressed in T-cell antigen receptor-activated human nonregulatory T cells. Recent data indicate that FOXP3 is also expressed by some non-lymphoid cells, in which it can repress various oncogenes that are restored following FOXP3 deletion or mutation. This review summarizes major advances in (1) the understanding of Foxp3 functions in human regulatory T cells, (2) the prognostic significance of Foxp3-expressing T cells in human malignancies and (3) the significance of Foxp3 expression in human tumor cells. Oncogene (2010) 29, 4121-4129; doi: 10.1038/onc.2010.174; published online 24 May 2010	[Ghiringhelli, F.] Univ Burgundy, Avenir Team, INSERM, Equipe Avenir,UMR 866, F-21000 Dijon, Burgundy, France; [Ladoire, S.; Ghiringhelli, F.] Ctr GF Leclerc, Dijon, France; [Apetoh, L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; UNICANCER; Centre Georges-Francois Leclerc; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Ghiringhelli, F (corresponding author), Univ Burgundy, Avenir Team, INSERM, Equipe Avenir,UMR 866, 7 Bd Jeanne Arc, F-21000 Dijon, Burgundy, France.	fghiringhelli@dijon.fnclcc.fr	Mignot, Grégoire/R-4976-2017; Apetoh, Lionel/AIC-2384-2022; Apetoh, Lionel/G-3310-2014	Mignot, Grégoire/0000-0002-0682-0152; Apetoh, Lionel/0000-0002-2774-438X; Apetoh, Lionel/0000-0002-2774-438X; ghiringhelli, francois/0000-0002-5465-8305; LADOIRE, Sylvain/0000-0002-0331-9194				Akbar AN, 2007, NAT REV IMMUNOL, V7, P231, DOI 10.1038/nri2037; Allan SE, 2005, J CLIN INVEST, V115, P3276, DOI 10.1172/JCI24685; Alvaro T, 2005, CLIN CANCER RES, V11, P1467, DOI 10.1158/1078-0432.CCR-04-1869; Badoual C, 2006, CLIN CANCER RES, V12, P465, DOI 10.1158/1078-0432.CCR-05-1886; Bates GJ, 2006, J CLIN ONCOL, V24, P5373, DOI 10.1200/JCO.2006.05.9584; Bettelli E, 2005, P NATL ACAD SCI USA, V102, P5138, DOI 10.1073/pnas.0501675102; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Burstein HJ, 2005, NEW ENGL J MED, V353, P1652, DOI 10.1056/NEJMp058197; Carreras J, 2006, BLOOD, V108, P2957, DOI 10.1182/blood-2006-04-018218; Chen CX, 2006, J BIOL CHEM, V281, P36828, DOI 10.1074/jbc.M608848200; Chen GY, 2008, J IMMUNOL, V180, P5163, DOI 10.4049/jimmunol.180.8.5163; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Coffer PJ, 2004, NAT REV IMMUNOL, V4, P889, DOI 10.1038/nri1488; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Curiel TJ, 2008, CURR OPIN IMMUNOL, V20, P241, DOI 10.1016/j.coi.2008.04.008; Dannull J, 2005, J CLIN INVEST, V115, P3623, DOI 10.1172/JCI25947; Du JG, 2008, J IMMUNOL, V180, P4785, DOI 10.4049/jimmunol.180.7.4785; Dumitriu IE, 2009, J IMMUNOL, V182, P2795, DOI 10.4049/jimmunol.0712671; Ebert LM, 2008, CANCER RES, V68, P3001, DOI 10.1158/0008-5472.CAN-07-5664; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Gao Q, 2007, J CLIN ONCOL, V25, P2586, DOI 10.1200/JCO.2006.09.4565; Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; Ghiringhelli F, 2004, EUR J IMMUNOL, V34, P336, DOI 10.1002/eji.200324181; Ghiringhelli F, 2007, CANCER IMMUNOL IMMUN, V56, P641, DOI 10.1007/s00262-006-0225-8; Gobert M, 2009, CANCER RES, V69, P2000, DOI 10.1158/0008-5472.CAN-08-2360; Haynes NM, 2008, CURR OPIN IMMUNOL, V20, P545, DOI 10.1016/j.coi.2008.05.008; Hinz S, 2007, CANCER RES, V67, P8344, DOI 10.1158/0008-5472.CAN-06-3304; Hiraoka N, 2006, CLIN CANCER RES, V12, P5423, DOI 10.1158/1078-0432.CCR-06-0369; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Jordanova ES, 2008, CLIN CANCER RES, V14, P2028, DOI 10.1158/1078-0432.CCR-07-4554; Josefowicz SZ, 2009, IMMUNITY, V30, P616, DOI 10.1016/j.immuni.2009.04.009; Jung DJ, 2010, J BIOL CHEM, V285, P7995, DOI 10.1074/jbc.M109.047985; Koh KP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008109; LADOIRE S, 2010, BREAST CANC IN PRESS; Ladoire S, 2008, CLIN CANCER RES, V14, P2413, DOI 10.1158/1078-0432.CCR-07-4491; Lal G, 2009, BLOOD, V114, P3727, DOI 10.1182/blood-2009-05-219584; Li B, 2007, P NATL ACAD SCI USA, V104, P4571, DOI 10.1073/pnas.0700298104; Liu JY, 2007, CANCER IMMUNOL IMMUN, V56, P1597, DOI 10.1007/s00262-007-0305-4; LIYANAGE UK, INT J CANC, V120, P2723; Manoukian G, 2009, EXPERT OPIN BIOL TH, V9, P1445, DOI 10.1517/14712590903348135; Medema RH, 2007, CELL, V129, P1253, DOI 10.1016/j.cell.2007.06.008; Merlo A, 2009, J CLIN ONCOL, V27, P1746, DOI 10.1200/JCO.2008.17.9036; Miller AM, 2006, J IMMUNOL, V177, P7398, DOI 10.4049/jimmunol.177.10.7398; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Mizukami Y, 2008, BRIT J CANCER, V98, P148, DOI 10.1038/sj.bjc.6604149; Morse MA, 2008, BLOOD, V112, P610, DOI 10.1182/blood-2008-01-135319; Ono M, 2007, NATURE, V446, P685, DOI 10.1038/nature05673; Pan F, 2009, SCIENCE, V325, P1142, DOI 10.1126/science.1176077; Powell DJ, 2007, J IMMUNOL, V179, P4919, DOI 10.4049/jimmunol.179.7.4919; Rasku MA, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-12; Roncador G, 2005, EUR J IMMUNOL, V35, P1681, DOI 10.1002/eji.200526189; Roux S, 2008, J CLIN INVEST, V118, P3751, DOI 10.1172/JCI35890; Rudensky AY, 2006, CELL, V126, P253, DOI 10.1016/j.cell.2006.07.005; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Salama P, 2009, J CLIN ONCOL, V27, P186, DOI 10.1200/JCO.2008.18.7229; Schubert LA, 2001, J BIOL CHEM, V276, P37672, DOI 10.1074/jbc.M104521200; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Siddiqui SA, 2007, CLIN CANCER RES, V13, P2075, DOI 10.1158/1078-0432.CCR-06-2139; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Spatz A, 2004, NAT REV CANCER, V4, P617, DOI 10.1038/nrc1413; Tai XG, 2005, NAT IMMUNOL, V6, P152, DOI 10.1038/ni1160; Taieb J, 2006, J IMMUNOL, V176, P2722, DOI 10.4049/jimmunol.176.5.2722; Tang QZ, 2008, NAT IMMUNOL, V9, P239, DOI 10.1038/ni1572; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Tsuji M, 2009, SCIENCE, V323, P1488, DOI 10.1126/science.1169152; van Loosdregt J, 2010, BLOOD, V115, P965, DOI 10.1182/blood-2009-02-207118; Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941; Walker MR, 2005, P NATL ACAD SCI USA, V102, P4103, DOI 10.1073/pnas.0407691102; Wan YSY, 2007, NATURE, V445, P766, DOI 10.1038/nature05479; Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435; Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; Wieczorek G, 2009, CANCER RES, V69, P599, DOI 10.1158/0008-5472.CAN-08-2361; Woo EY, 2001, CANCER RES, V61, P4766; Woo YL, 2008, J CLIN PATHOL, V61, P969, DOI 10.1136/jcp.2008.056200; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Xu LL, 2007, J IMMUNOL, V178, P6725, DOI 10.4049/jimmunol.178.11.6725; Yang XO, 2008, IMMUNITY, V29, P44, DOI 10.1016/j.immuni.2008.05.007; Yoshioka T, 2008, BRIT J CANCER, V98, P1258, DOI 10.1038/sj.bjc.6604294; Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563; Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774; Ziegler SF, 2006, ANNU REV IMMUNOL, V24, P209, DOI 10.1146/annurev.immunol.24.021605.090547; Zitvogel L, 2008, BLOOD, V112, P4364, DOI 10.1182/blood-2008-09-176693; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806; Zuo T, 2007, J CLIN INVEST, V117, P3765, DOI 10.1172/JCI32538; Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034	90	94	104	4	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2010	29	29					4121	4129		10.1038/onc.2010.174	http://dx.doi.org/10.1038/onc.2010.174			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20498631				2022-12-17	WOS:000280151500001
J	Wang, S; Huang, X; Lee, CK; Liu, B				Wang, S.; Huang, X.; Lee, C-K; Liu, B.			Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin	ONCOGENE			English	Article						erbB3; erbB2; Survivin; paclitaxel resistance; breast cancer	GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; MONOCLONAL-ANTIBODY; ESTROGEN-RECEPTOR; SIGNALING PATHWAY; ACTIVATION LEADS; TAXOL; OVEREXPRESSION; TRASTUZUMAB; MECHANISMS	The coexpression of erbB3 and erbB2 is frequently observed in breast cancer; and erbB3 has a critical role in erbB2 promotion of breast cancer progression and anti-estrogen resistance. In this study, we determine the role of erbB3 in erbB2-mediated paclitaxel resistance in breast cancer cells. The overexpression of exogenous erbB3 via either stable or transient transfection in erbB2-overexpressing, but not epidermal growth factor receptor (EGFR)-expressing, breast cancer cells significantly decreases paclitaxel-induced growth inhibition and apoptosis. Consistently, knockdown of erbB3 expression with a specific short hairpin RNA (shRNA) in breast cancer cells with coexpression of both erbB2 and erbB3 enhances paclitaxel-induced apoptosis evidenced by increased DNA fragmentation, poly (ADP-ribose) polymerase ( PARP) cleavage and activation of caspase- 3 and -8. Furthermore, while forced overexpression of erbB3 increases, specific knockdown of erbB3 decreases the expression levels of Survivin only in the erbB2-overexpressing breast cancer cells. Targeting Survivin with specific shRNA overcomes paclitaxel resistance without effect on the expression levels of either erbB2 or erbB3. Mechanistic studies indicate that the specific phosphoinositide 3-kinase (PI-3K), Akt and mammalian target of rapamycin (mTOR) inhibitors, but not the mitogen-activated protein kinase kinase (MEK) inhibitor, not only abrogate erbB3-mediated upregulation of Survivin, but also reinforce the erbB2/erbB3-coexpressing breast cancer cells to paclitaxel-induced growth inhibition. These data demonstrate that heterodimerization of erbB2/erbB3 is a prerequisite for erbB2 tyrosine kinase activation; and elevated expression of erbB3 is required for erbB2-mediated paclitaxel resistance in breast cancer cells via PI-3K/Akt/mTOR signaling pathway-dependent upregulation of Survivin. Our studies suggest that new strategies targeting erbB3 or Survivin may enhance the efficacy of chemotherapeutic agents against erbB2-overexpressing breast cancer. Oncogene (2010) 29, 4225-4236; doi: 10.1038/onc.2010.180; published online 24 May 2010	[Wang, S.; Huang, X.; Liu, B.] Univ Colorado Denver, Sch Med, Dept Pathol, Aurora, CO 80045 USA; [Lee, C-K] Univ Colorado Denver, Sch Med, Dept Med, Myeloma & Amyloidosis Program, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Liu, B (corresponding author), Univ Colorado Denver, Sch Med, Dept Pathol, MS-8104,POB 6511,12801 E 17th Ave, Aurora, CO 80045 USA.	bolin.liu@ucdenver.edu	Wang, Shuiliang/R-4080-2019	Wang, Shuiliang/0000-0002-5054-9064; Liu, Bolin/0000-0003-0150-8650	Susan G Komen for the Cure	Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation)	We thank Dr Haihua Gu for providing the pLKO.1-ErbB3shRNA expression vector and lentivirus packaging plasmids pCMV-VSVG and pCMV-DA. 9. We also thank Ms Lisa Litzenberger for her excellent art preparation. This work was supported in part by a research Grant from Susan G Komen for the Cure (to BL).	ALIMANDI M, 1995, ONCOGENE, V10, P1813; Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Asanuma H, 2005, CANCER RES, V65, P11018, DOI 10.1158/0008-5472.CAN-05-0491; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Bieche I, 2003, INT J CANCER, V106, P758, DOI 10.1002/ijc.11273; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Cochrane DR, 2009, MOL CANCER THER, V8, P1055, DOI 10.1158/1535-7163.MCT-08-1046; deFazio A, 2000, INT J CANCER, V87, P487, DOI 10.1002/1097-0215(20000815)87:4<487::AID-IJC5>3.0.CO;2-J; Ferlini C, 2007, CURR CANCER DRUG TAR, V7, P704, DOI 10.2174/156800907783220453; Grupka NL, 2004, ARCH PATHOL LAB MED, V128, P974; Hawthorne VS, 2009, MOL CANCER RES, V7, P592, DOI 10.1158/1541-7786.MCR-08-0316; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Huang XP, 2010, CANCER RES, V70, P1204, DOI 10.1158/0008-5472.CAN-09-3321; Huang XP, 2009, CANCER RES, V69, P8403, DOI 10.1158/0008-5472.CAN-09-2146; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Jensen EV, 2003, CLIN CANCER RES, V9, P1980; Kim A, 2005, BREAST CANCER RES, V7, pR708, DOI 10.1186/bcr1281; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Liu BL, 2007, INT J CANCER, V120, P1874, DOI 10.1002/ijc.22423; Liu BL, 2009, MOL CANCER RES, V7, P1882, DOI 10.1158/1541-7786.MCR-08-0509; Liu Q, 2008, CANCER BIOL THER, V7, P1053, DOI 10.4161/cbt.7.7.6100; Lu J, 2009, CLIN CANCER RES, V15, P1326, DOI 10.1158/1078-0432.CCR-08-0954; Mita AC, 2008, CLIN CANCER RES, V14, P5000, DOI 10.1158/1078-0432.CCR-08-0746; Morgillo F, 2006, CANCER RES, V66, P10100, DOI 10.1158/0008-5472.CAN-06-1684; Morris PG, 2009, EXPERT REV ANTICANC, V9, P175, DOI 10.1586/14737140.9.2.175; Nahta R, 2007, ONCOGENE, V26, P3637, DOI 10.1038/sj.onc.1210379; Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509; Oh SH, 2008, CLIN CANCER RES, V14, P1581, DOI 10.1158/1078-0432.CCR-07-0952; Orr GA, 2003, ONCOGENE, V22, P7280, DOI 10.1038/sj.onc.1206934; Pack SD, 2004, CANCER RES, V64, P789, DOI 10.1158/0008-5472.CAN-03-1982; Saloustros E, 2008, EXPERT OPIN PHARMACO, V9, P2603, DOI 10.1517/14656566.9.15.2603 ; Schulze WX, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100012; Seve P, 2008, LANCET ONCOL, V9, P168, DOI 10.1016/S1470-2045(08)70029-9; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tan M, 2002, MOL CELL, V9, P993, DOI 10.1016/S1097-2765(02)00510-5; THOR AD, 1989, CANCER RES, V49, P7147; Vaira V, 2007, ONCOGENE, V26, P2678, DOI 10.1038/sj.onc.1210094; van Amerongen R, 2006, GENE DEV, V20, P1975, DOI 10.1101/gad.1460806; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Xia WL, 2006, CANCER RES, V66, P1640, DOI 10.1158/0008-5472.CAN-05-2000; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu DH, 1996, ONCOGENE, V13, P1359	49	94	97	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2010	29	29					4225	4236		10.1038/onc.2010.180	http://dx.doi.org/10.1038/onc.2010.180			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20498641				2022-12-17	WOS:000280151500010
J	Senapati, S; Rachagani, S; Chaudhary, K; Johansson, SL; Singh, RK; Batra, SK				Senapati, S.; Rachagani, S.; Chaudhary, K.; Johansson, S. L.; Singh, R. K.; Batra, S. K.			Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway	ONCOGENE			English	Article						MIC-1; prostate; cancer; metastasis	TGF-BETA SUPERFAMILY; FOCAL-ADHESION KINASE; MORPHOGENETIC PROTEIN; BONE METASTASES; GROWTH-FACTOR; WEIGHT-LOSS; EXPRESSION; MEMBER; MIC-1; ACTIVATION	An elevated level of macrophage inhibitory cytokine-1 (MIC-1) is reported in the sera of patients with metastatic prostate cancer compared with that of benign diseases and healthy adults. We investigated the mechanistic role of MIC-1 overexpression in the metastasis of prostate cancer cells. Our study showed a progressive increase in secretory MIC-1 production correlated with the increase in the metastatic potential of PC-3 and LNPCa prostate cancer metastatic variants. Further, the in vitro studies using 'loss-' and 'gain'-of-function approaches showed that ectopic overexpression of MIC-1 (PC-3-MIC-1) and forced downregulation of MIC-1(PC-3M-siMIC-1) enhanced and reduced the motility and invasiveness of these cells, respectively. Supporting our in vitro observations, all the mice orthotopically implanted with PC-3-MIC-1 cells developed metastasis compared with none in the PC-3-vector group. Our results showed that MIC-1 overexpression was associated with apparent changes in actin organization. In addition, an enhanced phosphorylation of focal adhesion kinase (FAK) and guanosine-5'-triphosphate (GTP)-bound RhoA was also seen; however, no significant change was observed in total FAK and RhoA levels in the PC-3-MIC-1 cells. Altogether, our findings show that MIC-1 has a role in prostate cancer metastasis, in part, by promoting the motility of these cells. Activation of the FAK-RhoA signaling pathway is involved in MIC-1-mediated actin reorganization, and thus, leads to an increase in the motility of prostate cancer cells. Oncogene (2010) 29, 1293-1302; doi:10.1038/onc.2009.420; published online 30 November 2009	[Batra, S. K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.	sbatra@unmc.edu		Senapati, Shantibhusan/0000-0001-7108-8255	Department of Defense [PC040502, PC074289]; NCI Cancer Center [P30 CA36727]; NATIONAL CANCER INSTITUTE [P30CA036727, R01CA078590] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported, in part, by grants from the Department of Defense (PC040502 and PC074289). We thank Dr Ajay P Singh for reading the paper and for his valuable suggestions. We also thank Erik Moore for his technical assistance and Kristi LW Berger for editing the paper. We also acknowledge the NCI Cancer Center Support Grant (P30 CA36727) to UNMC.	Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Banyard J, 1998, CANCER METAST REV, V17, P449, DOI 10.1023/A:1006150007710; Barrack ER, 1997, PROSTATE, V31, P61; Bauskin AR, 2005, CANCER RES, V65, P2330, DOI 10.1158/0008-5472.CAN-04-3827; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bottner M, 1999, CELL TISSUE RES, V297, P103, DOI 10.1007/s004410051337; Chen SJ, 2007, PROSTATE, V67, P557, DOI 10.1002/pros.20551; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969; Fairlie WD, 1999, J LEUKOCYTE BIOL, V65, P2, DOI 10.1002/jlb.65.1.2; Hodge JC, 2003, CANCER RES, V63, P1359; Hromas R, 1997, BBA-GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167-4781(97)00122-X; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Johnen H, 2007, NAT MED, V13, P1333, DOI 10.1038/nm1677; Karan D, 2003, BIOCHEM BIOPH RES CO, V305, P598, DOI 10.1016/S0006-291X(03)00823-4; Karan D, 2002, CARCINOGENESIS, V23, P967, DOI 10.1093/carcin/23.6.967; Karan D, 2009, CANCER RES, V69, P2, DOI 10.1158/0008-5472.CAN-08-1230; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; Lambert JR, 2006, J CELL PHYSIOL, V208, P566, DOI 10.1002/jcp.20692; Lawton LN, 1997, GENE, V203, P17, DOI 10.1016/S0378-1119(97)00485-X; Lee DH, 2003, CANCER RES, V63, P4648; Liu T, 2003, CANCER RES, V63, P5034; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; Patrikainen L, 2007, EUR J CLIN INVEST, V37, P126, DOI 10.1111/j.1365-2362.2007.01763.x; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Robinson Victoria L, 2004, Cancer Treat Res, V118, P1; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Selander KS, 2007, CANCER EPIDEM BIOMAR, V16, P532, DOI 10.1158/1055-9965.EPI-06-0841; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; Wakchoure S, 2009, PROSTATE, V69, P652, DOI 10.1002/pros.20913; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100; Zhai JB, 2003, J BIOL CHEM, V278, P24865, DOI 10.1074/jbc.M302381200	35	94	104	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1293	1302		10.1038/onc.2009.420	http://dx.doi.org/10.1038/onc.2009.420			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19946339	Green Accepted			2022-12-17	WOS:000275170600005
J	Zhu, S; Sachdeva, M; Wu, F; Lu, Z; Mo, YY				Zhu, S.; Sachdeva, M.; Wu, F.; Lu, Z.; Mo, Y-Y			Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner	ONCOGENE			English	Article						cell invasion; metastasis; miRNA; miR-224; CXCR4; Ubc9	CANCER-CELLS; REPRESSORS ZEB1; RT-PCR; SUMO; MICRORNAS; PROTEIN; ALPHA; EXPRESSION; INDUCTION; RECEPTOR	Ubc9 is an E2-conjugating enzyme that transfers the activated small ubiquitin-like modifier (SUMO) to protein substrates, and thus it has an important function in sumoylation-mediated cellular pathways. We have earlier reported that Ubc9 promotes tumor growth in the xenograft mouse model using breast cancer cell line MCF-7 in part through regulation of Bcl-2 expression. In this study, we show that ectopic expression of wild-type Ubc9 (Ubc9-WT) promotes cell invasion and metastasis. Surprisingly, the dominant negative mutant Ubc9 (Ubc9-DN) also causes the same phenotype, indicating that the ability of Ubc9 to promote invasion and metastasis is distinct from its ability to conjugate SUMO to protein substrates. Of considerable interest, several microRNAs such as miR-224 are regulated by Ubc9. Although ectopic expression of Ubc9 causes downregulation of miR-224, suppression of Ubc9 by Ubc9-siRNAs leads to its upregulation. We further show that miR-224 can inhibit cell invasion and directly targets CDC42 and CXCR4, and that suppression of CDC42 and CXCR4 by RNAi causes inhibition of Ubc9-mediated invasion. Together, these results show a molecular link between Ubc9 and the metastasis genes such as CDC42 and CXCR4, and thus provide new insight into the mechanism by which Ubc9 promotes tumor invasion and metastasis. Oncogene (2010) 29, 1763-1772; doi:10.1038/onc.2009.459; published online 21 December 2009	[Zhu, S.; Sachdeva, M.; Wu, F.; Lu, Z.; Mo, Y-Y] So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL 62794 USA	Southern Illinois University System; Southern Illinois University	Mo, YY (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, 825 N Rutledge,POB 19626, Springfield, IL 62794 USA.	ymo@siumed.edu	Mo, Yin-Yuan/B-6141-2011; zhu, shoumin/F-4564-2011; Mo, Yin-Yuan/R-8255-2019		NCI [CA102630]; Illinois Department of Public Health; NATIONAL CANCER INSTITUTE [R01CA102630] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Illinois Department of Public Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Joan Massague for providing LM2-4142 cells. This study is supported by grants CA102630 from NCI and postdoctoral fellowship award from Illinois Department of Public Health.	Baek SH, 2006, CELL CYCLE, V5, P1492, DOI 10.4161/cc.5.14.3008; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Guo YG, 2008, BIOCHEM BIOPH RES CO, V374, P570, DOI 10.1016/j.bbrc.2008.07.064; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He XY, 2007, CANCER RES, V67, P11099, DOI 10.1158/0008-5472.CAN-07-2672; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kaul S, 2002, J BIOL CHEM, V277, P12541, DOI 10.1074/jbc.M112330200; Kim JH, 2006, NAT CELL BIOL, V8, P631, DOI 10.1038/ncb1415; Kobayashi S, 2004, ENDOCR RES, V30, P617, DOI 10.1081/ERC-200043789; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kurihara I, 2005, J BIOL CHEM, V280, P6721, DOI 10.1074/jbc.M411820200; Kurtzman AL, 2001, P NATL ACAD SCI USA, V98, P5602, DOI 10.1073/pnas.101129698; Lao KQ, 2006, BIOCHEM BIOPH RES CO, V343, P85, DOI 10.1016/j.bbrc.2006.02.106; Liu LB, 2007, DIABETES, V56, P1977, DOI 10.2337/db06-1100; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; Lu ZH, 2006, EXP CELL RES, V312, P1865, DOI 10.1016/j.yexcr.2006.02.017; Ma L, 2008, TRENDS GENET, V24, P448, DOI 10.1016/j.tig.2008.06.004; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; McDoniels-Silvers AL, 2002, CLIN CANCER RES, V8, P1127; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Mo YY, 1999, EXP CELL RES, V252, P50, DOI 10.1006/excr.1999.4616; Mo YY, 2005, EXPERT OPIN THER TAR, V9, P1203, DOI 10.1517/14728222.9.6.1203; Mo YY, 2005, ONCOGENE, V24, P2677, DOI 10.1038/sj.onc.1208210; Moschos SJ, 2007, ONCOGENE, V26, P4216, DOI 10.1038/sj.onc.1210216; Nacerddine K, 2005, DEV CELL, V9, P769, DOI 10.1016/j.devcel.2005.10.007; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pillai RS, 2005, RNA, V11, P1753, DOI 10.1261/rna.2248605; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Sentis S, 2005, MOL ENDOCRINOL, V19, P2671, DOI 10.1210/me.2005-0042; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Singh SK, 2008, NATURE, V453, P223, DOI 10.1038/nature06863; Tomoiu A, 2006, J VIROL, V80, P10218, DOI 10.1128/JVI.00375-06; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Wilke K, 1997, GENOMICS, V45, P1, DOI 10.1006/geno.1997.4885; Wu FT, 2009, CLIN CANCER RES, V15, P1550, DOI 10.1158/1078-0432.CCR-08-0820; Zamore PD, 2005, SCIENCE, V309, P1519, DOI 10.1126/science.1111444; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	41	94	99	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1763	1772		10.1038/onc.2009.459	http://dx.doi.org/10.1038/onc.2009.459			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20023705	Green Accepted			2022-12-17	WOS:000276022800006
J	Hao, L; Rizzo, P; Osipo, C; Pannuti, A; Wyatt, D; Cheung, LWK; Sonenshein, G; Osborne, BA; Miele, L				Hao, L.; Rizzo, P.; Osipo, C.; Pannuti, A.; Wyatt, D.; Cheung, L. W-K; Sonenshein, G.; Osborne, B. A.; Miele, L.			Notch-1 activates estrogen receptor-alpha-dependent transcription via IKK alpha in breast cancer cells	ONCOGENE			English	Article						breast cancer; estrogen; ER alpha; IKK alpha; Notch-1	NF-KAPPA-B; EPIDERMAL-GROWTH-FACTOR; CYCLIN D1; INDEPENDENT ACTIVATION; KINASE PATHWAY; C-MYC; GENE; TARGET; BINDING; EXPRESSION	Approximately 80% of breast cancers express the estrogen receptor-alpha (ER alpha) and are treated with anti-estrogens. Resistance to these agents is a major cause of mortality. We have shown that estrogen inhibits Notch, whereas anti-estrogens or estrogen withdrawal activate Notch signaling. Combined inhibition of Notch and estrogen signaling has synergistic effects in ER alpha-positive breast cancer models. However, the mechanisms whereby Notch-1 promotes the growth of ER alpha-positive breast cancer cells are unknown. Here, we demonstrate that Notch-1 increases the transcription of ER alpha-responsive genes in the presence or absence of estrogen via a novel chromatin crosstalk mechanism. Our data support a model in which Notch-1 can activate the transcription of ER alpha-target genes via IKK alpha-dependent cooperative chromatin recruitment of Notch-CSL-MAML1 transcriptional complexes (NTC) and ER alpha, which promotes the recruitment of p300. CSL binding elements frequently occur in close proximity to estrogen-responsive elements (EREs) in the human and mouse genomes. Our observations suggest that a hitherto unknown Notch-1/ER alpha chromatin crosstalk mediates Notch signaling effects in ER alpha-positive breast cancer cells and contributes to regulate the transcriptional functions of ER alpha itself. Oncogene (2010) 29, 201-213; doi:10.1038/onc.2009.323; published online 19 October 2009	[Pannuti, A.; Miele, L.] Univ Mississippi, Med Ctr, Inst Canc, Jackson, MS 39216 USA; [Hao, L.; Rizzo, P.; Osipo, C.; Wyatt, D.; Cheung, L. W-K] Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Breast Canc Program, Maywood, IL USA; [Cheung, L. W-K] Loyola Univ Chicago, Dept Prevent Med & Bioinformat Core, Maywood, IL USA; [Sonenshein, G.] Boston Univ, Dept Biochem, Boston, MA 02215 USA; [Osborne, B. A.] Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA	University of Mississippi; University of Mississippi Medical Center; Loyola University Chicago; Loyola University Chicago; Boston University; University of Massachusetts System; University of Massachusetts Amherst	Miele, L (corresponding author), Univ Mississippi, Med Ctr, Inst Canc, 2500 N State St,Guyton 2 Bldg,Suite G751-05, Jackson, MS 39216 USA.	lmiele@ci.umsmed.edu		Miele, Lucio/0000-0002-5853-7287; rizzo, paola/0000-0001-7174-9674	Schmitt Fellowship Foundation;  [P01AG025531]; NATIONAL INSTITUTE ON AGING [P01AG025531] Funding Source: NIH RePORTER	Schmitt Fellowship Foundation; ; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by Grant P01AG025531 (LM, BAO) and the Schmitt Fellowship Foundation (LH). We are grateful to Geraldine Weinmaster, Peter Strack and Rafi Kopan for the gift of reagents and cell lines, and to Sarah Bray for helpful discussions.	Aguilera C, 2004, P NATL ACAD SCI USA, V101, P16537, DOI 10.1073/pnas.0404429101; Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; Arsura M, 2003, ONCOGENE, V22, P412, DOI 10.1038/sj.onc.1206132; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Baonza A, 2005, DEV CELL, V8, P529, DOI 10.1016/j.devcel.2005.01.019; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Callahan R, 2004, J MAMMARY GLAND BIOL, V9, P145, DOI 10.1023/B:JOMG.0000037159.63644.81; Callahan R, 2001, J MAMMARY GLAND BIOL, V6, P23, DOI 10.1023/A:1009512414430; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Cenni B, 1999, TRENDS ENDOCRIN MET, V10, P41, DOI 10.1016/S1043-2760(98)00121-0; Cheng PY, 2001, J IMMUNOL, V167, P4458, DOI 10.4049/jimmunol.167.8.4458; Dickson BC, 2007, MODERN PATHOL, V20, P685, DOI 10.1038/modpathol.3800785; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; DUBIK D, 1992, ONCOGENE, V7, P1587; Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006; ElShamy WM, 2004, NAT CELL BIOL, V6, P954, DOI 10.1038/ncb1171; Fernandez-Majada V, 2007, P NATL ACAD SCI USA, V104, P276, DOI 10.1073/pnas.0606476104; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Gallahan D, 1996, CANCER RES, V56, P1775; Gillesby BE, 1997, BIOCHEMISTRY-US, V36, P6080, DOI 10.1021/bi962131b; Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Hayward P, 2005, DEVELOPMENT, V132, P1819, DOI 10.1242/dev.01724; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200; Jehn BM, 1999, J IMMUNOL, V162, P635; JELTSCH JM, 1987, NUCLEIC ACIDS RES, V15, P1401, DOI 10.1093/nar/15.4.1401; Ribeiro MSJ, 2007, BIOCHEM J, V404, P289, DOI 10.1042/BJ20061900; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kiaris H, 2004, AM J PATHOL, V165, P695, DOI 10.1016/S0002-9440(10)63333-0; Klinakis A, 2006, P NATL ACAD SCI USA, V103, P9262, DOI 10.1073/pnas.0603371103; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Likhite VS, 2006, MOL ENDOCRINOL, V20, P3120, DOI 10.1210/me.2006-0068; Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087; Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354; Martin MB, 2000, ENDOCRINOLOGY, V141, P4503, DOI 10.1210/en.141.12.4503; Miele L, 2006, CLIN CANCER RES, V12, P1074, DOI 10.1158/1078-0432.CCR-05-2570; Miele L, 2008, EXPERT REV ANTICANC, V8, P1197, DOI 10.1586/14737140.8.8.1197; Nam YS, 2007, P NATL ACAD SCI USA, V104, P2103, DOI 10.1073/pnas.0611092104; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006; Perissi V, 2005, NAT REV MOL CELL BIO, V6, P542, DOI 10.1038/nrm1680; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Reedijk M, 2008, BREAST CANCER RES TR, V111, P439, DOI 10.1007/s10549-007-9805-3; Rizzo P, 2008, CANCER RES, V68, P5226, DOI 10.1158/0008-5472.CAN-07-5744; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Shen Q, 2008, ONCOGENE, V27, P366, DOI 10.1038/sj.onc.1210643; Song LL, 2008, ONCOGENE, V27, P5833, DOI 10.1038/onc.2008.190; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Vooijs M, 2004, J BIOL CHEM, V279, P50864, DOI 10.1074/jbc.M409430200; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Wu J, 2005, MOL CELL BIOL, V25, P1458, DOI 10.1128/MCB.25.4.1458-1474.2005; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	61	94	98	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					201	213		10.1038/onc.2009.323	http://dx.doi.org/10.1038/onc.2009.323			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19838210	Green Accepted			2022-12-17	WOS:000273650000004
J	Justilien, V; Fields, AP				Justilien, V.; Fields, A. P.			Ect2 links the PKC iota-Par6 alpha complex to Rac1 activation and cellular transformation	ONCOGENE			English	Article						gene amplification; anchorage-independent growth; invasion; Rac1; Mek-Erk signaling; cytokinesis	CYTOKINESIS REGULATOR ECT2; EXCHANGE FACTOR ECT2; KINASE-C-IOTA; DETECTS FREQUENT; LUNG-CANCER; G2/M PHASE; PROTEIN; CARCINOMAS; AMPLIFICATION; HYBRIDIZATION	Protein kinase C iota (PKC iota) promotes non-small cell lung cancer (NSCLC) by binding to Par6 alpha and activating a Rac1-Pak-Mek1,2-Erk1,2 signaling cascade. The mechanism by which the PKC iota-Par6 alpha complex regulates Rac1 is unknown. Here we show that epithelial cell transforming sequence 2 (Ect2), a guanine nucleotide exchange factor for Rho family GTPases, is coordinately amplified and overexpressed with PKC iota in NSCLC tumors. RNA interference-mediated knockdown of Ect2 inhibits Rac1 activity and blocks transformed growth, invasion and tumorigenicity of NSCLC cells. Expression of constitutively active Rac1 (RacV12) restores transformation to Ect2-deficient cells. Interestingly, the role of Ect2 in transformation is distinct from its well-established role in cytokinesis. In NSCLC cells, Ect2 is mislocalized to the cytoplasm where it binds the PKC iota-Par6 alpha complex. RNA interference-mediated knockdown of either PKC iota or Par6 alpha causes Ect2 to redistribute to the nucleus, indicating that the PKC iota-Par6 alpha complex regulates the cytoplasmic localization of Ect2. Our data indicate that Ect2 and PKC iota are genetically and functionally linked in NSCLC, acting to coordinately drive tumor cell proliferation and invasion through formation of an oncogenic PKC iota-Par6 alpha-Ect2 complex. Oncogene (2009) 28, 3597-3607; doi:10.1038/onc.2009.217; published online 20 July 2009	[Justilien, V.; Fields, A. P.] Mayo Clin, Coll Med, Dept Canc Biol, Jacksonville, FL 32224 USA	Mayo Clinic	Fields, AP (corresponding author), Mayo Clin, Coll Med, Dept Canc Biol, Griffin Canc Res Bldg,Rm 212,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	fields.alan@mayo.edu			National Institutes of Health [CA081436]; V Foundation for Cancer Research; Mayo Foundation; NATIONAL CANCER INSTITUTE [R01CA081436] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); V Foundation for Cancer Research; Mayo Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Dr Roderick P Regala for assistance with the ectopic tumor studies, Dr Andras Khoor and Capella Weems for analysis of primary NSCLC tumors, Pam Kreinest and Brandy Eden. eld for immunohistochemistry, Dr Lee Jamieson and Alyssa Kunz for technical assistance, and Drs E Aubrey Thompson and Nicole R Murray for critical review of the paper. This work was supported in part by grants from the National Institutes of Health (CA081436), The V Foundation for Cancer Research and The Mayo Foundation to APF.	Balsara BR, 1997, CANCER RES, V57, P2116; Brass N, 1996, EUR J CANCER, V32A, P1205, DOI 10.1016/0959-8049(96)00016-0; FREDERICK LA, 2008, ONCOGENE; Hara T, 2006, ONCOGENE, V25, P566, DOI 10.1038/sj.onc.1209078; Hirata D, 2009, CLIN CANCER RES, V15, P256, DOI 10.1158/1078-0432.CCR-08-1672; Imoto I, 2001, BIOCHEM BIOPH RES CO, V286, P559, DOI 10.1006/bbrc.2001.5428; Kanada M, 2008, MOL BIOL CELL, V19, P8, DOI 10.1091/mbc.E07-04-0370; Kim JE, 2005, J BIOL CHEM, V280, P5733, DOI 10.1074/jbc.M409298200; Liu XF, 2004, MOL CELL BIOL, V24, P6665, DOI 10.1128/mcb.24.15.6665-6675.2004; Liu XF, 2006, CELL SIGNAL, V18, P1604, DOI 10.1016/j.cellsig.2006.01.007; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Niiya F, 2006, ONCOGENE, V25, P827, DOI 10.1038/sj.onc.1209124; Niiya F, 2005, J BIOL CHEM, V280, P36502, DOI 10.1074/jbc.M508007200; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Saito S, 2004, J BIOL CHEM, V279, P7169, DOI 10.1074/jbc.M306725200; Saito S, 2003, J CELL BIOCHEM, V90, P819, DOI 10.1002/jcb.10688; Salhia B, 2008, AM J PATHOL, V173, P1828, DOI 10.2353/ajpath.2008.080043; Sano M, 2006, ONCOL REP, V16, P1093; Snaddon J, 2001, BRIT J CANCER, V84, P1630, DOI 10.1054/bjoc.2001.1848; Solski PA, 2004, J BIOL CHEM, V279, P25226, DOI 10.1074/jbc.M313792200; Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320; Sugita M, 2000, CANCER GENET CYTOGEN, V117, P9, DOI 10.1016/S0165-4608(99)00135-1; TAKAI S, 1995, GENOMICS, V27, P220, DOI 10.1006/geno.1995.1033; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200; Zhang ML, 2008, HEPATOB PANCREAT DIS, V7, P533	27	94	103	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2009	28	41					3597	3607		10.1038/onc.2009.217	http://dx.doi.org/10.1038/onc.2009.217			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KJ	19617897	Green Accepted			2022-12-17	WOS:000270851800001
J	Knobbe, CB; Lapin, V; Suzuki, A; Mak, TW				Knobbe, C. B.; Lapin, V.; Suzuki, A.; Mak, T. W.			The roles of PTEN in development, physiology and tumorigenesis in mouse models: a tissue-by-tissue survey	ONCOGENE			English	Review						PTEN; mouse; conditional gene-targeting; KO	TUMOR-SUPPRESSOR GENE; PTEN/PI3K PATHWAY GOVERNS; HEMATOPOIETIC STEM-CELLS; MICE LACKING PTEN; CRE RECOMBINASE; NEGATIVE REGULATION; CONDITIONAL LOSS; DEFICIENT MICE; LUNG-CANCER; SOMA SIZE	In 1997, PTEN (phosphatase and tensin homologue deleted on chromosome 10, 10q23.3) was identified as an important tumor suppressor gene that is inactivated in a wide variety of human cancers. Ever since, PTEN's function has been extensively studied, and huge progress has been made in understanding PTEN's role in normal physiology and disease. In this review, we will systematically summarize the important data that have been gained from gene inactivation studies in mice and will put these data into physiological context using a tissue-by-tissue approach. We will cover mice exhibiting complete and constitutive inactivation of Pten as well as a large number of strains in which Pten has been conditionally deleted in specific tissues. We hope to highlight not only the tumor suppressive function of Pten but also its roles in embryogenesis and in the maintenance of the normal physiological functions of many organ systems.	[Knobbe, C. B.; Lapin, V.; Mak, T. W.] Univ Toronto, Campbell Family Inst Breast Canc Res, Toronto, ON, Canada; [Lapin, V.; Mak, T. W.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Suzuki, A.] Kyushu Univ, Med Inst Bioregulat, Div Embryon & Genet Engn, Fukuoka 812, Japan	University of Toronto; University of Toronto; Kyushu University	Mak, TW (corresponding author), Princess Margaret Hosp, Univ Hlth Network, 7th Floor,Room 706,620 Univ Ave, Toronto, ON M5G 2C1, Canada.	tmak@uhnres.utoronto.ca	Knobbe-Thomsen, Christiane B/D-3116-2019; Suzuki, Akira/GYD-6697-2022; Knobbe-Thomsen, Christiane/J-4963-2014	Suzuki, Akira/0000-0002-5950-8808; Knobbe-Thomsen, Christiane/0000-0003-1231-0076	Alexander-von-Humboldt Foundation; Canadian Institutes of Health Research	Alexander-von-Humboldt Foundation(Alexander von Humboldt Foundation); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We thank Mary Saunders for editing. CBK is supported by the Alexander-von-Humboldt Foundation. VL is supported by a Doctoral Research Award from the Canadian Institutes of Health Research.	Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Anzelon AN, 2003, NAT IMMUNOL, V4, P287, DOI 10.1038/ni892; Aveyard JS, 1999, BRIT J CANCER, V80, P904, DOI 10.1038/sj.bjc.6690439; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; Backman SA, 2002, CURR OPIN NEUROBIOL, V12, P516, DOI 10.1016/S0959-4388(02)00354-9; Butler MG, 2005, J MED GENET, V42, P318, DOI 10.1136/jmg.2004.024646; Chalhoub N, 2006, BRAIN RES, V1100, P32, DOI 10.1016/j.brainres.2006.05.013; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; DeMarzo AM, 2003, LANCET, V361, P955, DOI 10.1016/S0140-6736(03)12779-1; Deocampo N D, 2003, Minerva Endocrinol, V28, P145; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Ford-Hutchinson AF, 2007, J BONE MINER RES, V22, P1245, DOI 10.1359/JBMR.070420; Fraser MM, 2004, CANCER RES, V64, P7773, DOI 10.1158/0008-5472.CAN-04-2487; Groszer M, 2006, P NATL ACAD SCI USA, V103, P111, DOI 10.1073/pnas.0509939103; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Hagenbeek TJ, 2008, LEUKEMIA, V22, P608, DOI 10.1038/sj.leu.2405056; Hagenbeek TJ, 2004, J EXP MED, V200, P883, DOI 10.1084/jem.20040495; Hamada K, 2005, GENE DEV, V19, P2054, DOI 10.1101/gad.1308805; He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928; Herman GE, 2007, GENET MED, V9, P268, DOI 10.1097/GIM.0b013e31804d683b; Hernando E, 2007, NAT MED, V13, P748, DOI 10.1038/nm1560; Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513; Inoue-Narita T, 2008, CANCER RES, V68, P5760, DOI 10.1158/0008-5472.CAN-08-0889; Kimura T, 2003, DEVELOPMENT, V130, P1691, DOI 10.1242/dev.00392; Kishimoto H, 2007, BLOOD, V109, P3316, DOI 10.1182/blood-2006-07-038059; Knobbe CB, 2002, NEURO-ONCOLOGY, V4, P196; Kola B, 2006, TRENDS ENDOCRIN MET, V17, P205, DOI 10.1016/j.tem.2006.05.006; Kurlawalla-Martinez C, 2005, MOL CELL BIOL, V25, P2498, DOI 10.1128/MCB.25.6.2498-2510.2005; Kuroda S, 2008, EUR J IMMUNOL, V38, P1331, DOI 10.1002/eji.200737302; Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781; Kwon CH, 2003, P NATL ACAD SCI USA, V100, P12923, DOI 10.1073/pnas.2132711100; Kwon CH, 2006, NEURON, V50, P377, DOI 10.1016/j.neuron.2006.03.023; Li G, 2002, DEVELOPMENT, V129, P4159; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li Y, 2001, BMC Mol Biol, V2, P2, DOI 10.1186/1471-2199-2-2; Liu JH, 2000, MOL CARCINOGEN, V29, P143, DOI 10.1002/1098-2744(200011)29:3<143::AID-MC3>3.0.CO;2-A; Liu XM, 2007, P NATL ACAD SCI USA, V104, P2259, DOI 10.1073/pnas.0604153104; Lomeli H, 2000, GENESIS, V26, P116, DOI 10.1002/(SICI)1526-968X(200002)26:2<116::AID-GENE4>3.0.CO;2-X; Lu TL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001237; Ma XQ, 2005, CANCER RES, V65, P5730, DOI 10.1158/0008-5472.CAN-04-4519; Maddison LA, 2000, GENESIS, V26, P154, DOI 10.1002/(SICI)1526-968X(200002)26:2<154::AID-GENE18>3.0.CO;2-2; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marandola P, 2004, ANN NY ACAD SCI, V1028, P294, DOI 10.1196/annals.1322.034; Marino S, 2002, DEVELOPMENT, V129, P3513; Marsit CJ, 2005, HUM PATHOL, V36, P768, DOI 10.1016/j.humpath.2005.05.006; Nguyen KTT, 2006, MOL CELL BIOL, V26, P4511, DOI 10.1128/MCB.00238-06; Nishio M, 2007, NAT CELL BIOL, V9, P36, DOI 10.1038/ncb1515; Ogawa S, 2007, BRAIN RES, V1168, P112, DOI 10.1016/j.brainres.2007.06.074; Oudit GY, 2008, CARDIOVASC RES, V78, P505, DOI 10.1093/cvr/cvn041; Ovchinnikov DA, 2000, GENESIS, V26, P145, DOI 10.1002/(SICI)1526-968X(200002)26:2<145::AID-GENE14>3.0.CO;2-C; Pasqualucci L, 2008, NAT GENET, V40, P108, DOI 10.1038/ng.2007.35; Plum L, 2006, J CLIN INVEST, V116, P1886, DOI 10.1172/JCI27123; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Postic C, 2001, RECENT PROG HORM RES, V56, P195, DOI 10.1210/rp.56.1.195; Ratnacaram CK, 2008, P NATL ACAD SCI USA, V105, P2521, DOI 10.1073/pnas.0712021105; Reddy P, 2008, SCIENCE, V319, P611, DOI 10.1126/science.1152257; Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; Shao J, 2007, CARCINOGENESIS, V28, P2476, DOI 10.1093/carcin/bgm186; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2000, CANCER RES, V60, P3605; Stanger BZ, 2005, CANCER CELL, V8, P185, DOI 10.1016/j.ccr.2005.07.015; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100; Stiles BL, 2006, MOL CELL BIOL, V26, P2772, DOI 10.1128/MCB.26.7.2772-2781.2006; Subramanian KK, 2007, BLOOD, V109, P4028, DOI 10.1182/blood-2006-10-055319; Suzuki A, 2007, BIOCHEM SOC T, V35, P172, DOI 10.1042/BST0350172; Suzuki A, 2004, BIOCHEM SOC T, V32, P362, DOI 10.1042/BST0320362; Suzuki A, 2003, J EXP MED, V197, P657, DOI 10.1084/jem.20021101; Suzuki A, 2003, CANCER RES, V63, P674; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tang JM, 2006, LUNG CANCER, V51, P181, DOI 10.1016/j.lungcan.2005.10.003; Taniyama K, 2001, J PATHOL, V194, P341, DOI 10.1002/path.908; Teng Y, 2006, CANCER RES, V66, P6972, DOI 10.1158/0008-5472.CAN-06-0507; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Tsuruta H, 2006, CANCER RES, V66, P8389, DOI 10.1158/0008-5472.CAN-05-4627; van Nederveen FH, 2006, J PATHOL, V209, P274, DOI 10.1002/path.1968; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Walker GJ, 2002, J INVEST DERMATOL, V119, P783, DOI 10.1046/j.1523-1747.2002.00217.x; Wang DS, 2000, INT J CANCER, V88, P620, DOI 10.1002/1097-0215(20001115)88:4<620::AID-IJC16>3.0.CO;2-Z; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wei QX, 2006, CANCER RES, V66, P7429, DOI 10.1158/0008-5472.CAN-06-0712; WIESTLER OD, 2000, WHO CLASSIFICATION T; Wijesekara N, 2005, MOL CELL BIOL, V25, P1135, DOI 10.1128/MCB.25.3.1135-1145.2005; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Xue L, 2008, P NATL ACAD SCI USA, V105, P2022, DOI 10.1073/pnas.0712059105; Yanagi S, 2007, J CLIN INVEST, V117, P2929, DOI 10.1172/JCI31854; Yang LL, 2005, CANCER RES, V65, P8671, DOI 10.1158/0008-5472.CAN-05-0800; Yeager N, 2007, CANCER RES, V67, P959, DOI 10.1158/0008-5472.CAN-06-3524; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Yoo LI, 2006, CANCER RES, V66, P1929, DOI 10.1158/0008-5472.CAN-05-1986; You MJ, 2002, P NATL ACAD SCI USA, V99, P1455, DOI 10.1073/pnas.022632099; Yue Q, 2005, DEVELOPMENT, V132, P3281, DOI 10.1242/dev.01891; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200; Zhu D, 2006, P NATL ACAD SCI USA, V103, P14836, DOI 10.1073/pnas.0605722103	102	94	98	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2008	27	41					5398	5415		10.1038/onc.2008.238	http://dx.doi.org/10.1038/onc.2008.238			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794876				2022-12-17	WOS:000259280700003
J	Hafner, N; Driesch, C; Gajda, M; Jansen, L; Kirchmayr, R; Runnebaum, IB; Durst, M				Hafner, N.; Driesch, C.; Gajda, M.; Jansen, L.; Kirchmayr, R.; Runnebaum, I. B.; Duerst, M.			Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts	ONCOGENE			English	Article						cervical cancer; HPV16; oncogene expression; physical state; integration	HUMAN-PAPILLOMAVIRUS TYPE-16; RISK HUMAN-PAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; IN-SITU HYBRIDIZATION; GENE-EXPRESSION; DNA-REPLICATION; E7 ONCOPROTEIN; MESSENGER-RNA; CANCER-CELLS; DIPS-PCR	Virus integration into the host genome is a characteristic step during cervical carcinogenesis. Experimental data provide evidence that integration could result in increased levels of oncogene (E6/E7) transcripts. This is the first study in which the level of viral transcripts is correlated to the physical state of the viral genome in cervical intraepithelial neoplasia (CIN) and cervical carcinomas (CxCa). Using the APOT-assayinteg rate-derived transcripts only were detected in 3/28 (11%) CIN and in 28/55 (51%) carcinomas, respectively. The remaining biopsies contained either episome-derived transcripts only or both mRNA species. SybrGreen real time reverse transcriptase-PCR assays were used to quantify viral gene expression for (i) all transcripts initiated from p97, (ii) full-length E6, (iii) E6*I and (iv) E5 transcripts (E6/E7) transcript levels showed a broad distribution but similar median values irrespective of histopathological grading and physical state of the viral genome. Biopsies with integrate-derived transcripts only generally lacked E5-specific mRNA. Our data do not support the hypothesis that HPV integration invariably results in high levels of oncogene transcripts. Instead, constitutive expression of oncogene transcripts rather than the level of expression appears to be decisive for transformation and the maintenance of the malignant phenotype.	[Hafner, N.; Driesch, C.; Jansen, L.; Runnebaum, I. B.; Duerst, M.] FSU Jena, Frauenklin, D-07743 Jena, Germany; [Gajda, M.] Klinikum Friedrich Schiller Univ, Inst Pathol, Jena, Germany; [Kirchmayr, R.] Gynakol Praxis, Ulm, Germany	Friedrich Schiller University of Jena	Durst, M (corresponding author), FSU Jena, Frauenklin, Bachstr 18, D-07743 Jena, Germany.	matthias.duerst@med.uni-jena.de	Häfner, Norman/B-6892-2012	Häfner, Norman/0000-0002-7012-483X				Alazawi W, 2002, CANCER RES, V62, P6959; Andersson S, 2006, INT J ONCOL, V29, P705; Arends MJ, 1998, J CLIN PATHOL, V51, P96, DOI 10.1136/jcp.51.2.96; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; De Marco L, 2007, J CLIN VIROL, V38, P7, DOI 10.1016/j.jcv.2006.09.008; DOEBERITZ MV, 1991, P NATL ACAD SCI USA, V88, P1411, DOI 10.1073/pnas.88.4.1411; Duensing S, 2004, INT J CANCER, V109, P157, DOI 10.1002/ijc.11691; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; Durst M, 1995, CANCER GENET CYTOGEN, V85, P105, DOI 10.1016/0165-4608(95)00155-7; DURST M, 1987, ONCOGENE, V1, P251; FALCINELLI C, 1993, J MED VIROL, V40, P261, DOI 10.1002/jmv.1890400402; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; Hammerly C, 2022, LINGUIST INQ, V53, P823, DOI 10.1162/ling_a_00422; Hopman AHN, 2005, INT J CANCER, V115, P419, DOI 10.1002/ijc.20862; Itoshima T, 2000, CLIN CANCER RES, V6, P2851; Jacobs MV, 1997, J CLIN MICROBIOL, V35, P791, DOI 10.1128/JCM.35.3.791-795.1997; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Klaes R, 1999, CANCER RES, V59, P6132; Luft F, 2001, INT J CANCER, V92, P9, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1144>3.0.CO;2-L; Melsheimer P, 2004, CLIN CANCER RES, V10, P3059, DOI 10.1158/1078-0432.CCR-03-0565; Middleton K, 2003, J VIROL, V77, P10186, DOI 10.1128/JVI.77.19.10186-10201.2003; Molden T, 2005, CANCER EPIDEM BIOMAR, V14, P367, DOI 10.1158/1055-9965.EPI-04-0410; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; Munoz N, 1992, IARC Sci Publ, P251; Nakagawa S, 2000, J MED VIROL, V62, P251, DOI 10.1002/1096-9071(200010)62:2<251::AID-JMV18>3.0.CO;2-V; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; Peitsaro P, 2002, J CLIN MICROBIOL, V40, P886, DOI 10.1128/JCM.40.3.886-891.2002; Pett MR, 2004, CANCER RES, V64, P1359, DOI 10.1158/0008-5472.CAN-03-3214; Riethdorf S, 2001, INT J GYNECOL PATHOL, V20, P177, DOI 10.1097/00004347-200104000-00011; ROMANCZUK H, 1992, P NATL ACAD SCI USA, V89, P3159, DOI 10.1073/pnas.89.7.3159; Rosty C, 2005, ONCOGENE, V24, P7094, DOI 10.1038/sj.onc.1208854; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SolinasToldo S, 1997, P NATL ACAD SCI USA, V94, P3854, DOI 10.1073/pnas.94.8.3854; Sotlar K, 2004, J MED VIROL, V74, P107, DOI 10.1002/jmv.20153; Van Tine BA, 2004, J VIROL, V78, P11172, DOI 10.1128/JVI.78.20.11172-11186.2004; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wentzensen N, 2004, CANCER RES, V64, P3878, DOI 10.1158/0008-5472.CAN-04-0009; ZerfassThome K, 1996, ONCOGENE, V13, P2323; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	44	94	99	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2008	27	11					1610	1617		10.1038/sj.onc.1210791	http://dx.doi.org/10.1038/sj.onc.1210791			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17828299				2022-12-17	WOS:000253815800013
J	Wendt, MK; Cooper, AN; Dwinell, MB				Wendt, M. K.; Cooper, A. N.; Dwinell, M. B.			Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells	ONCOGENE			English	Article						chemokine; DNA hypermethylation; cancer; metastasis; CXCR4	CHEMOKINE RECEPTOR CXCR4; BREAST-CANCER; FACTOR-I; DOWN-REGULATION; HOST-DEFENSE; TUMOR-GROWTH; EXPRESSION; GENE; HYPERMETHYLATION; ACTIVATION	Expression of the chemokine receptor CXCR4 has been linked with increased metastasis and decreased clinical prognosis in breast cancer. The current paradigm dictates that CXCR4 fosters carcinoma cell metastasis along a chemotactic gradient to organs expressing the ligand CXCL12. The present study asked if alterations in autocrine CXCR4 signaling via dysregulation of CXCL12 in mammary carcinoma cells modulated their metastatic potential. While CXCR4 was consistently detected, expression of CXCL12 characteristic of human mammary epithelium was silenced by promoter hypermethylation in breast cancer cell lines and primary mammary tumors. Stable re-expression of functional CXCL12 in ligand null cells increased orthotopic primary tumor growth in the mammary fat-pad model of tumorigenesis. Those data parallel increased carcinoma cell proliferation measured in vitro with little-to-no-impact on apoptosis. Moreover, re-expression of autocrine CXCL12 markedly reduced metastatic lung invasion assessed using in vivo bioluminescence imaging following tail vein injection. Consistent with those data, decreased metastasis reflected diminished intracellular calcium signaling and chemotactic migration in response to exogenous CXCL12 independent of changes in CXCR4 express ion. Together these data suggest that an elevated migratory signaling response to ectopic CXCL12 contributes to the metastatic potential of CXCR4-expressing mammary carcinoma cells, subsequent to epigenetic silencing of autocrine CXCL12.	[Wendt, M. K.; Cooper, A. N.; Dwinell, M. B.] Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Dwinell, MB (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	mdwinell@mcw.edu		Wendt, Mike/0000-0002-3665-7413				Agace WW, 2000, CURR BIOL, V10, P325, DOI 10.1016/S0960-9822(00)00380-8; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Balkwill F, 2004, SEMIN CANCER BIOL, V14, P171, DOI 10.1016/j.semcancer.2003.10.003; Baylin SB, 2005, COLD SH Q B, V70, P427, DOI 10.1101/sqb.2005.70.010; Brauweiler A, 2007, J IMMUNOL, V178, P3353, DOI 10.4049/jimmunol.178.6.3353; Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9; Dewan MZ, 2006, BIOMED PHARMACOTHER, V60, P273, DOI 10.1016/j.biopha.2006.06.004; Ellison G, 2002, J CLIN PATHOL-MOL PA, V55, P294, DOI 10.1136/mp.55.5.294; Garcia-Moruja C, 2005, J MOL BIOL, V348, P43, DOI 10.1016/j.jmb.2005.02.016; Gazitt Y, 2004, LEUKEMIA, V18, P1, DOI 10.1038/sj.leu.2403173; Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hesselgesser J, 1998, J IMMUNOL, V160, P877; Jenkins DE, 2005, BREAST CANCER RES, V7, pR444, DOI 10.1186/bcr1026; Kimura R, 2003, GENES IMMUN, V4, P356, DOI 10.1038/sj.gene.6363978; McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481; Moyer RA, 2007, LAB INVEST, V87, P807, DOI 10.1038/labinvest.3700595; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagasawa T, 1996, P NATL ACAD SCI USA, V93, P14726, DOI 10.1073/pnas.93.25.14726; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Salvucci O, 2006, BREAST CANCER RES TR, V97, P275, DOI 10.1007/s10549-005-9121-8; Schrader AJ, 2002, BRIT J CANCER, V86, P1250, DOI 10.1038/sj.bjc.6600221; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Smith JM, 2005, AM J PHYSIOL-GASTR L, V288, pG316, DOI 10.1152/ajpgi.00208.2004; Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Ueda Y, 2006, CANCER RES, V66, P5665, DOI 10.1158/0008-5472.CAN-05-3579; Wendt MK, 2006, ONCOGENE, V25, P4986, DOI 10.1038/sj.onc.1209505; Zeelenberg IS, 2003, CANCER RES, V63, P3833; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	34	94	97	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2008	27	10					1461	1471		10.1038/sj.onc.1210751	http://dx.doi.org/10.1038/sj.onc.1210751			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17724466				2022-12-17	WOS:000253548200013
J	Miquel, C; Jacob, S; Grandjouan, S; Aime, A; Viguier, J; Sabourin, JC; Sarasin, A; Duval, A; Praz, F				Miquel, C.; Jacob, S.; Grandjouan, S.; Aime, A.; Viguier, J.; Sabourin, J-C; Sarasin, A.; Duval, A.; Praz, F.			Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability	ONCOGENE			English	Article						colorectal cancer; MSI phenotype; DNA repair; DNA damage signalling; chemotherapy	MONONUCLEOTIDE REPEATS; DEFICIENT CANCERS; MRE11 EXPRESSION; TARGET GENES; MUTATIONS; SEQUENCES; CARCINOGENESIS; PATHOGENESIS	Accumulation of frameshift mutations at genes containing coding mononucleotide repeats is thought to be the major molecular mechanism by which mismatch repair-deficient cells accumulate functional alterations. These mutations resulting from microsatellite instability ( MSI) can affect genes involved in pathways with a putative oncogenic role, but may also arise in genes without any expected role in MSI carcinogenesis because of the high mutation background of these tumours. We here screened 39 MSI colorectal tumours for the presence of mutations in 25 genes involved in DNA damage signalling and repair pathways. Using a maximum likelihood statistical method, these genes were divided into two different groups that differed significantly in their mutation frequencies, and likely represent mutations that do or do not provide selective pressure during MSI tumour progression. Interestingly, the so-called real-target mutational events were found to be distributed among genes involved in different functional pathways of the DNA metabolism, for example, DNA damage signalling ( DNA-PKcs, ATR), double-strand break ( DSB) repair ( DNA-PKcs, RAD50), mismatch repair ( MSH3, MSH6, MBD4) and replication ( POLD3). In particular, mutations in MRE11 and/or RAD50 were observed in the vast majority of the tumours and resulted in the concomitant loss of immunohistochemical expression of both proteins. These data might explain why MSI colorectal cancers ( CRC) behave differently in response to a wide variety of chemotherapeutic agents, notably those targeting DNA. More generally, they give further insights into how MSI leads to functional changes with synergistic effects in oncogenic pathways.	Univ Paris 06, U762, INSERM, CEPH, F-75010 Paris, France; Inst Gustave Roussy, Dept Pathol, Villejuif, France; Hop Cochin, Serv Oncogenet Digest, F-75674 Paris, France; CNRS Genet Instabil & Canc, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	Praz, F (corresponding author), Univ Paris 06, U762, INSERM, CEPH, 27 Rue Juliette Dodu, F-75010 Paris, France.	praz@cephb.fr	PRAZ, Françoise/AAF-7761-2020; miquel, catherine/B-5536-2013; PRAZ, Françoise/A-7291-2008	PRAZ, Françoise/0000-0002-5353-8889; PRAZ, Françoise/0000-0002-5353-8889				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Boland CR, 1998, CANCER RES, V58, P5248; Brennetot C, 2005, INT J CANCER, V113, P446, DOI 10.1002/ijc.20586; Duval A, 2002, CANCER RES, V62, P2447; Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513; Fallik D, 2003, CANCER RES, V63, P5738; Giannini G, 2004, ONCOGENE, V23, P2640, DOI 10.1038/sj.onc.1207409; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jacob S, 2002, BIOCHIMIE, V84, P27, DOI 10.1016/S0300-9084(01)01362-1; Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907; Li HR, 2004, CANCER RES, V64, P4760, DOI 10.1158/0008-5472.CAN-04-0975; Mori Y, 2001, CANCER RES, V61, P6046; Ottini L, 2004, CARCINOGENESIS, V25, P2337, DOI 10.1093/carcin/bgh257; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; Sonoda E, 2003, EMBO J, V22, P3188, DOI 10.1093/emboj/cdg308; Suzuki K, 2002, CANCER RES, V62, P1961; Takemura H, 2006, J BIOL CHEM, V281, P30814, DOI 10.1074/jbc.M603747200; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421; Yanamadala S, 2003, MOL CANCER RES, V1, P747	22	94	96	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2007	26	40					5919	5926		10.1038/sj.onc.1210419	http://dx.doi.org/10.1038/sj.onc.1210419			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17384679				2022-12-17	WOS:000249123100009
J	Murkoster, SS; Werbing, V; Sipos, B; Debus, MA; Witt, M; Grossmann, M; Leisner, D; Kotteritzsch, J; Kappes, H; Kloppel, G; Altevogt, P; Folsch, UR; Schafer, H				Muerkoester, S. Sebens; Werbing, V.; Sipos, B.; Debus, M. A.; Witt, M.; Grossmann, M.; Leisner, D.; Koetteritzsch, J.; Kappes, H.; Kloeppel, G.; Altevogt, P.; Foelsch, U. R.; Schaefer, H.			Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells	ONCOGENE			English	Article						chemoresistance; pancreatic ductal adenocarcinoma; L1CAM; NO	CARCINOMA-CELLS; OVARIAN CARCINOMAS; CANCER CELLS; TUMOR-GROWTH; L1 CD171; MIGRATION; PROGRESSION; INHIBITION; BINDING	Pancreatic ductal adenocarcinoma (PDAC) is characterized by rapid tumor progression, high metastatic potential and profound chemoresistance. We recently reported that induction of a chemoresistant phenotype in the PDAC cell line PT45-P1 by long-term chemotherapy involves an increased interleukin 1 beta (IL1b)-dependent secretion of nitric oxide (NO) accounting for efficient caspase inhibition. In the present study, we elucidated the involvement of L1CAM, an adhesion molecule previously found in other malignancies, in this NO-dependent chemoresistance. Chemoresistant PT45-P1res cells, but not chemosensitive parental PT45-P1 cells, express high levels of L1CAMin an IL beta-dependent fashion. PT45-P1res cells subjected to short interfering RNA (siRNA)- mediated L1CAM knock-down exhibited reduced inducible nitric oxide synthase expression and NO secretion, as well as a significant increase of anticancer drug-induced caspase activation, an effect reversed by the NO donor S-nitroso-N-acetyl-D,L-penicillamine. Conversely, overexpression of L1CAMin PT45-P1 cells conferred anti-apoptotic protection to anti-cancer drug treatment. Interestingly, L1CAM ectodomain shedding, in example, by ADAM10, as reported for other L1CAM-related activities, seemed to be dispensable for antiapoptotic protection by L1CAM. Neither the shedded L1CAM ectodomain was detected in chemoresistant L1CAM-expressing PT45-P1 cells nor did the administration of various metalloproteinase inhibitors affect L1CAM-dependent chemoresistance. Immunohistochemical analysis revealed L1CAM expression in 80% of pancreatic cancer specimens, supporting a potential role of L1CAMin the malignancy of this tumor. These findings substantiate our understanding of the molecular mechanisms leading to chemoresistance in PDAC cells and indicate the importance of L1CAMin this scenario.	UKHS, Clin Internal Med, Lab Mol Gastroenterol & Hepatol, D-24105 Kiel, Germany; UKHS, Dept Pathol, Kiel, Germany; German Canc Res Ctr, Tumor Immunol Programme, D-6900 Heidelberg, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; Helmholtz Association; German Cancer Research Center (DKFZ)	Schafer, H (corresponding author), UKHS, Clin Internal Med, Lab Mol Gastroenterol & Hepatol, Campus Kiel,Schittenhelmstr 12, D-24105 Kiel, Germany.	hschaef@1med.uni-kiel.de	Schäfer, Heiner/C-1055-2011; Sebens, Susanne/C-1222-2010					Arlt A, 2002, CANCER RES, V62, P910; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Arlt MJE, 2006, CANCER RES, V66, P936, DOI 10.1158/0008-5472.CAN-05-1818; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; Castellani V, 2002, EMBO J, V21, P6348, DOI 10.1093/emboj/cdf645; Fogel M, 2003, LANCET, V362, P869, DOI 10.1016/S0140-6736(03)14342-5; Fukahi K, 2004, CLIN CANCER RES, V10, P581, DOI 10.1158/1078-0432.CCR-0930-03; Gast D, 2005, INT J CANCER, V115, P658, DOI 10.1002/ijc.20869; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Hortsch M, 2000, MOL CELL NEUROSCI, V15, P1, DOI 10.1006/mcne.1999.0809; Izumoto S, 1996, CANCER RES, V56, P1440; Kaifi JT, 2006, MODERN PATHOL, V19, P399, DOI 10.1038/modpathol.3800547; Kaifi JT, 2006, WORLD J GASTROENTERO, V12, P94, DOI 10.3748/wjg.v12.i1.94; KALTHOFF H, 1993, ONCOGENE, V8, P289; Lockhart AC, 2005, GASTROENTEROLOGY, V128, P1642, DOI 10.1053/j.gastro.2005.03.039; Loers G, 2005, J NEUROCHEM, V92, P1463, DOI 10.1111/j.1471-4159.2004.02983.x; Maretzky T, 2005, MOL CELL BIOL, V25, P9040, DOI 10.1128/MCB.25.20.9040-9053.2005; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Meier F, 2006, INT J CANCER, V119, P549, DOI 10.1002/ijc.21880; Miyamoto H, 2004, PANCREAS, V28, P38, DOI 10.1097/00006676-200401000-00006; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; Muerkoster S, 2004, CANCER RES, V64, P1331, DOI 10.1158/0008-5472.CAN-03-1860; Muerkoster SS, 2006, ONCOGENE, V25, P4628, DOI 10.1038/sj.onc.1209806; Schachner M, 1997, CURR OPIN CELL BIOL, V9, P627, DOI 10.1016/S0955-0674(97)80115-9; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schneider G, 2005, GASTROENTEROLOGY, V128, P1606, DOI 10.1053/j.gastro.2005.04.001; St Croix Brad, 1997, Current Opinion in Oncology, V9, P549; Wey JS, 2005, BRIT J CANCER, V93, P233, DOI 10.1038/sj.bjc.6602663	28	94	97	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2759	2768		10.1038/sj.onc.1210076	http://dx.doi.org/10.1038/sj.onc.1210076			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17086212				2022-12-17	WOS:000246210600010
J	Imamichi, Y; Konig, A; Gress, T; Menke, A				Imamichi, Y.; Koenig, A.; Gress, T.; Menke, A.			Collagen type I-induced Smad-interacting protein 1 expression downregulates E-cadherin in pancreatic cancer	ONCOGENE			English	Article						pancreatic cancer; Smad-interacting protein 1 (SIP1); extracellular matrix (ECM); E-cadherin	TRANSCRIPTION FACTOR SNAIL; GENE-EXPRESSION; SIP1; BINDING; INVASION; FAMILY; TARGET; CELLS; CARCINOMAS; REPRESSION	Pancreatic cancer is a devastating disease with poor prognosis. Production of large quantities of extracellular matrix and early metastasis are characteristics of this disease. One important step in the development of various cancers is the loss of E-cadherin gene expression or inactivation of E-cadherin mediated cell-cell adhesion. It has been shown that collagen type I promotes down-regulation of E-cadherin expression, which correlates with enhanced cell migration and invasiveness. In this context, we elucidated the role of Smad-interacting protein 1 (SIP1), which has been discussed as a negative regulator of E-cadherin gene expression. We demonstrate that SIP1 upregulation shows an inverse relationship with E-cadherin in advanced pancreatic tumour stages. In Panc-1 cells, SIP1 expression can be induced by exposure to collagen type I in a src-dependent manner. In addition, overexpression of SIP1 reduces E-cadherin mRNA and protein levels. Taken together, these results suggest that SIP1 is involved in the progression of pancreatic cancer and plays a role in mediating signal transduction from collagen type I to downregulate E-cadherin expression.	Univ Hosp Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Hosp Giessen & Marburg, Dept Gastroenterol Endocrinol & Metab, Marburg, Germany	Ulm University; University Hospital of Giessen & Marburg	Imamichi, Y (corresponding author), Univ Hosp Ulm, Dept Internal Med 1, Robert Koch Str 8, D-89081 Ulm, Germany.	yukiko.imamichi@uni-ulm.de		Gress, Thomas/0000-0002-9333-5461				Avizienyte E, 2005, CURR OPIN CELL BIOL, V17, P542, DOI 10.1016/j.ceb.2005.08.007; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; D'Souza-Schorey C, 2005, TRENDS CELL BIOL, V15, P19, DOI 10.1016/j.tcb.2004.11.002; Erickson AC, 2003, EXPERT OPIN THER TAR, V7, P71, DOI 10.1517/14728222.7.1.71; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Hajra KM, 2002, CANCER RES, V62, P1613; Heidenblut AM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh130; HENNIG G, 1995, ONCOGENE, V11, P475; Long JY, 2005, J BIOL CHEM, V280, P35477, DOI 10.1074/jbc.M504477200; Maeda G, 2005, INT J ONCOL, V27, P1535; Menke A, 2001, CANCER RES, V61, P3508; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Miyoshi A, 2004, BRIT J CANCER, V90, P1265, DOI 10.1038/sj.bjc.6601685; MOLLENHAUER J, 1987, Pancreas, V2, P14, DOI 10.1097/00006676-198701000-00003; PIGNATELLI M, 1994, J PATHOL, V174, P243, DOI 10.1002/path.1711740403; Postigo AA, 2003, EMBO J, V22, P2453, DOI 10.1093/emboj/cdg226; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Seidel B, 2004, ONCOGENE, V23, P5532, DOI 10.1038/sj.onc.1207718; Van de Putte T, 2003, AM J HUM GENET, V72, P465, DOI 10.1086/346092; van Grunsven LA, 2003, J BIOL CHEM, V278, P26135, DOI 10.1074/jbc.M300597200; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	30	94	98	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2381	2385		10.1038/sj.onc.1210012	http://dx.doi.org/10.1038/sj.onc.1210012			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17043655				2022-12-17	WOS:000245466000014
J	Pawson, T; Warner, N				Pawson, T.; Warner, N.			Oncogenic re-wiring of cellular signaling pathways	ONCOGENE			English	Review						fusion proteins; domains; protein-protein interactions	RECEPTOR TYROSINE KINASE; LEUKEMIA-LIKE DISEASE; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; SH2 DOMAIN; BCR; BINDING; ACTIVATION; PHOSPHORYLATION; AUTOINHIBITION	Signaling pathways in mammalian cells are assembled and regulated by a finely controlled network of protein - protein and protein - phospholipid interactions, mediated by dedicated signaling domains and their cognate binding motifs. The domain-based modular architecture of signaling proteins may have facilitated the evolution of complex biological systems, and can be exploited experimentally to generate synthetic signaling pathways and artificial mechanisms of autoregulation. Pathogenic proteins, such as those encoded by bacteria and viruses, frequently form ectopic signaling complexes to respecify cellular behavior. In a similar fashion, proteins expressed as a consequence of oncogenic fusions, mutations or amplifications can elicit ectopic protein - protein interactions that re-wire signaling pathways, in a fashion that promotes malignancy. Compounds that directly or indirectly reverse these aberrant interactions offer new possibilities for therapy in cancer.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Ctr Syst Biol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Ctr Syst Biol, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	pawson@mshri.on.ca	Pawson, Tony J/E-4578-2013; Warner, Neil/ABE-7329-2020	Warner, Neil/0000-0002-9207-5979				Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Bhattacharyya RP, 2006, ANNU REV BIOCHEM, V75, P655, DOI 10.1146/annurev.biochem.75.103004.142710; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Dueber JE, 2003, SCIENCE, V301, P1904, DOI 10.1126/science.1085945; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Gruenheid S, 2001, NAT CELL BIOL, V3, P856, DOI 10.1038/ncb0901-856; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; He YP, 2002, BLOOD, V99, P2957, DOI 10.1182/blood.V99.8.2957; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Howard PL, 2003, P NATL ACAD SCI USA, V100, P11267, DOI 10.1073/pnas.1934711100; Hu JJ, 2003, MOL CELL, V12, P1379, DOI 10.1016/S1097-2765(03)00487-8; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kim JH, 2005, BLOOD, V105, P1717, DOI 10.1182/blood-2004-03-0849; Kong-Beltran M, 2006, CANCER RES, V66, P283, DOI 10.1158/0008-5472.CAN-05-2749; Liu BA, 2006, MOL CELL, V22, P851, DOI 10.1016/j.molcel.2006.06.001; Llorca O, 2005, EMBO J, V24, P1330, DOI 10.1038/sj.emboj.7600617; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Million RP, 2000, BLOOD, V96, P664; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Pawson T, 2000, GENE DEV, V14, P1027; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; ROWLEY JD, 1990, CANCER, V65, P2178, DOI 10.1002/1097-0142(19900515)65:10<2178::AID-CNCR2820651004>3.0.CO;2-#; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou J, 2006, P NATL ACAD SCI USA, V103, P9238, DOI 10.1073/pnas.0603324103; Zhu J, 2005, CANCER CELL, V7, P143, DOI 10.1016/j.ccr.2005.01.005	44	94	98	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2007	26	9					1268	1275		10.1038/sj.onc.1210255	http://dx.doi.org/10.1038/sj.onc.1210255			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322911	Bronze			2022-12-17	WOS:000244558700003
J	Roesch-Ely, M; Nees, M; Karsai, S; Ruess, A; Bogumil, R; Warnken, U; Schnolzer, M; Dietz, A; Plinkert, PK; Hofele, C; Bosch, FX				Roesch-Ely, M.; Nees, M.; Karsai, S.; Ruess, A.; Bogumil, R.; Warnken, U.; Schnoelzer, M.; Dietz, A.; Plinkert, P. K.; Hofele, C.; Bosch, F. X.			Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer	ONCOGENE			English	Article						proteomics; SELDI-TOF-MS; HNSCC; field cancerization; protein biomarkers	SQUAMOUS-CELL CARCINOMA; GENETICALLY ALTERED FIELDS; HUMAN NEUTROPHIL PEPTIDE-1; TUMOR-DISTANT EPITHELIA; LYMPH-NODE METASTASIS; CLINICAL-IMPLICATIONS; HUMAN-PAPILLOMAVIRUS; IN-SITU; IDENTIFICATION; CANCERIZATION	Development of head and necksquamous cell carcinoma (HNSCC) is a multistep process and in many cases involves a phenomenon coined 'field cancerization'. In order to identify changes in protein expression occurring at different stages of tumorigenesis and field cancerization, we analysed 113 HNSCCs and 73 healthy, 99 tumor-distant and 18 tumor-adjacent squamous mucosae by SELDI-TOF-MS on IMAC30 ProteinChip Arrays. Forty-eight protein peaks were differentially expressed between healthy mucosa and HNSCC. Calgizarrin (S100A11), the Cystein proteinase inhibitor Cystatin A, Acyl-CoA-binding protein, Stratifin (14-3-3 sigma), Histone H4, alpha- and beta-Hemoglobin, a C-terminal fragment of beta-hemoglobin and the alpha-defensins 1-3 were identified by mass spectrometry. The alpha-defensins showed various alterations in expression as validated by immunohistochemistry (IHC). Supervised prediction analysis revealed excellent classification of healthy mucosa (94.5% correctly classified) and tumor samples (92.9% correctly classified). Application of this classifier to the tumor-adjacent and tumor-distant mucosa samples disclosed dramatic changes: only 59.6% of the tumor-distant biopsies were classified as normal, 27.3% were predicted as aberrant or HNSCC. Strikingly, 72% of the tumor-adjacent mucosae were predicted as aberrant. These data provide evidence for the existence of genetically altered fields with inconspicuous histology. Comparison of the protein profiles in the tumor-distant-samples with clinical outcome of 32 patients revealed a significant association between aberrant profiles with tumor relapse events (P = 0.018; Fisher's exact test, two-tailed). We conclude that proteomic pro. ling in conjunction with protein identification greatly outperforms histopathological diagnosis and may have significant predictive power for clinical outcome and personalized risk assessment.	Univ Heidelberg, Dept Otolaryngol Head & Neck Surg, Mol Biol Lab, D-69120 Heidelberg, Germany; Ciphergan Biosyst GmbH, Berlin, Germany; German Canc Res Ctr, Prot Anal Facil, D-6900 Heidelberg, Germany; Univ Leipzig, Dept Ear Nose & Throat, D-7010 Leipzig, Germany; Univ Heidelberg, Dept Oral & Maxillofacial Surg, Heidelberg, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Leipzig University; Ruprecht Karls University Heidelberg	Bosch, FX (corresponding author), Univ Heidelberg, Dept Otolaryngol Head & Neck Surg, Mol Biol Lab, INF 400, D-69120 Heidelberg, Germany.	franz.bosch@med.uni-heidelberg.de	Hofele, Christof/D-4882-2015; Nees, Matthias/AAT-5577-2020; Roesch-Ely, Mariana/H-5981-2013; Nees, Matthias/W-6596-2018	Hofele, Christof/0000-0002-6332-5684; Nees, Matthias/0000-0002-9034-301X				Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179; Ai H, 1999, MUTAT RES-GEN TOX EN, V439, P223, DOI 10.1016/S1383-5718(98)00199-5; Ai H, 2001, LARYNGOSCOPE, V111, P1853, DOI 10.1097/00005537-200110000-00034; Albrethsen J, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-8; ALHO H, 1995, CELL GROWTH DIFFER, V6, P309; Andl T, 1998, CANCER RES, V58, P5; Bedi GC, 1996, CANCER RES, V56, P2484; Braakhuis BJM, 2005, SEMIN CANCER BIOL, V15, P113, DOI 10.1016/j.semcancer.2004.08.004; Braakhuis BJM, 2002, HEAD NECK-J SCI SPEC, V24, P198, DOI 10.1002/hed.10042.abs; Braakhuis BJM, 2003, CANCER RES, V63, P1727; Buhimschi IA, 2005, BJOG-INT J OBSTET GY, V112, P173, DOI 10.1111/j.1471-0528.2004.00340.x; Califano J, 1996, CANCER RES, V56, P2488; Carr S, 2004, MOL CELL PROTEOMICS, V3, P531, DOI 10.1074/mcp.T400006-MCP200; Chavakis T, 2004, FASEB J, V18, P1306, DOI 10.1096/fj.03-1009fje; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Ely MR, 2005, EUR J CELL BIOL, V84, P431, DOI 10.1016/j.ejcb.2005.01.003; Freier K, 2003, CANCER RES, V63, P1179; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Garcia SB, 1999, J PATHOL, V187, P61, DOI 10.1002/(SICI)1096-9896(199901)187:1<61::AID-PATH247>3.0.CO;2-I; Gasco M, 2002, CANCER RES, V62, P2072; Hegedus CM, 2005, LEUKEMIA, V19, P1713, DOI 10.1038/sj.leu.2403897; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Homann N, 2001, CLIN CANCER RES, V7, P290; Kerkhoff C, 1998, BBA-MOL CELL RES, V1448, P200, DOI 10.1016/S0167-4889(98)00144-X; Le Bihan MC, 2004, PROTEOMICS, V4, P2739, DOI 10.1002/pmic.200300759; Lundy FT, 2004, ORAL ONCOL, V40, P139, DOI 10.1016/S1368-8375(03)00142-8; Melle C, 2004, CANCER RES, V64, P4099, DOI 10.1158/0008-5472.CAN-03-3807; Muller CA, 2002, AM J PATHOL, V160, P1311, DOI 10.1016/S0002-9440(10)62558-8; NEES M, 1993, CANCER RES, V53, P4189; Partridge M, 2000, CANCER RES, V60, P3893; Petrescu AD, 2003, J BIOL CHEM, V278, P51813, DOI 10.1074/jbc.M303858200; Prevo LJ, 1999, CANCER RES, V59, P4784; Shiraishi T, 1998, INT J CANCER, V79, P175, DOI 10.1002/(SICI)1097-0215(19980417)79:2<175::AID-IJC13>3.3.CO;2-P; Simon R, 2003, J NATL CANCER I, V95, P14, DOI 10.1093/jnci/95.1.14; Sinha AA, 2002, CANCER-AM CANCER SOC, V94, P3141, DOI 10.1002/cncr.10604; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; SmithMcCune K, 1997, OBSTET GYNECOL, V89, P482, DOI 10.1016/S0029-7844(97)80037-3; SODER AI, 1995, CANCER RES, V55, P5030; Tabor MP, 2004, CLIN CANCER RES, V10, P3607, DOI 10.1158/1078-0432.CCR-03-0632; Tabor MP, 2001, CLIN CANCER RES, V7, P1523; Tolson JR, 2006, PROTEOMICS, V6, P697, DOI 10.1002/pmic.200500033; Vlahou A, 2001, AM J PATHOL, V158, P1491, DOI 10.1016/S0002-9440(10)64100-4; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; Wiesner A, 2004, CURR PHARM BIOTECHNO, V5, P45, DOI 10.2174/1389201043489675; Wilkins MR, 2006, PROTEOMICS, V6, P4, DOI 10.1002/pmic.200500856; Wolf C, 2004, LARYNGOSCOPE, V114, P698, DOI 10.1097/00005537-200404000-00019; Wright George L Jr, 2002, Expert Rev Mol Diagn, V2, P549, DOI 10.1586/14737159.2.6.549	47	94	99	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 4	2007	26	1					54	64		10.1038/sj.onc.1209770	http://dx.doi.org/10.1038/sj.onc.1209770			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16819514				2022-12-17	WOS:000243236500006
J	Leiblich, A; Cross, SS; Catto, JWF; Phillips, JT; Leung, HY; Hamdy, FC; Rehman, I				Leiblich, A.; Cross, S. S.; Catto, J. W. F.; Phillips, J. T.; Leung, H. Y.; Hamdy, F. C.; Rehman, I.			Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer	ONCOGENE			English	Article						prostate cancer; hypermethylation; proteomic; benign prostatic hyperplasia; metastatic	PROTEOMIC ANALYSIS; EXPRESSION; HYPOXIA; GROWTH; TISSUE; SITES; LDH	In order to identify novel candidates associated with prostate cancer metastasis, we compared the proteomic pro. le of the poorly metastatic human prostate cancer cell line LNCaP, with its highly metastatic variant LNCaP-LN3, by two- dimensional gel electrophoresis. A major protein spot ( pI of 5.9 and molecular weight of 37 kDa) was seen in LNCaP cells, but not in LNCaP- LN3 cells and was identified as lactate dehydrogenase- B ( LDHB), by tandem mass spectrometry. Furthermore, enzyme kinetic assays and zymography showed a higher LDH enzyme activity in LNCaP cells compared with LNCaP-LN3. Bisulphite- modified DNA sequencing showed promoter hypermethylation in LNCaP- LN3 cells but not in LNCaP, Du145, PC3, CWR22 or BPH45 cells. Treatment of LNCaP- LN3 cells with 5'- azacytidine caused re-expression of LDHB transcripts. In tissues, LDHB promoter hypermethylation occurred at a higher frequency in prostate cancer, 14/ 31 ( 45%), compared to adjacent nonmalignant or benign tissue, 2/ 19 ( 11%) ( P < 0.025). Immunohistochemistry showed a higher frequency of LDHB expression in benign or nonmalignant tissues, 59/ 73 ( 81%), compared to cancer cases, 3/ 53 ( 6%) ( P < 0.001). Absent LDHB expression was also seen in 7/ 7 ( 100%) cases of metastatic cancer in bone. Our data are the first to show loss of LDHB expression in prostate cancer, the mechanism of which appears to involve promoter hypermethylation.	Univ Sheffield, Div Clin Sci S, Acad Urol Unit, Sheffield S10 2JF, S Yorkshire, England; Univ Sheffield, Div Genom Med, Acad Unit Pathol, Sheffield S10 2JF, S Yorkshire, England; Univ Newcastle, No Inst Canc Res, Urol Res Grp, Newcastle Upon Tyne, Tyne & Wear, England	University of Sheffield; University of Sheffield; Newcastle University - UK	Rehman, I (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Acad Urol Unit, Glossop Rd,Floor K, Sheffield S10 2JF, S Yorkshire, England.	i.rehman@sheffield.ac.uk		Leung, Hing Y./0000-0002-3933-3975; Hamdy, Freddie/0000-0003-2627-2154; Cross, Simon/0000-0003-2044-1754; catto, james/0000-0003-2787-8828	MRC [G0100444] Funding Source: UKRI; Medical Research Council [G0100444] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahram M, 2002, MOL CARCINOGEN, V33, P9, DOI 10.1002/mc.10019; Allen S, 2003, J BIOL CHEM, V278, P6371, DOI 10.1074/jbc.M209915200; Banks RE, 2000, LANCET, V356, P1749, DOI 10.1016/S0140-6736(00)03214-1; BERGMEYER HU, 1974, METHOD ENZYMAT AN, P574; Bhandari MS, 2005, EUR J CANCER, V41, P941, DOI 10.1016/j.ejca.2005.02.008; Brizel DM, 2001, INT J RADIAT ONCOL, V51, P349, DOI 10.1016/S0360-3016(01)01630-3; Cheung PK, 2004, CANCER RES, V64, P5929, DOI 10.1158/0008-5472.CAN-04-1216; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; Chu LW, 2001, CANCER GENET CYTOGEN, V127, P161, DOI 10.1016/S0165-4608(01)00389-2; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; Ding SJ, 2004, PROTEOMICS, V4, P982, DOI 10.1002/pmic.200300653; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; Graves PR, 2002, MICROBIOL MOL BIOL R, V66, P39, DOI 10.1128/MMBR.66.1.39-63.2002; Grayhack J T, 1980, Prostate, V1, P227, DOI 10.1002/pros.2990010208; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Gronberg H, 2003, LANCET, V361, P859, DOI 10.1016/S0140-6736(03)12713-4; Hamdy FC, 2001, CANCER TREAT REV, V27, P143, DOI 10.1053/ctrv.2000.0208; Himpel S, 2001, BIOCHEM J, V359, P497, DOI 10.1042/0264-6021:3590497; HOLBROOK JJ, 1975, LACTATE DEHYDROGENAS, P191; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Klingler HC, 1999, PROSTATE, V41, P110; Koukourakis MI, 2005, NEOPLASIA, V7, P1, DOI 10.1593/neo.04373; Li LC, 2005, JNCI-J NATL CANCER I, V97, P103, DOI 10.1093/jnci/dji010; Liu XH, 2003, ELECTROPHORESIS, V24, P3445, DOI 10.1002/elps.200305574; Maekawa M, 2003, CLIN CHEM, V49, P1518, DOI 10.1373/49.9.1518; MARKERT CL, 1975, SCIENCE, V189, P102, DOI 10.1126/science.1138367; MartinezZaguilan R, 1996, CLIN EXP METASTAS, V14, P176, DOI 10.1007/BF00121214; Meehan KL, 2002, PROSTATE, V50, P54, DOI 10.1002/pros.10032; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Rehman I, 2005, PROSTATE, V65, P322, DOI 10.1002/pros.20302; Rehman I, 2004, UROLOGY, V64, P1238, DOI 10.1016/j.urology.2004.06.063; Rehman I, 2004, HUM PATHOL, V35, P1385, DOI 10.1016/j.humpath.2004.07.015; Rehman I, 1996, ONCOGENE, V12, P2483; RETHORE MO, 1976, ANN GENET-PARIS, V19, P140; Salplachta J, 2000, ACTA VET BRNO, V69, P267, DOI 10.2754/avb200069040267; Schulz WA, 2003, MOL HUM REPROD, V9, P437, DOI 10.1093/molehr/gag064; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Shi Q, 2001, ONCOGENE, V20, P3751, DOI 10.1038/sj.onc.1204500; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Stern R, 2002, EXP CELL RES, V276, P24, DOI 10.1006/excr.2002.5508; TAKENO T, 1989, BIOCHEM J, V257, P921, DOI 10.1042/bj2570921; Tsoi SCM, 2001, PLACENTA, V22, P317, DOI 10.1053/plac.2000.0620; Vaupel P, 2004, ONCOLOGIST, V9, P4, DOI 10.1634/theoncologist.9-90005-4; Walenta S, 2004, SEMIN RADIAT ONCOL, V14, P267, DOI 10.1016/j.semradonc.2004.04.004; Walenta S, 2004, CURR MED CHEM, V11, P2195, DOI 10.2174/0929867043364711	45	94	101	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2953	2960		10.1038/sj.onc.1209262	http://dx.doi.org/10.1038/sj.onc.1209262			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16547507				2022-12-17	WOS:000237448200015
J	Abdul-Ghani, R; Serra, V; Gyorffy, B; Jurchott, K; Solf, A; Dietel, M; Schafer, R				Abdul-Ghani, R; Serra, V; Gyorffy, B; Jurchott, K; Solf, A; Dietel, M; Schafer, R			The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1	ONCOGENE			English	Article						phosphoinositol 3-kinase; LY294002; multidrug resistance-associated protein MRP1; colon cancer; doxorubicin	BREAST-CANCER CELLS; MULTIDRUG-RESISTANCE; INDUCED APOPTOSIS; ADENOCARCINOMA CELLS; SIGNALING PATHWAY; ACTIVATION LEADS; ERK ACTIVATION; RAS ONCOGENES; EXPRESSION; 3-KINASE	Multidrug resistance may be achieved by the activation of membrane transporters, detoxification, alterations in DNA repair or failure in apoptotic pathways. Recent data have suggested an involvement of mitogenic signalling pathways mediated by Ras and phosphoinositol-3-kinase (PI3K/Akt) in controlling multidrug resistance. Since these pathways are important targets for therapeutic interference, we sought to investigate whether blocking effectors kinases by specific inhibitors would result in a sensitization toward cytotoxic drugs. We found that cotreatment of drug-resistant HT29RDB colon cancer cells with the topoisomerase inhibitor doxorubicin and the PI3K-inhibitor LY294002 resulted in massive apoptosis, while cotreatment with the Mek inhibitors PD98059 or U0126 had no effect. This suggested that the PI3K-pathways controls cell survival and drug resistance in these cells. Besides blocking Akt phosphorylation, the PI3K-inibitor increased the intracellular doxorubicin concentration threefold. LY294002 inhibits drug export in a competitive manner as revealed by measuring drug efflux in the presence and the absence of inhibitor. The efficacy of drug efflux inhibition by LY294002 was similar to that achieved by the MRP1 inhibitors MK571 and genistein. We conclude that the PI3K inhibitor LY294002 may have therapeutic potential when combined with doxorubicin in the treatment of MRP1-mediated drug resistance.	Univ Med Berlin, Inst Pathol, Lab Mol Tumor Pathol, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schafer, R (corresponding author), Univ Med Berlin, Inst Pathol, Lab Mol Tumor Pathol, Schumannstr 20-21, D-10117 Berlin, Germany.	reinhold.schaefer@charite.de	Gyorffy, Balazs/AAA-9135-2021; Serra, Violeta/AAG-8328-2019; Schäfer, Reinhold/AAB-5110-2021	Gyorffy, Balazs/0000-0002-5772-3766; Jurchott, Karsten/0000-0003-1589-0037; Serra, Violeta/0000-0001-6620-1065				Agullo G, 1997, BIOCHEM PHARMACOL, V53, P1649, DOI 10.1016/S0006-2952(97)82453-7; Bates SE, 2001, J BIOENERG BIOMEMBR, V33, P503, DOI 10.1023/A:1012879205914; BERG J, 2002, BIOCH ENYZMES BASIC; BOS JL, 1989, CANCER RES, V49, P4682; Brognard J, 2001, CANCER RES, V61, P3986; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; Chang FM, 2003, INT J ONCOL, V22, P469; CHEN TR, 1987, CANCER GENET CYTOGEN, V27, P125, DOI 10.1016/0165-4608(87)90267-6; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Chen ZH, 2003, MOL CANCER THER, V2, P543; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Clark AS, 2002, MOL CANCER THER, V1, P707; Ding S, 2001, BRIT J CANCER, V85, P1175, DOI 10.1054/bjoc.2001.2044; DiSimone D, 1997, ANTICANCER RES, V17, P3587; Filipeanu CM, 2000, FEBS LETT, V474, P107, DOI 10.1016/S0014-5793(00)01585-4; GEKELER V, 1995, BIOCHEM BIOPH RES CO, V208, P345, DOI 10.1006/bbrc.1995.1344; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Guise S, 2001, J NEUROSCI RES, V63, P257, DOI 10.1002/1097-4547(20010201)63:3<257::AID-JNR1019>3.0.CO;2-T; GYORFFY B, 2005, IN PRESS ONCOGENE; Han JW, 1997, CANCER RES, V57, P176; Hu LM, 2002, CANCER RES, V62, P1087; Jin W, 2003, BRIT J CANCER, V89, P185, DOI 10.1038/sj.bjc.6601048; Kaushal GP, 2001, KIDNEY INT, V60, P1726, DOI 10.1046/j.1523-1755.2001.00026.x; Kim R, 2005, CANCER-AM CANCER SOC, V103, P1551, DOI 10.1002/cncr.20947; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Kok JW, 2000, INT J CANCER, V87, P172, DOI 10.1002/1097-0215(20000715)87:2<172::AID-IJC3>3.0.CO;2-K; KOPNIN BP, 1995, ONCOL RES, V7, P299; Krasilnikov MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P59; Lee JT, 2004, CANCER RES, V64, P8397, DOI 10.1158/0008-5472.CAN-04-1612; Liu XM, 2001, BRIT J CANCER, V85, P1403, DOI 10.1054/bjoc.2001.2107; Mizutani H, 2005, LIFE SCI, V76, P1439, DOI 10.1016/j.lfs.2004.05.040; Nakashio A, 2000, CANCER RES, V60, P5303; Nakashio A, 2002, INT J CANCER, V98, P36, DOI 10.1002/ijc.10166; Ng SSW, 2000, CANCER RES, V60, P5451; Plasschaert SLA, 2003, CLIN CANCER RES, V9, P5171; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SRIVASTAVA AK, 1985, BIOCHEM BIOPH RES CO, V131, P1, DOI 10.1016/0006-291X(85)91761-9; Stavrovskaya AA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P95; van Zanden JJ, 2004, BIOCHEM PHARMACOL, V67, P1607, DOI 10.1016/j.bcp.2003.12.032; van Zuylen L, 2000, INVEST NEW DRUG, V18, P205, DOI 10.1023/A:1006487003814; Vanhaesebroeck B, 1996, CANCER SURV, V27, P249; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(00)00088-5; Wang QD, 2002, CLIN CANCER RES, V8, P1940; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Yu DH, 1996, ONCOGENE, V13, P1359; Zhao YQ, 2004, J CELL BIOCHEM, V91, P621, DOI 10.1002/jcb.10751; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	54	94	108	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1743	1752		10.1038/sj.onc.1209201	http://dx.doi.org/10.1038/sj.onc.1209201			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16288223				2022-12-17	WOS:000236013700006
J	Zhou, JM; Zhu, XF; Lu, YJ; Deng, R; Huang, ZS; Mei, YP; Wang, Y; Huang, WL; Liu, ZC; Gu, LQ; Zeng, YX				Zhou, JM; Zhu, XF; Lu, YJ; Deng, R; Huang, ZS; Mei, YP; Wang, Y; Huang, WL; Liu, ZC; Gu, LQ; Zeng, YX			Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines	ONCOGENE			English	Article						G-quadruplex; telomerase inhibition; senescence	INHIBITS TUMOR-GROWTH; DRUG DESIGN; IN-VIVO; DNA; MAINTENANCE; TARGET; COMPOUND; LIGANDS; BINDING; LENGTH	Agents stabilizing G-quadruplexes have the potential to interfere with telomere replication by blocking the elongation step catalysed by telomerase or telomerase-independent mechanism and could therefore act as antitumor agents. In this study, we found that quindoline derivatives interacted preferentially with intramolecular G-quadruplex structures and were novel potent telomerase inhibitors. Treatment with quindoline derivatives reproducibly inhibited telomerase activity in human leukemia K562 cells and colon cancer SW620 cells. N'-(10H-Indolo [3,2-b] quinolin-11-yl)- N, N-dimethylpropane- 1,3-diamine (SYUIQ-5), (one of quindoline derivatives), when added to K562 and SW620 cell culture at nonacute cytotoxic concentrations, increased time of population doublings of K562 and SW620 cells, induced a marked cessation in cell growth and cellular senescence phenotype after 35 and 18 days, respectively. Growth cessation was accompanied by a shortening of telomere length, and induction of p16, p21 and p27 protein expression. However, another compound SYUIQ-7 with greater IC50 for telomerase had no obvious cellular effect in nonacute cytotoxic concentrations. These results indicate that quindoline derivatives as novel potent G-quadruplex interactive agents induce senescence and telomere shortening in cancer cells and therefore are promising agents for cancer treatment.	Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, Guangzhou 510060, Peoples R China; Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510060, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Zhu, XF (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, 651 Dongfeng Rd E, Guangzhou 510060, Peoples R China.	xfzhu70@public.guangzhou.gd.cn; yxzeng@gzsums.edu.cn	huang, wen/GXW-0661-2022					Bierer DE, 1998, J MED CHEM, V41, P2754, DOI 10.1021/jm970735n; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bonjean K, 1998, BIOCHEMISTRY-US, V37, P5136, DOI 10.1021/bi972927q; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Burger AM, 2005, CANCER RES, V65, P1489, DOI 10.1158/0008-5472.CAN-04-2910; Caprio V, 2000, BIOORG MED CHEM LETT, V10, P2063, DOI 10.1016/S0960-894X(00)00378-4; der-Sarkissian H, 2004, ONCOGENE, V23, P1221, DOI 10.1038/sj.onc.1207152; Dixon IM, 2005, CHEMBIOCHEM, V6, P123, DOI 10.1002/cbic.200400113; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Fedoroff OY, 1998, BIOCHEMISTRY-US, V37, P12367, DOI 10.1021/bi981330n; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gowan SM, 2002, MOL PHARMACOL, V61, P1154, DOI 10.1124/mol.61.5.1154; Grand CL, 2002, MOL CANCER THER, V1, P565; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Han HY, 2000, TRENDS PHARMACOL SCI, V21, P136, DOI 10.1016/S0165-6147(00)01457-7; Hurley LH, 2000, PHARMACOL THERAPEUT, V85, P141, DOI 10.1016/S0163-7258(99)00068-6; ISHIKAWA Y, 2001, NUCL ACIDS RES S, V1, P107; Izbicka E, 1999, CANCER RES, V59, P639; Keith WN, 2001, J PATHOL, V195, P404; Kelland LR, 2001, LANCET ONCOL, V2, P95, DOI 10.1016/S1470-2045(00)00226-6; Kerwin SM, 2000, CURR PHARM DESIGN, V6, P441, DOI 10.2174/1381612003400849; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lisgarten JN, 2002, NAT STRUCT BIOL, V9, P57, DOI 10.1038/nsb729; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Neidle S, 2002, NAT REV DRUG DISCOV, V1, P383, DOI 10.1038/nrd793; Pennarun G, 2005, ONCOGENE, V24, P2917, DOI 10.1038/sj.onc.1208468; Perry PJ, 1999, ANTI-CANCER DRUG DES, V14, P373; Perry PJ, 1999, J MED CHEM, V42, P2679, DOI 10.1021/jm990084q; Read M, 2001, P NATL ACAD SCI USA, V98, P4844, DOI 10.1073/pnas.081560598; Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477; Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099; Schultes CM, 2004, BIOORG MED CHEM LETT, V14, P4347, DOI 10.1016/j.bmcl.2004.05.090; Schwarze SR, 2001, ONCOGENE, V20, P8184, DOI 10.1038/sj.onc.1205049; Sun DY, 1997, J MED CHEM, V40, P2113, DOI 10.1021/jm970199z; Tauchi T, 2003, ONCOGENE, V22, P5338, DOI 10.1038/sj.onc.1206833; Wong JMY, 2003, LANCET, V362, P983, DOI 10.1016/S0140-6736(03)14369-3	41	94	102	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					503	511		10.1038/sj.onc.1209067	http://dx.doi.org/10.1038/sj.onc.1209067			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16170347				2022-12-17	WOS:000234897400002
J	van Limpt, V; Schramm, A; Lakeman, A; van Sluis, P; Chan, A; van Noesel, M; Baas, F; Caron, H; Eggert, A; Versteeg, R				van Limpt, V; Schramm, A; Lakeman, A; van Sluis, P; Chan, A; van Noesel, M; Baas, F; Caron, H; Eggert, A; Versteeg, R			The Phox2B homeobox gene is mutated in sporadic neuroblastomas	ONCOGENE			English	Article						Phox2B; mutations; neuroblastoma; TrkA	N-MYC; ALLELIC LOSS; EXPRESSION; MUTATIONS; REARRANGEMENTS; AMPLIFICATION; DNA	Neuroblastomas are embryonal tumours of the sympathoadrenal lineage with a clinical course ranging from spontaneous regression to fatal progression. The Phox2B homeobox transcription factor functions in the differentiation of the sympatho-adrenal lineage. Targets of Phox2B are, for example, genes of the ( nor) adrenalin synthesis route, like Dopamine Beta Hydroxylase (DBH). Congenital Central Hypoventilation Syndrome was recently found to result from Phox2B mutations and two such patients in addition developed neuroblastoma. A germline mutation in Phox2B was identified in a family with hereditary neuroblastoma. Here, we report the first analysis of Phox2B in a series of 237 sporadic neuroblastomas and 22 cell lines. Six frameshift mutations were found in exons 2 and 3; including one in cell line SK-N-SH. Two patients showed de novo constitutional mutations. One of them was diagnosed with Haddad syndrome. All analysed cases expressed the mutated and wild-type Phox2B alleles. Ectopic expression of TrkA, the Nerve Growth Factor receptor, strongly downregulated Phox2B and DBH expression in cell line SH-SY5Y. However, TrkA and Phox2B showed a positive correlation in a panel of 66 neuroblastoma tumours. Although Phox2B mutations are infrequent ( 2.3%), they implicate a role for the Phox2B pathway in oncogenesis.	Univ Amsterdam, Acad Med Ctr, Dept Human Genet, NL-1100 DE Amsterdam, Netherlands; Univ Childrens Hosp Essen, Dept Oncol Hematol & Endocrinol, D-45122 Essen, Germany; Univ Amsterdam, Acad Med Ctr, Dept Neurogenet, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pediat Oncol, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Duisburg Essen; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Versteeg, R (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Genet, POB 22700, NL-1100 DE Amsterdam, Netherlands.	r.versteeg@amc.uva.nl	Schramm, Alexander/G-5688-2010; Eggert, Angelika/AAE-6907-2022; Versteeg, Rogier/AAQ-1765-2020; Baas, Frank/F-9574-2010	Schramm, Alexander/0000-0001-7670-7529; Eggert, Angelika/0000-0003-3476-8184; Baas, Frank/0000-0003-3912-5428; Versteeg, Rogier/0000-0001-7172-0388				Amiel J, 2003, NAT GENET, V33, P459, DOI 10.1038/ng1130; Bonfield JK, 1998, NUCLEIC ACIDS RES, V26, P3404, DOI 10.1093/nar/26.14.3404; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; Caron H, 1996, HUM GENET, V97, P834; Easton J, 1998, CANCER RES, V58, P2624; Eggert A, 2002, CANCER RES, V62, P1802; Eggert A, 2000, ONCOGENE, V19, P2043, DOI 10.1038/sj.onc.1203518; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Huber K, 2002, ANN NY ACAD SCI, V971, P554, DOI 10.1111/j.1749-6632.2002.tb04526.x; LANZ RB, 1995, NUCLEIC ACIDS RES, V23, P138, DOI 10.1093/nar/23.1.138; Lavoie H, 2003, HUM MOL GENET, V12, P2967, DOI 10.1093/hmg/ddg329; LIMPT VA, 2003, INT J CANCER, V105, P61; Molenaar JJ, 2003, GENE CHROMOSOME CANC, V36, P242, DOI 10.1002/gcc.10166; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; MULLENBACH R, 1989, TRENDS GENET, V5, P391; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Perri P, 2002, ONCOGENE, V21, P8356, DOI 10.1038/sj.onc.1206009; ROSS RA, 1983, J NATL CANCER I, V71, P741; Sasaki A, 2003, HUM GENET, V114, P22, DOI 10.1007/s00439-003-1036-z; SCHULTE JH, 2004, IN PRESS ONCOGENE; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; Spieker N, 2001, GENE CHROMOSOME CANC, V31, P172, DOI 10.1002/gcc.1130.abs; Spieker N, 2001, GENOMICS, V71, P214, DOI 10.1006/geno.2000.6408; Stanke M, 2004, MOL CELL NEUROSCI, V25, P374, DOI 10.1016/j.mcn.2003.10.021; Trochet D, 2004, AM J HUM GENET, V74, P761, DOI 10.1086/383253; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; VANROY N, 1995, EUR J CANCER, V31A, P530, DOI 10.1016/0959-8049(95)00004-3; Weese-Mayer DE, 2003, AM J MED GENET A, V123A, P267, DOI 10.1002/ajmg.a.20527; Yang CY, 1998, J NEUROCHEM, V71, P1813	34	94	98	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9280	9288		10.1038/sj.onc.1208157	http://dx.doi.org/10.1038/sj.onc.1208157			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516980				2022-12-17	WOS:000225638000013
J	Hagihara, A; Miyamoto, K; Furuta, J; Hiraoka, N; Wakazono, K; Seki, S; Fukushima, S; Tsao, MS; Sugimura, T; Ushijima, T				Hagihara, A; Miyamoto, K; Furuta, J; Hiraoka, N; Wakazono, K; Seki, S; Fukushima, S; Tsao, MS; Sugimura, T; Ushijima, T			Identification of 27 5 ' CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers	ONCOGENE			English	Article						methylation; pancreatic cancer; CpG island; silencing	REPRESENTATIONAL DIFFERENCE ANALYSIS; TUMOR-SUPPRESSOR GENE; REDUCED EXPRESSION; HUMAN BREAST; ADENOCARCINOMA; CARCINOMA; CELLS; LUNG; RAS; INACTIVATION	Aberrantly methylated DNA fragments were searched for in human pancreatic cancers, using the genome scanning technique: methylation-sensitive-representational difference analysis (MS-RDA). MS-RDA isolated 111 DNA fragments derived from CpG islands (CGIs), and 35 of them were from CGIs in the 5' regions of known genes. Methylation-specific PCR (MSP) of the CGIs in seven pancreatic cancer cell lines and two pancreatic ductal epithelial cell lines showed that 27 CGIs in the 5' regions were aberrantly methylated in at least one of the cancer cell lines. Quantitative reverse-transcription-PCR analysis showed that downstream genes of all the CGIs were either not expressed or only very weakly expressed in cancer cell lines with the aberrant methylation. In the pancreatic ductal epithelial cell lines, 18 genes were expressed at various levels, and nine genes were not expressed at all. Treatment of a cancer cell line with a demethylating agent, 5-aza-2'-deoxycytidine, restored the expression of 13 genes, RASGRF2, ADAM23, NEF3, NKX2-8, HAND1, EGR4, PRG2, FBN2, CDH2, TLL1, NPTX1, NTSR1 and THBD, showing their silencing by methylation of their 5' CGIs. MSP of 24 primary pancreatic cancers showed that all these genes, except for THBD, were methylated in at least one cancer. Some of those were suggested to be potentially involved in pancreatic cancer development and progression.	Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, Tokyo 1040045, Japan; Osaka City Univ, Grad Sch Med, Dept Pathol, Abeno Ku, Osaka 5458585, Japan; Osaka City Univ, Grad Sch Med, Dept Internal Med, Abeno Ku, Osaka 5458585, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	National Cancer Center - Japan; Osaka Metropolitan University; Osaka Metropolitan University; National Cancer Center - Japan; University of Toronto	Ushijima, T (corresponding author), Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	tushijim@ncc.go.jp	Tsao, Ming Sound/AFQ-7332-2022; Ushijima, Toshikazu/AAP-5742-2021; Tsao, Ming-Sound/M-3503-2017	Tsao, Ming Sound/0000-0002-9160-5405; Ushijima, Toshikazu/0000-0003-3405-7817; 				Agathanggelou A, 2003, CANCER RES, V63, P5344; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Arozarena I, 2004, MOL CELL BIOL, V24, P1516, DOI 10.1128/MCB.24.4.1516-1530.2004; Asada K, 2003, ONCOLOGY-BASEL, V64, P380, DOI 10.1159/000070297; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Clark TG, 1999, DEVELOPMENT, V126, P2631; Costa FF, 2004, ONCOGENE, V23, P1481, DOI 10.1038/sj.onc.1207263; Furukawa T, 1996, AM J PATHOL, V148, P1763; GRIFFIN CA, 1994, GENE CHROMOSOME CANC, V9, P93, DOI 10.1002/gcc.2870090204; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HERMAN JG, 1995, CANCER RES, V55, P4525; Horikoshi N, 1999, BIOCHEM BIOPH RES CO, V261, P864, DOI 10.1006/bbrc.1999.1123; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Julien JP, 1998, PROG NUCLEIC ACID RE, V61, P1, DOI 10.1016/S0079-6603(08)60823-5; Kaneda A, 2003, ANN NY ACAD SCI, V983, P131, DOI 10.1111/j.1749-6632.2003.tb05968.x; Kaneda A, 2002, CANCER RES, V62, P6645; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Liu N, 1998, AM J PATHOL, V153, P263, DOI 10.1016/S0002-9440(10)65567-8; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mitchell MS, 2000, CANCER RES, V60, P6448; Miyamoto K, 2003, ONCOGENE, V22, P274, DOI 10.1038/sj.onc.1206146; Omeis IA, 1996, GENOMICS, V36, P543, DOI 10.1006/geno.1996.0503; Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226; Qiu CP, 2003, ONCOGENE, V22, P1253, DOI 10.1038/sj.onc.1206233; Riley P, 1998, NAT GENET, V18, P271, DOI 10.1038/ng0398-271; Rozenblum E, 1997, CANCER RES, V57, P1731; Sato N, 2003, CANCER RES, V63, P3735; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Takai D, 2001, ONCOGENE, V20, P7505, DOI 10.1038/sj.onc.1204940; Tourtellotte WG, 1999, DEVELOPMENT, V126, P5061; Toyota M, 1999, CANCER RES, V59, P2307; Ueki T, 2000, CANCER RES, V60, P1835; Ueki T, 2001, CANCER RES, V61, P8540; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; Wilentz RE, 2000, CANCER RES, V60, P2002	36	94	107	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8705	8710		10.1038/sj.onc.1207783	http://dx.doi.org/10.1038/sj.onc.1207783			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467763				2022-12-17	WOS:000224988800018
J	Hesson, L; Bieche, I; Krex, D; Criniere, E; Hoang-Xuan, K; Maher, ER; Latif, F				Hesson, L; Bieche, I; Krex, D; Criniere, E; Hoang-Xuan, K; Maher, ER; Latif, F			Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas	ONCOGENE			English	Article						methylation; gliomas; RASSF1A; BLU	TUMOR-SUPPRESSOR GENE; CARCINOMA IN-SITU; CELL LUNG-CANCER; PROMOTER HYPERMETHYLATION; CHROMOSOME 3P21.3; DUCTAL CARCINOMA; HUMAN NEOPLASIA; BREAST CANCERS; SLIT2 GENE; CPG ISLAND	RASSF1A is a major tumor suppressor gene located at 3p21.3. We investigated the role of aberrant promoter region hypermethylation of RASSF1A in a large series of adult gliomas. RASSF1A was frequently methylated in both primary tumors (36/63; 57%) and tumor cell lines (7/7; 100%). Hypermethylation of RASSF1A in glioma cell lines correlated with loss of expression and treatment with a demethylating agent-reactivated RASSF1A gene expression. Furthermore, re-expression of RASSF1A suppressed the growth of glioma cell line H4 in vitro. Next, we investigated whether other members of the RASSF gene family were also inactivated by methylation. NORE1B and RASSF3 were not methylated in gliomas, while NORE1A and RASSF5/AD037 demonstrated methylation in glioma cell lines but not in primary tumors. We then investigated the methylation status of three other candidate 3p21.3 tumor suppressor genes. CACNA2D2 and SEMA3B were not frequently methylated, but the BLU gene located just centromeric to RASSF1 was frequently methylated in glioma cell lines (7/7) and in 80% (35/44) of glioma tumors. In these tumor cell lines, BLU expression was restored after treatment with a demethylating agent. Loss of BLU gene expression in glioma tumors correlated with BLU methylation. There was no association between RASSF1A and BLU methylation. RASSF1A methylation increased with tumor grade, while BLU methylation was seen at similar frequencies in all grades. Our data implicate RASSF1A and BLU promoter methylation in the pathogenesis of adult gliomas, while other RASSF family members and CACNA2D2 and SEMA3B appear to have only minor roles. In addition, RASSF1A and BLU methylation appear to be independent and specific events and not due to region-wide changes in DNA methylation.	Univ Birmingham, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Ctr Rene Huguenin, INSERM, E0017, Lab Oncogenet, F-92210 St Cloud, France; Tech Univ Dresden, Univ Klinikum Carl Gustan Carus, Dept Neurosurg, D-01307 Dresden, Germany; Hop La Pitie Salpetriere, INSERM, U495, Paris, France; Federat Neurol Mazarin, Paris, France; Univ Birmingham, Canc Res UK Renal Mol Oncol Res Grp, Birmingham B15 2TG, W Midlands, England	University of Birmingham; Institut National de la Sante et de la Recherche Medicale (Inserm); Rene Huguenin Hospital; Technische Universitat Dresden; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	flatif@hgmp.mrc.ac.uk	Bièche, Ivan/O-7399-2017; Hesson, Luke/HDM-0311-2022; MAHER, EAMONN R/A-9507-2008; Krex, Dietmar/E-6833-2014; Hoang-Xuan, Khe/O-7527-2017	Bièche, Ivan/0000-0002-2430-5429; MAHER, EAMONN R/0000-0002-6226-6918; 				Agathanggelou A, 2003, ONCOGENE, V22, P1580, DOI 10.1038/sj.onc.1206243; Agathanggelou A, 2003, CANCER RES, V63, P5344; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Bieche I, 2001, CANCER RES, V61, P1652; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Carboni GL, 2003, ONCOGENE, V22, P615, DOI 10.1038/sj.onc.1206134; Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687; Dallol A, 2003, CANCER RES, V63, P1054; Dallol A, 2002, CANCER RES, V62, P5874; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 1998, CANCER RES, V58, P4515; FEINSTEIN PG, 1995, GENETICS, V140, P573; Harada K, 2002, CANCER RES, V62, P5897; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; Honorio S, 2003, ONCOGENE, V22, P147, DOI 10.1038/sj.onc.1206057; Honorio S, 2003, ONCOGENE, V22, P461, DOI 10.1038/sj.onc.1206119; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; Kuroki T, 2003, CANCER RES, V63, P3352; LeBoeuf RD, 1998, J BIOL CHEM, V273, P361, DOI 10.1074/jbc.273.1.361; Lerman MI, 2000, CANCER RES, V60, P6116; Liu XQ, 2003, INT J CANCER, V106, P60, DOI 10.1002/ijc.11166; Louis DN, 2002, CANCER CELL, V1, P125, DOI 10.1016/S1535-6108(02)00040-5; Lusher ME, 2002, CANCER RES, V62, P5906; Masselink H, 2000, ONCOGENE, V19, P1538, DOI 10.1038/sj.onc.1203421; Michelson RJ, 1999, J BIOL CHEM, V274, P30510, DOI 10.1074/jbc.274.43.30510; Mitic LL, 2000, AM J PHYSIOL-GASTR L, V279, pG250, DOI 10.1152/ajpgi.2000.279.2.G250; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Shivapurkar N, 2002, CANCER BIOL THER, V1, P65, DOI 10.4161/cbt.1.1.45; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3	40	94	109	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2408	2419		10.1038/sj.onc.1207407	http://dx.doi.org/10.1038/sj.onc.1207407			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14743209				2022-12-17	WOS:000220427700015
J	Ueda, K; Arakawa, H; Nakamura, Y				Ueda, K; Arakawa, H; Nakamura, Y			Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53	ONCOGENE			English	Article						DUSP5; p53; Erk1/2	ACTIVATED PROTEIN-KINASE; P53-DEPENDENT APOPTOSIS; GENE; IDENTIFICATION; PHOSPHATASE; EXPRESSION; MUTATIONS; PHOSPHORYLATION; STIMULATION; GROWTH	Dual-specificity phosphatase 5 (DUSP5), a VH1-Iike enzyme that hydrolyses nuclear substrates phosphorylated on both tyrosine and serine/threonine residues, has a potential role in deactivation of mitogen- or stress-activated protein kinases. Using cDNA-microarray technology, we found that the expression of DUSP5 mRNA was dramatically increased by exogenous p53 in U373MG, a p53-mutant glioblastoma cell line. Transcription of DUSP5 was also remarkably activated by endogenous p53 in response to DNA damage in colon-cancer cells (p53+/+) that contained wild-type p53, but not in p53-/- cells. Chromatin-immunoprecipitation (ChIP) and reporter assays demonstrated that endogenous p53 protein would bind directly to the promoter region of the DUSP5 gene, implying p53-dependent transcriptional activity. Overexpression of DUSP5 suppressed the growth of several types of human cancer cells, in which Erk1/2 was significantly dephosphorylated. If, as the results suggest, DUSP5 is a direct target of p53, it represents a novel mechanism by which p53 might negatively regulate cell-cycle progression by downregulating mitogen- or stress-activated protein kinases.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Arakawa, Hirofumi/L-3459-2013	Arakawa, Hirofumi/0000-0001-6077-0638				Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Furuhata T, 1996, ONCOGENE, V13, P1965; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Iiizumi M, 2002, CANCER RES, V62, P1246; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; Kim TI, 2002, ANN NY ACAD SCI, V973, P241, DOI 10.1111/j.1749-6632.2002.tb04641.x; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kovanen PE, 2003, J BIOL CHEM, V278, P5205, DOI 10.1074/jbc.M209015200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARTELL KJ, 1994, GENOMICS, V22, P462, DOI 10.1006/geno.1994.1411; Marti F, 2001, J IMMUNOL, V166, P197, DOI 10.4049/jimmunol.166.1.197; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MIYASHITA T, 1995, CELL, V80, P293; Mori T, 2002, NEOPLASIA, V4, P268, DOI 10.1038/sj.neo.7900235; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; Ng CC, 1999, GENE CHROMOSOME CANC, V26, P329, DOI 10.1002/(SICI)1098-2264(199912)26:4<329::AID-GCC7>3.0.CO;2-C; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Ochi K, 2002, NEOPLASIA, V4, P82, DOI 10.1038/sj.neo.7900211; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Ono K, 2000, CANCER RES, V60, P5007; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Shiraishi K, 2000, CANCER RES, V60, P3722; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; Takei Y, 1998, GENE CHROMOSOME CANC, V23, P1; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Urano T, 1997, CANCER RES, V57, P3281; Yoo J, 2002, ARCH PATHOL LAB MED, V126, P1096	31	94	98	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5586	5591		10.1038/sj.onc.1206845	http://dx.doi.org/10.1038/sj.onc.1206845			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944906	Bronze			2022-12-17	WOS:000184865900007
J	Nowicki, MO; Pawlowski, P; Fischer, T; Hess, G; Pawlowski, T; Skorski, T				Nowicki, MO; Pawlowski, P; Fischer, T; Hess, G; Pawlowski, T; Skorski, T			Chronic myelogenous leukemia molecular signature	ONCOGENE			English	Article						BCR/ABL; CML; microarrays; gene profiling	ABL TYROSINE KINASE; CHRONIC MYELOID-LEUKEMIA; BCR/ABL-MEDIATED LEUKEMOGENESIS; ACUTE LYMPHOBLASTIC-LEUKEMIA; BCR-ABL; GENE-EXPRESSION; HEMATOPOIETIC-CELLS; PHILADELPHIA-CHROMOSOME; CYCLIN D2; SIGNALING PATHWAYS	To obtain comprehensive information about the genes involved in BCR/ABL-dependent leukemogenesis, samples from 15 chronic myelogenous leukemia (CML) patients and seven normal donors were analysed using a cDNA microarray assay. After subtraction of the artificial, random or cross-hybridization signals, data about 5315 genes have been effectively analysed in all samples. The assay revealed greater than or equal to4-fold difference in the average expression of 263 genes in all CML samples when compared to normal counterparts, with 148 genes being upregulated and 115 being downregulated. Differentially expressed genes include those associated with BCR/ABL-induced abnormalities in signal transduction, gene transactivation, cell cycle, apoptosis, adhesion, DNA repair, differentiation, metabolism and malignant progression. Interestingly, CML-blast crisis cells in peripheral blood differ from those from bone marrow, indicating major changes in gene expression profiles upon entering into the bloodstream. Moreover, BCR/ABL modulates expression of genes, which are involved in regulation of chromosome/chromatin/DNA dynamics during S and M cell cycle phase. Moreover, the ability of CML cells to recognize and respond to a pathogen infection may be compromised. Altogether, this work provides a large body of information regarding gene expression profiles associated with CML and also represents a source of potential targets for CML therapeutics.	Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA; UC Irvine, Coll Med, Dept Pathol, Orange, CA USA; Univ Mainz, Dept Med 3, D-55131 Mainz, Germany	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of California System; University of California Irvine; Johannes Gutenberg University of Mainz	Skorski, T (corresponding author), Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Biolife Sci Bldg,Room 419,1900 N 12th St, Philadelphia, PA 19122 USA.			Nowicki, Michal/0000-0002-5807-0007	NCI NIH HHS [CA87300] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1995, P NATL ACAD SCI USA, V92, P9540, DOI 10.1073/pnas.92.21.9540; AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; AKIYAMA H, 1991, REV INFECT DIS, V13, P815; Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; Behrens P, 2001, ANTICANCER RES, V21, P2413; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dang CV, 1999, MOL CELL BIOL, V19, P1; Dasari VK, 2001, J UROLOGY, V165, P1335, DOI 10.1016/S0022-5347(01)69895-1; Deininger MWN, 2001, CANCER RES, V61, P8005; Deininger MWN, 2000, CANCER RES, V60, P2049; Dotti G, 1999, BRIT J HAEMATOL, V105, P163, DOI 10.1111/j.1365-2141.1999.01299.x; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; EPNER DE, 1990, ANN INTERN MED, V113, P3, DOI 10.7326/0003-4819-113-1-3; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fukada T, 2001, J BIOL CHEM, V276, P25512, DOI 10.1074/jbc.M101354200; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grimley PM, 1999, CYTOKINE GROWTH F R, V10, P131, DOI 10.1016/S1359-6101(99)00011-8; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; HEHLMANN R, 1994, BLOOD, V84, P4064, DOI 10.1182/blood.V84.12.4064.bloodjournal84124064; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Hofmann WK, 2002, LANCET, V359, P481, DOI 10.1016/S0140-6736(02)07678-X; Huang HT, 2000, CANCER RES, V60, P6868; Itoh M, 2001, Rinsho Ketsueki, V42, P209; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Janowska-Wieczorek A, 2002, LEUKEMIA, V16, P1160, DOI 10.1038/sj.leu.2402486; Jena N, 2002, CANCER RES, V62, P535; Johansson B, 2002, ACTA HAEMATOL-BASEL, V107, P76, DOI 10.1159/000046636; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; Maio M, 1998, INT J ONCOL, V13, P305; Majsterek I, 2002, CELL BIOL INT, V26, P363, DOI 10.1006/cbir.2002.0865; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nieborowska-Skorska M, 2002, BLOOD, V99, P4531, DOI 10.1182/blood.V99.12.4531; Ohmine K, 2001, ONCOGENE, V20, P8249, DOI 10.1038/sj.onc.1205029; Olesen SH, 2001, CARCINOGENESIS, V22, P813, DOI 10.1093/carcin/22.5.813; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Peled A, 2002, STEM CELLS, V20, P259, DOI 10.1634/stemcells.20-3-259; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; Pierce A, 2002, ONCOGENE, V21, P3068, DOI 10.1038/sj.onc.1205424; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; RATAJCZAK MZ, 1992, BLOOD, V79, P1956; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Salgia R, 1999, BLOOD, V94, P4233; Sattler M, 1999, MOL CELL BIOL, V19, P7473; Sattler M, 2001, INT J HEMATOL, V73, P278, DOI 10.1007/BF02981952; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Schadt EE, 2000, J CELL BIOCHEM, V80, P192; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; Skorski T, 1998, BLOOD, V91, P406, DOI 10.1182/blood.V91.2.406.406_406_418; Skorski T, 2002, NAT REV CANCER, V2, P351, DOI 10.1038/nrc799; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Soto T, 1999, APPL ENVIRON MICROB, V65, P2020; Tauchi T, 2001, EXP HEMATOL, V29, P356, DOI 10.1016/S0301-472X(00)00673-1; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vieira SAD, 2001, GENE CHROMOSOME CANC, V32, P353, DOI 10.1002/gcc.1200; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wildi S, 2001, GUT, V49, P409, DOI 10.1136/gut.49.3.409; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	73	94	103	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2003	22	25					3952	3963		10.1038/sj.onc.1206620	http://dx.doi.org/10.1038/sj.onc.1206620			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813469				2022-12-17	WOS:000183612000015
J	Deng, CX				Deng, CX			Roles of BRCA1 in centrosome duplication	ONCOGENE			English	Review						BRCA1; GADD45; p53; centrosome amplification	GENETIC INSTABILITY; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATION; BREAST-CANCER; ESTROGEN-RECEPTOR; DNA-DAMAGE; P53; MICE; PHOSPHORYLATION; TUMORIGENESIS	Centrosome duplication is under precise control and occurs only once in a normal mammalian cell cycle. Disruption of this process causes centrosome amplification, unequal segregation of chromosomes and, ultimately, tumorigenesis. Recent studies indicate that breast cancer suppressor gene 1 (BRCA1) plays an important role in regulating centrosome duplication. BRCA1 is located in the centrosome and binds to gamma-tubulin. It interacts with a variety of proteins that regulate centrosome duplication, including BRCA2, CDK2 - Cyclin A, CDK2 - Cyclin E, Gadd45, p21, p53 and Rb. Furthermore, targeted disruption of murine BRCA1 results in centrosome amplification, suggesting that BRCA1 serves as a negative regulator for centrosome duplication. This review will examine these data and discuss possible relationships between BRCA1 and its interacting proteins in centrosome duplication.	NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Deng, CX (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, 10-9N105,10 Ctr Dr, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001, ZIADK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; Alberg Anthony J., 1999, Current Opinion in Oncology, V11, P435, DOI 10.1097/00001622-199911000-00003; Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Brodie S G, 2001, Trends Genet, V17, pS18, DOI 10.1016/S0168-9525(01)02451-9; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Deng CX, 2000, BIOESSAYS, V22, P728; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Deng CX, 2002, ENVIRON MOL MUTAGEN, V39, P171, DOI 10.1002/em.10069; Deng CX, 2001, MUTAT RES-FUND MOL M, V477, P183, DOI 10.1016/S0027-5107(01)00119-1; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hinchcliffe EH, 2001, CURR BIOL, V11, pR698, DOI 10.1016/S0960-9822(01)00412-2; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hsu LC, 2001, CANCER RES, V61, P7713; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lange BMH, 2002, CURR OPIN CELL BIOL, V14, P35, DOI 10.1016/S0955-0674(01)00291-5; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Merrick BA, 2001, BIOCHEMISTRY-US, V40, P4053, DOI 10.1021/bi002045i; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Pihan GA, 1998, CANCER RES, V58, P3974; PRICE BD, 1995, ONCOGENE, V11, P73; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Tarapore P, 2001, ONCOGENE, V20, P6851, DOI 10.1038/sj.onc.1204848; Tarapore P, 2000, CANCER INVEST, V18, P148, DOI 10.3109/07357900009038246; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Winey M, 1999, CURR BIOL, V9, pR449, DOI 10.1016/S0960-9822(99)80279-6; Winey M, 1996, CURR BIOL, V6, P962, DOI 10.1016/S0960-9822(02)00639-5; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; ZHANG W, 1994, CANCER RES, V54, P4448; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	62	94	96	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	2002	21	40					6222	6227		10.1038/sj.onc.1205713	http://dx.doi.org/10.1038/sj.onc.1205713			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214252	Bronze			2022-12-17	WOS:000177840500011
J	Glondu, M; Liaudet-Coopman, E; Derocq, D; Platet, N; Rochefort, H; Garcia, M				Glondu, M; Liaudet-Coopman, E; Derocq, D; Platet, N; Rochefort, H; Garcia, M			Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells	ONCOGENE			English	Article						cathepsin-D; antisense RNA; breast cancer; growth; metastasis	HUMAN GLIOBLASTOMA CELLS; ESTROGEN-RECEPTOR; BASEMENT-MEMBRANE; PROCATHEPSIN-D; INVASIVENESS; INVASION; PROTEIN; RNA; TUMORIGENICITY; MACROPHAGES	Overexpression of cathepsin-D in primary breast cancer has been associated with rapid development of clinical metastasis. To investigate the role of this protease in breast cancer growth and progression to metastasis, we stably transfected a highly metastatic human breast cancer cell line, MDA-MB-231, with a plasmid containing either the full-length cDNA for cathepsin-D or a 535 bp antisense cathepsin-D cDNA fragment. Clones expressing antisense cathepsin-D cDNA that exhibited a 70-80% reduction in cathepsin-D protein, both intra- and extracellularly compared to controls, were selected for further experiments. These antisense-transfected cells displayed a reduced outgrowth rate when embedded in a Matrigel matrix, formed smaller colonies in soft agar and presented a significantly decreased tumor growth and experimental lung metastasis in nude mice compared with controls. However, manipulating the cathepsin-D level in the antisense cells has no effect on their in vitro invasiveness. These studies demonstrate that cathepsin-D enhances anchorage-independent cell proliferation and subsequently facilitates tumorigenesis and metastasis of breast cancer cells. Our overall results provide the first evidence on the essential role of cathepsin-D in breast cancer, and support the development of a new cathepsin-D-targeted therapy.	Univ Montpellier 1, INSERM, U540, F-34090 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Garcia, M (corresponding author), Univ Montpellier 1, INSERM, U540, 60 Rue Navacelles, F-34090 Montpellier, France.		Liaudet-Coopman, Emmanuelle/N-4744-2017	Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690				Authier F, 2002, J BIOL CHEM, V277, P9437, DOI 10.1074/jbc.M110188200; Bissell MJ, 1999, CANCER RES, V59, p1757S; Castagnino P, 1998, ONCOGENE, V17, P481, DOI 10.1038/sj.onc.1201957; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Coyne CP, 2001, MOL IMMUNOL, V38, P347, DOI 10.1016/S0161-5890(01)00074-8; Edwards DR, 1998, NATURE, V394, P527, DOI 10.1038/28961; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; Ferrandina G, 1997, BRIT J CANCER, V76, P661, DOI 10.1038/bjc.1997.442; Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048; FUSEK M, 1994, BIOCHEM J, V303, P775, DOI 10.1042/bj3030775; GARCIA M, 1990, ONCOGENE, V5, P1809; GARCIA M, 1985, CANCER RES, V45, P709; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; Garcia M, 1996, STEM CELLS, V14, P642, DOI 10.1002/stem.140642; Glondu M, 2001, ONCOGENE, V20, P6920, DOI 10.1038/sj.onc.1204843; Haeckel C, 1998, INT J CANCER, V77, P153, DOI 10.1002/(SICI)1097-0215(19980703)77:1<153::AID-IJC23>3.3.CO;2-2; Hasegawa S, 1998, INT J CANCER, V76, P812, DOI 10.1002/(SICI)1097-0215(19980610)76:6<812::AID-IJC8>3.0.CO;2-0; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; JOHNSON MD, 1993, CANCER RES, V53, P873; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; Kirschke H, 2000, EUR J CANCER, V36, P787, DOI 10.1016/S0959-8049(00)00014-9; Kondraganti S, 2000, CANCER RES, V60, P6851; Laurent-Matha V, 1998, J CELL SCI, V111, P2539; LIAUDET E, 1994, ONCOGENE, V9, P1145; LIAUDET E, 1995, CELL GROWTH DIFFER, V6, P1045; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; Mohanam S, 2001, ONCOGENE, V20, P3665, DOI 10.1038/sj.onc.1204480; Montcourrier P, 1997, CLIN EXP METASTAS, V15, P382, DOI 10.1023/A:1018446104071; Platet N, 1998, INT J CANCER, V75, P750, DOI 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; Rochefort H, 1999, APMIS, V107, P86, DOI 10.1111/j.1699-0463.1999.tb01530.x; ROCHEFORT H, 1992, EUR J CANCER, V28A, P1780, DOI 10.1016/0959-8049(92)90003-K; ROGER P, 1994, HUM PATHOL, V25, P863, DOI 10.1016/0046-8177(94)90004-3; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Stetler-Stevenson W G, 2001, Surg Oncol Clin N Am, V10, P383; STEWART AJ, 1994, INT J CANCER, V57, P715, DOI 10.1002/ijc.2910570518; Tedone T, 1997, FASEB J, V11, P785, DOI 10.1096/fasebj.11.10.9271363; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; WORMINGTON WM, 1986, P NATL ACAD SCI USA, V83, P8639, DOI 10.1073/pnas.83.22.8639	42	94	106	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5127	5134		10.1038/sj.onc.1205657	http://dx.doi.org/10.1038/sj.onc.1205657			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140763				2022-12-17	WOS:000176975900011
J	Ren, SX; Cai, HR; Li, ML; Furth, PA				Ren, SX; Cai, HR; Li, ML; Furth, PA			Loss of Stat5a delays mammary cancer progression in a mouse model	ONCOGENE			English	Article						Stat5a; mammary cancer; mouse model; SV40 T antigen, apoptosis	TRANSCRIPTION FACTORS; BREAST-CANCER; GLAND DEVELOPMENT; CELL-SURVIVAL; GROWTH-FACTOR; ACTIVATION; PROLACTIN; EXPRESSION; MICE; SIGNALS	A genetic study was conducted to determine if activated Stat5a contributes to mammary carcinogenesis and to evaluate the mechanism. Similar to human breast cancers, a proportion of mammary adenocarcinomas in the WAP-TAg transgenic mouse model demonstrate constitutive Stat5a/b and Stat3 activation. Stat5a activation is linked to mammary epithelial cell survival and differentiation, and proliferation in hematopoetic cell lineages. Breeding WAP-TAg mice to mice carrying germ-line deletions of the Stat5a gene generated mice with reduced levels of Stat5a. Hemizygous loss of the Stat5a allele significantly reduced levels of Stat5a expression without altering mammary gland development or transgene expression levels. In comparison to mice carrying two wild-type Stat5a alleles, hemizygous loss of the Stat5a allele reduced the number of mice with palpable tumors at 7 months of age (67% from 100%, P<0.05), resulted in smaller tumors at 7 months of age (3.8 cm(3) from 7.6 cm(3), P=0.003), delayed first tumor appearance (208 days from 188 days, P=0.01), and increased the apoptotic index in the adenocarcinomas (4.3+0.3 from 1.2+0.2, P=0.016). Neither cell proliferation nor differentiation in the cancers was altered. Decreasing Stat5a activation levels could be a therapeutic approach for reducing survival of breast cancer cells.	Georgetown Univ, Dept Oncol, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA	Georgetown University; University System of Maryland; University of Maryland Baltimore	Furth, PA (corresponding author), Georgetown Univ, Dept Oncol, Vincent T Lombardi Canc Res Ctr, Res Bldg,E518,3970 Reservoir Rd NW, Washington, DC 20007 USA.	paf3@georgetown.edu						Berclaz G, 2001, INT J ONCOL, V19, P1155; Birkenkamp KU, 2001, LEUKEMIA, V15, P1923, DOI 10.1038/sj.leu.2402317; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; Canbay E, 1997, BIOCHEM J, V324, P231, DOI 10.1042/bj3240231; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Gallego MI, 2001, DEV BIOL, V229, P163, DOI 10.1006/dbio.2000.9961; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gouilleux-Gruart V, 1997, LEUKEMIA LYMPHOMA, V28, P83, DOI 10.3109/10428199709058334; Hennighausen L, 1997, J BIOL CHEM, V272, P7567, DOI 10.1074/jbc.272.12.7567; Hennighausen L, 1997, J MAMMARY GLAND BIOL, V2, P365, DOI 10.1023/A:1026347313096; Humphreys RC, 1999, CELL GROWTH DIFFER, V10, P685; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Kieslinger M, 2000, GENE DEV, V14, P232; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Li ML, 2000, ONCOGENE, V19, P1010, DOI 10.1038/sj.onc.1203271; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Liu XW, 1998, CELL GROWTH DIFFER, V9, P795; Maru Y, 2001, INT J HEMATOL, V73, P308, DOI 10.1007/BF02981955; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Ormandy CJ, 1997, J MAMMARY GLAND BIOL, V2, P355, DOI 10.1023/A:1026395229025; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; Schaber JD, 1998, CANCER RES, V58, P1914; Shang YF, 1999, ONCOGENE, V18, P6725, DOI 10.1038/sj.onc.1203084; Snow JW, 2002, BLOOD, V99, P95, DOI 10.1182/blood.V99.1.95; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; Sternberg DW, 2001, BLOOD, V98, P3390, DOI 10.1182/blood.V98.12.3390; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162	35	94	97	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4335	4339		10.1038/sj.onc.1205484	http://dx.doi.org/10.1038/sj.onc.1205484			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082622				2022-12-17	WOS:000176174200017
J	Driouch, K; Prydz, H; Monese, R; Johansen, H; Lidereau, R; Frengen, E				Driouch, K; Prydz, H; Monese, R; Johansen, H; Lidereau, R; Frengen, E			Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors	ONCOGENE			English	Article						breast cancer; expression analysis; tumor suppressor genes	FRAGILE SITE FRA16D; CHROMOSOME ARM 16Q; ALLELIC IMBALANCE; MULTIPLE-MYELOMA; PROSTATE-CANCER; DELETED REGIONS; HIGH-FREQUENCY; HETEROZYGOSITY; CARCINOMAS; PROGRESSION	The presence of putative tumor-suppressor genes on chromosome 16q23.2-24.1 has been suggested by LOH analysis in several cancer types. This region overlaps with the fragile site FRA16D and the region of homozygous deletions found in several cancer types. The candidate gene WWOX/FOR has been mapped within this region. The mouse homologue of the WWOX protein has been defined as an apoptogenic protein and an essential partner of p53 in cell death, supporting WWOX as a tumor suppressor gene candidate. We performed an expression study of the WWOX/FOR gene in a series of human breast tumors and breast cancer cell lines, and detected reduced expression of the WWOX/ FOR transcript in a series of breast cancer cells. Furthermore, identification of two distinct alternative WWOX transcripts expressed at high levels in human tumors suggests an involvement of the WWOX gene in breast cancer progression.	Ctr Rene Huguenin, INSERM E0017, F-92211 St Cloud, France; Univ Oslo, Ctr Biotechnol, N-0349 Oslo, Norway	Institut National de la Sante et de la Recherche Medicale (Inserm); Rene Huguenin Hospital; University of Oslo	Driouch, K (corresponding author), Ctr Rene Huguenin, INSERM E0017, 35 Rue Dailly, F-92211 St Cloud, France.			Frengen, Eirik/0000-0002-8387-2247				ALDAZ CM, 1995, CANCER RES, V55, P3976; Bednarek AK, 2000, CANCER RES, V60, P2140; Bieche I, 1999, CANCER RES, V59, P2546; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLETONJANSEN AM, 1994, GENE CHROMOSOME CANC, V9, P101, DOI 10.1002/gcc.2870090205; Davidson JM, 2000, BRIT J CANCER, V83, P1309, DOI 10.1054/bjoc.2000.1458; DENG G, 1994, CANCER RES, V54, P499; DORIONBONNET F, 1995, GENE CHROMOSOME CANC, V14, P171, DOI 10.1002/gcc.2870140304; Driouch K, 1997, GENE CHROMOSOME CANC, V19, P185, DOI 10.1002/(SICI)1098-2264(199707)19:3<185::AID-GCC8>3.0.CO;2-U; Driouch K, 1998, CANCER RES, V58, P2081; Elo JP, 1997, CANCER RES, V57, P3356; Frengen E, 2000, GENOMICS, V68, P118, DOI 10.1006/geno.2000.6286; Grundy RG, 1998, BRIT J CANCER, V78, P1181, DOI 10.1038/bjc.1998.651; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; LARSEN F, 1992, GENET ANAL-BIOMOL E, V9, P80, DOI 10.1016/1050-3862(92)90002-M; LARSSON C, 1990, GENE CHROMOSOME CANC, V2, P191, DOI 10.1002/gcc.2870020305; LATIF F, 1992, CANCER RES, V52, P1451; Latil A, 1997, CANCER RES, V57, P1058; Li CD, 1999, GENE CHROMOSOME CANC, V24, P175, DOI 10.1002/(SICI)1098-2264(199903)24:3<175::AID-GCC1>3.3.CO;2-8; LINDBLOM A, 1993, CANCER RES, V53, P3707; Mangelsdorf M, 2000, CANCER RES, V60, P1683; Mashimo T, 1998, CANCER RES, V58, P4572; Osoegawa K, 2001, GENOME RES, V11, P483, DOI 10.1101/gr.169601; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Paige AJW, 2000, CANCER RES, V60, P1690; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; SATO T, 1991, CANCER RES, V51, P5794; SHEN Y, 1994, GENOMICS, V22, P68, DOI 10.1006/geno.1994.1346; SKIRNISDOTTIR S, 1995, INT J CANCER, V64, P112, DOI 10.1002/ijc.2910640207; Suzuki H, 1996, GENE CHROMOSOME CANC, V17, P225, DOI 10.1002/(SICI)1098-2264(199612)17:4<225::AID-GCC4>3.0.CO;2-5; TAKITA K, 1992, CANCER RES, V52, P3914; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; TSUDA H, 1994, CANCER RES, V54, P513; Watson JEV, 1999, GENOME RES, V9, P226	38	94	97	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1832	1840		10.1038/sj.onc.1205273	http://dx.doi.org/10.1038/sj.onc.1205273			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896615				2022-12-17	WOS:000174284500005
J	Bosc, DG; Goueli, BS; Janknecht, R				Bosc, DG; Goueli, BS; Janknecht, R			HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1	ONCOGENE			English	Article						ER81; gene transcription; HER2/Neu; MAP kinase; matrix metalloproteinase-1; protein phosphorylation	PROTEIN-KINASE; MAP-KINASE; MATRIX-METALLOPROTEINASES; INTERSTITIAL COLLAGENASE; BREAST-CANCER; PEA3 GROUP; EXPRESSION; CELL; PHOSPHORYLATION; BINDING	In this study, we show that the ETS transcription factor ER81 directly binds to and activates the promoter of the matrix metalloproteinase gene, MMP-1. Further, the oncoprotein HER2/Neu synergizes with ER81 to stimulate MMP-1 transcription, The activation of ER81 by HER2/Neu is mediated by MAP kinases, which phosphorylate ER81 in its N-terminal activation domain. Four respective phosphorylation sites have been identified. Blocking phosphorylation at these sites decreases ER81 transcriptional activity, which can be further diminished by abolishment of phosphorylation at two non-MAP kinase sites, Altogether, our results reveal mechanisms of how phosphorylation of ER81 regulates the expression of target genes such as MMP-1, which may be important for many physiological processes from embryogenesis to adulthood as well as for tumor metastasis.	Mayo Clin & Mayo Grad Sch Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Janknecht, R (corresponding author), Mayo Clin & Mayo Grad Sch Med, Dept Biochem & Mol Biol, Guggenheim Bldg 1501A,200 1st St SW, Rochester, MN 55905 USA.	janknecht.ralf@mayo.edu		Janknecht, Ralf/0000-0003-1741-1562	NCI NIH HHS [CA 85257, R01 CA085257] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Benbow U, 1999, CLIN CANCER RES, V5, P203; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BredemeierErnst I, 1997, FEBS LETT, V408, P47, DOI 10.1016/S0014-5793(97)00387-6; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Brummer O, 1999, VIRCHOWS ARCH, V435, P566, DOI 10.1007/s004280050442; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Buttice G, 1996, ONCOGENE, V13, P2297; Buzard GS, 1999, J CANCER RES CLIN, V125, P653, DOI 10.1007/s004320050330; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Chapman SC, 1999, J BIOL CHEM, V274, P18625, DOI 10.1074/jbc.274.26.18625; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; Durko M, 1997, BBA-MOL CELL RES, V1356, P271, DOI 10.1016/S0167-4889(97)00004-9; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fini ME, 1998, BIOL EXTRAC, P299; Garbett EA, 2000, J CLIN PATHOL-MOL PA, V53, P99, DOI 10.1136/mp.53.2.99; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Hung MC, 1999, SEMIN ONCOL, V26, P51; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Johansson N, 2000, J CELL SCI, V113, P227; Kindler-Rohrborn A, 2000, CANCER RES, V60, P4756; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MOLL UM, 1990, HISTOCHEMISTRY, V94, P555, DOI 10.1007/BF00272621; MONTE D, 1995, ONCOGENE, V11, P771; MUIR D, 1995, CLIN EXP METASTAS, V13, P303, DOI 10.1007/BF00133486; Nakopoulou L, 1999, HUM PATHOL, V30, P436, DOI 10.1016/S0046-8177(99)90120-X; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Papoutsopoulou S, 2000, MOL CELL BIOL, V20, P7300, DOI 10.1128/MCB.20.19.7300-7310.2000; Pearson KL, 1999, BBA-GENE STRUCT EXPR, V1489, P354, DOI 10.1016/S0167-4781(99)00166-9; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Shingleton WD, 1996, BIOCHEM CELL BIOL, V74, P759, DOI 10.1139/o96-083; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Sunami E, 2000, Oncologist, V5, P108, DOI 10.1634/theoncologist.5-2-108; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; White LA, 1997, CONNECT TISSUE RES, V36, P321, DOI 10.3109/03008209709160231; Yang BS, 1996, MOL CELL BIOL, V16, P538	56	94	94	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2001	20	43					6215	6224		10.1038/sj.onc.1204820	http://dx.doi.org/10.1038/sj.onc.1204820			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593430				2022-12-17	WOS:000171206300013
J	Hardwick, JCH; van den Brink, GR; Offerhaus, GJ; van Deventer, SJH; Peppelenbosch, MP				Hardwick, JCH; van den Brink, GR; Offerhaus, GJ; van Deventer, SJH; Peppelenbosch, MP			NF-kappaB, p38 MAPK and JNK are highly expressed and active in the stroma of human colonic adenomatous polyps	ONCOGENE			English	Article						polyp; JNK; NF-kappaB; p38 MAPK; COX-2; NSAIDs	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TERMINAL KINASE; PROTEIN-KINASE; SODIUM-SALICYLATE; CYCLOOXYGENASE 2; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; B ACTIVATION; CANCER CELLS; INHIBITION	The factors that govern the progression from colonic adenomatous polyp to colon cancer are poorly understood. The observation that NSAIDs act as chemopreventative agents and reduce the size of colonic polyps suggests the involvement of inflammatory signalling, but inflammatory signalling in colonic polyps has not been studied. We investigated the expression of the active forms of NF-kappaB, JNK and p38 MAPK using immunohistochemistry with activation specific antibodies in human colonic adenomas, We show that active NF-kappaB is seen in stromal macrophages that also express COX-2 and TNF-alpha, active JNK is seen in stromal and intraepithelial T-lymphocytes and periendothelial cells of new blood vessels, and active p38 MAPK is most highly expressed in macrophages and other stromal cells. These results demonstrate the presence of active inflammatory signal transduction in colonic polyps and that these are predominantly in the stroma, In the case of NF-kappaB this coincides with the cellular localisation of COX-2. These results support evidence that NSAIDs may act through effects on stromal cells rather than epithelial cells.	Univ Amsterdam, Acad Med Ctr, Dept Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Hardwick, JCH (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Expt Internal Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Hardwick, James/J-4862-2013	Hardwick, James/0000-0002-9575-5099; Peppelenbosch, Maikel/0000-0001-9112-6028				Bak AW, 1998, LIFE SCI, V62, pPL367; Bamba H, 1999, INT J CANCER, V83, P470, DOI 10.1002/(SICI)1097-0215(19991112)83:4<470::AID-IJC6>3.3.CO;2-6; Chan ED, 1997, P NATL ACAD SCI USA, V94, P13169, DOI 10.1073/pnas.94.24.13169; Chapple KS, 2000, AM J PATHOL, V156, P545, DOI 10.1016/S0002-9440(10)64759-1; Charalambous D, 1996, J GASTROEN HEPATOL, V11, P307, DOI 10.1111/j.1440-1746.1996.tb01376.x; Chen KD, 1998, J BIOL CHEM, V273, P749, DOI 10.1074/jbc.273.2.749; Chiu CH, 1997, CANCER RES, V57, P4267; DIGIORGIO A, 1992, INT SURG, V77, P256; Gaweco AS, 2000, HEPATOLOGY, V31, P1183, DOI 10.1053/he.2000.6983; Hakansson L, 1997, BRIT J CANCER, V75, P374, DOI 10.1038/bjc.1997.61; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Hull MA, 1999, BRIT J CANCER, V79, P1399, DOI 10.1038/sj.bjc.6690224; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Janne PA, 2000, NEW ENGL J MED, V342, P1960, DOI 10.1056/NEJM200006293422606; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Licato LL, 1997, GASTROENTEROLOGY, V113, P1589, DOI 10.1053/gast.1997.v113.pm9352861; Licato LL, 1998, DIGEST DIS SCI, V43, P1454, DOI 10.1023/A:1018894227169; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Omori S, 2000, KIDNEY INT, V58, P27, DOI 10.1046/j.1523-1755.2000.00137.x; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Piazza GA, 1997, CANCER RES, V57, P2452; Pirvola U, 2000, J NEUROSCI, V20, P43, DOI 10.1523/JNEUROSCI.20-01-00043.2000; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; SANO H, 1995, CANCER RES, V55, P3785; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; Schwenger P, 1999, J CELL PHYSIOL, V179, P109, DOI 10.1002/(SICI)1097-4652(199904)179:1<109::AID-JCP13>3.0.CO;2-W; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; SVENNEVIG JL, 1984, BRIT J CANCER, V49, P375, DOI 10.1038/bjc.1984.60; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; van den Brink GR, 2000, J IMMUNOL, V164, P3353, DOI 10.4049/jimmunol.164.6.3353; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	44	94	96	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2001	20	7					819	827		10.1038/sj.onc.1204162	http://dx.doi.org/10.1038/sj.onc.1204162			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314016				2022-12-17	WOS:000166924400005
J	Wittau, N; Grosse, R; Kalkbrenner, F; Gohla, A; Schultz, G; Gudermann, T				Wittau, N; Grosse, R; Kalkbrenner, F; Gohla, A; Schultz, G; Gudermann, T			The galanin receptor type 2 initiates multiple signaling pathways in small cell lung cancer cells by coupling to G(q), G(i) and G(12) proteins	ONCOGENE			English	Article						G-protein-coupled receptor; mitogenic signaling; multiple signaling; neuropeptides	GROWTH-FACTOR RECEPTOR; STRESS FIBER FORMATION; PHOSPHOLIPASE C-BETA; ACTIVATED G-PROTEINS; SMOOTH-MUSCLE CELLS; TYROSINE KINASE; MEMBRANE DEPOLARIZATION; NEUROENDOCRINE PEPTIDE; LYSOPHOSPHATIDIC ACID; MOLECULAR-CLONING	Neuropeptides like galanin produced and released by small cell lung cancer (SCLC) cells are considered principal mitogens in these tumors. We identified the galanin receptor type 2 (GALR2) as the only galanin receptor expressed in H69 and H510 cells. Photoaffinity labeling of G proteins in H69 cell membranes revealed that GALR2, activates G proteins of three subfamilies: G(q), G(i), and G(12). In H-69 cells, galanin-induced Ca2+ mobilization was pertussis toxin-insensitive. While phorbol ester-induced extracellular signal-regulated kinase (ERK) activation required protein kinase C (PKC) activity, preincubation of 1169 cells with the PKC-inhibitor GF109203X had no effect on galanin-dependent ERK activity. A rise of the intracellular calcium concentration was necessary and sufficient to mediate galanin-induced ERK activation, In support of Gi coupling, stimulation of GALR2 expressed in HEK293 cells inhibited isoproterenol-induced cAMP accumulation and raised cAMP levels in COS-7 cells when coexpressed with a chimeric G alpha(S)-G alpha(i) protein. In 1169 cells, galanin activated the monomeric GTPase RhoA and induced stress fiber formation in Swiss 3T3 cells expressing GALR2, Thus, we provide the first direct evidence that in SCLC the mitogenic neuropeptide galanin, interacting with GALR2, simultaneously activates multiple classes of G proteins and signals through the Gq phospholipase C/calcium sequence and a G(12)/Rho pathway.	Univ Marburg, Fachbereich Humanmed, Inst Pharmakol & Toxikol, D-35033 Marburg, Germany; Univ Klinikum Benjamin Franklin, Inst Pharmakol, D-14195 Berlin, Germany	Philipps University Marburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Gudermann, T (corresponding author), Univ Marburg, Fachbereich Humanmed, Inst Pharmakol & Toxikol, Karl Von Frisch Str 1, D-35033 Marburg, Germany.			Grosse, Robert/0000-0002-3380-5273; Gohla, Antje/0000-0002-7442-1487				ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; Barr AJ, 1997, J BIOL CHEM, V272, P2223; BARTFAI T, 1993, CRIT REV NEUROBIOL, V7, P229; BEDECS K, 1995, INT J BIOCHEM CELL B, V27, P337, DOI 10.1016/1357-2725(95)00008-D; Beekman A, 1998, CANCER RES, V58, P910; BEPLER G, 1988, J CANCER RES CLIN, V114, P235, DOI 10.1007/BF00405828; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; Bloomquist BT, 1998, BIOCHEM BIOPH RES CO, V243, P474, DOI 10.1006/bbrc.1998.8133; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Grosse R, 2000, J BIOL CHEM, V275, P9193, DOI 10.1074/jbc.275.13.9193; Grosse R, 2000, J BIOL CHEM, V275, P12251, DOI 10.1074/jbc.275.16.12251; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; HABERTORTOLI E, 1994, P NATL ACAD SCI USA, V91, P9780, DOI 10.1073/pnas.91.21.9780; Heasley LE, 1996, J BIOL CHEM, V271, P349, DOI 10.1074/jbc.271.1.349; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; Jarpe MB, 1998, J BIOL CHEM, V273, P3097, DOI 10.1074/jbc.273.5.3097; KALKBRENNER F, 1995, EMBO J, V14, P4728, DOI 10.1002/j.1460-2075.1995.tb00154.x; KAO JPY, 1994, METHOD CELL BIOL, V40, P155; Kask K, 1995, CELL MOL NEUROBIOL, V15, P653, DOI 10.1007/BF02071130; Komatsuzaki K, 1997, FEBS LETT, V406, P165, DOI 10.1016/S0014-5793(97)00257-3; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Kuhn B, 1996, MOL ENDOCRINOL, V10, P1697, DOI 10.1210/me.10.12.1697; LASSEN U, 1995, J CLIN ONCOL, V13, P1215, DOI 10.1200/JCO.1995.13.5.1215; LAUGWITZ KL, 1994, METHOD ENZYMOL, V237, P283; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; MOODY TW, 1985, LIFE SCI, V37, P105, DOI 10.1016/0024-3205(85)90413-8; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Pang L, 1998, J NEUROCHEM, V71, P2252; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rozengurt Enrique, 1999, Current Opinion in Oncology, V11, P116; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schoneberg T, 1999, MOL CELL ENDOCRINOL, V151, P181, DOI 10.1016/S0303-7207(99)00017-9; SETHI T, 1991, CANCER RES, V51, P1674; SETHI T, 1991, CANCER RES, V51, P3621; SETHI T, 1992, CANCER RES, V52, pS2737; Seufferlein T, 1996, CANCER RES, V56, P5758; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Smith KE, 1997, J BIOL CHEM, V272, P24612, DOI 10.1074/jbc.272.39.24612; Smith KE, 1998, J BIOL CHEM, V273, P23321, DOI 10.1074/jbc.273.36.23321; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.biochem.63.1.101; Tokman MG, 1997, CANCER RES, V57, P1785; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VIALLET J, 1990, J CLIN INVEST, V86, P1904, DOI 10.1172/JCI114923; Wang S, 1998, BIOCHEMISTRY-US, V37, P6711, DOI 10.1021/bi9728405; Wang S, 1997, MOL PHARMACOL, V52, P337, DOI 10.1124/mol.52.3.337; Wang SK, 1998, DRUG NEWS PERSPECT, V11, P458; Wang SK, 1997, J BIOL CHEM, V272, P31949, DOI 10.1074/jbc.272.51.31949; WONG YH, 1994, METHOD ENZYMOL, V238, P81; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	71	94	97	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2000	19	37					4199	4209		10.1038/sj.onc.1203777	http://dx.doi.org/10.1038/sj.onc.1203777			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980593				2022-12-17	WOS:000089032900002
J	Kim, SH; Forman, AP; Mathews, MB; Gunnery, S				Kim, SH; Forman, AP; Mathews, MB; Gunnery, S			Human breast cancer cells contain elevated levels and activity of the protein kinase, PKR	ONCOGENE			English	Article						PKR; breast cancer; translation; p58; eIF2B	TETRATRICOPEPTIDE REPEAT PROTEIN; SYNTHESIS INITIATION-FACTOR; RNA-BINDING PROTEIN; NF-KAPPA-B; MALIGNANT TRANSFORMATION; CELLULAR INHIBITOR; EXPRESSION; APOPTOSIS; PATHWAY; P68	PKR is a double-stranded (ds) RNA activated protein kinase whose expression is induced by interferon. Activated PKR phosphorylates its cellular substrate, eIF2, an essential initiation factor of translation. Prior evidence from a murine model system suggested that PKR may act as a tumor suppressor, but the evidence from human tumors is equivocal. To study PKR function in human breast cancer, PKR activity was measured in mammary carcinoma cell lines and nontransformed mammary epithelial cell lines. If PKR functioned as a tumor suppressor in this system, its activity would be higher in nontransformed cells than in carcinoma cells. On the contrary, PKR autophosphorylation and the phosphorylation of its substrate, the v.-subunit of eLF2, is 7 - 40-fold higher in lysates prepared from breast carcinoma cell lines than in those from nontransformed epithelial cell lines. Correspondingly, a larger proportion of eIF2 alpha is present in a phosphorylated state in carcinoma cell lines than in nontransformed cell lines. Protein synthesis is not inhibited by the high eIF2 alpha phosphorylation in carcinoma cells, probably because they contain higher levels of eIF2B, the initiation factor that is inhibited by eIF2 alpha phosphorylation, The dramatically lower PKR activity in nontransformed cell lines is partially due to lower PKR protein levels (2-4-fold) as well as to the presence of a PKR inhibitor. The nontransformed cells contain P58, a known cellular inhibitor of PKR that physically interacts with PKR and may be responsible for the low PKR activity in these cells. Taken together, these observations call into question the role of PKR as a tumor suppressor and suggest a positive regulatory role of PKR in growth control of breast cancer cells.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Gunnery, S (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.				NIAID NIH HHS [AI34552] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034552] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; Basu S, 1997, CANCER RES, V57, P943; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Beretta L, 1996, ONCOGENE, V12, P1593; Brand SR, 1997, J BIOL CHEM, V272, P8388, DOI 10.1074/jbc.272.13.8388; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Donze O, 1999, VIROLOGY, V256, P322, DOI 10.1006/viro.1999.9618; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; Gunnery S, 1998, METHODS, V15, P189, DOI 10.1006/meth.1998.0623; Haines GK, 1996, TUMOR BIOL, V17, P5, DOI 10.1159/000217961; Haines GK, 1998, TUMOR BIOL, V19, P52, DOI 10.1159/000029974; Harlow E, 1998, ANTIBODIES LAB MANUA; JARAMILLO ML, 1995, CANCER INVEST, V13, P327, DOI 10.3109/07357909509094468; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langland JO, 1999, BIOCHEMISTRY-US, V38, P6361, DOI 10.1021/bi982410u; Lee SB, 1997, VIROLOGY, V231, P81, DOI 10.1006/viro.1997.8494; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MUNDSCHAU LJ, 1995, J BIOL CHEM, V270, P3100, DOI 10.1074/jbc.270.7.3100; OFFERMANN MK, 1995, EUR J BIOCHEM, V232, P28, DOI 10.1111/j.1432-1033.1995.tb20777.x; OLDFIELD S, 1994, EUR J BIOCHEM, V221, P399, DOI 10.1111/j.1432-1033.1994.tb18752.x; Patel RC, 1999, J BIOL CHEM, V274, P20432, DOI 10.1074/jbc.274.29.20432; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; Polyak SJ, 1996, J BIOL CHEM, V271, P1702, DOI 10.1074/jbc.271.3.1702; REICHEL PA, 1985, NATURE, V313, P196, DOI 10.1038/313196a0; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Savinova O, 1997, METHODS, V11, P419, DOI 10.1006/meth.1996.0438; Shimada A, 1998, CANCER RES, V58, P4434; Tang NM, 1999, MOL CELL BIOL, V19, P4757; Williams BRG, 1997, BIOCHEM SOC T, V25, P509, DOI 10.1042/bst0250509; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198; Zamanian-Daryoush M, 1999, ONCOGENE, V18, P315, DOI 10.1038/sj.onc.1202293	41	94	97	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2000	19	27					3086	3094		10.1038/sj.onc.1203632	http://dx.doi.org/10.1038/sj.onc.1203632			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871861				2022-12-17	WOS:000087903900006
J	Chauhan, D; Hideshima, T; Pandey, P; Treon, S; Teoh, G; Raje, N; Rosen, S; Krett, N; Husson, H; Avraham, S; Kharbanda, S; Anderson, KC				Chauhan, D; Hideshima, T; Pandey, P; Treon, S; Teoh, G; Raje, N; Rosen, S; Krett, N; Husson, H; Avraham, S; Kharbanda, S; Anderson, KC			RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells	ONCOGENE			English	Article						multiple myeloma; irradiation; dexamethasone; apoptosis	FOCAL TYROSINE KINASE; HEMATOPOIETIC-CELLS; ACTIVATION; INTERLEUKIN-6; ASSOCIATION; PYK2; PHOSPHORYLATION; MEGAKARYOCYTES; STIMULATION; PAXILLIN	Related Adhesion Focal Tyrosine Kinase (RAFTK; also known as Pyk2), is a member of the Focal Adhesion Kinase (FAK) subfamily and is activated by TNF alpha, UV light and increases in intracellular calcium levels. However, the function of RAFTK remains largely unknown. Our previous studies demonstrated that treatment with dexamethasone (Dex), ionizing radiation (IR), and anti-Fas mAb induces apoptosis in multiple myeloma (MM) cells. In the present study, we examined the potential role of RAFTK during induction of apoptosis in human MM cells triggered by these three stimuli. Dex-induced apoptosis, in contrast to apoptosis triggered by anti-Fas mAb or IR, is associated with activation of RAFTK. Transient overexpression of RAFTK wild type (RAFTK WT) induces apoptosis, whereas transient overexpression of Kinase inactive RAFTK (RAFTK K-M) blocks Dex-induced apoptosis. In contrast, transient overexpression of RAFTK K-M has no effect on apoptosis triggered by IR or Fas. In Dex-resistant cells, Dex does not trigger either RAFTK activation or apoptosis. Finally, interleukin-6 (IL-6), a known survival factor for MM cells, inhibits both activation of RAFTK and apoptosis of MM.1S cells triggered by Dex. Our studies therefore demonstrate Dex-induced RAFTK-dependent, and IR or Fas induced RAFTK-independent apoptotic signaling cascades in MM cells.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med & Hematol Oncol, Boston, MA 02115 USA; Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Anderson, KC (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02215 USA.				NCI NIH HHS [CA50947, CA75216] Funding Source: Medline; NHLBI NIH HHS [HL55445] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050947, R01CA075216] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055445] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASTEIR A, 1997, J BIOL CHEM, V272, P19719; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Avraham S, 1997, LEUKEMIA LYMPHOMA, V27, P247, DOI 10.3109/10428199709059681; Berg NN, 1997, J IMMUNOL, V159, P1753; CHAUHAN D, 1995, J EXP MED, V182, P1801, DOI 10.1084/jem.182.6.1801; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Derkinderen P, 1998, EUR J NEUROSCI, V10, P1667, DOI 10.1046/j.1460-9568.1998.00174.x; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; FU X, 1998, BLOOD, V92, P241; Hamel W, 1996, CYTOMETRY, V25, P173, DOI 10.1002/(SICI)1097-0320(19961001)25:2<173::AID-CYTO6>3.0.CO;2-I; HARDIN J, 1994, BLOOD, V84, P3063; HARDIN JA, 1992, J IMMUNOL METHODS, V154, P99, DOI 10.1016/0022-1759(92)90217-H; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Pandey P, 1999, J BIOL CHEM, V274, P8618, DOI 10.1074/jbc.274.13.8618; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Swanson KD, 1998, J BIOL CHEM, V273, P19965, DOI 10.1074/jbc.273.32.19965; THORNBERRY AT, 1997, APOPTOSIS, P155; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tsuchida M, 1999, J BIOL CHEM, V274, P6735, DOI 10.1074/jbc.274.10.6735; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	31	94	95	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6733	6740		10.1038/sj.onc.1203082	http://dx.doi.org/10.1038/sj.onc.1203082			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597281				2022-12-17	WOS:000083792000015
J	Brown, CY; Mize, GJ; Pineda, M; George, DL; Morris, DR				Brown, CY; Mize, GJ; Pineda, M; George, DL; Morris, DR			Role of two upstream open reading frames in the translational control of oncogene mdm2	ONCOGENE			English	Article						translation; oncogene; polysomes; messenger RNA; neoplasms	WILD-TYPE P53; DECARBOXYLASE MESSENGER-RNA; SOFT-TISSUE SARCOMAS; HUMAN TUMOR-CELLS; ENHANCED TRANSLATION; PROTEIN; AMPLIFICATION; GENE; OVEREXPRESSION; SUPPRESSION	Overexpression of oncoprotein MDM2 has been found in a significant number of human soft tissue tumors. In a subset of these tumors, overexpression is a result of enhanced translation of mdm2 mRNA, There are two transcripts from the mdm2 gene that differ only in their 5' leaders: a long form (L-mdm2) and a short form (S-mdm2) that arise from the use of different promoters. L-mdm2 mRNA contains two upstream open reading frames (uORFs) and this mRNA was loaded with ribosomes inefficiently in comparison with S-mdm2, The 5' leader of L-mdm2 was sufficient to transfer translational repression to a reporter gene and the two uORFs acted synergistically to achieve full suppression. In contrast, the 5' leader of S-mdm2 allowed efficient translation of an attached reporter gene in the tumor cells. These results are consistent with a model in which overexpression of MDM2 in certain tumors results from a change in mRNA structure due to a switch in promoter usage.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of Washington; University of Washington Seattle; University of Pennsylvania	Morris, DR (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.		Morris, David/G-4503-2011		NCI NIH HHS [CA39053, CA66741] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066741, R01CA039053] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BUTZ K, 1995, ONCOGENE, V10, P927; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; CORDONCARDO C, 1994, CANCER RES, V54, P794; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HILL JR, 1992, J BIOL CHEM, V267, P21886; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; JUVEN T, 1993, ONCOGENE, V8, P341; KASTAN MB, 1991, CANCER RES, V51, P6304; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LADANYI M, 1993, CANCER RES, V53, P16; Landers JE, 1997, CANCER RES, V57, P3562; LANDERS JE, 1994, ONCOGENE, V9, P2745; LEACH FS, 1993, CANCER RES, V53, P2231; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Mize GJ, 1998, J BIOL CHEM, V273, P32500, DOI 10.1074/jbc.273.49.32500; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORRIS DR, 1997, MRNA METABOLISM POST, P165; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Ruan H, 1997, MRNA FORMATION FUNCT, P305, DOI 10.1016/B978-012587545-5/50017-; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	33	94	95	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5631	5637		10.1038/sj.onc.1202949	http://dx.doi.org/10.1038/sj.onc.1202949			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523842				2022-12-17	WOS:000083016500003
J	Keane, MM; Ettenberg, SA; Nau, MM; Banerjee, P; Cuello, M; Penninger, J; Lipkowitz, S				Keane, MM; Ettenberg, SA; Nau, MM; Banerjee, P; Cuello, M; Penninger, J; Lipkowitz, S			cbl-3: a new mammalian cbl family protein	ONCOGENE			English	Article						cbl proteins; EGF receptor; signal transduction	PROTOONCOGENE C-CBL; PHOSPHOTYROSINE-BINDING DOMAIN; SIGNAL-TRANSDUCTION; V-CBL; NEGATIVE REGULATOR; POINT MUTATIONS; TYROSINE KINASE; ONCOGENE; MOTIF; ACTIVATION	We have cloned a new human gene, cbl-3, which encodes a protein with marked homology to the cbl family of proteins. The predicted protein encoded by this gene retains the conserved phosphotyrosine binding domain (PTB) in the N-terminal and the zinc finger but is significantly shorter (MW 52.5 kDa) than the other mammalian cbl proteins. The protein lacks the extensive proline rich domain and leucine zipper seen in c-cbl and cbl-b and structurally most resembles the C. elegans and Drosophila cbl proteins. The gene is ubiquitously expressed with highest expression in the aerodigestive tract, prostate, adrenal gland, and salivary gland. The protein is phosphorylated and recruited to the EGFR upon EGF stimulation and inhibits EGF stimulated MAP kinase activation. In comparison to the other mammalian cbl proteins (e.g. cbl-b), cbl-3 interacts with a restricted range of proteins containing Src Homology 3 regions, An alternatively spliced form of the cbl-3 protein was also identified which deletes a critical region of the PTB domain and which does not interact with the EGFR nor inhibit EGF stimulated MAP kinase activation. These data demonstrate that cbl-3, a novel mammalian cbl protein, is a regulator of EGFR mediated signal transduction.	Bethesda Naval Hosp, Dept Genet, Med Branch, NCI, Bethesda, MD 20889 USA; Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Amgen Inst, Toronto, ON, Canada; Univ Toronto, Dept Immunol, Ontario Canc Inst, Amgen Inst, Toronto, ON, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Lipkowitz, S (corresponding author), NCI, Dept Genet, Med Branch, Natl Naval Med Ctr, Bldg 8,Room 5101, Bethesda, MD 20889 USA.		Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777	NATIONAL CANCER INSTITUTE [Z01SC007263, ZIASC007263] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Battey, 1986, BASIC METHODS MOL BI; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8995; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JONGEWARD GD, 1995, GENETICS, V139, P1553; KEANE MM, 1995, ONCOGENE, V10, P2367; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RIVEROLEZCANO OM, 1994, FEBS LETT, V338, P183, DOI 10.1016/0014-5793(94)80361-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WILUSZ J, 1989, NUCLEIC ACIDS RES, V17, P3899, DOI 10.1093/nar/17.10.3899; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	43	94	101	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3365	3375		10.1038/sj.onc.1202753	http://dx.doi.org/10.1038/sj.onc.1202753			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362357				2022-12-17	WOS:000080589300007
J	Kogel, D; Plottner, O; Landsberg, G; Christian, S; Scheidtmann, KH				Kogel, D; Plottner, O; Landsberg, G; Christian, S; Scheidtmann, KH			Cloning and characterization of Dlk, a novel serine/threonine kinase that is tightly associated with chromatin and phosphorylates core histones	ONCOGENE			English	Article						serine/threonine kinase; histone phosphorylation; nuclear targeting; GFP-fusion protein; baculovirus system	SUPPRESSOR PROTEIN P53; DNA-REPLICATION; T-ANTIGEN; RETINOBLASTOMA PROTEIN; MAMMALIAN-CELLS; RAT P53; BINDING; FAMILY; DEATH; GENES	We cloned a cDNA coding for a novel serine/threonine kinase, Dlk, a protein of 448 amino acids with a predicted molecular weight of 51.3 kDa, The kinase domain shows 81% amino acid sequence identity to the recently identified DAP kinase (death associated protein kinase) (Deiss et al,, Genes & Dev,, 9, 15-30, 1995), therefore, the new kinase was called Dlk, for DAP like kinase. Northern analyses revealed a single mRNA species of 1.7 kb which was ubiquitously expressed. However, expression levels varied considerably in different cell lines and tissues. Moreover, expression was downregulated upon UV irradiation. Dlk exhibited autophosphorylation activity, predominantly towards threonine residues and phosphorylated the regulatory subunit of myosin light chain, but in this case exclusively at serine residues. Dlk seems to be tightly associated with insoluble nuclear structures, presumably chromatin, since it was resistant to various rigorous extraction procedures but it was partially released upon DNase I digestion of nuclei. Consistent with this, purified Dlk phosphorylated core histones H3, H2A and H4 as exogenous substrates and endogenous histone H3 in kinase assays with nuclear extracts. Expression as GFP-fusion protein revealed a diffuse as well as a speckled nuclear staining suggesting an association with replication or transcription centers.	Univ Bonn, Inst Genet, D-53117 Bonn, Germany	University of Bonn	Scheidtmann, KH (corresponding author), Univ Bonn, Inst Genet, Romerstr 164, D-53117 Bonn, Germany.			Kogel, Donat/0000-0003-1209-0210				BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; GRANA X, 1995, ONCOGENE, V11, P211; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lohrum M, 1996, ONCOGENE, V13, P2527; MARTIN W, 1992, EXP CELL RES, V200, P41, DOI 10.1016/S0014-4827(05)80069-2; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MULLER E, 1995, ONCOGENE, V10, P1175; MULLER E, 1993, ONCOGENE, V8, P2193; PARDOLL DM, 1980, CELL, V19, P527, DOI 10.1016/0092-8674(80)90527-9; PICKSLEY SM, 1994, CURR OPIN CELL BIOL, V6, P853, DOI 10.1016/0955-0674(94)90056-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Scheidtmann KH, 1996, INT J ONCOL, V9, P1277; SCHIRMBECK R, 1991, J VIROL, V65, P2578, DOI 10.1128/JVI.65.5.2578-2588.1991; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SMIGHT DB, 1988, GENE, V67, P31; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cb.09.110193.001405; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401	37	94	96	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	1998	17	20					2645	2654		10.1038/sj.onc.1202204	http://dx.doi.org/10.1038/sj.onc.1202204			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840928				2022-12-17	WOS:000077058900012
J	Townsend, KJ; Trusty, JL; Traupman, MA; Eastman, A; Craig, RW				Townsend, KJ; Trusty, JL; Traupman, MA; Eastman, A; Craig, RW			Expression of the antiapoptotic MCL1 gene product is regulated by a mitogen activated protein kinase-mediated pathway triggered through microtubule disruption and protein kinase C	ONCOGENE			English	Article						MCL1; BCL2; mitogen activated protein kinase; extracellular signal-regulated kinase	MYELOID-LEUKEMIA CELLS; NECROSIS-FACTOR-ALPHA; HAMSTER OVARY CELLS; MAP KINASE; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; TRANSCRIPTIONAL REGULATION; INDUCED APOPTOSIS; FAMILY MEMBER; DNA-SYNTHESIS	Members of both the mitogen activated protein (MAP) kinase and BCL2 gene families, acting in concert with other gene products, are involved in the regulation of cell viability. However, the relationship between these families, and the signal transduction networks that control viability-regulating genes, are only beginning to be elucidated, MCL1 is a viability-promoting member of the BCL2 family that exhibits a rapid increase in expression in response to specific differentiation- and apoptosis-inducing stimuli. The signal transduction pathway involved in eliciting this increase has now been investigated. In the ML-1 human myeloblastic leukemia cell line, a rapid and sustained increase in phosphorylation of the extracellular signal-regulated kinase (ERK) members of the MAP kinase family was found to precede the increase in MCL1 expression produced by 12-O-tetradecanoylphorbol 13-acetate (TPA) or the microtubule-disrupting agents colchicine and vinblastine. ERK activation was necessary for the increase in MCL1, as inhibition of the increase in ERK phosphorylation (with the inhibitor PD 98059) prevented the increase in MCL1 expression and caused rapid cell death by apoptosis, In addition, other agents that markedly increased ERK phosphorylation (lipopolysaccharide, okadaic acid) also increased MCL1 expression. In contrast, agents that did not have this marked effect did not increase MCL1, Upstream components in this ERK-mediated pathway were also identified, where the pathway was found to be stimulated by microtubule disruption acting through protein kinase C (PKC). These results indicate that expression of the MCL1 viability-enhancing gene is regulated through a cytoskeletal disruption-induced ERK-mediated signal, transduction pathway. They therefore suggest a mechanism through which the cytoskeleton and MAP kinases can exert effects on cell viability.	Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA	Dartmouth College	Craig, RW (corresponding author), Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.				NATIONAL CANCER INSTITUTE [R01CA057359, T32CA009658, R55CA050224, R01CA050224] Funding Source: NIH RePORTER; NCI NIH HHS [CA57359, CA50224, CA09658, R01 CA057359] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BASU A, 1992, BIOCHEMISTRY-US, V31, P3824, DOI 10.1021/bi00130a013; BHALLA K, 1993, LEUKEMIA, V7, P563; Blagosklonny MV, 1997, CANCER RES, V57, P130; BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; BOTTERI FM, 1990, J BIOL CHEM, V265, P13327; BRADSHAW TD, 1992, INT J CANCER, V51, P144, DOI 10.1002/ijc.2910510125; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; CARNEY DH, 1986, ANN NY ACAD SCI, V466, P919, DOI 10.1111/j.1749-6632.1986.tb38477.x; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; CRAIG RW, 1984, CANCER RES, V44, P2421; CROSSIN KL, 1981, CELL, V23, P61, DOI 10.1016/0092-8674(81)90270-1; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Ding AH, 1996, J EXP MED, V183, P1899, DOI 10.1084/jem.183.4.1899; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Duke R. C., 1991, CURRENT PROTOCOLS IM, V1; Dziarski R, 1996, J INFECT DIS, V174, P777, DOI 10.1093/infdis/174.4.777; Glanz J, 1997, SCIENCE, V276, P678; Golstein P, 1997, SCIENCE, V275, P1081, DOI 10.1126/science.275.5303.1081; Guan X P, 1989, Cancer Commun, V1, P111; Haldar S, 1996, CANCER RES, V56, P1253; Haldar S, 1997, CANCER RES, V57, P229; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOHMANN HP, 1992, J BIOL CHEM, V267, P2065; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Itoh T, 1996, J BIOL CHEM, V271, P27931, DOI 10.1074/jbc.271.44.27931; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KILEY SC, 1995, J CELL SCI, V108, P1003; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; LIU MK, 1994, J IMMUNOL, V153, P2642; MANFREDI JJ, 1982, J CELL BIOL, V94, P688, DOI 10.1083/jcb.94.3.688; MANIE S, 1993, J BIOL CHEM, V268, P13675; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MAY WS, 1994, J BIOL CHEM, V269, P26865; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OFlaherty JT, 1996, J BIOL CHEM, V271, P17821, DOI 10.1074/jbc.271.30.17821; Plevin R, 1996, BIOCHEM J, V318, P657, DOI 10.1042/bj3180657; REYNOLDS JE, 1994, CANCER RES, V54, P6348; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; SAKAGAMI H, 1984, CANCER RES, V44, P3330; SAKAMAKI K, 1994, FEBS LETT, V353, P133, DOI 10.1016/0014-5793(94)01024-2; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SHINOHARAGOTOH Y, 1991, EXP CELL RES, V193, P161, DOI 10.1016/0014-4827(91)90551-5; SORENSON CM, 1988, CANCER RES, V48, P4484; VERLHAC MH, 1993, DEV BIOL, V158, P330, DOI 10.1006/dbio.1993.1192; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wilkie N, 1996, J BIOL CHEM, V271, P32447, DOI 10.1074/jbc.271.50.32447; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhan QM, 1997, ONCOGENE, V14, P1031, DOI 10.1038/sj.onc.1200927; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	69	94	96	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1223	1234		10.1038/sj.onc.1202035	http://dx.doi.org/10.1038/sj.onc.1202035			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771965				2022-12-17	WOS:000075803300004
J	Thompson, DA; Belinsky, G; Chang, THT; Jones, DL; Schlegel, R; Munger, K				Thompson, DA; Belinsky, G; Chang, THT; Jones, DL; Schlegel, R; Munger, K			The human papillomavirus-16 E6 oncoprotein decreases the vigilance of mitotic checkpoints	ONCOGENE			English	Article						viral oncoproteins; mitosis; checkpoint; human papillomavirus; cyclin-dependent kinases; p53 tumor suppressor	INDUCED PREMATURE MITOSIS; CELL-CYCLE CHECKPOINTS; LARGE T-ANTIGEN; GROWTH ARREST; GENE-EXPRESSION; DNA-DAMAGE; MUTATIONAL ANALYSIS; IONIZING-RADIATION; HUMAN FIBROBLASTS; EPITHELIAL-CELLS	The E6 and E7 proteins of the high risk human papillomaviruses (HPVs) are consistently expressed in HPV-positive cervical carcinomas, We investigated the ability of HPV-16 E6 and E7 to disrupt mitotic checkpoints in normal diploid human cells, Acute expression of HPV-16 E6, but not HPV-16 E7, decreased the fidelity of multiple checkpoints controlling entry into and exit from mitosis, After irradiation, nearly 50% of cells containing HPV-16 E6 readily entered mitosis as opposed to less than 10% of control cells, Consistent with this, asynchronous populations of cells expressing HPV-16 E6 had increased cdc2-associated histone Hi kinase activity relative to control populations, In addition, HPV-16 E6 increased sensitivity to chemically-induced S-phase premature mitosis and decreased mitotic spindle assembly checkpoint function relative to control populations, HPV-16 E6 mutants with a reduced ability to target p53 for degradation were unable to abrogate mitotic checkpoints, suggesting a possible mechanism by which HPV-16 E6 disrupts mitotic checkpoints, Expression of a mutant p53 gene yielded an intermediate phenotype relative to HPV-16 E6, generating moderate increases in sensitivity to chemically-induced S-phase PCC and mitotic spindle disruption and a heightened propensity to enter mitosis after irradiation.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Mol & Cellular Toxicol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.			Thompson, David/0000-0003-2372-7766; Munger, Karl/0000-0003-3288-9935	NATIONAL CANCER INSTITUTE [R01CA066980] Funding Source: NIH RePORTER; NCI NIH HHS [CA 66980] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; CLARKE PR, 1995, J CELL SCI, V108, P1217; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; Di Leonardo A, 1997, CANCER RES, V57, P1013; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; GU ZM, 1995, J VIROL, V69, P8051, DOI 10.1128/JVI.69.12.8051-8056.1995; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HASHIDA T, 1991, J GEN VIROL, V72, P1569, DOI 10.1099/0022-1317-72-7-1569; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; HICKMAN ES, 1994, ONCOGENE, V9, P2177; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; KATAYOSE D, 1995, BIOCHEM BIOPH RES CO, V215, P446, DOI 10.1006/bbrc.1995.2485; KAUFMANN WK, 1995, CANCER RES, V55, P7; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUNGER K, 1993, BIOCHIM BIOPHYS ACTA, V1155, P111, DOI 10.1016/0304-419X(93)90025-8; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; OSHIMA J, 1993, ONCOGENE, V8, P2987; PAULES RS, 1995, CANCER RES, V55, P1763; Pines J, 1996, BIOCHEM SOC T, V24, P15, DOI 10.1042/bst0240015; POWELL SN, 1995, CANCER RES, V55, P1643; Russell KJ, 1996, INT J RADIAT ONCOL, V36, P1099, DOI 10.1016/S0360-3016(96)00432-4; RUSSELL KJ, 1995, CANCER RES, V55, P1639; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; STEINBECK RG, 1995, ACTA ONCOL, V34, P171, DOI 10.3109/02841869509093952; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; STEINMANN KE, 1994, ONCOGENE, V9, P387; STEWART N, 1995, ONCOGENE, V10, P109; Stoppler MC, 1996, J VIROL, V70, P6987; TAM SW, 1995, J CELL BIOCHEM, V59, P339, DOI 10.1002/jcb.240590306; TSANG NM, 1995, ONCOGENE, V10, P2403; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	56	94	97	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3025	3035		10.1038/sj.onc.1201495	http://dx.doi.org/10.1038/sj.onc.1201495			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444951				2022-12-17	WOS:000070968000003
J	Tortora, G; Damiano, V; Bianco, C; Baldassarre, G; Bianco, AR; Lanfrancone, L; Pelicci, PG; Ciardiello, F				Tortora, G; Damiano, V; Bianco, C; Baldassarre, G; Bianco, AR; Lanfrancone, L; Pelicci, PG; Ciardiello, F			The RI alpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor	ONCOGENE			English	Article						growth factors; signal transduction; breast cells	MAMMARY EPITHELIAL-CELLS; C-HA-RAS; REGULATORY SUBUNIT; ANTISENSE OLIGODEOXYNUCLEOTIDE; DEPENDENT ACTIVATION; NUCLEOTIDE EXCHANGE; HL-60 LEUKEMIA; MESSENGER-RNA; CAMP; DIFFERENTIATION	Functional interactions between protein kinase A (PKA) and epidermal growth factor receptor (EGF-R) signalling pathways have been suggested. Unlike the type II isoform of PKA (PKAII), the type I (PKAI) and/or its regulatory submit RI alpha are generally overexpressed in cancer cells and are induced following transforming growth factor alpha (TGF alpha)/EGF-R-dependent transformation. Downregulation of RI alpha/PKAI inhibits TGF alpha expression and EGF-R-dependent signalling. We have previously shown that addition of EGF to quiescent human normal epithelial MCF-10A cells determines PKAI expression and cell membrane translocation before cells enter S phase, while PKAI inhibition prevents S phase entry. Constitutive overexpression of PKAI confers the ability to grow in serum free medium, bypassing EGF requirement. Here we demonstrate a direct interaction of PKAI, but not of PKAII, with the activated EGF-R, that occurs within 5 min following EGF treatment of MCF-10A cells, Moreover, induction of mitogen-activated protein kinase (MAPK) activity following EGF-R activation is mimicked by PKAI overexpression and inhibited by downregulators of PKAI. Finally, the PKAI-EGF-R association occurs through the binding of RI alpha to the SH3 domain(s) of Grb2 adaptor protein, thus allowing the recruitment of the PKAI holoenzyme to the activated EGF-R. This is the first demonstration of a direct interaction of PKAI with the activated EGF-R macromolecular signalling complex.	EUROPEAN INST ONCOL,DEPT EXPT ONCOL,I-20141 MILAN,ITALY	IRCCS European Institute of Oncology (IEO)	Tortora, G (corresponding author), UNIV NAPLES,DIPARTIMENTO ENDOCRINOL & ONCOL MOL & CLIN,CATTEDRA ONCOL MED,VIA PANSINI 5,I-80131 NAPLES,ITALY.		Baldassarre, Gustavo/K-1350-2016; Tortora, Giampaolo/HGB-6261-2022; Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019	Baldassarre, Gustavo/0000-0002-9750-8825; Lanfrancone, Luisa/0000-0002-4523-3815; Ciardiello, Fortunato/0000-0002-3369-4841; Tortora, Giampaolo/0000-0002-1378-4962				BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHOCHUNG YS, 1993, PHARMACOL THERAPEUT, V60, P265, DOI 10.1016/0163-7258(93)90010-B; CIARDIELLO F, 1990, J BIOL CHEM, V265, P1016; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; CIARDIELLO F, 1993, INT J CANCER, V53, P438, DOI 10.1002/ijc.2910530315; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GILL GN, 1984, J BIOL CHEM, V259, P7755; GRIFFITHS G, 1990, J CELL SCI, V96, P691; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LAXMINARAYANA D, 1993, J CLIN INVEST, V92, P2207, DOI 10.1172/JCI116823; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PEPE S, 1994, CYTOMETRY, V15, P73, DOI 10.1002/cyto.990150112; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; TORTORA G, 1994, ONCOGENE, V9, P3233; TORTORA G, 1991, P NATL ACAD SCI USA, V88, P2011, DOI 10.1073/pnas.88.5.2011; TORTORA G, 1994, CELL GROWTH DIFFER, V5, P753; TORTORA G, 1990, P NATL ACAD SCI USA, V87, P705, DOI 10.1073/pnas.87.2.705; TORTORA G, 1989, FEBS LETT, V242, P363, DOI 10.1016/0014-5793(89)80502-2; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	24	94	98	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					923	928		10.1038/sj.onc.1200906	http://dx.doi.org/10.1038/sj.onc.1200906			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050991				2022-12-17	WOS:A1997WK34400005
J	Poirel, H; Oury, C; Carron, C; Duprez, E; Laabi, Y; Tsapis, A; Romana, SP; Mauchauffe, M; LeConiat, M; Berger, R; Ghysdael, J; Bernard, OA				Poirel, H; Oury, C; Carron, C; Duprez, E; Laabi, Y; Tsapis, A; Romana, SP; Mauchauffe, M; LeConiat, M; Berger, R; Ghysdael, J; Bernard, OA			The TEL gene products: Nuclear phosphoproteins with DNA binding properties	ONCOGENE			English	Article						TEL; ETS; translocation; transcription factor; leukemia; translocation	ACUTE LYMPHOBLASTIC-LEUKEMIA; EWINGS-SARCOMA TRANSLOCATION; TRANSCRIPTIONAL ACTIVATION; ETS-FAMILY; CHROMOSOMAL TRANSLOCATION; C-ETS-1 PROTOONCOGENE; EWS GENE; FUSION; DOMAIN; CHILDHOOD	The human TEL gene is involved in several 12p13 chromosomal abnormalities present in various human hematological malignancies, the most frequent being the t(12;21)(p13;q22), specific for childhood acute lymphoblastic leukemia, The predicted product of TEL harbours an amino acid region similar to the ETS DNA binding domain. We now report the isolation of the murine TEL cDNA and the characterization of the human TEL proteins. Human and murine TEL proteins are particularly homologous within their aminoterminal regions and their ETS domains. TEL proteins are nuclear and display specific DNA binding activity toward classical ETS binding sites. In addition, we show that TEL mRNAs initiate translation at either of the two first in-frame ATGs (codon 1 and 43) to encode 50 kDa and 57 kDa TEL proteins. In vivo, each of these primary translational products is modified by multiple phosphorylation events.	INST GENET MOL,INSERM,U301,F-75010 PARIS,FRANCE; INST GENET MOL,SD 401 301 CNRS,F-75010 PARIS,FRANCE; CTR UNIV ORSAY,INST CURIE,SECT RECH,F-91405 ORSAY,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay			duprez, estelle a/R-2357-2016; Carron, Clémence/AAG-6304-2021; GHYSDAEL, Jacques/F-3377-2013; Bernard, Olivier A./E-5721-2016	Carron, Clemence/0000-0002-8776-7380; Oury, Cecile/0000-0002-7561-0132; Bernard, Olivier/0000-0002-0463-9747; Romana, Serge Pierrick/0000-0003-3435-239X				BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BERNARD OA, 1996, IN PRESS LEUKEMIA LY; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BUIJS A, 1995, ONCOGENE, V10, P1511; CAVE H, 1995, BLOOD, V86, P3869, DOI 10.1182/blood.V86.10.3869.bloodjournal86103869; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GHYSDAEL J, 1995, PATHOL BIOL, V43, P202; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JANKNECHT R, 1995, ONCOGENE, V10, P1209; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JEON IS, 1995, ONCOGENE, V10, P1229; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MCLEAN TW, 1996, IN PRESS BLOOD; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Rabault B, 1996, ONCOGENE, V13, P877; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; ROSENFELD C, 1977, NATURE, V267, P841, DOI 10.1038/267841a0; Sambrook J, 1989, MOL CLONING LAB MANU; SATO Y, 1995, BLOOD, V86, P1525, DOI 10.1182/blood.V86.4.1525.bloodjournal8641525; SETH A, 1990, ONCOGENE, V5, P1761; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STEGMAIER K, 1995, BLOOD, V86, P38, DOI 10.1182/blood.V86.1.38.bloodjournal86138; VENAUT AM, 1981, CANC GENET CYTOGENET, V3, P327; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	45	94	95	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					349	357		10.1038/sj.onc.1200829	http://dx.doi.org/10.1038/sj.onc.1200829			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018121				2022-12-17	WOS:A1997WD51600011
J	Zornig, M; Schmidt, T; Karsunky, H; Grzeschiezek, A; Moroy, T				Zornig, M; Schmidt, T; Karsunky, H; Grzeschiezek, A; Moroy, T			Zinc finger protein GFI-1 cooperates with MYC and PIM-1 in T-cell lymphomagenesis by reducing the requirements for IL-2	ONCOGENE			English	Article						oncogene cooperation; MoMuLV mutagenesis; proviral integration; zinc finger; IL-2 independence; tumour progression	MURINE LEUKEMIA-VIRUS; E-MU-MYC; C-MYC; TRANSGENIC MICE; N-MYC; PROVIRAL INSERTION; GENE; DNA; RNA; EXPRESSION	The clonality of lymphomas that originate in myc/pim-1 bitransgenic mice due to synergistic action of both oncogenes indicates the requirement of additional events for progression to full malignancy, To isolate genes that cooperate with both myc and pim-1, we have used provirus tagging with E mu L-myc/pim-1 double transgenic mice, We find accelerated tumour formation in infected animals and show that the gfi-1 gene and neighbouring loci on mouse chromosome 5 are occupied by proviruses in about 53% of the tumours leading in all cases to high level gfi-1 expression. In agreement with data from Gilks et al, (1993) we find that forced expression of the gfi-1 encoded zinc finger protein in IL-2 dependent T-cells provokes increased survival upon IL-2 depletion and we present evidence that this occurs at least in part through stimulation of proliferation, Our data suggest that gfi-1 is a proto-oncogene and very efficiently engages in a tripartite oncogene cooperation with both mye and pim-1 genes in T-cell lymphomagenesis.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY	Philipps University Marburg			Moroy, Tarik/D-9923-2011					ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ASKEW DS, 1991, ONCOGENE, V6, P1915; BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; BERNS A, 1991, Current Biology, V1, P28, DOI 10.1016/0960-9822(91)90118-G; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BREUER ML, 1989, EMBO J, V8, P743, DOI 10.1002/j.1460-2075.1989.tb03434.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CUYPERS HT, 1984, CELL, V37, P141; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; GOTO Y, 1992, J BIOL CHEM, V267, P15252; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HAUPT Y, 1993, ONCOGENE, V8, P3161; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HOGAN B, 1986, MANIPULATION MOUSE E; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JAENISCH R, 1975, P NATL ACAD SCI USA, V72, P4008, DOI 10.1073/pnas.72.10.4008; LEWIS S, 1982, CELL, V30, P807, DOI 10.1016/0092-8674(82)90285-9; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; LIAO XB, 1995, J VIROL, V69, P7132, DOI 10.1128/JVI.69.11.7132-7137.1995; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MOROY T, 1991, ONCOGENE, V6, P1941; MOROY T, 1991, MOL F ONCOLOGY, P455; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; REIK W, 1985, P NATL ACAD SCI USA, V82, P1141, DOI 10.1073/pnas.82.4.1141; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; Sambrook J, 1989, MOL CLONING LAB MANU; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176	50	94	98	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1789	1801						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622900				2022-12-17	WOS:A1996UG45800022
J	Perletti, GP; Folini, M; Lin, HC; Mischak, H; Piccinini, F; Tashjian, AH				Perletti, GP; Folini, M; Lin, HC; Mischak, H; Piccinini, F; Tashjian, AH			Overexpression of protein kinase C epsilon is oncogenic in rat colonic epithelial cells	ONCOGENE			English	Article						signal transduction; ras; colon cancer; tumorigenesis	TRANSFORM FIBROBLASTS; HA-RAS; EXPRESSION; GROWTH; ALPHA; MODEL	We have analysed the expression of five protein kinase C [PKC] isoforms in an in vitro model using nontumorigenic rat colonic epithelial cells FRC/TEX CL D [D/ WT] and in the related tumorigenic Ha-ras-transformed FRC/TEX CL D/H-ras line [D/ras]. The PKC subspecies alpha, delta, epsilon and zeta were expressed at the protein level in both D/WT and D/ras cells, while beta PKC was undetectable in both lines. The levels of expression of the delta and zeta isoforms were similar in D/WT and D/ras cells. alpha PKC expression was decreased and epsilon PKC was increased in D/ras cells compared to the D/WT line, To assess whether overexpression of epsilon PKC was linked to the transformed phenotype, we have generated from D/WT cells two clones (D/epsilon-5 and D/epsilon-9) which stably overexpress epsilon PKC about fivefold. Overexpression of epsilon PKC caused marked morphological changes in both transfected clones, which were accompanied by increased saturation densities and anchorage-independent colony formation in semisolid agar. These growth effects were attenuated or reversed by chronic incubation with phorbol 12-myristate 13-acetate. Furthermore, D/epsilon-5 and D/epsilon-9 cells formed tumors in athymic nude mice with 100% incidence while the parental D/WT or vector alone (D/MV12) controls produced no tumors. We conclude that epsilon PKC can act as an oncoprotein when modestly overproduced in nontumorigenic D/WT colonic cells, and that this isoform of PKC may be linked to ras-modulated signal transduction leading to neoplastic transformation in colonic epithelium.	HARVARD UNIV,SCH PUBL HLTH,DEPT MOLEC & CELLULAR TOXICOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; GSF,FORSCHUNGSZENTRUM HAEMATOL,INST CLIN MOL BIOL & TUMOR GENET,D-81377 MUNICH,GERMANY; UNIV MILAN,IST FARMACOL,MILAN,ITALY	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Milan			Mischak, Harald/E-8685-2011; Folini, Marco/B-9607-2017	Folini, Marco/0000-0002-1811-4407; Mischak, Harald/0000-0003-0323-0306	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00002] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; CACACE AM, 1993, ONCOGENE, V8, P2095; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; CRAVEN PA, 1992, CANCER RES, V52, P2216; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIDSON LA, 1994, ARCH BIOCHEM BIOPHYS, V312, P547, DOI 10.1006/abbi.1994.1344; DELAGE S, 1993, CANCER RES, V53, P2762; DENT P, 1995, MOL CELL BIOL, V15, P4125; DOI S, 1994, CARCINOGENESIS, V11, P197; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; KLINGEL R, 1991, GUT, V62, P1508; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KURANAMI M, 1995, J SURG RES, V58, P233, DOI 10.1006/jsre.1995.1036; KURANAMI M, 1995, AM J SURG, V169, P57, DOI 10.1016/S0002-9610(99)80110-X; LIAO L, 1994, CELL GROWTH DIFFER, V5, P1185; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MONNAT M, 1987, INT J CANCER, V40, P293, DOI 10.1002/ijc.2910400302; MONTANER S, 1995, ONCOGENE, V10, P2213; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PONGRACZ J, 1995, INT J CANCER, V61, P35, DOI 10.1002/ijc.2910610107; PORIES SE, 1993, GASTROENTEROLOGY, V104, P1346, DOI 10.1016/0016-5085(93)90343-B; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHAEFFER WI, 1976, CANCER LETT, V1, P259; SPANDIDOS DA, 1984, BRIT J CANCER, V49, P681, DOI 10.1038/bjc.1984.108; TOKER A, 1994, J BIOL CHEM, V269, P32358	31	94	97	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					847	854						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632907				2022-12-17	WOS:A1996TW68600016
J	REYMOND, A; BRENT, R				REYMOND, A; BRENT, R			P16 PROTEINS FROM MELANOMA-PRONE FAMILIES ARE DEFICIENT IN BINDING TO CDK4	ONCOGENE			English	Article						P16(INK4A); CDK4; CDK6; CKI, MELANOMA; 2-HYBRIDS	TRANSFORMATION	The tumor suppressor candidate p16(INK4) is a cyclin-dependent kinase inhibitor that inhibits cell proliferation, The p16 coding gene is often mutated in glioblastomas, pancreatic adenocarcinomas and melanoma-prone pedigrees, but, until recently, the significance of these allelic variants has remained unclear. Here, we used interaction mating and coprecipitation to measure interaction of seven p16 allelic variants detected in melanoma-prone pedigrees with Cyclin-dependent kinases (Cdks), We found that most variants were deficient in interaction with Cdk4 and Cdk6. One defective variant was found both in cancer prone families and in the control population and therefore previously defined as a common polymorphism. Another variant, which is weakly linked to familial cancer, is only slightly affected in interaction with Cdks. These results are consistent with the idea that p16 allelic variants that decrease Cdk interaction predispose individuals who carry them to an increased risk of cancer. Moreover, they suggest that determination of affinity between p16 mutants and partner proteins may help identify functionally-significant allelic variants not detected by classical human genetic techniques.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	REYMOND, A (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,50 BLOSSOM ST,BOSTON,MA 02114, USA.			Reymond, Alexandre/0000-0003-1030-8327				AUSBEL FM, 1987, CURRENT PROTOCOLS MO; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOLEMIS E, 1992, MOL CELL BIOL, V8, P1614; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REYMOND A, 1993, NUCLEIC ACIDS RES, V21, P3615, DOI 10.1093/nar/21.16.3615; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	24	94	94	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1173	1178						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566978				2022-12-17	WOS:A1995RX18000021
J	STRAND, D; UNGER, S; CORVI, R; HARTENSTEIN, K; SCHENKEL, H; KALMES, A; MERDES, G; NEUMANN, B; KRIEGSCHNEIDER, F; COY, JF; POUSTKA, A; SCHWAB, M; MECHLER, BM				STRAND, D; UNGER, S; CORVI, R; HARTENSTEIN, K; SCHENKEL, H; KALMES, A; MERDES, G; NEUMANN, B; KRIEGSCHNEIDER, F; COY, JF; POUSTKA, A; SCHWAB, M; MECHLER, BM			A HUMAN HOMOLOG OF THE DROSOPHILA TUMOR-SUPPRESSOR GENE L(2)GL MAPS TO 17P11.2-12 AND CODES FOR A CYTOSKELETAL PROTEIN THAT ASSOCIATES WITH NONMUSCLE MYOSIN-II HEAVY-CHAIN	ONCOGENE			English	Article						TUMOR SUPPRESSOR GENE; DROSOPHILA L(2)GL GENE; HUMAN CHROMOSOME 17; CYTOSKELETON; NONMUSCLE MYOSIN II	BREAST-CANCER; RECESSIVE ONCOGENE; OVARIAN-CARCINOMA; CHROMOSOME 17P; ALLELE LOSSES; P53 MUTATIONS; MELANOGASTER; EXPRESSION; EZRIN; DELETIONS	Inactivation of the tumour suppressor gene lethal(2) giant larvae (D-lgl) of Drosophila leads to malignant transformation of the presumptive adult optic centers in the larval brain and tumours of the imaginal discs. These from the disorganization of a in which the D-LGL protein participates. Here we describe the isolation of a cDNA encoding the human homologue to the D-lgl gene designated as hugl. The hugl cDNA detects a locus spanning at least 25 kilobases (kb) in human chromosome band 17p11.2-12, which is centromeric to the p53 gene and recognizes a 4.5 kb RNA transcript. The hugl gene is expressed in brain, kidney and muscle but is barely seen in heart and placenta. Sequence analysis of the hugl cDNA demonstrates a long open reading frame, which has the potential to encode a protein of 1057 amino acids with a predicted molecular weight of 115 kDaltons (kD). To further substantiate and identify the HUGL protein, we have prepared polyclonal rabbit antibodies against synthetic peptides corresponding to the amino and carboxyl termini of the conceptual translation product of the hugl gene. The affinity-purified anti-HUGL antibodies recognize a single protein with an apparent molecular weight of similar to 115 kD, Similar to the Drosophila protein, HUGL is part of a cytoskeletal network and, is associated with nonmuscle myosin II heavy chain and a kinase that specifically phosphorylates HUGL at serine residues.	DEUTSCH KREBSFORSCHUNGSZENTRUM, DEPT CYTOGENET, D-69120 HEIDELBERG, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, DEPT MOLEC GENOME ANAL, D-69120 HEIDELBERG, GERMANY; UNIV WURZBURG, INST MED RADIAT & CELL RES, D-97078 WURZBURG, GERMANY; MED CLIN 3, D-68305 MANNHEIM, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Wurzburg	STRAND, D (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM, DEPT DEV GENET, NEUENHEIMER FELD 280, D-69120 HEIDELBERG, GERMANY.							ADAMSON R, 1994, ONCOGENE, V9, P2077; ALBRECHT S, 1994, NEUROPATH APPL NEURO, V20, P74, DOI 10.1111/j.1365-2990.1994.tb00959.x; ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; BARDI G, 1993, INT J CANCER, V55, P422, DOI 10.1002/ijc.2910550317; BARKER PE, 1993, METHODS MOL GENETICS, V2, P129; BOEDIGHEIMER M, 1993, DEVELOPMENT, V118, P1291; BRIDGES CB, 1944, CARNEGIE I WASHINGTO, V522; Bryant Peter J., 1993, Trends in Cell Biology, V3, P31, DOI 10.1016/0962-8924(93)90147-S; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; COLLINS C, 1991, GENOMICS, V11, P997, DOI 10.1016/0888-7543(91)90025-A; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; ECCLES DM, 1990, ONCOGENE, V5, P1599; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; GATEFF E, 1994, INT J DEV BIOL, V38, P565; GATEFF E, 1969, NATL CANCER I MONOGR, P365; GATEFF E, 1989, Critical Reviews in Oncogenesis, V1, P221; GOLUBOVSKY MD, 1980, GENETICA, V52-3, P139; Golubovsky MD, 1978, DROSOPH INF SERV, V53, P179; GREEN MM, 1979, GENETICS, V92, P823; GRIFFIN CA, 1988, CANCER RES, V48, P175; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISOMURA M, 1994, GENE CHROMOSOME CANC, V9, P173, DOI 10.1002/gcc.2870090305; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JACOB L, 1987, CELL, V50, P215, DOI 10.1016/0092-8674(87)90217-0; JOHANSSON M, 1994, INT J ONCOL, V5, P17; JONES E, 1994, GENE CHROMOSOME CANC, V11, P163, DOI 10.1002/gcc.2870110305; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; LUTZELSCHWAB R, 1986, MOL GEN GENET, V204, P58, DOI 10.1007/BF00330187; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MECHLER B, 1990, CANCER SURV, V9, P505; MECHLER BM, 1994, J BIOSCIENCES, V19, P537; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; MECHLER BM, 1990, TUMOR SUPPRESSOR GEN, P123; MERTENS F, 1994, GENE CHROMOSOME CANC, V10, P221, DOI 10.1002/gcc.2870100402; OPPER M, 1987, ONCOGENE, V1, P91; OREILLY DR, 1992, BACULOVIRUS EXPRESSI; RADFORD DM, 1993, CANCER RES, V53, P2947; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; SATO N, 1992, J CELL SCI, V103, P131; SATO T, 1990, CANCER RES, V50, P7184; SAVELYEVA L, 1994, AM J HUM GENET, V55, P334; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; STAND D, 1994, J CELL BIOL, V127, P1361; STRAND D, 1991, ADV ENZYME REGUL, V31, P339, DOI 10.1016/0065-2571(91)90022-E; STRAND D, 1994, J CELL BIOL, V127, P1345, DOI 10.1083/jcb.127.5.1345; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; TOMOTSUNE D, 1993, NATURE, V365, P69, DOI 10.1038/365069a0; TOROK I, 1993, ONCOGENE, V8, P1537; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSAO SW, 1991, ANTICANCER RES, V11, P1975; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7	60	94	97	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					291	301						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7542763				2022-12-17	WOS:A1995RK95700010
J	GRAY, DA; INAZAWA, J; GUPTA, K; WONG, A; UEDA, R; TAKAHASHI, T				GRAY, DA; INAZAWA, J; GUPTA, K; WONG, A; UEDA, R; TAKAHASHI, T			ELEVATED EXPRESSION OF UNPH, A PROTOONCOGENE AT 3P21.3, IN HUMAN LUNG-TUMORS	ONCOGENE			English	Article						UBIQUITIN PROTEASE; 3P21; LUNG CANCER	CANCER CELL-LINES; TRE ONCOGENE; GENE FAMILY; DELETION; REGION; HETEROZYGOSITY; CHROMOSOME-17; HYBRIDIZATION; CLONING; MARKERS	The murine Unp proto-oncogene encodes a nuclear ubiquitin protease whose overexpression leads to oncogenic transformation of NIH3T3 cells. We have cloned cDNAs originating from the human homolog of this gene, designated herein as Unph (Unp, human), and have used these cDNAs to map the gene to 3p21.3, a region frequently rearranged in human tumor cells. Unph mRNA levels are consistently elevated in small cell tumors and adenocarcinomas of the lung, suggesting a possible causative role for the gene in the neoplastic process.	UNIV OTTAWA,DEPT MED,OTTAWA,ON K1H 8M5,CANADA; UNIV OTTAWA,DEPT BIOCHEM,OTTAWA,ON K1H 8M5,CANADA; KYOTO PREFECTURAL UNIV MED,DEPT HYG,KAMIGYO KU,KYOTO 602,JAPAN; AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	University of Ottawa; University of Ottawa; Kyoto Prefectural University of Medicine; Aichi Cancer Center	GRAY, DA (corresponding author), OTTAWA REG CANC CTR,501 SMYTH RD,OTTAWA,ON K1H 8L6,CANADA.		Takahashi, Takashi/I-7262-2014; /U-3554-2018	Takahashi, Takashi/0000-0003-0615-7001; /0000-0002-8634-4984				ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; BAKER RT, 1992, J BIOL CHEM, V267, P23364; CHEN LC, 1994, CANCER RES, V54, P3021; DALY MC, 1993, ONCOGENE, V8, P1721; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GUPTA K, 1993, ONCOGENE, V8, P2307; GUPTA K, 1994, ONCOGENE, V9, P1729; HAINSWORTH PJ, 1991, CANCER GENET CYTOGEN, V553, P205; HIBI K, 1992, ONCOGENE, V7, P445; HIBI K, 1994, ONCOGENE, V9, P611; HIDA T, 1993, JPN J CLIN ONCOL, V23, P14; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PINES J, 1994, NATURE, V371, P742, DOI 10.1038/371742a0; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; SHKEDY D, 1994, FEBS LETT, V348, P126, DOI 10.1016/0014-5793(94)00582-6; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; YAMAKAWA K, 1993, ONCOGENE, V8, P327; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YUN K, 1993, CANCER RES, V53, P5166	27	94	100	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2179	2183						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784062				2022-12-17	WOS:A1995RB70300013
J	BLYTH, K; TERRY, A; OHARA, M; BAXTER, EW; CAMPBELL, M; STEWART, M; DONEHOWER, LA; ONIONS, DE; NEIL, JC; CAMERON, ER				BLYTH, K; TERRY, A; OHARA, M; BAXTER, EW; CAMPBELL, M; STEWART, M; DONEHOWER, LA; ONIONS, DE; NEIL, JC; CAMERON, ER			SYNERGY BETWEEN A HUMAN C-MYC TRANSGENE AND P53 NULL GENOTYPE IN MURINE THYMIC LYMPHOMAS - CONTRASTING EFFECTS OF HOMOZYGOUS AND HETEROZYGOUS P53 LOSS	ONCOGENE			English	Article						MYC; P53; LYMPHOMA	WILD-TYPE; P53-DEFICIENT MICE; CELL-LINE; APOPTOSIS; MUTATIONS; COOPERATION; EXPRESSION; ONCOGENE; LEUKEMIA; TUMORS	Activation of the c-myc oncogene and functional loss of the p53 tumour suppressor gene are among the most frequently recorded genetic lesions in neoplasia but their combined effect has not previously been investigated. By breeding together mice transgenic for human c-myc (CD2-myc) and mice carrying an inactive p53 allele (p53(-/-)) we found that these genetic lesions act synergistically in vivo, Offspring carrying the CD2-myc transgene and the homozygous p53 null mutation (p53(-/-)/CD2-myc) were viable but developed thymic lymphomas with dramatically increased frequency and reduced latency compared to both parental groups. The tumour phenotype was similar to that previously recorded for CD2-myc mice (predominantly CD3+, CD4+8+) but tumour clonal complexity and metastasis was significantly greater in the p53(-/-)/CD2-myc mice, In contrast, no significant increase in tumour incidence was seen in p53(+/-)/CD2-myc vs p53(+/+)/CD2-myc mice over a 6 month observation period, However, the loss of wild type p53 in a proportion of tumour cells in p53(+/-)/CD2-myc lymphomas suggests that wild type allele loss can occur as a late progression step rather than an initiating step in these tumours, We suggest that p53 loss of function may collaborate with the CD2-myc transgene at more than one stage in thymic lymphoma development.	UNIV GLASGOW, SCH VET, DEPT VET PATHOL, GLASGOW G61 1QH, LANARK, SCOTLAND; UNIV GLASGOW, SCH VET, DEPT VET ANIM HUSBANDRY, GLASGOW G61 1QH, LANARK, SCOTLAND; BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA	University of Glasgow; University of Glasgow; Baylor College of Medicine				Blyth, Karen/0000-0002-9304-439X				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1992, CANCER SURV, V15, P119; ASKEW DS, 1991, ONCOGENE, V6, P1915; BARTEK J, 1991, ONCOGENE, V6, P1699; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BORN W, 1988, J IMMUNOL, V140, P3228; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EISENMAN RN, 1989, ONCOGENES MOL ORIGIN, P175; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FARRUGIA MM, 1994, BLOOD, V83, P191; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HAUPT Y, 1993, ONCOGENE, V8, P3161; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MARCU KB, 1980, CELL, V22, P187, DOI 10.1016/0092-8674(80)90167-1; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; NEIL JC, 1984, NATURE, V308, P814, DOI 10.1038/308814a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PURDIE CA, 1994, ONCOGENE, V9, P603; RAGIMOV N, 1993, ONCOGENE, V8, P1183; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; SMITH ML, 1993, CARCINOGENESIS, V14, P503, DOI 10.1093/carcin/14.3.503; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STEWART M, 1993, INT J CANCER, V53, P1023; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176	41	94	95	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1717	1723						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753548				2022-12-17	WOS:A1995QX46900004
J	CRIPPS, KJ; PURDIE, CA; CARDER, PJ; WHITE, S; KOMINE, K; BIRD, CC; WYLLIE, AH				CRIPPS, KJ; PURDIE, CA; CARDER, PJ; WHITE, S; KOMINE, K; BIRD, CC; WYLLIE, AH			A STUDY OF STABILIZATION OF P53 PROTEIN VERSUS POINT MUTATION IN COLORECTAL-CARCINOMA	ONCOGENE			English	Note							TUMOR SUPPRESSOR GENE; MONOCLONAL-ANTIBODIES; TISSUE-SECTIONS; BREAST-CANCER; WILD-TYPE; EXPRESSION; ANTIGEN	Abnormalities of the p53 tumour suppressor gene occur in many types of cancer including approximately 60% of colorectal carcinomas. This study investigates in 47 colorectal carcinomas the relationship between stabilised p53 protein detected by immunocytochemistry (ICC), and p53 mutation. 27 cases stained positively with the antibody PAb1801. Sequencing of exons 5-8 revealed 19 mutations in 18 of these cases (one tumour contained two different mutations). A rapid, non-radioactive method was developed to screen for mutations in this region of the gene involving Single Strand Conformational Polymorphism analysis (SSCP) and a MspI restriction digestion. This screen detected 17/19 (89%) of the sequenced mutations, and a further four mutations in 20 PAb1801 negative cases that were confirmed by sequencing. Reproducibility of ICC in detecting stabilised protein was assessed by restaining the 47 cases with the antibody DO7 after pre-treatment to optimise detection. Fewer cases were negative with DO7 although overall concordance with PAb1801 was good. A substantial proportion of carcinomas with stabilised p53 as detected by ICC do not contain mutations in exons 5-8, whilst some mutations (the majority in exon 6) are not associated with stabilisation.			CRIPPS, KJ (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PATHOL,CRC LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.			Purdie, Colin/0000-0002-1258-4010				BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BARTEK J, 1991, ONCOGENE, V6, P1699; BODNER SM, 1992, ONCOGENE, V7, P743; CARDER P, 1993, ONCOGENE, V8, P1397; CATTORETTI G, 1993, J PATHOL, V171, P83, DOI 10.1002/path.1711710205; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; DUNN JM, 1993, BRIT J SURG, V80, P1410, DOI 10.1002/bjs.1800801118; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALL PA, 1993, ONCOGENE, V8, P203; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACQUEMIER J, 1994, BRIT J CANCER, V69, P846, DOI 10.1038/bjc.1994.164; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PURDIE CA, 1991, AM J PATHOL, V138, P807; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RODRIGUEZ NR, 1990, P NATL ACAD SCI USA, V89, P12028; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SOUSSI T, 1990, ONCOGENE, V5, P945; TENERIELLO MG, 1993, CANCER RES, V53, P3101; TOMINAGA O, 1993, ONCOGENE, V8, P2653; VILLUENDAS R, 1993, BLOOD, V82, P3151; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOJTESEK B, 1993, BRIT J CANCER, V67, P1254, DOI 10.1038/bjc.1993.234; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOJTESEK B, 1993, J CELL SCI, V105, P607; WYNFORDTHOMAS D, 1992, J PATHOL, V166, P329, DOI 10.1002/path.1711660402	35	94	95	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2739	2743						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058340				2022-12-17	WOS:A1994PC05400038
J	CARNERO, A; CUADRADO, A; DELPESO, L; LACAL, JC				CARNERO, A; CUADRADO, A; DELPESO, L; LACAL, JC			ACTIVATION OF TYPE-D PHOSPHOLIPASE BY SERUM STIMULATION AND RAS-INDUCED TRANSFORMATION IN NIH3T3 CELLS	ONCOGENE			English	Article							PROTEIN-KINASE-C; SWISS 3T3 CELLS; PHOSPHATIDYLCHOLINE BREAKDOWN; PHOSPHATIDATE PHOSPHOHYDROLASE; 2ND MESSENGERS; POINT MUTATION; HYDROLYSIS; CHOLINE; DIACYLGLYCEROL; ONCOGENE	Mitogenic stimulation of NIH3T3 fibroblasts with growth factors or ras oncogenes is associated with an increase in the levels of phosphorylcholine and diacylglycerol. Both metabolites could be generated as a result of direct activation of a phosphatidylcholine-specific phospholipase C (PC-PLC) or by a more complex pathway, involving activation of phospholipase D followed by choline kinase and phosphatidic acid-hydrolase. We show evidence indicating that the generation of phosphorylcholine and diacylglycerol follow independent mechanisms in both serum-treated and in ras-transformed NIH3T3 cells. No significant activation of a PC-PLC enzyme was observed. Instead, activation of a phosphatidylcholine-specific phospholipase D (PC-PLD) was detected. Moreover, while a fivefold constitutive activation of the endogenous PLD activity and a twofold increase on the levels of phosphatidic acid were observed in uas-transformed cells, very small alterations on these parameters were detected at late times after serum stimulation of quiescent cells. Thus, cell proliferation induced by uas oncogenes in fibroblasts cells may be functionally linked to activation of a PC-PLD enzyme. The differences found in the activation of this enzyme between ras-transformed and normal cells may constitute an important difference in mitogenic signalling between normal and transformed cells.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			del Peso, Luis/K-9391-2014; IBIS, CANCER/P-3323-2015; Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	del Peso, Luis/0000-0003-4014-5688; Lacal, Juan Carlos/0000-0002-1908-2777; Carnero, Amancio/0000-0003-4357-3979; Cuadrado, Antonio/0000-0002-3444-9012; Cuadrado, Antonio/0000-0002-4039-7140				BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; BLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; CANNON JG, 1988, PHARMACEUT RES, V5, P359, DOI 10.1023/A:1015955527100; CARNERO A, 1993, J CELL BIOCHEM, V52, P440, DOI 10.1002/jcb.240520408; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; COOK SJ, 1991, BIOCHIM BIOPHYS ACTA, V1092, P265, DOI 10.1016/0167-4889(91)90166-U; COOK SJ, 1991, BIOCHEM J, V280, P431, DOI 10.1042/bj2800431; CORVEN EJ, 1989, CELL, V59, P45; CUADRADO A, 1993, ONCOGENE, V8, P2959; DALY PF, 1987, J BIOL CHEM, V262, P14875; DUGAN LL, 1986, J CHROMATOGR, V378, P317, DOI 10.1016/S0378-4347(00)80728-8; EXTON JH, 1990, J BIOL CHEM, V265, P1; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; KOUL O, 1987, ARCH BIOCHEM BIOPHYS, V253, P453, DOI 10.1016/0003-9861(87)90199-8; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MURRAY JJ, 1990, BIOCHEM J, V270, P63, DOI 10.1042/bj2700063; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; PREISS J, 1986, J BIOL CHEM, V261, P8597; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; WARDEN CH, 1985, J BIOL CHEM, V260, P6006; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0	38	94	94	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1387	1395						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152799				2022-12-17	WOS:A1994NH40100010
J	SLACK, RS; HAMEL, PA; BLADON, TS; GILL, RM; MCBURNEY, MW				SLACK, RS; HAMEL, PA; BLADON, TS; GILL, RM; MCBURNEY, MW			REGULATED EXPRESSION OF THE RETINOBLASTOMA GENE IN DIFFERENTIATING EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article							E2F TRANSCRIPTION FACTOR; MOUSE PGK-1 GENE; RETINOIC ACID; NEUROECTODERMAL DIFFERENTIATION; NEURAL DIFFERENTIATION; SUSCEPTIBILITY GENE; MAMMALIAN-CELLS; STEM-CELLS; PROTEIN; PRODUCT	The expression of the retinoblastoma susceptibility (RB) gene was investigated in P19 embryonal carcinoma cells and in these cells induced to differentiate with retinoic acid (RA) or with dimethyl sulfoxide (DMSO). In undifferentiated cells very low levels of RB mRNA and protein were present. DMSO-treated P19 cell cultures develop into mesodermal and endodermal cells and RB expression increased only slightly in these differentiating celts. RA-treated P19 cells develop into neuroectoderm and this differentiation was accompanied by a marked increase in RB expression with mRNA levels increasing 15 fold by 4-6 days following initiation of RA treatment. No such increase occurred in mutant cells that fail to respond to RA. The RB promoter did not appear to be directly activated by RA. Nevertheless, the increase in RB expression in RA-treated cells appeared to be due to enhanced initiation of transcription because cells transfected with a reporter gene driven by the RB promoter expressed the reporter gene with kinetics similar to that of the RB gene. Thus the activation of the RB gene appears to be achieved indirectly by RA-induced factor(s) in differentiating neuroectodermal cells. The post-mitotic neurons that developed in RA-treated cultured contained only the hypophosphorylated form of the RB protein. Recent studies (Clarke et aL, 1992; Jacks et al., 1992; Lee et al., 1992) have shown that mice lacking the RB gene have abnormalities in early brain development suggesting that the rapid rise in RB expression and the hypophosphorylation of the protein are essential for neuronal cell differentiation.	UNIV OTTAWA,DEPT CHEM,OTTAWA K1N 6N5,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Ottawa; University of Toronto				Slack, Ruth/0000-0002-1552-2835				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; AIZAWA T, 1991, DEV BRAIN RES, V59, P89, DOI 10.1016/0165-3806(91)90033-F; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DARLAND T, 1991, ONCOGENE, V6, P1367; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; EDWARDS SA, 1991, DEV BIOL, V148, P165, DOI 10.1016/0012-1606(91)90327-Y; Gill M., UNPUB; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MULLEN RJ, 1992, UNPUB; MURRAY EJ, 1991, MOL CELL BIOL, V1, P5534; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; PRATT MAC, 1992, UNPUB; ROSENSTRAUS MJ, 1982, DEV BIOL, V89, P516, DOI 10.1016/0012-1606(82)90340-2; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; RUSTGI AK, 1991, SYMPT QUANT BIOL, V56, P163; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SMITH SC, 1987, J CELL PHYSIOL, V131, P74, DOI 10.1002/jcp.1041310112; STAINES WA, 1992, UNPUB; STARNAUD R, 1989, ONCOGENE, V4, P1077; STARNAUD R, 1988, ONCOGENE, V3, P553; WEIGEL RJ, 1990, P NATL ACAD SCI USA, V87, P9878, DOI 10.1073/pnas.87.24.9878; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	54	94	94	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1585	1591						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502481				2022-12-17	WOS:A1993LE06400022
J	CHANG, KS; FAN, YH; STASS, SA; ESTEY, EH; WANG, G; TRUJILLO, JM; ERICKSON, P; DRABKIN, H				CHANG, KS; FAN, YH; STASS, SA; ESTEY, EH; WANG, G; TRUJILLO, JM; ERICKSON, P; DRABKIN, H			EXPRESSION OF AML1 ETO FUSION TRANSCRIPTS AND DETECTION OF MINIMAL RESIDUAL DISEASE IN T(8 21)-POSITIVE ACUTE MYELOID-LEUKEMIA	ONCOGENE			English	Article							BONE-MARROW TRANSPLANTATION; POLYMERASE CHAIN-REACTION; MESSENGER-RNA; TRANSLOCATION BREAKPOINT; T(15-17) TRANSLOCATION; RAR-ALPHA; GENE; AMPLIFICATION; CLASSIFICATION; T(14-18)	The t(8;21) translocation breakpoint, which is observed in acute myeloid leukemia (AML), has recently been cloned and a fusion transcript identified. We have now designed primer sets capable of amplifying the breakpoint junction of the fusion transcript by the reverse transcription-polymerase chain reaction (RT-PCR). Primer set 821U/821D1 amplified a 200-bp DNA fragment, and primer set 821U/821D2 amplified a 1.2-kb DNA fragment in all t(8;21)-positive AML tested. Sequence analysis of the amplified DNA fragments demonstrated that all fusion transcripts were fused at exactly the same site, indicating that this translocation breakpoint occurs within a single intron of the AML1 and ETO genes. Forty-five cycles of RT-PCR were used to detect residual t(8;21)-positive leukemia cells in three patients who had been in complete remission for 1, 3 and 5 years. Minimal residual disease was found in all three samples. Northern blot analysis demonstrated that two fusion transcripts of 7 and 10 kb were expressed in the t(8;21)-positive AML and that the ETO gene is not normally expressed in the hematopoietic system. Expression of a normal 5.5-kb ETO mRNA was found in the lung. From these results we concluded that expression of the ETO gene in t(8;21)-positive AML was activated as a result of the translocation.	UNIV COLORADO,CTR HLTH SCI & CANC,DIV MED ONCOL,DENVER,CO 80262	University of Colorado System; University of Colorado Denver	CHANG, KS (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DIV LAB MED,HEMATOPATHOL PROGRAM,HOUSTON,TX 77030, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD017449] Funding Source: NIH RePORTER; NICHD NIH HHS [P01HD017449] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CHANG KS, 1992, MOL CELL BIOL, V12, P800, DOI 10.1128/MCB.12.2.800; CHANG KS, 1992, BLOOD, V79, P554; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CRESCENZI M, 1988, P NATL ACAD SCI USA, V85, P4869, DOI 10.1073/pnas.85.13.4869; DELFAU MH, 1990, LEUKEMIA, V4, P1; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DOBROVIC A, 1988, BLOOD, V72, P3063; ERICKSON P, 1992, BLOOD, V80, P1825; GAO JZ, 1991, P NATL ACAD SCI USA, V88, P4882, DOI 10.1073/pnas.88.11.4882; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; LANGE W, 1989, BLOOD, V73, P1735; LEE MS, 1987, SCIENCE, V237, P175, DOI 10.1126/science.3110950; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PIGNON JM, 1990, LEUKEMIA, V4, P83; SHIMIZU K, 1991, GENE CHROMOSOME CANC, V3, P163, DOI 10.1002/gcc.2870030302	24	94	98	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					983	988						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455949				2022-12-17	WOS:A1993KT22000021
J	BECKER, D; LEE, PL; RODECK, U; HERLYN, M				BECKER, D; LEE, PL; RODECK, U; HERLYN, M			INHIBITION OF THE FIBROBLAST GROWTH-FACTOR RECEPTOR 1 (FGFR-1) GENE IN HUMAN MELANOCYTES AND MALIGNANT MELANOMAS LEADS TO INHIBITION OF PROLIFERATION AND SIGNS INDICATIVE OF DIFFERENTIATION	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; TUMOR-NECROSIS-FACTOR; STRUCTURAL ARRANGEMENT UNDERLIES; 3RD IMMUNOGLOBULIN DOMAIN; MOLECULAR-CLONING; ANTISENSE OLIGODEOXYNUCLEOTIDES; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; CELL-SURFACE; EXPRESSION	Fibroblast growth factor receptor (FGFR-1) is expressed as a single 3.5-kb mRNA transcript in normal human melanocytes and in malignant melanomas as determined upon Northern hybridization to a cDNA clone encoding the membrane-spanning form of the human FGFR-1. Polyclonal antisera directed against the chicken FGFR recognized a 145-kDa protein in primary and metastatic melanomas. Antisense oligodeoxynucleotides targeted against the translation start site and a splice donor-acceptor site of human FGFR-1, in addition to inhibiting the proliferation of normal human melanocytes and malignant melanomas, caused extensive dendrite formation and severe disruption of cell-cell contact - morphological changes that were not observed upon inhibition of the genes encoding basic fibroblast, growth factor (bFGF) and retinoic acid-alpha receptor. Thus, unlike in the case of the ligand bFGF, expression of the FGFR-1 may represent a requisite to prevent human melanocytes and malignant melanomas from undergoing (terminal) differentiation.	SCRIPPS CLIN & RES FDN,DIV BIOCHEM,LA JOLLA,CA 92037; WISTAR INST,PHILADELPHIA,PA 19104	Scripps Research Institute; The Wistar Institute	BECKER, D (corresponding author), UNIV PITTSBURGH,PITTSBURGH CANC INST,DEPT MED,BIOMED SCI TOWER,E1057,PITTSBURGH,PA 15261, USA.							ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; BECKER D, 1984, MOL CELL BIOL, V4, P2247, DOI 10.1128/MCB.4.11.2247; BECKER D, 1989, GENOMICS, V4, P97, DOI 10.1016/0888-7543(89)90320-0; BECKER D, 1990, ONCOGENE, V5, P1133; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BLAM SB, 1988, ONCOGENE, V3, P129; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; FEIGE JJ, 1988, J BIOL CHEM, V263, P14023; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIALLONGO A, 1986, P NATL ACAD SCI USA, V83, P6741, DOI 10.1073/pnas.83.18.6741; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HALABAN R, 1988, ONCOGENE RES, V3, P177; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HERLYN M, 1988, EXP CELL RES, V179, P322, DOI 10.1016/0014-4827(88)90271-6; HERLYN M, 1987, LAB INVEST, V56, P461; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KOIKE S, 1990, EMBO J, V9, P3247; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RODECK U, 1991, J INVEST DERMATOL, V97, P20, DOI 10.1111/1523-1747.ep12477822; RODECK U, 1987, INT J CANCER, V40, P687, DOI 10.1002/ijc.2910400520; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WRNER S, 1992, MOL CELL BIOL, V12, P82; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	52	94	98	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2303	2313						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437152				2022-12-17	WOS:A1992JW66500024
J	FISHER, RJ; MAVROTHALASSITIS, G; KONDOH, A; PAPAS, TS				FISHER, RJ; MAVROTHALASSITIS, G; KONDOH, A; PAPAS, TS			HIGH-AFFINITY DNA PROTEIN INTERACTIONS OF THE CELLULAR ETS1 PROTEIN - THE DETERMINATION OF THE ETS BINDING MOTIF	ONCOGENE			English	Article							LONG TERMINAL REPEAT; GEL-ELECTROPHORESIS; SEQUENCE; PHOSPHORYLATION; OPERATOR; COMPLEX; DOMAIN; VIRUS; GENE	ETS1 protein purified from CEM cells was used to select its optimum DNA-binding sequence (pu) G/CC(a)GGA-AGT(c) (py). The sequence CCGGAAGT (ETS1-3) was preferred 5:1 over CAGGAAGT (PEA3). Quantitative electrophoretic mobility-shift assays (EMSA) indicated that the purified ETS1 protein binds to either ETS1-3 or PEA3 oligonucleotide probes with high affinity (K(a) = 0.5-4.0 x 10(10) M-1) and that the purified ETS1 has different binding capacities for ETFS1-3 and PEA3 oligonucleotide probes. The ETS1 protein binds 2-5 times more ETS1-3 than PEA3. Competitive binding experiments showed that the ETS1-3 and PEA3 probes effectively compete for the binding of ETS1-3. However, changing the core DNA-binding sequence from GGAA to AGAA eliminates competition. Since the human ETS1 protein selected the same DNA sequence from a mixture of random oligonucleotides as did the Drosophila E74A protein (one of the most divergent members of the ETS family), this strongly suggests that all proteins containing the ETS 85 amino acid domain (sequences which define the ETS family) will bind to the same sequence.	NCI,FREDERICK CANC RES & DEV CTR,MOLEC ONCOL LAB,POB B,FREDERICK,MD 21702; DYNCORP,PROGRAM RESOURCES INC,FREDERICK CANC RES & DEV CTR,CELLULAR BIOCHEM LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Fisher, Robert/B-1431-2009					BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CANN JR, 1989, J BIOL CHEM, V264, P17032; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HUBBARD AJ, 1990, BIOCHEMISTRY-US, V29, P9241, DOI 10.1021/bi00491a019; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOIZUMI S, 1990, ONCOGENE, V5, P675; LABARCA C, 1980, ANAL BIOCHEM, V100, P188; LIN S, 1972, J MOL BIOL, V72, P71; MAVROTHALASSITIS G, 1990, DNA CELL BIOL, V9, P783, DOI 10.1089/dna.1990.9.783; MEISTERERNST M, 1988, NUCLEIC ACIDS RES, V16, P4419, DOI 10.1093/nar/16.10.4419; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; SETH A, 1991, IN PRESS TRENDS GENE; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; ZABEL U, 1991, J BIOL CHEM, V266, P252	23	94	95	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2249	2254						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766672				2022-12-17	WOS:A1991GX73500011
J	MOROY, T; VERBEEK, S; MA, A; ACHACOSO, P; BERNS, A; ALT, F				MOROY, T; VERBEEK, S; MA, A; ACHACOSO, P; BERNS, A; ALT, F			E-MU N-MYC AND E-MU L-MYC COOPERATE WITH E-MU PIM-1 TO GENERATE LYMPHOID TUMORS AT HIGH-FREQUENCY IN DOUBLE-TRANSGENIC MICE	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; C-MYC; NEOPLASTIC TRANSFORMATION; EMBRYO FIBROBLASTS; CELL LYMPHOMAS; T DEVELOPMENT; EXPRESSION; ENHANCER; ONCOGENE; GENES	Transgenic mice that contain the L-myc gene under the control of the immunoglobulin heavy-chain enhancer (E-mu) express the transgene preferentially in T cells, develop thymic hyperplasia and are predisposed to T-cell lymphomas. An analogous E-mu N-myc transgene is expressed preferentially in pre-B and B cells and provokes the development of B-cell neoplasias. Animals with an E-mu pim-1 construct express the transgene in both B and T cells, but succumb to T-cell lymphomas. Complementation of the E-mu N- and L-myc transgenic mice by breeding with E-mu pim-1 animals leads to much more rapid development and a dramatically higher incidence of lymphoid malignancies, but the lineage specificity prescribed by the E-mu N- and L-myc transgenes is maintained. The different oncogenic potential of myc genes is illustrated by the average latency period of tumor manifestation in double transgenics. Whereas c-myc/pim-1 animals develop pre-B-cell leukemia prenatally, the mean latency period for N-myc/pim-1 and L-myc/pim-1 mice is 36 and 94 days respectively. The N- and L-myc transgenes are expressed at high levels in tumors from double transgenic mice, but expression of the endogenous c- and N-myc genes is undetectable, directly implicating the myc transgenes in the tumor formation process.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,701 W 168TH ST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; NETHERLANDS CANC INST,DIV MOLEC GENET,1066 CX AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,DEPT BIOCHEM,1066 CX AMSTERDAM,NETHERLANDS	Columbia University; Howard Hughes Medical Institute; Columbia University; Columbia University; Netherlands Cancer Institute; University of Amsterdam			Moroy, Tarik/D-9923-2011		NCI NIH HHS [CA23767, CA42335] Funding Source: Medline; NIAID NIH HHS [AI 20047] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042335, P01CA023767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020047, R01AI020047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; COLLUM R, 1990, CANCER CELLS, V3, P69; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; DEPINHO R, 1987, GENE DEV, V8, P1311; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; GOUGH NM, 1981, P NATL ACAD SCI-BIOL, V78, P509, DOI 10.1073/pnas.78.1.509; HOGAN B, 1986, MANIPULATION MOUSE E; IWAMOTO A, 1987, J EXP MED, V165, P591, DOI 10.1084/jem.165.3.591; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEGOUY E, 1987, EMBO J, V6, P3359, DOI 10.1002/j.1460-2075.1987.tb02657.x; LEWIS S, 1982, CELL, V30, P807, DOI 10.1016/0092-8674(82)90285-9; MA A, 1991, MOL CELL BIOL, V11, P440, DOI 10.1128/MCB.11.1.440; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MANIATIS T, 1983, MOL CLONING; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; NISEN PD, 1986, CANCER RES, V46, P6217; PERRY RP, 1980, P NATL ACAD SCI-BIOL, V77, P1937, DOI 10.1073/pnas.77.4.1937; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7202; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; YANCOPOULOS G, 1984, P NATL ACAD SCI USA, V82, P5455; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; YUKAWA K, 1989, J EXP MED, V170, P711, DOI 10.1084/jem.170.3.711; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	39	94	96	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					1941	1948						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1658705				2022-12-17	WOS:A1991GX11900001
J	HIBSHOOSH, H; JOHNSON, M; WEINSTEIN, IB				HIBSHOOSH, H; JOHNSON, M; WEINSTEIN, IB			EFFECTS OF OVEREXPRESSION OF ORNITHINE DECARBOXYLASE (ODC) ON GROWTH-CONTROL AND ONCOGENE-INDUCED CELL-TRANSFORMATION	ONCOGENE			English	Article							POLYAMINE-BIOSYNTHETIC ENZYMES; PROTEIN KINASE-C; VITAMIN-A ACID; IRREVERSIBLE INHIBITION; GENE AMPLIFICATION; MOUSE EPIDERMIS; TUMOR PROMOTION; INDUCTION; FIBROBLASTS; DIFLUOROMETHYLORNITHINE	The enzyme ornithine decarboxylase (ODC) has been implicated in the control of cell growth, differentiation and tumor promotion. To further elucidate its precise role a murine ODC cDNA was inserted into the retrovirus-derived vector pMV7 and retrovirus-like particles were used to infect NIH3T3 and rat 6(R6) fibroblasts. Derivatives were obtained that stably express a 5-40 fold increase in ODC enzyme activity. Despite these high levels of enzyme activity the cells retained a normal morphology and displayed no major changes in growth properties in monolayer culture or in agar suspension. On the other hand, R6 cells that expressed high levels of ODC displayed a marked increase in susceptibility to morphologic transformation by an activated c-H-ras oncogene. These results provide the first evidence that ODC can cooperate with an activated oncogene in the process of cell transformation. Although the mechanism is not known, these findings may be relevant to the multistage carcinogenic process.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University; Columbia University	HIBSHOOSH, H (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,CTR COMPREHENS CANC,NEW YORK,NY 10032, USA.							ALHONENHONGISTO L, 1987, BIOCHEM J, V247, P651, DOI 10.1042/bj2470651; Bachrach U., 1973, FUNCTION NATURALLY O; BOLLAG W, 1971, EXPERIENTIA, V27, P90, DOI 10.1007/BF02137760; BOLLAG W, 1972, EUR J CANCER, V8, P689, DOI 10.1016/0014-2964(72)90153-3; BOUTWELL RK, 1979, ADV ENZYME REGUL, P89; BOUTWELL RK, 1979, NATURALLY OCCURRING, P287; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cohen S.S., 1971, INTRO POLYAMINES; FOZARD JR, 1982, ARCH PHARM, V320, P72; GAZITT Y, 1980, CANCER RES, V40, P1727; HADDOX MK, 1979, CANCER RES, V39, P4930; HADDOX MK, 1979, CANCER RES, V39, P2476; HADDOX MK, 1980, CANCER RES, V40, P604; HISTON WDW, 1982, PROSTATE, V3, P383; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HSIAO WLW, 1987, MOL CELL BIOL, V7, P3380, DOI 10.1128/MCB.7.10.3380; HSIAO WLW, 1984, SCIENCE, V226, P552, DOI 10.1126/science.6436974; JANNE J, 1968, ACTA CHEM SCAND, V22, P1349, DOI 10.3891/acta.chem.scand.22-1349; KAHANA C, 1985, P NATL ACAD SCI USA, V82, P1673, DOI 10.1073/pnas.82.6.1673; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOWE NJ, 1983, CARCINOGENESIS, V4, P671, DOI 10.1093/carcin/4.6.671; LOWE NJ, 1982, CLIN RES, V30, pA158; MAMONT PS, 1978, BIOCHEM BIOPH RES CO, V81, P58, DOI 10.1016/0006-291X(78)91630-3; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; OBRIEN TG, 1975, CANCER RES, V35, P2426; OBRIEN TG, 1975, CANCER RES, V35, P1662; POLVINEN K, 1988, BIOCHEM BIOPH RES CO, V155, P373, DOI 10.1016/S0006-291X(88)81095-7; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RUSSELL D, 1968, P NATL ACAD SCI USA, V60, P1420, DOI 10.1073/pnas.60.4.1420; RUSSELL DH, 1985, DRUG METAB REV, V16, P1, DOI 10.3109/03602538508991430; RUSSELL DH, 1971, P NATL ACAD SCI USA, V68, P523, DOI 10.1073/pnas.68.3.523; RUSSELL DH, 1969, MOL PHARMACOL, V5, P253; RUSSELL DH, 1973, POLYAMINES NORMAL NE, P1; RUSSELL DH, 1978, POLYAMINES MARKERS N; SPORN MB, 1976, FED PROC, V35, P1332; STEGLICH C, 1985, SOMAT CELL MOLEC GEN, V11, P11, DOI 10.1007/BF01534730; TAKIGAWA M, 1983, CANCER RES, V43, P3732; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683	42	94	103	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					739	743						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1711188				2022-12-17	WOS:A1991GT82500008
J	STURZBECHER, HW; BRAIN, R; MAIMETS, T; ADDISON, C; RUDGE, K; JENKINS, JR				STURZBECHER, HW; BRAIN, R; MAIMETS, T; ADDISON, C; RUDGE, K; JENKINS, JR			MOUSE P53 BLOCKS SV40 DNA-REPLICATION INVITRO AND DOWNREGULATES T-ANTIGEN DNA HELICASE ACTIVITY	ONCOGENE			English	Article									ESTONIAN BIOCTR,TARTU 202400,ESTONIA,USSR	Estonian Biocentre	STURZBECHER, HW (corresponding author), MARIE CURIE RES INST,CELL PROLIFERAT LAB,OXTED RH8 0TL,SURREY,ENGLAND.		Maimets, Toivo/E-9268-2017	Maimets, Toivo/0000-0001-6461-3365				BRADLEY MK, 1987, P NATL ACAD SCI USA, V84, P4026, DOI 10.1073/pnas.84.12.4026; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CLARK R, 1981, J BIOL CHEM, V256, P1854; COLE CN, 1986, J VIROL, V57, P539, DOI 10.1128/JVI.57.2.539-546.1986; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DEB S, 1986, MOL CELL BIOL, V6, P4578, DOI 10.1128/MCB.6.12.4578; DEB S, 1986, MOL CELL BIOL, V6, P1663, DOI 10.1128/MCB.6.5.1663; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DELUCIA AL, 1983, J VIROL, V46, P143, DOI 10.1128/JVI.46.1.143-150.1983; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, V1, P99; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GIACHERIO D, 1979, J BIOL CHEM, V254, P8113; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HANDA H, 1981, J BIOL CHEM, V256, P478; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUBSCHER U, 1985, NUCLEIC ACIDS RES, V13, P5471, DOI 10.1093/nar/13.15.5471; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, ONCOGENE HDB; JENKINS JR, 1988, IN PRESS J VIROL; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LI JJ, 1986, MOL CELL BIOL, V6, P1117, DOI 10.1128/MCB.6.4.1117; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARGOLSKEE RF, 1984, J VIROL, V49, P386, DOI 10.1128/JVI.49.2.386-393.1984; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PAUCHA E, 1986, J VIROL, V57, P50, DOI 10.1128/JVI.57.1.50-64.1986; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; ROVINSKI B, 1988, ONCOGENE, V2, P445; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SIMMONS DT, 1988, P NATL ACAD SCI USA, V85, P2086, DOI 10.1073/pnas.85.7.2086; SIMMONS DT, 1986, J VIROL, V57, P776, DOI 10.1128/JVI.57.3.776-785.1986; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STAHL H, 1985, J VIROL, V54, P473, DOI 10.1128/JVI.54.2.473-482.1985; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; STURZBECHER HW, 1988, IN PRESS CANCER CELL, V6; TACK LC, 1986, J VIROL, V58, P635, DOI 10.1128/JVI.58.2.635-646.1986; TACK LC, 1988, J VIROL, V62, P1028, DOI 10.1128/JVI.62.3.1028-1037.1988; TEGTMEYER P, 1983, J VIROL, V46, P151, DOI 10.1128/JVI.46.1.151-161.1983; TJIAN R, 1978, CELL, V13, P165, DOI 10.1016/0092-8674(78)90147-2; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WIEKOWSKI M, 1987, J VIROL, V61, P411, DOI 10.1128/JVI.61.2.411-418.1987; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790	62	94	94	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					405	413						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	2856250				2022-12-17	WOS:A1988Q773900008
J	SPECTOR, DL; WATT, RA; SULLIVAN, NF				SPECTOR, DL; WATT, RA; SULLIVAN, NF			THE V-MYC AND C-MYC ONCOGENE PROTEINS COLOCALIZE INSITU WITH SMALL NUCLEAR RIBONUCLEOPROTEIN-PARTICLES	ONCOGENE			English	Article									SK&F LABS, MOLEC ONCOL GRP, SWEDELAND, PA 19479 USA		SPECTOR, DL (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.				NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BACHMANN M, 1986, P NATL ACAD SCI USA, V83, P7770, DOI 10.1073/pnas.83.20.7770; BENNETT FC, 1985, EXP CELL RES, V157, P379, DOI 10.1016/0014-4827(85)90123-5; BERGET SM, 1986, CELL, V46, P691, DOI 10.1016/0092-8674(86)90344-2; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLACK DL, 1986, CELL, V46, P697, DOI 10.1016/0092-8674(86)90345-4; BONA M, 1981, J MOL BIOL, V151, P81, DOI 10.1016/0022-2836(81)90222-9; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DENG JS, 1981, J CELL BIOL, V91, P654, DOI 10.1083/jcb.91.3.654; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; EISENMAN RN, 1985, MOL CELL BIOL, V5, P114, DOI 10.1128/MCB.5.1.114; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; GALLI G, 1983, CELL, V34, P823, DOI 10.1016/0092-8674(83)90539-1; GERACE L, 1978, J CELL BIOL, V79, P546, DOI 10.1083/jcb.79.2.546; GOUSTIN AS, 1985, CELL, V41, P301, DOI 10.1016/0092-8674(85)90083-2; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; Graessmann A, 1980, Methods Enzymol, V65, P816; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HERNANDEZ N, 1983, CELL, V35, P89, DOI 10.1016/0092-8674(83)90211-8; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KACZMAREK L, 1986, J BIOL CHEM, V261, P802; KANAI Y, 1981, P NATL ACAD SCI-BIOL, V78, P2801, DOI 10.1073/pnas.78.5.2801; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAMER A, 1984, CELL, V38, P299, DOI 10.1016/0092-8674(84)90551-8; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; LESER GP, 1984, J BIOL CHEM, V259, P1827; MCKEON FD, 1984, CELL, V36, P83, DOI 10.1016/0092-8674(84)90076-X; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; MORGAN JH, 1985, J NATL CANCER I, V75, P937, DOI 10.1093/jnci/75.5.937; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; MULLER R, 1983, NATURE, V304, P454, DOI 10.1038/304454a0; MULLER W, 1975, EUR J BIOCHEM, V54, P385, DOI 10.1111/j.1432-1033.1975.tb04149.x; Northway J.D., 1972, CLIN IMMUNOL IMMUNOP, V1, P140, DOI [10.1016/0090-1229(72)90013-X, DOI 10.1016/0090-1229(72)90013-X]; NYMAN U, 1986, J CELL BIOL, V102, P137, DOI 10.1083/jcb.102.1.137; OCHS RL, 1985, BIOL CELL, V54, P123, DOI 10.1111/j.1768-322X.1985.tb00387.x; PADGETT RA, 1983, CELL, V35, P101, DOI 10.1016/0092-8674(83)90212-X; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PERSSON H, 1986, MOL CELL BIOL, V6, P942, DOI 10.1128/MCB.6.3.942; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P2500, DOI 10.1073/pnas.80.9.2500; REDDY R, 1983, J BIOL CHEM, V258, P3965; ROGERS J, 1980, P NATL ACAD SCI-BIOL, V77, P1877, DOI 10.1073/pnas.77.4.1877; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHEER U, 1984, P NATL ACAD SCI-BIOL, V81, P1431, DOI 10.1073/pnas.81.5.1431; SHARP GC, 1972, AM J MED, V52, P148, DOI 10.1016/0002-9343(72)90064-2; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SMELAND E, 1985, P NATL ACAD SCI USA, V82, P6255, DOI 10.1073/pnas.82.18.6255; SMITH HC, 1985, J CELL BIOL, V101, P560, DOI 10.1083/jcb.101.2.560; SMITH HC, 1986, MOL CELL BIOCHEM, V70, P151; SPECTOR DL, 1983, BIOL CELL, V49, P1; SPECTOR DL, 1984, BIOL CELL, V51, P109, DOI 10.1111/j.1768-322X.1984.tb00289.x; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; SPECTOR DL, 1986, EXP CELL RES, V163, P87, DOI 10.1016/0014-4827(86)90560-4; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; SULLIVAN N, 1986, CURR TOP MICROBIOL, V132, P355; SULLIVAN NF, 1986, CANCER RES, V46, P6427; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; WANG K, 1982, METHOD ENZYMOL, V85, P514; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WINQVIST R, 1984, EMBO J, V3, P2947, DOI 10.1002/j.1460-2075.1984.tb02237.x; YANG VW, 1981, P NATL ACAD SCI-BIOL, V78, P1371, DOI 10.1073/pnas.78.3.1371	82	94	94	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1987	1	1					5	12						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6351	2963988				2022-12-17	WOS:A1987J635100001
J	Liang, YR; Song, XJ; Li, YM; Su, P; Han, DW; Ma, TT; Guo, RB; Chen, B; Zhao, WJ; Sang, YT; Zhang, N; Li, XY; Zhang, HW; Liu, Y; Duan, Y; Wang, LJ; Yang, QF				Liang, Yiran; Song, Xiaojin; Li, Yaming; Su, Peng; Han, Dianwen; Ma, Tingting; Guo, Renbo; Chen, Bing; Zhao, Wenjing; Sang, Yuting; Zhang, Ning; Li, Xiaoyan; Zhang, Hanwen; Liu, Ying; Duan, Yi; Wang, Lijuan; Yang, Qifeng			circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer	ONCOGENE			English	Article							OSTEOSARCOMA CELLS; WNT/BETA-CATENIN; RNA; CHEMORESISTANCE; METASTASIS; EXPRESSION; CIRCHIPK3; CIRCPVT1; ABUNDANT; MARKER	Increasing evidence has indicated that circular RNAs (circRNAs) play a critical role in cancer development. However, only a small number of circRNAs have been experimentally validated and functionally annotated. In this study, using a high-throughput microarray assay, we identified a novel circRNA, circKDM4C, which was downregulated in breast cancer tissues with metastasis. Furthermore, we analyzed a cohort of breast cancer patients and found that circKDM4C expression was decreased in breast cancer tissues, and lower circKDM4C expression was associated with poor prognosis and metastasis in breast cancer. Functionally, we demonstrated that circKDM4C significantly repressed breast cancer proliferation, metastasis, and doxorubicin resistance in vitro and in vivo. Mechanistically, using a dual-luciferase activity assay and AGO2 RNA immunoprecipitation, circKDM4C was identified as a miR-548p sponge. We also found that PBLD was a direct target of miR-548p, which functioned as a tumor suppressor in breast cancer. Moreover, miR-548p overexpression was able to reverse the circKDM4C-induced attenuation of malignant phenotypes and elevated expression of PBLD in breast cancer cells. Taken together, our data indicate that circKDM4C might have considerable potential as a prognostic biomarker in breast cancer, and support the notion that therapeutic targeting of circKDM4C/miR-548p/PBLD axis may be a promising treatment approach for breast cancer patients.	[Liang, Yiran; Song, Xiaojin; Li, Yaming; Han, Dianwen; Ma, Tingting; Sang, Yuting; Zhang, Ning; Li, Xiaoyan; Zhang, Hanwen; Liu, Ying; Duan, Yi; Yang, Qifeng] Shandong Univ, Qilu Hosp, Dept Breast Surg, Jinan 250012, Shandong, Peoples R China; [Su, Peng] Shandong Univ, Qilu Hosp, Dept Pathol, Jinan 250012, Shandong, Peoples R China; [Guo, Renbo] Shandong Univ, Shandong Canc Hosp, Dept Urol, Jinan 250117, Shandong, Peoples R China; [Chen, Bing; Zhao, Wenjing; Wang, Lijuan; Yang, Qifeng] Shandong Univ, Qilu Hosp, Pathol Tissue Bank, Jinan 250012, Shandong, Peoples R China	Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong University	Yang, QF (corresponding author), Shandong Univ, Qilu Hosp, Dept Breast Surg, Jinan 250012, Shandong, Peoples R China.; Yang, QF (corresponding author), Shandong Univ, Qilu Hosp, Pathol Tissue Bank, Jinan 250012, Shandong, Peoples R China.	qifengy_sdu@163.com	Zhang, Ning/GNP-1966-2022; Zhang, Hanwen/CAG-1998-2022; Zhang, Ning/GOJ-8058-2022; yang, qiang/GYJ-0971-2022	Zhang, Ning/0000-0002-6430-4236; Yang, Qifeng/0000-0003-0576-8513	National Natural Science Foundation of China [81272903, 81672613, 81502285, 81602329]; China Postdoctoral Science Foundation [2018M630787]; Key Research and Development Program of Shandong Province [2015GSF118093, 2016GSF201119]; Natural Science Foundation of Shandong Province [ZR2014HQ078]; Shandong Science and Technology Development Plan [2016CYJS01A02]; Special Support Plan for National High Level Talents ("Ten Thousand Talents Program")	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Key Research and Development Program of Shandong Province; Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Shandong Science and Technology Development Plan; Special Support Plan for National High Level Talents ("Ten Thousand Talents Program")	This work was supported by the National Natural Science Foundation of China (No. 81272903; No. 81672613; No. 81502285; No. 81602329), China Postdoctoral Science Foundation to NZ (2018M630787), the Key Research and Development Program of Shandong Province (No. 2015GSF118093, No. 2016GSF201119), the Natural Science Foundation of Shandong Province (ZR2014HQ078), the Shandong Science and Technology Development Plan (2016CYJS01A02), and the Special Support Plan for National High Level Talents ("Ten Thousand Talents Program") to QY.	Barrett SP, 2015, ELIFE, V4, DOI 10.7554/eLife.07540; Bray F, 2018, CA CANC J CLIN; Cai JC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15870; Chen GW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0204-3; Chen J, 2017, CANCER LETT, V388, P208, DOI 10.1016/j.canlet.2016.12.006; Chen LL, 2015, RNA BIOL, V12, P381, DOI 10.1080/15476286.2015.1020271; COCQUERELLE C, 1993, FASEB J, V7, P155, DOI 10.1096/fasebj.7.1.7678559; Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027; Gao DF, 2017, EPIGENOMICS-UK, V9, P1175, DOI 10.2217/epi-2017-0055; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Huang GL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131225; Huang SL, 2019, CIRCULATION, V139, P2857, DOI 10.1161/CIRCULATIONAHA.118.038361; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Jones SE, 2008, CLIN BREAST CANCER, V8, P224, DOI 10.3816/CBC.2008.n.025; Ke ZY, 2019, J CELL PHYSIOL, V234, P1699, DOI 10.1002/jcp.27041; Kim C, 2018, CELL, V173, P879, DOI 10.1016/j.cell.2018.03.041; Li AM, 2016, ONCOTARGET, V7, P524, DOI 10.18632/oncotarget.6358; Li DM, 2013, WORLD J GASTROENTERO, V19, P2781, DOI 10.3748/wjg.v19.i18.2781; Li DM, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1637-7; Li F, 2015, ONCOTARGET, V6, P6001, DOI 10.18632/oncotarget.3469; Li RC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0852-y; Li YW, 2017, EMBO REP, V18, P1646, DOI 10.15252/embr.201643581; Long JA, 2010, HEPATOB PANCREAT DIS, V9, P296; Maishman T, 2017, ANN SURG, V266, P165, DOI 10.1097/SLA.0000000000001930; O'Reilly EA, 2015, BBA CLIN, V3, P257, DOI 10.1016/j.bbacli.2015.03.003; Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733; Sang MX, 2018, CANCER LETT, V426, P37, DOI 10.1016/j.canlet.2018.03.049; Shi L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.556; Shi ZM, 2017, FEBS J, V284, P1096, DOI 10.1111/febs.14045; Tan SY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0887-9; Wan L, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/1579490; Wang KF, 2017, CANCER LETT, V394, P1, DOI 10.1016/j.canlet.2016.12.036; Wang L., 2018, JOULE, V2, P1, DOI DOI 10.1016/j.mtnano.2018.04.007; Wang Y, 2016, CANCER LETT, V382, P137, DOI 10.1016/j.canlet.2016.08.024; Wei XF, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.541; Xie F., 2018, AXIS, V17, P144, DOI DOI 10.1186/S12943-018-0892-Z; Xiong W, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8421614; Xu H, 2018, CANCER LETT, V412, P69, DOI 10.1016/j.canlet.2017.09.030; Zeng KX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0454-8; Zhang J, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0719-3; Zhang J, 2007, J PROTEOME RES, V6, P4423, DOI 10.1021/pr0703425; Zheng QP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11215; Zhong ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep30919; Zhu KP, 2018, INT J BIOL SCI, V14, P321, DOI 10.7150/ijbs.24360	44	93	95	3	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2019	38	42					6850	6866		10.1038/s41388-019-0926-z	http://dx.doi.org/10.1038/s41388-019-0926-z			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE5UU	31406252				2022-12-17	WOS:000490758200004
